<SEC-DOCUMENT>0001397702-21-000021.txt : 20210301
<SEC-HEADER>0001397702-21-000021.hdr.sgml : 20210301
<ACCEPTANCE-DATETIME>20210301171127
ACCESSION NUMBER:		0001397702-21-000021
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210301
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silk Road Medical Inc
		CENTRAL INDEX KEY:			0001397702
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				208777622
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38847
		FILM NUMBER:		21699208

	BUSINESS ADDRESS:	
		STREET 1:		1213 INNSBRUCK DR.
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94089-2918
		BUSINESS PHONE:		6505669060

	MAIL ADDRESS:	
		STREET 1:		1213 INNSBRUCK DR.
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94089-2918
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>silk-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:13b527d4-ea1a-4469-9dba-fa8b61e78c7f,g:43b528fe-3601-4224-908f-a46b4c727eef,d:26a0ed258dae4ee5a9edb8a3b963e1bf--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:silk="http://silkroadmed.com/20201231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>silk-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl80L2ZyYWc6MTI1ZWQ3ZjhkOWUwNGZmMTk1YzVkZTYwZDYzZmU0YmIvdGFibGU6MmZmMDI4Y2FlMmIwNDU2ODkxZWU3MzFmZDY1MGY0NTgvdGFibGVyYW5nZToyZmYwMjhjYWUyYjA0NTY4OTFlZTczMWZkNjUwZjQ1OF8zLTEtMS0xLTA_615d4611-41a8-4f28-b1fe-808f3062905c">0001397702</ix:nonNumeric><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl80L2ZyYWc6MTI1ZWQ3ZjhkOWUwNGZmMTk1YzVkZTYwZDYzZmU0YmIvdGFibGU6MmZmMDI4Y2FlMmIwNDU2ODkxZWU3MzFmZDY1MGY0NTgvdGFibGVyYW5nZToyZmYwMjhjYWUyYjA0NTY4OTFlZTczMWZkNjUwZjQ1OF8xMS0xLTEtMS0w_583324b3-ac86-489c-84c8-51d09401b84c">2020</ix:nonNumeric><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl80L2ZyYWc6MTI1ZWQ3ZjhkOWUwNGZmMTk1YzVkZTYwZDYzZmU0YmIvdGFibGU6MmZmMDI4Y2FlMmIwNDU2ODkxZWU3MzFmZDY1MGY0NTgvdGFibGVyYW5nZToyZmYwMjhjYWUyYjA0NTY4OTFlZTczMWZkNjUwZjQ1OF8xMi0xLTEtMS0w_c1051ba0-a530-4473-8b14-4a339f697946">FY</ix:nonNumeric><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl80L2ZyYWc6MTI1ZWQ3ZjhkOWUwNGZmMTk1YzVkZTYwZDYzZmU0YmIvdGFibGU6MmZmMDI4Y2FlMmIwNDU2ODkxZWU3MzFmZDY1MGY0NTgvdGFibGVyYW5nZToyZmYwMjhjYWUyYjA0NTY4OTFlZTczMWZkNjUwZjQ1OF8xMy0xLTEtMS0w_03c66ea3-3d89-42d2-ad85-7ef3157ccd27">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ifd8381d4b2db4351a5d965b163ba7b2f_D20190313-20190313" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83OS9mcmFnOjQzYzY0NWRkMWIwMTRkY2ZhMjM0MTM0NjJkNzM2NjY2L3RleHRyZWdpb246NDNjNjQ1ZGQxYjAxNGRjZmEyMzQxMzQ2MmQ3MzY2NjZfMTM_ec25cec9-cf0f-45fb-ad9e-689486fcfad2">.3704</ix:nonFraction><ix:nonNumeric contextRef="i47ab4f535e3f49f092f4f09308ca5685_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA3ODg_1daeb587-69ed-44f7-8b16-4ee5917c9839">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_79e4f10b-3b5e-4ec2-876c-6e585e344f6b">us-gaap:OtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_da5af1e9-78c6-47d2-b916-faffbda32183">us-gaap:OtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_0c14a90d-c468-4d50-8bda-f4b6abb57993">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_df5558d5-a823-4bc7-8d24-11cd3b6290f9">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_14124f2c-b99c-42a3-914f-b88bb1e2da04">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_eb1aa98b-cafb-4393-b523-5f94410b69b5">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="silk-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i57b888d1afed467eb6e8156312b035a4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ifb6f5fd1061f4f56989bc588eebd18c4_I20210226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i309aa475c33d46f1bcb008fc1f8ff1b4_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab4311acf1a24c2d80c7837fb213c678_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad606b34524243b1a8e5075ac03d3736_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b884248218456fa51f8f0609280bfe_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9001a76c96354d44be43663ad10864e5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd1291d3588454f997c52cc2495c69d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20487a9e41eb468fb7da6d0324133121_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c754289625a475e91ebf3960393d1df_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b0757eda174b29929c9539b4972205_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d9057d66f44539a8d04ef9162bb079_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ce8733a67e34fdbb3a3c3db64b74607_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52336bc12b324590bba4f1ab5687f560_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ad6abb0fc2410f8d14252857b9b662_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a224585ac174008bad3bf2831eec2f0_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c86486a74044d0b4999de7a19e56b8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c78658e347043038c35c1cacd0e7415_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9452f0bca2304c67ac02c051e36f8823_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib95c642c97784f95b54de6ac4683cf00_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5363da9b40b8433589b18ba5d4349ec4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168f9b03b66f4d37bb7151521137ed70_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i268ced4ae9024a918193193003914ad4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie206f45400684e03b789ee66287deddc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad40d41effba4a3785f2f35c5cc9b839_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4f40364954436caf47b6d23cb6d6e4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f23accfdbc34e51924d5a95ddcb0253_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65d3e7d28b94209a448cb72c6adae4f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8990e088bd584d108b3b67f167d02e78_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c4d9ba8d16c449c80e25e34837c0084_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7ee782a5ac4726825924882652fb3b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i864f0448c9b44f6abc0aa0fc934ca527_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ed96d628e884154a23064db50466351_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f0db448912c4166941130ebb1e99a3a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f8aa68dc9bd43a0878ae2aa5eaa1801_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4702b7d22d1a40a59e7c037cc5eef2a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d7ed4748adc465582c5b79aad061342_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0886aab4e9464bd081f28baaadbc2c24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79caa187be2c4546967d3d07d999a1f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82f9aab73bb74d4eb978e25668f669a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35b094dd513647c39d1b0a77a875ab5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0693226ab445409dac81b6a1a31b8e74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe3473f98e7473a96d28715e29fab03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027bc0bdf8734670ba15f197c3fa9de7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b505ad720547b7906b11f5bbf2fbdb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73fdcaf51beb4164910ff49230c96c68_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea0497ce3b1475f81a9c6c00b0c512b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32dc6dca82f54b3997404bec4ab31270_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7c87ccb914d486b82d6cfe0e26711e6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c12d1da942447109063cebb275e8ba0_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8b27155c8474ab98f936002ff227c64_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:SecondPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie87e6a507693455e82f8b7d021987453_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic360f0c60b9e4bd4a3301ef5a705c91f_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:SecondPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec4ce25ed9c841df9c17121f68205ba4_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0619a3b111784379874d71f11398ec42_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingSharesFromCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i856f24feae584b14a8bc751fcb0a507a_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingSharesFromExistingShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0280538aac42a28763dda42b85838a_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ifd8381d4b2db4351a5d965b163ba7b2f_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i827e3aa981f94e4497963dc63008de63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1750d8abb53f482ab006e6bbcc0efe15_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47ab4f535e3f49f092f4f09308ca5685_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b870409832446b94306158afef68a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74860ed5b6ab4871aeb814ec7a0a16b6_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if853e1713db04046a3e29718f77e312d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a8a6cae4d84ca78f3412deeef72360_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a23db6a3861435b9f2516a8cd29279a_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc64e5be1b148b388a24c6ea4bc296c_D20190501-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d32e7c3bb6454a8aac9d997e7acdc7_D20190501-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8bdec6a3f3f428d912d079b56925396_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id91c2dc9412d49f38b2911de8b92a20c_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75afb4faf7c744e2b28602b04897dd79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64b54eeb36b1445a892442bd09bf6ddc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f6cfd36e8754556bf275ccd4408ac9d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc08d2bf3b1d4a4db5e64a2c8d4dc1eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f590d47a7f349109aeb1d59166be0f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af5a51a24f74e2abff8b55e1f406aac_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05cef1eab034c14aabf2595f65c6875_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d19235df8b24d9391e616dafdce6fe6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e6007a041b04fe18293a2b10afdf234_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9af4d8ce709e4c3a9540ae056f21e76a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0208f9e90c6a42fda50fc3adb6581207_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib88ecc9d7eb744238cc66553830ad1a1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1b45f2b2f54a72b7d8efc23d3f0bb1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070da31579db44ef9c24774b3df5e7d7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3673ffce8656493c860435c0fb39bfb4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>silk:segment</xbrli:measure></xbrli:unit><xbrli:context id="i88621eee6a92415596259056062149ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59487565bf824f58aa85388dbb1688de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf154cdda1c64eb98fa4cb83db6a1660_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2975ca8ff7e249fdbd6927130f924215_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b799836f284366bc42899fe369b6df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic870ec31c6844cae91979478b320f851_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ee5649064aa4f26bf11ca63f1d732f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae39ce199b8414db9c118472a65f406_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f2c499fbaf46cabadb242b9424f8cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i357686f6ae35429994f069e2387042a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848eba092bd94a8eb9a2e17f4201aecc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82ec25c5c50d45fc9b7ac1bcf6ed42c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa5d33e615f45ee93d158502b82303c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c7a65d68ecf48be802607860d75752b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f0fd943be2845489302e8030bd481fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8db444997bb6463980bb4456c1bf3dc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98cf98f0f8c4bdbb7f693b02e6b6929_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23170ae30bd4aa09beb7fe13e61ced2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ecc085e11174791b09ea7310d702ac7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i433402cf26a940318305dcd5eb794a03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e033ae2fd394f23bcf5460a5a476a6d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3306f9c046324cf5b42a9b1bac4a0df4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0704a28bb0740d0ae4c8aa19953a7c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98694aaa0a3e4704bba4075c12779e77_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i737fbec56ae2400498ccdfd111434ebd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i942c1c56732d4c25a0dce9c90e7135bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93aba04a024740cab28993b7f08897a6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9ad97bd146043ccb94ce8bb1534c274_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f54e063bd140a59132d57ef7c54d00_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5276c031eb8401ab73fc33a537f9a9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0f25b2baff49b08a617afd300f27b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i318e00b0a9b344bda4f823f595370143_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b13adf4f0254c9cac128597de2f1736_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb08f575e4245cb9aca4fe1623d37ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0dc412721304b3b9720878497766ff1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14399a34c4744effb088c2e934ae2d39_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bcb916e401b434c9e7347ae76804c6c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65720dad45e548d784f15ef6efe4dfce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40fbd6b3dba34ba6ac8a848b3683d371_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8480cdb559440dba9a27448e6c477b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7abdb02107cf49099d5551ac177162e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaabfa66f9d644e5b250778ca77caced_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0af3756b9464f89a2924477109ebf89_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f81260903074be0978bdc8c0d05b714_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec2284f03df4813bfbdf100ea317939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11882955ba914a4abd7f7f72b573da68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c6e1731892948749cc2a36087515f22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i889ad813d9384574aeee41f8e250fdd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6666fe4580be47429377090735b4b572_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda1fee3df294d8280213184a71db82b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2210e9a79df74613aaba46b9b6c9d830_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6207be23c9e413d86cc481a1129e296_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a569c77aa3c40dd9b99313f06d7bd3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c76492ae1149d3aa274942d50fabd3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2533cb6af194baeb29f893a563753d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if68f3a12f75a43e0a5f0f1a0e2ed2345_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="silk:LossContingencyReceivableTypeAxis">silk:LossContingencyReceivableInventoryExcessAndObsolescenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc53679edcca491daa58c1d5d9e40d2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89117551e1cd4e1894164ae6a96705b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28498ef5e5d649ccab003692d7a48278_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58bbd4394762445f9a301c74072434aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6603001cf648480982c9106b4e14992e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4bfd4cf869646a3aabf0014c3294512_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c17ea580834042872a256eb3032b57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719a20f0f78a457f87d7472704e63aa1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69721672eec41c2a595f99de0a0defc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b0413075134cc583c0faa97c7be5d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf16e6187b0a4304bc8897195133e968_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib85c4555200f4f429465863d9f50f535_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f5ec93120bb4972be5e2507b780398c_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ecba85ef204349b335af3072288f5f_D20170401-20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecdd1fc58174421a9bfdd8f134ae6e23_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed5ecc368374169a71abc3cc9f49aa5_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdeb572f838a40fdaa6ba2d0bfd368c1_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i103121e7190f43fabe96184573d85e5a_I20190501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7abc563c49034717a7c3322581f18eb8_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5936ba61c97f46c9abe460c3748fc302_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36fa0eb7334c455888e30aa07d6532a5_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c39c1b02c34d54a55c972e504f4f10_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb3cbb6159547ebb60630ca78155e84_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="silk:DebtInstrumentRateScenarioAxis">silk:RateScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b6bd6e7c434a7c95a35ff5a9531de1_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="silk:DebtInstrumentRateScenarioAxis">silk:RateScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa3b08c2ee1f40f29b52fda52abcfcbd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb1a73d258b47deacf93ec34c1d3916_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="silk:DebtInstrumentRateScenarioAxis">silk:RateScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65ad62ac27904958945aa2aa614f9585_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="silk:DebtInstrumentRateScenarioAxis">silk:RateScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb2c47acc6f844248688d675a456ddad_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:SuccessFeeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i907e8be526f045dba75ef70a204b7872_D20201029-20201029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-29</xbrli:startDate><xbrli:endDate>2020-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i907e1c4c4cf446efb027c2d919844c24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c3729f2464e47ab98755aaf4d5239ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66136b6bed6c411a82f197a4d3385b6a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62faf7ea655c489e8fb700ba32e5a72a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib33b63c59a7142df9c638019a56d357b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb165d229e594aed955a8ab2194b3631_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8035f9f9ec5d4b46adb98b3f8e400ff1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>silk:vote</xbrli:measure></xbrli:unit><xbrli:context id="i603554706e704e14a87cd579bfc1f1cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionExercisedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i096b9866423f47bfbd8c84a4319b04fc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionExercisedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbdb361087f54a5fbd3ebc590fca7604_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ab7ad3a56f48299ce1b6e914d7b413_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480f0a71d7df4da79168f1094a28dc8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09057e7a1c6b4809a7a1631278acc9b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf29cfa1d6194741a8ec14f28d1e4578_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1e51514e02474c89b155e4a5550726_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae992978a7d4deda30dcb028e032db0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic097536e6675494dbb4e914fc5bcd668_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i360f4f24adde40d8b482c84b661efed8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i470f2ac36ec446a29f50d256c7548d9e_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i214a26dd5e864dbeba676287ebd8859d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f4737d591bc4039af44f3bd9c4891fd_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd542f1734634f0a802415b0d28a90a1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf45438ba5c4c2aa9a094bb5bd64ede_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1037c5333249bbbd1ae376d9910c53_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie77759ae85f849f99b4e3b1e0c06210e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a8b1f2479ef489b833a827057b3ee5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0182ac39bf451580f9e5a338dd2281_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708be08da99c40d39705d37410604fa8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:NonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c59c6933b34539813d0d966133cca9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i659d64912c544b77817ed68d2f7ce05c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea3f51adc9c4505b898323c41931f67_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490bf68acdbb4450bf64bafef197e4fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i715cd558a0134ebba2c8252d957a7ce6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2c087f244e24d669ad5f5b19aa67a98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3dc08fdedf4e33bd6817d15104fe6e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fdd1471eaa54f92a52745ec56a48110_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8945e1adfb3b4ab09fa3fa5891d357c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c8d5b84586400b86587503b81287f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc46ca644c744b70aac67133ea9f52f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36011f19453e484790ec3753ef0eb829_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b4be470462491987f832241f434403_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b5473c83d5146e19f1b3858891c78b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9b2814a79c4dd08d65788445d6db8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74888ea9613946dd8a212a7d91cda76a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4ed4e74601414e92a601aa67b10327_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd02705d3de468ba9f3a47573c3dde9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia49153bfeb6f42bdb3736ba316591747_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0a90922eee49f89e3692455daf46fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia787b8a99022442987a046c7b0ae1e90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7bb98d16e744c886f33a907325392b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1ab64a372d04ae8b13ae564c7b1d519_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8621a9d17f8c4c759e18a0b9f4998461_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d07d3d83db94418805af6f5704d41c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a74532b17b4cbeb8fc651e11ede5be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a577dab858449659f2138be0247edb3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6691dffc917441fa983264255b9af82b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia05420dcc8d84d7787c80598f1ef5734_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4be24da3ca849f38e1fe9ffb7f6d2ba_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727cdef9482140249c0cb804bb673e7c_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i321ada78d4e34140b6929a8c206aa114_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ccbf5504e084eaeb3d0c1e776fc48ea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61cd83f3fb4e4e00b85103543a357d2e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15e03a06afa4556856fc6b3d9b3f42e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5fe2fcafee2473d94c7bb24e4dee4b2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39165a89986a4d5fa6d41c395d548242_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0309977823e74b8bb43d525e2c1862f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a041d34a42449bda00947d0a4241c05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb3f38d9acbf408aab3a51c21d51d4d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b5e58dd5ca74c379c458d4f10ca54f9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c8f7f1217049b0ac9c547630982b6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc78fcf595b4b6b89684111bad3f5a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79c98c09f3d34127ac384e5836c541d5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f27a96dad34a63a114ecba634391a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9290967454ec461ab5eab6e110e7984c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b062b857ecd47d58f12e164875b8b8e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a66f92a0c54ee4abd3a59a6da8d88b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0efe8bfdcede4d06a33afef06da15dc1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib74c8c93648e47c981153a6846f18a61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ee605997eef429381c095e0eaf512c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e58304a7fe546fa982e73d2e64be31d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3bb7213b7c542eb8d9d50fda0c137d5_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">silk:NeuroCoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c1f3c48bdb4a6ea8c16f7a38160b11_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">silk:NeuroCoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3380644612b74549867fb107a4a32b56_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">silk:NeuroCoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i326ed72d5faa4423a7380a120ab921a4_I20181217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">silk:NeuroCoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dca7000583a43869c1389cf6ac8d3d2_D20181217-20181217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">silk:NeuroCoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-17</xbrli:startDate><xbrli:endDate>2018-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea6234882cf424bb9e6d52bf97c9471_I20181217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e220b1dfe342f2bad86c21ce171b0e_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa4295aab3c4fd19f5369890a74eb95_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3233352a710471b8cc9cd69d34e703f_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01975501aeed437d860ef21eff36403e_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39997c7638c9433ca55684c8301b703a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="silk:LossContingencyReceivableTypeAxis">silk:LossContingencyReceivableInventoryHeldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79e280b94b7942cf91af6b3df5b509da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="silk:LossContingencyReceivableTypeAxis">silk:LossContingencyReceivableInventoryInProcessOfRecallMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i637453fe4b3642f9aa11f791b415ea8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="silk:LossContingencyReceivableTypeAxis">silk:LossContingencyReceivableDirectCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4fa9083290c443aa2e74fa476c35c40_D20210226-20210226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-26</xbrli:startDate><xbrli:endDate>2021-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief509a5e508844398122e436481d4a37_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218af6b8a4044434bc70398d3d719486_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d98a257f74a444e815e2acdecdd06e8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4bfdb1605af43cb8614f33f8d1a6537_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2401d30b2e994f16b50e95b7e08d7413_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe63293076b44c03b2d249cf8f39228c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515fd7b45a0d4244a919c02bb006219a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1814d8a10cb43efae417d1231483bf2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_1"></div><div style="min-height:0pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:right"><span><br/></span></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.736%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF84OQ_aea317ef-bd3a-4049-8f4f-c708dc0ae7e7">10-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6N2JjYWRlZTEzZWU3NDY3OWE3Zjc4Nzc0OTA0NTQ4ZTQvdGFibGVyYW5nZTo3YmNhZGVlMTNlZTc0Njc5YTdmNzg3NzQ5MDQ1NDhlNF8wLTAtMS0xLTA_fe09ddb1-c74d-4eac-865d-fe6b5a09dbf0">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the fiscal year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8xMzE_c8d39cd2-e22c-48ef-8b4e-86afbc036f7a"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8xMzE_fa3a0bdf-0c2f-4409-9d9d-3a3f2157238c">December 31</ix:nonNumeric>, 2020</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> .</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NmM3ZGM4YzM1OWI1NDIwYmI1YTBkN2U2N2Q3OGRhMTkvdGFibGVyYW5nZTo2YzdkYzhjMzU5YjU0MjBiYjVhMGQ3ZTY3ZDc4ZGExOV8wLTAtMS0xLTA_b8f5e3f9-1aa4-4064-a5a9-f46ecd561d50">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the transition period from      to      </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yODI3_2828ffce-141e-4a54-9b43-912af953407c">001-38847</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.736%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:15pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yMjI_41fcbabe-9c27-4427-9246-62ebc6482205">SILK ROAD MEDICAL, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.736%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NjY5OWM1MjA0ZjMwNGI0OGFlMDEyZjEyNjFmMTdmMzcvdGFibGVyYW5nZTo2Njk5YzUyMDRmMzA0YjQ4YWUwMTJmMTI2MWYxN2YzN18wLTAtMS0xLTA_9a475793-42a8-44c7-897f-c7d2faacb8a6">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3841</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NjY5OWM1MjA0ZjMwNGI0OGFlMDEyZjEyNjFmMTdmMzcvdGFibGVyYW5nZTo2Njk5YzUyMDRmMzA0YjQ4YWUwMTJmMTI2MWYxN2YzN18wLTItMS0xLTA_ae818f7a-79fb-4561-9c73-53e73e8de316">20-8777622</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Primary Standard Industrial<br/>Classification Code Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.58pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yODc_dd00d5b2-6779-4918-8e28-0e3c00dcf20d">1213 Innsbruck Dr.</ix:nonNumeric> <ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yOTA_b31c26ac-1b76-430d-aa45-391a3b483ab8">Sunnyvale</ix:nonNumeric>, <ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yOTQ_ac01e3e7-f823-4ffc-ad0b-6d0cb6732bb0">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yOTc_9b559257-fcba-4ec2-8473-dcd9c8bed31b">94089</ix:nonNumeric>, (<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8zMDI_d5a303a5-2225-4386-8464-48023f5ab8d5">408</ix:nonNumeric>) <ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8zMDY_11a7ad66-8c22-41a7-bad3-d0ee2d5ce0f4">720-9002</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.58pt;font-weight:700;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.736%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NDk3OWIyZTk0Njk0NGZmMDk4MTIyZTQxYjNiOGFiYTMvdGFibGVyYW5nZTo0OTc5YjJlOTQ2OTQ0ZmYwOTgxMjJlNDFiM2I4YWJhM18xLTAtMS0xLTA_297a6d7e-548e-4e72-9699-fc9fc5576417">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NDk3OWIyZTk0Njk0NGZmMDk4MTIyZTQxYjNiOGFiYTMvdGFibGVyYW5nZTo0OTc5YjJlOTQ2OTQ0ZmYwOTgxMjJlNDFiM2I4YWJhM18xLTEtMS0xLTA_62f23321-0436-4e44-a895-ab3c0be9cd1c">SILK</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NDk3OWIyZTk0Njk0NGZmMDk4MTIyZTQxYjNiOGFiYTMvdGFibGVyYW5nZTo0OTc5YjJlOTQ2OTQ0ZmYwOTgxMjJlNDFiM2I4YWJhM18xLTItMS0xLTA_02d7e0d6-a79d-4458-8fdb-cfce51e2af68">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8zMjk4NTM0ODk1NDEw_127e01f3-cb2f-40d8-b9fa-724d6042b28f">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#9746;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF84Mjk_fa607275-0fe1-42e8-9b3a-ffbe7b76caef">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8xMTg0_4a8be9d2-dfcb-4d43-aea5-9e4ced74ad30">Yes</ix:nonNumeric>&#160;&#160;&#9746;   No&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8xNTEw_04473caa-1770-44bd-b17c-9ed1e8a68be6">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6ODZkY2QxYTI3ZTAxNGExYmFjNWFkYmJiYzA2N2JlYmQvdGFibGVyYW5nZTo4NmRjZDFhMjdlMDE0YTFiYWM1YWRiYmJjMDY3YmViZF8wLTAtMS0xLTYyNTk_9115d21a-0874-4b7f-846e-37359f0e40d9">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6ODZkY2QxYTI3ZTAxNGExYmFjNWFkYmJiYzA2N2JlYmQvdGFibGVyYW5nZTo4NmRjZDFhMjdlMDE0YTFiYWM1YWRiYmJjMDY3YmViZF8xLTQtMS0xLTA_ebc9757d-3491-42a0-9f9b-f93d25308db2">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6ODZkY2QxYTI3ZTAxNGExYmFjNWFkYmJiYzA2N2JlYmQvdGFibGVyYW5nZTo4NmRjZDFhMjdlMDE0YTFiYWM1YWRiYmJjMDY3YmViZF8yLTEtMS0xLTA_43128282-0b4e-4e6b-9740-2201669abf5e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#9744;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8zMjk4NTM0ODk1NDA4_44367f83-51fc-4f05-89ef-bfdbb76271e7">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Y</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">es  <ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yMjU3_f841a1d3-6699-4fed-ad08-fcad6f52dfea">&#9744;</ix:nonNumeric> No  &#9746;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="i57b888d1afed467eb6e8156312b035a4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yMzg1_c201a84f-73fb-45de-80ef-ed57af4fa4f9">1.4</ix:nonFraction>&#160;billion as of June 30, 2020 based on the closing sale price of the registrant&#8217;s common stock on the NASDAQ Global Select Market on such date.  Shares held by persons who may be deemed affiliates have been excluded.  This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February 26, 2021, the number of outstanding shares of the registrant's common stock, par value $0.001 per share, was <ix:nonFraction unitRef="shares" contextRef="ifb6f5fd1061f4f56989bc588eebd18c4_I20210226" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yODIy_58f65cc0-fcac-4936-b1ed-6189af24cb8e">34,365,398</ix:nonFraction>.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_10">Part I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_16">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_16">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_19">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_19">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_22">Item 2. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_22">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_25">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_25">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_28">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_28">80</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_31">Part II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_34">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_34">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_37">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_37">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_37">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_40">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_40">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_43">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_43">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_43">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_46">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_46">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_46">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_133">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_133">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_133">136</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_136">Item 9A.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_136">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_136">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_139">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_139">138</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_142">Part III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_145">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_145">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_145">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_148">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_148">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_148">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_151">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_151">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_151">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_154">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_154">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_154">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_157">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_157">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_157">140</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_160">Part IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_163">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_163">Exhibits and Financial Statement Schedule</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_163">141</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_169">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_169">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_169">144</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_172">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_172">144</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.020%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAUTIONARY NOTES REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to conduct further clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and expected timeline related to our products, or developing new products, to address additional indications or to obtain regulatory approvals or clearances or otherwise;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected use of our products by physicians;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the number of procedures that will be performed with our products, the number of physicians we expect to train, and the number of our sales territories;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and expand regulatory clearances for our current products and any new products we create;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected growth of our business and our organization;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding government and third-party payer coverage and reimbursement;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain and recruit key personnel, including the continued expansion of our sales and marketing infrastructure;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain an adequate supply of materials and components for our products from our third-party suppliers, most of whom are single-source suppliers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture sufficient quantities of our products with sufficient quality;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our products and our business;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to expand our business into new geographic markets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our compliance with extensive Nasdaq requirements and government laws, rules and regulations both in the United States and internationally;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and develop new and planned products and/or acquire new products;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the impact of the COVID-19 pandemic on our business;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments and projections relating to our competitors or our industry; and</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intended use of net proceeds from our public offerings.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management&#8217;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Annual Report on Form 10-K may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements speak only as of the date of this Annual Report on Form 10-K. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K to conform these statements to actual results or to changes in our expectations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed with the SEC as exhibits to this Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I</span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_13"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a medical device company focused on reducing the risk of stroke and its devastating impact.  We believe a key to stroke prevention is minimally-invasive and technologically advanced intervention to safely and effectively treat carotid artery disease, one of the leading causes of stroke.  We have pioneered a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which we seek to establish as the standard of care.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines the benefits of innovative endovascular techniques with fundamental surgical principles.  TCAR using our portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.  We are the first and only company to obtain FDA approvals, secure specific Medicare reimbursement coverage, and commercialize products engineered and indicated specifically for transcarotid use, in patients who require carotid revascularization and are at high risk for adverse events from carotid endarterectomy and who meet certain treatment criteria.  As of December 31, 2020, more t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">han 26,000 TC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AR procedures have been performed globally, including more than 10,300 in the United States in 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carotid artery disease is the progressive buildup of plaque causing narrowing of the arteries in the front of the neck, which supply blood flow to the brain.  Plaque can embolize, or break away from the arterial wall, and travel toward the brain and interrupt critical blood supply, leading to an ischemic stroke.  Carotid artery disease is one of the leading causes of stroke, and stroke is one of the most catastrophic, debilitating, and costly conditions worldwide.  We believe the best way to mitigate the mortality, morbidity and cost burden of stroke is to prevent strokes in the first place.  Clinical evidence has demonstrated that with proper diagnosis and treatment, stroke due to carotid artery disease is mostly preventable. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there were approximately 4.3 million people with carotid artery disease in the United States in 2019, with an estimated 432,000 new diagnoses in 2019, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and existing treatment options have substantial safety and effectiveness limitations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main goal of treating carotid artery disease is to prevent a future stroke.  Unfortunately, one of the main complications of existing treatments for carotid artery disease is causing a stroke, along with other procedure-related adverse events.  When intervention beyond medical management is warranted, the current standard of care for reduction in stroke risk is an invasive carotid revascularization procedure called carotid endarterectomy, or CEA.  To perform a CEA, a physician makes a large incision in the neck, cuts the carotid artery open, and then removes the plaque from inside the vessel.  CEA was first performed in 1953, and while generally effective at reducing stroke risk in the long term, large randomized clinical trials have demonstrated that CEA is associated with a significant risk of adverse events, including cranial nerve injury, heart attack, wound complications, and, in some cases, even stroke and death.  These risks are elevated in certain patient populations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the invasiveness of CEA, transfemoral carotid artery stenting, or CAS, was developed in the 1990s.  The CAS procedure uses minimally-invasive catheters traveling from a puncture site in the groin to place a stent in the carotid artery in the neck to restrain the plaque and prevent embolization that could cause a stroke.  While both CEA and CAS have been clinically demonstrated to reduce long-term stroke risk, randomized clinical trials and other studies have shown that CAS, relative to CEA, often results in an almost two-fold increase in stroke within 30 days following treatment, which we believe is due to inadequate protection of the brain.  We believe this represents an unacceptable trade-off relative to the current standard of care of CEA.  As such, after almost 30 years of development, CAS has achieved limited adoption and narrow reimbur</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sement coverage in the United States.  CEA remains the standard of care and represented approximately 82% of the approximately 166,000 carotid revascularization </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures performed in the United States in 2019. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, we believe reducing the rate of morbidity and mortality of CEA is an unmet clinical need that continues to persist.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TCAR is a minimally-invasive procedure that addresses the morbidity of CEA and the 30-day stroke risk of CAS while maintaining a reduction in long-term stroke risk beyond the first 30 days.  TCAR starts with a small incision in the neck slightly above the collarbone, otherwise known as transcarotid access, through which our ENROUTE&#174; Transcarotid Stent System, or ENROUTE stent, is placed during a period of temporary high-rate blood flow reversal that is enabled by our ENROUTE&#174; Transcarotid Neuroprotection System, or ENROUTE NPS. Blood flow reversal directs embolic debris that could cause a stroke away from the brain, while the stent braces the plaque and prevents embolization to afford a reduction in long-term stoke risk.  We believe that by meeting the standard of brain protection and reduction in 30-day and long-term stroke risk afforded by CEA, while providing benefits commensurate with an endovascular, minimally-invasive approach, TCAR could become the preferred alternative for carotid revascularization.  Additionally, we believe that as our technology becomes more widely adopted, TCAR may become a compelling alternative for patients who are treated with medical management alone each year.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the estimated</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 432,000 ne</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">w carotid artery disease diagnoses that occurred in the United States in 2019, we believe a total annual U.S. market opportunity of approximatel</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y $2.8 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">billion exists for our portfolio of TCAR products.  There were approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166,000 ca</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rotid revascularization procedures performed in 2019, which we estimate to represent a market conversion opportunity greater th</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an $1.1 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">billion.  More than&#160;10,300</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TCAR procedures were performed in 2020 in the United States using our products, representing just over</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2% </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of annual diagnoses of carotid artery disease.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety, effectiveness and clinical advantages of TCAR have been demonstrated in multiple clinical trials, post-market studies and registries that have been published in peer-reviewed journals representing outcomes in more than 7,000 patients to date.  The results of our U.S. pivotal trial, ROADSTER, reflect the lowest reported 30-day stroke rate for any prospective, multicenter clinical trial of carotid stenting of which we are aware.  Our ROADSTER 2 post-approval study was completed in 2019 and showed a thirty-day stroke rate of 0.6% in the FDA-analysis population.  Additionally, data on real-world outcomes of TCAR relative to CEA and CAS have continued to accrue through the ongoing TCAR Surveillance Project, or TSP, which is an ongoing open-ended registry sponsored by the Society for Vascular Surgery through the Vascular Quality Initiative, or VQI.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   In a VQI study published in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of the American Medical Association</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in December 2019, a propensity matched analysis of 3,286 high surgical risk patients in each cohort showed in-hospital stroke or death was 1.6% for TCAR versus 3.1% for CAS. The differences favoring TCAR persisted through 30 days and 1 year.  In a VQI study published in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annals of Surgery</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in September 2020, a propensity matched analysis of 6,384 high surgical risk patients in each cohort demonstrated significant reduction in the risk of postoperative myocardial infarction and cranial nerve injury after TCAR compared to CEA, with no differences in the rates of in-hospital stroke/death (1.6% TCAR and 1.6% CEA).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture the ENROUTE NPS and distribute our portfolio of TCAR products from our facility in Sunnyvale, California.  We market and sell our products in the United States through a direct sales organization consisting o</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f 44 sales representatives, known as area managers, or AMs, and 73 clinical support specialists, known as therapy developme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt specialists, or TDSs, as of December 31, 2020, that are focused on driving adoption of TCAR among the approximately 2,750 physicians and 750 hospitals in the United States that we believe are responsible for approximately 80% of carotid revascularization procedures each year.  While our current commercial focus is on the U.S. market, our ENROUTE NPS and ENROUTE stent have obtained CE Mark approval, allowing us to commercialize in Europe in the future.  We are also pursuing regulatory clearances in China and Japan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TCAR is reimbursed based on established current procedural technology, or CPT, codes and International Classification of Diseases, or ICD-10, codes related to carotid stenting that track to Medicare Severity Diagnosis Related Group, or MS&#8208;DRG classifications.  In September 2016, the Centers for Medicare and Medicaid Services, or CMS, made coverage available for TCAR in symptomatic and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asymptomatic patients at high risk for adverse events from CEA, or high surgical risk, treated at facilities participating in the Society for Vascular Surgery&#8217;s TCAR Surveillance Project using FDA-cleared and approved transcarotid devices.  Our ENROUTE NPS and stent are currently the only FDA-cleared and approved transcarotid devices.  Carotid artery disease is most often a disease of the elderly and, as such, CMS is the primary payer for carotid revascularization procedures, and we estimate that the high surgical risk patient population represents approximately two-thirds of the treated patient population.  We plan to pursue expansion of FDA labeling for the ENROUTE stent, currently indicated for use in certain patients at high risk for adverse events from CEA, and, upon FDA approval of broader indication(s), pursue CMS coverage for our products in the remaining one-third of treated patients who qualify under such broader indication(s), including patients who are deemed standard surgical risk.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced considerable growth since we began commercializing our products in the United States in late 2015.  Our revenue increased to</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $75.2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million for the year ended December 31, 2020 compared to $63.4 million and $34.6&#160;million for the years ended December 31, 2019 and 2018, respectively, representing growth of&#160;19% and 83%, respectively.  Our net losses were $47.4 million, $52.4 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$37.6 m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">illion for the years ended December 31, 2020, 2019 and 2018, respectively.  As of December 31, 2020, 2019 and 2018, our accumulated deficit was $238.9&#160;million, $191.5 million and $139.1 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Product Portfolio</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TCAR is enabled by our proprietary portfolio of TCAR products designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.  In addition to enabling the safety and effectiveness of TCAR, our proprietary products are specifically designed to enable a short learning curve, consistent ease of use and physician comfort.  Our products are also currently the only devices cleared and approved by the FDA specifically for transcarotid use.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, our product portfolio consists of the following four single use components.  Based on our experience, the full product portfolio is used in the majority of TCAR procedures.  In the future we plan to continue to expand our product portfolio to include additional tools and devices to support the TCAR procedure.</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ENROUTE Transcarotid Neuroprotection System</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="silk-20201231_g1.jpg" alt="silk-20201231_g1.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"/></div></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Used to directly access the common carotid artery and initiate temporary blood flow reversal</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Allows for flow modulation enabling lesion imaging and patient tolerability</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Only FDA-cleared transcarotid neuroprotection system </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ENROUTE Transcarotid Stent System</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="silk-20201231_g2.jpg" alt="silk-20201231_g2.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:138px"/></div></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Self-expanding, self-tapering stent that conforms to pa</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">tient </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Transcarotid delivery system improves the accuracy and the overall ergonomics of the TCAR procedure </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Only FDA approved transcarotid stent system </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ENHANCE Transcarotid Peripheral Access Kit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="silk-20201231_g3.jpg" alt="silk-20201231_g3.jpg" style="height:14px;margin-bottom:5pt;vertical-align:text-bottom;width:158px"/></div></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Used to gain initial access to the common carotid artery </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Only access kit specifically designed for use in the common carotid artery</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ENROUTE 0.014&#8221; Guidewire</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="silk-20201231_g4.jpg" alt="silk-20201231_g4.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:87px"/></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Main conduit for navigating and crossing the target lesion for delivery of interventional devices</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Short working length and proprietary tip designed for TCAR</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ENROUTE NPS (510(k) K153485) is cleared for transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis and who have appropriate anatomy, and the ENROUTE stent (PMA P140026) is approved for use in conjunction with the ENROUTE NPS for the treatment of patients at high risk for adverse events from CEA who require carotid revascularization and meet certain criteria.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Data</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety, effectiveness and clinical advantages of TCAR have been demonstrated in multiple clinical trials, post-market studies and registries that have been published in peer-reviewed journals representing outcomes in more than 7,000 patients to date.  Our first-in-human trial, the PROOF Study, was initiated as a feasibility study to assess the safety and performance of the ENROUTE NPS and later was expanded to support CE marking of the ENROUTE NPS.  Data from the PROOF Study were also used to support FDA approval of the investigational device exemption, or IDE, for the ROADSTER Study.  Data from the pivotal cohort of the ROADSTER Study supported FDA 510(k) clearance of the ENROUTE NPS, and a subset of the data supported pre-market, or PMA, approval of the ENROUTE stent.  The results of the pivotal phase of the ROADSTER study were published in November 2015 in the Journal of Vascular Surgery.  We have completed a post market approval study, ROADSTER 2, which was designed to evaluate the outcomes in TCAR procedures using the ENROUTE stent used in conjunction with the ENROUTE NPS in broader, &#8220;real&#8209;world&#8221; use in 692 patients.  Data on TCAR outcomes also continues to accrue through the Society for Vascular Surgery-sponsored TCAR Surveillance Project, an ongoing real&#8209;world, open-ended regis</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">try.  The VQI 2020 Annual Report stated close to 16,000 TCAR procedures have been submitted to the registry as of December 31, 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Key Clinical Trials</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PROOF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ROADSTER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ROADSTER 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TCAR Surveillance Project</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Study Type</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First in Human<br/>CE Marking<br/>DW-MRI Sub-Study</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Pivotal IDE Study</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Post-Approval Study</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Real world observation </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patients</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 pivotal<br/>56 DW-MRI Sub-<br/>Study</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 Lead-in         141 Pivotal<br/>78 Continued<br/>Access<br/>52 Stent Sub-<br/>Study</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">692</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Open Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Profile</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">High Surgical Risk and Standard Surgical Risk</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">High Surgical Risk</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">High Surgical Risk</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">High Surgical Risk</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status/Publication</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complete<br/>J Endovasc Ther.  2017 Apr;24(2):265-270</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complete<br/>J Vasc Surg.  2015 Nov;62(5):1227-34<br/>(pivotal cohort only)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complete       Stroke 2020;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">16,000 patients as of December 31, 2020 Annals of Surgery: September 15, 2020                                        Complete Journal of the American Medical Association: December 2019    </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Complete Journal of the American College of Surgeons: January 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carotid Stent Systems Used</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CE Marked Carotid Stents, including the Cordis Precise Stent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA Approved Carotid Stents, including the Cordis Precise Stent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ENROUTE Transcarotid Stent System</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ENROUTE Transcarotid Stent System</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of TCAR Clinical Trial Outcomes </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:36.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROOF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pooled ROADSTER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROADSTER 2</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ITT population</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ITT population</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Per-protocol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ITT population</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Per-protocol</span></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stroke at 30 days</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All stroke</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All stroke and death</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other adverse events at 30 days</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Myocardial infarction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cranial Nerve Injury*</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Acute)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NR</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cranial Nerve Injury</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(persisting at 6 months)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 %**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NR</span></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Procedural information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mean procedure time (mins)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mean length of stay </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(days)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Only tabulated for ITT population.</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Evaluated at 90 days.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PROOF First-in-human Clinical Trial</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first-in-human trial, the PROOF Study, was a single-arm trial conducted at one trial site in Europe from 2009 to 2012.  The PROOF Study was initiated as a feasibility study to assess the safety and performance of the ENROUTE NPS in a limited number of patients, initially enrolling 10 patients.  The PROOF Study was later expanded to 75 patients to collect the clinical data necessary to support CE marking of the ENROUTE NPS.  Data from the PROOF Study were also used to support FDA approval of the IDE for the ROADSTER Study.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PROOF Study enrolled patients that were classified as high surgical risk, as well as patients classified as standard surgical risk.  The results from the PROOF Study demonstrated that TCAR was technically feasible and resulted in a minor stroke incidence of 1.3% within 30 days (zero major strokes), which was significantly lower than that reported for CAS in prior clinical trials.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, a sub-study of 56 patients underwent pre- and post-procedure diffusion-weighted magnetic resonance image scanning, or DW-MRI, to detect new white lesions on the ipsilateral side of the brain as a sensitive surrogate marker of microemboli and brain injury.  The analysis resulted in only 18% of the treatment population presenting with ipsilateral new white lesions, which was also comparable to that reported for CEA in prior clinical trials and significantly less than that reported in prior CAS trials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ROADSTER 2 U.S. Post Market Approval Study</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ROADSTER 2 Post Approval Study was a condition of PMA approval for the ENROUTE stent.  The study evaluated the outcomes in TCAR using the ENROUTE stent in conjunction with the ENROUTE NPS in broader, &#8220;real world&#8221; use.  Like the sub-analysis from the ROADSTER Study that led to PMA approval of the ENROUTE stent, the primary endpoint, which was assessed on a PP basis, was the rate of procedural success at 30 days in high surgical risk patients with a three year minimum life expectancy.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ROADSTER 2 post approval study enrolled 692 patients at 42 sites.  61.8% of the participating patients were treated by physicians that did not participate in the ROADSTER Study.  The FDA mandated that at least 70% of the sites be new sites.  Enrollment commenced in 2015.  Enrollment and final 30-day </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">follow-up assessments were completed in 2019 and the results were published in the journal </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stroke</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in August 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ROADSTER 2 final report submitted to the FDA in October 2019, data on 632 patients treated PP were presented. The procedural success rate in ROADSTER 2 was 97.9%.  The lower bound of the 2-sided 95% exact binomial confidence intervals of the observed procedural success rate significantly exceeds the a priori threshold of 85% (p&lt;0.0001). The primary endpoint of ROADSTER 2 was met and, as a result the rate of procedural success in ROADSTER 2 compares favorably to the rate of procedural success in the in the ROADSTER Sub-Study population which was 98.1%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from a subset of ROADSTER 2 subjects (n=155) is being analyzed to assess the incidence of ipsilateral stroke from day 31 through day 365 post-procedure.  These data are expected to be published in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Society for Vascular Surgery&#8217;s TCAR Surveillance Project</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCAR Surveillance Project was implemented in September 2016 as an initiative of the Society for Vascular Surgery Patient Safety Organization.  The TCAR Surveillance Project is an ongoing, open-ended registry that was designed to monitor the safety and effectiveness of transcarotid stents placed directly into the carotid artery while reversing blood flow within the carotid artery.  It is intended to compare TCAR with CEA in centers that participate in the Society for Vascular Surgery Vascular Quality Initiative, or VQI.  The TCAR Surveillance Project was reviewed by the FDA and deemed to be a scientifically valid extension study of TCAR, thereby allowing CMS to provide coverage within the parameters of the existing National Coverage Determination.  The Society for Vascular Surgery VQI is designed to improve the quality, safety, effectiveness and cost of vascular health care by collecting and exchanging information, and it is available to all providers of vascular health care and their respective institutions.  Because data from CAS procedures are also collected in the Society for Vascular Surgery VQI, comparisons of TCAR to CAS can also be made.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible patients must meet the inclusion criteria specified for the TCAR Surveillance Project.  Generally, patients must be at high surgical risk and must have had their TCAR procedure performed using any FDA-cleared transcarotid proximal embolic protection device utilizing flow reversal, such as our ENROUTE NPS, and any FDA-approved transcarotid stent, such as our ENROUTE stent</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the ENROUTE stent and the ENROUTE NPS are the only such devices cleared and approved by the FDA. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TCAR procedures entered into the Society for Vascular Surgery VQI CAS registry for the TCAR Surveillance Project are eligible for reimbursement by Medicare if the patients meet the requirements set forth above.  We believe the TCAR Surveillance Project represents a unique collaboration between a physician specialty society, the FDA and CMS.  We believe it also marks the first time that CMS has granted broader reimbursement for a stent-based treatment paradigm for carotid artery disease in a registry not managed by industry.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCAR Surveillance Project is intended to be a repository for TCAR procedures and outcomes data to broaden the clinical evidence base for TCAR.  TCAR is one of many surgical and endovascular procedures that is tracked by the Society for Vascular Surgery VQI.  Over time, it is expected that physicians and academic researchers will query the database and produce publications in peer review journals, and present data at medical conferences, regarding the safety and effectiveness of TCAR in real world use.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary outcome measure of the TCAR Surveillance Project is one-year ipsilateral stroke or death.  The TCAR Surveillance Project also tracks in-hospital stroke, death and myocardial infarction.  Other secondary outcomes, such as cranial nerve injury and re-intervention, are also being reported.  For the secondary outcome measures, any stroke will be counted and in-hospital stroke events are not limited to the ipsilateral side.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Society for Vascular Surgery Vascular Quality Initiative 2020 Annual Report, it was reported that 421 centers have contributed almost 16,000 TCAR procedures to the CAS VQI registry as of December 31, 2020.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TCAR Surveillance Project: TCAR vs. CAS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a study published in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of the American Medical Association</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in December of 2019, TCAR was compared to CAS in a propensity score matched analysis with 3,286 pairs. TCAR was associated with a lower risk of in-hospital stroke or death (1.6% vs 3.1%; P &lt; .001), stroke (1.3% vs 2.4%; P = .001), and death (0.4% vs 1.0%; P = .008). As expected with two minimally invasive procedures, there was no statistically significant difference in the risk of perioperative  MI between the two cohorts (0.2% for TCAR vs. 0.3% for TFCAS; P = .47). At 1 year using Kaplan-Meier life-table estimation, TCAR was associated with a lower risk of ipsilateral stroke or death (5.1% vs 9.6%; hazard ratio, 0.52 [95%CI, 0.41 to 0.66]; P &lt; .001). TFCAS was associated with more radiation (median fluoroscopy time, 5 minutes [interquartile range {IQR}, 3 to 7] vs 16 minutes [IQR, 11 to 23]; P &lt; .001) and more contrast usage (median contrast used, 30 mL [IQR, 20 to 45] vs 80 mL [IQR, 55 to 122]; P &lt; .001).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TCAR Surveillance Project: TCAR vs. CEA</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a study published in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annals of Surgery</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in September of 2020, TCAR was compared to CEA in propensity score matched high surgical risk patients who underwent TCAR and CEA for carotid artery stenosis (2016-2019). Propensity scores were calculated based on baseline clinical variables and used to match patients in the two treatment groups (n=6,384 each). The primary endpoint was the combined outcome of perioperative stroke and/or death. No significant differences were observed between TCAR and CEA in terms of in-hospital stroke/death [TCAR,1.6% vs. CEA,1.6%, P=.945], stroke [1.4% vs. 1.4%, P=.881], or death [0.4% vs. 0.3%, P=.662]. Compared to CEA, TCAR was associated with lower rates of in-hospital myocardial infarction [0.5% vs. 0.9%, P=.005], cranial nerve injury [0.4% vs. 2.7%, P&lt;.001], and post-procedural hypertension [13% vs.18.8%, P&lt;.001]. They were also less likely to stay in the hospital for more than one day [26.4% vs. 30.1%, P&lt;.001]. No significant interaction was observed between procedure and symptomatic status in predicting postoperative outcomes. At one year, the incidence of ipsilateral stroke or death was similar between the two groups [HR (95%CI): 1.09 (0.87-1.36), P=.44]. This propensity-score matched analysis demonstrated significant reduction in the risk of postoperative myocardial infarction and cranial nerve injury after TCAR compared to CEA, with no differences in the rates of stroke/death.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a study published in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annals of Surgery</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in September of 2020, TCAR was compared to CEA in propensity score matched high surgical risk patients who underwent TCAR and CEA for carotid artery stenosis (2016-2019). Propensity scores were calculated based on baseline clinical variables and used to match patients in the two treatment groups (n=6,384 each). The primary endpoint was the combined outcome of perioperative stroke and/or death. No significant differences were observed between TCAR and CEA in terms of in-hospital stroke/death [TCAR,1.6% vs. CEA,1.6%, P=.945], stroke [1.4% vs. 1.4%, P=.881], or death [0.4% vs. 0.3%, P=.662]. Compared to CEA, TCAR was associated with lower rates of in-hospital myocardial infarction [0.5% vs. 0.9%, P=.005], cranial nerve injury [0.4% vs. 2.7%, P&lt;.001], and post-procedural hypertension [13% vs.18.8%, P&lt;.001]. They were also less likely to stay in the hospital for more than one day [26.4% vs. 30.1%, P&lt;.001]. No significant interaction was observed between procedure and symptomatic status in predicting postoperative outcomes. At one year, the incidence of ipsilateral stroke or death was similar between the two groups [HR (95%CI): 1.09 (0.87-1.36), P=.44]. This propensity-score matched analysis demonstrated significant reduction in the risk of postoperative myocardial infarction and cranial nerve injury after TCAR compared to CEA, with no differences in the rates of stroke/death. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TCAR Surveillance Project: Learning Curve</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a study published in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of the American College of Surgeons</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in January 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kashyap, et al, examined the learning curve of TCAR performed by surgeons participating in the TCAR Surveillance </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Project.  The authors reviewed 3,456 TCAR procedures performed by 417 unique practitioners at 178 centers.  Patients were grouped into four levels based upon the physicians&#8217; experience with TCAR at the time of procedure: novice (1-5 cases), intermediate (6-20 cases), advanced (20-30 cases) and expert (&gt;30 cases). Of the patients analyzed, 41% of patients were treated by novice physicians, 40% of patients were treated by intermediate physicians, 9% of patients were treated by advanced physicians and 10% of patients were treated by expert physicians. There was no significant difference in the baseline characteristics by surgeon case experience with three exceptions; expert physicians were more likely to treat patients with moderate or severe congestive heart failure, novice and intermediate physicians were more likely to treat patients with prior CEA or CAS, and advanced and expert physicians were more likely to treat patients with CMS medical high-risk criteria. There was a statistically significant reduction in operative time (novice 81.7 mins, expert 59.6 mins; p&lt;.001) and flow reversal time (novice 12.2 mins, expert 9.7 mins; p&lt;.001) over the four levels. There was a decrease in fluoroscopy time and contrast usage up to the advanced level. Bleeding complications were significantly less frequent in the advanced and expert groups of physicians. There was no difference in the incidence of cranial nerve injury across the groups of physicians. Expert physicians were more likely to use local anesthesia compared to the other three categories of physicians.  There was no difference in the technical failure rate across the four categories of physicians.  The rate of composite stroke, stroke alone and death did not differ between the categories.  The authors noted that TCAR novices can achieve the same clinical outcomes as expert practitioners, while in comparison CAS requires more than 50 cases to achieve proficiency.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing and Planned TCAR Studies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Society for Vascular Surgery&#8217;s TCAR Surveillance Project, we have two enrolling studies focused on evaluating the incidence of new white lesions using DW-MRI following the TCAR procedure. This DW-MRI study is based in the European Union enrolling up to 50 patients to evaluate the rate of sub-clinical embolization, or incidence of new white lesions, as detected on DW-MRI in recently symptomatic patients.  The primary endpoint is the rate of new white lesions as seen on DW-MRI through the 30-day follow-up period compared to pre-procedure baseline white lesions.  The evaluation of the presence of new white lesions is conducted by an independent neuroradiologist.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a similar study at four hospitals in the United States and one in the European Union.  We have obtained Institutional review board and ethics committee approvals and enrollment began in June 2019.  The objective here is to also evaluate the incidence of post-procedure DW-MRI lesions compared to baseline in patients (asymptomatic or symptomatic) who were treated with the TCAR procedure.  The primary endpoint is the rate of ipsilateral new white lesions through 30 days with a maximum enrollment of up to 75 patients in this study.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Strategy</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are approximatel</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y 2,750&#160;physicians that perform an estimated 80% </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of annual carotid revascularization procedures in the United States.  Vascular surgeons, who we believe represent the specialty most frequently responsible for managing the care of and receiving referrals for patients with carotid artery disease, are skilled in endovascular procedures and our sales, marketing, professional education and medical affairs efforts are focused on driving adoption and supporting their practice development by offering them an innovative, safe, effective and minimally-invasive alternative for treating carotid artery disease.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we market and sell our portfolio of TCAR products through a direct sales organization consisting </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 44 sales representatives, known as area managers, or AMs, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December 31, 2020.  The AMs are complemented by one or more Therapy Development Specialists in each territory.  Our sales professionals have substantial experience launching and establishing new disruptive therapies and converting open surgical procedures to minimally-invasive alternatives.  We primarily market our products directly to vascular surgeons, their staffs, operating room managers and hospital administrators.  We also market to other specialists with experience in CEA and/or CAS with the appropriate skill set for TCAR, including neurosurgeons, cardiothoracic surgeons and non-surgical interventionalists in radiology, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">neuroradiology and cardiology.  We do not currently sell our products in markets outside the United States.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AMs are responsible for developing territory business plans, targeting and opening new accounts, promoting the benefits of TCAR and our products, and driving adoption and penetration of TCAR. In addition, they help physicians and their staff to build TCAR programs, drive certain referral initiatives, and provide resources to help with practice development, reimbursement and patient education. Together with the TDSs, they also support the training and proper use of our TCAR portfolio of products and provide clinically consultative support for patient selection, pre-procedure planning, procedure support, and post-procedure care. As we continue to grow the size of our U.S. sales organization, with a focus on increasing adoption of TCAR by existing customers and expanding our current customer base, we expect to focus on adding a strategic mix of area managers and therapy development specialists. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we support our sales organization with marketing and market and practice development initiatives.  We plan to continue to expand and enhance our marketing and analytics capabilities to support our growing commercial organization and customer base.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Professional Education and Sales Training </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on developing strong relationships with our customers and devote significant resources to training and educating physicians in the use of TCAR and our associated products.  Our Office of Medical Affairs leads our physician education and training programs in addition to disseminating the scientific information and clinical data supporting TCAR.  The Office of Medical Affairs also leads compliance activities.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our practice is to require physicians to complete a training program before performing TCAR, which is also a regulatory requirement derived from the PMA approval of the ENROUTE stent.  To facilitate training, we have developed a robust training course including clinical and procedural details as well as hands-on workshops designed to provide the highest potential for successful outcomes.  We conduct physician training courses in large group, in-person formats as well as virtual and small group, socially distanced formats as needs have dictated during the COVID-19 pandemic.  We also provide training through physician proctors on an as needed basis.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we have trained and certified approximately 1,800 physicians in the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the Office of Medical Affairs, our highly specialized area managers and therapy development specialists, along with other key employees, receive in-depth training and develop a thorough understanding of carotid artery disease, patient selection, imaging interpretation, procedure planning, reimbursement and regulatory policies to meaningfully support our customers and maintain compliance.  Our extensive training and continuous education program consists of foundational training, procedure observation, and sales skills development.  Our personnel are selected based on their focus on patient outcomes and the entire customer experience in addition to their technical aptitude.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since achieving regulatory clearances and approvals for our portfolio of TCAR products, we have made significant progress securing reimbursement codes and payer coverage.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the ROADSTER trial, the Society for Vascular Surgery helped to guide modifications of existing CPT reimbursement coding descriptions to ensure their applicability to TCAR.  In 2015, we also confirmed with CMS that TCAR, like CAS, was considered under the purview of the National Coverage Determination 20.7, or NCD, for Percutaneous Transluminal Angioplasty.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agency for Healthcare Research and Quality Healthcare Cost</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Utilization Project, CMS is the primary payer for carotid revascularization procedures, representing approximately 79% of the payer mix for CEA and CAS procedures in 2017. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TCAR is currently covered by CMS in high surgical risk patients who are symptomatic with greater than or equal to 70% stenosis.  As of September 2016, TCAR </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is also covered by CMS in the TCAR Surveillance Project for high surgical risk patients who are either symptomatic with greater than or equal to 50% stenosis or asymptomatic with greater than or equal to 80% stenosis.  We intend to seek FDA label expansion for our ENROUTE stent and CMS coverage for TCAR in standard surgical risk patients, as well as seek new and expanded coverage for TCAR in commercial payer coverage policies.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TCAR, like CAS, is only reimbursed by Medicare as an inpatient procedure and therefore reimbursed to hospitals under the DRG system.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three key aspects of reimbursement in the United States: coding, coverage and payment.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Coding</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> refers to distinct numeric and alphanumeric billing codes that are used by healthcare providers to report the provision of medical procedures and the use of supplies for specific patients to payers.  CPT codes are published by the American Medical Association and are used to report medical services and procedures performed by or under the direction of physicians.  Medicare pays physicians for services based on submission of a claim using one or more specific CPT codes.  Physician payment for procedures may vary according to site of service.  Hospitals are reimbursed for inpatient procedures based on Medicare Severity Diagnosis Related Group, or MS-DRG classifications derived from ICD-10-CM diagnosis and ICD-10-PCS codes that describe the patient&#8217;s diagnoses and procedure(s) performed during the hospital stay.  MS-DRGs closely calibrate payment for groups of services based on the severity of a patient&#8217;s illness.  One single MS-DRG payment is intended to cover all hospital costs associated with treating an individual during his or her hospital stay, with the exception of physician charges associated with performing medical procedures, which are reimbursed through CPT codes and payments.  </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> refers to the amount paid to providers for specific procedures and supplies.  Payment is generally determined by the specific CPT and billing code.  In addition, there may be separate numeric codes, under which the billing code is classified, to establish a payment amount.  </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Coverage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> refers to decisions made by individual payers as to whether or not to pay for a specific procedure and related supplies and if so, under what conditions, including specific diagnoses and clinical indications.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coding for Physicians</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Society for Vascular Surgery helped to guide an editorial change by the American Medical Association to CPT 37215 to be inclusive of TCAR.&#160; The Category I CPT code for TCAR, effective January 1, 2015, is CPT 37215: Transcatheter placement of intravascular stent(s), cervical carotid artery, open or percutaneous, including angioplasty, when performed, and radiological supervision and interpretation; with distal embolic protection.  Published CMS guidance confirms that reverse flow embolic protection systems, such as our ENROUTE NPS, qualify as distal embolic protection under this code.  This code has a 90-day global period.  Coverage and payment for CPT code 37215 is only available from CMS in the inpatient setting, subject to the terms of the National Coverage Determination Manual Section 20.7, and only available in facilities certified to have met CMS&#8217;s minimum facility standards for performing carotid artery stenting, which include local credentialing requirements.  Hospitals participating in the VQI are considered to meet CMS&#8217;s minimum facility standards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coding for Hospitals</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a&#160;number of appropriate ICD-10-CM diagnosis codes that describe occlusions and stenosis of carotid arteries for asymptomatic patients as well as cerebral infarction due to embolus and thrombus of carotid arteries for symptomatic patients, which establish medical necessity. &#160;As of October 1, 2020, the proper ICD-10-PCS procedure codes for TCAR includes a code for carotid stenting [e.g. 037(H/J/K/L)3(D/E/F/G)Z] and a code for extracorporeal reverse flow neuroprotection [e.g. X2(H/J) 336] and the appropriate MS-DRGs for TCAR are 034 when the patient presents with major complications or co-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">morbidities (MCC), 035 when the patient presents with a complication or co-morbidity (CC), and 036 for patients without complications or co-morbidities.   </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payment for Physicians</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 national average physician professional fee payment for CPT code 37215 is approximately $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,014</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We believe physicians feel this level of payment represents a reasonable amount for TCAR.  CEA procedures are reimbursed under CPT code 35301, for which the 2021 national average physician professional fee payment is $1,150.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payment for Hospitals</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The national unadjusted 2021 payment amounts for MS-DRGs 034, 035 and 036 are </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25,546, $15,022 and $11,898,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> respectively.&#160; Based on prior procedure volumes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assigned to MS-DRGs</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we estimate that the average payment amount across these three codes is $14,855 in 2021.&#160; These single MS DRG payments are intended to cover all hospital costs associated with treating an individual during his or her hospital stay, with the exception of physician charges associated with performing medical procedures. We believe that facilities feel this level of payment represents a reasonable amount for the treatment of patients with TCAR. CEA procedures are reimbursed under MS-DRGs 037, 038 and 039. &#160;We expect the national unadjusted 2021 payment amounts for MS-DRGs 037, 038 and 039 to be $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,922, $11,215 and $7,784,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> respectively.&#160; Based on prior procedure volumes, we estimate that the average payment amount across these three codes to be $10,198. &#160;The base payment amounts for MS-DRGs may vary greatly by individual acute-care hospital for a number of reasons including but not limited to geographic, teaching status, case-mix index, and use of electronic health record systems.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the NCD 20.7 for Percutaneous Transluminal Angioplasty, TCAR is TCAR is currently covered by CMS in high surgical risk patients who are symptomatic with greater than or equal to 70% stenosis.  The TCAR Surveillance Project is an FDA-approved extension study, and as such, as of September 2016, TCAR is also covered by CMS in the VQI&#8217;s TCAR Surveillance Project for high surgical risk patients who are either symptomatic with greater than or equal to 50% stenosis or asymptomatic with greater than or equal to 80% stenosis.  For billing purposes, facilities and providers can submit claims for the TCAR Surveillance Project using National Clinical Trial identifier NCT02850588.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients at high risk for adverse events from CEA are defined as having significant comorbidities or anatomic risk factors and would be poor candidates for CEA.  Symptoms of carotid artery stenosis include carotid transient ischemic attack, focal cerebral ischemia producing a nondisabling stroke, and transient monocular blindness.  The determination that a patient is at high risk for adverse events from CEA and the patient&#8217;s symptoms arising from carotid artery stenosis must be documented in the patient&#8217;s medical records.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has created a list of minimum standards modeled in part on professional society statements on competency.  All facilities must at least meet CMS standards in order to receive coverage for CAS, inclusive of TCAR, for high surgical risk patients.  Participation in the Society for Vascular Surgery&#8217;s Vascular Quality Initiative can provide evidence of compliance to these standards to CMS.The ENROUTE NPS and the ENROUTE stent are also included&#160;in the CREST-2 Companion Registry, or C2R, but not in the CREST 2 randomized clinical trial itself.  The objective of C2R is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial (clinicaltrials.gov ID NCT02089217).  Patient eligibility will include standard surgical risk and high surgical risk patients with symptomatic or asymptomatic carotid artery disease.  Patients will be followed for the occurrence of post-procedural complications.  The primary safety and quality endpoint for C2R is the occurrence of any stroke or death within the 30-day period following the stenting procedure.  The safety and quality results from C2R will guide selection of interventionists for participation in the CREST-2 randomized clinical trial.  Enrollment into C2R began in 2015 and will continue until publication of the primary results of the randomized trial.  Providers can bill CMS for TCAR patients enrolled in this registry using&#160;NCT02240862.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research, Development and Clinical Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities encompass basic research, clinical research and product development.  Our engineering team has mechanical engineering, project management, materials science, and prototyping expertise.  In addition, our clinical research organization has trial design and management, data collection and biostatistics expertise.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development efforts are currently focused on improving and expanding our portfolio of TCAR products and their labeled indications for use to further improve and simplify the treatment experience for a broad base of patients and physicians.  We have worked together with vascular surgeons and other physicians to develop our products.  We believe our research and development capabilities, clinical and regulatory organizations and unique insights will enable us to continue to lead this emerging category. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of our ROADSTER 2 Post Approval Study, our current clinical program consists of ongoing studies in the European Union and United States to evaluate the rate of sub-clinical embolization as detected through DW-MRI in recently symptomatic patients.  We expect to utilize the results of these clinical studies to support our marketing efforts and encourage continued adoption of TCAR.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a broad intellectual property platform addressing the transcarotid approach and, in the future, we intend to leverage our expertise to develop new products targeting market opportunities and disease states that could benefit from the physiologic and engineering advantages made possible by our transcarotid approach, including in the heart, aortic arch and brain. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended December 31, 2020, 2019 and 2018, our research, development and clinical expenses were $21.3 million, $12.3 million and $10.3 million, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TCAR is a relatively new procedure category and as such the basis of competition for our products is with respect to alternative carotid revascularization procedures.  We are positioning TCAR as an alternative to the existing procedures CEA and CAS, and therefore compete primarily with manufacturers of medical devices used in those procedures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major manufacturers of products, such as patches and shunts, used in connection with CEA include LeMaitre Vascular, Getinge / Maquet, Baxter, Terumo, Gore and Edwards.  Many of these companies are large public companies or divisions of publicly-traded companies and have several competitive advantages, including established relationships with vascular surgeons who commonly perform the CEA procedure, significantly greater name recognition and significantly greater sales and marketing resources.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies with actively marketed FDA-approved stents and embolic protection devices for use with CAS procedures include Abbott, Medtronic, Boston Scientific, and Cardinal.  Other companies have approved devices not currently marketed in the United States, including Gore, Terumo and InspireMD.  Additionally, some companies have stents and other products in ongoing IDE or planned IDE trial in the US, including Terumo and InsprireMD.  Many of these companies have several competitive advantages including the following: more established sales and marketing programs and networks, larger portfolio of products, longer operating histories, established relationships with healthcare professionals and greater name recognition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to competing for market share for TCAR, we also compete against these companies for personnel, including qualified personnel that are necessary to grow our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the principal competitive factors in our market include the following:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient outcomes and adverse event rates;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient experience;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acceptance by treating physicians and referral sources;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Physician learning curve;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ease-of-use and reliability;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient recovery time and level of discomfort;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Economic benefits and cost savings;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Availability of reimbursement; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Strength of clinical evidence.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete against manufacturers of medications used for medical management of carotid artery disease, including aspirin and statins.  Many such companies are large public companies or divisions of publicly-traded companies and have several competitive advantages including the following: established treatment patterns where drugs are generally first-line therapy and invasive procedures or surgery are considered later; established relationships with general practitioners who commonly prescribe such medications; significantly greater name recognition; and significantly greater sales and marketing resources, including direct-to-consumer advertising.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we may compete with medical device and pharmaceutical manufacturers outside the United States when we pursue plans to market our products internationally.  Among other competitive advantages, such companies may have more established sales and marketing programs and networks, established relationships with healthcare professionals and greater name recognition in such markets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect the intellectual property and proprietary technology that we believe is important to our business, which includes seeking and maintaining patents covering our technology and products, proprietary processes and any other inventions that are commercially or strategically important to the development of our business.  We also rely upon trademarks to build and maintain the integrity of our brand, and we seek to protect the confidentiality of trade secrets that may be important to the development of our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To protect our proprietary rights, we rely on a combination of trademark, copyright, patent, trade secret and other intellectual property laws, employment, confidentiality and invention assignment agreements, and protective contractual provisions with our employees, contractors, consultants, suppliers, partners and other third parties.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we o</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">wned 99 patents globally, of which 59 were issued U.S. patents and 40 were patents outside of the United States. &#160;Our patents expire between November 2024 and May 2037. Our material patents, their jurisdiction, expiration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> date and the product to which they relate, are listed in the table below:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent No.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Related Product</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002,728</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/2/2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,343,089</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/22/2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System<br/>Transcarotid Stent System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,157,760</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2030</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,784,355</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/7/2029</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,740,834</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/6/2029</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,011,364</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/10/2031</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833,555</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/26/2029</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173,425</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/18/2028</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173,425</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/18/2028</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173,425</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/18/2028</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173,425</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/18/2028</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Great Britain</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173,425</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/18/2028</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,290,290</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/18/2028</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,693,661</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/18/2028</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcarotid Neuroprotection System</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we h</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ad 75 pending patent applications globally, including 37 in the United States and 38 outside the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had trademark registrations for &#8220;Silk Road Medical,&#8221; the &#8220;Silk Road Medical&#8221; logo, &#8220;TCAR,&#8221; &#8220;Enroute&#8221; and the &#8220;Enroute&#8221; logo and &#8220;Enhance&#8221; in the United States, and various other countries.  Including these trademark registrations,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our trademark portfolio contained 86 trademark registrations/ applications.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends on the legal term for patents in the countries in which they are granted.  In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a nonprovisional patent application in the applicable country.  We cannot assure that patents will be issued from any of our pending applications or that, if patents are issued, they will be of sufficient scope or strength to provide meaningful protection for our technology.  Notwithstanding the scope of the patent protection available to us, a competitor could develop treatment methods or devices that are not covered by our patents.  Furthermore, numerous U.S. and foreign-issued patents and patent applications owned by third parties exist in the fields in which we are developing products. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, there may be applications unknown to us, which applications may later result in issued patents that our existing or future products or technologies may be alleged to infringe.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry.  In the future, we may need to engage in litigation to enforce patents issued or licensed to us, to protect our trade secrets or know-how, to defend against claims of infringement of the rights of others or to determine the scope and validity of the proprietary rights of others.  Litigation could be costly and could divert our attention from other functions and responsibilities.  Furthermore, even if our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market.&#8221;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse determinations in litigation could subject us to significant liabilities to third parties, could require us to seek licenses from third parties and could prevent us from manufacturing, selling or using the product, any of which could severely harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to maintain certain intellectual property and proprietary know-how as trade secrets, and generally require our partners to execute non-disclosure agreements prior to any substantive discussions or disclosures of our technology or business plans.  Our trade secrets include proprietary account analytics, user training methods, and operational processes.  For more information, please see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture the ENROUTE NPS at our approximately 31,000 square foot facility in Sunnyvale, California.  This facility provides approximately 8,000 square feet of space for our production and distribution operations, including manufacturing, quality control and storage. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While we believe our existing facility will be sufficient to meet our manufacturing needs for at least the next three years we supplement our distribution operations with a third-party logistics and warehousing service </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and are considering additional leased facilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing and distribution operations are subject to regulatory requirements of the FDA&#8217;s Quality System Regulation, or QSR, for medical devices sold in the United States, set forth in 21 CFR part 820, and the European Medical Device Directive 93/42/EEC and amendments, or MDD, for medical devices marketed in the European Union. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The new EU Medical Regulations take effect in May 2021, our design examination certificates under the MDD remain valid until their expiration.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the EU MDR will be executed prior to the expiration of the current MDD certificates. We are also subject to applicable local regulations relating to the environment, waste management and health and safety matters, including measures relating to the release, use, storage, treatment, transportation, discharge, disposal, sale, labeling, collection, recycling, treatment and remediation of hazardous substances.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA monitors compliance with the QSR through periodic inspections of our facilities.  Our suppliers&#8217; facilities are also subject to FDA regulations, including the QSR, and unannounced inspections by the FDA and other similar regulatory authorities.  Our European Union Notified Body, British Standards Institute, or BSI, monitors compliance with the MDD requirements through both annual scheduled audits and periodic unannounced audits of our manufacturing facilities as well as our contract manufacturers&#8217; facilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure, or the failure of our suppliers, to maintain acceptable quality requirements and compliance with all applicable healthcare laws and regulatory requirements could result in the shutdown or significant disruption of our manufacturing operations or th</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e voluntary or involuntary recall </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our products, which could harm our business.  In the event that one of our suppliers fails to maintain acceptable quality requirements or regulatory compliance, we may have to qualify a new supplier and could experience a material adverse effect to manufacturing and manufacturing delays as a result.  For example, in the first </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter of 2021, we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by one of our third-party suppliers, Cordis. Our decision to recall these lots was based on complaints we received about tips detaching from the stent delivery system as well as internal testing that we conducted. Recalls like this one could interrupt the delivery of our TCAR products to customers or may cause us to have to qualify a new supplier, either of which could cause our results of operations to be adversely impacted.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quality management system is ISO 13485 and MDD Certified. We have been an FDA registered medical device establishment and California licensed medical device manufacturer since 2011.  We moved to our current Sunnyvale, California facility in June 2018, which was registered with the FDA in June 2018 and was issued a California device manufacturing license&#160;in August 2018.  An ISO 13485 audit was conducted in September 2018 and our facility was recommended for certification.&#160; </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducted a total of five establishment inspections of our manufacturing facility in Sunnyvale, California in 2014, 2015, 2016 and 2020.  A one-observation Form 483 Notice of Observation was issued in April 2015 relating to a transcription error in patient line listings and no additional follow up with the FDA was required.  In February 2020, a one-observation Form 483 Notice of Observation was issued relating to the calibration method used for a specific type of measurement tool. In response, we initiated a Corrective and Preventive Action, or CAPA, and the Form 483 Notice of Observation was officially closed in June 2020.  We believe that we are in compliance, in all material respects, with all applicable FDA requirements, including the QSR.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since obtaining ISO 13485 certification in 2011, BSI has conducted scheduled surveillance audits annually, recertification audits every third year, and periodic unannounced audits since the initial certification period starting in 2011 for compliance with ISO 13485 and MDD.  The most recent recertification audit was conducted in November 2020, and no major non-conformities were identified.  The most recent surveillance audit was conducted in October 2019, and no major non-conformities were identified.  The most recent unannounced audit was conducted in July 2014, and no major non-conformities were identified.  We believe that we are in compliance, in all material respects, with all ISO 13485 and MDD requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing of the materials and components of the ENROUTE NPS are provided by approved suppliers, all of which are single source suppliers of key components, sub-assemblies and materials.  We purchase finished transcarotid access kit, guidewires and stents through contract manufacturers.  Cardinal is our contract manufacturer and currently the sole source supplier for the ENROUTE stent.  We typically maintain several months&#8217; worth of ENROUTE stents in inventory, and we estimate that it would take between one and two years to qualify a second source supplier for our ENROUTE stent.  The suppliers for the ENROUTE NPS and our other product lines are evaluated, qualified and approved through a stringent supplier management program, which includes various evaluations, assessments, qualifications, validations, testing and inspection to ensure the supplier can meet acceptable quality requirements.  We implement a strict change control policy with our key suppliers to ensure that no component or process changes are made without our prior approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Order quantities and lead times for components purchased from suppliers are based on our forecasts derived from historical demand and anticipated future demand.  Lead times for components may vary depending on the size of the order, time required to fabricate and test the components, specific supplier requirements and current market demand for the components, sub-assemblies and materials.  We perform assembly, testing, inspection and final product release activities for the ENROUTE NPS.  Finished ENROUTE NPS devices are ethylene oxide sterilized at a qualified supplier.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United States Food &amp; Drug Administration</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and operations are subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations, as well as other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal and state regulatory bodies in the United States.  The laws and regulations govern, among other things, product design and development, pre-clinical and clinical testing, manufacturing, packaging, labeling, storage, record keeping and reporting, clearance or approval, marketing, distribution, promotion, import and export, and post-marketing surveillance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the United States will require either a premarket notification to the FDA requesting permission for commercial distribution under Section&#160;510(k) of the Federal Food, Drug and Cosmetic Act, or FDCA, also referred to as a 510(k) clearance, or approval from the FDA of a PMA application.  Both the 510(k) clearance and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees, unless an exemption is available.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device classification</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, medical devices are classified into one of three classes-Class&#160;I, Class&#160;II or Class&#160;III-depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class&#160;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials.  Some Class&#160;I devices, also called Class&#160;I reserved devices, also require premarket clearance by the FDA through the 510(k) premarket notification process described below.  Most Class&#160;I products are exempt from the premarket notification requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class&#160;II devices are those that are subject to the General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device.  These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance.  Most Class&#160;II devices are subject to premarket review and clearance by the FDA.  Premarket review and clearance by the FDA for Class&#160;II devices is accomplished through the 510(k) premarket notification process.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class&#160;III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process.  The safety and effectiveness of Class&#160;III devices cannot be reasonably assured solely by the General Controls and Special Controls described above.  Therefore, these devices are subject to the PMA application process, which is generally more costly and time consuming than the 510(k) process.  Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction.  Accordingly, a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies.  The PMA application must provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a new medical device does not qualify for the 510(k) premarket notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class III. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification process. This process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk and requires PMA or that general controls would be inadequate to control the risks and special controls cannot be developed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investigational device process</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, absent certain limited exceptions, human clinical trials intended to support medical device clearance or approval require an IDE application.  Some types of studies deemed to present &#8220;non-significant risk&#8221; are deemed to have an approved IDE once certain requirements are addressed and IRB approval is obtained.  If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials.  The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound.  The IDE application must be approved in advance by the FDA for a specified number of subjects.  Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate institutional review boards at the clinical trial sites.  There can be no assurance that submission of an IDE will result in the ability to commence clinical trials, and although the FDA&#8217;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety and effectiveness, even if the trial meets its intended success criteria.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical trials must be conducted in accordance with the FDA&#8217;s IDE regulations that govern investigational device labeling, prohibit promotion and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators.  Clinical trials must further comply with the FDA&#8217;s good clinical practice regulations for institutional review board approval and for informed consent and other human subject protections.  Required records and reports are subject to inspection by the FDA.  The results of clinical testing may be unfavorable, or, even if the intended safety and effectiveness success criteria are achieved, may not be considered sufficient for the FDA to grant marketing approval or clearance of a product.  The commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous reasons, including, but not limited to, the following:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients do not enroll in clinical trials at the rate expected;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients do not comply with trial protocols;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient follow-up is not at the rate expected;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients experience adverse events;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients die during a clinical trial, even though their death may not be related to the products that are part of the trial;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Device malfunctions occur with unexpected frequency or potential adverse consequences;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Side effects or device malfunctions of similar products already in the market that change the FDA&#8217;s view toward approval of new or similar PMAs or result in the imposition of new requirements or testing;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Institutional review boards and third-party clinical investigators may delay or reject the trial protocol;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations, or other FDA or IRB requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party investigators are disqualified by the FDA;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing responsibilities, records, and reports of sponsors of clinical investigations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party clinical investigators have significant financial interests related to us or our study such that the FDA deems the study results unreliable, or the company or investigators fail to disclose such interests;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in government regulations or administrative actions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA concludes that our trial design is unreliable or inadequate to demonstrate safety and effectiveness.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The 510(k) approval process</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent,&#8221; as defined in the statute, to a legally marketed predicate device.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process.  To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device.  Clinical data is sometimes required to support substantial equivalence.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review.  If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification.  If it is accepted for filing, the FDA begins a substantive review.  The Medical Device User Fee Amendments sets a performance goal of 90 days for FDA review of a 510(k) submission, but the review time can be delayed if FDA raises questions or requests addition information during the review process.  As a practical matter, clearance often takes longer, and clearance is never assured.  Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process.  If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the de novo process.  A manufacturer can also submit a petition for direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application or de novo classification.  The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination.  Many minor modifications are accomplished by a letter-to-file in which the manufacture documents the change in an internal letter-to-file.  The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such change.  The FDA can always review these letters to file in an inspection.  If the FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission is required for the modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products.  For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals.  The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k) clearance pathway.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, in September 2019, the FDA finalized guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA intends to develop and maintain a list device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The PMA approval process</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review.  If it is not, the agency will refuse to file the PMA.  If it is, the FDA will accept the application for filing and begin the review.  The FDA, by statute and by regulation, has 180 days to review a filed PMA application, although the review of an application more often occurs over a significantly longer period of time.  During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA.  The FDA considers a PMA or PMA supplement to have been voluntarily </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">withdrawn if an applicant fails to respond to an FDA request for information (e.g., major deficiency letter) within a total of 360 days.  Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee&#8217;s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it.  The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes.  Overall, the FDA review of a PMA application generally takes between one and three years, but may take significantly longer.  The FDA can delay, limit or deny approval of a PMA application for many reasons, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The device may not be shown safe or effective to the FDA&#8217;s satisfaction;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing process or facilities may not meet applicable requirements; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in FDA approval policies or adoption of new regulations may require additional data.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA.  When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter.  If the FDA&#8217;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter.  The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available.  The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process.  PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and may or may not require as extensive technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In approving a PMA application, as a condition of approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer term safety and effectiveness data for the device.  The FDA may also require post-market surveillance for certain devices cleared under a 510(k) notification, such as implants or life-supporting or life-sustaining devices used outside a device user facility.  The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pervasive and Continuing Regulation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device is placed on the market, numerous regulatory requirements continue to apply.  These include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA&#8217;s QSR, which requires manufacturers, including their suppliers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical device reporting, or MDR, regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical device</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recalls, wh</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ich require that manufacturers report to the FDA any recall of a medical device, provided the recall was initiated to either reduce a risk to health posed by the device, or to remedy a violation of the FDCA caused by the device that may present a risk to health; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered with the FDA as a medical device manufacturer and a specification developer and have obtained a manufacturing license from the California Department of Public Health, or CDPH.  The FDA and CDPH have broad post-market and regulatory enforcement powers.  We are subject to unannounced inspections by the FDA and the Food and Drug Branch of CDPH to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of our suppliers.  Additionally, our Notified Body, BSI, regularly inspects our manufacturing, design and operational facilities to ensure ongoing ISO&#160;13485 compliance in order to maintain our CE mark.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Warning letters, fines, injunctions, consent decrees and civil penalties;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Repair, replacement, refunds, recall or seizure of our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating restrictions, partial suspension or total shutdown of production;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusing our requests for 510&#160;(k) clearance or premarket approval of new products, new intended uses or modifications to existing products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Withdrawing 510 (k) clearance or premarket approvals that have already been granted; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Criminal prosecution.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Union</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of TCAR products is regulated in the European Union as a medical device per the European Union Directive 93/42/EEC, also known as the MDD.  The MDD sets out the basic regulatory framework for medical devices in the European Union.  The system of regulating medical devices operates by way of a certification for each medical device.  Each certified device is marked with the CE mark which shows that the device has a Certificat de Conformit&#233;.  There are national bodies known as Competent Authorities in each member state which oversee the implementation of the MDD within their </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdiction.  The means for achieving the requirements for the CE mark vary according to the nature of the device.  Devices are classified in accordance with their perceived risks, similarly to the U.S. system.  The class of a product determines the conformity assessment required before the CE mark can be placed on a product.  Conformity assessments for our products are carried out as required by the MDD.  Each member state can appoint Notified Bodies within its jurisdiction.  If a Notified Body of one member state has issued a Certificat de Conformit&#233;, the device can be sold throughout the European Union without further conformance tests being required in other member states.  The CE mark is contingent upon continued compliance with the applicable regulations and the quality system requirements of the ISO&#160;13485 standard.  Our current CE mark is issued by BSI.  When the new EU Medical Regulations take effect in May 2021, our design examination certificates under the MDD remain valid until their expiration.  Compliance with the EU MDR will be executed prior to the expiration of the current MDD certificates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Insurance Portability and Accountability Act</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, established federal protection for the privacy and security of health information.  Under HIPAA, the Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information used or disclosed by &#8220;Covered Entities,&#8221; including healthcare providers and their Business Associates.  HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers.  The privacy regulations protect medical records and other protected health information by limiting their use and release, giving patients the right to access their medical records and limiting most disclosures of health information to the minimum amount necessary to accomplish an intended purpose.  The HIPAA security standards require the adoption of administrative, physical, and technical safeguards and the adoption of written security policies and procedures.  HIPAA requires Covered Entities to execute Business Associate Agreements with their Business Associates and subcontractors, who provide services to Covered Entities and who need access to protected health information.  In addition, companies that would not otherwise be subject to HIPAA may become contractually obligated to follow HIPAA requirements through agreements with Covered Entities and Business Associates, and some of our customers may require us to agree to these provisions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, HIPAA and other federal privacy regulations, such as Section 5 of the Federal Trade Commission Act, there are a number of state laws regarding the privacy and security of health information and personal data that apply to us.  The compliance requirements of these laws, including additional breach reporting requirements, and the penalties for violation vary widely, and new privacy and security laws in this area are evolving.  Requirements of these laws and penalties for violations vary widely.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our operations are found to be in violation of HIPAA, HITECH, or their implementing regulations, we may be subject to penalties, including civil and criminal penalties, fines, and exclusion from participation in federal or state healthcare programs, and the curtailment or restructuring of our operations.  HITECH increased the civil and criminal penalties that may be imposed against Covered Entities, their Business Associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Federal, State and Foreign Fraud and Abuse Laws</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal and state governments have enacted, and actively enforce, a number of laws to address fraud and abuse in federal healthcare programs.  Our business is subject to compliance with these laws.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Kickback Statutes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a federal healthcare program, such as Medicare or Medicaid.  A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including, for example, gifts, certain discounts, the furnishing of free supplies, equipment or services, credit arrangements, payment of cash and waivers of payments.  Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered businesses, the statute has been violated.  Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $104,330 for each violation, plus up to three times the remuneration involved.  Civil penalties for such conduct can further be assessed under the federal False Claims Act.  Violations can also result in criminal penalties, including criminal fines of up to $100,000 and imprisonment of up to 10 years.  Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid.  In addition, some kickback allegations have been claimed to violate the Federal False Claims Act.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Office of Inspector General, or OIG, of the HHS has issued a series of regulations known as &#8220;safe harbors.&#8221; These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they will not be prosecuted under the Anti-Kickback Statute.  The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is per se illegal or that prosecution will be pursued.  However, conduct and business arrangements that do not fully satisfy an applicable safe harbor may result in increased scrutiny by government enforcement authorities such as OIG.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have adopted laws similar to the Anti-Kickback Statute.  Some of these state prohibitions apply to referral of recipients for healthcare products or services reimbursed by any source, not only government healthcare programs, and may apply to payments made directly by the patient.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government officials have focused their enforcement efforts on the marketing of healthcare services and products, among other activities, and recently have brought cases against companies, and certain individual sales, marketing and executive personnel, for allegedly offering unlawful inducements to potential or existing customers in an attempt to procure their business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal False Claims Act</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act, or FCA, imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program.  The </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provisions of the FCA allow a private individual to bring actions on behalf of the federal government alleging that the defendant has violated the FCA and to share in any monetary recovery.  In addition, various states have enacted false claims laws analogous to the FCA, and many of these state laws apply where a claim is submitted to any third-party payer and not only a federal healthcare program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an entity is determined to have violated the FCA, it may be required to pay up to three times the actual damages sustained by the government, plus civil fines and penalties ranging from $11,665 and $23,331 for each false claim, subject to adjustment for inflation.  As part of any settlement, the government may require the entity to enter into a corporate integrity agreement, which imposes certain compliance, certification and reporting obligations.  There are many potential bases for liability under the FCA.  Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government.  The federal government has used the FCA to assert liability on the basis of kickbacks, or in instances in which manufacturers have provided billing or coding advice to providers that the government considered to be inaccurate.  In these cases, the manufacturer faces liability for &#8220;causing&#8221; a false claim.  In addition, the federal government has prosecuted companies under the FCA in connection with off-label promotion of products.  Our activities relating to the reporting of discount and rebate information and other information affecting federal, state and third-party </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement of our products and the sale and marketing of our products may be subject to scrutiny under these laws.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, collaborators, vendors, principal investigators, consultants, independent contractors, and commercial partners. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.  While we are unaware of any current matters, we are unable to predict whether we will be subject to actions under the FCA or a similar state law, or the impact of such actions.  Whether or not we are successful in defending against any such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations, which could have a material adverse effect on our business and financial condition. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Civil Monetary Penalties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Civil Monetary Penalty Act of 1981 imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Payments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Physician Payments Sunshine Act, known as &#8220;Open Payments&#8221; and enacted as part of the Affordable Care Act, requires all pharmaceutical and medical device manufacturers of products covered by Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to HHS:&#160;payments and transfers of value to physicians, certain other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members.  Additionally, on October 24, 2018, President Trump signed into law the &#8220;Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act&#8221; which in part (under a provision entitled &#8220;Fighting the Opioid Epidemic with Sunshine&#8221;) extends the reporting and transparency requirements for physicians in the Physician Payments Sunshine Act to physician assistants, nurse practitioners, and other mid-level practitioners (with reporting requirements going into effect in 2022 for payments made in 2021).  Applicable manufacturers are required to submit annual reports to CMS.  Failure to submit required information may result in civil monetary penalties of up to $176,495 per annual report for failing to report payments in a timely manner.  Knowingly failing to submit payment information may result in a civil money penalty of up to $1,176,638.  We are subject to Open Payments and the information we disclose may lead to greater scrutiny, which may result in modifications to established practices and additional costs.  Additionally, similar reporting requirements have also been enacted on the state level domestically, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with healthcare professionals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Corrupt Practices Act</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business.  The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including international subsidiaries, if any, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Laws</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, various countries have adopted anti-bribery laws providing for severe consequences in the form of criminal penalties and significant fines for individuals or companies committing a bribery offense.  Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, in the United Kingdom, under the U.K.  Bribery Act 2010, a bribery occurs when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities, including any function of a public nature.  Bribery of foreign public officials also falls within the scope of the U.K.  Bribery Act 2010.  An individual found in violation of the U.K.  Bribery Act 2010, faces imprisonment of up to ten years.  In addition, the individual can be subject to an unlimited fine, as can commercial organizations for failure to prevent bribery.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also international privacy laws that impose restrictions on the access, use, and disclosure of health information.  All of these laws may impact our business.  Our failure to comply with these privacy laws or significant changes in the laws restricting our ability to obtain required patient information could significantly impact our business and our future business plans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Centers for Medicare and Medicaid Services</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare is a federal program administered by CMS through fiscal intermediaries and carriers.  Available to individuals age 65 or over, and certain other individuals, the Medicare program provides, among other things, healthcare benefits that cover, within prescribed limits, the major costs of most medically necessary care for such individuals, subject to certain deductibles and copayments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has established guidelines for the coverage and reimbursement of certain products and procedures by Medicare.  In general, in order to be reimbursed by Medicare, a healthcare procedure furnished to a Medicare beneficiary must be reasonable and necessary for the diagnosis or treatment of an illness or injury, or to improve the functioning of a malformed body part.  The methodology for determining coverage status and the amount of Medicare reimbursement varies based upon, among other factors, the setting in which a Medicare beneficiary received healthcare products and services.  Any changes in federal legislation, regulations and policy affecting CMS coverage and reimbursement relative to the procedure using our products could have a material effect on our performance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS also administers the Medicaid program, a cooperative federal/state program that provides medical assistance benefits to qualifying low income and medically needy persons.  State participation in Medicaid is optional, and each state is given discretion in developing and administering its own Medicaid program, subject to certain federal requirements pertaining to payment levels, eligibility criteria and minimum categories of services.  The coverage, method and level of reimbursement vary from state to state and is subject to each state&#8217;s budget restraints.  Changes to the availability of coverage, method or level of reimbursement for TCAR may affect future revenue negatively if reimbursement amounts are decreased or discontinued.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All CMS programs are subject to statutory and regulatory changes, retroactive and prospective rate adjustments, administrative rulings, interpretations of policy, intermediary determinations, and government funding restrictions, all of which may materially increase or decrease the rate of program payments to healthcare facilities and other healthcare providers, including those paid for TCAR.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United States Health Reform</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions.  Changes in healthcare policy could increase our costs, decrease our revenue and impact sales of and reimbursement for our current and future products.  The ACA substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry.  The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably.  Among policy makers and payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access.  Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products.  The cost containment measures that payers and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of the Affordable Care Act in the United States, for example, has changed healthcare financing and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly.  The Affordable Care Act imposed, among other things, a 2.3% federal excise tax, with limited exceptions, on any entity that manufactures or imports Class&#160;I, II and III medical devices offered for sale in the United States that began on January&#160;1, 2013.  Through a series of legislative amendments, the tax was suspended for 2016 through 2019.  In December 2019, this excise tax was permanently repealed for medical device sales, effective after December 31, 2019.  The Affordable Care Act also provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research, and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models.  Additionally, the Affordable Care Act has expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.  We do not yet know the full impact that the Affordable Care Act will have on our business.  There have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect additional challenges and amendments </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the future.  It is unclear how efforts to repeal and replace the ACA will impact the healthcare industry or our business operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted.  For example, the Budget Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken.  Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that there will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payers to reduce costs while expanding individual healthcare benefits.  Certain of these changes could impose additional limitations on the rates we will be able to charge for our current and future products or the amounts of reimbursement available for our current and future products from governmental agencies or third-party payers.  Current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Building and Supporting Human Capital </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We understand the commitment our employees make to our company and we take our commitment to them very seriously. Consistent with this commitment, we strive to create a work environment in which everyone is empowered to develop, to contribute, and to thrive. We strongly believe our corporate culture is the operating system that powers the company. We talk about it, obsess over it, and have even given it a name &#8211; Cartwheel Culture. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Cartwheel Culture is uniquely ours and it&#8217;s one we love and nurture every day. Our Cartwheel Culture provides a shared set of beliefs that drives everyday behaviors. These include: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Courage: We think big. We act boldly. We take on new challenges. We challenge ourselves and our colleagues to try new things that are difficult. We take smart risks. We explore new ideas and do things differently. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Focus on Core Strength: We unleash our strengths and shore up weaknesses in our company, in every department and in each member of TCAR Nation. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Flexibility: We view opportunities and challenge from all angles&#8230;even upside down. We explore all possibilities and are both willing and able to respond to changing circumstances and expectations. We make it a priority to listen and understand other people&#8217;s ideas and viewpoints. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Lend a Hand: We actively support each other to achieve our common goal. Teamwork Matters. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Persistence: We believe that innovation comes from persistence and learning from our mistakes. We are persistent in the pursuit of our goals and believe that it&#8217;s better to try and sometimes fail than to sit tight and fail for sure. We learn from the mistakes we make and move forward. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to Diversity and Inclusion </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, we had 281 employees, all located within the United States. 188 employees were engaged in marketing, sales, and administrative activities, 40 were engaged in research and development activities, and 53 were engaged in manufacturing operations. During 2020, the number of employees increased by 57. Our workforce consists of a highly skilled, diverse, and engaged team dedicated to the company&#8217;s mission and goals.  We are proud of the gender diversity in our organization with female&#8217;s representing 48% of our organization. This ratio is consistent across leadership roles within the company, where women represent 50% of our people leaders and 44% of our executive leaders. We strive to create an inclusive work environment that represents the diversity in the communities we live and work.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to a Workplace Free of Discrimination and Harassment</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our focus on our Cartwheel Culture, we strive to create a workplace that is free of bias, prejudice, discrimination and harassment. Our employment policies are designed to protect all employees and provide for their welfare and guides our behaviors and interactions. In short, we do not tolerate discrimination or harassment. We are also committed to maintaining a workplace free from harassment based on any protected characteristic. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to Equal Employment Opportunity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to maintaining a work environment in which all individuals are treated with respect and dignity. Everyone has the right to work in a professional atmosphere that promotes equal employment opportunities in all aspects of employment and personnel matters (including, without limitation, recruiting and hiring, job assignment, compensation, opportunities for advancement, evaluation, benefits, training, discipline, and termination), and prohibits discriminatory practices. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to Creating a Safe, Healthy and Secure Work Environment </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to providing a safe, healthy and secure work environment for all employees and visitors. Safety is extremely important to the company and we comply with all applicable health, safety and environmental laws as well as our Safety Programs. These Safety Programs and associated procedures have been developed and implemented throughout the company&#8217;s facility with employees&#8217; safety in mind. These programs include an Injury and Illness Prevention Program, an Emergency Action Plan, an Exposure Control Plan, a Hazard Communication Program and a Hazardous Waste Management Program. In addition, any employee working in a hospital operating room is required to wear a dosimetry badge that monitors occupational radiation exposure and compliance with annual limits. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic has forced our society to accept new ways of working and interacting and this will continue to cause a shift in how we operate both in our Sunnyvale headquarters location and in the hospitals in which we work. Our headquarters is located in Santa Clara County which was the first county in the nation to issue a shelter in place order. As COVID-19 started to spread across the U.S., we implemented a remote work policy earlier than our county required, as a precautionary measure to ensure the health and safety of our headquarter based employees. This shift required that we and every member of TCAR Nation to embrace a new way of working and put new energy into creating an office environment that is safe, healthy, and inspiring to work in. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to Competitive and Fair Compensation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that employees should be compensated fairly for their contributions to the company. We practice paying competitive salaries and hourly wages. In order to ensure we pay our employees competitively, annual benchmarking is completed on all positions throughout the company. We use external benchmarking surveys to guide our assessment of salary competitiveness. Each position is evaluated based on level of the role, the complexity of the position, and years of experience required. Our compensation program consists of the three primary components: base salary, annual bonus targets (non-sales), commission plans (sales), and equity. In addition, all employees are eligible to participate in our Employee Stock Purchase Program. The Compensation Committee is responsible for our executive compensation programs for our executive officers and reports to our board of directors on its discussions, decisions and other actions.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to Learning and Development</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the professional development of our employees is a critical element to the success of our company. We have an extensive training and development program in place for our salesforce. This includes a robust clinical training continuum for our therapy development specialists, area managers and area directors. We also actively support the professional education of our production team to ensure the manufacture of a quality product. We also offer leadership development training for managers.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to the Health and Wellbeing of our Employees</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our top priorities are to maintain the health and wellbeing of our employees and their families. To achieve this goal, we offer a comprehensive employee benefits package with a variety of options. These programs include Medical, Dental, Vision, Life Insurance, Disability Programs, Retirement Programs including a match on the 401(k), Flexible Spending Accounts (FSAs), Health Savings Accounts (HSAs) with a generous employer contribution, EAP, and an ESPP. We pay 83% of healthcare premium costs on behalf of our employees. For new parents, we offer up to 160 hours of child bonding leave and provided a benefit for new moms who travel for business that allows for them to pump milk and ship it back home. In addition, we provide paid vacation and holiday time. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to Corporate Philanthropy </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our corporate philanthropy program, Lend a Hand, we are committed to supporting social causes and educational initiatives that help build stronger and healthier communities. Over the years, we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been involved in a variety of projects including holiday gift drives, school backpack drives, the hand making and donation of blankets to a local rehabilitation and healthcare center near our headquarters. We also provide support by sponsoring the Stroke Awareness Foundation&#8217;s Fight Stroke Walk, building bikes for under privileged children at our National Sales meeting, and during the COVID-19 pandemic, we made a financial and in-kind donation to the Valley Medical Foundation and a financial donation to Meals on Wheels. We also used our logistics team to distribute PPE Equipment including face masks, frocks, gloves, shoe covers, beard covers and hair nets that was donated by a third party to hospitals around the U.S. Most recently, employees participated in the Cycle Nation fundraising event with the American Heart Association.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and other Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware on March 21, 2007 as Silk Road Medical, Inc. Our principal executive offices are located at 1213 Innsbruck Drive, Sunnyvale, CA 94089, and our telephone number is (408) 720-9002. Our website address is www.silkroadmed.com. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that information we post on social media channels could be deemed to be material information. We encourage investors, our customers and others interested in our company to review the information we post on our Facebook page (https://www.facebook.com/SilkRoadMed/) and Twitter feed (https://twitter.com/silkroadmed). The information on, or that may be accessed through, our website and social media channels is not incorporated by reference into this Annual Report on Form 10-K and should not be considered a part of this Annual Report on Form 10-K.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have identified the following risks and uncertainties that may have a material adverse effect on our business, financial condition, results of operations and future growth prospects. Our business could be harmed by any of these risks. The risks and uncertainties described below are not the only ones we face. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition, results of operations and future prospects. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing these risks, you should also refer to the other information contained in this Annual Report on Form 10-K, including our condensed financial statements and related notes. Please also see &#8220;Cautionary Notes Regarding Forward-Looking Statements.&#8221;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Principal Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risks and uncertainties are among the most significant we face.  However, the risks and uncertainties identified in this subsection are not the only ones we face, and are qualified in their entirety by reference to all of the risk factors described in Item 1A. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Risks Related to Our Business</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is dependent upon the broad adoption of TCAR by hospitals and physicians.  Physicians may not adopt our products unless they are able to determine, based on experience, clinical data, medical society recommendations and other analyses, that our products provide a safe and effective treatment alternative for carotid artery disease.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adoption of TCAR depends upon positive clinical data and medical society recommendations, and negative clinical data or medical society recommendations would adversely affect our business.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not able to maintain adequate levels of third-party coverage and reimbursement for the procedures using our products, if third parties rescind or modify their coverage, or if patients are left with significant out-of-pocket costs, it would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic and efforts to reduce its spread have impacted, and may in the future periods negatively impact, our business and operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on Cordis, a Cardinal Health Company, or Cordis, to supply the ENROUTE stent, and if Cordis fails to supply the ENROUTE stent in sufficient quantities or at all, it will have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on a limited number of single source suppliers to manufacture our components, sub-assemblies and materials, which makes us vulnerable to supply shortages and price fluctuations that could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses, we expect to incur operating losses in the future and we may not be able to achieve or sustain profitability.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property Risks</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market our products.  It is possible that U.S. and foreign patents and pending patent applications or trademarks controlled by third parties may be alleged to cover our products, or that we may be accused of misappropriating third parties&#8217; trade secrets.  An adverse result in any litigation proceeding could put one or more of our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success will depend on our ability to obtain, maintain and protect our intellectual property rights. Our intellectual property could be challenged, invalidated, infringed, and circumvented by third parties.  Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to protect our intellectual property rights throughout the world. A company may attempt to commercialize competing products utilizing our proprietary design, trademarks or tradenames in foreign countries where we do not have sufficient patent protection and where legal recourse may be limited.  This may have a significant commercial impact on our future foreign business operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect our business.  We rely on suppliers, vendors, outsourcing partners, consultants, alliance partners and other third parties to research, develop, manufacture and commercialize our products and manage certain parts of our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Risks</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products have in the past and could in the future be subject to product recalls that could harm our reputation or increase the probability of inspection by, or additional scrutiny from, the FDA</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Additional recalls of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our products would divert managerial attention and could be expensive, harm our reputation with customers and harm our financial condition and results of operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the CMS fee schedules may harm our revenue and operating results.  Reductions of reimbursement by Medicare or Medicaid for procedures that use our products or changes in policy regarding coverage of these procedures may be implemented from time to time.  In addition, reductions in the reimbursement rates and changes in payment policies of other third-party payers may occur from time to time.  Any decline in the amount that payers reimburse our customers for TCAR could make it difficult for customers to continue using, or to adopt, our products and could create additional pricing pressure for us.  </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with broad based healthcare and other governmental regulations, we could face substantial fines and penalties and our business, results of operations and financial condition could be adversely affected. Our arrangements with physicians, hospitals and medical centers expose us to broadly applicable fraud and abuse and other laws and regulations that may restrict the financial arrangements and relationships through which we market, sell and distribute our products.  Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.  </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to obtain and maintain necessary regulatory clearances or approvals for our products, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations would be harmed.  The FDA can delay, limit or deny clearance or approval of a device or a new indication for many reasons, and even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product.  Additionally, we may experience regulatory delays or may be unsuccessful in our effort to seek a label expansion for the ENROUTE stent in standard surgical risk patients, or obtain reimbursement from CMS or other payors, any of which would materially limit our market opportunity.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may fail to demonstrate competent and reliable evidence of the safety and effectiveness of our products, which would prevent or delay commercialization of our products in development.  Clinical testing is expensive and can take many years to complete, and its </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcome is inherently uncertain.  We cannot be certain that our planned clinical trials or any other future clinical trials will be successful.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses, we expect to incur operating losses in the future and we may not be able to achieve or sustain profitability.  </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception in March 2007.  For the years ended December 31, 2020, 2019 and 2018, we had a net loss of $47.4 million, $52.4 million, and $37.6 million, respectively, and we expect to continue to incur additional losses in the future.  As of December 31, 2020, we had an accumulated deficit of $238.9 million.  To date, we have financed our operations primarily through equity and debt financings and from sales of our portfolio of TCAR products that enable transcarotid artery revascularization, or TCAR.  The losses and accumulated deficit have primarily been due to the substantial investments we have made to develop our products, as well as for costs related to general research and development, including clinical and regulatory initiatives to obtain marketing approval, sales and marketing efforts and infrastructure improvements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the next several years, we expect to continue to devote a substantial amount of our resources to expand commercialization efforts and increase adoption of TCAR using our products, improve and expand reimbursement for TCAR, and develop additional products.  In addition, as a public company, we incur significant legal, accounting, Director &amp; Officer liability insurance and other expenses that we did not incur as a private company, all of which continue to increase.  Accordingly, we expect to continue to incur operating losses for the foreseeable future and we cannot assure you that we will achieve profitability in the future or that, if we do become profitable, we will sustain profitability.  Our failure to achieve and sustain profitability in the future will make it more difficult to finance our business and accomplish our strategic objectives, which would have a material adverse effect on our business, financial condition and results of operations and cause the market price of our common stock to decline.  In addition, failure of our products to significantly penetrate the target markets would negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on, and currently sell products to enable, TCAR, which is our only product offering.  </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, all of our revenue has been derived, and we expect it to continue to be derived in the near term, from sales of our products that enable TCAR.  TCAR is a relatively new treatment option for certain patients diagnosed with carotid artery disease and, as a result, physician awareness of TCAR and our products, and experience with TCAR and our products, is limited.  A number of factors that are outside of our control may contribute to fluctuations in our financial results, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Physician and hospital demand for our products and the extent of adoption of TCAR, including the rate at which physicians recommend our products and TCAR to their patients;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Positive or negative media coverage, or public, patient and/or physician perception, of our products and TCAR or competing products and procedures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any safety or effectiveness concerns that arise regarding our products or TCAR;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unanticipated delays in product development or product launches;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to maintain our current or obtain further regulatory clearances or approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in, or failure of, product, component and material deliveries by our third-party suppliers; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Introduction of new products or procedures for treating carotid artery disease that compete with our products and the TCAR procedure.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is therefore difficult to predict our future financial performance and growth, and such forecasts are inherently limited and subject to a number of uncertainties.  If our assumptions regarding the risks and uncertainties we face, which we use to plan our business, are incorrect or change due to circumstances in our business or our markets, or if we do not address these risks successfully, our operating and financial results could differ materially from our expectations and our business could suffer.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we devote substantially all of our resources to our products that enable TCAR and rely on our products and the adoption of TCAR as our sole source of revenue, any factors that negatively impact our products or TCAR, or result in a decrease in sales of products, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent upon the broad adoption of TCAR by hospitals and physicians.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth and profitability largely depends on our ability to increase physician awareness of TCAR and on the willingness of physicians to adopt our products and TCAR, and to recommend the procedure to their patients.  Physicians may not adopt our products unless they are able to determine, based on experience, clinical data, medical society recommendations and other analyses, that our products provide a safe and effective treatment alternative for carotid artery disease.  Even if we are able to raise awareness among physicians, physicians tend to be slow in changing their medical treatment practices and may be hesitant to select our products or TCAR for recommendation to patients for a variety of reasons, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Long-standing relationships with competing companies and distributors that sell other products, such as stents and embolic protection devices for transfemoral carotid artery stenting, or CAS;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competitive response and negative selling efforts from providers of alternative carotid revascularization products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Perceived liability risk generally associated with the use of new products and procedures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lack or perceived lack of sufficient clinical evidence, including long-term data, supporting clinical benefits;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reluctance to change to or use new products and procedures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Perceptions that our products are unproven; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Time commitment and skill development that may be required to gain familiarity and proficiency with TCAR and our products.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians play a significant role in determining the course of a patient&#8217;s treatment for carotid artery disease and, as a result, the type of treatment that will be recommended or provided to a patient.  We focus our sales, marketing and education efforts primarily on vascular surgeons, and aim to educate referring physicians such as vascular surgeons, cardiologists, radiologists, neurologists, neurosurgeons and general practitioners regarding the patient population that would benefit from TCAR.  However, we cannot assure you that we will achieve broad education or market acceptance among these practitioners.  For example, if diagnosing physicians that serve as the primary point of contact for patients are not made aware of TCAR, they may not refer patients to physicians for treatment using our products, and those patients may instead not seek treatment at all or may be treated with alternative procedures.  In addition, some physicians may choose to utilize TCAR on only a subset of their total patient population or may not adopt TCAR at all.  If a physician experiences an adverse event in one or more of their TCAR patients or elects to convert TCAR to CEA mid-procedure, they may not continue offering and performing TCAR at the same rate or at all.  Further, as TCAR is a new procedure, it may not fit into the workstreams of certain physicians.  If we are not able to effectively demonstrate that TCAR is beneficial in a broad range of patients, adoption of TCAR will be limited and may not occur as rapidly as we anticipate or at all, which would have a material adverse effect on our business, financial condition and results of operations.  We </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cannot assure you that TCAR or our products will achieve broad market acceptance among hospitals and physicians.  Any failure of TCAR or our products to satisfy demand or to achieve meaningful market acceptance and penetration will harm our future prospects and have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the medical device industry&#8217;s relationship with physicians is under increasing scrutiny by the Health and Human Services Office of the Inspector General, or OIG, the Department of Justice, or DOJ, state attorneys general, and other foreign and domestic government agencies.  Our failure to comply with laws, rules and regulations governing our relationships with physicians, or an investigation into our compliance by the OIG, DOJ, state attorneys general or other government agencies, could significantly harm our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most cases, before physicians can use our products for the first time, our products must be approved for use by a hospital's new product or value analysis committee, or the staff of a hospital or health system.  Following such approval, we may be required to enter into a purchase contract.  Such approvals or requirements to enter into a purchase contract could deter or delay the use of our products by physicians.  We cannot provide assurance that our efforts to obtain such approvals, enter into purchase contracts, or generate adoption will be successful or increase the use of our products, and if we are not successful, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of TCAR depends upon positive clinical data and medical society recommendations, and negative clinical data or medical society recommendations would adversely affect our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate of adoption of TCAR and sales of our products that facilitate the procedure is heavily influenced by clinical data.  Although the Society for Vascular Surgery&#8217;s TCAR Surveillance Project contains real world data comparing procedures, we have not conducted head-to-head clinical trials to compare TCAR to the procedures historically available to patients, such as CEA or CAS, which may limit the adoption of TCAR.  Additionally, the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trial is currently funded by the National Institutes of Health, which compares the effectiveness of each of CEA and CAS with best medical management solutions.  Although we estimate that</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enrollment will not be completed until 2024, int</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">erim results have been released from time to time.  At the completion of the four-year follow-up, the trial could conclude that medical management alone achieves the same therapeutic results as CEA and/or CAS, which could have an adverse impact on the adoption of TCAR.  Finally, our competitors and third parties may also conduct clinical trials of our products without our participation.  Unfavorable or inconsistent clinical data from existing or future clinical trials conducted by us, our competitors or third parties, the interpretation of our or other clinical data or findings of new or more frequent adverse events, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As physicians are influenced by guidelines issued by physician organizations, such as the Society for Vascular Surgery, the rate of adoption of TCAR and sales of our products that facilitate the procedure are also heavily influenced by medical society recommendations.  We believe the Society for Vascular Surgery&#8217;s Clinical Practice Guidelines, or SVS Guidelines, are of particular importance to the broader market acceptance of TCAR.  The most current SVS Guidelines on the management of carotid artery disease, which were last published in 2011, do not specifically mention TCAR as a treatment for carotid artery disease, but generally discuss CAS and embolic protection methods, including flow reversal.  The proposed updated SVS Guidelines on the management of carotid artery disease are currently publicly available for comment through February 24, 2021.  If the next version of the SVS Guidelines do not recommend TCAR, or if the Society for Vascular Surgery issues a negative or limited statement regarding TCAR, physicians may not adopt or continue to use TCAR or our products at the same rate or at all, which would have a material adverse effect on our business, financial condition and results of operations.  Additionally, if key opinion leaders who currently support TCAR cease to recommend TCAR or our products, our business, financial condition and results of operations will be adversely affected.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of TCAR depends upon appropriate physician training, and inadequate training may lead to negative patient outcomes, affect adoption of TCAR and adversely affect our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of TCAR depends in part on the skill of the physician performing the procedure and on our customers&#8217; adherence to appropriate patient selection and proper techniques provided in training sessions conducted by our training faculty.  For example, we train our customers to ensure correct use of our ENROUTE NPS and proper deployment of our ENROUTE stent.  However, physicians rely on their previous medical training and experience when performing TCAR, and we cannot guarantee that all such physicians will have the necessary surgical and endovascular skills to perform the procedure.  While we mandate physician attendance at our TCAR training program or training with proctors, we do not control which physicians perform TCAR or how much training they receive.  Physicians who have not completed our training sessions may nonetheless attempt to perform TCAR.  If physicians perform TCAR in a manner that is inconsistent with its labeled indications, with components that are not our products or without adhering to or completing our training sessions, their patient outcomes may not be consistent with the outcomes achieved in our and other clinical trials, studies or registries of TCAR.  This result may negatively impact the perception of patient benefit and safety and limit adoption of TCAR and our products that facilitate the procedure, which would have a material adverse effect on our business, financial condition and results of operations.  Additionally, physician organizations may adopt physician credentialing guidelines requiring TCAR training more extensive than our training program.  If physicians conclude that we do not provide adequate TCAR training, they may be less likely to adopt TCAR and our products, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic and efforts to reduce its spread have impacted, and may in the future periods negatively impact, our business and operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19 and its variants, or COVID-19, in the United States has resulted in travel restrictions impacting our sales professionals and therapy development specialists who support them. However, our field-based team continues to be available to support TCAR procedures, either in person or virtually. Members of our field team may, however, choose not to enter hospitals due to preexisting conditions, personal choice, or on doctors&#8217; orders or may be unable to enter hospitals due to hospital policy. During the second quarter we also cancelled or rescheduled most of our training programs, resulting in fewer new physicians trained on the TCAR procedure relative to our plans. In addition, hospitals may reduce staffing and postpone certain procedures in response to COVID-19 or divert resources to treat those patients with COVID-19. Some hospitals have also restricted or limited access for non-patients, including our sales professionals and therapy development specialists, which has negatively impacted our access to physicians and their patients. Our business and operations may be impacted by new hospital sanitization and social distancing protocols, as well as increased competition for operating room and hybrid operating rooms within hospitals that have dedicated certain resources only to COVID-19 patients. Additionally, we anticipate that an increase in the unemployment rate due to the impact of COVID-19 may decrease the number of potential patients with health insurance, which may result in fewer diagnoses, a lower number of procedures, or a shift to procedures which are reimbursed by government payers. As hospitals cancel and defer elective surgeries, it reduces their revenue and impacts their financial results, which could result in pricing pressure on our products as they seek cost savings. Prolonged restrictions relating to COVID-19 could adversely affect our procedures and the revenue we derive as a result. Additionally, some hospitals may have cash flow problems or cease doing business due to the impact of COVID-19 on their operations, which could reduce the number of hospitals where TCAR is performed and adversely affect our ability to collect amounts due to us and our revenue as a result. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these challenges to continue to impact the number of TCAR procedures in 2021, but the extent cannot be quantified at this time. Our customers&#8217; patients are also experiencing the economic impact of the current pandemic.&#160;Even an important surgical procedure like TCAR may be less of a priority than other priorities for those patients who have lost their jobs, are furloughed, have reduced work hours or are worried about the continuation of their medical insurance. Patients may also be reluctant to visit </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their physicians at their offices or in hospitals due to fear of contracting COVID-19. Physicians may not be performing as many diagnostic tests for their patients and the labs where these tests are performed may not be open, staffed adequately or open the entire day. Even where physicians continue to treat symptomatic patients, treatment of asymptomatic patients is being deferred in many cases in areas where COVID-19 cases and hospitalizations are significant. The reduction in diagnostic testing and physician visits, the increase in deferred treatment, and patient behaviors are translating into fewer than expected TCAR procedures being performed in the current environment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental mandates related to COVID-19 or other infectious diseases have impacted, and we expect them to continue to impact, our personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which would disrupt our supply chain and/or reduce our margins. For instance, in March 2020, the Health Officers of the county of Santa Clara</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">where our headquarters, distribution and ENROUTE NPS assembly and packaging facility is located, issued a mandatory shelter-in-place order. The Health Officers have since issued orders relaxing certain requirements but requiring all businesses in the county to continue to require workers to do their jobs from home whenever possible, and provided further that workers are permitted to go into work only to complete the job duties they cannot complete from home. While we have continued to operate with remote employees and essential employees on site, an extended implementation of this governmental mandate could impact our ability to operate effectively and conduct ongoing manufacturing or research and development activities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we are considered an essential business under applicable state rules and we restarted our manufacturing operations during the third quarter. We have necessary components and raw materials on hand and appropriate distancing policies and protocols</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> established to continue manufacturing and other operations. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect the COVID-19 pandemic to impact our business over the short term as some procedures are temporarily deferred or cancelled altogether, we have taken swift and proactive measures to minimize business disruptions and preserve financial flexibility through our follow-on public offering in May 2020 and the refinancing of our debt obligations in October 2020.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In assessing our own cash conservation options, we undertook preemptive steps to curtail spending and reduce non-essential sales, general, and administrative expenses. Some expenses, including physician training courses and advertising campaigns, were deferred to later time periods or canceled outright. In the event that COVID-19 continues to limit our procedures and resulting revenue, we may have to reduc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e our employees&#8217; work hours, furlough employees, reduce salaries, variable compensation and benefits, or implement a reduction-in-force. We may also solicit voluntary leaves of absence from our employees as a cash conservation strategy. Our ongoing operations may be impacted as a result of employees assuming additional roles and responsibilities within our organization and we would have fewer resources available to run our operations, which would reduce our expenses, but could also negatively impact our business operations and revenue as a result. We may also encounter voluntary departures of key employees due to any of the foregoing actions that we undertake. If key personnel or large groups of our employees contract the virus, that may also impact our business and operations. In the meantime, we have taken steps to provide for our employees, including providing the ability for employees to work remotely and implementing strategies to support appropriate social distancing techniques for onsite employees. We are also assessing our business continuity plans in the context of this pandemic.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak and persistence of COVID-19 in international markets that we have targeted for our international expansion has delayed preparation for and launch of such expansion efforts. Regulatory timelines for approval in some countries have been delayed. The spread of an infectious disease, including COVID-19, could also result in the inability of our suppliers to deliver components or raw materials to us on a timely basis. If there were a shortage of supply, the cost of these materials or components may increase and harm our ability to provide our products on a cost-effective basis. In connection with any supply shortages in the future, reliable and cost-effective replacement sources may not be available on short notice or at all, and this may force us to increase prices and face a corresponding decrease in demand for our products. In the event that any of our suppliers were to discontinue production of our key product components, developing alternate sources of supply for these </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">components would be time consuming, difficult and costly. The extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including the duration and severity of the pandemic, the actions taken to reduce the transmission of COVID-19, and the speed with which normal economic and operating conditions resume, among others.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted by the CARES Act, we have deferred the employer portion of social security taxes. We continue to review and may seek other available benefits under CARES Act. We cannot predict the manner in which such benefits will be allocated or administered and we cannot assure you that we will be able to access such benefits in a timely manner or at all. Certain of the benefits under the CARES Act have not previously been administered on the present scale or at all. Government or third party program administrators may impose additional conditions and restrictions on our operations and the benefits may otherwise provide less relief than we contemplate. If the U.S. government or any other governmental authority agrees to provide crisis relief assistance that we accept, it may impose certain requirements on the recipients of the aid, including restrictions on executive officer compensation, dividends, prepayment of debt, limitations on debt and other similar restrictions that will apply for a period of time after the aid is repaid or redeemed in full. We cannot assure you that any such government crisis relief assistance will not significantly limit our corporate activities or be on terms that are favorable to us. Such restrictions and terms could adversely impact our business and operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we anticipate that the COVID-19 pandemi</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c may c</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ontinue to impact clinical and regulatory matters. COVID-19 is delaying enrollment in clinical trials across the medical device industry and may affect any new trials we decide to pursue. Our ongoing diffusion weighted imaging trials in the US and Europe are experiencing patient enrollment delays. Additionally, we may experience regulatory delays in our effort to seek a label expansion for the ENROUTE stent in standard surgical risk patients, as the FDA has from time to time diverted resources to address the impact of COVID-19. COVID-19 may cause disruptions that could have a material adverse impact on our clinical trial plans and timelines, including:</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in receiving authorizations from local regulatory authorities, ethics committees and institutional review boards to initiate planned clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruptions in global shipping that may affect the transport of clinical trial materials;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in necessary interactions with local regulators, ethics committees and other third parties and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusal of the FDA to accept data from clinical trials in affected geographies.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the delay or denial of regulatory approvals or clearances of our product.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA and other global health regulatory agencies may also experience disruptions in their operations as a result of the COVID-19 pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced and, as a result, review, inspection and other timelines may be materially delayed. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in response to the global pandemic of COVID-19, in March 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products, and temporarily postpone routine surveillance inspections of domestic manufacturing facilities. In July 2020, the FDA announced its intentions to restart prioritized domestic on-site inspections, but noted that the resumption of inspections would depend on data about the COVID-19 trajectory in a given state and locality and the rules and guidelines put in place by state and local governments.  The FDA is either continuing, on a case-by-case basis, to conduct only &#8220;mission-critical&#8221; inspections, or, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">where possible to do so safely, resuming prioritized domestic inspections, which generally include pre-approval and surveillance inspections.  Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. It is unknown how long such delays or disruptions could last. Any elongation or de-prioritization of our clinical or other product development activities or delay in regulatory review resulting from such disruptions could materially affect our results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of COVID-19 is highly uncertain and subject to change. This impact could have a material, adverse impact on our liquidity, capital resources, operations and business and those of the third parties on which we rely. The extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. We do not yet know the full extent of potential delays or impacts on our business, financial condition and results of operations. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of COVID-19 on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity and our ability to operate.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including driving hospitals to tighten budgets and curtail spending, which would negatively impact our sales and business. In addition, higher unemployment or reductions in business benefits plans could result in fewer commercially insured patients, which could negatively impact our revenue and business as a result. A weak or declining economy could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business and we cannot anticipate all of the ways in which the economic climate and financial market conditions could adversely affect our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to maintain sufficient levels of inventory in order to protect ourselves from supply interruptions, but keep limited components, sub-assemblies, materials and finished products on hand. To ensure adequate inventory supply and manage our operations with our manufacturing partners and suppliers, we forecast anticipated materials requirements and demand for our products in order to predict inventory needs and then place orders with our suppliers based on these predictions. Our ability to accurately forecast demand for our products would be negatively affected by many factors, including our rapid growth, product recalls, pandemics, failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our products, our failure to accurately forecast customer acceptance of new products, changes to hospital capacity, staffing, procedure and protocol changes, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory levels in excess of customer demand may result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fs. Co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nversely, if we underestimate customer demand for our products or our own requirements for components, subassemblies and materials, our manufacturing partners and suppliers may not be able to deliver components, sub-assemblies and materials to meet our requirements and our manufacturing may be affected by the impact of COVID-19 on our suppliers, which could result in inadequate inventory levels or interruptions, delays or cancellations of deliveries to our customers, any of which would damage our reputation, customer relationships and business. In addition, several components, sub-assemblies and materials incorporated into our products require lengthy order lead times, and additional supplies or materials may not be available when required on terms that are acceptable to us or our manufacturing partners, or at all, and our manufacturing partners and suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, any of which could have an adverse effect on our ability to meet customer demand for our products and our results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited long-term data regarding the safety and effectiveness of our products, including our ENROUTE stent and TCAR generally.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products enable TCAR, which is a relatively new procedure, and our success depends on acceptance of our products and TCAR by the medical industry, including physicians and hospitals.  The FDA reviews our products for safety and effectiveness, prior to commercial launch of these products. Thereafter, physicians, through their own use of the products and evaluation of clinical data, make their own decisions as to whether our products are safe and effective for their patients and improve their clinical outcomes.  Important factors upon which the effectiveness of our products, including our ENROUTE stent, will be measured include but are not limited to long-term data regarding the risk of stroke and death and the rates of restenosis and reintervention following TCAR.  The long-term clinical benefits of procedures that use our products are not fully known.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited data on the ENROUTE stent and TCAR up to one year.  Any f</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ailure of our stent or in-stent restenosis of the carotid artery following deployment of the stent could deter physicians from adopting our products and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of short-term clinical experience of our products do not necessarily predict long-term clinical benefit.  We believe that physicians will compare the rates of long-term risk of stroke and death, as well as restenosis and reintervention for procedures using our products, against alternative procedures, such as CEA and CAS.  If the long-term data do not meet physicians&#8217; expectations, or if long-term data indicate that our products are not as safe or effective as other treatment options or as current short-term data would suggest, our products may not become widely adopted, physicians may recommend alternative treatments for their patients and our business could be harmed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to maintain adequate levels of third-party coverage and reimbursement for the procedures using our products, if third parties rescind or modify their coverage, or if patients are left with significant out-of-pocket costs, it would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TCAR is currently covered under certain circumstances for certain patients by the Centers for Medicare and Medicaid Services, and has been covered by some commercial payers, independent networks and other entities not governed by the National Coverage Determination.  In the United States, we derive our revenue from sales to hospitals and medical centers, which typically bill all or a portion of the costs and fees associated with our products to various third-party payers, including Medicare, Medicaid, Veterans&#8217; Administration, private commercial insurance companies, health maintenance organizations and other healthcare-related organizations, and then bill patients for any applicable deductibles or co-payments.  For example, our contracts are with the hospitals and medical centers that purchase our products for use with TCAR and not with the commercial payers.  As a result, access to adequate coverage and reimbursement for our products by third-party payers is essential to the acceptance of our products by our customers.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, in the United States, there is no uniform policy of coverage and reimbursement for medical device products and services among third-party payers, so coverage and reimbursement can differ significantly from payer to payer, and each coverage decision and level of reimbursement is independent.  As a result, third-party reimbursement may not be available or adequate for our products, and there is no guarantee that we will be able to maintain our current levels of coverage or reimbursement or be able to expand coverage to other insurance carriers.  Further, payers continually review new technologies for possible coverage and can, without notice, deny or limit coverage for products and procedures or delay coverage approval until further clinical data are available.  As a result, the coverage determination process is often a time-consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained.  If third-party reimbursement is not available or adequate for TCAR procedures using our products, or if there is any decline in the amount that payers are willing to reimburse our customers for TCAR or our products, new customers may not adopt, or may reduce their rate of adoption of, our products and we could experience additional pricing pressure, any of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are covered for Medicare beneficiaries under a National Coverage Determination, or NCD, for Percutaneous Transluminal Angioplasty and for non-Medicare beneficiaries based on prior authorizations and individual insurer medical police</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. Based on reimbursement information regarding CEA and CAS, we estimate that approximately 79% of carotid procedures are reimbursed by the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, and the remaining approximately 21% are reimbursed by commercial and other payers.  Medicare is managed by CMS, which make the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">final determination regarding Medicare hospital and physician coverage and payment.  Any future reconsideration of the applicable Medicare NCD may result in expansion of coverage of CAS and TCAR procedures based on FDA-approved indications or continued coverage limitations to CMS approved CAS investigational studies.  CMS reimburses hospital inpatient services based on Medicare Severity Diagnosis Related Groups, or MS-DRGs.  All CAS and CEA procedures are currently paid only as Medicare inpatient procedures.  CMS policy focus on hospital price transparency, site (e.g. inpatient, outpatient, ambulatory surgery center and office) neutral payments and MS-DRG refinements may place additional downward pressure on future hospital inpatient payments.  Medicare payments to physicians are based on a Resource Based Relative Value System.  CMS policy changes to increase reimbursement for physician primary care services may result in reductions to physician payments for specialty services and procedures.  As a result of any reductions in payments to hospitals and physicians for TCAR procedures, TCAR utilization may decline, which would have a material adverse effect on our business, financial condition and results of operations.  Additionally, patients may elect to reduce or defer out-of-pocket costs during times of economic uncertainty or periods of legislative change.  If hospital, physician and/or patient </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demand for TCAR, and thus our products that facilitate the procedure, is adversely affected by third-party reimbursement policies and decisions, it will have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, reimbursement systems in foreign markets vary significantly by country and by region within some countries, and reimbursement approvals must be obtained on a country-by-country basis.  In certain international markets, a product must be approved for reimbursement before it can be approved for sale in that country.  Additionally, many international markets have government-managed healthcare systems that control reimbursement for products and procedures.  In most markets there are both private insurance systems and government-managed systems.  If sufficient levels of coverage and reimbursement are not available for TCAR or our current or future products, in either the United States or internationally, the demand for our products and our revenues will be adversely affected.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, when payers combine their operations, the combined company may elect to reimburse for TCAR at the lowest rate paid by any of the participants in the consolidation or use its increased size to negotiate reduced rates.  If one of the payers participating in the consolidation does not reimburse for TCAR at all, the combined company may elect not to reimburse for TCAR, which would adversely impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in our intellectual property license from Cordis, a Cardinal Health Company, we could lose license rights that are important to our business. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a license agreement with Cordis Corporation, or Cordis, which was acquired by Cardinal Health, under which Cordis has granted us a worldwide, non-exclusive, royalty-bearing license to certain of its intellectual property related to the PRECISE&#174; carotid stent for transcervical treatment of carotid artery disease with an intravascular stent for certain applications for accessing blood vessels through the neck and cervical area. This license agreement imposes, and we expect that any future license agreements will impose, certain diligence, royalty, and other obligations on us. If we fail to comply with these obligations, our licensors, including Cardinal Health, may have the right to reduce the scope of our rights or terminate these agreements, in which event we may not be able to develop and market any product that is covered by these agreements. Termination of this license for failure to comply with such obligations or for other reasons, or reduction or elimination of our licensed rights under it or any other license, may result in our having to negotiate new or reinstated licenses on less favorable terms or our not having sufficient intellectual property rights to operate our business or cause us to enter into a new license for a different stent. The occurrence of such events could materially harm our business and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we in-license, and any failure by us or our licensors, including Cordis, to obtain, maintain, defend and enforce these rights could have a material adverse effect on our business. In some cases we do not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Cordis to supply the ENROUTE stent, and if Cordis fails to supply the ENROUTE stent in sufficient quantities or at all, it will have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on Cordis to manufacture the ENROUTE stent pursuant to a supply agreement between us and Cordis Corporation, which was acquired by Cordis.  We strive to maintain an inventory of several months&#8217; worth of ENROUTE stents to guard against potential shortfalls in supply, and we estimate that it would take one to two years to find an alternative supplier for our ENROUTE stent and multiple years to identify and seek approval for another stent, and in each case qualify it for use with our other products.  In addition, Cordis currently manufactures the ENROUTE stent at a facility in Juarez, Mexico. This facility </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has previously and in the future could become subject to a COVID-19 outbreak which would cause Cordis to temporarily shut down manufacturing operations, which would in turn present risk to the ongoing supply of our stents used in TCAR procedures.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The current political and trade relationship between the United States and Mexico is strained due to the prior administration and could deteriorate further.  If Cordis's ability to manufacture</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the ENROUTE stent is interrupted as a result, or if Cordis experiences a product recall or breaches its supply agreement with us, we may not have a sufficient number of stents for delivery to support TCAR procedures.  Any shortfall in the supply of ENROUTE stents may result in lower adoption rates for TCAR, fewer TCAR procedures being performed generally, and a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TCAR involves surgical risks and is contraindicated in certain patients, which may limit adoption.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks of TCAR using our products include the risks that are common to surgical and endovascular procedures, including perforation, dissection, embolization, bleeding, infection, nerve injury and restenosis.  Endovascular procedures occurring in the carotid arteries also include the additional risks of stroke, heart attack and death.  We are aware of certain characteristics and features of TCAR that may prevent widespread market adoption, including the fact that physicians would need to adopt a new procedure, and that training for physicians will be required to enable them to effectively operate our products.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current products are contraindicated, and therefore should not be used, in certain patients.  Our ENROUTE NPS is contraindicated in patients in whom antiplatelet and/or anticoagulation therapy is contraindicated; patients with uncorrected bleeding disorders; patients with severe disease of the ipsilateral common carotid artery; and patients with uncontrollable intolerance to flow reversal.  Our ENROUTE stent is contraindicated in patients in whom antiplatelet and/or anticoagulation therapy is contraindicated; patients in whom the ENROUTE NPS is unable to be placed; patients with uncorrected bleeding disorders; patients with known allergies to nitinol; and patients with lesions in the ostium of the common carotid artery.  Our ENHANCE peripheral access kit is contraindicated in patients with a known or suspected obstruction in the vessel.  Our ENROUTE guidewire is contraindicated in patients judged not acceptable for percutaneous intervention.  Additionally, patients that lack at least five centimeters of common carotid artery free of significant disease are not indicated for our ENROUTE NPS.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face manufacturing risks that could adversely affect our ability to manufacture products and could reduce our gross margins and negatively affect our business and operating results.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy depends on our ability to manufacture our current and future products in sufficient quantities and on a timely basis to meet customer demand, while adhering to product quality standards, complying with regulatory quality system requirements and managing manufacturing costs.  We have a facility located in Sunnyvale, California, where we assemble and package certain of our products, and inspect, release and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ship all of our products, either directly to our customers or to our third-party logistics </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and warehousing service</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently produce our ENROUTE NPS at this facility, and we and the contract manufacturers of our other products do not have redundant facilities.  If our or our manufacturing partners&#8217; facilities suffers damage, or a force majeure event, this could materially impact our ability to operate.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous other risks relating to our manufacturing capabilities, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quality and reliability of components, sub-assemblies and materials that we source from third-party suppliers, who are required to meet our quality specifications, the majority of which are our single source suppliers for the products they supply;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our manufacturing partners&#8217; inability to secure components, sub-assemblies and materials in a timely manner, in sufficient quantities or on commercially reasonable terms;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our manufacturing partners&#8217; inability to maintain compliance with quality system requirements or pass regulatory quality inspections;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our manufacturing partners&#8217; failure to develop products in a timely manner or to required specifications or to increase production capacity or volumes to meet demand;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our manufacturing partners&#8217; inability to design or modify production processes to enable us to produce future products efficiently or implement changes in current products in response to design or regulatory requirements; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternative suppliers for components in a timely manner.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As demand for our products increases, we will have to invest additional resources to purchase components, sub-assemblies and materials, hire and train employees and enhance our manufacturing processes.  If we fail to increase our production capacity efficiently, we may not be able to fill customer orders on a timely basis, our sales may not increase in line with our expectations and our operating margins could fluctuate or decline.  In addition, although we expect some of our products in development to share product features, components, sub-assemblies and materials with our existing products, the manufacture of these products may require modification of our or our manufacturing partners&#8217; current production processes or unique production processes, the hiring of specialized employees, the identification of new suppliers for specific components, sub-assemblies and materials or the development of new manufacturing technologies.  It may not be possible for us or our manufacturing partners&#8217; to manufacture these products at a cost or in quantities sufficient to make these products commercially viable or to maintain current operating margins, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on a limited number of single source suppliers to manufacture our components, sub-assemblies and materials, which makes us vulnerable to supply shortages and price fluctuations that could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on single source suppliers for the components, sub-assemblies and materials for our ENROUTE NPS.  These components, sub-assemblies and materials are critical and there are relatively few alternative sources of supply.  We have not qualified or obtained necessary regulatory approvals for additional suppliers for most of these components, sub-assemblies and materials, and we do not carry a significant inventory of these items.  While we believe that alternative sources of supply may be available, we cannot be certain whether they will be available if and when we need them, or that any alternative suppliers would be able to provide the quantity and quality of components and materials that we would need to manufacture our products if our existing suppliers were unable to satisfy our supply requirements.  To utilize other supply sources, we would need to identify and qualify new suppliers to our quality standards and obtain any additional regulatory approvals required to change suppliers, which could result in manufacturing delays and increase our expenses.  Our manufacturing partners rely on single source suppliers as well, and are subject to the foregoing risks.  </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our manufacturing partners&#8217; dependence on third-party suppliers subjects us to a number of risks that could impact our ability to manufacture our products and harm our business, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruption of supply resulting from modifications to, or discontinuation of, a supplier&#8217;s operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in product shipments resulting from uncorrected defects, reliability issues or a supplier&#8217;s failure to produce components that consistently meet our quality specifications;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Price fluctuations due to a lack of long-term supply arrangements with our suppliers for key components;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to obtain adequate supply in a timely manner or on commercially reasonable terms;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulty identifying and qualifying alternative suppliers for components in a timely manner;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability of suppliers to comply with applicable provisions of the QSR or other applicable laws or regulations enforced by the FDA and state regulatory authorities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to adequately ensure the quality of products and components manufactured by third parties;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Production delays related to the evaluation and testing of products and components from alternative suppliers and corresponding regulatory qualifications;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in delivery by our suppliers due to changes in demand from us or their other customers; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An outbreak of disease or similar public health threat, such as the existing threat of COVID-19, particularly as it may impact our supply chain.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we require our third-party suppliers to supply us with components that meet our specifications and comply with applicable provisions of the QSR and other applicable legal and regulatory requirements in our agreements and contracts, and we perform incoming inspection, testing or other acceptance activities to ensure the components meet our requirements, there is a risk that our suppliers will not always act consistent with our best interests, and may not always supply components that meet our requirements or supply components in a timely manner.   For example, in the first quarter of 2021, we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by one of our third-party suppliers, Cordis. Our decision to recall these lots was based on complaints we received about tips detaching from the stent delivery system as well as internal testing that we conducted. We believe the root cause of the detachment was a single operator at Cordis, who, over a specific timeframe, produced lots in which a small number of units were not reliably manufactured to specification.  Recalls like this one could cause the supply of our TCAR products to customers to be interrupted, us to incur additional expenses, have to purchase replacement products, negative publicity or damage to our reputation, any of which could cause our results of operations to be adversely impacted.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to maintain sufficient levels of inventory in order to protect ourselves from supply interruptions, but keep limited components, sub-assemblies, materials and finished products on hand.  To ensure adequate inventory supply and manage our operations with our manufacturing partners and suppliers, we forecast anticipated materials requirements and demand for our products in order to predict inventory needs and then place orders with our suppliers based on these predictions.  Our ability to accurately forecast demand for our products could be negatively affected by many factors, including our rapid growth, failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our products, our failure to accurately forecast customer acceptance of new products, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory levels in excess of customer demand may result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs.  Conversely, if we underestimate customer demand for our products or our own requirements for components, subassemblies and materials, our manufacturing partners and suppliers may not be able to deliver components, sub-assemblies and materials to meet our requirements, which could result in inadequate inventory levels or interruptions, delays or cancellations of deliveries to our customers, any of which would damage our reputation, customer relationships and business.  In addition, several components, sub-assemblies and materials incorporated into our products require lengthy order lead times, and additional supplies or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materials may not be available when required on terms that are acceptable to us or our manufacturing partners, or at all, and our manufacturing partners and suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, any of which could have an adverse effect on our ability to meet customer demand for our products and our results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual results may fluctuate significantly and may not fully reflect the underlying performance of our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual results of operations, including our revenue, net income or net loss and cash flow, may vary significantly in the future, and period-to-period comparisons of our operating results may not be meaningful.  Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance.  Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business.  Fluctuations in quarterly and annual results may decrease the value of our common stock.  Because our quarterly results may fluctuate, period-to-period comparisons may not be the best indication of the underlying results of our business and should only be relied upon as one factor in determining how our business is performing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited total addressable market based on our current labeling restrictions.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total addressable market for TCAR is limited by a number of factors. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Approximately 166,000 patients with carotid artery disease in the United States received treatment in the form of surgical or endovascular intervention in 2019.  Of this</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> group, we estimate that approximately one-third would be outside the scope of the FDA-approved labeling for the ENROUTE stent, as those patients are not deemed to be at high risk for adverse events from CEA, or high surgical risk.  The current FDA-approved labeling for the ENROUTE stent is limited to patients at high risk for adverse events from CEA. Patients at high risk for adverse events from CEA are defined as having significant comorbidities and/or anatomic risk factors, and/or advanced age, that would make them riskier candidates for CEA.  Furthermore, the safety and effectiveness of TCAR has not been established for certain patients. For example, the FDA-cleared labeling for the ENROUTE NPS states that patients should have at least five centimeters of common carotid artery free of significant disease for initial access to the artery and positioning of the ENROUTE sheath.  In addition, per the FDA-approved labeling for the ENROUTE stent, TCAR is limited to asymptomatic patients with carotid artery stenosis of at least 80% and symptomatic patients with carotid artery stenosis of at least 50%, both of which must also be high surgical risk. In addition, physicians may choose to perform CEA in patients with certain anatomical characteristics, including heavily calcified carotid arteries, calcified lesions and severe vessel tortuosity.  Finally, current labeling for our products includes contraindications for certain patients, thus further reducing our total addressable market. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanding the addressable market for TCAR is dependent upon labeling and reimbursement expansion initiatives.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ENROUTE stent is not currently indicated for use in standard surgical risk patients.  To access a larger portion of the market for carotid artery disease, we will need to obtain approval by the FDA for a label expansion of the ENROUTE stent in standard surgical risk patients and obtain corresponding reimbursement coverage expansion for TCAR.  FDA approval of an ENROUTE stent label expansion may require additional data from clinical studies or registries</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which we are pursuing.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, there are no guarantees that we will be able to obtain such clinical study or registry data or FDA approval of a label expansion for the ENROUTE stent, or that any label expansion or additional reimbursement coverage will be sufficient to adequately access the standard risk portion of the market for carotid artery disease patients.  If we are unable to obtain labeling and reimbursement coverage expansion, it may have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in public health insurance coverage and government reimbursement rates for the TCAR procedures using our products could affect the adoption of our products and our future revenue.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government is considering ways to change, and has changed, the manner in which healthcare services are paid for in the United States.  Individual states may also enact legislation that impacts Medicaid payments to hospitals and physicians.  In addition, CMS establishes Medicare payment levels for hospitals and physicians on an annual basis, which can increase or decrease payment to such entities.  Internationally, medical reimbursement systems vary significantly from country to country, with some countries limiting medical centers&#8217; spending through fixed budgets, regardless of levels of patient treatment, and other countries requiring application for, and approval of, government or third-party reimbursement.  Even if we succeed in bringing our products to market in additional foreign countries, uncertainties regarding future healthcare policy, legislation and regulation, as well as private market practices, could affect our ability to sell our products in commercially acceptable quantities at acceptable prices.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and profitability.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to reduce costs, many hospitals in the United States have become members of Group Purchasing Organizations, or GPOs, and Integrated Delivery Networks, or IDNs.  GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors and then offer these negotiated prices to affiliated hospitals and other members.  GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process.  Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors.  Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs.  Furthermore, the increasing leverage of organized buying groups reduces market prices for our products and/or require administrative fees, thereby reducing our revenue and/or margins.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders.  Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers.  Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days&#8217; notice.  Accordingly, the members of such groups may choose to purchase alternative products due to the price or quality offered by other companies, which could result in a decline in our revenue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to achieve or maintain satisfactory pricing and margins for our products.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of medical devices have a history of price competition, and we can give no assurance that we will be able to achieve satisfactory prices for our products or maintain prices at the levels we have historically achieved.  Any decline in the amount that payers reimburse our customers for TCAR could make it difficult for customers to continue using, or to adopt, our products and could create additional pricing pressure for us.  If we are forced to lower the price we charge for our products, our gross margins will decrease, which will adversely affect our ability to invest in and grow our business.  If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could erode.  We will continue to be subject to significant pricing pressure, which could harm our business and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any growth that we experience in the future will require us to expand our sales, general and administrative personnel, manufacturing and distribution operations, and facilities and information technology infrastructure.  In addition to the need to scale our organization, future growth will impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees.  Rapid expansion in personnel could mean that less experienced people </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture, market and sell our products, which could result in inefficiencies and unanticipated costs, reduced quality and disruptions to our operations.  In addition, rapid and significant growth may strain our administrative and operational infrastructure.  Our ability to manage our business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures.  If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As demand for our products or any of our future products increases, we will need to continue to scale our capacity, expand customer service, billing and systems processes and enhance our internal quality assurance program.  We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available to facilitate the growth of our business.  Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs or inability to meet increased demand.  If we encounter difficulty meeting market demand, quality standards or physician expectations, our reputation could be harmed and our business could suffer.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our recent growth in our business, we are actively searching for additional space to provide offices and facilities for the employees we expect to hire.  Starting in the third quarter of 2020 we supplemented our distribution </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations with third-party logistics and warehousing services in another part of the country and are considering additional leased facilities inside and outside of the San Francisco Bay area.  There is competition for office, shipping and warehousing space in the San Francisco Bay area and elsewhere and we can provide no assurance that we will find additional space or that such space will be on reasonable terms.  If we are unable to obtain additional space or support on commercially reasonable terms our costs may go up or our business operations may be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our manufacturing facility becomes damaged or inoperable, or if we are required to vacate a facility, we may be unable to produce the products we manufacture or we may experience delays in production or an increase in costs, which could adversely affect our results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain our research and development, manufacturing and non-field-based sales, general and administrative operations in a building located in Sunnyvale, California, which is situated on or near earthquake fault lines, and we do not have redundant facilities.  Should our building be significantly damaged or destroyed by natural or man-made disasters, such as earthquakes, fires or other events, it could take months to relocate or rebuild, during which time our employees may seek other positions, our research, development and manufacturing would cease or be delayed and our products may be unavailable.  Moreover, the use of a new facility or new manufacturing, quality control, or environmental control equipment or systems generally requires FDA review and, with respect to certain products, approval of a PMA supplement.  Because of the time required to authorize manufacturing in a new facility under FDA, the State of California and non-U.S. regulatory requirements, we may not be able to resume production on a timely basis even if we are able to replace production capacity in the event we lose manufacturing capacity.  While we maintain property and business interruption insurance, such insurance has limits and would only cover the cost of rebuilding and relocating and lost revenue, but not general damage, losses caused by earthquakes, losses we may suffer due to our products being replaced by competitors&#8217; products or loss in value due to associated decreases in our stock price.  The inability to perform our research, development and manufacturing activities, combined with our limited inventory of materials and components and manufactured products, may cause physicians to discontinue using our products or harm our reputation, and we may be unable to reestablish relationships with such physicians in the future.  Consequently, a catastrophic event at our facility could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the current lease for our manufacturing facility expires in 2024, and our operations are growing at a pace that may require us to find a replacement or expansion facility sooner.  We may be unable to renew our lease or find a new facility on commercially reasonable terms.  I</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f we were unable or unwilling to renew at the proposed rates, relocating our manufacturing facility would involve significant expense in connection with the movement and installation of key manufacturing equipment and any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">necessary recertification with regulatory bodies, and we cannot assure investors that such a move would not delay or otherwise adversely affect our manufacturing activities or operating results.  If our manufacturing capabilities were impaired by our move, we may not be able to manufacture and ship our products in a timely manner, which would adversely impact our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on our manufacturing partners to supply certain of our products, and our partners are subject to similar risks with respect to their facilities.  If our manufacturing partners&#8217; facilities are damaged or destroyed and their ability to supply products to us is limited, it could negatively affect our reputation, physician relationships and TCAR adoption, all of which could have a material adverse effect on our business, financial condition and results of operations.  Several of our products are sterilized at a particular third party facility, with limited alternate facilities. If an event occurs that results in damage to or closure of one or more of such facilities, we may be unable to sterilize such products at the previous levels or at all. Because of the time required to approve and license a sterilization facility, a third party may not be available on a timely basis to replace capacity in the event sterilization capacity is lost.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail in our training initiatives, to increase our sales and marketing capabilities or to develop broad brand awareness, our growth will be impeded and our business will suffer.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on our direct sales force to sell our products in targeted geographic regions in the U.S., and any failure to maintain and grow our direct sales force could harm our business.  The members of our direct sales force are highly trained and possess substantial technical and clinical expertise, which we believe is critical in driving adoption of TCAR.  The members of our U.S. sales force are at-will employees.  The loss of these personnel to competitors, or otherwise, could materially harm our business.  If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical and clinical expertise and qualifications, or if we are unable to successfully instill such technical and clinical expertise in replacement personnel, our revenues and results of operations could be materially harmed.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to generate future growth, we plan to continue to expand and leverage our sales, marketing, and medical affairs infrastructure to increase our trained physician and hospital customer base and our business.  Identifying and recruiting qualified sales, marketing and medical affairs personnel and training them on TCAR, on applicable federal and state laws and regulations, and on our internal policies and procedures requires significant time, expense and attention.  It often takes several months or more before a sales representative is fully trained and productive.  Our sales force may subject us to higher fixed costs than those of companies with competing products, such as stents, that utilize independent third parties, which could place us at a competitive disadvantage.  Our business may be harmed if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our products.  Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time or timely reduce fixed costs, could have a material adverse effect on our business, financial condition and results of operations.  Our ability to increase our customer base and achieve broader market acceptance of our products will depend to a significant extent on our ability to expand our marketing efforts.  We plan to dedicate significant resources to our marketing programs.  Our business may be harmed if our marketing efforts and expenditures do not generate a corresponding increase in revenue.  In addition, we believe that developing and maintaining broad awareness of our brand is critical to achieving broad acceptance of our products and penetrating new accounts.  Brand promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand.  Our medical affairs department may not train physicians at a rate sufficient to expand our physician base in a manner consistent with our business plan.  If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad adoption of our products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market for our products is highly competitive.  If our competitors are able to develop or market carotid artery disease treatments that are safer, more effective or gain greater acceptance in the marketplace, than any products we develop, our commercial opportunities will be reduced or eliminated.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is highly competitive, subject to change and significantly affected by new product introductions and other activities of industry participants.  We are initially positioning TCAR as an alternative to CEA and CAS in high surgical risk patients.  CEA has historically been performed by vascular surgeons as the primary surgical solution for carotid artery disease.  The major manufacturers of products, such as patches and shunts, used in connection with CEA include LeMaitre Vascular, Getinge / Maquet, Baxter, Terumo, Gore and Edwards.  Some competitors market products for use in CAS, such as peripheral access kits, stents, distal and proximal embolic protection devices, guidewires, balloons and sheaths.  Such companies include Abbott, Boston Scientific, Cardinal Health, Medtronic, Terumo, Gore, Contego Medical and InspireMD.  These technologies, other products that are in current clinical trials, new drugs or additional indications for existing drugs could demonstrate better safety, effectiveness, clinical results, lower costs or greater physician and patient acceptance.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete, or may compete in the future, against other companies which have longer operating histories, more established products and greater resources, which may prevent us from achieving significant market penetration or improved operating results.  These companies enjoy several competitive advantages, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Greater financial and human capital resources;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significantly greater name recognition;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Established relationships with vascular surgeons and other treating specialties, referring physicians, customers and third-party payers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Additional lines of products, and the ability to offer rebates or bundle products to offer greater discounts or incentives to gain a competitive advantage; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Established sales, marketing and worldwide distribution networks.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the size of the market opportunity for the treatment of carotid artery disease, we believe potential competitors have historically dedicated and will continue to dedicate significant resources to aggressively promote their products or develop new products.  New treatment options may be developed that could compete more effectively with our products due to the prevalence of carotid artery disease and the extensive research efforts and technological progress that exist within the market.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defects or failures associated with our products could lead to additional recalls, s</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">afety alerts or litigation, as well as significant costs and negative publicity.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks associated with manufacture, distribution and use of medical devices that are placed inside the human body, including the risk that patients may be severely injured by or even die from the misuse or malfunction of our products caused by design flaws or manufacturing defects.  In addition, component failures, design defects, off-label uses or inadequate disclosure of product-related information could also result in an unsafe condition or the injury or death of a patient.  These problems could lead to a recall or market withdrawal of, or issuance of a safety alert relating to, our products and could result in significant costs, negative publicity and adverse competitive pressure.  For example, in the first quarter of 2021, we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by one of our third-party suppliers, Cordis. Our decision to recall these lots was based on complaints we received about tips detaching from the stent delivery system as well as internal testing that we conducted. We believe the root cause of the detachment was a single operator at Cordis, who, over a specific timeframe, produced lots in which a small number of units were not reliably manufactured to specification.  The circumstances giving rise to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recalls are unpredictable, and any recalls of existing or future products increase the probability of inspection by, or additional scrutiny from, the FDA and could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide a limited warranty that our products are free of material defects and conform to specifications, and offer to repair, replace or refund the purchase price of defective products.  As a result, we bear the risk of potential warranty claims on our products.  In the event that we attempt to recover some or all of the expenses associated with a warranty claim against us from our suppliers or vendors, we may not be successful in claiming recovery under any warranty or indemnity provided to us by such suppliers or vendors and any recovery from such vendor or supplier may not be adequate.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry has historically been subject to extensive litigation over product liability claims.  Operating in the area of the neck with the brain as the end organ is dangerous and presents risks of adverse events such as bleeding, arterial dissection, cranial nerve injury, myocardial infarction, stroke and death, which subject us to a greater risk of being involved in litigation than companies with products used in less critical areas of the body.  We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury or death, even if due to physician error.  In addition, an injury or death that is caused by the activities of our suppliers, such as those that provide us with components and raw materials, or by an aspect of a treatment used in combination with our products, such as a complementary drug or anesthesia, may be the basis for a claim against us by patients, hospitals, physicians or others purchasing or using our products, even if our products were not the actual cause of such injury or death.  We may choose to settle any claims to avoid fault and complication not due to failure of our products.  An adverse outcome involving one of our products could result in reduced market acceptance and demand for all of our products, and could harm our reputation and our ability to market our products in the future.  In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the suspension or delay of regulatory reviews of our premarket notifications or applications for marketing.  Any of the foregoing problems could disrupt our business and have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we carry product liability insurance in the United States and in other countries in which we conduct business, including for clinical trials and product marketing, we can give no assurance that such coverage will be available or adequate to satisfy any claims.  Product liability insurance is expensive, subject to significant deductibles and exclusions, and may not be available on acceptable terms, if at all.  If we are unable to obtain or maintain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we could be exposed to significant liabilities.  A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business, financial condition and results of operations.  Defending a suit, regardless of its merit or eventual outcome, could be costly, could divert management&#8217;s attention from our business and might result in adverse publicity, which could result in reduced acceptance of our products in the market, product recalls or market withdrawals.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to file adverse event reports under Medical Device Reporting, or MDR, regulations with the FDA, which reports are publicly available on the FDA&#8217;s website.  We are required to file MDRs if our products may have caused or contributed to a serious injury or death or malfunctioned in a way that could likely cause or contribute to a serious injury or death if it were to recur.  Any such MDR that reports a significant adverse event could result in negative publicity, which could harm our reputation and future sales.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to compete depends on our ability to innovate successfully and deliver any new products in a timely manner.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our products is competitive, dynamic, and marked by rapid and substantial technological development and product innovation.  New entrants or existing competitors could attempt to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop products that compete directly with ours.  Demand for our products and future related products could be diminished by equivalent or superior products and technologies offered by competitors.  If we are unable to innovate successfully, our products could become obsolete and our revenue would decline as our customers purchase our competitors&#8217; products.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently focused on development of existing products for TCAR and other indications, new products for TCAR and new products for other indications.  If we are unable to develop new products, applications or features due to constraints, such as insufficient cash resources, high employee turnover, inability to hire personnel with sufficient technical skills or a lack of other research and development resources, we may not be able to maintain our competitive position compared to other companies.  Furthermore, many of our competitors devote a considerably greater amount of funds to their research and development programs than we do, and those that do not may be acquired by larger companies that would allocate greater resources to research and development programs.  Our failure or inability to devote adequate research and development resources or compete effectively with the research and development programs of our competitors could harm our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any significant delays in our product launches may significantly impede our ability to enter or compete in a given market and may reduce the sales that we are able to generate from these products.  We may experience delays in any phase of a product development, including during research and development, clinical trials, regulatory review, manufacturing and marketing.  Delays in product introductions could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure of TCAR to meet patient expectations or the occurrence of adverse events from TCAR could impair our financial performance.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success depends upon patients having an experience with TCAR that meets their expectations in order to increase physician demand for our products as a result of positive feedback, social media and word-of-mouth.  Patients may be dissatisfied if their expectations of the procedure and results, among other things, are not met.  Despite what we believe to be the safety profile of our products, patients may experience adverse events such as arterial restenosis or dissection, cranial nerve injury, wound complications, transient ischemic attacks, stroke, heart attack, and death.  If the results of TCAR do not meet the expectations of the patients, or patients experience adverse events, it could discourage patients from referring TCAR to others.  For example, although we have not received any reports of strokes, deaths or other long-term patient sequelae from the tip detachments that triggered our recent recall, if there were to be patient injury, dissatisfied patients may express negative opinions through social media or we may otherwise suffer reputational damage or become subject to product liability lawsuits.  Any failure to meet patient expectations and any resulting negative publicity or lawsuits could harm our reputation and future sales.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees could harm our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends largely on the continued services of key members of our executive management team and others in key management positions.  For example, the services of Erica Rogers, our Chief Executive Officer, and Lucas Buchanan, our Chief Financial and Chief Operating Officer, are essential to driving adoption of our products, executing on our corporate strategy and ensuring the continued operations and integrity of financial reporting within our company.  In addition, the services of Andrew Davis, our Chief Commercial Officer, are critical to driving the growth in sales of our products.  Any of our employees may terminate their employment with us at any time.  We do not currently maintain key person life insurance policies on any of our employees.  If we lose one or more key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our research and development programs, and sales efforts depend on our ability to attract and retain highly skilled engineers and sales professionals.  We may not be able to attract or retain </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualified engineers and sales professionals in the future due to the competition for qualified personnel.  We have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications.  Many of the companies with which we compete for experienced personnel have greater resources than we do.  When we hire employees from competitors or other companies, their former employers have previously and may in the future attempt to assert that these employees or we have breached legal obligations, which may result in a diversion of our time and resources and, potentially, damages.  In addition, job candidates and existing employees, particularly in the San Francisco Bay Area, often consider the value of the stock awards they receive in connection with their employment along with salary, benefits and other factors.  If the perceived benefits of our stock awards decline, either because we are a public company or for other reasons, it may harm our ability to recruit and retain highly skilled employees.  If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The use, misuse or off-label use of our products may result in injuries that lead to product liability suits, which could be costly to our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ENROUTE stent has been approved by the FDA for the treatment of high surgical risk patients who require carotid revascularization and meet certain treatment parameters.  If physicians expand the patient population in which they elect to use our products that is outside of the intended use approved by the FDA, then the use, misuse, or off-label use of our products may result in outcomes and adverse events including stroke, myocardial infarction and death, potentially leading to product liability claims.  Our products are not indicated for use in all patients with carotid artery disease, and therefore cannot be marketed or advertised in the United States for certain uses without additional approvals or clearances from the FDA.  However, we cannot prevent a physician from using our products for off-label applications or using components or products that are not our products when performing TCAR.  In addition, we cannot guarantee that physicians are trained by us or their peers prior to utilizing our products.  Complications resulting from the use of our products off-label or use by physicians who have not been trained appropriately, or at all, may expose us to product liability claims and harm our reputation.  Moreover, if the FDA determines that our promotional materials or physician training, including our paid consultants&#8217; educational materials, constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to enforcement action, including warning letters, untitled letters, fines, penalties, or seizures.  If we are found to have promoted such off-label uses, we may become subject to significant liability.  The federal government has levied large civil and criminal fines and/or other penalties against companies for alleged improper promotion and has investigated, prosecuted, and/or enjoined several companies from engaging in off-label promotion.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our products are defectively designed, manufactured or labeled, contain defective components or are misused, we may become subject to costly litigation initiated by physicians, hospitals or patients.  Product liability claims are especially prevalent in the medical device industry and could harm our reputation, divert management&#8217;s attention from our core business, be expensive to defend and may result in sizable damage awards against us.  Although we maintain product liability insurance, we may not have sufficient insurance coverage for future product liability claims.  We may not be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities.  Any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation, significantly increase our expenses, and reduce product sales.  Product liability claims could cause us to incur significant legal fees and deductibles and claims in excess of our insurance coverage would be paid out of cash reserves, harming our financial condition and operating results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need substantial additional funding and may not be able to raise capital when needed, which could force us to delay, reduce or eliminate our product development programs and commercialization efforts.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents and investments and expected revenue will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months.  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we have based these estimates on assumptions that may prove to be incorrect, and we could spend our available financial resources much faster than we currently expect.  Our future funding requirements will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The degree and rate of market acceptance of TCAR and our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Whether we acquire third-party companies, products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restructuring, refinancing or repayment of debt;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The scope and timing of investment in our sales force; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The scope and timing of investment in physician training;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The scope, rate of progress and cost of our current or future clinical studies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The scope, rate of progress and cost of our research and development activities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The scope, rate of progress and cost of additional regulatory clearances or approvals; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The costs associated with any current or future product recall that may occur;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The costs of attaining, defending and enforcing our intellectual property rights;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of COVID-19 on our business and operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The emergence of competing technologies or other adverse market developments; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rate at which we expand internationally.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek to raise additional capital through equity offerings or debt financings and such additional financing may not be available to us on acceptable terms, or at all.  In addition, any additional equity or debt financing that we raise may contain terms that are not favorable to us or our stockholders.  For example, if we raise funds by issuing equity or equity-linked securities, the issuance of such securities could result in dilution to our stockholders.  Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock.  In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of debt securities issued or borrowings could impose significant restrictions on our operations including restrictive covenants, such as limitations on our ability to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, and other operating restrictions that could adversely affect our ability to conduct our business.  </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms, such as relinquishment or licensing of certain technologies or products that we otherwise would seek to develop or commercialize ourselves, or reserve for future potential arrangements when we might otherwise be able to achieve more favorable terms.  In addition, we may be forced to work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs to us.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain adequate financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, or delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products.  If this were to occur, our ability to grow and support our business and to respond to market challenges could be significantly limited, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a significant amount of debt, which may affect our ability to operate our business and secure</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> additional financing in the future.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had an aggregate of approximately $49.0&#160;million in principal outstanding under our Loan Agreement with Stifel Bank. We must make significant interest-only monthly payments under the Loan Agreement, which has diverted and will continue to divert resources from other activities.  Our obligations under the Loan Agreement </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are collateralized by substantially all of our assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding intellectual property, and we are subject to c</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ustomary affirmative and negative covenants, including covenants limiting our ability and the ability of our subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The covenants related to the Loan Agreement, as well as any future financing agreements into which we may enter, may restrict our ability to finance our operations and engage in, expand or otherwise pursue our business activities and strategies.  While we have not previously breached and are not currently in breach of these or any other covenants contained in our Loan Agreement, there can be no guarantee that we will not breach these covenants in the future. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our ability to comply with these covenants may be affected by events beyond our control, and future breaches of any of these covenants could result in a default under the Loan Agreement.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If not waived, future defaults could cause all of the outstanding indebtedness under the Loan Agreement to become immediately due and payable, termination of commitments to extend further credit, a 5% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement.  I</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f we do not have or are unable to generate sufficient cash available to repay our debt obligations when they become due and payable, either upon maturity or in the event of a default, our assets could be foreclosed upon and we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate and continue our business as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire other companies or technologies, or enter into license agreements, distribution arrangements or strategic partnerships, which could fail to result in a commercial product or generate sales, divert our management&#8217;s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our operating results.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently have no agreements or commitments to complete any such transactions, we may in the future seek to acquire, license or invest in businesses, products or technologies that we believe could complement or expand our portfolio, enhance our technical capabilities or otherwise offer growth opportunities.  We could also seek to enter into distribution arrangements or strategic partnerships with third parties that we believe could increase our revenue or offer other commercial benefits.  However, we cannot assure you that we would be able to successfully complete any acquisition, license agreement or distribution agreement we choose to pursue, or that we would be able to successfully integrate any business or product or technology in a cost-effective and non-disruptive manner.  Similarly, we cannot guarantee that we would derive benefits from any distribution arrangement or other strategic partnership.  The pursuit of potential acquisition, license or partnering opportunities may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable transactions, whether or not they are consummated.  We may not be able to identify desirable acquisition targets or strategic partners, or be successful in entering into an agreement with any particular target or partner, or obtain the expected benefits of any acquisition, license, investment or other strategic partnership arrangement.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the growth of our operations has been largely organic, and we have limited experience in acquiring other businesses or technologies.  We may not be able to successfully integrate any acquired personnel, operations and technologies, or effectively manage the combined business following an acquisition.  Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm our operating results.  In addition, if an acquired business, product or technology fails to meet our expectations, our operating results, business and financial condition may suffer.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards may be limited</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had U.S. federal and state net operating loss carryforwards, or NOLs, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $241.9&#160;million and $209.8 million, respectively.  Our U.S. federal NOLs arising in tax years ending on or before December 31, 2017 are subject to expiration and will begin to expire in 2027 (U.S. federal NOLs arising in tax years ending after December 31, 2017 are not subject to expiration) and our state NOLs will begin to expire in 2028.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use these NOLs to offset taxable income for U.S. federal and state income tax purposes.  However, Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, may limit the NOLs we may use in any year for U.S. federal income tax purposes in the event of certain changes in ownership of our company.  An &#8220;ownership change&#8221; pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period.  Similar rules may apply under state tax laws.  Although we have not performed a formal study under Section 382 of the Code, we believe we may have experienced at least one &#8220;ownership change&#8221; in the past and may have experienced others.  In addition, future issuances or sales of our stock, including certain transactions involving our stock that are outside of our control, could result in future &#8220;ownership changes.&#8221; &#8220;Ownership changes&#8221; that have occurred in the past or that may occur in the future could result in the imposition of an annual limit on the amount of pre-ownership change NOLs and other tax attributes we can use to reduce our taxable income or income tax liability, potentially increasing and accelerating our liability for income taxes, and also potentially causing those tax attributes to expire unused.  Any limitation on using NOLs could, depending on the extent of such limitation and the NOLs previously used, result in our retaining less cash after payment of U.S. federal and state income taxes during any year in which we have taxable income, rather than losses, than we would be entitled to retain if such NOLs were available as an offset against such income for U.S. federal and state income tax reporting purposes, which could adversely impact our operating results.  Furthermore, under the Tax Cuts and Jobs Act of 2017, although the treatment of U.S. federal NOLs arising in tax years beginning on or before December 31, 2017 has generally not changed, U.S. federal NOLs arising in tax years beginning after December 31, 2017 may only be used to offset 80% of our taxable income.  This change may require us to pay U.S. federal income taxes in future years despite generating a loss for federal income tax purposes in prior years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As international expansion of our business occurs, it will expose us to market, regulatory, political, operational, financial, legal and economic risks associated with doing business outside of the United States.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term strategy is to increase our international presence, including but not limited to securing regulatory approvals in Japan and China.  We have the right to affix the CE Mark to our products, allowing us to commercialize in Europe in the future.  This strategy may include establishing and maintaining physician outreach and education capabilities outside of the United States and expanding our relationships with international distributors, providers and payers.  Doing business internationally involves a number of risks, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties in staffing and managing our international operations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multiple, conflicting and changing laws and regulations such as tax laws, privacy laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduced or varied protection for intellectual property rights in some countries; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtaining regulatory clearance where required for our products in various countries;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Requirements to maintain data and the processing of that data on servers located within such countries;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems;  </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties in adequately training and managing international distributors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limits on our ability to penetrate international markets if we are required to manufacture our products locally;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial risks, such as longer payment cycles, difficulty collecting accounts receivable, foreign tax laws and complexities of foreign value-added tax systems, the effect of local and regional financial pressures on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions on the site-of-service for use of our products and the economics related thereto for physicians, providers and payers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Natural disasters, political and economic instability, including wars, terrorism, political unrest, outbreak of disease, boycotts, curtailment of trade and other market restrictions; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory and compliance risks that relate to maintaining accurate information and control over activities subject to regulation under the United States Foreign Corrupt Practices Act of 1977, or FCPA, U.K. Bribery Act of 2010 and comparable laws and regulations in other countries.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our future international expansion and operations and, consequently, have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to the terms of our intellectual property license with Cordis, there are certain restrictions on our ability to sell the ENROUTE stent through select direct competitors of Cordis Corporation.  If we are unable to locate international distributors that are not select direct competitors to Cordis Corporation, to market and sell our ENROUTE stent, our ability to expand our business internationally may be harmed, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or our customers or patients, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may become exposed to, or collect and store sensitive data, including procedure-based information and legally-protected health information, credit card, and other financial information, insurance information, and other potentially personally identifiable information.  We also store sensitive intellectual property and other proprietary business information.  Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology, or IT, and infrastructure, and that of our other technology partners, may be vulnerable to cyber attacks by hackers or viruses or breached due to employee error, malfeasance or other disruptions.  We rely extensively on IT systems, networks and services, including internet sites, data hosting and processing facilities and tools, physical security systems and other hardware, software and technical applications and platforms, some of which are managed, hosted, provided and/or used by third-parties or their vendors, to assist in conducting our business.  A significant breakdown, invasion, corruption, destruction or interruption of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations.  The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices.  We could also experience a business interruption, theft of confidential information or reputational damage </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers.  Although the aggregate impact on our operations and financial condition has not been material to date, we have been the target of events of this nature and expect them to continue as cybersecurity threats have been rapidly evolving in sophistication and becoming more prevalent in the industry.  We are investing in protections and monitoring practices of our data and IT to reduce these risks and continue to monitor our systems on an ongoing basis for any current or potential threats.  There can be no assurance, however, that our efforts will prevent breakdowns or breaches to our or our third-party providers&#8217; databases or systems that could adversely affect our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be adversely affected by violations of the FCPA and similar worldwide anti-bribery laws and any investigation, and the outcome of any investigation, by government agencies of possible violations by us of the FCPA could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCPA and similar worldwide anti-bribery laws prohibit companies and their intermediaries from corruptly providing any benefits to government officials for the purpose of obtaining or retaining business.  We are in the process of further enhancing policies and procedures intended to help ensure compliance with these laws.  In the future, we may operate in parts of the world that have experienced governmental corruption to some degree.  Moreover, because of the significant role government entities play in the regulation of many foreign healthcare markets, we may be exposed to heightened FCPA and similar risks arising from our efforts to seek regulatory approval of and reimbursement for our products in such countries.  We cannot assure you that our internal control policies and procedures will protect us from improper acts committed by our employees or agents.  Violations of these laws, or allegations of such violations, would significantly disrupt our business and have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market our products.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage.  It is possible that U.S. and foreign patents and pending patent applications or trademarks controlled by third parties may be alleged to cover our products, or that we may be accused of misappropriating third parties&#8217; trade secrets.  Additionally, our products include components that we purchase from vendors, and may include design components that are outside of our direct control.  Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products or to use product names.  Moreover, in recent years, individuals and groups that are non-practicing entities, commonly referred to as &#8220;patent trolls,&#8221; have purchased patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements.  From time to time, we may receive threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products and business operations infringe or violate the intellectual property rights of others.  The defense of these matters can be time consuming, costly to defend in litigation, divert management&#8217;s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments.  Vendors from whom we purchase hardware or software may not indemnify us in the event that such hardware or software is accused of infringing a third-party&#8217;s patent or trademark or of misappropriating a third-party&#8217;s trade secret.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our products. Competitors may also contest our patents, if issued, by showing the patent examiner that the invention was not original, was not novel or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was obvious. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees and consultants and any other partners or collaborators who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if such patents, trademarks, or trade secrets are successfully asserted against us, this may harm our business and result in injunctions preventing us from selling our products, license fees, damages and the payment of attorney fees and court costs.  In addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties.  Although patent, trademark, trade secret, and other intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties.  We may be unable to obtain necessary licenses on satisfactory terms, if at all.  If we do not obtain necessary licenses, we may not be able to redesign our products to avoid infringement.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, interference or derivation proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office, or USPTO, may be necessary to determine priority with respect to our patents, patent applications, trademarks or trademark applications.  We may also become involved in other proceedings, such as reexamination, inter parties review, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others.  Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing our products or using product names, which would have a significant adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may file lawsuits or initiate other proceedings to protect or enforce our patents, trademarks or other intellectual property rights, which could be expensive, time consuming and unsuccessful.  Competitors may infringe our issued patents, trademarks or other intellectual property.  To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming.  Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property.  In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.  Furthermore, even if our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business&#160;caused by the infringer&#8217;s competition in the market.  An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success will depend on our ability to obtain, maintain and protect our intellectual property rights.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to remain competitive, we must develop, maintain and protect the proprietary aspects of our brands, technologies and data.  We rely on a combination of contractual provisions, confidentiality procedures and patent, copyright, trademark, trade secret and other intellectual property laws to protect the proprietary aspects of our brands, technologies and data.  These legal measures afford only limited </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection, and competitors or others may gain access to or use our intellectual property and proprietary information.  Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining and maintaining other intellectual property rights.  We may not be able to obtain or maintain intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage.  In addition, our trade secrets, data and know-how could be subject to unauthorized use, misappropriation, or disclosure to unauthorized parties, despite our efforts to enter into confidentiality agreements with our employees, consultants, clients and other vendors who have access to such information, and could otherwise become known or be independently discovered by third parties.  Our intellectual property, including trademarks, could be challenged, invalidated, infringed, and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks.  If any of the foregoing occurs, we could be forced to re-brand our products, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm.  Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion.  Failure to obtain and maintain intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses.  The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our trademarks, data, technology and other intellectual property and services, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on our ability to obtain, maintain, expand, enforce, and defend the scope of our intellectual property portfolio or other proprietary rights, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights.  The process of applying for and obtaining a patent is expensive, time consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our proprietary rights at all.  Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary.  In addition, the issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties.  Our patent applications may not result in issued patents and our patents may not be sufficiently broad to protect our technology.  Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.  Issued patents may be challenged, narrowed, invalidated or circumvented.  Decisions by courts and governmental patent agencies may introduce uncertainty in the enforceability or scope of patents owned by or licensed to us.  Furthermore, the issuance of a patent does not give us the right to practice the patented invention.  Third parties may have blocking patents that could prevent us from marketing our own products and practicing our own technology.  Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products.  In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement.  In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid, unenforceable or not infringed; competitors may then be able to market products and use manufacturing and analytical processes that are substantially similar to ours.  Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information that is not patentable or that we elect not to patent.  However, trade secrets can be difficult to protect and some courts are less willing or unwilling to protect trade </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secrets.  To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators and others upon the commencement of their relationship with us.  We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes.  We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence generally of these confidentiality restrictions.  These contracts may not provide meaningful protection for our trade secrets, know-how, or other proprietary information in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information.  There can be no assurance that such third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by competitors.  Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate.  In addition, the laws of many foreign countries will not protect our intellectual property or other proprietary rights to the same extent as the laws of the United States.  Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to international markets or require costly efforts to protect our technology.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property or other proprietary information protection is incomplete, we are exposed to a greater risk of direct competition.  A third party could, without authorization, copy or otherwise obtain and use our products or technology, or develop similar technology.  Our competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology.  Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our products, brand and business.  The theft or unauthorized use or publication of our trade secrets and other confidential business information could reduce the differentiation of our products and harm our business, the value of our investment in research and development or acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary information.  Any of the foregoing could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible that others will independently develop the same or similar technology or otherwise obtain access to our unpatented technology, and in such cases we could not assert any trade secret rights against such parties.  Costly and time consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions.  If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology similar to ours or competing technologies, our competitive market position could be materially and adversely affected.  In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products, we may not be able to stop a competitor from marketing products that are the same as or similar to our products, which would have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may attempt to commercialize competing products utilizing our proprietary design, trademarks or tradenames in foreign countries where we do not have sufficient patent protection and where legal recourse may be limited.  This may have a significant commercial impact on our foreign business operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents or trademarks on our current and future products in all countries throughout the world would be prohibitively expensive.  The requirements for patentability and trademarking may differ in certain countries, particularly developing countries.  The laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States.  Consequently, we may not be able to prevent third parties from utilizing our inventions and trademarks in all countries outside the United States.  Competitors may use our technologies or trademarks in jurisdictions where we have not obtained patent or trademark protection to develop or market their own products and further, may export otherwise infringing products to territories where we have patent and trademark protection, but enforcement on infringing activities is inadequate.  These products or trademarks may compete with our products or trademarks, and our patents, trademarks or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.  The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trademarks and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents and trademarks or marketing of competing products in violation of our proprietary rights generally.  Proceedings to enforce our patent and trademarks rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents and trademarks at risk of being invalidated or interpreted narrowly and our patent or trademark applications at risk, and could provoke third parties to assert claims against us.  We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.  In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties.  In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents.  This could limit our potential revenue opportunities.  Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.  Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees and consultants were previously employed at or engaged by other medical device, biotechnology or pharmaceutical companies, including our competitors or potential competitors.  Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment.  Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, misappropriated the intellectual property or disclosed the alleged trade secrets or other proprietary information, of these former employers or competitors.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity.  Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all.  If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An inability to incorporate technologies or features that are important or essential to our products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our products.  In addition, we may lose valuable intellectual property rights or personnel.  Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management.  Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives.  A loss of key personnel or their work product could hamper or prevent our ability to commercialize our products, which could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents.  In 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law.  The Leahy-Smith Act includes a number of significant changes to U.S. patent law.  These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation.  These also include provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings.  Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier.  The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in 2013.  Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.  The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications.  Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted.  Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted.  We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies.  Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on suppliers, vendors, outsourcing partners, consultants, alliance partners and other third parties to research, develop, manufacture and commercialize our products and manage certain parts of our business.  Using these third parties poses a number of risks, such as: (i) they may not perform to our standards or legal requirements; (ii) they may not produce reliable results; (iii) they may not perform in a timely manner; (iv) they may not maintain confidentiality of our proprietary information; (v) disputes may arise with respect to ownership of rights to technology developed with our partners; and (vi) disagreements could cause delays in, or termination of, the research, development or commercialization of our products or result in litigation or arbitration.  Moreover, some third parties are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, in addition to country-specific privacy and data security risk given current legal and regulatory environments.  Failure of third parties to meet their contractual, regulatory, and other obligations may materially affect our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trademarks, service marks, tradenames and brand names to distinguish our products from the products of our competitors, and have registered or applied to register these trademarks.  We cannot assure you that our trademark applications will be approved.  During trademark registration proceedings, we may receive rejections.  Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections.  In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks.  Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.  In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources towards advertising and marketing new brands and managing through regulatory implications such as relabeling.  At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion.  Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection.  Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs.  In March 2010, the Affordable Care Act was enacted in the United States, which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers.  Among other ways in which it may affect our business, the Affordable Care Act:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanded the eligibility criteria for Medicaid programs.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet know the full impact that the Affordable Care Act will have on our business.  The taxes imposed by the Affordable Care Act and the expansion in the government&#8217;s role in the U.S. healthcare industry may result in decreased sale of our products and, lower reimbursement by payers for our products, all of which may have a material adverse effect on our business, financial condition and results of operations.  The Biden </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the U.S. Congress may take further action regarding the Affordable Care Act, including, but not limited to, repeal or replacement.  Most recently, the Tax Cuts and Jobs Act of 2017 was enacted, which, among other things, removes penalties for not complying with the individual mandate to carry health insurance.  Additionally, all or a portion of the Affordable Care Act and related subsequent legislation may be modified, repealed or otherwise invalidated through judicial challenge, which could result in lower numbers of insured individuals, reduced coverage for insured individuals and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted.  On August&#160;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken.  On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.  The Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, enacted on April&#160;16, 2015, repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments which beg</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an in 2019 t</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hat are based on various performance measures and physicians&#8217; participation in alternative payment models such as accountable care organizations.  It is unclear what effect new quality and payment programs, such as MACRA, may have on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect additional state and federal healthcare policies and reform measures to be adopted in the future.&#160; Any of these could make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained.&#160; They could result in reduced demand for our products or result in additional pricing pressure.&#160; Any such reforms could have a material adverse effect on our industry generally and on our customers.&#160; Any changes of, or uncertainty with respect to, future coverage or reimbursement rates could affect demand for our products, which in turn could impact our ability to successfully commercialize our products and could have an adverse material effect on our business, financial condition and results of operations. &#160;Changes and reforms in the European Union and other countries where we may decide to commercialize could have similar effects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the CMS fee schedules may harm our revenue and operating results.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government payers, such as Centers for Medicare and Medicaid Services, or CMS, as well as insurers, have increased their efforts to control the cost, utilization and delivery of healthcare services.  From time to time, the U.S. Congress has considered and implemented changes in the CMS fee schedules in conjunction with budgetary legislation.  Reductions of reimbursement by Medicare or Medicaid for procedures that use our products or changes in policy regarding coverage of these procedures, such as adding requirements for payment, or prior authorizations, may be implemented from time to time.  Reductions in the reimbursement rates and changes in payment policies of other third-party payers may occur as well.  Similar changes in the past have resulted in reduced payments for procedures that use medical device products as well as added costs and have added more complex regulatory and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative requirements.  Further changes in federal, state, local and third-party payer regulations or policies may have a material adverse impact on the demand for our products and on our business.  Actions by agencies regulating insurance or changes in other laws, regulations, or policies may also have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with broad based healthcare and other governmental regulations, we could face substantial fines and penalties and our business, results of operations and financial condition could be adversely affected.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we offer are highly regulated, and there can be no assurance that the regulatory environment in which we operate will not change significantly and adversely in the future.  Our arrangements with physicians, hospitals and medical centers will expose us to broadly applicable fraud and abuse and other laws and regulations that may restrict the financial arrangements and relationships through which we market, sell and distribute our products.  Our employees, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.  Federal and state healthcare laws and regulations that may affect our ability to conduct business, include, without limitation:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal and state laws and regulations regarding billing and claims payment applicable to TCAR and regulatory agencies enforcing those laws and regulations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA prohibitions against the advertisement, promotion and labeling of our products for off-label uses, or uses outside the specific indications approved by the FDA;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Anti-Kickback Statute, which broadly prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the CMS programs.  A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation.  Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.  Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $176,495 for each violation, plus up to three times the remuneration involved.  Civil penalties for such conduct can further be assessed under the federal False Claims Act.  Violations can also result in criminal penalties, including criminal fines of up to $100,000 and imprisonment of up to 10&#160;years.  Similarly, violations can result in mandatory exclusion from participation in government healthcare programs, including Medicare and Medicaid;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government.  These laws can apply to manufacturers who provide inaccurate information on coverage, coding, and reimbursement of their products to persons who bill third-party payers.  Private individuals can bring False Claims Act &#8220;qui tam&#8221; actions, on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in amounts paid by the entity to the government in fines or settlement.  When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties ranging from $11,655 to $23,331 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making, or causing to be made, false statements relating to healthcare matters;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FCPA, the U.K. Bribery Act of 2010, and other local anti-corruption laws that apply to our international activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Physician Payment Sunshine Act, or Open Payments, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or Affordable Care Act, and its implementing regulations, which requires manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to licensed physicians, certain other healthcare professionals, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations, to report annually ownership and investment interests held by physicians and their immediate family members.  Additionally, on October 24, 2018, President Trump signed into law the &#8220;Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act&#8221; which in part (under a provision entitled &#8220;Fighting the Opioid Epidemic with Sunshine&#8221;) extends the reporting and transparency requirements for physicians in the Physician Payments Sunshine Act to physician assistants, nurse practitioners, and other mid-level practitioners (with reporting requirements going into effect in 2022 for payments made in 2021).  Applicable manufacturers are required to submit annual reports to CMS.  Our failure to submit required information on time may result in civil monetary penalties of $11,766 per failure up to an aggregate of $176,495 per year (or up to an aggregate of $1.177 million per year for &#8220;knowing failures&#8221;), for all payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; HIPAA also created criminal liability for knowingly and willfully falsifying or concealing a material fact or making a materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.  Failure to comply with the HIPAA privacy and security standards when applicable can result in civil monetary penalties up to $59,522 per violation, not to exceed $1.79&#160;million per calendar year for non-compliance of an identical provision, and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment.  State attorneys general can also bring a civil action to enjoin a HIPAA violation or to obtain statutory damages on behalf of residents of his or her state; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers or patients; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm customers, foreign and state laws, including the E.U. General Data Protection Regulation, or GDPR, governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and state laws related to insurance fraud in the case of claims involving private insurers.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions or safe harbors, it is possible that some of our activities, such as stock-option compensation paid to physicians, could be subject to challenge under one or more of such laws.  Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.  We may be subject to private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf of the federal or state governments.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth of our business and sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures.  The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations.  Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.  If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant criminal, civil, and administrative penalties, damages, fines, imprisonment, for individuals, exclusion from participation in government programs, such as Medicare and Medicaid, and we could be required to curtail or cease our operations.  Any of the foregoing consequences could seriously harm our business and our financial results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain and maintain necessary regulatory clearances or approvals for our products, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations would be harmed.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to extensive regulation by the FDA in the United States and by regulatory agencies in other countries where we do business.  Government regulations specific to medical devices are wide ranging and govern, among other things:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product design, development and manufacture;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Laboratory, preclinical and clinical testing, labeling, packaging, storage and distribution;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Premarketing clearance or approval;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Record keeping;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product marketing, promotion and advertising, sales and distribution; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Post marketing surveillance, including reporting of deaths or serious injuries a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd recalls and correction and removals.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a new medical device, or a new intended use for an existing product, can be marketed in the United States, a company must first submit and receive either 510(k) clearance pursuant to Section 510(k) of the Food, Drug and Cosmetic Act, or the FDCA, or approval of a premarket approval, or PMA, application from the FDA, unless an exemption applies.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many cases, the process of obtaining PMA approval, which was required for the ENROUTE stent, is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process.  In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, in order to clear the proposed device for marketing.  To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device.  Clinical data is sometimes required to support substantial equivalence.  In the PMA </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval process, the FDA must determine that a proposed device is safe and effective for its intended use based on extensive data, including technical, pre-clinical, clinical trial, manufacturing and labeling data.  The PMA process is typically required for devices for which the 510(k) process cannot be used and that are deemed to pose the greatest risk.  Modifications to products that are approved through a PMA application generally need prior FDA approval of a PMA supplement.  Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k), or such modification may put the device into class III and require PMA approval.  The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but may last longer.  The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained.  Any delay or failure to obtain necessary regulatory approvals or clearances would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our products are safe or effective for their intended uses;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The disagreement of the FDA or the applicable foreign regulatory body with the design, conduct or implementation of our clinical trials or the analyses or interpretation of data from pre-clinical studies or clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Serious and unexpected adverse device effects experienced by participants in our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The applicable regulatory authority may identify significant deficiencies in our manufacturing processes, facilities or analytical methods or those of our third party contract manufacturers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA or foreign regulatory authorities may audit our clinical trial data and conclude that the data is not sufficiently reliable to support approval or clearance.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, regulators may determine that our financial relationships with our principal investigators resulted in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical trial site or the utility of the clinical trial itself.  Even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product.  Moreover, the FDA and European Union regulatory authorities strictly regulate the labeling, promotion and advertising of our products, including comparative and superiority claims vis a vis competitors&#8217; products, that may be made about products.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of approving a PMA application, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients when necessary to protect the public health or to provide additional safety and effectiveness data for the device.  As a part of our PMA approval, we agreed with the FDA to conduct a post-approval study at a minimum of 30 sites in the United States to evaluate the safety and effectiveness of our products in at least 600 subjects. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We completed enrollment in this study and submitted our final report to the FDA. In February 2020 we received notice from the FDA of their review and that we have fulfilled the post-approval study requirement.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A PMA supplement with the updated labeling was submitted to FDA in December 2019 and subsequently approved by FDA in June 2020. The updated labeling included outcomes and adverse event data from the ROADSTER 2 Post-Approval Study. Failure to have conducted the post-approval study in compliance with applicable regulations or to have timely completed required post-approval studies or comply with other post-approval requirements could result in withdrawal of approval of the PMA, which would harm our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are required to investigate all product complaints we receive, and timely file reports with the FDA, including MDRs that require that we report to regulatory authorities if our products may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur.&#160; If these reports are not submitted in a timely manner, regulators may impose sanctions and we may be subject to product liability or regulatory enforcement actions, including warning letters, untitled letters, fines, civil penaltie</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s, recalls, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seizures, operating restrictions, denial of requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products, withdrawal of current 510(k) clearances or premarket approvals and narrowing of approved or cleared product labeling, all of which could harm our business.&#160; In addition, the FDA may provide notice of and conduct additional inspections, such as &#8220;for cause&#8221; inspections, of our business, sites and facilities as part of its review process.  We previously identified the need to implement corrective actions to our complaint handling procedures, which may have caused a delay in timely submission of 51 MDR reports to the FDA since we began commercialization in 2015.&#160; As of January 31, 2021, we had filed</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 258 M</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DR reports with the FDA for adverse events and device malfunctions including, but not limited to, stroke, arterial dissection,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tip detachment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, stent thrombosis and wound complications.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">itiate a correction or removal action for our products to reduce a significant risk to health posed by our products, we would be required to submit a publicly available correction and removal report to the FDA and, in many cases, similar reports to other regulatory agencies.  This report could be classified by the FDA as a device recall which could lead to an additional inspection by, or increased scrutiny from, the FDA, other international regulatory agencies and our customers regarding the quality and safety of our products.  Furthermore, the submission of these reports could be used by competitors against us and cause physicians to delay or cancel prescriptions, which could harm our reputation.  For example, in the first quarter of 2021, we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by one of our third-party suppliers, Cordis. Our decision to recall these lots was based on complaints we received about tips detaching from the stent delivery system as well as internal testing that we conducted. We believe the root cause of the detachment was a single operator at Cordis, who, over a specific timeframe, produced lots in which a small number of units were not reliably manufactured to specification.  Recalls like this one could cause the supply of our TCAR products to customers to be interrupted, us to incur additional expenses, negative publicity or damage to our reputation, any of which could cause our results of operations to be adversely impacted. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the Federal Trade Commission, or FTC, also regulate the advertising, promotion and labeling of our products to ensure that the claims we make are consistent with our regulatory clearances and approvals, that there is adequate and reasonable scientific data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect.  If the FDA or FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including adverse publicity, warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and state authorities have broad investigation and enforcement powers.  Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizure of our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating restrictions, partial suspension or total shutdown of production;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Denial of our requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Withdrawal of 510(k) clearance or premarket approvals that have already been granted; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Criminal prosecution.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, our business and financial condition could be harmed.  In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our products.  For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law.  The Cures Act, among other things, is intended to modernize the regulation of medical devices and spur innovation, but its ultimate implementation is unclear.  If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate competent and reliable evidence of the safety and effectiveness of our products, which would prevent or delay commercialization of our products in development.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to conduct clinical studies that demonstrate competent and reliable evidence that our products are safe and effective before we can commercialize our products.&#160; Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain.  We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our products for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our products. Even if regulatory approval is secured for any of our products, the terms of such approval may limit the scope and use of our products, which may also limit their commercial potential.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material modifications to our products may require new 510(k) clearances, premarket approval, or CE Marks, or may require us to recall or cease marketing our products until new clearances or approvals are obtained.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Material modifications to the intended use or technological characteristics of our products will require new 510(k) clearances, premarket approvals or CE Marks prior to implementing the modifications, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained.  Furthermore, changes to our manufacturing facility or supplier of components used in our products require prior FDA approval of a PMA supplement.  The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance; however, the FDA can review a manufacturer&#8217;s decision.  Any modification to an </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA cleared device that would significantly affect its safety or effectiveness or that would constitute a major change in its intended use would require a new 510(k) clearance or approval of a PMA supplement.  We may not be able to obtain additional 510(k) clearances or premarket approvals for new products or for modifications to, or additional indications for, our products in a timely fashion, or at all.  Delays in obtaining required future clearances would harm our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.  We have made modifications to our products in the past that we believe do not require additional clearances or approvals, and we may make additional modifications in the future.  If the FDA or an EU Notified Body disagrees and requires new clearances or approvals for any of these modifications, we may be required to recall and to stop selling or marketing our products as modified, which could harm our operating results and require us to redesign our products.  In these circumstances, we may be subject to significant enforcement actions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, or our suppliers, fail to comply with the FDA&#8217;s QSR or the European Union&#8217;s Medical Device Directive, our manufacturing or distribution operations could be delayed or shut down and our revenue could suffer.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing and design processes and those of our third-party component suppliers are required to comply with the FDA&#8217;s Quality System Regulation, or QSR, and the European Union&#8217;s Medical Device Directive, or MDD, both of which cover procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of our products.  We are also subject to similar state requirements and licenses, and to ongoing ISO 13485 compliance in our operations, including design, manufacturing, and service, to maintain our CE Mark.  In addition, we must engage in extensive recordkeeping and reporting and must make available our facilities and records for periodic unannounced inspections by governmental agencies, including the FDA, state authorities, EU Notified Bodies and comparable agencies in other countries.  If we fail a regulatory inspection, our operations could be disrupted and our manufacturing interrupted.  Failure to take timely and adequate corrective action in response to an adverse regulatory inspection could result in, among other things, a shutdown of our manufacturing or product distribution operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our device, operating restrictions and criminal prosecutions, any of which would cause our business to suffer.  Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements, which may result in manufacturing delays for our products and cause our revenue to decline.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are registered with the FDA as a medical device specifications developer and manufacturer.  The FDA has broad post-market and regulatory enforcement powers.  We are subject to unannounced inspections by the FDA and the Food and Drug Branch of the California Department of Public Health, or CDPH, and our Notified Body to determine our compliance with the QSR and other regulations at both our design and manufacturing facilities, and these inspections may include the manufacturing facilities of our suppliers.  These inspections may be initiated as a result of concerns regarding the safety of our products or the components thereof.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can provide no assurance that we will continue to remain in material compliance with the QSR or MDD.  If the FDA, CDPH or our notified body in the European Union, BSI, inspect any of our facilities and discover compliance problems, we may have to cease manufacturing and product distribution until we can take the appropriate remedial steps to correct the audit findings.  Taking corrective action may be expensive, time consuming and a distraction for management and if we experience a delay at our manufacturing facility we may be unable to produce our products, which would harm our business.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the transition from the MDD to the new European Union Medical Device Regulation, or MDR, notified bodies are required to seek designation to operate as conformity assessment authorities under the new law,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is effective in May 2021. BSI, our notified body, successfully obtained designation to operate as conformity assessment authorities under the new law.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The impact of the new EU Medical Device Regulation may be costly and disruptive to our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union has released regulations to ensure patient safety with the use of pharmaceuticals, medical devices and in-vitro diagnostics that will go into effect starting in May 2021. The new regulations replace predecessor directives and emphasize a global convergence of regulations.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major changes include:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reclassification of some products;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Greater emphasis on clinical data;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data transparency, including publication of clinical trial data and safety summaries;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Defined content and structure for technical files to support registration;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unique device identification system;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Greater burden on post-market surveillance and clinical follow-up;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduction of adverse event reporting time from 30 to 15 days after the event; and </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">More power to notified bodies.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complying with these new regulations may result in Europe being less attractive as a &#8220;first market&#8221; destination.  Marketing authorization timelines will become more protracted and the costs of operating in Europe will increase. A significantly more costly path to regulatory compliance is anticipated.  Adjusting to the new Medical Device Regulation may prove to be costly and disruptive to our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products have and may in the future be subject to product recalls that could harm our reputation.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar governmental authorities in other countries have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or defects in design or manufacture.  A government mandated or voluntary recall by us has occurred, and could occur again in the future, as a result of component failures, manufacturing errors or design or labeling defects.  In January 2021, we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System.  Additional recalls of our products would divert managerial attention, be expensive, harm our reputation with customers and harm our financial condition and results of operations.  Additional recall announcements could also negatively affect our stock price.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with environmental laws and regulations could be expensive, and failure to comply with these laws and regulations could subject us to significant liability.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and manufacturing operations involve the use of hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances.  Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence.  Compliance with environmental laws and regulations may be expensive and noncompliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs.  Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations.  We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes.  The expense associated with environmental regulation and remediation could harm our financial condition and operating results.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in analysts&#8217; estimates, investors&#8217; perceptions, recommendations by securities analysts or our failure to achieve analysts&#8217; estimates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Periodic fluctuations in our revenue, which could be due in part to the way in which we recognize revenue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General market conditions and other factors unrelated to our operating performance or the operating performance of our competitors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in reimbursement by current or potential payers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in operating performance and stock market valuations of other technology companies generally, or those in the medical device industry in particular;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual or anticipated changes in regulatory oversight of our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The loss of key personnel, including changes in our board of directors and management;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product recalls or</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> other problems associated with our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Legislation or regulation of our market;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lawsuits threatened or filed against us, including litigation by current or former employees alleging wrongful termination, sexual harassment, whistleblower or other claims;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The announcement of new products, product enhancements or new product trials by us or our competitors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced or completed acquisitions of businesses or technologies by us or our competitors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements related to patents issued to us or our competitors and related litigation; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developments in our industry.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and harm our business, results of operations, financial condition and reputation. These factors may materially and adversely affect the market price of our common stock.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our share price and trading volume could decline.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business, our market and our competitors.  We do not have any control over these analysts.  If one or more of the analysts who cover us downgrade our shares or change their opinion of our business, our share price would likely decline.  If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lapse of lock-up and other legal restrictions on resale, the trading price of our common stock could decline.  If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.  Any sales of securities by these stockholders could have a material adverse effect on the market price of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, our directors, officers and each stockholder holding 5% or more of our outstanding common stock and their affiliates beneficially owned approximately 37.1%</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur outstanding common stock in the aggregate. Actions taken by these stockholders may have the effect of delaying or preventing a change in control, might adversely affect the market price of our common stock and may not be in the best interests of other stockholders.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are obligated to maintain proper and effective internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, to furnish a report by management on the effectiveness of our internal control over financial reporting.  This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting.  We are required to comply with, among other requirements, the auditor attestation requirements of Section 404.  If we have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compliance with Section 404 requires that we incur substantial accounting expense and expend significant management efforts</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We have engaged outside consultants who function in the capacity of an internal audit group, and we will continue to hire additional consultants, accounting and financial staff with appropriate public company experience and technical accounting knowledge as we maintain the system and process documentation necessary to perform the evaluation needed to comply with Section 404.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future.  Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations.  If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting, we could los</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e investor confidence in the accuracy and completeness of our financial reports, the market price of our ordinary shares could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.  Failure to remedy our current and any future material weakness in our internal control over financial reporting, or to implement or maintain other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our amended and restated certificate of incorporation and bylaws, and Delaware law, could discourage a change in control of our company or a change in our management.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and bylaws contain provisions that might enable our management to resist a takeover.  These provisions include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A classified board of directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance notice requirements applicable to stockholders for matters to be brought before a meeting of stockholders and requirements as to the form and content of a stockholders&#8217; notice;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A supermajority stockholder vote requirement for amending certain provisions of our amended and restated certificate of incorporation and bylaws;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allowing stockholders to remove directors only for cause;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A requirement that the authorized number of directors may be changed only by resolution of the board of directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allowing all vacancies, including newly created directorships, to be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum, except as otherwise required by law;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A requirement that our stockholders may only take action at annual or special meetings of our stockholders and not by written consent;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limiting the forum to Delaware for certain litigation against us; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limiting the persons that can call special meetings of our stockholders to our board of directors, the chairperson of our board of directors, the chief executive officer or the president, in the absence of a chief executive officer.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions might discourage, delay or prevent a change in control of our company or a change in our management.  The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.  In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder.  See &#8220;Description of Capital Stock.&#8221;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; abilities to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders, (3)&#160;any action asserting a claim against the company or any director or officer of the company arising pursuant to any provision of the Delaware General Corporation Law, (4)&#160;any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or bylaws, or (5)&#160;any other action asserting a claim that is governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware or federal court located within the State of Delaware if the Court of Chancery does not have jurisdiction, in all cases subject to the court&#8217;s having jurisdiction over indispensable parties named as defendants. A complaint asserting a cause of action under the Securities Act may be brought in state or federal court.  With respect to the Securities Exchange Act of 1934, or Exchange Act, only claims brought derivatively under the Exchange Act would be subject to the forum selection clause described above.  The enforceability of similar choice of forum provisions in other companies' certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that, in connection with any action, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation and bylaws to be inapplicable or unenforceable in such action.  Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.  Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation and bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and operating results.  Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of our stock.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends and do not anticipate paying cash dividends in the foreseeable future.  The payment of dividends will depend on our earnings, capital requirements, financial condition, prospects for future earnings and other factors our board of directors may deem relevant.  In addition, our loan agreement limits our ability to, among other things, pay dividends or make other distributions or payments on account of our common stock, in each case subject to certain exceptions.  If we do not pay dividends, our stock may be less valuable because a return on your investment will only occur if our stock price appreciates and you then sell our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control.  We are required, pursuant to Section 404, to evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on the internal control over financial reporting.  This assessment will include disclosure of any material weaknesses identified by our management in our internal control over financial reporting.  We are also required to comply with, among other requirements, the auditor attestation requirements of Section 404.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have a material weaknesses in our internal control over financial reporting in the future, we may not detect errors on a timely basis and our financial statements may be materially misstated.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compliance with Section 404 requires that we incur substantial accounting expense and expend significant management effort</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. We engage outside consultants who function in the capacity of an internal audit group, and we will need to continue to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge as we continue to compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our evaluation of our internal control, if we identify any material weaknesses in our internal control over financial reporting in the future, we will be unable to assert that our internal control over financial reporting is effective.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future.  Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations.  If we have a material weakness or significant deficiency in our internal control over financial reporting in the future, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our ordinary shares could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions or other remedies.  Failure to remedy any material weakness in our internal control over financial reporting, or to maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_22"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease approximately 31,000 square feet for our corporate headquarters and manufacturing facility located in Sunnyvale, California under a lease agreement which terminates in 2024. We have an additional option to extend the lease term for a period of five&#160;years.  The option must be exercised no more than 12&#160;months and no less than nine months prior to the expiration of the applicable term.  Our operations are growing at a pace that may require us to find a replacement or expansion facility sooner.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We believe that additional space can be obtained on commercially reasonable terms as needed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_25"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time we may become involved in legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_28"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II</span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_34"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Price Range of Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock began trading on the NASDAQ Global Select Market under the symbol &#8220;SILK&#8221; on April 4, 2019. Prior to that time, there was no public market for our common stock.  In our initial public offering, our common stock priced at $20.00 per share on April 3, 2019.  The following table sets forth on a per share basis, for the periods indicated, the low and high sale prices of our common stock as reported by the NASDAQ Global Select Market.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Quarter (beginning April 4, 2019)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth Quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth Quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At February 26, 2021, there were approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72 </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders of record of our common stock, and the closing price per share of our common stock was $54.77.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid, and do not anticipate declaring or paying, any cash dividends on any of our capital stock. We do not anticipate paying any dividends in the foreseeable future, and we currently intend to retain all available funds and any future earnings for use in the operation of our business, to finance the growth and development of our business and for future repayment of debt. Future determinations as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then-existing conditions, including our operating results, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, our term loan agreement limits our ability to pay dividends or make other distributions or payments on account of our common stock, in each case subject to certain exceptions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 5 regarding equity compensation plans is incorporated by reference from the information under the captions &#8220;Equity Compensation Plan Information&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; that will be contained in the Proxy Statement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph illustrates a comparison of the total cumulative stockholder return on our stock with the total return for</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (i) the NASDAQ Composite Index (U.S.) and (ii) the NASDAQ Medical Equipment Index for the period from April 4, 2019 (the first day of trading of our common stock), through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31, 2020.  The graph assumes an investment of $100 in our common stock at market close on April 4, 2019 and the reinvestment of dividends, if any. The comparisons in the table are not intended to forecast or be indicative of possible future performance of our common stock. This graph shall not be deemed &#8220;soliciting material&#8221; or be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended (the "Securities Act"), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span><img src="silk-20201231_g5.jpg" alt="silk-20201231_g5.jpg" style="height:416px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$100 investment in stock or index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Apr. 4, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Jun. 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sep. 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Dec. 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Mar. 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Jun. 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sep. 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Dec. 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Silk Road Medical, Inc. (SILK)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NASDAQ Composite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NASDAQ Medical Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our initial public offering of 6,000,000 shares of common stock was effected through a registration statement on Form S-1 (File No. 333-230045), which was declared effective on April 3, 2019 and pursuant to which we sold an aggregate 6,000,000 shares of our common stock at a public offering price of $20.00 per share for an aggregate offering price of $120.0 million. On April 4, 2019, the underwriters fully exercised their option to purchase 900,000 additional shares of common stock from the selling stockholders pursuant to the underwriting agreement. When our initial public offering closed on April 8, 2019, we received net proceeds of $109.1 million, after deducting underwriting discounts and commissions of $8.4 million and other expenses of $2.5 million. No payments for such expenses were </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made directly or indirectly to any of our officers or directors or persons holding 10 percent or more of our securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated acted as representatives of the underwriters for the offering. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on April 4, 2019 pursuant to Rule 424(b) of the Securities Act.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we completed an underwritten public offering of 6,808,154 shares of common stock through a registration statement on Form S-3/ASR (File No. 333-238007), which was automatically effective upon filing on May 5, 2020. Pursuant to this registration statement we sold an aggregate 1,923,076 shares of our common stock at a public offering price of $39.00 per share for an aggregate offering price of $75.0 million, and certain selling stockholders sold an additional 4,885,078 shares of common stock. We received cash proceeds of approximately $70.5 million, net of underwriting discounts and commissions of approximately $3.8 million and offering costs of approximately $0.7 million. On May 20, 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common stock from the selling stockholders pursuant to the underwriting agreement. We did not receive any of the proceeds from the sale of the shares of common stock by the selling stockholders.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">J.P. Morgan Securities LLC and BofA Securities, Inc. acted as representatives of the underwriters for the offering. There has been no material change in the planned use of proceeds from the public offering as described in our final prospectus supplement filed with the SEC on May 7, 2020 pursuant to Rule 424(b) of the Securities Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_37"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Selected Financial Data</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derived the selected statements of operations data for the years ended December&#160;31, 2020, 2019 and 2018 and the balance sheets data as of December 31, 2020 and 2019 from our audited financial statements appearing elsewhere in this Annual Report on Form 10-K.  The balance sheet data as of December 31, 2018 is derived from our audited financial statements which is not included herein.  You should read this data together with our audited financial statements and related notes thereto included elsewhere in this and the information under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The selected financial data included in this section are not intended to replace the audited financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K.  Our historical results are not necessarily indicative of our future results.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations Data:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share and per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,859)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,065)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,395)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,415)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Silk Road Medical, Inc. common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,415)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,629)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.44)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.28)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.16)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used to compute net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,965,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,956,679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets Data:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 7. Management&#8217;s Discussion And Analysis Of Financial Condition And Results Of Operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with the section entitled &#8220;Selected financial data&#8221; and our audited financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K.  This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions, that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management.  Our actual results could differ materially from those discussed in these forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this Annual Report on Form 10-K entitled &#8220;Risk Factors.&#8221;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a medical device company focused on reducing the risk of stroke and its devastating impact.  We believe a key to stroke prevention is minimally-invasive and technologically advanced intervention to safely and effectively treat carotid artery disease, one of the leading causes of stroke.  We have pioneered a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which we seek to establish as the standard of care.  We manufacture and sell in the United States our portfolio of TCAR products, which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began commercializing our products in the United States in late 2015.  Our products are currently the only devices cleared and approved by the FDA specifically for transcarotid use.  While our current commercial focus is on the U.S. market, our products have obtained CE Mark approval, allowing us to commercialize in Europe in the future.  We are also pursuing regulatory clearances in select international markets.  TCAR is reimbursed based on established current procedural technology, or CPT, codes and International Classification of Diseases, or ICD-10, codes related to carotid stenting that track to Medicare Severity Diagnosis Related Group, or MS-DRG, classifications.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designed our commercial strategy and built our direct sales force with a particular focus on vascular surgery practices.  Vascular surgeons are skilled in endovascular procedures, and our sales and marketing efforts are focused on driving adoption and supporting their practice development by offering them an innovative, safe, effective and minimally-invasive alternative for treating carotid artery disease.  We also market to other specialists with experience in CEA or CAS with the appropriate skill set for TCAR, including neurosurgeons, cardiothoracic surgeons and non-surgical interventionalists in radiology, neuroradiology and cardiology.  We also work on developing strong relationships with physicians and hospitals that we have identified as key opinion leaders.  We consider the hospitals and medical centers where the procedure is performed to be our customers, as they typically are responsible for purchasing our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture and distribute the ENROUTE NPS at our facility in Sunnyvale, California, using components and sub-assemblies manufactured both in-house and by third party manufacturers and suppliers.  We purchase our other products from third-party contract manufacturers, including our ENROUTE stent.  Many of these third-party manufacturers and outside vendors are currently single-source suppliers.  While we expect that our existing manufacturing facility will be sufficient to meet our anticipated growth through at least the next three years, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we supplement our distribution operations with a third-party logistics and warehousing service and are considering additional leased facilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we completed our initial public offering by issuing 6,000,000 shares of common stock, at a public offering price of $20.00 per share, for net proceeds of approximately $109.1 million after deducting underwriting discounts and commissions and expenses. In August 2019, we completed a secondary public offering of 4,200,000 shares of common stock by selling stockholders, and the exercise </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in full of the underwriters' option to purchase 630,000 additional shares of common stock from selling stockholders, at a public offering price of $39.50 per share. We received no proceeds from the sale of our common stock by the selling stockholders. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our initial public offering in April 2019, our primary sources of capital were private placements of convertible preferred stock, debt financing arrangements and revenue from sales of our products.  As of&#160;December 31, 2020, we had cash and cash equivalents of $69.5&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, short term investments of $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.0</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million, long-term debt of $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.5&#160;million and an accumulated deficit of $238.9</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;mill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we completed an underwritten public offering of 6,808,154 shares of our common stock, of which we offered 1,923,076 shares for sale and the remaining 4,885,078 shares were offered for sale by certain selling stockholders, at a public offering price of $39.00 per share.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the public offering, we received cash proceeds of approximately $70.5 million, net of underwriting discounts and commissions and offering costs which were paid by us. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in May 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common stock from the selling stockholders.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any of the proceeds from the sale of the shares of common stock by the selling stockholders.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks related to public health crises such as the global pandemic associated with COVID-19. In December 2019, a novel strain of coronavirus, SARS-CoV-2, was reported to have surfaced in Wuhan, China. Since then, SARS-CoV-2, and the resulting disease COVID-19, has spread to most countries, and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact our operations and revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The pandemic has also reduced our expectations for the growth rate in the number of TCAR procedures to be performed in the future. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as many health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended, canceled or deferred to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will significantly reduce our expected revenue while the pandemic continues.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As well, due to presumed fear and anxiety, some patients are not accessing routine or emergency health care which may impact our expected procedures and revenue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state and local jurisdictions have imposed, and others in the future may impose, &#8220;shelter-in-place&#8221; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Beginning in the first quarter of 2020, the governor of California, where our facilities are located, issued &#8220;shelter-in-place&#8221; or &#8220;stay at home&#8221; orders restricting non-essential activities, travel and business operations for an indefinite period of time, subject to certain exceptions for necessary activities. Such orders or restrictions have resulted in our facilities periodically closing, work stoppages, slowdowns and delays, travel restrictions and cancellation of events, among other effects, thereby negatively impacting our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other disruptions or potential disruptions include restrictions on our personnel to travel and access customers for selling, marketing, training, case support and product development feedback; delays in approvals by regulatory bodies; delays in product development efforts; and additional government requirements or other incremental mitigation efforts that may further impact our capacity to manufacture, sell and support the use of our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these challenges to continue to impact our expected number of procedures throughout 2021, but the extent cannot be quantified at this time. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our procedure volumes were lowest in April, then recovered in May and further in June and throughout the second half of 2020, although we continue to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience regional variability and procedure slowdowns due to the resurgence of COVID-19 cases and related restrictions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive all of our revenue from the sale of our portfolio of TCAR products to hospitals and medical centers in the United States.  Each of our products is purchased individually, and the majority of our revenue is derived from sales of the ENROUTE NPS and ENROUTE stent.  No single customer accounted for 10% or more of our revenue during the during the years ended December 31, 2020, 2019 and 2018.&#160; We expect revenue to increase in absolute dollars as we expand our sales territories</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and trained physician base, add new accounts  a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd as existing physicians perform more TCAR procedures.  However, we anticipate the COVID-19 pandemic will continue to impact revenue in the short term as some procedures are temporarily deferred due to restrictions on elective surgical procedures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our revenue to fluctuate from quarter-to-quarter due to a variety of factors, including seasonality.  For example, in the first quarter, our results can be harmed by adverse weather and by resetting of annual patient healthcare insurance plan deductibles, both of which may cause patients to delay elective procedures.  Holiday and summer vacations by physicians and/or their patients can also affect procedure volumes that in turn affect hospital ordering patterns. We have also seen procedure volumes moderate during major medical conferences when significant portions of our customer base are attending the conferences.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Gross Margin</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture the ENROUTE NPS in California at our facility in Sunnyvale.  We purchase our other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and sub-assemblies, direct labor, manufacturing overhead, reserves for excess, obsolete and non-sellable inventories as well as distribution-related expenses.  Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as those incurred for shipping our products and royalties related to the sale of our ENROUTE stent.  We expense all inventory provisions as cost of goods sold.  We record adjustments to our inventory valuation for estimated excess, obsolete and non-sellable inventories based on assumptions about future demand, past usage, changes to manufacturing processes and overall market conditions.  We expect cost of goods sold to increase in absolute dollars to the extent more of our products are sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate gross margin as gross profit divided by revenue.  Our gross margin has been and will continue to be affected by a variety of factors, primarily average selling prices, product sales mix, production and ordering volumes, manufacturing costs, product yields, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">replacement of expired product, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">headcount and cost-reduction strategies.  We expect our gross margin to increase over the long-term as our production and ordering volumes increase and as we spread the fixed portion of our overhead costs over a larger number of units produced, potentially offset by any investments in additional operational infrastructure.  We intend to use our design, engineering and manufacturing know-how and capabilities to further advance and improve the efficiency of our manufacturing processes, which we believe will reduce costs and have a positive long-term impact on our gross margin.  However, our gross margin could fluctuate from quarter to quarter as we introduce new products, due to the timing of certain manufacturing engineering projects, as we adopt new manufacturing processes and technologies and as we expand our distribution operations and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infrastructure to support long term growth and risk mitigation.  In addition, the COVID-19 pandemic may continue to negatively impact our gross margin in the near term due to unfavorable production variances as a result of lower production and lower demand.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development, or R&amp;D, expenses consist primarily of engineering, product development, clinical studies to develop and support our products, regulatory expenses, medical affairs, and other costs associated with products and technologies that are in development.  These expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses.  Additionally, R&amp;D expenses include costs associated with our clinical studies, including clinical trial design, clinical trial site initiation and study costs, data management, related travel expenses and the cost of products used for clinical trials, internal and external costs associated with our regulatory compliance and quality assurance functions and overhead costs.  We expect R&amp;D expenses as a percentage of revenue to vary over time depending on the level and timing of our new product development efforts, as well as our clinical development, clinical trial and other related activities.  We anticipate the COVID-19 pandemic shelter-in-place policies and restrictions to continue to delay our product development efforts and clinical and regulatory matters throughout 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative, or SG&amp;A, expenses consist primarily of compensation for personnel, including stock-based compensation, related to selling and marketing functions, physician education programs, commercial operations and analytics, reimbursement, finance, information technology and human resource functions.  Other SG&amp;A expenses include sales commissions, training, travel expenses, promotional activities, marketing initiatives, market research and analysis, conferences and trade shows, professional services fees (including legal, audit and tax fees), insurance costs, general corporate expenses and allocated facilities-related expenses.  We expect SG&amp;A expenses to continue to increase in absolute dollars as we expand our infrastructure to both drive and support the anticipated growth in revenue and due to additional legal, accounting, insurance and other expenses associated with being a public company.  In addition, we will continue exploring sales and marketing expansion opportunities in international geographies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the COVID-19 pandemic to continue to modulate our SG&amp;A expenses over the short term primarily as a result of the reduction in employee and physician travel, tradeshow and other expenses. Given the continued uncertainties we also undertook preemptive steps to curtail near-term spending during the second quarter of 2020, including temporarily delaying previously contemplated executive salary increases to the third quarter, slowing hiring initiatives and reducing non-essential sales, general, and administrative expenses. Some expenses originally planned for the second and third quarter of 2020, including physician training courses and advertising campaigns, were deferred to later time periods or canceled outright. The outbreak and persistence of COVID-19 in international markets that we have targeted for our international expansion may also delay preparation for and launch of such expansion efforts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income (Expense), net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income (expense), net consists primarily of cash interest incurred on our outstanding indebtedness and non-cash interest related to the amortization of debt discount and issuance costs associated with our debt agreements.  Our interest expense was partially offset by interest income earned on our investments. We expect our interest expense to decline due to the decrease in interest rate as a result of the extinguishment of the debt outstanding under the loan agreement with CRG in October 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net primarily consists of gains and losses resulting from the remeasurement of the fair value of our convertible preferred stock warrant liability at each balance sheet date. We recorded adjustments to the estimated fair value of the convertible preferred stock warrants until they were exercised in connection with our initial public offering in April 2019.  At such time, the final fair value </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the warrant liability was reclassified to stockholders&#8217; equity and we no longer record any related periodic fair value adjustments.</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"><tr><td style="width:1.0%"></td><td style="width:49.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,859)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,065)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,395)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,054)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,063)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,365)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,415)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,630)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December 31, 2020 and 2019</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue increased </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.9&#160;million, or&#160;19%, to $75.2&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million during the year ended December&#160;31, 2020, compared to $63.4 million during the year ended December&#160;31, 2019.  The increase in revenue was attributable to an increase in the number of products sold as we expanded our sales territories, increased the number of new accounts, trained more physicians in TCAR and as physicians performed more TCAR procedures.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although revenue increased during the year ended December 31, 2020, as compared with the prior year, the COVID-19 pandemic negatively impacted revenue as some procedures were cancelled or deferred due to restrictions on elective surgical procedures and some patients did not access routine or emergency health care or return for deferred procedures. Revenue for the year ended December 31, 2020, included the recognition of $1.3 million in deferred revenue in the second quarter due to a decrease in the provision for sales returns. In the past, we shipped products with shorter than normal shelf life to customers. To the extent those products were not used before expiry, we established a reserve given the potential we may accept a return and provide an exchange. The decrease in the provision for sales returns was due to the full expiration of these shorter shelf life products during the second quarter, coupled with the downward trend of our historical returns experience. Excluding the contribution of the $1.3 million, revenue for the year ended December 31, 2020 increased $10.6 million, or 17%, compared to the year ended December 31, 2019. We do not anticipate future potential decreases in the sales return provision to materially impact subsequent quarters.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold and Gross Margin. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of goods sold increased $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4 million, or&#160;34%, to $21.3&#160;million during the year ended December&#160;31, 2020, compared to $15.9&#160;million during the yea</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r ended December&#160;31, 2019.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This increase was attributable to the increase in the number of products sold and also to unfavorable production variances as a result of temporarily idled manufacturing operations and lower than anticipated demand due to the COVID-19 pandemic</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Gross margin for the year ended December&#160;31, 2020 decreased to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;72</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%, compared to 75% in the year ended December&#160;31, 2019.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin decreases were driven by unfavorable production variances as a result of temporarily idled manufacturing operations, lower than anticipated demand and the timing of certain manufacturing engineering projects, partially offset by the decrease in our provision for sales returns.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $9.0&#160;million, or 73%, to $21.3 million during the year ended December&#160;31, 2020, compared to $12.3&#160;million during the year ended December&#160;31, 2019.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&amp;D expenses was primarily attributable to an increase of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.8 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million in clinical and regulatory expense, $2.4 million in personnel-related expenses including stock-based compensation, an increase of $1.2 million in outside services, an increase of $0.7 million in product development materials and costs, an increase of $0.3 million relating to depreciation and the allocation of facilities and related expenses and an increase of $0.2 million relating to educational grants, partially offset by a decrease of $0.5 million in travel expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a decrease of $0.1 million in software related expense. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in clinical and regulatory expense was attributable to our continued efforts t</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o obtain label expansion of the ENROUTE stent in standard surgical risk patients.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SG&amp;A expenses increased $12.3&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or&#160;19%, to </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$75.5&#160;million during the year ended December&#160;31, 2020, compared to $63.2&#160;million during the year ended December&#160;31, 2019.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in SG&amp;A costs was due to the continued commercialization of our products and general corporate and other costs associated with operating as a public company for a full year. During the current period our SG&amp;A expense growth was partially offset by cost control initiatives and the continued slowdown in travel, tradeshow and other expenses resulting from the COVID-19 pandemic.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in SG&amp;A expenses is primarily attributable to an increase of $14.6 million in payroll and personnel-related expenses, an increase of $1.8 million in consulting, legal and professional fees, an increase of $1.0 million in insurance costs, an increase of $0.8 million in software related expense and an increase of $0.2 million in costs attributable to the COVID-19 pandemic, partially offset by a decrease of $3.7 million in physician training and travel related costs and a decrease of $2.4 million in marketing, tradeshow and promotional costs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Personnel-related expenses included stock-based compensation expense of $5.8&#160;million and $2.4&#160;million for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income (Expense), Net. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no significant changes within other income (expense), net during the year ended December 31, 20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20, compared to the year ended December 31, 2019. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreases in our net interest expense, attributable to the decrease in interest rate as a result of the extinguishment of the debt outstanding under the loan agreement with CRG in October 2020, were partially offset by decreases in interest income due to lower interest rates during the year ended December 31, 2020 as compared with the prior period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other income (expense), net decreased to an expense of $0.1&#160;million during the year ended December&#160;31, 2020, compared to an expense of $21.1 million during the year ended December 31, 2019. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net for the year ended December 31, 2019, was primarily attributed to the remeasurement of our convertible preferred stock warrants and recognition of the change in fair value during the period. We recorded adjustments to the estimated fair value of the convertible preferred stock warrants until they were exercised in connection with our initial public offering in April 2019.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December 31, 2019 and 2018</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue increased $28.8&#160;million, or&#160;83%, to $63.4&#160;million during the year ended December&#160;31, 2019, compared to $34.6 million during the year ended December&#160;31, 2018.  The increase in revenue was attributable to an increase in the number of products sold as we expanded our sales territories, increased the number of new accounts, trained more physicians in TCAR and as physicians performed more TCAR procedures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold and Gross Margin. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of goods sold increased $5.0 million, or&#160;46%, to $15.9&#160;million during the year ended December&#160;31, 2019, compared to $10.9&#160;million during the year ended December&#160;31, 2018.  This increase was attributable to the increase in the number of products sold and additional manufacturing overhead costs as we invested significantly in our operational infrastructure to support anticipated future growth.  Gross margin for the year ended December&#160;31, 2019 increased to&#160;75%, compared to 69% in the year ended December&#160;31, 2018.  Gross margin increased as our production and ordering volumes increased and we were able to spread the fixed portion of our overhead costs over a larger number of units produced.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R&amp;D expenses increased $2.0 million, or&#160;20%, to $12.3&#160;million during the year ended December&#160;31, 2019, compared to $10.3&#160;million during the year ended December&#160;31, 2018.  The increase in R&amp;D expenses was primarily attributable to an increase of $1.4 million in personnel-related expenses including stock-based compensation, an increase of $0.3 million in clinical and regulatory expense, an increase of $0.3 million relating to educational grants, an increase of $0.2 million in product development materials and costs, an increase of $0.2 million in software related expense, and an increase of $0.1 million in outside services, partially offset by a decrease in travel and the allocation of facilities expense. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SG&amp;A expenses increased $28.4&#160;million, or&#160;82%, to $63.2&#160;million during the year ended December&#160;31, 2019, compared to $34.8&#160;million during the year ended December&#160;31, 2018.  The increase in SG&amp;A expenses is primarily attributable to an increase of $17.9 million in personnel-related expenses, an increase of $2.5 million in consulting, legal and professional fees, an increase of $2.2 million in marketing, tradeshow and promotional costs, an increase of $1.9 million in travel expenses, an increase of $1.3 million in insurance costs, an increase of $1.1 million in physician training and travel related costs, an increase of $0.8 million in software related expense, and an increase of $0.7 million relating to depreciation and the allocation of facilities and related expenses.  Personnel-related expenses included stock-based compensation expense of $2.4&#160;million and $0.6&#160;million for the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income (Expense), Net. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest income (expense), net decreased</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.9&#160;million, or&#160;21%, to an expense of $3.3&#160;million during the year ended December&#160;31, 2019, compared to an expense of $4.2&#160;million during the year ended December&#160;31, 2018.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This decreased expense was attributable to interest income earned on our investments, partially offset by the additional interest expense associated with the $15.0&#160;million of additional borrowings in September 2018 under our term loan agreement. As of December 31, 2019 and 2018, the aggregate outstanding principal balance (including interest paid-in-kind) under the term loan agreement was $44.9 million and $44.2&#160;million, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other income (expense), net increased to an expense of $21.1&#160;million during the year ended December&#160;31, 2019, compared to an expense of $12.1 million during the year ended December 31, 2018.  The decrease was primarily attributed to the remeasurement of our convertible preferred stock warrants and recognition of the change in fair value.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December 31, 2020, we had cash and cash equivalents of $69.5</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;million and investments of $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.0</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million, an accumulated deficit of $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238.9</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;million and $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.5</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;million </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding under our Loan Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2020, we entered into a Loan and Security Agreement, or Loan Agreement, with Stifel Bank which provides for a $50.0 million loan facility, comprised of a $50.0 million secured revolving credit facility, with a $2.0 million subfacility for the issuance of letters of credit and other ancillary banking services, and a $50.0 million secured term loan facility, provided that amounts outstanding under both facilities may not exceed an aggregate principal amount of $50.0 million at any time.  Any borrowings under the revolving loan facility mature on October 29, 2022, or October 29, 2023 if as of October 29, 2022, no event of default has occurred and we are in compliance with the terms of the Loan Agreement. Borrowings under the term loan facility mature on October 29, 2024.  Also on October 29, 2020, we drew down $49.0 million under the term loan facility and used the majority of the proceeds to pay off and terminate our prior loan agreement with CRG.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we completed our initial public offering by issuing 6,000,000 shares of common stock, at a public offering price of $20.00 per share, for net proceeds of approximately $109.1 million after deducting underwriting discounts and commissions and expenses. In August 2019, we completed a secondary public offering of 4,200,000 shares of common stock by selling stockholders, and the exercise in full of the underwriters' option to purchase 630,000 additional shares of common stock from selling </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders, at a public offering price of $39.50 per share. We received no proceeds from the sale of the common stock by the selling stockholders.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we completed an underwritten public offering of 6,808,154 shares of our common stock, of which we offered 1,923,076 shares for sale and the remaining 4,885,078 shares were offered for sale by certain selling stockholders, at a public offering price of $39.00 per share.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the public offering, we received cash proceeds of approximately $70.5 million, net of underwriting discounts and commissions and offering costs which were paid by us. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in May 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common stock from the selling stockholders.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any of the proceeds from the sale of the shares of common stock by the selling stockholders.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our initial public offering, our primary sources of capital were private placements of convertible preferred stock, debt financing agreements and revenue from the sale of our products.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the first quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by one of our third-party suppliers, Cordis, a Cardinal Health Company. Our decision to recall these lots was based on complaints we received about tips detaching from the stent delivery system as well as internal testing that we conducted. We believe the root cause of the detachment was a single operator at Cordis, who, over a specific timeframe, produced lots in which a small number of units were not reliably manufactured to specification.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s a result of the voluntary recall we have reflected a current asset of $4.2 million on our balance sheet as of December 31, 2020, relating to the replacement lots and other direct recall costs expected to be received from Cordis. This amount includes $2.2 million of recalled ENROUTE stent delivery systems held in our inventory as of December 31, 2020, an estimated $1.7 million of ENROUTE stent delivery systems in the process of being returned from our customers and other direct recall costs of $0.2 million. In addition, we have established an accrual of $1.7 million relating to our obligation to provide replacement ENROUTE stent delivery systems to our customers as of December 31, 2020.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents and available-for-sale investments as of December 31, 2020, together with our expected revenue, will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for each of the periods presented below:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:54.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,541)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December 31, 2020 was $42.1 million, consisting primarily of a net loss of $47.4 million and an increase in net operating assets of $5.2 million, partially offset by non-cash charges of $10.5 million. The increase in net operating assets was primarily due to increases in accounts receivable and inventories to support the growth of our operations and the repayment of paid in kind interest to CRG, partially offset by increases in accounts payable and accrued liabilities due to timing of payments and the growth of our operations. The non-cash charges primarily </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted of stock-based compensation, depreciation and amortization, provision for excess and obsolete inventories, amortization of premiums on investments, non-cash interest expense and loss on debt extinguishment related to our term loan agreement with CRG.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the y</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ear ended December</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;31, 2019 was $29.6&#160;million, consisting primarily of a net loss of $52.4&#160;million and a decrease in net operating assets of $3.0&#160;million, partially offset by non-cash charges of $25.8&#160;million.  The decrease in net operating assets was primarily due to an increase in accounts receivable, inventories and prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support the growth of our operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by increases in accounts payable and accrued liabilities, due to timing of payments and growth of our operations.  The non-cash charges primarily consisted of depreciation, stock-based compensation, non-cash interest expense and other charges related to our term loan agreement, accretion of discounts on investments, and an increase in the fair value of the convertible preferred stock warrants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2018 was $21.7&#160;million, consisting primarily of a net loss of $37.6&#160;million partially offset by an increase in net operating assets of $0.9&#160;million and non-cash charges of $15.0&#160;million.  The increase in net operating assets was primarily due to an increase in accounts receivable, inventories and prepaid expenses and other current assets to support the growth of our operations, partially offset by increases in accrued and other liabilities, due to timing of payments and growth of our operations.  The non-cash charges primarily consisted of depreciation, stock-based compensation, non-cash interest expense and other charges related to our term loan agreement, and an increase in the fair value of the convertible preferred stock warrants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities in the year ended December 31, 2020 was $9.4 million. Cash used in investing reflected purchases of purchases of property and equipment of $0.8 million and net purchases of investments of $8.6 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities in the year ended December&#160;31, 2019 w</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $70.0&#160;milli</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on consisting of purchases of available-for-sale investments of $69.4 million and purchases of property and equipment of $535,000.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities in the year ended December&#160;31, 2018 was $2.3&#160;million primarily consisting of purchases of property and equipment.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities in the year ended December 31, 2020 was $81.7 million, consisting of proceeds of $70.6 million from our public offering in May 2020, net of issuance costs paid, proceeds from the issuance of debt of $48.5 million, net of issuance costs paid, and proceeds of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million from stock option exercises and purchases under our employee stock purchase plan, partially offset by repayment of debt of $40.0 million and $2.5 million in premiums paid on loss on extinguishment of debt.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities in the year ended December&#160;31, 2019 was $113.8&#160;million, primarily attributable to proceeds of $109.4 million from our initial public offering, net of issuance costs paid, proceeds of $2.6 million from stock option exercises and purchases under our employee stock purchase plan and warrant exercises of $1.8 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities in the year ended December&#160;31, 2018 was $15.4&#160;million primarily attributable to proceeds of $15.0 million from additional borrowings under the term loan agreement, and $0.7 million of proceeds from the exercise of stock options, partially offset by cash paid for deferred initial public offering costs of $0.2 million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Agreement</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, our principal obligations consist of the operating lease for our facility, our Loan Agreement with Stifel Bank and non-cancellable inventory purchase commitments. The non-cancellable purchase commitments primarily consist of ENROUTE stents and other inventory components.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2020, we drew down $49.0 million under the term loan facility with Stifel Bank using the majority of the proceeds to pay off outstanding amounts under our loan agreement with CRG and to terminate the CRG loan agreement. The principal amount of outstanding term loans under the Loan Agreement with Stifel Bank shall be repaid in equal monthly installments beginning on May 29, 2022, or November 29, 2022 if we achieve revenue for the year ending December 31, 2021 of at least 80% of our board-approved financial projections for such fiscal year. The term loan may not be reborrowed once repaid, but we may prepay the term loan at any time without premium or penalty. We are also obligated to pay a fee to the lender upon the occurrence of certain liquidity events, along with other customary fees for a loan facility of this size and type.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Loan Agreement are secured by substantially all of our assets. The Loan Agreement requires that we maintain unrestricted cash and cash equivalents with Stifel Bank or at Stifel Bank Affiliates of at least $20.0 million. In addition, for any fiscal quarter where our unrestricted cash and cash equivalents maintained with Stifel Bank or at Stifel Bank Affiliates are less than $60.0 million for any day during such fiscal quarter, we must comply with a minimum revenue covenant. Additionally, the Loan Agreement contains customary affirmative and negative covenants, including covenants limiting our ability and the ability of our subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events of default under the Loan Agreement include, among others, payment defaults, material misrepresentations, breaches of covenants, cross defaults with certain other material indebtedness, bankruptcy and insolvency events, and judgment defaults. The occurrence of an event of default could result in the acceleration of our obligations under the Loan Agreement, the termination of the lender&#8217;s commitments, a 5% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the aggregate outstanding principal balance under the Loan Agreement was</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.0</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lion.  As of the date of this Annual Report on Form 10-K, we were in compliance with all covenants under the term loan agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis License Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2010, we entered into a license agreement, or the Cordis License Agreement, with Cordis Corporation, or Cordis, which is now a subsidiary of Cardinal Health. Pursuant to the Cordis License Agreement, Cordis has granted us a worldwide, non-exclusive, royalty-bearing license to certain of its intellectual property related to the PRECISE carotid stent, or the Licensed IP, for transcervical treatment of carotid artery disease with an intravascular stent for certain applications for accessing blood vessels through the neck and cervical area. Cordis may not license the Licensed IP in our licensed field of use to any other third party during the term of the Cordis License Agreement.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid Cordis a one-time license execution fee and are obligated to pay royalties to Cordis on a calendar quarter basis during the term of the Cordis License Agreement, calculated based on net sales of the licensed products we sell during the preceding quarterly period. The license granted under Cordis License Agreement shall remain in full force and effect on a country by country basis until the last to expire of the Licensed IP in such country.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cordis License Agreement requires us to work exclusively with either Cordis or Confluent Medical Technologies, Inc. (f/k/a Nitinol Devices and Components, Inc.), or Confluent, for the development, manufacture and supply of the licensed products. If either Cordis or Confluent cannot continue to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture or supply the licensed products, we can seek a third party manufacturer with the prior written consent of Cordis.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the right to assign or transfer the Cordis License Agreement to an entity that succeeds all or substantially all of our equity or assets.  The Cordis License Agreement may be terminated by either party in the event of uncured material breach by the other party that remains uncured for 60 days (or 30 days for payment related breaches), or bankruptcy of the other party.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Supply Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2011, we entered into a supply agreement, or Cordis Supply Agreement, with Cordis and have since entered into four amendments in March and July 2012, April 2013 and April 2018. Pursuant to the Cordis Supply Agreement, Cordis has assisted in the development of a transcarotid stent delivery system according to our specifications with a PRECISE carotid stent implant, or ENROUTE stent, has supplied the ENROUTE stent through preclinical and clinical trials, and continues to supply the ENROUTE stent for our commercial sale. The Cordis Supply Agreement will continue in full force and effect until the earlier to occur of (i) termination of the Cordis License Agreement; (ii) our election if and when Cordis approves another manufacturer; (iii) mutual written termination; or (iv) termination pursuant to the terms therein. The Cordis Supply Agreement may be terminated by either party in the event of uncured material breach by the other party that remains uncured for 30 days, or bankruptcy of the other party.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated under the Cordis Supply Agreement to purchase a minimum volume of the ENROUTE stent annually.  This obligation is binding until the natural expiration of the Cordis License Agreement, due to expiration of the last-to-expire of the Licensed IP, if the Cordis License Agreement remains in effect through such natural expiration.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cordis has the exclusive right to manufacture and supply the ENROUTE stent during the term of the Cordis Supply Agreement. However, if Cordis is not able to supply the ENROUTE stent, upon our election, Cordis shall permit Confluent or a third party manufacturer to provide supply of the ENROUTE stent, provided that Cordis retains the right to manufacture and supply the ENROUTE stent to us to the extent it is able to do so. Notwithstanding the foregoing, we, without Cordis&#8217; consent, may work directly with Confluent for the development and supply of next-generation products that materially expand or change the specification of the ENROUTE stent. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease our headquarters in Sunnyvale, California pursuant to a lease agreement which terminates in October&#160;2024.  We have an additional option to extend the lease term for a period of five&#160;years.  The option must be exercised no more than 12&#160;months and no less than nine months prior to the expiration of the applicable term.  The facility lease is for approximately 31,000 square feet.&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, such as structured finance, special purpose entities, or variable interest entities.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal obligations consist of the operating lease for our facility, our Loan Agreement and non-cancellable inventory purchase commitments.  The following table sets out, as of December&#160;31, 2020, our contractual obligations due by period:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:48.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loan agreement with Stifel Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cancellable purchase commitments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cancellable purchase commitments primarily consist of ENROUTE stents and other inventory components.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles.  The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures.  Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are more fully described in Note&#160;2 of our audited financial statements included in this Annual Report on Form 10-K, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to our financial condition and results of operations and require our most difficult, subjective and complex judgments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Codification, or ASC, Topic 606,&#160;&#8220;Revenue from Contracts with Customers,&#8221; using the modified retrospective method applied to contracts which were not completed as of that date effective January 1, 2018. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, we perform the following five steps: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">identify the contract(s) with a customer; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">identify the performance obligations in the contract; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">determine the transaction price;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">allocate the transaction price to the performance obligations in the contract; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated from the sale of our products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of our products to customers, either upon shipment of the product or delivery of the product to the customer under our standard terms and conditions.&#160;&#160;Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the goods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For sales where the sales representative hand delivers product directly to the hospital or medical center from the sales representative&#8217;s trunk stock inventory, we recognize revenue upon delivery, which represents the point in time when control transfers to the customer.  For sales which are sent directly to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by us or the sales representative to the customer after delivery under either method of sale. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accept product returns at our discretion or if the product is defective as manufactured.  We establish estimated provisions for returns based on historical experience and consideration of other factors that we believe could significantly impact our expected returns, which provisions are classified within accrued liabilities on our balance sheet.&#160; We have elected to expense shipping and handling costs as incurred and include them within cost of goods sold.  In those cases where we invoice shipping and handling costs to customers, we will classify the amounts billed as a component of revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to our financial statements included elsewhere in this Annual Report on Form 10-K for new accounting pronouncements not yet adopted as of the date of this Annual Report on Form 10-K.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include risk related to interest rate sensitivities and foreign currency exchange rate sensitivity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and investments of $147.5 million as of December 31, 2020; which consisted of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bank deposits, money market funds, U.S. government securities, corporate bonds/notes, asset-backed securities and commercial paper.  The primary objectives of our investment activities are the preservation of capital and support of our liquidity requirements.  Our investments are exposed to market risk due to fluctuations in interest rates, which may affect our income and the fair market value of our investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.  A hypothetical 10% change in interest rates would not have a material impact on the value of our cash and cash equivalents or our investments as of December 31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, our cash and cash equivalents were maintained with two financial institutions in the United States, and our current deposits are in excess of insured limits.  We have reviewed the financial statements of these institutions and believe each to have sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us.  Our cash equivalents and investments are invested in highly rated money market funds, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities, corporate bonds/notes, asset-backed securities and commercial paper</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable primarily relate to revenue from the sale of our products to hospitals and medical centers in the United States.  No customer represented 10% or more of our accounts receivable as of December&#160;31, 2020 or 2019.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is primarily conducted in U.S. dollars.  Any transactions that may be conducted in foreign currencies are not expected to have a material effect on our results of operations, financial position or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_46"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Silk Road Medical, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Index to Financial Statements</span></div></td></tr></table></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_49"></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page(s)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_52">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_52">100</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_55">Balance Sheets as of December 31, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_55">102</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_61">Statements of Operations and Comprehensive Loss for the years ended December 31, 2020, December 31, 2019 and December 31, 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_61">103</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_67">Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) for the years ended December 31, 2020, December 31, 2019 and December 31, 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_67">104</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_73">Statements of Cash Flows for the years ended December 31, 2020, December 31, 2019  and December 31, 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_73">105</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_76">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_76">106</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_52"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Silk Road Medical, Inc.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Silk Road Medical, Inc. (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related statements of operations and comprehensive loss, of redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and of cash flows for each of the three years in the period ended December 31, 2020, including the related notes and financial statement schedule appearing under Item 15(b) (collectively referred to as the &#8220;financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Accounting Principle</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2 to the financial statements, the Company changed the manner in which it accounts for leases in 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes </span></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the financial statements, the Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives. Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#8217;s standard terms and conditions. The Company&#8217;s total revenue was $75.2 million for the year ended December 31, 2020. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to revenue recognition is a critical audit matter are the significant audit effort in performing procedures and evaluating audit evidence related to the accuracy and occurrence of revenue transactions.   </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included testing the effectiveness of controls relating to the revenue recognition process, including controls over the accuracy and occurrence of revenue transactions. These procedures also included, among others, evaluating, on a test basis, the accuracy and occurrence of transactions recognized as revenue by obtaining and inspecting invoices, customer purchase orders, customer master supply agreements, shipping documents and cash receipts from customers, where applicable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ PricewaterhouseCoopers LLP </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 1, 2021</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2013.</span></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_55"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Silk Road Medical, Inc.<br/>Balance Sheets</span></td></tr></table></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except share and per share data)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNS0xLTEtMS0w_5fe78cb0-30e9-48e0-ac81-b21dffa3482d">69,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNS0zLTEtMS0w_ad02ab82-7d09-4d5f-8673-d1f3020e70ce">39,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNi0xLTEtMS0w_2928ed48-4ad8-4e84-835d-1e951d7a8232">78,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNi0zLTEtMS0w_13c153c9-19a2-42b7-bcad-c0a2bb0c32b1">51,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNy0wLTEtMS0wL3RleHRyZWdpb246MWUzY2NkOWU0MmMzNDA1MjkzYTIyMjEzNTQ3OWI4OGNfNDY_3b3c0e82-e2c0-47f6-b279-16fefd2e3b10">13</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNy0wLTEtMS0wL3RleHRyZWdpb246MWUzY2NkOWU0MmMzNDA1MjkzYTIyMjEzNTQ3OWI4OGNfNTM_ca01ce24-b504-4d0c-8389-a20990e89d96">45</ix:nonFraction> at December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNy0xLTEtMS0w_5dae2fe3-eb1a-4aba-a3d6-e73e1825c4ee">9,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNy0zLTEtMS0w_26302b6d-e5f4-41fe-b176-7842b97aee3a">8,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfOC0xLTEtMS0w_a1340a19-fc18-47cc-b802-f61d0f7216f8">9,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfOC0zLTEtMS0w_759686d3-9859-4619-b527-4fb691724969">10,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfOS0xLTEtMS0w_16c5d081-abb6-4919-9c22-7e99f00c86da">6,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfOS0zLTEtMS0w_2702362b-7747-4a56-badc-e19c821a9b6e">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTAtMS0xLTEtMA_aeaa3b8b-5e8a-4320-a5f8-e36155553d17">173,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTAtMy0xLTEtMA_1fc1134e-0816-463f-8232-a88234b8c8ff">112,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTEtMS0xLTEtMA_e117f540-b336-4a99-a794-e917f8c599cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTEtMy0xLTEtMA_4c7e7f54-0808-45f7-9f30-be5a0f637aa9">18,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTItMS0xLTEtMA_fdaeb885-2cf4-4165-982e-b1ac8f22479f">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTItMy0xLTEtMA_cb48bc69-0f57-4038-b8e1-ad687da13960">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTMtMS0xLTEtMA_91ac1c68-4e98-40ce-ac5c-a089afa6ce38">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTMtMy0xLTEtMA_c50e97ed-1f69-434b-bf34-1fb7ccabc230">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTQtMS0xLTEtMA_16f44668-ab5b-4e5f-a3e2-05224a5ca8ee">2,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTQtMy0xLTEtMA_066afb1f-5f68-41fc-958c-5eeec721fdc2">3,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTUtMS0xLTEtMA_c2c6f6c2-eec8-4ad0-8542-e102d2836fde">179,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTUtMy0xLTEtMA_82b43faa-6672-4481-84db-e77ee1fd56da">137,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTktMS0xLTEtMA_e25d4195-b1ab-4fd2-9edc-36b303b9bc31">2,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTktMy0xLTEtMA_8ca6706c-3e39-4d6e-9ba5-1142f4ef29fb">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjAtMS0xLTEtMA_ecb0bedc-c7e9-4288-803f-739b4fad9761">16,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjAtMy0xLTEtMA_02ba214c-4797-4279-978e-c4eb3c66420d">15,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjEtMS0xLTEtMA_0e8f5753-67a4-4d93-8237-285914e7d1f1">19,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjEtMy0xLTEtMA_b0d816dd-8449-479e-82da-a6a4d72f750a">16,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjItMS0xLTEtMA_32e13da8-c5f3-437d-b8fb-f8eee0322b0e">48,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjItMy0xLTEtMA_46e2d0e1-0102-4b3c-8c69-f7ae0f6bb5b4">44,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjQtMS0xLTEtMA_0b0106b2-988c-41ed-9dc2-f5573b41b058">3,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjQtMy0xLTEtMA_aa3535e8-584d-49af-9038-e2baf495c7ac">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjUtMS0xLTEtMA_d1dc85be-71a5-4d12-a858-04b0d998e7eb">71,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjUtMy0xLTEtMA_20483946-b998-450b-a92a-1ee1d40b2688">65,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjctMS0xLTEtMA_1f032063-5cf0-4ee0-b4f6-e36ee21de134"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjctMy0xLTEtMA_f7bd5dcf-f3f8-4536-ae32-166f07b5aaad"></ix:nonFraction></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjNiYjVjMzBiM2M0YTRlYzRiNDdlNTdjMjhmNzEzMjkwXzIx_af624094-e749-4005-9a50-39cf8ba2c059"><ix:nonFraction unitRef="usdPerShare" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjNiYjVjMzBiM2M0YTRlYzRiNDdlNTdjMjhmNzEzMjkwXzIx_ba6763af-99fb-4a51-a548-b631e2db33a4">0.001</ix:nonFraction></ix:nonFraction> par value </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares authorized: <ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFhNDM2MDYxYzQzMTQ2NTdhNTZiODI2ZmNkNDYyMDQ1XzMyOTg1MzQ4ODM0NjM_0b4dedde-aa69-4463-8d03-2a9f9dd530a2"><ix:nonFraction unitRef="shares" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFhNDM2MDYxYzQzMTQ2NTdhNTZiODI2ZmNkNDYyMDQ1XzMyOTg1MzQ4ODM0NjM_607ba188-1fdf-4ea3-8561-1bcfd1854fd7">5,000,000</ix:nonFraction></ix:nonFraction> at December 31, 2020 and 2019</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmJiMGJjMWFkNTA3YzQwNTRiZTkwZGIwNTAxNjA5YWUzXzM1_5e3cffdf-195e-48b0-b40a-8b84944a34d3"><ix:nonFraction unitRef="shares" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmJiMGJjMWFkNTA3YzQwNTRiZTkwZGIwNTAxNjA5YWUzXzM1_b71f439f-fe22-4661-bd3d-09ddb3d041f4"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmJiMGJjMWFkNTA3YzQwNTRiZTkwZGIwNTAxNjA5YWUzXzM1_c089e634-76f9-42e3-bd89-55af794afd02"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmJiMGJjMWFkNTA3YzQwNTRiZTkwZGIwNTAxNjA5YWUzXzM1_ff053595-15f7-4ad6-aab3-844e74d373bc">None</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at December 31, 2020 and 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMS0xLTEtMA_bdf63c72-d016-4787-84cd-37ca785d13e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMy0xLTEtMA_893972cb-7640-4342-b548-6a5fa688cfa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmExMGQyZGUzOWUyZTRiMDY4YWI3YzhlNzVkMmJjYzM2XzE4_6cde1fa8-19e3-425f-8d32-c4cdc6edb695"><ix:nonFraction unitRef="usdPerShare" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmExMGQyZGUzOWUyZTRiMDY4YWI3YzhlNzVkMmJjYzM2XzE4_e4c311c2-5007-4927-a307-df85dfa213c2">0.001</ix:nonFraction></ix:nonFraction> par value </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares authorized: <ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOmIyMmQ1ZDRiNTI3OTQ5ZDRiOTRlMGVkNTgyODZmZjA0XzIz_091acddc-6c03-4ec0-a134-a67a4b58e87b">100,000,000</ix:nonFraction> at December 31, 2020 and 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjY3Njg0NWI4ZWZjYTRjMmU5MWI3MjFlMWRlYmY4NTA2XzM1_a3167292-54c4-4db4-8b13-e440d9e6f896"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjY3Njg0NWI4ZWZjYTRjMmU5MWI3MjFlMWRlYmY4NTA2XzM1_dadec27c-2754-4d53-a2be-c25436d4f8fa">34,249,649</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjY3Njg0NWI4ZWZjYTRjMmU5MWI3MjFlMWRlYmY4NTA2XzQy_33ae8c54-ae59-4803-ad37-a0bed8003713"><ix:nonFraction unitRef="shares" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjY3Njg0NWI4ZWZjYTRjMmU5MWI3MjFlMWRlYmY4NTA2XzQy_35b30280-a3ed-4283-a92e-11f08ff2bdf9">31,255,267</ix:nonFraction></ix:nonFraction> at December 31, 2020 and 2019, respectively </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMS0xLTEtMA_6676c460-b29e-4306-b84d-6d3651c12a01">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMy0xLTEtMA_092de956-4879-4d7e-af7a-8d898c7a4f84">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDEtMS0xLTEtMA_e8d2e00f-925b-4940-8ff8-05081a638ded">346,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDEtMy0xLTEtMA_1020ea6c-da14-4f6b-9032-9b8c17d94212">263,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDItMS0xLTEtMA_6c5268d1-db08-4bf1-9945-73c56a5f99c3">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDItMy0xLTEtMA_93ea384a-db2e-46fb-88c9-5419d5fcb622">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDMtMS0xLTEtMA_900336ef-9c45-4e3b-88ce-7ab97b7cfe11">238,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDMtMy0xLTEtMA_cc272cef-14c4-430b-96ab-a0732fca1fad">191,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDQtMS0xLTEtMA_2dcc562a-114b-46a6-baba-3a607fd9e0f7">107,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDQtMy0xLTEtMA_0818c4ae-e778-4403-a08d-423e7b061e44">71,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDUtMS0xLTEtMA_85189458-c375-4ef9-97be-b5b259ba609b">179,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDUtMy0xLTEtMA_0585be80-4ac4-4af6-af0c-153cfcc594a4">137,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_61"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Silk Road Medical, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Statements of Operations and Comprehensive Loss</span></div></td></tr></table></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share and per share data)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMi0xLTEtMS0xOTU4_6b9b9267-e2c5-4de5-9f91-868caaeb502b">75,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMi0xLTEtMS0w_a3e2e642-6b7d-4726-bd32-e874d1ca4498">63,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMi0zLTEtMS0w_690bc153-30b9-4c61-a9ec-a4a0c3b1fc5a">34,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMy0xLTEtMS0xOTU4_b30e0358-1ddb-4adb-8f25-0156a2aa3147">21,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMy0xLTEtMS0w_386b22a0-db51-40dc-b921-c53e0a07d1a4">15,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMy0zLTEtMS0w_ec284171-1c35-4e45-8240-dd8587a5c658">10,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNC0xLTEtMS00Mzg_38086ddb-4206-4022-9306-b57cffc64226">53,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNC0xLTEtMS0w_afa19bd3-73b4-4f1a-8512-f17f2116e48e">47,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNC0zLTEtMS0w_920dc876-f2a0-466f-9e52-5036ef27d59a">23,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNi0xLTEtMS0xOTU4_9e1c3289-60f0-4d6a-8941-ee230ebf33a6">21,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNi0xLTEtMS0w_1f5b8627-e6f0-4940-b7b8-35aba05343f4">12,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNi0zLTEtMS0w_2d20a93f-4449-448a-9d1e-e3fce9a528db">10,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNy0xLTEtMS0xOTU4_7c537c7d-6ac9-44c6-967e-c04fa47f4bfd">75,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNy0xLTEtMS0w_a148e4ed-93b0-4a80-9f7d-1add7eea3160">63,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNy0zLTEtMS0w_dad62029-ae7d-4c2c-b289-c093d5d2f510">34,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOC0xLTEtMS00Mzg_d528bf04-1dd8-4444-a726-3fb6ea4d100d">96,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOC0xLTEtMS0w_7bd0af60-7fd8-4e47-8dc1-a0985765a8ac">75,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOC0zLTEtMS0w_51e79759-7960-47c4-8881-b3861b9bbafd">45,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOS0xLTEtMS0xOTU4_08e2b6a2-9913-463c-8107-523458a6e3dc">42,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOS0xLTEtMS0w_db79eb8a-fc7f-4348-a647-c62f6931c314">28,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOS0zLTEtMS0w_94eb90ba-337a-4821-a337-5befbf60f5ac">21,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTAtMS0xLTEtMTk1OA_a20d2658-af0d-4296-a935-7502a742d0a2">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTAtMS0xLTEtMA_3905a7b8-f1cb-4faa-a095-c6d315d80da0">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTAtMy0xLTEtMA_f73839ad-a530-4486-abbc-721e2d0acbfa">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTEtMS0xLTEtMTk1OA_180896c4-b105-4751-b2e3-13a40c10fe50">4,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTEtMS0xLTEtMA_c17f937c-b9f4-4693-901b-213be6aa002d">4,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTEtMy0xLTEtMA_111928fa-af7b-42a8-ad39-67cd2cbb08a6">4,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItMS0xLTEtMTk1OA_54fb68c0-2e11-4f20-a4f5-4f443f8f1bcd">1,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItMy0xLTEtNDM0_f6907ecd-d3b0-4cf5-90eb-dcbee9328026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItNS0xLTEtNDM0_a3cc3c65-c441-408d-8202-40b547b3f51f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTMtMS0xLTEtMTk1OA_569af0d9-cdc4-4efe-8a11-eb317090c0db">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItMS0xLTEtMA_874c4df8-9c75-47f0-9fb9-9c929ca34978">21,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItMy0xLTEtMA_f9c7de27-0d57-4978-b93b-a04f8e145139">12,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTQtMS0xLTEtNDM4_2ca8aaad-8791-4e7a-9733-5e0bc1ff9069">47,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTMtMS0xLTEtMA_0ead4990-9065-4886-9e5d-201d5b954b84">52,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTMtMy0xLTEtMA_a4b578b1-ab1e-4132-9b45-9e0201179281">37,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTUtMS0xLTEtMTk1OA_2992678b-7eb0-4754-9935-ac154f3edba8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTQtMS0xLTEtMA_509e4bcd-300e-4dcc-b3fd-e5be00f4c1a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTQtMy0xLTEtMA_a6ff0983-8daf-4848-aadd-62ae37d9e591">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Silk Road Medical, Inc. common stockholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTYtMS0xLTEtNDQy_37ffc5d6-9100-44dd-a5a6-d66cc7c9c79b">47,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTUtMS0xLTEtMA_7682c77b-4ea7-4c13-b558-078574790b91">52,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTUtMy0xLTEtMA_26db3b64-37e8-4624-8ca0-ac8798709c2f">37,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTgtMS0xLTEtMTk1OA_4d0510e9-b49d-417b-96a4-2ecaf23100c4">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTctMS0xLTEtMA_2c65c997-3fb2-401c-9f86-8f0b0b8e4f23">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTctMy0xLTEtMA_f1f7078e-9c5b-4344-b866-dcaf5fcccbd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTktMS0xLTEtNDQy_82855d4b-69a2-4caf-be8b-2fef454c0769">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTgtMS0xLTEtMA_660a7b46-e547-4345-b0d2-dc29f9d2484e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTgtMy0xLTEtMA_c9497007-44b0-47b4-8d91-d079e5d960d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss attributable to Silk Road Medical, Inc. common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjAtMS0xLTEtNDQy_d7abdc0d-404d-426f-ab79-344d468ae62f">47,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTktMS0xLTEtMA_5fa9b221-c1a9-4cc8-a5f5-9660329f79dd">52,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTktMy0xLTEtMA_4213d119-92ee-441d-9e32-4c54ab3d06a9">37,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjEtMS0xLTEtMTk1OA_d58108fa-4b89-4615-a10f-55fd9c46d52f">1.44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjAtMS0xLTEtMA_878d5131-1b7d-49b3-8a33-687506fce9af">2.28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjAtMy0xLTEtMA_d73e595a-e264-4836-bf7c-24f6c295835c">39.16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used to compute net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjItMS0xLTEtMTk1OA_2058f712-9ffc-4ffe-9bcb-056a768eab59">32,965,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjEtMS0xLTEtMA_38c88b8d-f7a0-40d2-b09a-af75201f6d17">22,956,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjEtMy0xLTEtMA_0180b0e4-f537-40f7-8689-d18bf19726cb">960,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_67"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.884%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Silk Road Medical, Inc. <br/>Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></td></tr></table></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.815%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share data)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-controlling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i309aa475c33d46f1bcb008fc1f8ff1b4_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMS0xLTEtMA_6dc47b9e-61d7-422b-bdb5-6355f6664ee1">21,233,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i309aa475c33d46f1bcb008fc1f8ff1b4_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMy0xLTEtMA_c598980a-dd1a-4922-8e95-bba1627af814">105,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab4311acf1a24c2d80c7837fb213c678_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtNi0xLTEtMA_b7a5b46d-2fcf-45b5-8bd3-ba9bd7dee898">663,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab4311acf1a24c2d80c7837fb213c678_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtOC0xLTEtMA_f968fff8-5578-4605-aa19-2c2a7dfc5364">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad606b34524243b1a8e5075ac03d3736_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTAtMS0xLTA_cf803ec3-3952-476c-be5e-372f51d6c1f1">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29b884248218456fa51f8f0609280bfe_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTItMS0xLTA_c580caaa-9146-4958-8b29-858547ea2411">101,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9001a76c96354d44be43663ad10864e5_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTQtMS0xLTA_d1232b28-b883-4e61-b6a2-5fc74966004e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd1291d3588454f997c52cc2495c69d_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTYtMS0xLTA_8d903a8a-4423-435c-a34d-2aa25c91a281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTgtMS0xLTA_8cc3369a-e795-4767-8b01-f91e9c82f0a9">98,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c754289625a475e91ebf3960393d1df_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTYtNi0xLTEtMA_6a17ad43-e2e8-4f05-b049-e2dd1d1c8096">438,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b0757eda174b29929c9539b4972205_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTYtMTAtMS0xLTA_7a3ffec8-a585-4867-a146-3b7034774bdb">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTYtMTgtMS0xLTA_c8a443aa-2000-41a9-b0f1-6277a34f4967">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b0757eda174b29929c9539b4972205_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTctMTAtMS0xLTA_8c329463-997c-498d-909c-7f67baa81cb7">911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTctMTgtMS0xLTA_d88a628d-28c9-43d6-873a-1e971baad335">911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">NeuroCo common stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d9057d66f44539a8d04ef9162bb079_D20180101-20181231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTktMTYtMS0xLTA_8fcfc5b0-4163-4579-b325-24820ffaf216">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTktMTgtMS0xLTA_28256cd5-5e8f-4e38-ad4f-4785f77c21e9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock in connection with NeuroCo merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c754289625a475e91ebf3960393d1df_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjAtNi0xLTEtMA_90072b5a-d96f-481c-a779-c21fcafa5dff">33,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjAtMTgtMS0xLTA_f4bbdc27-881d-4247-a609-9acfcdf64d49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cumulative effect of change in accounting principle - ASC 606 adoption</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce8733a67e34fdbb3a3c3db64b74607_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjEtMTItMS0xLTA_586d9086-57bc-4712-b595-dde6e4fe97e7">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52336bc12b324590bba4f1ab5687f560_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjEtMTgtMS0xLTA_e9638a42-c843-4bca-93bc-be801222cd33">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cumulative effect of change in accounting treatment - ASU 2016-09</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ad6abb0fc2410f8d14252857b9b662_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjItMTAtMS0xLTA_bfcb6fe5-686c-42f2-b789-7af1957a9f5c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a224585ac174008bad3bf2831eec2f0_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjItMTItMS0xLTA_445c835e-8605-4fc2-b6b2-cfc19bcd82b8">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c86486a74044d0b4999de7a19e56b8_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjItMTgtMS0xLTA_76f05786-8296-4114-b250-08237a9179d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c78658e347043038c35c1cacd0e7415_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjMtMTItMS0xLTA_1942bb50-b273-4a1f-af26-0b270cb087ad">37,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55d9057d66f44539a8d04ef9162bb079_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjMtMTYtMS0xLTA_57c2ca89-eddb-4df1-bb9d-59750458a5b4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjMtMTgtMS0xLTA_aa8ed86d-9b1a-4098-ad7c-d157206fcdba">37,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9452f0bca2304c67ac02c051e36f8823_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMS0xLTEtMA_a035de72-b794-4230-93c0-4eac01a4ea20">21,233,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9452f0bca2304c67ac02c051e36f8823_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMy0xLTEtMA_007871f3-f3c3-4aa9-93f7-00288fe35861">105,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib95c642c97784f95b54de6ac4683cf00_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtNi0xLTEtMA_2dac167d-371d-41fe-bbef-96d457b1aa8b">1,135,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib95c642c97784f95b54de6ac4683cf00_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtOC0xLTEtMA_011feaca-3a2e-4c84-96f2-46c9597ef77d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5363da9b40b8433589b18ba5d4349ec4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTAtMS0xLTA_c08a7a95-e288-437a-8da2-f92b98ff2402">4,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i168f9b03b66f4d37bb7151521137ed70_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTItMS0xLTA_add8e822-abd0-4a40-873c-2f2a5a49ff62">139,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268ced4ae9024a918193193003914ad4_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTQtMS0xLTA_a38285e4-b868-43ad-a687-974a0269f7d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie206f45400684e03b789ee66287deddc_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTYtMS0xLTA_81c0f660-f539-4e73-8afe-09b956fd0c97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTgtMS0xLTA_d36efe67-5f6c-4202-91bc-53fb72dc7688">134,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Exercise of Series C preferred stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad40d41effba4a3785f2f35c5cc9b839_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjUtMS0xLTEtMA_80ea311f-50ae-46d4-b345-0a0dbaff74fd">292,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad40d41effba4a3785f2f35c5cc9b839_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjUtMy0xLTEtMA_281008e2-7b4d-4402-a908-60deed68a8ea">1,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Exercise of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjYtNi0xLTEtMA_4765e639-547a-4c02-bb6f-f43f76e75bb6">3,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjYtMTAtMS0xLTA_06340415-3872-4610-b143-d10c7e849802">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjYtMTgtMS0xLTA_fa130500-c7c2-43ed-aa87-e9e2202ddeb3">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock in connection with IPO, net of underwriting discount, commissions and offering costs of $<ix:nonFraction unitRef="usd" contextRef="icd4f40364954436caf47b6d23cb6d6e4_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQxNTE3MDZlZjAxNzRiZmQ4MDgyODQ5OGViODM3ZjBkXzE2NDkyNjc0NDE3ODM_223c44dc-1258-4b2d-a401-f9393d88d0f7">10,961</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctNi0xLTEtMA_ff9623e2-aaaa-4086-9bd6-713113bbf4d0">6,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctOC0xLTEtMA_684a035d-4bf9-4d18-b85c-72437563f988">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f23accfdbc34e51924d5a95ddcb0253_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctMTAtMS0xLTA_a8935bed-116b-4363-b7ce-4e7a49e3ca30">109,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4f40364954436caf47b6d23cb6d6e4_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctMTgtMS0xLTA_aefb17b9-eb12-447b-9510-44cfa3178094">109,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock upon IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtMS0xLTEtMA_fb737128-3c09-40f2-aa80-ba635ddb227f">23,178,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtMy0xLTEtMA_651e78d5-cbf6-4825-bc4e-fa79bb7ff65a">144,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtNi0xLTEtMA_30e52158-c5a1-4a96-854a-5586d0b03239">23,178,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtOC0xLTEtMA_8134e888-329b-45b2-a8cd-f0fc8c14d47b">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f23accfdbc34e51924d5a95ddcb0253_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtMTAtMS0xLTA_c7b6abcf-c8a3-4671-a410-97996098a1e1">144,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4f40364954436caf47b6d23cb6d6e4_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtMTgtMS0xLTA_c5a731da-a3df-48da-9b3a-a2e1e41210c0">144,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net exercise of Series C preferred stock warrants upon IPO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjktMS0xLTEtMA_9333d810-cf6f-45e3-9a70-04a2ac3aaefc">1,653,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjktMy0xLTEtMA_f687fc03-3de4-4b28-928a-a5dccb952787">37,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net exercise of common stock warrants upon IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="silk:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzAtNi0xLTEtMA_0ac58aca-44af-4e0c-9773-d17e2adebeab">2,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzEtNi0xLTEtMA_d39f5bdc-41d4-498c-b480-659d0e07abea">873,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzEtOC0xLTEtMA_e2e6305c-1f43-4575-81c3-2b29cd70637d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzEtMTAtMS0xLTA_72f2a593-5939-4e2f-884a-e8ec1df026b9">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzEtMTgtMS0xLTA_758bb789-d6f9-473e-8cdb-ae5e38b6ac1d">1,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzItNi0xLTEtMA_b90c559b-2f59-495f-95b2-8a976dac7e0c">61,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzItMTAtMS0xLTA_9f6a3b9e-4a19-4dcb-992d-40070983f000">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzItMTgtMS0xLTA_63d03419-dda5-47fd-bf4f-50944d16c04c">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzMtMTAtMS0xLTA_5f6f33c8-180d-4367-8aa0-b59365072adb">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzMtMTgtMS0xLTA_645b112d-b083-4110-9907-0511a14572a3">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia65d3e7d28b94209a448cb72c6adae4f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzUtMTItMS0xLTA_e2ea8f03-c234-43bc-ad3c-755a7ef7ff48">52,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzUtMTgtMS0xLTA_a7038c84-d3cd-436b-8438-9d35002a493e">52,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized gains on investments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8990e088bd584d108b3b67f167d02e78_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMTQtMS0xLTA_c8c284a7-7ecb-4c09-85c5-8dd9fae45e85">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMTgtMS0xLTA_07df0bc6-a6d3-4ccd-b142-37d7306e2f36">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c4d9ba8d16c449c80e25e34837c0084_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMS0xLTEtMA_3b2c5cca-85f8-4325-8f5b-e3d69ff48d19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c4d9ba8d16c449c80e25e34837c0084_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMy0xLTEtMA_457a5c6a-1cbd-4195-95d1-f142cc65e8c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a7ee782a5ac4726825924882652fb3b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctNi0xLTEtMA_3b3383ae-cec9-4aa2-ac52-23648dcc24b8">31,255,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7ee782a5ac4726825924882652fb3b_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctOC0xLTEtMA_94e04dba-e0a8-4ea5-9f06-72e6b90fdcc2">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864f0448c9b44f6abc0aa0fc934ca527_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTAtMS0xLTA_baafc4c5-0a5a-4dbd-b965-4cd2a32a3ff8">263,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ed96d628e884154a23064db50466351_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTItMS0xLTA_a522d20e-fa4c-40e5-bf8d-5761b9a8b3a4">191,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0db448912c4166941130ebb1e99a3a_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTQtMS0xLTA_827bc1d1-350c-417b-95c3-675774c3174e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8aa68dc9bd43a0878ae2aa5eaa1801_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTYtMS0xLTA_c35d187c-607f-4843-88da-b3fea9177687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTgtMS0xLTA_0cc8e3a2-614a-4fbb-97f4-27679e779db2">71,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock in connection with public offering, net of underwriting discount, commissions and offering costs of $<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMC0xLTEtNTEwL3RleHRyZWdpb246NDc4ODgyODZjN2I0NDZiYmI4YzU0ZDE1NTgwOTMzY2VfMTY0OTI2NzQ0MTc5NA_ac225780-88c9-45ff-a924-93bdb91d6d03">4,457</ix:nonFraction> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtNi0xLTEtNTE3_179c21a7-29e1-4e02-ab47-449c5ad4fd1f">1,923,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtOC0xLTEtNTE3_66718621-5e83-4aa8-a9fc-b837e9c25d48">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMTAtMS0xLTUxNw_ccd26bc6-293d-445c-aee7-4629259e568d">70,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMTgtMS0xLTUxNw_fa9aaa96-4289-4621-a02a-1a17cc19ba3a">70,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctNi0xLTEtNTE3_293fc076-8b68-4d91-a7b1-9581d40822b2">1,018,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctOC0xLTEtNTE3_3cb16b0e-4193-4ad0-907a-82d9ab467b10">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTAtMS0xLTUxNw_5ae395dc-56cd-41d4-8efc-8783cce4f764">3,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTgtMS0xLTUxNw_bce9a7ec-27d8-436f-a379-a75973b5ea17">3,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzgtNi0xLTEtNTE3_6f0d9c25-8e45-4bbc-9578-148a2cac1a00">52,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzgtMTAtMS0xLTUxNw_8fab0a58-a2ee-414b-9427-857c97e4efc0">1,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzgtMTgtMS0xLTUxNw_b779417d-0ef2-4671-be9c-13cc973c54be">1,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzktMTAtMS0xLTUxNw_28ae70c8-46af-4757-b8ea-27d1d04da767">7,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzktMTgtMS0xLTUxNw_4a37af56-c09e-43a0-ae03-7cc8b7519ed7">7,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4702b7d22d1a40a59e7c037cc5eef2a3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDAtMTItMS0xLTUxNw_2c16f0d9-7594-4e1e-84b1-8bd722640b7e">47,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDAtMTgtMS0xLTUxNw_1f617f21-457d-46cf-8a7c-cca24dffe999">47,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized gains on investments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7ed4748adc465582c5b79aad061342_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDEtMTQtMS0xLTUxNw_b56ce339-11ed-4b44-b4e4-4985eec10b89">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDEtMTgtMS0xLTUxNw_c370f543-d852-4982-adbc-ad1f17024673">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0886aab4e9464bd081f28baaadbc2c24_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMS0xLTEtNTEz_c22bd362-4b26-4d84-bbc7-246a0b7268d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0886aab4e9464bd081f28baaadbc2c24_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMy0xLTEtNTEz_28eb3276-3005-4923-8298-aead1efbfb98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79caa187be2c4546967d3d07d999a1f2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItNi0xLTEtNTE3_192f8f78-ef32-49c0-93fc-8edabe283b35">34,249,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79caa187be2c4546967d3d07d999a1f2_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItOC0xLTEtNTE3_6b002963-eacf-47d8-914e-75fe9fb24e72">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f9aab73bb74d4eb978e25668f669a1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTAtMS0xLTUxNw_aab952c1-e68c-4da2-a7f3-6d1eb38215e7">346,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35b094dd513647c39d1b0a77a875ab5b_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTItMS0xLTUxNw_82b2be47-2240-4cfb-99db-46cb87fee6b1">238,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0693226ab445409dac81b6a1a31b8e74_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTQtMS0xLTUxNw_7ca6c958-37f9-4e77-8b7d-4c8ad5e1c840">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbe3473f98e7473a96d28715e29fab03_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTYtMS0xLTUxNw_c2182c4f-0b6a-4397-be98-e5c75c72fbbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTgtMS0xLTUxNw_2bd41c1a-70d7-4715-9d5e-91ee9a2a2ffa">107,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_73"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Silk Road Medical, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Statements of Cash Flows</span></div></td></tr></table></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.920%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMy0xLTEtMS0yNDcx_e86b9774-aaa1-492a-a0b5-fbdf98eaad18">47,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMy0xLTEtMS0w_ffe4e115-0021-4df2-bd02-314fc0db5ce1">52,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMy0zLTEtMS0w_6c297243-c0ec-4a12-abb7-5e4ce29f19f4">37,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNS0xLTEtMS0yNDc1_46652e5f-fa28-463c-9085-f6119bacd39c">789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNS0xLTEtMS0w_7e530f2f-e623-4a68-9c46-5a859a286f2d">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNS0zLTEtMS0w_ec7bfa2f-2adf-45f9-90dc-2b44f83d28b5">517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNi0xLTEtMS0yNDc1_f803d35d-ed05-4f77-b145-89fcf22eaff5">7,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNi0xLTEtMS0w_3996060f-2b06-4b14-bc79-9b8a24fbe5ca">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNi0zLTEtMS0w_5e31f0b8-6367-4e1e-9a9c-9192d5f59289">911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in fair value of redeemable convertible preferred stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNy0xLTEtMS0yNDc1_84573b5b-5fc4-4d28-8704-a0a5db5d5fe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNy0xLTEtMS0w_3dc66c01-ed2e-4302-9d64-da58004d44e0">21,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNy0zLTEtMS0w_2fb1edb8-40a4-402b-ab36-415bae8f96d7">11,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of premiums (accretion of discounts) on investments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOC0xLTEtMS0yNDc1_f893494d-bcba-4999-acfc-4e5f36b0e41a">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOC0xLTEtMS0w_e2a4110f-211d-45bf-a6ac-737a90d71db5">309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOC0zLTEtMS0w_cd2ab901-3675-4d4f-ab66-9bd3ebbf709e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOS0xLTEtMS0yNDc1_bfa86aa0-9975-4b33-91cf-e72c9e93d2c8">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOS0xLTEtMS0w_16b1a176-0bee-44fe-86a1-02109cbef904">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOS0zLTEtMS0w_8a78fc40-3a3e-4dd4-94c3-e8d5f53d2c73">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTAtMS0xLTEtMjQ3NQ_a9e1fb95-9794-431f-bd81-30f8fb4d080e">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTAtMS0xLTEtMA_32db6623-362c-47bc-978e-b3f5a29730ff">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTEtMS0xLTEtMjQ3NQ_4cb8f5fe-bab2-4816-bdf4-729edf1fedfa">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTEtMS0xLTEtMA_ce428221-c73f-4b86-8207-fb4000b51eab">672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTEtMy0xLTEtMA_d878aa96-7fd4-483b-b1ea-e99dc9901205">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItMS0xLTEtMjQ3NQ_acde8203-2c7c-4163-b646-ecb9c3175a1f">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItMy0xLTEtMjQ3OQ_dba02469-d58e-4755-aa54-0e3c3a04516b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItNS0xLTEtMjQ3OQ_6d7b09ab-9953-4402-bb8b-f1ecae4da7c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTQtMS0xLTEtMjQ3NQ_474059fa-5ace-4629-84ce-add9e11c761f">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItMS0xLTEtMA_c6062a57-d83b-436f-8a80-a18f2aaf1506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItMy0xLTEtMA_30ef1f95-d5fb-401a-89d3-bcc5bd50d251">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in provision for doubtful accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTUtMS0xLTEtMjQ3NQ_a5886554-3aee-4fbc-a5fd-570cb8ac8818">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTMtMS0xLTEtMA_0ab1926b-c4f2-4430-8811-51239542455d">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTMtMy0xLTEtMA_4531a074-3246-4250-83b4-c70e2f5ebfc2">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision for excess and obsolete inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTYtMS0xLTEtMjQ3NQ_3ed2aca4-4d15-4124-b58d-213e8514e218">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTQtMS0xLTEtMA_3e6b4640-a8e1-421f-b485-b5542bb8be39">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTQtMy0xLTEtMA_fef8f03f-e2a5-42c7-ab5b-21e7de0773b7">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTgtMS0xLTEtMjQ4NQ_7d7625b6-2020-40c3-8446-c1f7e8d11f8c">437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTYtMS0xLTEtMA_f8216878-a31b-4a7c-9ef8-b24f42b72a3d">2,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTYtMy0xLTEtMA_c7870cab-bfdf-4269-927c-6b1d4e131ff3">446</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTktMS0xLTEtMjQ4NQ_063ae58c-5362-42a0-8c5d-d1bec9d88975">2,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTctMS0xLTEtMA_f26f260e-e062-4dcf-b564-38176087e9d1">4,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTctMy0xLTEtMA_75febab3-d701-454f-9c53-86cf4f17b5e9">2,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjAtMS0xLTEtMjQ4NQ_4b01b26c-4462-4d60-a88b-f5e4167c552e">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTgtMS0xLTEtMA_620bdcab-5f62-4d9f-a6bf-c3ad4c3717a5">1,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTgtMy0xLTEtMA_683cd6a8-1399-41e1-b47c-4f0377b4c864">1,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjEtMS0xLTEtMjQ4NQ_17419e06-997d-40b5-af7b-3ced761f7ead">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTktMS0xLTEtMA_3edcd164-645a-4ca2-aaf8-22eaec8eea3b">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTktMy0xLTEtMA_15059aba-9b47-41bf-8f30-cea827f935ec">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjItMS0xLTEtMjQ4NQ_f7fff9ac-5030-4178-8759-03a3d1da0509">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjAtMS0xLTEtMA_0c4969ac-27f4-49cf-b0a3-bea245e34dca">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjAtMy0xLTEtMA_4d95bb6b-424b-4e32-b071-bc285883277c">309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjMtMS0xLTEtMjQ4NQ_91b13b4c-e1d6-4fe1-8fea-6b35093995c7">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjEtMS0xLTEtMA_c82e5665-c5fa-49f4-93ef-2b01d77e8033">4,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjEtMy0xLTEtMA_ed0629a4-74e6-4a24-bd5f-a9840d3d11ae">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjQtMS0xLTEtMjQ4NQ_48a5754d-318f-4ea8-9086-c40dc0cd0df5">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjItMS0xLTEtMA_3311d7a6-70ea-4e6b-9397-1fae4b435eba">769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjItMy0xLTEtMA_ec7e35a7-a068-47f2-a56c-e28848a1eb1a">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of interest paid in kind</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="silk:RepaymentOfPaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjQtMS0xLTEtNzc4Ng_c91f01c7-fbc8-4c0a-b0d7-9832af59a808">3,813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="silk:RepaymentOfPaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjQtMy0xLTEtNzc4Ng_705d11c0-8c01-4b33-aa3d-66c0df9c4ef4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="silk:RepaymentOfPaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjQtNS0xLTEtNzc4Ng_a98a46bf-5c8d-4157-8290-c477c0b77545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjMtMS0xLTEtNTIy_75907d8b-a958-42a8-8b57-dce160b70f0a">42,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjMtMS0xLTEtMA_722d6577-ca8a-4bdb-b60c-e269fdaa7083">29,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjMtMy0xLTEtMA_2eff823e-e9e7-44f5-a90c-d63890238a76">21,695</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjctMS0xLTEtMjQ5Mw_084b7a28-b9aa-41f6-9a5a-cac2c9d6613c">842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjUtMS0xLTEtMA_ae7cfa70-a2ce-48cb-bfdc-c94b417bf291">535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjUtMy0xLTEtMA_64567c06-f584-4c6e-a5cb-3b1fefb73a15">2,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjgtMS0xLTEtMjQ5Mw_cc2085bf-17b9-40c3-9b2f-d878f1d920e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjYtMS0xLTEtMA_aa553bf8-3f51-4e28-92aa-b5b1ec176bfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjYtMy0xLTEtMA_ed928f6e-4c13-4b4b-b338-9ded67a37110">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjktMS0xLTEtMjQ5Mw_01675c5f-436b-43ff-b71b-b22b21c214a1">79,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjctMS0xLTEtMA_1e374267-5bfb-4e8d-bb09-320d0b06c1ea">69,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjctMy0xLTEtMA_89f0b691-7ac4-483a-a888-7d48e00115de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtMS0xLTEtMjQ5Mw_822c4946-ca88-4d6e-9ded-62be5892d519">71,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtMy0xLTEtMjQ5Nw_92c19cca-591f-4d82-80a8-9d1e7fb975a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtNS0xLTEtMjQ5Nw_aabf70b1-7da9-40b0-824b-4ed33a73af1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjgtMS0xLTEtNTI2_48154048-4e94-487b-825b-5539e5bd21f6">9,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjgtMS0xLTEtMA_ae62c984-164d-4d88-ab61-2454d5eb27cb">69,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjgtMy0xLTEtMA_13336a7d-5da8-4115-a46e-f10d9980e05f">2,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzMtMS0xLTEtMjUwMg_653a6281-d894-4d80-9911-cd4ea00e366b">70,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtMS0xLTEtMA_6f093f9a-4e7b-4dbf-86d6-fb98fe128558">109,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtMy0xLTEtMA_b860ed83-b1aa-445f-94b9-34514a9bcf73">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzQtMS0xLTEtMjUwMg_9eefe07d-1136-448b-947a-2f1aeba07908">48,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzEtMS0xLTEtMA_9672601d-294c-4b88-aba8-f9415f80b8a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzEtMy0xLTEtMA_01d74817-9442-4ed2-9ee5-be3dd2729904">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzUtMS0xLTEtMjUwMg_fc1bcfc8-bf7a-40a2-bce5-31fd475a52c6">5,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzItMS0xLTEtMA_9dda1eb6-e358-4b53-a54c-c1e7a44335b6">2,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzItMy0xLTEtMA_32e8dd0b-2b4e-443c-a6fd-698abd1ce698">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from exercise of redeemable convertible preferred stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027bc0bdf8734670ba15f197c3fa9de7_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzYtMS0xLTEtMjUwMg_8924e7ae-8fa0-4008-aeef-a82677c05020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b505ad720547b7906b11f5bbf2fbdb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzMtMS0xLTEtMA_a62d554d-7af5-4159-abd9-07b876339cd1">1,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73fdcaf51beb4164910ff49230c96c68_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzMtMy0xLTEtMA_61318440-6dac-49c2-9967-fa13709126cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea0497ce3b1475f81a9c6c00b0c512b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzctMS0xLTEtMjUwMg_9690c31b-f266-44d7-b6ff-663bec85b268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32dc6dca82f54b3997404bec4ab31270_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzQtMS0xLTEtMA_1e7d5811-6c29-484a-8798-d9bb2a2efa8e">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7c87ccb914d486b82d6cfe0e26711e6_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzQtMy0xLTEtMA_351c88aa-ca16-4d4e-a891-6958e3d30dd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMS0xLTEtMjUwMg_5da56f69-de4b-472d-b8db-d55dc7e6d7b5">40,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMy0xLTEtMjUwNg_e6e57df7-4f1e-4a64-949b-1f114cce6602">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtNS0xLTEtMjUwNg_85201000-5145-45ef-84ad-f3b9e9ea7d85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments of prepayment penalty and lender fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMS0xLTEtMjUwMg_1f735d8e-65ae-46a2-8957-93f6580ab936">2,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMy0xLTEtMjUwNg_fb2116bc-b614-4ee2-96cd-ef78166825fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktNS0xLTEtMjUwNg_d3014f1c-1fcd-4a67-af22-294bc346139a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDAtMS0xLTEtMjUwMg_35d49bd5-48ac-4095-86f0-ca7dddcacd3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzUtMS0xLTEtMA_ce39fb58-5c5c-4c4d-9976-c51af23b1737">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzUtMy0xLTEtMA_963226b9-a776-43d9-8667-faf4ee367306">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzYtMS0xLTEtNTMw_4ee4bb1e-09fd-479a-a045-f8e0572bfe53">81,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzYtMS0xLTEtMA_22ec9c7f-d84e-4aad-8a18-c1e209a88841">113,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzYtMy0xLTEtMA_fbcad84d-f303-477c-9661-4be60f5cb063">15,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzctMS0xLTEtNTMw_982cf9f5-8601-459c-b705-fcd65128dbc2">30,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzctMS0xLTEtMA_6c767b2b-209c-465c-901e-9fb5608c5136">14,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzctMy0xLTEtMA_614e3162-83fb-480f-96ec-b6ec235a8318">8,541</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMS0xLTEtNTMw_acf86725-e946-466f-aac6-75af06ba8b93">39,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMS0xLTEtMA_b522d706-767b-44dd-892f-ceaa51d5de1d">25,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMy0xLTEtMA_17625b7f-4bf1-49fd-aadd-d839eed6529f">33,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMS0xLTEtNTMw_d56168a5-60c0-4087-91e6-ea254b8da240">69,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMS0xLTEtMA_db749c37-0e46-4da4-accf-dfebb1f7ab97">39,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMy0xLTEtMA_16a38968-eb84-41f5-9bd1-c8197c5e9a9e">25,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDEtMS0xLTEtNTM0_a16a831d-38ac-4de3-ba3b-eea6218ef483">7,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDEtMS0xLTEtMA_06b746b9-33eb-4381-998f-75923ade5288">4,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDEtMy0xLTEtMA_94f4308e-ec25-4906-a65c-3c285cd82c41">2,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities for purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDMtMS0xLTEtNTM4_05ce1c6d-6356-407c-9c74-d4616c921e99">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDMtMS0xLTEtMA_7a500a88-e758-4574-bc5c-91759666a0d7">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDMtMy0xLTEtMA_d472dfd5-6f4e-41d3-bc11-52527d0d4777">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Landlord paid tenant improvements</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDQtMS0xLTEtNTQy_3545ec05-7254-4d0e-8407-2ffbb544002e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDQtMS0xLTEtMA_73ad0f3a-06b9-475f-88f0-963ceb9b109d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDQtMy0xLTEtMA_95da0f9f-0b5b-4d84-a79d-d244952a5bb7">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unpaid deferred offering costs</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="silk:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDUtMS0xLTEtNTQ2_160e6559-da38-4624-854c-f1f78e8db277">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="silk:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDUtMS0xLTEtMA_87dbd689-b39c-41a2-b443-20d6524dbec6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="silk:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDUtMy0xLTEtMA_0d4617f3-9150-4ffc-a06c-ff431ff09a72">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use asset obtained in exchange for lease obligation</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDYtMS0xLTEtNTUw_5148c29e-bc8d-4374-a8d7-9fd7f818d851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDYtMS0xLTEtMA_d968ad99-9e79-419e-aa2a-32d69f10bbcf">3,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net exercise of redeemable convertible preferred stock warrants to preferred stock</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDctMS0xLTEtNTUw_036df761-aeb9-4db5-b3ad-e4363760a9fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDctMS0xLTEtMA_208940f8-fae4-422e-92e5-d117be5f9d4e">37,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDctMy0xLTEtMA_1087b670-d1e9-4f0d-bff1-11996597ba23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDgtMS0xLTEtNTUw_5b3e06bf-ff06-46e7-b252-e48f0e68b1da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDgtMS0xLTEtMA_9361fde6-31ec-4ed2-9869-d49dc9676817">144,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDgtMy0xLTEtMA_85bced6d-1cc3-4a90-8678-81b68406c9c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_76"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMzQ4NA_d1a65aa4-fe99-4dea-b0c1-6468e9671557" continuedAt="i712d4e2948d048219f35f27927002297" escape="true">Formation and Business of the Company </ix:nonNumeric></span></div><ix:continuation id="i712d4e2948d048219f35f27927002297" continuedAt="ie78d9a8355434446be695eb4eb1f97ea"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Silk Road Medical, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on March&#160;21,&#160;2007.  The Company has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke.  The Company&#8217;s portfolio of TCAR products enable a new procedure, referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles.  The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.  The Company commercialized its products in the United States in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2016. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception.  As of December&#160;31, 2020, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTA0OA_e462d0ae-4f34-40b4-a3c1-39657121e90e">238,891,000</ix:nonFraction>.  The Company expects to incur losses for the foreseeable future.  The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> believes tha</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t its cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTE3Nw_668b6e53-0e95-4b43-8ca9-e4e34c8f7556">69,466,000</ix:nonFraction> and available-for-sale investments of $<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTIxOA_4a8d1d2a-2e03-4791-80be-4574a6ed6ff0">78,016,000</ix:nonFraction> at December&#160;31, 2020, as well as its expected revenues will provide sufficient funds to allow the Company to fund its planned current operations for the next twelve months from the issuance of these financial statements.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2019, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a 1-for-2.7 reverse stock split of the Company&#8217;s common stock and redeemable convertible preferred stock to be consummated prior to the effectiveness of the Company&#8217;s planned initial public offering (&#8220;IPO&#8221;).  The reverse stock split was effected on March 27, 2019.  The par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split.  All the common stock, redeemable convertible preferred stock, stock options and warrants, and related per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Public Offerings</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjMxMw_f9901ed5-a74d-4d46-aaed-62db5b3353f8">6,000,000</ix:nonFraction> shares of its common stock in its IPO at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0c12d1da942447109063cebb275e8ba0_I20190430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjM4NA_1f70cc6d-f7e1-4184-bf1d-25cc76e39e24">20.00</ix:nonFraction> per share, for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjQzMg_8c31b4d6-3703-4a40-8b17-b6867830abb1">109,119,000</ix:nonFraction> after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430" decimals="-3" format="ixt:numdotdecimal" name="silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjUwNw_49c4a40c-5491-4ad9-8e1c-f4534932448c">8,400,000</ix:nonFraction> and expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjU0MA_fb7920aa-c5ae-4b44-94b9-873d0d31b3a3">2,481,000</ix:nonFraction>. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock and the Company's outstanding warrants to purchase shares of common and redeemable convertible preferred stock were exercised, or automatically net exercised absent a prior election. The exercises resulted in the reclassification of the fair value of the related redeemable convertible preferred stock warrant liability to additional paid-in capital. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company completed a secondary public offering of <ix:nonFraction unitRef="shares" contextRef="ie8b27155c8474ab98f936002ff227c64_D20190801-20190831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMzEwMg_8a7bf1d4-814e-455a-82aa-d4f5d78a9202">4,200,000</ix:nonFraction> shares of its common stock sold by certain selling stockholders, and the exercise in full of the underwriters' option to purchase <ix:nonFraction unitRef="shares" contextRef="ie87e6a507693455e82f8b7d021987453_D20190801-20190831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMzIzNQ_519c26df-8ecf-4dda-bd8c-828f7f658b9b">630,000</ix:nonFraction> additional shares of its common stock from certain selling stockholders, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic360f0c60b9e4bd4a3301ef5a705c91f_I20190831" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMzM0MQ_8e8d5003-185e-4ecb-9385-fa11cb955bcd">39.50</ix:nonFraction> per share. The Company did not receive any of the proceeds from the sale of the shares of its common stock from the selling stockholders.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="iec4ce25ed9c841df9c17121f68205ba4_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjIzMg_8fc15e2a-e77c-4bbf-a07b-c5d202b56f80">6,808,154</ix:nonFraction> shares of its common stock, of which <ix:nonFraction unitRef="shares" contextRef="i0619a3b111784379874d71f11398ec42_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjIzNg_f914f44a-195c-4a32-94fc-90cbf2194498">1,923,076</ix:nonFraction> shares were offered for sale by the Company and the remaining <ix:nonFraction unitRef="shares" contextRef="i856f24feae584b14a8bc751fcb0a507a_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI0MA_19b7b58a-ed30-42a0-a127-683aae4d071e">4,885,078</ix:nonFraction> shares were offered for sale by certain selling stockholders, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifa0280538aac42a28763dda42b85838a_I20200531" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI0NA_18fe5e39-46ed-4594-bac3-ee6513bfa4c1">39.00</ix:nonFraction> per share. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie78d9a8355434446be695eb4eb1f97ea">The Company received cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI0OA_634740b8-6ed1-48cf-8f89-4d6ca0009eb3">70,543,000</ix:nonFraction> after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531" decimals="-3" format="ixt:numdotdecimal" name="silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI1Mg_fe54ba88-8178-4ad1-8d03-8b468bb6b33d">3,750,000</ix:nonFraction> and expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI1Ng_c59640f8-241e-4332-9a85-a2a16235a691">707,000</ix:nonFraction>. Also, in May 2020, the underwriters fully exercised their option to purchase <ix:nonFraction unitRef="shares" contextRef="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI2MA_a41a33eb-4918-42ef-8242-da277373f86e">1,021,223</ix:nonFraction> additional shares of common stock from the selling stockholders.  The Company did not receive any of the proceeds from the sale of the shares of its common stock by the selling stockholders.</ix:continuation></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_82"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODU_5aee194d-5fd6-4672-aaa5-8ddaa1df1a12" continuedAt="i5c34bdd6f1964f37a3f288ed1ec5b83b" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i5c34bdd6f1964f37a3f288ed1ec5b83b" continuedAt="ieb733487481d4c15aa5c08233d074afe"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODE_a59031f2-1305-4bd0-9546-0708ef8b73e0" continuedAt="iec763dbfcf6d476493ce8b2519508510" escape="true">Basis of Preparation</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iec763dbfcf6d476493ce8b2519508510">The accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</ix:continuation>  </span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjQ_2eb38d15-2bfc-4131-a750-053bcc99b057" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the coronavirus (&#8220;COVID-19&#8221;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTk_dd845088-e706-4fc9-993b-1f4bce318a8e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2020 and 2019.  The carrying amounts of certain of the Company&#8217;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTg_a0ba25cb-36e7-4a3b-b3a7-00b4edf3962d" continuedAt="i829742e0692345018f4500a12b957a2e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of December&#160;31, </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="ieb733487481d4c15aa5c08233d074afe" continuedAt="ic65d7c047212450082bb4b5702238135"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i829742e0692345018f4500a12b957a2e">2020, the Company&#8217;s cash equivalents are comprised of investments in money market funds and commercial paper.  As of December 31, 2019, the Company&#8217;s cash equivalents are entirely comprised of investments in money market funds.</ix:continuation>  </span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjU_712267db-bb5f-4431-8232-5a4da341c6d5" escape="true"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzM_9b67d406-94b9-424b-a3c0-f5a84f55ecff" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfMi0xLTEtMS0w_587ab64c-35c6-4853-b253-ff0953a51009">69,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfMi0zLTEtMS0w_14d51e6e-d271-4da8-9606-bf59d7fb451b">39,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfMy0xLTEtMS0w_d4d38447-ad73-40f8-ae65-9eeb07f9c4d8">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfMy0zLTEtMS0w_33ebec99-2ac5-45d5-9715-f84bbeaff22a">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfNC0xLTEtMS0w_99b28aa3-f2d7-4bf0-b955-5601e2aa1e35">69,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfNC0zLTEtMS0w_20b9a931-fcf4-42ca-9429-4cb290b412b6">39,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash as of December&#160;31, 2020 and 2019 consists of a letter of credit of $<ix:nonFraction unitRef="usd" contextRef="i827e3aa981f94e4497963dc63008de63_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzczNQ_813945bb-0e2f-4ddf-9269-ebf7dcbd195f"><ix:nonFraction unitRef="usd" contextRef="i1750d8abb53f482ab006e6bbcc0efe15_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzczNQ_baef506e-3abd-4470-aaf3-f849170233f1">310,000</ix:nonFraction></ix:nonFraction> representing collateral for the Company&#8217;s facility lease. </span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkyOTg1NA_810fe43c-58ba-4e3c-a85d-b0c9a507acb2" continuedAt="i1ffc993de6544a798d23c9aaed4ea023" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy.  Money market funds are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method. Realized gains and losses are included in earnings and are der</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived for specific-identification method for determining the costs of investments sold and were insignificant for the year ended December 31, 2020 and 2019. Amortization of premiums and accretion of discounts are reported as a component of interest income.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ffc993de6544a798d23c9aaed4ea023">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment.</ix:continuation> </span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzI_8a7a8c0d-05c0-40da-b226-fa2cc3eca9fc" continuedAt="ie8aa1faef1c140cfac0738eba84978d2" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks related to public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#8217;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#8217;s revenue while the pandemic continues.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="ic65d7c047212450082bb4b5702238135" continuedAt="i5fefb36645204682bb9bfcaf428a1699"><ix:continuation id="ie8aa1faef1c140cfac0738eba84978d2"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable are due from a variety of health care organizations in the United States.  At December&#160;31, 2020 and 2019, no customer represented 10% or more of the Company&#8217;s accounts receivable.  For the years ended December&#160;31, 2020, 2019 and 2018, there were no customers that represented 10% or more of revenue.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manufactures certain of its commercial products in-house.  Certain of the Company&#8217;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis, a Cardinal Health Company (see Note 14 - Subsequent Events).  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#8217;s financial position and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#8217;s currently approved portfolio.  If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div></ix:continuation><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjA_6e1f9171-6d65-4973-a1f1-73e7bf885969" continuedAt="i0fdec1301a2e4db3a45944fb987bf263" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest.  The Company estimates allowances for doubtful accounts.  Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#8217; financial condition.  The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected.  These specific allowances are reevaluated and adjusted as </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i5fefb36645204682bb9bfcaf428a1699" continuedAt="i108e1090bd584f5a93a2cc66f938eb24"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0fdec1301a2e4db3a45944fb987bf263">additional information is received that impacts the amount reserved.</ix:continuation>  During the years ended December 31, 2020, 2019 and 2018, the Company did not experience any material credit-related losses.</span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjY_9ec5d0e7-415f-4b05-84e0-1f620ac5833c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value.  Cost is determined using the first-in, first-out method for all inventories.  Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.  The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate.  The Company&#8217;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements.  The estimate of excess quantities is judgmental and primarily dependent on the Company&#8217;s estimates of future demand for a particular product.  If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Current Assets</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prepaid expenses and other current assets balance at December 31, 2020 included $<ix:nonFraction unitRef="usd" contextRef="i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA5OTUxMTY3ODAyMA_3bc2690d-3014-45b5-b167-c41b48168e22">4,160,000</ix:nonFraction> associated with the Company's voluntary recall (see Note 14 - Subsequent Events). The amount relates to the replacement lots and other direct costs to be received from Cord</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is. </span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjE_fd4f7ef7-6219-408d-8ec4-5db333a938e8" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost less accumulated depreciation or amortization.  Repairs and maintenance costs are expensed as incurred.  Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA3ODg_1daeb587-69ed-44f7-8b16-4ee5917c9839">three</span> to <ix:nonNumeric contextRef="ia0b870409832446b94306158afef68a2_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkyOTg1OA_c2aa4d6e-3b45-42e1-afa4-7823cf4fb939">five years</ix:nonNumeric>.  Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset.  When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Njk_10a58f93-0785-4436-9483-6f1152547387" continuedAt="i02f41a29c1684ba88449f33b7f5dba29" escape="true">Deferred Public Offering Costs</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i02f41a29c1684ba88449f33b7f5dba29">Specific incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering.</ix:continuation>  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DeferredOfferingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkyOTg2MQ_e1ab4a62-0d8a-4e0c-a3d8-26b4a1a2b2fa">No</ix:nonFraction> deferred offering costs were capitalized as of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As of December&#160;31, 2019, there were $<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTE0Mjk_64c6476d-f005-4524-82eb-7fe4b640bbc8">950,000</ix:nonFraction> of offering costs primarily consisting of legal and accounting fees that were capitalized in other non-current assets on the balance sheet of which $<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTE1ODA_d86a0f1f-10b0-41fe-ac44-2d3d14432386">233,000</ix:nonFraction> had been paid.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzY_5f722ed9-9673-413d-a24c-15e9c6146770" continuedAt="ic9d9f147987d459681b88a96ae8dd8fd" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic9d9f147987d459681b88a96ae8dd8fd">The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable.  If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount.  Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value.</ix:continuation>  The Company did not record any impairment of long-lived assets during the years ended December&#160;31, 2020, 2019 and 2018.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i108e1090bd584f5a93a2cc66f938eb24" continuedAt="i5a66d65abc794ae4b0ba258edc13647e"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjI_d47a25de-5550-4d49-b79c-dce40c0f47d2" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  As a result of adopting ASC 842, the Company recorded an operating lease right-of-use ("ROU") asset of $<ix:nonFraction unitRef="usd" contextRef="i74860ed5b6ab4871aeb814ec7a0a16b6_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTI3NTI_e683fbda-66da-4876-ad6b-d771c9291c50">3,982,000</ix:nonFraction> included within other non-current assets and operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i74860ed5b6ab4871aeb814ec7a0a16b6_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTI4MzE_c51747c8-2f04-4678-9fc7-e3745357d73f">5,190,000</ix:nonFraction> included within accrued liabilities and other liabilities on the balance sheet related to its facility lease, based on the present value of the future lease payments on the date of adoption.  The operating lease right-of-use asset also includes adjustments for prepayments and excludes lease incentives.  The adoption did not have an impact on prior periods or on the Company's statements of operations and comprehensive loss.</span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="silk:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Nzc_21168a97-3302-49d3-a74c-a9926f866fd6" continuedAt="i1f178e6e57fd43c9b69713b9459e9ce7" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosure impact of the adoption of ASC 842 on the balance sheet was as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjustments Due to ASC 842</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if853e1713db04046a3e29718f77e312d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMS0xLTEtMS0w_9763f940-c5bb-402e-b41a-ddc3f6dd2c04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a8a6cae4d84ca78f3412deeef72360_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMS0zLTEtMS0w_936bb72f-a675-4bb2-8bf5-70125e6d472a">3,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a23db6a3861435b9f2516a8cd29279a_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMS01LTEtMS0w_1fc68387-ed6d-46ed-a118-dbe285539422">3,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if853e1713db04046a3e29718f77e312d_I20191231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMi0xLTEtMS0w_e13e0319-163d-47c2-8009-b4fa6369e6ef">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a8a6cae4d84ca78f3412deeef72360_I20190101" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMi0zLTEtMS0w_6f0facb7-ae41-4156-8d9a-3b202ecd9c9b">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a23db6a3861435b9f2516a8cd29279a_I20190101" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMi01LTEtMS0w_fce87e13-0947-4cc6-8c52-65d5f64c7a9a">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if853e1713db04046a3e29718f77e312d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMy0xLTEtMS0w_44b87343-d371-44da-8f1a-9826c4885e0f">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a8a6cae4d84ca78f3412deeef72360_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMy0zLTEtMS0w_2077da0f-1c97-4113-8698-2e9b8d07fd98">3,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a23db6a3861435b9f2516a8cd29279a_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMy01LTEtMS0w_ee2b815e-137f-4ce1-929a-924922c61117">4,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#8217;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="silk:WarrantsClassifiedAsLiabilitiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzQ_a883a221-1c56-47a8-8c00-1e249ac8e5eb" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock Warrant Liability</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the statements of operations and comprehensive loss.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised. Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#8217; equity. Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i5a66d65abc794ae4b0ba258edc13647e" continuedAt="i6452228e1fdd4c80b1d579e21b793d6b"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTU_4ca9f9c7-46ef-46e9-b437-d22bbe1ef40a" continuedAt="i5f68015be5474ba7ad0fdbb714b1b8ee" escape="true">Redeemable Convertible Preferred Stock</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f68015be5474ba7ad0fdbb714b1b8ee">Prior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#8217; equity on the balance sheet as events triggering the liquidation preferences were not solely within the Company&#8217;s control.</ix:continuation> Upon the closing of the Company's IPO, all shares of convertible preferred stock then outstanding converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1cc64e5be1b148b388a24c6ea4bc296c_D20190501-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTY0OTY_ea34bf22-4a3c-488f-8245-b89be3bf7375">23,178,555</ix:nonFraction> shares of common stock resulting in the reclassification of $<ix:nonFraction unitRef="usd" contextRef="i29d32e7c3bb6454a8aac9d997e7acdc7_D20190501-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTY1NTk_0edbe4a7-f746-4fa2-90af-1c81707e9d9d">144,140,000</ix:nonFraction> from outside of stockholders&#8217; equity to additional paid-in capital.</span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODA_72b02e4c-f9a3-4fe6-806f-e41541ae1acf" continuedAt="ia1ce322e24ae4a63a90b0af454c5378e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606,&#160;&#8220;Revenue from Contracts with Customers.&#8221;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2018, the date of adoption, the Company recognized the cumulative-effect of initially applying ASC 606 as an adjustment to decrease accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="id8bdec6a3f3f428d912d079b56925396_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkzMzg2OA_6d8fdd13-1ecf-4fd1-be20-5092577e2d16">87,000</ix:nonFraction>.  Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">identify the contract(s) with a customer; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">identify the performance obligations in the contract; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">determine the transaction price;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">allocate the transaction price to the performance obligations in the contract; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTc4MDE_b5f88ea0-b2ca-4973-881a-6a05f4f206b6">71,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTc4MDg_9de9cd00-6e0e-45ff-ba96-4b12e1e69bae">102,000</ix:nonFraction>, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#8217;s standard terms and conditions.&#160;&#160;The Company&#8217;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For sales where the Company&#8217;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#8217;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectibility is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale.  As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i6452228e1fdd4c80b1d579e21b793d6b" continuedAt="i4a118b7ee3cd46258c688603191f97b4"><ix:continuation id="ia1ce322e24ae4a63a90b0af454c5378e"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short.  Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component.  The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of revenue&#160;in the&#160;statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on our balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manufactures certain of its portfolio of TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#8217;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.</span></div></ix:continuation><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTY_59c3c429-51d6-4559-bcd7-b72ab777065b" continuedAt="ie0c4e1768ea14d4185586c18faacb0f0" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses research and development costs as incurred.  Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#8217;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development.  Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses.  Additionally, research and development expenses include costs associated with our clinical studies including clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements.  The Company </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i4a118b7ee3cd46258c688603191f97b4" continuedAt="id10d7d8a45e540b99e6e742759b87689"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie0c4e1768ea14d4185586c18faacb0f0">determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.</ix:continuation></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzU_36a063ee-5581-4ff2-aaee-f856705546b2" continuedAt="i5d7bb88c4e69417fab922e79d5d4ea8b" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5d7bb88c4e69417fab922e79d5d4ea8b">The Company expenses advertising costs as incurred.  Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items.</ix:continuation>  Advertising costs of $<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA5OTUxMTY2NTc4NQ_cb229276-db6d-475d-a2b4-5f324d1ce667">194,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA5OTUxMTY2NTc4OQ_fd4add6a-234e-4c28-8913-128a0ff5d497">362,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA5OTUxMTY2NTc5Mw_26892611-3ced-4473-87ea-fb65b63959ea">186,000</ix:nonFraction> were expensed during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Nzg_54d3623f-5415-4ad2-86cc-a4048b8c4711" continuedAt="i347d39982cd64df994cca2497d8fc030" escape="true">Foreign Currency</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i347d39982cd64df994cca2497d8fc030">The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net.</ix:continuation>  The Company had no material foreign currency exchange gains or losses during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODI_f5052938-95a3-4054-b243-662f979dc7cf" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock&#8211;Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 718,&#160;&#8220;Compensation-Stock Compensation.&#8221;  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions.  The Company accounts for option forfeitures as they occur.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made an accounting policy election under Accounting Standards Update (ASU) No. 2016-09, "Stock Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting to account for forfeitures as they occur, resulting in a cumulative-effect adjustment to increase accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="id91c2dc9412d49f38b2911de8b92a20c_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkzNDM5OQ_c8c11ba9-faba-4809-89bc-a944e3182848">13,000</ix:nonFraction> as of January 1, 2018, the date of adoption.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Njc_64403ee5-fde3-4970-813b-25f3f89d0ce6" continuedAt="i979891e2cca746dc814874bdbfb5e8d9" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="id10d7d8a45e540b99e6e742759b87689" continuedAt="i8ec4b3032ac8461ca3c5cacf8ca214fb"><ix:continuation id="i979891e2cca746dc814874bdbfb5e8d9"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is <ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkyOTg2Nw_b838c7fb-d7ba-4d55-8263-7cddc86e69cd">no</ix:nonFraction> provision for income taxes.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes.&#8221;  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  <ix:nonFraction unitRef="usd" contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMjc0NTI_1d7b1a45-8872-4aaa-826c-2f44631f2373"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMjc0NTI_4650de9a-f3fa-4541-9972-3455d1715212"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMjc0NTI_6f918352-294d-4793-a741-bb92fd94d23f">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> liability related to uncertain tax positions is recorded on the financial statements.  It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.</span></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Nzk_0b96aad6-5cea-4a42-8ba8-3f7508b9cc48" continuedAt="i6bf024ca48df470b9e4d63281e921499" escape="true">Comprehensive Loss</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="i6bf024ca48df470b9e4d63281e921499" continuedAt="iaea8b4d66b114f2e8e1d363d9d2b1a14"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020 and 2019</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaea8b4d66b114f2e8e1d363d9d2b1a14">, the Company&#8217;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive income.  Accumulated other comprehensive loss is presented in the accompanying balance sheets as a component of stockholders' equity.</ix:continuation>  For the year ended December 31, 2018, there was no difference between the Company's comprehensive loss and its net loss.  </span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODM_cece876e-7446-4dac-833c-0a0edb29e54a" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#8217;s redeemable convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODQ_9194e385-a8be-45af-89ac-4768ea395249" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share was determined as follows (in thousands, except share and per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Silk Road Medical, Inc. common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMi0xLTEtMS0w_ec97f9ce-ac86-4c8b-9411-5b37ec6a78fd">47,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMi0zLTEtMS0w_4b26ac4b-00b9-4a9e-aa61-8ee719f13e24">52,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMi01LTEtMS0yNzEy_6d0f51d3-2c79-4a7e-a6c9-fb456931ed15">37,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common stock outstanding used to compute net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMy0xLTEtMS0w_696f8d5d-ed07-40cd-9ae0-5376b81495f1">32,965,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMy0zLTEtMS0w_f3970bec-faf2-4abd-bfa6-6d3c33f073f7">22,956,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMy01LTEtMS0yNzEy_68b7069f-2fb6-4f6f-8d62-3f7ed1f45d39">960,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfNC0xLTEtMS0w_a548c589-a8da-4e24-8d97-6d4c6e929345">1.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfNC0zLTEtMS0w_f2d69e0d-3ff8-4eaa-93bc-ad28221ab53d">2.28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfNC01LTEtMS0yNzEy_8cab424b-884d-4f1b-80af-c12732122676">39.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i8ec4b3032ac8461ca3c5cacf8ca214fb"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTc_28f30ce1-2f99-4975-bbfc-b124a8adab00" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#8217;s net loss:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75afb4faf7c744e2b28602b04897dd79_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMi0xLTEtMS0w_508552ad-b790-40d8-af88-726b26d8d7c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64b54eeb36b1445a892442bd09bf6ddc_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMi0zLTEtMS0w_ffd94eff-6d0e-4720-931c-a991c81b18a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f6cfd36e8754556bf275ccd4408ac9d_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMi01LTEtMS0yNzI1_c99004f7-8b6d-4311-897a-968d7cf1df40">21,233,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock warrants outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc08d2bf3b1d4a4db5e64a2c8d4dc1eb_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMy0xLTEtMS0w_48ac8fa0-7876-441a-aac1-a596203ada88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f590d47a7f349109aeb1d59166be0f8_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMy0zLTEtMS0w_6f7eaa20-627a-4ff4-b60b-70e3e5dd9861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5af5a51a24f74e2abff8b55e1f406aac_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMy01LTEtMS0yNzI1_8817a391-84c4-47ba-a78e-975fce43ea84">2,672,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic05cef1eab034c14aabf2595f65c6875_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNC0xLTEtMS0w_29bfd6a1-967f-44b4-be48-e73b2ecbc1a7">4,237,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d19235df8b24d9391e616dafdce6fe6_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNC0zLTEtMS0w_3024de86-5180-4982-9bf7-5fc203ec07b7">4,310,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e6007a041b04fe18293a2b10afdf234_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNC01LTEtMS0yNzI1_c82a8ac9-4f38-4e08-8fc3-57f8a589d4a4">4,364,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9af4d8ce709e4c3a9540ae056f21e76a_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNS0xLTEtMS0w_4d1e2e4b-c26c-4d0f-a09d-a2b9d300794d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0208f9e90c6a42fda50fc3adb6581207_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNS0zLTEtMS0w_1203f2d4-740f-4f48-9996-c6d735c49832">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib88ecc9d7eb744238cc66553830ad1a1_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNS01LTEtMS0yNzI1_f37b00e5-4df3-4b10-a8b7-67794262afad">7,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c1b45f2b2f54a72b7d8efc23d3f0bb1_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi0xLTEtMS0yNzIw_739664d0-2f4f-4d72-a5f2-efee4c54144d">68,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i070da31579db44ef9c24774b3df5e7d7_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi0zLTEtMS01MTkw_dfc9c8e5-319d-4a95-bf0c-450c1439d2d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3673ffce8656493c860435c0fb39bfb4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi01LTEtMS0yNzI1_59980690-c2a9-4ba0-a512-ed759790d849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi0xLTEtMS0w_84973b10-dbe7-45c0-9c86-b471cf1607a6">4,306,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi0zLTEtMS0w_29307e1c-80f1-45a2-bf79-0b52cb0f20ec">4,310,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNy01LTEtMS0yNzI1_2c3c14d0-890b-4dd3-8660-4d07bb86fb6a">28,277,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzE_b55606f0-8a2b-4691-b5c2-fd0799a1e269" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business as <ix:nonFraction unitRef="segment" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzAwMzQ_1f84d5ce-f753-4e12-8365-297e0fd62a86"><ix:nonFraction unitRef="segment" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzAwMzQ_2bd56ecb-ef1f-4c40-90f3-2b8426305aaa">one</ix:nonFraction></ix:nonFraction> reportable and operating segment.  The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Primarily all of the Company&#8217;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment.  All of the Company&#8217;s revenue was in the United State</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s for the years ended December&#160;31, 2020, 2019 and 2018, based on the shipping location of the external customer.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_88"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84OC9mcmFnOjRlZWE0YWRkN2YxOTQ1MTI5YTQ2ZWUyYjM2ZTkzYjk0L3RleHRyZWdpb246NGVlYTRhZGQ3ZjE5NDUxMjlhNDZlZTJiMzZlOTNiOTRfMzE0NQ_0512b368-d4f1-4d57-adfe-3aa9f5e7acc9" continuedAt="i302d845ef2d64d24b5e54048eef78ccb" escape="true"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84OC9mcmFnOjRlZWE0YWRkN2YxOTQ1MTI5YTQ2ZWUyYjM2ZTkzYjk0L3RleHRyZWdpb246NGVlYTRhZGQ3ZjE5NDUxMjlhNDZlZTJiMzZlOTNiOTRfMzE0Ng_576692ab-7ef3-4fbd-b924-4927a76eeb47" continuedAt="i1a05ce3f528042bcb1a76eaba49979d6" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i302d845ef2d64d24b5e54048eef78ccb" continuedAt="i924c09ac346847a88cae12766f9ab038"><ix:continuation id="i1a05ce3f528042bcb1a76eaba49979d6" continuedAt="idcfad9835a034021abe3f60269286e72"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 was determined to originally be effective for the Company on January 1, 2023.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  During the year ended </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i924c09ac346847a88cae12766f9ab038"><ix:continuation id="idcfad9835a034021abe3f60269286e72"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020, the Company no longer qualified as a smaller reporting company, accordingly </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">became effective for the Company on January 1, 2021. The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 became effective for the Company on January 1, 2021.  The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_91"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RleHRyZWdpb246ZGQxY2Y0ZDBiZWQ4NDI2NTg5ZGZiNDNlODcwM2MxMmFfMzk5Nw_a7627d1c-6e66-41d8-a70e-d09ff39abf6b" continuedAt="ia3828348a92b4a878e7e30a7ecbfcb66" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ia3828348a92b4a878e7e30a7ecbfcb66" continuedAt="i5b06c84644fa4713b89d074c1857946e"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, investments, and the Company's previously outstanding preferred stock warrants.  Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.  A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; quoted prices in active markets are identical assets and liabilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; observable inputs other than quotes prizes in active markets for identical assets and liabilities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; unobservable inputs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.  The Company&#8217;s cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.  The corporate bonds/notes, commercial paper, asset-backed securities and U.S. government securities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RleHRyZWdpb246ZGQxY2Y0ZDBiZWQ4NDI2NTg5ZGZiNDNlODcwM2MxMmFfMzI5ODUzNDg5MDcxMw_bb081e8a-55aa-4dc7-8988-54f8583f5dde" continuedAt="i870fc1bc1f1c49d79de72fe3cc159ce5" escape="true">The following tables sets forth by level within the fair value hierarchy the Company&#8217;s assets and liabilities that are reported at fair value as of December&#160;31, 2020 and 2019, using the inputs defined above (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i5b06c84644fa4713b89d074c1857946e"><ix:continuation id="i870fc1bc1f1c49d79de72fe3cc159ce5"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88621eee6a92415596259056062149ea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfMy0xLTEtMS0yNzMz_9fa7a850-ea46-4091-bd61-123be763764b">60,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59487565bf824f58aa85388dbb1688de_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfMy0zLTEtMS0yNzMz_21be9220-8e8b-4771-9126-33322b8af4b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf154cdda1c64eb98fa4cb83db6a1660_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfMy01LTEtMS0yNzMz_c7612d21-a586-45ba-8a53-5002f223ff37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2975ca8ff7e249fdbd6927130f924215_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfMy03LTEtMS0yNzMz_e7513fd1-999a-496a-9a5e-85b9dc5dfb26">60,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b799836f284366bc42899fe369b6df_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNC0xLTEtMS0yNzMz_bee617f1-a698-4048-8d52-674c55135b57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic870ec31c6844cae91979478b320f851_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNC0zLTEtMS0yNzMz_cb021367-4076-4d60-97a2-82e1da21eb38">39,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ee5649064aa4f26bf11ca63f1d732f7_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNC01LTEtMS0yNzMz_e11385f0-483a-4130-a1e5-88e234a4a3b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae39ce199b8414db9c118472a65f406_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNC03LTEtMS0yNzMz_04862851-ec14-40ae-a535-d6a71ae7d21c">39,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f2c499fbaf46cabadb242b9424f8cd_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNS0xLTEtMS0yNzMz_46c12e1a-be14-49cc-ab9d-4c84bc76e40b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357686f6ae35429994f069e2387042a0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNS0zLTEtMS0yNzMz_481970a9-741e-4602-81c6-a3ae6c140ee4">7,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848eba092bd94a8eb9a2e17f4201aecc_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNS01LTEtMS0yNzMz_f29db5f1-93a6-45ae-8f58-d272ffd83356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82ec25c5c50d45fc9b7ac1bcf6ed42c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNS03LTEtMS0yNzMz_081e4d8f-046b-447a-a7c2-a1e159463d73">7,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa5d33e615f45ee93d158502b82303c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNi0xLTEtMS0yNzMz_f684d6d8-4e21-46bb-a8ea-3eb8448c4a2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c7a65d68ecf48be802607860d75752b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNi0zLTEtMS0yNzMz_40bc43fe-2a7b-41f3-ac72-81e661d8b450">38,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0fd943be2845489302e8030bd481fa_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNi01LTEtMS0yNzMz_438b9c09-ef1a-4016-a5cf-b0ec97a2bf2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db444997bb6463980bb4456c1bf3dc6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNi03LTEtMS0yNzMz_f4c6d4b8-386d-4c58-8f51-9c601602e43e">38,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic98cf98f0f8c4bdbb7f693b02e6b6929_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNy0xLTEtMS0yNzMz_69e7b15e-fc2c-4b16-80bf-a52c90815b27">60,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23170ae30bd4aa09beb7fe13e61ced2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNy0zLTEtMS0yNzMz_c62623f0-ba0e-4465-af9d-02bf0f9e28f4">86,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ecc085e11174791b09ea7310d702ac7_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNy01LTEtMS0yNzMz_951bd12c-ebc7-44e1-887b-796101d10dd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433402cf26a940318305dcd5eb794a03_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNy03LTEtMS0yNzMz_74ef6380-e34e-4eed-a4d1-6d64a38da935">146,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e033ae2fd394f23bcf5460a5a476a6d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfMy0xLTEtMS0w_67ebc696-a87d-4789-bb75-eeb3b6f4dc68">34,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3306f9c046324cf5b42a9b1bac4a0df4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfMy0zLTEtMS0w_e2214f05-41d6-4b76-9d82-62e84af25d3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0704a28bb0740d0ae4c8aa19953a7c1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfMy01LTEtMS0w_2ecb6b07-e397-435e-9815-67d299690444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98694aaa0a3e4704bba4075c12779e77_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfMy03LTEtMS0w_29a119c7-c8a9-491a-bd21-8b1c13de2226">34,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i737fbec56ae2400498ccdfd111434ebd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNC0xLTEtMS0w_e368d7ca-7b58-46bb-bfb6-a2f887089e65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i942c1c56732d4c25a0dce9c90e7135bc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNC0zLTEtMS0w_ce516335-ba01-4eef-af10-5dc3056f9189">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93aba04a024740cab28993b7f08897a6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNC01LTEtMS0w_9a956252-f760-475b-af00-08cf065477f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ad97bd146043ccb94ce8bb1534c274_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNC03LTEtMS0w_9a27f283-7a1b-415b-8001-dc7201049485">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f54e063bd140a59132d57ef7c54d00_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNS0xLTEtMS0w_33421d42-5ea3-48eb-bca1-8c2c76b6d3e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5276c031eb8401ab73fc33a537f9a9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNS0zLTEtMS0w_16fb901b-6eaf-4e73-a226-64bebe009bc3">10,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0f25b2baff49b08a617afd300f27b4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNS01LTEtMS0w_7547ac9d-7a89-4e57-829b-ec4d26108330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318e00b0a9b344bda4f823f595370143_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNS03LTEtMS0w_76fa8c7d-d94f-4e60-9d11-340c44444cf3">10,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b13adf4f0254c9cac128597de2f1736_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNi0xLTEtMS0w_7795251a-07d8-4955-98e0-2525545d9151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb08f575e4245cb9aca4fe1623d37ca_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNi0zLTEtMS0w_cf56d1f2-f72f-419d-a04e-c51e7b0b11cc">44,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0dc412721304b3b9720878497766ff1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNi01LTEtMS0w_30ab3443-910f-4368-82c9-dcce16d18e09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14399a34c4744effb088c2e934ae2d39_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNi03LTEtMS0w_09abe690-f03b-4e84-8fb5-5ad8e34b361f">44,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bcb916e401b434c9e7347ae76804c6c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNy0xLTEtMS0w_ac6b2f08-7574-4205-baa3-ffd67fce0d20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65720dad45e548d784f15ef6efe4dfce_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNy0zLTEtMS0w_aa375611-a5dd-4c67-8835-13723a8b8d39">5,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40fbd6b3dba34ba6ac8a848b3683d371_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNy01LTEtMS0w_dc13e410-72d2-43a5-90de-01656539786d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8480cdb559440dba9a27448e6c477b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNy03LTEtMS0w_569e581e-5499-4eaa-8513-956c16b31dc7">5,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7abdb02107cf49099d5551ac177162e1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfOC0xLTEtMS0w_6054eda1-0810-4d79-8850-ac11354551fc">34,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaabfa66f9d644e5b250778ca77caced_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfOC0zLTEtMS0w_242101ac-61ec-47c4-ab15-2465148a7ebd">69,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af3756b9464f89a2924477109ebf89_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfOC01LTEtMS0w_cb9514fe-e779-4bee-9501-d6f9e70578f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f81260903074be0978bdc8c0d05b714_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfOC03LTEtMS0w_66717428-df95-4a45-80a9-2120c869f33e">104,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between fair value hierarchy levels during the years ended December&#160;31, 2020 and 2019.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_94"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTgx_62c55076-fe4d-435b-b817-27fd8c54a2df" continuedAt="ia183a054bbea42738a7a95b43fc2c4ea" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ia183a054bbea42738a7a95b43fc2c4ea" continuedAt="i0bf20293f12147e5b18a1e4ebe051a77"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTgy_11a3daff-5a9b-4000-b4cd-179f76252740" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's available-for-sale investments as of December&#160;31, 2020 and 2019 are as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec2284f03df4813bfbdf100ea317939_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMy0xLTEtMS0yNzM5_fc4a6401-3f88-46f7-9af3-416cee965007">60,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec2284f03df4813bfbdf100ea317939_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMy0zLTEtMS0yNzM5_7b515781-ea84-4f1c-8230-d002d76653db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec2284f03df4813bfbdf100ea317939_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMy01LTEtMS0yNzM5_672a03a6-2b20-45fd-963a-4e5a09a3a734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec2284f03df4813bfbdf100ea317939_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMy03LTEtMS0yNzM5_7e8b9090-197b-43dd-a108-089c1c8b387d">60,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11882955ba914a4abd7f7f72b573da68_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNC0xLTEtMS0yNzM5_4a08edd1-6f95-44a4-b88a-d5c5305adffe">39,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11882955ba914a4abd7f7f72b573da68_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNC0zLTEtMS0yNzM5_63a61ec5-4b93-4db9-8c36-5bc330bfc8b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11882955ba914a4abd7f7f72b573da68_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNC01LTEtMS0yNzM5_fcd816de-94aa-49c4-bcac-c165a7ca9f70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11882955ba914a4abd7f7f72b573da68_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNC03LTEtMS0yNzM5_fdba3c10-f54d-476b-9d49-4d5b20e56455">39,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6e1731892948749cc2a36087515f22_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNS0xLTEtMS0yNzM5_9596fa9a-144a-45d5-ac75-f9736635c4fd">7,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6e1731892948749cc2a36087515f22_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNS0zLTEtMS0yNzM5_68b3a9d4-b9be-4694-92ab-d4f07227f789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6e1731892948749cc2a36087515f22_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNS01LTEtMS0yNzM5_52c82959-df98-46af-a39c-11f4a42de244">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6e1731892948749cc2a36087515f22_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNS03LTEtMS0yNzM5_a46d3f42-a9a3-4898-b69c-611e24b545c2">7,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNi0xLTEtMS0yNzM5_891dd9a7-92d1-42bf-bae6-01ce942759ad">38,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNi0zLTEtMS0yNzM5_6899e52e-c815-4632-9c7b-aa0fb261d095">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNi01LTEtMS0yNzM5_829cfc95-3cc9-484d-aa5b-67bec590352a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNi03LTEtMS0yNzM5_8d571426-2ab2-4f2c-a1ca-0d39ed9c0bbd">38,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNy0xLTEtMS0yNzQz_d1ae400a-ff61-42f5-8097-7119c4ea0f70">146,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNy0zLTEtMS0yNzQz_e4b7e13e-6470-4ab5-aea3-84a578fa15b7">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNy01LTEtMS0yNzQz_8abf47a2-5a13-4901-978d-01c060837f2d">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNy03LTEtMS0yNzQz_05c5a840-9299-433e-abb7-94103c81a303">146,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i889ad813d9384574aeee41f8e250fdd0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMTAtNy0xLTEtMjc1Mw_12793fa5-9047-48e0-8331-d27e7630ab9f">68,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6666fe4580be47429377090735b4b572_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMTEtNy0xLTEtMjc1Mw_dc4a122a-6478-4a47-bc54-35a99e802c27">78,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMTItNy0xLTEtMjc1Nw_3c149995-0fd6-4953-aaf3-903b3e079219">146,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda1fee3df294d8280213184a71db82b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMy0xLTEtMS0w_0176f45b-7137-41c0-883e-ab83f0a1b6b0">34,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda1fee3df294d8280213184a71db82b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMy0zLTEtMS0w_6e663dae-0bfe-45ff-92c9-de1c4aaab615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda1fee3df294d8280213184a71db82b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMy01LTEtMS0w_9028d2d7-60fa-4380-b130-39df9ee1c204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda1fee3df294d8280213184a71db82b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMy03LTEtMS0w_9ac909ea-cf47-4940-b3fa-72b9ce423ddb">34,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNC0xLTEtMS0w_ce491292-9d8a-4d1b-aaf3-fd27793e61e5">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNC0zLTEtMS0w_1fa9354c-8c54-4d06-bea1-b5308a56eaf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNC01LTEtMS0w_7b4330e1-9686-47f8-97bc-94a2c91dc304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNC03LTEtMS0w_6a22f92e-5724-4137-8562-6e61f7c1d6b1">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNS0xLTEtMS0w_2eb559c0-6b21-4afa-b605-58658035dfcd">10,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNS0zLTEtMS0w_2b3caa06-6024-4be6-adc2-ec166a2766dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNS01LTEtMS0w_3ea6e90f-51a7-496d-a9e0-1dd5c64f8121">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNS03LTEtMS0w_ece85b8a-7eb9-428b-85d5-3aad57b6b4bb">10,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNi0xLTEtMS0w_85cd5272-f4a2-4632-a4c2-1477c3978878">44,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNi0zLTEtMS0w_3aff07a1-898b-4ec7-85f3-4fcf89aca54a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNi01LTEtMS0w_c5902711-6936-4d0f-af7a-e41f98e0d2f1">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNi03LTEtMS0w_f04602ba-6c75-4594-8ca3-91b5b16730c0">44,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6207be23c9e413d86cc481a1129e296_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNy0xLTEtMS0w_4e0d8a7f-c41e-42d8-838e-b007e3e64ee8">5,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6207be23c9e413d86cc481a1129e296_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNy0zLTEtMS0w_e3ac904c-6378-4655-8fa7-a0a6c5c1abc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6207be23c9e413d86cc481a1129e296_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNy01LTEtMS0w_7a405b9c-34cb-4357-8076-7873b3719fb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6207be23c9e413d86cc481a1129e296_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNy03LTEtMS0w_a8945095-f48f-402d-a342-eabfc89c5007">5,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfOC0xLTEtMS0w_ebaa2cfc-39a6-4731-824c-f836e6fa790f">104,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfOC0zLTEtMS0w_3ae697fe-35de-4c33-83b2-58d401de8fe7">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfOC01LTEtMS0w_7536355d-8596-4117-82b6-3a1865fba29b">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfOC03LTEtMS0w_e3679eb3-a0a0-4570-8e4a-0f44a7b22959">104,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a569c77aa3c40dd9b99313f06d7bd3e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMTEtNy0xLTEtMA_5ac51dda-3ef6-4597-a412-05da75d5a859">34,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c76492ae1149d3aa274942d50fabd3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMTItNy0xLTEtMA_02dc34d0-54f4-4354-92a7-aaaf7f21d0b8">51,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2533cb6af194baeb29f893a563753d3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMTMtNy0xLTEtMA_89225d71-19c4-4b60-98bb-458eb7bf3467">18,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMTQtNy0xLTEtMA_09197332-e079-4da5-bb3b-61bc5cae7bfb">104,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i0bf20293f12147e5b18a1e4ebe051a77" continuedAt="ibea7a02c37474a2aa6f0a48c19f2a276"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTgz_35973a52-00d5-4501-ae52-f5159f9bf04a" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of the Company&#8217;s cash equivalents, short-term and long-term investments classified by maturity as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:62.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts maturing within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfMi0xLTEtMS0yNzc0_7032bc92-bf94-4e40-87a1-bb6b957391f7">146,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfMi0xLTEtMS0w_f7aae190-5809-4825-af59-bf78735c77b6">85,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:zerodash" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfMy0xLTEtMS0yNzc0_d91395fa-3728-4e0b-8bf3-c0ca22c53ade">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfMy0xLTEtMS0w_b5f6337b-59a9-4157-807b-5a066761d59d">18,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfNC0xLTEtMS0yNzc0_1540f8a8-0cfc-4870-9c88-34f536a5b208">146,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfNC0xLTEtMS0w_0f2d4e05-57f3-4a53-9c70-b6e1ad16d21f">104,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale investments held as of December&#160;31, 2020 had a weighted average days to maturity of <ix:nonNumeric contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" format="ixt-sec:durday" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyODgzOQ_3f4c72fd-c33d-4e7b-9668-3e2fe41bec7d">135</ix:nonNumeric> days. </span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTg0_58ff5103-1bed-4bc4-b069-1a53dcde0de3" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6e1731892948749cc2a36087515f22_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfMy0xLTEtMS0yNzYx_ebd246e4-0591-468c-b45d-aa14d75b54cb">5,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6e1731892948749cc2a36087515f22_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfMy0zLTEtMS0yNzYx_9b25de14-799a-45e5-9bfa-cf2b40c26911">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfMy0xLTEtMS0w_93ad1b59-6ce8-459d-8be9-2d4010471f52">10,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfMy0zLTEtMS0w_5c4a2442-c052-42ef-866b-d0ab558870ee">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNC0xLTEtMS0yNzYx_5a62869a-c584-49d3-a2bb-c62d2398eb29">10,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNC0zLTEtMS0yNzYx_201e863a-f53c-45c4-911d-3656c3b33c96">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNC0xLTEtMS0w_5bb9690c-02c9-4282-933d-e941c77af797">19,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNC0zLTEtMS0w_f1d35ab6-5f0e-440e-951f-4423ecb09a4c">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNS0xLTEtMS0yNzYx_b4941aa2-022c-412c-a495-6c62c30989a3">15,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNS0zLTEtMS0yNzYx_ac908a4b-a2cf-4382-bb0c-6694df17451b">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNS0xLTEtMS0w_76c75fab-efd6-4278-9771-929196ae700a">29,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNS0zLTEtMS0w_4ea76d8c-b694-4bd5-8acf-bf44d81d2507">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTg1_32672263-6c06-453b-a80d-c55519794cb8" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventories were as follows (in thousands): </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfMi0xLTEtMS0w_1981f9dd-b93f-46cc-b2a7-9eb82101ffc7">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfMi0zLTEtMS0w_250dfe7c-4d77-4216-b559-720409eedb97">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfMy0xLTEtMS0w_529f42a0-265e-458a-b407-a09cc49bcdd4">10,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfMy0zLTEtMS0w_e0eb2c3e-6fdf-4dca-b794-d9214bc81fca">9,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNC0xLTEtMS0w_dd620708-7bef-433e-831b-f27e11a4027e">12,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNC0zLTEtMS0w_552927dd-1e17-4cfc-a9d1-35ee2c5a1f41">10,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reserve for excess and obsolete</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNS0xLTEtMS01NjYw_8d3fa5ce-b5f2-448f-898b-2745e06397f8">2,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNS0zLTEtMS01NjYw_5d379b88-2884-4db7-88bf-5c9b3f82f79c">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNi0xLTEtMS01NjYw_baa59ee5-43b0-4ee2-be09-4b9c62e52d50">9,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNi0zLTEtMS01NjYw_5bed226f-b981-4554-8616-fa06fd311cf1">10,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, there were <ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfNjY1_52a67ef4-a224-42af-bd2e-88eb316c4116"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfNjY1_d768bb63-0c4d-4d00-854c-92fa3c192f05">no</ix:nonFraction></ix:nonFraction> work-in-process inventories. The reserve for excess and obsolete inventory at December 31, 2020, included $<ix:nonFraction unitRef="usd" contextRef="if68f3a12f75a43e0a5f0f1a0e2ed2345_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyOTA2OQ_ab885a40-9be3-49f0-ba8c-30bbb64643e3">2,377,000</ix:nonFraction> associated with the Company's voluntary product recall (see Note 14 - Subsequent Events).</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="ibea7a02c37474a2aa6f0a48c19f2a276"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTg2_246fb968-4298-4c38-8821-ca2ed4da694f" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc53679edcca491daa58c1d5d9e40d2b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfMi0xLTEtMS0w_af8c1a9d-fc39-43cd-81fb-a77aab45f057">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89117551e1cd4e1894164ae6a96705b1_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfMi0zLTEtMS0w_a0efb6bc-097e-4a5b-964b-5c56712b3f8e">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28498ef5e5d649ccab003692d7a48278_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfMy0xLTEtMS0w_77dd8a7b-1908-45ad-b922-cc608347a550">1,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58bbd4394762445f9a301c74072434aa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfMy0zLTEtMS0w_1c84dd04-1999-4ecf-b3a2-342bd43639ee">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6603001cf648480982c9106b4e14992e_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNC0xLTEtMS0w_8ad79946-f5c6-4b81-acd3-8d57b45b2957">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4bfd4cf869646a3aabf0014c3294512_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNC0zLTEtMS0w_9ea7fad4-960a-4aa0-b3d6-64837df03226">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c17ea580834042872a256eb3032b57_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNS0xLTEtMS0w_73189a69-d355-4ae9-a8cf-d07272b087ce">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719a20f0f78a457f87d7472704e63aa1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNS0zLTEtMS0w_61b5f01d-925e-4c0c-ad6f-d0c9759d87d6">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNi0xLTEtMS0w_36e8668a-6240-4919-b0c5-1683a45906a7">4,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNi0zLTEtMS0w_40ac4130-97c6-4fad-8549-f2893e1d1e97">3,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNy0xLTEtMS0w_ee19a461-80d5-4cfd-9de1-f747b456577e">2,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNy0zLTEtMS0w_752c823b-f5ed-4196-a71d-7667e39f4000">1,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add:  Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie69721672eec41c2a595f99de0a0defc_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfOC0xLTEtMS0w_d09cd7bb-3006-4ba7-9b3d-3f3e8c3223e1">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b0413075134cc583c0faa97c7be5d8_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfOC0zLTEtMS0w_7f2dba1f-e086-4b24-8ce2-01bcf6240f3f">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfOS0xLTEtMS0w_f8413a23-69d2-45a5-a833-813845cb02ce">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfOS0zLTEtMS0w_0235f093-45e5-4c9e-85c0-5a4e9a0b493f">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyODg1MA_a2ea66b4-7a37-4a92-b22d-69e4fd4b5b6d">789,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyODg1NA_38625576-a8de-4a5f-ae54-41c53d3d9ee1">712,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyODg1OA_a7df33ff-027b-40e6-b5a4-62ccd0309287">517,000</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Liabilities</span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTg3_1fe2c2a9-cada-4f1b-994e-0c1c9e9c2cdd" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMi0xLTEtMS0w_ea70349b-0bbf-4083-abb0-da451a2aae97">9,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMi0zLTEtMS0w_c4f1b784-24cf-4ac3-8b5b-7a4550ce71bd">9,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for sales returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="silk:ProvisionsForSalesReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMy0xLTEtMS0w_c75767aa-cbd7-4968-ab04-5fbcd2529a82">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="silk:ProvisionsForSalesReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMy0zLTEtMS0w_b87eb378-1aff-4c1d-b786-306e12bbe053">2,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNC0xLTEtMS0w_071eca8c-b100-4953-aa00-03db399a61e2">2,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNC0zLTEtMS0w_d4a29aa5-5d1a-4204-ba04-61317a2c089e">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recall replacement obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNS0xLTEtMS02MDg0_604acaf9-6a0c-4ae6-bd23-338d4db3df6c">1,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNS0zLTEtMS02MDg0_7d5bc29d-e7c0-4a9d-8586-617e31a586f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNS0xLTEtMS0w_e3de8e99-f0d4-4376-b336-a9698a042f72">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNS0zLTEtMS0w_6604681f-f771-475d-8f28-dc4a6266fb26">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNi0xLTEtMS0w_46291c25-e2fa-4b1b-a4ca-185c04c848a4">518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNi0zLTEtMS0w_d0258ae5-4b26-4460-a96f-a062c0e81452">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNy0xLTEtMS0w_b234611d-895d-4770-a18e-97977b17bc07">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNy0zLTEtMS0w_38b2fbce-7dc6-4160-a653-30777df5bbba">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued travel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="silk:AccruedTravelExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfOC0xLTEtMS0w_7b09d44f-6c87-4f88-8f67-a83c2740b6a3">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="silk:AccruedTravelExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfOC0zLTEtMS0w_66249753-7f52-4537-8000-5aa035fbbcba">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="silk:AccruedClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfOS0xLTEtMS0w_abec8e8a-d0a2-4c42-920c-e7908d9dc425">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="silk:AccruedClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfOS0zLTEtMS0w_e377d75d-cbc1-4760-92e5-0734c847ab76">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMTAtMS0xLTEtMA_c01f623a-19ed-4dea-a711-5d26110d76eb">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMTAtMy0xLTEtMA_67b765c5-ba3d-4080-af70-0bc206089e5a">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMTEtMS0xLTEtMA_a17956dd-4abd-470e-ad80-0d595f1ec6f6">16,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMTEtMy0xLTEtMA_57d1cb04-6838-48d0-ae4f-70a02fd31f7c">15,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_97"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfNTE0MA_8bbe2b5a-6d7c-4db3-a7cc-bd428f3c6e9f" continuedAt="i083e1298102142c1b8e3e24c785e3277" escape="true">Long-term Debt</ix:nonNumeric></span></div><ix:continuation id="i083e1298102142c1b8e3e24c785e3277" continuedAt="iadf3affd4fc14594aad6142b3c7ff60e"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRG</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2015, the Company entered into a term loan agreement with CRG.  The term loan agreement provides for up to $<ix:nonFraction unitRef="usd" contextRef="icf16e6187b0a4304bc8897195133e968_I20151031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTY4_5c27dfbb-d531-48d1-8ca6-abdc2e8d2553">30,000,000</ix:nonFraction> in term loans split into two tranches as follows: (i) the Tranche A Loans provided for $<ix:nonFraction unitRef="usd" contextRef="ib85c4555200f4f429465863d9f50f535_I20151031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMjU3_fe978448-1148-4e2e-961e-6adaff1e5950">20,000,000</ix:nonFraction> in term loans, and (ii) the Tranche B Loans provided for up to $<ix:nonFraction unitRef="usd" contextRef="i9f5ec93120bb4972be5e2507b780398c_I20151031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMzIz_3b051b41-eafb-49e8-8834-25f5899cdbea">10,000,000</ix:nonFraction> in term loans.  The Company drew down the Tranche A Loans on October 13, 2015.  The Tranche B Loans were available to be drawn prior to March 29, 2017.  In January 2017, the term loan agreement was </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="iadf3affd4fc14594aad6142b3c7ff60e" continuedAt="ia3127b0343e548bbaacd95ffb7ec7312"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amended to extend the commitment period of the Tranche B Loans to April 28, 2017.  In April 2017, the Company drew down $<ix:nonFraction unitRef="usd" contextRef="i40ecba85ef204349b335af3072288f5f_D20170401-20170430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfNjQ0_ed4604b9-79f1-4657-bed8-d9f5c96814e7">5,000,000</ix:nonFraction> of the available Tranche B Loans.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the term loan agreement was amended to provide for additional term loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="iecdd1fc58174421a9bfdd8f134ae6e23_I20180930" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTU5Ng_0c7cca59-d5ea-4a9d-8555-d931f76e6779">25,000,000</ix:nonFraction>.  In September 2018, the Company drew down an additional $<ix:nonFraction unitRef="usd" contextRef="i5ed5ecc368374169a71abc3cc9f49aa5_D20180901-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTkzOA_39b9a7b7-6050-45d1-a6a4-4213d9de0911">15,000,000</ix:nonFraction> under the amended term loan agreement with CRG, no additional draw was taken.  U</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nder the terms of the amended term loan agreement, the related fixed interest rate was <ix:nonFraction unitRef="number" contextRef="icdeb572f838a40fdaa6ba2d0bfd368c1_I20190430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njg4Mg_860b938c-deae-4a0e-a616-ffe73ed42869">10.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i103121e7190f43fabe96184573d85e5a_I20190501" decimals="INF" name="silk:DebtInstrumentInterestRatePaidInCash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njg4OQ_7f94fe6c-840b-4f42-a32b-5735cecdd700">8.0</ix:nonFraction>% of the interest was due and payable in cash and at the election of the Company, <ix:nonFraction unitRef="number" contextRef="i103121e7190f43fabe96184573d85e5a_I20190501" decimals="INF" name="silk:DebtInstrumentInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njg5Ng_f50b8551-2125-4964-a90a-06937edfa0c0">2.0</ix:nonFraction>% of the interest due and payable may be "paid in kind". </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All unpaid principal, and accrued and unpaid interest, was due and payable in full on December 31,&#160;2022. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2020, in connection with the consummation of the Loan and Security agreement with Stifel Bank as noted below, the Company repaid all amounts outstanding under the term loan with CRG.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stifel Bank</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company entered into a Loan and Security Agreement, or Loan Agreement, with Stifel Bank which provides for a $<ix:nonFraction unitRef="usd" contextRef="i7abc563c49034717a7c3322581f18eb8_I20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NjkyNA_5c12ae7d-19ce-4e87-9dd0-a821f10e3bab">50,000,000</ix:nonFraction> loan facility, comprised of a $<ix:nonFraction unitRef="usd" contextRef="i5936ba61c97f46c9abe460c3748fc302_I20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk0MQ_1c90dc19-f0d0-47ef-97dc-7f2684cb4fbc">50,000,000</ix:nonFraction> secured revolving credit facility, with a $<ix:nonFraction unitRef="usd" contextRef="i36fa0eb7334c455888e30aa07d6532a5_I20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NjkzNw_d4f6b5d9-475f-4cf5-ba6b-b7685f2f9ab4">2,000,000</ix:nonFraction> subfacility for the issuance of letters of credit and other ancillary banking services, and a $<ix:nonFraction unitRef="usd" contextRef="i7abc563c49034717a7c3322581f18eb8_I20201031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk1NQ_db4bb3ed-e27f-4ce2-8331-0537ab56a8cc">50,000,000</ix:nonFraction> secured term loan facility, provided that amounts outstanding under both facilities may not exceed an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ie5c39c1b02c34d54a55c972e504f4f10_I20201031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantMaximumBorrowingThreshold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk2OQ_511d6b75-6032-4d8f-9ccf-4e3cffcfcc89">50,000,000</ix:nonFraction> at any time.  Any borrowings under the revolving loan facility mature on October 29, 2022, or October 29, 2023 if as of October 29, 2022, no event of default has occurred and we are in compliance with the terms of the Loan Agreement. Borrowings under the term loan facility mature on October 29, 2024.  Interest under the revolving credit facility is the greater of a) <ix:nonFraction unitRef="number" contextRef="ifcb3cbb6159547ebb60630ca78155e84_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk3Ng_cc522e0f-194c-49d2-82f5-13f6fe003bc6">0.5</ix:nonFraction>% above the "Prime Rate" as published by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or b) <ix:nonFraction unitRef="number" contextRef="i51b6bd6e7c434a7c95a35ff5a9531de1_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk4NA_c0796e18-c522-4690-8f4f-64a58fb145bf">4.75</ix:nonFraction>%.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in October 2020, the Company drew down $<ix:nonFraction unitRef="usd" contextRef="ifa3b08c2ee1f40f29b52fda52abcfcbd_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk5OA_e13aa9d3-f4c8-47e3-be87-9cbfa9970348">49,000,000</ix:nonFraction> under the term loan facility and used the majority of the proceeds to pay off and terminate the prior term loan agreement with CRG totaling $<ix:nonFraction unitRef="usd" contextRef="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzAxOA_5b513273-9d46-48d0-8552-c7ceb68b8e71">46,674,000</ix:nonFraction>, which included a prepayment premium of $<ix:nonFraction unitRef="usd" contextRef="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzU4OA_28395fd0-3f00-45ab-8270-cfa749b08850">305,000</ix:nonFraction>, a final interest payment of $<ix:nonFraction unitRef="usd" contextRef="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzYyMQ_3ca41de5-13b8-4653-a401-d0176a6bfdfb">365,000</ix:nonFraction> and a facility fee of $<ix:nonFraction unitRef="usd" contextRef="ie5c39c1b02c34d54a55c972e504f4f10_I20201031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzY0Nw_f7fec8f7-5045-46b6-8f15-efe37ce80896">2,191,000</ix:nonFraction>.  The Company recognized a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzkyOA_2abc35c0-375b-4057-9bae-3d610ee90fce">1,119,000</ix:nonFraction> in connection with the early termination of the term loan agreement with CRG. The principal amount of outstanding term loans under the Loan Agreement with Stifel Bank shall be repaid in equal monthly installments beginning on May 29, 2022, or November 29, 2022 if the Company achieves revenue for the year ending December 31, 2021 of at least <ix:nonFraction unitRef="number" contextRef="ie5c39c1b02c34d54a55c972e504f4f10_I20201031" decimals="INF" name="silk:RepaymentsOfDebtRevenueTargetPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzAwNA_486c1020-fcf8-4328-8dea-c6a1e8eee491">80</ix:nonFraction>% of the board-approved financial projections for such fiscal year.  Interest under the term loan facility is the greater of a) <ix:nonFraction unitRef="number" contextRef="ifeb1a73d258b47deacf93ec34c1d3916_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzA2MA_6947bb66-a416-4e8f-a775-7110bf775f1f">0.75</ix:nonFraction>% above the "Prime Rate" as published by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or b) <ix:nonFraction unitRef="number" contextRef="i65ad62ac27904958945aa2aa614f9585_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzA2OA_c679e788-a5d7-4d08-856a-6e54640eece1">4.75</ix:nonFraction>%.  The term loan may not be reborrowed once repaid, but the Company may prepay the term loan at any time without premium or penalty. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also concurrently entered in a Success Fee Agreement in October 2020 with Stifel Bank, which requires that the Company pay Stifel Bank the lesser of <ix:nonFraction unitRef="number" contextRef="idb2c47acc6f844248688d675a456ddad_D20201001-20201031" decimals="4" name="silk:DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzA3Ng_348c2daf-fd67-4037-9118-2a037a380bc1">0.75</ix:nonFraction>% of the original principal amount of all credit extensions made under the Loan Agreement or $<ix:nonFraction unitRef="usd" contextRef="idb2c47acc6f844248688d675a456ddad_D20201001-20201031" decimals="-3" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantLiquidityEventPaymentAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzA4Nw_953d38c6-2159-4415-9584-49502855eb40">375,000</ix:nonFraction> in the event the Company completes a Liquidity Event (liquidation, merger, sale of the Company or change in control).  The Success Fee Agreement terminates on October 29, 2025.  The Company has determined the probability of a Liquidity Event to be remote and accordingly, has not recognized a liability as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under the Loan Agreement are secured by substantially all of the Company's assets. Beginning on January 15, 2021, the Loan Agreement requires that the Company maintain unrestricted cash and cash equivalents with Stifel Bank or at Stifel Bank Affiliates of at least $<ix:nonFraction unitRef="usd" contextRef="i7abc563c49034717a7c3322581f18eb8_I20201031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzEwMQ_452c83fd-fc41-49ab-b9ea-bd22836a8b00">20,000,000</ix:nonFraction>. In addition, for any fiscal quarter where the Company's unrestricted cash and cash equivalents maintained with Stifel Bank or at Stifel Bank Affiliates (or prior to January 15, 2021, Stifel Bank or certain other banks) are less than $<ix:nonFraction unitRef="usd" contextRef="i7abc563c49034717a7c3322581f18eb8_I20201031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzExNQ_89e2afd0-a72a-4e3b-bb94-e96d5cab547b">60,000,000</ix:nonFraction> for any day during such fiscal quarter, the Company must comply with a minimum </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="ia3127b0343e548bbaacd95ffb7ec7312"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue covenant. Additionally, the Loan Agreement contains customary affirmative and negative covenants, including covenants limiting the Company's ability and the ability of the Company's subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events of default under the Loan Agreement include, among others, payment defaults, material misrepresentations, breaches of covenants, cross defaults with certain other material indebtedness, bankruptcy and insolvency events, and judgment defaults. The occurrence of an event of default could result in the acceleration of our obligations under the Loan Agreement, the termination of the lender&#8217;s commitments, a <ix:nonFraction unitRef="number" contextRef="i907e8be526f045dba75ef70a204b7872_D20201029-20201029" decimals="INF" name="silk:DebtInstrumentCovenantDebtDefaultRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMzI5ODUzNDkzMzQ4Mw_a4cc573d-3c60-4690-b965-225464f1817a">5</ix:nonFraction>% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the aggregate outstanding principal balance under the Loan Agreement was $<ix:nonFraction unitRef="usd" contextRef="ifa3b08c2ee1f40f29b52fda52abcfcbd_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzEyOQ_e13aa9d3-f4c8-47e3-be87-9cbfa9970348">49,000,000</ix:nonFraction> and the annual interest rate was <ix:nonFraction unitRef="number" contextRef="i907e1c4c4cf446efb027c2d919844c24_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTY0OTI2NzQ5MTIxOQ_7c4d88fa-7685-4791-a10f-d3a8f1e069f3">4.75</ix:nonFraction>%.  As of December&#160;31, 2020, the Company was in compliance with all applicable financial covenants.  As of December&#160;31, 2020, management does not believe that it is probable that the above events of default will be triggered within the next twelve months, therefore, the debt is classified as long-term on the balance sheet.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfNTE0MQ_7a73baf5-4c22-424f-babd-1e72dc0df46d" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities under the Stifel Bank term loan agreement as of December&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfMS0yLTEtMS0w_774078a4-a15a-4119-a690-31c812f008d5">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfMi0yLTEtMS0w_f2a82081-3c4c-4a31-bbcc-9e73a89178bd">14,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfMy0yLTEtMS0yODEz_649e9e50-80d6-4c0b-b179-6936c780a23f">20,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfMy0yLTEtMS0w_9bf4da7d-f8ef-4829-a0ce-6767f36fb6b7">17,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="silk:LongTermDebtGrossBeforeAccretionOfClosingFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfNC0yLTEtMS0w_77d5c15b-0477-4500-a510-b6ec9e73d1b1">55,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="silk:LongTermDebtUnpaidInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfNy0yLTEtMS0w_ece1f130-3213-4d6a-99d8-e5ec0b80b1ac">6,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount representing debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfOC0yLTEtMS0w_c3e25111-e14d-4c6e-8de6-bfadce5d5cfa">467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfOS0yLTEtMS0w_5d76c560-3391-49e2-a980-eb20661c9900">48,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM4MzA_9dbaa901-3431-4c09-b851-c4d333823bcc" continuedAt="ic5008599ae644cc987b42e3dbe56a021" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ic5008599ae644cc987b42e3dbe56a021" continuedAt="i633ccccc31954d96b71181cec96a9e3d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Lease and Rights of Use</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating lease obligation consists of leased office, laboratory, and manufacturing space under a non-cancellable operating lease that expires in October&#160;2024. The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional period of <ix:nonNumeric contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM2NQ_b7e63321-e579-4e2d-b7a0-9f2e05bc1fcd">five years</ix:nonNumeric>.   Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM5OA_3f4366bc-b92d-4a3e-8485-e4af3268ef52"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM5OA_8f9aff4c-124f-495b-9e06-eed92e25ebce">870,000</ix:nonFraction></ix:nonFraction> for each of the years ended December&#160;31, 2020 and 2019.  Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzEwOTk1MTE2MzE4MzE_f062c4d6-928e-4402-a0db-cfb8cf18532d">769,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzEwOTk1MTE2MzE4MzU_3ae63d48-83a9-46ac-af78-f2d747464998">721,000</ix:nonFraction> for the years ended December&#160;31, 2020 and 2019.  As of December&#160;31, 2020, the weighted average discount rate was approximately <ix:nonFraction unitRef="number" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzYwMA_f4f582af-d732-4ac6-b798-539c34989631">6.50</ix:nonFraction>% and the weighted average remaining lease term was <ix:nonNumeric contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzY1Mw_ce74ea78-8619-4186-af33-c422947a4ad3">3.83</ix:nonNumeric> years.  As of December 31, 2019, the weighted average discount rate was approximately <ix:nonFraction unitRef="number" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzEwOTk1MTE2MzIwMDg_19bbc0f5-8e89-46b2-a72f-eb1164c9e060">6.50</ix:nonFraction>% and the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i633ccccc31954d96b71181cec96a9e3d" continuedAt="i0a61d9a4659d4d79a057285607bd341c"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted average remaining lease term was <ix:nonNumeric contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzEwOTk1MTE2MzIwMTU_fd89226d-2725-441b-b122-156b36d50b32">4.83</ix:nonNumeric> years.  <ix:continuation id="i1f178e6e57fd43c9b69713b9459e9ce7" continuedAt="i16442e99a5e7487d968cee18f8328984">Balance sheet information as of December&#160;31, 2020 consists of the following (in thousands):</ix:continuation></span></div><div style="margin-bottom:9pt"><ix:continuation id="i16442e99a5e7487d968cee18f8328984"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_79e4f10b-3b5e-4ec2-876c-6e585e344f6b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_da5af1e9-78c6-47d2-b916-faffbda32183">other non-current assets</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMi0xLTEtMA_aad1a0d5-2244-47c7-836e-d1969dc8d88c">2,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtNC0xLTEtMjg0NA_ab3daeee-1e4d-4347-81da-a6999a218654">3,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_0c14a90d-c468-4d50-8bda-f4b6abb57993"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_df5558d5-a823-4bc7-8d24-11cd3b6290f9">accrued liabilities</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMi0xLTEtMA_61462177-4255-4622-9411-210d1338e823">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItNC0xLTEtMjg0NA_1877390c-fd37-4a83-8615-a0b506960163">769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_14124f2c-b99c-42a3-914f-b88bb1e2da04"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_eb1aa98b-cafb-4393-b523-5f94410b69b5">other liabilities</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMi0xLTEtMA_c363c3bf-e8b4-48c3-b103-e869d40154f2">2,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtNC0xLTEtMjg0NA_e486c261-7417-4302-b9df-698830a7a8a1">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzQtMi0xLTEtMA_8cbeceaf-2da0-4d11-89c1-5891ccdfd69c">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzQtNC0xLTEtMjg0NA_6f3d7ca6-63d9-4257-874d-53c29d12729e">4,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM4MzI_0bc55911-02e5-4865-924a-bbd4e8d994a8" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's operating lease maturities as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzItMi0xLTEtMA_0ebcaa56-a6e7-4e3a-b1fb-1cc16b06bb46">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzMtMi0xLTEtMA_24704091-a412-4d87-98bb-8871b8d902a7">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzQtMi0xLTEtMA_0f223ef7-3b63-43fa-8e5c-affc2371f9d4">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzUtMi0xLTEtMA_e5d15d1c-4aa9-485e-9add-24b8a01c690b">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzYtMi0xLTEtMA_71b6604b-785b-4571-ae60-e8b2f49bfdff">4,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzctMi0xLTEtMA_cd998b68-0a12-41d4-9114-7393b26baddd">493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzgtMi0xLTEtMA_aa5ccca1-d1da-4bea-a6fa-e4ecf92e443d">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Obligations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business.  As of December&#160;31, 2020, the Company had non-cancellable purchase obligations to suppliers of $<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzExNzI_1a26d699-0098-4509-9d3c-ea055ebe4091">6,601,000</ix:nonFraction>.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements with suppliers and other parties that contain a variety of representations and warranties and may provide for indemnification of the counterparty.  The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made.  To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws.  The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity.  The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance.  The Company believes that the fair value of these indemnification obligations is minimal.  Accordingly, the Company has not recognized any liabilities relating to these obligations as of December&#160;31, 2020.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i0a61d9a4659d4d79a057285607bd341c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations or cash flows. From time to time, the Company may pursue litigation to assert its legal right and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were <ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzMyOTg1MzQ4ODczOTI_0415bcab-c3ee-4aa1-83b5-77c956c9d89c"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzMyOTg1MzQ4ODczOTI_fc0ad889-726a-49ae-821d-1b2ea10c5836">no</ix:nonFraction></ix:nonFraction> contingent liabilities requiring accrual at December&#160;31, 2020 and 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, a former employee, through counsel, advised the Company that he had filed a charge of discrimination against the Company with the California Department of Fair Employment &amp; Housing, or DFEH.  The former employee&#8217;s complaint alleged sexual harassment and retaliation in violation of the California Department of Fair Employment &amp; Housing Act.  The complaint did not allege specific damages. The Company and the former employee participated in mediation on July 30, 2019 and reached a settlement that required the Company to pay an amount that was not material to its financial statements, which amount was fully paid as of December 31, 2019.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_103"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzgzNw_044960bb-468d-4b96-8309-358885910077" continuedAt="ia64b1f6b53874c1bb186dd45f5917ee5" escape="true">Redeemable Convertible Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="ia64b1f6b53874c1bb186dd45f5917ee5" continuedAt="i20db59c2b4d74b6a9521151029b10497"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Company's IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does <ix:nonFraction unitRef="shares" contextRef="i1c3729f2464e47ab98755aaf4d5239ee_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzM1Mw_20ab400e-08ef-40af-a885-81658fcf5d10"><ix:nonFraction unitRef="shares" contextRef="i1c3729f2464e47ab98755aaf4d5239ee_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzM1Mw_65bd368c-2d67-4411-984a-3f74b2eb0231"><ix:nonFraction unitRef="shares" contextRef="i66136b6bed6c411a82f197a4d3385b6a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzM1Mw_7fc95ce2-76c6-456b-b8e5-bddfacbf9182"><ix:nonFraction unitRef="shares" contextRef="i66136b6bed6c411a82f197a4d3385b6a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzM1Mw_d323750c-cb98-404d-a10d-46e0bc2244d6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t have any redeemable convertible preferred stock issued or outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock Warrant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Company's IPO, all of the outstanding redeemable convertible preferred stock warrants were exercised, or net exercised based on the IPO price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i62faf7ea655c489e8fb700ba32e5a72a_I20201231" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzYzNQ_983fd72a-0ea4-40ec-9dea-8295502de822">20.00</ix:nonFraction> per share, into <ix:nonFraction unitRef="shares" contextRef="ib33b63c59a7142df9c638019a56d357b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzY1NA_e7d6630c-02eb-46fd-a7c8-5961abae5930">1,945,365</ix:nonFraction> shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does <ix:nonFraction unitRef="shares" contextRef="idb165d229e594aed955a8ab2194b3631_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzMyOTg1MzQ4ODQ1NDU_133b35c2-ea99-4ff8-a6de-3db79ff96974"><ix:nonFraction unitRef="shares" contextRef="idb165d229e594aed955a8ab2194b3631_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzMyOTg1MzQ4ODQ1NDU_155ae54d-9b0b-4731-9729-7b3a1c14774d"><ix:nonFraction unitRef="shares" contextRef="i8035f9f9ec5d4b46adb98b3f8e400ff1_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzMyOTg1MzQ4ODQ1NDU_89185a85-90c3-4095-8299-6bcf2ccc62cf"><ix:nonFraction unitRef="shares" contextRef="i8035f9f9ec5d4b46adb98b3f8e400ff1_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzMyOTg1MzQ4ODQ1NDU_b34434c7-79b0-4ac5-b060-69e6c1ee553f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t have any redeemable convertible preferred stock warrants outstanding.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_109"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:continuation id="i20db59c2b4d74b6a9521151029b10497" continuedAt="i81794f05805d4e788c1c2329b137f5b3">Stockholders' Equity (Deficit)</ix:continuation></span></div><ix:continuation id="i81794f05805d4e788c1c2329b137f5b3" continuedAt="id25e061b08924db2b63e02e858f54475"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to <ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzE2OQ_1e18cf16-e260-4872-ad78-129657a96276">5,000,000</ix:nonFraction> shares of preferred stock with $<ix:nonFraction unitRef="usdPerShare" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzIwMw_df592550-b576-4b64-ac69-a11bc5b55f02">0.001</ix:nonFraction> par value per share, of which <ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzMyOTg1MzQ4ODQ2MDg_2501990d-967a-4300-a6f2-1e81d0102f82"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzMyOTg1MzQ4ODQ2MDg_3ce31dae-fbef-4dcd-b690-0368f45a2367">no</ix:nonFraction></ix:nonFraction> shares were issued and outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to <ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzQwMg_45d14840-ecf4-4a2b-afb5-30eb6e5e4102">100,000,000</ix:nonFraction> shares of common stock with $<ix:nonFraction unitRef="usdPerShare" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzQzMw_11793c26-534f-4b60-8f18-587b2ff04164">0.001</ix:nonFraction> par value per share, of which <ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzQ2Ng_dfcec7a3-4606-47e4-a68a-fcf3f0874511"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzQ2Ng_fe52dc00-7b4b-45d1-b4da-1878dd4de319">34,249,649</ix:nonFraction></ix:nonFraction> shares were issued and outstanding.  The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors.  As of December&#160;31, 2020, <ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzY3MA_46b062bf-8c03-4280-bf00-f0528ed8a70d">no</ix:nonFraction> dividends have been declared to date.  Each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="silk:CommonStockVotePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzc1NA_c9bb6bdb-ac74-4e9e-9c88-45c92185ae22">one</ix:nonFraction> vote.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="id25e061b08924db2b63e02e858f54475"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzExMzQ_d42e5993-ec0b-4164-8893-2933aae65d72" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company had reserved common stock for future issuances as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercise of options under stock plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i603554706e704e14a87cd579bfc1f1cb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzYtMS0xLTEtMA_15d32dda-0e68-43c7-95db-98e948f1d006">4,237,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i096b9866423f47bfbd8c84a4319b04fc_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzYtMy0xLTEtMA_880db812-4576-40e6-b2ef-168737239acf">4,310,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of options and restricted stock units under stock plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbdb361087f54a5fbd3ebc590fca7604_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzctMS0xLTEtMA_618238c8-eae5-4cf5-8fe3-c95a8797f1b3">1,790,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03ab7ad3a56f48299ce1b6e914d7b413_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzctMy0xLTEtMA_463bc497-94af-4b09-af95-f531431da2ac">1,554,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i480f0a71d7df4da79168f1094a28dc8e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzgtMS0xLTEtMA_1f921fa5-a7b4-45cc-8ea2-c644b9fef45f">632,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09057e7a1c6b4809a7a1631278acc9b9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzgtMy0xLTEtMA_31a39d45-0551-45bf-a309-b4e686593124">372,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzEwLTEtMS0xLTA_15e2493c-bb5c-4a81-ba94-ef8c220c84f5">6,660,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzEwLTMtMS0xLTA_e6e25936-9a7e-45bd-b7b0-3906e872119c">6,237,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock Warrant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the common stock warrants were cash, or net exercised based on the IPO price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i62faf7ea655c489e8fb700ba32e5a72a_I20201231" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzk4Mg_84800136-05a8-4e68-8447-5156cb217365">20.00</ix:nonFraction> per share into <ix:nonFraction unitRef="shares" contextRef="iaf29cfa1d6194741a8ec14f28d1e4578_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzEwMDA_19853876-729c-4289-a2e2-aeed35805677">5,968</ix:nonFraction> shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does <ix:nonFraction unitRef="shares" contextRef="i1a1e51514e02474c89b155e4a5550726_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzMyOTg1MzQ4ODQ2MDA_35a42250-e274-4beb-abbd-8f731aaf44e0"><ix:nonFraction unitRef="shares" contextRef="i0ae992978a7d4deda30dcb028e032db0_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzMyOTg1MzQ4ODQ2MDA_b3c15f32-51c6-47cf-9699-7b8e60b38745">no</ix:nonFraction></ix:nonFraction>t have any common stock warrants outstanding.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_112"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMTE_21e26c4a-8f67-4800-b4db-1cee76e34dd7" continuedAt="i6461f699f17146ad9c1a269902e8b81d" escape="true">Stock Option Plans</ix:nonNumeric></span></div><ix:continuation id="i6461f699f17146ad9c1a269902e8b81d" continuedAt="ic0cec8c7a27d45a3a994fbc1daf2b865"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2007, the Company established its 2007 Stock Option Plan which provided for the granting of stock options to employees, directors and consultants of the Company.  In connection with its acquisition of NeuroCo in December 2018, the Company also assumed NeuroCo&#8217;s 2015 Equity Incentive Plan.  In March 2019, the Company's Board of Directors approved the termination of the 2007 Stock Option Plan and the NeuroCo 2015 Equity Incentive Plan and the adoption of the 2019 Equity Incentive Plan, or the 2019 Plan, which became effective immediately prior to the Company's IPO.  The 2019 Plan provides for the grant of ISOs to employees and for the grant of NSOs, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants.  A total of <ix:nonFraction unitRef="shares" contextRef="ic097536e6675494dbb4e914fc5bcd668_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzg1MA_bc84b39e-3231-4eaa-acca-daee36323860">2,317,000</ix:nonFraction> shares of common stock were initially reserved for issuance pursuant to the 2019 Plan.  In addition, the shares reserved for issuance under the 2019 Plan will also include shares reserved but not issued under the 2007 Stock Option Plan, plus any share awards granted under the 2007 Stock Option Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased.  In addition, the number of shares available for issuance under the 2019 Plan will also include an annual increase on the first day of each fiscal year, equal to the lesser of (i) <ix:nonFraction unitRef="shares" contextRef="i360f4f24adde40d8b482c84b661efed8_I20190331" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE0NTk_92f4976f-5d0a-489c-ab6d-c2a9ea604bd0">3,000,000</ix:nonFraction> shares; (ii) <ix:nonFraction unitRef="number" contextRef="i470f2ac36ec446a29f50d256c7548d9e_D20190301-20190331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE0NzU_1d60b403-b4ea-4889-9d72-d02e57e74b08">4.0</ix:nonFraction>% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) an amount as determined by the Board of Directors.  As of December&#160;31, 2020, the Company has reserved <ix:nonFraction unitRef="shares" contextRef="i214a26dd5e864dbeba676287ebd8859d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE2Nzc_94f8c3b3-5ce3-4d70-9b87-1423ecfdaab9">3,635,009</ix:nonFraction> shares of common stock for issuance under the 2019 Plan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyMzQ_d83caff1-132f-4d9c-b101-0ba53983b78b" continuedAt="i0142417b4d134238acc1f6bda03daf45" escape="true">A summary of the shares available for issuance under the 2007 Stock Option Plan, NeuroCo 2015 Equity Incentive Plan and 2019 Plan, or the Plans, is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="ic0cec8c7a27d45a3a994fbc1daf2b865" continuedAt="ic784711df36641648a5be402e175f20c"><div style="margin-bottom:9pt"><ix:continuation id="i0142417b4d134238acc1f6bda03daf45" continuedAt="i2129ef483fa248fa887dc1a4692f53f4"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f4737d591bc4039af44f3bd9c4891fd_I20171231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzEtMi0xLTEtMzA5Mw_3edcb848-359b-48b2-8964-c2b880cca5b8">328,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd542f1734634f0a802415b0d28a90a1_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzItMi0xLTEtMzA5Mw_34f331cb-58e9-4a54-b26a-695139126104">223,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd542f1734634f0a802415b0d28a90a1_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzMtMi0xLTEtMzA5Mw_35a2a2d8-21ab-454e-be7b-be9f0a0b2f73">629,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd542f1734634f0a802415b0d28a90a1_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzQtMi0xLTEtMzA5Mw_8263b187-9e0e-441f-85b3-88545d787355">135,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bf45438ba5c4c2aa9a094bb5bd64ede_I20181231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzEtMi0xLTEtMzA2MQ_1217a540-c475-4962-bd20-865332826b96">57,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf1037c5333249bbbd1ae376d9910c53_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzItMi0xLTEtMzA2MQ_4613623b-373c-4912-96e7-c5b7993a66cd">2,317,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idf1037c5333249bbbd1ae376d9910c53_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzQtMi0xLTEtMzA2MQ_c8e829be-a736-4cf1-906c-42664f02ae33">848,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf1037c5333249bbbd1ae376d9910c53_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzUtMi0xLTEtMzA2MQ_3b47166c-6e6f-44a4-b267-a2ffee0e2b35">27,824</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie77759ae85f849f99b4e3b1e0c06210e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzEtMi0xLTEtMjkwNw_343054b6-f725-4283-9134-86c756005629">1,554,690</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a8b1f2479ef489b833a827057b3ee5a_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzItMi0xLTEtMjkwNw_f4982a45-ea7f-4f96-b0c2-976e336cb585">1,250,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted/Awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7a8b1f2479ef489b833a827057b3ee5a_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzMtMi0xLTEtMjkwNw_943b8029-7699-467f-9b22-f131c05aa89b">1,079,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a8b1f2479ef489b833a827057b3ee5a_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzQtMi0xLTEtMjkwNw_0ba27499-a084-4426-86fb-6a6e1bb82e9f">65,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i214a26dd5e864dbeba676287ebd8859d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzUtMi0xLTEtMjkwNw_7a8825f5-c599-4c14-88fc-201180c5dc3d">1,790,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of ISOs and NSOs shall not be less than <ix:nonFraction unitRef="number" contextRef="i2c0182ac39bf451580f9e5a338dd2281_I20201231" decimals="INF" name="silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE3OTY_59b66205-950e-49a4-900d-41863b76bc46">100</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i708be08da99c40d39705d37410604fa8_I20201231" decimals="INF" name="silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE4MDM_541e768d-7504-4799-83cc-872589a69a61">85</ix:nonFraction>%, respectively, of the estimated fair value of the shares on the date of grant as determined by the Board of Directors.  The exercise price of ISOs and NSOs granted to a 10% stockholder shall not be less than <ix:nonFraction unitRef="number" contextRef="i63c59c6933b34539813d0d966133cca9_I20201231" decimals="INF" name="silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzIwMTM_c9f9e2bd-4c91-4daa-a666-17079f6511ed">110</ix:nonFraction>% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors.  To date, options have a term of <ix:nonNumeric contextRef="i659d64912c544b77817ed68d2f7ce05c_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzIxNTM_a399ca49-c563-49f2-926a-60eb5063278c">ten years</ix:nonNumeric> and generally vest over <ix:nonNumeric contextRef="i659d64912c544b77817ed68d2f7ce05c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzIxODA_c112bb16-c6f1-4fa9-b6db-4864485ed967">4</ix:nonNumeric> years from the date of grant.</span></div><ix:continuation id="i2129ef483fa248fa887dc1a4692f53f4" continuedAt="i708f3b47f6054b1590a4628b3b50b48e"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's Plans is set forth below:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.137%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2017</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzctMy0xLTEtMA_fda1a90b-62b4-477e-97ee-a55e5a87c3d6">4,308,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzctNS0xLTEtMA_562ad58f-b0ca-4eab-a12d-acb3e816f40e">3.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ea3f51adc9c4505b898323c41931f67_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzctNy0xLTEtMA_d28a3af7-c749-4e48-82f8-486c6bd17e6e">7.81</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzctOS0xLTEtMA_49ff7759-c103-499e-9a97-dbbab3faad30">5,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzktMy0xLTEtMA_557935ca-91e0-4089-943a-79038a4396d5">629,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzktNS0xLTEtMA_1e381401-949a-4fec-9c58-b089952cd7da">6.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEwLTMtMS0xLTA_79d49285-dace-4344-892f-f4519eef745d">438,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEwLTUtMS0xLTA_077be997-3833-4cbc-a87d-b6e4c702aa84">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzExLTMtMS0xLTA_88bcbccc-6da2-4851-bd81-037528f8fc45">135,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzExLTUtMS0xLTA_54961682-68cc-4326-97c5-4541c988d85b">1.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEyLTMtMS0xLTA_4338f4f5-1b00-49f5-96f9-58907aa19996">4,364,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEyLTUtMS0xLTA_159eaad4-efca-4480-a360-72b1e2fcee39">3.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEyLTctMS0xLTA_1080f05a-7595-450b-9dd2-818e3d2a66a4">7.36</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEyLTktMS0xLTA_6c24efda-9a21-4cf5-b859-8ceb5dfaa762">33,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE0LTMtMS0xLTA_d2d617a2-39ae-44ac-865a-f4fcb781a35f">848,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE0LTUtMS0xLTA_ff715614-ff84-457c-ba2f-964d6762986c">22.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE1LTMtMS0xLTA_29f7b21c-1b47-4fbf-a5d6-4416bea677d3">873,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE1LTUtMS0xLTA_91a7b1c1-52a1-4e6b-92ec-9f1cc8498f31">1.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE2LTMtMS0xLTA_86491c4a-a858-49f2-a8eb-65b7c8d34744">27,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE2LTUtMS0xLTA_922c6a38-8951-4092-a115-7df635ecb308">8.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE3LTMtMS0xLTA_2a99185e-8fd7-4dc2-b81b-c6d3c792637b">4,310,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE3LTUtMS0xLTA_befd1f33-4a9d-437b-8eb8-f5e61cc74f91">7.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE3LTctMS0xLTA_b1b40877-63d3-4676-a7ae-1b441cd14a04">7.27</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE3LTktMS0xLTA_279a74d6-e8ca-407a-bf71-66b2eeae5bbb">140,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTMtMS0xLTI5MjY_0bd2a7d3-97f0-4490-946e-ff8d5e93a8b0">1,010,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTUtMS0xLTI5MjY_4a6f5604-4b5b-407f-9ebf-6080fd60634e">40.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTMtMS0xLTI5MjY_26aad6a3-2d60-4eff-b596-bc252087c381">1,018,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTUtMS0xLTI5MjY_831f85d2-37d1-4f62-b170-2f74803d1010">3.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIwLTMtMS0xLTI5MjY_bd2cf980-0ca9-4e45-a16e-7618c406e288">65,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIwLTUtMS0xLTI5MjY_847bfaad-4ed1-4f40-8cd7-ebd9baaf6bac">23.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIxLTMtMS0xLTI5MjY_0faf97e0-12a4-4753-8e0e-1452270e5462">4,237,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIxLTUtMS0xLTI5MjY_dcd58872-005f-42b3-ac07-ab277cd2308d">16.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIxLTctMS0xLTI5MjY_aaf4c2a9-15a4-4c7f-b4a9-eb15dfbc0cdd">7.38</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIxLTktMS0xLTI5MjY_16644333-58d0-40d2-8498-0e2034ff6fbb">197,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTMtMS0xLTA_1889caf8-f876-4d63-bccd-e5f1778cf99f">2,392,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTUtMS0xLTA_4f99611f-2af2-4895-86e5-3f5b26f8e825">8.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTctMS0xLTA_06ad3786-ee72-4195-8721-938e29c987a3">6.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTktMS0xLTA_17a3e493-eca5-49dd-a241-11792236bcfb">130,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTMtMS0xLTA_a4616c9b-358e-42c6-8914-a01217d61253">4,237,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTUtMS0xLTA_46d70cca-c107-48c4-b59f-7c8072f499ee">16.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTctMS0xLTA_97cf382d-0580-4bc4-bee5-d0a25b05e14b">7.38</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTktMS0xLTA_fcf02801-fc95-419e-bfe7-9f643038427b">197,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="ic784711df36641648a5be402e175f20c" continuedAt="iaaa378d172294e34844f77404fa445cc"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5NTE_3e49d25b-0bdc-4e7f-beb7-7f5609509bb2">47,861,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5NTc_3d32476f-ee6e-4bdc-a31d-0d85c386097e">24,867,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5NjE_6d8d0104-2a46-46cd-908e-2bdf42a26287">787,000</ix:nonFraction>, respectively.  The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise.  The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5Nzg_21da1e89-5ca6-4464-8671-952f4c4507b0">18.22</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5ODQ_a541c234-3df2-43fd-bd3c-43d670544361">10.17</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5ODg_322b5e82-b4c6-4895-b128-5fe8ce16cc93">2.93</ix:nonFraction> per share, respectively.  The total fair value of options vested during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwMTA_a1332b7a-d48a-4ea5-b354-4418f1af048e">5,138,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwMTY_ee7b8e9c-6fbf-4bbf-a4f6-0eb43649faef">2,221,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwMjA_3af125c5-8a68-4692-9252-17c27701ae87">569,000</ix:nonFraction>, respectively, based on the grant date fair value.</span></div><ix:continuation id="i708f3b47f6054b1590a4628b3b50b48e"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding and vested as of December&#160;31, 2020:</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Vested</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i490bf68acdbb4450bf64bafef197e4fb_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItMC0xLTEtMC90ZXh0cmVnaW9uOmU0MmVmODJmZmQ5YjQ3YTRiZTczMDkwYjMwNjFlMWRlXzQ_b590dd17-ee89-449d-ad52-cdc7d5933f3a">1.35</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i715cd558a0134ebba2c8252d957a7ce6_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItMC0xLTEtMC90ZXh0cmVnaW9uOmU0MmVmODJmZmQ5YjQ3YTRiZTczMDkwYjMwNjFlMWRlXzk_d7128e8c-2845-4df6-bd3a-14c3598e0134">3.16</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2c087f244e24d669ad5f5b19aa67a98_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItMi0xLTEtMA_58d466f7-d7b0-41bd-93b3-fb923d1ef2b3">1,214,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e3dc08fdedf4e33bd6817d15104fe6e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItNC0xLTEtMA_16e01d61-6b58-4ca3-9148-8af5f8efa47b">5.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2c087f244e24d669ad5f5b19aa67a98_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItNi0xLTEtMA_31bb05aa-1d26-451b-b261-88d87414c490">1.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2c087f244e24d669ad5f5b19aa67a98_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItOC0xLTEtMA_908a90c1-72d9-4d0d-a49a-89ee03e1973c">1,128,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2c087f244e24d669ad5f5b19aa67a98_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItMTAtMS0xLTA_eff85f64-6e98-4088-aafa-c7a55567d95d">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6fdd1471eaa54f92a52745ec56a48110_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtMC0xLTEtMC90ZXh0cmVnaW9uOjU0YjFiNjQzMGEwZjQ1OTRhZjJlNDMyZTcxNmZkYjRiXzQ_acaa8680-42e6-4ba2-bedb-68c7e601efb1">4.73</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i8945e1adfb3b4ab09fa3fa5891d357c6_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtMC0xLTEtMC90ZXh0cmVnaW9uOjU0YjFiNjQzMGEwZjQ1OTRhZjJlNDMyZTcxNmZkYjRiXzk_cbe92416-7b9a-4b7d-b899-23feb11ceff1">7.10</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8c8d5b84586400b86587503b81287f6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtMi0xLTEtMA_2bb2870b-53d1-4e8c-8c11-c3aa0831f267">722,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icc46ca644c744b70aac67133ea9f52f4_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtNC0xLTEtMA_cb747954-4499-49c8-a9f8-875c6a239dc6">7.17</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8c8d5b84586400b86587503b81287f6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtNi0xLTEtMA_c8914628-9394-4ca7-ace5-ee607b4fb77a">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8c8d5b84586400b86587503b81287f6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtOC0xLTEtMA_0180fcc2-2029-4b2f-bb95-7207c0cbd762">443,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8c8d5b84586400b86587503b81287f6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtMTAtMS0xLTA_3a8de4ce-9639-476c-91f9-a94489dd4651">5.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i36011f19453e484790ec3753ef0eb829_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtMC0xLTEtMC90ZXh0cmVnaW9uOjY2MmRjOGM4NjVkYjQ5MzJhOTViOGEyYWRkOGI5NTM2XzQ_dbc81c7d-9f07-438b-b39b-6bcdd9395b8e">8.27</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i19b4be470462491987f832241f434403_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtMC0xLTEtMC90ZXh0cmVnaW9uOjY2MmRjOGM4NjVkYjQ5MzJhOTViOGEyYWRkOGI5NTM2Xzk_3215b760-8acf-4f37-aca9-78ef94f5ae4b">12.41</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b5473c83d5146e19f1b3858891c78b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtMi0xLTEtMA_c4baaa5a-755d-45db-8c1c-a65b370ff6c4">564,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f9b2814a79c4dd08d65788445d6db8e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtNC0xLTEtMA_9b9f9c5b-cf79-4ea8-809c-fbf0bb26b750">7.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b5473c83d5146e19f1b3858891c78b7_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtNi0xLTEtMA_edbe8213-7252-4384-b09c-aa9a55d18d02">11.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b5473c83d5146e19f1b3858891c78b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtOC0xLTEtMA_967cd241-00b3-404c-a516-02d5603132c1">394,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b5473c83d5146e19f1b3858891c78b7_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtMTAtMS0xLTA_7be749e9-4de5-40d3-ae45-7d567ddb1d16">11.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i74888ea9613946dd8a212a7d91cda76a_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgyOWM1NTA2Yjc4YjQ0YmFiZGViMjUwZjVjODkxMjVkXzQ_75952813-c78b-421e-91ac-78e57aa3d95a">20.00</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd4ed4e74601414e92a601aa67b10327_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgyOWM1NTA2Yjc4YjQ0YmFiZGViMjUwZjVjODkxMjVkXzk_4818146e-01a9-489e-89ae-9e18f7ec5bde">30.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfd02705d3de468ba9f3a47573c3dde9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtMi0xLTEtMA_1bd7f87a-a026-4a76-92eb-b1b9c21b83ab">656,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia49153bfeb6f42bdb3736ba316591747_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtNC0xLTEtMA_1ecd3a01-7bd4-4f26-8ea3-626f073bbcdf">8.26</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idfd02705d3de468ba9f3a47573c3dde9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtNi0xLTEtMA_32c77c08-93cb-489c-a354-57fd12f24c80">20.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfd02705d3de468ba9f3a47573c3dde9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtOC0xLTEtMA_e999465a-466f-4905-9419-cf3ef31804ea">270,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idfd02705d3de468ba9f3a47573c3dde9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtMTAtMS0xLTA_87ef8103-880a-47d9-8691-6495dd743cbb">20.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ice0a90922eee49f89e3692455daf46fa_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMC0xLTEtMzE4Ni90ZXh0cmVnaW9uOmVhY2QxYTRjMjc3ZTQwNzZiNDgxM2MxNzNiMmFiNWU0XzEwOTk1MTE2Mjc3ODA_34620aad-c2d2-434e-a22a-87153cc60998">30.93</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ia787b8a99022442987a046c7b0ae1e90_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMC0xLTEtMzE4Ni90ZXh0cmVnaW9uOmVhY2QxYTRjMjc3ZTQwNzZiNDgxM2MxNzNiMmFiNWU0XzEwOTk1MTE2Mjc3ODY_75dd3cad-14c1-498b-bfff-397e0bd13a97">46.40</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c7bb98d16e744c886f33a907325392b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMi0xLTEtMzIwNQ_e609561b-f861-47d5-a768-ba158aa987ed">771,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1ab64a372d04ae8b13ae564c7b1d519_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtNC0xLTEtMzIwNQ_3ccb2ec2-7345-4adc-8e1c-073e3903152a">9.21</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c7bb98d16e744c886f33a907325392b_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtNi0xLTEtMzIwNQ_579ea372-b366-416e-b337-9b08b4c91384">33.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c7bb98d16e744c886f33a907325392b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtOC0xLTEtMzIwNQ_73edf341-f434-40b0-8f09-15491b0be6a9">136,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c7bb98d16e744c886f33a907325392b_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMTAtMS0xLTMyMDU_298bf0d5-e433-469b-a726-e8c09af52552">33.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8621a9d17f8c4c759e18a0b9f4998461_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctMC0xLTEtMzE5Mi90ZXh0cmVnaW9uOjBjZDc1NDA5ZjY1MTRmMWQ5NjEwYWM5OTk3ZTBiOWFlXzEwOTk1MTE2Mjc3ODA_c017eddd-6417-4808-8fb5-4e5c4a136d7c">47.20</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i0d07d3d83db94418805af6f5704d41c9_I20201231" decimals="2" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctMC0xLTEtMzE5Mi90ZXh0cmVnaW9uOjBjZDc1NDA5ZjY1MTRmMWQ5NjEwYWM5OTk3ZTBiOWFlXzEwOTk1MTE2Mjc3ODY_73741bf9-3692-4a00-ba04-6a174b0e0b29">70.80</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67a74532b17b4cbeb8fc651e11ede5be_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctMi0xLTEtMzIwNQ_45848052-a6b6-4793-9228-e78d409aaea0">308,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a577dab858449659f2138be0247edb3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctNC0xLTEtMzIwNQ_7f7d0537-de5f-4afb-a89e-5790661450ca">9.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67a74532b17b4cbeb8fc651e11ede5be_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctNi0xLTEtMzIwNQ_5eba88af-585b-4aac-9c25-213ab7c57f2c">58.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67a74532b17b4cbeb8fc651e11ede5be_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctOC0xLTEtMzIwNQ_cf9c789c-e41c-44da-ac88-2e8fc38f84cc">18,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67a74532b17b4cbeb8fc651e11ede5be_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctMTAtMS0xLTMyMDU_5db55fa4-bc9a-4799-b73e-b3b8b69f00dd">51.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMi0xLTEtMA_63d57f5a-03d7-435f-8d87-0d8140c0df25">4,237,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtNC0xLTEtMA_048497e3-d490-4cab-8e01-da57ec7e979b">7.38</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtNi0xLTEtMA_2ff50140-608c-44d2-a382-39e5ae2f5f53">16.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtOC0xLTEtMA_bb5dcd1e-c089-49c1-a731-5302c47c0226">2,392,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMTAtMS0xLTA_9190e35b-8f03-47d6-81d8-3dbfd4974402">8.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company began granting restricted stock units, or RSUs, under the 2019 Plan.  RSUs generally vest over <ix:nonNumeric contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyMzU_7f971367-ab7a-47cc-8933-0c28fcfe401b">four years</ix:nonNumeric> in annual equal increments, <ix:nonFraction unitRef="shares" contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyNTA_2a7a8c61-017c-4317-9def-c31fadf9cbbb">no</ix:nonFraction> RSUs vested during the year ended December 31, 2020.  The fair value of RSUs is based on the Company&#8217;s closing stock price on the date of grant.  <ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyMzM_d914ba0b-82f8-4db1-8f5f-56542b709903" continuedAt="ib5b35dadee3746bdb374ae8b5a218dec" escape="true">A summary of RSUs activity for the year ended December 31, 2020 is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="ib5b35dadee3746bdb374ae8b5a218dec"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6691dffc917441fa983264255b9af82b_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzEtMi0xLTEtMzE3NA_7fd02ab8-1f10-4648-a332-9ff9f8532ed1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i6691dffc917441fa983264255b9af82b_I20191231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzEtNC0xLTEtNTM2NA_e42aa887-9746-4e0b-9d9d-125d52e5e2dd"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted stock granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzItMi0xLTEtMzE3NA_3d0a345e-247b-49ec-a276-b2457ae6abeb">69,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzItNC0xLTEtMzE3OQ_dab05314-a57f-47db-a0f2-9ebc56e7258b">46.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzMtMi0xLTEtMzE3NA_b56f17d7-f41a-4a84-8264-b747eca7f2fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzMtNC0xLTEtNTM2NA_5df56d8f-9740-4bd3-b31e-774d4f5e0cd8"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted stock forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzQtMi0xLTEtMzE3NA_6683786a-fb0d-4ad4-97e3-7b5990e06939">644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzQtNC0xLTEtMzE3OQ_53aa6c8c-c14d-465b-8e85-98b6fb6b9ac6">44.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzUtMi0xLTEtMzE3NA_b644e625-0797-4ae2-9740-1f340671fd25">68,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzUtNC0xLTEtMzE3OQ_bcf771ed-3505-4080-a4f6-b0994d1228b6">46.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzYtMi0xLTEtMzE3NA_19268a2e-59ea-4809-97ca-fa7ab95997c5">68,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzYtNC0xLTEtMzE3OQ_842b0d12-652d-40b0-86f5-724cb8850973">46.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company's Board of Directors adopted the 2019 Employee Stock Purchase Plan, or the 2019 ESPP, under which eligible employees are permitted to purchase common stock at a discount through payroll deductions.  A total of <ix:nonFraction unitRef="shares" contextRef="ie4be24da3ca849f38e1fe9ffb7f6d2ba_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyNzc_ee217688-dcc3-4fe3-a617-985ab98fd769">434,000</ix:nonFraction> shares of common stock were initially reserved for </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="iaaa378d172294e34844f77404fa445cc" continuedAt="i2740a22ed31246518471927d7e2c473f"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance and is increased on the first day of each fiscal year by an amount equal to the lesser of (i)&#160;<ix:nonFraction unitRef="shares" contextRef="ie4be24da3ca849f38e1fe9ffb7f6d2ba_I20190331" decimals="-3" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzM0NDg_23815bd0-cdaf-4215-8375-90b9605736f7">1,200,000</ix:nonFraction> shares (ii)&#160;<ix:nonFraction unitRef="number" contextRef="i727cdef9482140249c0cb804bb673e7c_D20190301-20190331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzM0NjM_c7929ecc-e42e-43ab-a5f8-7c619a1fcf93">1.0</ix:nonFraction>% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii)&#160;an amount as determined by the Board of Directors.  As of December 31, 2020, the Company has reserved <ix:nonFraction unitRef="shares" contextRef="i321ada78d4e34140b6929a8c206aa114_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyNjU_d5092568-fff7-454e-81a6-727137539a05">746,552</ix:nonFraction> shares of common stock for issuance under the 2019 ESPP.  The price of the common stock purchased will be the lower of <ix:nonFraction unitRef="number" contextRef="i727cdef9482140249c0cb804bb673e7c_D20190301-20190331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzM2OTE_e8eee6e1-39c5-4adb-ab3f-11a479aa6ca8">85</ix:nonFraction>% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period.  The 2019 ESPP was effective upon adoption by the Company's Board of Directors but was not in use until the completion of the Company's IPO in April 2019.  The 2019 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&#160;423 of the Internal Revenue Code of 1986, as amended.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzQxMzg_4388cf64-d5f5-4a4c-8d7a-c292377cf843">114,175</ix:nonFraction> shares of common stock have been issued to employees participating in the 2019 ESPP and <ix:nonFraction unitRef="shares" contextRef="i321ada78d4e34140b6929a8c206aa114_I20201231" decimals="INF" format="ixt:numdotdecimal" name="silk:CommonStockCapitalSharesAvailableForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzQyMjk_9f527540-46f1-4164-a18c-86a0e6d653d0">632,377</ix:nonFraction> shares were available for future issuance under the 2019 ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of stock options using the Black&#8211;Scholes option pricing model.  The fair value of employee and nonemployee stock options is being amortized on a straight&#8211;line basis over the requisite service period of the awards.  <ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMTA_c6a5ea9f-e5c0-44dc-8398-c4c256552976" continuedAt="i87304ee81631473f9e73cd1d022edc6a" escape="true">The fair value of employee and nonemployee stock options was estimated using the following assumptions for the years ended December&#160;31, 2020, 2019 and 2018:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="i87304ee81631473f9e73cd1d022edc6a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.314%"><tr><td style="width:1.0%"></td><td style="width:43.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.707%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47ab4f535e3f49f092f4f09308ca5685_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjZlZGYxY2UzMDYzMTRiMTE5NTZhMDhjNzExNjE2ZDJhXzQ_264d85d8-19a9-4602-878d-8a70b4892110">5.25</ix:nonNumeric> - <ix:nonNumeric contextRef="ia0b870409832446b94306158afef68a2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjZlZGYxY2UzMDYzMTRiMTE5NTZhMDhjNzExNjE2ZDJhXzk_2bfae5c4-d073-4a7b-9654-c4b13b92dda2">6.25</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ccbf5504e084eaeb3d0c1e776fc48ea_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMS0xLTEtMC90ZXh0cmVnaW9uOjRmZDY5YTc2Zjk2MDQxYjhiZGNmMTFhN2I3YjFlOWYzXzQ_043de89f-4301-452d-8637-1af32fe79664">5.00</ix:nonNumeric> - <ix:nonNumeric contextRef="i61cd83f3fb4e4e00b85103543a357d2e_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMS0xLTEtMC90ZXh0cmVnaW9uOjRmZDY5YTc2Zjk2MDQxYjhiZGNmMTFhN2I3YjFlOWYzXzk_802da864-cc2d-40f1-b102-229151925b53">6.25</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if15e03a06afa4556856fc6b3d9b3f42e_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMy0xLTEtMC90ZXh0cmVnaW9uOmIzNTU5ODg3YzMyMzQyMjk4ZGNlNmQxZGY0MWE0NjE3XzEwOTk1MTE2Mjc3ODg_ce139e6e-5130-4d8f-a32d-585a993ff214">5.00</ix:nonNumeric> - <ix:nonNumeric contextRef="ia5fe2fcafee2473d94c7bb24e4dee4b2_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMy0xLTEtMC90ZXh0cmVnaW9uOmIzNTU5ODg3YzMyMzQyMjk4ZGNlNmQxZGY0MWE0NjE3XzEwOTk1MTE2Mjc3OTI_ad249618-1665-4273-b6ab-919d3ecfa450">6.25</ix:nonNumeric></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjQ0OWE3YTNlOTZlNTQ1NGY5OWM5M2JhNTI5MzcwNTJkXzQ_83c7af69-3ece-46e0-9c3a-a5e22ef41ea4">43.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjQ0OWE3YTNlOTZlNTQ1NGY5OWM5M2JhNTI5MzcwNTJkXzk_ffbc4469-0838-438b-b623-3227866e5b9c">50.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMS0xLTEtMC90ZXh0cmVnaW9uOmQxY2ZiODkyZjUzOTQ5NDk4N2ZkOTc1NGIzMzM4OTkzXzQ_dbc4c060-67e6-4078-8362-f6e9f09b6bc5">42.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMS0xLTEtMC90ZXh0cmVnaW9uOmQxY2ZiODkyZjUzOTQ5NDk4N2ZkOTc1NGIzMzM4OTkzXzk_5dd952e2-05ae-44f0-bb34-850159b34f70">42.9</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMy0xLTEtMC90ZXh0cmVnaW9uOmI1MDBmYWQ4YWEzNzRhOGE5NTI4ZTI5OGY2MTMwNzZkXzEwOTk1MTE2Mjc3ODg_17e31ac2-95d2-420c-8dd8-c8c6517f7cdf">38.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMy0xLTEtMC90ZXh0cmVnaW9uOmI1MDBmYWQ4YWEzNzRhOGE5NTI4ZTI5OGY2MTMwNzZkXzEwOTk1MTE2Mjc3OTI_8f75d2eb-7510-4599-aae4-c8b6a9013556">38.8</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjgyOTY2YjJkNTQwNjRjMWFhZTZkNDBmZmNhOWFkY2M5XzQ_88efbfe0-c032-4749-953e-4e228d879673">0.32</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjgyOTY2YjJkNTQwNjRjMWFhZTZkNDBmZmNhOWFkY2M5Xzk_b77f91d8-9ab3-4e1d-a318-6aac4c51a687">1.41</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmEzYjlmZDRmNTk0YzRhYzU4YjRlNmUyNjk1OGJjYzA2XzQ_fec4e8d4-1307-4a1c-984e-9a8955714722">1.47</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmEzYjlmZDRmNTk0YzRhYzU4YjRlNmUyNjk1OGJjYzA2Xzk_0971d1da-b098-4ed8-861f-1b185e94a69e">2.54</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmViOTM3YWViZDFiYjQzMGFhNjg5YTk2MDg3ZWZhZTAzXzEwOTk1MTE2Mjc3ODg_9fa2c03d-04eb-4be7-ac6e-a39fe12e992c">2.68</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmViOTM3YWViZDFiYjQzMGFhNjg5YTk2MDg3ZWZhZTAzXzEwOTk1MTE2Mjc3OTI_78abc53f-2c1d-4a9a-917e-70d1a57ec3e4">2.98</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzUtMS0xLTEtNTM0NA_9b8b56f4-ad0f-4ef3-ae8b-65b88aa07e1b">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzUtMS0xLTEtMA_b73a3e34-75fd-4fe0-9940-8e582b031455">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzUtMy0xLTEtMA_db101879-2549-47d8-9e53-1464fcda971b">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to completion of the Company's IPO, the fair value of common stock was determined by the Company&#8217;s Board of Directors, who considered, among other things, contemporaneous valuations of the Company&#8217;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.  For stock options granted after the completion of the IPO, the fair value of the underlying common stock is based on the closing price of the Company's common stock on The NASDAQ Global Market on the date of grant.  The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding.  The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the &#8220;simplified method,&#8221; whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option.  The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as the Company does not have sufficient trading history for the Company&#8217;s common stock.  The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the&#160;Company&#8217;s common stock becomes available.  The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the&#160;Company&#8217;s stock options.  The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company made an accounting policy election to account for forfeitures as they occur. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i2740a22ed31246518471927d7e2c473f"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="silk:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMTQ_e1c6d95b-be84-45e1-8940-d080496cf8e7" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the shares to be issued under the Company&#8217;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:64.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzItMi0xLTEtMzI0Ng_f928b39c-625e-4c4d-9608-b1c871c09fa6">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i39165a89986a4d5fa6d41c395d548242_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzItMi0xLTEtMC90ZXh0cmVnaW9uOjFhYWQ3NTJmOTMwNTQ3NDViYzFiYmE0ZDk4NWNhY2EyXzEwOTk1MTE2Mjc3ODg_92484b85-974b-4359-9539-68455fe691a5">0.50</ix:nonNumeric> - <ix:nonNumeric contextRef="i0309977823e74b8bb43d525e2c1862f0_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzItMi0xLTEtMC90ZXh0cmVnaW9uOjFhYWQ3NTJmOTMwNTQ3NDViYzFiYmE0ZDk4NWNhY2EyXzEwOTk1MTE2Mjc3OTI_578f020b-3686-494c-86b0-879168c5a90c">0.63</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzMtMi0xLTEtMzI0OS90ZXh0cmVnaW9uOjE4YTY1NTM1YjdjYzRlNDBhYzJkNzk3ZGQyMGRjMjkyXzEwOTk1MTE2Mjc3ODA_31401562-c283-465b-9d59-b2e6910c3d72">44.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzMtMi0xLTEtMzI0OS90ZXh0cmVnaW9uOjE4YTY1NTM1YjdjYzRlNDBhYzJkNzk3ZGQyMGRjMjkyXzEwOTk1MTE2Mjc3ODY_1ad9cdaa-c7f0-49a6-9934-89811d4bbf3e">76.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzMtMi0xLTEtMC90ZXh0cmVnaW9uOjQzZWUwZTJmODliMDQxYTdhYmViMzUwOThkNzdmMmI4XzEwOTk1MTE2Mjc3ODg_34e98194-d822-4b58-a1f7-ee5d1eec45d9">44.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzMtMi0xLTEtMC90ZXh0cmVnaW9uOjQzZWUwZTJmODliMDQxYTdhYmViMzUwOThkNzdmMmI4XzEwOTk1MTE2Mjc3OTI_0c208073-1668-4b76-8025-83c3b8d9babf">47.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzQtMi0xLTEtMzI1My90ZXh0cmVnaW9uOjE0YTE5YTU5ZTIxMjRkZmQ5ODIyZWIxODQ3ZDJiMGJhXzEwOTk1MTE2Mjc3ODA_4f6a3045-30e2-4b63-b170-429a43a0a466">0.10</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzQtMi0xLTEtMzI1My90ZXh0cmVnaW9uOjE0YTE5YTU5ZTIxMjRkZmQ5ODIyZWIxODQ3ZDJiMGJhXzEwOTk1MTE2Mjc3ODY_d834f6fd-9d11-49cd-a0e6-2446254b75a0">1.58</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzQtMi0xLTEtMC90ZXh0cmVnaW9uOmFlYWFkMWNmNDFiODQ4NTM4ODFmNWY4ZjgxNmYxZmMwXzEwOTk1MTE2Mjc3ODg_d31c8003-45e2-4fd6-91b8-039d6f475481">1.58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzQtMi0xLTEtMC90ZXh0cmVnaW9uOmFlYWFkMWNmNDFiODQ4NTM4ODFmNWY4ZjgxNmYxZmMwXzEwOTk1MTE2Mjc3OTI_0d26bf71-473b-4359-9887-79c9940cffe0">2.45</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzUtMi0xLTEtMzI1OA_95717a0c-c0c4-42f0-9f8e-7156b47fb839">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzUtMi0xLTEtMA_a2277477-66a5-482d-86c0-f119ff7bb1e4">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMTY_e0f2a9d1-bf5c-4b9a-b2a9-bd68eb81fd35" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation expense included in the statements of operations for all periods presented (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.604%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a041d34a42449bda00947d0a4241c05_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzItMS0xLTEtMA_02772f18-8d33-4d20-a47a-cf22ce23cee8">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3f38d9acbf408aab3a51c21d51d4d1_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzItMy0xLTEtMA_9a970f4b-59e2-42d5-b55c-d45ec7d3b20c">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5e58dd5ca74c379c458d4f10ca54f9_D20180101-20181231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzItNS0xLTEtMzI5MA_f1a649c6-b2b8-47b0-8aaa-239d9c3d7e82">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c8f7f1217049b0ac9c547630982b6a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzMtMS0xLTEtMA_54644a65-7cf0-4348-8ee1-61304fb28525">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc78fcf595b4b6b89684111bad3f5a3_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzMtMy0xLTEtMA_a30ed15d-2ef2-459e-b34d-0cce69c149a6">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c98c09f3d34127ac384e5836c541d5_D20180101-20181231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzMtNS0xLTEtMzI5MA_c527d994-4bbe-499f-9469-2205e38bc066">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f27a96dad34a63a114ecba634391a9_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzQtMS0xLTEtMA_e3ca1535-9cfe-4ec0-81bb-ad8917147a5a">5,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9290967454ec461ab5eab6e110e7984c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzQtMy0xLTEtMA_bbdf2e42-9924-47f9-8f29-c38bde2e484c">2,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b062b857ecd47d58f12e164875b8b8e_D20180101-20181231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzQtNS0xLTEtMzI5MA_7087e45d-320d-4216-a896-7a726f110d03">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzUtMS0xLTEtMA_aa954618-44f2-4b44-8f79-0531b295f289">7,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzUtMy0xLTEtMA_0b8f43af-54fd-433b-b649-cbc8f8b591da">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzUtNS0xLTEtMzI5MA_61a3aa23-0523-4827-9848-3143707f8631">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was total unrecognized compensation costs of $<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcwMzY_f4c684b8-73fa-491d-9911-9427bcd00464">20,188,000</ix:nonFraction> related to stock options expected to be recognized over a period of approximately <ix:nonNumeric contextRef="ic2a66f92a0c54ee4abd3a59a6da8d88b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcxMzI_f4bc9018-de04-423f-a374-cc03225306bb">3.02</ix:nonNumeric> years, a total of $<ix:nonFraction unitRef="usd" contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwMzM_d684e606-6eec-4c18-9a46-428c8ee3c370">2,716,000</ix:nonFraction> of unrecognized compensation costs related to unvested RSUs expected to be recognized over a period of approximately <ix:nonNumeric contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwNDY_99f57270-658a-4089-917b-cdd4e7ddb418">3.48</ix:nonNumeric> years and $<ix:nonFraction unitRef="usd" contextRef="i321ada78d4e34140b6929a8c206aa114_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcxMzk_046e2545-76aa-4a1b-8e86-0631fbc9cfed">295,000</ix:nonFraction> related to the ESPP, which the Company will recognize over <ix:nonNumeric contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMDY_2b7bdc2e-9e3b-4832-9850-2ae89b37a7ae">0.38</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-bottom:12pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_118"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTQ_87859206-2252-47f0-ac28-839cf9d76251" continuedAt="i7a585fa0cc4a4ac8ac9558849b0a66e6" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i7a585fa0cc4a4ac8ac9558849b0a66e6" continuedAt="ie227ced259d54acb936e914cb0c324e2"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTU_282220fc-d44e-4fb7-9b28-b4914e9c1d21" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income before taxes are as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzItMS0xLTEtMA_701b9bd3-5dac-4df9-b557-2ab7bb93652c">47,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzItMy0xLTEtMA_6a7fd54a-a2c0-45d5-ad35-39902af346cc">52,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzItNS0xLTEtMzMxMw_0fd66255-2e54-45fb-a430-b5e66a000bdc">37,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzMtMS0xLTEtMA_b5c80ae6-b9ec-498a-b017-a3321c98e996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzMtMy0xLTEtMA_acf48c92-ae05-4dfa-a93e-c813b681d7e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzMtNS0xLTEtMzMxMw_85bc6c71-fd5f-4ed3-b4c6-91873904b25c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzQtMS0xLTEtMA_65b8b7d8-a408-4dc4-94f0-bc683f91ced1">47,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzQtMy0xLTEtMA_85caf0fd-056d-45fb-a6ae-20391b1dc417">52,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzQtNS0xLTEtMzMxMw_f5385427-cb5d-4053-820c-d7e067c28b5c">37,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="ie227ced259d54acb936e914cb0c324e2" continuedAt="i7856c3b4c3474fad9c0a3823368cabfb"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTY_d6c25b38-e481-498b-9138-c343486d80b5" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory U.S. federal rate to the Company&#8217;s effective tax rate is as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:55.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzItMS0xLTEtMA_e6d936d2-b58c-4868-b240-08e3da6593c2">9,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzItMy0xLTEtMA_c7b63b87-97cd-4f0f-8af7-04f2a6ad17c6">11,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzItNS0xLTEtMzMyMw_e853f45a-be52-4e6b-a973-c28d4f3f2b2a">7,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzMtMS0xLTEtMA_cdf0ea4a-1901-4570-b878-1c4e2d7c25da">1,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzMtMy0xLTEtMA_6bb8215f-92a0-4d9e-9265-e3063c6e196a">2,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzMtNS0xLTEtMzMyMw_568e6b62-b7c9-4dce-8a43-1e022ef4d987">1,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzQtMS0xLTEtMA_75f83341-37a0-4722-8321-283e12f032e3">8,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzQtMy0xLTEtMA_906e0232-2d99-4ef8-83a2-33322d37a4cc">4,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzQtNS0xLTEtMzMyMw_ab0e7228-bded-4c1d-ae2b-94eda3e3f7ac">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on Series C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="silk:EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzUtMS0xLTEtMA_9fcb5d3b-3ae4-4046-acde-5ad0343f02f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="silk:EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzUtMy0xLTEtMA_46cd6a40-c533-4665-8d6a-fd598567eae0">5,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="silk:EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzUtNS0xLTEtMzMyMw_f5cb36d3-0e5f-4d26-8e6e-d6bd77e3b299">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzYtMS0xLTEtMA_f73e7b71-3481-4ade-b1c3-7406d59ca5f8">22,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzYtMy0xLTEtMA_2b18a8fc-c516-4d8a-90d8-5feaa643f2f1">12,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzYtNS0xLTEtMzMyMw_ea2cb0df-8af2-4878-9d5b-9d1e747001d3">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzctMS0xLTEtMA_68235020-5166-4a5f-bff2-4e1b9a808e6f">1,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzctMy0xLTEtMA_78d29314-5a0c-4ec7-9e2c-0c30e6e4fc22">319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzctNS0xLTEtMzMyMw_4ccec77d-6b2d-4fa9-9531-92cc1592ad7c">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzgtMS0xLTEtMA_581c72db-1b20-4377-911d-af5a770d1c96">491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzgtMy0xLTEtMA_4b9319c3-56fc-49f7-95df-11bb983da9a7">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzgtNS0xLTEtMzMyMw_ffc97d53-6ca0-4a7e-a29e-a990fc8c65a9">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzktMS0xLTEtMA_fe05601b-23e6-45f6-96ba-93e9844a8fdb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzktMy0xLTEtMA_d16c76bd-f4a4-4e13-952a-562c30189459">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzktNS0xLTEtMzMyMw_52df7453-0b2c-436a-96c8-75b5067bb5bf">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's provision for income taxes are included within other income (expense) on the statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTc_904b9265-60e6-40f2-b4ff-abf28b28e16d" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2020 and 2019 consist of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzMtMS0xLTEtMA_0aef361e-1dcd-4a24-866b-f57e5f997815">63,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzMtMy0xLTEtMA_65bf43e7-35bf-42d0-987f-75fd81dd4eb6">44,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzQtMS0xLTEtMA_aed01b51-55b3-4cdf-8f5a-72187d7f221d">7,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzQtMy0xLTEtMA_4290465c-7e5b-43f2-825b-760a1edd476d">5,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized start-up costs/Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzUtMS0xLTEtMA_68e08d8a-73e0-4e7b-8b84-91f16f214d4a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzUtMy0xLTEtMA_603bfa4d-2fb1-4ebb-9e07-79b8229e1e93">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzYtMS0xLTEtMA_4fad98c8-6310-4352-945b-dbcd42cdd95d">2,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzYtMy0xLTEtMA_431a6ddd-a139-4d04-90d2-b943bc100dd4">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzctMS0xLTEtMA_efe9e30c-9ba3-4373-96f1-c5fda42ed217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzctMy0xLTEtMA_5862febc-29f3-477b-ac39-4b043871248b">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzgtMS0xLTEtMA_bdbf0847-f785-4c64-bd57-d77b8550199b">1,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzgtMy0xLTEtMA_2c18cbd4-0343-429f-9dc5-ec916289a3da">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="silk:DeferredTaxAssetsOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzktMS0xLTEtMA_3de6edcc-3eb7-4772-8242-f7c5384d8beb">935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="silk:DeferredTaxAssetsOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzktMy0xLTEtMA_be4072f4-48ec-4439-80c2-ee9fa1c62eab">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEwLTEtMS0xLTQ5MTU_c2d1ec24-f5bd-4a07-9e07-f55e6ab08246">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEwLTMtMS0xLTQ5MTU_7d5f5fda-74bc-4dd6-b292-ca070db44616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEwLTEtMS0xLTA_8c56e91e-73ad-4de9-9616-16696faf26dc">76,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEwLTMtMS0xLTA_bb4b60fc-c869-40d9-8cc4-8b21697c3586">53,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzExLTEtMS0xLTA_2e319846-ba90-4611-906e-6fd2e31f2189">75,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzExLTMtMS0xLTA_0749e3f2-999f-403f-a34d-a70d25733893">53,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEzLTEtMS0xLTA_384b6273-9019-4e5f-b1e9-fc8685198574">707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEzLTMtMS0xLTA_576a7fdc-a09d-4cbc-8a41-2c2f9507ac67">862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE1LTEtMS0xLTQ5MjQ_7ed2645d-5f06-4bb7-b25d-cff4c49d97d1">216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE1LTMtMS0xLTQ5MjQ_5004c80e-5731-420b-8928-04c583b4d281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE0LTEtMS0xLTA_86196b0f-58f0-436c-a769-8d05bb83cc6b">923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE0LTMtMS0xLTA_14edf7f0-a45c-41c8-9235-a31632787078">862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE1LTEtMS0xLTA_2167e83e-d2a8-4ae9-aa46-d1e4d4c0c769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE1LTMtMS0xLTA_a7679ea4-3290-4711-867a-9c5d245fe564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.  Management believes it is more likely than not that the deferred tax assets will not be realized; accordingly, a valuation allowance has been established on U.S. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><ix:continuation id="i7856c3b4c3474fad9c0a3823368cabfb"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net deferred tax assets.  The valuation allowance increased $<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzEwNjc_6fdbac1d-62fd-42f2-819e-84e5ebb7bc32">22,163,000</ix:nonFraction> during the year ended December&#160;31, 2020 and increased by $<ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzExMTI_7c9e1776-8ffd-46f4-b29b-831d85a95eab">12,826,000</ix:nonFraction> during the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company had net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i0efe8bfdcede4d06a33afef06da15dc1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzEyMTg_f510583b-ea0c-47af-a740-739d039b3057">241,908,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib74c8c93648e47c981153a6846f18a61_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzEyMjU_5db78322-d2b6-4d4c-b4af-2d072e48d3db">209,771,000</ix:nonFraction> for federal and state income tax purposes, respectively.  The federal and state net operating loss carryforwards begin to expire in 2027 and 2028, respectively.  Federal NOL carryforwards generated in tax years beginning in 2018 are not subject to expiration.  Federal NOLs that arose on or after January 1, 2018 can be carried forward indefinitely against future income, but can only be used to offset a maximum of <ix:nonFraction unitRef="number" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="2" name="silk:OperatingLossCarryforwardOffsetMaximumPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzE2NDQ_d8d962aa-961f-41e2-b1fc-a295d61123ec">80</ix:nonFraction>% of the Company's federal taxable income in any year.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code and similar provisions under state law.  Federal tax legislation enacted in December 2017, commonly known as the Tax Cuts and Jobs Act, contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes.  A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders, who own at least 5% of the Company&#8217;s stock, increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period.  The Company may have previously experienced, and may in the future experience, one or more Section 382 &#8220;ownership changes,&#8221; including in connection with the Company&#8217;s initial public offering.  If so, the Company may lose some or all of the tax benefits of its NOLs and tax credits.  The extent of such limitations for prior years, if any, has not yet been formally determined.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i1ee605997eef429381c095e0eaf512c5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzI4NzA_a55a8fea-48d8-47b1-a9bb-de689b5b701a">6,275,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2e58304a7fe546fa982e73d2e64be31d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzI4Nzc_31d5f038-a3f7-453c-b6ac-b133d66665c8">3,463,000</ix:nonFraction> of federal and state research and development credit carryforwards, respectively.  If not utilized, the federal credits will expire beginning in 2027.  The California Research and Development credits can be carried forward indefinitely.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzMxNDM_f7f10208-9821-4ffe-8125-a643c9073f17">2,019,000</ix:nonFraction> of unrecognized tax benefits.  The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized would increase or decrease within twelve months of the year ended December&#160;31, 2020. If recognized, $<ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzMzODY_f44d314e-57f1-45fb-b633-9f4610d75ec5">0</ix:nonFraction> would affect the effective tax rate.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense.  There was <ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM1NDE_504c2a63-297c-499b-b10a-3d2da64f04cf"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM1NDE_c281e0e2-b725-46e0-92d9-8710e2afc580"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM1NDE_f37b2916-b72e-4e33-8ac1-a3b0ef9a0131">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> such expense recorded during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTg_bfe0a3e3-b370-4ffb-b642-b73587848cef" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the unrecognized tax benefits from January 1, 2018 to December&#160;31, 2020 is as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"><tr><td style="width:1.0%"></td><td style="width:59.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.855%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at the beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzItMS0xLTEtMA_0b0b7810-4191-4e91-a68d-20478831cdf9">1,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzItMy0xLTEtMA_bbdaac9e-2b57-484a-bb23-5575930f6450">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzItNS0xLTEtMzM2Mg_1099a0f2-66a4-4754-b5d0-9d439f8cbd08">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current years&#8217; tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzMtMS0xLTEtMA_2c0a8b45-ea34-4a41-ac79-069340873e41">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzMtMy0xLTEtMA_4337d783-582c-47e1-8fb8-c0907e83c7f3">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzMtNS0xLTEtMzM2Mg_142e6c9d-4c16-4d8d-8c40-212a85aa184a">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior years&#8217; tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzQtMS0xLTEtMA_4a88eb16-ca15-4527-96c3-4473ae46f63e">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzQtMy0xLTEtMA_f1f27710-7b69-427e-864e-31fab517d3be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzQtNS0xLTEtMzM2Mg_ac2c4d64-478e-4685-a5ad-83d273e50a3e">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzUtMS0xLTEtMA_97743374-322c-4350-adc6-89e2c4e5a2e8">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzUtMy0xLTEtMA_dd13b5fd-eaf8-45f5-ae82-98be974a16b9">1,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzUtNS0xLTEtMzM2Mg_da471485-0d56-4880-bd87-f8a0abc84815">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has no federal or state tax examinations in progress nor has it had any federal or state tax examinations since its inception.  As a result of the Company&#8217;s net operating loss carryforwards, all of its tax years are subject to federal and state tax examination.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_121"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzQxMDg_ae0e6156-8659-4699-99c7-14f8633e1954" continuedAt="ic127d7b9a687403989dd6b58a06d45ee" escape="true">Acquisition of Variable Interest Entity - NeuroCo</ix:nonNumeric></span></div><ix:continuation id="ic127d7b9a687403989dd6b58a06d45ee"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2014, the Board of Directors of the Company approved the sale of certain intellectual property of Silk Road Medical, Inc., to a newly incorporated entity, NeuroCo, Inc.  In consideration for the intellectual property, a promissory note was executed between the two parties for the principal sum of $<ix:nonFraction unitRef="usd" contextRef="ic3bb7213b7c542eb8d9d50fda0c137d5_I20141231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzM2OQ_c743866c-8b71-4540-a416-43fa0cfbf5e3">498,000</ix:nonFraction> with an interest rate of <ix:nonFraction unitRef="number" contextRef="ic3bb7213b7c542eb8d9d50fda0c137d5_I20141231" decimals="INF" name="silk:NotesReceivableRelatedPartiesInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzM5Nw_ae0d241a-e714-4fd7-b9f3-b294a90304df">2.74</ix:nonFraction>% per annum, payable on the earlier of <ix:nonNumeric contextRef="if9c1f3c48bdb4a6ea8c16f7a38160b11_D20140101-20141231" format="ixt-sec:duryear" name="silk:NotesReceivableRelatedPartiesTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzQzNw_28d558fa-21d8-4dff-a612-83de37235903">10</ix:nonNumeric> years from the date of promissory note, or upon the occurrence of an event of default.  The intellectual property transfer was recorded at its carrying value of zero as of December&#160;31, 2014.  During 2015 NeuroCo issued $<ix:nonFraction unitRef="usd" contextRef="i3380644612b74549867fb107a4a32b56_D20150101-20151231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzY1Mw_c080f3a1-befc-4281-890f-8977930cb4ed">154,000</ix:nonFraction> in common stock to stockholders of the Company.  During the year ended December 31, 2018, NeuroCo issued common stock upon the exercise of stock options.  These common stock issuance amounts, as they are related to non-controlling investors, were reported as non-controlling interests in subsidiary in the Company&#8217;s financial statements and are offset by NeuroCo losses consolidated by the Company.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, NeuroCo incurred research and development related expenses paid for by the Company which were added into the original promissory note.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had identified NeuroCo as a VIE of which the Company is the primary beneficiary.  Pursuant to the accounting guidance for consolidating VIEs the main consideration was given to the fact that the amount of total equity investment at risk is not sufficient to permit NeuroCo to finance its activities without additional subordinated financial support.  Additionally, NeuroCo and Silk Road Medical had the same Board of Directors and senior management composition, determining the Company to have the power to direct the activities that most significantly impact NeuroCo&#8217;s economic performance and the obligation to absorb losses and the right to receive benefits.  Accordingly, the financial results of NeuroCo were included in the Company&#8217;s financial statements.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2018, the Company and NeuroCo entered into the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) pursuant to which the Company acquired all assets and assumed all liabilities of NeuroCo (the &#8220;Merger&#8221;).  The Merger closed on the same day (the &#8220;Closing&#8221;) and was consummated through a stock-for-stock transaction based on the relative values of the Company&#8217;s and NeuroCo&#8217;s equity.  In consideration for <ix:nonFraction unitRef="number" contextRef="i326ed72d5faa4423a7380a120ab921a4_I20181217" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzI0MDQ_52ad7ad9-b8d2-4110-9744-14ad0dffd1c3">100</ix:nonFraction>% equity interest of NeuroCo, the Company issued <ix:nonFraction unitRef="shares" contextRef="i6dca7000583a43869c1389cf6ac8d3d2_D20181217-20181217" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzI0NTQ_623ff30a-b032-4350-ba81-7154ae61fbd2">33,462</ix:nonFraction> shares of its common stock and the above promissory note in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i6dca7000583a43869c1389cf6ac8d3d2_D20181217-20181217" decimals="-3" format="ixt:numdotdecimal" name="silk:BusinessCombinationConsiderationTransferredNotesPayableForgiven" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzI1NDU_0b015cfb-7acd-481f-92af-fa95df6effdb">1,600,000</ix:nonFraction> as of the Closing was settled and canceled.  As a result of the Merger, NeuroCo merged into the Company with the Company being the surviving corporation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company already controlled and consolidated NeuroCo and retained the control over NeuroCo&#8217;s business after the Merger, the Company accounted for the acquisition of equity interest in NeuroCo as an equity transaction.  Therefore, the Company did not recognize a gain or loss in its net loss or comprehensive loss for acquisition of NeuroCo.  As the carrying amount of the non-controlling interest as of the Closing was <ix:nonFraction unitRef="usd" contextRef="i4ea6234882cf424bb9e6d52bf97c9471_I20181217" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzMxMjc_c926f8a8-35c8-434d-8ebc-b536f52e74e0">zero</ix:nonFraction>, the Company recorded the consideration paid as a decrease to the Company&#8217;s additional paid-in capital within stockholder&#8217;s equity. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Merger, the Company assumed NeuroCo&#8217;s 2015 Equity Incentive Plan (the &#8220;NeuroCo Plan&#8221;) along with all of NeuroCo&#8217;s rights and obligations under the NeuroCo Plan, except that the number of shares and exercise price of the assumed options have been adjusted based on the Merger exchange ratio of the Company&#8217;s common stock and NeuroCo&#8217;s common stock.  Similarly, the Company assumed outstanding warrants to purchase NeuroCo&#8217;s common stock such that the number of shares and exercise price of the assumed warrants have been adjusted based on the Merger exchange ratio of the Company&#8217;s common stock and NeuroCo&#8217;s common stock.  The options and warrants to purchase shares of the Company&#8217;s common stock were fully vested upon issuance, as they were replacing fully vested options and warrants to purchase NeuroCo common stock.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_124"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:DefinedContributionPlanDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzY4MQ_162fe4a7-14e9-411e-a6ee-8f89728d5bf5" continuedAt="ib38424678f4c4991af390c663b4c24de" escape="true">401(k) Plan</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib38424678f4c4991af390c663b4c24de">The Company has a qualified retirement plan under section&#160;401(k)&#160;of the Internal Revenue Code (&#8220;IRC&#8221;) under which participants may contribute up to <ix:nonFraction unitRef="number" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzE2OQ_f0bd91a7-8158-4958-8c51-a28fd482a143">90</ix:nonFraction>% of their eligible compensation, subject to maximum deferral limits specified by the IRC.  The Company may make a discretionary matching contribution to the 401(k)&#160;plan and may make a discretionary employer contribution to each eligible employee each year.  Through December 31, 2019, the Company has made <ix:nonFraction unitRef="usd" contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzQ3Nw_95fd5649-9e64-4bdb-b804-d5817580356c">no</ix:nonFraction> contributions to the 401(k)&#160;plan.  Beginning in January 2020, the Company started matching employees' contributions to the 401(k) plan at <ix:nonFraction unitRef="number" contextRef="i74e220b1dfe342f2bad86c21ce171b0e_D20200101-20200101" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzYxOA_077c154a-bccc-41d6-9f3e-a5ada21fc0e1">50</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="i74e220b1dfe342f2bad86c21ce171b0e_D20200101-20200101" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzYzNA_1bf681ca-733b-4f41-9adc-e0ee73505b42">5</ix:nonFraction>% of compensation deferred to the 401(k) plan.  The Company's matching contributions were $<ix:nonFraction unitRef="usd" contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzEwOTk1MTE2Mjg2OTQ_617d8290-e5c7-4fba-ab51-05f1037d5f2f">959,000</ix:nonFraction> for the year ended December 31, 2020.</ix:continuation></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_127"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzY5Mw_e07b9aab-a88a-41c5-a632-5d100d89413d" continuedAt="i7bab29495eb54e198055f242286f72a2" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i7bab29495eb54e198055f242286f72a2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Equity Incentive Plan</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the number of shares of common stock authorized for issuance under the 2019 Plan was automatically increased by <ix:nonFraction unitRef="shares" contextRef="ibaa4295aab3c4fd19f5369890a74eb95_I20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2Mjg2NDI_d1feeb32-7c3b-4d6b-a83d-1fd974296e37">1,369,985</ix:nonFraction> shares, which was ratified by the Company's Board of Directors in January 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company&#8217;s Board of Directors approved the grant of options to purch</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ase <ix:nonFraction unitRef="shares" contextRef="ic3233352a710471b8cc9cd69d34e703f_D20210201-20210228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzczMDY_7167eab9-1d47-43af-b183-b1a585d45ff0">19,305</ix:nonFraction> shares of common stock under the 2019 Plan with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3233352a710471b8cc9cd69d34e703f_D20210201-20210228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzczMTA_935f6e9f-e75e-4a83-b493-d045f223bdf5">59.33</ix:nonFraction> per share. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the number of shares of common stock authorized for issuance under the 2019 ESPP was automatically increased by <ix:nonFraction unitRef="shares" contextRef="i01975501aeed437d860ef21eff36403e_I20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2Mjg2NTI_8594e0b0-18e0-49c5-9d0a-34a815e3613f">342,496</ix:nonFraction> shares, which was ratified by the Company's Board of Directors  in January 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voluntary Recall</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January and February 2021, the Company announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by one of its third-party suppliers, Cordis. The decision to recall these lots was based on complaints received about tips detaching from the stent delivery system as well as internal testing that the Company conducted. The Company believes the root cause of the detachment was a single operator at Cordis, who, over a specific timeframe, produced lots in which a small number of units were not reliably manufactured to specification.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the voluntary recall the Company reflected a current asset of $<ix:nonFraction unitRef="usd" contextRef="i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzY4NTA_71431060-b5c1-4717-8d35-63233d9df09d">4,160,000</ix:nonFraction> on its balance sheet as of December 31, 2020, relating to the replacement lots and other direct costs to be received from Cordis. This amount includes $<ix:nonFraction unitRef="usd" contextRef="i39997c7638c9433ca55684c8301b703a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzY4NjA_ea93ca83-b81c-4ef9-a5de-7fe8b2b29732">2,227,000</ix:nonFraction> of recalled ENROUTE stent delivery systems held in the Company's inventory as of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i79e280b94b7942cf91af6b3df5b509da_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzY4NzA_abb882e8-c83c-4255-9189-5b93db46d159">1,696,000</ix:nonFraction> of ENROUTE stent delivery systems in the process of being returned from its customers and other direct costs of $<ix:nonFraction unitRef="usd" contextRef="i637453fe4b3642f9aa11f791b415ea8c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzcwNjE_e693d25f-a79a-4b11-b627-37b17698cf41">237,000</ix:nonFraction>. In addition, the Company established an accrual of $<ix:nonFraction unitRef="usd" contextRef="i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzY4ODM_90a6ee67-499a-4bc7-9b07-29ed86584c7a">1,696,000</ix:nonFraction> relating to its obligation to provide replacement ENROUTE stent delivery systems to its customers as of December 31, 2020.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Bonus to be Settled in Shares</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, the Company's Compensation Committee of the Board of Directors approved that the bonus for certain employees would partially be paid in RSUs.  Actual shares were awarded to employees on February 26, 2021 as a fixed dollar amount converted to <ix:nonFraction unitRef="shares" contextRef="id4fa9083290c443aa2e74fa476c35c40_D20210226-20210226" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzczNjY_51b77ff4-9566-4c4c-aeeb-ab56b364b390">14,952</ix:nonFraction> fully vested RSUs using the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trailing <ix:nonNumeric contextRef="id4fa9083290c443aa2e74fa476c35c40_D20210226-20210226" format="ixt-sec:durday" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzMyOTg1MzQ4OTQ1OTE_6af59dac-d6a0-423e-a27b-c1da64a32ad4">30</ix:nonNumeric>-day average stock price.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90ZXh0cmVnaW9uOmRlMTU4ZDY2OTBhNDQ0ZTE5NWZhNDRmNmIwN2QyYTg5XzE5OQ_d498d79b-e3dc-4c92-90ea-8ac53f96e4eb" continuedAt="i54501c6930c64b28a323d4d69601a12b" escape="true">Quarterly Financial Information (unaudited)</ix:nonNumeric></span></div><ix:continuation id="i54501c6930c64b28a323d4d69601a12b"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90ZXh0cmVnaW9uOmRlMTU4ZDY2OTBhNDQ0ZTE5NWZhNDRmNmIwN2QyYTg5XzIwMA_b80ebe70-a123-441d-be56-7389a6158e11" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected unaudited quarterly financial data for the years ended December&#160;31, 2020, and 2019 (in thousands, except per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzItMi0xLTEtMzM4MA_a0dfe6a9-35ee-461e-9ce2-044f71a20f72">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzItNC0xLTEtMzM4MA_76978ca8-b862-41b2-81d6-08d3f05e684b">20,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzItNi0xLTEtMzM4MA_824845bc-4d83-4e29-b500-e0b3c23e29d3">15,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzItOC0xLTEtMzM4MA_353d06ca-9378-427b-a508-802e73dccc8a">18,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzMtMi0xLTEtMzM4MA_bcc532cd-18b3-48cc-9f80-0395992d4c2a">15,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzMtNC0xLTEtMzM4MA_aa1c1f10-dda7-4352-9ad3-8b41225163ad">14,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzMtNi0xLTEtMzM4MA_c225002a-fb48-4819-8c56-d9e023bbac38">9,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzMtOC0xLTEtMzM4MA_52e68a44-4a01-474e-a616-955330344b31">13,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzQtMi0xLTEtMzM4MA_3796708d-c0be-4073-b1b1-6739c90767e1">16,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzQtNC0xLTEtMzM4MA_adceeb20-8a50-4389-954b-14e5141dad66">10,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzQtNi0xLTEtMzM4MA_90e78a70-1c90-41ac-99f2-f659e41cdf87">10,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzQtOC0xLTEtMzM4MA_1955d422-65ca-45e4-bd18-52ddaf55b800">9,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzUtMi0xLTEtMzM4MA_d6d2cd8b-2e14-4f39-9c18-c42418fd9895">0.49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzUtNC0xLTEtMzM4MA_57ff5b87-550d-4eda-bfb4-c690e8c822a0">0.31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzUtNi0xLTEtMzM4MA_10ace032-3e2d-455c-9283-7d599a9cb372">0.32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzUtOC0xLTEtMzM4MA_8af2a2af-780a-485d-94e8-ebbbd04808d8">0.32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzItMi0xLTEtMA_40be8ad2-454c-4aa2-bc62-0441332273a7">18,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzItNC0xLTEtMA_2ea96973-0a8e-41fd-8749-884565c75e15">17,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzItNi0xLTEtMA_89db2fce-cb86-4b02-af7f-4ed01b3d2ae3">14,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief509a5e508844398122e436481d4a37_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzItOC0xLTEtMA_4525ada7-0a89-4059-b14c-735e1ed380b7">12,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzMtMi0xLTEtMA_b4cc096e-c7d4-4096-840f-77f353ed555d">13,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzMtNC0xLTEtMA_a67805ef-59cf-411d-883c-8ccb63facc2d">12,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzMtNi0xLTEtMA_1a8aefed-9c3e-4278-a359-9c04dc217f9c">11,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief509a5e508844398122e436481d4a37_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzMtOC0xLTEtMA_0882ebb8-d291-40b6-af17-f950486b126c">9,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzQtMi0xLTEtMA_62d44f8e-24e8-4468-b377-4ab908c12e22">8,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzQtNC0xLTEtMA_3d90a59e-7c7d-4b5e-8e47-c011101a25e6">8,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzQtNi0xLTEtMA_4657bfad-be7a-4f77-a9b0-90e8ac48f84f">11,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief509a5e508844398122e436481d4a37_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzQtOC0xLTEtMA_59dfd556-421a-4b5b-9150-da14112b209c">24,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzUtMi0xLTEtMA_b6ce638f-9bf0-4ff2-8af2-a3b90376701b">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzUtNC0xLTEtMA_11e0b652-c6bd-4eb3-8fdf-a17ec3d46d67">0.26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzUtNi0xLTEtMA_f2933e42-7fc2-4fe3-b27c-c7a7e33294d2">0.42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief509a5e508844398122e436481d4a37_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzUtOC0xLTEtMA_d1fcf081-ef7c-4f2e-953d-05932b3d6f67">20.12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_136"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, refers to controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to a company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2020, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2020 based on the framework in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2020 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remediation of Previously Identified Material Weaknesses in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously identified and disclosed two material weaknesses in our internal control over financial reporting for the year ended December 31, 2017 relating to the following:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We did not maintain a sufficient complement of resources with an appropriate level of accounting knowledge, experience, and training, commensurate with our structure and financial reporting requirements.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We did not appropriately design and implement controls over the review and approval of manual journal entries and the related supporting journal entry calculations resulting in inappropriate segregation of duties over manual journal entries.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the oversight of senior management and our audit committee, we began the implementation of certain of these measures in 2018 and continued to develop remediation plans and implemented additional measures throughout 2019 and 2020.  We have remediated the material weaknesses through the following actions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the hiring of personnel with technical accounting and financial reporting knowledge, experience, and training.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of accounting and financial reporting procedures and systems to improve the completeness, timeliness and accuracy of our financial reporting and disclosures, including controls over manual journal entries.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has completed its design, testing and evaluation of the enhanced and newly implemented internal controls and determined that as of December 31, 2020, the controls were designed and operating effectively and have been operating effectively for a sufficient period for management to conclude that the material weaknesses have been remediated.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_139"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART III</span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_145"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_148"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.<br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_154"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_157"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_163"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;Exhibits and Financial Statement Schedule</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Financial Statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements included in "Index to Financial Statements" in Part II, Item 8 are filed as part of this registration statement on Form 10-K.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.24pt"><ix:nonNumeric contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90ZXh0cmVnaW9uOjM2NzY2YzU4YTQ5MDRhZGM5MmZlYzlhZGJlNjBkZTg0XzMyOTg1MzQ4ODQwNzM_ea49f775-48fd-455f-9c82-565e0c35be60" continuedAt="ie592937d979b4326958545555b6f9af4" escape="true">Financial Statement Schedule.</ix:nonNumeric></span></div><ix:continuation id="ie592937d979b4326958545555b6f9af4"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. The table below presents Schedule II, Valuation and Qualifying Accounts, detailing the activity of the allowance for doubtful accounts receivable for the years ended December 31, 2020, 2019 and 2018 (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Write offs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218af6b8a4044434bc70398d3d719486_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzItMi0xLTEtNTQxMA_e8ae6836-b680-4a0a-a601-179e35d6f1d8">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d98a257f74a444e815e2acdecdd06e8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzItNC0xLTEtNTQxMA_43fe65ba-f4c5-4c4d-a551-f72fdb9ccf6c">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d98a257f74a444e815e2acdecdd06e8_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzItNi0xLTEtNTQxMA_7e6818cc-bffc-4910-beaa-89c3fd035634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4bfdb1605af43cb8614f33f8d1a6537_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzItOC0xLTEtNTQxMA_0dad686b-bb04-4f0c-a291-08c5d8b1dedb">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401d30b2e994f16b50e95b7e08d7413_I20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzMtMi0xLTEtNTQxMA_85f39eed-94bd-4760-99a4-7d1c6c5185e5">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe63293076b44c03b2d249cf8f39228c_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzMtNC0xLTEtNTQxMA_be1da27e-da7a-4763-ad02-ae6d9c4045f6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe63293076b44c03b2d249cf8f39228c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzMtNi0xLTEtNTQxMA_9338ee25-224f-4190-ae1e-a3a128454b51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218af6b8a4044434bc70398d3d719486_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzMtOC0xLTEtNTQxMA_4ae99812-1fd9-4d5f-a79e-940a390ba899">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515fd7b45a0d4244a919c02bb006219a_I20171231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzQtMi0xLTEtNTQxMA_9692cae6-55f9-463a-b66f-a38a261a6244">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1814d8a10cb43efae417d1231483bf2_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzQtNC0xLTEtNTQxMA_6a9a8712-edd3-4b7c-802d-0ed995944bad">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1814d8a10cb43efae417d1231483bf2_D20180101-20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzQtNi0xLTEtNTQxMA_5b18c763-6bf7-43c1-bf8a-f8893f6aefbe">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401d30b2e994f16b50e95b7e08d7413_I20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzQtOC0xLTEtNTQxMA_8c27e2e7-0e65-4426-ac83-fce20ebe7f25">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Exhibits.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Exhibit&#160;Index immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement on Form 10-K, which Exhibit&#160;Index is incorporated herein by reference.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished<br/>Herewith</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019004024/srmexhibit31.htm">3.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019004024/srmexhibit31.htm">Amended and Restated Certificate of Incorporation of the registrant</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-38847</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/8/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019004024/srmexhibit32.htm">3.2</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019004024/srmexhibit32.htm">Amended and Restated Bylaws of the registrant</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-38847</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/8/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit41followons-.htm">4.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit41followons-.htm">Specimen Common Stock Certificate of the registrant</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit42followons-.htm">4.2</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit42followons-.htm">Amended and Restated Registration Rights Agreement by and among the registrant and certain stockholders, dated July 7, 2017</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit43followons-.htm">4.3</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit43followons-.htm">Amended and Restated Stockholders Agreement by and among the registrant and certain stockholders, dated July 7, 2017</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit44followons-.htm">4.4</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit44followons-.htm">Amendment to the Amended and Restated Registration Rights Agreement, dated March 21, 2019</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk2020ex45descriptionofr.htm">4.5</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk2020ex45descriptionofr.htm">Description of the registrant&#8217;s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit101followons.htm">10.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit101followons.htm">Form of Indemnification Agreement for directors and executive officers</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit102followons.htm">10.2+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit102followons.htm">2007 Stock Plan, as amended, and related form agreement</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit103followons.htm">10.3+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit103followons.htm">2019 Employee Stock Purchase Plan and related form agreements</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit104followons.htm">10.4+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit104followons.htm">Executive Incentive Compensation Plan</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit105followons.htm">10.5+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit105followons.htm">2019 Equity Incentive Plan and related form agreements</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit106followons.htm">10.6#</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit106followons.htm">Supply Agreement by and between the registrant and Cordis Corporation, dated October 21, 2011, as amended by the Amendment dated March 12, 2012, the Second Amendment to Supply Agreement dated July 12, 2012, the Third Amendment to Supply Agreement dated April 19, 2013 and the Fourth Amendment to Supply Agreement dated April 9, 2018</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit107followons.htm">10.7#</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit107followons.htm">License Agreement by and between the registrant and Cordis Corporation, dated December 17, 2010</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit108followons.htm">10.8</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit108followons.htm">Quality Assurance Agreement by and among the registrant and Lake Region Medical and affiliates, dated May 4, 2015</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit109followons.htm">10.9#</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit109followons.htm">Amended and Restated Manufacturing and Supply Agreement by and between the registrant and Galt Medical Corporation, dated January 10, 2018</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1010-followo.htm">10.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1010-followo.htm">Term Loan Agreement by and among the registrant, certain affiliates of CRG Partners III L.P. as lenders and certain subsidiary guarantors, dated October 13, 2015, as amended by Amendment No. 1 to Term Loan Agreement dated January 3, 2017, Amendment No. 2 to Term Loan Agreement dated June 22, 2017, Amendment No. 3 to Term Loan Agreement dated November 30, 2017, Amendment No. 4 to Term Loan Agreement dated June 25, 2018, Amendment No. 5 to Term Loan Agreement dated September 4, 2018, Amendment No. 6 to Term Loan Agreement dated November 14, 2018 and effective as of October 31, 2018, and Amendment No. 7 to Term Loan Agreement dated June 11, 2019</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1011followon.htm">10.11</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1011followon.htm">Lease Agreement by and between the registrant and Hanover Properties Ltd., dated November 30, 2017</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1012followon.htm">10.12</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1012followon.htm">Director Offer Letter for Donald Zurbay dated as of February 6, 2018</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1013followon.htm">10.13+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1013followon.htm">Confirmatory Employment Letter between the registrant and Erica Rogers, dated as of March 21, 2019</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1014followon.htm">10.14+</a></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1014followon.htm">Confirmatory Employment Letter between the registrant and Lucas Buchanan, dated as of March 21, 2019</a></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1015followon.htm">10.15+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1015followon.htm">Confirmatory Employment Letter between the registrant and Richard Ruedy, dated as of March 21, 2019</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1016followon.htm">10.16+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1016followon.htm">Confirmatory Employment Letter between the registrant and Andrew Davis, dated as of March 21, 2019</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1017followon.htm">10.17+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1017followon.htm">Change in Control and Severance Agreement between the registrant and Erica Rogers, dated as of March 21, 2019</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1018followon.htm">10.18+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1018followon.htm">Change in Control and Severance Agreement between the registrant and Lucas Buchanan, dated as of March 21, 2019</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1019followon.htm">10.19+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1019followon.htm">Change in Control and Severance Agreement between the registrant and Richard Ruedy, dated as of March 21, 2019</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1020followon.htm">10.20+</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1397702/000162828019010142/srmexhibit1020followon.htm">Change in Control and Severance Agreement between the registrant and Andrew Davis, dated as of March 21, 2019</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233044</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1397702/000139770220000040/silkroad-8xkaexredactedloa.htm">10.21</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1397702/000139770220000040/silkroad-8xkaexredactedloa.htm">Loan and Security Agreement, dated as of October 29, 2020, by and between Silk Road Medical, Inc. and Stifel Bank.</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K/A</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-230045</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/4/2020</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk202010-kex231consent.htm">23.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk202010-kex231consent.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_172">24.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_172">Power of Attorney</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk2020ex311certification.htm">31.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk2020ex311certification.htm">Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk2020ex312certification.htm">31.2</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk2020ex312certification.htm">Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk2020ex321certification.htm">32.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="silk2020ex321certification.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document<br/></span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a grant of confidential treatment.  The omitted information has been filed separately with the SEC.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i26a0ed258dae4ee5a9edb8a3b963e1bf_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i26a0ed258dae4ee5a9edb8a3b963e1bf_172"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SILK ROAD MEDICAL, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Erica J. Rogers</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erica J. Rogers</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lucas W. Buchanan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lucas W. Buchanan</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Operating Officer and Chief Financial Officer </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Erica J.  Rogers and Lucas W.  Buchanan, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated: </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Erica J. Rogers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 6.62pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erica J. Rogers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lucas W. Buchanan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 6.62pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer and Chief Financial Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lucas W. Buchanan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rick D. Anderson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 6.62pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rick D. Anderson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kevin J. Ballinger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 6.62pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin J. Ballinger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Tony M. Chou</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 6.62pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tony M. Chou, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jack W. Lasersohn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 6.62pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jack W. Lasersohn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elizabeth H. Weatherman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 6.62pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth H. Weatherman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald J. Zurbay</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 6.62pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donald J. Zurbay</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>silk2020ex45descriptionofr.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i397a9d185bb94b8ebe163fc5bdf2e472_1"></div><div style="min-height:51.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 4.5</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Silk Road Medical, Inc. (the &#8220;Company&#8221;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended&#58; our common stock, par value $0.001 per share.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As used in this summary, the terms &#8220;Silk Road Medical,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Silk Road Medical, Inc.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Description of Common Stock</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a description of the material terms and provisions relating to our common stock.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description is a summary that is not complete and is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation and our amended and restated bylaws, and to provisions of the Delaware General Corporation Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Copies of our amended and restated certificate of incorporation and our amended and restated bylaws, each of which may be amended from time to time, are included as exhibits to the Annual Report on Form 10-K to which this description is an Exhibit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Voting Rights</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our stockholders do not have cumulative voting rights in the election of directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, holders of a majority of the voting shares are able to elect all of the directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividends</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to preferences that may be applicable to any then outstanding convertible preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidation</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of convertible preferred stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rights and Preferences</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fully Paid and Nonassessable</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of our outstanding shares of common stock are fully paid and nonassessable.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 4.5</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-Takeover Effects or Provisions of our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and Delaware Law</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws that are in effect contain provisions that could make the following transactions more difficult&#58; acquisition of us by means of a tender offer&#59; acquisition of us by means of a proxy contest or otherwise&#59; or removal of our incumbent officers and directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stock holders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of a non-friendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delaware Anti-Takeover Statute</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to Section 203 of the General Corporation Law of the State of Delaware, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested holder&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">On or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock that is not owned by the interested stockholder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In general, Section 203 defines business combination to include the following&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 4.5</font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In general, Section 203 defines interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation or any entity or person affiliated with or controlling or controlled by such entity or person.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Undesignated Preferred Stock</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire us.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Special Stockholder Meetings</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our board of directors, the chairperson of our board of directors, or our Chief Executive Officer or President.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This provision might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our common stock to take any action, including the removal of directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Requirements for Advance Notification of Stockholder Nominations and Proposals</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Advance Notice of Stockholder Business</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a stockholder is submitting a stockholder proposal related to the business of the company, such stockholder must&#58; (i) be a stockholder of record at the time notice is given, (ii) submit the notice in a timely manner, and (iii) such business must be of a proper matter for stockholder action in accordance with our bylaws and applicable law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To be in proper written form, a stockholder&#8217;s notice related to the business of the company must contain the following items&#58; (i) a brief description of the business intended to be brought before the annual meeting, the text of the proposed business (including the text of any resolutions proposed for consideration) and the reasons for conducting such business at the annual meeting, (ii) the name and address of the stockholder proposing such business, (iii) the class and number of shares that are held of record or are beneficially held by the stockholder, (iv) whether and the extent to which any hedging activities have been entered into by or on behalf of such stockholder with respect to our securities, (v) any material interest of the stockholder in such business, (vi) a statement whether such stockholder will deliver a proxy statement or form of proxy to holders required under applicable law to carry the proposal.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Advance Notice of Director Nominations</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a stockholder is submitting a nomination in connection with an annual meeting, such stockholder must&#58; (i) be a stockholder of record at the time notice if given, and (ii) submit the notice in a timely manner.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To be in proper written form, a stockholder&#8217;s notice related to director nominations must contain the following items with respect to each nominee&#58; (i) the name, age, business address and residence address of the nominee, (ii) the principal occupation or employment of the nominee, (iii) the class and number of shares of the company that are held of record or are beneficially owned by the nominee and any derivative positions held or beneficially held by the nominee, (iv) whether and the extent to which any hedging activities have been entered into by or on behalf of the nominee with respect to our securities, (v) a description of all arrangements or understandings between or among the stockholder, any nominee or any other person or persons pursuant to which the nominations are to be made by the stockholder and (vi) a written statement executed by the nominee acknowledging and representing that the nominee intends to serve a full term on our board of directors if elected.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to the stockholder, the notice must contain the following items&#58; (i) the name and address of the stockholder proposing such business, (ii) the class and number of shares that are held of </font></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 4.5</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">record or are beneficially held by the stockholder, (iii) whether and the extent to which any hedging activities have been entered into by or on behalf of such stockholder with respect to our securities, (iv) any material interest of the stockholder in such business, and (v) a statement whether such stockholder will deliver a proxy statement or form of proxy reasonably believed by such stockholder to be necessary to elect such nominee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Elimination of Stockholder Action by Written Consent</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation and our amended and restated bylaws eliminate the right of stockholders to act by written consent without a meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result, a holder controlling a majority of our common stock would not be able to amend our amended and restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our amended and restated bylaws.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Classified Board&#59; Election and Removal of Directors</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation and amended and restated bylaws authorizes only our board of directors to fill vacant directorships, including newly created seats.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the number of directors constituting our board of directors are permitted to be set only by a resolution adopted by our board of directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These provisions prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This makes it more difficult to change the composition of our board of directors but promotes continuity of management.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors is divided into three classes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The directors in each class will serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors up for election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our amended and restated certificate of incorporation provides that directors may only be removed for cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For more information on the classified board, see the section entitled &#8220;Management&#8212;Board of Directors&#8221; in our Annual Report on Form 10-K to which this description is an Exhibit. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Exclusive Forum</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation and bylaws provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action asserting a claim against the company or any director or officer of the company arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or bylaws, or (4) any other action asserting a claim that is governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware or federal court located within the State of Delaware if the Court of Chancery does not have jurisdiction, in all cases subject to the court&#8217;s having jurisdiction over indispensable parties named as defendants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A complaint asserting a cause of action under the Securities Act may be brought in state or federal court.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to the Securities Exchange Act of 1934, or Exchange Act, only claims brought derivatively under the Exchange Act would be subject to the forum selection clause described above.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that, in connection with any action, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation and bylaws to be inapplicable or unenforceable in such action.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any person or entity purchasing or otherwise acquiring any interest in our shares of common stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</font></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 4.5</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Amendment of Charter Provisions</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least 66 2&#47;3% of the voting power of our then outstanding voting stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated bylaws may have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These provisions may also have the effect of preventing changes in our management.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exchange Listing</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is quoted on The Nasdaq Global Market under the symbol &#8220;SILK.&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Transfer Agent</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transfer agent for our common stock is American Stock Transfer &#38; Trust Company, LLC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transfer agent&#8217;s address is 6201 15th Avenue, Brooklyn, NY 11219.</font></div><div><font><br></font></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>silk202010-kex231consent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8f36a5729fba47cd955ad233a97b8493_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 23.1</font></div></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statement on Form S-3  (No. 333-238007) and S-8 (No. 333-236841 and 333-230778) of Silk Road Medical, Inc. of our report dated March 1, 2021 relating to the financial statements and financial statement schedule</font><font style="color:#ff0000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%">and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%">PricewaterhouseCoopers LLP  </font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%">San Jose, California </font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%">March 1, 2021</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>silk2020ex311certification.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ide4a9cb28fbf41a88b7845405d4e5ece_1"></div><div style="min-height:33.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Securities Exchange Act Rules 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I, Erica J. Rogers, certify that&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I have reviewed this Annual Report on Form 10-K of Silk Road Medical, Inc.&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have&#58;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:41.101%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Erica J. Rogers</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Erica J. Rogers</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March 1, 2021</font></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>silk2020ex312certification.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i534914b3249a4d248b24c7ab10ac8ed8_1"></div><div style="min-height:33.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 31.2</font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Securities Exchange Act Rules 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Lucas W. Buchanan, certify that&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I have reviewed this Annual Report on Form 10-K of Silk Road Medical, Inc.&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have&#58;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.022%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Lucas W. Buchanan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lucas W. Buchanan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Operating Officer and Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March 1, 2021</font></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>silk2020ex321certification.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4137ffd294334bb4ad7d9272ec92ff64_1"></div><div style="min-height:56.25pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 32.1</font></div></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">In connection with the Annual Report of Silk Road Medical, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">The Report, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#47;s&#47; Erica J. Rogers</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Erica J. Rogers</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Date&#58; March 1, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:62.272%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#47;s&#47; Lucas W. Buchanan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Lucas W. Buchanan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Chief Operating Officer and Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Date&#58; March 1, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:56.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>silk-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:13b527d4-ea1a-4469-9dba-fa8b61e78c7f,g:43b528fe-3601-4224-908f-a46b4c727eef-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:silk="http://silkroadmed.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://silkroadmed.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://silkroadmed.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://silkroadmed.com/role/BalanceSheets">
        <link:definition>1001002 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://silkroadmed.com/role/BalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperationsandComprehensiveLoss" roleURI="http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" roleURI="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical">
        <link:definition>1005006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FormationandBusinessoftheCompany" roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompany">
        <link:definition>2101101 - Disclosure - Formation and Business of the Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FormationandBusinessoftheCompanyDetails" roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails">
        <link:definition>2402401 - Disclosure - Formation and Business of the Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Deferred Initial Public Offering Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLeasesDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - ASC 842 Impact on Condensed Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails">
        <link:definition>2412408 - Disclosure - Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>2413409 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails">
        <link:definition>2414410 - Disclosure - Summary of Significant Accounting Policies - Advertising Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails">
        <link:definition>2415411 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails">
        <link:definition>2416412 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails">
        <link:definition>2417413 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails">
        <link:definition>2418414 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails">
        <link:definition>2419415 - Disclosure - Summary of Significant Accounting Policies - Segment and Geographical Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncements" roleURI="http://silkroadmed.com/role/RecentAccountingPronouncements">
        <link:definition>2120103 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://silkroadmed.com/role/FairValueMeasurements">
        <link:definition>2121104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://silkroadmed.com/role/FairValueMeasurementsTables">
        <link:definition>2322302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" roleURI="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails">
        <link:definition>2423416 - Disclosure - Fair Value Measurements - Recurring Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://silkroadmed.com/role/BalanceSheetComponents">
        <link:definition>2124105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsTables">
        <link:definition>2325303 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails">
        <link:definition>2426417 - Disclosure - Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails">
        <link:definition>2427418 - Disclosure - Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsNarrativeDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails">
        <link:definition>2428419 - Disclosure - Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails">
        <link:definition>2429420 - Disclosure - Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofInventoryDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails">
        <link:definition>2430421 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsPropertyPlantandEquipmentDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails">
        <link:definition>2431422 - Disclosure - Balance Sheet Components - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>2432423 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://silkroadmed.com/role/LongtermDebt">
        <link:definition>2133106 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://silkroadmed.com/role/LongtermDebtTables">
        <link:definition>2334304 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtCRGNarrativeDetails" roleURI="http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails">
        <link:definition>2435424 - Disclosure - Long-term Debt - CRG Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtStifelBankNarrativeDetails" roleURI="http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails">
        <link:definition>2436425 - Disclosure - Long-term Debt - Stifel Bank Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtFutureMaturitiesUndertheTermLoanDetails" roleURI="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails">
        <link:definition>2437426 - Disclosure - Long-term Debt - Future Maturities Under the Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://silkroadmed.com/role/CommitmentsandContingencies">
        <link:definition>2138107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesTables">
        <link:definition>2339305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseNarrativeDetails" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails">
        <link:definition>2440427 - Disclosure - Commitments and Contingencies - Lease Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesBalanceSheetInformationDetails" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails">
        <link:definition>2441428 - Disclosure - Commitments and Contingencies - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails">
        <link:definition>2442429 - Disclosure - Commitments and Contingencies - Operating Lease Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1">
        <link:definition>2442429 - Disclosure - Commitments and Contingencies - Operating Lease Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails">
        <link:definition>2443430 - Disclosure - Commitments and Contingencies - Purchase Obligation and Contingencies Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStock" roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock">
        <link:definition>2144108 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockNarrativeDetails" roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails">
        <link:definition>2445431 - Disclosure - Redeemable Convertible Preferred Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficit" roleURI="http://silkroadmed.com/role/StockholdersEquityDeficit">
        <link:definition>2146109 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitTables" roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitTables">
        <link:definition>2347306 - Disclosure - Stockholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitNarrativeDetails" roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails">
        <link:definition>2448432 - Disclosure - Stockholders' Equity (Deficit) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails" roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails">
        <link:definition>2449433 - Disclosure - Stockholders' Equity (Deficit) - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlans" roleURI="http://silkroadmed.com/role/StockOptionPlans">
        <link:definition>2150110 - Disclosure - Stock Option Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansTables" roleURI="http://silkroadmed.com/role/StockOptionPlansTables">
        <link:definition>2351307 - Disclosure - Stock Option Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansNarrativeDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails">
        <link:definition>2452434 - Disclosure - Stock Option Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansActivityUnderCompensationPlanDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails">
        <link:definition>2453435 - Disclosure - Stock Option Plans - Activity Under Compensation Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansInformationbyExercisePriceDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails">
        <link:definition>2454436 - Disclosure - Stock Option Plans - Information by Exercise Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansRSUsDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansRSUsDetails">
        <link:definition>2455437 - Disclosure - Stock Option Plans - RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansFairValueofStockOptionsDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails">
        <link:definition>2456438 - Disclosure - Stock Option Plans - Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansStockbasedCompensationDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails">
        <link:definition>2457439 - Disclosure - Stock Option Plans - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://silkroadmed.com/role/IncomeTaxes">
        <link:definition>2158111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://silkroadmed.com/role/IncomeTaxesTables">
        <link:definition>2359308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeBeforeTaxesDetails" roleURI="http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails">
        <link:definition>2460440 - Disclosure - Income Taxes - Components of Income Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUSStatutoryRateDetails" roleURI="http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails">
        <link:definition>2461441 - Disclosure - Income Taxes - Reconciliation of U.S Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails">
        <link:definition>2462442 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://silkroadmed.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2463443 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>2464444 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofVariableInterestEntityNeuroCo" roleURI="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo">
        <link:definition>2165112 - Disclosure - Acquisition of Variable Interest Entity - NeuroCo</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofVariableInterestEntityNeuroCoDetails" roleURI="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails">
        <link:definition>2466445 - Disclosure - Acquisition of Variable Interest Entity - NeuroCo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://silkroadmed.com/role/A401kPlan">
        <link:definition>2167113 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://silkroadmed.com/role/A401kPlanDetails">
        <link:definition>2468446 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://silkroadmed.com/role/SubsequentEvents">
        <link:definition>2169114 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://silkroadmed.com/role/SubsequentEventsDetails">
        <link:definition>2470447 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationunaudited" roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited">
        <link:definition>2171115 - Disclosure - Quarterly Financial Information (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationunauditedTables" roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables">
        <link:definition>2372309 - Disclosure - Quarterly Financial Information (unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationunauditedDetails" roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails">
        <link:definition>2473448 - Disclosure - Quarterly Financial Information (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccounts" roleURI="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts">
        <link:definition>2174116 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsScheduleIIDetails" roleURI="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails">
        <link:definition>2475449 - Disclosure - Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="silk_DebtInstrumentCovenantMaximumBorrowingThreshold" abstract="false" name="DebtInstrumentCovenantMaximumBorrowingThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_DebtInstrumentRateScenarioAxis" abstract="true" name="DebtInstrumentRateScenarioAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="silk_CommonStockCapitalSharesAvailableForFutureIssuance" abstract="false" name="CommonStockCapitalSharesAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_TermLoanTrancheAMember" abstract="true" name="TermLoanTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="silk_IncentiveStockOptionMember" abstract="true" name="IncentiveStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_RateScenarioTwoMember" abstract="true" name="RateScenarioTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_LossContingencyReceivableDirectCostsMember" abstract="true" name="LossContingencyReceivableDirectCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_ExercisePriceTwoMember" abstract="true" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_ExercisePriceThreeMember" abstract="true" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" abstract="false" name="WarrantsClassifiedAsLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="silk_ExercisePriceOneMember" abstract="true" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_OperatingLossCarryforwardOffsetMaximumPercent" abstract="false" name="OperatingLossCarryforwardOffsetMaximumPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_IncentiveandNonqualifiedStockOptionExercisedMember" abstract="true" name="IncentiveandNonqualifiedStockOptionExercisedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_AccruedClinicalExpensesCurrent" abstract="false" name="AccruedClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" abstract="false" name="CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum" abstract="false" name="DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_DebtInstrumentMaximumBorrowingCapacity" abstract="false" name="DebtInstrumentMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" abstract="false" name="PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="silk_VoluntaryRecallMember" abstract="true" name="VoluntaryRecallMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_IncentiveandNonqualifiedStockOptionMember" abstract="true" name="IncentiveandNonqualifiedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" abstract="false" name="DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_TwoThousandNineteenStockOptionPlanMember" abstract="true" name="TwoThousandNineteenStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" abstract="false" name="TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" abstract="false" name="DebtInstrumentCovenantLiquidityEventPaymentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_PreferredStockWarrantsMember" abstract="true" name="PreferredStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="silk_TermLoanTrancheBMember" abstract="true" name="TermLoanTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_RedeemableConvertiblePreferredStockWarrantsMember" abstract="true" name="RedeemableConvertiblePreferredStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="silk_ExercisePriceSixMember" abstract="true" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_StockIssuanceCostsIncurredButNotYetPaid" abstract="false" name="StockIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" abstract="false" name="TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_IncentiveandNonqualifiedStockOptionIssuedMember" abstract="true" name="IncentiveandNonqualifiedStockOptionIssuedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtInstrumentInterestRatePaidInKind" abstract="false" name="DebtInstrumentInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_RateScenarioOneMember" abstract="true" name="RateScenarioOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_ProvisionsForSalesReturns" abstract="false" name="ProvisionsForSalesReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember" abstract="true" name="LossContingencyReceivableInventoryExcessAndObsolescenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_RepaymentOfPaidInKindInterest" abstract="false" name="RepaymentOfPaidInKindInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_ExercisePriceFourMember" abstract="true" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_ExercisePriceFiveMember" abstract="true" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtInstrumentInterestRatePaidInCash" abstract="false" name="DebtInstrumentInterestRatePaidInCash" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_CommonStockWarrantMember" abstract="true" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions" abstract="false" name="DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_LongTermDebtUnpaidInterest" abstract="false" name="LongTermDebtUnpaidInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_NeuroCoIncMember" abstract="true" name="NeuroCoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_LossContingencyReceivableTypeAxis" abstract="true" name="LossContingencyReceivableTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="silk_LongTermDebtGrossBeforeAccretionOfClosingFees" abstract="false" name="LongTermDebtGrossBeforeAccretionOfClosingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_DebtMaximumBorrowingCapacity" abstract="false" name="DebtMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="silk_AccruedTravelExpensesCurrent" abstract="false" name="AccruedTravelExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_NotesReceivableRelatedPartiesTerm" abstract="false" name="NotesReceivableRelatedPartiesTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="silk_RepaymentsOfDebtRevenueTargetPercentage" abstract="false" name="RepaymentsOfDebtRevenueTargetPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage" abstract="false" name="NotesReceivableRelatedPartiesInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_CommonStockVotePerShare" abstract="false" name="CommonStockVotePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="silk_LoanAndSecurityAgreementMember" abstract="true" name="LoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_SuccessFeeAgreementMember" abstract="true" name="SuccessFeeAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtInstrumentCovenantDebtDefaultRate" abstract="false" name="DebtInstrumentCovenantDebtDefaultRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_NonqualifiedStockOptionsMember" abstract="true" name="NonqualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven" abstract="false" name="BusinessCombinationConsiderationTransferredNotesPayableForgiven" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_PublicStockOfferingSharesFromCompanyMember" abstract="true" name="PublicStockOfferingSharesFromCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_SecondPublicOfferingMember" abstract="true" name="SecondPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_LossContingencyReceivableInventoryHeldMember" abstract="true" name="LossContingencyReceivableInventoryHeldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_LossContingencyReceivableTypeDomain" abstract="true" name="LossContingencyReceivableTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_LossContingencyReceivableInventoryInProcessOfRecallMember" abstract="true" name="LossContingencyReceivableInventoryInProcessOfRecallMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_PublicStockOfferingSharesFromExistingShareholdersMember" abstract="true" name="PublicStockOfferingSharesFromExistingShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtInstrumentRateScenarioDomain" abstract="true" name="DebtInstrumentRateScenarioDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" abstract="false" name="CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>silk-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:13b527d4-ea1a-4469-9dba-fa8b61e78c7f,g:43b528fe-3601-4224-908f-a46b4c727eef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://silkroadmed.com/role/CoverPage" xlink:type="simple" xlink:href="silk-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheets" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5380cd88-b2a5-4b54-b4d4-01c840204074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4a556446-921f-4d14-8f16-a628f08b8c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5380cd88-b2a5-4b54-b4d4-01c840204074" xlink:to="loc_us-gaap_AccountsPayableCurrent_4a556446-921f-4d14-8f16-a628f08b8c96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1ee5a0a5-6938-43c2-bf2b-19dff38a24fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5380cd88-b2a5-4b54-b4d4-01c840204074" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1ee5a0a5-6938-43c2-bf2b-19dff38a24fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb4ff890-3d3b-4ebb-9ceb-6dbfdf556482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d78771c7-16c8-43e8-a0a5-27dd2ba026c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb4ff890-3d3b-4ebb-9ceb-6dbfdf556482" xlink:to="loc_us-gaap_Liabilities_d78771c7-16c8-43e8-a0a5-27dd2ba026c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d78c35f5-0439-4a4b-be60-db8671f5e1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb4ff890-3d3b-4ebb-9ceb-6dbfdf556482" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d78c35f5-0439-4a4b-be60-db8671f5e1e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6cd2cec1-d038-433b-95d8-f2a0f1648178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb4ff890-3d3b-4ebb-9ceb-6dbfdf556482" xlink:to="loc_us-gaap_StockholdersEquity_6cd2cec1-d038-433b-95d8-f2a0f1648178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4884183e-6559-4723-a37f-a0bd321f500c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b1b5cfe8-8fc3-44d2-9b78-ec19ef129e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4884183e-6559-4723-a37f-a0bd321f500c" xlink:to="loc_us-gaap_LiabilitiesCurrent_b1b5cfe8-8fc3-44d2-9b78-ec19ef129e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_610349d8-3435-41e2-9a18-24abae26ba4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4884183e-6559-4723-a37f-a0bd321f500c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_610349d8-3435-41e2-9a18-24abae26ba4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1826beb2-52b9-4a4f-a655-d4a0cc868217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4884183e-6559-4723-a37f-a0bd321f500c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1826beb2-52b9-4a4f-a655-d4a0cc868217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_63493363-a351-4655-86fc-f39ce6885d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_63493363-a351-4655-86fc-f39ce6885d64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_af1d37f3-8452-4ad2-b539-92129f06b89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="loc_us-gaap_LongTermInvestments_af1d37f3-8452-4ad2-b539-92129f06b89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d652a83c-79b0-40e2-acd3-1856c7027df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d652a83c-79b0-40e2-acd3-1856c7027df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9a60a239-496b-4c00-80b8-f5534a9654f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="loc_us-gaap_AssetsCurrent_9a60a239-496b-4c00-80b8-f5534a9654f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b1051ea0-9fc3-491d-a7ae-97f26042e5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53cae177-1a19-44c0-8b35-d9a208a65829" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b1051ea0-9fc3-491d-a7ae-97f26042e5c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77548b7a-9aab-42f4-87d7-da18964530e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fdf5f2b2-159e-47c0-98d4-23b7f0b87124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_77548b7a-9aab-42f4-87d7-da18964530e8" xlink:to="loc_us-gaap_PreferredStockValue_fdf5f2b2-159e-47c0-98d4-23b7f0b87124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6f90e24f-8ffc-4142-b17e-6a885a227f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_77548b7a-9aab-42f4-87d7-da18964530e8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6f90e24f-8ffc-4142-b17e-6a885a227f1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9274c20a-808a-40e0-bf4c-0f2b05315ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_77548b7a-9aab-42f4-87d7-da18964530e8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9274c20a-808a-40e0-bf4c-0f2b05315ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_12f7c940-2c11-4a5c-a207-f5c2a09d0317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_77548b7a-9aab-42f4-87d7-da18964530e8" xlink:to="loc_us-gaap_CommonStockValue_12f7c940-2c11-4a5c-a207-f5c2a09d0317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9f14dc4e-7417-4b9e-8d11-be7b3999deed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_77548b7a-9aab-42f4-87d7-da18964530e8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9f14dc4e-7417-4b9e-8d11-be7b3999deed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d7120ffa-d685-4b85-8cef-2af0d0ff2c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_b86bcee9-b7d4-473b-a7ca-c698eec84fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7120ffa-d685-4b85-8cef-2af0d0ff2c3d" xlink:to="loc_us-gaap_ShortTermInvestments_b86bcee9-b7d4-473b-a7ca-c698eec84fbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_88aefd9a-119d-4312-be05-1fe52da4f251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7120ffa-d685-4b85-8cef-2af0d0ff2c3d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_88aefd9a-119d-4312-be05-1fe52da4f251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e38310bb-7b15-4e92-9873-6fd5d7e29343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7120ffa-d685-4b85-8cef-2af0d0ff2c3d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e38310bb-7b15-4e92-9873-6fd5d7e29343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5ff19e7f-c288-459a-8115-8cc1677c1f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7120ffa-d685-4b85-8cef-2af0d0ff2c3d" xlink:to="loc_us-gaap_InventoryNet_5ff19e7f-c288-459a-8115-8cc1677c1f75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_df37657d-7dca-426a-9d15-f088802a4d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7120ffa-d685-4b85-8cef-2af0d0ff2c3d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_df37657d-7dca-426a-9d15-f088802a4d3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="silk-20201231.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dc2064cf-2055-43f1-8394-938a53b5c9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_67640b66-9427-42a6-8bc0-dc09bb5bb5f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dc2064cf-2055-43f1-8394-938a53b5c9b6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_67640b66-9427-42a6-8bc0-dc09bb5bb5f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5a0d5d15-750b-4bde-8c44-424fb0f3d449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dc2064cf-2055-43f1-8394-938a53b5c9b6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5a0d5d15-750b-4bde-8c44-424fb0f3d449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_169d01c0-f823-43cb-bed2-ef9ffa9063c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dc2064cf-2055-43f1-8394-938a53b5c9b6" xlink:to="loc_us-gaap_OperatingIncomeLoss_169d01c0-f823-43cb-bed2-ef9ffa9063c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2ae11265-db9e-4bc1-b0bb-e6e72fa3aca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dc2064cf-2055-43f1-8394-938a53b5c9b6" xlink:to="loc_us-gaap_InterestExpense_2ae11265-db9e-4bc1-b0bb-e6e72fa3aca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_45443bd1-bc80-46b2-85ce-2c8ce2f404b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dc2064cf-2055-43f1-8394-938a53b5c9b6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_45443bd1-bc80-46b2-85ce-2c8ce2f404b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4d69e4ee-c589-4933-9459-def8f80dfd57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fb4b1431-6629-43d9-9cc9-33daf3f187db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4d69e4ee-c589-4933-9459-def8f80dfd57" xlink:to="loc_us-gaap_ProfitLoss_fb4b1431-6629-43d9-9cc9-33daf3f187db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_129d7df2-73cb-43d3-b901-637387241f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4d69e4ee-c589-4933-9459-def8f80dfd57" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_129d7df2-73cb-43d3-b901-637387241f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_476c40f0-aeb9-4b82-a586-f05d1e28686a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0bbbddc0-e3fa-43fc-a306-799aa695c91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_476c40f0-aeb9-4b82-a586-f05d1e28686a" xlink:to="loc_us-gaap_NetIncomeLoss_0bbbddc0-e3fa-43fc-a306-799aa695c91e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_375d541b-7dfa-45a5-a4c1-4a87308f452c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_476c40f0-aeb9-4b82-a586-f05d1e28686a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_375d541b-7dfa-45a5-a4c1-4a87308f452c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1af056f1-842c-4999-894d-98f9ceefa7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_b4abfb4a-86d2-455c-9551-b0041a557afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1af056f1-842c-4999-894d-98f9ceefa7d9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_b4abfb4a-86d2-455c-9551-b0041a557afb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_64f51dac-33bf-4d87-aed6-218c8fa7f953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0e4b2bd3-5039-4ef6-8503-c8032ce83e16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_64f51dac-33bf-4d87-aed6-218c8fa7f953" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0e4b2bd3-5039-4ef6-8503-c8032ce83e16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_29680350-fdf9-4f10-a66e-f6bdc9fb472d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_64f51dac-33bf-4d87-aed6-218c8fa7f953" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_29680350-fdf9-4f10-a66e-f6bdc9fb472d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2ce239d1-b92b-41dd-a724-a03fb4cfa09b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_d88e595f-3c8a-4d43-9293-b7cc84cfaadd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2ce239d1-b92b-41dd-a724-a03fb4cfa09b" xlink:to="loc_us-gaap_GrossProfit_d88e595f-3c8a-4d43-9293-b7cc84cfaadd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0ff1ad12-c615-40d8-bd56-aba0f8cbca66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2ce239d1-b92b-41dd-a724-a03fb4cfa09b" xlink:to="loc_us-gaap_OperatingExpenses_0ff1ad12-c615-40d8-bd56-aba0f8cbca66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_36462f68-5cb3-4434-80bc-dd9261e53253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_03cf24f2-76bb-42c5-b001-900933b88693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_36462f68-5cb3-4434-80bc-dd9261e53253" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_03cf24f2-76bb-42c5-b001-900933b88693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e5b5db11-baf4-481e-95ac-2bdf67f6f918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_36462f68-5cb3-4434-80bc-dd9261e53253" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e5b5db11-baf4-481e-95ac-2bdf67f6f918" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="silk-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="silk-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="silk-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0eabd67b-f531-4fc9-b7d7-a7227716d53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cd88c706-8e2e-40b5-9409-6cbecc8349a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0eabd67b-f531-4fc9-b7d7-a7227716d53e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cd88c706-8e2e-40b5-9409-6cbecc8349a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01b146a5-bdd1-4d94-92bc-d04dd0f9b04e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0eabd67b-f531-4fc9-b7d7-a7227716d53e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01b146a5-bdd1-4d94-92bc-d04dd0f9b04e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3cc30c2a-5b78-44ff-8d99-2199f3ebead2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0eabd67b-f531-4fc9-b7d7-a7227716d53e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3cc30c2a-5b78-44ff-8d99-2199f3ebead2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6945512-8a11-48fd-ae19-d6990cdcf5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_59ca5f6d-c0e8-4c02-9a97-799fa0282a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6945512-8a11-48fd-ae19-d6990cdcf5d5" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_59ca5f6d-c0e8-4c02-9a97-799fa0282a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2d29b5fa-f17c-4035-b853-cd0dfbf98091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6945512-8a11-48fd-ae19-d6990cdcf5d5" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2d29b5fa-f17c-4035-b853-cd0dfbf98091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efd6530c-3646-400e-a67c-c00f9294f5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6945512-8a11-48fd-ae19-d6990cdcf5d5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efd6530c-3646-400e-a67c-c00f9294f5d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_c6c1d845-04b7-4e3b-bfd4-37a62f992cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6945512-8a11-48fd-ae19-d6990cdcf5d5" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_c6c1d845-04b7-4e3b-bfd4-37a62f992cf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b26f892e-93a8-43d0-9d68-073f4588c6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_cd414c94-32fb-44c3-bdc2-4a19b9389753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b26f892e-93a8-43d0-9d68-073f4588c6b0" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_cd414c94-32fb-44c3-bdc2-4a19b9389753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_8a72f3eb-91a5-4445-9f5d-38be04fe2c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b26f892e-93a8-43d0-9d68-073f4588c6b0" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_8a72f3eb-91a5-4445-9f5d-38be04fe2c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_83e96c9d-ebbd-4851-ad17-f94042823053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b26f892e-93a8-43d0-9d68-073f4588c6b0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_83e96c9d-ebbd-4851-ad17-f94042823053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_80a94ffe-413e-48cf-a308-b9a951f0644f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b26f892e-93a8-43d0-9d68-073f4588c6b0" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_80a94ffe-413e-48cf-a308-b9a951f0644f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_6565fa4b-8288-4967-95b7-2f4980dbf83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b26f892e-93a8-43d0-9d68-073f4588c6b0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_6565fa4b-8288-4967-95b7-2f4980dbf83f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b6867932-ec69-4034-9c4e-63a7e28a18b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b26f892e-93a8-43d0-9d68-073f4588c6b0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b6867932-ec69-4034-9c4e-63a7e28a18b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e4716a71-cb6d-4f70-819f-c02059a2e31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b26f892e-93a8-43d0-9d68-073f4588c6b0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e4716a71-cb6d-4f70-819f-c02059a2e31f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1d1f0ca4-be58-42ab-a8e0-02bfd777b249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1d1f0ca4-be58-42ab-a8e0-02bfd777b249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_4d1951fa-db75-42b3-bd0c-e2c274dde4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_4d1951fa-db75-42b3-bd0c-e2c274dde4ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RepaymentOfPaidInKindInterest_3ab05f79-c313-4e6d-9a7e-fd4089eca488" xlink:href="silk-20201231.xsd#silk_RepaymentOfPaidInKindInterest"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_silk_RepaymentOfPaidInKindInterest_3ab05f79-c313-4e6d-9a7e-fd4089eca488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f3b55b36-7ef3-4aa3-b50c-13ba210fe1ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_ShareBasedCompensation_f3b55b36-7ef3-4aa3-b50c-13ba210fe1ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e24ba276-93ad-4e80-9f9c-a287537e33b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e24ba276-93ad-4e80-9f9c-a287537e33b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_6af974b2-6350-4720-9d17-1d84534cd601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_6af974b2-6350-4720-9d17-1d84534cd601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_25584744-192e-494c-966f-ea8269f1ccc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_25584744-192e-494c-966f-ea8269f1ccc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d6e51925-2f4c-4eca-8385-121721b69300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_InventoryWriteDown_d6e51925-2f4c-4eca-8385-121721b69300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_812cc1e0-2035-4545-9e26-e54b9e460359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_812cc1e0-2035-4545-9e26-e54b9e460359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10b3429a-d299-4c32-b7c5-0e6952b20ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10b3429a-d299-4c32-b7c5-0e6952b20ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_44d4d8af-4f30-46f6-9cff-4bd421801e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_44d4d8af-4f30-46f6-9cff-4bd421801e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_5eb52c3b-27b5-4746-a510-45b110a9bb51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_PaidInKindInterest_5eb52c3b-27b5-4746-a510-45b110a9bb51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_875d4718-bee0-445d-abd3-4b214c4267b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_875d4718-bee0-445d-abd3-4b214c4267b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73302f94-4674-42ee-b689-186194982ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73302f94-4674-42ee-b689-186194982ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_47b34df1-48c9-4c2a-863b-f5cb182605c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_47b34df1-48c9-4c2a-863b-f5cb182605c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_63bbb4ed-e8a4-4dd8-b43a-2bc08b61bfda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_63bbb4ed-e8a4-4dd8-b43a-2bc08b61bfda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_31400b56-369c-4575-b292-66f75d5bb5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_ProfitLoss_31400b56-369c-4575-b292-66f75d5bb5f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4eea6003-e294-4c9d-b093-b3f9c423539d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4eea6003-e294-4c9d-b093-b3f9c423539d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23beda93-0185-4807-a788-9823f47d44a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23beda93-0185-4807-a788-9823f47d44a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1e9e64f9-1f98-46e6-9027-6aee62608cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ac3613d-01e8-461a-a313-da4e643a5055" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1e9e64f9-1f98-46e6-9027-6aee62608cab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="simple" xlink:href="silk-20201231.xsd#FormationandBusinessoftheCompany"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#FormationandBusinessoftheCompanyDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d433bdc7-4c5e-4bb7-91e2-43d9f2cd532c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c92a3fdd-30eb-458d-bd7d-f2363a4c5227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d433bdc7-4c5e-4bb7-91e2-43d9f2cd532c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c92a3fdd-30eb-458d-bd7d-f2363a4c5227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_210d3997-75d3-4d74-bbab-93ae9f8611db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d433bdc7-4c5e-4bb7-91e2-43d9f2cd532c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_210d3997-75d3-4d74-bbab-93ae9f8611db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="silk-20201231.xsd#RecentAccountingPronouncements"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="silk-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="silk-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_32a8426c-606e-4031-bb4e-d3c1f42407de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cc1597b2-3fdb-4e67-923e-6e32350f93ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_32a8426c-606e-4031-bb4e-d3c1f42407de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cc1597b2-3fdb-4e67-923e-6e32350f93ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponents"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_783b2ad5-3317-44f7-9061-e20d8c96f8d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5b71a1f9-cea4-4735-b695-84ca321da35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_783b2ad5-3317-44f7-9061-e20d8c96f8d3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5b71a1f9-cea4-4735-b695-84ca321da35f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c44d46df-ce73-40ed-a69f-757f4d3d5b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_783b2ad5-3317-44f7-9061-e20d8c96f8d3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c44d46df-ce73-40ed-a69f-757f4d3d5b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bb314150-7407-41d0-9b39-9a36425eb357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_783b2ad5-3317-44f7-9061-e20d8c96f8d3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bb314150-7407-41d0-9b39-9a36425eb357" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc31a761-72f1-451a-935c-be65438ac5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_df5da18c-adfd-437a-a600-248312c8a546" xlink:href="silk-20201231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc31a761-72f1-451a-935c-be65438ac5b7" xlink:to="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_df5da18c-adfd-437a-a600-248312c8a546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_c119ba5a-9d67-47ba-984c-94a9a87bb003" xlink:href="silk-20201231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc31a761-72f1-451a-935c-be65438ac5b7" xlink:to="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_c119ba5a-9d67-47ba-984c-94a9a87bb003" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_31da414d-6cc0-4860-a15d-dd7542b3b24d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_e3302058-7a7f-41d1-bf7c-2b82d3cb159a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_31da414d-6cc0-4860-a15d-dd7542b3b24d" xlink:to="loc_us-gaap_InventoryFinishedGoods_e3302058-7a7f-41d1-bf7c-2b82d3cb159a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_db6de646-cc88-4ca7-84ef-51e5de78d876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_31da414d-6cc0-4860-a15d-dd7542b3b24d" xlink:to="loc_us-gaap_InventoryRawMaterials_db6de646-cc88-4ca7-84ef-51e5de78d876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c8dd7764-c28e-43c6-9a62-2406efc1c3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_93a899c9-d1e4-4150-8fb1-3b29a466e221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c8dd7764-c28e-43c6-9a62-2406efc1c3e5" xlink:to="loc_us-gaap_InventoryGross_93a899c9-d1e4-4150-8fb1-3b29a466e221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_b756f768-4c42-4f19-9609-7af328b46fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c8dd7764-c28e-43c6-9a62-2406efc1c3e5" xlink:to="loc_us-gaap_InventoryValuationReserves_b756f768-4c42-4f19-9609-7af328b46fa3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6952ac8c-5a8e-45b5-82c5-cd125dfdc61c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_80ced931-4bca-474b-9519-f3f5f48e9a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6952ac8c-5a8e-45b5-82c5-cd125dfdc61c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_80ced931-4bca-474b-9519-f3f5f48e9a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1cd1ccee-9c0d-4672-a8c8-669db5b85145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6952ac8c-5a8e-45b5-82c5-cd125dfdc61c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1cd1ccee-9c0d-4672-a8c8-669db5b85145" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_068bb970-6865-4344-8c54-ab8991577187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_068bb970-6865-4344-8c54-ab8991577187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_d609d641-ad09-44d8-afed-5db70beca728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_d609d641-ad09-44d8-afed-5db70beca728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ProvisionsForSalesReturns_a6ae147f-6ba8-48bc-bfa9-43b372181af5" xlink:href="silk-20201231.xsd#silk_ProvisionsForSalesReturns"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_silk_ProvisionsForSalesReturns_a6ae147f-6ba8-48bc-bfa9-43b372181af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dbcee8f7-f518-40da-81d7-0e3266526e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dbcee8f7-f518-40da-81d7-0e3266526e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedClinicalExpensesCurrent_3a50f6e0-d755-49ee-bda2-2ebe05311285" xlink:href="silk-20201231.xsd#silk_AccruedClinicalExpensesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_silk_AccruedClinicalExpensesCurrent_3a50f6e0-d755-49ee-bda2-2ebe05311285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedTravelExpensesCurrent_d0b8127a-cdfe-470c-b7ab-e9f76dd94db6" xlink:href="silk-20201231.xsd#silk_AccruedTravelExpensesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_silk_AccruedTravelExpensesCurrent_d0b8127a-cdfe-470c-b7ab-e9f76dd94db6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_27f5c5d1-d459-442c-97f4-3177741fa8da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_27f5c5d1-d459-442c-97f4-3177741fa8da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_e7cecb7e-1239-4a29-8e96-e6fd9baebef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_us-gaap_AccruedSalariesCurrent_e7cecb7e-1239-4a29-8e96-e6fd9baebef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_cbc90a50-9ab8-4fd9-bf1a-44195983bf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_cbc90a50-9ab8-4fd9-bf1a-44195983bf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6da955c7-24e4-4d4e-974e-327cb24b058b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c10bd9fc-eb05-4df8-a777-0fe4358ced44" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6da955c7-24e4-4d4e-974e-327cb24b058b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebt" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebt"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtCRGNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtStifelBankNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtFutureMaturitiesUndertheTermLoanDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_54eeae94-9d10-4218-95da-a76c14483385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtUnpaidInterest_c2da1551-60ba-4865-a2bc-a6edeaf0b395" xlink:href="silk-20201231.xsd#silk_LongTermDebtUnpaidInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_54eeae94-9d10-4218-95da-a76c14483385" xlink:to="loc_silk_LongTermDebtUnpaidInterest_c2da1551-60ba-4865-a2bc-a6edeaf0b395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f362a377-f58b-40bf-8e1f-8f47bb0ae40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_54eeae94-9d10-4218-95da-a76c14483385" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f362a377-f58b-40bf-8e1f-8f47bb0ae40b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_9c0633a3-856f-4ad9-a9dd-278accf05bb0" xlink:href="silk-20201231.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_54eeae94-9d10-4218-95da-a76c14483385" xlink:to="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_9c0633a3-856f-4ad9-a9dd-278accf05bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_1a75f40c-9572-425e-ab1e-766e43058198" xlink:href="silk-20201231.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6134836c-5f78-4e23-850e-9380cda4f203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_1a75f40c-9572-425e-ab1e-766e43058198" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6134836c-5f78-4e23-850e-9380cda4f203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f18ca0cb-5649-405a-ae51-e579d949d08c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_1a75f40c-9572-425e-ab1e-766e43058198" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f18ca0cb-5649-405a-ae51-e579d949d08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8ad11338-ad02-449f-93b0-0fe59c0c84b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_1a75f40c-9572-425e-ab1e-766e43058198" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8ad11338-ad02-449f-93b0-0fe59c0c84b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3c5cc1ac-771e-4bbf-85a8-29cb4b301554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_1a75f40c-9572-425e-ab1e-766e43058198" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3c5cc1ac-771e-4bbf-85a8-29cb4b301554" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesLeaseNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f7ccffef-5fe3-4faf-80ec-109df3e0ea97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9ee7ad83-6b5e-4ac7-9893-e52786a68d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f7ccffef-5fe3-4faf-80ec-109df3e0ea97" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9ee7ad83-6b5e-4ac7-9893-e52786a68d20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f6c0f577-2698-41ae-a353-0251d099b185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f7ccffef-5fe3-4faf-80ec-109df3e0ea97" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f6c0f577-2698-41ae-a353-0251d099b185" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e96607e-dcc0-41d9-b227-e48a2d03b6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1597a11c-c547-487c-9341-2394385e2fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e96607e-dcc0-41d9-b227-e48a2d03b6c3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1597a11c-c547-487c-9341-2394385e2fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_47974e84-afe5-4bcd-b76a-8a2892585d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e96607e-dcc0-41d9-b227-e48a2d03b6c3" xlink:to="loc_us-gaap_OperatingLeaseLiability_47974e84-afe5-4bcd-b76a-8a2892585d23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7e7471cf-7d3e-48f5-852e-b352a5d07747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7e7471cf-7d3e-48f5-852e-b352a5d07747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_682767be-e069-46fd-b888-311e996f1ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_682767be-e069-46fd-b888-311e996f1ed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_871b4581-83fe-4c33-8094-73c05c9b37b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_871b4581-83fe-4c33-8094-73c05c9b37b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_84feff64-b43a-4dfe-baf4-1d2f490f1d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_292ca686-3709-4158-a397-0281f903227d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_84feff64-b43a-4dfe-baf4-1d2f490f1d98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="silk-20201231.xsd#RedeemableConvertiblePreferredStock"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#RedeemableConvertiblePreferredStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitTables" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficitTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficitTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficitNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlans" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlans"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansActivityUnderCompensationPlanDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansInformationbyExercisePriceDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansRSUsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansFairValueofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansStockbasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesComponentsofIncomeBeforeTaxesDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fe05fc4c-ce3c-4b94-85ee-0a0137b08559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_57c356ea-72fd-4e39-85ee-e8a30bd99aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fe05fc4c-ce3c-4b94-85ee-0a0137b08559" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_57c356ea-72fd-4e39-85ee-e8a30bd99aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2b83f12a-1ad1-46d4-9518-0b4774442906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fe05fc4c-ce3c-4b94-85ee-0a0137b08559" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2b83f12a-1ad1-46d4-9518-0b4774442906" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesReconciliationofUSStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c4972673-129f-4800-b961-21a348afb2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c4972673-129f-4800-b961-21a348afb2dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f76e34ea-da70-4c19-889d-7a7cbd16b159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f76e34ea-da70-4c19-889d-7a7cbd16b159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_4887ef2d-ae78-4d43-af95-cd813bcc3446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_4887ef2d-ae78-4d43-af95-cd813bcc3446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount_0792178f-e2ab-4676-9934-bcfd321e49c2" xlink:href="silk-20201231.xsd#silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="loc_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount_0792178f-e2ab-4676-9934-bcfd321e49c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_811467e4-6315-463b-9afc-23abeda52758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_811467e4-6315-463b-9afc-23abeda52758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_2d38caac-bc3e-41b0-9352-bf54ecf39fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_2d38caac-bc3e-41b0-9352-bf54ecf39fb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_cbc7719b-1fcf-4def-805c-c34b9473d3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a022bf8c-bc69-4bb4-9581-8529d1d7a0c8" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_cbc7719b-1fcf-4def-805c-c34b9473d3f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesNetDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c61b922f-3534-4c40-b6f7-5436038090d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8e1077cb-1a5d-4969-aed4-88fbc23f59f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c61b922f-3534-4c40-b6f7-5436038090d3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8e1077cb-1a5d-4969-aed4-88fbc23f59f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54a8d345-e9cd-4f0f-aed7-a44e4dc81e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c61b922f-3534-4c40-b6f7-5436038090d3" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_54a8d345-e9cd-4f0f-aed7-a44e4dc81e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DeferredTaxAssetsOperatingLeaseLiability_54e04926-3609-41ca-92d5-9fdc4e8e909b" xlink:href="silk-20201231.xsd#silk_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c61b922f-3534-4c40-b6f7-5436038090d3" xlink:to="loc_silk_DeferredTaxAssetsOperatingLeaseLiability_54e04926-3609-41ca-92d5-9fdc4e8e909b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_5fa5bc5c-9d38-47f1-bec1-daa36735e5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c61b922f-3534-4c40-b6f7-5436038090d3" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_5fa5bc5c-9d38-47f1-bec1-daa36735e5c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187493b0-fc16-44ef-84c9-4581ae7639c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c61b922f-3534-4c40-b6f7-5436038090d3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187493b0-fc16-44ef-84c9-4581ae7639c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4ce8a668-6d46-438f-bf82-2ccc1a6faa77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c61b922f-3534-4c40-b6f7-5436038090d3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4ce8a668-6d46-438f-bf82-2ccc1a6faa77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2c24df69-9914-45af-a46f-c1b44ec6cd90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c61b922f-3534-4c40-b6f7-5436038090d3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2c24df69-9914-45af-a46f-c1b44ec6cd90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_227a0054-5b2d-4e8e-96de-83a560296584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c61b922f-3534-4c40-b6f7-5436038090d3" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_227a0054-5b2d-4e8e-96de-83a560296584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f3a78e85-5659-449a-ae0c-2cdcec5080a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ad74535f-413c-4555-8cc9-0f73e666451b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f3a78e85-5659-449a-ae0c-2cdcec5080a6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ad74535f-413c-4555-8cc9-0f73e666451b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b80466fc-f253-4fa8-9bc1-4d72b8207b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f3a78e85-5659-449a-ae0c-2cdcec5080a6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b80466fc-f253-4fa8-9bc1-4d72b8207b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_25e985f7-ce90-48a7-8837-51bc065e9016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5d0a1f45-2ccd-4900-9b09-01cda5bf04e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_25e985f7-ce90-48a7-8837-51bc065e9016" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5d0a1f45-2ccd-4900-9b09-01cda5bf04e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a6655d00-6f74-4c1e-beda-b92615ee5218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_25e985f7-ce90-48a7-8837-51bc065e9016" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a6655d00-6f74-4c1e-beda-b92615ee5218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_277f40fa-7f45-48d2-ab59-f5386b6dd3ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_25e985f7-ce90-48a7-8837-51bc065e9016" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_277f40fa-7f45-48d2-ab59-f5386b6dd3ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo" xlink:type="simple" xlink:href="silk-20201231.xsd#AcquisitionofVariableInterestEntityNeuroCo"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#AcquisitionofVariableInterestEntityNeuroCoDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlan" xlink:type="simple" xlink:href="silk-20201231.xsd#A401kPlan"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/A401kPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#A401kPlanDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SubsequentEvents" xlink:type="simple" xlink:href="silk-20201231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SubsequentEventsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited" xlink:type="simple" xlink:href="silk-20201231.xsd#QuarterlyFinancialInformationunaudited"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables" xlink:type="simple" xlink:href="silk-20201231.xsd#QuarterlyFinancialInformationunauditedTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#QuarterlyFinancialInformationunauditedDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="simple" xlink:href="silk-20201231.xsd#ScheduleIIValuationandQualifyingAccounts"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>silk-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:13b527d4-ea1a-4469-9dba-fa8b61e78c7f,g:43b528fe-3601-4224-908f-a46b4c727eef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CoverPage" xlink:type="simple" xlink:href="silk-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CoverPage" xlink:type="extended" id="i6511639f51f345edb83089b11de4211a_CoverPage"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheets" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheets"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheets" xlink:type="extended" id="idf807cd5450b414e86ee710f587d0002_BalanceSheets"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetsParenthetical" xlink:type="extended" id="i29b1bfe61bca4d2dbede1016f1e765c3_BalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="silk-20201231.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i314fc8da16354cf8992e5909637150f8_StatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="silk-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="idd41e5182f2e4c4f937a0e4589c955cf_StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_abd969e1-67f1-4dbc-b934-cd5de1c2956d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_abd969e1-67f1-4dbc-b934-cd5de1c2956d" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_385f5708-0e22-48f3-b79c-9bdabeec74d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_385f5708-0e22-48f3-b79c-9bdabeec74d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_7e6e1423-5ae1-4ad7-a274-dddf9d0a1457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_7e6e1423-5ae1-4ad7-a274-dddf9d0a1457" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1c8c3730-eee9-41b3-ac9d-0e29cd09ecf8" xlink:href="silk-20201231.xsd#silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1c8c3730-eee9-41b3-ac9d-0e29cd09ecf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b0f7636c-dc17-4917-96fa-b769cf8dcade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b0f7636c-dc17-4917-96fa-b769cf8dcade" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_7f37fd2e-b86b-4808-b53c-2de647418c19" xlink:href="silk-20201231.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_7f37fd2e-b86b-4808-b53c-2de647418c19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_60647fd0-99b5-41fb-b677-a955ae520b13" xlink:href="silk-20201231.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_60647fd0-99b5-41fb-b677-a955ae520b13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_31f7b887-c88f-412b-bbd8-be7b5444c248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b0cfc870-bcee-4b1c-911b-2ba3f258c845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_abd969e1-67f1-4dbc-b934-cd5de1c2956d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_25133498-1e6a-47ee-bfab-d0bf029d803b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_SharesOutstanding_25133498-1e6a-47ee-bfab-d0bf029d803b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_162018ba-b5e1-4781-95f5-d23470acfea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_162018ba-b5e1-4781-95f5-d23470acfea7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2f412294-b7b2-45d8-9bbd-40be90871ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2f412294-b7b2-45d8-9bbd-40be90871ac8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0e4a653-72d6-4c57-80e2-f6c94120f175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0e4a653-72d6-4c57-80e2-f6c94120f175" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80e907f2-ba6b-4e3b-9f58-e5ec722b81ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80e907f2-ba6b-4e3b-9f58-e5ec722b81ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4765d26f-2a57-4283-ae82-9689366d3db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4765d26f-2a57-4283-ae82-9689366d3db6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_6236b543-4577-461a-b3a4-a62cb8409fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_6236b543-4577-461a-b3a4-a62cb8409fee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_0444634e-971d-485f-8861-d3848f105a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_0444634e-971d-485f-8861-d3848f105a85" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants_3cff74fd-0ea5-449f-9e12-130b34a2d310" xlink:href="silk-20201231.xsd#silk_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants_3cff74fd-0ea5-449f-9e12-130b34a2d310" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c3f19486-0072-48d1-ad34-270a8672457f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c3f19486-0072-48d1-ad34-270a8672457f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9216fa77-f9a1-41c2-b5f4-cf08e79dc4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9216fa77-f9a1-41c2-b5f4-cf08e79dc4bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c18a9bcf-7df3-4c40-9db4-468857cff450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c18a9bcf-7df3-4c40-9db4-468857cff450" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_0b320b51-f39d-4c4b-83a1-9b953dc2c564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_0b320b51-f39d-4c4b-83a1-9b953dc2c564" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4e2e99b2-9f02-4661-9b21-94c859cb971d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4e2e99b2-9f02-4661-9b21-94c859cb971d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_de9c3047-14df-4c4c-ae4a-9663616407c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_de9c3047-14df-4c4c-ae4a-9663616407c2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3c616845-555b-4d86-a197-88efe054da82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_ProfitLoss_3c616845-555b-4d86-a197-88efe054da82" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e2516c2-8d22-484a-994f-9615c0f32be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e2516c2-8d22-484a-994f-9615c0f32be5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d035cd82-038c-4ed3-910d-01412052ac46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d035cd82-038c-4ed3-910d-01412052ac46" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3944206a-c424-4935-8bcd-3a559e63e4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ebf0895-e835-4352-8ce0-d3f986ea7c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_abd969e1-67f1-4dbc-b934-cd5de1c2956d" xlink:to="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f24a8466-0805-41a8-828b-d37468f0c065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f24a8466-0805-41a8-828b-d37468f0c065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f24a8466-0805-41a8-828b-d37468f0c065_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f24a8466-0805-41a8-828b-d37468f0c065" xlink:to="loc_us-gaap_EquityComponentDomain_f24a8466-0805-41a8-828b-d37468f0c065_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f24a8466-0805-41a8-828b-d37468f0c065" xlink:to="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ec2fd341-9c18-46db-abd7-abeab96a1a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_PreferredStockMember_ec2fd341-9c18-46db-abd7-abeab96a1a19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bdbd4c3f-ee60-49f9-8b11-6499521ea585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_CommonStockMember_bdbd4c3f-ee60-49f9-8b11-6499521ea585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d537f60d-423d-4555-b8df-7774c92360fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d537f60d-423d-4555-b8df-7774c92360fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_421aa29c-31c1-4158-a909-0ae96dd88ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_RetainedEarningsMember_421aa29c-31c1-4158-a909-0ae96dd88ac0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3388ec06-9ecd-4681-a1c4-2c3f46347fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3388ec06-9ecd-4681-a1c4-2c3f46347fee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a0d11f42-f2c3-4a4e-982b-7ef51e24d115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a0d11f42-f2c3-4a4e-982b-7ef51e24d115" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cbd1ce4d-0c9a-4b2a-bb35-ecd8928cdbd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cbd1ce4d-0c9a-4b2a-bb35-ecd8928cdbd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_cbd1ce4d-0c9a-4b2a-bb35-ecd8928cdbd7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cbd1ce4d-0c9a-4b2a-bb35-ecd8928cdbd7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_cbd1ce4d-0c9a-4b2a-bb35-ecd8928cdbd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4fb73b54-7af2-4f61-960f-818f8e01dc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cbd1ce4d-0c9a-4b2a-bb35-ecd8928cdbd7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4fb73b54-7af2-4f61-960f-818f8e01dc4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_0776344c-a653-477e-9d82-21d3ab4eb775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4fb73b54-7af2-4f61-960f-818f8e01dc4e" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_0776344c-a653-477e-9d82-21d3ab4eb775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_fd11fdf9-286e-42ad-8231-c63aee0b6f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4fb73b54-7af2-4f61-960f-818f8e01dc4e" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_fd11fdf9-286e-42ad-8231-c63aee0b6f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_80a34787-5ae5-44bf-949c-925878bb2d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_80a34787-5ae5-44bf-949c-925878bb2d31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80a34787-5ae5-44bf-949c-925878bb2d31_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_80a34787-5ae5-44bf-949c-925878bb2d31" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80a34787-5ae5-44bf-949c-925878bb2d31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86a4ade5-9302-4cdc-a2e8-878e63beb3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_80a34787-5ae5-44bf-949c-925878bb2d31" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86a4ade5-9302-4cdc-a2e8-878e63beb3bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_19a8b617-f694-4eec-b8da-e4b900710333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86a4ade5-9302-4cdc-a2e8-878e63beb3bf" xlink:to="loc_us-gaap_IPOMember_19a8b617-f694-4eec-b8da-e4b900710333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_94a616ee-f934-4600-9bd3-949d49969d13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_94a616ee-f934-4600-9bd3-949d49969d13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_94a616ee-f934-4600-9bd3-949d49969d13_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_94a616ee-f934-4600-9bd3-949d49969d13" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_94a616ee-f934-4600-9bd3-949d49969d13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b142242f-8dd4-4da1-860e-c296eb12adde" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_94a616ee-f934-4600-9bd3-949d49969d13" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b142242f-8dd4-4da1-860e-c296eb12adde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a909424e-868f-4833-a5bc-fa48cd92a427" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b142242f-8dd4-4da1-860e-c296eb12adde" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a909424e-868f-4833-a5bc-fa48cd92a427" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="silk-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended" id="i1a7488a55f874b7b94466a4199ab279e_StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="silk-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="idfd5dcb1053545c3ace5ff9682c41a64_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_23fc5514-229e-4b45-a278-a4248fb90a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:to="loc_us-gaap_ProfitLoss_23fc5514-229e-4b45-a278-a4248fb90a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_4dbf1bf4-5005-40c7-9133-d8f710f3653a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_4dbf1bf4-5005-40c7-9133-d8f710f3653a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3f105462-bf87-451d-9893-1d8edbbb27e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_ShareBasedCompensation_3f105462-bf87-451d-9893-1d8edbbb27e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_bccd6326-63df-4309-bdbb-e486c6daeff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_bccd6326-63df-4309-bdbb-e486c6daeff0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d5db21cc-305d-4c3a-9c74-1cd3c4a7fd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d5db21cc-305d-4c3a-9c74-1cd3c4a7fd68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bfb942d4-6039-4d14-a25d-b3f0a6fe0ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bfb942d4-6039-4d14-a25d-b3f0a6fe0ab7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b75a1421-24cd-4021-82fd-ed5bbe0c4694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b75a1421-24cd-4021-82fd-ed5bbe0c4694" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_00e7f43a-eb9c-47cb-bed6-3ca3a31853c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_PaidInKindInterest_00e7f43a-eb9c-47cb-bed6-3ca3a31853c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b28335d1-9bb6-4e0d-95b8-0e6ffda09c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b28335d1-9bb6-4e0d-95b8-0e6ffda09c72" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_879b920e-2db9-458b-87cd-c420deab3aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_879b920e-2db9-458b-87cd-c420deab3aae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6551a620-747a-45eb-993f-48b612c9f415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6551a620-747a-45eb-993f-48b612c9f415" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_9dfbdf55-66fc-437e-a1a4-76bad547006d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_InventoryWriteDown_9dfbdf55-66fc-437e-a1a4-76bad547006d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2e19aa8-e858-49ed-8ddf-9bc183c233ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2e19aa8-e858-49ed-8ddf-9bc183c233ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5efba32b-a37c-48c5-9372-650346ff895d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5efba32b-a37c-48c5-9372-650346ff895d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d90261b-83ce-4441-bb2f-13fc138b84ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d90261b-83ce-4441-bb2f-13fc138b84ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_46697b1c-8d12-42a7-9161-7adb550dbc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_46697b1c-8d12-42a7-9161-7adb550dbc7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_917ec090-552b-4ffb-bbb8-35e81235f124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_917ec090-552b-4ffb-bbb8-35e81235f124" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_45605602-be46-4083-ae96-5567b4f3c2cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_45605602-be46-4083-ae96-5567b4f3c2cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_28ea6c04-eab1-49c8-9a69-d43ba9567bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_28ea6c04-eab1-49c8-9a69-d43ba9567bea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RepaymentOfPaidInKindInterest_bd3bda33-7996-424a-90ba-4d02883dd2b7" xlink:href="silk-20201231.xsd#silk_RepaymentOfPaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_silk_RepaymentOfPaidInKindInterest_bd3bda33-7996-424a-90ba-4d02883dd2b7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73748294-13b7-44db-b630-57e6e77126ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73748294-13b7-44db-b630-57e6e77126ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0d14b9bb-b8b1-4796-8347-9c45f38f4665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0d14b9bb-b8b1-4796-8347-9c45f38f4665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_14f080fe-e570-410b-902c-24a959246a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_14f080fe-e570-410b-902c-24a959246a89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8b2120c3-6901-4bb9-99bf-5816231196cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8b2120c3-6901-4bb9-99bf-5816231196cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_6ddb4ec2-728c-4430-81a5-7f332f73dce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_6ddb4ec2-728c-4430-81a5-7f332f73dce3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_482db316-28da-41a7-8a71-5680c0e5875c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_482db316-28da-41a7-8a71-5680c0e5875c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_d1056c73-fae3-4a17-b104-aa8c1e85f265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_d1056c73-fae3-4a17-b104-aa8c1e85f265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_772df7fb-9e46-45ef-9f34-34c529f1613f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_772df7fb-9e46-45ef-9f34-34c529f1613f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_04de52d6-435c-4fe6-93ca-5a7862c4f450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_04de52d6-435c-4fe6-93ca-5a7862c4f450" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_f8459032-ef27-4604-81d9-229bc2fe5dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_f8459032-ef27-4604-81d9-229bc2fe5dbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6acba508-55e9-48cd-978c-3f9776cd6d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6acba508-55e9-48cd-978c-3f9776cd6d5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_dd5867d0-8b8b-447f-ac2b-13303e6b8a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_dd5867d0-8b8b-447f-ac2b-13303e6b8a60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_dbc72978-55df-4524-99e6-2ec9f730ba7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_dbc72978-55df-4524-99e6-2ec9f730ba7f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_93019dd7-fbe4-42f8-aa81-f0b059671927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_93019dd7-fbe4-42f8-aa81-f0b059671927" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d61a3c98-a758-497f-942f-f731c6724377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d61a3c98-a758-497f-942f-f731c6724377" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f40139f-c8c2-4b26-a031-5707d54f683e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f40139f-c8c2-4b26-a031-5707d54f683e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9a4157a-7e4e-4962-8f1f-cdbf26ee37ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2ca9f611-4558-4591-8d6d-f7c662346f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2ca9f611-4558-4591-8d6d-f7c662346f45" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e36654e2-b54c-4f41-83dd-de35876b9115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2ca9f611-4558-4591-8d6d-f7c662346f45" xlink:to="loc_us-gaap_InterestPaidNet_e36654e2-b54c-4f41-83dd-de35876b9115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08a2feb2-0e2b-44c9-af27-69d7c1e17383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08a2feb2-0e2b-44c9-af27-69d7c1e17383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_0433dbf6-ca86-4014-ae70-18eca305285c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_0433dbf6-ca86-4014-ae70-18eca305285c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_StockIssuanceCostsIncurredButNotYetPaid_81f9b054-ed40-4605-9107-3d33d69f3473" xlink:href="silk-20201231.xsd#silk_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_silk_StockIssuanceCostsIncurredButNotYetPaid_81f9b054-ed40-4605-9107-3d33d69f3473" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b1d51338-38a5-485d-8b57-e200da8f2ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b1d51338-38a5-485d-8b57-e200da8f2ff8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_69b9d3ea-b80c-4510-b77d-867d691dd300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_69b9d3ea-b80c-4510-b77d-867d691dd300" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_00199d58-aa15-4050-95da-98872e832534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_00199d58-aa15-4050-95da-98872e832534" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ab9532a-b346-4593-99e4-88761d31d9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_StatementTable_3ab9532a-b346-4593-99e4-88761d31d9e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a082ea74-dd0a-4d9e-8e6f-3630f0db9b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3ab9532a-b346-4593-99e4-88761d31d9e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a082ea74-dd0a-4d9e-8e6f-3630f0db9b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a082ea74-dd0a-4d9e-8e6f-3630f0db9b82_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a082ea74-dd0a-4d9e-8e6f-3630f0db9b82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a082ea74-dd0a-4d9e-8e6f-3630f0db9b82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3a2311ab-b3a8-467c-83f2-4c69454a525c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a082ea74-dd0a-4d9e-8e6f-3630f0db9b82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3a2311ab-b3a8-467c-83f2-4c69454a525c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_66fa5417-1401-4ce0-a2d9-47f0214146b3" xlink:href="silk-20201231.xsd#silk_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3a2311ab-b3a8-467c-83f2-4c69454a525c" xlink:to="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_66fa5417-1401-4ce0-a2d9-47f0214146b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_10eaaeac-f71a-43ae-a411-2581288b2d12" xlink:href="silk-20201231.xsd#silk_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3a2311ab-b3a8-467c-83f2-4c69454a525c" xlink:to="loc_silk_CommonStockWarrantMember_10eaaeac-f71a-43ae-a411-2581288b2d12" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="simple" xlink:href="silk-20201231.xsd#FormationandBusinessoftheCompany"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="extended" id="i4dfbffcd38784fb38b3eccca4f297ced_FormationandBusinessoftheCompany"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#FormationandBusinessoftheCompanyDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="extended" id="ia5b2ad5c37d84fb7a4b570c8c8cb4c09_FormationandBusinessoftheCompanyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae275b2c-4047-4565-baec-8c5cd9c2845c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae275b2c-4047-4565-baec-8c5cd9c2845c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_371db3c1-4a8d-4df0-9696-2493b419f482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_371db3c1-4a8d-4df0-9696-2493b419f482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d5324a21-d56f-4300-805e-c41de66fa563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d5324a21-d56f-4300-805e-c41de66fa563" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_02a78f55-7221-4b58-940d-73a9df82d920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_02a78f55-7221-4b58-940d-73a9df82d920" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a73f5a54-8b67-40e9-a8b8-4cc840b89610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a73f5a54-8b67-40e9-a8b8-4cc840b89610" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b5207b4d-a58d-4ae7-85c2-52042beb3890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b5207b4d-a58d-4ae7-85c2-52042beb3890" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a58b831a-9daa-4217-a74b-f8d862f8cd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a58b831a-9daa-4217-a74b-f8d862f8cd87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0967d28e-ec88-4f8b-b547-0886b7052ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0967d28e-ec88-4f8b-b547-0886b7052ca0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_aaca6010-4a1c-4ec2-9817-a56730185045" xlink:href="silk-20201231.xsd#silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_aaca6010-4a1c-4ec2-9817-a56730185045" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_76ad1ac3-04b8-448c-8877-1fc6b81b874d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_SubsequentEventTable_76ad1ac3-04b8-448c-8877-1fc6b81b874d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77427f84-16f5-4c11-9d3b-686fdb34c556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_76ad1ac3-04b8-448c-8877-1fc6b81b874d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77427f84-16f5-4c11-9d3b-686fdb34c556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77427f84-16f5-4c11-9d3b-686fdb34c556_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77427f84-16f5-4c11-9d3b-686fdb34c556" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77427f84-16f5-4c11-9d3b-686fdb34c556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77427f84-16f5-4c11-9d3b-686fdb34c556" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_208084ca-c51e-4a7f-904d-d66c6988b9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:to="loc_us-gaap_IPOMember_208084ca-c51e-4a7f-904d-d66c6988b9d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SecondPublicOfferingMember_da867d0f-ad3b-4203-ac4a-b9ffe7ff418a" xlink:href="silk-20201231.xsd#silk_SecondPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:to="loc_silk_SecondPublicOfferingMember_da867d0f-ad3b-4203-ac4a-b9ffe7ff418a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_cf5b5996-54a7-441f-9950-2745ed87d7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:to="loc_us-gaap_OverAllotmentOptionMember_cf5b5996-54a7-441f-9950-2745ed87d7bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingMember_8beeefea-10c8-48b5-a106-fbcb3c98db36" xlink:href="silk-20201231.xsd#silk_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:to="loc_silk_PublicStockOfferingMember_8beeefea-10c8-48b5-a106-fbcb3c98db36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromCompanyMember_8828d1d1-c6fb-4837-90e8-a718a8f2c06f" xlink:href="silk-20201231.xsd#silk_PublicStockOfferingSharesFromCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_PublicStockOfferingMember_8beeefea-10c8-48b5-a106-fbcb3c98db36" xlink:to="loc_silk_PublicStockOfferingSharesFromCompanyMember_8828d1d1-c6fb-4837-90e8-a718a8f2c06f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember_b1484e8c-f5ba-4614-9f1c-bad7804e7e8a" xlink:href="silk-20201231.xsd#silk_PublicStockOfferingSharesFromExistingShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_PublicStockOfferingMember_8beeefea-10c8-48b5-a106-fbcb3c98db36" xlink:to="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember_b1484e8c-f5ba-4614-9f1c-bad7804e7e8a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i03d70dd9a95f45f3810aa258f7538194_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i093308624cc0423f9abebe0c21ef1672_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i67d64c755e4e4118a61430788b46e6dc_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="id8e35ea88b244d1baaafab4b4dce415e_SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7eb28bb6-ae00-4bed-9a1d-d87ed374f7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7eb28bb6-ae00-4bed-9a1d-d87ed374f7fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2d5384a2-f00f-4cb6-aa3a-d7692ee80dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2d5384a2-f00f-4cb6-aa3a-d7692ee80dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44d38c44-6396-456a-a0ab-bae5c590bb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44d38c44-6396-456a-a0ab-bae5c590bb39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_4d39bb99-65cb-4bf5-a558-28892ea0105f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_4d39bb99-65cb-4bf5-a558-28892ea0105f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d11d1d7a-5bcf-41e4-b82e-59a6e564db64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_4d39bb99-65cb-4bf5-a558-28892ea0105f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d11d1d7a-5bcf-41e4-b82e-59a6e564db64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d11d1d7a-5bcf-41e4-b82e-59a6e564db64_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d11d1d7a-5bcf-41e4-b82e-59a6e564db64" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d11d1d7a-5bcf-41e4-b82e-59a6e564db64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f3b82900-7802-4ec6-b5bd-a935af3c791e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d11d1d7a-5bcf-41e4-b82e-59a6e564db64" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f3b82900-7802-4ec6-b5bd-a935af3c791e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_d8f250ab-44f0-4799-8e11-fe3e273426c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f3b82900-7802-4ec6-b5bd-a935af3c791e" xlink:to="loc_us-gaap_LetterOfCreditMember_d8f250ab-44f0-4799-8e11-fe3e273426c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails" xlink:type="extended" id="ia2818288b90741c285892376e30bae0f_SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_8424721a-8c15-4968-b16f-340f9f4cba6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable_06321448-e23d-43c2-afee-a4f1e1cd4aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_8424721a-8c15-4968-b16f-340f9f4cba6c" xlink:to="loc_us-gaap_LossContingencyReceivable_06321448-e23d-43c2-afee-a4f1e1cd4aa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_8ad8fe8e-55a9-46b1-a8ff-336ac64811b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_8424721a-8c15-4968-b16f-340f9f4cba6c" xlink:to="loc_us-gaap_ValuationAllowanceTable_8ad8fe8e-55a9-46b1-a8ff-336ac64811b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ef334a79-1060-4f6f-b80e-e8922a30940f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_8ad8fe8e-55a9-46b1-a8ff-336ac64811b3" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ef334a79-1060-4f6f-b80e-e8922a30940f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ef334a79-1060-4f6f-b80e-e8922a30940f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ef334a79-1060-4f6f-b80e-e8922a30940f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ef334a79-1060-4f6f-b80e-e8922a30940f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6e8f260b-f7ec-4f96-9ba8-fcb5bdd8903c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ef334a79-1060-4f6f-b80e-e8922a30940f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6e8f260b-f7ec-4f96-9ba8-fcb5bdd8903c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_VoluntaryRecallMember_c42f67ff-aafb-4527-908d-2ea91fd29220" xlink:href="silk-20201231.xsd#silk_VoluntaryRecallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6e8f260b-f7ec-4f96-9ba8-fcb5bdd8903c" xlink:to="loc_silk_VoluntaryRecallMember_c42f67ff-aafb-4527-908d-2ea91fd29220" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="i9602ab424b2445009f4994ff897dc822_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_db1eab71-3f37-4c0f-8a3a-1745ec7fdc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d4fc4e0e-6b77-4645-adca-6d19d23d30e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_db1eab71-3f37-4c0f-8a3a-1745ec7fdc4d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d4fc4e0e-6b77-4645-adca-6d19d23d30e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c637e29f-7e69-4953-bb6e-a8e2781cef74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_db1eab71-3f37-4c0f-8a3a-1745ec7fdc4d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c637e29f-7e69-4953-bb6e-a8e2781cef74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c242370-d111-40ec-8881-bb5fb6347d12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c637e29f-7e69-4953-bb6e-a8e2781cef74" xlink:to="loc_srt_RangeAxis_0c242370-d111-40ec-8881-bb5fb6347d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c242370-d111-40ec-8881-bb5fb6347d12_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0c242370-d111-40ec-8881-bb5fb6347d12" xlink:to="loc_srt_RangeMember_0c242370-d111-40ec-8881-bb5fb6347d12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99a04853-cfe5-4522-b16f-fa95aecc2e7e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0c242370-d111-40ec-8881-bb5fb6347d12" xlink:to="loc_srt_RangeMember_99a04853-cfe5-4522-b16f-fa95aecc2e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_57497328-b691-4b40-b769-368146881ca5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_99a04853-cfe5-4522-b16f-fa95aecc2e7e" xlink:to="loc_srt_MinimumMember_57497328-b691-4b40-b769-368146881ca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92b4300c-973f-4167-bb6e-4d019bf0bd10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_99a04853-cfe5-4522-b16f-fa95aecc2e7e" xlink:to="loc_srt_MaximumMember_92b4300c-973f-4167-bb6e-4d019bf0bd10" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails" xlink:type="extended" id="i46d616ed7b16441cae4c0afce27c0085_SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended" id="i6ac204dc2e0f46b19e9f7c2942828203_SummaryofSignificantAccountingPoliciesLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_357e996b-ac83-444b-8ccf-031d9d95f6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdbc47a2-a5db-4b03-a4f3-826df119f88a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_357e996b-ac83-444b-8ccf-031d9d95f6de" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdbc47a2-a5db-4b03-a4f3-826df119f88a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_37e8d0f2-2aaf-40d5-976b-f2deb0fa6704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_357e996b-ac83-444b-8ccf-031d9d95f6de" xlink:to="loc_us-gaap_OperatingLeaseLiability_37e8d0f2-2aaf-40d5-976b-f2deb0fa6704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_929e6df9-dd99-4253-9741-072495d79fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_357e996b-ac83-444b-8ccf-031d9d95f6de" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_929e6df9-dd99-4253-9741-072495d79fc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6dd8e994-5b15-4442-bae5-ab0b1aeb239e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_929e6df9-dd99-4253-9741-072495d79fc2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6dd8e994-5b15-4442-bae5-ab0b1aeb239e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6dd8e994-5b15-4442-bae5-ab0b1aeb239e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6dd8e994-5b15-4442-bae5-ab0b1aeb239e" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6dd8e994-5b15-4442-bae5-ab0b1aeb239e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_77e5e00d-5da0-4241-a7b9-fc4680b35fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6dd8e994-5b15-4442-bae5-ab0b1aeb239e" xlink:to="loc_us-gaap_TypeOfAdoptionMember_77e5e00d-5da0-4241-a7b9-fc4680b35fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_68994ad3-4542-424e-af81-3e8cfe97d9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_77e5e00d-5da0-4241-a7b9-fc4680b35fdb" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_68994ad3-4542-424e-af81-3e8cfe97d9b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails" xlink:type="extended" id="id9b917dad9bb408fa21dec9869a3f288_SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_47234cca-e5f3-4499-96b2-7512a4c82762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_47234cca-e5f3-4499-96b2-7512a4c82762" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7ac13f6d-859a-476f-8ae0-b49c13e5ad54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7ac13f6d-859a-476f-8ae0-b49c13e5ad54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2cf87255-c7e5-4a2b-b945-ee4a5503f98b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2cf87255-c7e5-4a2b-b945-ee4a5503f98b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d2ded2df-5405-405c-9d61-ecd223a3e68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d2ded2df-5405-405c-9d61-ecd223a3e68a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_090bfcb4-8e81-496d-9b09-0c3836a61de4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d2ded2df-5405-405c-9d61-ecd223a3e68a" xlink:to="loc_srt_RestatementAxis_090bfcb4-8e81-496d-9b09-0c3836a61de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_090bfcb4-8e81-496d-9b09-0c3836a61de4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_090bfcb4-8e81-496d-9b09-0c3836a61de4" xlink:to="loc_srt_RestatementDomain_090bfcb4-8e81-496d-9b09-0c3836a61de4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f8b5327c-d940-46d8-a273-fa59e67d8de5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_090bfcb4-8e81-496d-9b09-0c3836a61de4" xlink:to="loc_srt_RestatementDomain_f8b5327c-d940-46d8-a273-fa59e67d8de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_970d19a8-8100-4762-9e6c-8c73a7657bb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_f8b5327c-d940-46d8-a273-fa59e67d8de5" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_970d19a8-8100-4762-9e6c-8c73a7657bb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_4b9a83bb-ec0f-45b9-92b4-58d9d01f40c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_f8b5327c-d940-46d8-a273-fa59e67d8de5" xlink:to="loc_srt_RestatementAdjustmentMember_4b9a83bb-ec0f-45b9-92b4-58d9d01f40c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_da17cb67-e8a8-4d22-9744-90658f7f92e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d2ded2df-5405-405c-9d61-ecd223a3e68a" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_da17cb67-e8a8-4d22-9744-90658f7f92e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_da17cb67-e8a8-4d22-9744-90658f7f92e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_da17cb67-e8a8-4d22-9744-90658f7f92e5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_da17cb67-e8a8-4d22-9744-90658f7f92e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d57855ef-4451-4d72-a569-37dfd31118d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_da17cb67-e8a8-4d22-9744-90658f7f92e5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d57855ef-4451-4d72-a569-37dfd31118d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_25f36f1d-9142-427d-b4b0-a03aacfd40c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d57855ef-4451-4d72-a569-37dfd31118d0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_25f36f1d-9142-427d-b4b0-a03aacfd40c1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="extended" id="ib4a309b52ba44f03b7c26f6aef758dbd_SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_915e9690-51ec-4263-b250-704032c575f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_f6813cce-1647-4d19-ba78-b152633b57f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_915e9690-51ec-4263-b250-704032c575f3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_f6813cce-1647-4d19-ba78-b152633b57f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_57b1ae0e-3ed0-421e-b7b5-b0a0a8c12106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_915e9690-51ec-4263-b250-704032c575f3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_57b1ae0e-3ed0-421e-b7b5-b0a0a8c12106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f9a06b39-fbfe-48a7-8337-e4ebcdd16f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_915e9690-51ec-4263-b250-704032c575f3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f9a06b39-fbfe-48a7-8337-e4ebcdd16f5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4506dafc-0657-4bd8-b030-f65d21177ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f9a06b39-fbfe-48a7-8337-e4ebcdd16f5a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4506dafc-0657-4bd8-b030-f65d21177ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4506dafc-0657-4bd8-b030-f65d21177ad8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4506dafc-0657-4bd8-b030-f65d21177ad8" xlink:to="loc_us-gaap_EquityComponentDomain_4506dafc-0657-4bd8-b030-f65d21177ad8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21110ad3-e102-485e-af01-7344d8616c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4506dafc-0657-4bd8-b030-f65d21177ad8" xlink:to="loc_us-gaap_EquityComponentDomain_21110ad3-e102-485e-af01-7344d8616c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_071e4776-cfb1-4d8b-96d5-2ca69d1ab897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21110ad3-e102-485e-af01-7344d8616c6c" xlink:to="loc_us-gaap_CommonStockMember_071e4776-cfb1-4d8b-96d5-2ca69d1ab897" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" id="i1a24f04cc7ef4aa7b116405348e450b7_SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_73798d3f-48fb-402b-bffa-3bd3041868e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_243968fb-afd2-4932-91c1-ce4f88f7c7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_73798d3f-48fb-402b-bffa-3bd3041868e6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_243968fb-afd2-4932-91c1-ce4f88f7c7d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_3fddb136-4141-41d9-9b6d-4ac1961c1f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_73798d3f-48fb-402b-bffa-3bd3041868e6" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_3fddb136-4141-41d9-9b6d-4ac1961c1f48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_73798d3f-48fb-402b-bffa-3bd3041868e6" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff86641-4876-4f6c-8abc-036785caf2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff86641-4876-4f6c-8abc-036785caf2c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3ff86641-4876-4f6c-8abc-036785caf2c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff86641-4876-4f6c-8abc-036785caf2c7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3ff86641-4876-4f6c-8abc-036785caf2c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_02f8937b-db4b-4715-bef8-8327c856e753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff86641-4876-4f6c-8abc-036785caf2c7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_02f8937b-db4b-4715-bef8-8327c856e753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_00907c4d-d07a-4dc1-9cf1-5dc5a61a453d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_02f8937b-db4b-4715-bef8-8327c856e753" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_00907c4d-d07a-4dc1-9cf1-5dc5a61a453d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4216375a-3b38-4cff-b662-80eb639a7c19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4216375a-3b38-4cff-b662-80eb639a7c19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4216375a-3b38-4cff-b662-80eb639a7c19_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4216375a-3b38-4cff-b662-80eb639a7c19" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4216375a-3b38-4cff-b662-80eb639a7c19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3197c640-0ee7-455e-ba6c-078f26c5e0cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4216375a-3b38-4cff-b662-80eb639a7c19" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3197c640-0ee7-455e-ba6c-078f26c5e0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a0b9ab3f-25d1-41dd-9eb7-c9634d447440" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3197c640-0ee7-455e-ba6c-078f26c5e0cd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a0b9ab3f-25d1-41dd-9eb7-c9634d447440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f1c1f001-585b-4de2-a735-54174418a98a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f1c1f001-585b-4de2-a735-54174418a98a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f1c1f001-585b-4de2-a735-54174418a98a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f1c1f001-585b-4de2-a735-54174418a98a" xlink:to="loc_us-gaap_EquityComponentDomain_f1c1f001-585b-4de2-a735-54174418a98a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1c6ae862-c979-4070-89ad-ebc92dd2b851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f1c1f001-585b-4de2-a735-54174418a98a" xlink:to="loc_us-gaap_EquityComponentDomain_1c6ae862-c979-4070-89ad-ebc92dd2b851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a9ca89ca-8d39-400f-b240-fdc83eaed1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1c6ae862-c979-4070-89ad-ebc92dd2b851" xlink:to="loc_us-gaap_RetainedEarningsMember_a9ca89ca-8d39-400f-b240-fdc83eaed1dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails" xlink:type="extended" id="if68230cb5b0049ba8da80be61f5ef846_SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended" id="ie7876c9b539a40a9a8ce9856e1e8e235_SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fd89f366-2215-44ad-9d32-0e8675a271e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0a6a86e-9816-466f-b8d0-9c5e592ac24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fd89f366-2215-44ad-9d32-0e8675a271e9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0a6a86e-9816-466f-b8d0-9c5e592ac24e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fd89f366-2215-44ad-9d32-0e8675a271e9" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8953ef47-ee74-47c4-b536-eed43151d46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8953ef47-ee74-47c4-b536-eed43151d46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8953ef47-ee74-47c4-b536-eed43151d46a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8953ef47-ee74-47c4-b536-eed43151d46a" xlink:to="loc_us-gaap_EquityComponentDomain_8953ef47-ee74-47c4-b536-eed43151d46a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_25a485d2-d59c-4ecf-b4fe-95ab7b46cad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8953ef47-ee74-47c4-b536-eed43151d46a" xlink:to="loc_us-gaap_EquityComponentDomain_25a485d2-d59c-4ecf-b4fe-95ab7b46cad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f570b21c-a019-48c7-aee8-add77d822df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25a485d2-d59c-4ecf-b4fe-95ab7b46cad2" xlink:to="loc_us-gaap_RetainedEarningsMember_f570b21c-a019-48c7-aee8-add77d822df8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a98682-032c-458d-b056-19e82dfee6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a98682-032c-458d-b056-19e82dfee6e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b1a98682-032c-458d-b056-19e82dfee6e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a98682-032c-458d-b056-19e82dfee6e4" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b1a98682-032c-458d-b056-19e82dfee6e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_eab0caa6-18e3-4615-a1aa-ce38d89af854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a98682-032c-458d-b056-19e82dfee6e4" xlink:to="loc_us-gaap_TypeOfAdoptionMember_eab0caa6-18e3-4615-a1aa-ce38d89af854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_92829ff6-70f7-4425-887b-f49fecf9012d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_eab0caa6-18e3-4615-a1aa-ce38d89af854" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_92829ff6-70f7-4425-887b-f49fecf9012d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f08bc52b-1220-416c-8a18-6c5cd60123cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f08bc52b-1220-416c-8a18-6c5cd60123cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f08bc52b-1220-416c-8a18-6c5cd60123cd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f08bc52b-1220-416c-8a18-6c5cd60123cd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f08bc52b-1220-416c-8a18-6c5cd60123cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_af5bff5e-e70d-4589-a2bf-ae0ce9e6f6eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f08bc52b-1220-416c-8a18-6c5cd60123cd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_af5bff5e-e70d-4589-a2bf-ae0ce9e6f6eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_44b2bea2-40a9-4822-baad-07144ad6d476" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_af5bff5e-e70d-4589-a2bf-ae0ce9e6f6eb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_44b2bea2-40a9-4822-baad-07144ad6d476" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="extended" id="i1eb6bafaf53c48638e0f8a0689186605_SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="extended" id="i99c1f3eed69d492e8dcacdb640357390_SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="extended" id="ide90e690d6ad4a4aa693943b8fd263e0_SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_533f51e0-910d-47c0-8846-7a1091e2064e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5946846-4940-4da4-897a-f164faf20830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_533f51e0-910d-47c0-8846-7a1091e2064e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5946846-4940-4da4-897a-f164faf20830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c5ff79f4-a582-4711-99be-9654c9ae32c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_533f51e0-910d-47c0-8846-7a1091e2064e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c5ff79f4-a582-4711-99be-9654c9ae32c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2739a22a-1e25-44af-9b11-a35ee611a854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c5ff79f4-a582-4711-99be-9654c9ae32c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2739a22a-1e25-44af-9b11-a35ee611a854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2739a22a-1e25-44af-9b11-a35ee611a854_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2739a22a-1e25-44af-9b11-a35ee611a854" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2739a22a-1e25-44af-9b11-a35ee611a854_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2739a22a-1e25-44af-9b11-a35ee611a854" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7249272a-0d3c-4b12-a9d1-a899ec7645d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7249272a-0d3c-4b12-a9d1-a899ec7645d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_8abe4d1c-3ac5-4336-9107-d7e9117f26c6" xlink:href="silk-20201231.xsd#silk_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_8abe4d1c-3ac5-4336-9107-d7e9117f26c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_83f5cb74-daf7-48b3-bbc5-99a14ecf9f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_us-gaap_EmployeeStockOptionMember_83f5cb74-daf7-48b3-bbc5-99a14ecf9f84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_86be6e44-52e9-4ea6-9e96-617877274ac8" xlink:href="silk-20201231.xsd#silk_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_silk_CommonStockWarrantMember_86be6e44-52e9-4ea6-9e96-617877274ac8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6006817b-a500-4df2-86fc-1242f5d746c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6006817b-a500-4df2-86fc-1242f5d746c6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="extended" id="i8bc33af7e5ee43c7800f839a0423cf15_SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="silk-20201231.xsd#RecentAccountingPronouncements"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="extended" id="ie1fa4217327749dca600d4e758aec23d_RecentAccountingPronouncements"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="silk-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="extended" id="ief8442effde847ed899a21c5e007b6c7_FairValueMeasurements"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="silk-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i119529dc030346ed95cb1ad4b6361535_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="extended" id="iaf05ef224c4c4b03aeefe78def2ac19c_FairValueMeasurementsRecurringAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f09ce13c-a31c-46ce-ae60-429f3a3ba730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9182cc8e-3f79-4ecc-a746-49763159fdd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f09ce13c-a31c-46ce-ae60-429f3a3ba730" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9182cc8e-3f79-4ecc-a746-49763159fdd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_99c883d0-4478-4cd5-83ca-d0d51f37b6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f09ce13c-a31c-46ce-ae60-429f3a3ba730" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_99c883d0-4478-4cd5-83ca-d0d51f37b6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f09ce13c-a31c-46ce-ae60-429f3a3ba730" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_914e6053-c2c0-4307-85c2-38f84f381514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_914e6053-c2c0-4307-85c2-38f84f381514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_914e6053-c2c0-4307-85c2-38f84f381514_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_914e6053-c2c0-4307-85c2-38f84f381514" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_914e6053-c2c0-4307-85c2-38f84f381514_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_50676151-6955-4a50-a70f-ac40f6e7ad19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_914e6053-c2c0-4307-85c2-38f84f381514" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_50676151-6955-4a50-a70f-ac40f6e7ad19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b7c11931-34a4-40f4-96db-8bb924a50bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_50676151-6955-4a50-a70f-ac40f6e7ad19" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b7c11931-34a4-40f4-96db-8bb924a50bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71f20d8e-172a-4336-9792-f44770f785b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71f20d8e-172a-4336-9792-f44770f785b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71f20d8e-172a-4336-9792-f44770f785b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71f20d8e-172a-4336-9792-f44770f785b4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71f20d8e-172a-4336-9792-f44770f785b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71f20d8e-172a-4336-9792-f44770f785b4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5d5ad783-1f6f-4d37-900a-ec3a368ce454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5d5ad783-1f6f-4d37-900a-ec3a368ce454" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_39f3a5f4-61f6-4ce7-858d-e98813e1d6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_39f3a5f4-61f6-4ce7-858d-e98813e1d6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d39982b6-6b1c-4d32-81c7-63f1552680d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d39982b6-6b1c-4d32-81c7-63f1552680d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ebe75529-cf0f-409b-9de0-db37b30f1e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ebe75529-cf0f-409b-9de0-db37b30f1e80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebe75529-cf0f-409b-9de0-db37b30f1e80_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ebe75529-cf0f-409b-9de0-db37b30f1e80" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebe75529-cf0f-409b-9de0-db37b30f1e80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ebe75529-cf0f-409b-9de0-db37b30f1e80" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_84f605d3-4087-4adb-9f74-93bd1cb0ba3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_84f605d3-4087-4adb-9f74-93bd1cb0ba3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_45951b5a-f4c9-4ff2-81fd-2d00900bc0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_45951b5a-f4c9-4ff2-81fd-2d00900bc0a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c3a94a79-6ae9-4c37-94a4-fc398a4ad23e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c3a94a79-6ae9-4c37-94a4-fc398a4ad23e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_538f1915-6b1d-4e8c-8ada-f47daaa370b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_538f1915-6b1d-4e8c-8ada-f47daaa370b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_734a2c78-5941-44be-a0d5-a965241d2d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_734a2c78-5941-44be-a0d5-a965241d2d34" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponents"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="extended" id="ie3c6776724e94b6b855372dc84e5087d_BalanceSheetComponents"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="extended" id="idb76e818ca3e4927818b8869c9c85bd2_BalanceSheetComponentsTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="extended" id="i3fd8db83be6c4dc59a534a1bcfc10c66_BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cc245e0d-3dd2-4b5f-877e-d0098acb5b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cc245e0d-3dd2-4b5f-877e-d0098acb5b2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00a56dd3-ce17-4671-9f13-48ce7da4bb50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00a56dd3-ce17-4671-9f13-48ce7da4bb50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_46224308-31ca-4949-87f6-d112977b639e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_46224308-31ca-4949-87f6-d112977b639e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87cdb6a9-029d-42c3-aba9-8780d79b8ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87cdb6a9-029d-42c3-aba9-8780d79b8ad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a13163ce-4559-4dfe-9912-dc675cbb99f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a13163ce-4559-4dfe-9912-dc675cbb99f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_af081b73-d3d8-4661-9a66-7d12182f6105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a13163ce-4559-4dfe-9912-dc675cbb99f3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_af081b73-d3d8-4661-9a66-7d12182f6105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af081b73-d3d8-4661-9a66-7d12182f6105_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_af081b73-d3d8-4661-9a66-7d12182f6105" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_af081b73-d3d8-4661-9a66-7d12182f6105_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_af081b73-d3d8-4661-9a66-7d12182f6105" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b696aa1a-844d-49e7-ba85-2fee7dd314d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b696aa1a-844d-49e7-ba85-2fee7dd314d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a575a9f0-5654-4ff9-b43a-fad1a4a2d3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_CommercialPaperMember_a575a9f0-5654-4ff9-b43a-fad1a4a2d3cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9d846ad5-24d8-469a-9a92-abcbb9e2d01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9d846ad5-24d8-469a-9a92-abcbb9e2d01e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_93c95a0d-6b00-4143-a1c3-668e4e75d316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_93c95a0d-6b00-4143-a1c3-668e4e75d316" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4004175a-815b-4169-ba9e-a0b15ae8ad65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4004175a-815b-4169-ba9e-a0b15ae8ad65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_ddb6bb78-1d63-4957-8431-74d278a9ca37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_CashEquivalentsMember_ddb6bb78-1d63-4957-8431-74d278a9ca37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_dcac2c40-e556-457e-b5cf-8dce3a05e5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_dcac2c40-e556-457e-b5cf-8dce3a05e5d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermInvestmentsMember_f6241f29-86da-43bb-958f-9c0dedcd5343" xlink:href="silk-20201231.xsd#silk_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_silk_LongTermInvestmentsMember_f6241f29-86da-43bb-958f-9c0dedcd5343" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="extended" id="i39cfec3dd8514ca4a8338956382fbe08_BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended" id="ie456cc09f1ea417f83ed663e40228f2c_BalanceSheetComponentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_c23d006b-3020-45ce-9625-05eaf7aa498a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_c23d006b-3020-45ce-9625-05eaf7aa498a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4aa74338-d786-4a9c-8f80-da756780d870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4aa74338-d786-4a9c-8f80-da756780d870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable_b9996575-2239-4490-a072-b0841b3ff78a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:to="loc_us-gaap_LossContingencyReceivable_b9996575-2239-4490-a072-b0841b3ff78a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a2c12353-5dda-45df-bf74-2d839b77ebe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:to="loc_us-gaap_Depreciation_a2c12353-5dda-45df-bf74-2d839b77ebe2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_31fefc94-428d-48e7-b3dd-aef6a021c2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:to="loc_us-gaap_InventoryCurrentTable_31fefc94-428d-48e7-b3dd-aef6a021c2df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeAxis_7920d16e-6859-4692-80a0-f3a6eabb7f2d" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_31fefc94-428d-48e7-b3dd-aef6a021c2df" xlink:to="loc_silk_LossContingencyReceivableTypeAxis_7920d16e-6859-4692-80a0-f3a6eabb7f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeDomain_7920d16e-6859-4692-80a0-f3a6eabb7f2d_default" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_silk_LossContingencyReceivableTypeAxis_7920d16e-6859-4692-80a0-f3a6eabb7f2d" xlink:to="loc_silk_LossContingencyReceivableTypeDomain_7920d16e-6859-4692-80a0-f3a6eabb7f2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeDomain_22ea390c-ec58-4b9b-bbc0-19c35dd9fb28" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_silk_LossContingencyReceivableTypeAxis_7920d16e-6859-4692-80a0-f3a6eabb7f2d" xlink:to="loc_silk_LossContingencyReceivableTypeDomain_22ea390c-ec58-4b9b-bbc0-19c35dd9fb28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember_6642c6f8-38c7-46fe-87b5-8c5f683e26ae" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_LossContingencyReceivableTypeDomain_22ea390c-ec58-4b9b-bbc0-19c35dd9fb28" xlink:to="loc_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember_6642c6f8-38c7-46fe-87b5-8c5f683e26ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9dc0b332-10eb-43d1-a052-2eaa23ac6c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_31fefc94-428d-48e7-b3dd-aef6a021c2df" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9dc0b332-10eb-43d1-a052-2eaa23ac6c38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_9dc0b332-10eb-43d1-a052-2eaa23ac6c38_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9dc0b332-10eb-43d1-a052-2eaa23ac6c38" xlink:to="loc_us-gaap_LossContingencyNatureDomain_9dc0b332-10eb-43d1-a052-2eaa23ac6c38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_96b13657-69f1-4033-9445-dfd0217dc843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9dc0b332-10eb-43d1-a052-2eaa23ac6c38" xlink:to="loc_us-gaap_LossContingencyNatureDomain_96b13657-69f1-4033-9445-dfd0217dc843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_VoluntaryRecallMember_f05073bf-2f8e-4888-a81f-d66d632fa406" xlink:href="silk-20201231.xsd#silk_VoluntaryRecallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_96b13657-69f1-4033-9445-dfd0217dc843" xlink:to="loc_silk_VoluntaryRecallMember_f05073bf-2f8e-4888-a81f-d66d632fa406" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended" id="i8d21fe0e84c34db282ab2f333edd8973_BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b841d08a-65bf-466e-adea-d3b9352e32dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b2229f2a-c14b-4be5-add7-bcc4867050c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b841d08a-65bf-466e-adea-d3b9352e32dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b2229f2a-c14b-4be5-add7-bcc4867050c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3fbe1928-b186-4aa2-b636-4e66cbe5ff69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b841d08a-65bf-466e-adea-d3b9352e32dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3fbe1928-b186-4aa2-b636-4e66cbe5ff69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_45910d7c-2227-4fff-9611-5babcfed512d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b841d08a-65bf-466e-adea-d3b9352e32dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_45910d7c-2227-4fff-9611-5babcfed512d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2aa8a372-66a3-4d4f-b49c-06f4f1099978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_45910d7c-2227-4fff-9611-5babcfed512d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2aa8a372-66a3-4d4f-b49c-06f4f1099978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2aa8a372-66a3-4d4f-b49c-06f4f1099978_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2aa8a372-66a3-4d4f-b49c-06f4f1099978" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2aa8a372-66a3-4d4f-b49c-06f4f1099978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_504e6c93-9661-4c91-a48c-db935978025d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2aa8a372-66a3-4d4f-b49c-06f4f1099978" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_504e6c93-9661-4c91-a48c-db935978025d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f230dbfa-d948-4f1e-9061-b9bc28fed68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_504e6c93-9661-4c91-a48c-db935978025d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f230dbfa-d948-4f1e-9061-b9bc28fed68a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d7b89fb-f507-426c-a115-3f195a86ab23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_504e6c93-9661-4c91-a48c-db935978025d" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d7b89fb-f507-426c-a115-3f195a86ab23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsScheduleofInventoryDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="extended" id="i9b4ea9201c8242b696425039aea9b747_BalanceSheetComponentsScheduleofInventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_5d56fc1b-3d61-42c9-93ff-c8c53aa7762e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryRawMaterials_5d56fc1b-3d61-42c9-93ff-c8c53aa7762e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_37ce4345-8530-4a47-ae5d-1a162ed74c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryFinishedGoods_37ce4345-8530-4a47-ae5d-1a162ed74c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0932259d-086e-4383-ab0c-14df0d5fa305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryGross_0932259d-086e-4383-ab0c-14df0d5fa305" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_5b50834e-04ff-4834-a1cc-41109008db95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryValuationReserves_5b50834e-04ff-4834-a1cc-41109008db95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bbf5f6fe-1f4e-4bc5-b693-145142e4a7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryNet_bbf5f6fe-1f4e-4bc5-b693-145142e4a7b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_99e930c8-3397-49d9-849f-e4d94553507a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_8dcffb94-3b3e-4d0b-b03d-f7e540463e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryCurrentTable_8dcffb94-3b3e-4d0b-b03d-f7e540463e1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d98a134a-0b1a-4526-b5a0-4f29a10ca2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_8dcffb94-3b3e-4d0b-b03d-f7e540463e1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d98a134a-0b1a-4526-b5a0-4f29a10ca2f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d98a134a-0b1a-4526-b5a0-4f29a10ca2f3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d98a134a-0b1a-4526-b5a0-4f29a10ca2f3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d98a134a-0b1a-4526-b5a0-4f29a10ca2f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0a98f862-1f75-4a41-8db9-3cd686be0223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d98a134a-0b1a-4526-b5a0-4f29a10ca2f3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0a98f862-1f75-4a41-8db9-3cd686be0223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_VoluntaryRecallMember_8365e2c2-2f6d-4a90-bb6e-a784cecda71c" xlink:href="silk-20201231.xsd#silk_VoluntaryRecallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0a98f862-1f75-4a41-8db9-3cd686be0223" xlink:to="loc_silk_VoluntaryRecallMember_8365e2c2-2f6d-4a90-bb6e-a784cecda71c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended" id="ia54b19bf07f34b408dac70ae8e4ac240_BalanceSheetComponentsPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_49ad21df-392e-4261-8462-897e15c4e9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_49ad21df-392e-4261-8462-897e15c4e9f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b33bbcf0-adf2-46f3-8d70-6ffc2c3183ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b33bbcf0-adf2-46f3-8d70-6ffc2c3183ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a7bb9ea3-217c-4007-83f8-8c8216790705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a7bb9ea3-217c-4007-83f8-8c8216790705" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6fdb61f2-ca64-4d72-8189-dad8fdd9893a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6fdb61f2-ca64-4d72-8189-dad8fdd9893a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e184113f-7235-4669-85d9-876a9480d859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6fdb61f2-ca64-4d72-8189-dad8fdd9893a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e184113f-7235-4669-85d9-876a9480d859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e184113f-7235-4669-85d9-876a9480d859_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e184113f-7235-4669-85d9-876a9480d859" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e184113f-7235-4669-85d9-876a9480d859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e184113f-7235-4669-85d9-876a9480d859" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1c8adc61-06fe-4016-a1c4-f25096d67e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1c8adc61-06fe-4016-a1c4-f25096d67e24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d12a3e41-07af-44ae-8a5b-024164e79301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_EquipmentMember_d12a3e41-07af-44ae-8a5b-024164e79301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a70bb533-5832-48d7-9324-30d360d71361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a70bb533-5832-48d7-9324-30d360d71361" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f2c4ae2b-d1e7-4f4b-81d8-561006a01450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f2c4ae2b-d1e7-4f4b-81d8-561006a01450" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_bf02a4c1-aca5-4988-9622-ff47bcaeee05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_ConstructionInProgressMember_bf02a4c1-aca5-4988-9622-ff47bcaeee05" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended" id="i23f922229d0d427394f39aeb0c5f9adb_BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebt" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebt"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebt" xlink:type="extended" id="i6378232a0c5349a2bda8efd05720a64a_LongtermDebt"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="extended" id="i393996bff8c54479a2e44003098149d6_LongtermDebtTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtCRGNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails" xlink:type="extended" id="iae11a85298a849f8a7dbf8596b8e17df_LongtermDebtCRGNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtMaximumBorrowingCapacity_f461a8cb-7288-44b1-a801-ef85f545baa3" xlink:href="silk-20201231.xsd#silk_DebtMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_silk_DebtMaximumBorrowingCapacity_f461a8cb-7288-44b1-a801-ef85f545baa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_8615515d-1749-4c8b-ab81-8095ef6e902a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_8615515d-1749-4c8b-ab81-8095ef6e902a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4730f626-980b-4df5-b041-7297db1813be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4730f626-980b-4df5-b041-7297db1813be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInKind_0f0e3f23-78b0-401a-9acf-fb472e97685d" xlink:href="silk-20201231.xsd#silk_DebtInstrumentInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_silk_DebtInstrumentInterestRatePaidInKind_0f0e3f23-78b0-401a-9acf-fb472e97685d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInCash_b8790523-2fdc-4dec-a30b-e32d3c0d24a2" xlink:href="silk-20201231.xsd#silk_DebtInstrumentInterestRatePaidInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_silk_DebtInstrumentInterestRatePaidInCash_b8790523-2fdc-4dec-a30b-e32d3c0d24a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0e3e5704-72bc-44bd-89b7-8a8b46184010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_us-gaap_DebtInstrumentTable_0e3e5704-72bc-44bd-89b7-8a8b46184010" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_77131635-7f52-475d-8db3-0e15f4e59f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0e3e5704-72bc-44bd-89b7-8a8b46184010" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_77131635-7f52-475d-8db3-0e15f4e59f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77131635-7f52-475d-8db3-0e15f4e59f0e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77131635-7f52-475d-8db3-0e15f4e59f0e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77131635-7f52-475d-8db3-0e15f4e59f0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77131635-7f52-475d-8db3-0e15f4e59f0e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanMember_44f80252-2a41-4a1e-a825-97194da5c083" xlink:href="silk-20201231.xsd#silk_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:to="loc_silk_TermLoanMember_44f80252-2a41-4a1e-a825-97194da5c083" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheAMember_6ff3e743-8c89-4a95-9738-44374acc030f" xlink:href="silk-20201231.xsd#silk_TermLoanTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:to="loc_silk_TermLoanTrancheAMember_6ff3e743-8c89-4a95-9738-44374acc030f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheBMember_9c12cf80-b0b1-4885-af7a-3a80128c8c0e" xlink:href="silk-20201231.xsd#silk_TermLoanTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:to="loc_silk_TermLoanTrancheBMember_9c12cf80-b0b1-4885-af7a-3a80128c8c0e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtStifelBankNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails" xlink:type="extended" id="id6f09b8e264a4a39a15c91c1c51401c1_LongtermDebtStifelBankNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5bba1191-a10a-4952-980b-24f3272bbbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5bba1191-a10a-4952-980b-24f3272bbbac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentMaximumBorrowingCapacity_c4cc41dd-406b-4657-a981-5b35ab01377d" xlink:href="silk-20201231.xsd#silk_DebtInstrumentMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentMaximumBorrowingCapacity_c4cc41dd-406b-4657-a981-5b35ab01377d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantMaximumBorrowingThreshold_9b19d2a3-8580-41b4-99e7-998415089202" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantMaximumBorrowingThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantMaximumBorrowingThreshold_9b19d2a3-8580-41b4-99e7-998415089202" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_56dc3d70-2d8a-45cb-a909-303135977c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_56dc3d70-2d8a-45cb-a909-303135977c56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_7ca3adb4-2f88-4990-9c61-211479155667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_7ca3adb4-2f88-4990-9c61-211479155667" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_7c0dbdae-25f2-4559-9ffb-9e4d0911b060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_7c0dbdae-25f2-4559-9ffb-9e4d0911b060" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_ed00a8fd-37f5-4432-8d6e-f2c2583925c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_ed00a8fd-37f5-4432-8d6e-f2c2583925c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_ac0a4387-dc88-42c4-812b-52c975bcdffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_InterestExpenseDebt_ac0a4387-dc88-42c4-812b-52c975bcdffe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1c2223e0-6c38-47c2-b3f6-7c617180d7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1c2223e0-6c38-47c2-b3f6-7c617180d7eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f8d0c936-353e-4860-8584-4f0750f70187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f8d0c936-353e-4860-8584-4f0750f70187" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RepaymentsOfDebtRevenueTargetPercentage_5664e529-178f-4178-ac16-f27a48e1d251" xlink:href="silk-20201231.xsd#silk_RepaymentsOfDebtRevenueTargetPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_RepaymentsOfDebtRevenueTargetPercentage_5664e529-178f-4178-ac16-f27a48e1d251" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_b13937f1-b9b3-4700-97ac-68b0c8bb44be" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_b13937f1-b9b3-4700-97ac-68b0c8bb44be" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_43576915-69c1-4fbe-97e0-e3a459ff3588" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantLiquidityEventPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_43576915-69c1-4fbe-97e0-e3a459ff3588" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum_af5110ee-47ec-4930-8fa7-4b23c592dd1f" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum_af5110ee-47ec-4930-8fa7-4b23c592dd1f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions_76cdd813-b904-4631-a5c0-b3cb400e0a14" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions_76cdd813-b904-4631-a5c0-b3cb400e0a14" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantDebtDefaultRate_29bbf651-3820-4f5b-aa87-25f9dd1a3de6" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantDebtDefaultRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantDebtDefaultRate_29bbf651-3820-4f5b-aa87-25f9dd1a3de6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f2de889-9eb6-4634-9563-1cbfe70cb217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f2de889-9eb6-4634-9563-1cbfe70cb217" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6f3ba28d-4222-4843-a357-14d91092dbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_us-gaap_DebtInstrumentAxis_6f3ba28d-4222-4843-a357-14d91092dbf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6f3ba28d-4222-4843-a357-14d91092dbf3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6f3ba28d-4222-4843-a357-14d91092dbf3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6f3ba28d-4222-4843-a357-14d91092dbf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7c261709-d8ff-4d46-aa58-d653770bf145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6f3ba28d-4222-4843-a357-14d91092dbf3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7c261709-d8ff-4d46-aa58-d653770bf145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LoanAndSecurityAgreementMember_8adb52d6-d796-4b6c-8484-f1ba733503e5" xlink:href="silk-20201231.xsd#silk_LoanAndSecurityAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7c261709-d8ff-4d46-aa58-d653770bf145" xlink:to="loc_silk_LoanAndSecurityAgreementMember_8adb52d6-d796-4b6c-8484-f1ba733503e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SuccessFeeAgreementMember_55828206-06c1-4249-a54c-643a4fdbefae" xlink:href="silk-20201231.xsd#silk_SuccessFeeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7c261709-d8ff-4d46-aa58-d653770bf145" xlink:to="loc_silk_SuccessFeeAgreementMember_55828206-06c1-4249-a54c-643a4fdbefae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7d5a20f5-9877-4529-83a5-67c0a2a5f0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_us-gaap_CreditFacilityAxis_7d5a20f5-9877-4529-83a5-67c0a2a5f0bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7d5a20f5-9877-4529-83a5-67c0a2a5f0bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7d5a20f5-9877-4529-83a5-67c0a2a5f0bd" xlink:to="loc_us-gaap_CreditFacilityDomain_7d5a20f5-9877-4529-83a5-67c0a2a5f0bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bbb9e233-8954-4a57-9050-fe15bc383fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7d5a20f5-9877-4529-83a5-67c0a2a5f0bd" xlink:to="loc_us-gaap_CreditFacilityDomain_bbb9e233-8954-4a57-9050-fe15bc383fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_0413a019-f118-4f61-bb54-51b7933574a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_bbb9e233-8954-4a57-9050-fe15bc383fbb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_0413a019-f118-4f61-bb54-51b7933574a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_7aac6c1b-100b-4a69-8d79-a2dfd08a3d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_bbb9e233-8954-4a57-9050-fe15bc383fbb" xlink:to="loc_us-gaap_LetterOfCreditMember_7aac6c1b-100b-4a69-8d79-a2dfd08a3d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05e828e4-87f5-4bc9-ada3-8f100f8fbe63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05e828e4-87f5-4bc9-ada3-8f100f8fbe63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05e828e4-87f5-4bc9-ada3-8f100f8fbe63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05e828e4-87f5-4bc9-ada3-8f100f8fbe63" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05e828e4-87f5-4bc9-ada3-8f100f8fbe63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2cc5d3cb-d6b4-45af-b98b-a4486e0da990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05e828e4-87f5-4bc9-ada3-8f100f8fbe63" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2cc5d3cb-d6b4-45af-b98b-a4486e0da990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5bef95e6-fcdc-4ef4-bb41-dcca61415f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2cc5d3cb-d6b4-45af-b98b-a4486e0da990" xlink:to="loc_us-gaap_LineOfCreditMember_5bef95e6-fcdc-4ef4-bb41-dcca61415f9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_75b4e247-69b9-4c02-89cd-6784afa9a082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2cc5d3cb-d6b4-45af-b98b-a4486e0da990" xlink:to="loc_us-gaap_SecuredDebtMember_75b4e247-69b9-4c02-89cd-6784afa9a082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_74b37a7c-8043-49a1-9d67-2b4c634348db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_us-gaap_VariableRateAxis_74b37a7c-8043-49a1-9d67-2b4c634348db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_74b37a7c-8043-49a1-9d67-2b4c634348db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_74b37a7c-8043-49a1-9d67-2b4c634348db" xlink:to="loc_us-gaap_VariableRateDomain_74b37a7c-8043-49a1-9d67-2b4c634348db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_257531b8-a139-4fa0-9917-4bde57288cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_74b37a7c-8043-49a1-9d67-2b4c634348db" xlink:to="loc_us-gaap_VariableRateDomain_257531b8-a139-4fa0-9917-4bde57288cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_8f101483-0c4d-408a-b1f9-40f6e6dd21d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_257531b8-a139-4fa0-9917-4bde57288cf5" xlink:to="loc_us-gaap_PrimeRateMember_8f101483-0c4d-408a-b1f9-40f6e6dd21d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentRateScenarioAxis_e5835996-3752-4bda-bd30-78062a8acb8b" xlink:href="silk-20201231.xsd#silk_DebtInstrumentRateScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_silk_DebtInstrumentRateScenarioAxis_e5835996-3752-4bda-bd30-78062a8acb8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentRateScenarioDomain_e5835996-3752-4bda-bd30-78062a8acb8b_default" xlink:href="silk-20201231.xsd#silk_DebtInstrumentRateScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_silk_DebtInstrumentRateScenarioAxis_e5835996-3752-4bda-bd30-78062a8acb8b" xlink:to="loc_silk_DebtInstrumentRateScenarioDomain_e5835996-3752-4bda-bd30-78062a8acb8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentRateScenarioDomain_8b5204fc-f7b1-4a03-835e-0f7084c7434d" xlink:href="silk-20201231.xsd#silk_DebtInstrumentRateScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_silk_DebtInstrumentRateScenarioAxis_e5835996-3752-4bda-bd30-78062a8acb8b" xlink:to="loc_silk_DebtInstrumentRateScenarioDomain_8b5204fc-f7b1-4a03-835e-0f7084c7434d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RateScenarioOneMember_efeec038-83b6-4cf0-99aa-bc54cdbf6253" xlink:href="silk-20201231.xsd#silk_RateScenarioOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_DebtInstrumentRateScenarioDomain_8b5204fc-f7b1-4a03-835e-0f7084c7434d" xlink:to="loc_silk_RateScenarioOneMember_efeec038-83b6-4cf0-99aa-bc54cdbf6253" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RateScenarioTwoMember_e9572002-865d-4a25-b5ff-9278bf7b7deb" xlink:href="silk-20201231.xsd#silk_RateScenarioTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_DebtInstrumentRateScenarioDomain_8b5204fc-f7b1-4a03-835e-0f7084c7434d" xlink:to="loc_silk_RateScenarioTwoMember_e9572002-865d-4a25-b5ff-9278bf7b7deb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtFutureMaturitiesUndertheTermLoanDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="extended" id="ic32cf820bfe94d3792393cfaa874bd59_LongtermDebtFutureMaturitiesUndertheTermLoanDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="extended" id="i7c03ca441fb049eb91e633d0c0fa63cf_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="ifd1e75d8ab5f4d3da8799b189cc24380_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesLeaseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="extended" id="i24a44ceacbff42a5bb47eac7ef6f30db_CommitmentsandContingenciesLeaseNarrativeDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesBalanceSheetInformationDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="extended" id="i8b05a670530c471c8080a99da95f1a8e_CommitmentsandContingenciesBalanceSheetInformationDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="extended" id="i771ead8b34954dd7a707a0ba49c00423_CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails" xlink:type="extended" id="i840e988384464d3cb516f37e96c74e34_CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="silk-20201231.xsd#RedeemableConvertiblePreferredStock"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended" id="i98679a831b934a1d9c520cf7e6cfa004_RedeemableConvertiblePreferredStock"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#RedeemableConvertiblePreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="extended" id="i82e4716f152c46699239cbbb346839ed_RedeemableConvertiblePreferredStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_f143aa19-4414-45d6-9a09-01e7a0d64801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_f143aa19-4414-45d6-9a09-01e7a0d64801" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_109af6c6-7005-41ab-ad26-e52d06a74dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_109af6c6-7005-41ab-ad26-e52d06a74dfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_931c58c1-c503-4f52-bd17-2220a2d631d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_931c58c1-c503-4f52-bd17-2220a2d631d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_4141480a-2d20-49e0-9f47-888d3ea5a2b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_4141480a-2d20-49e0-9f47-888d3ea5a2b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_205b6cd4-d5e2-4a94-a381-c655380c1997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:to="loc_us-gaap_StatementClassOfStockAxis_205b6cd4-d5e2-4a94-a381-c655380c1997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_205b6cd4-d5e2-4a94-a381-c655380c1997_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_205b6cd4-d5e2-4a94-a381-c655380c1997" xlink:to="loc_us-gaap_ClassOfStockDomain_205b6cd4-d5e2-4a94-a381-c655380c1997_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9437e562-3be3-4ed9-a27e-3b3b754d2b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_205b6cd4-d5e2-4a94-a381-c655380c1997" xlink:to="loc_us-gaap_ClassOfStockDomain_9437e562-3be3-4ed9-a27e-3b3b754d2b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7b1fea35-674d-4f9d-ab64-add933f77a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9437e562-3be3-4ed9-a27e-3b3b754d2b4e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7b1fea35-674d-4f9d-ab64-add933f77a61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_fa5ff630-fbf3-4cc4-8865-34b2f587cd37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_fa5ff630-fbf3-4cc4-8865-34b2f587cd37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_fa5ff630-fbf3-4cc4-8865-34b2f587cd37_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fa5ff630-fbf3-4cc4-8865-34b2f587cd37" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_fa5ff630-fbf3-4cc4-8865-34b2f587cd37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4399d4b9-1858-4dc6-9763-cb04ea9c4593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fa5ff630-fbf3-4cc4-8865-34b2f587cd37" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4399d4b9-1858-4dc6-9763-cb04ea9c4593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PreferredStockWarrantsMember_e9793fad-8de4-48b2-be27-c206e63e7f8c" xlink:href="silk-20201231.xsd#silk_PreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4399d4b9-1858-4dc6-9763-cb04ea9c4593" xlink:to="loc_silk_PreferredStockWarrantsMember_e9793fad-8de4-48b2-be27-c206e63e7f8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8ea5b920-011b-47e6-8e80-b4e1a297b141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8ea5b920-011b-47e6-8e80-b4e1a297b141" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ea5b920-011b-47e6-8e80-b4e1a297b141_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8ea5b920-011b-47e6-8e80-b4e1a297b141" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8ea5b920-011b-47e6-8e80-b4e1a297b141_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20dbff9e-ad7c-46e2-afa6-f2125144ce6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8ea5b920-011b-47e6-8e80-b4e1a297b141" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20dbff9e-ad7c-46e2-afa6-f2125144ce6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_0cbc4ed7-07f3-419f-a2e6-3a8248f1ba89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20dbff9e-ad7c-46e2-afa6-f2125144ce6a" xlink:to="loc_us-gaap_IPOMember_0cbc4ed7-07f3-419f-a2e6-3a8248f1ba89" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficit" xlink:type="extended" id="ie7d29deda1604952934937a0d292b472_StockholdersEquityDeficit"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitTables" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficitTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficitTables" xlink:type="extended" id="iaa9787b0c37041ef929c321d0dcfa08b_StockholdersEquityDeficitTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficitNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended" id="ib61053d5b4cc4209878080fa4ffd08fe_StockholdersEquityDeficitNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_80c71824-90e7-455a-ab29-975f4320f96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_80c71824-90e7-455a-ab29-975f4320f96a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1a375efb-f09a-46de-bd9d-0386f7baaf5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1a375efb-f09a-46de-bd9d-0386f7baaf5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_63ddce06-831c-444b-b8e4-0b4f8e6342f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_63ddce06-831c-444b-b8e4-0b4f8e6342f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_44a28a88-9c2c-4873-9833-0673be1a0738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_PreferredStockSharesIssued_44a28a88-9c2c-4873-9833-0673be1a0738" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6a1e8d5b-0330-433b-bf4a-dfcde8fb33df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6a1e8d5b-0330-433b-bf4a-dfcde8fb33df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_babf975f-afaa-4e60-b073-5c47a46aecbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_babf975f-afaa-4e60-b073-5c47a46aecbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_805c2730-8656-417b-b4f2-b080164d75f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_CommonStockSharesIssued_805c2730-8656-417b-b4f2-b080164d75f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1424479d-c756-4c44-84e5-40b1f91c6e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1424479d-c756-4c44-84e5-40b1f91c6e42" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_ac33d08b-e2e2-4a02-8dd4-2c976923de64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_DividendsCommonStock_ac33d08b-e2e2-4a02-8dd4-2c976923de64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockVotePerShare_619d277d-f244-4b43-8094-f0f7559138d8" xlink:href="silk-20201231.xsd#silk_CommonStockVotePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_silk_CommonStockVotePerShare_619d277d-f244-4b43-8094-f0f7559138d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8372c13a-3b2b-4f6c-93a6-ec6b2fb7d6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8372c13a-3b2b-4f6c-93a6-ec6b2fb7d6bd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_81df71bb-43fc-4e77-8e10-006b1ecc25dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_81df71bb-43fc-4e77-8e10-006b1ecc25dc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_edf2a02a-2be7-4919-a240-43f1565d18a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_edf2a02a-2be7-4919-a240-43f1565d18a9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9c68253f-751b-4865-bc9d-3f4083b56e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9c68253f-751b-4865-bc9d-3f4083b56e2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_acca362d-6e38-47da-ab89-6c9c6e416dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9c68253f-751b-4865-bc9d-3f4083b56e2a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_acca362d-6e38-47da-ab89-6c9c6e416dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_acca362d-6e38-47da-ab89-6c9c6e416dcc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_acca362d-6e38-47da-ab89-6c9c6e416dcc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_acca362d-6e38-47da-ab89-6c9c6e416dcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_56de3e6d-cb80-4edd-a3c2-cf22531ad1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_acca362d-6e38-47da-ab89-6c9c6e416dcc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_56de3e6d-cb80-4edd-a3c2-cf22531ad1ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_cc3aa361-1e03-45bb-aa3b-7c802ded44b8" xlink:href="silk-20201231.xsd#silk_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_56de3e6d-cb80-4edd-a3c2-cf22531ad1ca" xlink:to="loc_silk_CommonStockWarrantMember_cc3aa361-1e03-45bb-aa3b-7c802ded44b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c3cab97f-54d5-4b3b-9f8c-432a4f4e8588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9c68253f-751b-4865-bc9d-3f4083b56e2a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c3cab97f-54d5-4b3b-9f8c-432a4f4e8588" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3cab97f-54d5-4b3b-9f8c-432a4f4e8588_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c3cab97f-54d5-4b3b-9f8c-432a4f4e8588" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3cab97f-54d5-4b3b-9f8c-432a4f4e8588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6af62d3-b02a-4551-a854-08227d89fcbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c3cab97f-54d5-4b3b-9f8c-432a4f4e8588" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6af62d3-b02a-4551-a854-08227d89fcbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_649bd0b7-0672-4278-b6e4-aeaf31cd4708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6af62d3-b02a-4551-a854-08227d89fcbe" xlink:to="loc_us-gaap_IPOMember_649bd0b7-0672-4278-b6e4-aeaf31cd4708" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails" xlink:type="extended" id="i578c440e08144fb1b1f314be63823da0_StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6d689a0a-0ec8-416e-97f5-44b2bdf707c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8562e7f2-c313-4764-a8eb-d7f64bf885b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d689a0a-0ec8-416e-97f5-44b2bdf707c6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8562e7f2-c313-4764-a8eb-d7f64bf885b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8b62d9ae-cf8f-4a9b-b3f7-40114872cb5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d689a0a-0ec8-416e-97f5-44b2bdf707c6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8b62d9ae-cf8f-4a9b-b3f7-40114872cb5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42b8e61c-086f-4a61-9b84-c7b5d0735469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b62d9ae-cf8f-4a9b-b3f7-40114872cb5b" xlink:to="loc_us-gaap_AwardTypeAxis_42b8e61c-086f-4a61-9b84-c7b5d0735469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42b8e61c-086f-4a61-9b84-c7b5d0735469_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_42b8e61c-086f-4a61-9b84-c7b5d0735469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42b8e61c-086f-4a61-9b84-c7b5d0735469_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_42b8e61c-086f-4a61-9b84-c7b5d0735469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionExercisedMember_75833adc-169a-418b-9d4f-41b709a72e4f" xlink:href="silk-20201231.xsd#silk_IncentiveandNonqualifiedStockOptionExercisedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:to="loc_silk_IncentiveandNonqualifiedStockOptionExercisedMember_75833adc-169a-418b-9d4f-41b709a72e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionIssuedMember_8fcedb73-3399-48e2-810d-9cdb176b8225" xlink:href="silk-20201231.xsd#silk_IncentiveandNonqualifiedStockOptionIssuedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:to="loc_silk_IncentiveandNonqualifiedStockOptionIssuedMember_8fcedb73-3399-48e2-810d-9cdb176b8225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_EmployeeStockPurchasePlanMember_22af85d2-cc6c-490f-92f9-377ac826f7bb" xlink:href="silk-20201231.xsd#silk_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:to="loc_silk_EmployeeStockPurchasePlanMember_22af85d2-cc6c-490f-92f9-377ac826f7bb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlans" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlans"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlans" xlink:type="extended" id="i4084637c63014c88b3f90b9e859fe362_StockOptionPlans"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="extended" id="i80959611f94442ac8a15fdaabee7de7d_StockOptionPlansTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="extended" id="idc9575ab97a04a97b22ef6e83da84821_StockOptionPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fc9c3f0a-414f-47c4-810a-f333dd222c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fc9c3f0a-414f-47c4-810a-f333dd222c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_c59fd63a-cb67-4798-8099-5a073ae508be" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_c59fd63a-cb67-4798-8099-5a073ae508be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3258114b-3896-471c-8619-a83e4c041e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3258114b-3896-471c-8619-a83e4c041e0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_54497754-7286-4d26-bdd7-3cb404fbb394" xlink:href="silk-20201231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_54497754-7286-4d26-bdd7-3cb404fbb394" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_694b8443-04cb-4d8e-9780-74ed002448be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_694b8443-04cb-4d8e-9780-74ed002448be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80c8a711-942c-46ad-8952-6b93913cc631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80c8a711-942c-46ad-8952-6b93913cc631" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_53da27a0-4f19-4797-9259-ffce3009183f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_53da27a0-4f19-4797-9259-ffce3009183f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2f429968-fd48-45d0-b966-5445d327035a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2f429968-fd48-45d0-b966-5445d327035a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1a8c427c-c0ab-46db-b8fa-e2b600123db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1a8c427c-c0ab-46db-b8fa-e2b600123db4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4e70398f-8abd-415a-bf68-82426c0b9d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4e70398f-8abd-415a-bf68-82426c0b9d94" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce23b320-9913-408a-84f0-b31620b1e61f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce23b320-9913-408a-84f0-b31620b1e61f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_91939651-d108-4a27-8ddc-948a42960f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_91939651-d108-4a27-8ddc-948a42960f46" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60e80b0a-836f-4daf-81e9-eb214457bfcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60e80b0a-836f-4daf-81e9-eb214457bfcf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance_b1932492-b098-4a6b-8b91-aa0e09fc5382" xlink:href="silk-20201231.xsd#silk_CommonStockCapitalSharesAvailableForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance_b1932492-b098-4a6b-8b91-aa0e09fc5382" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93a8cbc0-6c17-4fd4-99c0-c003dc8e1be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93a8cbc0-6c17-4fd4-99c0-c003dc8e1be6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbdeaab2-6a5c-44ec-b15d-87bad376d89d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbdeaab2-6a5c-44ec-b15d-87bad376d89d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_67edffea-0f56-4dae-a385-21ff360547f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_67edffea-0f56-4dae-a385-21ff360547f1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3b51576f-5acd-49c3-9ecb-d62141d61ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3b51576f-5acd-49c3-9ecb-d62141d61ce6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_960c3bde-1bcd-429b-81cb-20b55be526a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:to="loc_us-gaap_PlanNameAxis_960c3bde-1bcd-429b-81cb-20b55be526a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_960c3bde-1bcd-429b-81cb-20b55be526a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_960c3bde-1bcd-429b-81cb-20b55be526a3" xlink:to="loc_us-gaap_PlanNameDomain_960c3bde-1bcd-429b-81cb-20b55be526a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_717dcbfd-6ba0-4ec0-8221-66b214e928ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_960c3bde-1bcd-429b-81cb-20b55be526a3" xlink:to="loc_us-gaap_PlanNameDomain_717dcbfd-6ba0-4ec0-8221-66b214e928ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember_787e2496-7204-4000-8b93-fc2ef16d23e7" xlink:href="silk-20201231.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_717dcbfd-6ba0-4ec0-8221-66b214e928ee" xlink:to="loc_silk_TwoThousandNineteenStockOptionPlanMember_787e2496-7204-4000-8b93-fc2ef16d23e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f68be088-d44d-4393-846b-288bd7da4a20" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:to="loc_srt_RangeAxis_f68be088-d44d-4393-846b-288bd7da4a20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f68be088-d44d-4393-846b-288bd7da4a20_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f68be088-d44d-4393-846b-288bd7da4a20" xlink:to="loc_srt_RangeMember_f68be088-d44d-4393-846b-288bd7da4a20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c315111-8258-40d5-9dbb-d06d656fd497" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f68be088-d44d-4393-846b-288bd7da4a20" xlink:to="loc_srt_RangeMember_7c315111-8258-40d5-9dbb-d06d656fd497" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a64d6b1d-e68a-4a34-9cf4-3b8795545762" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c315111-8258-40d5-9dbb-d06d656fd497" xlink:to="loc_srt_MaximumMember_a64d6b1d-e68a-4a34-9cf4-3b8795545762" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_711c7ab5-143a-4455-95d9-022403b6486d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:to="loc_us-gaap_AwardTypeAxis_711c7ab5-143a-4455-95d9-022403b6486d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_711c7ab5-143a-4455-95d9-022403b6486d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_711c7ab5-143a-4455-95d9-022403b6486d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_711c7ab5-143a-4455-95d9-022403b6486d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_711c7ab5-143a-4455-95d9-022403b6486d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionMember_08ffeadc-d0b0-4535-b786-846ada60577e" xlink:href="silk-20201231.xsd#silk_IncentiveandNonqualifiedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:to="loc_silk_IncentiveandNonqualifiedStockOptionMember_08ffeadc-d0b0-4535-b786-846ada60577e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveStockOptionMember_fc807a3c-b8e3-4175-bfac-62f97c23b827" xlink:href="silk-20201231.xsd#silk_IncentiveStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_IncentiveandNonqualifiedStockOptionMember_08ffeadc-d0b0-4535-b786-846ada60577e" xlink:to="loc_silk_IncentiveStockOptionMember_fc807a3c-b8e3-4175-bfac-62f97c23b827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NonqualifiedStockOptionsMember_70ece2eb-5c80-496d-815b-b1325c373459" xlink:href="silk-20201231.xsd#silk_NonqualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_IncentiveandNonqualifiedStockOptionMember_08ffeadc-d0b0-4535-b786-846ada60577e" xlink:to="loc_silk_NonqualifiedStockOptionsMember_70ece2eb-5c80-496d-815b-b1325c373459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5e71071f-7a54-4359-92d7-c43645cfc01d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:to="loc_us-gaap_EmployeeStockMember_5e71071f-7a54-4359-92d7-c43645cfc01d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_64c07388-3dbd-4782-b848-138ddc41ccd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:to="loc_us-gaap_EmployeeStockOptionMember_64c07388-3dbd-4782-b848-138ddc41ccd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0bbe0701-cd4c-4340-ba38-5c8375005edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0bbe0701-cd4c-4340-ba38-5c8375005edd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_890b7f66-9da4-4d3d-a9cd-a7d6b8679226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_890b7f66-9da4-4d3d-a9cd-a7d6b8679226" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_890b7f66-9da4-4d3d-a9cd-a7d6b8679226_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_890b7f66-9da4-4d3d-a9cd-a7d6b8679226" xlink:to="loc_us-gaap_RelatedPartyDomain_890b7f66-9da4-4d3d-a9cd-a7d6b8679226_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e87f7dbc-062f-49b8-a8f7-8db8e37c52e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_890b7f66-9da4-4d3d-a9cd-a7d6b8679226" xlink:to="loc_us-gaap_RelatedPartyDomain_e87f7dbc-062f-49b8-a8f7-8db8e37c52e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_1dc6ab8e-7d9b-4645-bc83-a6464d860b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e87f7dbc-062f-49b8-a8f7-8db8e37c52e3" xlink:to="loc_us-gaap_PrincipalOwnerMember_1dc6ab8e-7d9b-4645-bc83-a6464d860b2c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansActivityUnderCompensationPlanDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="extended" id="i1ddb09ba7bb44c9e8fcfbc3c92c1fb0b_StockOptionPlansActivityUnderCompensationPlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:href="silk-20201231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_287aed3a-2e5f-4822-bd9f-c445a16ec750" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_287aed3a-2e5f-4822-bd9f-c445a16ec750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_83cafc11-b5e8-4594-abf8-ac563dc44226" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_83cafc11-b5e8-4594-abf8-ac563dc44226" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_c48b843c-ab0b-4632-bff2-1ce852a2aa3d" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_c48b843c-ab0b-4632-bff2-1ce852a2aa3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_46154707-8007-4a90-96b7-9b76433b6671" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_46154707-8007-4a90-96b7-9b76433b6671" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_91a30a8c-e68e-46d2-a1b8-efcd9e26c0f5" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4a0f382-066e-48b0-825d-9ca9760324ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4a0f382-066e-48b0-825d-9ca9760324ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d126f6e3-4df7-428d-b9e1-12f42354a62e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d126f6e3-4df7-428d-b9e1-12f42354a62e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1c1deda-c903-4793-963a-a3da5fee9940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1c1deda-c903-4793-963a-a3da5fee9940" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b5867bb5-9e38-4d9d-a50e-65c1ccc2afe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b5867bb5-9e38-4d9d-a50e-65c1ccc2afe9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6447ede7-6304-4f00-9f7f-b1767423f435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3036c854-b744-4686-a878-07748a1c37a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3036c854-b744-4686-a878-07748a1c37a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4c2bb4bf-73c5-4f2f-938c-ad2c29a7de48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4c2bb4bf-73c5-4f2f-938c-ad2c29a7de48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5d61002-911f-45f0-9608-4bf479e96b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5d61002-911f-45f0-9608-4bf479e96b75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5cf4d986-e77c-4689-8ffd-77e14fa15d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5cf4d986-e77c-4689-8ffd-77e14fa15d6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7fef6dbe-6804-4c3b-8bb4-9e729fe5800b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7fef6dbe-6804-4c3b-8bb4-9e729fe5800b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2c0b8974-0496-4929-9c9d-003dfc4a8a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2c0b8974-0496-4929-9c9d-003dfc4a8a5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f57fdf5-9511-4d3f-8354-abe998b9aa70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1eb38777-7754-4821-8a66-e52cd95561da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1eb38777-7754-4821-8a66-e52cd95561da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4226655f-59ae-40e1-8297-24d819d74f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4226655f-59ae-40e1-8297-24d819d74f1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c75c5696-7175-4c8e-bc92-7704fe38ce74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c75c5696-7175-4c8e-bc92-7704fe38ce74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a1705ee0-e1bf-41d7-adcf-57bd74bdbc5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a1705ee0-e1bf-41d7-adcf-57bd74bdbc5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6d19d5d6-986c-4c06-bdf8-c55345d56237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6d19d5d6-986c-4c06-bdf8-c55345d56237" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc3645ab-608e-412e-8e4b-b9ebfa5e3435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc3645ab-608e-412e-8e4b-b9ebfa5e3435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_02935ad9-4787-4612-ae70-975521893a4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_02935ad9-4787-4612-ae70-975521893a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e8eedc43-429e-489f-8dc3-74d14214fb91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e8eedc43-429e-489f-8dc3-74d14214fb91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e1a9a7e-e680-46f4-9266-3137a635d2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e1a9a7e-e680-46f4-9266-3137a635d2bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4b5b6061-ec93-4442-99f0-296ae4447907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e1a9a7e-e680-46f4-9266-3137a635d2bf" xlink:to="loc_us-gaap_PlanNameAxis_4b5b6061-ec93-4442-99f0-296ae4447907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4b5b6061-ec93-4442-99f0-296ae4447907_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4b5b6061-ec93-4442-99f0-296ae4447907" xlink:to="loc_us-gaap_PlanNameDomain_4b5b6061-ec93-4442-99f0-296ae4447907_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9f5008f0-814f-4048-af24-176a8ddeeba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4b5b6061-ec93-4442-99f0-296ae4447907" xlink:to="loc_us-gaap_PlanNameDomain_9f5008f0-814f-4048-af24-176a8ddeeba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember_2a55ccee-6b80-42f2-920c-56ca87a7b14f" xlink:href="silk-20201231.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9f5008f0-814f-4048-af24-176a8ddeeba6" xlink:to="loc_silk_TwoThousandNineteenStockOptionPlanMember_2a55ccee-6b80-42f2-920c-56ca87a7b14f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansInformationbyExercisePriceDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails" xlink:type="extended" id="i12c0a7f098e342469480a2219f536669_StockOptionPlansInformationbyExercisePriceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_3fe95ab1-45b4-4e5d-b308-5e063c71e9ef" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_3fe95ab1-45b4-4e5d-b308-5e063c71e9ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a84f5943-458d-4a92-a1b5-a44a1b9158e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a84f5943-458d-4a92-a1b5-a44a1b9158e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b4b94e42-a769-40c6-823c-7492a50d9920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b4b94e42-a769-40c6-823c-7492a50d9920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b08aa886-ad80-4221-aaa8-afd946382101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b08aa886-ad80-4221-aaa8-afd946382101" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1d17abc4-5cd0-4710-803f-7cd95da59a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1d17abc4-5cd0-4710-803f-7cd95da59a70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a9e268ad-2c32-488a-b824-f72fc0eda183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a9e268ad-2c32-488a-b824-f72fc0eda183" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e7278da9-4146-4ae8-b10b-600db384ac80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e7278da9-4146-4ae8-b10b-600db384ac80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f3e6eea6-e620-475a-a8b2-4ca4142bbf68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e7278da9-4146-4ae8-b10b-600db384ac80" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f3e6eea6-e620-475a-a8b2-4ca4142bbf68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f3e6eea6-e620-475a-a8b2-4ca4142bbf68_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f3e6eea6-e620-475a-a8b2-4ca4142bbf68" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f3e6eea6-e620-475a-a8b2-4ca4142bbf68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f3e6eea6-e620-475a-a8b2-4ca4142bbf68" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceOneMember_03183d8e-0144-4439-9344-fb24467fcbc2" xlink:href="silk-20201231.xsd#silk_ExercisePriceOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceOneMember_03183d8e-0144-4439-9344-fb24467fcbc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceTwoMember_58cef9a2-fe36-4b91-8553-4dde1613b48f" xlink:href="silk-20201231.xsd#silk_ExercisePriceTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceTwoMember_58cef9a2-fe36-4b91-8553-4dde1613b48f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceThreeMember_6d783f27-71cd-42de-8887-74f87db2abd0" xlink:href="silk-20201231.xsd#silk_ExercisePriceThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceThreeMember_6d783f27-71cd-42de-8887-74f87db2abd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceFourMember_794210f9-c144-4591-a3be-4cfaf0621616" xlink:href="silk-20201231.xsd#silk_ExercisePriceFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceFourMember_794210f9-c144-4591-a3be-4cfaf0621616" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceFiveMember_ace3c0f6-5a34-4e59-a754-86dfec5d6540" xlink:href="silk-20201231.xsd#silk_ExercisePriceFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceFiveMember_ace3c0f6-5a34-4e59-a754-86dfec5d6540" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceSixMember_ccb260a5-f13e-4634-9400-973f6421301b" xlink:href="silk-20201231.xsd#silk_ExercisePriceSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceSixMember_ccb260a5-f13e-4634-9400-973f6421301b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3b915d2-33cc-4d6d-8189-024a0bd82fdc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e7278da9-4146-4ae8-b10b-600db384ac80" xlink:to="loc_srt_RangeAxis_d3b915d2-33cc-4d6d-8189-024a0bd82fdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3b915d2-33cc-4d6d-8189-024a0bd82fdc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d3b915d2-33cc-4d6d-8189-024a0bd82fdc" xlink:to="loc_srt_RangeMember_d3b915d2-33cc-4d6d-8189-024a0bd82fdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98c8dd04-94ad-42db-8d5f-3a96a67345d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d3b915d2-33cc-4d6d-8189-024a0bd82fdc" xlink:to="loc_srt_RangeMember_98c8dd04-94ad-42db-8d5f-3a96a67345d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb94c60e-f7e4-4ddb-988b-a9564c6d9714" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98c8dd04-94ad-42db-8d5f-3a96a67345d7" xlink:to="loc_srt_MinimumMember_bb94c60e-f7e4-4ddb-988b-a9564c6d9714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_04e7c358-9288-4782-b00f-8ef396e59276" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98c8dd04-94ad-42db-8d5f-3a96a67345d7" xlink:to="loc_srt_MaximumMember_04e7c358-9288-4782-b00f-8ef396e59276" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansRSUsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="extended" id="ie2c35f90b60c405888c5d68af8735290_StockOptionPlansRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_950d7709-393e-4e34-8738-6e9ff40ae3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_950d7709-393e-4e34-8738-6e9ff40ae3f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ddbf774e-d240-4735-acd2-a5d6b85bff87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ddbf774e-d240-4735-acd2-a5d6b85bff87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_506eacc3-8a15-4fd9-b746-705ee41f8e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_506eacc3-8a15-4fd9-b746-705ee41f8e8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9a30042a-bffb-4448-9c74-b665ab007ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9a30042a-bffb-4448-9c74-b665ab007ffb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7dbfe9cd-f082-48fa-aadc-969a8cd85395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7dbfe9cd-f082-48fa-aadc-969a8cd85395" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eca4672b-f1eb-44ed-87ed-30126d2cb7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_950d7709-393e-4e34-8738-6e9ff40ae3f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a7672c9-aa9a-4d27-a5df-f0a34cb47cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a7672c9-aa9a-4d27-a5df-f0a34cb47cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d8707bd-b7af-4e64-be2f-ff0681285979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d8707bd-b7af-4e64-be2f-ff0681285979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_94165fc9-7269-4c94-8c17-304ab5e78245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_94165fc9-7269-4c94-8c17-304ab5e78245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_716509f6-e412-4ce1-87d2-3b79b3b766df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_716509f6-e412-4ce1-87d2-3b79b3b766df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2710a238-216b-4111-a668-8eb7b88aa6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1865ea5c-af3b-4807-b1c8-c0e23e89ddb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_950d7709-393e-4e34-8738-6e9ff40ae3f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1865ea5c-af3b-4807-b1c8-c0e23e89ddb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9e84bae9-3aa5-49d8-be95-cbdbbfffccc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1865ea5c-af3b-4807-b1c8-c0e23e89ddb0" xlink:to="loc_us-gaap_AwardTypeAxis_9e84bae9-3aa5-49d8-be95-cbdbbfffccc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e84bae9-3aa5-49d8-be95-cbdbbfffccc7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9e84bae9-3aa5-49d8-be95-cbdbbfffccc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e84bae9-3aa5-49d8-be95-cbdbbfffccc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2419f278-a6b6-4364-ae21-5222e0a4ac93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9e84bae9-3aa5-49d8-be95-cbdbbfffccc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2419f278-a6b6-4364-ae21-5222e0a4ac93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_03c81d3c-5bc1-46fb-a058-4330caf0db6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2419f278-a6b6-4364-ae21-5222e0a4ac93" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_03c81d3c-5bc1-46fb-a058-4330caf0db6d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansFairValueofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="extended" id="ic6521992a8464545900d5f3a4f0a7e2d_StockOptionPlansFairValueofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6635c59-46d4-4281-b4eb-514f59288f29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6635c59-46d4-4281-b4eb-514f59288f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5724b4bb-661e-474b-b0f3-8dcc3dfc15cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5724b4bb-661e-474b-b0f3-8dcc3dfc15cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_753480c4-5853-4c08-8ff7-3b0fe1dc28da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_753480c4-5853-4c08-8ff7-3b0fe1dc28da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_57f4b2f0-c148-453b-a2f9-91270f0959f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_57f4b2f0-c148-453b-a2f9-91270f0959f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fa3415de-ee0e-4ad1-8be7-2712d6caca6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fa3415de-ee0e-4ad1-8be7-2712d6caca6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5f5d8c7f-bb9c-4efc-81c5-4b7029897e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5f5d8c7f-bb9c-4efc-81c5-4b7029897e2f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b12d9664-feef-4c4f-90d1-93c7f5cabbb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b12d9664-feef-4c4f-90d1-93c7f5cabbb8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_90d9d662-c6e3-4964-b727-4ebd6db3ef65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b12d9664-feef-4c4f-90d1-93c7f5cabbb8" xlink:to="loc_us-gaap_AwardTypeAxis_90d9d662-c6e3-4964-b727-4ebd6db3ef65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90d9d662-c6e3-4964-b727-4ebd6db3ef65_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_90d9d662-c6e3-4964-b727-4ebd6db3ef65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90d9d662-c6e3-4964-b727-4ebd6db3ef65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7c22d11-dec6-453b-846a-016cfaff6aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_90d9d662-c6e3-4964-b727-4ebd6db3ef65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7c22d11-dec6-453b-846a-016cfaff6aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9ac9608c-d7ca-4983-bb93-ef741ec17064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7c22d11-dec6-453b-846a-016cfaff6aef" xlink:to="loc_us-gaap_EmployeeStockMember_9ac9608c-d7ca-4983-bb93-ef741ec17064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1ba9ad6c-45a2-48d1-9e46-275a2f2869de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b12d9664-feef-4c4f-90d1-93c7f5cabbb8" xlink:to="loc_srt_RangeAxis_1ba9ad6c-45a2-48d1-9e46-275a2f2869de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ba9ad6c-45a2-48d1-9e46-275a2f2869de_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1ba9ad6c-45a2-48d1-9e46-275a2f2869de" xlink:to="loc_srt_RangeMember_1ba9ad6c-45a2-48d1-9e46-275a2f2869de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c4551e5-7368-4dc7-a779-82f23376c0a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1ba9ad6c-45a2-48d1-9e46-275a2f2869de" xlink:to="loc_srt_RangeMember_9c4551e5-7368-4dc7-a779-82f23376c0a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f2f8d5d7-4f69-467c-89f9-5e31edd62849" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c4551e5-7368-4dc7-a779-82f23376c0a9" xlink:to="loc_srt_MinimumMember_f2f8d5d7-4f69-467c-89f9-5e31edd62849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_47f97bd7-1acd-4036-8766-ad211a9a00af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c4551e5-7368-4dc7-a779-82f23376c0a9" xlink:to="loc_srt_MaximumMember_47f97bd7-1acd-4036-8766-ad211a9a00af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="extended" id="i8dc0207fdac84ce69f7605a33beed96f_StockOptionPlansStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf516d75-1c58-45fa-8e6b-21b19ae1c6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595b920b-007b-41ec-8b3c-fca94bd46ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf516d75-1c58-45fa-8e6b-21b19ae1c6b1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595b920b-007b-41ec-8b3c-fca94bd46ca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e3592a92-9314-4513-a2b8-27d676ab3fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf516d75-1c58-45fa-8e6b-21b19ae1c6b1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e3592a92-9314-4513-a2b8-27d676ab3fdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3cf5c39b-09e5-498b-8d27-126ca9a00fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e3592a92-9314-4513-a2b8-27d676ab3fdc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3cf5c39b-09e5-498b-8d27-126ca9a00fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3cf5c39b-09e5-498b-8d27-126ca9a00fed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3cf5c39b-09e5-498b-8d27-126ca9a00fed" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3cf5c39b-09e5-498b-8d27-126ca9a00fed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3cf5c39b-09e5-498b-8d27-126ca9a00fed" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_8aa861d5-c7b5-4179-9d4d-bb8cab25d517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:to="loc_us-gaap_CostOfSalesMember_8aa861d5-c7b5-4179-9d4d-bb8cab25d517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b40aee01-86e8-46c7-9d68-bfcc6395d016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b40aee01-86e8-46c7-9d68-bfcc6395d016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ca281b29-52ee-4df9-aacb-25a89f01b1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ca281b29-52ee-4df9-aacb-25a89f01b1e3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/IncomeTaxes" xlink:type="extended" id="i2baab0324b18424880e83ab549d8b401_IncomeTaxes"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/IncomeTaxesTables" xlink:type="extended" id="i118c46eb28ee47dd8cb0683bca8cdf02_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesComponentsofIncomeBeforeTaxesDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails" xlink:type="extended" id="i497a1008e93b4385bdf2c711a196bedc_IncomeTaxesComponentsofIncomeBeforeTaxesDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesReconciliationofUSStatutoryRateDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails" xlink:type="extended" id="i9c13cfd50d614dfab5a1541d104a93cb_IncomeTaxesReconciliationofUSStatutoryRateDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesNetDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended" id="ie411632a54004c639138b887f0161ff3_IncomeTaxesNetDeferredTaxAssetsDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i27299264ab5a436faee0ae08d853c5ad_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c5866c4c-c651-4193-9c9e-519358412fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c5866c4c-c651-4193-9c9e-519358412fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d0a67577-2b9c-491a-9344-164301bf5666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d0a67577-2b9c-491a-9344-164301bf5666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_OperatingLossCarryforwardOffsetMaximumPercent_ceba7093-fc2f-46e7-b68a-c8494cc0ef71" xlink:href="silk-20201231.xsd#silk_OperatingLossCarryforwardOffsetMaximumPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_silk_OperatingLossCarryforwardOffsetMaximumPercent_ceba7093-fc2f-46e7-b68a-c8494cc0ef71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e72e632b-8e44-45c2-bc7d-c6fd5a1f3033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e72e632b-8e44-45c2-bc7d-c6fd5a1f3033" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d376111f-68ac-49bc-863c-268f17b1385f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d376111f-68ac-49bc-863c-268f17b1385f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3dec4e79-39f0-40e8-b6c4-1eed6b6e2cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3dec4e79-39f0-40e8-b6c4-1eed6b6e2cf1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3b5382c7-f9f5-4321-acb5-5c43bb769540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3b5382c7-f9f5-4321-acb5-5c43bb769540" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0fed40af-5432-4d1e-b488-d718e4d2a554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0fed40af-5432-4d1e-b488-d718e4d2a554" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1e45d2be-d98f-4fc7-a24c-aeac988264fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0fed40af-5432-4d1e-b488-d718e4d2a554" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1e45d2be-d98f-4fc7-a24c-aeac988264fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1e45d2be-d98f-4fc7-a24c-aeac988264fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1e45d2be-d98f-4fc7-a24c-aeac988264fd" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1e45d2be-d98f-4fc7-a24c-aeac988264fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8e59c468-7c10-4dd6-a33f-ad2ee7632b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1e45d2be-d98f-4fc7-a24c-aeac988264fd" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8e59c468-7c10-4dd6-a33f-ad2ee7632b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_d747d1b9-2c48-464e-b9e8-8d67bc6797ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8e59c468-7c10-4dd6-a33f-ad2ee7632b26" xlink:to="loc_us-gaap_ResearchMember_d747d1b9-2c48-464e-b9e8-8d67bc6797ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4b3cade5-d701-4e46-b68f-bd677bb70206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0fed40af-5432-4d1e-b488-d718e4d2a554" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4b3cade5-d701-4e46-b68f-bd677bb70206" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4b3cade5-d701-4e46-b68f-bd677bb70206_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4b3cade5-d701-4e46-b68f-bd677bb70206" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4b3cade5-d701-4e46-b68f-bd677bb70206_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2d1c6469-47a2-4d77-80f0-674d7cc2b3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4b3cade5-d701-4e46-b68f-bd677bb70206" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2d1c6469-47a2-4d77-80f0-674d7cc2b3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_b0414954-f719-4eae-b045-6922817148e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2d1c6469-47a2-4d77-80f0-674d7cc2b3b7" xlink:to="loc_us-gaap_DomesticCountryMember_b0414954-f719-4eae-b045-6922817148e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_16728f5d-22d9-4f81-84cf-476128e89f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2d1c6469-47a2-4d77-80f0-674d7cc2b3b7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_16728f5d-22d9-4f81-84cf-476128e89f7f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i88bde41c6c9d4624aa150a983ac9a8ea_IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo" xlink:type="simple" xlink:href="silk-20201231.xsd#AcquisitionofVariableInterestEntityNeuroCo"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo" xlink:type="extended" id="i7f009d3478074bde8688f2cf7e5a788f_AcquisitionofVariableInterestEntityNeuroCo"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#AcquisitionofVariableInterestEntityNeuroCoDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails" xlink:type="extended" id="ib1bce0598c7b4a28985d433f3b40aed7_AcquisitionofVariableInterestEntityNeuroCoDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_4c830ddc-7edf-4d23-8e95-9a85bf9afb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_4c830ddc-7edf-4d23-8e95-9a85bf9afb18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage_a5b7e075-37cb-4325-9c8e-a65f48d1f9c5" xlink:href="silk-20201231.xsd#silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage_a5b7e075-37cb-4325-9c8e-a65f48d1f9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NotesReceivableRelatedPartiesTerm_893d18f4-063b-4927-bc7c-34721ec8fe3a" xlink:href="silk-20201231.xsd#silk_NotesReceivableRelatedPartiesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_silk_NotesReceivableRelatedPartiesTerm_893d18f4-063b-4927-bc7c-34721ec8fe3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5be5afb4-3076-4bb9-b723-4c83446b8349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5be5afb4-3076-4bb9-b723-4c83446b8349" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_dbd964f2-1b62-4446-991f-ff475050907e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_dbd964f2-1b62-4446-991f-ff475050907e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_27f1a17f-7fd6-403f-a096-e72c46f36063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_27f1a17f-7fd6-403f-a096-e72c46f36063" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven_5792837f-7337-4870-bc3b-2129e4112736" xlink:href="silk-20201231.xsd#silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven_5792837f-7337-4870-bc3b-2129e4112736" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_18bc129a-0b8e-4ba3-8c01-5dd3dad4cebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_18bc129a-0b8e-4ba3-8c01-5dd3dad4cebc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_059a4267-4849-419a-a363-ae1204509275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_059a4267-4849-419a-a363-ae1204509275" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6749ad5c-b57b-426d-84be-385f802f9245" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_059a4267-4849-419a-a363-ae1204509275" xlink:to="loc_dei_LegalEntityAxis_6749ad5c-b57b-426d-84be-385f802f9245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6749ad5c-b57b-426d-84be-385f802f9245_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6749ad5c-b57b-426d-84be-385f802f9245" xlink:to="loc_dei_EntityDomain_6749ad5c-b57b-426d-84be-385f802f9245_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_85124080-ef0a-4dd4-86b7-de93630b42e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6749ad5c-b57b-426d-84be-385f802f9245" xlink:to="loc_dei_EntityDomain_85124080-ef0a-4dd4-86b7-de93630b42e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NeuroCoIncMember_faf93adb-e930-49e2-a82c-45a3d247a872" xlink:href="silk-20201231.xsd#silk_NeuroCoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_85124080-ef0a-4dd4-86b7-de93630b42e9" xlink:to="loc_silk_NeuroCoIncMember_faf93adb-e930-49e2-a82c-45a3d247a872" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_12c2faf1-6f58-4e66-985c-9eea79430487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_059a4267-4849-419a-a363-ae1204509275" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_12c2faf1-6f58-4e66-985c-9eea79430487" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12c2faf1-6f58-4e66-985c-9eea79430487_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_12c2faf1-6f58-4e66-985c-9eea79430487" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12c2faf1-6f58-4e66-985c-9eea79430487_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e511f79b-4598-4743-a08b-d608314d7bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_12c2faf1-6f58-4e66-985c-9eea79430487" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e511f79b-4598-4743-a08b-d608314d7bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NeuroCoIncMember_01106909-0d17-467c-ae1b-36e97e626126" xlink:href="silk-20201231.xsd#silk_NeuroCoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e511f79b-4598-4743-a08b-d608314d7bf1" xlink:to="loc_silk_NeuroCoIncMember_01106909-0d17-467c-ae1b-36e97e626126" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlan" xlink:type="simple" xlink:href="silk-20201231.xsd#A401kPlan"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/A401kPlan" xlink:type="extended" id="i1c3123912e87411bab13b117092ddeed_A401kPlan"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#A401kPlanDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="extended" id="i571d402159a64bfa82bc7f4c0ffe745c_A401kPlanDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SubsequentEvents" xlink:type="simple" xlink:href="silk-20201231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SubsequentEvents" xlink:type="extended" id="i708ae097209c44deb229fbcbef855537_SubsequentEvents"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SubsequentEventsDetails" xlink:type="extended" id="i36f2d5f7b8854cfe97247dfbf2676557_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3745c7fa-994b-49f8-a686-a0c9b953d1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3745c7fa-994b-49f8-a686-a0c9b953d1ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62646b3f-fd0d-49d6-b536-549d840217aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62646b3f-fd0d-49d6-b536-549d840217aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14fecf9a-995c-4c96-b96d-c66831bfaa3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14fecf9a-995c-4c96-b96d-c66831bfaa3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cfe0dfda-26ac-4c30-97a6-45efc5e68eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cfe0dfda-26ac-4c30-97a6-45efc5e68eed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca782a18-dbc8-4e71-9a23-2b77a96f26ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca782a18-dbc8-4e71-9a23-2b77a96f26ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable_185b7bc3-43a8-4f88-a6bb-ea3d9a04c2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_LossContingencyReceivable_185b7bc3-43a8-4f88-a6bb-ea3d9a04c2b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_34bb85d2-d77f-4b22-b9ca-aba5748f768a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_34bb85d2-d77f-4b22-b9ca-aba5748f768a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_28c8008a-ab0d-4d17-b697-ad4709be24f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_28c8008a-ab0d-4d17-b697-ad4709be24f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod_cc7c2a42-3e71-4a9d-b0c8-d3ddc1435aee" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod_cc7c2a42-3e71-4a9d-b0c8-d3ddc1435aee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fcc283c9-0639-4a22-b19c-77618789681c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fcc283c9-0639-4a22-b19c-77618789681c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fcc283c9-0639-4a22-b19c-77618789681c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fcc283c9-0639-4a22-b19c-77618789681c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fcc283c9-0639-4a22-b19c-77618789681c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b4c69f4b-9220-44ed-8d40-9bc92aeb159c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fcc283c9-0639-4a22-b19c-77618789681c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b4c69f4b-9220-44ed-8d40-9bc92aeb159c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1ea730f3-1220-4ab5-bf14-ae7c3308d20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b4c69f4b-9220-44ed-8d40-9bc92aeb159c" xlink:to="loc_us-gaap_SubsequentEventMember_1ea730f3-1220-4ab5-bf14-ae7c3308d20b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_67fbd956-c8e5-4182-ad2a-3ef78ac5bfa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_us-gaap_PlanNameAxis_67fbd956-c8e5-4182-ad2a-3ef78ac5bfa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_67fbd956-c8e5-4182-ad2a-3ef78ac5bfa4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_67fbd956-c8e5-4182-ad2a-3ef78ac5bfa4" xlink:to="loc_us-gaap_PlanNameDomain_67fbd956-c8e5-4182-ad2a-3ef78ac5bfa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8c83a32a-f14c-460b-9330-70aa5c46487a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_67fbd956-c8e5-4182-ad2a-3ef78ac5bfa4" xlink:to="loc_us-gaap_PlanNameDomain_8c83a32a-f14c-460b-9330-70aa5c46487a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember_c840eda8-56f9-4c94-8f83-3c08a10e4a29" xlink:href="silk-20201231.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8c83a32a-f14c-460b-9330-70aa5c46487a" xlink:to="loc_silk_TwoThousandNineteenStockOptionPlanMember_c840eda8-56f9-4c94-8f83-3c08a10e4a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9ce1018a-029b-494f-b023-1471350556ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_us-gaap_AwardTypeAxis_9ce1018a-029b-494f-b023-1471350556ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ce1018a-029b-494f-b023-1471350556ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9ce1018a-029b-494f-b023-1471350556ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ce1018a-029b-494f-b023-1471350556ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89103195-f5e9-410a-9fea-37d245792317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9ce1018a-029b-494f-b023-1471350556ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89103195-f5e9-410a-9fea-37d245792317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9db258bb-2dbd-4436-be45-337d1200c950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89103195-f5e9-410a-9fea-37d245792317" xlink:to="loc_us-gaap_EmployeeStockMember_9db258bb-2dbd-4436-be45-337d1200c950" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1ddae3f0-02e7-43a4-82f7-3462f3f5f4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89103195-f5e9-410a-9fea-37d245792317" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1ddae3f0-02e7-43a4-82f7-3462f3f5f4a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeAxis_f2477a49-c532-490d-9160-c9d94b3b9571" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_silk_LossContingencyReceivableTypeAxis_f2477a49-c532-490d-9160-c9d94b3b9571" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeDomain_f2477a49-c532-490d-9160-c9d94b3b9571_default" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_silk_LossContingencyReceivableTypeAxis_f2477a49-c532-490d-9160-c9d94b3b9571" xlink:to="loc_silk_LossContingencyReceivableTypeDomain_f2477a49-c532-490d-9160-c9d94b3b9571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_silk_LossContingencyReceivableTypeAxis_f2477a49-c532-490d-9160-c9d94b3b9571" xlink:to="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableInventoryHeldMember_9006d757-5be8-4af7-acc1-927ebbd8af6e" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableInventoryHeldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:to="loc_silk_LossContingencyReceivableInventoryHeldMember_9006d757-5be8-4af7-acc1-927ebbd8af6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableInventoryInProcessOfRecallMember_128c074e-41ed-412f-8b2b-ba9274bdce65" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableInventoryInProcessOfRecallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:to="loc_silk_LossContingencyReceivableInventoryInProcessOfRecallMember_128c074e-41ed-412f-8b2b-ba9274bdce65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableDirectCostsMember_e152a1b7-8995-4a81-aa9c-fa2e3a2f455e" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableDirectCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:to="loc_silk_LossContingencyReceivableDirectCostsMember_e152a1b7-8995-4a81-aa9c-fa2e3a2f455e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6e694087-ecee-4409-b9fb-6ab60a4cb3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6e694087-ecee-4409-b9fb-6ab60a4cb3da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6e694087-ecee-4409-b9fb-6ab60a4cb3da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6e694087-ecee-4409-b9fb-6ab60a4cb3da" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6e694087-ecee-4409-b9fb-6ab60a4cb3da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6feedf91-b51c-4d66-84fd-9edf146156c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6e694087-ecee-4409-b9fb-6ab60a4cb3da" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6feedf91-b51c-4d66-84fd-9edf146156c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_VoluntaryRecallMember_c42a67ae-0144-4e3d-bc4d-2e101e202d8d" xlink:href="silk-20201231.xsd#silk_VoluntaryRecallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6feedf91-b51c-4d66-84fd-9edf146156c6" xlink:to="loc_silk_VoluntaryRecallMember_c42a67ae-0144-4e3d-bc4d-2e101e202d8d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited" xlink:type="simple" xlink:href="silk-20201231.xsd#QuarterlyFinancialInformationunaudited"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited" xlink:type="extended" id="i795d3ca29ca74997b74062a7bfd077c8_QuarterlyFinancialInformationunaudited"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables" xlink:type="simple" xlink:href="silk-20201231.xsd#QuarterlyFinancialInformationunauditedTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables" xlink:type="extended" id="i964e5841365349d2b86f06da5fd17f08_QuarterlyFinancialInformationunauditedTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#QuarterlyFinancialInformationunauditedDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails" xlink:type="extended" id="i90e66c05b1e6458ab4b0d00f14d31b25_QuarterlyFinancialInformationunauditedDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="simple" xlink:href="silk-20201231.xsd#ScheduleIIValuationandQualifyingAccounts"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="extended" id="i4d4d98906e7f4914b3d67a5c10b97f4c_ScheduleIIValuationandQualifyingAccounts"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails" xlink:type="extended" id="ie6d4ba47b0fe4bc6ab7d0d51c0927b6e_ScheduleIIValuationandQualifyingAccountsScheduleIIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_577f24d4-482c-406e-9487-d62e91118a86" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_577f24d4-482c-406e-9487-d62e91118a86" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d0c83c65-c50d-4941-8c1d-cfe75d642732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d0c83c65-c50d-4941-8c1d-cfe75d642732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_48ff6ca2-73f5-49c4-8487-e9dc9feb7bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_48ff6ca2-73f5-49c4-8487-e9dc9feb7bff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_17d29ffc-1cb8-462c-b5be-a5d9c0f943a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_17d29ffc-1cb8-462c-b5be-a5d9c0f943a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ef40f92c-590c-43a2-81a1-11a89e75b0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_015bf95c-8f85-4cea-8b13-c9ff7750b459" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_577f24d4-482c-406e-9487-d62e91118a86" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_015bf95c-8f85-4cea-8b13-c9ff7750b459" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d1c3a2e-ac86-4105-8474-02519ced1cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_015bf95c-8f85-4cea-8b13-c9ff7750b459" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d1c3a2e-ac86-4105-8474-02519ced1cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3d1c3a2e-ac86-4105-8474-02519ced1cf3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d1c3a2e-ac86-4105-8474-02519ced1cf3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3d1c3a2e-ac86-4105-8474-02519ced1cf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_517ea4e2-70ce-450f-8b91-c684af6d060b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d1c3a2e-ac86-4105-8474-02519ced1cf3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_517ea4e2-70ce-450f-8b91-c684af6d060b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_26ccb01a-1708-4952-b109-cac29d5d943d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_517ea4e2-70ce-450f-8b91-c684af6d060b" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_26ccb01a-1708-4952-b109-cac29d5d943d" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>silk-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:13b527d4-ea1a-4469-9dba-fa8b61e78c7f,g:43b528fe-3601-4224-908f-a46b4c727eef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_silk_NotesReceivableRelatedPartiesTerm_be528a99-93bc-4e43-8389-ed7683020924_terseLabel_en-US" xlink:label="lab_silk_NotesReceivableRelatedPartiesTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable, term</link:label>
    <link:label id="lab_silk_NotesReceivableRelatedPartiesTerm_label_en-US" xlink:label="lab_silk_NotesReceivableRelatedPartiesTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Term</link:label>
    <link:label id="lab_silk_NotesReceivableRelatedPartiesTerm_documentation_en-US" xlink:label="lab_silk_NotesReceivableRelatedPartiesTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NotesReceivableRelatedPartiesTerm" xlink:href="silk-20201231.xsd#silk_NotesReceivableRelatedPartiesTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_NotesReceivableRelatedPartiesTerm" xlink:to="lab_silk_NotesReceivableRelatedPartiesTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_596c8bb5-a579-4dda-9ed9-224e6f88077a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dcd69c50-4f50-43bb-8843-97b817d499f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_fbcc7a53-84f5-4291-b413-985ec97d9185_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5c716166-724b-43e6-8230-73ad9437dbb0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e4374b1c-e5c4-439c-a2a2-bac918a95aad_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_04376198-6740-47d9-ae90-bf3534fe78cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_08fdc3c2-42be-4bbb-bfb3-8cb96606aca5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_c72ecf84-1b46-4f74-b4d1-32ed97fd3476_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon IPO (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0aa8045-d806-4836-98df-84e80cb59817_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f7629be1-70af-42ca-a91c-846e73a2e1eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e1ed75b3-2d9a-4bf6-9b36-fff75da1e9fe_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6b65ada9-41b4-4c88-9fbb-2a3d6f07dbc8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInKind_c9c5ec4e-2f80-4b25-bc84-038670a94e13_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate paid-in-kind</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInKind_label_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Paid-In-Kind</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInKind_documentation_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Paid-In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInKind" xlink:href="silk-20201231.xsd#silk_DebtInstrumentInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentInterestRatePaidInKind" xlink:to="lab_silk_DebtInstrumentInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0de80ad2-c38a-4aaa-b17d-5f09f4130a14_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_d475ba70-a72f-429a-8060-7adaae56759f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae473e04-cc2a-44e1-afa4-201a7c22e900_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a26040ec-9654-4361-af99-e2ee0301af1b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_362528f7-9535-4425-8ab5-c48de911cf0a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for excess and obsolete inventories</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_IncentiveStockOptionMember_82e90fb9-2757-40f9-b599-9124e4af1ddf_terseLabel_en-US" xlink:label="lab_silk_IncentiveStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ISO</link:label>
    <link:label id="lab_silk_IncentiveStockOptionMember_label_en-US" xlink:label="lab_silk_IncentiveStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:label id="lab_silk_IncentiveStockOptionMember_documentation_en-US" xlink:label="lab_silk_IncentiveStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveStockOptionMember" xlink:href="silk-20201231.xsd#silk_IncentiveStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_IncentiveStockOptionMember" xlink:to="lab_silk_IncentiveStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_c730557d-bbbb-4b43-8335-32a651f958bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockAbstract_9784675b-288e-4b78-a370-99d025be67ea_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockAbstract_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockAbstract" xlink:to="lab_us-gaap_DividendsCommonStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_ffa302d8-69c4-443e-8f8f-1536e8db5198_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3db61c6f-c294-4b4e-a816-a72a4da5f3ed_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants_d948fb3e-6ed8-40f2-a8f4-aa5c8a3b4acf_terseLabel_en-US" xlink:label="lab_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:label id="lab_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="silk-20201231.xsd#silk_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f6c58e3-e3ac-442b-96c5-e331fc1ee8c8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_1aabe42b-1008-45a1-a434-6f332351d87d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c79fcd3e-cc5e-488c-bf37-9f79f8ad0c63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_d9a89f9f-cee2-408d-a3dd-a55adfff42d9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recall replacement obligation</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_685e6293-42c5-4358-a2ad-6d1827a35b51_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_2481d272-a3be-4fd1-8d39-873b6c13c7ad_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0f1cec19-1888-4400-a70a-0819c9534ebd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PublicStockOfferingMember_c1076895-a53d-48e4-ba42-20a1112cd4c2_terseLabel_en-US" xlink:label="lab_silk_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_silk_PublicStockOfferingMember_label_en-US" xlink:label="lab_silk_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_silk_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_silk_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingMember" xlink:href="silk-20201231.xsd#silk_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PublicStockOfferingMember" xlink:to="lab_silk_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f9a9890d-ba9a-41cf-bb82-1660da2bd613_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fa548b54-1337-4e6c-a1c8-f3daef20a941_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_271f141b-7c71-4f6c-b014-7ac1b6f50b3f_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption amount</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_label_en-US" xlink:label="lab_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Event, Payment Amount</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_documentation_en-US" xlink:label="lab_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Event, Payment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantLiquidityEventPaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:to="lab_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_8f59a8d0-d9ea-44a7-90a5-a3c580e7d5cd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon IPO</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_165cf1f2-6572-4fa1-8291-55053aa5c971_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_0969259e-3464-4467-b58a-62eb5a0c1990_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_69a6990b-6175-4e9e-b5d2-942f7291a660_terseLabel_en-US" xlink:label="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grant</link:label>
    <link:label id="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_label_en-US" xlink:label="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_documentation_en-US" xlink:label="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:href="silk-20201231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:to="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_23d8f9ca-febf-4c6d-b7ff-10b6b22c68bf_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_51261237-3506-4244-97a4-acf0e8a4b6a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_079ebc3c-c4a0-476e-ac3f-cd0b44f7d14c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9d9c79c2-b714-4169-bf9f-4df88b858e6d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_430c6dbe-94be-4cd4-a47b-9f37b84a9cf7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_147487cd-d7b5-4049-b486-d9f63283c4ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_2598154d-97ba-444b-bd9f-96177dc4d5dc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_263f0394-f6ea-4bcc-9f05-6e544eb4227f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_10d91f88-a86e-432b-9143-29d6b4e077ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a39bc272-1d91-4f11-a491-bfbd180dab97_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage employee contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c8087aa7-ff7d-461e-bd91-868a65875767_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46064cd2-e4e5-403f-945d-0d403a5c6b12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7ce3912f-5b1d-4336-9cdb-c168bf2e34bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option vesting term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_29998e15-f7ca-4f7a-95e3-7c65b9dfb403_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_02a7e50e-7613-4940-bd8f-bbd839848b13_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9e5f2977-11bb-4940-a0ce-c6e6de198fd7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1d9a47a9-30d2-4815-ad49-120011b839da_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_93477ac7-1352-430e-aacc-3f6712eeffc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fda07ecf-6a41-445d-b5ca-9b852679fb3b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a9d683dd-8352-4f23-81cb-96a3a75d29a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_fec8ad50-44db-4854-bc1a-c037a38455bf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_05e19935-db6d-4697-a9e3-69fbd283041e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_16e2458d-e093-4003-9f81-bdfcb2c98a34_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock outstanding</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5f75f9f3-eb00-4e3e-b946-449bb99e4117_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_4f1c9274-c586-4f02-af11-85ae9abc0770_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0e59e8c6-8f85-4497-aa40-b271347a3da8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_da8b3462-fcda-48e8-887f-ca78d5a31595_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ab6cf483-e8ea-4757-a8bd-307b63efc524_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_90555fc4-2822-4d35-87e8-cc8d42163ecb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset in other non-current assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_fcbfcc40-92f4-4a7f-9e69-41e32704d456_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a6b5e67-9ccd-463f-a159-0dfa56523da2_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_215dd98e-8ca1-4985-85bd-c499e5cb8600_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_51a1f1d1-3eba-42c1-950b-a38f5ecc79f6_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_00a2c759-c18f-45b4-95b8-5ad2187e6d1f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1611e68b-5f51-4fcd-bd1b-1c26584c6c7c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bdb8d9a2-539c-4068-b1f5-6bd202513a6f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_420d57c5-495d-4806-961b-a767431ae286_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7f9cec1d-91db-4a20-929a-5f3d98463719_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14c6ecd5-0876-498c-8b9a-ba36317b0803_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Measure on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_04698688-3025-409b-9aac-e88d591f291c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs related to the ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivable_a8d5ccb5-0e58-4442-9f22-4ad2e3eb7def_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency receivable</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivable_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivable" xlink:to="lab_us-gaap_LossContingencyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e989dfd6-a429-4fca-b011-076b0d2f06d5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_9f1eecc1-3059-42d8-a6f0-e3df6f54ff7b_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_48d05467-71bc-4ca5-820e-b454cf252165_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d0715096-1e32-4fc7-9ab5-45bcfa8de384_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_c1c887c2-30b6-42b2-b00d-3c42c3e78317_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized: 5,000,000 at December 31, 2020 and 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e604afb5-7a1f-42f1-abb4-6a59d03a3011_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_5ad81313-d935-43c0-b356-42a1a7a02f12_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TermLoanMember_41c564da-09f2-4d8a-9855-b0c560054f5b_terseLabel_en-US" xlink:label="lab_silk_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_silk_TermLoanMember_label_en-US" xlink:label="lab_silk_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_silk_TermLoanMember_documentation_en-US" xlink:label="lab_silk_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanMember" xlink:href="silk-20201231.xsd#silk_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TermLoanMember" xlink:to="lab_silk_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e0041c7b-6d1c-44bd-a1b9-b300b9fa1832_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_36c3e609-da4d-447c-94d8-1f06b6382cd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b3e8b627-8f40-4adf-9d56-ab6707245a08_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_7fa9dcfa-f494-4e0e-baee-bec143199afa_totalLabel_en-US" xlink:label="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross before accretion of closing fees</link:label>
    <link:label id="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_label_en-US" xlink:label="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross, Before Accretion Of Closing Fees</link:label>
    <link:label id="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_documentation_en-US" xlink:label="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross, Before Accretion Of Closing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:href="silk-20201231.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:to="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d15b1d1c-4f8f-447b-8c54-d345bcca4fc0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_08ebdff4-907f-4a3e-b66d-84f6bf265679_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_EmployeeStockPurchasePlanMember_a60b2ada-382e-43a7-b237-4c5904312e35_terseLabel_en-US" xlink:label="lab_silk_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_silk_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_silk_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_silk_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_silk_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_EmployeeStockPurchasePlanMember" xlink:href="silk-20201231.xsd#silk_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_EmployeeStockPurchasePlanMember" xlink:to="lab_silk_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_7a97a42e-15d3-4422-96c3-a20f874df175_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of prepayment penalty and lender fees</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_df2b0efc-3db7-4665-ac07-0fe903fd997a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium fee</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a5e95f33-e2a6-4de8-9df8-80c3114d4013_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0101aa58-f529-4bd7-9f73-bb5431864159_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ccbbe44d-9077-476d-b1f9-519f4d4cac5f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_dab648ce-e048-47ec-a063-bf6fb5ee5c62_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process inventories</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0b11c27e-d268-4022-80ca-f902fee739cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_f040a3e7-b20f-4e4e-a822-b6ddc5556b00_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled receivables</link:label>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_961fb040-85fb-4a17-99b3-1c74da39f150_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_bb0cb215-85ab-4481-acd2-7ad9cc30e322_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_59d2b49a-d325-44d9-9ee5-2db9df7d3115_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ff8f745a-dd9e-4c86-86d7-585144e68b98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_471ff7fe-eaaf-4904-a7b6-e3a2995e977f_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_4111f58a-b6b7-4fc0-9abc-5d5f1163f33d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_6d4f2abb-64e2-4179-94bd-5f5f3c4753bb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_91ee527c-86c4-4aaf-a43e-16495687d184_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a4f5ee1f-724d-4937-bf68-2d867108883b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1eb6f633-cf29-40a1-848b-a32b0f72f3a0_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ExercisePriceFiveMember_948b271b-2b24-4290-a7a6-f324e03a3099_terseLabel_en-US" xlink:label="lab_silk_ExercisePriceFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Five</link:label>
    <link:label id="lab_silk_ExercisePriceFiveMember_label_en-US" xlink:label="lab_silk_ExercisePriceFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Five [Member]</link:label>
    <link:label id="lab_silk_ExercisePriceFiveMember_documentation_en-US" xlink:label="lab_silk_ExercisePriceFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceFiveMember" xlink:href="silk-20201231.xsd#silk_ExercisePriceFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ExercisePriceFiveMember" xlink:to="lab_silk_ExercisePriceFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_caa56913-e271-49f7-911b-0af8a74b8000_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d66237a5-b62a-4ccf-84f9-e31feba901f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with NeuroCo merger (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LossContingencyReceivableTypeAxis_91592c84-377a-481b-9f5d-d6f9abfb3d0e_terseLabel_en-US" xlink:label="lab_silk_LossContingencyReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Type [Axis]</link:label>
    <link:label id="lab_silk_LossContingencyReceivableTypeAxis_label_en-US" xlink:label="lab_silk_LossContingencyReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Type [Axis]</link:label>
    <link:label id="lab_silk_LossContingencyReceivableTypeAxis_documentation_en-US" xlink:label="lab_silk_LossContingencyReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeAxis" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LossContingencyReceivableTypeAxis" xlink:to="lab_silk_LossContingencyReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_39d8781d-614b-4a36-add9-ee79b06a9dbc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Weighted Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_7e5d4a1e-9df5-4806-8f31-fb5f87513411_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentCovenantMaximumBorrowingThreshold_d5390a34-58d9-4a7c-b281-c22c60098fb3_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantMaximumBorrowingThreshold_label_en-US" xlink:label="lab_silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Borrowing Threshold</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantMaximumBorrowingThreshold_documentation_en-US" xlink:label="lab_silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Borrowing Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantMaximumBorrowingThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:to="lab_silk_DebtInstrumentCovenantMaximumBorrowingThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_2380faf1-d81c-4eec-9ede-78ba06a15a67_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_258a8f32-7474-47d7-bbe7-84c241ca6d40_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4f47fdd8-7f51-4008-b6b8-c662f6a4c530_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_fb8bb32a-afb3-406a-b0e4-f4dfca0c6314_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_22085b7c-a4e0-4429-88b0-eacd64f6c4cc_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_618f36ce-cb61-4d29-8209-7a464b22c56c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1b75140c-05c5-4eae-b726-94f7325da336_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInCash_4f505a69-f77a-4217-9e57-efd196b3492b_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate paid in cash</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInCash_label_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Paid In Cash</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInCash_documentation_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Paid In Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInCash" xlink:href="silk-20201231.xsd#silk_DebtInstrumentInterestRatePaidInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentInterestRatePaidInCash" xlink:to="lab_silk_DebtInstrumentInterestRatePaidInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c0f5567f-6d2b-471f-9e8e-187999f24c27_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_45906b80-04de-404c-a738-4048a192c8b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average days to maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_393e688a-d5bd-4343-a108-ab545e41bf52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_0c1fa2b2-cc35-42dd-bac2-df9652ad62ca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_834bde7e-fd60-46d3-af26-df3f5717e726_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_5c5a411a-db0d-4f26-aca7-9bf814861fd9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6dbe583d-f122-4e50-b420-0cdc705ff01f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_55b33b1c-d73b-4628-a19c-c45b42a529bb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c24f5b79-0eae-4a1c-8b3a-14481fa2d9ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_156f4ccc-975f-426a-831e-4405135f5d83_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued and sold common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_facb2b52-a7a6-4702-996e-00c74385e5f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3212fd72-c98b-48a6-a7e8-c65c19c8074b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1d9190d3-fd83-424b-b0db-a50f4ecc13b2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_dbebefdd-e35a-4f4c-9a81-5620725fff3c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87be0321-fee9-4eed-8064-70ac2233f90f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PublicStockOfferingSharesFromCompanyMember_91232c3c-03b8-410f-bd0e-90ed8828190e_terseLabel_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Company</link:label>
    <link:label id="lab_silk_PublicStockOfferingSharesFromCompanyMember_label_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Company [Member]</link:label>
    <link:label id="lab_silk_PublicStockOfferingSharesFromCompanyMember_documentation_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromCompanyMember" xlink:href="silk-20201231.xsd#silk_PublicStockOfferingSharesFromCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PublicStockOfferingSharesFromCompanyMember" xlink:to="lab_silk_PublicStockOfferingSharesFromCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_303089ae-8d40-44eb-a0a0-bd0c2e898b74_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_39e25c27-ede6-48f5-8522-282f463ccbfb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_66583185-6a31-48b1-9e0d-5d65b58deac8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Determination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_41f424b8-1a02-4dac-916d-05cd634e40ab_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Shares Available for Issuance</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_410ca5f7-1f5e-4dd7-9e7a-f4dc1beb3d4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6a94690b-ddf6-42be-8774-513203d4a0a6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development and Clinical Trials</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_20d29808-a5c8-4816-9db4-474fe3cef6be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_NonqualifiedStockOptionsMember_a30ee381-6a02-4795-b98b-939f4facf742_terseLabel_en-US" xlink:label="lab_silk_NonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NSO</link:label>
    <link:label id="lab_silk_NonqualifiedStockOptionsMember_label_en-US" xlink:label="lab_silk_NonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Stock Options [Member]</link:label>
    <link:label id="lab_silk_NonqualifiedStockOptionsMember_documentation_en-US" xlink:label="lab_silk_NonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NonqualifiedStockOptionsMember" xlink:href="silk-20201231.xsd#silk_NonqualifiedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_NonqualifiedStockOptionsMember" xlink:to="lab_silk_NonqualifiedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6dc35ab8-002a-4dd7-8e35-c2cd258719fd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TermLoanTrancheAMember_693b1b86-7b29-4b1f-944e-feba9072da38_terseLabel_en-US" xlink:label="lab_silk_TermLoanTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche A</link:label>
    <link:label id="lab_silk_TermLoanTrancheAMember_label_en-US" xlink:label="lab_silk_TermLoanTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche A [Member]</link:label>
    <link:label id="lab_silk_TermLoanTrancheAMember_documentation_en-US" xlink:label="lab_silk_TermLoanTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheAMember" xlink:href="silk-20201231.xsd#silk_TermLoanTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TermLoanTrancheAMember" xlink:to="lab_silk_TermLoanTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d630ba58-d739-443b-b1a7-eb83bb4c1834_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9e2198e1-de4a-4aa5-9c6a-373b85a3c287_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_b9ad296e-fa15-42fb-be8e-e221b359c702_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_b6cbaedd-9377-4948-9511-5dc06a8f74e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_002c2ff0-f0f0-41d1-a6dd-06fab84bb76e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DeferredTaxAssetsOperatingLeaseLiability_88183995-eeda-4a40-89d3-c52b73d34d2c_terseLabel_en-US" xlink:label="lab_silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_silk_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_silk_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="silk-20201231.xsd#silk_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_silk_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_93e8b3fa-73c5-4fd4-8a92-391320d8175e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04f9c9e7-28dd-4b5e-9325-56154d5ed908_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_3b670785-bca0-4d00-a37d-b187fbf37019_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Cash Equivalents, Short-Term and Long-Term Equivalents</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_188d63e4-f7dd-4321-8218-d718e509f03d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_259a4933-b7dc-48e2-8586-6b8ad2ebc1f6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_OperatingLossCarryforwardOffsetMaximumPercent_c27a5384-9988-4b84-8b94-b3309811bfd9_terseLabel_en-US" xlink:label="lab_silk_OperatingLossCarryforwardOffsetMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent maximum of federal taxable income to offset with net operating losses</link:label>
    <link:label id="lab_silk_OperatingLossCarryforwardOffsetMaximumPercent_label_en-US" xlink:label="lab_silk_OperatingLossCarryforwardOffsetMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward, Offset Maximum, Percent</link:label>
    <link:label id="lab_silk_OperatingLossCarryforwardOffsetMaximumPercent_documentation_en-US" xlink:label="lab_silk_OperatingLossCarryforwardOffsetMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward, Offset Maximum, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_OperatingLossCarryforwardOffsetMaximumPercent" xlink:href="silk-20201231.xsd#silk_OperatingLossCarryforwardOffsetMaximumPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_OperatingLossCarryforwardOffsetMaximumPercent" xlink:to="lab_silk_OperatingLossCarryforwardOffsetMaximumPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d46db21a-f680-43e3-b144-50f92df1fd48_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionIssuedMember_e5f3e141-5c1a-4ee5-a339-fcf7e188bdeb_terseLabel_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of options and restricted stock units under stock plan</link:label>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionIssuedMember_label_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and Nonqualified Stock Option, Issued [Member]</link:label>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionIssuedMember_documentation_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and Nonqualified Stock Option, Issued [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:href="silk-20201231.xsd#silk_IncentiveandNonqualifiedStockOptionIssuedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:to="lab_silk_IncentiveandNonqualifiedStockOptionIssuedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_f1a76277-0d66-4cb4-8d87-06f4ffeb5b16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of redeemable convertible preferred stock warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8621446b-6ab0-4ab8-b0ba-b0195df8c426_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_54efb97e-6c33-4a93-941e-f26bd6ce00d7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expensed not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_88eef3de-1ca0-42b2-a9f9-547d0774ee37_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8dc0b058-71b7-44d2-bb5b-57351a25dd47_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_d55500d9-bcc0-44ac-9960-740b887912f3_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_de19828a-2bf6-489f-b210-2281bf702c2a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CommonStockWarrantMember_f15e3a1e-2b29-424f-ae30-705c579093aa_terseLabel_en-US" xlink:label="lab_silk_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants outstanding</link:label>
    <link:label id="lab_silk_CommonStockWarrantMember_label_en-US" xlink:label="lab_silk_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:label id="lab_silk_CommonStockWarrantMember_documentation_en-US" xlink:label="lab_silk_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember" xlink:href="silk-20201231.xsd#silk_CommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CommonStockWarrantMember" xlink:to="lab_silk_CommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_e7f75a83-9cc8-4bb8-af1e-959bf5941a89_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_c19cf41b-97bb-4587-8c0e-41ffebcdf5fa_terseLabel_en-US" xlink:label="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:label id="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_label_en-US" xlink:label="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1 [Table Text Block]</link:label>
    <link:label id="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_documentation_en-US" xlink:label="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:href="silk-20201231.xsd#silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:to="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a39acfd9-329e-4112-8c7e-99518d9c529a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_815b5958-e4ee-47df-9eef-6c2a7ed00546_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_d369f21e-5fee-478e-9cc7-3e613161c059_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_6bc7df2f-158b-4cd7-a6d0-605c4512a440_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landlord paid tenant improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements" xlink:to="lab_us-gaap_PaymentsForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e4dee5dd-fc4b-4fde-9113-5e1371cadb37_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_19ccf9cc-8409-4701-9b4f-720e2bfc05e4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at End of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_470e2fbd-d75c-46e6-8d3f-59cf1e7d489d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_c6cb91eb-1af6-40e6-8fd2-b82c8b9c8032_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with NeuroCo merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8ba2e185-fff1-490d-891f-6d8718a03dab_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c6954a41-b680-415b-8eef-105c0af272e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8089c70d-df47-494a-b109-590c79b899ab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_aa79405b-045d-4b23-9e98-34d33adf8dbc_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fd98c65e-d72d-446e-9e0d-15b5c945dea9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_85a54da8-1748-48b5-a5da-fc084ce08d89_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_93bacefb-323d-478d-b39e-145a61a60a71_terseLabel_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts maturing after one year through two years</link:label>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_label_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years</link:label>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_documentation_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:href="silk-20201231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:to="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage_bb5bb756-9a9e-4d01-83e0-71f3c3cb570b_terseLabel_en-US" xlink:label="lab_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable, interest rate</link:label>
    <link:label id="lab_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage_label_en-US" xlink:label="lab_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage" xlink:href="silk-20201231.xsd#silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage" xlink:to="lab_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_ce1bc7ef-e6b9-4d2d-8a8f-9b77294861cd_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:to="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_43101192-f68d-45e2-ba3c-04a40da6461c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f8f17cc7-7645-4fc4-91f5-84cb31469443_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2a74bcd1-2066-41ca-aa87-4e82a8472954_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1474b2d1-180e-42d6-85a8-9aa3ead88d04_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise/issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f8ccac46-52cd-409b-99ee-12e71e240a39_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of common stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_917f3093-77a5-4263-8a5d-fd7c68b7c5c7_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentRateScenarioDomain_184297e8-ac80-43d6-b82f-9e786103527d_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentRateScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Rate Scenario [Domain]</link:label>
    <link:label id="lab_silk_DebtInstrumentRateScenarioDomain_label_en-US" xlink:label="lab_silk_DebtInstrumentRateScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Rate Scenario [Domain]</link:label>
    <link:label id="lab_silk_DebtInstrumentRateScenarioDomain_documentation_en-US" xlink:label="lab_silk_DebtInstrumentRateScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Rate Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentRateScenarioDomain" xlink:href="silk-20201231.xsd#silk_DebtInstrumentRateScenarioDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentRateScenarioDomain" xlink:to="lab_silk_DebtInstrumentRateScenarioDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_dd9b1e22-661a-465b-a9cd-4bed5ff9fa01_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_36dcf6f2-e3a5-4803-badf-9abf3af90fb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_2177b083-fe49-4c1c-9322-c27e65285dc3_negatedTerseLabel_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon IPO (in shares)</link:label>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_label_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares</link:label>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_documentation_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:href="silk-20201231.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:to="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_a6e424db-75f6-48a3-abcb-75d288dddff0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven_feb5604f-986f-4a33-a9ca-dc337f8f35c2_terseLabel_en-US" xlink:label="lab_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration given, amount of notes payable forgiven</link:label>
    <link:label id="lab_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven_label_en-US" xlink:label="lab_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Notes Payable Forgiven</link:label>
    <link:label id="lab_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven_documentation_en-US" xlink:label="lab_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Notes Payable Forgiven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven" xlink:href="silk-20201231.xsd#silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven" xlink:to="lab_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2903c8e4-6989-4b65-a5b5-5267f579ff6a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee59141b-821f-4447-972f-d16fc04916bd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_53a1f6e3-f0c1-402a-b27a-5fe811cbfd0f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PreferredStockWarrantsMember_ee1955d9-506c-4c2d-abbd-e4a4fbffb98a_terseLabel_en-US" xlink:label="lab_silk_PreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Warrants</link:label>
    <link:label id="lab_silk_PreferredStockWarrantsMember_label_en-US" xlink:label="lab_silk_PreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_silk_PreferredStockWarrantsMember_documentation_en-US" xlink:label="lab_silk_PreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PreferredStockWarrantsMember" xlink:href="silk-20201231.xsd#silk_PreferredStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PreferredStockWarrantsMember" xlink:to="lab_silk_PreferredStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_74ed4af6-298c-4ac8-8797-3b3c70a223f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20fb7195-5599-427c-9f13-7278e14d4464_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3944e32b-4926-45a1-8d7a-252a22da9e92_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ce4e84a-ee46-4f24-bb4a-03c9d75a3bea_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ProvisionsForSalesReturns_4150ba53-6fa1-4bca-9806-ada467e1672b_terseLabel_en-US" xlink:label="lab_silk_ProvisionsForSalesReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for sales returns</link:label>
    <link:label id="lab_silk_ProvisionsForSalesReturns_label_en-US" xlink:label="lab_silk_ProvisionsForSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Sales Returns</link:label>
    <link:label id="lab_silk_ProvisionsForSalesReturns_documentation_en-US" xlink:label="lab_silk_ProvisionsForSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Sales Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ProvisionsForSalesReturns" xlink:href="silk-20201231.xsd#silk_ProvisionsForSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ProvisionsForSalesReturns" xlink:to="lab_silk_ProvisionsForSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_2ed78107-18e5-4425-bfc2-ed7df015de49_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6e191667-e915-46d6-afaa-cf911b4d4dde_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk, and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_4fdb54f3-0569-4b67-b68d-6785861783e7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_369ee920-cbc9-4ba7-8839-c0cee23d58ee_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_8fdd89d8-67fb-4aff-b41e-0c79c798db8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f800ca7a-20d2-4b64-9af0-5b35d3403d93_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_2d048818-10a2-432b-880c-fd872e8a98c2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cd4803cb-2050-4053-9b7c-f55598bd102f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_b7ec00d1-8384-4996-82f6-60b4236a5b4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a8fb89d7-f9e6-4031-9f78-a089293c5923_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_f592d540-3633-47be-855b-364dae951bec_terseLabel_en-US" xlink:label="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_label_en-US" xlink:label="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Classified As Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_documentation_en-US" xlink:label="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Classified As Liabilities [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:href="silk-20201231.xsd#silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:to="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_acc7a96d-1cd5-4374-9456-17c21a827027_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d34e372d-561c-408e-9af5-df25ada81b79_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expensed not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dfb7b82e-9185-443a-9ab0-eee80875b45b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_66c65189-0951-4413-a77e-34ad4d428270_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_474a1d81-d371-4a7c-bfc6-4089eb54e3a7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_ebfc0774-89a6-470a-a350-9e8f60faf4a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserved Common Stock for Future Issuances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_NeuroCoIncMember_565dfc49-5972-4b55-81e9-d68eca4dd455_terseLabel_en-US" xlink:label="lab_silk_NeuroCoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NeuroCo, Inc</link:label>
    <link:label id="lab_silk_NeuroCoIncMember_label_en-US" xlink:label="lab_silk_NeuroCoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NeuroCo, Inc [Member]</link:label>
    <link:label id="lab_silk_NeuroCoIncMember_documentation_en-US" xlink:label="lab_silk_NeuroCoIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NeuroCo, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NeuroCoIncMember" xlink:href="silk-20201231.xsd#silk_NeuroCoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_NeuroCoIncMember" xlink:to="lab_silk_NeuroCoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00db6505-0024-48ba-a052-38c7585dfdf7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_AccruedClinicalExpensesCurrent_f48c9aa2-cede-4373-8a3a-cf5343ac3d8c_terseLabel_en-US" xlink:label="lab_silk_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical expenses</link:label>
    <link:label id="lab_silk_AccruedClinicalExpensesCurrent_label_en-US" xlink:label="lab_silk_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses, Current</link:label>
    <link:label id="lab_silk_AccruedClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_silk_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedClinicalExpensesCurrent" xlink:href="silk-20201231.xsd#silk_AccruedClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_AccruedClinicalExpensesCurrent" xlink:to="lab_silk_AccruedClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c0733dbf-8f86-4b68-9324-b1364d965c4f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ac93c18d-e84b-4d3c-9454-cbb599d2bfc6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock_66cc89af-de1f-44fe-93d8-b2169cb3a91b_verboseLabel_en-US" xlink:label="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of ASC 842 Impact of Adoption on Condensed Consolidated Balance Sheet</link:label>
    <link:label id="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock_17aabb68-bfb7-4e5d-83e3-f8c36fa872ba_terseLabel_en-US" xlink:label="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Information</link:label>
    <link:label id="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="silk-20201231.xsd#silk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2d75184e-ba3c-4521-a6d2-b211e280a81d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_00eede61-0a38-44eb-b5b1-93a7b5853738_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred initial public offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentRateScenarioAxis_f124d64d-7bc1-41c0-953e-58d1b51f04ca_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentRateScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Rate Scenario [Axis]</link:label>
    <link:label id="lab_silk_DebtInstrumentRateScenarioAxis_label_en-US" xlink:label="lab_silk_DebtInstrumentRateScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Rate Scenario [Axis]</link:label>
    <link:label id="lab_silk_DebtInstrumentRateScenarioAxis_documentation_en-US" xlink:label="lab_silk_DebtInstrumentRateScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Rate Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentRateScenarioAxis" xlink:href="silk-20201231.xsd#silk_DebtInstrumentRateScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentRateScenarioAxis" xlink:to="lab_silk_DebtInstrumentRateScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LossContingencyReceivableInventoryInProcessOfRecallMember_33e2759b-917e-4e10-912e-6d1df13dcaab_terseLabel_en-US" xlink:label="lab_silk_LossContingencyReceivableInventoryInProcessOfRecallMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Inventory in Process of Recall</link:label>
    <link:label id="lab_silk_LossContingencyReceivableInventoryInProcessOfRecallMember_label_en-US" xlink:label="lab_silk_LossContingencyReceivableInventoryInProcessOfRecallMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Inventory In Process Of Recall [Member]</link:label>
    <link:label id="lab_silk_LossContingencyReceivableInventoryInProcessOfRecallMember_documentation_en-US" xlink:label="lab_silk_LossContingencyReceivableInventoryInProcessOfRecallMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Inventory In Process Of Recall</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableInventoryInProcessOfRecallMember" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableInventoryInProcessOfRecallMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LossContingencyReceivableInventoryInProcessOfRecallMember" xlink:to="lab_silk_LossContingencyReceivableInventoryInProcessOfRecallMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5fb6e815-b42a-4d63-bf47-42e54b5abdff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2105196a-9eaf-440e-9c63-49b2a68f0969_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_f94a9062-0469-4950-9247-dfef1426cc75_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eb7c9653-98a4-4cc5-8c46-9f541a5cd487_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_ac359fc8-3ad8-418e-bfff-7f75b47e115f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of change in accounting treatment - ASU 2016-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_9892c808-9dd8-4cb9-9b64-9e466e12b241_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201609Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9d8af50a-b074-4f32-8925-6e598c6dc81b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4f73e79f-67b0-4a4c-bd37-485d83540bdd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ExercisePriceFourMember_173c9445-5848-4480-be78-6bff0a53da93_verboseLabel_en-US" xlink:label="lab_silk_ExercisePriceFourMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Four</link:label>
    <link:label id="lab_silk_ExercisePriceFourMember_label_en-US" xlink:label="lab_silk_ExercisePriceFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Four [Member]</link:label>
    <link:label id="lab_silk_ExercisePriceFourMember_documentation_en-US" xlink:label="lab_silk_ExercisePriceFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceFourMember" xlink:href="silk-20201231.xsd#silk_ExercisePriceFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ExercisePriceFourMember" xlink:to="lab_silk_ExercisePriceFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_ce09e6c6-4172-4994-b018-95697674f2a7_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9ccbdcd1-0c9b-4042-909c-19d73f35fbd4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_3ac676bb-5a22-4cc2-9929-accd1e9bc6a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_003eecc6-4ae1-4000-9dc5-867a1284c05b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized start-up costs/Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_c59b2acb-0116-4f05-9a8d-1588976446ac_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_d1f6d277-3298-493f-b3fb-96eafa313f78_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_63988039-99df-4a2d-8ba3-7279b6157e70_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e70a83da-255e-4c6a-ae39-5c115afd7db2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_1df0d3e3-5a21-4df4-be66-bb8b071f699c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9930a609-6cac-443f-82bb-b1d6affbe50f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_c4dde2f6-7496-4380-b3e5-7c5596a723e6_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2d24d6db-c764-4351-a492-3bda5c65baad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_884a86dc-2da5-4da9-a8f1-913dd628a025_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_74d014ec-8f47-4fb5-acb4-526d23ab79c3_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ExercisePriceThreeMember_bc40a4e2-76f4-468e-903e-4842c84cff24_verboseLabel_en-US" xlink:label="lab_silk_ExercisePriceThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Three</link:label>
    <link:label id="lab_silk_ExercisePriceThreeMember_label_en-US" xlink:label="lab_silk_ExercisePriceThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Three [Member]</link:label>
    <link:label id="lab_silk_ExercisePriceThreeMember_documentation_en-US" xlink:label="lab_silk_ExercisePriceThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceThreeMember" xlink:href="silk-20201231.xsd#silk_ExercisePriceThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ExercisePriceThreeMember" xlink:to="lab_silk_ExercisePriceThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_ed88226f-399a-454a-8ba7-32b4796e60b6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_757684b3-cba2-4e2f-9001-6e054937e0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_9f5b636c-a31a-462b-9912-3f5788dbd74e_terseLabel_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts maturing within one year</link:label>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_label_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year</link:label>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_documentation_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:href="silk-20201231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:to="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_afd3b4e5-08cf-44c9-9b31-eb115c7bb95d_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_d018e728-2130-4ae7-93ab-067fda616322_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f358ef2c-1b6e-471f-9e16-02477db5cf88_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eafc841d-cd49-40a5-bac3-21f3a48058c6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3784f377-3ac6-4ce5-a907-a30c1c96dd95_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f056511-1b85-4186-872f-0a33a2c5197d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_d6d664ab-020e-4166-973c-a07cc2de3c47_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2de71cb7-e14b-4a21-8069-36a3e9209e0c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8773fea5-3a32-4172-b6eb-16a1af240ffe_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_fd084f89-6207-4a0d-a0b6-f733734e9ffd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7d7fc7b7-605b-452c-bcd2-748870c1ad9c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0d64ef2e-37ad-4163-8a8c-a22e4af60f51_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_07f5de3b-b176-4559-8a4e-2f62a334b096_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_SuccessFeeAgreementMember_a0e24c2e-48ae-4a8a-b3ce-fcf754882c0a_terseLabel_en-US" xlink:label="lab_silk_SuccessFeeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Fee Agreement</link:label>
    <link:label id="lab_silk_SuccessFeeAgreementMember_label_en-US" xlink:label="lab_silk_SuccessFeeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Fee Agreement [Member]</link:label>
    <link:label id="lab_silk_SuccessFeeAgreementMember_documentation_en-US" xlink:label="lab_silk_SuccessFeeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Fee Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SuccessFeeAgreementMember" xlink:href="silk-20201231.xsd#silk_SuccessFeeAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_SuccessFeeAgreementMember" xlink:to="lab_silk_SuccessFeeAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c7ec8e76-0210-4405-b09a-6cc2de7be300_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1adced01-4df2-4e62-9d74-dca9a54c6aa2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability, noncurrent, statement of financial position extensible list</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_276abc2f-0b6f-4736-a594-bd1bd39fafb7_terseLabel_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10% Stockholders</link:label>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_label_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrincipalOwnerMember" xlink:to="lab_us-gaap_PrincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_4a7c949d-624d-45a3-9e7e-ce6fe5b1c217_negatedLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted/Awarded (in shares)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:to="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_8564c575-4a4c-4dff-9d2c-e2591b0a7377_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_dcd8fba7-a06b-4f13-ad75-4ea563f1dfa6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_386a15b9-1aba-483c-95c1-213331c729b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_f8d46a74-82b2-4ba8-92bc-db61aaedcc1d_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of redeemable convertible preferred stock warrants to preferred stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_94f5746d-88c9-42ce-b29b-bc95e6957b98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability in other liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_00e6a477-7cb0-42b0-ad14-0cc6d3c97b1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_ab1efb00-74f4-44e0-b9c5-fee7987adf4c_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_2e665a44-c623-43a2-9633-7ad158935f53_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_c3d09af2-bc4b-4585-b75f-0e896bf38e18_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty expense</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7f79bb06-5150-49ee-8af3-9219be4fad9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amount representing debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_551f88bf-c9f8-4b7e-ba91-2caa55e78096_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7dabd3df-b34e-498f-95dd-0938d2221f9b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_271c0f87-7d9b-4a59-bbaf-3f4aa2451bd7_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of original principal threshold</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_label_en-US" xlink:label="lab_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_documentation_en-US" xlink:label="lab_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:to="lab_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b25c0905-337c-4074-9f62-b41fa30ddd90_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_RateScenarioOneMember_711667b4-b5e9-4fc2-ad42-6d387a6a1f58_terseLabel_en-US" xlink:label="lab_silk_RateScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Scenario One</link:label>
    <link:label id="lab_silk_RateScenarioOneMember_label_en-US" xlink:label="lab_silk_RateScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Scenario One [Member]</link:label>
    <link:label id="lab_silk_RateScenarioOneMember_documentation_en-US" xlink:label="lab_silk_RateScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Scenario One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RateScenarioOneMember" xlink:href="silk-20201231.xsd#silk_RateScenarioOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_RateScenarioOneMember" xlink:to="lab_silk_RateScenarioOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_8c39593e-41c4-48f5-935e-390fc61c87b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount_22f4bc94-565f-45e3-9a3c-27221ff0df95_terseLabel_en-US" xlink:label="lab_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Series C warrant liability</link:label>
    <link:label id="lab_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount_label_en-US" xlink:label="lab_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Warrant Liability Adjustment, Amount</link:label>
    <link:label id="lab_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount_documentation_en-US" xlink:label="lab_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Warrant Liability Adjustment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" xlink:href="silk-20201231.xsd#silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" xlink:to="lab_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b49588dc-950b-4e3a-afb6-986ffa2021f8_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2aa23e28-9c4c-4356-a4c6-4f767c96dc1e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Silk Road Medical, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ca19ed6-43fd-4600-a1d3-ffb2014a4407_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5464363b-6ef8-46ae-8556-1e0156a10df0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_1d224c30-8e24-4525-99fe-c4de9b19a837_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_528a3b5f-ad95-4f21-916c-9e2dbda2f637_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f1589ec5-84e3-40e1-a308-ba805384f682_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_ce025498-f15e-41cd-aff3-4d6f96a74b12_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write offs</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_b18300ff-749b-41ec-8959-48b92564bcdb_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1bd1592-50bd-468d-94cb-5fd9eb7ad4ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6d3ee2eb-cc3a-45ca-8cbc-a979fac4c88e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_980488be-1105-4d33-86b6-28a144ed72b4_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Adjustment</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_c262fbf6-acc7-4a1d-881d-d1f45a0ef3a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_edcc800c-9d52-4628-87f0-78ec50c8c065_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_495a91c3-c680-41e7-acd4-a117c2b16c9e_terseLabel_en-US" xlink:label="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of Series C preferred stock warrants upon IPO (in shares)</link:label>
    <link:label id="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="silk-20201231.xsd#silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_ef622386-a396-4962-9695-cc2490ad39fe_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities requiring accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_200878e8-ae29-4c1b-ae11-d496ed802721_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_6185d861-b4b4-439e-bb93-e2fecc62b5cf_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_64b93f7f-791b-48b3-8969-145281c45262_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability, current, statement of financial position extensible list</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_c437e597-023d-4fca-b32f-86c9f7986486_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_78051b27-ee0f-42c2-badc-f0aa91d4a607_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_958f7afe-183d-494d-80a5-0893b0d1ae83_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2a93cd5a-e150-4321-9929-0a70f5a41333_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod_0121b937-e756-463c-94d8-1633b29af6cc_terseLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing stock price period</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Trailing Stock Price Period</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Trailing Stock Price Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod" xlink:to="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_17613def-9949-4e8e-86a3-bd7d90a28c60_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fa55a8d5-13e8-45d8-b5e4-5135ee39d31c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_f923d809-5dd6-4646-810f-2a7801f7505e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1852a780-066d-4f61-b68b-2454e25cab19_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ef459ae2-5fc6-4f36-b64c-fbf24744abd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_34fec1c5-8b25-4819-871c-023954a85693_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1e16ee8d-e65f-45f8-a9a9-a1974892598f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7de9b732-cb8a-4ccc-bc9c-5cb70a96249d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of the Available-For-Sale Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_d74833fd-97df-4181-bb31-de13d136ff53_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information (unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_eaa8b346-44ea-4d1f-bf72-d64e2fa37e49_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of matching contribution of the employee's pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_7d4b96aa-6846-4dbc-bd3a-54a2e477fbd4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_351c8b46-1246-4d8f-b3ac-30fc594bc631_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_9e9b5f2b-93c6-4000-9709-34b5e63f6d44_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of minimum payments</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e0ee8520-aa04-4577-8771-ff2ceab91d85_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9632061c-c4f2-47d6-a5ed-caac484c3b2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtMaximumBorrowingCapacity_67f3114d-3d69-431d-a1fc-b35bfeebf912_terseLabel_en-US" xlink:label="lab_silk_DebtMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan agreement amount</link:label>
    <link:label id="lab_silk_DebtMaximumBorrowingCapacity_label_en-US" xlink:label="lab_silk_DebtMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_silk_DebtMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_silk_DebtMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtMaximumBorrowingCapacity" xlink:href="silk-20201231.xsd#silk_DebtMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtMaximumBorrowingCapacity" xlink:to="lab_silk_DebtMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_22db7d2a-7a13-4e34-bd87-c02386cf71f3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (accretion of discounts) on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8a7a3c84-ead6-4afa-8fee-eca49cbe0237_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_727fc73b-a2f0-45af-8ddd-e2d3ff0c5235_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember_c36b53b8-213f-4c23-b18e-b850ab1a998c_terseLabel_en-US" xlink:label="lab_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Excess and Obsolescence</link:label>
    <link:label id="lab_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember_label_en-US" xlink:label="lab_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Inventory Excess And Obsolescence [Member]</link:label>
    <link:label id="lab_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember_documentation_en-US" xlink:label="lab_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Inventory Excess And Obsolescence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember" xlink:to="lab_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b543ce7d-49ee-4b97-b865-5d4a8a5a5acc_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_846b5131-f198-4168-b50b-140230e1a86c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3a8612a2-5239-4fca-b395-9e1945800be8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_a0c48fad-6677-4199-bcd8-31f2175e2c50_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Public Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_85108541-3741-4324-87f8-2e1d763a4656_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4ead0899-23f2-42ce-8b1d-c1ff0e499046_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c4ad70a1-44d4-486b-a8ba-a08b6750902e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3d148076-11eb-4140-9544-ce2a2c867d50_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_fb582e12-f683-4528-bec7-ce4a4cb391e9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e9cb2274-3496-41e7-a15a-7eff92aea791_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b113baaa-571e-41af-947e-e1872efd1096_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability in accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9d2d65f6-6b05-4f2a-87f3-b0100e56c6c2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs of unvested RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_66f82de6-a380-4e44-90ce-cb6c6290a109_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_f9cd6100-9a34-4e6a-b6a0-9dbba36a1b49_periodStartLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_1b245555-8559-4838-bdae-0d7e2c9e5b7d_periodEndLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_751cbe38-e2a5-406e-9745-c3793d24a775_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_09ba54ad-86db-49d0-904d-955b81c2af80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_f254a873-5dba-4da1-a4a0-dbbc0314f243_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_66ece6c7-0df7-4509-ba7c-2e1f3a7eeb8a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution match percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_e1932290-82ce-4508-a703-be71eb845818_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_97ef281b-d2af-4a64-8fe2-a80d78fc3d3a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e7422397-cd6f-42c6-9910-1e68763ecccb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_41e92b6d-3698-42d7-bb4b-2e9e121def19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d4c4c94b-46ae-4edd-ab84-a505b78c36ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_003ef537-3ad6-4cd7-bbe3-3c365bb0f267_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bdf2ce34-e245-48d3-b779-54b16958d804_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5e8e242e-028a-43ff-a75b-4e670a05ac66_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a1d452fc-2129-4d1e-99cb-0a6d5b780233_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fac74ac1-f63e-46ac-a88f-95304c2685f7_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5d3ab292-3b50-4909-ba48-48c7c3d526ff_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_98383acb-312f-4da6-9360-16c85357ad25_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TermLoanTrancheBMember_6cc75817-da11-4287-8409-2c9229845001_terseLabel_en-US" xlink:label="lab_silk_TermLoanTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche B</link:label>
    <link:label id="lab_silk_TermLoanTrancheBMember_label_en-US" xlink:label="lab_silk_TermLoanTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche B [Member]</link:label>
    <link:label id="lab_silk_TermLoanTrancheBMember_documentation_en-US" xlink:label="lab_silk_TermLoanTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheBMember" xlink:href="silk-20201231.xsd#silk_TermLoanTrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TermLoanTrancheBMember" xlink:to="lab_silk_TermLoanTrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0f15a16b-42ae-4b75-8685-7cd70740e376_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_65f7fb43-236a-4d5a-9664-031be8273b7e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2d9c2ea7-1de5-4957-b838-9ac4ca5573b4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_a657d4b5-76cf-4bb2-9438-0121ffc08e87_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a936d540-f65f-4a5c-8e25-8a917cc7ef36_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a4a6fdb6-7b86-4acf-b6af-f5ffb2c62c10_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_489396d0-6324-46fa-944d-a42c51897290_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_7893b402-1566-4480-b96c-78e682e51e23_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_0101ab67-1aea-40fb-be35-cf74901be1c6_terseLabel_en-US" xlink:label="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of stock issuance underwriting discounts and commissions</link:label>
    <link:label id="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_label_en-US" xlink:label="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Stock Issuance Underwriting Discounts And Commissions</link:label>
    <link:label id="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_documentation_en-US" xlink:label="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Stock Issuance Underwriting Discounts And Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:href="silk-20201231.xsd#silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:to="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_4992b8d9-9a8e-4320-ae76-47f72220d0d8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_440de537-9f00-4e53-a9bf-0e409f46ffbc_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4e761d9d-21b3-4103-a404-272d43e5376b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_22402d71-1422-408b-a0d3-434a0ad09b64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_034b6628-8b31-43af-bcc2-db94509d24dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_e42eeea7-e523-43d7-9004-68a1fb930479_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_fbe2d0b8-0a5d-42d7-b917-c77d10a58de2_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of Series C preferred stock warrants upon IPO</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2cb0e268-8570-41a6-ab69-49673b347d94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_febe86fe-bb32-4588-9879-89f3bfa92a26_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_67f1d9ef-175a-463a-b523-6881270f305e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_69bf36f8-f380-422a-a622-9015606fbac2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_5cb4de7a-91a8-4ef0-ae80-0ef4acd42ed0_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions_79a03745-55fd-4075-b40f-03fd251596d1_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum unrestricted cash and cash equivalents</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions_label_en-US" xlink:label="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Threshold For Revenue Restrictions</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions_documentation_en-US" xlink:label="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Threshold For Revenue Restrictions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions" xlink:to="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_37f79596-52a4-4ad2-b19c-b5a1aeaec6bd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b2098456-e8f9-4cfb-97b8-fa64ed30b013_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $13 and $45 at December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_5df0cd19-d66e-401e-94ff-10be11186f4c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished products</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9499069c-9c73-4ed0-acee-80ae0f62e589_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1cec35dd-cfff-4f8e-b192-e148f114ca70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_52d110e1-4900-4604-8aae-151df10c26cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3fe711d1-83e6-4e3c-9680-f6fe56c74fd2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_edfc92e5-9556-43c3-a998-8eaf9960a443_terseLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares allowable under the plan (in shares)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_ccd848a7-3cb9-42d8-894a-82c212f5d70d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9f10d4d7-9c84-4cf6-9c07-e546ea8a469e_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5ccf2d7b-2d0d-40ac-8f8f-56d2f53d40be_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_6ec38ff0-3be3-47de-97b7-a3128c2360ec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_f49969dc-e5da-425d-a03c-0206f375027c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Due to ASC 842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9a1bf33b-ffde-480e-9296-b703adf92daf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e9fb9bfb-79a4-408e-8472-801a669dc763_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9a287c6d-39e7-4e6b-89da-3eef0eb3b467_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares used to compute net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6e88dd92-01d2-4f0b-9aee-eece6138e572_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common stock outstanding used to compute net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_afa000fa-0119-4b30-98df-285c61ec4822_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_4ad42bb0-ea74-4cff-bdd4-2e843e0fe038_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cf7ff464-6eb8-4db1-b564-e66a1ced2676_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of purchase of price of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_19be3d59-80d7-474c-9cb0-7b152fe2e7d4_negatedTerseLabel_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon IPO</link:label>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_label_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease For Conversion Of Convertible Securities, Value</link:label>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_documentation_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease For Conversion Of Convertible Securities, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:href="silk-20201231.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:to="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e936ec6-d883-4af7-a971-d0c7210dfb0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5c5dc43d-f1fd-44c4-a077-6cafb577df8a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7f9454ba-89cf-4331-9261-c8e5a843ab66_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_RepaymentOfPaidInKindInterest_529da71e-a0bb-4d49-86af-92284a5138ab_negatedTerseLabel_en-US" xlink:label="lab_silk_RepaymentOfPaidInKindInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of interest paid in kind</link:label>
    <link:label id="lab_silk_RepaymentOfPaidInKindInterest_label_en-US" xlink:label="lab_silk_RepaymentOfPaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Paid-In-Kind Interest</link:label>
    <link:label id="lab_silk_RepaymentOfPaidInKindInterest_documentation_en-US" xlink:label="lab_silk_RepaymentOfPaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Paid-In-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RepaymentOfPaidInKindInterest" xlink:href="silk-20201231.xsd#silk_RepaymentOfPaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_RepaymentOfPaidInKindInterest" xlink:to="lab_silk_RepaymentOfPaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0e93d1e5-1b25-4be4-9653-4fe215396985_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_942f2eaf-a06c-4601-92b6-64043d6cac27_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_78f3428b-147c-40e0-a98a-554e334d9b28_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_abbf6cff-16c3-4035-87e3-9d8fe2765cb7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_55c53b67-a186-4753-bb0a-dc38ac2132ac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LossContingencyReceivableTypeDomain_6d38108e-9f05-4a53-94d2-8397370319b8_terseLabel_en-US" xlink:label="lab_silk_LossContingencyReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Type [Domain]</link:label>
    <link:label id="lab_silk_LossContingencyReceivableTypeDomain_label_en-US" xlink:label="lab_silk_LossContingencyReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Type [Domain]</link:label>
    <link:label id="lab_silk_LossContingencyReceivableTypeDomain_documentation_en-US" xlink:label="lab_silk_LossContingencyReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeDomain" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LossContingencyReceivableTypeDomain" xlink:to="lab_silk_LossContingencyReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_228f4027-12da-4bb8-bde6-b5bcabe6c6cc_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_8635ac7e-ec2a-4730-97e3-d572da5ad63a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_25260756-fb8c-4d95-8e22-1c6fd0fa449e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_cbda6b35-660a-4681-ab65-c820d45a0bc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of outstanding shares of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_688ecddc-1274-4a93-934f-a33fbdf74077_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1dcc25d5-3c07-4ea0-9293-5bcec996a10b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_d33c9e72-5b60-4449-bb5e-edce680da726_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1f62623d-921f-4e6d-854e-7ce740e2a0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d2a3dc1a-196c-4fd4-b703-74e5dca9993a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_e9fa167c-7fbf-4414-93b9-1562aca4ae14_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_cb00c5e6-fb14-4eec-b731-265f515c1bab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expect to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_9c68b569-92ad-4b4c-a37a-bee8d682b076_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_207f63e4-bf19-4a98-be81-918176ab81a6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_8f81752d-6ceb-490e-909c-893ac158bde9_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum_91c90c34-5f3f-47b8-ad99-699c63a72ac6_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum unrestricted cash and cash equivalents</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum_label_en-US" xlink:label="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Minimum</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum_documentation_en-US" xlink:label="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum" xlink:to="lab_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_bc2671ef-7cad-4d64-b381-11ecbf7e3657_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd1225cd-fac8-4cdf-b730-451189c81199_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ac4de44e-a7c5-49ac-9a00-2e672e13aff6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_05302375-4c1a-47fe-9cc4-6bc0e1fd4f53_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ae096eca-271e-4ceb-bab7-50a6ad925293_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_efccae63-27c9-40b8-a9c7-06d786aa986a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_fc9fe7be-e0aa-4f0f-b5c7-618e5eb7d758_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset, statement of financial position extensible list</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f9f3dfc3-e847-4a66-8b5e-e712de9d0e36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_04bdae85-7975-42ab-892b-1283fdd3998d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9ae745fb-c96f-4dd0-9b5f-5366f39205c0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16d11226-43ab-41b1-96e3-28f5c70d7730_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_316c529b-afdf-46b9-9c86-c4eed6bfa56c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_30e0cedb-fdbd-4a4e-9845-4fd301447c30_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_31e30c37-ec22-43b7-a716-7d2de2b2b99f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_97e8a03c-44b7-4d4d-a330-46cee7470a96_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_2259286f-d352-40d3-950d-e81ca21d0d4d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_77df2964-b34c-4062-b7f0-76019bf79b2f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reserve for excess and obsolete</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_3acca68d-bd25-439f-b58a-4a090c0e064a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d78a6df4-97ba-419c-a6c0-36161a0e62fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_8019a7a8-45f3-4bc7-9d54-a745fd1f6d66_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3f982fd8-8892-4c1b-91f1-ca0e0a4e0265_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6f543e63-9846-4bb8-a169-b459d447fa18_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_9e802940-5d55-45df-89ab-5a9ca1ebc30a_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_e7dd1fa1-d66b-40ec-ab43-fe3144528bd1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_13300e91-242c-4a01-90cf-01f81806a8dc_terseLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized (in shares)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:to="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d425def9-e4c5-4936-a8d9-213113d9a265_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_60ea381b-f5a1-42f0-831e-d0601129d77a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued and outstanding: 34,249,649 and 31,255,267 at December 31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_9f90b9c9-67e4-48a4-b2ba-c11eecd77ac4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f36d89e8-68e6-4141-aa8f-7fd2bb94e27c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_dbce57bb-f04c-4a4b-8afd-1a9cac1ddd32_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d77bdf44-498c-41ba-ac66-1a3b9b315a43_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_67eb143a-bfb2-4ab6-846d-d395c7b19fcd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_SecondPublicOfferingMember_cc4f2cd6-ff88-4190-a6f0-b9c4e3565e70_terseLabel_en-US" xlink:label="lab_silk_SecondPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Public Offering</link:label>
    <link:label id="lab_silk_SecondPublicOfferingMember_label_en-US" xlink:label="lab_silk_SecondPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Public Offering [Member]</link:label>
    <link:label id="lab_silk_SecondPublicOfferingMember_documentation_en-US" xlink:label="lab_silk_SecondPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SecondPublicOfferingMember" xlink:href="silk-20201231.xsd#silk_SecondPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_SecondPublicOfferingMember" xlink:to="lab_silk_SecondPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_59890fcd-f5aa-4acd-a37d-f5f39fcef84c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b092b3da-eeba-4cb8-851d-cb52ac1f6d2d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_212ee919-b9fe-4658-b0b4-7349c9c90dd5_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_76f45b6b-d837-4f1b-b272-51284668c354_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_9589a71e-304b-4c10-96e2-86cfc853af72_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a3eab6dd-0400-4dd8-9304-46692133df9e_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LossContingencyReceivableInventoryHeldMember_00de0da3-6699-4e24-b1ef-7940835f78fd_terseLabel_en-US" xlink:label="lab_silk_LossContingencyReceivableInventoryHeldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Inventory Held</link:label>
    <link:label id="lab_silk_LossContingencyReceivableInventoryHeldMember_label_en-US" xlink:label="lab_silk_LossContingencyReceivableInventoryHeldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Inventory Held [Member]</link:label>
    <link:label id="lab_silk_LossContingencyReceivableInventoryHeldMember_documentation_en-US" xlink:label="lab_silk_LossContingencyReceivableInventoryHeldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Inventory Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableInventoryHeldMember" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableInventoryHeldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LossContingencyReceivableInventoryHeldMember" xlink:to="lab_silk_LossContingencyReceivableInventoryHeldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_df91b63e-f3aa-4e78-8566-c2a4910a4e2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67a1efaa-c19e-4819-a413-1edbbba1d234_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e35b6ba9-0bb4-4b78-b125-e73f9c8cd70d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_393bf91b-923b-4c46-be39-5e1cb4424668_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_075eb25f-a114-4a3a-84bf-be88e4019070_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_bb22f778-9b8b-4094-bf38-f366c248036e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_57298460-26e6-4ab7-b99c-6d6d20cc96ab_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_707d7c00-d423-431b-8e8b-a5ff0b269f1d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a402074e-9675-425c-878b-57b11a4d8e08_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_StockIssuanceCostsIncurredButNotYetPaid_6c8aee3a-8c6f-4b56-beae-f5dc5bd66450_terseLabel_en-US" xlink:label="lab_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid deferred offering costs</link:label>
    <link:label id="lab_silk_StockIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_silk_StockIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:href="silk-20201231.xsd#silk_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_e78f9ecf-4e7c-4a72-b81e-69a1ee647748_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt pay off</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_89753e35-c3dd-4d3d-acf3-1c663d2fe175_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_RateScenarioTwoMember_cf809e22-b519-4269-8d5d-cfdcd16d4cbf_terseLabel_en-US" xlink:label="lab_silk_RateScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Scenario Two</link:label>
    <link:label id="lab_silk_RateScenarioTwoMember_label_en-US" xlink:label="lab_silk_RateScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Scenario Two [Member]</link:label>
    <link:label id="lab_silk_RateScenarioTwoMember_documentation_en-US" xlink:label="lab_silk_RateScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Scenario Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RateScenarioTwoMember" xlink:href="silk-20201231.xsd#silk_RateScenarioTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_RateScenarioTwoMember" xlink:to="lab_silk_RateScenarioTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_2a5e9ec1-d7b1-4fb5-99be-1cb3d6250a14_terseLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price (in USD per share)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding And Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding And Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_98c0c750-c8dc-4e7b-ad03-eedf7758a253_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_091cd5fc-b55f-4b60-99b5-cf045221e228_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_4a1b128d-c557-4f03-935a-2f082d5f1a25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0388cea6-4c6f-4d6c-9142-a7db75bf1055_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c0a60de3-af4d-469e-9cfc-b8b3a1011782_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d1b5025e-fad4-49b9-8814-d5471e688183_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_84cedfce-6806-4fba-9b07-e49fbec6a5a6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_1ca61535-5055-4ac8-b448-4b3fbc25efb9_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_464fd10c-fb6a-46bb-b687-a3e40efdc44e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest limitation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d594bfc3-a552-4df7-8b06-82ed89fc200e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_b7667e72-ab45-4857-8954-acd4497fd0ec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as consideration (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_5f29d769-1fde-48a0-ac71-77fab99de074_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of change in accounting principle - ASC 606 adoption</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5f0e1568-28b2-4ab2-a7c0-ae10d3405762_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_77a5359f-b7ad-4632-9e33-8a124c074e62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_1c8956d3-1b35-45bd-bdcf-d2ee4a553078_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_04e6e147-f8ce-45f4-a4d2-a5e45d288c9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ad30a11-95bd-49c9-acac-b0bec782abe9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e4bc9530-5e00-4753-9e8d-df81d52785e0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_0c2b32b4-202b-4906-9354-aa1c9a83e5da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LongTermDebtUnpaidInterest_51a35bc7-039c-461e-9e52-0827d45c973b_negatedTerseLabel_en-US" xlink:label="lab_silk_LongTermDebtUnpaidInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amount representing interest</link:label>
    <link:label id="lab_silk_LongTermDebtUnpaidInterest_label_en-US" xlink:label="lab_silk_LongTermDebtUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Unpaid Interest</link:label>
    <link:label id="lab_silk_LongTermDebtUnpaidInterest_documentation_en-US" xlink:label="lab_silk_LongTermDebtUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Unpaid Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtUnpaidInterest" xlink:href="silk-20201231.xsd#silk_LongTermDebtUnpaidInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LongTermDebtUnpaidInterest" xlink:to="lab_silk_LongTermDebtUnpaidInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_00dba272-a2ba-4a80-af7c-bfba2ed11ddd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_23b53d03-2ade-48a9-8113-f4a6d5f57a8c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_7ae9f712-60e1-4827-b7cb-b14661211412_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentMaximumBorrowingCapacity_00bdf039-d5f8-4b73-b89a-ce353dd107a4_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt amount</link:label>
    <link:label id="lab_silk_DebtInstrumentMaximumBorrowingCapacity_label_en-US" xlink:label="lab_silk_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_silk_DebtInstrumentMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_silk_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentMaximumBorrowingCapacity" xlink:href="silk-20201231.xsd#silk_DebtInstrumentMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentMaximumBorrowingCapacity" xlink:to="lab_silk_DebtInstrumentMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fb101857-6fe1-4cc2-85e0-3bf0338d9f03_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6cb77a59-e0e4-4aff-a70e-7810aed07f54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_24ee1e10-95ee-490b-976d-6c077d86e112_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to prior years&#8217; tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f6722a86-b4cf-4861-892b-462334febcca_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current years&#8217; tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_28de3614-f072-456c-ab2c-d27e1a9ecf2b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ce5bdce5-afdd-4392-beac-fc3a3c3f025b_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_005d5aba-e855-4e1c-b720-de07a35e9664_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c326e16e-9f59-48bd-8f30-db71ecc3dd7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_a653f5c2-7854-4604-83a5-f7d379c4c65a_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_3d487ef4-c012-46cc-a031-8983dcd6cf7c_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b8146e1f-a869-4dc7-9b81-9a4df17c85a4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d8f2e1d8-7149-4069-871b-f76d6ebd7bfd_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_ba1ea852-445a-4d64-ad23-34be4b54d6a6_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e8343966-aa65-43f5-ada4-7f5d4d0bbeaa_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6a63f4d9-bd8a-4375-bb1b-1bc91558255c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e86d2bb6-61f3-4c59-950a-2ed48f20fd13_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_dd1decb4-de9e-4a27-8159-c6e82e10b753_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Silk Road Medical, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_301385b6-d7a5-43e4-a804-2a8f6ac360d9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Silk Road Medical, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LossContingencyReceivableDirectCostsMember_debce727-d42a-40ae-949c-6ae36afd796b_terseLabel_en-US" xlink:label="lab_silk_LossContingencyReceivableDirectCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Direct Costs</link:label>
    <link:label id="lab_silk_LossContingencyReceivableDirectCostsMember_label_en-US" xlink:label="lab_silk_LossContingencyReceivableDirectCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Direct Costs [Member]</link:label>
    <link:label id="lab_silk_LossContingencyReceivableDirectCostsMember_documentation_en-US" xlink:label="lab_silk_LossContingencyReceivableDirectCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Receivable, Direct Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableDirectCostsMember" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableDirectCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LossContingencyReceivableDirectCostsMember" xlink:to="lab_silk_LossContingencyReceivableDirectCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_556dd7e5-5e84-4431-855f-b1ceffd92b4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_547a9874-6772-44d6-a8bf-131272e20b32_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_207ec1f1-f12c-44ce-805b-b7089f64fa02_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5df0b701-489a-49a5-952d-3a5bc8bc27c4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_47713d3b-b751-423b-af68-c138650dc02b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_782aca3c-fc4b-4b4c-98be-7a9987c71e51_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_41f0c9ff-01ad-4f9d-aaef-b1345e862cc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_VoluntaryRecallMember_a108ed2f-0c13-4bed-a3b2-6f8149c3dfec_terseLabel_en-US" xlink:label="lab_silk_VoluntaryRecallMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Recall</link:label>
    <link:label id="lab_silk_VoluntaryRecallMember_label_en-US" xlink:label="lab_silk_VoluntaryRecallMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Recall [Member]</link:label>
    <link:label id="lab_silk_VoluntaryRecallMember_documentation_en-US" xlink:label="lab_silk_VoluntaryRecallMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Recall</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_VoluntaryRecallMember" xlink:href="silk-20201231.xsd#silk_VoluntaryRecallMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_VoluntaryRecallMember" xlink:to="lab_silk_VoluntaryRecallMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0cb94689-53c1-4d29-b849-39fc822282af_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_RepaymentsOfDebtRevenueTargetPercentage_0c9d7cd0-c71e-4ee9-95fd-933d83b9a0e4_terseLabel_en-US" xlink:label="lab_silk_RepaymentsOfDebtRevenueTargetPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue for debt repayment</link:label>
    <link:label id="lab_silk_RepaymentsOfDebtRevenueTargetPercentage_label_en-US" xlink:label="lab_silk_RepaymentsOfDebtRevenueTargetPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Debt, Revenue Target, Percentage</link:label>
    <link:label id="lab_silk_RepaymentsOfDebtRevenueTargetPercentage_documentation_en-US" xlink:label="lab_silk_RepaymentsOfDebtRevenueTargetPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Debt, Revenue Target, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RepaymentsOfDebtRevenueTargetPercentage" xlink:href="silk-20201231.xsd#silk_RepaymentsOfDebtRevenueTargetPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_RepaymentsOfDebtRevenueTargetPercentage" xlink:to="lab_silk_RepaymentsOfDebtRevenueTargetPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_0d9bf6d0-2d3c-4db6-b6c6-c4db2f007bcc_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NeuroCo common stock issuance</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_57c5e8d2-60b9-4184-8094-4a051c58964f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8344d420-bc0c-4724-94b6-37a9452d2dd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_dda575d5-2242-445e-bf8b-7aca5f2cf0d6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_AccruedTravelExpensesCurrent_dc9914c2-bcde-44f7-b4cb-8dce9dbb48b5_terseLabel_en-US" xlink:label="lab_silk_AccruedTravelExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued travel expenses</link:label>
    <link:label id="lab_silk_AccruedTravelExpensesCurrent_label_en-US" xlink:label="lab_silk_AccruedTravelExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Travel Expenses, Current</link:label>
    <link:label id="lab_silk_AccruedTravelExpensesCurrent_documentation_en-US" xlink:label="lab_silk_AccruedTravelExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Travel Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedTravelExpensesCurrent" xlink:href="silk-20201231.xsd#silk_AccruedTravelExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_AccruedTravelExpensesCurrent" xlink:to="lab_silk_AccruedTravelExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_94b9a2ca-7a3a-4e5e-8ce0-58fa4e1c745f_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_21952c65-cf63-44ce-9bc7-a023e010b792_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_018fecef-be4e-4c63-ab53-86ecb9133820_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_9c405979-3e1e-4a04-b3ce-c51bf094dbd7_terseLabel_en-US" xlink:label="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise threshold as a percentage of fair value of shares</link:label>
    <link:label id="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_label_en-US" xlink:label="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price</link:label>
    <link:label id="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_documentation_en-US" xlink:label="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:href="silk-20201231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:to="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a17a4a0c-60d2-467b-9b76-e850772f13fb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e49d5ca7-f02a-498b-8d47-fa838759547f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cfde030e-1a27-4c5f-8210-fbc99e5acf5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense Relating to Stock Options to Employees and Nonemployees</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_effca447-3902-496d-a439-a03376c6657b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3aa129bd-38aa-48fb-ba2a-87c76ef74862_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d7fdc09-9c36-463e-b406-06c1115d86e5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_43995554-e1eb-4e45-b4bd-e27b49b962d9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_cd725a51-8db7-43f4-921d-e57734bd1467_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable:</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedParties_a6fbd6d5-e57a-4ce9-afa3-aa10842abb51_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory note amount</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedParties" xlink:to="lab_us-gaap_NotesReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_64a16ff8-f0a2-4ff4-8d2b-6b1134b94207_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_e9fae1ea-ed44-4710-a23d-a9a876c210d4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer discretionary contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_dd36eb73-c4db-4377-b0ef-42027103f463_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_77d77fdf-8140-4ef5-b458-ea7131f35aa1_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4cf7070b-42e7-4d38-980e-7a30df21dc1b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise/issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_aeaff71b-3ba4-4494-a0b9-b568c53d523f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ExercisePriceOneMember_56d03bf1-37ff-42c8-8ae7-a8c3bb51f26a_terseLabel_en-US" xlink:label="lab_silk_ExercisePriceOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price One</link:label>
    <link:label id="lab_silk_ExercisePriceOneMember_label_en-US" xlink:label="lab_silk_ExercisePriceOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price One [Member]</link:label>
    <link:label id="lab_silk_ExercisePriceOneMember_documentation_en-US" xlink:label="lab_silk_ExercisePriceOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceOneMember" xlink:href="silk-20201231.xsd#silk_ExercisePriceOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ExercisePriceOneMember" xlink:to="lab_silk_ExercisePriceOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_1804718f-d523-4b2d-bd0d-a9fd2f5c74cc_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_0d94a83d-69d3-4760-be78-5bbc9d1fc342_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a11de353-97a6-43a8-8ce1-38c00e21a490_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a54f3ef0-4ed2-48b0-a29f-fac7927a0328_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss, Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_92f28bd4-9d27-44ea-ad0c-51d0672be073_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_e479f1ba-adb0-495d-899a-36741dc1e52a_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in provision for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionMember_71847002-1c74-4d79-949e-db9af1d429fe_terseLabel_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ISO and NSO</link:label>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionMember_label_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and Nonqualified Stock Option [Member]</link:label>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionMember_documentation_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and Nonqualified Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionMember" xlink:href="silk-20201231.xsd#silk_IncentiveandNonqualifiedStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_IncentiveandNonqualifiedStockOptionMember" xlink:to="lab_silk_IncentiveandNonqualifiedStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94563ccc-fe08-45c5-aaae-35e7a75adc9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_59f0e582-adc0-4acd-b6ba-bdea895227ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5c255b2e-cd85-4caf-bf5f-86ed1b262a5a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_cb783d20-0006-479e-9232-801454ea6a67_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_db477d4d-e39c-4d11-b50a-ab9eb4fc145b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_010c4562-0a4a-4587-b969-aee45001cc7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionExercisedMember_18aec44a-9c08-4803-bc22-7274ce3c8785_terseLabel_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options under stock plan</link:label>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionExercisedMember_label_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and Nonqualified Stock Option, Exercised [Member]</link:label>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionExercisedMember_documentation_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and Nonqualified Stock Option, Exercised [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:href="silk-20201231.xsd#silk_IncentiveandNonqualifiedStockOptionExercisedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:to="lab_silk_IncentiveandNonqualifiedStockOptionExercisedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1e2f9ad-4d3b-43c9-9138-5d6d5ce8b027_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_854a2178-1af6-4353-816a-f89762eb686a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Variable Interest Entity - NeuroCo</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LongTermInvestmentsMember_6ec46b4e-e7b9-4031-987f-4bc3b8ea20a9_terseLabel_en-US" xlink:label="lab_silk_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_silk_LongTermInvestmentsMember_label_en-US" xlink:label="lab_silk_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments [Member]</link:label>
    <link:label id="lab_silk_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_silk_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermInvestmentsMember" xlink:href="silk-20201231.xsd#silk_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LongTermInvestmentsMember" xlink:to="lab_silk_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_5cf20902-4217-49d0-8a18-e6da47ac1cc2_terseLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_441c4d3e-9d9a-40aa-b28f-1c5581ac84b6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_f0a6d6c4-fe28-483e-aed6-0e12e58f7639_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_87dc1e9f-a41d-4d73-ae37-97680f491b36_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4b639194-9377-448b-90db-6e427b1014bb_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87993cb7-32c4-4a9b-9f82-4eb0cea0cb79_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Preparation and Adjustment to Prior Period Financial Statements</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f648d57a-0072-4599-bdfe-f866354b806f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance_2a8eeebb-8fd5-4e81-b402-56b839ec6ebf_terseLabel_en-US" xlink:label="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance_label_en-US" xlink:label="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Available For Future Issuance</link:label>
    <link:label id="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance_documentation_en-US" xlink:label="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Available For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:href="silk-20201231.xsd#silk_CommonStockCapitalSharesAvailableForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:to="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3bc76e2d-01cd-4344-83b8-d6a861e24512_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_ce889e4b-1cc1-415a-a0f2-dbfd37a102c1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_3b3fa96b-de83-4e17-b2ca-860c08ec446e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_9023c20c-16d7-4c83-9308-205cbd368224_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_cdc93747-3937-4329-b11a-c4f419eac9cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_47b6ab0d-7dfb-4c84-b5e1-5354082372af_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3d73d0a3-ac6c-4a8d-90a2-3733e74ad33c_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LoanAndSecurityAgreementMember_e874add4-fd78-4801-b7f4-57a02a6c92ef_terseLabel_en-US" xlink:label="lab_silk_LoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement</link:label>
    <link:label id="lab_silk_LoanAndSecurityAgreementMember_label_en-US" xlink:label="lab_silk_LoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan And Security Agreement [Member]</link:label>
    <link:label id="lab_silk_LoanAndSecurityAgreementMember_documentation_en-US" xlink:label="lab_silk_LoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan And Security Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LoanAndSecurityAgreementMember" xlink:href="silk-20201231.xsd#silk_LoanAndSecurityAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LoanAndSecurityAgreementMember" xlink:to="lab_silk_LoanAndSecurityAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_49897743-82e3-465c-94f7-beeba8843c64_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_509f85da-512a-4840-a652-c6c39841cf8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80154a11-5dd2-4ed5-99fc-6c039f6c845d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_185b8df5-f321-4a67-9706-696d2e1a11fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4db5feef-f72f-41ca-adcb-946661e5ecd7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d9404135-a413-47ef-93ff-3a5ee5606bf2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Formation and Business of the Company</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f978fdf-8df9-4fa3-beb3-e7efdd7fd8ca_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f90fc63a-17e0-41eb-895b-6f9087a309b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_c438075a-ea74-4b01-b083-a1034a7a4833_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0e3bd32c-2070-46e3-828e-569f23bbb097_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ef9e3745-6640-4310-90a2-7b23b7267355_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_29396736-933e-4077-859a-394818cd1cd7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c7daa38-54a9-4845-8cd2-700301910382_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_261281f2-bd73-4b68-a5cf-7d4071370fd5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df1bf572-505d-47fe-90ae-b73fb4085766_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember_ed9000b5-6a75-481d-9386-ccfce3617b30_terseLabel_en-US" xlink:label="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock warrants outstanding</link:label>
    <link:label id="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember_label_en-US" xlink:label="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember_documentation_en-US" xlink:label="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:href="silk-20201231.xsd#silk_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:to="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e47ad4e5-c2da-4d29-ad07-32c3495ca222_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5496d0c0-ba91-45e8-b3cc-43b0c913c0a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Maturities Under the Term Loan Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_155586e6-7e99-4688-93d4-e933c459cddb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_a4d144c8-8346-4a42-8fe8-505853d2732d_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_43590357-4fcc-48d9-83aa-4b52fc035289_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c48b385a-5842-40ea-9c5d-877c9a5912d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ab2f94e1-a34d-469e-ae42-3aca2e315c1b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ExercisePriceSixMember_30570916-9524-4a6b-b120-fcb26883eaa3_terseLabel_en-US" xlink:label="lab_silk_ExercisePriceSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Six</link:label>
    <link:label id="lab_silk_ExercisePriceSixMember_label_en-US" xlink:label="lab_silk_ExercisePriceSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Six [Member]</link:label>
    <link:label id="lab_silk_ExercisePriceSixMember_documentation_en-US" xlink:label="lab_silk_ExercisePriceSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceSixMember" xlink:href="silk-20201231.xsd#silk_ExercisePriceSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ExercisePriceSixMember" xlink:to="lab_silk_ExercisePriceSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3c6a2756-0aaf-42c4-804c-c6021f2c9996_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_bf876066-05fc-4f92-84cf-e916c73146ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_6672f81b-35b3-47b0-b1dc-5b42c1946107_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_4a1f9dd3-a179-42c1-b781-630f83970aa5_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_e2274168-ba09-429a-ab8c-e1f6aecef8b4_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0f8d87bf-55fd-4ae6-a209-eaa2496d651a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2e48a3de-ac01-4319-af0d-3071d17edf7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_e0751c8e-60a2-4cf9-8b88-4c444b2c3c27_verboseLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:to="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5810cadb-7a14-4d91-9753-d52eda0d5ee1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2a307a5d-9877-465d-abe2-80d120965081_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_fb2da25c-c19b-474e-9e85-46702500ce9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_51f46885-5811-42ab-9bc4-38a92abe1acf_terseLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_fb24cb83-52e9-480d-8ba0-b339e067e70d_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6251d6d6-56e6-4ff2-8fab-9ac44f993070_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_8273663e-c3eb-48c3-887d-a26bad2608b8_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_466664b3-9933-4fdd-af5b-3f4928e021a1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_43620ee5-51e3-4fbe-a9ff-842e22852b8d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fef37586-8cf7-4e8b-a01f-af3b5b8420a0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_16e53488-4adf-4091-b4eb-a294acc45084_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_05f8aa84-a22c-43a9-b207-f3e928646f93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CommonStockVotePerShare_63ce5835-ba1a-4713-8f71-0945c36fa67b_terseLabel_en-US" xlink:label="lab_silk_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes entitled per share of common stock</link:label>
    <link:label id="lab_silk_CommonStockVotePerShare_label_en-US" xlink:label="lab_silk_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:label id="lab_silk_CommonStockVotePerShare_documentation_en-US" xlink:label="lab_silk_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockVotePerShare" xlink:href="silk-20201231.xsd#silk_CommonStockVotePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CommonStockVotePerShare" xlink:to="lab_silk_CommonStockVotePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_dbbd49b7-48af-488d-a320-f34b6dfbd8d8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d9ab531f-081d-416c-9cdb-a6db945584f0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4f449730-3c86-4ff0-ae57-dde790961bce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_caa83969-6447-4f40-9564-75fd9582d201_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6968da78-18bb-449f-b8da-6c9520911f75_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ExercisePriceTwoMember_5c679309-ada2-4455-9f0e-6ccd16c8d429_verboseLabel_en-US" xlink:label="lab_silk_ExercisePriceTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Two</link:label>
    <link:label id="lab_silk_ExercisePriceTwoMember_label_en-US" xlink:label="lab_silk_ExercisePriceTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Two [Member]</link:label>
    <link:label id="lab_silk_ExercisePriceTwoMember_documentation_en-US" xlink:label="lab_silk_ExercisePriceTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceTwoMember" xlink:href="silk-20201231.xsd#silk_ExercisePriceTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ExercisePriceTwoMember" xlink:to="lab_silk_ExercisePriceTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6cf9c152-5918-47d3-b1f7-f2d031732da8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_37b9dce3-de99-49a6-850c-1d0d72b17a5e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_4ae1fc7e-51b1-449e-893b-8236c74774d3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest in Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:to="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_97aa9955-89b7-4e47-bb85-e6b6152753aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe322eb4-4f8d-4523-b5be-3f7121b80581_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_5cf47fe0-13a0-4754-a4b0-ad5e24704f7a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d67d59f7-9e1d-4db6-a714-5f88ef6ab591_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6db3be9d-08fe-4289-a322-5b06079f7c0c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98ff6ba2-0fd2-4cd7-a130-fa5636293639_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_a5cff9c4-ce78-48c3-9307-2c1a8f3603ea_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for accounts receivables</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf28587f-7110-4376-8c63-83c862bcd2af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b79117b8-13a5-495b-b541-5644f8fa4733_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds/notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ac08060c-6471-4ca6-945c-b14a38672f03_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c24f4584-283b-472d-a23b-1f677a4b43c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_483df044-5aa1-4689-95be-0c4ef8aff8b8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember_62548f88-e293-410d-9911-977e4c4ed2b1_terseLabel_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Existing Shareholders</link:label>
    <link:label id="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember_label_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Existing Shareholders [Member]</link:label>
    <link:label id="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember_documentation_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Existing Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:href="silk-20201231.xsd#silk_PublicStockOfferingSharesFromExistingShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:to="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4018ee0c-9e81-4fea-a7ee-6614ada2dd1f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TwoThousandNineteenStockOptionPlanMember_ff49052b-a0d9-4a2e-8826-550dd702ffb0_terseLabel_en-US" xlink:label="lab_silk_TwoThousandNineteenStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:label id="lab_silk_TwoThousandNineteenStockOptionPlanMember_label_en-US" xlink:label="lab_silk_TwoThousandNineteenStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Stock Option Plan [Member]</link:label>
    <link:label id="lab_silk_TwoThousandNineteenStockOptionPlanMember_documentation_en-US" xlink:label="lab_silk_TwoThousandNineteenStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember" xlink:href="silk-20201231.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TwoThousandNineteenStockOptionPlanMember" xlink:to="lab_silk_TwoThousandNineteenStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_8c7c6ae0-2e5c-49f9-b00c-f4dfd3967ea7_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b9123b36-95a8-45fb-b7c7-62590fa840d7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b2bd86f5-81f4-4cee-8917-c27853701464_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d3845e16-0378-4b58-a1de-3b63327c01a4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentCovenantDebtDefaultRate_88c1bf17-abc3-4a1d-965c-d9c743bb68a6_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentCovenantDebtDefaultRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt default rate</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantDebtDefaultRate_label_en-US" xlink:label="lab_silk_DebtInstrumentCovenantDebtDefaultRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Default Rate</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantDebtDefaultRate_documentation_en-US" xlink:label="lab_silk_DebtInstrumentCovenantDebtDefaultRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Default Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantDebtDefaultRate" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantDebtDefaultRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentCovenantDebtDefaultRate" xlink:to="lab_silk_DebtInstrumentCovenantDebtDefaultRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_15d4dbd7-9c8b-4742-9d94-77d41f8a2267_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b2797e97-af33-4a0a-98ac-740fb7b6a577_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_09eedd53-e4a2-475e-8efb-d13092a69960_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_08c9fb58-f343-415c-b3d7-451fc19e28e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_9bf3752a-7eb3-4849-82f0-c58aa3ce6507_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Investments in Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bf880ebc-6986-4afc-8496-e2cfefecd6aa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c791e5b7-a621-4dab-b192-7c740e8b7455_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_27229408-246a-448c-8cb5-8460a10613be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_67a45770-8a46-4efb-832c-be3f48978411_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>silk-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:13b527d4-ea1a-4469-9dba-fa8b61e78c7f,g:43b528fe-3601-4224-908f-a46b4c727eef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://silkroadmed.com/role/CoverPage" xlink:type="simple" xlink:href="silk-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1c6f1174-57e8-4646-a0bf-92d2e7c593a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_DocumentType_1c6f1174-57e8-4646-a0bf-92d2e7c593a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_f359c85b-85e2-4387-96b5-4e3ab59e5e52" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_DocumentAnnualReport_f359c85b-85e2-4387-96b5-4e3ab59e5e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_424f6e2a-f66f-467f-b9f2-691ffb1bc2d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_DocumentPeriodEndDate_424f6e2a-f66f-467f-b9f2-691ffb1bc2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bda5a7fc-5584-462d-b6ff-8e7689d15c22" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_CurrentFiscalYearEndDate_bda5a7fc-5584-462d-b6ff-8e7689d15c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2f45d4e3-857b-47d0-ab02-d354d208e381" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_DocumentTransitionReport_2f45d4e3-857b-47d0-ab02-d354d208e381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a63fafd6-397d-4a28-ab7a-cbfa5dabc40a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityFileNumber_a63fafd6-397d-4a28-ab7a-cbfa5dabc40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b6c083f4-a636-42c3-9488-5e73636bb71b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityRegistrantName_b6c083f4-a636-42c3-9488-5e73636bb71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9d0b47fc-491d-4798-9542-6fb1f1c4b877" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9d0b47fc-491d-4798-9542-6fb1f1c4b877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ce9db319-4986-44e8-9404-bd593ef32eb0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityTaxIdentificationNumber_ce9db319-4986-44e8-9404-bd593ef32eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e6c95345-aa65-4971-ae25-15437fda313a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityAddressAddressLine1_e6c95345-aa65-4971-ae25-15437fda313a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4c41b301-c7df-4003-a2de-b36ab685775a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityAddressCityOrTown_4c41b301-c7df-4003-a2de-b36ab685775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8285ce54-168b-4237-ac5a-3a9b29e027a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityAddressStateOrProvince_8285ce54-168b-4237-ac5a-3a9b29e027a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a334faa1-c19d-461a-81ff-923ad558d3db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityAddressPostalZipCode_a334faa1-c19d-461a-81ff-923ad558d3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_051211e8-e68a-4272-9f49-8e8b259b375b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_CityAreaCode_051211e8-e68a-4272-9f49-8e8b259b375b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f5b08703-0179-4078-94f3-8b105188f962" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_LocalPhoneNumber_f5b08703-0179-4078-94f3-8b105188f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ad0a29e0-f849-447d-a83a-e946ca0397b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_Security12bTitle_ad0a29e0-f849-447d-a83a-e946ca0397b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d512ee8b-9f71-4039-8ebf-1df550e60e96" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_TradingSymbol_d512ee8b-9f71-4039-8ebf-1df550e60e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_293139b4-21d4-4bc5-9e33-13f302f525d0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_SecurityExchangeName_293139b4-21d4-4bc5-9e33-13f302f525d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_121ec9e1-20f0-45b0-b11a-1d1c937b5102" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_121ec9e1-20f0-45b0-b11a-1d1c937b5102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_a23da91e-215d-4c58-9d63-2dccd6d57336" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityVoluntaryFilers_a23da91e-215d-4c58-9d63-2dccd6d57336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_aa24b759-acb7-474b-b9cb-5599be31344a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityCurrentReportingStatus_aa24b759-acb7-474b-b9cb-5599be31344a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a5b655f6-b176-4224-8725-216bec52e665" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityInteractiveDataCurrent_a5b655f6-b176-4224-8725-216bec52e665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7862eb16-a410-4fbd-b24d-17cb2a0c9898" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityFilerCategory_7862eb16-a410-4fbd-b24d-17cb2a0c9898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0af50a70-a05f-4797-8b3b-ca7238c007fe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntitySmallBusiness_0af50a70-a05f-4797-8b3b-ca7238c007fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6db3045b-5eba-4342-b168-740305120d9b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityEmergingGrowthCompany_6db3045b-5eba-4342-b168-740305120d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_e8023ceb-6085-41ac-8250-76f9d9d94582" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_IcfrAuditorAttestationFlag_e8023ceb-6085-41ac-8250-76f9d9d94582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5b2e6099-e04c-4270-a18a-523f223f76ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityShellCompany_5b2e6099-e04c-4270-a18a-523f223f76ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_a94f8304-2f1b-4f37-ae81-0fe7b7a28a1b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityPublicFloat_a94f8304-2f1b-4f37-ae81-0fe7b7a28a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d126e310-c00f-48c7-b76f-4142f344e65d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d126e310-c00f-48c7-b76f-4142f344e65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3d1c9c19-7648-4d95-a5de-4a9f9ca939a1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_EntityCentralIndexKey_3d1c9c19-7648-4d95-a5de-4a9f9ca939a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0cbcea4a-b223-4e4d-97ea-19e7186a790b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_DocumentFiscalYearFocus_0cbcea4a-b223-4e4d-97ea-19e7186a790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0608a6a3-e607-4e03-bcad-93a763a22849" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0608a6a3-e607-4e03-bcad-93a763a22849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5ae2fd7e-66ca-4617-aa2d-57da87210fd0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8552a6db-9f4a-4948-9455-bd5756cd3df5" xlink:to="loc_dei_AmendmentFlag_5ae2fd7e-66ca-4617-aa2d-57da87210fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheets" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_104ef638-4555-4655-a1d9-7d9a752f6081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_10cddc75-5028-4a10-b8aa-dd0b9a73d475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_104ef638-4555-4655-a1d9-7d9a752f6081" xlink:to="loc_us-gaap_AssetsAbstract_10cddc75-5028-4a10-b8aa-dd0b9a73d475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d3fc59c8-b5a8-4e2f-93c9-158c57f3acc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10cddc75-5028-4a10-b8aa-dd0b9a73d475" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d3fc59c8-b5a8-4e2f-93c9-158c57f3acc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8919f4e-6ada-4ea5-89db-6714569a1164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3fc59c8-b5a8-4e2f-93c9-158c57f3acc5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8919f4e-6ada-4ea5-89db-6714569a1164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a7af1638-e9c4-497d-9def-01f73707d4a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3fc59c8-b5a8-4e2f-93c9-158c57f3acc5" xlink:to="loc_us-gaap_ShortTermInvestments_a7af1638-e9c4-497d-9def-01f73707d4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1d3224e4-25e3-41bc-997a-80f0aea84e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3fc59c8-b5a8-4e2f-93c9-158c57f3acc5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1d3224e4-25e3-41bc-997a-80f0aea84e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5e682bde-8f58-4f3f-a7cb-b2c0932e6416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3fc59c8-b5a8-4e2f-93c9-158c57f3acc5" xlink:to="loc_us-gaap_InventoryNet_5e682bde-8f58-4f3f-a7cb-b2c0932e6416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_28b9b880-33b1-47fb-9058-405139019fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3fc59c8-b5a8-4e2f-93c9-158c57f3acc5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_28b9b880-33b1-47fb-9058-405139019fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e6bbf666-31fa-4bf4-894d-b2ea92ab5497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d3fc59c8-b5a8-4e2f-93c9-158c57f3acc5" xlink:to="loc_us-gaap_AssetsCurrent_e6bbf666-31fa-4bf4-894d-b2ea92ab5497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_4db3347a-d848-4eec-970f-bb35088fd947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10cddc75-5028-4a10-b8aa-dd0b9a73d475" xlink:to="loc_us-gaap_LongTermInvestments_4db3347a-d848-4eec-970f-bb35088fd947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7e62c2ce-9af2-455a-b479-6cf14d5582a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10cddc75-5028-4a10-b8aa-dd0b9a73d475" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7e62c2ce-9af2-455a-b479-6cf14d5582a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d4d08534-d969-48e7-be96-a69db458ae30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10cddc75-5028-4a10-b8aa-dd0b9a73d475" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d4d08534-d969-48e7-be96-a69db458ae30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8ba1842d-d777-411a-9d52-20adc036fd41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10cddc75-5028-4a10-b8aa-dd0b9a73d475" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8ba1842d-d777-411a-9d52-20adc036fd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_53baf521-76fe-4624-a148-19b61f1f3c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_10cddc75-5028-4a10-b8aa-dd0b9a73d475" xlink:to="loc_us-gaap_Assets_53baf521-76fe-4624-a148-19b61f1f3c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24a03485-cef0-4da7-8495-5e030f824e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_104ef638-4555-4655-a1d9-7d9a752f6081" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24a03485-cef0-4da7-8495-5e030f824e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bf8f2176-0724-4185-94f8-daca5a3b187c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24a03485-cef0-4da7-8495-5e030f824e79" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bf8f2176-0724-4185-94f8-daca5a3b187c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7de20f0a-a14e-4a30-9b9f-5a1101de5558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bf8f2176-0724-4185-94f8-daca5a3b187c" xlink:to="loc_us-gaap_AccountsPayableCurrent_7de20f0a-a14e-4a30-9b9f-5a1101de5558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_887e7fa0-f38b-4a95-9d0c-facf653fc3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bf8f2176-0724-4185-94f8-daca5a3b187c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_887e7fa0-f38b-4a95-9d0c-facf653fc3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7666c094-71eb-405e-a1a7-1dbdadf0ac65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bf8f2176-0724-4185-94f8-daca5a3b187c" xlink:to="loc_us-gaap_LiabilitiesCurrent_7666c094-71eb-405e-a1a7-1dbdadf0ac65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_be31ad14-a159-41bf-be11-bd5540e61d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24a03485-cef0-4da7-8495-5e030f824e79" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_be31ad14-a159-41bf-be11-bd5540e61d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_90e8b877-659d-40f5-9029-9fbb0d67b4a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24a03485-cef0-4da7-8495-5e030f824e79" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_90e8b877-659d-40f5-9029-9fbb0d67b4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f9ec4cb5-bd4b-4493-a656-e820d83388aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24a03485-cef0-4da7-8495-5e030f824e79" xlink:to="loc_us-gaap_Liabilities_f9ec4cb5-bd4b-4493-a656-e820d83388aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e18c9fb6-aaa8-4ae0-a948-fe40821f6659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24a03485-cef0-4da7-8495-5e030f824e79" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e18c9fb6-aaa8-4ae0-a948-fe40821f6659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2d86b1e6-7d69-480f-9725-e6ef2f58c32e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24a03485-cef0-4da7-8495-5e030f824e79" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2d86b1e6-7d69-480f-9725-e6ef2f58c32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fb4e3ee5-b283-444e-b812-553ca90acede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d86b1e6-7d69-480f-9725-e6ef2f58c32e" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fb4e3ee5-b283-444e-b812-553ca90acede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6422a6b4-44a6-4176-a218-c41a567a89c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fb4e3ee5-b283-444e-b812-553ca90acede" xlink:to="loc_us-gaap_PreferredStockValue_6422a6b4-44a6-4176-a218-c41a567a89c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockAbstract_25aaf11f-b516-40a1-afd4-7163cad2d528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d86b1e6-7d69-480f-9725-e6ef2f58c32e" xlink:to="loc_us-gaap_DividendsCommonStockAbstract_25aaf11f-b516-40a1-afd4-7163cad2d528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b3eb64d3-6145-4285-b8a8-d135455c07cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCommonStockAbstract_25aaf11f-b516-40a1-afd4-7163cad2d528" xlink:to="loc_us-gaap_CommonStockValue_b3eb64d3-6145-4285-b8a8-d135455c07cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2976b045-8b03-4a11-941c-e4447b0b6eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d86b1e6-7d69-480f-9725-e6ef2f58c32e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2976b045-8b03-4a11-941c-e4447b0b6eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_185b9d8e-af6d-4b70-8722-77e1035990f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d86b1e6-7d69-480f-9725-e6ef2f58c32e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_185b9d8e-af6d-4b70-8722-77e1035990f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_673a27ab-92fb-4de3-a2af-be92412c9b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d86b1e6-7d69-480f-9725-e6ef2f58c32e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_673a27ab-92fb-4de3-a2af-be92412c9b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_428d4b6d-9e97-43b4-b3ae-047cf62e0bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d86b1e6-7d69-480f-9725-e6ef2f58c32e" xlink:to="loc_us-gaap_StockholdersEquity_428d4b6d-9e97-43b4-b3ae-047cf62e0bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fa889edf-40d9-4a31-9553-e734fc161b70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24a03485-cef0-4da7-8495-5e030f824e79" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fa889edf-40d9-4a31-9553-e734fc161b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b0bcd9f8-b2b8-430e-9739-71709f845559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_558d306f-67ef-49cf-8cf1-12074d745b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0bcd9f8-b2b8-430e-9739-71709f845559" xlink:to="loc_us-gaap_AssetsAbstract_558d306f-67ef-49cf-8cf1-12074d745b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3355d270-8594-46ab-9c2e-fe53cc4aebf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_558d306f-67ef-49cf-8cf1-12074d745b7b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3355d270-8594-46ab-9c2e-fe53cc4aebf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_050df44b-4b93-406c-b5f8-d5cb58ff3cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3355d270-8594-46ab-9c2e-fe53cc4aebf4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_050df44b-4b93-406c-b5f8-d5cb58ff3cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_53a598ab-0e31-45f8-a613-1ef3173f4342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0bcd9f8-b2b8-430e-9739-71709f845559" xlink:to="loc_us-gaap_StockholdersEquityAbstract_53a598ab-0e31-45f8-a613-1ef3173f4342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_957fae86-7206-48ce-bbb9-066086340c91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_53a598ab-0e31-45f8-a613-1ef3173f4342" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_957fae86-7206-48ce-bbb9-066086340c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_981c1124-8fe1-4552-a922-23dfb9deace3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_957fae86-7206-48ce-bbb9-066086340c91" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_981c1124-8fe1-4552-a922-23dfb9deace3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_66dd2d8d-04d8-4ee8-b23c-db9480c25a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_957fae86-7206-48ce-bbb9-066086340c91" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_66dd2d8d-04d8-4ee8-b23c-db9480c25a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9c9d7a76-1819-463c-8010-3fc1b14fdd08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_957fae86-7206-48ce-bbb9-066086340c91" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9c9d7a76-1819-463c-8010-3fc1b14fdd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_031e3071-5a5e-4d12-ade4-0e75f18e53af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_957fae86-7206-48ce-bbb9-066086340c91" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_031e3071-5a5e-4d12-ade4-0e75f18e53af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockAbstract_5e38b74a-5b11-4b7b-a678-a353837d1c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_53a598ab-0e31-45f8-a613-1ef3173f4342" xlink:to="loc_us-gaap_DividendsCommonStockAbstract_5e38b74a-5b11-4b7b-a678-a353837d1c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d81efda2-7643-4505-bd1e-6930e66e5971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCommonStockAbstract_5e38b74a-5b11-4b7b-a678-a353837d1c96" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d81efda2-7643-4505-bd1e-6930e66e5971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_240e1616-97ff-47ab-a73e-4afa600ad18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCommonStockAbstract_5e38b74a-5b11-4b7b-a678-a353837d1c96" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_240e1616-97ff-47ab-a73e-4afa600ad18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4e743719-cc6b-4f44-8b30-0937c9b46b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCommonStockAbstract_5e38b74a-5b11-4b7b-a678-a353837d1c96" xlink:to="loc_us-gaap_CommonStockSharesIssued_4e743719-cc6b-4f44-8b30-0937c9b46b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b23e1987-766a-45a6-b02c-bf12fe54aceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCommonStockAbstract_5e38b74a-5b11-4b7b-a678-a353837d1c96" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b23e1987-766a-45a6-b02c-bf12fe54aceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="silk-20201231.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_725872cd-29b6-4c36-aeff-3352e58bb37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_725872cd-29b6-4c36-aeff-3352e58bb37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0d9bffde-5f86-45e3-a45a-28da84d1b0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0d9bffde-5f86-45e3-a45a-28da84d1b0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c4d12f34-1bfb-4789-ab45-d4236d274551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_GrossProfit_c4d12f34-1bfb-4789-ab45-d4236d274551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9e2adec6-325a-4dce-93f2-83fbef632c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9e2adec6-325a-4dce-93f2-83fbef632c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4ef789be-54e2-4ae2-b917-927697317083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9e2adec6-325a-4dce-93f2-83fbef632c3d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4ef789be-54e2-4ae2-b917-927697317083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bd0d0f9c-1ad5-47dc-8734-1916bd36dda4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9e2adec6-325a-4dce-93f2-83fbef632c3d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bd0d0f9c-1ad5-47dc-8734-1916bd36dda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a28f90db-d866-467a-beac-c1ea13cd0144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9e2adec6-325a-4dce-93f2-83fbef632c3d" xlink:to="loc_us-gaap_OperatingExpenses_a28f90db-d866-467a-beac-c1ea13cd0144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5017116a-5526-4a0e-919d-7a0b3d612772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_OperatingIncomeLoss_5017116a-5526-4a0e-919d-7a0b3d612772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_dcec0373-bfc4-4bd4-adc0-fab572626876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_dcec0373-bfc4-4bd4-adc0-fab572626876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e60e2d5f-cfe7-4d97-a632-5cfce9f2cfb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_InterestExpense_e60e2d5f-cfe7-4d97-a632-5cfce9f2cfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2f1c5e99-2aff-4671-8abe-f7750fdff50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2f1c5e99-2aff-4671-8abe-f7750fdff50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_309d8380-c272-43fd-967b-f63d92a8772f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_309d8380-c272-43fd-967b-f63d92a8772f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_557522b6-106c-458e-964e-9156bb8b9985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_ProfitLoss_557522b6-106c-458e-964e-9156bb8b9985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eeaa25d2-c69a-4733-a038-b01b162be4ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eeaa25d2-c69a-4733-a038-b01b162be4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f2cb859-3d70-4cae-93b5-892ea5d01c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_NetIncomeLoss_0f2cb859-3d70-4cae-93b5-892ea5d01c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a1cd4851-ffeb-4b74-8aec-582f608c35d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a1cd4851-ffeb-4b74-8aec-582f608c35d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_821828f2-657c-4ec7-b820-c24752a5b8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a1cd4851-ffeb-4b74-8aec-582f608c35d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_821828f2-657c-4ec7-b820-c24752a5b8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_632e60b2-15bd-48c2-b536-6314ce50511f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a1cd4851-ffeb-4b74-8aec-582f608c35d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_632e60b2-15bd-48c2-b536-6314ce50511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_259478c5-eb8b-4676-ba11-b2d311514384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_259478c5-eb8b-4676-ba11-b2d311514384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_897594d0-d989-47af-bafd-b8e5a37bc081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_897594d0-d989-47af-bafd-b8e5a37bc081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c596d34e-844f-4bb1-8bc8-31b0beac9b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f4be3a05-b97d-4dd3-a97c-870c2e4be66a" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c596d34e-844f-4bb1-8bc8-31b0beac9b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="silk-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a42c6dbb-11a2-4bf7-a5b6-fb72b4a6475f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a42c6dbb-11a2-4bf7-a5b6-fb72b4a6475f" xlink:to="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f24a8466-0805-41a8-828b-d37468f0c065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f24a8466-0805-41a8-828b-d37468f0c065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f24a8466-0805-41a8-828b-d37468f0c065" xlink:to="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ec2fd341-9c18-46db-abd7-abeab96a1a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_PreferredStockMember_ec2fd341-9c18-46db-abd7-abeab96a1a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bdbd4c3f-ee60-49f9-8b11-6499521ea585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_CommonStockMember_bdbd4c3f-ee60-49f9-8b11-6499521ea585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d537f60d-423d-4555-b8df-7774c92360fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d537f60d-423d-4555-b8df-7774c92360fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_421aa29c-31c1-4158-a909-0ae96dd88ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_RetainedEarningsMember_421aa29c-31c1-4158-a909-0ae96dd88ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3388ec06-9ecd-4681-a1c4-2c3f46347fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3388ec06-9ecd-4681-a1c4-2c3f46347fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a0d11f42-f2c3-4a4e-982b-7ef51e24d115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b4241c83-06b0-4e93-82f3-691209572eb0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a0d11f42-f2c3-4a4e-982b-7ef51e24d115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cbd1ce4d-0c9a-4b2a-bb35-ecd8928cdbd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cbd1ce4d-0c9a-4b2a-bb35-ecd8928cdbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4fb73b54-7af2-4f61-960f-818f8e01dc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cbd1ce4d-0c9a-4b2a-bb35-ecd8928cdbd7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4fb73b54-7af2-4f61-960f-818f8e01dc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_0776344c-a653-477e-9d82-21d3ab4eb775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4fb73b54-7af2-4f61-960f-818f8e01dc4e" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_0776344c-a653-477e-9d82-21d3ab4eb775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_fd11fdf9-286e-42ad-8231-c63aee0b6f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4fb73b54-7af2-4f61-960f-818f8e01dc4e" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_fd11fdf9-286e-42ad-8231-c63aee0b6f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_80a34787-5ae5-44bf-949c-925878bb2d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_80a34787-5ae5-44bf-949c-925878bb2d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86a4ade5-9302-4cdc-a2e8-878e63beb3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_80a34787-5ae5-44bf-949c-925878bb2d31" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86a4ade5-9302-4cdc-a2e8-878e63beb3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_19a8b617-f694-4eec-b8da-e4b900710333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86a4ade5-9302-4cdc-a2e8-878e63beb3bf" xlink:to="loc_us-gaap_IPOMember_19a8b617-f694-4eec-b8da-e4b900710333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_94a616ee-f934-4600-9bd3-949d49969d13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_94a616ee-f934-4600-9bd3-949d49969d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b142242f-8dd4-4da1-860e-c296eb12adde" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_94a616ee-f934-4600-9bd3-949d49969d13" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b142242f-8dd4-4da1-860e-c296eb12adde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a909424e-868f-4833-a5bc-fa48cd92a427" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b142242f-8dd4-4da1-860e-c296eb12adde" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a909424e-868f-4833-a5bc-fa48cd92a427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_abd969e1-67f1-4dbc-b934-cd5de1c2956d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb774309-a156-4af7-ae2d-4632d38dd332" xlink:to="loc_us-gaap_StatementLineItems_abd969e1-67f1-4dbc-b934-cd5de1c2956d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_abd969e1-67f1-4dbc-b934-cd5de1c2956d" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_385f5708-0e22-48f3-b79c-9bdabeec74d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_385f5708-0e22-48f3-b79c-9bdabeec74d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_7e6e1423-5ae1-4ad7-a274-dddf9d0a1457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_7e6e1423-5ae1-4ad7-a274-dddf9d0a1457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1c8c3730-eee9-41b3-ac9d-0e29cd09ecf8" xlink:href="silk-20201231.xsd#silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1c8c3730-eee9-41b3-ac9d-0e29cd09ecf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b0f7636c-dc17-4917-96fa-b769cf8dcade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b0f7636c-dc17-4917-96fa-b769cf8dcade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_7f37fd2e-b86b-4808-b53c-2de647418c19" xlink:href="silk-20201231.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_7f37fd2e-b86b-4808-b53c-2de647418c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_60647fd0-99b5-41fb-b677-a955ae520b13" xlink:href="silk-20201231.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_60647fd0-99b5-41fb-b677-a955ae520b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_31f7b887-c88f-412b-bbd8-be7b5444c248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_31f7b887-c88f-412b-bbd8-be7b5444c248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b0cfc870-bcee-4b1c-911b-2ba3f258c845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b0601e69-b549-4586-abd0-02694920cd20" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b0cfc870-bcee-4b1c-911b-2ba3f258c845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_abd969e1-67f1-4dbc-b934-cd5de1c2956d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_25133498-1e6a-47ee-bfab-d0bf029d803b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_SharesOutstanding_25133498-1e6a-47ee-bfab-d0bf029d803b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_162018ba-b5e1-4781-95f5-d23470acfea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_162018ba-b5e1-4781-95f5-d23470acfea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2f412294-b7b2-45d8-9bbd-40be90871ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2f412294-b7b2-45d8-9bbd-40be90871ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0e4a653-72d6-4c57-80e2-f6c94120f175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0e4a653-72d6-4c57-80e2-f6c94120f175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80e907f2-ba6b-4e3b-9f58-e5ec722b81ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80e907f2-ba6b-4e3b-9f58-e5ec722b81ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4765d26f-2a57-4283-ae82-9689366d3db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4765d26f-2a57-4283-ae82-9689366d3db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_6236b543-4577-461a-b3a4-a62cb8409fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_6236b543-4577-461a-b3a4-a62cb8409fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_0444634e-971d-485f-8861-d3848f105a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_0444634e-971d-485f-8861-d3848f105a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants_3cff74fd-0ea5-449f-9e12-130b34a2d310" xlink:href="silk-20201231.xsd#silk_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants_3cff74fd-0ea5-449f-9e12-130b34a2d310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c3f19486-0072-48d1-ad34-270a8672457f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c3f19486-0072-48d1-ad34-270a8672457f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9216fa77-f9a1-41c2-b5f4-cf08e79dc4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9216fa77-f9a1-41c2-b5f4-cf08e79dc4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c18a9bcf-7df3-4c40-9db4-468857cff450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_c18a9bcf-7df3-4c40-9db4-468857cff450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_0b320b51-f39d-4c4b-83a1-9b953dc2c564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_0b320b51-f39d-4c4b-83a1-9b953dc2c564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4e2e99b2-9f02-4661-9b21-94c859cb971d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4e2e99b2-9f02-4661-9b21-94c859cb971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_de9c3047-14df-4c4c-ae4a-9663616407c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_de9c3047-14df-4c4c-ae4a-9663616407c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3c616845-555b-4d86-a197-88efe054da82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_ProfitLoss_3c616845-555b-4d86-a197-88efe054da82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e2516c2-8d22-484a-994f-9615c0f32be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e2516c2-8d22-484a-994f-9615c0f32be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d035cd82-038c-4ed3-910d-01412052ac46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d035cd82-038c-4ed3-910d-01412052ac46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3944206a-c424-4935-8bcd-3a559e63e4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_SharesOutstanding_3944206a-c424-4935-8bcd-3a559e63e4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ebf0895-e835-4352-8ce0-d3f986ea7c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c459d823-3669-481c-91f8-fcd8d2a18ebd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ebf0895-e835-4352-8ce0-d3f986ea7c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="silk-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d37fdaf9-c288-4fa8-a629-cba69fd9da47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ec972d85-2c4d-4252-98a0-b40917c42120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d37fdaf9-c288-4fa8-a629-cba69fd9da47" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ec972d85-2c4d-4252-98a0-b40917c42120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="silk-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ab9532a-b346-4593-99e4-88761d31d9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6e2f297d-93d7-4864-9a8f-21339dedf2e3" xlink:to="loc_us-gaap_StatementTable_3ab9532a-b346-4593-99e4-88761d31d9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a082ea74-dd0a-4d9e-8e6f-3630f0db9b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ab9532a-b346-4593-99e4-88761d31d9e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a082ea74-dd0a-4d9e-8e6f-3630f0db9b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3a2311ab-b3a8-467c-83f2-4c69454a525c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a082ea74-dd0a-4d9e-8e6f-3630f0db9b82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3a2311ab-b3a8-467c-83f2-4c69454a525c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_66fa5417-1401-4ce0-a2d9-47f0214146b3" xlink:href="silk-20201231.xsd#silk_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3a2311ab-b3a8-467c-83f2-4c69454a525c" xlink:to="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_66fa5417-1401-4ce0-a2d9-47f0214146b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_10eaaeac-f71a-43ae-a411-2581288b2d12" xlink:href="silk-20201231.xsd#silk_CommonStockWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3a2311ab-b3a8-467c-83f2-4c69454a525c" xlink:to="loc_silk_CommonStockWarrantMember_10eaaeac-f71a-43ae-a411-2581288b2d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ab9532a-b346-4593-99e4-88761d31d9e9" xlink:to="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_23fc5514-229e-4b45-a278-a4248fb90a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:to="loc_us-gaap_ProfitLoss_23fc5514-229e-4b45-a278-a4248fb90a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_4dbf1bf4-5005-40c7-9133-d8f710f3653a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_4dbf1bf4-5005-40c7-9133-d8f710f3653a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3f105462-bf87-451d-9893-1d8edbbb27e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_ShareBasedCompensation_3f105462-bf87-451d-9893-1d8edbbb27e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_bccd6326-63df-4309-bdbb-e486c6daeff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_bccd6326-63df-4309-bdbb-e486c6daeff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d5db21cc-305d-4c3a-9c74-1cd3c4a7fd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d5db21cc-305d-4c3a-9c74-1cd3c4a7fd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bfb942d4-6039-4d14-a25d-b3f0a6fe0ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bfb942d4-6039-4d14-a25d-b3f0a6fe0ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b75a1421-24cd-4021-82fd-ed5bbe0c4694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b75a1421-24cd-4021-82fd-ed5bbe0c4694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_00e7f43a-eb9c-47cb-bed6-3ca3a31853c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_PaidInKindInterest_00e7f43a-eb9c-47cb-bed6-3ca3a31853c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b28335d1-9bb6-4e0d-95b8-0e6ffda09c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b28335d1-9bb6-4e0d-95b8-0e6ffda09c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_879b920e-2db9-458b-87cd-c420deab3aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_879b920e-2db9-458b-87cd-c420deab3aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6551a620-747a-45eb-993f-48b612c9f415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6551a620-747a-45eb-993f-48b612c9f415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_9dfbdf55-66fc-437e-a1a4-76bad547006d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0456ce7f-e001-42e1-a5b5-f778b8c66fd1" xlink:to="loc_us-gaap_InventoryWriteDown_9dfbdf55-66fc-437e-a1a4-76bad547006d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2e19aa8-e858-49ed-8ddf-9bc183c233ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2e19aa8-e858-49ed-8ddf-9bc183c233ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5efba32b-a37c-48c5-9372-650346ff895d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5efba32b-a37c-48c5-9372-650346ff895d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d90261b-83ce-4441-bb2f-13fc138b84ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d90261b-83ce-4441-bb2f-13fc138b84ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_46697b1c-8d12-42a7-9161-7adb550dbc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_46697b1c-8d12-42a7-9161-7adb550dbc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_917ec090-552b-4ffb-bbb8-35e81235f124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_917ec090-552b-4ffb-bbb8-35e81235f124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_45605602-be46-4083-ae96-5567b4f3c2cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_45605602-be46-4083-ae96-5567b4f3c2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_28ea6c04-eab1-49c8-9a69-d43ba9567bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_28ea6c04-eab1-49c8-9a69-d43ba9567bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RepaymentOfPaidInKindInterest_bd3bda33-7996-424a-90ba-4d02883dd2b7" xlink:href="silk-20201231.xsd#silk_RepaymentOfPaidInKindInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2e7cd59-ff17-43ae-8cf0-d1d915e048a2" xlink:to="loc_silk_RepaymentOfPaidInKindInterest_bd3bda33-7996-424a-90ba-4d02883dd2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73748294-13b7-44db-b630-57e6e77126ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e5de2ad-3a7f-4543-a1da-08a802d08738" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_73748294-13b7-44db-b630-57e6e77126ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0d14b9bb-b8b1-4796-8347-9c45f38f4665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0d14b9bb-b8b1-4796-8347-9c45f38f4665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_14f080fe-e570-410b-902c-24a959246a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_14f080fe-e570-410b-902c-24a959246a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8b2120c3-6901-4bb9-99bf-5816231196cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8b2120c3-6901-4bb9-99bf-5816231196cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_6ddb4ec2-728c-4430-81a5-7f332f73dce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_6ddb4ec2-728c-4430-81a5-7f332f73dce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_482db316-28da-41a7-8a71-5680c0e5875c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_477556f3-da82-4411-acac-f230369f7bcf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_482db316-28da-41a7-8a71-5680c0e5875c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_d1056c73-fae3-4a17-b104-aa8c1e85f265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_d1056c73-fae3-4a17-b104-aa8c1e85f265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_772df7fb-9e46-45ef-9f34-34c529f1613f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_772df7fb-9e46-45ef-9f34-34c529f1613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_04de52d6-435c-4fe6-93ca-5a7862c4f450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_04de52d6-435c-4fe6-93ca-5a7862c4f450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_f8459032-ef27-4604-81d9-229bc2fe5dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_f8459032-ef27-4604-81d9-229bc2fe5dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6acba508-55e9-48cd-978c-3f9776cd6d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6acba508-55e9-48cd-978c-3f9776cd6d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_dd5867d0-8b8b-447f-ac2b-13303e6b8a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_dd5867d0-8b8b-447f-ac2b-13303e6b8a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_dbc72978-55df-4524-99e6-2ec9f730ba7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_dbc72978-55df-4524-99e6-2ec9f730ba7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_93019dd7-fbe4-42f8-aa81-f0b059671927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cfc3728d-5b84-46f3-8425-9d9a7ecd2aa3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_93019dd7-fbe4-42f8-aa81-f0b059671927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d61a3c98-a758-497f-942f-f731c6724377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d61a3c98-a758-497f-942f-f731c6724377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f40139f-c8c2-4b26-a031-5707d54f683e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f40139f-c8c2-4b26-a031-5707d54f683e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9a4157a-7e4e-4962-8f1f-cdbf26ee37ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9a4157a-7e4e-4962-8f1f-cdbf26ee37ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2ca9f611-4558-4591-8d6d-f7c662346f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2ca9f611-4558-4591-8d6d-f7c662346f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e36654e2-b54c-4f41-83dd-de35876b9115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2ca9f611-4558-4591-8d6d-f7c662346f45" xlink:to="loc_us-gaap_InterestPaidNet_e36654e2-b54c-4f41-83dd-de35876b9115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a759881c-55a0-4f52-aaca-c29758f47fe4" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08a2feb2-0e2b-44c9-af27-69d7c1e17383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08a2feb2-0e2b-44c9-af27-69d7c1e17383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_0433dbf6-ca86-4014-ae70-18eca305285c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_0433dbf6-ca86-4014-ae70-18eca305285c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_StockIssuanceCostsIncurredButNotYetPaid_81f9b054-ed40-4605-9107-3d33d69f3473" xlink:href="silk-20201231.xsd#silk_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_silk_StockIssuanceCostsIncurredButNotYetPaid_81f9b054-ed40-4605-9107-3d33d69f3473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b1d51338-38a5-485d-8b57-e200da8f2ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b1d51338-38a5-485d-8b57-e200da8f2ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_69b9d3ea-b80c-4510-b77d-867d691dd300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_69b9d3ea-b80c-4510-b77d-867d691dd300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_00199d58-aa15-4050-95da-98872e832534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54d29aed-8d25-4695-9f35-7a3e58d78073" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_00199d58-aa15-4050-95da-98872e832534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="simple" xlink:href="silk-20201231.xsd#FormationandBusinessoftheCompany"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1920f754-b040-4818-90ed-4bba1246863d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_62eaced3-b1c8-43a1-8617-2209335558b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1920f754-b040-4818-90ed-4bba1246863d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_62eaced3-b1c8-43a1-8617-2209335558b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#FormationandBusinessoftheCompanyDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60407876-497e-4caf-a745-a28dd215de42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_76ad1ac3-04b8-448c-8877-1fc6b81b874d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60407876-497e-4caf-a745-a28dd215de42" xlink:to="loc_us-gaap_SubsequentEventTable_76ad1ac3-04b8-448c-8877-1fc6b81b874d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77427f84-16f5-4c11-9d3b-686fdb34c556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_76ad1ac3-04b8-448c-8877-1fc6b81b874d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77427f84-16f5-4c11-9d3b-686fdb34c556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77427f84-16f5-4c11-9d3b-686fdb34c556" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_208084ca-c51e-4a7f-904d-d66c6988b9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:to="loc_us-gaap_IPOMember_208084ca-c51e-4a7f-904d-d66c6988b9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SecondPublicOfferingMember_da867d0f-ad3b-4203-ac4a-b9ffe7ff418a" xlink:href="silk-20201231.xsd#silk_SecondPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:to="loc_silk_SecondPublicOfferingMember_da867d0f-ad3b-4203-ac4a-b9ffe7ff418a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_cf5b5996-54a7-441f-9950-2745ed87d7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:to="loc_us-gaap_OverAllotmentOptionMember_cf5b5996-54a7-441f-9950-2745ed87d7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingMember_8beeefea-10c8-48b5-a106-fbcb3c98db36" xlink:href="silk-20201231.xsd#silk_PublicStockOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c6e7ed6d-21c7-4d3b-994c-2829da193734" xlink:to="loc_silk_PublicStockOfferingMember_8beeefea-10c8-48b5-a106-fbcb3c98db36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromCompanyMember_8828d1d1-c6fb-4837-90e8-a718a8f2c06f" xlink:href="silk-20201231.xsd#silk_PublicStockOfferingSharesFromCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_PublicStockOfferingMember_8beeefea-10c8-48b5-a106-fbcb3c98db36" xlink:to="loc_silk_PublicStockOfferingSharesFromCompanyMember_8828d1d1-c6fb-4837-90e8-a718a8f2c06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember_b1484e8c-f5ba-4614-9f1c-bad7804e7e8a" xlink:href="silk-20201231.xsd#silk_PublicStockOfferingSharesFromExistingShareholdersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_PublicStockOfferingMember_8beeefea-10c8-48b5-a106-fbcb3c98db36" xlink:to="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember_b1484e8c-f5ba-4614-9f1c-bad7804e7e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_76ad1ac3-04b8-448c-8877-1fc6b81b874d" xlink:to="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae275b2c-4047-4565-baec-8c5cd9c2845c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae275b2c-4047-4565-baec-8c5cd9c2845c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_371db3c1-4a8d-4df0-9696-2493b419f482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_371db3c1-4a8d-4df0-9696-2493b419f482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d5324a21-d56f-4300-805e-c41de66fa563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d5324a21-d56f-4300-805e-c41de66fa563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_02a78f55-7221-4b58-940d-73a9df82d920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_02a78f55-7221-4b58-940d-73a9df82d920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a73f5a54-8b67-40e9-a8b8-4cc840b89610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a73f5a54-8b67-40e9-a8b8-4cc840b89610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b5207b4d-a58d-4ae7-85c2-52042beb3890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b5207b4d-a58d-4ae7-85c2-52042beb3890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a58b831a-9daa-4217-a74b-f8d862f8cd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a58b831a-9daa-4217-a74b-f8d862f8cd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0967d28e-ec88-4f8b-b547-0886b7052ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0967d28e-ec88-4f8b-b547-0886b7052ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_aaca6010-4a1c-4ec2-9817-a56730185045" xlink:href="silk-20201231.xsd#silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6f7083c-d2f7-4263-a97d-806ed842edd3" xlink:to="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_aaca6010-4a1c-4ec2-9817-a56730185045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ce438868-61b6-4cb2-9e19-6902d33bc722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_b7f06efc-379f-43a5-8686-e3b0f56700c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce438868-61b6-4cb2-9e19-6902d33bc722" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_b7f06efc-379f-43a5-8686-e3b0f56700c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_634df2f2-57a5-4a6d-9f1c-f0f58cd11481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_634df2f2-57a5-4a6d-9f1c-f0f58cd11481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_52fb9d84-49d0-4580-8313-92f021eec663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_UseOfEstimates_52fb9d84-49d0-4580-8313-92f021eec663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a92c8d29-9fd2-45ff-bcd4-4a1d598c120c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a92c8d29-9fd2-45ff-bcd4-4a1d598c120c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_52f14287-8648-43c2-9d6e-7f678d4b9dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_52f14287-8648-43c2-9d6e-7f678d4b9dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_b34f2e1f-80c1-4824-901d-449848446db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_b34f2e1f-80c1-4824-901d-449848446db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_589b389a-6179-4c2d-99ce-29c93350b4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_589b389a-6179-4c2d-99ce-29c93350b4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_329b0221-ef44-4eb6-a35a-1bbe88a0677e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_329b0221-ef44-4eb6-a35a-1bbe88a0677e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_7b1a8c49-0c17-48ce-9fd7-11a182ab8d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_7b1a8c49-0c17-48ce-9fd7-11a182ab8d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8ac8d5c9-c95b-4204-93e2-fba08c3317e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8ac8d5c9-c95b-4204-93e2-fba08c3317e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_841de2b4-6362-45df-812d-1de9b07539a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_841de2b4-6362-45df-812d-1de9b07539a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_471e63e5-7733-4724-8733-da32c54af461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_471e63e5-7733-4724-8733-da32c54af461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_98fa541c-a5fe-47a7-903c-9ab6cc811bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_98fa541c-a5fe-47a7-903c-9ab6cc811bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_c525be33-69b2-41ec-b312-d37dff1fc0e9" xlink:href="silk-20201231.xsd#silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_c525be33-69b2-41ec-b312-d37dff1fc0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_c96a36b6-d94f-4d03-bc67-7e4250aa5c48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_c96a36b6-d94f-4d03-bc67-7e4250aa5c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d806b7ae-7e30-4f21-9bca-8fdab1286c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d806b7ae-7e30-4f21-9bca-8fdab1286c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1129d051-3d2f-4e4a-a2cf-5112ad2aaf44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1129d051-3d2f-4e4a-a2cf-5112ad2aaf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_f6207930-38d1-4af9-8b8d-b17924a559d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_f6207930-38d1-4af9-8b8d-b17924a559d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_87928483-64f9-4fcb-a5f9-68fc8d137824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_87928483-64f9-4fcb-a5f9-68fc8d137824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6ae0759b-aec7-432b-a635-0cab13f649f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6ae0759b-aec7-432b-a635-0cab13f649f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c810c778-709d-46fc-94d5-883835711392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c810c778-709d-46fc-94d5-883835711392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8f3508c7-19bd-4b96-a1f9-d9a59af03967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8f3508c7-19bd-4b96-a1f9-d9a59af03967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_13fb4439-bbb6-4b45-956d-6a840d013e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_13fb4439-bbb6-4b45-956d-6a840d013e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_bff536bb-816e-41b2-a7dc-5e91145557b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_bff536bb-816e-41b2-a7dc-5e91145557b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e5ea96ec-709e-433a-8d05-f4bd578d54af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8081b43-a980-4d8d-85c5-b1e1964e0fbc" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e5ea96ec-709e-433a-8d05-f4bd578d54af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_cf07c30e-d8d2-4693-9240-94998588c48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_cf07c30e-d8d2-4693-9240-94998588c48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_478334e3-e046-4e23-a761-bb32cef5ff2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_478334e3-e046-4e23-a761-bb32cef5ff2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock_3af07a5d-7be9-44be-9427-32bd7bc4d840" xlink:href="silk-20201231.xsd#silk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c" xlink:to="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock_3af07a5d-7be9-44be-9427-32bd7bc4d840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5bcf3961-6fde-4320-8e74-ba34979c9fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5bcf3961-6fde-4320-8e74-ba34979c9fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a8e5eeda-f99e-4bdc-896f-4cfddd989869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6be856e-c148-4a08-abed-75cb5e7fe80c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a8e5eeda-f99e-4bdc-896f-4cfddd989869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_83222e62-9e8d-47b1-8980-69a78f9e6616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_4d39bb99-65cb-4bf5-a558-28892ea0105f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83222e62-9e8d-47b1-8980-69a78f9e6616" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_4d39bb99-65cb-4bf5-a558-28892ea0105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d11d1d7a-5bcf-41e4-b82e-59a6e564db64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_4d39bb99-65cb-4bf5-a558-28892ea0105f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d11d1d7a-5bcf-41e4-b82e-59a6e564db64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f3b82900-7802-4ec6-b5bd-a935af3c791e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d11d1d7a-5bcf-41e4-b82e-59a6e564db64" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f3b82900-7802-4ec6-b5bd-a935af3c791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_d8f250ab-44f0-4799-8e11-fe3e273426c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f3b82900-7802-4ec6-b5bd-a935af3c791e" xlink:to="loc_us-gaap_LetterOfCreditMember_d8f250ab-44f0-4799-8e11-fe3e273426c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_4d39bb99-65cb-4bf5-a558-28892ea0105f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7eb28bb6-ae00-4bed-9a1d-d87ed374f7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7eb28bb6-ae00-4bed-9a1d-d87ed374f7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2d5384a2-f00f-4cb6-aa3a-d7692ee80dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2d5384a2-f00f-4cb6-aa3a-d7692ee80dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44d38c44-6396-456a-a0ab-bae5c590bb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_18a1beae-f9a7-41ac-9bd7-00d6c862d142" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44d38c44-6396-456a-a0ab-bae5c590bb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_30cf133f-81be-478e-ac4a-f346f52ad662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_8ad8fe8e-55a9-46b1-a8ff-336ac64811b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30cf133f-81be-478e-ac4a-f346f52ad662" xlink:to="loc_us-gaap_ValuationAllowanceTable_8ad8fe8e-55a9-46b1-a8ff-336ac64811b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ef334a79-1060-4f6f-b80e-e8922a30940f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_8ad8fe8e-55a9-46b1-a8ff-336ac64811b3" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ef334a79-1060-4f6f-b80e-e8922a30940f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6e8f260b-f7ec-4f96-9ba8-fcb5bdd8903c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ef334a79-1060-4f6f-b80e-e8922a30940f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6e8f260b-f7ec-4f96-9ba8-fcb5bdd8903c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_VoluntaryRecallMember_c42f67ff-aafb-4527-908d-2ea91fd29220" xlink:href="silk-20201231.xsd#silk_VoluntaryRecallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6e8f260b-f7ec-4f96-9ba8-fcb5bdd8903c" xlink:to="loc_silk_VoluntaryRecallMember_c42f67ff-aafb-4527-908d-2ea91fd29220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_8424721a-8c15-4968-b16f-340f9f4cba6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_8ad8fe8e-55a9-46b1-a8ff-336ac64811b3" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_8424721a-8c15-4968-b16f-340f9f4cba6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable_06321448-e23d-43c2-afee-a4f1e1cd4aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_8424721a-8c15-4968-b16f-340f9f4cba6c" xlink:to="loc_us-gaap_LossContingencyReceivable_06321448-e23d-43c2-afee-a4f1e1cd4aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e7af2d58-5d24-4c13-8087-fa73cb51ab87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c637e29f-7e69-4953-bb6e-a8e2781cef74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e7af2d58-5d24-4c13-8087-fa73cb51ab87" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c637e29f-7e69-4953-bb6e-a8e2781cef74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c242370-d111-40ec-8881-bb5fb6347d12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c637e29f-7e69-4953-bb6e-a8e2781cef74" xlink:to="loc_srt_RangeAxis_0c242370-d111-40ec-8881-bb5fb6347d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99a04853-cfe5-4522-b16f-fa95aecc2e7e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0c242370-d111-40ec-8881-bb5fb6347d12" xlink:to="loc_srt_RangeMember_99a04853-cfe5-4522-b16f-fa95aecc2e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_57497328-b691-4b40-b769-368146881ca5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_99a04853-cfe5-4522-b16f-fa95aecc2e7e" xlink:to="loc_srt_MinimumMember_57497328-b691-4b40-b769-368146881ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92b4300c-973f-4167-bb6e-4d019bf0bd10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_99a04853-cfe5-4522-b16f-fa95aecc2e7e" xlink:to="loc_srt_MaximumMember_92b4300c-973f-4167-bb6e-4d019bf0bd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_db1eab71-3f37-4c0f-8a3a-1745ec7fdc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c637e29f-7e69-4953-bb6e-a8e2781cef74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_db1eab71-3f37-4c0f-8a3a-1745ec7fdc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d4fc4e0e-6b77-4645-adca-6d19d23d30e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_db1eab71-3f37-4c0f-8a3a-1745ec7fdc4d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d4fc4e0e-6b77-4645-adca-6d19d23d30e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_94e5aef9-0ff8-403a-b098-865e396e46ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_706c7d74-8008-4ede-91fe-319ae36ae533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94e5aef9-0ff8-403a-b098-865e396e46ad" xlink:to="loc_us-gaap_DeferredOfferingCosts_706c7d74-8008-4ede-91fe-319ae36ae533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c08f7245-171d-42db-974c-6e00861f3565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94e5aef9-0ff8-403a-b098-865e396e46ad" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c08f7245-171d-42db-974c-6e00861f3565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d15af695-b1a4-4c2d-a8af-b5d8518ff2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_929e6df9-dd99-4253-9741-072495d79fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d15af695-b1a4-4c2d-a8af-b5d8518ff2f5" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_929e6df9-dd99-4253-9741-072495d79fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6dd8e994-5b15-4442-bae5-ab0b1aeb239e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_929e6df9-dd99-4253-9741-072495d79fc2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6dd8e994-5b15-4442-bae5-ab0b1aeb239e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_77e5e00d-5da0-4241-a7b9-fc4680b35fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6dd8e994-5b15-4442-bae5-ab0b1aeb239e" xlink:to="loc_us-gaap_TypeOfAdoptionMember_77e5e00d-5da0-4241-a7b9-fc4680b35fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_68994ad3-4542-424e-af81-3e8cfe97d9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_77e5e00d-5da0-4241-a7b9-fc4680b35fdb" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_68994ad3-4542-424e-af81-3e8cfe97d9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_357e996b-ac83-444b-8ccf-031d9d95f6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_929e6df9-dd99-4253-9741-072495d79fc2" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_357e996b-ac83-444b-8ccf-031d9d95f6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdbc47a2-a5db-4b03-a4f3-826df119f88a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_357e996b-ac83-444b-8ccf-031d9d95f6de" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdbc47a2-a5db-4b03-a4f3-826df119f88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_37e8d0f2-2aaf-40d5-976b-f2deb0fa6704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_357e996b-ac83-444b-8ccf-031d9d95f6de" xlink:to="loc_us-gaap_OperatingLeaseLiability_37e8d0f2-2aaf-40d5-976b-f2deb0fa6704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_519b491e-84e3-46f1-b448-6d34c2b36799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d2ded2df-5405-405c-9d61-ecd223a3e68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_519b491e-84e3-46f1-b448-6d34c2b36799" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d2ded2df-5405-405c-9d61-ecd223a3e68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_090bfcb4-8e81-496d-9b09-0c3836a61de4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d2ded2df-5405-405c-9d61-ecd223a3e68a" xlink:to="loc_srt_RestatementAxis_090bfcb4-8e81-496d-9b09-0c3836a61de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f8b5327c-d940-46d8-a273-fa59e67d8de5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_090bfcb4-8e81-496d-9b09-0c3836a61de4" xlink:to="loc_srt_RestatementDomain_f8b5327c-d940-46d8-a273-fa59e67d8de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_970d19a8-8100-4762-9e6c-8c73a7657bb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_f8b5327c-d940-46d8-a273-fa59e67d8de5" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_970d19a8-8100-4762-9e6c-8c73a7657bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_4b9a83bb-ec0f-45b9-92b4-58d9d01f40c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_f8b5327c-d940-46d8-a273-fa59e67d8de5" xlink:to="loc_srt_RestatementAdjustmentMember_4b9a83bb-ec0f-45b9-92b4-58d9d01f40c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_da17cb67-e8a8-4d22-9744-90658f7f92e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d2ded2df-5405-405c-9d61-ecd223a3e68a" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_da17cb67-e8a8-4d22-9744-90658f7f92e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d57855ef-4451-4d72-a569-37dfd31118d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_da17cb67-e8a8-4d22-9744-90658f7f92e5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d57855ef-4451-4d72-a569-37dfd31118d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_25f36f1d-9142-427d-b4b0-a03aacfd40c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d57855ef-4451-4d72-a569-37dfd31118d0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_25f36f1d-9142-427d-b4b0-a03aacfd40c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d2ded2df-5405-405c-9d61-ecd223a3e68a" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_47234cca-e5f3-4499-96b2-7512a4c82762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_47234cca-e5f3-4499-96b2-7512a4c82762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7ac13f6d-859a-476f-8ae0-b49c13e5ad54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7ac13f6d-859a-476f-8ae0-b49c13e5ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2cf87255-c7e5-4a2b-b945-ee4a5503f98b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_efd7ab08-d0a1-4029-ab8f-7090611ba2ec" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2cf87255-c7e5-4a2b-b945-ee4a5503f98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_425af8c3-0811-4664-95b6-e18a9a4601fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f9a06b39-fbfe-48a7-8337-e4ebcdd16f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425af8c3-0811-4664-95b6-e18a9a4601fb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f9a06b39-fbfe-48a7-8337-e4ebcdd16f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4506dafc-0657-4bd8-b030-f65d21177ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f9a06b39-fbfe-48a7-8337-e4ebcdd16f5a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4506dafc-0657-4bd8-b030-f65d21177ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21110ad3-e102-485e-af01-7344d8616c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4506dafc-0657-4bd8-b030-f65d21177ad8" xlink:to="loc_us-gaap_EquityComponentDomain_21110ad3-e102-485e-af01-7344d8616c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_071e4776-cfb1-4d8b-96d5-2ca69d1ab897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21110ad3-e102-485e-af01-7344d8616c6c" xlink:to="loc_us-gaap_CommonStockMember_071e4776-cfb1-4d8b-96d5-2ca69d1ab897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_915e9690-51ec-4263-b250-704032c575f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f9a06b39-fbfe-48a7-8337-e4ebcdd16f5a" xlink:to="loc_us-gaap_ClassOfStockLineItems_915e9690-51ec-4263-b250-704032c575f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_f6813cce-1647-4d19-ba78-b152633b57f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_915e9690-51ec-4263-b250-704032c575f3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_f6813cce-1647-4d19-ba78-b152633b57f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_57b1ae0e-3ed0-421e-b7b5-b0a0a8c12106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_915e9690-51ec-4263-b250-704032c575f3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_57b1ae0e-3ed0-421e-b7b5-b0a0a8c12106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_62d772b1-441a-409b-a2ee-14d2aab58df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62d772b1-441a-409b-a2ee-14d2aab58df8" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff86641-4876-4f6c-8abc-036785caf2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff86641-4876-4f6c-8abc-036785caf2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_02f8937b-db4b-4715-bef8-8327c856e753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff86641-4876-4f6c-8abc-036785caf2c7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_02f8937b-db4b-4715-bef8-8327c856e753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_00907c4d-d07a-4dc1-9cf1-5dc5a61a453d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_02f8937b-db4b-4715-bef8-8327c856e753" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_00907c4d-d07a-4dc1-9cf1-5dc5a61a453d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4216375a-3b38-4cff-b662-80eb639a7c19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4216375a-3b38-4cff-b662-80eb639a7c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3197c640-0ee7-455e-ba6c-078f26c5e0cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4216375a-3b38-4cff-b662-80eb639a7c19" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3197c640-0ee7-455e-ba6c-078f26c5e0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a0b9ab3f-25d1-41dd-9eb7-c9634d447440" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3197c640-0ee7-455e-ba6c-078f26c5e0cd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a0b9ab3f-25d1-41dd-9eb7-c9634d447440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f1c1f001-585b-4de2-a735-54174418a98a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f1c1f001-585b-4de2-a735-54174418a98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1c6ae862-c979-4070-89ad-ebc92dd2b851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f1c1f001-585b-4de2-a735-54174418a98a" xlink:to="loc_us-gaap_EquityComponentDomain_1c6ae862-c979-4070-89ad-ebc92dd2b851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a9ca89ca-8d39-400f-b240-fdc83eaed1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1c6ae862-c979-4070-89ad-ebc92dd2b851" xlink:to="loc_us-gaap_RetainedEarningsMember_a9ca89ca-8d39-400f-b240-fdc83eaed1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_73798d3f-48fb-402b-bffa-3bd3041868e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a8bc3ed8-32f4-4b93-9f1a-034fa69078a8" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_73798d3f-48fb-402b-bffa-3bd3041868e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_243968fb-afd2-4932-91c1-ce4f88f7c7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_73798d3f-48fb-402b-bffa-3bd3041868e6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_243968fb-afd2-4932-91c1-ce4f88f7c7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_3fddb136-4141-41d9-9b6d-4ac1961c1f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_73798d3f-48fb-402b-bffa-3bd3041868e6" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_3fddb136-4141-41d9-9b6d-4ac1961c1f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68a6d7f9-c958-4691-99f7-a80312e65269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_ad9d54cf-c04e-4eba-ae51-46b574f7640a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68a6d7f9-c958-4691-99f7-a80312e65269" xlink:to="loc_us-gaap_AdvertisingExpense_ad9d54cf-c04e-4eba-ae51-46b574f7640a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_60d8a8f5-7c40-4145-87e6-bd62f66c4467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_60d8a8f5-7c40-4145-87e6-bd62f66c4467" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8953ef47-ee74-47c4-b536-eed43151d46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8953ef47-ee74-47c4-b536-eed43151d46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_25a485d2-d59c-4ecf-b4fe-95ab7b46cad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8953ef47-ee74-47c4-b536-eed43151d46a" xlink:to="loc_us-gaap_EquityComponentDomain_25a485d2-d59c-4ecf-b4fe-95ab7b46cad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f570b21c-a019-48c7-aee8-add77d822df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25a485d2-d59c-4ecf-b4fe-95ab7b46cad2" xlink:to="loc_us-gaap_RetainedEarningsMember_f570b21c-a019-48c7-aee8-add77d822df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a98682-032c-458d-b056-19e82dfee6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a98682-032c-458d-b056-19e82dfee6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_eab0caa6-18e3-4615-a1aa-ce38d89af854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a98682-032c-458d-b056-19e82dfee6e4" xlink:to="loc_us-gaap_TypeOfAdoptionMember_eab0caa6-18e3-4615-a1aa-ce38d89af854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_92829ff6-70f7-4425-887b-f49fecf9012d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_eab0caa6-18e3-4615-a1aa-ce38d89af854" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_92829ff6-70f7-4425-887b-f49fecf9012d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f08bc52b-1220-416c-8a18-6c5cd60123cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f08bc52b-1220-416c-8a18-6c5cd60123cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_af5bff5e-e70d-4589-a2bf-ae0ce9e6f6eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f08bc52b-1220-416c-8a18-6c5cd60123cd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_af5bff5e-e70d-4589-a2bf-ae0ce9e6f6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_44b2bea2-40a9-4822-baad-07144ad6d476" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_af5bff5e-e70d-4589-a2bf-ae0ce9e6f6eb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_44b2bea2-40a9-4822-baad-07144ad6d476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fd89f366-2215-44ad-9d32-0e8675a271e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a7e0eb66-868f-4963-81ae-fa57de8c5ff8" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fd89f366-2215-44ad-9d32-0e8675a271e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0a6a86e-9816-466f-b8d0-9c5e592ac24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fd89f366-2215-44ad-9d32-0e8675a271e9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0a6a86e-9816-466f-b8d0-9c5e592ac24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_421e8753-6af2-4746-bbfd-24edb424fb73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_bffb5b2e-9c5b-4682-93db-498201781001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_421e8753-6af2-4746-bbfd-24edb424fb73" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_bffb5b2e-9c5b-4682-93db-498201781001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0f65430f-22e4-44cf-b679-67445ca3cb2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_421e8753-6af2-4746-bbfd-24edb424fb73" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_0f65430f-22e4-44cf-b679-67445ca3cb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e437a1d0-740a-4344-a3ad-3116390ea293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd" xlink:to="loc_us-gaap_NetIncomeLoss_e437a1d0-740a-4344-a3ad-3116390ea293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3e6648b9-81ef-441f-8975-e290609a4a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3e6648b9-81ef-441f-8975-e290609a4a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_509dcdb9-6a08-422e-a32d-478fca1e0839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01d8897a-7c88-4991-aa0b-dc211cc8dcfd" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_509dcdb9-6a08-422e-a32d-478fca1e0839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_17b387d6-ed05-49ab-9d97-0f68edfed618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c5ff79f4-a582-4711-99be-9654c9ae32c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_17b387d6-ed05-49ab-9d97-0f68edfed618" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c5ff79f4-a582-4711-99be-9654c9ae32c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2739a22a-1e25-44af-9b11-a35ee611a854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c5ff79f4-a582-4711-99be-9654c9ae32c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2739a22a-1e25-44af-9b11-a35ee611a854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2739a22a-1e25-44af-9b11-a35ee611a854" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7249272a-0d3c-4b12-a9d1-a899ec7645d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7249272a-0d3c-4b12-a9d1-a899ec7645d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_8abe4d1c-3ac5-4336-9107-d7e9117f26c6" xlink:href="silk-20201231.xsd#silk_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_8abe4d1c-3ac5-4336-9107-d7e9117f26c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_83f5cb74-daf7-48b3-bbc5-99a14ecf9f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_us-gaap_EmployeeStockOptionMember_83f5cb74-daf7-48b3-bbc5-99a14ecf9f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_86be6e44-52e9-4ea6-9e96-617877274ac8" xlink:href="silk-20201231.xsd#silk_CommonStockWarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_silk_CommonStockWarrantMember_86be6e44-52e9-4ea6-9e96-617877274ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6006817b-a500-4df2-86fc-1242f5d746c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfc5de50-ffb3-4db5-b57b-fef7b42efd63" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6006817b-a500-4df2-86fc-1242f5d746c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_533f51e0-910d-47c0-8846-7a1091e2064e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c5ff79f4-a582-4711-99be-9654c9ae32c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_533f51e0-910d-47c0-8846-7a1091e2064e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5946846-4940-4da4-897a-f164faf20830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_533f51e0-910d-47c0-8846-7a1091e2064e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5946846-4940-4da4-897a-f164faf20830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_72b63c31-9b0a-47e9-a781-3a7cc73f5a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7a227439-6460-4240-8dd6-163b3292146c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_72b63c31-9b0a-47e9-a781-3a7cc73f5a43" xlink:to="loc_us-gaap_NumberOfReportableSegments_7a227439-6460-4240-8dd6-163b3292146c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7d048557-eb8a-4d82-abe1-c85fd31e0381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_72b63c31-9b0a-47e9-a781-3a7cc73f5a43" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7d048557-eb8a-4d82-abe1-c85fd31e0381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="silk-20201231.xsd#RecentAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_659038f6-aea6-443a-bf2a-ec269e445648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_64ad4cb5-e156-46c1-8f00-393a0156e591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_659038f6-aea6-443a-bf2a-ec269e445648" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_64ad4cb5-e156-46c1-8f00-393a0156e591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="silk-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c2d60a53-4c66-454b-9dc6-208bf41c5031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a7d82d6d-119b-43ba-8165-79b4ccce08ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c2d60a53-4c66-454b-9dc6-208bf41c5031" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a7d82d6d-119b-43ba-8165-79b4ccce08ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="silk-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_46f90a9d-7dd1-4e69-ad90-1979e21a7246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1c083576-c87e-407f-b9ee-31cdbdd02f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_46f90a9d-7dd1-4e69-ad90-1979e21a7246" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1c083576-c87e-407f-b9ee-31cdbdd02f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9e170c5b-107b-4ca5-94b5-e8bfa69f431c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9e170c5b-107b-4ca5-94b5-e8bfa69f431c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_914e6053-c2c0-4307-85c2-38f84f381514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_914e6053-c2c0-4307-85c2-38f84f381514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_50676151-6955-4a50-a70f-ac40f6e7ad19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_914e6053-c2c0-4307-85c2-38f84f381514" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_50676151-6955-4a50-a70f-ac40f6e7ad19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b7c11931-34a4-40f4-96db-8bb924a50bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_50676151-6955-4a50-a70f-ac40f6e7ad19" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b7c11931-34a4-40f4-96db-8bb924a50bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71f20d8e-172a-4336-9792-f44770f785b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71f20d8e-172a-4336-9792-f44770f785b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71f20d8e-172a-4336-9792-f44770f785b4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5d5ad783-1f6f-4d37-900a-ec3a368ce454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5d5ad783-1f6f-4d37-900a-ec3a368ce454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_39f3a5f4-61f6-4ce7-858d-e98813e1d6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_39f3a5f4-61f6-4ce7-858d-e98813e1d6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d39982b6-6b1c-4d32-81c7-63f1552680d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f4b0c53f-2b77-4c74-9fbe-e87160cad3da" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d39982b6-6b1c-4d32-81c7-63f1552680d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ebe75529-cf0f-409b-9de0-db37b30f1e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ebe75529-cf0f-409b-9de0-db37b30f1e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ebe75529-cf0f-409b-9de0-db37b30f1e80" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_84f605d3-4087-4adb-9f74-93bd1cb0ba3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_84f605d3-4087-4adb-9f74-93bd1cb0ba3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_45951b5a-f4c9-4ff2-81fd-2d00900bc0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_45951b5a-f4c9-4ff2-81fd-2d00900bc0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c3a94a79-6ae9-4c37-94a4-fc398a4ad23e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c3a94a79-6ae9-4c37-94a4-fc398a4ad23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_538f1915-6b1d-4e8c-8ada-f47daaa370b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_538f1915-6b1d-4e8c-8ada-f47daaa370b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_734a2c78-5941-44be-a0d5-a965241d2d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a9235a05-ee4c-4206-ae1b-4981288edb7b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_734a2c78-5941-44be-a0d5-a965241d2d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f09ce13c-a31c-46ce-ae60-429f3a3ba730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_54976582-5ef8-41b6-a7c2-e250815858a8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f09ce13c-a31c-46ce-ae60-429f3a3ba730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9182cc8e-3f79-4ecc-a746-49763159fdd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f09ce13c-a31c-46ce-ae60-429f3a3ba730" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9182cc8e-3f79-4ecc-a746-49763159fdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_99c883d0-4478-4cd5-83ca-d0d51f37b6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f09ce13c-a31c-46ce-ae60-429f3a3ba730" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_99c883d0-4478-4cd5-83ca-d0d51f37b6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0669ec37-0285-4d08-acaa-ea8f2ec6c847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_21cffbe9-5274-4128-8367-19f40b5d50cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0669ec37-0285-4d08-acaa-ea8f2ec6c847" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_21cffbe9-5274-4128-8367-19f40b5d50cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54f01050-809e-4fb9-89c9-3fe516d57947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_65a0f1f7-5d6c-4367-8e21-a34360c07912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54f01050-809e-4fb9-89c9-3fe516d57947" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_65a0f1f7-5d6c-4367-8e21-a34360c07912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_096d3f00-5c19-4593-9379-0db787390473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54f01050-809e-4fb9-89c9-3fe516d57947" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_096d3f00-5c19-4593-9379-0db787390473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_78b92b55-43e6-4b27-a117-05b8196c5ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54f01050-809e-4fb9-89c9-3fe516d57947" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_78b92b55-43e6-4b27-a117-05b8196c5ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_64fe12ff-bd20-4fe9-ab01-2c7c18144740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54f01050-809e-4fb9-89c9-3fe516d57947" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_64fe12ff-bd20-4fe9-ab01-2c7c18144740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b80e0670-4048-4554-a160-89886c1a0f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54f01050-809e-4fb9-89c9-3fe516d57947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b80e0670-4048-4554-a160-89886c1a0f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_25721848-a7b6-402a-b72d-d8bb92f8caa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54f01050-809e-4fb9-89c9-3fe516d57947" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_25721848-a7b6-402a-b72d-d8bb92f8caa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86eb83d1-ed08-41fb-96d8-b6b7e0bb1aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a13163ce-4559-4dfe-9912-dc675cbb99f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86eb83d1-ed08-41fb-96d8-b6b7e0bb1aac" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a13163ce-4559-4dfe-9912-dc675cbb99f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_af081b73-d3d8-4661-9a66-7d12182f6105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a13163ce-4559-4dfe-9912-dc675cbb99f3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_af081b73-d3d8-4661-9a66-7d12182f6105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_af081b73-d3d8-4661-9a66-7d12182f6105" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b696aa1a-844d-49e7-ba85-2fee7dd314d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b696aa1a-844d-49e7-ba85-2fee7dd314d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a575a9f0-5654-4ff9-b43a-fad1a4a2d3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_CommercialPaperMember_a575a9f0-5654-4ff9-b43a-fad1a4a2d3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9d846ad5-24d8-469a-9a92-abcbb9e2d01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9d846ad5-24d8-469a-9a92-abcbb9e2d01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_93c95a0d-6b00-4143-a1c3-668e4e75d316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_93c95a0d-6b00-4143-a1c3-668e4e75d316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4004175a-815b-4169-ba9e-a0b15ae8ad65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4004175a-815b-4169-ba9e-a0b15ae8ad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_ddb6bb78-1d63-4957-8431-74d278a9ca37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_CashEquivalentsMember_ddb6bb78-1d63-4957-8431-74d278a9ca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_dcac2c40-e556-457e-b5cf-8dce3a05e5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_dcac2c40-e556-457e-b5cf-8dce3a05e5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermInvestmentsMember_f6241f29-86da-43bb-958f-9c0dedcd5343" xlink:href="silk-20201231.xsd#silk_LongTermInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_95043665-c991-47cb-a575-9df74a3c6882" xlink:to="loc_silk_LongTermInvestmentsMember_f6241f29-86da-43bb-958f-9c0dedcd5343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a13163ce-4559-4dfe-9912-dc675cbb99f3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cc245e0d-3dd2-4b5f-877e-d0098acb5b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cc245e0d-3dd2-4b5f-877e-d0098acb5b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00a56dd3-ce17-4671-9f13-48ce7da4bb50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00a56dd3-ce17-4671-9f13-48ce7da4bb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_46224308-31ca-4949-87f6-d112977b639e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_46224308-31ca-4949-87f6-d112977b639e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87cdb6a9-029d-42c3-aba9-8780d79b8ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cfc71a05-9be6-47ec-903f-4c13fee04b08" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87cdb6a9-029d-42c3-aba9-8780d79b8ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84a83c94-165c-42a9-85b2-5cd9826c57d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_9d94cdd7-9649-4e1e-b848-ec9a86cd9fe0" xlink:href="silk-20201231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84a83c94-165c-42a9-85b2-5cd9826c57d7" xlink:to="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_9d94cdd7-9649-4e1e-b848-ec9a86cd9fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_66c54d41-c677-4663-98ee-f54c7a7c3d1d" xlink:href="silk-20201231.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84a83c94-165c-42a9-85b2-5cd9826c57d7" xlink:to="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_66c54d41-c677-4663-98ee-f54c7a7c3d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2b3107cc-90d0-4a01-a3dd-e0ce6a127f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84a83c94-165c-42a9-85b2-5cd9826c57d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2b3107cc-90d0-4a01-a3dd-e0ce6a127f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7be6244e-457b-48d6-87c7-0a2dd5b273a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_31fefc94-428d-48e7-b3dd-aef6a021c2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7be6244e-457b-48d6-87c7-0a2dd5b273a2" xlink:to="loc_us-gaap_InventoryCurrentTable_31fefc94-428d-48e7-b3dd-aef6a021c2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeAxis_7920d16e-6859-4692-80a0-f3a6eabb7f2d" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_31fefc94-428d-48e7-b3dd-aef6a021c2df" xlink:to="loc_silk_LossContingencyReceivableTypeAxis_7920d16e-6859-4692-80a0-f3a6eabb7f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeDomain_22ea390c-ec58-4b9b-bbc0-19c35dd9fb28" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_LossContingencyReceivableTypeAxis_7920d16e-6859-4692-80a0-f3a6eabb7f2d" xlink:to="loc_silk_LossContingencyReceivableTypeDomain_22ea390c-ec58-4b9b-bbc0-19c35dd9fb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember_6642c6f8-38c7-46fe-87b5-8c5f683e26ae" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_LossContingencyReceivableTypeDomain_22ea390c-ec58-4b9b-bbc0-19c35dd9fb28" xlink:to="loc_silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember_6642c6f8-38c7-46fe-87b5-8c5f683e26ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9dc0b332-10eb-43d1-a052-2eaa23ac6c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_31fefc94-428d-48e7-b3dd-aef6a021c2df" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9dc0b332-10eb-43d1-a052-2eaa23ac6c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_96b13657-69f1-4033-9445-dfd0217dc843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9dc0b332-10eb-43d1-a052-2eaa23ac6c38" xlink:to="loc_us-gaap_LossContingencyNatureDomain_96b13657-69f1-4033-9445-dfd0217dc843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_VoluntaryRecallMember_f05073bf-2f8e-4888-a81f-d66d632fa406" xlink:href="silk-20201231.xsd#silk_VoluntaryRecallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_96b13657-69f1-4033-9445-dfd0217dc843" xlink:to="loc_silk_VoluntaryRecallMember_f05073bf-2f8e-4888-a81f-d66d632fa406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_31fefc94-428d-48e7-b3dd-aef6a021c2df" xlink:to="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_c23d006b-3020-45ce-9625-05eaf7aa498a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_c23d006b-3020-45ce-9625-05eaf7aa498a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4aa74338-d786-4a9c-8f80-da756780d870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4aa74338-d786-4a9c-8f80-da756780d870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable_b9996575-2239-4490-a072-b0841b3ff78a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:to="loc_us-gaap_LossContingencyReceivable_b9996575-2239-4490-a072-b0841b3ff78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a2c12353-5dda-45df-bf74-2d839b77ebe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a7c22bff-5aa8-469d-9d12-422b4323369c" xlink:to="loc_us-gaap_Depreciation_a2c12353-5dda-45df-bf74-2d839b77ebe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_461c8000-ada0-434b-8523-ccacaa043c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_45910d7c-2227-4fff-9611-5babcfed512d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_461c8000-ada0-434b-8523-ccacaa043c15" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_45910d7c-2227-4fff-9611-5babcfed512d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2aa8a372-66a3-4d4f-b49c-06f4f1099978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_45910d7c-2227-4fff-9611-5babcfed512d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2aa8a372-66a3-4d4f-b49c-06f4f1099978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_504e6c93-9661-4c91-a48c-db935978025d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2aa8a372-66a3-4d4f-b49c-06f4f1099978" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_504e6c93-9661-4c91-a48c-db935978025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f230dbfa-d948-4f1e-9061-b9bc28fed68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_504e6c93-9661-4c91-a48c-db935978025d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f230dbfa-d948-4f1e-9061-b9bc28fed68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d7b89fb-f507-426c-a115-3f195a86ab23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_504e6c93-9661-4c91-a48c-db935978025d" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d7b89fb-f507-426c-a115-3f195a86ab23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b841d08a-65bf-466e-adea-d3b9352e32dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_45910d7c-2227-4fff-9611-5babcfed512d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b841d08a-65bf-466e-adea-d3b9352e32dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b2229f2a-c14b-4be5-add7-bcc4867050c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b841d08a-65bf-466e-adea-d3b9352e32dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b2229f2a-c14b-4be5-add7-bcc4867050c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3fbe1928-b186-4aa2-b636-4e66cbe5ff69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b841d08a-65bf-466e-adea-d3b9352e32dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3fbe1928-b186-4aa2-b636-4e66cbe5ff69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd38b910-3a28-41f1-92a5-99d7a61c94e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_8dcffb94-3b3e-4d0b-b03d-f7e540463e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd38b910-3a28-41f1-92a5-99d7a61c94e7" xlink:to="loc_us-gaap_InventoryCurrentTable_8dcffb94-3b3e-4d0b-b03d-f7e540463e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d98a134a-0b1a-4526-b5a0-4f29a10ca2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_8dcffb94-3b3e-4d0b-b03d-f7e540463e1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d98a134a-0b1a-4526-b5a0-4f29a10ca2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0a98f862-1f75-4a41-8db9-3cd686be0223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d98a134a-0b1a-4526-b5a0-4f29a10ca2f3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0a98f862-1f75-4a41-8db9-3cd686be0223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_VoluntaryRecallMember_8365e2c2-2f6d-4a90-bb6e-a784cecda71c" xlink:href="silk-20201231.xsd#silk_VoluntaryRecallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0a98f862-1f75-4a41-8db9-3cd686be0223" xlink:to="loc_silk_VoluntaryRecallMember_8365e2c2-2f6d-4a90-bb6e-a784cecda71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_8dcffb94-3b3e-4d0b-b03d-f7e540463e1e" xlink:to="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_5d56fc1b-3d61-42c9-93ff-c8c53aa7762e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryRawMaterials_5d56fc1b-3d61-42c9-93ff-c8c53aa7762e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_37ce4345-8530-4a47-ae5d-1a162ed74c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryFinishedGoods_37ce4345-8530-4a47-ae5d-1a162ed74c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0932259d-086e-4383-ab0c-14df0d5fa305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryGross_0932259d-086e-4383-ab0c-14df0d5fa305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_5b50834e-04ff-4834-a1cc-41109008db95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryValuationReserves_5b50834e-04ff-4834-a1cc-41109008db95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bbf5f6fe-1f4e-4bc5-b693-145142e4a7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryNet_bbf5f6fe-1f4e-4bc5-b693-145142e4a7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_99e930c8-3397-49d9-849f-e4d94553507a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_83383a95-fa28-43eb-8468-6e1ab6f597ea" xlink:to="loc_us-gaap_InventoryValuationReserves_99e930c8-3397-49d9-849f-e4d94553507a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85e4f411-3fd2-4d7d-8af3-64cdece48093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6fdb61f2-ca64-4d72-8189-dad8fdd9893a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85e4f411-3fd2-4d7d-8af3-64cdece48093" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6fdb61f2-ca64-4d72-8189-dad8fdd9893a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e184113f-7235-4669-85d9-876a9480d859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6fdb61f2-ca64-4d72-8189-dad8fdd9893a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e184113f-7235-4669-85d9-876a9480d859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e184113f-7235-4669-85d9-876a9480d859" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1c8adc61-06fe-4016-a1c4-f25096d67e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1c8adc61-06fe-4016-a1c4-f25096d67e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d12a3e41-07af-44ae-8a5b-024164e79301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_EquipmentMember_d12a3e41-07af-44ae-8a5b-024164e79301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a70bb533-5832-48d7-9324-30d360d71361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a70bb533-5832-48d7-9324-30d360d71361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f2c4ae2b-d1e7-4f4b-81d8-561006a01450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f2c4ae2b-d1e7-4f4b-81d8-561006a01450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_bf02a4c1-aca5-4988-9622-ff47bcaeee05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fad1726e-a403-4ace-91ea-8f0e5933d258" xlink:to="loc_us-gaap_ConstructionInProgressMember_bf02a4c1-aca5-4988-9622-ff47bcaeee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6fdb61f2-ca64-4d72-8189-dad8fdd9893a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_49ad21df-392e-4261-8462-897e15c4e9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_49ad21df-392e-4261-8462-897e15c4e9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b33bbcf0-adf2-46f3-8d70-6ffc2c3183ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b33bbcf0-adf2-46f3-8d70-6ffc2c3183ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a7bb9ea3-217c-4007-83f8-8c8216790705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e25b3a19-a47d-45c9-8c6f-2712039ace08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a7bb9ea3-217c-4007-83f8-8c8216790705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_22775f9a-a8e9-4ffb-91be-f74f951d51ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_us-gaap_AccruedSalariesCurrent_22775f9a-a8e9-4ffb-91be-f74f951d51ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ProvisionsForSalesReturns_17273bc6-1e3c-46d1-80fe-821420088a8d" xlink:href="silk-20201231.xsd#silk_ProvisionsForSalesReturns"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_silk_ProvisionsForSalesReturns_17273bc6-1e3c-46d1-80fe-821420088a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_faa0f5bc-f2ca-4441-be7c-a8d146ca8c60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_faa0f5bc-f2ca-4441-be7c-a8d146ca8c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_9261c39d-b434-416f-b8cb-97e6050942f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_9261c39d-b434-416f-b8cb-97e6050942f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0b0e237a-1e89-41d7-8642-d41509197e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0b0e237a-1e89-41d7-8642-d41509197e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_79467c98-367d-4c83-a903-9a95b286ea12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_79467c98-367d-4c83-a903-9a95b286ea12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_850a0d11-dd79-4c67-9cc5-9adb7c183251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_850a0d11-dd79-4c67-9cc5-9adb7c183251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedTravelExpensesCurrent_8f1d8c2a-c98b-43c3-8816-785544640374" xlink:href="silk-20201231.xsd#silk_AccruedTravelExpensesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_silk_AccruedTravelExpensesCurrent_8f1d8c2a-c98b-43c3-8816-785544640374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedClinicalExpensesCurrent_7582e8df-4325-4373-8039-ef10e24089ee" xlink:href="silk-20201231.xsd#silk_AccruedClinicalExpensesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_silk_AccruedClinicalExpensesCurrent_7582e8df-4325-4373-8039-ef10e24089ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_194552ad-7435-4997-b09e-69153d5d3427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_194552ad-7435-4997-b09e-69153d5d3427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9efd5853-a310-4da6-b5ab-1510468a3c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f26c8e4f-3759-4b4f-aede-36f3977593c2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9efd5853-a310-4da6-b5ab-1510468a3c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebt" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f52c1e87-4de7-4e9f-b517-afd161939973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_90c30a00-1707-4bc9-9f08-692ec6764429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f52c1e87-4de7-4e9f-b517-afd161939973" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_90c30a00-1707-4bc9-9f08-692ec6764429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8ab108ff-78de-40ef-a68c-775cdddfd32b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8431ffca-d966-4aca-9036-f88b9f971f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ab108ff-78de-40ef-a68c-775cdddfd32b" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8431ffca-d966-4aca-9036-f88b9f971f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtCRGNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b77a96bc-1bf6-4790-a747-7af52a33b2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0e3e5704-72bc-44bd-89b7-8a8b46184010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b77a96bc-1bf6-4790-a747-7af52a33b2ca" xlink:to="loc_us-gaap_DebtInstrumentTable_0e3e5704-72bc-44bd-89b7-8a8b46184010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_77131635-7f52-475d-8db3-0e15f4e59f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0e3e5704-72bc-44bd-89b7-8a8b46184010" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_77131635-7f52-475d-8db3-0e15f4e59f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77131635-7f52-475d-8db3-0e15f4e59f0e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanMember_44f80252-2a41-4a1e-a825-97194da5c083" xlink:href="silk-20201231.xsd#silk_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:to="loc_silk_TermLoanMember_44f80252-2a41-4a1e-a825-97194da5c083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheAMember_6ff3e743-8c89-4a95-9738-44374acc030f" xlink:href="silk-20201231.xsd#silk_TermLoanTrancheAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:to="loc_silk_TermLoanTrancheAMember_6ff3e743-8c89-4a95-9738-44374acc030f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheBMember_9c12cf80-b0b1-4885-af7a-3a80128c8c0e" xlink:href="silk-20201231.xsd#silk_TermLoanTrancheBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5205ca62-36dd-4e2e-8dd7-b3cb6f93cd6d" xlink:to="loc_silk_TermLoanTrancheBMember_9c12cf80-b0b1-4885-af7a-3a80128c8c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0e3e5704-72bc-44bd-89b7-8a8b46184010" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtMaximumBorrowingCapacity_f461a8cb-7288-44b1-a801-ef85f545baa3" xlink:href="silk-20201231.xsd#silk_DebtMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_silk_DebtMaximumBorrowingCapacity_f461a8cb-7288-44b1-a801-ef85f545baa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_8615515d-1749-4c8b-ab81-8095ef6e902a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_8615515d-1749-4c8b-ab81-8095ef6e902a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4730f626-980b-4df5-b041-7297db1813be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4730f626-980b-4df5-b041-7297db1813be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInKind_0f0e3f23-78b0-401a-9acf-fb472e97685d" xlink:href="silk-20201231.xsd#silk_DebtInstrumentInterestRatePaidInKind"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_silk_DebtInstrumentInterestRatePaidInKind_0f0e3f23-78b0-401a-9acf-fb472e97685d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInCash_b8790523-2fdc-4dec-a30b-e32d3c0d24a2" xlink:href="silk-20201231.xsd#silk_DebtInstrumentInterestRatePaidInCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3c236abc-6824-4148-af01-1395bf9859e6" xlink:to="loc_silk_DebtInstrumentInterestRatePaidInCash_b8790523-2fdc-4dec-a30b-e32d3c0d24a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantDebtDefaultRate_42cf4bcc-2cee-4665-9bde-1dc60590f3dd" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantDebtDefaultRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b77a96bc-1bf6-4790-a747-7af52a33b2ca" xlink:to="loc_silk_DebtInstrumentCovenantDebtDefaultRate_42cf4bcc-2cee-4665-9bde-1dc60590f3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtStifelBankNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_971e9a74-3daa-428f-93dd-81260786fd79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_971e9a74-3daa-428f-93dd-81260786fd79" xlink:to="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6f3ba28d-4222-4843-a357-14d91092dbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_us-gaap_DebtInstrumentAxis_6f3ba28d-4222-4843-a357-14d91092dbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7c261709-d8ff-4d46-aa58-d653770bf145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6f3ba28d-4222-4843-a357-14d91092dbf3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7c261709-d8ff-4d46-aa58-d653770bf145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LoanAndSecurityAgreementMember_8adb52d6-d796-4b6c-8484-f1ba733503e5" xlink:href="silk-20201231.xsd#silk_LoanAndSecurityAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7c261709-d8ff-4d46-aa58-d653770bf145" xlink:to="loc_silk_LoanAndSecurityAgreementMember_8adb52d6-d796-4b6c-8484-f1ba733503e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SuccessFeeAgreementMember_55828206-06c1-4249-a54c-643a4fdbefae" xlink:href="silk-20201231.xsd#silk_SuccessFeeAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7c261709-d8ff-4d46-aa58-d653770bf145" xlink:to="loc_silk_SuccessFeeAgreementMember_55828206-06c1-4249-a54c-643a4fdbefae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7d5a20f5-9877-4529-83a5-67c0a2a5f0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_us-gaap_CreditFacilityAxis_7d5a20f5-9877-4529-83a5-67c0a2a5f0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bbb9e233-8954-4a57-9050-fe15bc383fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7d5a20f5-9877-4529-83a5-67c0a2a5f0bd" xlink:to="loc_us-gaap_CreditFacilityDomain_bbb9e233-8954-4a57-9050-fe15bc383fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_0413a019-f118-4f61-bb54-51b7933574a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_bbb9e233-8954-4a57-9050-fe15bc383fbb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_0413a019-f118-4f61-bb54-51b7933574a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_7aac6c1b-100b-4a69-8d79-a2dfd08a3d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_bbb9e233-8954-4a57-9050-fe15bc383fbb" xlink:to="loc_us-gaap_LetterOfCreditMember_7aac6c1b-100b-4a69-8d79-a2dfd08a3d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05e828e4-87f5-4bc9-ada3-8f100f8fbe63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05e828e4-87f5-4bc9-ada3-8f100f8fbe63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2cc5d3cb-d6b4-45af-b98b-a4486e0da990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05e828e4-87f5-4bc9-ada3-8f100f8fbe63" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2cc5d3cb-d6b4-45af-b98b-a4486e0da990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5bef95e6-fcdc-4ef4-bb41-dcca61415f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2cc5d3cb-d6b4-45af-b98b-a4486e0da990" xlink:to="loc_us-gaap_LineOfCreditMember_5bef95e6-fcdc-4ef4-bb41-dcca61415f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_75b4e247-69b9-4c02-89cd-6784afa9a082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2cc5d3cb-d6b4-45af-b98b-a4486e0da990" xlink:to="loc_us-gaap_SecuredDebtMember_75b4e247-69b9-4c02-89cd-6784afa9a082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_74b37a7c-8043-49a1-9d67-2b4c634348db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_us-gaap_VariableRateAxis_74b37a7c-8043-49a1-9d67-2b4c634348db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_257531b8-a139-4fa0-9917-4bde57288cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_74b37a7c-8043-49a1-9d67-2b4c634348db" xlink:to="loc_us-gaap_VariableRateDomain_257531b8-a139-4fa0-9917-4bde57288cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_8f101483-0c4d-408a-b1f9-40f6e6dd21d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_257531b8-a139-4fa0-9917-4bde57288cf5" xlink:to="loc_us-gaap_PrimeRateMember_8f101483-0c4d-408a-b1f9-40f6e6dd21d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentRateScenarioAxis_e5835996-3752-4bda-bd30-78062a8acb8b" xlink:href="silk-20201231.xsd#silk_DebtInstrumentRateScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_silk_DebtInstrumentRateScenarioAxis_e5835996-3752-4bda-bd30-78062a8acb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentRateScenarioDomain_8b5204fc-f7b1-4a03-835e-0f7084c7434d" xlink:href="silk-20201231.xsd#silk_DebtInstrumentRateScenarioDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_DebtInstrumentRateScenarioAxis_e5835996-3752-4bda-bd30-78062a8acb8b" xlink:to="loc_silk_DebtInstrumentRateScenarioDomain_8b5204fc-f7b1-4a03-835e-0f7084c7434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RateScenarioOneMember_efeec038-83b6-4cf0-99aa-bc54cdbf6253" xlink:href="silk-20201231.xsd#silk_RateScenarioOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_DebtInstrumentRateScenarioDomain_8b5204fc-f7b1-4a03-835e-0f7084c7434d" xlink:to="loc_silk_RateScenarioOneMember_efeec038-83b6-4cf0-99aa-bc54cdbf6253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RateScenarioTwoMember_e9572002-865d-4a25-b5ff-9278bf7b7deb" xlink:href="silk-20201231.xsd#silk_RateScenarioTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_DebtInstrumentRateScenarioDomain_8b5204fc-f7b1-4a03-835e-0f7084c7434d" xlink:to="loc_silk_RateScenarioTwoMember_e9572002-865d-4a25-b5ff-9278bf7b7deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_327b0864-42e4-419d-8e9a-7eb1f9e20ce7" xlink:to="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5bba1191-a10a-4952-980b-24f3272bbbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5bba1191-a10a-4952-980b-24f3272bbbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentMaximumBorrowingCapacity_c4cc41dd-406b-4657-a981-5b35ab01377d" xlink:href="silk-20201231.xsd#silk_DebtInstrumentMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentMaximumBorrowingCapacity_c4cc41dd-406b-4657-a981-5b35ab01377d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantMaximumBorrowingThreshold_9b19d2a3-8580-41b4-99e7-998415089202" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantMaximumBorrowingThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantMaximumBorrowingThreshold_9b19d2a3-8580-41b4-99e7-998415089202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_56dc3d70-2d8a-45cb-a909-303135977c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_56dc3d70-2d8a-45cb-a909-303135977c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_7ca3adb4-2f88-4990-9c61-211479155667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_7ca3adb4-2f88-4990-9c61-211479155667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_7c0dbdae-25f2-4559-9ffb-9e4d0911b060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_7c0dbdae-25f2-4559-9ffb-9e4d0911b060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_ed00a8fd-37f5-4432-8d6e-f2c2583925c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_ed00a8fd-37f5-4432-8d6e-f2c2583925c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_ac0a4387-dc88-42c4-812b-52c975bcdffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_InterestExpenseDebt_ac0a4387-dc88-42c4-812b-52c975bcdffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1c2223e0-6c38-47c2-b3f6-7c617180d7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1c2223e0-6c38-47c2-b3f6-7c617180d7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f8d0c936-353e-4860-8584-4f0750f70187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f8d0c936-353e-4860-8584-4f0750f70187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RepaymentsOfDebtRevenueTargetPercentage_5664e529-178f-4178-ac16-f27a48e1d251" xlink:href="silk-20201231.xsd#silk_RepaymentsOfDebtRevenueTargetPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_RepaymentsOfDebtRevenueTargetPercentage_5664e529-178f-4178-ac16-f27a48e1d251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_b13937f1-b9b3-4700-97ac-68b0c8bb44be" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold_b13937f1-b9b3-4700-97ac-68b0c8bb44be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_43576915-69c1-4fbe-97e0-e3a459ff3588" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantLiquidityEventPaymentAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount_43576915-69c1-4fbe-97e0-e3a459ff3588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum_af5110ee-47ec-4930-8fa7-4b23c592dd1f" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum_af5110ee-47ec-4930-8fa7-4b23c592dd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions_76cdd813-b904-4631-a5c0-b3cb400e0a14" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions_76cdd813-b904-4631-a5c0-b3cb400e0a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantDebtDefaultRate_29bbf651-3820-4f5b-aa87-25f9dd1a3de6" xlink:href="silk-20201231.xsd#silk_DebtInstrumentCovenantDebtDefaultRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_silk_DebtInstrumentCovenantDebtDefaultRate_29bbf651-3820-4f5b-aa87-25f9dd1a3de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f2de889-9eb6-4634-9563-1cbfe70cb217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8abd1ba9-ee7d-485e-93c5-0db4e02c465a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f2de889-9eb6-4634-9563-1cbfe70cb217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#LongtermDebtFutureMaturitiesUndertheTermLoanDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_06b1b9bd-f6ce-4e3e-aac2-85e5b9b74361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_06b1b9bd-f6ce-4e3e-aac2-85e5b9b74361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_746690be-fde0-44eb-b6ed-a397fbf162a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_746690be-fde0-44eb-b6ed-a397fbf162a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_99fdb47b-b01d-4e3b-92c7-22798ab820a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_99fdb47b-b01d-4e3b-92c7-22798ab820a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2d8749f0-7207-4d53-aca6-1ebc02573ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2d8749f0-7207-4d53-aca6-1ebc02573ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_d6e745d9-d4a7-47df-b162-a7aee16e324c" xlink:href="silk-20201231.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_d6e745d9-d4a7-47df-b162-a7aee16e324c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtUnpaidInterest_14835b74-04d5-48ae-a79d-73d600a7c507" xlink:href="silk-20201231.xsd#silk_LongTermDebtUnpaidInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="loc_silk_LongTermDebtUnpaidInterest_14835b74-04d5-48ae-a79d-73d600a7c507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_99bf2710-fb8a-4d49-86d5-d1faf10ab238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_99bf2710-fb8a-4d49-86d5-d1faf10ab238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3f62544f-ac48-4d52-a8f5-7b23ca6c2d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94c5033f-6610-4525-83a7-7234950592d4" xlink:to="loc_us-gaap_LongTermDebt_3f62544f-ac48-4d52-a8f5-7b23ca6c2d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24833b92-29ba-48b8-baec-31f741afdce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9e4f7038-fe5e-4035-a545-004dc26e0282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24833b92-29ba-48b8-baec-31f741afdce0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9e4f7038-fe5e-4035-a545-004dc26e0282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fa213b5-adaa-4cc9-a117-eda299b086b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock_978fecc7-7575-48e5-ae42-8e358e6561ec" xlink:href="silk-20201231.xsd#silk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fa213b5-adaa-4cc9-a117-eda299b086b0" xlink:to="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock_978fecc7-7575-48e5-ae42-8e358e6561ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4fabc39a-9b08-4cea-a6f6-9b0fce9e4349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fa213b5-adaa-4cc9-a117-eda299b086b0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4fabc39a-9b08-4cea-a6f6-9b0fce9e4349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesLeaseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ae6de9-463a-42b2-a327-a119beb1b9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_47fd3742-cca5-4459-af4e-0f61c143468d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ae6de9-463a-42b2-a327-a119beb1b9e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_47fd3742-cca5-4459-af4e-0f61c143468d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_405e39c1-3428-44e9-98da-460525166188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ae6de9-463a-42b2-a327-a119beb1b9e2" xlink:to="loc_us-gaap_OperatingLeaseCost_405e39c1-3428-44e9-98da-460525166188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_6da51895-0b5d-4033-9852-c4b4d0fc38c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ae6de9-463a-42b2-a327-a119beb1b9e2" xlink:to="loc_us-gaap_OperatingLeasePayments_6da51895-0b5d-4033-9852-c4b4d0fc38c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f108b4f0-9484-4327-b5bf-ab7d9491ce51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ae6de9-463a-42b2-a327-a119beb1b9e2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f108b4f0-9484-4327-b5bf-ab7d9491ce51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_db3224f1-d866-4282-88ca-b5e53c81b814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ae6de9-463a-42b2-a327-a119beb1b9e2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_db3224f1-d866-4282-88ca-b5e53c81b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a36e969f-0652-464c-a690-3c4c38206582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a36e969f-0652-464c-a690-3c4c38206582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_98d2d6de-2b91-4b27-9a5d-40d7ce4a2a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_98d2d6de-2b91-4b27-9a5d-40d7ce4a2a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1724c076-afc8-42a3-80ef-370605f0851d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1724c076-afc8-42a3-80ef-370605f0851d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7e055bb5-6df7-4a37-a925-f505f11db3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="loc_us-gaap_OperatingLeaseLiability_7e055bb5-6df7-4a37-a925-f505f11db3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_35a3f71b-6695-4db1-bfbc-f7395a0e5193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_35a3f71b-6695-4db1-bfbc-f7395a0e5193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8612e31b-ae63-41c3-ba63-9a4d0d9360b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8612e31b-ae63-41c3-ba63-9a4d0d9360b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_4ae22929-1151-43bb-b446-4fc92f9c29aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d703b934-1dcf-49ae-9153-dc339f7aa542" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_4ae22929-1151-43bb-b446-4fc92f9c29aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e9f8112-fae2-40e0-b652-67dcee21be65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e9f8112-fae2-40e0-b652-67dcee21be65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d93deba8-948e-47ea-9ee9-804a6983c52f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d93deba8-948e-47ea-9ee9-804a6983c52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_245f6b83-dad9-4fe6-8afe-931258df826b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_245f6b83-dad9-4fe6-8afe-931258df826b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_be9f655b-a1c7-47ac-ac34-03c3f4147243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_be9f655b-a1c7-47ac-ac34-03c3f4147243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61bd161f-9f91-470a-bf4b-7aff78e3e335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61bd161f-9f91-470a-bf4b-7aff78e3e335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3be5a13b-599e-4901-a5e0-addd19a67b60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3be5a13b-599e-4901-a5e0-addd19a67b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_45061df8-e7e7-4223-ba2b-297c3d5ebb3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31cbddcf-14f7-4798-953c-e3868d43135c" xlink:to="loc_us-gaap_OperatingLeaseLiability_45061df8-e7e7-4223-ba2b-297c3d5ebb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4d58bea1-64bf-4377-bb97-594065136307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_f5e627a5-d382-4d52-b975-bcbad619f890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4d58bea1-64bf-4377-bb97-594065136307" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_f5e627a5-d382-4d52-b975-bcbad619f890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_c9b16753-0d8c-4e24-babf-d5f7c03124fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4d58bea1-64bf-4377-bb97-594065136307" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_c9b16753-0d8c-4e24-babf-d5f7c03124fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="silk-20201231.xsd#RedeemableConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_e834554c-9966-4f5b-94f5-12ad11b9f511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bcdf498e-3961-4735-bca6-f74911d1e0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_e834554c-9966-4f5b-94f5-12ad11b9f511" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bcdf498e-3961-4735-bca6-f74911d1e0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#RedeemableConvertiblePreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_0423c234-bc9b-45af-8447-a430a8484228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_0423c234-bc9b-45af-8447-a430a8484228" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_205b6cd4-d5e2-4a94-a381-c655380c1997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:to="loc_us-gaap_StatementClassOfStockAxis_205b6cd4-d5e2-4a94-a381-c655380c1997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9437e562-3be3-4ed9-a27e-3b3b754d2b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_205b6cd4-d5e2-4a94-a381-c655380c1997" xlink:to="loc_us-gaap_ClassOfStockDomain_9437e562-3be3-4ed9-a27e-3b3b754d2b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7b1fea35-674d-4f9d-ab64-add933f77a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9437e562-3be3-4ed9-a27e-3b3b754d2b4e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7b1fea35-674d-4f9d-ab64-add933f77a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_fa5ff630-fbf3-4cc4-8865-34b2f587cd37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_fa5ff630-fbf3-4cc4-8865-34b2f587cd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4399d4b9-1858-4dc6-9763-cb04ea9c4593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fa5ff630-fbf3-4cc4-8865-34b2f587cd37" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4399d4b9-1858-4dc6-9763-cb04ea9c4593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PreferredStockWarrantsMember_e9793fad-8de4-48b2-be27-c206e63e7f8c" xlink:href="silk-20201231.xsd#silk_PreferredStockWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4399d4b9-1858-4dc6-9763-cb04ea9c4593" xlink:to="loc_silk_PreferredStockWarrantsMember_e9793fad-8de4-48b2-be27-c206e63e7f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8ea5b920-011b-47e6-8e80-b4e1a297b141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8ea5b920-011b-47e6-8e80-b4e1a297b141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20dbff9e-ad7c-46e2-afa6-f2125144ce6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8ea5b920-011b-47e6-8e80-b4e1a297b141" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20dbff9e-ad7c-46e2-afa6-f2125144ce6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_0cbc4ed7-07f3-419f-a2e6-3a8248f1ba89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20dbff9e-ad7c-46e2-afa6-f2125144ce6a" xlink:to="loc_us-gaap_IPOMember_0cbc4ed7-07f3-419f-a2e6-3a8248f1ba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_90bc30c1-fdc3-43cf-9f79-759308a2d534" xlink:to="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_f143aa19-4414-45d6-9a09-01e7a0d64801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_f143aa19-4414-45d6-9a09-01e7a0d64801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_109af6c6-7005-41ab-ad26-e52d06a74dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_109af6c6-7005-41ab-ad26-e52d06a74dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_931c58c1-c503-4f52-bd17-2220a2d631d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_931c58c1-c503-4f52-bd17-2220a2d631d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_4141480a-2d20-49e0-9f47-888d3ea5a2b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_f414908c-b0ee-4869-a2d6-5f8849663609" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_4141480a-2d20-49e0-9f47-888d3ea5a2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_105bde30-1e0b-4a2e-a1ff-3aff603e2ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8a189ac0-0462-4741-9a8c-b1b9ff669aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_105bde30-1e0b-4a2e-a1ff-3aff603e2ac5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8a189ac0-0462-4741-9a8c-b1b9ff669aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitTables" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficitTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficitTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d05f681a-6a49-440a-89c2-cd6f38c3c92a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_75638ae0-fada-4a6d-91f3-87ac976dc03b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d05f681a-6a49-440a-89c2-cd6f38c3c92a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_75638ae0-fada-4a6d-91f3-87ac976dc03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficitNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_589c3b45-b987-4fc8-928d-e39b294f7129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9c68253f-751b-4865-bc9d-3f4083b56e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_589c3b45-b987-4fc8-928d-e39b294f7129" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9c68253f-751b-4865-bc9d-3f4083b56e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_acca362d-6e38-47da-ab89-6c9c6e416dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9c68253f-751b-4865-bc9d-3f4083b56e2a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_acca362d-6e38-47da-ab89-6c9c6e416dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_56de3e6d-cb80-4edd-a3c2-cf22531ad1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_acca362d-6e38-47da-ab89-6c9c6e416dcc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_56de3e6d-cb80-4edd-a3c2-cf22531ad1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_cc3aa361-1e03-45bb-aa3b-7c802ded44b8" xlink:href="silk-20201231.xsd#silk_CommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_56de3e6d-cb80-4edd-a3c2-cf22531ad1ca" xlink:to="loc_silk_CommonStockWarrantMember_cc3aa361-1e03-45bb-aa3b-7c802ded44b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c3cab97f-54d5-4b3b-9f8c-432a4f4e8588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9c68253f-751b-4865-bc9d-3f4083b56e2a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c3cab97f-54d5-4b3b-9f8c-432a4f4e8588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6af62d3-b02a-4551-a854-08227d89fcbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c3cab97f-54d5-4b3b-9f8c-432a4f4e8588" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6af62d3-b02a-4551-a854-08227d89fcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_649bd0b7-0672-4278-b6e4-aeaf31cd4708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6af62d3-b02a-4551-a854-08227d89fcbe" xlink:to="loc_us-gaap_IPOMember_649bd0b7-0672-4278-b6e4-aeaf31cd4708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9c68253f-751b-4865-bc9d-3f4083b56e2a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_80c71824-90e7-455a-ab29-975f4320f96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_80c71824-90e7-455a-ab29-975f4320f96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1a375efb-f09a-46de-bd9d-0386f7baaf5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1a375efb-f09a-46de-bd9d-0386f7baaf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_63ddce06-831c-444b-b8e4-0b4f8e6342f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_63ddce06-831c-444b-b8e4-0b4f8e6342f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_44a28a88-9c2c-4873-9833-0673be1a0738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_PreferredStockSharesIssued_44a28a88-9c2c-4873-9833-0673be1a0738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6a1e8d5b-0330-433b-bf4a-dfcde8fb33df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6a1e8d5b-0330-433b-bf4a-dfcde8fb33df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_babf975f-afaa-4e60-b073-5c47a46aecbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_babf975f-afaa-4e60-b073-5c47a46aecbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_805c2730-8656-417b-b4f2-b080164d75f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_CommonStockSharesIssued_805c2730-8656-417b-b4f2-b080164d75f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1424479d-c756-4c44-84e5-40b1f91c6e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1424479d-c756-4c44-84e5-40b1f91c6e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_ac33d08b-e2e2-4a02-8dd4-2c976923de64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_DividendsCommonStock_ac33d08b-e2e2-4a02-8dd4-2c976923de64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockVotePerShare_619d277d-f244-4b43-8094-f0f7559138d8" xlink:href="silk-20201231.xsd#silk_CommonStockVotePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_silk_CommonStockVotePerShare_619d277d-f244-4b43-8094-f0f7559138d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8372c13a-3b2b-4f6c-93a6-ec6b2fb7d6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8372c13a-3b2b-4f6c-93a6-ec6b2fb7d6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_81df71bb-43fc-4e77-8e10-006b1ecc25dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_81df71bb-43fc-4e77-8e10-006b1ecc25dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_edf2a02a-2be7-4919-a240-43f1565d18a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6525793c-2b06-425b-98b6-1b6d172fc248" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_edf2a02a-2be7-4919-a240-43f1565d18a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_37f2a550-85b9-48d0-aa61-958eac17b583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8b62d9ae-cf8f-4a9b-b3f7-40114872cb5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_37f2a550-85b9-48d0-aa61-958eac17b583" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8b62d9ae-cf8f-4a9b-b3f7-40114872cb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42b8e61c-086f-4a61-9b84-c7b5d0735469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b62d9ae-cf8f-4a9b-b3f7-40114872cb5b" xlink:to="loc_us-gaap_AwardTypeAxis_42b8e61c-086f-4a61-9b84-c7b5d0735469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_42b8e61c-086f-4a61-9b84-c7b5d0735469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionExercisedMember_75833adc-169a-418b-9d4f-41b709a72e4f" xlink:href="silk-20201231.xsd#silk_IncentiveandNonqualifiedStockOptionExercisedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:to="loc_silk_IncentiveandNonqualifiedStockOptionExercisedMember_75833adc-169a-418b-9d4f-41b709a72e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionIssuedMember_8fcedb73-3399-48e2-810d-9cdb176b8225" xlink:href="silk-20201231.xsd#silk_IncentiveandNonqualifiedStockOptionIssuedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:to="loc_silk_IncentiveandNonqualifiedStockOptionIssuedMember_8fcedb73-3399-48e2-810d-9cdb176b8225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_EmployeeStockPurchasePlanMember_22af85d2-cc6c-490f-92f9-377ac826f7bb" xlink:href="silk-20201231.xsd#silk_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c0f6e01-ca08-4f94-b253-c4621dad0af0" xlink:to="loc_silk_EmployeeStockPurchasePlanMember_22af85d2-cc6c-490f-92f9-377ac826f7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6d689a0a-0ec8-416e-97f5-44b2bdf707c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b62d9ae-cf8f-4a9b-b3f7-40114872cb5b" xlink:to="loc_us-gaap_ClassOfStockLineItems_6d689a0a-0ec8-416e-97f5-44b2bdf707c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8562e7f2-c313-4764-a8eb-d7f64bf885b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d689a0a-0ec8-416e-97f5-44b2bdf707c6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8562e7f2-c313-4764-a8eb-d7f64bf885b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlans" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlans"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d43e9c4e-2b41-4c8e-b199-76a49b9c8a16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_560091c2-7819-4870-b140-395c7c0ef62d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d43e9c4e-2b41-4c8e-b199-76a49b9c8a16" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_560091c2-7819-4870-b140-395c7c0ef62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4444f6a5-3791-4d88-8448-14b954cce3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_033a5741-8548-4df7-b7fb-eb2e24d4970b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4444f6a5-3791-4d88-8448-14b954cce3de" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_033a5741-8548-4df7-b7fb-eb2e24d4970b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_aac880ce-3812-49b6-b56f-23688ccac9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4444f6a5-3791-4d88-8448-14b954cce3de" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_aac880ce-3812-49b6-b56f-23688ccac9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_921cb0d1-ab71-41b5-bfce-3ec0e1270bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4444f6a5-3791-4d88-8448-14b954cce3de" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_921cb0d1-ab71-41b5-bfce-3ec0e1270bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_7b1e6a4e-30d7-4ec9-b114-edcd9eed4d18" xlink:href="silk-20201231.xsd#silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4444f6a5-3791-4d88-8448-14b954cce3de" xlink:to="loc_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_7b1e6a4e-30d7-4ec9-b114-edcd9eed4d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5d03a170-a766-4cf9-b654-17f2950205e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4444f6a5-3791-4d88-8448-14b954cce3de" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5d03a170-a766-4cf9-b654-17f2950205e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cccbfbd8-df4c-4949-899f-a629ab1c7c10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cccbfbd8-df4c-4949-899f-a629ab1c7c10" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_960c3bde-1bcd-429b-81cb-20b55be526a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:to="loc_us-gaap_PlanNameAxis_960c3bde-1bcd-429b-81cb-20b55be526a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_717dcbfd-6ba0-4ec0-8221-66b214e928ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_960c3bde-1bcd-429b-81cb-20b55be526a3" xlink:to="loc_us-gaap_PlanNameDomain_717dcbfd-6ba0-4ec0-8221-66b214e928ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember_787e2496-7204-4000-8b93-fc2ef16d23e7" xlink:href="silk-20201231.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_717dcbfd-6ba0-4ec0-8221-66b214e928ee" xlink:to="loc_silk_TwoThousandNineteenStockOptionPlanMember_787e2496-7204-4000-8b93-fc2ef16d23e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f68be088-d44d-4393-846b-288bd7da4a20" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:to="loc_srt_RangeAxis_f68be088-d44d-4393-846b-288bd7da4a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c315111-8258-40d5-9dbb-d06d656fd497" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f68be088-d44d-4393-846b-288bd7da4a20" xlink:to="loc_srt_RangeMember_7c315111-8258-40d5-9dbb-d06d656fd497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a64d6b1d-e68a-4a34-9cf4-3b8795545762" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c315111-8258-40d5-9dbb-d06d656fd497" xlink:to="loc_srt_MaximumMember_a64d6b1d-e68a-4a34-9cf4-3b8795545762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_711c7ab5-143a-4455-95d9-022403b6486d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:to="loc_us-gaap_AwardTypeAxis_711c7ab5-143a-4455-95d9-022403b6486d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_711c7ab5-143a-4455-95d9-022403b6486d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionMember_08ffeadc-d0b0-4535-b786-846ada60577e" xlink:href="silk-20201231.xsd#silk_IncentiveandNonqualifiedStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:to="loc_silk_IncentiveandNonqualifiedStockOptionMember_08ffeadc-d0b0-4535-b786-846ada60577e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveStockOptionMember_fc807a3c-b8e3-4175-bfac-62f97c23b827" xlink:href="silk-20201231.xsd#silk_IncentiveStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_IncentiveandNonqualifiedStockOptionMember_08ffeadc-d0b0-4535-b786-846ada60577e" xlink:to="loc_silk_IncentiveStockOptionMember_fc807a3c-b8e3-4175-bfac-62f97c23b827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NonqualifiedStockOptionsMember_70ece2eb-5c80-496d-815b-b1325c373459" xlink:href="silk-20201231.xsd#silk_NonqualifiedStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_IncentiveandNonqualifiedStockOptionMember_08ffeadc-d0b0-4535-b786-846ada60577e" xlink:to="loc_silk_NonqualifiedStockOptionsMember_70ece2eb-5c80-496d-815b-b1325c373459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5e71071f-7a54-4359-92d7-c43645cfc01d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:to="loc_us-gaap_EmployeeStockMember_5e71071f-7a54-4359-92d7-c43645cfc01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_64c07388-3dbd-4782-b848-138ddc41ccd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:to="loc_us-gaap_EmployeeStockOptionMember_64c07388-3dbd-4782-b848-138ddc41ccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0bbe0701-cd4c-4340-ba38-5c8375005edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63b951de-e632-4d3c-8f9b-58279ae17d99" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0bbe0701-cd4c-4340-ba38-5c8375005edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_890b7f66-9da4-4d3d-a9cd-a7d6b8679226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_890b7f66-9da4-4d3d-a9cd-a7d6b8679226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e87f7dbc-062f-49b8-a8f7-8db8e37c52e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_890b7f66-9da4-4d3d-a9cd-a7d6b8679226" xlink:to="loc_us-gaap_RelatedPartyDomain_e87f7dbc-062f-49b8-a8f7-8db8e37c52e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_1dc6ab8e-7d9b-4645-bc83-a6464d860b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e87f7dbc-062f-49b8-a8f7-8db8e37c52e3" xlink:to="loc_us-gaap_PrincipalOwnerMember_1dc6ab8e-7d9b-4645-bc83-a6464d860b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7bb6f2d-f042-42f1-ba63-8a4a92b28d51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fc9c3f0a-414f-47c4-810a-f333dd222c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fc9c3f0a-414f-47c4-810a-f333dd222c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_c59fd63a-cb67-4798-8099-5a073ae508be" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_c59fd63a-cb67-4798-8099-5a073ae508be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3258114b-3896-471c-8619-a83e4c041e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3258114b-3896-471c-8619-a83e4c041e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_54497754-7286-4d26-bdd7-3cb404fbb394" xlink:href="silk-20201231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice_54497754-7286-4d26-bdd7-3cb404fbb394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_694b8443-04cb-4d8e-9780-74ed002448be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_694b8443-04cb-4d8e-9780-74ed002448be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80c8a711-942c-46ad-8952-6b93913cc631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80c8a711-942c-46ad-8952-6b93913cc631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_53da27a0-4f19-4797-9259-ffce3009183f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_53da27a0-4f19-4797-9259-ffce3009183f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2f429968-fd48-45d0-b966-5445d327035a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2f429968-fd48-45d0-b966-5445d327035a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1a8c427c-c0ab-46db-b8fa-e2b600123db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1a8c427c-c0ab-46db-b8fa-e2b600123db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4e70398f-8abd-415a-bf68-82426c0b9d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4e70398f-8abd-415a-bf68-82426c0b9d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce23b320-9913-408a-84f0-b31620b1e61f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce23b320-9913-408a-84f0-b31620b1e61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_91939651-d108-4a27-8ddc-948a42960f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_91939651-d108-4a27-8ddc-948a42960f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60e80b0a-836f-4daf-81e9-eb214457bfcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60e80b0a-836f-4daf-81e9-eb214457bfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance_b1932492-b098-4a6b-8b91-aa0e09fc5382" xlink:href="silk-20201231.xsd#silk_CommonStockCapitalSharesAvailableForFutureIssuance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance_b1932492-b098-4a6b-8b91-aa0e09fc5382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93a8cbc0-6c17-4fd4-99c0-c003dc8e1be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93a8cbc0-6c17-4fd4-99c0-c003dc8e1be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbdeaab2-6a5c-44ec-b15d-87bad376d89d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbdeaab2-6a5c-44ec-b15d-87bad376d89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_67edffea-0f56-4dae-a385-21ff360547f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_67edffea-0f56-4dae-a385-21ff360547f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3b51576f-5acd-49c3-9ecb-d62141d61ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c39d68-b947-40f1-a95a-bab19f8e7262" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3b51576f-5acd-49c3-9ecb-d62141d61ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansActivityUnderCompensationPlanDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bae0a3c2-ecc6-40dd-b7c7-cef31d1706cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e1a9a7e-e680-46f4-9266-3137a635d2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bae0a3c2-ecc6-40dd-b7c7-cef31d1706cd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e1a9a7e-e680-46f4-9266-3137a635d2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4b5b6061-ec93-4442-99f0-296ae4447907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e1a9a7e-e680-46f4-9266-3137a635d2bf" xlink:to="loc_us-gaap_PlanNameAxis_4b5b6061-ec93-4442-99f0-296ae4447907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9f5008f0-814f-4048-af24-176a8ddeeba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4b5b6061-ec93-4442-99f0-296ae4447907" xlink:to="loc_us-gaap_PlanNameDomain_9f5008f0-814f-4048-af24-176a8ddeeba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember_2a55ccee-6b80-42f2-920c-56ca87a7b14f" xlink:href="silk-20201231.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9f5008f0-814f-4048-af24-176a8ddeeba6" xlink:to="loc_silk_TwoThousandNineteenStockOptionPlanMember_2a55ccee-6b80-42f2-920c-56ca87a7b14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e1a9a7e-e680-46f4-9266-3137a635d2bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:href="silk-20201231.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_287aed3a-2e5f-4822-bd9f-c445a16ec750" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_287aed3a-2e5f-4822-bd9f-c445a16ec750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_83cafc11-b5e8-4594-abf8-ac563dc44226" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized_83cafc11-b5e8-4594-abf8-ac563dc44226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_c48b843c-ab0b-4632-bff2-1ce852a2aa3d" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross_c48b843c-ab0b-4632-bff2-1ce852a2aa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_46154707-8007-4a90-96b7-9b76433b6671" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod_46154707-8007-4a90-96b7-9b76433b6671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_91a30a8c-e68e-46d2-a1b8-efcd9e26c0f5" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_d45259c3-7e4a-43b9-a744-cfc867b8b8e9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber_91a30a8c-e68e-46d2-a1b8-efcd9e26c0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4a0f382-066e-48b0-825d-9ca9760324ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4a0f382-066e-48b0-825d-9ca9760324ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d126f6e3-4df7-428d-b9e1-12f42354a62e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d126f6e3-4df7-428d-b9e1-12f42354a62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1c1deda-c903-4793-963a-a3da5fee9940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1c1deda-c903-4793-963a-a3da5fee9940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b5867bb5-9e38-4d9d-a50e-65c1ccc2afe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b5867bb5-9e38-4d9d-a50e-65c1ccc2afe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6447ede7-6304-4f00-9f7f-b1767423f435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b5657d9-f1da-4089-a5ef-ebedcb17ed36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6447ede7-6304-4f00-9f7f-b1767423f435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3036c854-b744-4686-a878-07748a1c37a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3036c854-b744-4686-a878-07748a1c37a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4c2bb4bf-73c5-4f2f-938c-ad2c29a7de48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4c2bb4bf-73c5-4f2f-938c-ad2c29a7de48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5d61002-911f-45f0-9608-4bf479e96b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5d61002-911f-45f0-9608-4bf479e96b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5cf4d986-e77c-4689-8ffd-77e14fa15d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5cf4d986-e77c-4689-8ffd-77e14fa15d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7fef6dbe-6804-4c3b-8bb4-9e729fe5800b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7fef6dbe-6804-4c3b-8bb4-9e729fe5800b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2c0b8974-0496-4929-9c9d-003dfc4a8a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2c0b8974-0496-4929-9c9d-003dfc4a8a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f57fdf5-9511-4d3f-8354-abe998b9aa70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_913fbd13-4725-405c-8c77-c1cfb35e999c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f57fdf5-9511-4d3f-8354-abe998b9aa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1eb38777-7754-4821-8a66-e52cd95561da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1eb38777-7754-4821-8a66-e52cd95561da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4226655f-59ae-40e1-8297-24d819d74f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4226655f-59ae-40e1-8297-24d819d74f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c75c5696-7175-4c8e-bc92-7704fe38ce74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c75c5696-7175-4c8e-bc92-7704fe38ce74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a1705ee0-e1bf-41d7-adcf-57bd74bdbc5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a1705ee0-e1bf-41d7-adcf-57bd74bdbc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6d19d5d6-986c-4c06-bdf8-c55345d56237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_1b23534e-857d-4d6c-8515-43bf679134cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6d19d5d6-986c-4c06-bdf8-c55345d56237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e8ecffe-8180-4918-9d1d-f1c2b633ca77" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc3645ab-608e-412e-8e4b-b9ebfa5e3435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc3645ab-608e-412e-8e4b-b9ebfa5e3435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_02935ad9-4787-4612-ae70-975521893a4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_02935ad9-4787-4612-ae70-975521893a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e8eedc43-429e-489f-8dc3-74d14214fb91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_d63ef415-e887-45bf-be18-14c0fbdaef68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e8eedc43-429e-489f-8dc3-74d14214fb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansInformationbyExercisePriceDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9075ef20-0246-42d2-963d-29a685bb4baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e7278da9-4146-4ae8-b10b-600db384ac80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9075ef20-0246-42d2-963d-29a685bb4baa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e7278da9-4146-4ae8-b10b-600db384ac80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f3e6eea6-e620-475a-a8b2-4ca4142bbf68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e7278da9-4146-4ae8-b10b-600db384ac80" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f3e6eea6-e620-475a-a8b2-4ca4142bbf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f3e6eea6-e620-475a-a8b2-4ca4142bbf68" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceOneMember_03183d8e-0144-4439-9344-fb24467fcbc2" xlink:href="silk-20201231.xsd#silk_ExercisePriceOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceOneMember_03183d8e-0144-4439-9344-fb24467fcbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceTwoMember_58cef9a2-fe36-4b91-8553-4dde1613b48f" xlink:href="silk-20201231.xsd#silk_ExercisePriceTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceTwoMember_58cef9a2-fe36-4b91-8553-4dde1613b48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceThreeMember_6d783f27-71cd-42de-8887-74f87db2abd0" xlink:href="silk-20201231.xsd#silk_ExercisePriceThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceThreeMember_6d783f27-71cd-42de-8887-74f87db2abd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceFourMember_794210f9-c144-4591-a3be-4cfaf0621616" xlink:href="silk-20201231.xsd#silk_ExercisePriceFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceFourMember_794210f9-c144-4591-a3be-4cfaf0621616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceFiveMember_ace3c0f6-5a34-4e59-a754-86dfec5d6540" xlink:href="silk-20201231.xsd#silk_ExercisePriceFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceFiveMember_ace3c0f6-5a34-4e59-a754-86dfec5d6540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ExercisePriceSixMember_ccb260a5-f13e-4634-9400-973f6421301b" xlink:href="silk-20201231.xsd#silk_ExercisePriceSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a57b04b-cc29-406a-a973-ea4bcd5219cc" xlink:to="loc_silk_ExercisePriceSixMember_ccb260a5-f13e-4634-9400-973f6421301b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3b915d2-33cc-4d6d-8189-024a0bd82fdc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e7278da9-4146-4ae8-b10b-600db384ac80" xlink:to="loc_srt_RangeAxis_d3b915d2-33cc-4d6d-8189-024a0bd82fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98c8dd04-94ad-42db-8d5f-3a96a67345d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d3b915d2-33cc-4d6d-8189-024a0bd82fdc" xlink:to="loc_srt_RangeMember_98c8dd04-94ad-42db-8d5f-3a96a67345d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb94c60e-f7e4-4ddb-988b-a9564c6d9714" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98c8dd04-94ad-42db-8d5f-3a96a67345d7" xlink:to="loc_srt_MinimumMember_bb94c60e-f7e4-4ddb-988b-a9564c6d9714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_04e7c358-9288-4782-b00f-8ef396e59276" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98c8dd04-94ad-42db-8d5f-3a96a67345d7" xlink:to="loc_srt_MaximumMember_04e7c358-9288-4782-b00f-8ef396e59276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e7278da9-4146-4ae8-b10b-600db384ac80" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_3fe95ab1-45b4-4e5d-b308-5e063c71e9ef" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_3fe95ab1-45b4-4e5d-b308-5e063c71e9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a84f5943-458d-4a92-a1b5-a44a1b9158e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a84f5943-458d-4a92-a1b5-a44a1b9158e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b4b94e42-a769-40c6-823c-7492a50d9920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b4b94e42-a769-40c6-823c-7492a50d9920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b08aa886-ad80-4221-aaa8-afd946382101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b08aa886-ad80-4221-aaa8-afd946382101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1d17abc4-5cd0-4710-803f-7cd95da59a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1d17abc4-5cd0-4710-803f-7cd95da59a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a9e268ad-2c32-488a-b824-f72fc0eda183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_ced8f3f7-e67b-4fcd-bd67-ea1ca0dfd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a9e268ad-2c32-488a-b824-f72fc0eda183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansRSUsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_727096e7-3a24-4aa8-8016-d55317716a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1865ea5c-af3b-4807-b1c8-c0e23e89ddb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_727096e7-3a24-4aa8-8016-d55317716a2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1865ea5c-af3b-4807-b1c8-c0e23e89ddb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9e84bae9-3aa5-49d8-be95-cbdbbfffccc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1865ea5c-af3b-4807-b1c8-c0e23e89ddb0" xlink:to="loc_us-gaap_AwardTypeAxis_9e84bae9-3aa5-49d8-be95-cbdbbfffccc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2419f278-a6b6-4364-ae21-5222e0a4ac93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9e84bae9-3aa5-49d8-be95-cbdbbfffccc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2419f278-a6b6-4364-ae21-5222e0a4ac93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_03c81d3c-5bc1-46fb-a058-4330caf0db6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2419f278-a6b6-4364-ae21-5222e0a4ac93" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_03c81d3c-5bc1-46fb-a058-4330caf0db6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_950d7709-393e-4e34-8738-6e9ff40ae3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1865ea5c-af3b-4807-b1c8-c0e23e89ddb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_950d7709-393e-4e34-8738-6e9ff40ae3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_950d7709-393e-4e34-8738-6e9ff40ae3f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ddbf774e-d240-4735-acd2-a5d6b85bff87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ddbf774e-d240-4735-acd2-a5d6b85bff87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_506eacc3-8a15-4fd9-b746-705ee41f8e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_506eacc3-8a15-4fd9-b746-705ee41f8e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9a30042a-bffb-4448-9c74-b665ab007ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9a30042a-bffb-4448-9c74-b665ab007ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7dbfe9cd-f082-48fa-aadc-969a8cd85395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7dbfe9cd-f082-48fa-aadc-969a8cd85395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eca4672b-f1eb-44ed-87ed-30126d2cb7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bb4543f8-750a-4a30-93cb-b9683e980834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eca4672b-f1eb-44ed-87ed-30126d2cb7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_950d7709-393e-4e34-8738-6e9ff40ae3f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a7672c9-aa9a-4d27-a5df-f0a34cb47cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a7672c9-aa9a-4d27-a5df-f0a34cb47cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d8707bd-b7af-4e64-be2f-ff0681285979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d8707bd-b7af-4e64-be2f-ff0681285979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_94165fc9-7269-4c94-8c17-304ab5e78245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_94165fc9-7269-4c94-8c17-304ab5e78245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_716509f6-e412-4ce1-87d2-3b79b3b766df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_716509f6-e412-4ce1-87d2-3b79b3b766df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2710a238-216b-4111-a668-8eb7b88aa6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73fcb1c7-133c-4b12-b04c-412d10d8982a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2710a238-216b-4111-a668-8eb7b88aa6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansFairValueofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26037b07-dbd4-4329-a099-efb0a4ead311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b12d9664-feef-4c4f-90d1-93c7f5cabbb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26037b07-dbd4-4329-a099-efb0a4ead311" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b12d9664-feef-4c4f-90d1-93c7f5cabbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_90d9d662-c6e3-4964-b727-4ebd6db3ef65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b12d9664-feef-4c4f-90d1-93c7f5cabbb8" xlink:to="loc_us-gaap_AwardTypeAxis_90d9d662-c6e3-4964-b727-4ebd6db3ef65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7c22d11-dec6-453b-846a-016cfaff6aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_90d9d662-c6e3-4964-b727-4ebd6db3ef65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7c22d11-dec6-453b-846a-016cfaff6aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9ac9608c-d7ca-4983-bb93-ef741ec17064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7c22d11-dec6-453b-846a-016cfaff6aef" xlink:to="loc_us-gaap_EmployeeStockMember_9ac9608c-d7ca-4983-bb93-ef741ec17064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1ba9ad6c-45a2-48d1-9e46-275a2f2869de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b12d9664-feef-4c4f-90d1-93c7f5cabbb8" xlink:to="loc_srt_RangeAxis_1ba9ad6c-45a2-48d1-9e46-275a2f2869de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c4551e5-7368-4dc7-a779-82f23376c0a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1ba9ad6c-45a2-48d1-9e46-275a2f2869de" xlink:to="loc_srt_RangeMember_9c4551e5-7368-4dc7-a779-82f23376c0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f2f8d5d7-4f69-467c-89f9-5e31edd62849" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c4551e5-7368-4dc7-a779-82f23376c0a9" xlink:to="loc_srt_MinimumMember_f2f8d5d7-4f69-467c-89f9-5e31edd62849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_47f97bd7-1acd-4036-8766-ad211a9a00af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c4551e5-7368-4dc7-a779-82f23376c0a9" xlink:to="loc_srt_MaximumMember_47f97bd7-1acd-4036-8766-ad211a9a00af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b12d9664-feef-4c4f-90d1-93c7f5cabbb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6635c59-46d4-4281-b4eb-514f59288f29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6635c59-46d4-4281-b4eb-514f59288f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5724b4bb-661e-474b-b0f3-8dcc3dfc15cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5724b4bb-661e-474b-b0f3-8dcc3dfc15cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_753480c4-5853-4c08-8ff7-3b0fe1dc28da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_753480c4-5853-4c08-8ff7-3b0fe1dc28da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_57f4b2f0-c148-453b-a2f9-91270f0959f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_57f4b2f0-c148-453b-a2f9-91270f0959f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fa3415de-ee0e-4ad1-8be7-2712d6caca6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fa3415de-ee0e-4ad1-8be7-2712d6caca6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5f5d8c7f-bb9c-4efc-81c5-4b7029897e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34468095-59ed-4fd6-a519-25216ed4289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5f5d8c7f-bb9c-4efc-81c5-4b7029897e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#StockOptionPlansStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89629370-35dc-4b80-8fe4-b745d68d10db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e3592a92-9314-4513-a2b8-27d676ab3fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89629370-35dc-4b80-8fe4-b745d68d10db" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e3592a92-9314-4513-a2b8-27d676ab3fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3cf5c39b-09e5-498b-8d27-126ca9a00fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e3592a92-9314-4513-a2b8-27d676ab3fdc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3cf5c39b-09e5-498b-8d27-126ca9a00fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3cf5c39b-09e5-498b-8d27-126ca9a00fed" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_8aa861d5-c7b5-4179-9d4d-bb8cab25d517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:to="loc_us-gaap_CostOfSalesMember_8aa861d5-c7b5-4179-9d4d-bb8cab25d517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b40aee01-86e8-46c7-9d68-bfcc6395d016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b40aee01-86e8-46c7-9d68-bfcc6395d016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ca281b29-52ee-4df9-aacb-25a89f01b1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e16ab9-d202-4d74-b543-4a2224c75260" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ca281b29-52ee-4df9-aacb-25a89f01b1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf516d75-1c58-45fa-8e6b-21b19ae1c6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e3592a92-9314-4513-a2b8-27d676ab3fdc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf516d75-1c58-45fa-8e6b-21b19ae1c6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595b920b-007b-41ec-8b3c-fca94bd46ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cf516d75-1c58-45fa-8e6b-21b19ae1c6b1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595b920b-007b-41ec-8b3c-fca94bd46ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1eccc285-f3f6-42b1-bafd-22ae245c20b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_342a3d4e-048a-4bd0-8769-c6d186fb1516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1eccc285-f3f6-42b1-bafd-22ae245c20b9" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_342a3d4e-048a-4bd0-8769-c6d186fb1516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f08e1639-a2bd-4e87-85ec-ad4720924b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f08e1639-a2bd-4e87-85ec-ad4720924b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1e1d50f4-5457-482a-ae95-3bbf67a85ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1e1d50f4-5457-482a-ae95-3bbf67a85ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f5b9f473-b01d-4a96-94e0-edcec0beadfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f5b9f473-b01d-4a96-94e0-edcec0beadfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_2dde9da3-3625-419d-abfc-a8d8bcbebbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c871d229-7e55-460f-b7f6-d769b75458b9" xlink:to="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_2dde9da3-3625-419d-abfc-a8d8bcbebbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesComponentsofIncomeBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_22592af1-667e-458f-a3e9-c8d6a3979931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8b988d10-981e-40ab-a3f5-3a78f104c60d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22592af1-667e-458f-a3e9-c8d6a3979931" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8b988d10-981e-40ab-a3f5-3a78f104c60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b5777227-0504-451e-acf4-b7829eb13a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22592af1-667e-458f-a3e9-c8d6a3979931" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b5777227-0504-451e-acf4-b7829eb13a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b64fadcc-fe26-41e4-8a41-165908201b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22592af1-667e-458f-a3e9-c8d6a3979931" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b64fadcc-fe26-41e4-8a41-165908201b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesReconciliationofUSStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f519de6b-47bd-4dec-8ee5-30b81d8237ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f519de6b-47bd-4dec-8ee5-30b81d8237ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c32a00c8-395b-4783-811e-17dfe27756d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c32a00c8-395b-4783-811e-17dfe27756d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_9bd6ce33-4a04-47ff-940d-fce3ab6cda8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_9bd6ce33-4a04-47ff-940d-fce3ab6cda8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount_734f0345-d93e-4b31-931f-e30e8b5a603d" xlink:href="silk-20201231.xsd#silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="loc_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount_734f0345-d93e-4b31-931f-e30e8b5a603d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_502a0395-2b08-43a3-b92c-a0ba4c852a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_502a0395-2b08-43a3-b92c-a0ba4c852a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7f802b05-ec0d-4394-84f3-f36073bb1d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7f802b05-ec0d-4394-84f3-f36073bb1d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_da4624e1-056a-47de-8fc0-f055b114bada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_da4624e1-056a-47de-8fc0-f055b114bada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2d5c720d-7a9a-4ef4-97bf-1646a66366a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a68d8e4-b107-4ab9-be62-26ccbd00877d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2d5c720d-7a9a-4ef4-97bf-1646a66366a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesNetDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_50bdb57e-8b62-4da9-b3a3-00239fa54a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50bdb57e-8b62-4da9-b3a3-00239fa54a59" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c0f7a29b-10b5-44dd-9012-8307c77f7a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c0f7a29b-10b5-44dd-9012-8307c77f7a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_fc74c65d-c6d4-4a99-b067-1779e14d8d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_fc74c65d-c6d4-4a99-b067-1779e14d8d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a3436be1-a57b-48b4-a3fb-ff726ac010e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a3436be1-a57b-48b4-a3fb-ff726ac010e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_6faa964d-8227-4c29-b231-ce3482ab75ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_6faa964d-8227-4c29-b231-ce3482ab75ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2184778e-5f60-4e26-bf8a-c3014d698805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2184778e-5f60-4e26-bf8a-c3014d698805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c5c5b42c-667d-479b-9968-8751c479d735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c5c5b42c-667d-479b-9968-8751c479d735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DeferredTaxAssetsOperatingLeaseLiability_c9e9cff7-1c37-4dc4-b3f7-c4843d9c5991" xlink:href="silk-20201231.xsd#silk_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_silk_DeferredTaxAssetsOperatingLeaseLiability_c9e9cff7-1c37-4dc4-b3f7-c4843d9c5991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_290743cc-4cf0-47ca-9f63-44e885b5098e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_290743cc-4cf0-47ca-9f63-44e885b5098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_50217a16-9186-4a7c-80be-4ff9dda916b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_50217a16-9186-4a7c-80be-4ff9dda916b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a8485f42-9fcf-4fa5-95a2-b72747cdb3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_ec4ec442-a0e4-4a44-adc5-5942e2a67cb3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a8485f42-9fcf-4fa5-95a2-b72747cdb3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ccaac2d-a657-49f3-9eac-11be1eacc388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50bdb57e-8b62-4da9-b3a3-00239fa54a59" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ccaac2d-a657-49f3-9eac-11be1eacc388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b8e22a55-faea-40ed-9e1f-a47019c01ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ccaac2d-a657-49f3-9eac-11be1eacc388" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b8e22a55-faea-40ed-9e1f-a47019c01ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_622d5265-be38-40d9-b742-94155ba7063a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ccaac2d-a657-49f3-9eac-11be1eacc388" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_622d5265-be38-40d9-b742-94155ba7063a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_46f631e9-a5d0-4742-b0ef-0b63a20a2682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ccaac2d-a657-49f3-9eac-11be1eacc388" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_46f631e9-a5d0-4742-b0ef-0b63a20a2682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7646c483-b18b-4e74-953c-d84d3cef0726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50bdb57e-8b62-4da9-b3a3-00239fa54a59" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7646c483-b18b-4e74-953c-d84d3cef0726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bef67955-c557-4703-8054-97eb9fce3d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0fed40af-5432-4d1e-b488-d718e4d2a554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bef67955-c557-4703-8054-97eb9fce3d70" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0fed40af-5432-4d1e-b488-d718e4d2a554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1e45d2be-d98f-4fc7-a24c-aeac988264fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0fed40af-5432-4d1e-b488-d718e4d2a554" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1e45d2be-d98f-4fc7-a24c-aeac988264fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8e59c468-7c10-4dd6-a33f-ad2ee7632b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1e45d2be-d98f-4fc7-a24c-aeac988264fd" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8e59c468-7c10-4dd6-a33f-ad2ee7632b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_d747d1b9-2c48-464e-b9e8-8d67bc6797ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8e59c468-7c10-4dd6-a33f-ad2ee7632b26" xlink:to="loc_us-gaap_ResearchMember_d747d1b9-2c48-464e-b9e8-8d67bc6797ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4b3cade5-d701-4e46-b68f-bd677bb70206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0fed40af-5432-4d1e-b488-d718e4d2a554" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4b3cade5-d701-4e46-b68f-bd677bb70206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2d1c6469-47a2-4d77-80f0-674d7cc2b3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4b3cade5-d701-4e46-b68f-bd677bb70206" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2d1c6469-47a2-4d77-80f0-674d7cc2b3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_b0414954-f719-4eae-b045-6922817148e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2d1c6469-47a2-4d77-80f0-674d7cc2b3b7" xlink:to="loc_us-gaap_DomesticCountryMember_b0414954-f719-4eae-b045-6922817148e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_16728f5d-22d9-4f81-84cf-476128e89f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2d1c6469-47a2-4d77-80f0-674d7cc2b3b7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_16728f5d-22d9-4f81-84cf-476128e89f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0fed40af-5432-4d1e-b488-d718e4d2a554" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c5866c4c-c651-4193-9c9e-519358412fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c5866c4c-c651-4193-9c9e-519358412fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d0a67577-2b9c-491a-9344-164301bf5666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d0a67577-2b9c-491a-9344-164301bf5666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_OperatingLossCarryforwardOffsetMaximumPercent_ceba7093-fc2f-46e7-b68a-c8494cc0ef71" xlink:href="silk-20201231.xsd#silk_OperatingLossCarryforwardOffsetMaximumPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_silk_OperatingLossCarryforwardOffsetMaximumPercent_ceba7093-fc2f-46e7-b68a-c8494cc0ef71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e72e632b-8e44-45c2-bc7d-c6fd5a1f3033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e72e632b-8e44-45c2-bc7d-c6fd5a1f3033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d376111f-68ac-49bc-863c-268f17b1385f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d376111f-68ac-49bc-863c-268f17b1385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3dec4e79-39f0-40e8-b6c4-1eed6b6e2cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3dec4e79-39f0-40e8-b6c4-1eed6b6e2cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3b5382c7-f9f5-4321-acb5-5c43bb769540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e4a50213-6439-4ac1-9b1e-b71bf9d23c99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3b5382c7-f9f5-4321-acb5-5c43bb769540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1dcd7a49-b5ca-4536-9fb2-4a754a13e3e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fad8058-8341-4951-8742-aa302b3bc1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dcd7a49-b5ca-4536-9fb2-4a754a13e3e8" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fad8058-8341-4951-8742-aa302b3bc1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f0462f51-9051-41a9-b2bb-ac0fa8b9eab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fad8058-8341-4951-8742-aa302b3bc1cf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f0462f51-9051-41a9-b2bb-ac0fa8b9eab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_738edf01-f38f-4275-ae70-4cf3015ea377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fad8058-8341-4951-8742-aa302b3bc1cf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_738edf01-f38f-4275-ae70-4cf3015ea377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e268e1fb-64cb-46ee-bcf2-21d3e363aa82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fad8058-8341-4951-8742-aa302b3bc1cf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e268e1fb-64cb-46ee-bcf2-21d3e363aa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6c443f2c-8d47-4fee-9686-d95c502827ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fad8058-8341-4951-8742-aa302b3bc1cf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6c443f2c-8d47-4fee-9686-d95c502827ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo" xlink:type="simple" xlink:href="silk-20201231.xsd#AcquisitionofVariableInterestEntityNeuroCo"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a6979146-70f4-4a3a-b880-cc1b0980f27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7dffb2d1-128a-44d6-bbaa-e33f98bb8e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a6979146-70f4-4a3a-b880-cc1b0980f27e" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7dffb2d1-128a-44d6-bbaa-e33f98bb8e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#AcquisitionofVariableInterestEntityNeuroCoDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c7829357-5cb1-4074-baec-f3fd1ff809ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_059a4267-4849-419a-a363-ae1204509275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c7829357-5cb1-4074-baec-f3fd1ff809ea" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_059a4267-4849-419a-a363-ae1204509275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6749ad5c-b57b-426d-84be-385f802f9245" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_059a4267-4849-419a-a363-ae1204509275" xlink:to="loc_dei_LegalEntityAxis_6749ad5c-b57b-426d-84be-385f802f9245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_85124080-ef0a-4dd4-86b7-de93630b42e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6749ad5c-b57b-426d-84be-385f802f9245" xlink:to="loc_dei_EntityDomain_85124080-ef0a-4dd4-86b7-de93630b42e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NeuroCoIncMember_faf93adb-e930-49e2-a82c-45a3d247a872" xlink:href="silk-20201231.xsd#silk_NeuroCoIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_85124080-ef0a-4dd4-86b7-de93630b42e9" xlink:to="loc_silk_NeuroCoIncMember_faf93adb-e930-49e2-a82c-45a3d247a872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_12c2faf1-6f58-4e66-985c-9eea79430487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_059a4267-4849-419a-a363-ae1204509275" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_12c2faf1-6f58-4e66-985c-9eea79430487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e511f79b-4598-4743-a08b-d608314d7bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_12c2faf1-6f58-4e66-985c-9eea79430487" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e511f79b-4598-4743-a08b-d608314d7bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NeuroCoIncMember_01106909-0d17-467c-ae1b-36e97e626126" xlink:href="silk-20201231.xsd#silk_NeuroCoIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e511f79b-4598-4743-a08b-d608314d7bf1" xlink:to="loc_silk_NeuroCoIncMember_01106909-0d17-467c-ae1b-36e97e626126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_059a4267-4849-419a-a363-ae1204509275" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_4c830ddc-7edf-4d23-8e95-9a85bf9afb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_4c830ddc-7edf-4d23-8e95-9a85bf9afb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage_a5b7e075-37cb-4325-9c8e-a65f48d1f9c5" xlink:href="silk-20201231.xsd#silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage_a5b7e075-37cb-4325-9c8e-a65f48d1f9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NotesReceivableRelatedPartiesTerm_893d18f4-063b-4927-bc7c-34721ec8fe3a" xlink:href="silk-20201231.xsd#silk_NotesReceivableRelatedPartiesTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_silk_NotesReceivableRelatedPartiesTerm_893d18f4-063b-4927-bc7c-34721ec8fe3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5be5afb4-3076-4bb9-b723-4c83446b8349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5be5afb4-3076-4bb9-b723-4c83446b8349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_dbd964f2-1b62-4446-991f-ff475050907e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_dbd964f2-1b62-4446-991f-ff475050907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_27f1a17f-7fd6-403f-a096-e72c46f36063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_27f1a17f-7fd6-403f-a096-e72c46f36063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven_5792837f-7337-4870-bc3b-2129e4112736" xlink:href="silk-20201231.xsd#silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven_5792837f-7337-4870-bc3b-2129e4112736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_18bc129a-0b8e-4ba3-8c01-5dd3dad4cebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_80b8d96c-8781-41fb-a705-6eb03014e350" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_18bc129a-0b8e-4ba3-8c01-5dd3dad4cebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlan" xlink:type="simple" xlink:href="silk-20201231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_99382fdf-e3f0-4fe4-aff4-005e21690a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_90e8563b-fe21-4e02-b229-49a73ea389df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_99382fdf-e3f0-4fe4-aff4-005e21690a64" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_90e8563b-fe21-4e02-b229-49a73ea389df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_9244740d-0d3a-4005-982e-b092aec876fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_9244740d-0d3a-4005-982e-b092aec876fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_333ac35a-f7d4-4d41-8e43-17803a2ab1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_333ac35a-f7d4-4d41-8e43-17803a2ab1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_731e1994-0217-49e7-9225-04eaf64bd81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_731e1994-0217-49e7-9225-04eaf64bd81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_a37cd693-722d-4589-8af7-8308f80db55d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c90e9437-588b-4d84-9348-fcc80caab2e5" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_a37cd693-722d-4589-8af7-8308f80db55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SubsequentEvents" xlink:type="simple" xlink:href="silk-20201231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f3d43cbb-a828-45d6-a7bc-3e10f3c9ee41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_a5313597-2ce4-4204-8b5e-788db16e7e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f3d43cbb-a828-45d6-a7bc-3e10f3c9ee41" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_a5313597-2ce4-4204-8b5e-788db16e7e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4735a69c-ec8d-4087-be17-f3e9295eedf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4735a69c-ec8d-4087-be17-f3e9295eedf4" xlink:to="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fcc283c9-0639-4a22-b19c-77618789681c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fcc283c9-0639-4a22-b19c-77618789681c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b4c69f4b-9220-44ed-8d40-9bc92aeb159c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fcc283c9-0639-4a22-b19c-77618789681c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b4c69f4b-9220-44ed-8d40-9bc92aeb159c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1ea730f3-1220-4ab5-bf14-ae7c3308d20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b4c69f4b-9220-44ed-8d40-9bc92aeb159c" xlink:to="loc_us-gaap_SubsequentEventMember_1ea730f3-1220-4ab5-bf14-ae7c3308d20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_67fbd956-c8e5-4182-ad2a-3ef78ac5bfa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_us-gaap_PlanNameAxis_67fbd956-c8e5-4182-ad2a-3ef78ac5bfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8c83a32a-f14c-460b-9330-70aa5c46487a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_67fbd956-c8e5-4182-ad2a-3ef78ac5bfa4" xlink:to="loc_us-gaap_PlanNameDomain_8c83a32a-f14c-460b-9330-70aa5c46487a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember_c840eda8-56f9-4c94-8f83-3c08a10e4a29" xlink:href="silk-20201231.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8c83a32a-f14c-460b-9330-70aa5c46487a" xlink:to="loc_silk_TwoThousandNineteenStockOptionPlanMember_c840eda8-56f9-4c94-8f83-3c08a10e4a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9ce1018a-029b-494f-b023-1471350556ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_us-gaap_AwardTypeAxis_9ce1018a-029b-494f-b023-1471350556ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89103195-f5e9-410a-9fea-37d245792317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9ce1018a-029b-494f-b023-1471350556ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89103195-f5e9-410a-9fea-37d245792317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9db258bb-2dbd-4436-be45-337d1200c950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89103195-f5e9-410a-9fea-37d245792317" xlink:to="loc_us-gaap_EmployeeStockMember_9db258bb-2dbd-4436-be45-337d1200c950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1ddae3f0-02e7-43a4-82f7-3462f3f5f4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89103195-f5e9-410a-9fea-37d245792317" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1ddae3f0-02e7-43a4-82f7-3462f3f5f4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeAxis_f2477a49-c532-490d-9160-c9d94b3b9571" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_silk_LossContingencyReceivableTypeAxis_f2477a49-c532-490d-9160-c9d94b3b9571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_LossContingencyReceivableTypeAxis_f2477a49-c532-490d-9160-c9d94b3b9571" xlink:to="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableInventoryHeldMember_9006d757-5be8-4af7-acc1-927ebbd8af6e" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableInventoryHeldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:to="loc_silk_LossContingencyReceivableInventoryHeldMember_9006d757-5be8-4af7-acc1-927ebbd8af6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableInventoryInProcessOfRecallMember_128c074e-41ed-412f-8b2b-ba9274bdce65" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableInventoryInProcessOfRecallMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:to="loc_silk_LossContingencyReceivableInventoryInProcessOfRecallMember_128c074e-41ed-412f-8b2b-ba9274bdce65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LossContingencyReceivableDirectCostsMember_e152a1b7-8995-4a81-aa9c-fa2e3a2f455e" xlink:href="silk-20201231.xsd#silk_LossContingencyReceivableDirectCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_LossContingencyReceivableTypeDomain_836c57f8-4262-4b90-8be6-1e6ac9a485ee" xlink:to="loc_silk_LossContingencyReceivableDirectCostsMember_e152a1b7-8995-4a81-aa9c-fa2e3a2f455e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6e694087-ecee-4409-b9fb-6ab60a4cb3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6e694087-ecee-4409-b9fb-6ab60a4cb3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6feedf91-b51c-4d66-84fd-9edf146156c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6e694087-ecee-4409-b9fb-6ab60a4cb3da" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6feedf91-b51c-4d66-84fd-9edf146156c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_VoluntaryRecallMember_c42a67ae-0144-4e3d-bc4d-2e101e202d8d" xlink:href="silk-20201231.xsd#silk_VoluntaryRecallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6feedf91-b51c-4d66-84fd-9edf146156c6" xlink:to="loc_silk_VoluntaryRecallMember_c42a67ae-0144-4e3d-bc4d-2e101e202d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_47b0dd38-e42e-4123-8948-5834db2aff2e" xlink:to="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3745c7fa-994b-49f8-a686-a0c9b953d1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3745c7fa-994b-49f8-a686-a0c9b953d1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62646b3f-fd0d-49d6-b536-549d840217aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62646b3f-fd0d-49d6-b536-549d840217aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14fecf9a-995c-4c96-b96d-c66831bfaa3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14fecf9a-995c-4c96-b96d-c66831bfaa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cfe0dfda-26ac-4c30-97a6-45efc5e68eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cfe0dfda-26ac-4c30-97a6-45efc5e68eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca782a18-dbc8-4e71-9a23-2b77a96f26ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca782a18-dbc8-4e71-9a23-2b77a96f26ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivable_185b7bc3-43a8-4f88-a6bb-ea3d9a04c2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_LossContingencyReceivable_185b7bc3-43a8-4f88-a6bb-ea3d9a04c2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_34bb85d2-d77f-4b22-b9ca-aba5748f768a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_34bb85d2-d77f-4b22-b9ca-aba5748f768a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_28c8008a-ab0d-4d17-b697-ad4709be24f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_28c8008a-ab0d-4d17-b697-ad4709be24f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod_cc7c2a42-3e71-4a9d-b0c8-d3ddc1435aee" xlink:href="silk-20201231.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7fc56674-1d5b-430a-8855-fcad9a398ae6" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod_cc7c2a42-3e71-4a9d-b0c8-d3ddc1435aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited" xlink:type="simple" xlink:href="silk-20201231.xsd#QuarterlyFinancialInformationunaudited"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1ab7dcd8-e9e6-4136-99c4-04f132ce87d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_5921d905-7e32-408b-a806-9d9a798f387d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1ab7dcd8-e9e6-4136-99c4-04f132ce87d2" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_5921d905-7e32-408b-a806-9d9a798f387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables" xlink:type="simple" xlink:href="silk-20201231.xsd#QuarterlyFinancialInformationunauditedTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b726c6d3-69f7-4595-b053-97cda5c7b48b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_79231865-df7b-4ffa-8a47-2993c1df6f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b726c6d3-69f7-4595-b053-97cda5c7b48b" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_79231865-df7b-4ffa-8a47-2993c1df6f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#QuarterlyFinancialInformationunauditedDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f0f667ff-1733-440e-be14-ea79e6147dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a90639c-94f9-4172-babb-0c2c1d79fd02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f0f667ff-1733-440e-be14-ea79e6147dc8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a90639c-94f9-4172-babb-0c2c1d79fd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b382e3eb-c321-4eb0-95c5-1796b88d4956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f0f667ff-1733-440e-be14-ea79e6147dc8" xlink:to="loc_us-gaap_GrossProfit_b382e3eb-c321-4eb0-95c5-1796b88d4956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d7bac3c1-e8f4-447c-bc5c-98c56df04aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f0f667ff-1733-440e-be14-ea79e6147dc8" xlink:to="loc_us-gaap_ProfitLoss_d7bac3c1-e8f4-447c-bc5c-98c56df04aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_d993ea5d-7f8e-4b45-b8af-4bae8591ba76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f0f667ff-1733-440e-be14-ea79e6147dc8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_d993ea5d-7f8e-4b45-b8af-4bae8591ba76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="simple" xlink:href="silk-20201231.xsd#ScheduleIIValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_78c1eb30-5ed8-42ef-91d1-78efb2489bda" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_915e3b5f-7514-4388-9a7e-4782cd7de7e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_78c1eb30-5ed8-42ef-91d1-78efb2489bda" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_915e3b5f-7514-4388-9a7e-4782cd7de7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails" xlink:type="simple" xlink:href="silk-20201231.xsd#ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_a3e5c2db-d446-4f0c-96da-351496f74d5b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_015bf95c-8f85-4cea-8b13-c9ff7750b459" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_a3e5c2db-d446-4f0c-96da-351496f74d5b" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_015bf95c-8f85-4cea-8b13-c9ff7750b459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d1c3a2e-ac86-4105-8474-02519ced1cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_015bf95c-8f85-4cea-8b13-c9ff7750b459" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d1c3a2e-ac86-4105-8474-02519ced1cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_517ea4e2-70ce-450f-8b91-c684af6d060b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d1c3a2e-ac86-4105-8474-02519ced1cf3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_517ea4e2-70ce-450f-8b91-c684af6d060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_26ccb01a-1708-4952-b109-cac29d5d943d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_517ea4e2-70ce-450f-8b91-c684af6d060b" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_26ccb01a-1708-4952-b109-cac29d5d943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_577f24d4-482c-406e-9487-d62e91118a86" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_015bf95c-8f85-4cea-8b13-c9ff7750b459" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_577f24d4-482c-406e-9487-d62e91118a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_577f24d4-482c-406e-9487-d62e91118a86" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d0c83c65-c50d-4941-8c1d-cfe75d642732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d0c83c65-c50d-4941-8c1d-cfe75d642732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_48ff6ca2-73f5-49c4-8487-e9dc9feb7bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_48ff6ca2-73f5-49c4-8487-e9dc9feb7bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_17d29ffc-1cb8-462c-b5be-a5d9c0f943a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_17d29ffc-1cb8-462c-b5be-a5d9c0f943a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ef40f92c-590c-43a2-81a1-11a89e75b0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6c8d1658-dd55-4339-81e1-5173b268a94c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ef40f92c-590c-43a2-81a1-11a89e75b0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>silk-20201231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" !4 3X# 1$  A$! Q$!_\0
M'0 !   ' 0$               $"! 4&!P@#"?_$ !P! 0  !P$
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M[?R/J?5.R^R^/?:,($"4Q$RLUP;X.BC49OD@0(%J*8I2C.;"I-\&8'H
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M7Q?UW[9XT\XRRF/1A\CC>YT47LZ(+92NL>H7MVO,1 F)CT)B<G)B)[F>E:
M    4\(Z,LLS2PGS"O9;5N,>             !8"_@
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MG(AZ/4:^Y_W8MRH\8?\ '__$ $(1  (" 0($ @4&"@H#      (# 00%$1(
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M6!::/W0CI"\:&)EF"+E9BCA2.F$6W64*]E1O=18DJ=O.+0$-%L1(1"4/'2R
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M/F"HQK8[S(ZAM4,@M' %[=8-R.&_?:U\1T.44>SOT41G98TOOEGD<D(BCB>
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M_)3H,)'6\G,JJ$C;4@DIEYK<-Q%C]-L*R\DLG#*0RD4^\$=O2QXL9/\ FI$
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M6"?!+#UETO[=D.W\>Z"'.[PZN15K$%'N-A^;4T(5;96R5OI5K[-29.:T4%J
M4$ W[.,% #LF46VK$!-*W]?&GHZ=Z"%[.\C6$4K&M*K[>3 '--S'DP8+2T2#
MIN+'> Y)A-QS"*S$$!4)XW Q6DGBS$VXX J[A72%E.2,:QT6DS8:O2J(*1,U
MZF:=P$J4)GRR /\ B 25R(H1$9472:W%]I1:6B% MVM1'+I<BY'[-CV9'M6/
M8?Q,'@2(4W<)0L0&I35!DQ7^BX,(5!HWBI1B'6'3R30S2JS51V:W:@CE0!<@
M4X%,IKWR)Z1G?+>0G;]YGI#S,ZUVA0XG:$<"S:J2 2%;BH6E6(%98A/M+9<H
MIS+;VT4Y@1D3>N*HO80UF B5"O3?7/+-5MBB@&I&&VI="V?8@_!$> "-.,^#
M6&:74W>J?A%Z+[5,'U))2_E-^31I.2G1C1!XW<A@Q5X"F2FZJ,Y560&E\9<6
M7-VF0R;V49Z,@,10('8"$$^U+WR?/[LKT>,OODGC>?=&+X79'-YC?-+X.-U^
M2.3-KB7VYNC3JKBOV>?6TZ./*]3%'A,RMM@LW+B,\1W?-#!3SCU#8.0Y-6'$
M,GKIRYRPN[OUH_*)<KOA3BBF<"F%T"@Q#$[S&R:LZ:E]<@[BHG4?DT#1YOXH
M'T'Y@OY8#^")P'FV 2K[GK$=75<9E.FLL$L\_J__ /\ ]U)UY2I"%S<!<2QZ
MZ;&@92V!F<,X@A.Y7F)<!:;L6M;9*W.<[>6-=.?X/-.BOV;8[>AC4Y+_ '6U
MBNI1V6=3PK7/MW\DZK7F/*Z.%BYF_51F83"V_($ADBB:"T("X I,F+7MFF$&
MRFLQS(EA@LV.*%JM:@BJX[DE-#],&P$1A?1732WWA3E(V]!N.,_-ZSWZ>T)[
M(C:_[KL=X]<OCME*[3O-K34CZ,53\I+F<8Y2K:6;<I?YE57B_P RJFI8$.:$
MM1H1Z$H(5EQJ%0I1P!:T&XQ$?'1SD1L%JVY4'7(@Z7> LN7&\[AXI[O.#UWC
M7@S#T\+OQ<9ZPUK^(OW&N?O*@U%>B6 80Q9K<MB@/* 7UPB-*D@LL!S4B4!I
MZ0XLLXL08H.J+JFP!$P-4'.R5LK>X4;>. (@HH+OW4>=5J5A2M:5M+]!(L3<
M,CA$"BJRY'? EI6K=_*-(E++5D9^Q/ !QAA2O1AIJPXECFNN2TEE&A0;@J#J
M<.M+8BKX!8O&-8[IWDO1PUZH2$LPC8NW>B&:;1\$)P4^=A5GME0#]TPC@+@!
M',+-25)8P5%[E4VY2)E: ;A5#BW 5-(AO6EL2&3"C5'<BXGJ2&!IAT9J*<E)
M8W%+OI!-T&.(;&_:@F-34Q3:IJ),.,Q0LMD8\HM)&UE29?&&V7C.OO[!Y"&Y
ME2RS>1H6KAR[[MQT/P_2K1AP/L<, T!*!'D  Z 1LSL;"VUHY<+7!9<$Q/'8
MX($,&_TFKVJ9:]:CU:&RH+054R^N53AH7#,,#>\8J7 %4E@"D'23@GR0AA5@
M&>5M0[^$;FW,_,(2$^)KK[QWY^N$X>^Y_8>I:KU_!F<F#1*\,H- 4JV&U2M[
M. 0\  Y5.HCF^K&STPUD!F[GV/VFO7 Z;#!K3:QJ7X49>9H;A?2$17S#K#ZO
M#WS5@8_ULQ72+AOGL&W$17(".P'DMDL2/5C4>\"7C1KR=<5\"'#5S=!+[" J
M:,1^"L5+>2E9Z?.GFXFCMSPT.U&QM8@Q(& I!+'UQ6J=Q.LH"H9"(,  /J8U
M"Y44P5NN,] ;4(K75XO"H!'@;V[QIO1B[GB!MKV+BY35REMEZ.45_D>1 K8
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M T##K]+!(ACF$$Y H'6I8O\ P;__Q  J$0$!  $$ 0,"!@,!       !$2$
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G1THKSI-T.Y-S?1UORXI,G[@E7AD4&W_.;BQ"=.+8"JQE_P#(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>silk-20201231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@) 24-#7U!23T9)3$4  0$   (P041"
M10(0  !M;G1R4D="(%A96B 'SP &  ,       !A8W-P05!03     !N;VYE
M                        ]M8  0    #3+4%$0D4
M                                              IC<')T    _
M #)D97-C   !,    &MW='!T   !G    !1B:W!T   !L    !1R5%)#   !
MQ     YG5%)#   !U     YB5%)#   !Y     YR6%E:   !]    !1G6%E:
M   ""    !1B6%E:   "'    !1T97AT     $-O<'ER:6=H=" Q.3DY($%D
M;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D    9&5S8P         1061O8F4@
M4D="("@Q.3DX*0
M
M6%E:(        /-1  $    !%LQ865H@                     &-U<G8
M         0(S  !C=7)V          $",P  8W5R=@         ! C,  %A9
M6B        "<&   3Z4   3\6%E:(        #2-  "@+   #Y5865H@
M    )C$  ! O  "^G/_; (0  0$! P,# @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @$! 0$" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @("_\  $0@(< RH P$B  (1 0,1 ?_$ !\   ,! 0 # 0$!
M 0        $" P $!08'" D*"__$ & 0  $!!@,'! (! P($ @( )P$  A$A
M,4'P46%Q X&1H;'!T002X?$%!A,'""(4,@D5(T(6,U(7)$-B<AA3@I(9)31$
M5&.B18.3)C4V9'-TA,+21F6%LK33XE64HZ3#_\0 '0$! 0$! 0$! 0$!
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M_/A ZP)[N<@)'BZ\7R2LXC+6,[Q@@TU-%^Z[ET0.-V[2W_2&L+O!)\.EGW3
M2E=SWH,_*=ZHOYYW]21]LKI>"4W>=Y@0976\T":WQBE(Y\>2(XPN!ZX( >@,
MD.WW2Z%.!T0??V@ RR.N+X7).X8Z.Z;TN^&_JBR<M/F]$!Y7V2D3A]B"?7*
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M_%\04 +%Q2W=Z(LV;^D#/N]=]%KTA>Y*!;TX[]M,,$ %T0^MZ:[RRF@;[=T
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MH''BM[TS[Y=U-G-]:7<T3"7.)EP0!^6FER1&MW<DN(W0[XW!8W3C;T#N[=$
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MY;XW/[K/\7+><>*U\(H#[KY=0AWY.N&Y'NA?FZ@H"2MI;QS\K ;RZMYK'O\
M%Y( _7[[NZHOOMWQ0=>?A8]^%]$&W6^]ZQ\21?>E-,D.TLX780%FX.6./B5Y
M("\+GO1 09U+P0O?<'(/G=^$7]^@%\D&%V^(^UB+R[YY+?->5(>$<KI]:( %
MKX1XS6OSRMZVF=[XX(,Z[EHB?%[G(/Z7P0N" NO+6Z+7X^TC^W1S]R(S\VY
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MT8ZY(D];^*("?B]UO6\.UN*4]>U,]R9W:2 ='7\H=3V=?PLZ[^L41A<'"^"
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M6^<*&%U0\$[\//) <.$[W<4']!=S3_"6^1L(!YOX368W)+RWWR3 2SAWG)R
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MA"^J'MG\7JCIE/AK8D@#-]#IHB+O/Y1'7==$K\,=7WX09T.=VYR)K>*P-RK
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MY)#RN W":!B;[<?A,*;[\*28&+JW6WH'=R?Y^R@:C2'"^"+^9UOLL/'-PN:
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M#\L;O<@^FZZQ0,^6]*#;]$!K>2QK=V] SH<.B%\;W)2T<9'[W6$P;Z=W2O!
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M\;^%@S]BXY]5CC9N119/&W!!O;?S>*SG<M-V4$[[U<D(Z6-$!!RU12C3?O\
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MW+/OE'IO1#K=! #0'G@@[QUDL1<;WK(''ATCAOT2/Q=6]\DXM_GD4F=UC?)
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MG=]((&]S_M8'HY29[^383! ^75%V[S*?9!TG_5\E,FGQQZH&PZID&7(WQN"
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M-!N3[O2JWMN5+WI?=8O@F?<SR^T (O W<%A25X:HBW'#NM<7&]4&OBF]MX6
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M7:=O6)D_6\\4#4?#B@_.Z7.J4CZK<$7<7'C"^2 C/"&,7S\HNPRE3XMZ3"L
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MP373Q]( +PL]42-+W<?"+K?;\$O6W[J(,"-V2+^_'5+ND.5N<B13N@QX=0Y
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MAWE5Q\=%N$M[\CQ2Y9TOB@/#M?5-A\68+ 7?(H$7VS') S1KFZX(/W9^+XH
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MM6<[[:8+'C>*!G[L#<5B,MWA+\WB@,).\Y\T&?;IHEK,=+[+&SC>/9-P%XH
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M\8(NI.%91[\J(!\GS?9"[TN!6%_59+7! '3CQ?NN"(Z7P1?1UW2:#)X6>VY
MX:TGC>B4TW=J='K#?]]%C=]."!#-_*%P1N^A1-]KW+<[?SY!!M[KDZL!/-;Y
MNZH.E7.Z($WUZ1%4&MWSS5 >F1M^"G=W@F%?C) >TKMR!,C?V.&Y,ZE+O>Y3
M,W4[=D!&Z_$<I)OG@*H.LS=XYH \(7IX0 F^WPFO*EX/1=A>?!%UWD4"M<X]
M;*&<N]FE,T'7?--?#I+R@P3/EHDNDO(P1%W1 #6YQ" -^<5MT$P'UT0;"[?R
M@@1?+LB3><I5&:6W("+Y+8Z<G>$7=J=$!@+O! V\;\D#=\4.3HWY6R.6%]T
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MX%;W8'"W:HCOT0?.Y(-RUY10N]^Y-B;<_P"T'Y2NW("[C8=#Y>L15\=$/=3
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M*!YYWNU6Y8?%=Z!M/*4F5R/=&[''>DX.Y6^10,ZE> 6QW<DONN>2//X!X9E
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MIH$7=QG$WSH@-.W&WRHL[A</*!OXT1^+^4&':=Q^T>6[RE?7?A>_--VY0O1
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M%\"@P.%]I(\H?"7Z=N1?TLURC-!F:7=XE,/-,S<$'>./1!^=]K<@V6$/%R3
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MDE!RNYH"*=+NL%@,I;KMR5J,GUO?R6 R."#$X8NW4C<(+7?!8:.L(@2@[""
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MN<;#DQDX4OF$O?E![_*.FB ^XZ>+W0<A?C?81%?//<@+N\$  YR\?28=X]D
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M-Z#BB[C?&\$!=?;A;DHZ7P6?=,9H@Y.[($Y7?/!8TCYUDZ8LI\=1QU6-]/M
M+LW%8\+OX2DV;\(@].2#;K^]Z8C*P'5K-$W"[<DR/T@6Z]$S\_JW.2XQX"!X
M]EAQX#/E(<$#LM7S'$W!9MK7E=P4G6<LE@;H^^F*!]7#L^Y+/2CF;@B#.?"Z
M(&??:#],D3TLI12Y4X8[Y)@UK1];T[( 1E?UR2ONE^$QJ.%]5@[Z0(;=?1,
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M+&[O)$4\)17BZ[P@@-^%G;H=+*P*S[[^*/0 G?X[/IH@_/ZOQ**WMZ(:[^B
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M+=S6N\NZQ%XOR1-QQET09W;Q\*>^&D'9WFJG?82M;["# _=V$']N=/I"Z/\
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MQW6%WTYHF[Q6%+X^$"@707-%TUB8V\9WSIM_-!@=?O'1 <J?%7+/NB9UR^$
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M;^T"+NS@MVL73-8GL@+^T+^TH$W@8_71-AG=X *3KOZ05?\ 6-A(_5$B]_1
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MS0-SN]4 W:##!V4,$+IPN&2WWD)7T6?RC\;D&=\_&29^5W/'FE?UY&J=UW5
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MBXWN3@TYO\.Y(,#IX=CK1.[S]WJD'C.B9_7! 77N[)3;[JG\\A\I",\+O*2
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MRWNSP6O<@'W>2 -<^/9-K/%SPL&1?6YH#?!.Z=FAO!(.M_2H+OZ0#M#??F2
M:H=SNZ8CGU@HM#"\KX(#[MSGNZ\"%@UB.>Y*S+IQ0N4!?) 7Z6.81?P2@RYO
MN:++I7'J@J*9:==8I3E=9Y4I1+*5TG1,#>ZIPP0(^[FB;$$6_FB0?-BWZ(&?
MI>:#_&GR>R7RZ\()AIXET0,#0ZW90+-WDL1.[Y.69X3!Z0U0$&Z+3XV^FJ,)
M06)=\<-T$#/[]+R6:YP^KX(AH=*:)6FOA K+ZBW=$Q%Q1#7+GTXJ9:NLN2!O
M=VT6#6Z4'X'PB2^?7(=T@%B5]$%!ABD(OXMR=W''DIDZ/AX[H&?GROZR6WJ;
ML87"-!BG!NEBZ("T<OOKE'1*!A>Z^"RSLK[\D!]U][Z(.R*)9W97),1N^:]D
M"C[S\51S&_=4;DI$<.8&ZW)CEO\ I!G[]\,W+/\ KX6O<E%>V-(H*#GWWY<8
MH-"X(^VK[^L4O#OIH@4"_A.;M^[PE-X( 87@@9UWT2>VX]*=TYP,DHOC?! "
M->].R9EF5R3%WSRZ9(,^3D] >MQBLR>+Y79?@F:%;XX=\E)^%NNY(']V7&^*
M1^3I5MWE-[LK\QX+0A,Q.,W.^D!+LKOY1!?COO@I$1N+E1EK6Q];T#_'7Q-(
M=#]2ZK%K7/HB_P"^Z $8;MW7.B#CSIG;W;TP-RZ\EFCWETY("&KOES6+-,OE
M29-S$GO5;O1 @*9F[JL<[IK/M19UZ=,$ /CHM?C<B>T.'1(^\O'1 W&PE-NQ
MK*Z)@1;P-*_2!. LW ]$ ?;H.AY5!?3MQFI 5PZ]7<40;^>F2 M-4PZ7\)2<
MN-\YH'YSC.-AR(P="-Y_"#"^#AN"+(=]9%W'JB1A@]9]+OJ4"@WVJD/V1-U\
M507"Z(FW(%=2EXI@SPI>#TCZ=DS)X=_G! PRO+NY B[N(1?=W-*&J4IUF@P&
M29]$'\ ]_! F9N=Y('(O-^*EVO["<F$[=!!W:];H@P[T[+.UPBL\7?Q%!IJ_
M+\,-R!GTNW"PEO7&-O08P="[BFQW;LT!!QNZH!:_*W&'7.B D\KIW6!OI<D3
M/.*&3^=PNJ!0*:_(TQ3.OR$O+LL&<8(&9/"[<B0^Z]_"&F-A'.:!?C*]*H.O
M#MV"S[N]R=VL-.'E K-=T#UNJ)._+L'6$0<']=?A(#65V>2 -"W5?/=S2\;O
MBG;K=+<IOO 5W504.FN-YS69,^F'V@-)HNQY/09^<*(M>+?2" '##.]R+\H7
M'EV0 '"[F@_G<?.:=V8KOA'Y2WY0;W[K=]K>Y^-]M%OH<*HLR=@]PZ7N0(,Q
M!W6PF]M?M.1K=^$8<@+\(%:TW&_A(#=WA-,U&6^FOU1*T+SN"!A8PNDDPW^
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M/NL3P&ZJ \RR^Y:($ZTZ7W0,:\<+YI77>&'):\TQG</E ']4/=AQQ?XLH/\
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M2OK=Z(NAI'&7REN\W1^4!%W>2I[IZ=<K*F*\+O1;#QR0$FDZ!^'E9V-W@.J
M,KNPL_ZN>J!;W8[^N]$W=(5\K-7B[-%@9WGE/1 Q:N[*#)QWWP\+$;Q-\*X7
M!*+Y6Y!42>?N[FF:W5OBH/O)T.2-C!U[T Z.QFL?B&%Q6=T,9S1/A '<YF\.
M"/SGWX+#&]/J:77+S*J!R;^/&F*5KQ&]R+[%:WGJL#WT0 #MU\+&\W7NP0PN
M(O@B_D0@Q&?2]$/=<;=@F)NW.ZK?,MU]4&)OZR0?Y&^(/Q5;)UT1Z3Y^?A!A
MV^LEB;\7! 7QY]%O;?._A ?DOSPWR/)$7?8H$?!I\WDL,,C]GP4#<[N7!(#7
M*_B45GX&Z_:!.-SOH@<?$M+^UC<;W+;OG?YF@ZN4;H@PECWP?\=D1G3SP^%F
M3C=7H;[D@4WO[3X(OQ&-QE>*;GPO=)(:W<NR#!O.^BV';+L@+\='ID ?WU^<
M;"/&@R>^&ZO5$9R?I"YH("+\]EM'5^9UQY+#=AQ0)E?1 P:RWW#JBT.=T4_C
M/[3>>[ZV*(,/E;SB=-!HB8.2ONZBB!O,;\?"Q'Q>&7!*<(41='O?+X"#,B9D
MX[R;\(AF[P\("^D-\T/F<H5\20,13YNW12OY0[7@$S[W HNN>F>J"8O&YIH<
MNE.P-5F;ZWY0X6Z]9H"-/.%E W=Q6?*OW/OQ6^ITNA087=A-= 3NMSD,=*7?
M!9G/?R=NY(,3WUXH/PA##@7=N"S4<Q()F1EC5 EG*Y<T#V%WHG?SP[_":&^R
M[2\4"-!]W-9UWRH@3XE>D<40;UI<D&=7K5%]]+QW+&Z7])'RUI=Q0'%\8?')
M8F[R2^%G6126B!WTQ<?-C<L3K]6[RD-W<$HL]+H$%N-_>Y3:.ZFL8Z?;DM(2
MN>N*WMN^J HNU^@.Z4,Y/=&\>RHZ5W! F-F/TF NZ1>CN0W.XX1X("R>7PB!
M*5]Z\\$"*XNOXJB_',WN0$GO=Q2D<\)WS6?POCT0]^66* GYN^R ....2SZR
MN2&^\D#/N[PFB<CI?/Z4S1_U\_:<FEN?W08F[PY+ WKX0?C<$!F/J7#%Z!];
MC@E1Z7WXA V1T<@QYU^$39\+#Y%U1-+O-!@+ZK&MRN79*3NKPO5TUAB@+0W?
M(0(Y=\$P':F%ZP0N^'! ?N_I "4G9]^Z($KNW(X>+XH$:\X<=:00?<KMRQW3
M-YHW"-Y( >Z$>5Y;BB3OZ:H>Z7'&\T#4I3E>":]WW;DO+=HE>;O*.2"ANZ:+
M!KAREPMZBP?D&M;\(\W\+^D%3UX9:.0(E&[^$ <KHB'\^[W9H&(\<;[(&]U%
MJ[^Z SUEOZH%Z_/5,!8\K/[8(D5?G=X(-?CIQB@_7&./+DL?B"#(Y]+E5 0:
M;MUQ"+^@[=)_*47N@B:0O#P@)OBZ??BE:PI*E\DP[40OO?)!O=G>"9_?=OBI
MN\\4P&5_" ON\.[YHG(X7<9(-7J'6$H[R04%ZZ+ WE?)!W>[U2D7U0,*:"N/
MUX6,<?'S96Z='&4<DH'7"K^B!B41\ ^-,TI.5S>_-87]=)(",<U-4!^+M]%-
M!9HWAY6 C/L=>'1 P="7"2PN^FB!B+[N'-9UW1S[*Q.O'ARJL&O/R$!(%(7A
MYDIOZSEP-Y)R=5F75?6B!".'3?WW!$'7[1?K?#CD@+=X0,1>-\DAO2KK@],1
MG##M]H#?A\W1  8Z9YSU3M#*\?+DHHZ.8E=A-[K[W5 1>"&F^%A*6K\;L-R+
MM0@1^ZMGDC-^7+7H>2+A,UQ/!:6,0-$ =?>]R-V;%$7=9OK<')=SOBE]$!?=
M]9<41=A ::=C";A1 6_XQYZ(#]]K"SG][BL<>^6:PI(TG@.J 9W\2BJ/W[TA
M^7[LM^2'G2%+H@T\*7P1A?S!#NZW9+>1OFZ" D=;^S)*^];N28;_ *F#\I'7
M._""A/"4;@47W]32 ]5NTKL(,Z1\W!'/F[=>6BP,KN5-4"=:=4&![7\%%]<!
MXOFAB+R^%KX4089W?TB<Q9^$I-\G;W+?7) Q-];"!O2" O@FRXWV0)WN5[T3
M>?TB=+W\MZ I>':\ )[NNX(#QT1!RO+<MI=.%Q080?=UL+.N^:+]?%SR6%\#
M?9 HYW&Y+$<[X=DU!=8I=U7(,_X\Y8<$;U^U@-//;=)8F[Z]B@ 'SPCSR6PS
MQOZ*V&'6QPF%@):W#2M4%+%WP0'T;^D6<;O)8[]QX0O- MA]]>2(&28#?2E^
M4':_%_"!;C*CS>B(&/"4;EFM]3C"]Z'QW0!KOC=O1]L!&*SLNI\+/DX^##QT
M0 W>: O>^XI@>>D+N"V._ED@#^]YVZ"QOZEN1=>@O! >)Y("#*Y7P@@>]W&&
MB'2-FY01!N&&-P0,S;[F)!/[<77U4@?&N-]4U_44#GZ^-$ER2;Y8]4P-=;N2
M#'I*F* PT^EC>^1Z00/<<X=*(&-.2S!MRV5RY069-[AP08G.MWFLZ/2-W@LZ
M>'Q>B%ON<>*#.N^\$V-Z:PDE[7V[($WG2Z(#ON^"S[N\%N/)R+LW/W( 1?FW
M(CMU6: J^^TDMWPD@/GNX5Z(&O#EUS6=;YOGO$TPQN" >WXC8>] :"=W]K=G
M7I18'QQZ:Q04TAC=E87?1 M4G?/PB=\>%FB!2;DZ\T'Z>-R)'-\#*_M8"<Z<
MD&?X'UU2@]^]Z(OM^"4Z[L;/)!7Q6\DI&G&<<);Y\$ >&1ROY3H)OX)@+TZ]
M#O0UM\/JB'NKA=\D% SAE;D2SC#??R@S4]T+X[^2 N^+OD@TB!=_4T'RX'IP
MH$&==N2WI#!9W1'F+^^B#!K(=U@,8WRNJQOQEGBL&OO66B!W<WW?= 7<D"UA
M1[GH W"M,T&:#T0.KKQ69,\X4\IRUSN\D"'I=\4KNO/H]._K7(6[)Z'MN%!R
M0,,\^T<D&QXO[&2:,G0UC=A*_%UR0(.R<X^;W9K$W?)!DRB_?=R0,<8I78][
M&;DQWPE<TA'&,+NJ 9=9/Z)V32?2_M(_M.XJFO-!B-<,KP- D(\QKN1:&J J
M?&$T#$;L%A76Y(#"\N*)O(W!!O;A\7R4_/C@7[D[5_%O2NN!0.STZ=D2U7?O
MS*7?=+*!ZH&?P&=_*745RZT1=2^6/-)AA<][M.:!P<46G0Z0D]+[3>F] T^K
MMR!L.C[?H,4#SQN7RC[J7\(1NYY(,&;QO&2S[EV?V1!OOWP6&[I>] !A"'-]
M-3])M.L'(6/GJC=W\@KHVZ_@)B+Z\$KIX4P5&1C"8Y75!*M3KUX*@+I?.O-'
MVTCP%[DC4*0OLY 8:\K"4GGW[=))106<_I%WQ=\T#@7U"Q.X7QNB Y=Y)2>?
MW<'!!@>%VX]).6;Z71(R/FYRHCQNB M6",86]*Z6I1]LS"[\+86] HRN?.,M
MX1(E]%$:=TQ-W9*!#=]>:W@'PL/J5X+.GJ@8 5O+*MA8BZ8/O@L!KA>*Q-F[
MD@ AUNX21)LOC")=W1=]<.>25\^QRY(,[.4M,?";&'G?;EF3?+FA[LL/&3B@
MQ(Z.*S[<'Z.ZH$<+YN1 N"#&F5-472O?@F+.;YI7XO=<T&?*=\K>L31U;O<M
M9RNB#OKMSF^:#98Y=EI2M_=,!XY0BE=>E$&?7N>*)NB4'*=>4+GDB<N%\D&=
M=7(>[S>.:>W9W-(T:]+W("SGWU$43Y0!6?;H4MQ0$B!GVPY\@D%9;W\N4$Y,
M(/\ C!WRE-B[X('9NZ6] S[:\X)0>2+\K^9("T+Y(^U2)N_&B9C3P@)9Y42@
MXWB/*;"[WI3SY>$#^Z^-%A=9)#<9??-;E+L]!8W!_+=%(#?2YH S[\8.0&L7
M?$+B@VC[N/TL:73/HB^D'92YX]4IN_K% P'%9HP';E\+,GI>JFT9&LO#QJ@8
M<)1N^"8_'*@0N[@BR,>/07@@QTO7GDL?D;[WK$86.D(11+5_*#!FW2C;JH^V
M[EX19^+W20:/#.\,T&R%W@L=^/:2!%^$"<,+AR0;W;CPYQ1<;OBM>]R?W9H$
M2F\)IB9W<.Z4"G+1 #?T9IP+A=$!6!IN^DI:OR@?VX];"WS=^4H-OOPL<I7Q
M09^.ZZGD$Q-+W)0.3C>2SY:W=4 !SESO<F=XO1(_A#CYEHF]UWB@+4K<_7O1
M)?&$?(1>\6[E@ASI\[CU0%V=Z+%FM_/PLZ](7O0OE- _7K<E._J]4V#N#G<+
MT6(I8^0@S]3R@YT#>3DQ=8W<DH$)UFY%W.[H@9G/SG=E(1/XOP$0;I928W#Y
M^D#LW<.BQ&_6>*Q-Y8H"EP#OMR  ]L<T_F]P2@Z!U]*H"[IEJ@(%]G6*J@.,
M[[*3_CKPSDG&-V$"@N+\+&2<GAQ?BL;!NX(/GD>3D#.O$W%8OB[6.<.?RL6?
MK<L?B[H@4F4KOY0&ERT^$79X]$K\'W#B@>[QP1'UW4_%D)P<#TOL@W7IO6)E
MS2D]X)2>WE!6["3=)\T>K_$[X($ZN=T\H,>.Z.:VD12XZ+>[*Z7O6'B)S0.&
M<HOL_4UM)^,,W+7>J1^_CNOB@N1KU@"D#.(=O6#72]5O<@Q%W].2@73Z^UM7
MX3O<B2(X^=.X0,_R_<4C^>/._"-:^?N:)9O1W1 KASQJDW:B+]^_BF'U\7HB
M_P"8^>W) '7<;U2CQXNB9]R?@@.#[O! &L,-9+$\NU/*(-^$;O2ZH%&%QM_P
MM;Z0QN%$?A[XB^N2S[/?5 </.2&FF5]T"<KPR\+?/AWR@Q-^>Z;K,\< @+NE
MN6)PII'2W(!<NW=,'0^NJ5]W>"#KR\]*(&=XX].B+KO) <L*:I2,;MT$!%=_
MB*=D\>6:3QTN2+.F5[T!:9S@;O@I@63?A5![XWY<E=NSN2 NW7T2.[:W])GT
ML[[<BYU-R #NG9:F_BY3'U2G"\T7ZW]A Y,NFZ*!-\M?"#-_7%9H#/A<4"<[
ML=:)@9ZURP0&?PFR^,7W5 IN[ JF(S0-_$G=%B<[NE4  KA"5_"9SG2ZN?0(
MLPQQOM%#W:U'QQ?&2#,MW)V$T/=GI=%F]_6]R!$[NJ @V>$T/%V%O;C\H7RI
M<D&-_"V/Q=Q1?K]=+"W2[@@&'7=*^Z-ZTO"KTCZ5Y6[NG9.72'A!C=V*X+"[
MOF@Z6OW\IA?9 H^KWS1=+>_2ZH"_G5,1T^]Y0 CD8< L=3PYZF7)"[Z#X6&
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MUEV;G! 7="+S6 EI)W;DL^II?'%!FE+MW! 37P/M8#/#-#%'YZ6] 36\LMZ
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M"=;N:Q-S.%O08,X8:WFAAR^7K#+?&Y($\K^=4# 7="D?.^W!.S7%;D<[CH@
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MTKG#B4CKNP@8^;O<B#U[WT6-]C\H;L'QO3H@86"E!I<8U1Z72:0ZC>'W#LY
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MA'*[?86SC&6MR0;"]>Y6(6?*['/@L></-T0 BD[^N28CQJB#.XE(6<+=A@]
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M=K"(9G<L/*#>VN_L@1R6.%,#HAE"6@H@/NY$2AI>Y8BCUB*[S+CI@L[1_!
M;XWJL!+*%W-;W7>]"3I/-SRXH&*#L,N?:"Q-]+>@_IYN" X.B_MX6,<L/*;)
MVN78:('ZOJ@/MQ2](<D6I1+^,LTMYWR0,A+/G]&Z(&X7O6?<+@@.'#A&N*WC
M+3>F)T??)*_@@U\A19UZ>."P.-WBE!Y61\8H&9&^CJ<%FA]89!$8)2;W2\E
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M!*'??CD/M$&[G]H 3+GI*^2;CD_#L$H&5BX(@]1T<@&-]*8HY<)<EMUTLP0
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M>/PE^OI,^5WY03:9G>^/T@!+?C-/Y(R2-=,.E[D% <+PZ]D&HN&O)!EJ#Y^
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M7:F-_21JID'WK@J[,]>DD"EGE2^J1T^GWO56C.Y^;@E)F;Z/0*18=N&9W=4
M;NCYK-''BL-+G>* LF9W<J.P3OZX7)3)P%WQ6?/KY&%*H 3WPS6&%NP/"*)9
MQB@ ZF/B\$!,88=5F1T'S)%F[DB1 V] HGQ(=3+C<UB9PW2PXZK#QPS\K$<'
M?/;1 P:K*YONM5FM'CO*RE=W=*]$S3G>='NO%!GZ3O1V*1V%WFF(PK>=YI"R
MZ\+.B Y4.%_:9D5^\'I3OWK,-<'SN!*#.PO$N1D#C3%^=Q3#5W=^/A,Y^Z4<
M [!!$#&$-U$PQL75Z9J[B4'9.08'"\*=%C1\H_)T"PPL/6-W1 7<EO;@Z3G
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M6!O="]4 :%G>B!SW.&+NBS^M.ZQ-SA"G;! ?CQN6:N+A12-;P5?;=:.=HBS
M$RR<'/@+<F]S_,I&^N"%_>:4COV=>6"(..<?$T":.\W@4SIW2X)'[O* .\97
M15!E5V"5GL+BB_K>ZB+=C?>]R4'C>&D-=42S]9]-V\K$72_I$8"\L;U6(?\
M!NQ1*_GNJZ_"9AK>@S0SSLN69\&Z/^D29X!WQ]30'R).E@@;C"B0\<^3E1\J
M>;W*9-7'CON?! \?N4KBE'$.KWR"+]]-,KJMX\6Z:#?;\2$1@^8[PX'>L#TO
MX0=?9 S0K<+?\*;NSM]::/5 T/I)CC=ND@8-3XP3OJ[S?12?-V"9]W) 6FD0
M=[[?>Y2N\TS[?=\4#D#.^RX/7>L&S9+9DSEN7:U=]U#:^G#0(:#Q4>4@>#_'
M?FQM2YD0D#''%>R"0+OK=@Y>-]+Z!AC_ &,@!>2?=PW($!PD7$%]^5G^?"Q\
M'XP0=9L[T#@<IXTBB>K^.*4&0RO[XI6K^<.Z B4+NJ8<8V[1*!XO6GA,+,+B
M@/NA)SH)B89\KZS2/G65QL5DAX[Y8SHY #I+HL*Z"E<4+W)M_6_E W"]<X>$
M!TNW)73W:)Q27>[J@!N^/18,GR^&[SP69,H<[E1,_)U]D!')],]R/OOM%*;=
M>.]*3G=W%!8'!(ILU=AU5$429EQ#NE^$0U-2!&4W0IAQ3NW:(AL8;GW<D&CQ
MNB!.L,IP[)7<8]H'#N@8G/ .-'B9O@M[Z.NYI#66F4+<E!G/=G4^$#D[KZ?:
M(O&^D$HJ(:2NY([[^N:#&CBF#6N-Y?4D&1A*[!W+%K ]+TXH#[7[G&-X32D7
M=\$2U*3KEFEF;X6$#LVZ5Y)2+=<"A[72I@]$-7E<,D&9KCCRX"9Q3^W?<$K9
MPL.I5$'=R0(<,;+UGJK3,K?<U,,Y"^<4!9.ZX;EGT=Q^%@J>UV,(SPH@D6K[
MNN)0!/CI-8C!]8WU09[.GDZ5\$%&#KAX\HF-,5,%W"Y+>Z9ERY:5@@(TO4JH
M:$)];[243NZ')8&^Q0.T-?I(RU.%]$Q._0W\\TI[OOP@9HX!RFR.@P^U4X=X
M]$OMK-T## Y8(,3DI-,ZBDK\;U5ITYPEI<L4I,X7/AT0,S]B5'(/PC*\4'3I
M\.5):XAZ!7F\+X)6C.DH 53LBZYX?;DK3M_) KM<[L( REE15]P=W<\)6@,$
M">Y\-[N]YJK&Z[BE-"YXCA>Y9^%Y.I;T&:,]<)1N20]H0K<U0GX?>Y*^N8CE
M\1W('E='=4"M ]#P3LX78ZH$+5*<N?!%DZWX1+7?EK<$H&<#OA"QW0.[)9EC
M=<$04/<_&OQ\(%^;\IA?3>4@$8P^KS*L!"%X((1E>&ORJAG)\NB1U=1E!7)0
M0)H^Q>B$];K;UB<;&'@H,GAW[('=/&SADBSH=:7K%->_-*\>+NB!0U'+7GP[
M)WWR&ZZ)/;E?3?HF]W9W"6'R@F>O+2WK,G6[FFAC'FLUR"!GU&G+% F5>$;J
MD+5+YS%T1]PKTNDD%,7#*XN2>W4?.>%R0]V&[RF)F[+H@4LW]?- B+N^28&Q
M?)!V#^%:G>@R1_:Z(M0E>J#.?6B!V# NN=YIW94N]$HJ07=(Y.0]\[Z64"'E
MRODJ,WI>Y(2+\("';/"-/*!_?1T+L>$KJ?>->J $3>K\5GYR\]$!9-TONJ,W
M>&&*E6>*= 7Y;B77CJB'3=RN*70N\8WCFE#1G$7AT^T%-#K?,HLZ*7NR[?%Y
M)PV.N/>]T4#->,Z( SG\W@@#P^';KP3#F#.XXH-E*[?N2@Y3C0QO@D+6&'+L
MF?QQG>2"GFR-9:( WX[)/=+!]PZYI@<[TM\D&?JYV-?GJF<_)*6N"S,[H.N)
M0$#NE:;H^[\Y*Q4FMSKJ@P\8=>"(TN^*7VW'3?@F[/?1 <*2W[LJK8>4C1D^
ME<3BF?)W!!,C UB'2L;BM&ZTY2BJ$UACVL)7W1 P%]O*2]:H@S&1RPO%8QC0
M87N0!HY;LWA3MUZ*H/"-W!ZWMPRSWH S*KQCR2/W0NY)VC07?1(#WXY]4%74
MYZ#D*=%,F\/H)BQ%[ZPQ@D?K='H"'X/OQ\ISGCK2WI$630C+=1!OI^F.*S&%
M\>B A"].?1.0Z/2[F@#;3KK+A](AK*Z3HB^\+Y;TK5XW!!F3]9IGTSXW58%^
MY_%W=*"+R%NR0._G<^BV@P\7JE?B.ENI@L+=2[D@9HU=;L[*#&7TF?WL(>V.
ML+O%!CW'"?%ZP[V='<$2.GP@:X/':^2 /LX_4^28G&\$,?%VY'"\-UP084^T
M'V[.^ZV&LO(N*-+O)!@U.["!IOO5!PI"]],TI.'7*Z(&+5.%]477*'VI,\[Z
M*A'*[S0$'=UDF9:LP SN"07POLF/;EAKY0%HZC@Y GSR6/9]]N:)I=Z]D" T
MZXOO)Z/NP6+-ZI1A0Y4KT0.!?;N:K =>BV=CSCS6?>=[D  ITNPL!RMVGE:]
M^6"!QT?A)R!B;^%KAW>@:/&[XWK'SQK<D!OA;L>"0,YF:8M2PS/58GOA?QD@
M.)WWP2@<'5BE?1WQ=,$WM?.[YP0$-<'.@B_ZO&:4 "4OO[6W[^_9 2<L;[.0
M9,4'W=.>JS+,2[K&Z20,#@^5+O)8#J,^&2!IIVAS6!X4W7D@(%W*7-'W<[I<
M4&A*.<,T-$! E?UQ1=+*[P0^978<E9/?GTLH&="W1^=VY*[/QE1$;NM]EAAP
M&LC<$&)RY+2B+^$;QK\2D@1KNRN'! OO^-=;Z)GX8[TGMB'/NF2H<-_.'A!@
M_=7PM\/NB4"=TPZHOW97?!!N/7E/5$WI?*"#.?>2!RZ89H')G>7!RQK#==R0
M?KNQ@B6>6^:!1/32-US6(N["+A/!#.X(-A\=436XC)*3\;]*+%UXWR0%]A$B
M;R;O<L!W=DC\(-<M]\$!6EWK)(U8QACIS3,F#JR\/X('R[22GM?SN1-WE@E[
M/XZYH* 8&_$*Y)73WWSHB^NHXNIHC&X($9'P_@@,/A&IPN\$HN[R0!I^?;G&
MBQ9?];T[](<J7S2OP^+<@(Z7+IN1Q$KWW-+[,22],&1NRGG\H" _YXK/GPEN
M?HL.C[X+.D)( 3-V7E_A8&%X=')#R=HB99\;D@9_D\ E.\:1=N6?"7#-W"%A
M*#IX^4%1\;N%R0]T^%-7:#FM[L[NM$IR0.='N^$@,1!WE.<:='S.Y39%;>+>
M@?#?>BSK[SYK/Y<]R!:Z7NMR !K(POI7<G?<SQ2-9<M(IQAGI(#H@SY7ON3U
MG[O#DI:N^1Z)G=W(%:9+C.[WI!A6^E%6[O()787?)!@,*PO"ZHV/I#C ]+Q2
M^Z_A V(NW+/II>]!]POL@32W% T\=RS^XTOZ19/1 5A=7]D&+59W#SHL#/=Q
M>C#MPI*25PIP" 9Q&'%%WEV?6WI/=N[77=1!^9O2YA!<!SGQO#KQ2$X<Q=.:
M0-WCNY)M;^*! S-<$SNHGYJI=!!VM;R3@<+LT0/NN(2$BJ!:N[Y(.J_3Q\H'
M=>3^25U\<%M\(#>@3IWG80,;ON@_"&MT19Z(%E\C% PJ^4;\(LCM=Z)<ON@=
MVYIK?=A!O;7(J?NW]KX!4!Z'=)3+51.X>$%7[[OM)8!T;G;E%DX_$G*AX4=G
MXIJ@.0XU0 OCP0]_"WWX1=>XO0!^6%C18QF,_FZHOIE?S\+&Z9(,)UXYV>29
MV'+-ZCH<M-=ZH,"Y]\.H09]^>*4M?'TF&Y8H$'18#4/6!C44=1.,H"-_/%!-
MD9_?9,SXE?%/YX^4K\QPI3KN0$BG#&P$NMTMU%GZW=4G,8W/L@):,W0RB77U
M6?DB^HTST3--4K3P@#E@)/K;[H@TU0&.D]2BS=U ST0$ET-V3[\)/=NOHB?F
MWVY(!=\D%0<<D7^/%ORS4B^GWAHF#(^C=Q0%G4NG>29JZ7+@@6L,7TO%8^-U
MB>N*!?:E]O&W03O?+&]42.GU>*!/;6/F^F"S/TE.47[XIBS#[/A  <@.>4DP
MW0OK$Y+ #7J\:87)(!& NYYP0,R<+A._*SR_XI?%,SGOSNR@ZIZ8WH@P9RX7
MTR6(R=T3$TODD:,3?P@H\2RWXHX]+LJ3JGL<KHG#58\LNF*#80N^:F6;FK/J
M,ZW7@L;K+1 C,+RZ53LF684RUA=U^$08.[NNY( 6L.=%@)/NW%+R3DY90?R\
M("_<.+\]))2U;G(>ZE?JZH/^./1!1DWC3@Z2SU(-7A=%4"'% KG+!NE\J)FC
M]XW;U)WQ SSAF@=HY_7@=<DC6%Z;ZH%KE\?2+Y_3O+D"D.W_ !?!&X7%$SRY
MY6 E)B>5XH""_P \U0#=P?P2 Z3M^G!.&AGI3ZS09HXS-+MZ0LSI=<TQH*_/
MUX6+-7X[[?X0 ,Z8W>Y+\PUN 6=W\QHC"4?K/#5 0WEP2"\>'-.R*VY8#,#3
MMWT08$/Q6;X_4?A*^ZHO="]V2# T='A'L.JQ;N4,@B+?SO%9LW?1!F,LK=<5
MBS.\N"S(AI=%B<3V?N0*[EPOPB3>=S\)PT.]^4C)0.R#=;Z*;6>GSV5"T:(-
M %[O%_:!,\1*YG1%F[XZK <N9Y.6 RGPUCQ0 'SA/[3DNIA>Y#!*_P"+Z( #
M=7^'>4S0UR.=XS6=9GP0(>\6[Q]("'P[W\IG0>.]A*S\'*"H#/,7@@B+\W +
M#R(7%4=/J\Z6Y!SKA?4H,3=QEDE'?I&^%%@<OD7#)%C'/E-!A"[YHG<_E./R
M@^@QLZ46?7<@/NI>OA#W='\KCR1O<E-NE&3P@,.EV<E1D\LKKW2L8G3+3NB3
M<NV"!RWCP4^5R1:URQ"0?%(0WZ\D&+-UNBSG9/WNN\42=V=OU<@,2+Q0#AGY
MX+$/Y.[>0-$2+[=YS3DR%W+! C(RO[Q3 5KNW?=$]'&Y=$"!$=CR0*;NPCPX
M1MZ(%Z)6A;I>$#B5WF[PL3D[6ES^TN\NAS"4&EZ7D@UV^WK9THG.L!UAS0(O
MM@@P./#"3DO*_I$780(W790%V,9RQQ=U2'?=[M50=^E[TI=.,N5;J@($A"5C
MNB_[?<TH-:<=-,EO=A=W- 2< [?=Y+#Q"F_S%+T%//18TO3B@.<,AXT28PN_
M*;VWK3KHF9&LKTL! !Y?S@,.Y2D?3L$YMUV$&AN?R0"["P-Z7@L;NW22],.F
M: \7Z[KE@L+ZV_1$8]8N<E?<WPZ]4!.4-+[+;[^*HG26.B4\*?#N*#3-S^DS
MO+_J3LTON[[KX)B?CKNB@).1@8J?2]R8F6I[VY =YW](,ZEP^4S];Q>D=<[W
MK>9Z"R4#.O2YI6FL^6=]53CXO!1:TA(;KXH&9/:_MR(.,)\W.OY0%[G+.SX/
MW>$&]V^[Z)2;RR\8XHD?&BP&-^;<@P&(PNY)G9Y2NCN"48"W793$<+NJ%R@W
M*X("Z7@<4;Q P1M^]_R@SKO"7A 3LIOF=_"4MNY[LKWHL&(I<<>"5DWQEW3S
MZ#%*;I>7%$9^N?QU@@03EA"5Q5/;C&[C-#?UN')!,[[=U3>!TNB#HWI$Z8(B
M\+>@9_;6AWY^$CYTE@C>>7RBZ_IR#=;'3E%*)Y:8IG5C'H@+O.XH'-!E'7)+
MCI?E ]^UY!-WC\<B@%Y7+(H/C=^$<,\>@N*5R!O-PRZ00:\]N*S^W=!]_%$
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M@G+73F<JZJ;Z.Z?2H*8:(,6OJ\**;/6QTW)FR+A=D*;)POB@>6-A$M8=G\$
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M!13G=%GRNG2BU\J8X(.^+ZH,>[TS#6(2@>/CES3.Z 2N\T"-;.+W5Y7P3.E
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M#.;[[H*/RYI 8]^4D6J'=?8Q=Q69./'?1 KLKKS@55T#>*(N5V]!\1.[@@S
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MZPNMZIMG6(Z3C+JLT/B6%R09X'C=9Y(SE<5M8.\&\4,<=,H7- '8OG'ZO2:
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M_5!D7AOWPPT04( EPN]R#NM\1%"ZOA#EFL[P@=JWWHL_KGFB-/J23:9 W>Y
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MS>/A WOI082R^4X:H>6947=;X4R6 [=G^.2"K;(N&GA1 EAT/6$DV0@;XYK
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MO<_<@<Y]KP69,G2=![Y*(-X"XU3 YEV/2\4&RA/*=A%YKI2YI<[O'@B#CN"
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M:S3/TIV0 CEON+D+SY2R6J:4XIASK1W*\$"-- Y(>T0QNMX(EEU+^J01=JY
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MZ("_G?/!!6Y8_2V7#MRB4GCXE?-,TU;N[W($/-!V[AIXB@;AC?F:HX0I2?-
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MT#AJ+OC5*9R>#<-$'5L;\Z(LM<+?PNB!79V3N^4Q#N^%NW(@7=O3$7#=>]
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MOW3=K])9.X=+/PM"6M@I0,<7.N:!I;ZPY(/TXN^BF98Q.+Q*%R=D@:U[<=R
M>Z0>>M @:T(KNP1=45$UG?-\L7( #PUR3G*]_?*$U,"]8C04ZHBFI?SZ0<@9
MDRZZX]]%L7AVD>J47R=R6^K[_:#&Z:ZIR*\+Z\%,@8G#3RF:O&7&:#.ZRN7:
M"I[<9TP4F3ON_LIAKPE\3+T"OGB?&4/"VK_B#^/S!$UUUQ2^X73#5Z OKRK]
MW@FPN'!U4OT>WD)O;?QB@7W5^=^_)%YS[4D,<,7(M0KVL=$GNPAYN2 O=I=\
M%GU&!OKW0,8'A<3A@A*5=U>OA _T!\;] F]T@(9_%O4W87>"8>'?.%?M!A5^
M<-_)"(A1W.G!$&9G2\/* ;GK(7)UX@Q6>+NJ/NX<2^W:I'9TB!1V2!@9%[LL
M;R2G&!O#+) 4PP=RO<G9&&MY4,D#LM3EE2.5A(6J%;H,!=P6(?/>ZW@9(% X
MU$H26!EOTNCT61GWA/D@;SOF@<"KL1KGTW)2)#*[JE#;WN@F=?;D@=DRAAQ2
MAK*MGRCO'/DY(_IQPXH*%J'2*(/.6>G1(T?D9NXK!J%Z(&::Q?30(%N\')7W
MR?.Y(84ZXH'99G/2GSS2%GG3N];#MR&]%WFD<$#@WRGGRHE&>GSX[*8,[-\T
MX&=WV0,&K%3?.BF_Q\:(NI@=\.^:!$QOOE<4# 9F[=HE!?K@+W!'/(PWI60'
MXC"<3<4# 4<LU6F66B/NG2CJ'% D3W.T^]<D&SH;Y7),!+N+O1)T?8W*@%3'
MJ, @$S2$KZ'-*R'<Q?A,T=PE/H@[#ZO%!@S#%W'2RGI&)$L\'*9'&;O"H"8O
MD1R?U02+H1D;A<LX6)=A/EIT4VCEI 3W)0*SG=Y('=A 99:\.KDSW@@<_E39
M->6&MQ*<-3I'?>"  \;AO")I#M]*8,]]POFG!N?#N^B BP@\W73*PC[J.A*W
M_:1H\SAXS0899Y2I\%,"^N3N=R2,M?"H+X.>@+AOO!*#K6&G)Z(:PMZ3?=.Z
M"CZW*9O18-;LA?)3#6?>)Y/L(^VYX1^XH*$X/O+NL&M>W=1)K;KZIF2(4TTE
MK<4#D"[Z)78PFZ3C&WT1/GC]( /K/L@0'?==/I "MY0S3N\?(I% =P@V'3"7
M,+&N'P@3ESP0?.$7W&00,[<*X\4[)W^'.%TE12]V\5XF_";O5W075 @>\@2%
M+R3YR,HQ(=<5F#&(QW(.G/>[&\P@<B#A O=GE\)611,!/$1SB'?:1JF&9W(
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MX_: D3S&-W@B&I#202MG%T>ZQ-'/=7"^:!GZ.N"P$_J7*\$LW\-^0[IW4?\
M?G[0$M;NF" .%WEN6Q%[T[("#,M<GG[1)C?'P4 S.3CXK?)-](,)$[KO)(3$
M=XTF'<]$YYNZ#ND=23AO$T (B[4WI@G+A%\X7T?N*+0^,W?-%)LR$\G0A75
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M&&+\UO=')\[DF]L[TCU0!_ /=ICN0]U]AI5;"-QO!8PSA&D[R0)[L!/K?)5
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M5"]U>=$#>.=R^EGW2_*W-SI?+TO*\+E- 2>.;K@A[IV*=_EZ8#L+HL1;NG!
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MK$'#&[^$"UXO#-W5$-=\MY0%J,71C6%_;D20[6(HY_RI@B0=?7<G9(<[C]H
M&9 NS6=+ =KN*9U)$7]3@C[35V[#S0H)XS=3'.*:DN'5R0F3_,/D.3LMW4^$
M&,7]H2[)6=Q=N<F(A"-,TH8=WJ>/)!5D1PB]S^*!)T .KZ< F9A1\)C+(+'
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M ODY,,W/QJ^+G<XK/=SS6+641<<.R  S>.<M]]$"U3.E].BQ%CEHB!<]>R!
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MB6KP^\$!)N\*HG@ILCZ?DF+0O..@<@#\KQWYI6FN-\7UY)GX/@]YS2M7K?-
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M=WQD@+RZ+IWR3BCA"NEPAN24(D:7>]8"0?P,L8\$ ?O=R'35$&IL2%[D&30
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M]]X.6PYXZ94Y+$5\O"WMZ::U>@+\C'=#LM[,QQEY,XH;HZT$YW)'>\<I2O!
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M]OG! Q-7W\22^^[OB$2-==Z4\[Z3<@):G70WP3%JSNY*;+($>%CK@B;L]4#
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MTZQI/3>I@C,8"5[TSX@@0Q'BF6B!@85#XW@L,1N\CI%('B!EF7:WN1#5WS0
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M.SR1?\N=8!LI95O-,,,88/*#/O'LL3.[A3BE)?B!UC]!8'J+O% &AONI3 :
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MO,WHB7:<OC)"^ZSM-*W5!FA.G2^ZHS0F3A;\1A/!3=$/D7F<G&WIFLX0GVO
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M!1&-,\0)Y[Y("R!-SW\AY6?&'$X8)&C"6.Z4UGR,^')!B8'K71!\.SMU>+T
M,9RZ?.03 P&_!Y\8]$ ?)PGWKN[(L"?//XP6.1=W\(@])PCAPX()MM3QI>B9
MFG<T=!_;)$C0OGCXAS0WY0G1\.B -,XEPRNP@[ 5H1NNJ( QC+7%ZP-.G-R
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M! A%C3"W(L#+2^W5;L^PM[>FEX(':<(2CVA>Y$M8.N9D\J>%Z.0:P$,]<H%
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MR2@Z73""4[^4=Z EL5?&$()F2)UAOU4]W&? 41WV*>4%B:],Y&Y*9RW4NNY
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MNE.''S=$%K=24+P2AKA*5PS"+G12LF;X_$?ATYH''2ZUL*7MQGVOX3EV[ W
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M-=RI%.3#'QW&*!Q%]8I0UEI?!!9D9YC?&\%G:97EU4PUA=T5!Q?PN>B!2SE
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M3QQTLO<FW\HNZYH"0 Z!$70EBF(LW;DC0A-_'@4632M-U=V2";4Y%SH7U>J
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M,Q9L(NXNE@<M;F@ -WE<$Y&+Z/69E#C-Q0(SQR#[ZH&?E-RDT,HOU@\53O\
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M0V[7M]Q!>TRSMMJT2[_$L;+8AHO :69KC\LQ_6+U7K]GLA[MMM6-DR*MM,L
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MP2&F6<7W-$X7O[I#H7XX:VY Q%> <[BMIO?%$"7.\4&M=SKHA,B3\=.2;^-
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MZH,#AIGH[1!EG5Y^J(OX/YAP.Y,_#'N7\N 0*Z$'X'2;]<U-PI# @7H53VR
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M*CYZ;TQ9XX8T2,F59OI&^27WU!R@>79 Y$W"&&.=ZU1#7.,JR^D*1AH:4'9
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M]4]3Z1KTVP'XMK8GT3# 9V/\)!8# TF^9)B3%Z]E&.-OOBM!'Q=\BQQP70(
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M![Y"L2@)+KA'.XQ"!JX8WI]20?"L)2=I\I?=6R,9.[H* 3<]V<#NO1*+SN:
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MPAC*G9%H"2S3+HR=Q-W!!0WNZNQ\+-/TEJD?+.#YV/E$\'!XOI@@7E'69JF
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M>L)76J/A\)8Q/&" FEY\<T&B)8PP?UXXI1M,I2+^'U)+PA5V?4'B]Z!P'1?
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M7)&G8C(7%\]R!<JO-NL*K[X)"!R=D_*X%+)QI, %Y04+72W=QN1&!Y5'QU2
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MV(:)++&U]%ZOT6R_EV^P$&V]MM-L\CW,N9(6=>)RB?R[=B:MMUO"'U#8_P!
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M@9R\;MVCTA;B8169..>$IB\$ ,XF MZ;WO>!D)THA+K>+D)1?)W- 63'VQ
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MQ&*5]'OQA&P@ :G,\KHF>(@##.N=N09&X<+Q=)%V/"&* LT#M+PAV6 %7OW
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M!^GA_)$CF@R$&?AEQOLE::GV=5S[I19K=1U$88/Y=4#,Z<3=A,3>,(90Z (
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MSG:1!<J,M&@+[MRFR<)]OGC).PS.,1+)!B9YF3SS\)FFL(=#KT&2B63-\7Q
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M;]D_8O5_CO5?J_H?R^V8VNQ?Z?T>T_&;%L'9--[,!AG^3U/\NU:V>R+0+/\
ML9<'  A?MK]5_IS^LM-#T3'J=AZ[:AS&T#?K VVQZDGW-;!WIRSLSMF=F0?=
M[L!$DKT#\C_5MG\%^P_E_P !^,_$_AF_Q6P_4-K^V;#^(?Z;U>Q/H6VMCZ[9
M^O\ 6D[1AVU]O\VR]P+;  9!(:ANFW';\HV;W2/AGYOY1?O'_"B_86-D/V7U
MW[7Z';>KV#.W]7^1'K6_4-[;_J?Y?R,[<3VC'^TL^Z))<8.7QO;?V6^I=LMM
MZO\ :_Q>Q)#VML7^H#.R(: 999]X?M/\B*A[H Q7^E;]I]-L_P _^$_(>E](
MT&&OR7H&]BR&Y;/:[79AIAEMSZEDO$"RXK\BL?VZ>MV6P&P_Y?Z=OV[)AAMH
MM>G=[F&7-.#0#GN>"_5*Z.$1Y+77,YWO/@_D3^O_ -J7X[9GV[?]A]5^0V3$
M QZ;TC.R:VCQ_BP-OM&G,^T_Y.99))%0]?7OP7]&/P?I=KL=CZ;\4UZW;-$D
M?ZW;;;U6VB/]_P#!L0QL@R"1!IQ#X U_8GK_ .@_J-EM-ILV?Q36T<1M/;LB
MQMB'P#V=@V6V*EDD!F3C,J7H?U7UOX?;?ZOTK'JO1[2(&T]1L"ULF6&H_P"7
M\K.U9@ ?\H2@8*1'5MZH<)F9VW>M_K7])OR>UV8V7XW\/MO2LO##/^G]&QZ
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M 7TG](_+-_F&CL_Q7K_PC'M;: 9V7KO2;3U(:$&B0UMMIZHG,![P]?=?Q?\
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MZ+($( SO3@4I$90<Z[+H)@S]2XFWH% USC&Q5.T?&+X46 Z4,GUCBL]W)WE
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M3@XNEYNJ!@Z<L=,2'XX06+CP,3EA>B1DORASS[43, C_ -JC,E]PW8(-[G0
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M=ET,UXI"S :O?$<)NP3 U@>SX(&][H.@9H,LNB(/PUZYR<AM#_VY0/+?;Y(
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M+37XOTC@/\BPUZ-L0+WEEL[(M8$_[JB,5W_HO[Y^Y^G9_*^J_;-NQZQOUO\
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MU_IR/>W_ !DL%HM?[8+X,U^#_5_2_P >R]/^D_F/R>U9)_B_UVQVK0>TY_\
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MSIB(V35'&VR?";S^+=54VSMWP_GQL]I_4UAC:-_D?ZD>O]$ T_9-;7\?ZO\
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MU-_JB6&OW;\JU^F?J6W;&T9_4_U]MEAIK8- D#\OZWW[1C^0.9(V7J=KZ[;
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MY#CK>:5VLN&6,,$2SH^I<)! '9=N6/>"+3X<Q]Q[+"K[-R2AI[Z5C?5 ^T.
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M>67^U>P?I'YW^FS;6R#/[;^+_)>HVQ(V8]7ZW:[-K;;1D?Y,L[,[+9^]H/\
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M'HAZ_8>HVNS]1LO2['TNQ_E].-BTSLG[+U7JAMFF]GM2VU_L&R]OM>W[GC]
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MO\=IM=D6620&7LP6*:IB+U1GOF,X\KI,1>T;-V7QF7^@_P!TH<*XO"\-^?\
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M\ZHOEU#MPOJI/'S<Z03"4['V@8-=WUT0+6&[/,H##CG@>,UN?=^'2<$%'5A
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M_#_K7Y'\;L]A^)]/^1_*[39[+TWJ_P 5M_Y?PGY#8G:;+:^J:V[#;(_U;7M
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M<NR_$_MK#1_D_6_TGU8?)AO:;)X./NV)<[JNG^KW]Y/X/\!ZX_@#Z7\[^?\
MSPV#'J&OQ?Z[^*VOY#;;/9[6&R_G]26MEZ78G:F##+6U::!<\ D!?*MA_6K^
MH?[![1^I?H/H_P!0] V'-?F/W;U)V_J=F"T62ULOQ?I/XMG[F0YO_J[9MFCC
M)9]73S/EFZ9S^[3'7.5^O;\'OOKMG^889VNT]9_3+]2]2PR'[;:,>M])LV2R
MS/\ D:VWIPS[0(OVC0&B_*7K_P"XS]9VGK&_Q6T_I;^O_EOR(:.QVFS_ !#7
MX[\I[6V2X;-IOTNPVK(++W?[X.<^ "]^_8/Z(>BVK?\ +_5C^I7Y?]Q]83[A
M^L?AMNWZ'\0&J;-C\7^,+/\ (R/]O_L2\D3)7V[]&_';;T^Q9]%^@_I'XO\
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MKQ[7M'TC'\.Q?M?;_(WM/4_ZH^\^X;,"?]%=E^L?H7ZFS[]ILOQ;7K-FR/\
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M=D"S[H>]Y7L?ZI_2W\9^. /I/0[([=MW\OJ=N/YO5;5H1]VT]1M/=M"U4_Y
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M:C^I^_ <@:1O 6Y,&=,W8+^=&U_XD7ZXS!D-'7U6QC.,'NB'<EX[:_\ $O\
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M;(@/?ZC:,, !ZSJQ$;9CLGZ[? FW?V?BZVOZL?O&PAM_TO\ ,;5D>S_/9?\
M)/4%T?>T#LO6@-Q<66#[7,DO:> _T3]P_O"_,?B=DWZW\Q^N_F-CZ7TQ!VS+
M?X_TK ##)?M&FRQZC:&4&0P]YFT OG'XS^JGK=@WM6_S']4MI^.8]SMC^*V!
M]!^S?DRS3_4_Z3T;>PV3;1_]E[-K:$2+:](_-_MG[I^5_)?C_2?J/K?5_G?Q
MOJ6VF/R>T_:_U#TGHOQ6R].7>W:,>[9;+:;9ID/:#+A%U2M1$[HF/^:\>/Y+
MJ_GG$>.S-_4#\#_6GTWY+T7XK:?B]O[/6?L/HV-OZ)AH%C;^FV&VV?OVGJF]
MD?\ )C^!G_%GW0.T<S$)?3?H'Y#8O'I_V_\ .LL-%Y9VK>QVSFC%KVM-,/#S
M%T@*+YS_ $7_ *&L_A]IZG\MZ_U[?Y;\WZX ;?UC6R8V.P]*PX?^POH?2L?X
M>F].Q)C9LN $U^B6_60<]I\9\- M6Y_!GGF[TT?@_P SLW'8?MGK&B!!GU/I
M/2[8;W!DD+I:_)?L>S<#ZG\%^39@\>I]'M/3M-"46MFTVR'U@OEOKO[DOPK'
MJ/4_CMAZ\>N];Z3:M;#U&Q]!LO4>O;V.V8'^6SV@]'L?4?Q[0#_V6T0VZ/M4
M]I_5;\GZ@/\ P_ZUZ]K9/)_UWY4[/\/Z/9L_^[&FO6$>I;9K_AZ4R,E-:(6>
MN/*WT?0?7?GML1_\-?T/\1ZYEQ#6T])M/1;1^/\ AZK8,F/_ +<]?$_V#]J_
M1_YF?3_G/T39>C]3M&@!L_\ D_HMNVT6JL?Z0_R-2_W!ESJKYW^S?U'V;3;6
MP_-?N.T]7ZC_ "'_ (?_ $?8-^I]0VU_[KVOY)IG:;1EHO\ :U[!Z4")>*>1
M_4OP_P"4VG_4_ ?K?XS]2V6T ]_Y;\TTU^9_8=JQ(--_RM-AELX-[5ID$R69
MSX=\7\OK"Q>-V7&\Q\?E$OKOX7] _0O6-[-C8?JNSV'\I+MIZK\/ZOT^QV9F
M&F]IM6F=ELQF\ KXAZK^Q3\1ZW\__P ^VOK_ $C/X#TC7L]/^"_!>F:]#Z;U
MC>R;_DV;?Y+UC/J-IM-K_$V7%CTO\3+4FRY?36?Z##U!9VO[#^Q?G?S3;1?M
M-BUZMKT?H@\O]H]+Z7^-C^-]"2[%?H+\)Z+8^D]/L?1^CV0V/IM@P-GL]FR]
MS+(I%Y+ZM/),WE3U5,VO33E-X^[$?6?APLL8DQLJG.+3V=_T>9_&?AO2>E].
MQ^/]'Z38>G]%LV6F-GZ38;)D; ,M%[?^$FCM"26VFGM-DDM$EZ]>]3_3W\5M
M!_G^(]"UD-@PRZ,P60*YZ+SX]4\S=5X$@'5D\W-?BW^XG^J7Y[\=^6_$>C]!
M^*]2W^M>M]+MCZW\UZ/T/K/RVV]#ZO9M%^R_Y=Z%IAHEIDL'9M^H;9V)>W_Z
M+CNNN(SGC$91,YS-MV[RAFF)G9E^#]$?D/T3\3L7[39[3U/X_:!F?H_R/J]B
MVR/_ &G9[/:D!SG_ .UT%\4_*?U!]3L/4?Z+]:_8OS7Y;UP#A^-/IMC^;<YX
M!VS7L88](Q(%OU7JMBZL5ZS^J'\)^1_ZGY7\O^>_)M[,%K:>C_)>F]3^#_'
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MC-BWZGU7\9(+;!]5M2RR/< XEG9Z4*^P>G8V>R99V>QV>SV6S9 ]K.S9998
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MP:KE31MO.MVY9=F_J=.R+<\<I^+]V';[+9L@,G9['8L,AP9]FSV3# #@&0R
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MN)'N88!J"$BU[[\XV3/RF/%TB)MNM/'/9W/?OR/]<_R'X0_Q_M_I_P 0-DT
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M)%F;SBX_*P(RAQA#>*1F@F8G*@J9.X(M/DX2T.6MX)WF;KN>6:6& S)Z S0
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MVN:HI X4X3P2(/R:/[W?UC_Y+]2\?_*F,_\ Y8IC^]G]:IZKU/\ ]+V8>_\
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M_P!3Z<8CW;4NP_[8XO)71L/[=?7/_P O6;( ?^C_ "F,(R$<)&@6O_#K0?\
M'U_Z.'_*E/Z<NEIV=$4]^M_5#^\#?]\_ZW%VV]5_[YL1+_Z+"IR4O_<Y_P!;
M=_YOJ2[_ -IV$7?_ $7<OX:L?VX^K@_\@S40V>T$7Q+40"1(11;_ +=?5" ]
M>Q,"++<Y._W1(''%9_\ #W0/\=B>%/\ 0U/Z;NE__I-'C/\ 6_N-M/[[/UP"
M#?JR!GZ<2I';+B:_OY_70^'JG$?^EZ5W$[62_ASMO[>O6Q]GJ]BU(Q:VH#\7
M.<'\ER,?V^>OD=OL3)[MHV7DUBR*?[0_%;C]'G1_^.K_ -$?]KC/Z<.F-W15
M/?%7]3^YK']_'ZZ?^WU8J?\ +TSH!U-K7!=VQ_OQ_7*M^J <(@^G(W.VN%9+
M^$[?]O7KP_\ ]B-BXT#;;P XR XQ5!_;KZYP?ZK8O#X?R;1PH"'0,(QE+-)_
M1[T?_CJ_]'])3^F_IG?T51/\\?\ <_NJW_?E^LB>V]3_ /X7N_\ IL5X]K_B
M _K0EM/4SK_ )&;_ .23J+^(&Q_MS]21_GZQEB3G?Y0FT_\ R#WY.,*H?^XY
M^I>0/6L.J2/:9" >U$/D?DI3^CWH[?IU?^G^CFS=7Z;>F<K=$T9]=7]4/[?_
M /P0/]9C_P!3U!W[#_\ B>5-O_B ?KD@?4F'_I^GU'_LRJ_B)_[CMMQ_\> M
M$-?]I#,@X.!:DXO?_N@X"2X&_P"WKUCS_P"Q6Q=,/#8>X1>*1?(G-P6O_#[H
M[=IM??-$?]KC5^G#IJ__ ,JP_P#5_4_N&/\ B _KU&=N75_F]/$;VUS[3_B#
M_K[W?Q^H_P#I_I\(_P#<[S1?P^']O_K2X?ZK85!!::I1SAWAG%*/[>_7&!]5
MZ=SB7O;+L'PQ#@Z4G%T=Q^CWH[?IE?\ -3_2Y3^G#IO=T7A^%7]3^XS'_$'_
M %Y_^6S]2R]\MMZ8N<(_]_"*NU_Q OUR/_Q1_P"_^GYN;PZ.R7\-MG_;]ZK_
M +O6>G9:=,>\C !Q@NK9?V\[<_[O7[%G_P!M9()$8N][GJ3^C[HW_&XD=]/]
M+M1^FWIJ?_RO#_U?U/[;G_B"_KU&?4$?_=?3P?\ ^]RXN='!0VO_ !!_P/N'
MMV6T(#)GZC8 DN@  \.Q,,L5_%YC^W%NOY/9AS-&0_@6W\."=C^W-H__ #S9
M_P#?&2-1_F)T]KYK'Z@]&?XS$W\Y4NG_ (S]-S;_ /QF%X_^Z7]E&?\ B*_@
M?\O_ &&V[(#@R?\ 4^G(.YDEP?4P>N?_ ."+?@_^[T^T)<8,^IV)<280=(AT
M2^,GB*_C7M?[>6W/9_);-Y$ ULVA(NBYHN$ZN,UQC^WW;?\ R?L3BX-#+&0J
M'"JZ1Z ]&?XO$_F_"'GQ/TU=/1_^687Q_P"Y_9-O_B/?AA[G^B;: $'>LV(:
MP _R9#+\GO? 37BO6_\ $F_&^YC_ $_XUEK9EQ:;VWKV&6F8N(_C8V9$I'WN
M!@0%_(%K^WKU <[UNP<,?<,)Q,SP="81']O6W_[O6^F<'AP][Q+P^1,EN/0#
MHK*9TFN>J:YS[;6[?)Q_\:NG]GV;1'93^,]C^S_IO^(C^$)(:].TRR&?_DO8
MD^[0@!V!>30JVT_XB7X%D.&Q;-/_ (JV-<@#PCN7\86?[>]I$M?D&"\@P9:(
M >Z'^0A.4AFK;/\ MZ,SZ_9@M5++1!=C_E@.RYU>@/1G^+Q/'\'IC],_3UO_
M );A]\6^;^Q#?_$;_" $,[!Y<?;[O5L $@N +F##%T5)O_B0_A !_P"PI::J
M1ZICVOQBR_+HOY!,_P!O;)$?R#)T89.L"U+*"FW_ &\U_P"8;.#X>T2DZ#0C
M=5(] ^B_\5B3WRS/Z8_2#_Z;A>7UYX/Z];3_ (D7X</]OHR3_P#?;(TA['RB
MN _\2K\3%_H63_E_\E/A26SF<GA?R-']OY?[3ZUF9 :_C<# '_$^XCVO@'@1
M!5#_ &]-%X'Y#9 O!!:!@?\ W@F!P H^JZ4^@?1._2<3^:KY0XU?IC](KY:!
MAQU:L?7X/ZR[7_B7_BJ>@!),/_8DN,0'?^7/I!ZZF?\ B4_B2(^A#YN'JH.R
M/\<Y<]%_)G9_V\LO(VGY$39 _P /]T'ES))(TXS78Q_;YZ=W_P!<C[GQ(9)#
M@8.B*3US4J]!^B(_WC%[=:O9X-T?I;]))S]AP8[:8CY_F_JO_P#!+/Q+@_T+
MH1_]B7C3_P N+\EQC_B7_BR/_B)@.,?_ &):D8"'\0(WUWK^7(_MZ],\/_)F
M!_V_QLE^!GF9]$[']O7IG_\ UR;,9>P  1<"L_J3T1_'Q9_S5?1N?TL^DG^"
MP(CLH^K^GFT_XEWX]S7M]!L3_P"A_P"Q.T@<6O\ ![GR=.BXV_\ B9^A'M=^
M/V+PX>[^;:D U=_@ XA[L#!?S2VG]OOIH ?DFH3?LA7_ -&F6BE_[C_Z>#_R
M+<'?^R0)OC-QE5;CT,Z'_C8O\U;-7Z5O2;=H>#'^6BWQ?TN;_P")KZ$/=^-V
M1?'_ ,_:FO\ [:Y^D%)C_B:^E)('X_8-!\ =IM@ ,R1'4#)?S2']!/3,Q_YC
MM8![QL1HYTR8Q<]3:_H?Z,P'Y';>\BNQ@7%Q#B'2SA%P5_4SH>/]KBW_ .;$
MNQ'Z5?2>?]TP?Y*/J_IPS_Q,O1L@^_\ '[ &8=MMK,R#O:<>,D[/_$R]#7T/
MIWESO_8C:N>Z,V8#5?S'_P#4-Z61_([1Y:$MB(?^B-9EU>"K_P"H7T=?7[=H
M9;)A]!A@Z6KJK/ZE]#_QL7NFMNG]*OI-_A,'^6CZ\]C^E&V_XF?HZ>C])@/^
MMMM?_1&\P4C_ ,37TG_R'Z2$S[]N1#_WD::K^<A_H1Z&(:];ZAX= L,5DX>W
MN."/_J']$(?ZKU!='_8Q&,+T5I]#>A_XN+;MK^BU?I1])]VBX$=M-#^B37_$
MY]+3T7I3A_EZASL9?*XVO^)YL0]WH/3-9,_SM0F'1$<,U_/C_P!17H'?_%7J
MHT_C8Y0> <#Q2,_T*]"/_CGU3\?;LQ.4?L$PK#?ZG]"_Q,7^;$W.4_I.]*9V
M:/@1UZN&_?W_ ,% V;X?C_3&$BSMW\/<Z&#YJC'_ !/]F7__  O],YQ_[/4
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MKUT';/TXC$GTK+MQ+8B1CN7Y%_\ 5A^.B_TWJ6H'_([=Y[1I$$NH$1_3+\;
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MK?VCA_X?![HCYRX1AZ=OTW&MUTZO_?.3^<G_ (<_<"?]WY-IE\1_I]NR /\
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M<OPS+PW^:_&SI^$;#\HCXH4^T=)MMM_E_!UHHP9G*G%S]V<7NVX/S?F[T?\
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M &CT?MB8+])_B?[7/PNR]W^LV_Y?\M[_ &AK9>I_([7TWHR&67#_ -@/QO\
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M7\MM/RG[%M_]S37YK\EZG;[$M3>/2[-K9^G#,9#9NHY?C#\=_=CZ_P!,&_\
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MW;-G_5-[:G\9(8_[L#OU7^Y+]N]?MMKL]C^E_CO0>FV'I#ZQOUOK_P CM_\
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M&_)>IV_Y#U7YWU?Y/;L;5K:>WW[7;?DMB7;39>H)>RU_*V"3%E[,OJ;/]?\
M]MVVW;]'Z7]-_%L_Z?9->H]5^2]7^3VVQ_',>F8]P_U+&T;V8#;+99(V>S9;
M+9#B8%ZY:7Z5:#@5U8>/B^KKHIIJJIJIKRBK*+3%-JKS&5--ZIX.F#T3CXD1
M5AT7B9F(G6IB8MMO%[Q;KL\[^F?TO_9?U[TVP_'_ (;UWX#\KZ+T3'\/I]EZ
MWT;?HO5M[%@DLL-^IV#V6MHZ'O:9(+@25[EL/[C?4>A:_B_;/U_\A^% A_K=
M@S_S'\88N_\ BCTP+>R9,_\ J;, "HBOAWX[^Y7]I]7M?4;+T_Z9^/\ 3[#T
M>P;V_J?R?K/R6VV?H"PRR6F6O3M-,,?R_P I!9#(:>Q F!!/A?2_W#_M/K&O
M5LG](_'>D]%Z+8,[7U?J_P C^0VC/I=K_('[-CTQVNSV;&W:VH>X,%OV%WO$
M5R_6[H^-;_XBF]$TTS>FJ\55?LTQ:,ZI]VTU1&V(=9Z%TG;.%MO-]:F,HVSM
MM$=N7!^^?U?^I'H/R##.V_'^O]+ZS9.>3Z?;,MNA!EID'W,O-&@'57;^<_J+
M^/\ 0L_S?D?R7I/1[,O _FV[&S+9P9!:!:S #1*_CS^P_J/[#^1]3Z[\QZ/]
M8VGZ</Q^S_U#/Y#T/Y/9?CV/7?R1V0],RR QZ]K;?]K38]C#O:TP"5T_TK_J
M%^U[+:>L]?\ E?U/T?[#L/Q09_U/Y#\AL=GZ+\EL"TU_T]CL=MZA@>F]7MB"
M"R-BP/<2]X>%='],.C\76U-)P[45QAU3.R*YM&I?9->>=.VG]ZVQFOH72*;?
MV<YQK6O&SMO;QM?<_>G[1^7_ %[\PV=KZ3]4_)_EO5LDEG\E^&_'>K_&;5\V
M2/RFQ/H#M(N/N:VFT9'^XAR^2L?A/WO8?EO0>H_5/2>OV7X-EEWK_P ?^Y_E
MOQ_J6(- _P#L-ZWTW\GK]D[9O99&U.W]S1BS I?R']X^S].SLV/5^BVWX'U+
M@6O3?L'IO6^B8, ?;LO5;'9;3TQ$?\6X,NG!R?T_]W?Y-MC:>I_'_AOP/YGT
MK&UV>R9V?XS]AV?J?6;9K:,DAVS&S'\99#)_Q;#R\>V*^EBZ?@Q1ZR<28PXF
M)]9A1>F<[;:8JIGA/GQ>6C1\36U=7/.-2O\ &W<_9O\ 3;^JC/Y-K\I^/]1Z
M=K\;^:_!>I8])^6]!M6V=K_&=KL_Y?3^H]-M67#;^C]5LWM;#:AEF(++3++0
M<O<?S/X#TGJ';3U/HO3>H:$/=M]AL]H1!SGMLDN/!?SC_5_ZR_G-IZ[\M^Z[
M+] 'I#M?3^B_#^I9V_K]ILO6>M9](UM-KLV-EL6MCLO?M0=M[?<66W!C_%IS
MU[=ZC^Z[]A'IS^5:_0OX?QAVS6P]/_/^5]GK?6[5E_\ (QZ3TQV3+9&S:9]I
M;:9]K7_83-?,PO3+HVN9IC2L.JJ,2<.T7F]?"+1G-LYM>(S[O77T)I,9^JF(
MM$[:<MV>?'9&W9D_3_YS^B7X3U/^6T_$^EV.T$?Y?2,GT>W9+PYIG:^G.S((
MGJO3]I_2O\GZ%[?Z[^U^OV.S#BSZ+\PRS^4]*0]X8&TVGM]3LP1 D;0D!?G7
MU?\ =Y^?9]/L?R.V_I]M-GZ?U)VG^F]&?R3/_,VV-E/:M>F&S+>S!(+++'\;
M39+F@'$/];V_]R7[?Z_T3'Y'TOZJ?P'H-LWM!L@SM-CM?RNUV; AM/?^2V88
M].Q!H/\ ],&RT\@N<O31Z2:'7%,T8NO%=<T4ZL53K54S:8B-7.(F)O.SK<J^
MC-(HO%=&K:,]:JG*)SC;.5[OU9ZG^L7YS\6Q_)^P_K8]9Z79A^T_)_@_4L;3
M9^T?^S&O2>I.SVC$ 26&6VC1D%>D_EOZV?H?["Q_'^7VWH6O5L.#!]=L6_Q_
MY3T[1E_I_5'^'U&R;!@#L=M.3POQPQ_4_P!.TVSZG]S]3L]O_D6MGZ#UO[*U
MZ[U9;?\ ^8?2>BV>TV6SR9V>S9;$@Y>]L_UG_ [7V^A]/^@>I_*[7;;(M[#9
M;+\,VTWMME_Z;&U]<RQM=HR[_O C,.7OJT_"B)G$KIHBTS_:3%%HB,Y^]E:.
M.41U/-3HV).5-%4YQ%Z<XO.Z\7S?1_SWJOSOH6_Q>R_IK^7_ &/\SZ9KU^P8
M]3Z#]@V'I?7?B-A^/;:?M6V/R^V:'Y!HAF&R99:VI#)>6G@/_HQL_4O99_D'
MM;]C):9!@&O:"T!5S+3P#@,5_#O^J7KOSNS#&S_I]^G_ )_];_.AKTWK'^G]
M<SM-@SZ4M_Y#U7X[9;7:AEEM_M(:99]HP7Z0_%?W@_E_QH9_7_VG]<V3?[9L
M/Q;'KF=AZ7\BP=E^0989!VGM;#&T_@]2'^[:[ AH@F$"O)@=/:'55ZNC2<*N
MN</UM-%-<53ZN/WXM55]VV_*)VQO=Z^C,>*=:<.8C6U)W?>F=^=OIO?TD_-_
MCMAZG9M;#U7I]EZG8-CVM;+;L,[39MAU66@074A%? ?SO]O/X/:D[38>@'XS
MU'_;ZG\5M=IZ#;,-&K]@TRP2)@- @N7Q'\Q_=!^P>E]-Z?U7J_T'U#+?K=AL
MMOZ?8>D]>-OM]DQM2R&1ZK8G9#:,--EH,#VLUF'0_/O]0/Z[_NNPVA9_(_BO
MS/I/YQLMLS^-_!;3\4-OZ5G;EK^#T_JMML?1^M]1LVVGLLEHM LD@MM B'BP
M_3#HZN:=32L.O6BJJ)IJME1E55>;?=B<M;9UN_V+I49>KJC=:\9SPBTS?)^K
M?ROX[]B_ LM>I_'_ )[TGYC\9L&26O3?L.TV?H]NRP/^W9_DQ[-D2!([9F-2
M5Q?J7]['XW;%O8_E/3^J_$^IV9_C]WJ&2U^/V[8_^1_R6S9:]+M&6C!ELML@
MSS7Y*]?_ %!]3Z$[#:_L'],_RGY[\LUL=AZAG_F/YO:_FMIZ;^:&QV6U].T-
MOLMFV\?[MGZ=EAEX_P A,?5OV?\ N _);'TS/HO7_P!+&_4G;,;!D?C_ $6V
M]+M]EZ?^=EVSV/JF1L7;%IY#+33O8R?]Q"]%/I/H56K;2,.K7IFNFUYF:?>R
MC]GKF)B;Y<'*KHG'C;A51:=6<Z8M,[MLQ,^'<_57HOWW\_\ D3[_ ,-L/P'X
MWT#3BQZ[UOKF_P IMMHP3!K9^E]#[-DR\1<WZDQ<\47GV?Z>?DMM_E^1_=OR
MY+30:_B_%>D_'_C=DP?_ $&6VMCZG;EE\_?M7EV*_FK^5]#^:]-MFMI^M_K7
MY']4_(D,;1MCT7YO8;7\0T6P&OX]MZ3;LM;%II@$C:?QL[-EX++!JO<?RO\
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M.U]2'Y+8O!_GV4C-L87))_S38P:&WV1%"&PXC*CLU\P/X(?^[,O]SS=.J _
M"'_5=A_D'.HM1B3P+1UOIW_,-E_[N8 +O^X;^3\G*S7Y#9?^[MG'_P!K9A1?
M*S^"9$]L/_?G_:5G\1L__=P,YM1Z[U/63PA9ICK?51^1V4';;9_^_A(?R.RF
M=MLW R]XX[L%\N/XE@?^SA&GN2#\3L__ '>/_?MW'DGK)X<]IJ_@^IG\EL8
M;;9P'_I"3ZX)V?R6QB[;,;FPX$<(A?*O^4;/_P"2!&GOWV%O^5;(?_' &/\
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M3<(:%'V])U TO1!5\X"EYK2R''3AP4GNC/ZKVY+-9O?0/@'Y].:!_<)PB:G
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MCX3W.^'=;0N'= A^IL[\^J!BW=X\ Y(6L0Z\,$6:OP<"(1\Y51 S+N-Q>@4
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MCP<)I@27X"%Z7B@SX^,76X(/D+^:I'.B(:\_*S(?6!>[R@J6_B7.\5O<(_\
M;=Z(,Z\J) T)$A_7'Y05#+Y.NZK%AV)^)W\A!G9ND88'YO5%HG&$CC8S0 M0
M@"=+'!*,7:O^,549Q?<,,:)2,[^D :Q&!S\)!*!C< #\)@,\9>/*Q  >[[[(
M&PZ+ WBZ^25T(>':7DL!0"><ZWX04WQE!*TS&O'XE1 'C 64X&)?#<$$V1EN
MO%%$M4["\4$6S^!K/IMH ?<T2!/_ "HY\'F(KCPC#;;+:@CVM DLO(>X.G,Q
MPQXEZ_FRW_=&T6&0S^0]0"TTR([0X@ESW$?X@P]PG +CVG]UK?N# ]?M_P#
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MR?\ _<J]J2RS_J_40]S1=MGN@ !BX/GEA%#U/]TFU/\ \=;< F)_G.XN+AA
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M3GX2S'I1ITQ?V2KQCYQ\G]FV=@Q_BR6V62ZI=#>2<'5/!8[-@^T!M@O>94$
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M?Y;4,P <##.#I2=5?Q&V/]=MM[0]MY(]P#VG$M$DG_<,IQ.2VU_KQMRVR#M
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MOM2S[3M6R TR[_)P'^3)D]YB)D.#L2K]E4^_.WJ=*,33LKTQ&V9SJ?W?V_\
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M,3,S$7O.7#*+3$1\W/3M!J]=B6JHHB:IJSPXQ*[S:9F:ZJHG;NW1D_MOZO\
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M_<Y^0]?LO1^K;_&-^IVNR9_@.TV?MVS30V;3]FWM -K_ ),#_P ML?[O;[2
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MM@6F2RTTP/Y-KM&R8EHD3 HPXM5> O@?Y+\XWM-F6?YO5/:9(9][7O9?[?\
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MK8!+O_C7TQF8^[VG"$CBY)_X]VE/7;(!\_\ 1[($5'^UDQ.^49KT)C\,(?\
M4V++W_\ <'@$'W'_ ,M[\BZ 72/U]N!9]1L(N,R" ZKF*0)$,7KU>U3QI[8R
M^;P^S8.RU6S]Z+_]O:]P_P#'GJ"(>OV0G/T\ =VR>XC>\.@(K;/^H'K 2/\
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MU/X1IG8;1MG\=Z7\!M_S/K]AZ[:N:]0UL/5CV;/:_CO6;1G^7TSMKMF@SM'
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M&CZ/3$41ATQ&)BTVIOLB)JRHIRM$;]EDJTR*[^LQ,7.;S/W9SXY3M[K/QO\
MFOZK[/TGI?5;']8:_J#^-_/#9$>@VNW_ '7T^R]/L=JR?\=IZCTW^NVO_28
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MK:?V7-_A_3;?\?ZT>H_8_P !MB?R3+7XS8G8?D/QOY9AEVT;])L6FR[8>O9
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MV/XKU/J]ML?3M>B_),;+;,[#U>QV^P9;V>WV&S9VA_BVA8;]K>SV?^#.U>(
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M'I=I^-]1^*_#[#\;Z/TO\G^KV/XX^H.S_*^G'_Q3Z3UP]W\;7NV0;;V1()?
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M^I#6RVWX_P##^FV>S9&R9'K-EZG\@TRRT/\ !CW-C9;/W>T_XN>][I%?BO\
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MHO\ A#>K9]5_K&_V'\+ZQI@[0^CV_J_0;?:;;T>TVI]VT;&R=_%M6_<0YK:
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M&2]>VO\ P>?RK6Q];[O6?K&S_(>I# VGJF=GM6MEZAAAS(V8V/\ IP/3,!D
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MQR"[_3_U^],V[^/TK99/_<6_:.) H_0SJOSM_P"X\>NFSM=F\.):.U:9D7N
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M^O;7][7I7N_\._DSFQZS\>T_$?\ F#43?)(?[V?1P?\ KOY9\G?ZC\<2=/\
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M%7O7=L_[]VQ_^<_[%,._]CVP'$0_R:8.XNR5_6G#M_<8WA1_4OM-''SCZO\
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M +3 WY378Q_7W]<+@/V?\.]W_P EL,ATID 7!6-+POXF'_/3]2\/L3HO O1
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M#0>X@Q$'A[I$Q=29>]?HC_ENQ(:/L9#P1+%Q#Q!X$<@8BBEM?Q.Q+G,BCO\
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M7^+7N!>1#_NP>Z9C""_0?^AV5-F(N=_B7N<?\9.CF8XKKV?IMFX?])EP$?\
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M'^3(!!K!YC =XT7Z2:]"\LOV8(9)>]T80+J"+X5&(<H;7T0(@P ?<(%W_;'
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M)X01@51OWWV0_.&W_5]L62?XVJ5=@Z !SB^!P"\VQ^M[5W^PA\B_*)$'BDW
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M[08!G9[ $!U-.A@G']*=E4^H)H1L-C X#_+#B5]@9V?I"\NV (+B1LZG*I&
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M]/Z=T/\ WH/ ZOBF'ZXQ%QV@P_\ 8?TT7"G^3WBI!(7WYG^D?Y6('ZO^<<R
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M;9V#8F0VPPT"!#_(%F0IJ N?TGKM@R6FMAL_3[-J31V.RV;#347_ .1899>
M<20L5XMXM;:U&#$/RB?[<OSK!_Z.U]*Q-I_X_P#9OROIW.PV7K-CZG9?^\N(
M*XMI_1;\Z TQZEGU'K-B''^'U&T_#_E-D_!YV/H]K$0]Q>8O(7[.V'Y\1/OH
MXN>]Q+HY O!0/YQESB61[0^<W!T3CI@O/5$99=G=FZVA_(#^M7]B9]7L_P Q
M^4_#^G];^L_DO7^DV.Q]6?4-,[7\?ZAG8-EMC_3L['U#3?HVB\AAGV_Z4->W
MW,,A?%?[:_ZK,_B1^8_2/Q/ZQM?SG['Z7;>GV/\ S'_6?Z':;#T#)9V?JMC^
M6]3MPTSZ;;,[0M[3TNV9]QVFT(!9]C(7]V/6_D=FTRTRT!M V"R=F6?<PT&X
M%EH-0+)!_P F5^6/R']*O3_CMM^<_.?JGX[\5M/RWY8>B'Y'T/Y9@-^@_(L_
MCV]JWL=F=NX[3TNT8.V:]C8+7O\ ;LV-H7,@C,4[_&/@M]VV.M^-_P Q_4#U
M.Q>/7_\ C?\ 5S$':_D?P?X_]M_"O9/^YKUWX[9[;:C9.(>TTTP?;-Q7I^R_
M<_S/J7M?@?RO],?V]Y?_ *7W>H_ ?EF@9,-^FVVW@V7_ .TAD/D*KTW]H/[+
M^':VS?KV_P EZ<-M[1MG:->G]1Z;9;(-MEL;)C\C^)VGJ/1[39,>[V[-OU&Q
M>&7>X37R_P!1_50^H?\ \S])^-_)$,D--_F_PWHOR[):</\ R_ROX;_3?E-B
M0)':>E::99_R)!"93M^7G?Y2Q%^[NF/E/F^W_G/ZN_E_QX+7Y_\ I;^0](S[
M7;;U'XOUOJMKZ0N,"-KL3M6/868^XD.,&EZ[L/[@OUK;;1AKU/HOSWH=LTR0
M=I_S;U#!V)A[MF-DUM V 2', ,.+GLN#RO3_ -3_ *R?Z:'H?1_G?2;)@N:/
MZC^T'\SZ-@%D/_F_ ?G&&_5;%C_VC^$!E[GP7WOT'[1^._+_ ,>P]5M/U?\
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M(>-IZK:^G],"7.<TRTT6F1D ]ZU>8M>8\F+Q.Z?@^Z_C?ZP?C1[6=L&?3M-
M ,[?W;$ODX#:LLS.KWKZ/^,_>O0;:.S:#0@"=FTQM'$P<Y@DF,W#BOPA^9_J
M!L -JSM_ROXID$>WVL,M^L:V9:>20S[?XP1)T9!R]4_6/ZF?B?2;5GU!]3ZC
M\CZK9;39;7TP9]$WZ0?R;)L->UIOT[+#36S;(<0T(!X!B58Q(V>=_P &J8GA
M+^K#?X1AH/\ :/\ (/?(F#WN$H:..:]+_.?HNRVSPTRRV&GC?!\PE_IU_5C;
M?F]GM?R7K/2;/T3>VVS]CZ?9L-LL?P,,!D%K^0^]IILO:]S0!<X.A'W?UWY[
MT^Q]HV_J-EL6FO<60VVR/<X1#++_ '$ $$N$'Q(>%9F.V%?EO\Y_;WZ;:EL#
M9'VMO]S!<6(S>PU[F8X.<ZB^-?D/[6-GL6SM_P 7M/5?B_4 O_G_ !GJ-IZ$
MOQ;V>S_]A]KB[:;$OQ7[O]1^Y>A9!+>W#1," "7ZDN#AN"^=_F_ZU_A_3O\
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MW9'1>D_@/0_QL@4=*(#J$>%YS\O^V>F]'L6_4>KV[&RV6S9>6FFI 0B#B?\
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MRQ!D$")BOGWZS^P>GV!]VR]*VPTTT_\ FVC9_)[0' ;3;_P>I$/^[W;;:?\
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M:+)#0+;(@TYEX!H#3S%*?TW82#;FV0X-$,O+Y@1EB*KVQO\ 7_3ES0&V#O\
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MO1>__P 6S_\ =.SBZ;+/B&J0;/9R&SV3H_\ 8R\$;MV[5(P36ZGH@_$^F_\
M=XWEET+W(G\7Z;_W:_+W,\A87OOMV<3_ !;)P_\ :&>)A\+?Q[/_ -U;,?\
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M1?V5&T& WOO1;^81)A#*F "Q/1&C?PH_FK_J7U-'NQX/XN;3_@Q?AH>S]O\
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MXG8?]WIO3-$C_NV&Q)XEB6JS/HE1NKCOH_\ <L:-.^N9[H?Y#F?[AOSS /\
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M1!C)T<4^TZX_?EF.BZ/<I?3=E_4 _P 9:?LQM_?[?XRRU_'_ !^W_=_)_O\
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MOV[;M^UM[+(@"TU[GDB#WS$YM"(3U;7K.>=C]Y-?U)V1/N8VON( ]S(::))
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MG#_M+)F_W&.,PY2:A]]_*?NH:]VS<0Q+_(,EEIDP<T"7<E^;/Z@_HGX/U_\
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M&[;=F;V\<OAS^+\F>K_2?V+U(+.W_&[7;%DAEO9;7TFR]^T9][R6-N63_%[
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MH_#%ELC\MZ4M;+9-[9O8M-D>H.S8#VFMGL2R&]K@/X_<2T0R "OS-ZO^X_\
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MP1%?4/T+^G_[RW_%M/RW['Z7T#'^X[/U+'I_6^H!:<]EMEAAIF$0/\P6071
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MD6-J(>UH[-IG: ,DN#V3"9>&9D P7,U^D_LWH?:-G^6VS;(!:+&TVHVNR)<
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M<X/)G(R&D LS6L4[WU3_ )QG_B 2:%V>IX+?\\<Z(>7>XS<^A(\+Y2U^9_\
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M^91 >!B_7'+FO0S^6EB67@2W"$5PG\B7D>YQ(C"(9E"/59FL?26_S #@6O\
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M\0.H_P G0%(!^;I)&/T5D/'\8><0]V9D_,=5OVZKCYL_9]/#R?QT:_M,]/\
MX^ST;@"2\LAY(K <81 #B7*K/]K?IW$'TH,9>UDQQ>X;W";C-?V%VOZ"RXL^
MT9@ %^L.$DFS_060XC9&'_M(PN3PI.F3Q\U]@IX1SVOX_M_VJ>G:>[TS$7./
MM$Q.#GAU3!]0%S?^XE;"!/IV( O'LB\&8#BY[E_8?_P S%KV!D&#G1)$#F\<
MU!O]!9!#F'AH1>'N+_\ <'8U3VRJ+9^=V?LZGAY/X^,_VI>G!</2OE/9C_YE
MP$3![Z!4VO\ :=Z=DLD^G9#B2_V >U]2YXK, O(BO[",_H; ]W^#B=T3KUX)
M6/T-AP'L!/N=$/>*B(EU<GMM7'GGJ7[.HX?!_( ?VJ[$ G_3L!F  ]K(+4)N
M<0'G=O3#^UO8$>UOT[$I>P_]KW/+IF2_KV?T)AS0#'M=&#-!"E'RDI#]!8@0
MP<W,3@XSH1Y3VVKBOL%/"_A#^0&T_M9V+PR/3,@4<Q*3W$X8& ? %R0_VK;
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MJI&FU<6?L^F-D1X/XW-?VK;)[CZ9B$H3_P#;<S'&KE79?VN[( .].'-%Y9+
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M^-'_ +B]LWN&P=B"Q![L@YXB(.PBNAG^V#90?Z<%\?\ :"_7#)[G3FO[&_\
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MIVS)<'D /=N $X:33'^C9#G,DR+C!SZN=.(AE%?U'_\ 5XQ'_I@M4/M>,7&
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MG9%XP9G#D^C]7+JV/],6RXECVB+P6?:<'3)#Q6+YO7]%S_3EF+]G[0YTG1?
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M(_QQS!R PGP4LT^/?\K:BYD,FDX@NX.\I!^,(?$^Z3())#((+Y1PRI)?:O\
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M09!?6_TO^JVQ_'AD_EMM^\?J^W88+#7\3/J?R'H&=ILV1_&TUM/?Z@_Q--P
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MQM0WZEH-M>YD,^[9EEEY#P2"5^O?4_U(_26&?_8G\C^*]0V\%MIC8EMEX/\
MC[&F6!%EG_%H";3WDKX[^?\ ZO?HS#.V/IO5^N8VK.T+3(]&?8-J0T/;[?Y=
MJPP\#_;[W.>]ZSJ<_3X,VWYOC^S_ !3319V7J/1M[-K:;7:>EV.T:]4UZAG:
M^J8]WLV +099V;6V89]VS.T889!/M:]I!7B6_P!7:]SF=CZYDO:!V>SV7^7O
MV8#6T9]C/^1.S_VM>T-!X+BT(GY5^Z?UD]:=OZC8_@OPVV_(^DVVW#6W:_)_
MDO0^GVAVWN::8)8V>T]066F-E[3_ "-%AH_Y29<%]3_0/WG\_P"KV;!9_5]B
MT/3;9C_+T_Y;8;3:;-OU>S9&S8?L_:V[:,LLML0<7DR:6)GO9B<^?+N^#VS]
M?V/I]CZCTOH?4^H;V'K?5[%OU7I_2^K9VFQVNW]/LP?Y-KLV=H 6F6#_ +W'
M_&+P'+[]^/\ 2,%AEK9-,[1AIS0VC!#3#3)D6&@2&AF"0>*_&W[M^'_(?E_S
MC?KV&6MA^4_7?P_K?Q/J?Q/N+9]+M/R'IMJ6=KM/5.)8;VG\[#7L+#7OV0+6
MSFORU^D?UT_)_I[7I?U+\KM_]#LVF-ML-EZ_\AL]IZST6S]0QZ8[;8^H],8-
M?Z9O; [+:LMM L-D%I@ +=.5NO?]&XWOZ5?I?]:F/UO_ )UZ;U_HQZOUGK?R
MWJ/5,G9---;9GT^T889V#&TV9<R&@RR]CVP(,'S7S;\W_<Z?5^MV89])^2_'
M,;4LL?ZC:>B:'IF=FSM#M/>WM7MP9:9]S_;%H#)3_4/V78_FO1>A_/\ Y;T7
MX)O_ %>PV'LVC]AMMIM-JVRVSLRW_/M=D=CZ38>UIL[;:@M--'V;%[ 7R3]Q
M_N3_ !?H=G^4V/HOU?8;;_EFT;]'Z+U+>SV+ ]=MV/\ )ML_P;1IK^!LP8:8
M8++8:9)#/M)*^V/SF_=W<PE4=3[GZ'\QL?7EL[+\KM?4-;3:LL,O]060TWM/
M:VX[,MLM2)?_ (N9< ]Y7E#^E;'WNV89&S;9;_B]0VR26O4L[0;,>G::BYMI
MGW'W@EG_  #,S#^6/YW^Z#\LS_'Z=C]8]'Z[;[%ID[?U^SV6VV;.U89:_D]O
MIF0RRSLMHP&AL?\ 4 M,MA@$;,$O2?CO[L_SVSVCV/PFR])Z/W^_9>G:_)M[
M-K9->T/]QVVU+#3;WM/:V+(!,BZ,FF>S/K8M.[Y/ZN;'^ENUVC'\S 8;99:V
MC#6S&V9+;]F&6RR&202?8T"RRR][/^V*]S]'^A;7T&Q:]=ZEC9['TFR_B:VN
MU:;8_C8&T(#'\A?!EY#):,&6H-57X _3_P"_+;;!DL_DMAZ=C9D>UH^H_(_B
M]L&7L^P-;/V-[-OWD0>'M$B3@O?_ -Z_N[]-^S>BV/ZA^._+^D])Z[\AZCTX
M8V+$=OZE@-,AOTK)V)_Q9:;#).T:_P!K4<%K5M'-_!NF_#MW_!_0'T.W_P 6
M2'%EH/9((:#H2(>'&A7PC^X3]1]1^3]/^/\ 2>CVY],RQZ\>H]3M0R=H2SL6
M2=FR=F/\=H2V066&_P# EF+Y+^<G[/\ H/[Y^K>N_P"<_C/S/K_4^AVOHO4-
M;3TGKO5M>K]"UZK9PV'I2/6-[;VC^-GW,M/V30;;+'N+(A]T_LA_O,_(_E/S
MFPVG[@?Q^R_'#TVVV0&Q]'M-CZ;T>W_C/^?J-HV&AM-I_-L3LMF67AG^7VU>
MGS\NIJSY%^U_VT>D]1MBU^1]'^S?D&=KMF&O5'8^C.QV&V<U_GM&@]D%IH_Y
MM,[-EQ<X"*_4O]+O[?/U#TH9VNQ_%['9>K;VS(:VGY#TQ9VW\7L;9;_^*066
M&F6OXRPX%EH$LE?T0_:/[D/U79,G:;7\IZ3;,;0,>[9;'TNT::V;0DT63LV2
M/:S-F#R"'A?%OS7]U/Z8QLR&]ML_4,C:,?\ 1'IO3[(G9'W?R;1@[9M@/<YS
M+;0(=#$W5W;>_9SV,S$SQ>M^@_3=BRS_ *?8^IV3+VQL]AM&-FR=@Y@N;ALG
M.)9=[8>UF)!<%XYK^G39VOI]FTWL_P#K%L;5IEEI^S!:=L&V!_WAL.&TD=FU
M_P"D(KTG\U_>/^CMG:-G\:6&]D=HSLOX/7^B]-[F7,^S:M'9[=OV%X=[0]ID
M%[B]?D;\K_=AZP^I;]1^"_)_A?0^BV?J=HQL6/6?DO4^JVNSV>T=_%LFRQL0
MQ &+8]S+0F0L33GS\F=68_')^]?3_P!,MN0-H[9,AD?]8-[0^[9-,[1K9-,N
M<7AEP+30=_BT#(KU'UW[I^-_'>N_)_AOR7K-GZ7U?X;\9L?S/Y [1EH;'T_X
MW;;7^#9^I;VX_P 0S[W/$V62"0Z7J_\ 27]]_:/7;'U'KF/R/ZWM=FSMO5;+
M:M#;-?\ 5;V&Q:V^W&S&T8]VT 88_P 6@/:T?;[2OEWY_P#H_P"I_:&/S?[7
MZ/US3.W_ &+\1Z;\#ZG^,LG8M^D_&>LV?J&!LO3@>\-?R;-IEL%HL[0-19_Q
M]IFK:?PW;IW<W;C?SP^7R?N?\8WLMML&/4>FVVRV^RV^Q]^QVVS:#>SVC#;'
M^#3+0@XO#B^2^8?JO]3/6_@OQ3'X/:_CFOR&TV.T]6TSZC8ML[,L?S>I;V^S
M:;8:V@9:;V7N#(:DT&06E_+7:_U,_>?P!_+_ (EC];_8?4;39>IV7J?P>W_&
M>F:]1^-:#/JFVMML?4.9+]CM-@TR/X66-FT"PTRTY[U](_!_U_\ VK:;7;;7
MU_X#\AZ0^I9]0T6_3?A]J&-G[MJPWZ?8,;-GTYVGI_8RRW[MH_;M;3:M,?R>
MW8LE76B_5VY;NKZ%5.5_#P?H7\__ %D]5ZC;[3_FWXG\SLO2;9IEGU'J=EZ?
M9^H#;() :VC.P][F666B?<2'X1>O$?EOS/X@[)C_ $37I?\ 5[<C:,[3UG_3
M:V&SV;1'MVC'J&?\=L=BPRS[ "62T#)R^&_U)_K[^U[#TNT]%^%])MMEL/5;
M7:L^H;:]#MQZX$[,-->I:]5ZEAC8G8[?:;3V[/T[#'_3_C:'^(BOQ=^3_J%^
MTLDM[?:G9;,,@?P>KVOIV]BPVYP:=M6=OM"]IQ;8_P!I=[7@16:9B><\LH\_
M@S:=MMGS?V2_"?@]GMMMZMGTOKQL?3^D&S#.U]1Z78;4;5K_ $[.WVC.R_B+
M&T]FS#0BXO>  ]?0OPWZ5ZO:DC8;7\;M&MFRRTV-HSZKT[0]S ;'MAM&6O<R
M68AX9)C@OX<_K?\ 7;\UZ1O9[3;_ )#\$&]F0T&F?]7Z?:A[V&@/]#L6 \LO
M$B&ABOTK^B?WY[?TVU&T]1^4V)_C88/LV>U]9MMG[-D2  /5>A9<6@\$!LDO
MT6M3S\O&W?D1$VYYR?U$_<?7;;\ QL/4?G=AL=CZ/;-C9#U'I_5L[5D;4LAM
MG9G9-;/9[0-$?[7N9)@^2\G_ $U_K#^&_.,^H:_ ?E_1_DSZ3:G8^JV?I]J#
MM=AM0 ]G:;,N;9=+W>WVEQ<U!?D_]0_K_P"G_J-ZC9_@OYMH-C^-_F]9ZP_Z
M/:,,-;)MC9[)G9,[9LL@- $?QAD!I_N+1>%\%_N+_L@_(>G;]3^8_1#Z\_D/
M4^KV'J0S^.]2UZ';#VL[/9;?9;0;/:;)G:,M[-AEMAHMD?R!HN#34;%/'?LG
MGOANVZ8S\G[E_J5_25O\I^0VGK?3;/;>MVVS]&SZ5CT>RV[6SV0'N]Q:VXV?
M^?N]Q!9)! %'%Z^)?K7]K+.P]2QM/RGZ;L=IZ3^5O^0[$M;7: MM%EOW,[79
ML!LM-?[P\O+W!\5]B_M)_8_R7ZWZ#U_I_P!F_#_D/6>MVVS]+M-AZCTK3>WV
MG\QV19]8?4[7U9]YVC_86(M,^YEH8%>T?U!_N4]6V=H-C^O_ )C9L_SLML-,
M,@MG9!_N&T]FQV@+1:);:]L&7D#W/>),1E//?L1[&?UG\)LMB/3>F_'[7\2]
MD[$AKT.UV+!<1%H[)EQ:_P ?XWAL$ XRXO0?TG]%[]KMO0?D=NPRUM7L;#9^
MM][#&S:V#)9]NQV[6T9#3.W]W^!#/N9+BXA>E>J_O8.Q :VWZOZ]MK_4;)KV
M[3TWJV]F-ELP/>RRSL_0M!EMIM[8;+Q,+Y%^_?WP_CMNQZLG]/;V?JOY6]KL
M]OZCTWY1D,!H>US7^D]#L6MJ V]IECWQ_P"YRLT1^$<\VV,13/7Y/URS_2?U
M +9'JV-K_P!9@;-G;;$L$^E;8_Q:;;V;18.U9VH]FT@&0#[@J>E_IQZP ML[
M+9[5H!HL,;+:-?\ 4+ !]ON;99V;+1_VL^]H NB5_+G\'_=C^0;]2TQZ?]L]
M!^(V31V19]-ZOTWY5G9;,-,O9V9:VS1_R>"6_>&0RT]@ .7Z8]-_=K^1]-Z?
M8_S_ +'^%_([+;;;9?CMG_RS9[/;^I:VWJRYG:#9,EK:L[)DMCW;=M@[+9--
M!DGW06=7A?P[-[<1NGX2^V?IW]5?Q7K=K_H_2_D-C_K1ZCUOI?\ 2;0^S;_S
M_CMK_#ZW9LLG_':?Z;:0;.S::9#V6@7$%>[?L/K=KZ/UOX'\MLMF=MZ7\;ZC
MU&V]7L=G!IMEO8M;-@,$2:#37N>?\2XA?SE_JG_;Q^P?A_2,?D?U;9C\CMOQ
MWI?RFU_'>C+37^K_ -=^9V_IO4^N]7_.R/XV_4>WT[MGLF@P&VFC_D]P7Y6_
M3_[J/ZC';,_C/SGX'\CL_3M;)G_4>H_(_B-N&-FWZ;;!MAA@M[#^)C:MA[.U
MVA+?\C#@Q[(E6:HC;EX\_%=6^SXQ$[<G]8?ZI?W+,G:^IVX]+ZS^/:^]K9L[
M?T7J-ML_3MML^S^1EKTX'O\ :"?<6FA[8.$U^:]K_1/TG[+M-EMO6_L/I-OL
MP#Z4[;T/\&Q]6?Y0Q[-DVSM&_P#4MM,,DLLEIAVS++3P(+M_#_W#_P"H]%L]
MEL6?0^G_ "+3/J&/5#\K^)'IMFUZC9;8-?RM,;+9[-CT_HFMBT6/2L[!O:[;
M;-,%K:M,"#7Y*_J!_<[M_P";U'HF/UO\=Z@[#;L_Q_D/3^@]3L#M P2-HUL-
MKLMBPW_#M6?:=F6FCM=F06BVW[@!F9B=W7$\^47C+<Y:LYY;,^=S]>>B_P"'
MA^ &R]5MMBTQM]AL/4-[%AK\CZWU 8VA9VC6S(_P]NS9>VQ_Y;#1B0#$E?2?
MUC^U+\?Z)GV_^$66F=D6F3M_1%GU6R=LPR6R6&VF-H"S[P&@/>0T\"(*_GG^
ME?WF?E?0MLL^G_'?E-GZ(;4;3_1,_P"H];Z=S&T_E(/I_7>G;9!:VG^36TV>
MUV334B2OW?\ TR_XBFQ:/\/YC\;ZEG9MML^XC\?ZOT33++1:;V[1+.S]1L=J
MWM&F_P#<6V& Z3PY6*.9W<+9WSV?)<][[]^M_H?XW9GV^GV+'I"&@_9[39[3
MTC0+A!S;+ W![^"^^_AOPXV0'\89  >/8XO<(.:#WC>N#]&_NQ_6_5L,LM,[
M;9,[1IHM_P"HV(]0\MR<0RV?\60 R]D&CE^$_P"I7]3?V;T^W_9?V7].V/IQ
M^,&TV^V]%^,_(^CV[.R;V7IP3_,#LVQ[#ZEEC_#9LL_XEMEX'^3M6B-O#N;?
MT-_+_L+'I_\ 3,-LM-[;U?J&/3;#9,!S3;;0+1:)HPPR"VW,N$'K^<O]ZWZS
M^8]3ZO\ &_DOQGY;\9^&'HV&=@&OR>RV?K/2;<--M'^%K9;0#^':;1IK_4M^
MHV;3&TV+&S#(:)+D_P"E?WD?B/V(?C?0_EMMZO\ 6_W/\;M_2;)O\?M/3>I.
MP;_(^MV(# ]%ZG9!H;1AL-.'N]OM>TR7EZ^K?U"_HU^RM>_;[?TOIOROIS_D
MTQMSM_<0\-$CW#:[-EHNB8&IHI5%N[./SSCR2\\YOYI_K?\ 47UFPV_I?0_E
M/4_C_7>NVWJ-MZ?_ %'H?7>H9]%MOXP&V-LSL?4[;;-;%K: ^XEEL>W_ &M,
M,^YRVQ_NZ# ]7ZG9[':MCT6R9;VNS9]6PR=HVTV=FQLMDP-FTRUM"7MM!P99
M89:)(7]3_P"F_P#3#]/]1L]EL_V7\!M?Q'Y-AIO^5OU3 _T7\I!9;_C];LMF
M&!_*"?\ ':ED@/9*^Q;?^SC]5VGIMOM?Q7XO\?LW[!K:;';^EV7I]L#MB?;L
M20TRTRV'-%[)<:&JMJK<9XWR^&VV7RND6CMMO?R>VW]XWIMOLO2>E_Y=Z3\M
M_/Z5G:;?T?K"QM0SM_<6&_2C^78G8DADLM?R#_'_ "<\.)'K6T_%_P!/?SK.
MQ]3ZW\)ZG]:_([3:[78#:_B&MMZ7:[/:;)Q;;:8V+.TV(V;1)]C?M8&T<?;"
M*_='[_\ V2?LGH-H/5?J'JOU/\O_  ;%EH_B/ROX38>A&W;.T99;9_YAL"6M
MBRT"0P66',M,AIIX>%[/^C?DFO1C_3_NW]._6_K7J=DR&=K^0V'I-E^4_"-G
M_P!+9_D/1,M>U@S'\FSV9#,6@%G;NB_?3/C:+]Q%.^/*?EO\'XG_ !7]N>W#
MF_U/^IWY%K8[-C^39_C_ ,EZ8>K#?L#V=G[O\FG- !DDLB)P"_I%_17]'::_
M'^@]3^3])L]G^0_B'^H::V;##1VK!]C33+(#A[R/<X'VN( >OKGX'\/^(]0Q
ML]O^-8]!MV" YOT_\34P]Q#$67/D79A>_;/TX9 #(#++(]H#G!V#-(TPWK<4
M<?E,Y==H\[M<[H^%G)Z38>P>T @>TET*"$17(P<7K;4R_P"UQ>*3J[OX7:=G
M.D'P'  %1VK (>YY>",(8&6Y*J?*!XO;[>1((S!A*A=U7CMLUF9N?0Y0K662
M\NWL8/(BZ <*ZKBVFR),7$._Q%/<<\N2Q8>$VNT?[G@@LD %[@T' _XF)=1Y
M B"O%^I;G_B,"1%_"3JA>P>HV1B\ E\P);N;MZ\7M=A6F8<2,<L9X),#U7:;
M0/< "7F9,,W2AT7C&@?< 2S%_P#M#W.J[*75>S^LV$)!Q! +@"\U?,;YKQ;/
MI3!S(<T'$B!#L-9Y@+-EN\%M-L09UDZ.1S-:8($EX)9)9E[8 E\'_)7DVOQ[
MWL@/J\S]P-7Y02'T\2"(5 JZ7QO4JINUK<8R>*9V4B\@EX.#IO[ XJQVQ#IR
M#B\2%O75_#$0JYVKQ$OXNG12;]*]S($W,U<Z^2YQ$\%O$3SVN<^KG%Y!$7%]
M7.IO,JIMAZC(^TFKP]V.=(@!,WZ ,N#()((F9D8Y<G#!=)](2#![,![@Z?3L
MYZENHBKJ0(#WN!A1YYXAZ3:>H<!@^1!+QG@<^*Z6=D^(+X.!#6\PJ_X4]KZ:
M;PXESG1#AB13"%)0"CHX/YC  %FH!A_[T#E0&.*3:>H+GA\WT?./-R\BSZ?_
M &O=,NGS-<@D:],^/M_VDQ$"XPX<5F8D>-]S3I^TM!Y(BTZ@?+,BJ3;--M ,
MAI[+G$$ $&%7.T"\CM/1@DP:,G$2W2Y1>F_TXB'1 >81NWK$T#@V,@]HL^W>
M]XQ/::@WM&G.+/N);>2"X&$["\I_HX/<*R':GF4TH].91((C"F'RLZLMTS&;
MQNT#19<28$M 2=+ZR/%>09;@/<U[WTPAK%U9051Z=\'.-,G7H_1*/3E[W.RA
M_EFLPS+F;V@!> T/:U&)(S:<]T)V$NS]4T9_[(@ !Y(=!Y >'3>%WM>C,'F,
M7P$18JAL]A[2 RR30DEP#],7/T6H@N;9,TH2R21!P$YU,CA2,NQ@/>T<?\0(
M@ 0<!/>9J>S#1_\ ?B 7.! U@ZXKHV?IF@'D],*;L!P7:(0VSVQ'M=]/-0,#
M!>3V/J"SA@^+LC@]^<EQ,^E, [_(&&!!C<@O+;+T_P#B[*(A+D":S>NM&]QF
M<Y7V>TC%H@F=0T8;M<0K,EH/:!<:B+@#%X @0[)\7R2,^GBR'N@\0)B_KEN7
M<PPTZ3S/A3$OGER6[)<[&U+O<1"CA_NH_49CLNH;5[+XEQ_R9UD0,CFN?9LD
M$_\ <*LON?&"ZO9$%QD00(/D]XQ'VJA@TT(/<^3Y!V0DBQM"#[FB'"$ Z<ID
M\)(#9D/&$7^<)HC9N(=$%\#%YJ<LD&:VI=_B]X@(1W/AHHLMF#4!1[R#NIDN
MIMC('H]SH S4V=F8"'M$I"4WAT=50VT]0U,1 B\8$3'AQ>G]Q%  ZA!+\1F9
MY*;.RW$SH-RJ=CB"]\,QIE4BJ"#+1!][1+F0X1?%J;G2@\16VC_^V!,27V1H
M-ZL-DZ%27QD,L2_@$YV<3!V#XDFI^%!P,E])R+4799/<]TE9O:>V#($QSO<G
M]KC)U)PU=(=4K&RB\OA*'P@YHDM/;$P]EFG_ +=GHG:VSA"#RX@QWETHXO72
MSZ<0<'$O)#@(O=$XGD-4W\-&G1!CC8B@\8UM29%SW/+C'=*.KTY?/W!XHXNS
M-Z273L_3.?"0)G-SX<7)#L(1A!Y=Q!:TTR0(TV__ &P!#O\ T7]*W%9AHB)(
M)=K%U!+=O6V3 ,0\F,"]W%PG2RJ'TTW/R[@.<\ZP0<VV]T'-/<,(O)B YSJ
MH[#8'_<0&6C_ +G]!&/0P*VS])'_ '$.C"'&?)5:8(FU4N<]^7V<'(([7:2>
M7N@='P TP<_<L-N26P7!Y@7C #VY9NSHK#88S>/#Q@2F&PF8$A_^1C/'=5TX
M*B;0+@\LYEWN!R#B*%RI[RYW^T5!J,B]V&0$$[.Q+@]P9B'8C'7G+!,QL: E
MSR/CGQD"H.C9-S?'_$;A1Q.?E=++3W A[(+G!^+SJ 8%1V>Q+X/>7Y 0=R+H
M+N8V#G 1>'1(<]\3B\X*CJ9VDHN#X,OH=;,#!>0V&U>0P]\(C+H]<'\#A[B
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MR$WW)ZJULXZN^WW!!,MR$=U->_R@0_!P,,O"4-1<[$/!ZX)R*NRRY?00LDW
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M$X8B.JBWZ 0) <(#7'*PLZVZ%U/P?--K^"9D&"S.!AQE$@4@5#_D(>7LO<!
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MWSC56ZQ3U/DC7Z\*,O!,B'E_!X#M0BU^N,P<R7%SWXX/<8;MZ^LM?C!/VD-
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MTQRFY?6C^,<?]H:>^( Z7Q0/XI]#P,/,=U$'R _K])!P?#"G&J#?X >YD@#
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MX$PD7..^B_1!_#/<75=*;GRI#K%SUS;3\&"'!D%P)MTY\7*33SSSVC\S;?\
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M<M^0_,OK?[6OPS3_ '>DV^T$1_GZG:MC0^ZD_N?AMK_:=^N$@-_BR^ /_6;
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MVQ_"_FO4?A=CM-NUM&#_ ">JV'J_3MM>QC9_R,L;/8>I8/O:8+1]K)"_6?\
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M08?Y3BK>QU'#*I.N'!'^,/<)"8E/3.>"#G:8FX.PB]P'>"/L+A03Z1[A=33
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MR_'"54'*61CD )^4HV,XUAGEURXKN9V57!\I1UU%/I*TS'+%S_EXL(.4,?\
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M@Z$\-W&A\+?P3?&,*.P=X.B\DRP(TB ['&\$W\<X/GQ."E6T>-8]+YQ^TO\
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M-2][ETL_CR 8&  >93N*]^9_'FHENS<=)HCT)+W!PDX@1,Y4[R5JI'S/;LM
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M_NIJ^CN"LVW#C+ C0<R_ZMZ+6SQO/XHNH[/A*[Q0&S.$-8ZCHLCC8V-(U)I
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M?2;_ $Y ?-\7$P#\M'37L+?IYP@<<H\ZT68]- OC=).PL(/76O2D@/ZQA$/
MMVBXMIZ!Y'^,)E\S-[E[BWZ5X!,(R $2*ZN4O]&7DC_T28S<9QH,N"EAZ(W^
M,>]PA&0?Q>]QCR4?^5"7M D\NG".6"]^'HA'&H)?6=SU2'T, X Z98YI;>/1
M3^.@Z9,C(1ZNX:*K'I&@0&F08_XNH)1Q?>*]O:]%-S)A#"(.]/\ Z45$7[AC
M? *33<>K[+T@?(#=S+HX^5V'TI)I[:.K!T3A1><_TCB]P B_*Q"*J-@(  N[
M0^5H>%9]*:.>(,Z.B\.(W1)Y*;7XXR#HYS?XPFO8V-C.&.<J@=0F9V)J1%YE
M%^1IU0>MCT;G.#R (X.AN<8X]$6?1%S0(<7@0%<MT_!7L+.SK.)<#B:8G57_
M -.'.B__ +C@:#C4O 4D>NL>@>7.H'E[AA!PX]D=IZ-Q+)D74K2)GR7G1LH$
M $A]81^5,[*$1 1$8B+YW!2W/X#PC&PR=C!SL,U':>DC "43/+4:=E[ =@^$
M "_(AX>/NLDC?IY4$7@X"N,<Z45'JY]&'F+\R)'!SI9KG/X\1A/"(R.=Z+VL
M^F=. ,GUSU&>Y8^E!#3Q)Q'D^%1Z@/08N $ 1%I_2<.2KLO1NE69<^.)Q#]W
M1>RL^CPB0-SL<S3*B+/I8@80-!?@E9F!X4>ARI*$7=,$_P#HH1%0*0?S*\__
M *:;)%1-6&Q% !BX/Z.=E54>#_TP ,!)THW5U$VR])B"/=!X!#G2W@TP7GO]
M-!]:/<[?B46&( $R,7&NF"H\$SZ($Q#YA]>!D_E2"L/1<'8< <%[ QL07P$0
M#*$ XRNBQV0'_;P/ N0>&9]) %Q.3Y"@.EA4.P$ )#(Q@7O@_3HO+-,ESP\Q
MI-+M&(!TL^,I@H/%^P8.BX/!<-,=ZDUL! &)-81W4U)7EQL'S,!0"!?2-,^R
M4;%X<Y[0+B\Q(^.<U(R'@F_1@P<67R..AD%XO:>C,00\,F!SXX+W#_3B+G"8
M%8U'AREM/2PQ(#ZZR?'?5+1P'IC'X^I >"^ Y1EF.:Z1LB8%D 0(>/\ +<[_
M &T<O8&O3O<?:''(OAY53Z>KGF >Y_ 8E35XCQ#/IC!SVB!/L[/>O->CV8#R
M67%PG%SZN'S%78]&]Q>[VN<Z9Q$G<5Y/8,2A[G3=6L<ZNHJ.O8;.K)$W .>,
M?G)>8]/Z>1XN)KEA427/Z?9B$P]T*=%YC8  ASM>$,@J+,,4+XO#Y.ES74QL
MN!B97Y68 J)PG2G!=+(ET?&%'8XE!-IFCC.D*0.<?E-[,MTHY15PQ2(F2-,_
MA,TQVUAD9 U0<H9G4ATD?XR7TK0V.Z["SB#NW.CS-$!@Z-B'UN0<0V$Q4F#Y
M$9C!.QL(TX"5V]=S&S<8Q?$"N!X/3D/!A(!US0>.9V(C4@Q)!UXX8)F?3C_+
M?=."[0Q(RJ0<95Z^4KL*NCD(ON"#F&QJ8"3YTAN4VMB,":O\_'9=>T8)!=!X
MF-"Z\59E@0#0+W1.,,.B#QPV6&DT!LYN<_$:2/1>6&Q%1P(B^CL,DK6P#W@"
ML;\(/&L;(Q$"*$8F&[?1;_3QQP$@/FB\@SL7/A,&0X\\>29ED0QA=P"#QPV&
M4,!//1'^*DXKR18!>?@O4SL!"#M3 G1W NY(/%-[ /!%)S?"4+E@J?Z:)SD<
M#3-SJ8Z+R36R$7B)X/4CL\L'1J,>RDRL1=XW_3B<07F.Z>'A59V<@[>!G$FB
M[CLWF>H(=2F?1.TQ5T&8 F&X +$TWV-1-K\YO%EB) $9]IG**F=C%X#P0\!T
M,-R\HTP]Y=$5<\$X7\(,L3@Y\@<?!6HCJ(F_>XF=ACE"F[=G%%K8S9%9'&KN
M2[=GL81 !XRPA;E0L#.O3GR*L,O&;/9&)AAE-[^,L51G8NJ\[HNRHN[^(S()
M'_:!SXX(L;$ F#1D(E\?BM%4<8V4B12;[GUDG&P^=/!NJ[F-F:@O@[_T79YK
M'9BIF^0GV0<7\<Q(FM/MTDS+ >,J$3Q[+J+,'[H /X7DG.SJZG>.M(((C8B-
M63RP^JI&?3\,)/L[EV 1 E#,WF]8[,F- !*N""#+ E@"-'89@\5CL:@/EA.I
MU"ZF&71(<(Z/PLA.&9SD@Y3LQ0.=(8.F$@V>5G'X7;[9PXWS0&Q$.\],T' =
ME&(J( P=GS1_C&#\<KTB.?>-A .$7:B"G[7:"[*#D9B#D;@;Y)OXP]Q$?:!!
M\7Z2@NT[)W^0_P!IQRZ+'9[GF_CH@\<&<I%SH.(3M;(;A3F_7)=C;,'.C'[&
M;TC&SIS,AEF2@XCLP>.MZ\%1MG_%DNB^5=[ET_QA[IRCS(R3'9AQCH.J#E&R
MQ^1??1+[*@3[5=A7!=AV8,"(3=\:HEC=-SN#D'"69!U72YK.<^.7WDZ2Z?89
M0=.CCU*9K95U-QD@X2S)V5'.L/>F.RK%_1_:$%W>R3HXE\KZ<T+&<^KZ(.,L
MB9E"[GJD.SC(^<S0.7>RQ.0$_.@R1:V1\/ UXH.(;/*4J[M\(ZIF]E6O0^%W
MACC'BZ^:#+&1&+^"*X&&)QB75@!?*:JULL71@.E\5UEG#R]VJ!#YXQ%88#PB
M(?PB0=!V<A% ;,;LL?C KH(=1SZ@<.,$0*.GHZ""3&S&H<_QHE89?$B.$GA=
M#+#HFITONFV;(B^$Y]-WE!PG90: W/C'X.Y%C92FX!VKO*[66?LTCG1!T2]\
MR,K&:#G8V,G@Q$!D!I"-$&MG,D2)T#^;J+I&/-YU-\$XQ +HONW(.=EB%*7T
M[H>T1=2='9+I.4J92%NF4IV<"#]^#B@YV14 .EIOQ199F]SI<8PQ5"Q04C C
M@Y.Z5RMR")9F7#(G/)1# $(OF[.XKK:% \Q><LOC%;^,:XP<\Z8(('9R?)_U
MX*S6RP$"#7LNEFIJ)XQY+- <<I&]SN0<QV3@"!$B$>NG2*!8@81,_GA@NAD/
M$B/CJE9W.)TE/P@C_&.0>0_1UT2M,8%VZ$I:KI=/=##*'=(TP)F;BYT'1B_&
MD$$?XZ8GJ(Z=.*1N=:"$'.N*ZC)[YNA-QPZ)2)PR?"/R@BVP]SJ'!\'XP6+,
MJD3TUIJ:KJ,0(2E"+[XI6L,)Y97!!RL[/@7YNU5&=DZ$\:OW=*!59 Y2O[3.
MJ8S^-W&*#F_BJ[)YR@+P3AF4<G3WZ_9RO_&'/>[*KST&2%7.GN&X]4$ Q6%8
M\@4Q9<'.A 1TQQS5<N]YIF2'NKQD(0-X(.9ISWF,-78E9EE^5,+@NEF;4A3$
M_:+0?I6+M/M!R>W"0,(E]YV+^V+G4IP,=:XK;/&@SW7C.B?.IFZ@PPMZ"8V<
MZ!^$1B"4/XL'8#(:[E1F;XPYAV";:"K)AE1_?!%<Y9<:QMX&1L)6=DYT]]>'
M(]55H\L2XZ#RLU2I<+=D-R)< Q,Q -OP$*I#T@16-N5@. XDW83 SRTCF]!S
M#9SQF_'K*5,TVF3R]TKX*S-7D"%)\^*S0RI>Y F^#A\9)0SB"XE\9.$(WFL
MY_M#@Z-0^O3PJ>R1D!41AVW(&]H<)3UE6!X\% ;.CW5A#/A<DX= 4P/$GAU1
M(PD?A!("<)2P-ZS1]@EQCQ,;P3@Y2%RX?"VCSIT<@4#2$).&0N:)9W$Y3NB8
M&@@_COZ(:F3\)W5%E)ID0(F'Y"4B[L%;9L3+XD0.=P2AJ@BX[X],^R(:Q@8(
MERM;.$I\KY!!IBM;Y1DF::ECCCT?;DP!!??/D9(U%K=9/:,=\AGN"HRPZ,^\
MA96+.$IX4O>@6<282CG>-493(HR#FX;XG!,!&3X& IOC+$1X(MM4&;^,J*;-
M  1/#''ED@H63@Y\W=>"4ASGP,9[MP@Z2SGF#XN^=V"S<7P<1!\3X#D&<';J
M"#AE=4CGN)$ 8/\ J'TG9;H-\'"^Z+6S-"Z=\HH"('#02T- Y GI2.IS^T&6
M<XX9Y#.FB=D4#@9R03]LJ?&^Y+/&>^ZE6?2]/M2$XC'- 'T%"<H>47T^GGYI
MBY.13)X,+<D;:B.9=6ZX/0 B4):]+@F(RX'S96&$7B>'"XN09,7T[T!J#W0,
M!"<09B?@W )8!]80-;S6;:$8&/*#OC71$,5, 2-X='Z0*):5RK2>:9ED# $2
MNQHI--O+G@8.%Y05&6)NAJ8V_P ($+$S[B:T>-82S3[,"KR3J=$OM C67 7B
MJLEXB\9ZH":Y930A "E(S*5L5$(@DD52%QD3"<JY]D%"#O,('"^R)/7+G\:(
M8 3RG'NY!H%XA#![Y0OR@!J_'"XYH@3 ?+%X0&KY'!W=58J"8"+JW1R!/;*(
MG0/^LH*KN76AX<5,LR.^B!:#B_%]1]H T;#N:+)A@1<\$'#?2Q<D6)&X_.:
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MJ0:0F#8"!W"6#EF&8N!?"=)9Q4Q%SX9W#NG+= ]\!$PS._@@#JP@7RZYK%F
M@3VL<N"F27]QCGAK1,R:/+L3>XH&W96_[1#IB$)RA=Q2OE.&)C=P3OGAG')
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MX.=  7!V&]59V='OH<GSE)^4J*[/IS.9CIP&Z7R@=FGN9= / $)PB;JY=[#
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MG718LR)GC?=9AD"D9QI.F: SQ%7US=Y3$X<XSH!77=)80=G X# CQ5,U%\@
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MR@7QQT09BKXZ='9)H2B2^!=)ZG*)$.VJ(:J*W]P0.TW1S]*0OLIL&KH!\S'
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M7:7;TA9! .HAS>;XJP':9EP. KO\)#LY^<I^46QG+E@^$ @.;Y/W].2!MFS
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MB1B^\/*0LOQ#I8[U3 'C65>^&2L"6?\ EC.KJVY,"\.<YQW%;WP(J2X0I?!
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MS,R'4'>"5Q>_=$QS@L9PI%WTFI&(9E.90 $S+IG@D PQB\T%U5&780(C&["
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M\N.::#IE[K^DC8D]T?%]$$2__: '$3H?#NSD&1E+-T9.&GTF]CX0A47>B+.
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MV,;D$P:>90$L=?/PEQ$U<_.G+HY;VS=6,)9?)"J08X/,\\^O5+[70?!UN'9
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MQ OY"Y_$TH8-15[ZQMRZF68F$*8?^T]^Z9EFIJ\0PNHD@XOXGSE/?0Q5&=E
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M&+J=$P8C_DZ?!TEC"-+<][[<@5IF+I:3A'<].RUA=]40U'4 WD%@,H"NEP0
M-1IU@>F:4ESPR)F;W3SRIB@W5TG9@WT4RR0(RH!$H.AC W@^$$28=8I&@8P=
M)W8BX+3@=^LIU0%EJ0B)=8K-B-8F5+?R<D#.60.5R1#4P8"X(' =.[?!8 9O
MA"4N<<=R5LT@Z52$0][@1?- A9J)U!UKNJ@P9F B0XY4Y/X*SN,H9?"1H"3J
MRDXH*D_[3P@(:>9*+_\ <[R?K'5<>R]:RTWM?3N:]VR9V;3319/M=M'^T,ES
MFB'1=_M@NHBZ 'KT"D2LQ9@T^D!$S>%0# U,HN=J@[1TI.XE,P-\WW>*J.-G
M8_Y%KW&+(9]O_:Y\2!B:Y. 72TS//.1A'0R1?"&'#?I! FLX." ^XR@7'A#!
M8='Z:N68Q@YXW6]4:-'7I7[03 T\G62#>SBS(1>XQB;HL&8X_3MRJU!Y=ERP
M[()A@5WY[NB=H P[S<YR!;UBZ. H_-(1ENK(7O0.U%PI"F'=)WD[+6N:),\7
M6-XXHLM!P &9.!IFJ![GAP?#CYO-9DS!$A#'?>"S+)B^^SH(PBY]\NREQ-@R
MSC'.?3FNADO=OUO[28.?PZ5.25@@OG\B_"#-A[P[)]R"1DT(C0F0\J[0$^C^
M@ZI'3FZ1QC7QP0-(#<2XSTO5;W0+QOWR@8)"-XN5\DX%&?LU#D +?!SM?*4-
M2D>DKZ*;>_7X2>Z,7NW/^NB"X,W2?=XN6H:%XXV[1!DO)'M(= -<SPDF?.9=
M9=U"H(9.7G/=Q2>S$UIPY<$Q:R/7E<7H,RP--^."0*@X/X<+CP2ED!_^3JF<
ML@IG:2A&WO%-U$6MVLI2O!0;W<^6=RP0 (?A*5_+D1G",KW;DX!.O7!(&]VN
M%DX(AHP(K++P_>HMC&#N6[F@TU(<Q*X;T'06AQ[#[U21=(N?#3/139B!C&G,
MZN2,DOG_ (O@X5S0699>8U,NYTG@B6.ERQ69XXQP6]QP^KP0 ASG3G5,#CCT
MZS[(L_ =PO#<D>,'1C'N@J<*2RO&F$$&GT,)$F<+T2 SPY%W.'58-0Q[.0.P
MT^+H7<4P9G!PW7!*"1,3.3\T62YP._K*P@++$Q6,*7N1!,-82ZT<E,8B:<9X
M97D@E[L)"?1W?DD]\7 D3A.=7<TQ+H5+WNH,QT<G]KM8CY?>Y I9G.-8;\NP
MT3;,QG$X;H;PE]LL=\J_?PB&7.:%(/RIIG@@Z"VZ3P:R<<YJ;;1F,IT\E2+S
M2?*.-X(D@6<"4#!J_CS\I@>)TMTU-EN1RK"Q+@C_ "BO3"[" L-%\1IK2*9H
M5?\ .2G_ "0$'"F5O0+\-\"Z'C@@8B$8O()!S[?:+^LJ'71(!K'S+(41 K6K
ML(P=(X('-7"$_I;9X&L70=D$'2(E6L=8.2L5GRMP0.R]Y<"XXEXEQ!3!@@$R
MR.*G[@^;JOQR3?R/>)%T!1 28/D;=\Y24]F2X$B-?O/I!%IK+(U=?).[K*OT
M>R#-#'A6%$C7>+M-<$Q.$'I0)ES\L+$7H.8,3#IXGGO'!7]H<[0.X(N?J_._
M"9AO$$"ZH$(G#!SL=7+ Y$RTOHJ@7CQ[X+ BIOIDY!S,SD0-=P"9^<:.GG\J
MKJ@0[VZ(1;9$B(X]91&_@@D1B#O#XG-9X<^3QA"M[LDK6&[QI1ST"Y_:FIPZ
M.0!E@0K7+C7+BK XXT,G\K*'M&#CEA?VE+\84SR*!=H9#A?=%Y=6,I//TK 3
M+QE"(<E(A?%!# .,*=]R9M^$,I'PJ0D_2[HA"$Y4D7><\$"^S=QK7BD:8AH;
M[*Q,=+ <D WUQGX00#%GE]E "&(@^Y.X9KH]NX.N&*'MF)=+R00=-SY]=?A(
M!1SGUZG)ZZ61.H?'KSH>T$C0LTPY<4$!LGY]XUPLHEB$>PNZJP9P^,9(G&6/
M*5/*"+;/^T2A.CB@ZF<Z%TLE0QS(ZNY]YT2LPU'+R?M!-K9Q>Z$KZYK-,7)Y
M%O746:G RK@D+-;X%!%G8.A;X=N*SG:1RXW!4#+R'P'P-RWLCCGIE801+/3/
MZW218V5<YP$.^E5T.X<H2=90(?*DJ U>@YO;'?./3RG:#I@Y./5.0[=<^:#N
M_2/V@7^,0:A"]\8\U'V1?(UP743($5PZU^DA:%1#A>]!'V0#A-]SDA_%/%PE
M+<3= ND#*S5UPDG:9DYT*NY7T0<+3,7/OY3LLTYT O@%9MFIGD79;Z.6]M./
MBZQ0<Y$75QI'LF88?DXWQL+I=AE#J?&FY*TS3"L7EZ#F]KJ4@D# B1OC7(88
MXKI=Q$-4Q9RB^&8DZ]4'(RZ677/PK@.WS6<XN+@(WX>G=0N<'.[;\4"-"4(X
MQY'%R0'6MQ5SOG(1#X1\I&C1U9Q=PQ029#\-RHV, ?GPA[,++Z.D'8U5/;.X
MNKD@BZ&Z5]=%B!OA!\_CNM[7N#B'C'*O9#VR,R.TM_= K3+M]2!NW7@@[+)\
M7QHKNIC<KBI-,S)H^M,[>$'.V* N&$Y\T2)#H<+I-4:&_=+?ABE#$62(1D3A
M3?P0#^.>%+MRQV7.!U^ETM-1+@_?UMZ7VX$9BZXH)-,5D1./QPXI'8NJ?C7Z
M5SLSB'9\R#Y4OXGSIF[CP"!1LZN&.^ET.28BKQR=14]@@'XQQ699A$3@[+L]
M!+VB!O+48A1]IH[1\]!U79[8.X//)U,'I6J0PE077L@Y6ARN 0(D[$?.+ET-
MBCA4:)0R'R(AQNB"1&^GU>B#;.()<[>ZG*JZ.<I/ZYT4B7>-Z"09YF4G#K>:
MQ8F^F;P^PK,[-\2!,0-P1.S_ /RM7:3R0<P8B<W2"?V1B71AVC7%58#MY,#R
M@B67S^?H8((-;*9D9E\'WP3>P.$SUBKEG+GQAE3<E]L)0!0<[3,A-Y %\S@@
MZ5*0?'&_I=+8J!$YP<Z.XJ;MPQZ.P*"8V<OAYO[2ABDA;G7DKLLSX9G5\,U7
M:,?[2'0AH7(.5T.%!#<@R)/G68?2E ."LRQ-\WOE ^:.P3>QVM1@@@"^!A)W
M;>J1C"8A@^_I%D6<=/" 8F#RH.[]$%&&,]1,Y12-,X5G?9=#.CWPA?P@)YXY
MW#X03]KG#'#DK,B)TN.&2)9,X.''SHF:%8NN.]  S02H_*)?\[EB9X3QY)O<
M('B_#3NAAE+/0UO!!79M:8C#X%$\>% Y1&A!/4;OA4!)>(OU#J95>$%0T^8E
ME.EO3"<OFA<N5L%X&,(1=!_,0@)*XA,93<1@<-R"C3-!@;.B8& #\0^F5.*F
M,"]TGB[,%C( %Q>'/-[D%&=I_P"D\1A*>[NF9:Q+L/D8I*.A.+Q"]4S36@#\
M(RQ[H'V;4:GATD$P$:%W4T4&8FKO'6W)RZ $6N5YS05,XX7\JK.GP'8+G>[*
M^W=4?#?#RZ=."!H8'%\]'=>JF"\PH_2]Z(9?+/'IFBTR!&LGB4,K+T#ML0(<
MYP%(0H.*1B9A0NO-5]T#%V&LXI&'!\'DS0"E8Q<,XA$O@X$8C//*X)0V'@"(
M#X]02GSF<.^2 >Z0F"9>#1SEGAXX;_'TD:8B\:?5.D41P X_7V@H6C/'&YHM
M"1A24YZ2R%5FA1[HC*-W!(344RSN* !AWN(F9..%'(LBLSCAD!FB"'@X0QYH
MLF,XN+LMZ $E[A&483N2;W0R#G0B/#\DNF&KCCFL&MYX<'WQ04)=CN-S4_<_
M"&[A1V*+M<Q=X)2U6&GFD:H,_=1\.JHS0N-PA404/<)3TMSOIRL2)#C)UWD#
M".ZFG5RQ-(N@,AF*_"4-#.\[Q2$S=CQQAUS06=4$&;L]=_)3#6(AD!UP69!B
M'AQH^O;1$"$Z.RL(,&\(OO@Z.Y!SA@<Y"^*8@.=_\T('Z"BZIB(N&)F_=,(*
M>Z$;[>$T<!./0142U)U2YV.N'A.6I/D(9ZYH"TU23W&-X+-,N,ZTI82-A[GP
M=TZ)@027@.? H'?2+GW>:S+,\ 09V_5(2"Z)G2F/!9MJ&.=R?TF@P=-Y!UA]
M8(OXT=S^**6#ZN)=U=86?A>N#J(*.@XFHW($N,! 0<)1'>OA*305KAQJ@6A$
M1)RX.?)R LLQ!C* DZ^:5\QB\#++#-Z<-O@XCZ@E]E'0,=,84^:H&9EB\E[N
M^%A$X9=<]))7Y.T$J71*7#*.;KI5 [3+X ]M[LUO=)]'/[.RRI5*6QB*5K0[
MW\D&#%SWOH^6:!@U-SQ$S<IO= D1?*3E5O*64]Y[*;( H75?-][IH*X.#J@F
M&X!)KQ=*@>_&CD#.X>,TWO=71D7NW(&?D)8QW=DHK-W:D.B'MQZ>+P6=7'#E
MO0!ONXU@ZRBR<'AX#Z T4?Y 3XQSPH[PF+)AO+L+Q,*H*$3@[&7 HN$"*1 =
M5]<G+"(ESRMR&.,>7+R@4F<#_EUDY.&H/.F8<I^[")QIGNJE8,JXFD+F$%6C
MKC#,(,MRJZ#NQN:! >8.@Z+Q\7%3D^+GR=CU@@JT"'\(F/PB^CGCA*MZI"UO
M-<;U>F!?U<[MSU0*V9.<Y]+BF:B^C]UN[H,L5WPD12^"0DT#M>IH@+L>>51P
M4O=(O,X;S#[51C"1U /2/%!K3Y(RZ>$%=J*GE7XS4 9XNW"-,4Y:SD[+<ZPI
M,F@>[/O5W) [Y'49/^TWNA31URYE3:&4B").UP1>:2?&B#,@DN,H.+G\^R?$
M4C*%YK?R'3CSW.CV19(>)>;X50(6).YEV71!IG04<,KDLTU?G+!2 /<YF9W/
MXH+^V<HP$9Y@8Z52AIP(]KG.D8DR?>:#XRU Q=-,3;^V4W&&-4!8:F#%XES<
MIEJ9=&@[7,\4WNRC[80@^D+<IN<\X]-/"!W0X/&?P_1*6C(<Y$82^W+&5'PL
M;WHAMU<GD'6OV)()OB,0^,I4 Z*D0(AY,'0A]8K,NB15Q>[/D1!#:-8/$W@3
M=S" !J3WF3P'V[-5#.3A42C&X(,DS(T>(WCCP2@F)KAD@=\CKGPPZJ@VFDXZ
MZX%18)KA"CO)Q18 K%TL']D#M-8_&EQ2OU^TK@1&!OA#"29_82PP'! "UB'A
M_+[3%J#GB#G#?#?N4R.^N?-*"XDFCK!"+8S+47#/(0Q[0503DY[QID/*B[4A
MJ>F<X P3L"#S4N#_ (G@B'#)T.8R>'NYA2+/_<#QERI4JSX<75I%^.6 W*38
MD\0!YYNF-R!7B&31E)2:VCY NQ,A2=4[34Q1[L*1E@-$H-"3#&3J0^T&:( S
M<Z$R<!GVB5F7AW?OIU2LLS:>\9\G.DJOK*FN[A-  <8"&3\">L%T 8".'GLY
M189>\TI)W&F?)*RU6\"[R]QH@):G DOC0.R*80=#,?/A-[N&<"7FF20G$0[\
M8H,V7@?Y;A731 .<7/+Q,QG?9#V@B#V781AG\>4H9(<,J2C?TBGV8=7&=PWK
M X1):WPY;U@88!^$7Y!%U'&&[PB*/<]U:CLI,D:_'0\DKIZP D,_BJ;9X5 ?
M\<$%&3E"8ODD-7%QT$!IR3!K>'R<[B_Z6 G33S;^""1!<0^$A)_'FE98=N(K
MSB]4<Z$2Z.](R(A[Q1V,X;D% W.$Y9OO1,#"LAHIL"9,A!WF>[Y3/R>"_=KC
MN03]NL27N."J\2W NANRYH%T9AXB1A#D4F F2A==EKA%P.D\U,. #HSTM\%B
M8Y.<(6Y_5 "@H^$Q&KT ?+(0IA<59ED2,'A]C-29+G.=G=-$66GYN/2<,)0X
M( YT'#=AW2LQ?_[34R&3E5H_?/CWBI-$2H_6?"#\4#!H4?0;[FM[= *XON*!
M(G@:.-_2;VO?JY]?A H#JQ?+'OIS3$<3I"-Z42EG7_&6<*[L$P.3W>'@ON.2
M!6FJ.,PX/N$$T@[ OGB8 )!J7\\_A9D/'^YV0(YU!?- [C%^HQ%X;TS#<#C!
MTA,8*?MR:AKAAS[(#4%_9!2+Q03\)FFL3.N>Z,4,=,H@8^5,M.DX$G,>2_)
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MC#7ZQDJ':8C=ECXJ@TR\ ASN)0:R!0T?@$ON=E$1^XOA*"5G R.#L]UZ)A7
M1=6%T0$$B>;A]<DN/3Z527Q=2EQ"1PHYV.L\=7\8H'#(@*+>[I0YX2PXJ;I$
M"3[SCBE?B-:O?#CE@@H#3CNY^%/W3@'#,.XIW5F#<,=Z?VXC0P<[- K\Y2#K
M@$P=SJ;EX4G!\(>'1FF/WA#":!O;-T097>2QV<0\.JZ?-T$[)PAPU?>:4E^M
M\4$2S%XERPLIC(4C#P_!%EAVDP^;\!2*=IB4>?#6EN03;9O+)(\T#X61A>JN
M68"Q1#VY1-;O)!%F,S#A'+HY4(#@Z>&Z60=K%#VNA4_551TC64(4OR@E[LNX
MU1]HCK=R2M&IQH.60*H^;CPZ!!, X:"^")T^//9$F^#]RS3,N&_F@F3@S.W7
M5!D2?/7"2HX/>]]-,'( ;Q-R"19F9OH[#HF#<PYPX;N2LTSCD99=DA9JXP<X
MWP0*69/UPGEN0A@2<,OA.V)!W4?/!;VQ?>F[-  S-[KQ\H.BX8&W<N"HR 'X
M=<.%$'1#G0@<2_KJ@0,4EF_DE:9P!C!T3<+<N@Y%[^5YJ#4Y%U9.?D@1H<LU
M%L&CP)R70T'"<1$UC=$7.QIINP039!CWQ,(WR0+JS#_K$XJKS$7>B! $3C \
MIH)M,OUX/AT[K,B0=$NG%.3@[N[KO3G%UWG! A#J1J_ <B5-QB\N\NMTL%T"
M- >P[] @6#!!SEE^Z5)2[:)V&.-8[GC1,R*[NKG9P2N,^:!FN]+IR2>S,Q?&
M6[ZYJIV;ZW>_>@!$0#J:WO01_CD7.+K\CPB&91?1U8R^E9QZNNA699H1\Z8.
M02]M72K@_&X9I8/A)V[)V]4Q=\9IV73OYW.\!!J(SD'SS*1MDS=>6<59MJ]<
M^W-,&7/?,XT#N]T02&!#I[[\H>V>8D\W952SY=?VE#, # G?<$$C/.D-+<LR
MQ'2>MSP3NC"48C *@9E#'!]\W8H)E@!T3AA5) Y!UO3;;,/?2ATTJL6<H1AO
M%O01]HH_+YZ99K>R>-*&_"ID0Y\'W-$B@F)'QUY((.BZ/9Y[XI@!.3NFY,Y\
MXO-].<TY9DZ4SD^W()%Q%9RS%\4K&LZ5I#56:9P !Q$D!LA#L[&\\4$7?]TY
MG['149:A*L;YJA9RS+S8YI7<#-T-"@0,\(:\/*D1(\@>?PND,<9NNF:F&8SA
MAV^D"?QY3AY<D+!!RE>;OIZZ"S..8%,N.2#+._,XH.<L0!=/C<*H@5ZC X]E
M<W"+\K<BVRYT9Y4[>$'-[*4,_'PF=#0'=83^WIP&*(ECNCOUH@B&0(3+IFW7
M@B&=:0?7A&"(9!(?*KN5\((.X#&#QU0 N>)HLL OPOZ3# \>QQ^]5@Z0=TGA
M5 C0H(AP 4PQ\0D9Q[KHK" J_P"JK%F#\(AT;S0<GMG0X\WO3LG>SC5]T5@S
M1\#$O#X+!F0!A+G6\9H$.RS?UTP@L0+='Z^4_MF,:O@,+PFD:&+XRURN2 NG
M(:NXK#9P!>Z.LH 05,W9'4=<EO; 0I,W'[0<[\=V9TP563N@Y_!#>_G6'RKL
M;/&)X"$G(%=#,LO<_OYJL1)[X\X/$$U<MU,?&*=U+N3I()M,@NP D<1;L$P9
M?$CA<$[%'QAA#G=%@P'.&.K_ +N2 AAV> )^,N*&SIG'#<=/K%-[9O!\B_B"
MSX]!5U-\."!VF.SI83N:4BDS"71V?54:D )^+\)1-YA$8H'!F#)YR<@69 @1
M!<9Y[NB++7/AFMI8RX YH&V=0Z[BBT,,*4-,X\D '3WX!]^58&\D$"UE@(7Q
M3"CJ<;RIHF+._I9%N2/Q $ZT?VF@0;2IG!_S;EU0(PD<\A\*?M$,<*.N2):Q
MF;D@;9SC6%,[SJ@6G_XB>?0.ODD$8 A_=R+)WN+B71E%PP^D#,4UD;EE5,84
MH3%[GX>%-DRA*+^<<46VL:QACD@F\S+G.&I-!&856:QC74QDCLV8?Y&)R#AD
M_MW4R,1%UG@@8-/F]PQ[Z%5 ^-^-S4QI.;Z^/"V57WG!!9LNG-Y=]YR2&7+-
M]TY+--9!]W!*:&#JD\W(, ?G0*GMJ'OKUOPI //"5?CZ3-&&KX#J#UF@#H1W
MUMRPP^?=ARA1+[2YU!#(7]JK#6_KH@SHS=J.6BBV^0>,Z.P5 8NKC&FH6,'P
MG"XUQ0(R).M\M%6#L#*WS[I2^H=E48 7DBVT_D#,OT[H(^XT=&/QJ7;I*I;Q
M$Q3ID@ Z@GJ]*T9NF_-P>+CV0,8>/%]4[P7&1P"B#B!+%]^%9F8!K=FKD$VL
M'POD>23^6)!!R??!,6AA'(!VFN:0;1_^+J0/8?:"VS )?)P.IPA\(@D6'C+P
MI N+C,]!;U4"1P-\;@@/OQEG>"4##'E<DP._*'/3)*-7.=*Y(':9F^%(<@,,
M\DGL@ZI=E 5,HHDCSWO%3?3"LR@S4YT<)1OD$K;-07F]U-4H8=(O.9OCR1+4
MI#*!KYDY!@YX+1)J!33-._'/@Y\=%G9%SY]3JE]@UN>2!FBYP$RX5W/0+=(R
MA=7K%F6 GU<] $&3G\799H&9%32(CV*9K/08#(543&7B5[UB3 TPX7P0,T*L
MS+KPZ+.=&'NJZ$L,/"P9SR#J7FB6'D85SPW<G(![YG.6;H#JF][\0X1RRU19
MF9"M*7O21>2YXQN)AW05T%SEU?T4?>'@UGB0/O!$$B9>9[K*Q8J8O$M<T#-.
MH_..]8M0@)[I&&CUBS1\,[DD:,  )?XO&9?7J@).0%-_#FBVSB"'"!\ZHD]!
M+B[DM[\L^6&YSD E6$Z3\=]$@+WX9O''7"-$SJPZN[P2LLP.Z/9 6B(DSIGB
M'=E@=[H2WP[K',3F"9Z&B4-?]KLO!*!BUCA#JXW%8&1#@X:QRI@X)FS P?)S
MJ/I>*D3(\?$KD@+3\0+NF:H^GE3]P<,!+O%&<:X"$*.09IL"42;>3>2S1>X0
M&,;?&(2AKB(AW!.VR]Q)B^,A1!-H3Y'GS3DN#R98GQ1(:F8?KI>]8BADZ/=^
M'= P:@#C]*C(#GP!!KA?%1J]\'"F%'R5O=1[^$'XWB@#)I!^$W#%W18MO>0!
M00$<X=>25@N_R@]TP.E8;D&CND_5 N;WW+3-Z4-_]W_O.>>0N"#3Q(3[P$>R
M+4',N(^8W! &H[X;\+JF(=!\<YQ["2+A EK".%]4FTB^>L(\C% /:(C"N./P
M5O8X.><(N$_"#+ '_I1!J_-'V/G$X?*!@-)4I8D5A YDQTPWK%C 5^7YA!D"
M47P!0,_'L782&_JD<^1C3+=D$[3<]8'YY(^X#O1[QQ0'VXB+L_A -2(%<([M
M;*@\/>"78OA?5,_VNC%J4IU &GE!4EX,P'N?A&1^)H@8%_G"6" '##%U=V%4
M6#,$AQ>+P*#$2R#HXW1  ;Y.%,7IB99U&DWU^DC0 A7.;S4YX(,T"\.,']I/
MP<F?(;LY*;!B2XN$'SX2?V6:$B_#0("X:X9/PO)8"!+R.G;R]*3)P&M0<$?<
M* Z7=$#"3C2.9#[TY*A,R^%*<:E3UN4R([D^V;J #T=VX/03-!%T!D:[M4&F
ML*8U$Y>5F3"0I(40]T>_,"&: !G&%3"%]43LQ &P,[@J,M 1,GOC#B^/BB5I
MK#=F_'%U$$VFG S#B! 1E ;J(,M0))=0 W'GT5&C 1!G2.K\.CD088F5#$X'
M&4D )+L'8ZV$2P^/U"FF"5V9W7?-4'*EV]Z"0:A(Z5XCIP68-36)RR%/E.YS
MW1B,B+D!O2%J6(C+H+JBR8X@SX1$C%3 #W1A(B>FF"TW$N%7#J[H=$WMD0(O
M<3CFB"VR8.(J;MR9EJA=#CS[I6@_H#TA/5T'HLP@XDU)'2W("VU"$,(2N1I%
M2>T(@,OS$3CA!79U(#]QOJ@<!$XSF9&B$0(:A%S\I'*,<*I03*P'2W?"VUV9
M'^0F'/%'>1BB")@3K .R19ZLRAEX$-V?A!IK$5+MU.05!7*!CR?TJD::@8$8
M TSWHC,/D0.+QO5&A(/ATN3QH@R7.<X6+[J?N>X.C+0:840$"<7OJL3$%D0=
M'=0.Q3$B1E3*ZH,M"8.1ON@3W$Q=!W>-GHE9%0\"@/0.QFFR!>1%PSG]OW+/
MB(N$G/?J@+516F^"VS$PYT XSYI6H',4$HWS1V=8!SC*KZ(&;!H/=#B,:0A%
M*9 $0+G@8T>JDP!,P\#C50::YN@^X]D#^T"#M\G]GN\IFC!T)9AY%S69#X9B
M!YN0:(C!YXN=TP0(62<WR<]^Y[J(C"/1&1A 4X/ET0.Z4I6<I( SFYT2[PMB
M(#,@=+*8" J]QMTU@S6$Y[^6:#>U]PT"26!+J898.S5L<]QY8N2DO@[RXYW!
M 61E-T18WJ+3+Y8A^1\\E<Y0'.]TDI9D7ZU?=4"-,3UH7;\L\\$'.>X.+C"L
M,YJAA$?8G9099B21$S-!\("R>$WFX2T5/:Z,!CG=4A^7@1X7!,T,7ZR<0ZXH
M'VAG0F .ZPH@UB->PW)VS4Y3D1=!-28#WOD:3<@+6SC.&1=QFD+,BYSZU,IX
M\$6F)T)#G8W5R'MD\2SAPMR AJ4W1>3XJG+ +R94(IIT0I_E#+?6J=T/\3D#
M+D@5DB0T#^3L?*9_'#'OBINU?49R1?0EYTZYH TU"5W;DO\ [:\'#H42_ X4
M<78X6] $B8 YPH(<D#9AYY1A+(/3 8O&73+1$GF*0+W16)&<M8R"!&C!QY\P
M0/H*;+;IO=0BHD\EW*755]M7/,R_/(HPI%U/N@01#4X%VDU5ED3C7%W+Z1+0
M@'@NFZE4&FP)/<9!T)8H*.AB=;AE1*IL-O? TUG)418F."K+4L7A] /M4,/D
MQ-\E,AU)D"W=,'!(Z#L7[]/&Y$*V"\5G)R?VS(J'EZ0LO<Z8@<UF3!V+ZTPX
M/0-[GN)AECA'+/FD]DYPDX=D=(NIAH@QGO+\8H'<:PS <;NB9ID.9P%<KQ42
MUOQT=GBF+9D74A&CNH0%P@:"+\3NL*@;B7<?A<KB\Q+C*0 R?HKL, !S,A&;
MYQG&Y(&(B:0A&3LQ5<S0>[_*1>)@WE(JK59F%*9.KS4B\1WPY#7'/5 VQ9,2
M2^LG%P0:,0##J7RZ:!8MDO E-QEG%-.)?D00]P>XCZT06+(G(NSEAN2-2(QX
M&W1P"4$0+WP Y\.*JT(;G'"4']$$&_\ M$!A@,LE5EF,3G'.&Y<XVA'^X5="
M5_2Z?< Y\R_ 0KIH@( ?&<8# X)6]I)T0(<XG+53V;<VB00S)S@[4ZI6=L*D
M/P?EP ZH*,UTNZHL$8GAEQLHL")J'%0#6KQA*/5 [9 C7"D<10HRJ0<-;T$T
M&@\/!DYP,Q>*+(?-TG?5.,:H)M$D Q<]W!\S@C_$"X-/#HSPDY,T(0+J"+_C
MB@]T&GEX@=)/N* $'_(@?XU?59DF!(GG(75,V)3 =8-R4OY)AS0BY[QRF?&]
M!U UU KTO<E:$"Z9[EUZ)&=HZ ,IE_?/).&I$8PWX]$$R''$0>*/RSU3.KN
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M!TD\JGQ92/J_+CBIEET(Q$TC+W&+X[Q1WA!5F#S1[K/>BH&GNPZRG7!9MJ
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MVR T\";AAFX]N"4.+W2B-_BF: ;39^7 U\8"J5ADN_RC,B,ABG(D)/PRB ]
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MF[)U$!V@S=*57],L4 S)V+M](0BBT78O,SVE]"25LU?KRK5!3W/>'Y^7J/\
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M,[JSE@IEISXPA-%EM^)QW2B@N #.#L<NN14ZG"KGI0#C*F.>;I)\Q7K*%.*
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M9&$>WU\H$R!%ZK$P+I/?\:C ("3$"O7.^:/NGN$JWY4V3@#.9RA#)-A)P.]
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M3R=SSMR#8QW7D@S"!WW?AGXFM<D ]E#?SAT09@\\*<IQ0:;\:'Y*+6GR3<T
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M&]Z?W2D*<D#!G=O\I"PZL*:+':$OW;Q<$H9?"3J7! I-:;G/^MSLT/># #A
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M&ZM @<EU-VZW9HLM;L]<N:FT(N?C6<OKFE+WN?I6W(,#,"D/O+NF=)_ &?!
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MFB6JDUHZ A.4 D9 GP DZ5)(*-$TD[/GUS0&&=,,G(\02(.EA+-9JC@_*^*
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MK@$Q.ESX>$!(G*Y7P0S>[ <MQ4Q2(.3HZQ5 !)W5 37AEA96;&\XX<>"Q:=
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MKS0!= N>7RZ]L^"<$9O=V4RYXJ<\+D@9G-SG?'-%D3,R<)3NPD:P?>]4#+X
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M?7)-\FQ8=%2:-0:USEP3DPX%_P T0$ESG/ISZ)"T_P W]I0U.,: X2==423
M/SI) 2QBX5Q*#X%PA &[R2.>\D%PQP^:T3$RSB)O^'004&F1OD$C+4#*9[\1
M)2)(@8R?,)WQ/= X,@]]X60@T'3O.ZI675,JRYT*JVT*"('+N@BU*472AQ2,
M?[9DF+]:Z9H^RM*;_%<$<R*0Q=4ZH,67SF(AV"SW"0SF/HH,'[E \+"U!JZ.
MM=R!VMG0F+IGMK7!R4!SL<SHFF^4[=T<I-,U[3N/>2"X-1#OBZYR2@9[LDK
M,'2%*Q1_C,"^ PJ.C^B E\ ,)WQ6?A(4QP+E-HC,ESL+\2BF9C".$)0',X(*
MG!]ZS4VC U=" AF':51]N>K\.\$S8X0UO)!'9MT(@Z)?T3D2?$.>Z47N W>$
M6FG.#@=.IL!9_,71! F<","3 _:S+3WN#G'_ !'*N"5U:"DR\T3AGB!"L2@9
MH5?AE.HQ3,PI, 64=FP]\'NGX&?9$ETAN>^.$8"ZH$;,A9^L-RQ8>X'G"*WN
MR?RUW^%1FE#H_EU/9!FH2I)U76Y; $ UE$$SCOMR1I\ Z?:+CA@F]M>K^ERS
M0,T)#,UNXU28.,+<Y M8&,\X3^$[&!,Z=I/H46ZFTVCP1  $\^_)1:D) .$:
M.G'<]T$FU;9#GF&%<P-:O0?_ .C 1X8<$0P,O\8.A&?VC[)1?B*G5]XJ3+&9
M=TA'*&Z"<PB_F\OIIV0 "F<+K@B [Q6>>,N:3:-N<(QEW=@,"IAB1+YAP>9C
M&R@HZ9!A<-V"S#3X.,J";I:#[3^T%\'5@:UE3KJFV8#WP>!]Z820+RP'G1%E
M\8Y UTT"S,R2 )N-77S43M(AV+@\NQ?]H*,@ZXF!W#+Z1+W<A@!(GC1_A&H>
M'!\)7''!':%U'@/  -"8UEJ@5DNJ#"F[D4D7N<ZI---Z):EB0'P>, 'THLTS
M<G$3R1;-M&I !PN>>>:+.<(D9APAE<4K7_:_4#&^*'\HB#B&B!,"75$,T[B7
M;KY*S>8=$1F"[GO47OB(GF;%$PVCL'%PS!^46S Q<8.CC/JL15\;EST6%'N$
MP:PIP5&RZ4ZG#(! C0Y\ <,8H"+A''0#.J)%3*%NKW6+,H3B\8=B["(1J*<A
MRSI1!JD*^UPH-46C(/<+@!?!(QK&HIP,T8.SP=":7:$/&. -/EW5*^8<]^!@
M73Z3DG#4:2AI@/.Y "R8&#M,)9+,C"CR34[D6FN!CIG<D '/CF*P([]$&;:D
MXOW;KTDL\/(EA496=R5X_P!L!*G(3B_D4D8F5PS&GV@9@1A2/8\ZJWMD:&E;
M^BI,M0?N F:$/N 2^\OB0'QE25.M4%"S2E':\D631V\B%X+,ZOC"^2G_ "/)
M#C)P>*Z]]Z!F9E\:/SI&B#!X.!IBE)C5\9:1+A@F9Q<^3[W4@@8&;M,^D0%.
M&>Z9N2=O@>&2F0_2(>^7G1!0;0FA>[3V@PCNN"5DT9]L)YZ<S%9@0 D^$:SG
MPDI[@YQXY2W8( V7.)#YP^>E<5TLBN<**+!P<Z<>'U54?6SV$*()Q]P$A$ET
M"]RH3.#X5B_,5W%*2^0?"9-\%0&IGC*(A*5A GNH3%T,0E:$->+Z"-$/:XDD
MTZWV0A4&DNOP@S#X^X5R.?!U%1MB;Y<7:=ECB*O&F$2@,8ET*^/M!0;1PB'#
MF7X.E+#%8MAP?$N>_5*T(1#C2O2P^"G[90W&,\LT#EK6'#7LG89D"Z,<OB@"
MF[!_*_B"9\G!\!. L50.11T [?'"F:4#%[Y@TG-*)YU=+<^XH8'4!\3PW(&(
MQ=E.$;C18MT,0\#S$3O>CGNK'&+H_2<&I@,(\T#"&FG7/.BSW=>-]UF6WB$H
M.-.$X(%SG2)>_I6]R!2R\X9X?<^J=D4D'EYA&4!WQ2,"#Q&,!@*PQ<F!X'&\
M,:H T079'C..[(($S!F(0E\)2P\X!\R>U(J@% "#$E]72<@5PBX&<GQ<'8WD
MD#1D0_OJ,.B>+@3 OG=9)34NE5_= S-0)O#SAI7>F(H_<.@\I'.ZX$903-$P
M(>3%VFN6<T&(E_B7D1?KACU3)&1C.)CP(3H'(W.,>PUE%4+8K3K27-1 ?)QC
M-[C"?9.3VP?! C33G%Q,XCM)R!9D07\IQ [:IO=68GQD^\U$M $/.9&Z6 !0
M5]QQ@>.$\DYW<<*#'-ZBRWE>6*=H82K+COJ@HR;Z.TX4JIAL0?7J+JLTU%P=
M"NZ\E,"1='&GR@H)-1D3-;W2?6!>]QXWJINK$Q(P5 [4/D<:.0!D3C#*5?"I
M[J%UW-)[1F[&:0LNK.7S'>@8MO#Y@/$0Y%EFO$:X)/?0B$MSKSXIP[&+W:.Z
MX(&,0="X1E?R@QF8<I(?6Z%>R<LS$2(X.SX()M1RTE"61NJ9EDQ!W"$KN"P$
MJ8.PS3-&!=,EV%_*#F]H#R>9W0P5&# N>_>,N<_A1.S,Y1+WU=;\DX9<7/I.
ML)(.B<94W_')<K34"S6._'.X*P/C1\MZ5EYD(T@.NJ# B$9.<,^Y0VC8A-V(
MB[47%9TP7/UEFL0'%SXSA09T0%DOQ%N>['HJUH'0&-WDDV(E@*$T'R-%FCA9
MF'WH@<,NB^9X8^,EFQ+&3J?/9+BZ!>XS3PF+I>2"0#IE[^0EI\)GR&%;X/4R
M][P,]=VY4?(91NW("#2(GOT4_=03+Z/WWN5'/$S.%'PY8A*R7/TA+B_/L@##
M5"!<LD=I!T'@N OFE]QGOAAD^H@MLVI@OC&.J!8"(@3C*%OBK$"!@!+<)ZO4
MFS(8P F0^:83=1QS^L$"MDU,Y.IGDG$8D[Z/^:I0,=)7NT2LL4>\(*Y%\7QK
M]<JXJIH*\XC/1W-<YQ)EPRUNB;:M2="0/QY0. \SC7=UAQ2;0%\J0PGR5&H#
M,\O,;P3:M/I,"\$ #3WOF'0TJK,C Q@74OX4F7?Y.#X /?UN24;6IGAW%:30
M,=G"-"\?* !IPUK\8+ OQR"1[P3&;I]MR"[!$:COX3-N<0]\C?:BYA O#R"(
MY'-4]SXX"?G>@Q9EC*ZCH>"HS0@.#G0YJ?NJU 8X&ZI07B<S!R"A%)&>NN0*
M#.>[#E=$I/\ DR<(9IVVHUDYYC>* .J Z7B%Q2^V(SN<TX&'SE=$@X.M^^P@
M.CXS$.57/Y)@7N?+-)[]XTZ:[T",R#,9H*!E[INB7\X(>Z6$8FF?2'"2 ,W&
M+@Z.-R3-,XG2^X0%D^8QX3S0]W_<)O,O%Z)0.SXB'2+\D:PK/.5OF@ :F_Q*
M*QMV/S]+/C+?RA\[DV W2="=V$!<]P,G6_.ZI29NQ! R XP?15(D_P#VN=K9
MYJ+< 72,AAIA!!GU$O*=EC&QV/=3$9=M7:*H/QA.MN08"G%W#?@@2Z(A>5Y+
M#"3G>?.Y C_<[&[<$" NH][GWV50'NSTC>6BC8WP<3S*NP<MYQZH#[8'-POY
M4P,X83LX)S@Y^C^:GD:B5\.* N$3RA*^25]<;'U5%\X/+W<KR6#4(W<R@'M/
M*=]>RPH+^SU3&^P4V#YPOB@Z1(.G1(Y_23^5S"@6Q#K*5S3LMRLF/1!4L@0B
M\2NN: P@_"4/&J4B\JCQY2G4B-!OF@J\G1G<,_OLD<(P.Y!T)TN-\$&1COO'
MD@=DR?STD@8<C#IV2..KX@/K@C@9.!'QOH@<TGE>B 8C &]>RI[)86^-N2^[
MD1PZT03]VY[]Y>[=95==[G109QF80<L3'(NC@3)V2!7ZSAE"5\D@$7TG//%4
M$^6,X_" G$SNF-P0$FL97<41UEP[X8I2U-_WH,D&/G.\IH"_&DWST09@7@NR
MIJG_ (WQC#E><4GLTY0O)!1IK"1J$AF)'#QEO0(H_+"\D6=H! @3PPA>* X
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MP($'">]!D.,]!=N08,!X>_>:SY+>W7CEV^D]V?&]9D3?"-NH@5AFKG1M]^$
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M>FY3-"2Z)M\50-!Q ,'0C"]4$R?^ZF6DB^:JR:X2X/KWQ2/$IUE Y[DH:_\
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M"KYNO>G;H]PA/MVZP01V6SQF/,('!'VNG%Q!\:&Y)FA5Y#G2N3TY$C#/=>]
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M^(W"C1E/ 4TNJYR2"\O,X2O#X05&SFZ(!N]4I#W/A01I59F9S$*SY3XIFF9
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MLMR7:&,=(&28"HI\D0T1(GB0-]PC3<@0&<*;_I%B;L,X42>VCZ46V3,[O,H
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M[H_KF@ 8 D*XIQ+C?PHLLR@/KSHG]TG"&X;Q?5 SZ=YZ97&282N-TJI>VO7
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M@+7_ *+J=[@E=B)2GP3#_P!(Y.OH](WEU@^]R#!G/O\ 7=4+H0G2^') 0#S
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MI(Y( 'NC-\([OB*ILZO%(2$3<'*1@8@NAH(?:):)>9" #W9]>FY&JI*XR+Q
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M:&<G4TS".T8?(N?$8/%-Z# D.@2#=Y*O\T'M!SH.SIQ7."8!SS&6!QO15/\
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MZ_"5\\!ON"!'W1.&G?%V$K@*CYOPBV(72B!SM)%_&.2P:G!UW.#IQ4F&*2A
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M8_)T=V*+347$7@I^Z0 +M7C-W0XT6]OU75V&2"@E$RA#&^B;^. ?0\+XI"S
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M_:H3D[@YVYWA0:RDY[].6[BG]T@,(W5]<)(&(?2$/&[N4NU(=$_[>FF. 5)
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M3/,B3XO%R!PRXEPGPN\4UW;@E]V=^!59_P!0P0'6\4X&$L,;B4CX0SGQ*9G
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M'I=.:81PW>:+$X6<+S0 OP@H0X'/.]V*DSC=O3E\MZ!<>PO1 3QGQ4VGB4<
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MY^$Y$LN9QS@C4VR#^,0S^.OPBTS_ -KN%<KUP2EG$OCSPQC5%H3S@,G(R 8
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MAB.1EC]\G:JH$W6XPFY39H[E\V%=MT'SC]OW(.1[SA=>R)!@XB.[XX)/:/\
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MYOCCWX.Y*1OZMP3,ZNIGH@#3.$.&D(I6,3?AZ?VXTSCN2AES]0;O@@5LE^O
M9[U3+!S];JE9Q?=ZN'(@^;K&B"A,Y0E*G90 EGE)Z8%[Z1CC=X+$\24#D882
M^+E.:DRWUW7T5/(^BEZ/N%T09S^UY"3DXTA+.X1460ZM?H15/=.[AT0*1$%\
M)B%S6]TXRKKE1[T&L!7B^' .X*9V;M2[?EO0$:X0[^-%4#IN-X50=D^$:QOA
M1*T:=4!>)DZ9ON+TI=I=]EG#%!V5':WGV0%IMX)9H84RO'<D&S!B7Z(OT,*8
MTNBG[\8 %F&B#I]LL^OC+L@\@8C$][Q0+=';K^DK0,W^?A SWO=)V>\Y:HDN
MA9&(O-(,99X)7/+GD$0G#%!7W4&[ 4NP@6G1K$=KP4@P7TB8Y9P5?;#"ZYUZ
M(,&1*-PLJA8 $\.6B3>]\3<AIP69:>Y]7_2 FC@\4^IZ9(@N(H_"]STGL+\@
M>Z#5 !69,T##= G@).6+3QBX5A@+YI66(@DN$^:);FX0O&IX(&?'<+WI@,X4
MCNA><5)@O,83W.Y\WHDP=G'(9#% 6FG.=N>;YI6&INGC?UO2MLBI+NOA.613
M&3GN^900NHPZIS/;RI;2)JX]!?!:&(SSNJ82?'ZT0%AD;G;QD^]ZIM!*3C"_
M%5!@OXWN&,MZ8&A=/COJ@!C&DKW)6HPI?;<@V'B&>[Y3!B$72QPQNB#>XR U
MKH?A4#4L:=:<D R)C2\4C(D <>/DH'+#R"7U&\CQP2GEE#4:%,^0,3E+?<5F
MI")G'P_X03,JZ$C>%1EY#G%[SPHIB4]17BJ,&DL]?%4"0<("&,!&'A*3/KFB
MSR!?8PN:S3;Z^!]8(#LQ76DL77HJ%F^C[SJE#4M.>)2MF7"&L4#-M4< XEYU
M4VB:8]T?9C&-0<I13-4A ^,OI!HUK+!8RB^91]PI>20F<9GM#09(+=?C.J@U
M3,Q)Z0QFFC*9U WY=XI?;B<>*#-M;G 2)I3+59DZAV(AN3M1$-QRA070I#N)
MGF#<D%&BZ(Y9S2-$",O/GLY)[I"M;O"B9H/B[7+#C<D"/U+S42&[Z5&6N&)P
M\8/2D%[@#*)/9^)6?,P=$/N'! 6S/<[/=B)8)F0X1?6+[E5(]]'T%-4&HT<+
MI;T!8:,G$CQYP3-F!?AUEI#!/LL'YXDNRHCM7/D79TA>B"3-(2@7SDG]DS1P
M<.7QJ]!\'NDX.OYX(/)#X[NIO1 I8Y].C^ZHR<H2 TGQR[J+YQ?$<INSMRJ&
M8.(^^,D#$Z1,#IEF$.@Z/P69 A#/&/?DHOG/3??5!5KY<9.,^'1!EG"?R@P
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M7"WK!K/IQC<DL<8R\?4D$HTN^V"(?4PN6;U, QWD97+3!4]L(4?*X($]N_7
MS59NPR>ZPE#5# T\;\"@S"?SIX>@K3A=RW( /JZLNER4WRSN57\DP!FZ_/5
MWLY>._!)>!%_:;W91Z?<?I8BKT ]SH<Y_"79-4 <X=YOHJ,D&!C!, X'K% I
M-+WK.!W=+NB7W/[ZSOFG,+OC@@+/:0I?VB_EXMSZ%(\",H5)&"WNB#2^/9!1
MJM\$/;!_)]WJL]SH2N^R3WT&@'/N@H!7IHD!W2=\J<M;^EGC#C=4%6FLHB>X
M\!B$&3Q?E*J7K2^6(2/Y<'"^:#I,/]N' I'8AVAW<\JHC$C/>_X\)@(8X7B;
MD@F1>OE!B)Y<+JJ/RWX7#1!^Z^U<9H&OM26N]*<-WS>];WSW.%5-[Y2P-TD@
M8M2^Q86=&]W!8CK;^"S;-12W009HQJ!E+-58Q?A"_*B"8BY951>8B5[N2!ZZ
M]!VU4/;WOGAR5&8$^)NIHG D>=<O!01]KHX2-R5&6)&...(\*GLR>)Y6,UG>
MV8PO$V)H)M\<_.CY;U/9B;Z]<CHNG+GGKT4&V3NHXH%:+I"#Z6Y,Y\<I76Y(
M 4X/\;W*#;$7OB)TT^:8H.T:7OYHDF8X;K^UF6X7]\<8(0^NM;D@S+#^?./*
M0PJM[#GK/@F8:E<ZK>^E<>K]>2 "&>"=^3QWN"FV/CQP4-HW7G*4D%"V3+'=
M"YX9J(-#;NBHP7B'S<>BWLSTY(&O7-./$A7MX4@,:$PDJL-;[^$ ?Q/<2S3,
MYTUI% @:ZV\BP@1*KC"\M\4#ED#K?#RC[]+^?A3)M^/W\I&#\==^B"@:QY7P
MPFI%MU'QG+[#D[^8P[_" 8H>?)VO! W\LH.??TIM'S=NXQ+6PJ_LMD0:<,T&
M9VF-<M*<N"+.0SA?'#1R7VBN]^!ONG8RMWG- 7X@0=>ZA3 F/B[FG>/$+T2B
MI[WD[P@PT!-WT0(OOF$I'^6#N6F2K/*5_:"1#A"N5[M4[(I(W#AT2MX3OEN"
MS6-\4#-B.Z5X)3'1T,5BU$7!U_2H2.3^*!&&#U.%%G8T\XWFG#4\?ATK>@S'
M!U.O.GP@+Q%]TOX22X7?!.1ES@^E^5(B@F[<$%F#VN-E(0Z57W)2]W%5]X='
M"YRF@FTQ+&,M;[*P,A2-[E-[WG#.W+9\;QR0%HBF5ZK;/7&^SDI.. +M>93;
M,#ENT0%O2[NB4'?SR3-\L[C%^BD!3ATZE!T!K"P,%)H@N?0"6C^2F]UR&85'
M3Q^I_$T#;,UR^N2<CO*YCO@I,B$<[X\ENEWN0,^J(-.6$;W)/=C>93YUPQ0,
M_28^NZ& N75*SFF!C*=Q08#A<DY:Z2W^.2FTTZ&>_P"?A -S?];M[D%!3-S]
MP[?*)9OG-3!,'7!!IJFLLD%&7W.%^%B8QE?2J1A_*%]!Q2AJ/*\$%'WWUEFB
M2^]W- &F%C!U5-EJ;\;XX(*EJ^K[R2MBL!<WH5ZQM_1.W&&%;[Z(%-]+JF =
MVNPHM9<<,?A.RUCO<@#WTM\$';G;[^U=D"??-*V,*:<-4"%4!4?;AE?E.R.U
MZE!BTY^][NZ9DPN%S0:9^GO2@.A2X\=P0((OSC\B\7)_;>@G=(A!^2#),0(=
M$#PH;Q3C<_EOTIJH2B_$71R8M?7CP@<'PL_#"^3]2H@QI?0K/I\\NN:!P+P[
M2WI@U'*^.:1AASR_BAIR04:9OX\(M"!OAW\("W<KQ1^KUMR#;-KKCA.64T6]
M7"#DKG4ATN:)$C6%GO1!(C#IWT0)PN5O5FH!^6=QBD @?J]4"/B^\ ,'13C:
M"[XZ*0:RW4P>."9F'5!5@=],HI&F_K"Z;E-[NW&YK/C+4W]!!8LU=O" )BZ0
MJ8V4F5+X=TSKB@SPD>Z+X551L\WB6BE[8N=G.M>" DWDJ"[^U#VN@#]X\>"<
M&[AV05;.#M:\K>ILY7"* X8Q(GTHF>Z1PPO/% 78N'FY8)B8'K*]\TK7P#<=
M$I;OI>,T!=@.--<$WM=4WXY*?NW;\\-/".&9^4&:JXQPOKY0V;&)I=]ENKOC
MZ1Z/0=#&U @.'4)-H7F&5_*FS?SOF@TW>OG!!BR[XPI#559<7RAE<J)66L8\
MLD0,*X<N"!&[@F9'1]G=P0:#J;W]N:S35!VPXH&=)QA9GRYI17K!)[I/UO3#
M<@]UX7Y0/&-RIPZK =-)5@LP9X5IN%O19%WG1 0<ANOZ0]LS=S0&5YZOW(M-
MY7V08;K\)FFL=?J^2DTU2[.:Q&H@]UP0,TW,4GT'.YH!HXP2/IUOHG#5^/"!
M#M*[J13AG.?*.:0LXW'M]IRP>DM:(-[=^5]$W32XJ;[E"\501&=Z<T$_9KNI
MEOJ^>Y5(&$99I 79GL[.;T&V\=SM;WH*"I* G;GYT2G>5G.-V[I) WNIG)(6
ML)B7+GT>J /S0_C<\U0+JY]PU5&!CQZW0N0($=U:=-Z++6&O@ZT0%ED!\*<5
M$C3<4S1RC?WU6.D>XE) KINK/@IAA\S WNI853AC ]_M*3'*^R!L!E=RDL6L
M_J5O4P=XYN?;LTW*^TM$%'WB[&XHDAT'2&M]%/XL:\E@S,X1^,T!!PW1ONLP
M)X7.X;T?=E=T19:G=A ??I<LWW-*T*ND]TN%TP3=!.[R2C![J00;%VO*WI7F
MEN^;B@UB+XVY2>9.?ON""_NQ<[/%3]TR)?=:ZI1 0G .UH[*W)AF!F@1HX'G
MB:Z4Q1!>,XUPY:HM,YX97BLRZ#M_)V] 63IC=P5/<\I73XYY7DE?E= @J3>G
MRX6Y1(/T[,*CW7TN:#(OQ@@B+?6_I,-F,-]?I/['7C;]4 3P08LF4(2OFD]N
M&$IPO/DG)<-VO) ,[L_B]R ,3E?2'6B9^CNVKL4&,Y#AVXIQ6_E S0%9G#O@
ME,W=>+_"#KX36;@+GAVP0$9]*ICRQO@2H,M'#2\?E4IAA<[<@.LK/TLR.5V<
MP]"+G8[I=^SD)2?&WQPY(,T[>1?%%@]=P[_:D6IY NC62;9TRP0,T8SLV([D
M1YRW:W-*&9F,X/IAN2P?73)R"Y'+E<L4'5W?/9*"(8T=K9U6?(.ACC#QCW0%
MH3=SZ)6<27TRL+-"6B#KX('VC3QIDEPQRR)[5[(^S/G=$/=0/N;NR#.SMV7(
M8I3%]'2OPL!]X1ZIF1#B8YRNLT$P*F=!WR3 5#O -=>RS675]()&1NGE*YH,
MU, 81+L,,IP3@2E)VC@[>LPV!/Y\WFB3]7EF@ .,0=UN1+7&_I+.<,CQ=Q2-
M0)+HWVZ/0-[<OB28\X7N2%KG?.X(,CG=YH*,"+QULE%LUF[D%A"MY:H-$CK\
M(-[C4@4C=R4HGG*)W&X16+S&CNZS)(AJZ^G% [?0<;Z(,Y[M,E+WQ<*F=4_O
MB,KO3!!4N N>]3C2=+[K>Z8.MFB5M[]+A<$!]KB"=+QEDAM&S1SOEZ4D/#[O
MC!/[A?*>Y!F"8O(,)! ,S=>.MT0)P$Z]UMC5^/U]_*"I)DZ.E\,$,J>.F?9!
MY$8FF>'5W)8:0OO#7) X@X#J\[]$2S6>#A6-A)G9N7E8&?#PBS)GU$ !+'2W
MJ)+S(CSKVXIW\83=0;EB>HE*-RH@+ @^._@-=%FS!XWNE>J/N+B!P=?RLU+'
M"[BB R*N<YW2^B?$Q=0FY]G8(B3KL($RTF-+[(,69AX/Q]S4RU00CR%OQ6?>
M&@6%OF<^R+!1)\,GBX)V12#X'QN0VC@("(A=\$&)#&4,,H(3-U"79E\?BZ(@
M0A$TXS2$0WP<B_<.L>^"(0!SSTCI\21)ARB(Z0X\43!^=2D9(QAEC@@;W5B,
M,'D)PS6P^%Z/2@T SUN:;*/2%+WH&;9EKP69$(P[GRB:6Z\%._#GS*!8X8<N
MO*"MLSB(B#];DE9:,G9@&JF#/'*XQTS0(69NQ3!@7IU[JK5":UE-!MJEO[!
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M6YR!V"#!^$^(5-K5SI#?\FBXF0[>>W#=\*@:I*[TP0.VT^(&$Q//DD8$GQ'
M#/>4_P#)3IP O1!F#Z!]*0BX! &V02\.>YQIVW)V1AB(<(*08PJ3?"-E59A
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M?=QX3['1$QE/?>2"-9.,L1<SS71LZW3QR7,VP>GP[56$)OB[?F>71 6K??5
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M@@R+O>K NQOMU4_GXTPU56,)QM^>B# \+WW 8*/N-<7#JJ%J_BPD:(IR-_2
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MD]KI"L'NO>G($<\XQFMLQG7EU>[<4"NH X"6=23<TSIO,!2+OI%HQA+0S0J
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M[K>LZO/"4!C]( _"8BM#<B@YP9X4G?E69-8OSKXBE$)"MWX5-HW_ +<Q2J"
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M*(P$:M%U[G(+"FGU"GA.#E&5WG519,W3KVAG<D[+3I;Y?$B@<"CXT?=O6:/
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M9'HE]W9TYWA1,6LL;O<L!=Y409]S.5T6!QII?!*,!TXIQ\X6_P"D&=,Y(/O
M_2#]W@B_M8M3N_E!1AH1&;_#\D/=PK&W)1=W!RPY7P0.&+GI?1%IK"[XK,GD
M*_"G<)WF@8&\=+@B_/YKNH]3::Y0^82O)9EJY7F4#%ON\_%N5&3;N/Q5<OOO
M[NBHRU>_H@9L];\OR2,G/?=#SDMM-H-]B2PQ#M#TNDD%_=$>,9)&B-+[\DHQ
MP-SHJ.$]T9O02?=51G=G=Y14F]G]\>EP5-F*7>]!4RO&^RE0\WS3/Y7P/PI$
M<(XWN0$,R'V2):JWMN[>H$YA[W:;N3T66CC>'D5W(*-V.V^JG&(E3MU2C<:8
M7@F]TL+L64!(=/Q1!UUMR$[C\0AQ1!TE?AR -EU)IF&H/E=:. 3-LOGIXU#D
MCL*7XC- 7WII4(>["[HE!$^%+=S0 ?N[6)810/\ &Z[@F X5/5*&KY<>B(-N
MNY("_G?RY*]]N='KB@^]T YZ+X7W0%ET*7>:=HB7$7!2$3/EP6:'CG&2 G*Q
M/YHI%DF5WFGTUO&>Y49:<_,W- OM=KT2--<9K>Z^L.\8K-"_F?%!@:;WT3<!
MYDAIS6!#]_S9*"@O='+3DIDSRA@?$53W[C <Z*),X#C3MX0$-<.H[2A0IFNN
M.^?C5!EF]_1%\-+>@FQFF9-,Y3^U1D_5[^:.T$B,ON]$#.= .Y7>20GJ \)
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M6Z8S468SP50:8];E3>E99Y0T??! HSWP6!G-T'YV/*=XC/#+<2I^YSKT^?E
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M>.2Q'U/1_1 -9:YT3,9EU]0@G[;MQ*(%_%]5M$2<$&9'TF#4\GPX3O&B49_
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M+XB%-;<H^ZDH]3WZ("SM)@ ET#A*F5S3>]V4MQO<E+3J0)GGNY\D33,TNG)
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MW3%L#, RI?)!)MHRJX.XWNW)W$!D'_(S/8;LM4I:$W1[>;FG)DXT=>?1 CC
MDN _[<^][S[GR.<+W#FE+;YSZ!;9-3I#GG3MQ0*1$OH(GQ6\%?9LQPKN^%!E
MK[H+/)7V=1@\V<T%FLAV<+WJ):=/[*9[X!PR=/=I)^:C[2\O&G06)3" -;1\
MIOZT\;UF7O,G$4,7J3#WQD/"Z=FSIB:<+AH@+%0Z$^D]*IF3)^<7<-7<E-K:
M.<1%[^>.:0$P?*:"Q9H]PXPKHA[9C)!]W>"SINK#S90!D\KC;ED?;1T!3-!&
MHF=R\GPJZ>74)&LL!"_,DQ?-U2\8X<D[!'9V&MP1E$%\QK?1/E4$90/FB#IG
M7D.JDT8AV3P@9HQTNW)2R^,12*Z60#KSP7/[8D&MO \(%9:=5TQEJ[2W*GOI
MC8@,G]%FV).EQ4MHQ*<I]K[H+D/>4K#>$8W/DIL/<Z.'A,SLZTPOZ04J\::Y
M*A,!2FE+=JN5A\0Z9Z8JFI([#X^4%3!U'3LJ;\)2O1%IK'IUQ?DD(K>1ON@/
MNW3EE?=ZH'&W\DC^\IF\J)2<( SZ3UY(*"$?B7D*;33HY\51B3J7V^%%H8GX
M%]4"!J<,=U]$[!@#"#\WX<?"9\X?3S?A-2#N* !F#C2+_'P7([++2XJ;)^!2
M\D[++OBZ7!!@.UNMST&B _D^?PE:F=V$47/%W/RY 6&J8I0RZ%";=SXK$7=A
M9D\L/-G%!0GAAUU3;(\).>-_!3]SYYC"XW529.&,<?L=$%VV72W/@Y)LSRW:
M9QL)V&GAQRQ?&6BS;+B^GSA>*!@UC=N2EQA@<(69($2/$7K!(["4S?CP@8@!
MQ#JB[@D#5-U]EF'E[KE8JY':LNF(\MWG[0.,.OGI13VQI&"=\ 1/H@TR#;X7
M/5!)DF)S[)WPK?-Q189H-)SA<DKR[R+X(,!-T;NRG,!"G,7I-,P-1=_86%7R
M=(7<D$66JU=AVWIP"8G-W;26J4,O?S75LRX<KH^\T'//EC,<)Q^T[$8&6F'5
M#:"-X\DNS;K=V8('9$QA?'[2M@TA&6(%N^$S YOUXX'%'Z-P0(P90394Y0X3
MQ2LL7\7Q6)B"_*: ^ZFE<!>:8?,KO!(1='W;EGNI=_"#.K.<!@1!5]LH[[R4
M?<;O*LU3(#!]XBP@H^^BG[;WX<DVS#I2^)I&K%<*[\D#,7P[5HB3*?0;T?9"
M]=%(F;IW;N&0/[>F:GIRP[?"<-7\=4[+.(%+TPP0(&9N^8:0^%)DT-'WVWKH
M:H[%Q4",+O)!5G9R,KO0K-,[LS\418/$.?K?*:VT:A"^-4$RR[C 7;D 9F6.
M-W1,(W'58,P.K\X4RO%!0],>KQ<GA*6LK[8/0F]URZ(OEO=*7GL@+H:;Z<PG
M%\9\]RD6_%\$?=5U_7) 2R)RN#EGT-+CH]^"Q:X8X_"6^.%N>@;9C"W7N1:O
MYU09#I9HOD_IP0 &[JLR:9.\\>80GQB/BP@&>CM+F@N&JX7\)'K,YX7Q0:/Q
MB_(^4!#%PO>$"U2M'NXXK%N!==G<E\]O* GA<]ZS+4(Y/O3DB6G0^;MRGEXC
MAN@Y ?<_G?RG9KKVXA+LV>/VY_1.&:(&>[?PN])/K=_2S;^*SO%]8H.K9;4.
M[8J3>TN[>D9IV-NAS@D:%YWR04+6?;KTWI@:Y.O)<Y9W1BF'9Q?B@S4<,W7$
MH'M(NWW14&SX]G>5-D/W/A]6Z"!N'5V*#)I#M=A(6I@W>."G[9[C=YO07;9O
M.]RBPSC"?WK]+9DXROJB+NM$#-M.E=XC0)V6KW< DU-;=>:+Q=NW( TUG?UT
M56&G;YWFN=IG3'MQN*S%XQO6J#H::P\7V43I?Q@F.<.V%YIGB)J^WVZ$T#,L
M6^?QQ*+,'0X7AS2?R4^[=-,&I1,C/,005:IE>2YFB7^.F'95+77?UZ+E::P'
MQ](.ID\WWX1VDYU[?:A[I7O3--7>:!@Q#PJ>T0R^B5SBZ7F:A5#4'#1U;?U0
M.T-3RI'HIXV/A;Z.>2=DZ3YH%!RA&6=W!$"3KSZ\%O=09OO'B@3?% 78>>7A
M!UYWV6]]PU0+5W#3I5!=EJ_BW*;1GA;LO" -RWWP2M9! KK&#[W+7''XQX)@
M,.F-^4?99[7P08!^->/@H/\ %;[9I@,*W]Y)"91QO'L@9YA<\[WA5]N#_!?;
M^ZBR08;J0WI_<ZY.TQ0$LW=A(R1>"/NX/OE(T2EEU\R@J1<])Y*;G<=UZ;WK
M,M2RG>%X*NT:%X2$;>@0 TTX]^DD[L==-?A!AL<(7<:HF]W+5 0UBZ[XH.Y/
ML=]ZG[G)BW>&^XH*,F]W#5.787A\KF+6Z^R(:K?QXR059:YPO!*T']TH.&'/
ML9923C2W7)!-EC=.=+^%4LW<K<AYOG!$C=SO6J"=*=+H@P88S&5YB"<,T^3=
M5$F5\1;GH'8+[OLF="!=3QX2,\#=;@GR=A>ZB!601'&\>NJ<'*Q][DI-\/HH
MM') S]SNE_"1KMEUGJ4AVM.T=+HD%B^2"GL,30SCD@R?CQP6#4\?KL[HE(,7
M">^\D!==WN4V@:)V6H7<$T)GOTR0(R3<<^"LZM;G=<E&X4NZ)SSRAA<8X40,
MT*8PQ0]@W:<+,D633CWL06?&M9<LT&)"8-S@>6"4C7X=YXI +R=P09H2.5]L
M]ZJR;X#MHIM&GS\=$63NO! X$?O#KX*+5XH--;G4[*+36MWH_%!3WWC]X+>+
MO!(R,)IQT?YGP04=?'JG#0OG>"E[L>-1!2#9T 0=8N/#@L&N-_84&6KRG*''
M1$_:"A-SLI.@?"$8WJE=?QUY)G9;KOF@+&^Q<NB8[HXN[54GBY?&GE4?>*#$
M_5\=5-V%F^29HTL7!9EJ\T$R>(CYWHAKG]_0HF-W?1((T=')!47AQZ8)"-1/
MAOOHHOW)FB^[-U0-[NM99ZIC3[T/!<Q?\7U5&+X8=4!:#N<_#_A,!7322>X=
MK>E.'U'#H@3:&6-SU^D66WS?K=AR0C*WPO!,+UPO>@HV'OX7BZ2  ^>7')#W
M<N,(?"+ ANJXW6&] ::'XOPB3=W!+[KN"S]Z!GVZM$K9NK^RSK')R)%9QY(%
M?6.E)9Y16:/W>-/A,#E=^430:O\ '2B"7\=]51GG>^"QA76\$K\MV6%Z(&>*
MW?T@'1G?QNJ@R*VZ_*Q=2XH"*#?]HDX7!(#<$?=K]!U-X09H\Z7;T!=Z\%B#
M<)H7>F*!@;Z7@]./*FR>%WBB[$U07+6Z^*F3G8SSQ2@OA%T!GPHL60.>MN0.
MZFO._I M:Y7;IJ8:KA<?-@MGMG?4:(,6Z7%9U7]+R^THV3[O[3LTXRC9^D#,
MPLNMW!*2=T.&2+1O HC7+O>2#$T@]_*X<T7' X<N*03Q[V<<(JC4C=ZY! /;
MW=R^.R(Z5O&\5!EJF-R5C35WQP=A! 32WO6 YN^,K@@_ZTI=4A:O!U,T#NGO
MKPRW)2USPA>N2P=]7Y4RS'#/E]9(*L-XNE?+%%IJ[JBP+SUN"0BQNL(*AJ\$
MC3=+OLD#5^?* -*=T%'W<NRP//F[!_3@D:?CP[)&3\99=WTT07+3GT=/2[DI
MD].5-]E!H/I\3OFF OD@+ UI9MT$[[F^X^$@&MW!%]QW#YWH,^Y"W.<L^ZW<
MUCV4\8.OP@+Y.NEA,#D[X\RR2LC2*+37V@8;GRWK,G@N=IOPLQM,?GXR?J@Z
MCC,*1%,?'";NZ+^$,\MV]8F7V@E*=]/I%G%_9U_:=JG6#X&"'/Y@@J!XOK;T
M11^XZ8("55.(NZ;D#OW<[^DH[8X2^X<DOOO 2%EV:)L7A((&SO!Z7VU'G"2F
MU=^8!%AIT1KF[*B"N6G>SHE.%_2(-+S ZH^ZN[EUUD$#A\];ODF=PER?>BD&
M^5C[3!KK6J $7"<["/OO7Z2^Z$Z=+N*1K=>6/T@=\MVA^_*JSU%.7V$@)KER
M4R#TN$T!:<E+5W90;IH*75 Z9/C<_@H*#O\ 4\$#>EU2,\I[OCDCH=V: F5U
MP\K,#Q/SBD(X87D@-;E?%!7S>^2'NI7OAPXH,B7GC"W)2'1NQD@HR,,,N:FT
M*YZ"\5F3F[/2X<%1IK>@Y"3K=R@J,G*]!>]4=E.[PWH'A;\?I!@U'2]#;TA-
MCG-9FCXWR1O7#EQI% 7/K=Q6RG+?@-?A(&Z?>].#NISZX(&%(#XONM[G2W>;
MW)VA"[N2B,)WX07?QCGW7,V8PF8<K*:CAU2L0A6M1N0(P]Y>_.[T5PZD#?/[
M6:[CY6'2Q]H%:.$[/)(PSK'Q])R.%R09$8\>WE <KHCC>]*VRZ-A*_<]!1EJ
MZ6_1!MISCUOZ<X)61QKV^X+-#/"Y=\T%F3(]B@#,SN'SB$K(I=_2+-W73!!G
MUB.EGH@2;COW23;.NN^7"*H"^CN'$6Y!$2=T3TE*%VY*!;KWK-MX73A@@5EK
M"4!RMZP,R^AOX0/SE@[1(TS07=$% +RY23LL5N$;WJ )L7B_HK>_F^]964#!
MN],KQ3/Y/=W4&#?;,*CCNOYGO0,3EBY(&H2\WI5$UWO?R*B3SC?P@9@F[\KI
M]U_&790G&_A,:/N%T0%IN[M\%F#(WEE;U,V,+F$(\9WF@KM#*,W<L>F 2 X\
M=UN1HZ\/A9@ 7C) KWZ.YOC.Q%(&G&$9_-X13-><N*PK<L,/(0#W7U^E1D]O
MAV%E(R+N4,$637[OH@8&](2@@T_3+A<)+ 8Y9QCTQ6:W7>A0+KG*%Z>$K6TU
MT?!.;Z) SB-^6B!V6PXO?=P2$5>;FL#3DBS6D,$  (CC1]^$P)RZ<>R=PPI&
M^B0,S^S=>E4# /? Y:2O[6=&[RP6!F1.AHFV8G<;^'(-RP2$2ATW%;:'==QR
M3,F9,S=>.B!60[?XZ:P6#<@+PW%(T9NP\50!,G1N]$%3.[&7-!HNCE3#X2C9
M8ZWK+!':,/=@^[J@?VO AS^W)6<.^[Z^4V_!TIX]PD?WN$XH*N?7YPO@ID:[
MM40V.6[18XUU[( #(ZXS>@V?H:+,X>-;P@Y-G\ WP0 6^.Y,S\.3^RLLZJ#N
M)N_"#,@TMT8)RSQ?=U19K=!9TXJ[&\KD@#3&'UX[%*<'F$/K=!4??E F$A<D
M",LNQ?@_&2!%'RN%P3@WAHI@UQO=C@@L#=,T&S=/G+X2 TG=]4C35+<YW&:!
MGB'?"^2ZV-D'/H<9R7#[9.W8KI#4!PM]1+B@4LNNZ*9:GENW\)9IVKO%#VP)
MA?>O=!!DE^0N]Y70S3C\<(*(9Y1=X5 'XB\T#%F;G3@IOZV;EHG? N^T@-XW
MR$4&:BRT)/MRGZ;TX9!GOXQOFG!W7V3-&$+ONEQFVGZS/!(PUF.WVE=\YO1:
M.4Y?(X(+,5WP!Z)O;VPORN=]1G$\+LH^\RY]8QXXH+-',B/C#D[1*S)_/27%
M1;%W7["8'&-B^R!FVJQ#S=\4Q#G!\272OS%+[*ZNP5@*UYY7@$!9'C3[Z9H!
MDQ.,@] -S?7+&01+>,A0W<D$"T8OIV\HL-O%QS.'0H$7B^WIF0X%\1S=@'<4
M!9C \-,$09.GSUYV](*PEE;]<D U7-Q[<T'03+$ODZQV2 C/2\MSU@<3/RDE
MTX0P$T#>Z8'U?1*^WN%_(1#-0Z.&%!V1 YPO#<@J3#ZO+%19#Z0J;YK 4= 0
M?6\%@#* YS0,T][A#'2]U$"UC=\%G&;Y9OO-*V95'3/-!F#PF(7R1;$A0WO^
MIJ9&XK TF!ETK.2"@9 K5U)9)QJ)6. 4FHY7),R70/&] @9TBXUM]P4Q-Q!R
MQE(J@ND!\20&Z<=Z ,L"+Z7;M')&1!_",P]V[#DBV)NE,UL%*SM Y^?@_=)%
M!T/CI?VAI4"*@VT1%\()P9O-.'R@HT(3O+SW46X0W:GQ])@V\N?&=R6:-'4B
M:?*!'.<7\YT%UFLZ/0#F].X1=)W:HY!#9U)&0N\T%=FSRXWFD+;G:XWN"J&G
M4$US@3)$C 5UN2"WN$<I^+S4GX4N?) \)[A=U1#$C259("RR9@P,W=LOM/[8
M/GIC@D#= (.T<<'JC.UA&4<+T^4"D8'#-0;>9P XG"&:N6L.;NE\5=@ #W%T
M='Y/PB@Y!"K\!U6()(TMUX43U/(2<Z]ZY_?&!$Y/BZKKR"!VFQ!F=>U$& \O
M,A+//)V:FP'RAB2Y[M*)V1A*+N#LM8T0",A)\<]_9=):<&3K#-Z V<'F <,.
M%A!J1XH)MA^1>3IA])72C$TQUX=DS\-[L\JP%N1=E*[U@@P EC$>/O-5.$A/
M5W5(6I.I,8NOE%'72(QE?9 S+4;CU3M-0$0>XKNR400[*^*&RB(O='". =H@
M):TG#SEE1$M<J 3CW^5@(8F/TE!E"0C+ER#^Z"GMX841:_[9/ENO@D]TG3B_
MQ>B?W3UF[=>&:!)1?AF$S#6 <1+-WG.J!8A-[B_#<ML\<12<>B $F+H!,E+5
M[H:6],A=0M&(^@_M=4L@]\?/?FJ-F.O)R#5'0\O!029;=/EAAKNR"IFZ-WRF
MIM@TEI%^?A+[L:.AA''J@?W1RY:O\)N?BM\$C3CICG'H@8.GS07+.$A)W:RI
M-7T.4$_NN7P[FB0^YZ5U0(Q"#L[N."+342,?%P0:#G:G"3[BCM#*$1RPWX\T
M"AF+QI9XIR<P?B^RE[XP>ZM_2(G'XOF@JT0[!^.EZ*#1H\\.>[/HGV[,'X8=
M>ZF6GNI?3Y0%E^4*ZV[X50(Z?;R_/>L&/G2? )S=\*( &^D(7"*EM ^.KQSK
M93LZRO[HE(H^4?*!0!.=)PL(&-9#HL3@-(90>E9[YU\H& A'E=,P@6JR$B[=
M;TSGSCE=PQ189@XUZ40%N6;ARPN279F>>*1L]/KBL*&N,];Q05<_)[ND<TFS
M9<='\97B@6OFEYZ)V>-SO! 6V)"6?!*XAQY]X=^"9HEPY>$&A!Y?XUI7H@8"
M1&[-/M&I=IYW)*P<]V>Z\%O(W7]H)NQ^/(3/CK96:I<+[+/D79&0%X('+;I"
ME>M\DO\ (_3IF[N@:[[CC7"2B2Y[LH20-R=]?1P@JOAFYWW>BYV18O(V$2:4
MI3I<D#L"-W#BF)KE,=THCC#326-YK9/NYH'>Z/2S#'HMG3D-=Z3XDB!=0[&]
M$%0*]-_SRHLPU3'%3DXSOM!$X\OH1?+5!5MKE?$24 )E6]W3E>/13:-]KH@P
MPK\IG5.GF]ZB2_45AT[8*S\9'JZ7'Y0(3""1GMP^T?;/CA/- <,_B\D!8:?.
MEQSP5&L>VZ.BB2XOD^@Q=V5 U;^E\$%&2./&\)K%H99?4OM(S4'=*G/=P2%\
M<?OL@JRU?E$"W/POX7*RT8 W]KIV=;\H&>Y_;FE%7:?2+1$97?Q1(R;KYO)
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MA"6?=.63!W6-ZRT5@2<9Z!^&[!5 H,#?GB%O;2\MV:8TQU[7-0$"W<[FE?\
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M0'>W(\ !?)!DWG>" GOQ[0O%;*/3G@APG?:$UGTHZO"_I!CG@)_"4910NQE
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MAI+(=J8/0%H_-+AX0<+I]HV?)R\H 84RXSY;D :-^?'9.^D;^7#<D)^3=T3
M5O1W9!,L'K.XQ" '&\%0&8RO<F#,W\OM C9YW#PI/Q'"C_(S52U??S7FE+I7
M'QD@5@_%+Z.<@*NDF<.6/?J$K)<<>_7&F&2!F1@./37DE#.[SU5&C>0N.Y(R
MU1V@Q04&',2PX*30PSLWA5.W?"RF+NEYH.1DX[\5ULLPAX.7;<H^T#14+6 R
MY=4&+\?$$S)O2-\4O\D(SO1#W5[<+H@H3AU%PICH@#)X=NNY)/<^4NGS@F>(
M;^=8T0%HUEYS?2B+(T^[MRFUW^;R4_?0?8=R\H*D1C#<Z]R=_;X'?JHAO'=N
MAI\IO=APUOR@)ANS0]WE_P 758A\M$P=OKC?=!;9X\+UNB5HUKW=C7PE]W3G
M3.$LGJ?NU'"XH"UYBX0N>])EORX!.P7[J7]A3;$:N%<Q'=D@9K#YB;X22,F.
M$9&3_B'%,-[[=NU2 <?,GUN*"[5[\;BA[X2>XN.5^$M_:F2ZR@++6$'RH ND
M&#M-U."Y7WV^U79]OJY(&9S[=>B+;7/E4_'! Y7=%%LREANNB!F"9JQROZ4F
M3'JJND[400;MQ?"^2F0^\5KO/!#'S"]:($]KGUSN2<-;\/-P6=NN^BV2!FAA
MP@Y39.[6^JH#6\M$@N[H@8M;OBX( 8BZP-$GMI+YUO>B<+X7B@Z*7N46J.EY
M='X\IO=?E2)D#OOAS05#3].>0T!HE^+P2D\W])YK.NWTMR"[51#*Y1W*0<_I
M>](3/MR<E8/WBY!U&I%QMT%/W0CUXWV2-;2D*<$'8\;J@H.O ?$D@9QSW8<)
M9O1]W"/S]A!^^?U>2 O,@:]D2S"[^U@Z%OO!!LSOR@##+C##6EN3-&E+?V^5
M-DX/[.EY5V2+?&Z()>VIF90W]9I2U#QCDNKW=[O<HPOSXD@#Y?#]55MOC<3J
ME=?5Z4\>YQ=><$# U+J=[>F.TP%GLH-M:X0O>L,+WGD@I[N\-<+U0 G3KQ19
M%RR1VE<[XZY()BGFQ>*<'3Y41K\ISE=\IH*.N644@9LON%$\)XPNGPBR0::8
MYQHZ: @T)N%O4BU$Y=2BS7+KT%4C1YPL9ON2!_>^4G]T*;H?&*P=]%SI!;2W
MN0.SRSGG<HH;24/%]$-IA#.[S2DS=I5UX( #092\H>XQUQMR8,.W_6[LD(P%
M;O<@SWY1^D[-7U<ZS\IJ#(Y_79RCVS@@H*TH'>:#)5%!OOKN4CEC?DIR'#SI
M.\((!B,>7?-(2[..#M^&B1K$%TKZ[D6KZPZ?2 ,M1=3IYW(F='WU2%F7#=ID
MF:(XR OF] S^+^%Z)PUR-;^5-@5.6N_7""9D3)\_,"@S0<#B7.<Z? (>V7"^
M_9!HR%RSNB<LX'E;D$?=%Q@F$X#ZN* 'B\N:QACNW=:8(&+=!'D^^'),&J5J
M^[T2!C"Y3699<\UPS05!PTN#NR4M.GPA7"XH;,.YE+[ _'Z[H&9,X7<D6C2H
MCEG#A-;9A[Q3GI\I"8FY3$.LD#,O^M7<JHEHI297N1)J;X=$# R&\H&KLY/D
MIM,USX9WN19Z0X8W) A,\'WQ5&FZ.F(<NI\H%Q#A\(!F49.WTG90,P)R,\XN
M2D[AUOX3^Z@N%N0+,L)W\:% ,G7\Y]'IFCA2,-T=W-2,X;OO+X5B,XFG2]Z#
M>Y^/9]/.KTWNP>#ANWPK-39;BXQ@_2]R<B)=#"E.J!V3PZH-""@R<GX.A?+D
MG?SM]U02!="$87CT1V9FY\[*#+$2;B>(T3F$A=4!R,\.FOTITUCEP3,;IGB_
MHBU9Q-^9("R?CG44A1,SB7!X%;U42UNR'A-[G@ W=T04]TL!;L4K;3H"L3RZ
M)'/?1Q&@#^/B:9D NGNY.UB] X;CN=&N]3::H,3%4++\P)"\JGJ5)IE[G& %
M!!!1DTQ%-U;>D!G!T8Q0$,I7HF$W0Q[OT0.,1E]HM-T&^B7W2<+Z^4OO?\#-
M [X/HX@2[K#'[+X.6][Q"0OA96)%W//X0(1.$!#FE?1T,[XJSZ.I'X,[>E8V
M=2?&* UO[\J(B6IN'A6:X!Q^K#LU(/XXZ^-R!S*1QL8WDA[WDPHX?(Q3-=+Z
MH;,N?#6[.Y K)+Y0ZON"=DQ+W"%8OS3"+H.=W,(4XO4RS=TH@QBXB0X2E\+H
M:#@ *S?V4&3A+C]JS1A?/J4"DTQKE>*YVFR^#L'TS=RCC!4]OQX[K$0I(Z$B
M6F:!6(F--V&J9O:<!&[G1(9!TRL6<I1NXH,^ F]XY_'-.R*&X8H&@%;Z(DN=
MD_(E S$:.A7*X8E -Y1%.,!T*7^2@GTR.ER2>[<8H*M-SA*80>_)[O)\GF@Q
ML_C7NF:V@&) #G9B<>#D&/&KH7802%N#P72P3H.D\/-W%(>F65O6)@!?'%!U
M>-F3D"G%V['Q;D/=('3"_'*K0#5'8\,9;D@<8'0&Y1^$$OX\(BG@WHG8!$C
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M7W7+) A^;^X:)@SK?Q) W>+T/=>$)7J@Q+HUYW90!^X3N2Q.A\5IQ3,\+O1
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MDU=&.ZAT"0B=?NB7^2@>^Z40':,]^"9D=[=XJE:,NOBX[D/=>^=Q06 Y<],
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M7CO""VMOASX(@7=9S0=7(CGWEDB^S*R@ GO/QHJ;M<)>.#D!CC5 Y9[L=_E
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M5Y2X)Q6_K)Z"C!XX;T?=?7RD9/U?(J;XOX?5N0 &,>MQIE-RNT,A<M>JD)B
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MPN[W(,6KNJ(;>ZETHIEJ=QT6&,KO#@@Z']:7>BB6XN[7')58-3S=HE]M7<D
M9.2!;ZWXS0)OG*XQ43CQEC#*'R@M[LKA?P@1Q=A2WI&6]XSN P566L(<<4&9
MJ_FG-Q=PZ\4NZ[CP4_=*<7CMGB@L[=/[O5!]+C>\I'_&%E9BMV]!FP[@;^]R
M+)QUO*Q%%IF6ZZI _I<$% SWODD-Q5!G5^[3(*;0N&XZ408TMV>F5$[/2G?P
M$61/3K<TKNF,900.>/T9<5GU[WP2>VC^E[I<%@*;Z7% X:N[=BB/)PTC@I&L
M#&?"MO69?\\[CD@<GMOR[H [W&]'<%1EFZ9UK""GP0;W4NX(!B-_%4KZC@J#
MP-9NCW0:[TDL#A?T>ZQ:YN??-+@[& ?<T#'G$"^B'G26=X+/^$2+?;WA 1>"
M1MJ[X1U2$R="\[Y(BNM\]R"?MD^[J4P-,N=_ 1/V[IAX4R-=W)!0"S\2?<$X
M:OGQ2LGIAA?-*6NG*' T@@H3>E=8Q"D7OWWJL#VW3>[RGGJ@HQM+Y=5BUQF+
MMTE$C#47AUHD]V1=]<?""P:NF6B8M7\SX54 U*..G1RLRQ?*$]Z!3A'K?'DF
MIOQN:?X ?>25]W;R@%\K"8@0Z/N2D63.-W-$82TE- U@#7N_DM;[JBRS=_:S
MKY=(!!OD??4CX0=A?+-,R><.B<B\+R\(.=]A49?AEO2EG2GT-.F]+[KZ'>@M
M"ECOT4&R1B]]Z6$_C'NEP%;O-!F34SOGS3^[33KQ^$CLL=/M*^/"-[M-4%PU
M=UQYH_RY4GXMRBZ>4<*5.[DLZ[J@I[KIFZ^J(IA'ST4P;OA](C<]]]!<$!]H
MN62+5_-Z($C>_A82%M_5Q=;KD@4;2AZ<+W*CZ5X6_HILCS.?ST6=>L;=@@+K
M[W%"WW@M?S>"873<@+-?/"-N2M8>+S0?D['M>,$H,W\[S'') 0S\F6^ZJGMI
M2R.P6]UWP)0+6F([(*"%!OSO1 &[T4O>:];XK!IV6=W5!1IJ^[Y*8!OL,+"/
MNW7OX26'.GU) 1\/Z0S*9H<KGS=BD?=_15&4& RL2/=3(QO*,]8*S1[?-XJ'
MSPR04&$<KZ\D2U\/$LE-_<9;O/5;WW=.J!W8]=Z/2$W64A-Y^<$P:G8Q0*62
M^[>_DYT$78&4.&,]X6?'A>'?!9^ND'(&?QAYDE)G+I?A*R\N^HWBB[+<YXON
M@F,^4;Q5V0YWGS?%#.![_25_Q+5^B#I+KS^-%-HWNO>@]POID4M.9Q@+>@86
M]W%3+5EVB)-\(V>2 C/3@[+=@@(:L\E5]QORE]O:SN09Z1EA\_*!G2OZ"QSQ
M^GWS2'.]U\D77.D$&?WZ9RBD:'7Q"ZIS].$7.Z.4B:1X9RNJ!@>UY:(LC*_J
M21D<C>6_<F9:=;[C- 75OA>*(;Y9V-4K35]HS"5SY5C&4WA!9DWK>],[!\@[
M=R^E-GG2Z[Y)O?K.X#B@+MW"\,D0,7W]QQ6)AE3MXE)(6N,'97S0#KJB+P.[
M@#84SM*8W>2?W<<+MU$&+/?>[F]*]T,(4PZ>$?=,8[H)7?$.7S)!4\>24D:7
M<D'W?)(0_L#)U\]$&]]B[*J,^T+D"H>QU\W:+##BZ.GR@LWM+A<,T6&M._'O
M12=>6=Q2@G[0=&^-;R2-'X\WY2AJZRLP2<;W(* W<4Q:-NOY@ILM7?::J\:=
MK'9 KK\<X02.GR3.T=?;%9])7;D"LG.YJI?RQO)(RQ%_?+HB3%TA9MR!@UNO
MIE5!HY7I2,LD&CA\PIWWH7C]H"^8S?=^4I9\?%R6R?6?6?)5 WWH@3Q3#7K+
M))[CT=>'E5(OY4C+Z%X(,^WPW_3D=77R$)*3(-887G+DG..G.D$%";T-_:P:
MOEN479NNF!1!UL<7H&+1RZ73-$"X)"UEKVOFM>>Y '.["_*HUM-.R4]8PQ^/
MA1VNS)$)X(.CWU^C>")/'PN;8[*#JWCS3D.XW"^:#I!\?84&Q6.Z\*UR3,M0
MXW!(&GPK;HV^B#,B5NU=Q3WQZ64HIOZ13#N[#&QF@8'CQ2-&^$K@@6KTUKT2
M&7C"FF,$%/Y+Z6$Y;[=;^ESL"^0\JI9?N\WI1 K1LRP51GA=RT4R,K\98Z)&
MFZBWH*-87*3^NJ!9S=?1*R,:<L%8F\D" "/>\>Z).FZ]Z0W]7-4#7*XH%#,X
M69*1G8%]54GK!([(\HX7NF@STT.-N[IO;=QA@EQSB@5H/=WWWE0JS%)][WJ3
M$[T"=\N'E S;5,NN*YB']H@:;M4W*Z)OX_/DQ^J(![8/Y8BY=T&#TRY;T&[U
M19$0?@7N079:=?E*3.L(WG<$#<KI52]_"?##3J@H#PNX)AGVTNBF_"%SX8X(
MEG,7Y0.^FZ=[TH.6>B0G=TC\I63NUY[T%9<NP6]\\11,#A;KF@#/?D@8'E9"
M#^<\[ZI6H^)1%V$:7<4&/-\'UOZ2 1ERNW)]+E?RIG&5X!!0F7;ENAV>I^V\
MWUR"&_YPN&"/L\:9H*>^D/B^*3VOT.Z\';TS+.N[EGOK%%[N0SE#YR0)M&8.
MK"?'DIAA^[/07%.=7RW7DB^DC+G>Z: --TZ9)V6WNN<A<TA''A$?* 8=\H.@
MF;KNJB$0U"_A*]U!?/D@L.6.5_"P^.6>B5EKP@#7KR$-]A [[I"7RI-GA6MZ
MHAV<(ZNE&WJ+37_;S""WLABZ6'*W169.^GSFD]U.SKQTQ2LYWOPP05]XCQS&
M<4 U497O"CF!-U;XJK!FZ&&7T@4B+X7NDL#P="-\TS9I]6%(,UUT""A:NN=^
M4">6,\MUE(T>'3+=.N:$77$4=J-R!O=6_/=$-&_JJ0";OB3[HLRR<>PC3'[0
M78KVOZ3.=EYNX*3+5W3IT)+X:[A=N0(^EWT56Y<N<[@HLLU=$V^YO0#1D^.Z
M=\4&?$::W;DP,0.+Z)PR\@ZY?79$,5UNYH,39ROS-2;#X=.D9*K9@<:TI&--
M%SEO 6YUX(*L!T)Y0IV[!6V8WWRZ\T@(WE9DRP)\OW(*'9U.&,W_ $IDTWB@
M^D?Y+[W#!9XG?"W();23N=TZ(,B(N*L!.&0^';OI+6D'[I7AQ0$,X32D[TP:
M@;L)'S?*%PO%!G2#X7)4V@T=AC?)*=J(.$KHE+3]797;D V>T><G^([^"H<?
MA((;C\.?G@E::OAS" LGCWTZIVGNM\:_*BR*F%X8<U;9F0=ONB!0UNF+UQ5&
M:NF_4782>R+J='WO2EMW%^>[-!1H&D[ND%(,F6.F7;DJ>ZHWZC+FE(J:P=1_
M.CGX(%#._5'/E35-AXN7!8-1==Z($:F+B:IFFIC 7N^D2SET?3XU2G_N+N_=
M!9VG&_A(TS+ANTTWG<IL@S-]8:+;1J4]_C3L@H&H.=6&5O=P0+4X0<+BD!D+
MO5,&<*]M>* %C#!_WDG8V;IT5&&L;O)<[;1QM]ZH*PG4UT0:&#PXOO7-1]\)
MQ-SO149:R@Z^2 !B$XN?=]4H8J<#?E8FG^T/Z=DPV@X9PR&>: OD^G2#K,$X
MEJ>$>#^"5ET^KH/T69?(O-QXH-_'&4,J..JHTUR?REK\('KGTN*5D=07<+#L
M$"LLU,HW@]%DC&%W#BG:C"O?/X4FF(3P,QPN2"G\@ZO4PW/264N*F&=U-.WP
MJLD94T?+@@=AG.<#><U1G,R'+MQBIMY'A7!<8::+<?\ 8YPS:)B2@\D=HYX^
M2_Y7*R16KJ7*3T&C%T>OSNX+,LN>^-=$!:;'^T"+K+Z;Z(-/A,QXYWJD K"-
M<HJ[(),I.^4"M-E[F93N\ J>[&[NJJ6'9'=P7/[GPE&.6$!U0='NPCGXP4WB
M+H4^LE!MJ@@S=$61G=>$$#,G>]YWZX($3^KP"/N<X2CP?=E!U: /F@=AMT.-
M=TTS+0B3]_/-<[\(8OY#R@UA03?>->*"[1+P;RNE$R7VRQ+@[KX3(,&^)Y8/
M"S3<7"WA!SN,?*8-1OI<4%&6G0,?KLBUE6&/$.ISZ3:QKE< CLZUO- @,S@,
MHK,MOY@\)OR3M,TQ(I#)3E)\W<$#SN^4%,LN@('LG9WSN_A9ICXPR0*PUP=G
M=[T_NO[ZI")"$.6?VF:ITQQ*!W:<0;=7RE$\7871,TUS&711+4>K[Z(+M&N%
MG12+41D/J]Z ;@Y^[MCYT0X4N&L-$#!N=W])"8OKP^.6BB[5_@)V1=QX(* T
MOGK-%H.B,8W1(SE;J9/I;J&7&]R ,M@OIKNF,$669NIQGTLJ;G1LY^>2('"-
MV=4&9!! H_G?PNAW'-]\%SB!#Z\_A4#7$<\]U$&:XQ'3#G]*K+;LJW.%<ESE
MJAY]\\.2#)U,39069:>22*",;W(M<%$FE-<[>F>_=TO&2 EF&DQV2ENXUES1
M=G?) L<<JN^=TT%60^S@3O699C.5V]!DSA<KP2LM1\F?*6!0%MF+Q#XQ%$C\
M51^MW7HN?O8U06' X7CS"0F+G'"/8IB9.NXH^R109HNXN^D!+0J>UMX08XY7
M#[0,R[CRI-*1U^?&B8L[[?9Y*9-]L0@ZA)[KK?TL9<0/KF_JIAN#H^3#AJL6
M\LH\[X( [5^Y4#6,(R[P7/[LA/CP1#=>W5^B"Q:G=[U-G:Y<X.3-&#ZBW<U,
M"NL\O'! S6(Y7?!4?WN-R4";Z^7::*C[W=-'/05X7?PB&Z6;P2 XW?!*^-UC
MP*!^5X4ZXH^U\KST2AJ7Q>'TJ#"\.(B8(%#6/?HJD;C<BH%F/7MQP=BF?3+%
M "1P<HF[HG?*58R1]NDKW9(&V;6^WNS0VCKPSN3DH&ZRE>^%W=$!8I"5[T72
MH/B]$H:Y8F>662=D]YQAB@P9<]\1#HZB1J$KA-R+1[_20-7?+>@8,S-PEC])
MGU@_EI<@MRE\348W)!TN?7'C=<T7\+L%*&;E)*R;Z71!4GAWMR8'C+7M;E/W
M3ZX^%I9;W;D!::P'WT4@-._U1]$ =].J7W76^B#H:.7B,%/*\N92@QZ7F],^
M_KL@8=GX\!OHM"FCL[^UG[KI>2F_+5][Z(&<;I#.:?K;S<$"83I'XW\\DCYE
M!O=B)=KXXJH+W8711:%GG?!#9[2G>8WH+D.//B/IR)%X>+=%3:SE9XY219.-
MX(&.ERW*@-TPC<%!LWAB^WH,M8WRYH+=!O=>2FT)N-NO58'/$\KS2/=/&^=$
M%F>7Q"_I%V(R?CTBLRV^-_'G)%K'=]7-!,::+!JC_JGRLV=<-$K/UV*"Q$']
M+JI/B[ZO'@J_R4\=L2ID/Y&$WOIW0'OE"$X=TI.&/.^&]'>E(E?9 P/;,:W!
M4)^$K)PU=2\N2S9OX01+<=YN&O%4?"\E(G+C&?94#5WD@ 9GQOHG#4WGZ0?G
M=Z12/^?-S0=0:Z8.Z&^20FCHW\)!?9*^[D@=^!/#-WPCE0],OE(#>$>_59IK
MCQNZ(*##Q.]RH'5NKZ7!<WOF;LJ?NOARR04O?I3%$M_#L(4ED.:E[I5I8O@I
MM-7=7S07]UY>;HL3<3@Y(&^G;OC1.(]-^#L$%087PN2F>\-,]\5FC#A2EB*F
MSA=.B!P<Y6=V>15 U2W.475$C<?&*<"R@H//&%Z+-<,NV4^*44[H$<^F/1 ?
M,-VG!^Y%W6+KPG@ILWNNDD[)NL+WH,1XOYFM[K?!8B5PO4H.D^[YH*,XT@Z^
M:8M4O>E!^IW;D'8W! Q:O.O9 AXX_:EM):C1#9M8FDS?+) TGS%\M<EF0^^R
M=V^\T@/A]U0%L[MU+X*6>?!;BZ'>^R>%UA#ZXH)ML2IVW=U5C2Y/1+7.Z=T"
M=+NJ!WI'RCI!*RUC"NMNDBU4@WN0.!*PHM986ZYI@;L) UD^\.:"@P.^WQZ)
M2+$L+WK!KAY&?U@@3&%X^$%6677"\D!=-VF:-W7NI$WR@4'0Z^')4#3KNRN9
MENSSW&:9IJ].<$%?Y F]^#[O?FN1@SY7WX*K[/3E.*"C7!W7Z^E/W3'"\T?=
MXN\U%_SK>$T%&FIY7 !%EJ^@WJ;1E/R^)^J)Z&R@Q:I@7V]*^Y9"]RG[OB[Q
M6<_K'Q)!T!JYV%O?E2_GX4O;F86$[JW=>*"WNQIAHIMTO/1$$0=]UEV6/>5W
MV";4MPU^G+,]#NO-$CF.!?UKFM[G>+^D%)=(=%(G(3-]$OON#[HB_/3=3NY!
MO=IFZ_K19EN]W@K 3EV=<4S+%XX71!09:9I3?.]$&F^&8Y[EGZ==9PX("#EN
MZ3ET2$S^IVY49.-;' XI",IYW3P@;WXXV2D_DUEA*PL.S[I),Z[#[<@P/;?!
M8GAQPX+>Z\N6]*^[H@IPB[IU3>[3PI%J?98&EZ=L$%O=C(6]!K'A?=#+#[[H
MOH'SO@@P$[T!R6;:I27U86<X'.[XT4W=[SG5 YQE#6"/NPI#<ZX[DF]VOVL2
M*>*(&:9A?V(<%@;I#7DB!"%[TI$ZW<$#OX#C?93]V,IPN2S5_2@\OTQQO!!8
M9:W>Y$G%(&N6N,4X(CQ?> E@@/OF]W$QAV*$)NRTJLT!=_90V@N%QSD@QRN&
M'4+ WA1U]EMGG>AL+->(/N-X(-WA&-X\\D@%W*F$$P^>5+X($(,RS=.'3)$M
M??9W9*6KO[1&AI"\*F6"!RU#=9N%(( S<<(71+E1;R?CA3)!T:\?I3A?S&RE
M9^+R6-^'9T04![EW*!HG]WU<^]%S@?6E]$P/;SPKD@=JX3ON@-K=SQ>D;:N%
MQIFD+-OC)!=LX7"]%%F^%]4XXTOP@3;K,O* DWYS09&6'PB_Q>>27W=A>[CD
M@8GE6MZIP[-SN"F^[LH%IU-UV]!1L^-\^_6:0%]!/>E_D[0\Z(AH4/"& ^T#
M@=T6H1$L*2X[U,MX/WXB$NEE8'EWLP08GEA?VD,XBX*K3-XX/4VR<;ICP0$&
M0Y]OM5NI4F#?)V=O3EOA7EPWH)M#<!>[#?O3^ZZ:_2#37$NCWO-2?]7%R!R;
MOZE@L!ERJE9'#E?VJ&[-N0.ZY;LO*F33QS<-RP:U^;Q6'6]9^$&]M]HK$8:<
MKE-7 TA=P4B9[AW0+\7\JA:X.O12.=GQ\K$]-+E6 0,^Y^4?=@)?247GP3>[
M@@/N^>4;WH&5X26#0N[(<B.\[G@4"8OX?.:!QMV\6Y/<^._HD=+"+T&#5)=+
MS1)CKGRUMZ1PXW#IR3C% [J0O=S1%XWE4)'T$XG 0PWQB@&OC+ZBY!=@C6^2
M1HY2\*/NP\7>*P:[T=$WF@LR=V6Z%/I:[<E8:OG)]E-[;WV;"!#8OA@ G9^L
MM.I\(-"]^*4&#K?905/?6]4 U@D?GT<#XY+.TXW%!5]SS^<]R .D7J-RO@B.
M74(.CVUK&-_2FT.-SI\)&3GQ-3'2"QWY_-Z(,#8T[8[D6NIN%$@/0=>N/E8M
M5X[K<@7A&-NXE,QI=?* '&%N3CQ&\T#--?>.#T T!V?&YH--#A*_*5V>.]!3
MW/YUOP@SI=R0'B)Z)O==T'E [5BZAW) "F2!/14!YWO[(.=MD;ZY8\JH@95N
MJ=IB\-!7-(T,./QF@#[[IAEE\(#/LF N1"!6^75W6<-$K\;,8I[A<M)I1K\7
M+Z0 '*QI/DL^_*8"O9S[HL;'QD@'NN5/O+@L+RO+)874;\UB>-E 0,KUTXIK
M(N>J0-;L+Z(@WOZ=W(%==RP6=H'G%%_3D+*Q:N>2!']1K\8JC+/5ZE[KUIFJ
M[]<STD@P:^-V6.*!,]+%\D"<;ETX(7O^4&>><Y43G35V'STP2@<L+Y+;KNJ!
MA7B8=:)VFG;O'*WJ/NXONYK%J'"/>X(#[[W7N1V?(=/BO:*1@5^WH^_M>.D4
M%6C=]$#5WUIBHM-<KAI](,M]A"[D@8LS)\.?>2U]NN$DGNX2=<C7<@PUATEI
M](*.Y<X)G#ZX*?\ (?NA^9XH--3I=.B!RURG>?'LP.'P[YZ*#+=#UI#ODK!N
M;I80>4#LWA5+\Y3N:V-WV2D&^ET@@S1G=SL(LLCZ\7-0#XC='"L,L$[^G'=5
M!1H\CP Q,'HNN3N\HI&#CGRQ57B5QN!03 [A.[@Z[R2%J]T!<BLQ%\;^_A V
M)'7+RL+XI6FGPY>-$H:UE"3KY(,V*!\NUP2AC$'?/X3,-3PO"F!"?W1S?>KD
M!9APLJ);C&7;$JC1F7?<^SU!D7"O*4N*"I.3_A'W3ZNAP[)0R_SX3'/"FB L
M_%7_  _%,P*J3[^,N:S+=QZWD@JVWIFD]SX[O-[DAQ-W)8%_'K2*"H/0CL+Q
M2OI'[\\$S-WE%1)MUTW(']S_ (TPRGHB0^Y8QF D]TOA]X)BWYW>,!B@8BER
MJ_2:)'2]V"S#?>_"Q.ZA^,.Z!74O'A@D=NN4%O?WE7,C*B0-\WN0.>-^+<E?
MT^;SP3ND:B[IN0#.MQL]0@#)GR6==,-T.28PDIM"4Y\;CQ06)A"'CYESR09+
MKX\DA.5-\*2NJH9",<;W(%)R@YT<7N ?W1]I/"EE_:+DMY]D[+5C$=;S0%SH
M0F3G+K]I'OS$=?N'!3::B<SNE<."KLQ%]WQ0(Z^FZ"8-/^-!6^*S35ROHE!O
MIQI@@9EOZN-YJI(=A33)_5RY]U=TL:]%4!^ZY7R0%DSB.G+&Z*;+59&W16(G
M&F_<46692X]-R!\]V3S7K%#W?&,+BD:,(7<T@OXL=D#AK>Z[?%8M5/3"F2 -
M<..@\\$";N]R!F3<U@UCF<+TZ)66.EQ1%Y]LLD#%V3G7KG]+!K+Z0/&7SR2^
MY^CK^T#/KP=RT0:$*_ Q6OD#T1)X0=@@GLSP'&Q-9^%+,LT_MFX887\K!B$:
M8WVH@4"IKQO#BE.UZ.TX<'IG8R$\[Y*1'.XYN0.3D[BZ0F,9:)C]\D=FQ]W<
MD[3I;S''=]( STZV0L3?S>24-1-\%3W0,,NCA<'H(V[O<E5G(7\( .$7WS&N
M\J9VCWW80$M%\ODNI%'VUQA?1%EH%_#,[D6B[[NJ >YUX7V2C:'1]WD@6L!8
MN1FBPZ&MGKT0,VUC4[J3N 4@U'Q;^4EMI=2Z0=N4_;(7H@Z&6H\K[ ]$C0+W
MTPC;D[3#G";IQ6]TKN.(0(SPYWC!58SD+^5-IG.Y7BJLC#ECCR0,6?-(8X;U
M(-1Y>+S1;/S]98*;.Z[>@S1^[QSDB,])2^X'>L?->UT0;;^.F^$$!:W/N^ZS
M$-]SI!!DW33-9L:\<QU<@:NO+>D:-;NRG=#K,V[HL!-\IY_&2";9Z=.KA6B?
M9Z[G7U2-F\8=!E#1!@S=A8W(*G:T$3,&6[12+6,^6?A!D\_J^*+I'.LA?5!T
M,B6X7O3/WTOHI$SGRX8I/<7Y.A&W[T#;0ZWGV68$7B[HIM[-YG?#>J,\OCL@
ML&W^/NW!)[N&#IN4V&JR^<.J($7T=;NR"P;@9 OAAO\ "F^F5W"*G[J"D8]]
M$2WA/[MR##/'A"Y23$Y.Y1O**YV6,>6#KDK,M3$CGH@HR>%?G>DVK3M(N1#5
M!(0?2_I%\WC/A<D"ASJOY#K\(D]]?OKH@UUN/&2;^-_S=Z()AF54[#$SC*&%
M[TI9=QCPA])MY^D"@NZGE!VEP3ANKKO@INW/?/.]4P#B\[N_A =IM(APY40+
M6.NZW(M\96[ I6F99/'?A>2"@CU+N 5FF9>(7"%%RAF6E]E7:-0&+^/P@S3,
MC*._E!199F+Q3#:R%E3_ )'%T3?)R#J;ATUMZ4#*QK13+;WXU)^.2SY#2-WQ
M0$ /X2..5\5JY9=2L690%XX)_:([JNPIF@FRT\RZ\^V"HVW@7'G=3FE9$23.
M6X7%!ISW_'2B"A;,<W8Y6]<Q',OX<U9\85EH9_"S>>> 02 QKO\ M*&J 0E>
M&"S0B_=A'#OJFI)PCP<@5EG>[.L/A7+4AA/++..$ES2@(POXH4P,KWYH*M0!
M/3I\N2[-J=8/["&"Q+]]_2/N&4W;KMR!VFY'(.KS2K!Q+,(/C&;MWPL@KLSC
M7EEJ@UE?:Y+3T..'P%FZ.,G2OA@@;9UOY1;;L7<U@UC=U6 ZWPH@++5WN<9(
M,-/UZZXNW;UCLQ%QA#Y4"S'/+H@ZFAAK?A$'?+'"Y*0&<NZ;W>!?E CS]7N[
M)7GG*=\E6Q#JH$Q+]T73KV07)W<+N"/M';XN"@U.-ZWHG8XN)CH\/W($9([1
M[#!':%T::WRDCM&1,;],<78+#.WPJ@=[P(7=X1#,4[.'2WW@].38HY ' 8\K
MMR3W7=XK$\H8NO/JD9.,+EE;T#DF57"]WVM[Y3==]%.KIW>2P:TK\:/^4%@U
M=TYI1,$2W:.X8H"F=Y?.J.^NA<[KD@Q,=[]VBH# "N/75*+\("[OD@PWST5V
M=W:^(>I.@8#6[J@P7B;G>.B"C='7>"4ZYO\ '= DW$/^>DTK+42)F^H0.R>3
M]+[R3NY0Z2RUYI0@TU'@_#=<4&:/3K6*ECW-,%1IFHWUO)(*CX?1 []_73.F
M24M/%Z[\5)H;LDWSSE+2"#;WOA &JQ)AK37I%R/NI.[FA=[NB"WNQLX:I U&
M(R#M:WR2E_+EN2AFK[P07 P=N\FRJ!E[]+)NJYA?%4]].-Y<T!]D\-(C!W5*
M&;T%<<WC-%O:7WN45,-4KTO/H@HV*:<\[A@4CW=_/=,Z>F%ZXJ9$#E"^<\D!
M'*\?")!'7CU0!RSQ6)PP#KX:Z(,#B+O+-/[N_2?<9*/\M]_E W?3%!6K[^(9
M:*P:[9[^;USNST/5-G<T%FMIPE*YI1>6%Q1)>Y]WBF @[A) H.+JNS0]TKW$
M=A1(WANRW)&@;N2 MM;NVB ;O*X%3<_.[<B6<S=\)205>\ETHGB,>R .5'.A
M>J#(P<8]/E9_&^]Q0._=>!W%(<=.F'=%J5Q2$XS$SN[("RT;OC@G9$O%RQ2
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MT'<P85W&W*;1^3QK\+>8Y[NFB+ B['[<<.J#3^[<>29D2,HWRHE:,M_/ZBJ
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MROFI>S@>.^YIV<Y8UWH&)PZX"Y;H)7Q'W!R5\Y==-+@F9T04(^ 3#3APDE'
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MU\.DD ^L-4%68X9/INPP1-+O))[LOBZZ(M7Y0$#"OE4OSE#!1!O*$1\S0+?
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M/(%!1HZRFZXA 'P>/92$]\/K'HG?XO- [L\",=UY(>[*[KCFE#5^$GNYY6]
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MTOBK>Z#I<9)62(N$WU0(TP8N<[JY4V3,'/QZTZ:*H:@<M.ND%)_#"+N%<D&
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M_A%TL\JUCR0*T<.T/M$2H_I\(.U-[MV.BQZ0STTK'<@P:U!P.8QZ(EK"[K1
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M@HDWV^?"J'7>'!(6>'D2=85\@0T=_P!)3WY[ZH;($/P<^?1-M(&%W05+DGQ
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MGSQ?R5!M/K.W+GC$7C*5Y)V3=!C.J#J!PW_.G5$PRP/%1]_7YUKV0]_"(O%
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M0L?%E!ML7R4FC1^<*GZIX2,@UPW80/9!7W=ZWCO@A]\9[LJ(NW<<K=BA]\4
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M"U2[[0P0;OS[^%8"S(0RLKE?AU%O3ANWY?: -N\/-QU3,Y?>KE$CH_LY]7K
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MDK0=+HMYTEGPZ51]SZ1C#OXX(,6MPH89>%$M^8Q/P^H3WNS4P*2GGOU/#*2
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M :IOTO"BFS.E;$OA4=TO1!9J6DLJ<U'W?7(IB;F^]ZB6N_00NLH(+%OGP^$
M92A8=P4MWTG9,A$PX0G>Y [OK&^B+L_G%!EJZ6=Z1HWUX8H&M[HV4 UK>?+P
M%C6W7DI=3>[N@L3?QHB3\=99*0M^^F.LE3V\(9O0(6JV5@V;A<D1;Q<0(:(&
MIJZ[H@Q'QCN'%,RS?$/AS2AO[R%->"):G"X!XLH,3@ZOR@#+Z?B@1*QK&J+-
MY7PB@?VW7C82M#1W*W\%1^64+NB4F=V/E!-\W\?M,#E\7A1*#3CN\Y)KU&?=
M 1\16:C\SNZ)/?-UWX3LX?>] H'"[.J!9WOL/Z)VS/Y<>-DJ7NI"\)71 Q9$
M/M!DTN\8[EK"G>4$%?=2&L+UY)'OA]6X::H-? P2^Z=RIK805(=IG*^2Q,X[
MCIX2-'6PG\5TZH'8[\K\)V&J.LW)18U<^]W9%URU-[T"[0V_#=N=+>E9:=4.
MN^:9H3OF4C0Z.UQ^JH+,[3XXXIGUO6]5%T(1T<_=)R4MY7=2@O[KSDHEJ+M;
MX?:'NZ1RW)F61G6-'=4&?C=V$6FI.Z^.LW(EGRI2MP^Z64#^Z0H-7A(R;K\.
MY[TK6%O^JH 2C=#X05;:G>6[HD>_7ER2[1F[XE!DN=IUP-Q07!ZWO0]S^USC
MG@@^>AY.'A%@3?=^)(&+,O.=.R86\8_'![U-MK<ZFIC?1,RU=_2 >WG*/-]N
MXH 2X^;@E;:,I=):=%@9EV=^>,D%2W=X8(^X0XNI9PDHF\)7FM[G0#W>)Y\(
M("?)L\D62Z.7U.RI^Z7)^<OGBJ,CQ?E Q-TXK,S?&H=C?Q)#)WQKNQ19/"WS
MI1!3QVY.2OZNW2N"FTU.[Z.2B@^S2^R X^3QOHB^YTX_: &%;^-<D7F7W;D#
M!OXI31,_&;W]IXGLIDNZ4T^DP^N@=K4H&:<*W@HMPQN\-4Q-+MW-Z!9S0%CN
M+\9(-#.FZPLR:8\773FLU>EV8( R+>X_*<-4Y7<TCL(W<$ ,I5X! Q/R-TNZ
MP;PPN%R6=*YW#>E99PN[Q0.3Q[:W1;V\JPOXR0:Q^\A]]%-O;.?=F'!!V,-
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MZ]%@*G!T>OGG@D';HZW<2@HRUQG&[HE.]URQ\)!II<BF'*^R @ST?VKG1/\
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M22 R[_%O*);PI;D#7WXY5<B_2_%5)IK-V]]9*@ZX7Q0.#]W@@V>$<H<.54P
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MYWX\O2M7><\7069&&_I>Y!H&\KT"#-'6\.CU)Q>_(9V_M%,_X%(31)L7?0&
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M@8EV%U<@33I2D[S0PWYY7@E:,Q]WH@=U],Y8*?2D*W\(^_,[KN:+]+^=R#,
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M<Z?*=JE.U]4&_EER6'%_(5).-%+[^>>]/[KQX91P059\U3D]+N55(F1RIWN
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M^#UPP*J!.N[G>]2#-8TQAD@#=RRW<4^S&/R^5Y.4P2_*QI.ZJK30#N!QW7)
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M>\*/Y7==R+OKO>]<UZ8JC#5Y?#M2@L[2X/CPS0)^7.O?N1?O=NSW/4FCG?)
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M4MUP2OPBY!=@U?<K\+/RNY*;/UE>"8-7*L7WP<@). PXW\H \KX8K87>L^B
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MW[O%';D",-+RNJ!@U&^NZ/),]_& +K>D98QOZY(NP%]NB!P.V5YG&"!G=O\
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M!N[*/N[@RX:O4S8Z;N27KCHZ^%'(*$XF^24F^WE &ZA8GGP>[XI5!L8:Q<J
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MX[T%?Y>,KM^^2M-Q._Z?F]1<K,LTNKG(#.&6J"5IJ( N\TR#R!?&"+/F>0O
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MIE"_"HR.EZKG8-]+[J_NW85?!  91ZZNEOU2MF>[1[^W)/?2["4>1'#I#E5
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MKB_N[6Y9H/\ /?BHC?WWUS^D?==/B\5D58,OF]-ZS8ZF^'PI,M:W#HG]VO9
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MCOM\-R)%YOYVY'VV,?JWH.ZW?A S-][.Y$WQFZ\DAOR#U19:G9.00*^[H2J
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MSIP\(#OO*W;D0U35V.%[U+WTMV%R1]U=V<$%/=GTONE#>>_"\*34FCQTW/\
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MA>ZG1!<-2[X[^*9KIITO)2/QR>IEO<(7=58@=C!4MHRI,MZTNB);E.'*Z^%
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MY\';U05ENP>]VCE$'''C+#3LC[J1GT\(+/= ?-S6!EXR=66BD6KR?909:K+
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MN"#K]V&CJ_*ILVA&=-7KD9;[1RRODK,M9 <^.:"S;64(Z.SN2FTS.SI"QR3
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M"Z\]+JN9G>.YFJ#:<\^'"J"AS/UO4AICN=P=]K$\L?&Y^&B5D2Z8=D%0U>]
M=+UA<DKXQPWW54)X8]D$YZ7AA\IG7<-%,_;[I4I/=*WNF>\$%&VL([^V7948
MSAOD9W\ATV365X7BJ,M2>>T7/X.B@H1A<*8)7]NWRG!WX'SK;EFX=GWAVR02
M]WV<^-::9H&HZ=,\2H$Z^'5O5-[M(\"@=_7AG@<BD:Z6 ^XO5'NX2N23WW<$
M#,EU#8FZ\E,V[.Y)V3*Y=-.R5XQAYU[($]V,N-P1::W;BAM*8]<I:14V3\8(
M'&D+-A,;RURTB%@72'"/P]..MOU(S08"[OMCA;M>]$VHQ?CO4O=PM_V@8-=I
M<DI.->R#PI-&N-,<M'R<@<&^D/M69/QGTSPC109RN^29\[+WH.E[N%Z9)&FK
MZ=>\5-^][JW*&J5_0Q$ON>DD2).!UIU\\,54Y"^J@6O+M_=#WZOSKH!\111:
MJX/\8Z*;0UOH.J<M72N7P]!FX[J+<5;.KGG))E79ZB1=CS6.'U*65O0 \.C?
MRL_CT^%A3,CN1GKHG;:%\$@.O*[@E+>^8<;Y%"Z=T#WNY<TV//3*:9PP=K.Z
MH$7AGOI1 7>.C[S3/'28-_*3W9'#<+U1.>,^OT@'2]XQ'TM?+O<$C1X\Y^$'
M]\[=](.@G"_#GJ!GIK82!JG+LLTUK+I) [Z:150+PX%<X:P>%1].L.EER#J9
M:QSSO+5(T9\)TPL(,F]+W(-=I2,*=T$_=AOY/A77')8M2N4(WP6(I*X_4N"W
MMN^=4 9RX;M[W)GY/,77I.B,LMT.=E1;;YUGT[(.@-2TXRXNYJH;PT^^ZXF6
MI7NC#JF&TO%!?'RZ7)*T<>-WP2!K"<,LB];.-CH@'OPQY_/RC[GZ<$"S7F;[
MA2.TK",MR#L#0L[HU"DWMN#Z4D+HHOQL<%,B_DQX105]\=_%.&LB7;G[N21G
M'A>H^TS$:;SCR0.<7'ZQPWK$7QRQI54:+N%\,% M1??W@@#1W78"(^.?RI;4
MY8])Y^4?=2Z=I?""H-TQ=D4!M.%UO))IQY<TWMN]X'%!4-7><GQHD+>9GBZ\
M\U-IN\[GT<E9:SRSWY86\+LFO3'SFF)PGW[9\5REL7E]<<E=AH;SGRU"#/OZ
MFB#/?N1-!V2^YSHGEQP05(XVYXT4";CI?A!ING4/.Z6J#35W?! 0UHZZW%4!
MQL.K?)089W/Y7GP50.LL2@':3L)[XK%K4W;E,MTN^RB=KE/<(WO2XZ?=07X#
MYX(N^^%P2,,Y?+[E)%K"&66'T@;^2GPXN0.=FGTI@.(N66?!$OYXYX=$%0UG
M8?PNB+LN#CPPMRSA$W*^Z<8997/)!)W75UW)*_+Y'-,1CB8SX?"0X/LW/>@<
MMX674*#+4;O%3=G&%YIGNS^<LJ!=(KR#M#.,_OQ5$GJ>#IWN4O>["F(X\$'Q
M?SA&"SK?,5,>&[44U3LLN$J7O4B>,L[K\*VSSA#%9"%L7W-N0]V'SPK6*S0T
ME2'#HLRR[<8>;P0.1".%_6$TNM+AK$(^^[MZ0V_3@@4-/>ZK\H_ X*@^G97E
M!2>Z%9"_E8F^$\Q2B"K#?S)V>>O.JS1?2^:YQ3YS[JYX95Z&%S0,)YWC2Z)&
MCO*3WY:'@M[>6;G><4%&6G1J</I3.U>;UG;E'W^?$*NL*K+.?RY ?=YROGV9
MF->4+YO4VV8PW:X:?:+L]]Z6$'2S+<[A(9J;8TGJALVK/GM+BCM&K=G,:>4
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M,W25#[G>'I@::PO*20'-UV[!$&[$[FH']W3 C)Z1UX6:I2:UCC+2^:<-6Z_
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M<G#Z\]%#^2_*7WW=A2)NDG!!4-'$W&;X?:J#>/U]+E&(NEE6]V&3LONM7H+
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M*31OI+[Q2L;O&?#DMSG%^&0Z?= N&*YVC;XZ7\H@]_O+HLT'OC,Y3F^W4*Q
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M=IX4%P<N-THL!WZ1\8J):^+[\$PVE*&/WD)H"UOX!U]$P;[<Y<9<H(/W\9)
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ML&IUOAF]05+7'ZSN*UP^Z9YJ):N4#\HAJQ<"@9]T6(X4O$)0:O[:&ZI3WXE
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ML.@&?<O@%BUUXV%%EJQ/?CA;EB:/NBDP*>^G>ZR3L-]ESLL]I:?%O5W8.N_
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MB+N<:)'\G3A>2R*C#<^GC%,_EQ^%/&^3D";\H+AK/E?!*^NLN7#!1#?PG?\
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M\/Z(D1=4-RA?@(_R<ZNN^"CR\YX)'XR=K\Z(N'O='NIENP=<4ONWNGKXT@H
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M]]:( 9.EE<.R1EKM+@._E5 X=NSN*'"-_D+3<_B]:S6!MUX>4I8QIAI/Z@J
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M!$AT[P2'"_K%;G*+<_F*!K$W>*9FO-W.\,5S/X.[A58,1PN]5F9N*''Y-\D
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MY\T0.TUK3KTZYKG:;/SC]I_=]76PDOP@5A[XPTMYW\5U"F=CZP2[/J_2_"Z
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MGVN#^1W>F+[JGV6WXXR\RH@\LR>[A?')<WJ!2-]_&BS.VS%YYI&FP7O$ [&
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MQ>Y)%F]HY[H;^3L#R7$SZAY@3N/?Z#ES[5LFL*2CJ[FCLV71G&,.%X(/-,,
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M'LIMM<^.]4!N@@/B<=>:ML6'1.MTBI;)BZ8[U<-X=D@,TSRPMRDT><980%\
MG]U_>3]ZC[JXW>&CDOP%WS'US6:.^ =)U(?5,E#WR<7T'W<5077Q56^0ZF&[
MW=,L$A:@_A2F<0*NK5(P.U>=Z%#:;3CC ::K(9EK+-_ [DY->EO*X2W'.0UT
MJ $X:S=C;HZ=D%_=U-XW!*&O.@,=3I3<N5K:JC^.#A<$2_/@LVUVN.B9AJG?
M)\NN07.V=\:6Z$822>Z/+(0178V<#SB_KX4W\N+I/-.N"B&[<G9\/ZOX9<WH
M%:)%?$1<^Z++4WA_Q"=(8G))M#*8X==,DK+/%^3M_>$\%;#H;VL,G$'7/LY1
M8,C=ZX*H9RW;EG2$L@>$YK56[AN ]^$Y/YQP^WIHW>*1U>(NX+%JWP"P.AD=
MKW9)6O,^L^G)<[+>CH6:0GO3EKOI5X^T#L0GO,LM'64P;T?&#L[ZJ7NA72\N
M*5GA\&XXH*M&^5A(UU=*F23W7B'X0RT1#6#MU93KP[H"6KXPS'1'9B?2^R5_
MC#.&&YXJY,QC_P!T<['E!9F_.5$K3=!'+$S?'QN46FW2'33DILFIE+45AJ8Y
M:(+@/XN.!^L*+*3^%OUIP2(/.LMSEH;EX"I[QYIB5R-F;X8@5X]LT ;NKO*U
M3%V:HZ[.MGYY6[BE:TO6&>BDPW<^.[59IJESIGTFLM+C:4REESXI U9I\ZQ2
M#CC-^=R*SKRC+L@S39QIUPU[A$-PJ_L]R5LW#&2 .ZF4.D-5148Q,;-U4VR[
M&Y[R@^,O&F5$2.D\[BY)\0S#5]>&28-4C"^.:E+2,>UZR6?+3H."@)-GHY -
M7E\)6SE=-XS2LCYZ3W=JKMW"[?F03;,WK\04O?GB'7 ]DGOEI<,EQ11HB%+C
M"N54XVE'9>.,AH\KG!K'([NR'N^W]/E655?41GOOD903^[+&9[?:B_665[N$
MT"9G'LX6Y0 CE7-49+H<*2LS*FR8RI'I"DD2U?/>ZN2!BV]U*4QA]TF@#COQ
M&O3Y4@<H0^OA6:W7/3 *R+,M7&&&B5K:89V[KFN;WF];A7)+[I:<;S4'0&Y.
M?NY4'7JCN='%]R,ES@\_$=,AA@J@YY3#YTGNS>B7=(:W5QW73)%IJQC]7)<_
MOW"7GAC1(-IWW[N"%G0&N;^(\\T_OEPU@Y<C37F^KZI"W30WU5NKK+3^UV4I
M=A.HOGQ@H!O"WX75/[K?D8* -^$GN^(8'DF)QPL!2)YPP!\+4<11^CW/O>9I
MG\LYW]O4 =V0C* '=,T85=YX9]%N,HS%3ANSPES09VGQ"L+T409:5@7PL+"<
M0^F L+G,CI]]'W70&N54S.,.@^?I<SP.G5V_PJ,M;[=6BLY1'$.=\:1>.PP\
M)2<HW-U\4K;<WX8X7<%/^7.#G=+^U:9C.Z769X8#ZU[R5 UVZ6[X7*6[E?1$
M-3S.KS?PLU;<E7:ROGQ2DT<[?.9XA8M6*\'*#;70ZI,BK)S^74=HJAJ)N"Y&
M6^+XW?!59;Q=9X/=96\\A3:WY40UXA)VF:<[3,SZVZRN=IJ[Y+43U(N\^):G
MXQ19;NY>4K,K^=:]$1SN+[[+E=57P@B&N&L97]J#1YW=99)"9[^R6%6FMY&<
M"7/=<T[-X:.PQ7*&I=\9IPUCHD,Q,_1T>Z;[U%X)0U<OD0TX*7NW2G<M$'W,
M2^=5JU^Q;N@4Z8<[?!#<(=OK-ZDTT.%5F=I<NRDSFEYX.@;3-\A$/ORD.TS?
M+DZX:!(TUA'?/.4=[E![IRN\,E:9W\&G4V:[H=.KU(,ZET>4'2Z<4O\ )K=U
M[IAM/F#MUYK5,\_)SJXQV&=6FF5]T?>[&^0R2%O#"L;E84FC82:<V(FSI9VF
M-9NQP72&1<5XIEISK?<ETL[?AS2:>#I$S/5Q=+0Z7#*X*)SIYO1#^6S$TA\J
M31G#*73JL6F&;Y\%6FIXWC3#@@#>L1BH^[/7=R>G![[R<4;CS6!E=[NB5IO.
M/"^Z$,:5Q^$'76*:V5DJG9 C,<+MRNPUDZ-([[HN0-6\\\XH>^Y/WJ7:C@\B
M&Q=!YBI-MB$+OD=ZY1M-T(2Y)?=*@N%O<A^:_N\7])?=.5,><WO^U/W\(5YR
MY[DGOCA/?A<\%NJ,N[Z,5SLZW3[Y<KGOBIEOE=U"+)SA$WD@UD]_GQ16)ROS
MM9MGD7^242J>Z?#"]ZY@-<;ODF!OS?59FKA&7Y-1M^6YU>Y\W3,144WI6QS?
M*[>$@SS?&OS+<J>[6(=$W'5(FR:W/65B#AO?SZ2\05 ;C'1V>&&"F6O-VY*6
M_BKLUAK6G@OCK;NNCDI9^IX6<EF6LKY.^G)B1,Z87OR1F:LYL1VKI>-US6]N
M <["[(T1#6?&#\1?PA[^N^5E&HOD?6["!Z)??XL=WIWSIQY4-.R+7=@UEYFM
M[I77=<TK1GB[>')/=S?@[I+=%&::N?JN.W>MPH]8M6(PZ')2#?&[C],TT^DK
MO!&YE@UXOCV5!IRY*+.!SA==()_=#&N\(S%4=ZIVFE;\X*?OQL9W!0)X\COR
M"9GH'WY0F=L&]M75O5W-4#(=TBZ_*C[[AG]+?R7#IHC6M M-7K92?R=9\MU-
M*)6CS@*ROAHA2.,Z\D)FRC+6MRG<@E(G#B8F14O?;L.RS35;PNBL.<5;%]FU
M(:Y/5??S?CT&4%QLM:UA=>LU4-;]*83TW(Z0H6N&5=4 >7:,*J):UO+'#%Z<
M-=WXRL)#&O\ @Z&6I9P-RO%.3?+>N46XB11!Q^-(<-4EJ)R=#]PE96]U/LV]
M29,\>5ZK'AWA<E'.=]]IRU/@.OD)0W@(.SW<GI"?A[C*!XHOQA S.6$T=*MR
MQVES=U2?RSA>$)C12X^7FWI0: 7AKR1*IM#H+>$WQSKPXR@A[K&&6JD_(QQR
MONL6L#&5YWDM6G@S%7%;WT[V+BA[I3B:"&ES4 =T+/PF9+G7#PZYJ0W3-U74
M[K!J=ZOH[)+[IPINUT1<._'PK,\"\+,&ZXV4?<,ST[:1S7._A"?--[[)=R^8
M*$3?X=RP:O# 3E\53 [J_!7&&JRU+QOR'5R/\DC'.WHLS99OA+ZC>:D&LX\M
M$_NZ0K84B98=5"YOY//+DG^,N7*WKGW7B_LJL96.R$J.L9S\HNZ'?=7U0?VW
MWXT3/PP=A#PEPCY7].0)L5RP=%(6]XOGDI?R?>_M5'*KRE9\^%W *C\I\OEV
M6JY0UD1&<G7R$DY-'4WAPY'&B7;C+.]SM3PCTG-<[^I=G\5"8F$XT=-^&^G=
M(6AP=OQHBS-XR,SIK@/NEN<E]X)0;K"3KR3BY0[Q'!:F<UB89EG+XEQD]4=X
MU=&Z.2,G/$9RZ#-;W94COL:3*LU9<-A)2W1[M(PET0.TW'EU2D]?CLYZB1'M
M]946%=C#6 <+QXP5-(WI\+CV9RW \CXP@NCW\(WG<"$#^XXY7Y0]^4QX'B*Y
M2U=B]4!M;TO">2U%.5R[I?A$>:Z?2D6LCE5QOBF!?WEJ@16Y7V61O?S>+S?1
M,#O$M93.$99)"SO.9A8[K=G>(RX)<4]VZ^?4)WY];'TH QXUYWDL^OV^$;KH
MB*OPU?RJE:MUR0!EPQ\>$I,YZ02[-4VLB;P?XAW1)N](O5'0SKFE]O#S*]RL
MDY9F9:EOC,/=Q5 996ZY%39-W1,&N?/RY:M?MAJ)O&2@PE>%>G1,_E7&I^Y*
M(.3KGB2[=HK,D>+JL),]63POJP:1NZQ5?QP,'SX<17-U5Y%O9OI/&Y8*VQ8
M=UN%O18R>6V-,N&6>2LVWB[Z?]?"YAM1 5TWUQ4VVZ%%-[I7=QBJOZ3O#Z4]
MFQV,XFD<!&056R!PMXP./*J)L<Y(?T>-+R>]=C(GAS$.Z\;[XY9WA5=FSVF-
MC.^R*3:-.)UA1PR[Y*[#4-UYN[*38J,Y1X7V3"$WP&^,1N<B0S0?06_@'*S&
MR&'&X1WKE.UOZEP69]1"L+WD4YH7=PV('@<GY+-L9#&;CFI,;=_W/YJ[<LUM
M*RAQOKDBN/:EQD1'J,.J?9-\OMU]E+:MX7QKBEV1U0=&T:&YSJV=ZAL]JXNS
M?H%3:,0EO?U\;E)F[RSS0=_O?'APIJN9MKB^]82,T6FQJZG6^ 7*=K2F(CG>
M"#I8-Y7(+H9.&6[JZPN ;6\\I<,59C:2XOQCC\(D2IM&G1/"[YJ3+4G^1*?P
MB2#'@[-3+=\.$$5U%U.4]]ZJ;.9=.W*33=,,3=)/4?YG;N> C5!U&\.'-28,
MN%96X]T/>_<(>7NGFB'3S>]\98"F'%!W;/:X7RLI=KM<],'XY=ESAH7CW4=H
M#QET<_IB@+4>&//,X(L# 6'\'.S2LV)279L^UZ;D#L;.4-^+Y(N=.#C+"PYZ
MZ67<KN84VC.]$(*V8'<YVG2:X \F>'"X+HVC<'2<N9C:6_O?5$N\@Q1[\[Y+
M-[09/^;Y+E;VT  ^6_A2RH^ZCZV-$'6RU@;UO),=HZ]:^(T4=FSEA<..]REM
M&[TZ.15QM/K.O*&:I[C(7@<^KGJ&S9>Z;G<\NQQ5BSK*!SQN6B"NSQSSYSO1
M4)%G'QFN)IISKG&^*YCMKGIWWH/(--#K+2^RD6\.UPLKE_E^H4RKR50SONB"
M@%=^5QF*JWL'#K?D+E_DQF_<[#.]5;W\7<KF@5H#IQ>_ZP*BWM,UR>I]0[ZO
M[7"SMG\..KT'8WM:8/GK=463\7>BFR)85UP'5=;# O=CA<$$&R=WQ<*9(LM/
MRQTOX6VGSVC>,5S?R.A'ZSN"@ZR>$M-_)=&RJ83U@892$>J\7_J)\(2R^W17
M3L6^GQJJ7>4]N6^>'1<7J&7=(V[<NO9'BZIN7TH[<7$UY6$'C]D>D,[PWKR#
M+0X=^J\8TTXO?K'1V:[&&I0PJ]\.E7XY(+AM]WPCFAMAI<MP^$C+=OA!3VFU
M&/T7UQR00:&YUN-7J@-V94LKG_D%+?UQQW)]G%V[7>_%SD9FJRK6ST%\HV$P
MV8OBZ,K<4YA&\7:+D;V]W-%F;.@=W0Y9J@-]KX*&R:?C*/:-S72UP(\76:*9
MEF(>.L>>OTH[5BGQH'TA-(-H00[4OZ=ND4?Y7AUV.R(XRV7RI2?!=+!.-;=<
MG.20N_A=3(J(2BY_.KI=T([$_=<;+[F@T16=\A#BJ-;.#\>*@1>-0BPV/9XT
MW]5T;+:B&$'OPS[%3+,..6!ZU^ES,LQ?&[DB7>3:-!W?R7,&HW$4>K[,5N[D
MH[=H#CO^.V"D<%68VT=^Y[L\%V;-N#L;X8A>&V;6L\(3P^5Y+9[0<E2X[2IT
MIP>N)O9O?1\<M8\UY$[0;M.:@VV,>+A&E\D'BVX/@9P(\8=538^IC'3#Q"\$
MNV;!&&DJ9=7+E9%8W\(DO/#;]!+.X^'KGVFV/$W!ZYMG]+H++_F\$5/9[2.-
M7R\27D61"$'V5QL;.+^M80=AXR78]PC-^5.\LGYHD./;[.CKXUZQ7CV=DXX.
MS=;AA%=VTVV5]?E^2Y&MI%[O'WA2$$(>1V?$5ISOLAM&8&L=(UU7"QM^SA]R
MAAN5&MH_CSH,D42UT2!K(C?;KP3,LU@(7])6FP.NMU1F[N8%8:^>'PH[8]QA
M&AHAL]N'4C8#ES>HVC\I<;F9Y(J8F'UN4W_:[6&)"PZ\%P[ $D&.KY]X<UY=
MAEPB/O,0^2A;S,QLG94N<.RVTVH=+Q;JU4-MMG2X?,5P%O>_.W.0#;;3[RUM
MVB1C'O6YK;4B_'A<NSVL:>(:1)^T+\'E0UNZ/GAP40V7QSPO<GV<1I=Z/@@U
ML\3V13_S.C<.V"P]8/C/.7*4EXSU.TIR)NZ)=@P\O/9)E(EYEG:/[;\4C;$)
M2N\DVSV;I\(ZN[H;;:/>[A"[Q2Y=QAJ@L2^W:+R>QVCO&4H_$9+Q+!GKE<MV
M*NWZB@<^'E"[K:]3'YPN&JH-IPOHO&;(/U%R76=J*;Q=;"*?W"KL-ZF?42<)
M5QKOMRYFC@^^<5F67NHYUO?#L@[OY8/'W*>^\8M-"-3ER46RX0.NGF"YF!4U
M=NCUY=B*-LW*^#U([/$7U.:NTT!K'"=\55B-CC>Y%<XV FX7=-Z3;;.&^B[F
MF0.9^H7BN+:[1]B3Z06(W_'O'CQLM7#-^_1=#.RRO .XO73LV.'/ZZ*A:XA\
M?"L2CA;V6^#C2/>Z+,LFN;G3O3HNEXX<>'-8'CI/6XU5CZEM[E)-P"BSM3&^
M,?I=FV:I=\ES[-F+[N]5Q1O:9.?ETRS4FMONERQ"[/XG[\[<[KP6;]*)=)JS
M*6V.$>K/SFK,>IZ<L^.7%2:].!3/GIAY5=GL *R@^W941=6%6=MB!K'!4_E
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M>*D/CU<BTTSCHZ<I;I("12S\9K Z<<G"]\U/^01CND[?3HBZ4M!AA<T%R=<
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MOW5:BKL"@RN]Z;W9U.#G0A=4'2NW_(2NE0QAEVGY4JVBK_CSCNW)A@)7+>H
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M$XZX+,; 2XWSR<[!&+6GMR>.C#/'A<A!4CP)&<G[XQ7E&/3@:]:RP"GM=@^
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M6EF*8>0=E#2%S^UO;8O?BN0>IIX,<Z)O]1R@;[\9*Z\K$1P7]HD+N2! AP=
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MFWPN-C@IABEGGIT3,@5A-SWC!&9C.QV=FZP["1Y.@N7:-'[H71NBHWMG#I'
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M.KJ+QGI_3W5]^,%?U3#A OA">@L*14DP[3MP7#IUA;UCKA6-;Y+PNR!?OG.
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M><8J]OAB^\5Q,;9G$<8V.27:>J&(W?=."MVXBV>S=^*[0C@(2Z\"E+,<(;G
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M+KPJ;[)K2+?S'&[DY8;=K$SQTZTW+!H5&4G/.=8<53W# <?%.;W+6M(DSM3
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M2V>VC/*.-+[JY+G'@^[D%:9V_(=FU#V0.EN)-XKPXV(9+W0P\<XR<]>18V\
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M,'?'5V6:@&X95IY?/IBM_)5_.$GCZ0>19:&.[!,2,!B_"C^>.2\1_-JZ7W>
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M6Y.&M^F<CIHN!ENX6_%/_))^-TD^HT5'8V;IE\H>ZL.+ES_R<'<]#EJ'*?\
M)RF7TH+J@ZO=]=$C6UAI7GU@]^07,=I>7S/NY*TT][]-,\(2@H.K9[:8-.#H
M4IU,50;2=!T.EYKQ['C&*8M>9CCX5'?_ "YNZ90$H1W/0+?;+CV7%[K\7%\%
M0-PN.[/EHI,CK9VF/B<K"<M]+A35< ;H#9P,B[@$W\N>.'''LK<=/\F'#F<Q
MD$/=C#)\ N4[6NHCIRWQ*/OM^3EF8_$= ;WWR3!O7CVE'HN/W\H4@=])H^[-
MTH9#&WT2W,#K:VO*N&_.HR2--<LKX:+F+?'<]VO-#W<,? X5P4ME,(Z!M9QH
M[E58[26$KP7$VU.C\Z/M\YE ;7,;H;USX?-7>=I.\W/?ATHD]](U[=I\ER^_
M&XN^T&FY^;XK41&^8\1T>Z>E.5[DG\CJT^./!1:VG.4(_02%J5RP=P6HF-D#
MK#3KQMV2<;3?/QQ7"6NKEAM>3M./)9C;\M^8[?Y,W7>0G13:VSN6;NN;U [3
M#=1TH[\=RY&FIZSP&ZA5V6WCR?OEO?GARAK-9IJYN%RK-Z\?L]KWZ.X">6Y4
M_D^(XCGTP5O^6_P'06L_BQ') -_&-(=XTS4/?ND)T<8;J)0W6--^_!T=%F*N
M-_D.D;3<)82K%#^3Z@+QR4/=K]#"W*#1SB9#[HFN.W^6=N="8=3<A_)C2+ZT
M=]+A+?<8<ZNHB&Z7=:\ D3(\@=I/=R[\^J3WXXQ=>3H17+[KGVG<DGOQS=N5
MHG<.WW^)\!SJ@-IVS+W+E_DUOJ[-(6]W!TL3<5F:K[N>>H=?\G"^8PP0_DW]
MX27"6^$ZU=+CTP3,MS-_/<K>N.L[76?(Y<_E#^2.M)93D80YKC+?BCKWPFA[
MK$;%:8+4H\@6\]\7.\0'TE::O<ZX+C_EIP.&:4;3MK]<([UC/C^/8KL?OW]I
MOTY+':<_C"-T"Y1M+$:/YOC2>J;WX0TSZ]%F_//E8=!VEN?2WX[D1M.RY2UU
M>^\$/?*[\K=N$CN#<_O?YA'FB3=/+SS"Y0WN%=WC@J!NP*/K>Y2J?'8+^[#7
M3.!XN\I2WAJ./?AFN;W\7U2EJ51FZFD^,Z)5N^D#J9VF<7SI>%E#^60XWGN<
MY<8VN;G.K4K>_P"A6YK%AY!AJ=WH4/Y,,I4A4>5Q#:<K/;+HF&TLV^PMS,;O
M(=7\GF]^*0-YEU_$ESM->75Y&&]<O\E'NWX6[NL7'D1M-?+J<0F.TX&]3N7&
MSM,Z93T/-.&YNQAAN[0JKK<1UAOY<?J28-7'2D/B2X@UAQ.5CZ5 >=]E)D6+
M4N1Y3S1]^5XZ\ES%J=>8W;M^]'W[HOGPU!<7*S.0Z?=1_'ENY+ TZ9:S7,#"
MN?B]4_O^<<;MRF!T%OE>Z'F2(:W"5]@N<MTCV-TYH>[Y[%]A:ICB.EMJ&57U
MD!>)T7CVVXU UTOE56+7"LL)&^RYVQ@'Y;H?23MVCMV.U[\)2X'I)='OL8XX
M=MZ\;LB[*-FPNE^+JNCG<UL=+3?(8V,$/=D+H0*9+E:;I@7[N$<<T&6N8Q\9
MT6=?J'=_)K][ZX)"W/*W=Y07-[[[I??7.'U&5N6H%/=2_CXFG9VE>(D[#@N5
MIK'Q+X\52AOY$!NX=8J7@=X;OGA/DM[NU8;B[BN,;3=N$-U%O?J+F["LIK5Q
MW,F4>#JRUQ6+7=T?MZXV&^W3#JF&TZT[:*"_OW'@1>3TI:EC0S/#NH$[G2ZN
M\I?=6>+G.DIK1V#J9:XO>Y]<8\-R/ONX4[+E#>&.#]]P0+>ACXXQ5B? =#1R
M>0_" 2@WT(S42U,63@?D)"UCYEEBN438=0;Z6.58.*S+4M2]SI\QV*Y WP=P
MW256=I1^?C==%NF=XZ0W7+Q"3W)??XT\XA<_\F<,82N27W<+[S5FJPZ_?G0I
M'^;P^%(-[\<X0?;E-IO6-/B+USF;B_OSTWH^[._B*XRWG-UQN!5/Y-\1*Y<J
M9KI3L'5[NDC;O"FTUH\X0T@=\YKF+?*,?&];^2X<'7Q4X#H::SRCRSGN#LW)
M"U]T)'2"F6^HWPA9HD+<Y]HUL]%8WV'2SM*!W.'G2:J_/G=?"\>&_,85QW9J
M@;F!8O"2E5]PZBUW&/!(6J@OR/"'2,7J!:U=3"'/."F=KC,Z:0K%*;CI+?:7
MFF:0[2DN0\N@"ZKU!^$]1K='<4G\EPOY@K,7B1V>[Q/#/!UO2%O&76F^\5!^
M%F8,8^$GNTGK.F:Y6Y[AU \H?-SDB6]UU'3FN7W8OQE3<M[LL;W*WF!T>^^&
MFY$-X1Y0"YO>/B$8@0R* :NB557'26YG$VYV4'B:WOXPY>>04/?3<,+ES<L&
MX/Q<]U90QZ/4F17W3K7Z-X+>_#7[>H?R4EFZ%G@@6[%-;Q<I<=C.TWTX?)GS
M1]_AXO6PN7W<KAP1#<H86-9P5B;#K]WSOOBEC Z7VP*D&K?"QDE]VO>#NDBZ
M'%6(OY!RWYO%ZWOS=VR._AO42UPFX<[WI/==P\*7%QM+CSX;D_OST?.:X_?Q
MF3+[Z+>^O"&<X=5N*N>?P'6-I1^&E_.J+]UZ917(-IA72&?G-'^3YCG?%2:8
MXP.@M:V,^*'\EUQ=!UO42UQH_OAWXI7YV=%D6]VG>'SPW(OMYZ<OE<[]*5))
MKIF$ONH^')_/>[!6F(WCJ]UG"ME%IK?!\+[1T<N7^2P;#S#1 [6?7A<(+6MF
M.D-"5UZ<4/Y;AUTW+D]U!PPRUST"4M]H!8D>1#<LYWI*B/NLZ<(.^5PL[1P/
M&/E/_+AE"D?-5=;=(Z@UJ_7%[G<%0-98=N_%<++?/-]YZ/FJLMTB95@89\7"
MJM5ML#L9:IWX(EK2N@EXQ7)[[?7/X[IOY.#_ ! W.2S;>+_R6[=#Y1]^9F8G
ML]<I;K>+NL>*(;X%];W?21P';[_B,#\.4=OM:0IQF.4G4S4AM'985E1V_AHO
M&>K]1.D;<EAQ^IVN'R-7XU7)[G[X91RN*Y]KM7FKW[O'E%EOII&\^2@Z0V<?
M)RXPS3ENDCG?R]<@;PUX8>,9+?R5&E\X(.@M7D;K!$<Y#<Z(TY+F]QQ&Z-QF
MF9VF.5OAV@]!TAJN'./0(EL8OW6>71<A-!NE@A[YON4\(U5F1V^Z64W9X5/1
M8MROK+-<O\DGNK?&"'\FN8EIKQA-0=8;XNX71\ECM.=FDQ]+D#<GUSP'3F=Z
M'O\ +L--WV@Z?=A8C%%EK?$3@_'=S7$=IB0[I6EOWIOY+N.]!V!O ^)]$0U(
M/E+',\5R^^<Z/H7_ %@Y*RWAQA(V_5!U^^?P.U=$"WORE2MO7/[MPXO6]W9Z
M#I&TUEE,4UNB<;333OO/Q!<)VDX77*+M$?Y.F=^4'66KR=Y0![8\7TT7-[\.
M60=T?.B!VO4XR=)!V>^;M'&[I!'WYOG)TKSBN+^2AY4I?A$MYY8:W+D@[PW1
M^CYC2Y(_R87EV>O'C:XRB-<,QGF'(_R2^M>,,)(/(_R9_)SONI-[3"_I<1VN
M)TP%  0'[\#-#^;NZX<':(.X-YQA"LM)"PM_))UREI%<(VN$N>B?^3ECUHZW
M(.OW:PD+WZ#1$-C?CA=P<N/^3'S\YYQ"/\PZ'IA;J(.Y^_Z@;FE+?F<KIN#Z
M+E_EZBO)Z0[63X4GP=C8"#I+8FZM^,4WORNI?GPEFN(-?&5>AMR/OEG5\,*0
MPWR0=A;^Y0ZNGR3!KSNM^\+Q[3>;M1*7W&J<;7M&6OSR0=OND'GJ=S\J811#
M6LXOQ-SJN'WRLPF+FZ!6][Y4<-^%P>@Z_=/XB]QT6.TTFN([2G'#,9OQ=X1.
MUSI&\WF6]!U/O,\]^Y+[N1Z?')RY?Y+=%^EX*7OOM<(H.LM5U?C9X!\TC;6O
M'ANMRYCM'X6_A&+N)4CM.\967_:#J]_#L9 X2=C,E2:;F1EKKIDY1.TO/M#!
M2;VGSKXF_!!?WN?&'!^.Z:B=I.]?&%5SM-YPO='S!2:VHOIO^T'4WM9N+G\'
MZXPW*);G<=]:;US'::P=4;W##MFIG:9U^1X"#H:VL,/O.AZX+AVOJ *QSG*&
M]RCM=MAG-QY4CS7@_6^L#(:?, RC.7UV0;\K^P,;$%IIH"&6LN^X+XC^>_K-
MLMDT61M60[/'B[ROG7]6?W<L!MEEH@LO<07.<>$H847\W?W7]^VK>V;8V>U;
M#+R^)<2\R#^\UNBB^<Y,Q5&_+>_J;Z'^N6S;+OY&2 Z1&0?5\8.XT7M.R_J_
ML'?Y;1D9^X &.&,W+^/OXK]M]0&?\=H7OB(@P=NU'$O7JW[A_6'U7IF"[:&$
M8-.E4%YH#1ZOJHF;1*^+^Y'HOZE>FVG^W:LQH6@'&M3"O%>U^G_8F&P/:VR1
MD07N'*'9?YYOT7^Z3:G;#8M[5H%X >T\%U(\9")7[A_4O[C6"R WM@&G";4=
M1I@8F96:\*J.=RQ+^HC7Y(-2:!/&S;T[/K9/.\.Z4)^S)?S\]!_<3LO<!_J
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M_&7^H'XO;[/;-$DN!($P[(U<Z6(.*]>#1$QG>>IRF=NWO['Z'_&_U0>"YID
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<YAK;S+],>-DH+PFW]7.(<!-^\[\G)UJ*96[_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>silk-20201231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20201231_g3.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" "[!]$# 1$  A$! Q$!_\0
M'0 !  (# 0$! 0            (# 00%!@<("?_$ !H! 0$! 0$! 0
M       ! @,$!0;_V@ , P$  A #$    ?[^
M
M
M
M
M                                                         %4G
MR/AY=.9^O>CV;]H
M
M                 'AN7#Y'Y_G\++['Z?;]/[>H
M
M                                          #YEQ\GROAX.!)]3[>O
MZ_W]V[=9       !@U9.+G'6UO?M       P 8(%<G)G/3F>WKIT+L
M                        ",2H
M                                   #Y[R\_P ^Y<--CR>/'[_?KV+U
M]EOOT-;V;KI5N6[-N3(,&"B34C1S.<G)F/.XX5G-Y^?VG7V?2^_IHDU2B2H@
MF"N(@K(I!(2148,$),V\C/+EL;3I['?3U>^H
M      'Y\\GI\]ROZ>]WFNU
M                              /%<^'SWEYH'/G/O7O;=Z<EAO6[I$F1
M.>SHYLB*V:59FLFDS"XFSV==?FOF_+>_Z_H_?]_H1DLML7*@96,JR*2,K$P#
M*C!$U9CS$YRG3VF]>VZ4                              #!^2?A_3\U
M^<^I^T?W?YK;Z9
M                    'D.?'R'/SX.+GEJM]B]Y6[5UNDJD:B:DFG%:7%A'
M*^V&\R6Y-NMZZ\)Q^7Z??T^WKM9=960 ,&!&168&25"$3J1 \;GCZ_>^A;ZK
M6@                               /@?Q_H_G[\I]K]R_NOS/8]/(
M                                                          #!
M3&# (F")YG'+C8\\Y?.3'J^GIOMX>9K)4S1E0O+BK6>SJ]A=K2.+-OY5-?E[
MEW\Q7[;Z>7W&]V'%SQZMWZ*])K:#)DD2,@E&:R2,@R9,$A7G<XZM;-OI-Z
M                              'S3Y_J_&GX3]-^POU'P_J?Z/Y>0
M                                                       #YIQY
M\T@4R=)?6;Z6&#! C0X^..U.=MOGLXVKWY\:USHQE+[92]#;8;KU=@Y>><D^
M;9W^#.7L\=KI+.?Z3:\7U[K)QG6IR=N[M)$@9,B@,1%28)@B#!$P<5C=:V:]
M'N@                                :G/7XQ_%?H^9\KU?L7]Q^<]/]
M;Q@
M8/D'#G9J[)R,O'>>^LUTNJZDD#%89\YGR=MTZVW QRYF]^AZ:Z#74NH+K2R,
M%VG:69YW/'PG/R[EW1KO^/<>KR;7["GD^O\ 359Q<W>/>]=368,5F,4C! B1
M!A"C!$B1*TY<E=SV&O;=-                                  >$\7I
M_)'X7])GR=/UA^H^)[K]-\N_ID
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M*(T32G*9.]+M=;LW<NI5;&:S2,T@8($1"LJ$5(*CC3GT.N]VOL&^H
M                                               P     #(
M                           ('@>>.@U@E7F^>=_6\%D8U(Y4E)Y+'F]'
M<8ETV.S=\N.39.3I-=)J]:4AJ6W<-6%LB4%I2:U2:TS%*$X^)K35ZV4MR2!
MR8(F"!@@0*4IEUTFMK.9F-Z76_I7T=@
M
M   !@\ASS @DS6SKHZLTFHB$P?/^?G]1<9:^9\O+T*V]]^I;MM;35$F6N/)\
MNS-KI;UVY==*LK-56Q+?6C9S\XZ>F_+U%E5D2M&21E28(D1;B,$2! E&+->9
MV7.;73NOL_;T
M                                                8@  !7S_ )>>
M^8W+KY!Q\/&FOJ77V[]NU;8L(IC:HG*DTLR2]"W<NL'.DX<QR6-:8@FWK5L5
M:WL-66YENK)DE;DD9(F!&*K00,1%*$C.=EO6O3[#U[@
M
M                      >!Y^?RG#R]_?3Q6/-\XY9]MV]V_=3N]@N2Q;K;
M4F;2WV[5;-N;()3)QN..[O7D7B^,</SOV/K^EZ^M7*5+@HN-:61945C$UL7:
MSO4N(V2LRL#!5,ZTG%G#U._3]>[^T
M
M        #S&.?#Y>;O:W\_Y</)NVM=2MVSMW7?UKIV]'5VC9K86VIF2LUXU9
M.+,U2><SP^;<?D>_Z_2^V^CZ(          YV<WV[5H
M
M                      'GL\_-<_)Z-V^7\O-N[]?H=;]!O7>WJ\
M $#)(
M                                                         XN<
M>&Y>/UVNO@\<_L/H]P
M
M                    &O)\GX>+U>M<JZ^E=?4
M
M                                          .'C'/SCT'3KN6@
M
M
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MV6XZ-!-&8I:="?\ O\0Z969M+LZ_(U:C(<0ZC[#U\B53S;/+;#31&\40D)V
M<4LR2\D)>DD-]0Y9)!5>,D*KL%(.YZ:D'=M-(=GAK'FM8\@ZHCE2U W)BP;#
MBQPB(-Q6R"6E"MD?-:2:%Z$&-M )""'[(S&8S&8S&?Z,QF,QF,_U72U-G*:9
M;*K1DE29;4E7Y O7#Y<Z19]\K*2R\W(;^PU:+5#T_32%EI5'4^M)/2"!2% I
M,<$3*QLCC!48S,V&4A3M/;!2H2P2R,9&"0I0.*^9%$R!J::"]1'F\$D\)%%5
M(J#L0T!*L_UOI^C/]7(9#2,C&1C28TC;S$6(DJB;+8@M,LN?D&\K$IUT,6[=
M]4MRH0YK$UO\_;C8W6QNMC>:&^R.0R.2P*H\TY'2W]#:#C6;[<5E XS8<I9*
M---D(,V2;'(2D*ER \AZ22(#(1#8((8,<9PP;:&PJ0:4U.\J+3B]@7,^])NR
MK,SJ15)E1II'75#:KQA;57-QV%)6DF\@23&@:!H&V-L;8VQMC0- VQH&@:!H
M&V-LAH(:1HTS/H(W^;\A7-:E(NJ!KNG#610KJIM9C?GA^KR2>.L31Y68854I
M@B//R7]DB&T0VAM#:(;1#:2)+:2))?3(/%I>54&&S55V@=1>6#<=<!-F-I0V
M%F&X.86NG11Y)H;M16)4AZ(4=V-(3=%*FRHU3=D<R:M4>.:XJI%O2:<]2$R<
MT[[@;(UATU$,BR(B&1#(9?R2/].8S&8,QF'O\A&63'^;\AO,M2&ZYAG,IDJA
M8D.PY<.K1)GYWXQ./<1 3&00G(-*&7KCW2<N=0U7*,KB,;=PYFQ<!CC5T<6N
M92>3 <17XYI*J)R<J3$F6S",<-O0U&;21-D0,V$@Y+0)R6H;$M8:AM-GF@AF
M0J$7E(7#VS:DR6Q/CTRK,7!AO44R8UI*8;I7 IQIGM:/)LD;]QTF.HJQ#>41
M_0E?3,:AJ&H:AJ&H;@W!N#6-8W!N#<&X-T;HW@ZZ2E(>$1S5(_(M<MJB7)%E
MX>W9;(I^*#E+>IUQTZH,H<;<+\K9D,R&I(U)&M(UH&XV-UL;S0WV1R&!R8XY
M,8<J,.5&'*BCEQ1RXHYD0<R(.9%',B#FQ!S8@YT0<^(/(1!SXH\C&,-'+-_=
M4D<EK3)FN+#/U&1C28TF-(T#0D:4BYZH42'&N!U;+3[CR'I+W9&$/H)P]IM,
MYDT[L19\VE('EZ6D>=IA!5QTM)G<M)(=II .[:/EVNDJ%1O:/$#-\LOB#5XT
MY*#4D.4^/)%1HI;4:U&6F&[7BI!6#1_+SJ/3VTMW#2S0BX*88[)1\_/TK25P
M4DP=P4HC.Z:(D^UT345U44PBZ*(X%W;0D$5V4-0*[:$9=JH>:+KHCJNZV_J1
M>= 6.X6^#NNA9+O.WTDY?ML-G%O6A5&;4[H8IU1I=_TSR_=[<'=K=,)O"@+'
M8:68*NTY0\Y (>>IP\U!!UV D%78!CST QY^!D_<]+CH._[=(SOZW2'?K=R[
MY;QCO5OCO5O$"OF@&1WQ0"(KWH)CN=#'=Z 8[I0QWFW\^Z4(=VH)&5[T P5[
M4$QWBW\DWW;J@=^VZ1KO>@(!7Q0#+O=NZN[T QWNW2'?+<(=^MHQWVV\SONV
MT@K_ +9-)7_;2B[[;9CO5NF.]6Z.]VX.]VZ"OJW5 [XM\AWFW@5\6^8[W;V9
M7U;QCO5O$#Q MM(/$&VB!WW;I#O%O_S)U,I]39GX/T7=52\5;?-G$VITX0,4
MK7G"/<5.DI*JP@F=#4.1',;K0W&QN-C6@:T#6@:T#6@:T#6@:T#6@:T#<0-Q
ML;K8W6AO-#>9&^P.1'')C#E1ARXHYD4<R(.;$'.B#GPQY&$'JO#:16+\O1A]
MW$S%-L[.Q,J%RU+D21R)(Y$@')D$3EX5)L(O&;J3(>-.^\-]T<AP<DP<KZ<H
M<LB'*!RTD.8C/GMCR#0\E'(>2CCR<4>6A@JM !U>G#S-+'FJ4/.4@>>HP[#0
MB'9;?'9K>!W3;A KHMPP=TVV0.[+9R.[K72.X6J.Y6F#O2T"'=;.!WM99#O%
MDCO-D#O%C9'?-B#O5B [\L(%?UA&#Q!L @>(E@@L2; S]E6$/9UAD"Q4L3/V
MI8P/%BQB"L7;(('B_91%[DLL>YK-'NBSQ[IM$>[+2'NZTQ[PM<>\K9"L<[;(
M>\Z 8/'6A#WM1@>.U)'O>G@L=Z=H<QQ2I;N,%*I#BL5YMROG4+JI4*FXO)BE
M%J4=UOR%/(>3IY!-2IZ@=2IX\I3$F=8IQ&=9I23J;])J*T0X:2?C-&[>3"(4
M9BY*^RNE5BM5NI&F[ZK(ZE>LIM=BWL;75+_49V'?"'/7M^Z'K"Q!;;<L^^H+
MK-M7PT3ENW-O%2[OC':K]PIETYU1,NM+4(TQW1,?CO(*1D.6)#REO5')<'U=
M?#Z2PKN=45.$]<)MK"NZ4(/"JYU$O">[=?J"ZMV'@T^B2SA%#0)&$5.?3Z@I
M.W)PD96MS!W='IB(&\%Z"',$: X?H^V\O1UIZSP0M,2,&K<=95@= (J-A+(M
MZJJH]7:E5&V*Q<<9/X>I!#X^+S:P(6T98-3"!8.RP>#LE0]-NCU ^#P74I1X
M-+R],K'IA0=P12\V?X>*:9_'6DCXZT<R^.E%(?'6C9_'.A#XXV^/CG0,OCI;
MX^.MOCXYVZ0^.=MCXZ6UG\=;:,?'6V1\=+8'QVM<?'2U1\<[4!?ATM0@7X=+
M3(?'2TA\<K/'QSL\'^'*SC'QSLX%^'.S2'QTLP'^'.S3'QRLH?'.S!\<+*'Q
MPLD?'"R@?X<+*,?'"RA\<+*'QQLP@?X<++,?'"RA\<;+'QPLH?&^RL_CC98^
M.%E#XWV2/0-G_P ];;;A3[/MFID[A!99J5A5MGT&ZFBZ??21U>_T@[9Q$!VS
MB-EUG$H%:^)&75,1C+J6(@ZAB'EU"_AT^_LNG7\.G7\.G7X.H7\.G7\.G7Z8
MZ9?V2;-OPATN^QTJ^AT:^0=C7L9=%O8=$O0QT2]!T6\S'0[O'0[L'0;J,G</
M[K2W5:)B!3PJDXP.JCV]B@8]=7WO^O+_ #/US?YCUM?ACUI>YE(P5Q*6^C!#
M$93R,,KU'K&]3/U;>1@\*[P4#PENM1)P@N?,\(KL'I^[<RPCO AZ?NPP6#=S
M&98(UT%@?6!Z,JACT343!8$S1Z+F#T5)'HN01%@9('HQX%@8YD6!:\O19 L"
MFPK ED>AV06!#)#T3&!8$0B!8$P!Z)IH+ NDA&!5%)1X'6\$X'6\0+!&VR'I
M&V1Z4MG(L%;7(_2]JCTO:P]+VH/35I9%@W:0].6@0+!VT"!8/VB0]/V@9EA#
M:!'ZEM$>J+1!85VB1^L+3!88VF0+#:U"!8>6N0+#^V"'1+9!6/;9 K,MXAT^
MWAU&@ [4H)@K5H21UBB [2M\S3;=&03]G40T.6#39%1=PVME3KU@4"7)A6)1
M8,LZ<PZOP,%1'0*>9';=,";=IJ1X2GD"I$,%2H!"?&CQBW59&XH5F W5D/88
M.D*7;35*CT&V)-'B):R!)"4*!(<"U[)-O\A284O)4&0%0#R53&%!N RT.*0X
MV8XB1QD#(B&DC!14K74F&.$PYJ:S(S^@(QF,QJ&8U#4-0UC6-9#6-PAN$-TA
MO)&ZD&ZD:B4ZW+82EB:PY.^WA_T0DMS0-(TD#/\ B]Y9#>6-Q9C4L:E#6H*<
M2)YDI*&\TFR%,LFI:M 4\61JUA*'PEJ4"C23'%?(&SH,WOJ>XH&V\8V1MH&V
M@;1#9(U<<QQG1PU@XSJ2+D$*HEU+*7%$G<6-Q1C<6-UP;K@W%C<6-Q8UK&M8
MW%@UK&I0U+!J<&I8-3@S<!&Z8_:(()6JH42GU,6]0*-0Y/V]5$?;7MRQMS0;
M,TR98-1<5(XJ1QDCC('%;'%9'&8%3;0EYM'[*D"M278B5*_<(<4$O*"9)$.6
MD<U.9SDF3SNZ3ML0'W^MTLR*W*,#H%&,=;H0ZM0!UFC$$6[2FP=%C&94Q2"7
M!JY)+L[1MJK;:$HE2E<8<<QL#CF..H<=0XYCC&.,H<90XRAQU#CF.,H<90XY
MCC*'&,<8QL*!QUA+.0_O3!+*5]R:^K0A@R4WD*XK]_!KE.J#[<76"AH!,-D-
MML;38-AO/C),*B&85"DCQTL%3)IA%)>'B3'BW NG22#D9] /4,W#&>02\-WZ
M;ZQOJ&^8*0-\AR"'(2.0D;Z!OH&\@;R1OI&^D;Z!OH&^@<A(Y"1R"!RLAR,P
MPM&B(M*YGW)N)O7#BJE-,[\E8J,33(B4-J,^;3)I;=;027C(R<4"68S&9C<<
M!..D.1)!3)9 JC*(%57 =50/*-!=49,G'XZBIR6&TU_0L'+D1U,--.T[P<\A
MXFH$7C*@0.GSB'$FD%1I9 XT@S)A9#9,;60VB!-$83'S!Q2(;1D>RHR3&4.&
MH<)0X2@=.-0.G/H)+*S328RBF?<FKEG"8T\>0DM52+^/=_O))C^@21J#<.6L
M(I<HPFD/ J2D%2V"!4Z*0X<8AQHXX[ V&0<9@P<&.8.F13#E#94#I3R"E4R6
MLGZ6:#H\%Q3G^L<2.HT,M-?<JJ?^"PK-$C^M46::D4"5-<:H*0U28+02VVC_
M $3(C!$1?>*H)UPX_P!$2#"_WE9^^[J-QM!+*4^O(J<UNS?OQ(@H>6Y35NFR
MPW';_P#67__$ %(1  $" @0)!@D(!P8& P    $  @,1$A,A4004,4%289&A
MT1!B<8&2\ 45(C)35).QX2 P0F!PHL'3!A8C,T!RTD-C@J.R\31$<X.SXH"0
MU/_:  @! P$!/P'_ .H1T<_1L&M#"'-\ZT;P@9@$9_MXPAU&#$/-EML_%$R
M5*Q8(?V70XC[>,-_X=_2S_4%:1G63+E6#16M!8<Y)GL0<#D/\(8C19/+J0(/
M\+,#.%70M-NV?N1PB$,YZ@4Q[7B;3,?:5A(!A&=X]Z #0BQKM2>70XWDVL M
M$L_<)L68L"$0CZ1'2A$-X*K-2I!4A>ICYB:) 5,(Q,]B=';I*LGDM[ZU%C4'
M-IT6M)SN[[%">";#,?CRS%ZI"]4E2U*EJ5(J94RIE3-Z\J]>5I*W2*D=(JC/
MZ11;K.TJB.Y5$#,HS)PS_LFPF@35">90FT9_4#!WM%)C\CQ*E<>FXHX.]QDP
M$NU9_BB""01(BP@_81'_ '9ZN5HFY\]2;" R*@J$E:%-RI<U4^:JYNL=2QAE
MYWK&H=YWK&8=YV$+&&YJ6PJN&BY5AT53=<$2^\*B3](IS+,ZH#I0!N7AMSG8
M5@L%A-*FUQ;FE.S\5@S2QK0;Y[E+O:I(-U*2DI*71RR4IJBI!2'RWV@C4F>:
MA*\(2^H. 88V"^C%M8ZREH]-[=XS+"\ AX6PQH!:'2F#.8<-9&47.RC(Y/8Y
MCBUPDX90?L'C?NSR26=V9-+I"3P>D(/.>2I6Y%8I!20:$6=2JVJBRX*3-2L4
MMR#1:I*A>2I2XHV2L_%>5F"#7*/X+$?"V84YUK)2!U6WJ@1(V6*W^%#;2I!#
MZA8#X0?@C@#Y4(FUN=NMD\A]ZPC!(.'PQ%A%LR/)>V671(OO9E&5MEBC08D!
MY9$;(YCF.L'[!HWF(#D#?*V(0VW*J;-5>M59O5$WJU6J<[%WRJ05'4J#N^Y4
M>0,)S*J8!GZ?>JD%LQWS)]CI2G(J?-*F;DZL)LD+\]G% .OU_P -GY!]0\%P
MR-@CZ4,^2?/AGS7C6+[B+1F4-V!^%89!_>2MAN\X:QG=_.WRM('*L,\%QL')
M+ 8D/5:X#J\X<X=<OKRYQ!LDJ15)%Q3'$_,1<B"DAE5(*L 1B',IDJVY20 S
MH-5 #BO)'>?N4[@3N]ZB1*&6S>FN:ZT&:$AE4,-^B1.R:D)\-ZD0+#J S*+-
MIF=1L_!4S=ML5(Z*UJ?S8^;/U&:YS'!['%KFF8<#(@K _#8,H6&@?]65AG9.
M(T?2_O&2-X=D6$>"\&PP5N#N <^9#F$%KMGDN^Z^VUJPG ,)P4FL9-NFVUO7
MG'09?7>5I5%2[Y40F "WO_NO)UKR;BIBX[5,7*;;CM4Q=O75O49QI#1SA 6<
MA,W20:@U!H4E)274K5*?+&ATPC"+<DPFQ'C*)IL0'(9)L8#S@3K"=A E)LI&
M_*G/G*9Z!T('4IKOE5O\,<R"'U&P?"X^#&<%Y /G,-K':G--A6#^'8$4!F%P
MZ!\V=KH<OYK8C.NL;S0HO@G <,%9@[VL)M#F$439.TC]GU$PSJ6$>!L,@3(9
M6-&=MCI?RG+_ (2Y.:YAD]I:;G @[_J_(W*14C<I&X[%(W'8I&X[%(W'8J)N
M.Q2-QV*1N.Q477'8J+M$["J)N.Q477%477%477'8J+KBJ+KE1=<J+KE1/<A2
MY9@_,Q7423*<BFQ)B<@J>6P(&E%E*5B#+$1) \EF]3%ZI"\*D+QM5)MX5(7H
MNUA5C<QZ52!UHT3JZ4 W,A-2FG-L0I2'E=^_2O*TE0)=,N*=8,J#P0J2FIJ:
M)Z%-4LTQM5,7C:I]"F+QM5*>0A3U^Y3[V*=YWA4A>-OQ4Q?[E/7[E2"G/)ES
MVJDBY$R/2FQ&TI$V[E,7C:.*ZV]IO%-AO=YHGT%O%%I&60ZQQ5$ZNTWBJ)U;
M0I'5M'%5;C=VAQ54_5VAQ18X99;0J)U;51.K:$&.-W:'%=8VA3%XVCBI3R$=
MH<5(ZMHXK9M"ET;1Q7?*%GE^*ET;0I=&T*71M"ER=\J[Y5)2*(EEY.L*4^22
MZQRR4K)\E$]RI<F2SYB7+UJ71\]"CQH#J4&(^&Z]KB-MZ@>'\(ABC&8V*,[F
M_LWGI !ANZX?6AX3\$X6T-CM##_>LD)_S-$1GW&!.\#^#<)%*!$ F/[%X>/N
M&)+K8U1/T<B"=7&#KA8?<0[[BB> \.A_1:>MP_U-'O3O!F'-RP''^4AWN*."
M82W+ BC_ +;N",**,L-_8=P5!^@[LE47:+MA5%VB=A5%VB=A5%VB=A5%VB=A
M5%VB=A5%VB=A5%VB[851=HG851=HNV%47:+MA5%VB[850=HNV%4':+MA5!^@
M[LE5<30?V3P57$T']D\%51/1O[#N"J8OHHG8=P53&]%$[#N"J(_H8O8=P6+Q
M_0Q>P[@L6PCT$7V;N"Q;"/01?9NX+%L(]!&]F_@L5PGU>-[-W!8IA7J\7L.X
M+$\*]7B]@K$L+]7B]DJ'X-PV(9""YO.B28T=)*A_HXX@4\+@ G,' 2ZWR]R=
M^CD:7DQ83LO_ #&#CWQ L)P(X,XM?.;9 B;<^<$3!&L3!5$7.V_^JHBX[?@J
M+;CM_P#541<[;\$,&:<T7=_2C@O,B;1_2J(T3M5$7%41HG;\%1&B=JHC0.]4
M>8=ZH\P[U0YAWJCS#O5'F'>J/,_U*AS#O5#F'>JLZ!WJ@= [U0/HSOXJ@?1[
MCQ56?1^_BJLZ&XJK=H;BJ#M#<JMWH]Q56[T>XJK?Z/<JI_H]RJW^CW*J?Z/<
MJI_H]RJGZ&X*J?H;E4O]&-RJHF@-@53$T!L:JJ)HC8U5471&QJJHFC9_A55$
MN'W551;A]U546[W*JBZMH55%[D*JB]R%51>[@JJ+>-O!5<32WJJB:6]5,32'
M:55$TOO*I?I;U41-,=HJHB:8VE5+],;^"J'Z8VG@L7?IMVG@L7=IMWK%G:8^
M]P6+NTQO6+'3&]8N[3&]8N[3W%8L=,;"L6.F-A6+<\;"L6Y\_P##\5B]\3[I
MXK%QI_=^*Q=NG]U'!V^D/9_":<QC?I&P7#B@6NSKR6\[H3HDP0UELLNM08)A
ML(<Z9))GTH6Y%)42J)U*2D4!/,I+"6@ 3&62#1+W<GFO#AE_!5Q'?O[E&C%U
M$ RGF37FS.93SR!N^,U2?DE8<MJF^Y>638#;EX"Y47SG;T=RJ+LNY .N/?OT
MH4LXR=*)LEUB2+I6 ')T=)M5.8([GIX*@\Y'&<\DTT2"UA33B#R3Y'6M(O36
MF7FY!OX*B9FQ472S:U1.I472L '64&N&8*3M4I7#*J#LY'4$&=&Q4-O0C#UR
MZ .]JJ]O0J)S$;%1\J=FQ$3N'5QFJ)EEZ+%+O)6WY=2D;]P1:=(_!47:2-,Y
M9=]:+29'WJJ+G-)D)$9,^I3;H#OU*DW0;WZDW"*'FL U@R_!&+/*P$W]PA%
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M%14@J(4A\B2D%1",,%%BB0*=A$U%\&@.I6NF;1=_LL#@.AV?0&07?P]%MP0
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MQ@>J]>23M,ZT';0J0M3HK1I5,'^7?Y^]R=ZJW\ *&?\ ,;"^#\$PYLL(A N
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M)!92SBG<X:LI9Q1',%E+>+-P64CBG>SO64>J=[,_>LH]4?964CBC>%E-D+K
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M*HK&%R)G:#:$#;6JM 5)4D:RG&05.8E7.4LX0,E.W9I0=+^<D73T=?8!$ST
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M=**CI <F17-UEL/$XB>%5F6 D+.TX__:  @! 0 &/P+_ .T&I:S)*$E2B<P
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M3EQ:U.?O97LTIR@3?M=?_EUMS5KUFG+CFBMHM&$]YVBLY>\X<-$S@E4MW?\
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MI 1? D@*F$@)E%1+"8X>30?4P/-&U5S05.)(&FG@*A 2RRXYHVB!GSJ4-'#
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M/P3C=$"DJFL;JHY]CXI"#)I]>B\%$&6B9\,4LBO[HC<$I^,(^Q)Y3%7$<B3
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M21/X59 </\7F6DS)GHKR1L$!/"/OE/\ $/SA#' Y+HALZ"F&5R)""BB<2,X
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ME%L)ZA&MQY,$!9ETR$.A<1(G22 P,47KHY)W-3[K!C"OYIJ7U_+PA*@D85"
MWH<*0F#HNF++UO6NYPX&A:B9MD(&$R*&=]A"-XGS3&LP*C9S$DIDH22#.W%6
MS/$3ITBRZ8F)WK^$\\9N-:6ZE&G01;H+6$<&EA =CP436T 6D"9<E,#-2*DC
MO9<:(=(LF(2(.]<"7:*(L0HC,0)C@F-U;X&=QM$?L6(2E2 V$L)V4BK WJ@
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MZSEX2)=0L#>DU,SAA\<RWCKZ5V*U@'(EAUKVXK*4+HR)E+ZCD)&J9!8#F"\
M/;I4*3.@W!++(2$Q  ;%;A\0JIB>*Q"PU)&633)I>2 QUXC>7(>-\-JQ* FM
M@9G205=!<Q@9JE)(J2PKJ GHIA_U*X@F2Q46TT9H^-!DMP<U5"=CABZ0$R\K
M5T62 HNC(80+3",$^RF6E\ 8!A$T@H*P9B1 8DR@1=D=H/JD:- ,\;,OC9BP
MK"P(2I$FJ-N45?)8! 8D#DC:H"F44PT$Z#4[I' \M.&4R5R:HB-[<G:R%N-4
M+<0 ]#IY00)2:98@MG<I2 3_ *]Q(*6(<LHZ0\O0P$(3/!D1/)H.@'7)4%3M
M014FX;I$CN7@R4M01<-D1-4+$PL8''G"EXI(9-9(=(*F 9 P78P 98V0ZD1D
M&%8QO)XS1AN R!D-WP1LUD[+E9; 9/CC6@Z+(8"F8\$;5!I)E@ XE]"<XR)A
M4B5$D#QJ_,\AM"6,F>E$< X)===8WQ3W-Z[XU:F^ZCF&\%M%6))*(COM?&,X
MTE2$2>2?MQ8*BF=<VF-#2)A[X,*B0#U$.Y>G&.DP4J]G*'JA87$$! "@$0)8
M#4X-($5,N0C CLCVG->1,X*WL.FP6#@4JFA4)4@H69G- ).#'2!NX!)AD;1"
MQLD4OPB0>27AD2T"5,%!X;>TCSX@B0-93B_&(2B(C%WG(<M$=PV5.A 4CE%R
MM30_,'%K$T\8A"X*D,9(DC,(VCKTV=*CQH]("&#HDF:2Y_(+F%R?;-143O8T
MYQK1%IQ*%J828-@QRQ:3R@6IK5Q)2#!(Z&D.M J03KB(*&X#"9.+ /1-@=_"
M<E;]$%-V@$"SLTL .XVEQ43U!@!"OZ-F^W;)G2Y>O8XWTCIO LM"P9.$1M*T
M]DY/9HZ63<ESU3TN,=N'- D;#*A3)P I!WJ-8TQ,Q7P$#_&>G)):4<3("MR=
MI5JI T!-1J1ILXMX-@+$N$.5>2EL-4EA'37,W-H2104VB(+.0D(B>EP/ET4C
M#48%1PD#NHC9)5P6+R*M1OR42F0 Q=2 5NY;@K+*&C>IT-=@[=@.*0="B1:-
MIQ6%9FNMIDE34I5R*85ECRV)0VYB]+HDD(U:E@*H"B<JX!SC<+2B@<IA1XP:
MSF?T#R"XD'PH #+<.2@<B$ E"(FR((??,>.ZH!$802<+%!GE-[Y'MZ3Q[_U,
M5OQ*$%.1)_[(6C1'*3LG%_C0)08BR0+O&31# :9T*0HH1RH,81[*-+[Y,  !
M)-JWFL.J]2EN-MFCE,SD@0< /S"XJJIB('K_ ">;G0@]2@%I(B-EY@[\)[8!
M.IV F^G0XZ;2B)9-?"DZ!2H!J:I-8$B&@J&&TL3)@ NR*Q2 <CS4%0"*O@X0
M"Q*,A$TB(@DGYK(FICU$:Z/-M(=3,6:I9[)131;!SP)FK4@RV"""0@JM:Q1G
M9<_0@RXX'A#/C\C 9"D%2$PJ7(  N@<5   "@$0456'6$CAF+%<JV>X'/=U8
ML74<O5I>N @>(J)F)(@]"^29<E%J!7)7J!,D/8@.8*>G;D94T4W-STYTM0P1
M%#1L@$Z ',BI"P$*P.4N!0L\25#$%*>0X1HCI.YT@/8SIN\JYI.A2BR]]82(
M(0.F(]8G-/<.4B**!SK'9@*M;% 66B5E@2+<LQD5J9,4A*D#!E(BXI#V@($
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M#"T+,#8))!C-8(F*D> GA+B,P@-]+&A8;2R3@0!?$PK *@N!R9O&C J%+45
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M\K62HI1ER?B"-9+",IC78U^'27F\"G:Q+TB.6'#Y"(UDHD-)3OFY^CQK-?"
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M8CT?:S:"'G_9N^CVQ2_&\_BJ()UQWYF\N;99<DCI*"VBIDW%O@PV)004Q/\
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M%Z0G5 %-(=F\B@J VO=+3E?_ .9O_]H # ,!  (  P   !
M
M
M
M
M
M        .J
M
M             !BD
M
M                   3#D        1^       "2"+P@
M               !
M                        !]V+8=B 2.O$D@>*TO.6T C S0
M                     0H
M                              ?2*25[)_X,:F/!&SD27 6P2:Q
M                           1X
M                                   #DLZA#G.:&R3+9T0" ;3;"8 :
M                                  T
M                                     #/( #J<)430-J%49VE 10:?
M1210!]                                 <^
M                                        !!7,_"9\;X[PG#'^1X8<
M2#0  R4 2074                                 :^@
M                                             "8)98)YWA\?G)A7
MY4#ND7911;:0S(275                                  ""_
M                                  220!+MM\T);P$E3[(240Q [BD2
MRVZ[W TR\2@LX*_.QH?J:2PT@0WK:7AU,1Z$\!/HM.C[;M;[J+<R@     4L
M$H9YO_T$#;&:AM<Q-1D,&<X7 V8RS9;#!LC[(FX(U4J"PAD:U ],.M^@Q+FI
MTD0SIS ?"<2?]SCI;!5G0C$D.=LU#,@S"'D.J9O8Y*T69=./?A@*D\XA1Z
M     <ZE4YYK3-)1D]9&/^ZWG%7\B^,"\"^@.AC] =\F8I[='.YV21) 8(HR
MW9*1)F7EF=AUGN;#4UN)6M;+:#>TK@IX>,
M                            "222220
M       "%>)3%L39= ]PW 9RP0YV&0 65?DU=?\ P
M
M              $T!*84-OW0FYE%&_-7B/\ 7+:N9DH#$60
M
M                        DEMIR3 .S31ZP9(2/:$&P&+$+;T9,
M
M                                 #F*"&]CG!:Z*OCU%4B%EWC0#SP
M
M                                      !/<."N@SK7< ?
M   T
M                                            #S=_        (
M
M                                                  2L
M
M                                                       /W@
M
M
M #\
M
M
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M<ZG1+X]M]2[/CY^F^A,(^3M_G(90\ZAR>NI2=N][_?::E*X]6'K5PG6)V=(
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M]/Q^M]41+]]_M;:4F5><??6>F@D20PK,>N)Z:5SBC;[7]SKNEPS9/$:ZV,I
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MZ9]YQ_?.K3,HSQ/1ZO.D!!=L/7<8W^NL56#,-\"3"]3^C*0$8-,XI^28[Z6
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M,3IP(DQ5/E&'Q/&D@Y#?Y(][3;<U$2[*W^O139&>-2V!RT_Q0/V;4F1+JQ?
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M/DY5/:OG:*A(XU3$>FU9C"^.IC3!-2N"'&+AJ??I>E-1L#>**CIOGK)>JB(
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M8K)($2M>?-7$15%]T7?$7&PV7WJ$65+;XQ'/?E<,JD.1/D</<Z#V.9-BHX-
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M-,A T& H7:^*;/080GR-4AKS$9 P!0L2< 0@XP"X( !YG*EF%MQKJEV*8.
M:#AJ@T@'@] 9?$3X#@H:(8[;C1JK=046PJLH(2>!84:A4&#:P)*LSL%-#C-J
M80RTL7>2YQX7&+!T&(T0..= Z@AHI<H@=$RR<KE,IE0"CR*"KEL9 Y*\16@
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MS#9N2T\:K$)^R2F\D2HK#H!6@W$5"B'*9(3!EJ ]J0&<9K5&.<>H Z6V :\
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M#%&IYW@M=22$ @0+$C!S]G::\5M0$]T%<.U-10$V&-@@0"!A&Q&""6AZ"0"
M\W@,"B+. 08%!;T-4V8;M$A $ &95X62$FCI =Y%*5IP]B4':4IVM2$@37R@
M4%A*:,BH5@*(=N+'\C\T*"(IA $5IB-H0)JS0,$03CMLV"A'2#& (&:KB0AD
M/=7S<!(V$PX[(D:1D2<B!H-V%B=$H7QH%B<[X$0@6+ :K0$;#5)0*:I>'8 <
MQ*HD!%U6:#0E!Y(03B^=KG$<H;%:04U.!<##7H@+DT!?(#CQ2T @8 N: CR
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M5!44!'E?A!9E +O9\!?@<-1WVT+JS(/.2C9AX^.20JM*" 8 H>+8O'<, =5
MBPQB5QEG"K ^D*.5\&V/3,\0 B.7223;2EA#]1/318 #0PH%("P@*!A3R5WW
M;VC0E 2"&%B3GF(78F0J%0<5,C.!66<M*A$%>%$O2>']4EUX%H:'(2E>5R,!
M':FC.F#8<%OM %K+5@042-$H-F*"J&T@#E!1""[1!.@P!A<3:3CDG+FB+H\@
M8 8@^M,) @4)'#H N@;5",&UJT5"N0 <$!P-4804!4HBM* IY,> 0"E?16AP
MHD(VVU BK04#%0&4!&DMP> TR!1CHQ1U&-!5T>(+ORH2-(.&P)0)QN-H''SD
M9ZI<2G&6JL@J[>E)P 3IL ?HRU)BB"U (&8/"JB:KH?3XA!H1#I[!(/.6ON5
MBKWB>]\E1=>^OH/W+=24:3.4=].EAYUJ&'060H<-)06/1?.L!"2.G?AYG4&7
M$[@F^ \<91$%-&=/,TO<+&[P 4A<14]_)Y_F\!5@NM):>_DC]_;Q'"3/9]O0
MX^ISO+=9@/L:GGY8YR)KR;*#W3P=^IY/'H"AL?$7!%:>)F]\0&($M\G0I&H!
M&O$L"H@BE,^6-.I'0L;Q(-QI0#TO<%7SXS'CJ#!2LI3JBQI\&=\6>C'&*V#8
M/<\?'LX0@4 [+'KR8#\:G6A0 Q0*E90H;'&!KBK0UYHIAA$>'N(BY"<PYAGU
M&G]7P]'XY#T?@Y#T?@Y#T?@Y#T?@Y#T?@Y#T?@Y#T?@Y#T?@Y#T?@Y#T?@Y#
MT?@Y Z)_05D*1/=*?KR/ WCPM"DZT!4^)P$(/K+F=8=>?7*K8R9<\S'?7?GK
MBI .UE]]R=^/Q..1S,/4Z3I3K%)(%I$!A"[:TZ%339Z[@04"(]'?27JW&C-B
M*"G0ZZ@>\\%[ZMR<9;6A3R^C[^?=J A4(TL*"?KK[]</3J Z3,",=192@/*"
M@5 RX-HY>G0K;!+JJ.A@(#CR[ *\&9$SN*6"1[M$0!X[P12EIJ1,N&=.E['+
M'2 OE&)VJ.@""<KJ]<?D'4!93T:Y=4/=$J@)45!&"E0<U,LC %JB ,12U@3$
MB:XX8542HL@0<'W9BA2A5 =_).S'@+%%6;- ]L(9I#H)P7Z^T$-L70[.VO4(
MAUIXVJ1%).WPL.&18-,:"A,1-51(EOM430A;$/R)>IV\((D-!17(])TE'+=<
M",&UVPVD",UQ]8W(A760O7:($(_=[%XE!':6M\J^\PIJO!U"RPF#5"F:T983
M19^.%FQ)0=$KK]"W3YE<-:'E!I\QUBH'8MFA @B.,H BN_7(C2=B03L1Q8!B
MYC&F&"D(=P+E5ZY(WH.;HV;3;W!*[;$8W<" #M:H)Q")#&3,18Z'T#")L'4D
M4=!7KL8TM@G:2GP*]8ZD1#R/0U \,,"AT*7&JK=$:IRSA,4 K,C%6$@$,/D*
M\)#& 7I0=^7SIM*>,(8P'!D!:)0$,- #H"-U2&\#319M1=' *==<6W.T"6G>
M2HEARD=MC4#IU04814KKM778@M3N#405L<P@KP FJ%,:I 9F^44P=@Y6DA>U
M2HA1%.^C :]K B JT".IN-*T-,PXHB%8R!$JA%H+XPI>8J).L !1C7K,>CP5
M !9M)9T2J)1&/Q>#M-2E$ BH:4  3500MS 55$==,TQ:IF8HE'07!&/S9")I
M&QM2J2@'HQ:$V]&[1UA>JI482"A8=T]BW*-Y\F N >3Q^$. 4-*]*/@LDVO]
MO11/8GY)R5KSK;U=84 ZN<:0DZ![UAX/=J&7ISA#6L(I)VH.1-&FUHVS3@RM
M*7L$@@,/#Z%N2#$HZTTA7A8IB41D>BC_ !]^-VK+EGTHE^_U^>'QD[U+[6/[
MU.#F)E"F^"QV>M\YQV)6576>EK#R? YQ#OA?K^]Z;W// A \Z5;="6]=]V\&
ME0J4\$I4CM# E/LH$'H"PV*XO;#7OBH]NMGM7#[E^7'@>4W%W'L+Q" Q130%
M:$Q#T-(!('#TB&:8&X EL( ,1.A0X(FB1)VU,?@IRH6&J547-;9U.R0$X$D#
MX *[#9O0> <1XZ(@#4&U(5"H!7?)RM,=5TZ&U0*[$I&*">-P<S@I(08GJ@IH
MI]3$$QX2E00'>Y8*U)&*&",@   V%?9LT^G>3H;:JH2% DK1.'2KK)5:)%I0
M$.B).].X51:#  2!,11Z]:(&4@!,].J'!VTW @B$60' 'B0@*H*0]M$0XZIH
M^FB%JP6@G"&QRTU3=ED%B$4#5\P$"/0,(C0Q+0B@;?3_ $)WN@14DI50NPB$
M@K [;@K(40V48+ *(.'D30)%$"3S!UY:@A0AX%%E 7:0H)X( U1-<$Q"05T@
ML:S;(9V[3 "][":0-7T3H:'A,FKL2&NJ"&XP&:%"^P\J"5(@"-D=@,4=YI*D
MB]^NO9D;!4 ,XJ,&VJ]*""WKM%,)U?L6!(0"B,P!05:8U6#:=%0.@JAY+@>K
MU7W$&KW(Z#Y("@",$"IL9,7X V(/FXB".O,'S  1)4>DE]/,R 19<DK,)X[?
M&I?2\3:V.P>S:$UX$'26\+&8E<J:N"8^15L<0U1,2.]H]=BY>O"PL(A*A#M&
M_+0!(3.!0=$$3L,@OA5!T]V<<DAQU'BC)-4(H,I>784I3OV&X%(D"-L<%0B0
M8)"@E8* RBFAO'9&TJ%)(&6O;)/[A+M-[(OYEYX,/4/]<_ZQ_KG_ %C_ %S_
M * YX(GJ'(= ^QR'H_!Q+UJ1 <D;-'Q?0\3P2E:()5<&OSWWR3J,SH\VU^_;
MP2%=^,4^D,!!#BI26(+:213")P;L((:C"G,*M5#,+B5B5 0"1J]D3O=XC**"
ML41: DJZ)O7,D&DBK4OB[?CQX2.,"ZQ-Z.DH;^2<<D508-T0D@7IGG@F;=7L
M/9"KJ%C[W@&!,4E84EJ#V4IWNB1ZT'L^1Z13LK&4PL!"K0L@P^X,(P!Q+BT-
MHME ,I%")IN&8AE6B^#P;T]^^^S59GD"-P0SXQJ-*,\8J$?9*)78K:+;6W((
MX&$?!@=4(Z(,YMZ%!P=T@0M O8&DIZXE'0I&5:Q(EA9A00I&HV,E6"H+A>!A
MG8+72!TLZ P-$2(*($4*B+$9M;$SRY<Q!>'(BZ/3W[11Q@!%; !2* IAQ,;*
M,8=('8VT@EJE)6!040Q.H0;L2YF"]D< @-)@9'&%AOETUZ%28J!4.M.JTGV%
M,RHPH%=JNI!*.[$%(+H^%W346W!LQ=YXD@.!=:13&@EZ,._#?FM"L;JF)\'=
M#P-9HT0H67M27%O5\&3846$[BHQ#&D@\N[$45>+BS UN(G;N=^!#P3B,FSX\
M7W%ZMJ6(70=P$M4.$%*A >A^@46Y4^2!IM,$7Z^F]518H78@I+;"T:2Y50:/
M@@KT+ [)>J+W[[9 0H$$!!7#.J*=M*2H"W$^B$KB"#%V =C"E4-";($>T@?A
M 'P.+D:,-7I@/0O=8@6K:>(!X-7# %_)Y%]8["@58-1/<:]'25V2J" N K(=
MH6'?]RDQ5#!4#7JBOBW9&N!:32KP:3Y[W%2/"002D$! "I6QE=Q#0,O2 6('
MDY1!FI0L0C%6#A D-9" 8 8R6J(@8HNZA;%8EWJ4-%!A&E.@1E/<,=U5.#%T
M07E]GD2A/2HI7 =KZ/0K)2Y2=EY= (5#53X:2NW2^-XOOG%[88(?KV:0W'!=
M'JJ=/"BO1W215.#R)235>$0#*DA %.(A '3NC:$LBP%0LG/)L1!NXD!9U(#E
M1QL 0#=:&$2T%]S<YXS^4@S5D-'TZBQR0"RL+L6 IY#4I35)GI [JFEG@,F#
MS0R(>(J18%1B-'+79AE5)04EJK'H<V04J+JDZQ 2>([VL$L)E*$4U=&O3Q'P
MBJ%@LE%D0 :Y8N$@9\ 0"BHH1(,6+4 7 BKTM9@Y-;@"20C7Y-R_23.'F2VH
MI$P!6L71D9A&$/AHL'00"HU4RJ/) 2&LJ>SV$2[KL>701*J,R:?GL '=2*"'
M0PX  '-<7$%XN$%V!&'$5&HX$+RSZ0,:Q1FAAB"JA. 0PHAJE7H&7S4>$$00
MEZ!Z%0\4/9N"YI Q9A,53.YZ"'%')K?6"&@6@0.F1<EBI0L, %J@.QO?#%VG
M0\"(#,MJ!ILX^DIV-!%7 0"AO@:N.Q0>.B),[&'C=B<16Y2 T392#:\/7M@+
MPD[AY1OJZ?"UPFPI&H%OH" 7K-A,X1N/X!2H1;T4,N'@"P&T$H+ AZ$HB \
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,R05*P" !_P#K+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>silk-20201231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@) 24-#7U!23T9)3$4  0$   (P041"
M10(0  !M;G1R4D="(%A96B 'SP &  ,       !A8W-P05!03     !N;VYE
M                        ]M8  0    #3+4%$0D4
M                                              IC<')T    _
M #)D97-C   !,    &MW='!T   !G    !1B:W!T   !L    !1R5%)#   !
MQ     YG5%)#   !U     YB5%)#   !Y     YR6%E:   !]    !1G6%E:
M   ""    !1B6%E:   "'    !1T97AT     $-O<'ER:6=H=" Q.3DY($%D
M;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D    9&5S8P         1061O8F4@
M4D="("@Q.3DX*0
M
M6%E:(        /-1  $    !%LQ865H@                     &-U<G8
M         0(S  !C=7)V          $",P  8W5R=@         ! C,  %A9
M6B        "<&   3Z4   3\6%E:(        #2-  "@+   #Y5865H@
M    )C$  ! O  "^G/_; (0  0$! @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @$! 0$" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @("_\  $0@(< Q5 P$B  (1 0,1 ?_$ !\  0 !! ,! 0$
M           ( 0<)"@(#!@4$"__$ $00 0 " @$# P,"! 0$! 4 "P ! @,$
M!081$@<3(0@)%"(Q%2-!43)A<? D@9&A%C/1X4)2L<'Q%T-B)32""ADF1%3_
MQ  9 0$  P$!                 @,$ 07_Q  V$0$!  (! P,"! 4#! (#
M 0   0(1(0,2,2)!401Q$S)A@4*1H;'P!13!(U+1X6+Q,W*R8__:  P# 0 "
M$0,1 #\ W^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M  !^+9WL.+M.7+BQ]X^/<R5Q]_\ 3RM'?_DYX=JMXF:6KDCO^]+UO'_6LS_T
M^ ?J'&+.0
M
M
M
M
M
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M[3#MX\D>6.],D?OWI>MX[?\ \LRFB_4.$7<P
M
M
M
M
M
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ML7PY,>:D_M;%DIDK_P!:6M'_ '=EWX<?L'#SA6+=W1R
M
M
M
M
M
M
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M $_U^#SAT<Q2)[J@
M
M
M
M
M
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M[8C'/Y_L3DKCM6-O!L:WZ<LS7%,Y,F*,/\V:V\/YGZHB9B.WRG.IC?%G\_\
M/AS2Z0^1QW/:6W$3J[>KLQ/?M.#8Q9N_:>T]O"]I^)B8_P"3ZOE'^B;CD.,7
MA7N"H
M
M
M
M
M
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MP
M
M
M
M
M
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M4[@J*=U0
M
M
M
M
M
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MJ'<
M
M
M
M
M
M                        <8K']H<@'#PC_+_O_P"KY7*=/Z.]CG%O:>IN
M8I_?'MZV'9I/^M<U+Q/Q,Q\P^P C?U/])WI]RLVML=,Z.')?MWRZ,9-&\?IM
M$16-:],=?B9C]-([1\?M\(V=8_;9Z5WL?M\;RO+:%/.,GL;7M\EKVM7';''E
M69UK_-)BLVFV2?&L1/E$S$Y(Q3ET,,KNXXV_.O\ /F_S2F=GBV?NP9>K/VN.
M=YG8Q[VUM].=4Y\&#7UZ5Y'2QZ=YP8</X_LTQVP3BKXXZT\<D[%;V^:S>*_"
M&_7GVS9T='8Q9_3#>T]V^WK9(YGI?DMF^/7PQARXLN'%HZ^38PVO[DUR_E33
MXB9[3'[QM*N,UC^GQ_H[>C++-V[U;W>KQX\[O'MS\3P=WC]+OCC?WUY_=I2Z
MGT\]=])WM' ]==2<'DKDU\=-3E<>UDQ^,VO,8]B8\>TQFI2(Q^S$6[Q;):;3
M$+H:/U+_ %&=,8)G+N<'U?J3JYYS98SXYV(IR%X_+F*9J8LM-S8KBG!>M)R3
M6E/#M6LMN[F>F=#D:SCW]'3W<?;MX;>M@V([?Y>[2_:/ZQV[3$_,=I1XZK^C
M/T[Y>)]WIW6T\D^/;-QN3+I6K-+SDK:N.DVUXM%YF?*<,S\S\_,L4^@LN_Q+
M?C?M\M&7U.]>F37Q[WYO'EK^].?<VZPK7-M]5^E')6KAM?8V.0U-#+^+K[&[
MJQH<=/Y%<>;#BPZ6K2]M2+WK.2]IM%K5_1-^_3;[JWIE?![&/GNH.F\D;$SB
MP;&;-_)PZVGX:VI;#F][#:^]N3[FW:F.TXZ5K3M7O$1D)ZA^WAHUULVMT]U3
MRO$X,]L%LNGL4C;U,\ZN6V76]^N/+K^=L4WO2MKTM'C,=Z3-80XZN^UOR,;D
M[FWPO2G66/WZ;6?#M4IKY]SQS^5L&7+;'JYZTRX)BMJ8,E(BU9[6^?-7.GU<
M>=;]7.K[?/%_I(GW89:ENN.;9[_MKQ[[3/Z$^LCAN2C!'&=>=/\ +U\<-,GY
MF/7C)-=;1MM\GM1.OET\G:<DUUM6DTO-LE;36N3M:E9&\'ZU[N7VJ[/$XL]K
M6T<5\G%\CCRTKFV]>VY?'X;-,/\ _":D4S[,^[VI6W:)M-9:Z?JC]NKC-/M;
M/Z?]2],Y*V_7O=/<CN6U*WC?F;6Q8LU=G6M'X=Z8M6D9/:K&.9R4F9GSL5/H
MEUQTM$6Z*]5N?U=G'.>)XGG]38K%+[.W.CGQ6V];)FQ7O35OCR;&UDI%K89F
MM8K->U;9UL_M^F5YG/ON<>/GW1QZ.-WSO5]N-\?KQ.?U_1MD<;ZY<%FBDYYW
M^/F],&2L;_'[&.OAM9+XM:??PUV->9V+4M[5:YIM:D1?MX=I7&X?JOC=^(G2
MW]/;[QY=M?9PY;>/?Q[S2M_.O:T3$^58[3$PU5^(^I3ZE.C=;3W=[7Z;ZRU,
ME<FYBCC=_#L[-9T;SPFE.?6K.#9U[X[7[:NO:M_/):F:U9O'E'L."^ZEJ:.7
M!_\ I ],.9XF,$X*1LX=/+VO3B:Y8MCQYO&D7G-RU_+DL^/+/;)$8?<F_?OH
MO6RGG'CCVOO-^>956/1MMDYN,F]<ZW_G^>VTOY1_I_K\*]X8*?1[[F7I5S%M
M?7T.O.5X7-:=+%EQ[^>_M1D[9][D\T8>0_(P3?),5X[2QS$36D1>V*(BMYGI
MT+]1^;E:8+\9U#TMU!3-/'XJ1&:F#/.QR&3)GMAG)I9KXH_ X_'.3:O.O6OO
M1X=J]X)]5C[\?RU[_P#CX<O1L_5.+O"J/FCZYQX5ON<)OXZ6QUS5S:.37Y"E
ML.?=MI:>3V^^ML^6Y>ONX<5,-[QAGRM/[=_9\=ZR=-[%O;GE,.MEB<L3BWZY
M-"]9PY?8RQ,[5,6.9QYNV.9I>T>7:L3,RNG4QOBQ4N@/R:V[BS5\\63'EIW[
M>>*]<E>\?O'E2;1WC_7O_D_1%O\ ?_LF.8
M
M
M
M
M
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M]I_HLF4OBRHOV#KC)#EY.CD
M
M
M
M
M
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MX_R_ZN42"H
M
M
M
M
M
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M_>)CX[+99?'*#F.,6B?]PKW=%0
M
M
M
M
M
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M)B?VF/\ 3O'^;L[IN*@
M
M
M
M
M
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MM/PLE1=HIW.X*AW
M
M
M
M
M
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M,I?%E^W\E=CN'&MN[DZ
M
M
M
M
M
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M_'RSDT[UQ[5:4SQCG)&O>U:9;XO<QTM,?KGO$O64R=X[_P!)_:?B8G^OQ/\
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MOB?COWB>_P PT2_TX0=HX1>)_P"3FZ
M
M
M
M
M
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M[\<HN8X^3E#H
M
M
M
M
M
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MK34FNO>,G#\A_"=^:<GO3CXG%.++.[HY-G8T*VY#-6N7!BQTK,>?S6%R./\
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MX6(.0IY0=P5
M
M
M
M
M
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M'<
M
M
M
M
M
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M$
M
M
M
M
M
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MHO2T1-;TM6U+1/\ 6MZ]ZS'Q_26G'*7F66?,NU=EGF:^[](I%N_[*NN
M
M
M
M
M
M
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M_P ERMV"D3W5
M
M
M
M
M
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M-RZU>+O[7E5<+/:O?#AYQ_7X_P!>ZODL1<@
M
M
M
M
M
M
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MO'_[59F._P#EW:<<Y?%E^UVKN-GF6/T#C%X_NKW2<5
M
M
M
M
M
M
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M6QTM,1-^[U];?W_S_O\ Y?T_W_W:)E+S++/T56.P4[G=T5
M
M
M
M
M
M
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M.EN3%LU)KK;&++DK?7R3BV*6Q5O[D7P98G%FK-(G%DK:F3QO6:QZ2<G;X_\
MM_[M-KA_OI<ITWGP\;Z[^A?,<%[=,>EGY;7TMG1C-J\1EOO\I&KGW,.''FR[
MW4-<%MK\7>C%CI$>=K6GM.3+T#^[GZ-]9WX[4X'U5V^ Y3<CC?/C^=[<EHSL
M<I;+RW+32W(4V*1@XO!6.)TZX.0P8,=[XZ8,&2:>#7TOKMZXWSVVX[UN[UYD
MFM:WZ[<;Q9[WO^TROCF>WOO[:Y_IJ^)RS[Q/=5$;I+UZY7?Q8\VGBZ?ZFPY*
M<7^KA>1_ VL6?FMW+31T\VOM6W-?W]?C<?\ $-_);:UK1$7C#I5B:0N1I^OW
M">$6Y&G(\+WQVS]^4T,M=>,'\3OQ&#-.]ISMZ5*;NY6M=&N7/CS[6+)CRTP1
M6T^.C#ZK"^^O,]4N/./F;LDW)9?/CF<<L^73L_S_ (\S]XOB/A<-U'H\CCME
MX_=U-[%3)?%?)J;&'9I3+BM-,F.\X;W\,F.];4R8[=KX[1:MZQ:)A]NL]U\J
M#D Z
M
M
M
M
M
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M?,2[XLL1<A3N=P5
M
M
M
M
M
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MK-S[?.O+ZHXQ;O\ _;_-R3
M
M
M
M
M
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MQYI^/Z6O:O?YB$9/4+Z!^C^:T\VGAC)J8<U:4OAV-?4Y3![>/+&:N&L;6/\
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MS1Y8<F/+7^^.]<D?'[_-)M^W[?Z_$KY8K?J'#SAS[N@
M
M
M
M
M
M
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M_P#O]O\ ZKMJU12)[_[_ /14
M
M
M
M
M
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MJ#D*=U0
M
M
M
M
M
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M;5U]C'DR4\H\HC)BBWNX[3'SXWI6W;^G]&B92^*JLL>H''RA7NDXJ*=U0
M
M
M
M
M
M
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M]_LOEWXY1LT[!3NKW=<
M
M
M
M
M
M                                             4E3Q_W\.0#AX1_^
M.\?_ '6LZW]$NDNH[1DYKI[B]_8K:+TW+ZN/%R&*]8[5R8>0P>UNX<E._P"B
M^//6])_568E=8!C@]8/ML](=48=Z(WN0C/O8\.+);J&F+K'!3#K9/=PX,5N=
MG+R.##[G>,GL\C%[4MXUFJ*?/_;;V^F=+9R]'<)L\3SL[]=S4Y_TVZUY;IC)
MIX,&*E8UO_"7-9LW"9Z[5ZWML:T;62EYOYQEK:E:LY:DPHZWT^.<QF4WVZ[?
M%[=9XY^G<LQWEA+>V3BY3QGE+/IYW&[QXNM<6R6:LU9-2S5\67Q/B-=KGO5C
MUPZ,VYX_E=WB>L.+V<FO&*GJWTGGZ<Y/4O&*9VZUZEX>N;BMK4I-:X\.Q%)F
MU[=^]N\S/L.A?N7\?IQL_P#B/HWU#Z&OIYHIM\ITW:O6W1E(FOQEI6L9[UP>
M,3D[4U:^-)CO/=GIV]+'GI;%FQTRXKQXWQY:1DQVC^UJ7BU+1_E:)A';K+Z2
M.@N:]R^3@<'&[.6MZVV^#R9>&S3[G?SM>NC./6S6M^TSGU\L_P!NT?#/C]'<
M9K'J9\?.6^.-3G>I-:G;V\7WTN_&QOYL?:?EU.9-;\2;M]5WOU;OOI9+TB^N
M'I;JJ<>/IWKKH3J[+:+_ /!8.5KT_P ['C$3%,FAN6RT]_\ O3PP_/>/T?TE
ME/JCJ:]*WY74Y#AXGQ[Y-S7G+J=Y[=NV[I3M:_C,3WBU[4CQ^;>,,87J3]HW
MIK>]R_%Y>&W/*F6N/!U+PF*=FDYN\>YBZ@X.W'\GAOC[Q..9PYI\HBU[6F/F
M,&G]'_K3Z9Y,NQTCU%UQQNICMC]C#QO*X?4+@*8:UGWL67@N8B.7C'>U8M$8
M:5C#CGQK>;=YB6>?5Z<E_P#R37.L;CE.;))CO.9<:MRN>/OQ+PA,<<KQZ?C=
MWOC>[J2SWU)CESJ;]YL*\3S^EOTC-H[>MN8IC_S-7/BV*?\ 7%:W;^WSV?6\
MH:W^A]87J5T[J<?R/6W2_0O6O(;6QMX-GC>DLW)]">H7$4TLE(P;FYI<I.#4
MV*;5+3;'CPVI'G\5M>(F4C>@_NL="SLUXWGN>ZG].^6M>*5XOU,Z>R[?&S?V
MYR=L?4/&UI_)M':)SY=R\Q':UNT3$NWZS'&W'/TY8_FG%D],RL[\;ET[9C9W
M=N=US+S+$.GAW_D]4W9Q,I?3=6]MDSU-7FXSPS9Q:/[N2+/IK]2?']0ZM-KC
M=C@.I-:<<6G<Z/Z@X_EXF)_:9X_-DU]W'^J/\$3F[1^U[3\3>?0]3>&SY*X+
M;L:>S:L6_%Y''EXW8[3\?&/=QX?.._Q%L<WI,_X;2T8=7'*;QREE\67B_;Y_
M9&XV<6:>_'3&3O$3'S$_,3':8F)CXGO'Q,3_ $[?]W;%HG]ECBH
M
M
M
M
M
M
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MTO6+UM%J3'>MJS%JS']XM69B?^4K95;N'&+=_P#?^?9R=
M
M
M
M
M
M
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M/^7_ .%J#F*1*H
M
M
M
M
M
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MM,?UB&C'*7Q=J'T!Q\H_W,?^JO?_ '\)"H
M
M
M
M
M
M
M #KM3^WQ^W_/]_\ K_S=@"T'67H1TGS\9/XGP6CER99F^38P4MH[=\DQX^Y;
M:T;:^>V2(^*WO>UJ1,^,QWE!SKG[5/IMR>2N6O#<-R./%BVZ8^-ZIX;5YK3K
M.Y;OEMCW->>.YC#DI7O[.;\W-DQ7[9(M-HB8RA!./'&_.N-\:]OTX^R.6,RF
MK^OZ:WYU9S-_HUR>H/MQ>L/0W)VW/3'K/J3IKC/SL.2NCT[SN3J7BM3CZVB)
MPTZ=ZKOCV+WQ5B9K37VLL12?9K?)7L_5R7U2>MW0VQR4]1\9T3UQHZ&77KBM
MM:?*>F/7F[AR6B9RTUL]/X;L9X[6F?;V:X\W;O'>.S8IM2)__/\ ^7R>9Z?T
MN1PVUN0T]7>U[]XMK[F##M8+1,3$Q;%GQWI/>)F)^._:7GW_ $["=O9<NGV[
MXQRNK;<=Y92\99:QLESF6NZW5K7/J;K5F.?Y=7*;LF._3OBZRW-W>_3.VSG>
M';I/[J_3FC^!3KOC>M?2Z>0Q4VM/-UOPG\4Z?V]7+-HIFUNHN+F\>W:U9I2V
M7-VCMWG'$3W3U]-/JRZ5ZIP5S]/\SP/5&*8[VR]+\SI[V2*S^UYT,^37V_'M
M\6C'.:T6_3XP_%ZD_1-T'U'3!7+Q^UQUM7'[6K'&;V?'IZ^.OSCPX^)V9VN(
MK@I;]48*:6/',]_*)AC-]:OLRX.0W<_,]+\YJ\=R^7+3+_$>/P7Z1YK'3'$1
M.'!O\)%^/\LW:+9;WX[!CO-?U8YB9:,L.I,KV9>C>7;CU++E,=SL[NKCCAC<
MNW\VNCC-[[?,DJQRQO&6.KJ>K"\2^^L,IE=3Y_%W?AFYTNON+S6ICMM5U<UX
MB:X-VE]+-/>>T5K79C'%[?WC':_;^O9ZVN:)B)B8F)^8M'^&8_RF.\3_ *Q,
M_P#=KG<#Z2_4OT!LXM*_J)OY^ U_=\?_ -('2].M>"K@IBCV,>;F>G<D\ABK
MES17'6VQAQ6IC_7.*?\ "]/T5]QKJWB=W=T^K/3+D]O\#'&3/U!Z+\E;F.*G
M7U^]=O>V^G^2]G:UL=)_5[5]3/X?-8CO$N?CY3C+"^+E>S6>L,?-LQWE->^\
M9QSXY)CCEW3'*>GM[NZ9=.>JZQUEG)T[\>GJ97>IK=;!L7<V+3TK^YSZ:]09
ML>CI]><-BY*TQ7^"];Z>UT3S=<MNWMX)G<QTUK9+UF)BWL3&2?FLQ$IV<7ZN
M:N7%BS9]/<QX,O?QW=.E.7X^>W]:[/&6SWBMNTS6U\%(\8[S-?V2Z?U73RNI
ME-^.V\93[XW5GCX,^EEC^;&S[Q=\>=XCJ?C^0C_@MW5V9B)[TQ9:6R5B/B?/
M%WC)3M^TQ:D=I^)>ABT+U:H
M
M
M
M
M
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M./Y_IWANQSEFY=Q19[>_P]L.NMO[_'_7_P"[L2<
M
M
M
M
M
M
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M8MVC]WOXR?[_ *3_ *3_ %_Y+9478*1*H
M
M
M
M
M
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MJK'KQP]R/V^?_HY1*;BH
M
M
M
M
M
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MQNKA=ZEO;,LIS)=;U-V;U?;<JW#Z66;_ !,/WNK^\U=?SK8X >@Q@
M
M
M
M
M
M
M                      "DJ@.OP_[_ -OC_P"DP[
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
(       !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>silk-20201231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 silk-20201231_g5.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YG82!4+B!6
M86X    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,V.0  DI(
M @    ,V.0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( @0#!@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M]O?X^?K_V@ , P$  A$#$0 _ /H36-8LM!TQ[_4WD2W1XX_W4+S.S.ZHBJB
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M?B#_ ,)S4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\
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MYI'_ #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\
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MS4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\
MC%'_  GFD?\ /GX@_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\
M">:1_P ^?B#_ ,)S4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_
M #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\ /GX@
M_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S
M4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C
M%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\ /GX@_P#"<U#_ .,5TE%
M'-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\ XQ7244 <W_PG
MFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY
M^(/_  G-0_\ C%'_  GFD?\ /GX@_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\
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M<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\
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M8B.\*"B%0SG##C  .!GN #VBBLSQ!XAL/#7AF\UW4W865G"9G*+EF'8 >I)
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MW63'*R]?,&  A!R&YVI/B!J>B>(O&NHRZ-J,]]I6EV%W=:3-K(>W@WQJ9%B
MB(4IEBS D/M)XS0![)17#2_%#3QXGAT^VM_.T_\ L)M=N]0\W M[?&5^4*=Q
M(Y^\./6N>\(?'BT\2^*+#2[S2(M/@U5F6PN(]5@N9&(&5$T*'="2.QSSQ[T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2M% 'A_BWX)Z]K/BK7[FPG\/W&GZO:1PPSZK!)-=6!CC*JL./E4,P4%^H!R
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M,R#=L<8*M@XSAE!QQG':N*TCX?\ C74O$/AZX\?:MH\VG^&CYEG'ID<@DNI
MNU7F+@!2, _+QG(QWKU6B@#B?AKX,U#P;%XB74YK:4ZIK4^H0_9V9ML;[<!L
MJ,-QR!D>]4-?\$^)]/\ '5UXM^'-]I45YJ<*0:C9:NDA@EV#"2!H_F#  #'3
MJ<UZ+10!Y3JOPT\6^)/A;J^C>)/%$-YKFH7:WL+",BUM64J1"G&[9\O7'&?N
M\'=4;X<^/=:\8R^(/%6H>'VFDT&YTM8K#SD6-G#A3\RDL/FR3D8S@#CGV&B@
M#R:R^%FMVVF_#BW>ZT\OX5G>2](D?$@)&/+^3D_7;575O@YK&JZ+X[M/[0LH
M)=?U1-0L'!=@FQMP67Y>,]/EW8Z\]#['10!Y#'\//'FK^.#XD\5W^@-*VAW&
MF"'3Q,BQL^[:?F4EA\V2<C&< <<YUU\&O$G]C>"HX)?#VHS^'[:6"XL=726:
MR<N3^\50 6(!Z,!R!Z5[?10!XA'\%?$5I\,4T"UO]);4K#Q(-8LY7$BP2HHP
M ZJN4/)^5=P&  ><CKO#7@?6(?''B+7O%1TR:/7=.M;:>WLWD*^8D024891A
M"<XY)QUKT&B@#R?P!\&Y_#WA?Q/I?B2_CO)M:B^P1W$#$F.S6,I&.5&&&YB0
M,C@<FJO@7X2Z]X?U_2FU=?"2:?HX<17&G:2GVV^/2-II'3*,.N4.2<@DYW#V
M*B@ KR&+X.ZI+\.+[1)]3MK75EUY]:TV[@!DCBDSE X91VW X!QD'YL8/KU%
M 'F6E^ /%&M>*+KQ%\0M0TK[9_9LNFV=MH\<AAB20'=(3)ABW)&.GO7)'X.^
M.I/!OAO2;JX\+W9\.7CO;V=SY[VEW$XSF<;<LZMG  P0QR?7WJB@#PZ#X)^(
M+?PGJND)=Z,'O/$$.JQF!7AB2->601A3LP>% )&.XKTKXC^&KSQA\.]6T'3)
M((KJ]C5(WN&*H"'5N2 3T'H:Z>B@#S7Q9\-M3O9?#>O>%+JTL?%&AK%$TTS,
M(;J$+AXG*J3CK@XZ$CC.1@^(O@]KUQXPU?4]!7PK-;:X\<MP^MZ>+J?3Y,8<
MP;D*N#UPV!T&!UKVBB@#S2]^'VO6'Q)\-^(_#%QI)MM/TN/2;V&[C:$F%9-S
M-$L2[ Q!; P%!QP1TXNX^"_Q _X0,^"+76/#YT.UOOM5K(ZS+<3+O+;9#M*K
M][=\H)R ,XKW^B@#C/#/@_4-&^)WC#Q'=36SV>N?9?LR1LQD3RHRK;P5 ')X
MP3^%<5_PI[Q!_P *"M/ _P!LTW^TX;W[0TOFR>25\TO@'9NS@_W>M>T44 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5S?Q&_Y)9XK_P"P->?^B'KI*YOXC?\ )+/%?_8&O/\ T0]
M'24444 <WX\_Y%VU_P"PSI7_ *<+>NDKF_'G_(NVO_89TK_TX6]=)0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_A(]#_Z#.G_^!2?XUI44 9O_  D>A_\ 09T__P "D_QH_P"$CT/_ *#.G_\
M@4G^-:5% &;_ ,)'H?\ T&=/_P# I/\ &C_A(]#_ .@SI_\ X%)_C6E10!F_
M\)'H?_09T_\ \"D_QH_X2/0_^@SI_P#X%)_C6E10!F_\)'H?_09T_P#\"D_Q
MH_X2/0_^@SI__@4G^-:5% &;_P )'H?_ $&=/_\  I/\:/\ A(]#_P"@SI__
M (%)_C6E10!F_P#"1Z'_ -!G3_\ P*3_ !H_X2/0_P#H,Z?_ .!2?XUI44 9
MO_"1Z'_T&=/_ / I/\:/^$CT/_H,Z?\ ^!2?XUI44 9O_"1Z'_T&=/\ _ I/
M\:/^$CT/_H,Z?_X%)_C6E10!F_\ "1Z'_P!!G3__  *3_&C_ (2/0_\ H,Z?
M_P"!2?XUI44 9O\ PD>A_P#09T__ ,"D_P :/^$CT/\ Z#.G_P#@4G^-:5%
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M44 9O_"1Z'_T&=/_ / I/\:/^$CT/_H,Z?\ ^!2?XUI44 9O_"1Z'_T&=/\
M_ I/\:/^$CT/_H,Z?_X%)_C6E10!F_\ "1Z'_P!!G3__  *3_&C_ (2/0_\
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M@#-_X2/0_P#H,Z?_ .!2?XT?\)'H?_09T_\ \"D_QK2HH S?^$CT/_H,Z?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH S=4_Y".C?]?K?^D\U9OQ&_Y)9XK_[ UY_Z(>M+5/\ D(Z-_P!?K?\
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MO_T+WA__ ,'T_P#\AUTE% '-_;O&_P#T+WA__P 'T_\ \AT?;O&__0O>'_\
MP?3_ /R'7244 <W]N\;_ /0O>'__  ?3_P#R'1]N\;_]"]X?_P#!]/\ _(==
M)10!S?V[QO\ ]"]X?_\ !]/_ /(='V[QO_T+WA__ ,'T_P#\AUTE% '-_;O&
M_P#T+WA__P 'T_\ \AT?;O&__0O>'_\ P?3_ /R'7244 <W]N\;_ /0O>'__
M  ?3_P#R'1]N\;_]"]X?_P#!]/\ _(==)10!S?V[QO\ ]"]X?_\ !]/_ /(=
M'V[QO_T+WA__ ,'T_P#\AUTE% '-_;O&_P#T+WA__P 'T_\ \AT?;O&__0O>
M'_\ P?3_ /R'7244 <W]N\;_ /0O>'__  ?3_P#R'1]N\;_]"]X?_P#!]/\
M_(==)10!S?V[QO\ ]"]X?_\ !]/_ /(='V[QO_T+WA__ ,'T_P#\AUTE% '-
M_;O&_P#T+WA__P 'T_\ \AT?;O&__0O>'_\ P?3_ /R'7244 <W]N\;_ /0O
M>'__  ?3_P#R'1]N\;_]"]X?_P#!]/\ _(==)10!S?V[QO\ ]"]X?_\ !]/_
M /(='V[QO_T+WA__ ,'T_P#\AUTE% '-_;O&_P#T+WA__P 'T_\ \AT?;O&_
M_0O>'_\ P?3_ /R'7244 <W]N\;_ /0O>'__  ?3_P#R'1]N\;_]"]X?_P#!
M]/\ _(==)10!S?V[QO\ ]"]X?_\ !]/_ /(='V[QO_T+WA__ ,'T_P#\AUTE
M% '-_;O&_P#T+WA__P 'T_\ \AT?;O&__0O>'_\ P?3_ /R'7244 <W]N\;_
M /0O>'__  ?3_P#R'1]N\;_]"]X?_P#!]/\ _(==)10!S?V[QO\ ]"]X?_\
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M_P#R'7245F(YO[=XW_Z%[P__ .#Z?_Y#H^W>-_\ H7O#_P#X/I__ )#KI**
M.;^W>-_^A>\/_P#@^G_^0Z/MWC?_ *%[P_\ ^#Z?_P"0ZZ2B@#EA<^(YM<TA
M=<TK2[.W^U.5DL]3DN'+>1+@%6@C &,\Y/0<<Y$OQ&_Y)9XK_P"P->?^B'K2
MU3_D(Z-_U^M_Z3S5F_$;_DEGBO\ [ UY_P"B'H Z2BBB@#F_'G_(NVO_ &&=
M*_\ 3A;UTE<WX\_Y%VU_[#.E?^G"WJIXB\::AIGB>+1-$T--3N/)CEE,MZ+?
M_6><45/D;<Q^SR=2J@[>>3M .OHKE]2\;P6'B[1O#Z:?=RSZE.T4LQC*PVI$
M#2A2^"KN0H^52<#))'RAHO$OB?Q!H.HVD-MH>FWL-]>1VEH/[5DCGE+#+'R_
MLY4!5#L?G^ZI[\4 =;17(6OCI[CQ+'9OIJII5QJ$^EVU^+DEWN859G5HMF%7
M,<JAMY)*=!FNOH YNQ_Y*GKO_8%TW_T??5TE<W8_\E3UW_L"Z;_Z/OJZ2@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILDB0
MQ/)*P5$4LS'H .IIU<=\2=6>T\/IIEIEKO5'$"*.I7C=^>0O_ JJ$>:20TKN
MQ1\"QOK_ (DU7Q5<J=KN8+0-_"HQ_3:/Q-=_6?H.DQZ'H5II\6/W,8#,/XFZ
ML?Q)-:%54ES2NM@;NPHHHK,04444 %%%% !1110 $!E(89!X(/>N9UCX?:!J
MY9S:_8YSSYMK\G/N.A_*NFHJHRE%W3&FT>5Z]'XM\"60:TU>2^TZ3,8>2/<8
M#VSG..O!!QQTZ51^&WB?58M<72RDM];73EG!.6A)/,F3V]?\>OKT\$5U;R07
M,:RQ2*5='&0P/8UF:!X8TSPW#*FF0E3,Y9W<[F([+GT';_'FNCVT7!J2U*YE
M;4UZ***Y2 HHHH S=4_Y".C?]?K?^D\U9OQ&_P"26>*_^P->?^B'K2U3_D(Z
M-_U^M_Z3S5F_$;_DEGBO_L#7G_HAZ .DHHHH YOQY_R+MK_V&=*_].%O7,_$
MK2-7U+5[$VGAE=550?L5]:2+!<V<WER@AY2X9$+&)@R<C:V03M!Z;QY_R+MK
M_P!AG2O_ $X6]=)0!R.JZ'JUQJ'@B1S]M?2KLR:A<AE7_ETEC+X)!.78<#/7
MTJ_<:5=7?Q#LM2FC_P! L-.E2%MPP9Y77<<9SD)'C.,8<^];]% 'F^G^%=7C
M\0V6G3:<T>FZ=X@N];74?.C*3+*LI2)5W;PX:X(.5 Q'P3D5Z-)&)8GC8L%=
M2I*L5.#Z$<@^XIU% 'G=GX+TMOB3K-N;K7-D>DV#@C7[X.2TUX#E_.W$?*,
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MF_\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^NDHH YO_ (0/2/\
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M (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\
MGS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$Y
MJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I
M**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-
M(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_
M (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\
MQBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S
M2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0
M?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_Q
MB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO
M_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\
M_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3F
MH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_
M (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\
MGS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$Y
MJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I
M**YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-
M(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_
M (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\
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MI'_/GX@_\)S4/_C%'_">:1_SY^(/_"<U#_XQ5F!TE%<W_P )YI'_ #Y^(/\
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M_P#)4]=_[ NF_P#H^^KI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%?\ V!KS_P!$/6EJG_(1T;_K];_TGFK-^(W_ "2SQ7_V!KS_ -$/0!TE%%%
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M_P!##X?_ /!#/_\ )E '245S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\
M\$,__P F4 =)17-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "90
M!TE%<W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E '245S?V'Q
MO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F4 =)17-_8?&__0P^'_\
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M'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "90!TE%<W]A\;_]##X?_P#!#/\
M_)E'V'QO_P!##X?_ /!#/_\ )E '245S?V'QO_T,/A__ ,$,_P#\F4?8?&__
M $,/A_\ \$,__P F4 =)17-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P
M0S__ "90!TE%<W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E '
M245S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F4 =)17-_8?&_
M_0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "90!TE%<W]A\;_]##X?_P#!
M#/\ _)E'V'QO_P!##X?_ /!#/_\ )E '245S?V'QO_T,/A__ ,$,_P#\F4?8
M?&__ $,/A_\ \$,__P F4 =)17-_8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'
M_P#P0S__ "90!TE%<W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\
M)E '245S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F4 =)17-_
M8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "90!TE%<W]A\;_]##X?
M_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E '245S?V'QO_T,/A__ ,$,_P#\
MF4?8?&__ $,/A_\ \$,__P F4 =)17-_8?&__0P^'_\ P0S_ /R91]A\;_\
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M&'P__P""&?\ ^3*/L/C?_H8?#_\ X(9__DR@#I**YO[#XW_Z&'P__P""&?\
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M79Z/6%KWC'1?#RE;ZZ#S@<6\/S2'\.WXXKS9?A__ ,)>P:V\&Z!X=TXG(?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (3S2/\ GS\0?^$YJ'_QBNDHH YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\
MGS\0?^$YJ'_QBNDHH YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$Y
MJ'_QBNDHH YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QBNDH
MH YO_A/-(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QBNDHH YO_A/-
M(_Y\_$'_ (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QBNDHH YO_A/-(_Y\_$'_
M (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QBNDHH YO_A/-(_Y\_$'_ (3FH?\
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MK6T=<3L/-G_WVZC\!@?A7;"$80<^KT_S/.J8FI.-MEV6B(/^$\TC_GS\0?\
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MQ_Y*GKO_ &!=-_\ 1]]725S=C_R5/7?^P+IO_H^^KI* "BBB@ HHHH ****
M"BBB@ HHHH *P?%GBFW\,Z=O($UY-\MO;CJY]3[#_P"M5KQ#X@L_#>E/>WK9
M[11 _-(WH/\ 'M7+^$O#]YJVJ'Q7XF7-S+S:6[#B)>QQV]A^/4UK"*MS2V_,
MI+JRUX-\+7%M<2:_XA)FU>Z^;#?\L >WL<<>PX]:[*BBHE)R=V)NX4445(C(
M\3>'X/$FARV,^%D^]#(1_JW'0_T/L:Q/ 7B">>*;0-9^34].^3#'F1!QGWQQ
M]1@UV5<1X[T6Y@FA\4Z&"M_8<S*H_P!9&.I/K@9S[9]*VIM27(_D4M=#MZ*S
MM!UJW\0:-#J%IPL@PZ'JC#JIK1K)IIV9(4444@"BBB@ HHHH **** "BBB@
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M?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F5TE% '-_8?&_P#T,/A__P $,_\
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MEIT=IJC_ #W+:?(UO"V>T7G!A@$?\M#QGKC [867C9E#+XB\/D$9!&@S<_\
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MW_Z&'P__ ."&?_Y,KI**HP.;^P^-_P#H8?#_ /X(9_\ Y,H^P^-_^AA\/_\
M@AG_ /DRNDHH YO[#XW_ .AA\/\ _@AG_P#DRC[#XW_Z&'P__P""&?\ ^3*Z
M2B@#F_L/C?\ Z&'P_P#^"&?_ .3*/L/C?_H8?#__ ((9_P#Y,KI** .;^P^-
M_P#H8?#_ /X(9_\ Y,H^P^-_^AA\/_\ @AG_ /DRNDHH YO[#XW_ .AA\/\
M_@AG_P#DRC[#XW_Z&'P__P""&?\ ^3*Z2B@#F_L/C?\ Z&'P_P#^"&?_ .3*
M/L/C?_H8?#__ ((9_P#Y,KI** .;^P^-_P#H8?#_ /X(9_\ Y,H^P^-_^AA\
M/_\ @AG_ /DRNDI"0JDL0 !DD]J .;:S\;*I9O$7A\ #))T*;C_R<KC'U#Q1
MXWU"XT"WU.QGT]&'GW]G8/;KCN"&F?<,] ",_3FM'6=9OO'>K/X?\-.8]-C/
M^F7HZ,/0>WM_%]*[C1=%L]!TR.QT^/9&G)8_>=N[$]S6+;J.RV/0C%85<\_C
M>R[>;\^R.<T?PSXKT+38['3M<\/QPIW.@S%G/=B?M?)J]]A\;_\ 0P^'_P#P
M0S__ "9725BZ[KXT[;:V:^??R\)$!G;GN?\ "JG.-.-WL<$I-OFDSG]<OO$V
MEQ"'4=<T>Y6=2K0VNDRP2;2#R':Y<#G_ &3G]1S:'5=7NK'2+28[79E5Y 72
M  $EBH(SW[CTS5_Q+/:>';%I-9_T_6[Q=\<)<A8ATW-@C(]O; Z9J#X7:E;7
M6L31ZC.3?;<VJD;01@[^G4X['TS7,L)7K25>:7+V=]OZU)Y)/WGL=7::)XNL
M(1%9ZWX=B0=ET"?GZG[9S4_V'QO_ -##X?\ _!#/_P#)E=)178DDK(9S?V'Q
MO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE%,#F_L/C?_H8?#_\
MX(9__DRC[#XW_P"AA\/_ /@AG_\ DRNDHH YO[#XW_Z&'P__ ."&?_Y,H^P^
M-_\ H8?#_P#X(9__ ),KI** .;^P^-_^AA\/_P#@AG_^3*/L/C?_ *&'P_\
M^"&?_P"3*Z2B@#F_L/C?_H8?#_\ X(9__DRC[#XW_P"AA\/_ /@AG_\ DRND
MHH YO[#XW_Z&'P__ ."&?_Y,H^P^-_\ H8?#_P#X(9__ ),KI** .;^P^-_^
MAA\/_P#@AG_^3*/L/C?_ *&'P_\ ^"&?_P"3*Z2B@#F_L/C?_H8?#_\ X(9_
M_DRC[#XW_P"AA\/_ /@AG_\ DRNDHH YO[#XW_Z&'P__ ."&?_Y,H^P^-_\
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M@-N 2$4$]]H]!70?\*Y\$?\ 0F^'_P#P5P?_ !-%C_R5/7?^P+IO_H^^KI*
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M1_T)OA__ ,%<'_Q-=)10!S?_  KGP1_T)OA__P %<'_Q-'_"N?!'_0F^'_\
MP5P?_$UTE% '-_\ "N?!'_0F^'__  5P?_$T?\*Y\$?]";X?_P#!7!_\3724
M4 <W_P *Y\$?]";X?_\ !7!_\31_PKGP1_T)OA__ ,%<'_Q-=)10!S?_  KG
MP1_T)OA__P %<'_Q-'_"N?!'_0F^'_\ P5P?_$UTE% '-_\ "N?!'_0F^'__
M  5P?_$T?\*Y\$?]";X?_P#!7!_\37244 <W_P *Y\$?]";X?_\ !7!_\31_
MPKGP1_T)OA__ ,%<'_Q-=)10!S?_  KGP1_T)OA__P %<'_Q-'_"N?!'_0F^
M'_\ P5P?_$UTE% '-_\ "N?!'_0F^'__  5P?_$T?\*Y\$?]";X?_P#!7!_\
M37244 <W_P *Y\$?]";X?_\ !7!_\31_PKGP1_T)OA__ ,%<'_Q-=)10!RP\
M)^'="US2+K0] TO3;A[IXVEL[*.%V4P2DJ2H!QD X]A4OQ&_Y)9XK_[ UY_Z
M(>M+5/\ D(Z-_P!?K?\ I/-6;\1O^26>*_\ L#7G_HAZ .DHHHH YOQY_P B
M[:_]AG2O_3A;UTE<WX\_Y%VU_P"PSI7_ *<+>N,^).E6USXRM-2O[*TU^S@C
MCBFT_P"TA;FS&RY=GB4\ R#!W%D.;=<$_P (!ZO17F^NQF\\;?#_ %F#5;R>
MPNKUC:V;$+$B-8RL'(QN=SC[S$X!( &6)R?$BA_$'B/7'A4ZOI.O:3::=.0#
M)%"YMM\:'J%?SYL@==W/2@#UZBO(=,4)XDTK7EA5=9OO%]_IUU. /,DM42X5
M8F/4HH@B('0%0>]>N2.4B=UC:1E4D(N,L?09(&?J10!SMC_R5/7?^P+IO_H^
M^KI*\[L_$>J#XDZS*/!FN,[:38*81-8[T FO"&/^D[<'<0,$GY3D#C/0?\)1
MJ_\ T(GB#_O_ *?_ /)5 '245S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0
MB>(/^_\ I_\ \E4 =)17-_\ "4:O_P!")X@_[_Z?_P#)5>;:TLVJ>/[^^O-/
MN-/9/+)MKEHV=&\M0,F-F7H,\,>HS@\5A7K*C#G9M3A&:DY.UE?_ (!Z+XQ\
M6?V'%'8:8GVC5[OY8(5&[9G@,1_(=Z/!WA/^P8)+S4'^T:M=?-/,QSMSSM!_
MF>YKB_"EE)I&H7%_I^FM?3GA&\MF$ /4#'<^OI^-=1)XB\4G_5:0J_[UI*?_
M &84ECZ3II1OKOH_\B6Z=[1EIZ,[2BN!DUSQH_W;../_ '=.D_JYJM)J7CI_
MNO)'_NZ9_CFH^N4O/[F"C!_;7X_Y'H]%>7R3^/9.M_> ?[.FJ/Z56DM_'$GW
MM2U0?[MJR_RJ?KE/L_N-%3I=:B^Z7^1ZS17CK:1XPD/[W4]<8>@$H_K2?\(S
MJ\G_ !]'79?7YG_JII?7(=G]S_R*]GA^M7\&>QDXZ\5!)?6D7^MNH4_WI *\
MC'@R-^;C3-<E/_77_P"U&IX_!^GI][PWJ\G^].W](Q1]<CV_/_(.7"K>H_\
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MGB#_ +_Z?_\ )5:SFY,;=SI**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$HU?\
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M>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\
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M=%__ %"LGPOX2N9[_P#X2+Q8?/U*7YHH&'RVX[<>OH.WUZ=%##QIKVE35O\
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MDHKF_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6@#I**YO\
MX1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\ ?C3_ /Y%H Z2BN;_ .$7U?\
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MDHKF_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6@#I**YO\
MX1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\ ?C3_ /Y%H Z2BN;_ .$7U?\
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MX !X&3VKJO\ A%]7_P"A[\0?]^-/_P#D6J488>/LJ6W<-(Z1.C50JA5   P
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M5&Y$ [>V?T':NSKF_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\
M_D6MY2<G=C;N=)17-_\ "+ZO_P!#WX@_[\:?_P#(M'_"+ZO_ -#WX@_[\:?_
M /(M2(Z2BN;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^1: .
MDHKF_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6@#I**YO\
MX1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\ ?C3_ /Y%H Z2BN;_ .$7U?\
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MDHKF_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\ _D6@#I**YO\
MX1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\ ?C3_ /Y%H Z2BN;_ .$7U?\
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M -$/0!TE%%% '-^//^1=M?\ L,Z5_P"G"WKI*YOQY_R+MK_V&=*_].%O724
M%%%% !1110!S=C_R5/7?^P+IO_H^^KI*YNQ_Y*GKO_8%TW_T??5TE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>9
M_%?P_=W/DZO:01O#!&5N"B?O!S]XGNH''M].GIE(0&4A@"",$'O6E.;A+F0T
M[.YY)\*-%OVU=M7\J-;)4:/?(F6=C_</;'<_4?3URF0PQ6\*0V\:11(-J(BA
M54>@ Z4^BK4=27,.3N[A11169(4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;JG
M_(1T;_K];_TGFK-^(W_)+/%?_8&O/_1#UI:I_P A'1O^OUO_ $GFK-^(W_)+
M/%?_ &!KS_T0] '24444 <WX\_Y%VU_[#.E?^G"WKI*YOQY_R+MK_P!AG2O_
M $X6]=)0!YOXHU_6;'XA6]G<:_)X?TV1X_LTCV*/:3C8S,)9G7 8N-FP21M@
MC'+ U%+XIUQ?'SVXU0^4NMI8K9"&(V?V8Q DM/C(N-QSY6_=T_=E3NK4\6^
MM3\2:HXBU[R=(O?EOK2>)I71#'Y3B!MP$>].""I ;+#DD%S?#R0WS0+JRC0G
MU9=7>Q^RYF\X,)-HFWX$?F*'QL+=1NQT *'_  E&K_\ "1_VA_:+?V;_ ,)'
M_8?]F^2FS9LV^9OV[]_F\_>V[>,9^:O1))$AB>69UCC12S.QP% ZDGL*Y(>!
MI1XE^U_VH#I7]I?VK]@^S?/]I\O9_K=W^KS\^W;G=_%CBNOH \[L_'W@]/B3
MK-TWBS0UMY-)L(TE.I0['99KPLH.[!(#J2.VX>HKH/\ A8_@C_H<O#__ (-(
M/_BJZ2B@#F_^%C^"/^AR\/\ _@T@_P#BJ/\ A8_@C_H<O#__ (-(/_BJZ2B@
M#F_^%C^"/^AR\/\ _@T@_P#BJIZM\5/!>FZ+>WT/B?1;V2UMY)EMH-2A:28J
MI(11NY8XP!ZFNPHH YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\ X-(/
M_BJZ2B@#F_\ A8_@C_H<O#__ (-(/_BJ/^%C^"/^AR\/_P#@T@_^*KI** .;
M_P"%C^"/^AR\/_\ @T@_^*H_X6/X(_Z'+P__ .#2#_XJNDHH YO_ (6/X(_Z
M'+P__P"#2#_XJC_A8_@C_H<O#_\ X-(/_BJZ2B@#F_\ A8_@C_H<O#__ (-(
M/_BJ/^%C^"/^AR\/_P#@T@_^*KI** ./U;XJ>"]-T6]OH?$^BWLEK;R3+;0:
ME"TDQ520BC=RQQ@#U-7/^%C^"/\ H<O#_P#X-(/_ (JNDHH YO\ X6/X(_Z'
M+P__ .#2#_XJC_A8_@C_ *'+P_\ ^#2#_P"*KI** .;_ .%C^"/^AR\/_P#@
MT@_^*H_X6/X(_P"AR\/_ /@T@_\ BJZ2B@#F_P#A8_@C_H<O#_\ X-(/_BJ/
M^%C^"/\ H<O#_P#X-(/_ (JNDHH YO\ X6/X(_Z'+P__ .#2#_XJC_A8_@C_
M *'+P_\ ^#2#_P"*KI** .;_ .%C^"/^AR\/_P#@T@_^*JGJWQ4\%Z;HM[?0
M^)]%O9+6WDF6V@U*%I)BJDA%&[ECC 'J:["B@#F_^%C^"/\ H<O#_P#X-(/_
M (JC_A8_@C_H<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\ ^#2#_P"*H_X6
M/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR
M\/\ _@T@_P#BJZ2B@#F_^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H<O#_ /X-
M(/\ XJNDHH YO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*K
MI** .;_X6/X(_P"AR\/_ /@T@_\ BJIZ3\5/!>I:+97TWB?1;*2ZMXYFMI]2
MA62$LH)1ANX89P1ZBNPHH YO_A8_@C_H<O#_ /X-(/\ XJC_ (6/X(_Z'+P_
M_P"#2#_XJNDHH YO_A8_@C_H<O#_ /X-(/\ XJC_ (6/X(_Z'+P__P"#2#_X
MJNDHH YO_A8_@C_H<O#_ /X-(/\ XJC_ (6/X(_Z'+P__P"#2#_XJNDHH YO
M_A8_@C_H<O#_ /X-(/\ XJC_ (6/X(_Z'+P__P"#2#_XJNDHH YO_A8_@C_H
M<O#_ /X-(/\ XJC_ (6/X(_Z'+P__P"#2#_XJNDHH X_2?BIX+U+1;*^F\3Z
M+9275O',UM/J4*R0EE!*,-W##."/45<_X6/X(_Z'+P__ .#2#_XJNDHH YO_
M (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\ X-(/_BJZ2B@#F_\ A8_@C_H<
MO#__ (-(/_BJ/^%C^"/^AR\/_P#@T@_^*KI** .;_P"%C^"/^AR\/_\ @T@_
M^*H_X6/X(_Z'+P__ .#2#_XJNDHH YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C
M_H<O#_\ X-(/_BJZ2B@#F_\ A8_@C_H<O#__ (-(/_BJIZ3\5/!>I:+97TWB
M?1;*2ZMXYFMI]2A62$LH)1ANX89P1ZBNPHH YO\ X6/X(_Z'+P__ .#2#_XJ
MC_A8_@C_ *'+P_\ ^#2#_P"*KI** .;_ .%C^"/^AR\/_P#@T@_^*H_X6/X(
M_P"AR\/_ /@T@_\ BJZ2B@#F_P#A8_@C_H<O#_\ X-(/_BJ/^%C^"/\ H<O#
M_P#X-(/_ (JNDHH YO\ X6/X(_Z'+P__ .#2#_XJC_A8_@C_ *'+P_\ ^#2#
M_P"*KI** .;_ .%C^"/^AR\/_P#@T@_^*H_X6/X(_P"AR\/_ /@T@_\ BJZ2
MB@#C])^*G@O4M%LKZ;Q/HME)=6\<S6T^I0K)"64$HPW<,,X(]15S_A8_@C_H
M<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^
M#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#B
MJZ2B@#F_^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJNDHH Y
MO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(
M_P"AR\/_ /@T@_\ BJIZ9\5/!>H6CS2^)]%M&6XFA$<VI0AF$<K(''S?=8*'
M![AA7844 <W_ ,+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %5TE
M% '-_P#"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5=)10!Q\_C
M;PYJWB/P]8Z)KFFZI<37\@,=E>QS-&HM9V+D*2=N0!GU85<^(W_)+/%?_8&O
M/_1#UTE<W\1O^26>*_\ L#7G_HAZ .DHHHH YOQY_P B[:_]AG2O_3A;UTE<
MWX\_Y%VU_P"PSI7_ *<+>NDH **** "BBB@ HHJ'[;;?;_L/GQ_:O*\[R-PW
M[,XW8ZXSQF@":BN*U/Q=K+MJQT;3[:"WT>&2:XNM19O+F*-(#&A7A3B/<22=
MH=/E.>,^:*3Q9XGGBNKF]TV>YT2WOM&9)VC-JY+^:=H.&96:'=N!!! Q@G(!
MVLVN:=!K#:4]ROV];1KTVX^]Y(;:7^F>*Y_1O',U[=:(-5TV*QM_$,+3:9)'
M=>:S83S D@V@*Q3YAM+#@C/ +94-NVHZ=X>\>:?IS_VQ)- VHI$"[/$Z""9%
M_P!A"1( /^>9.,L<O3X>M#XFM38V%I9:;9WJW<-PE_/+(J#YC#'"^4A!?[VP
MA2H V^@!Z%1110 4444 %%%% !165+XGT6#6ETF;4(DO68((SG&\C(0M]T.1
MR%)R1R!65/JNN:Q="VT?R--MX9KJ.[OY )_*,3((U"DK@N&+9.0 A'<&@#JJ
MSUUS3G\1R:$MRIU*.U%V\'<1%BH;\Q_+U%>:Z3&/'.IH_BA%CO=2T6.XT>\A
M)3R'1Y%DE@!)*,0T$G!)*L <@5JZ=;37^F>&/&EC8*=6EFC.J>0-QGCE1892
M#_=5DCD&.,1].: )X/'U[%_9FIZF+%=)U756TN.&(-Y]M)O=$9W)PV2F&4*N
MW=U;%=]7$ZQ\/X]2U^>XAATFUM;R2&6YECL<7;%'5V7S V/G*)EL9 '?@CMJ
M "BBB@ HHHH ***RKKQ/HMEK$>EW6H117DC*HC;. S?=4MT5F[*2">P- &K1
M7,7&JZUJU\]CHH@L8[>ZFAN[UP)O*"(C)A"5^9O,'7( 4^H(XW20OC?6+8^+
MTC=M2TEO[)N8<H(Y(;B57G@Y.QWC:WD!!SM&,D T >DG7=.'B0:#]I7^TC:F
M\^S]_*#!-W_?1Q7(CQ]>VZV^JWZV*Z/<ZR^D"! WVBW997B$CMG:<LF2FT;5
M.=QQBJUA9W-_H?A_Q?;68FUV&[C747A&3=)_QZS$?[& )0!Q\@/4\Z.O_#^/
M6-;N9X(=(MK>_5!=SBQ_TLX8%P) P'SJ%7)&1COV .VHHHH **** "BBB@ H
MJ![VVCOHK*2>-;J:-Y(X2PW.J%0Q [@%US]17/W>MZSJ-TEGX<MX;8^9<I/?
M7T3310F%D4+L1U)+[B1EA@*2>>* .GJE=:Q866J6&G75RD=YJ!D%K"?O2[%W
M/CZ#FO/--O;SQUJD']I7MUI;W6B)=:6;"Z>.-9DFD2:8 $"48-N0'!&U\8^8
MYMW=I+XG\#6?BZ"QW^*+"&.5%3))EMY"984!Z!R)$R,$@KGH, %]/'TT9M]0
MOK*WAT2[U5M*BF%QF9)!(T0=UQM"F1", Y4$$]P.VK@-=\!'6-3FDT^PTZUM
M-1*33W3R3+<0N3^\98?N%V7Y=^489.=V<5W] !1110 4444 %%%5+K5+*QO;
M*TN[E(KB_D:.VC8\RLJ%R!]%4F@"W17,WNKZSJ&I7&EZ'##;-;Z@+:XO)/WO
ME0FV6;S F5^8LXC R0/O'/2N/LY!XL\0:=#XTBAOK*=+ZRL;A5,<4EQ#/@2H
MN3MD:,,58'(\MRI - '<7OC31-/U0V%Q<2^8DT<$TJ6TCPP2/C8DDH4HA.Y>
M"1]Y<XR,XVH>,=5M)]9U*.&R;1="NQ;7T!5C<[-D;O.&SM 59-VPJ20N=PR!
M7+-JXDT72- O+:]O);C4KAM3GM+5YWO?L,XC!^48#2M'&2QV@!7!QQ76WOAK
M4M6>^OM,G71TUZS$&HV5];+,ZD*4$B[)-HDV':02RG:OH<@'9@AE!4Y!Y!'>
MBHK6W2SLX;:+/EPQK&NXY. ,#/Y5+0 4444 %%%% !165JWB;1M#N(X=6U"*
MUDD&X!\_*N<;F(&$7/&YL#/&:H:CJ^KWFHRZ7H,,,<L5Y%%/=R'S!#"T+2&7
M9E<G< @&3RP/0$4 =)6%JWC/1=$O'MK^>8-"%:X>*VDDCM0WW3*ZJ5C!_P!H
MCCGIS7#03?\ "2^)--M_&<=MJ>F&:_TVVGV%(9KF-T*2!,D"3:DRA@<@QMMQ
MNJM>WRKX3C\.WT-U=S:CJDVG:C=V]N]Q+=6]LVS)" Y=XUBC). "S$GY: .I
MU3Q?J]K=Z]>6EO:/I?AV=(KVV='-S,GDQS/*C X4*DG"E3NV'E:[2.1)8UDC
M8,C@,K \$'O7'S:'JFKW$^L:2_\ 8CZM:?9;^RU*V$S84L$E 23 ?:QXR005
M!P174Z=8Q:9I=I86Y8Q6L*0H7.2550HS[X% %FBBB@ HHHH ***R]7\3:/H+
MQIJ]_%:M(I<!\G:H(!=L#Y5&1EC@#/6@#4HKG-2UG5;G4)M*T"& 3I);[[J0
M^8L4,BN3)LRN2/+V@9Y)!Z BN-%Q)K_B;3[7QDMMJFCQ7]]I,<ABV0SW(6)X
MI2F2 Z[;B('/#C(P30!W&L^,M%T&Y>#49Y@T,:RW#0VTDJVT9) >5D4B->#R
MV. 3T!-9&K>*]9@U#6IM*MK.>QT 1M=6SJQN+I&C$K-$P8*N%;@%6W,I&5ZU
MRFH7@M?"-SX<N8[NYGOM3ET6[O(()+F::SC!;)V@LSF$K%N[.Q8]#77'1M3U
M&Z&N:%_Q(I[RU^QW=GJ=J)0\:,WE/MCD^5AN; )Y5L$ B@#K;>>*ZMHKBW<2
M0RH'C<=&4C(/Y5)5+1=+AT/0=/TFU9WAL+:.VC9SEBJ*%!/O@5=H **** "B
MBB@ HJ"XO;:UEMXKF>.*2ZD\J!78 R/M+;5]3M5CCT!K&U;7+\7DNFZ'9"2^
M66&-IIP6BA217;S653D@;",97)(&1UH Z"LC6O%&D>'W1-3N)%D=#((X+>2=
MP@ZN5C5BJ#NQ  ]:X==4U#Q%XHLM'\27#16<=U?:>TVES2VB75U&D,D; J^X
M80W V;B-\9/.!A+[7I-)\%W\UZ^_Q"MT?#IOVB9RP#L8Y611\Q$3^80HY;('
M:@#:N_'EPK:IJ.GV4%UH6C21I>SB8B9D:&.9IHUVX**DJGD@MAL=!N[56#*&
M4@@C(([UYUIGAV\-C,?"5J;'3KNPCTR:UUJ%XF98H_+CN%4?-]P[2KA2VQ>5
MQD]YIEBNF:19V"2-*MK D(=_O,%4#)]^* +5%%% !1110 5S?Q&_Y)9XK_[
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M4M%% !1110 4444 <K;>,)=9T>ZNM+TN]MXI+![O3[V=$:.X7'RL%5BPSD,
MP&1Z'BLG6K;Q%-:PZ_I,NI7US)-:S6MK9W"PQPVP6-IE>-V"2,_[T#.2-R@%
M<$UBZ7\/;O3)K'38]#_TFPOU,?B3SHR7L%; MV^;S<B'$6S;LX#9S7:Q^#+:
M?1=(M=1N;M;G3[);1Y;*\E@\U=JAP=I&02H//([$4 <5>:A9W>@>(D1;IK/Q
M) FLZ'=1VSNQF,*!4& <2))&C@'^\,9VG'27'AS7-6\)^(=,\^/3KG4[I'65
MTWIY;1P><N%8'!(F3J#WST-=A9VEOI]C!9V4*06UO&L442#"HJC  'H *FH
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M]% !1110 4444 %<WI_C2UU#6+>S33[Z*"\>:.SOI4017+19WA0&+CA2064
MA3CMGI*X/QAI%_JVK)'IN@W$5_ 8O[/UN*\5(K==X:0LF\,.X*A6W@@$XSM
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MST^?[))+/'=/%'(7W#Y55 <$[3DDAN!6=I^ME=7M=:UNWN##+9'0M:\R'?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D=%D1D=0RL,%2,@CTI:* $1%CC5(U"(H 55& !Z"EHH
MH **** "BBB@ HHHH **** "BBB@ KF_B-_R2SQ7_P!@:\_]$/725S?Q&_Y)
M9XK_ .P->?\ HAZ .DHHHH YOQY_R+MK_P!AG2O_ $X6]=)7-^//^1=M?^PS
MI7_IPMZZ2@ HHHH **** .$TSPGX=UWQ;XPNM<T#2]2N$U:*-9;RRCF=5%A:
M$*"P)QDDX]S6O_PKGP1_T)OA_P#\%<'_ ,31X7_Y&+QE_P!AF/\ ]-]I724
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M*)_M3J!#^Y.<AN =QP >MW7@/X?V4'G7OA7PU;Q;E3S)=.MT7<S!5&2O4L0
M.Y(%%MX#^']XCO:>%?#4ZI(T3M%IUNP5U8JRG"\$$$$=B,5P/C.^\_6=1M_$
M&ISP:BFI:/\ V9IZ7,B13VYF@9W$)(#_ +WSLN0678HR. 6V>N^;KNJ1>+/$
MFI:98PW5[_94L-Y(CRW"ZA.AC15)\\HBP!82&&&QM.: /1O^%<^"/^A-\/\
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M_P#P5P?_ !-;&D2+-HME)'//<*T"$37,1CED^4?,ZE5*L>I&!@]A5R@#F_\
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M$7,*&7&\J-VT$#/?&>: .>_X5SX(_P"A-\/_ /@K@_\ B:/^%<^"/^A-\/\
M_@K@_P#B:Z2B@#F_^%<^"/\ H3?#_P#X*X/_ (FC_A7/@C_H3?#_ /X*X/\
MXFNDHH YO_A7/@C_ *$WP_\ ^"N#_P")H_X5SX(_Z$WP_P#^"N#_ .)KI**
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M-N1D<C->9Z=XPNK+PS#>ZMXBO%2]\-:A]DFNIV1[BZ6Y8+M'&9=I7 4;@.
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M1_T)OA__ ,%<'_Q-=)10!S?_  KGP1_T)OA__P %<'_Q-'_"N?!'_0F^'_\
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M?_%5TE% '-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE%
M'-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$
M?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$?]#EX?\
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M_P#BJ/\ A8W@C_H<O#__ (-(/_BJZ2B@#F_^%C>"/^AR\/\ _@T@_P#BJ/\
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MZ'+P_P#^#2#_ .*KI** .;_X6-X(_P"AR\/_ /@T@_\ BJ/^%C>"/^AR\/\
M_@T@_P#BJZ2B@#F_^%C>"/\ H<O#_P#X-(/_ (JC_A8W@C_H<O#_ /X-(/\
MXJNDHH YO_A8W@C_ *'+P_\ ^#2#_P"*H_X6-X(_Z'+P_P#^#2#_ .*KI**
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M6-X(_P"AR\/_ /@T@_\ BJZ2B@#F_P#A8W@C_H<O#_\ X-(/_BJ/^%C>"/\
MH<O#_P#X-(/_ (JNDHH YO\ X6-X(_Z'+P__ .#2#_XJC_A8W@C_ *'+P_\
M^#2#_P"*KI** .;_ .%C>"/^AR\/_P#@T@_^*H_X6-X(_P"AR\/_ /@T@_\
MBJZ2B@#C?#FM:5KOQ(U^ZT/4[/4K=-)TZ-I;.X69%837I*DJ2,X(./<5>^(W
M_)+/%?\ V!KS_P!$/725S?Q&_P"26>*_^P->?^B'H Z2BBB@#F_'G_(NVO\
MV&=*_P#3A;UTE<WX\_Y%VU_[#.E?^G"WKI* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_B-_R2SQ7_V!KS_T
M0]=)7-_$;_DEGBO_ + UY_Z(>@#I**** .;\>?\ (NVO_89TK_TX6]=)7/\
MC:TO;SPVJZ99R7UQ#J%C=?9XG17D6*[BE<*795SM1L9(J/\ X2C5_P#H1/$'
M_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\
MT_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\
M^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J
M.DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHK
MF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\
MA*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7
M_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A
M$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?
M]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\
M3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\
MY*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_
MX2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5
M_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H
M1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'
M_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\
MT_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\
M^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J
M.DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHK
MF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\
MA*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7
M_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A
M$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?
M]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\
M3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\
MY*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_
MX2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5
M_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H
M1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'
M_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\
MT_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\
M^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J
M.DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHK
MF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\
MA*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7
M_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A
M$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?
M]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\
M3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\
MY*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_
MX2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5
M_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H
M1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'
M_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\
MT_\ ^2J .DKF_B-_R2SQ7_V!KS_T0]'_  E&K_\ 0B>(/^_^G_\ R561XLU/
M7M=\%ZWI%GX'UQ+C4-/GM8FEN+ (K/&R@L1<DXR>< T =W1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>silk-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:silk="http://silkroadmed.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="silk-20201231.xsd" xlink:type="simple"/>
    <context id="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i57b888d1afed467eb6e8156312b035a4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifb6f5fd1061f4f56989bc588eebd18c4_I20210226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="ib21091e7ea584a0eb4262bf6edfcce74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65f3a8f4af9542fb8f31ed746073f14b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i309aa475c33d46f1bcb008fc1f8ff1b4_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iab4311acf1a24c2d80c7837fb213c678_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iad606b34524243b1a8e5075ac03d3736_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i29b884248218456fa51f8f0609280bfe_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9001a76c96354d44be43663ad10864e5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0cd1291d3588454f997c52cc2495c69d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i20487a9e41eb468fb7da6d0324133121_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8c754289625a475e91ebf3960393d1df_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic8b0757eda174b29929c9539b4972205_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i55d9057d66f44539a8d04ef9162bb079_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2ce8733a67e34fdbb3a3c3db64b74607_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i52336bc12b324590bba4f1ab5687f560_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i22ad6abb0fc2410f8d14252857b9b662_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6a224585ac174008bad3bf2831eec2f0_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i61c86486a74044d0b4999de7a19e56b8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i1c78658e347043038c35c1cacd0e7415_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9452f0bca2304c67ac02c051e36f8823_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib95c642c97784f95b54de6ac4683cf00_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5363da9b40b8433589b18ba5d4349ec4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i168f9b03b66f4d37bb7151521137ed70_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i268ced4ae9024a918193193003914ad4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie206f45400684e03b789ee66287deddc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id50f1ea2e05745ff8b96e3859d79bf00_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iad40d41effba4a3785f2f35c5cc9b839_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd4f40364954436caf47b6d23cb6d6e4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f23accfdbc34e51924d5a95ddcb0253_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia65d3e7d28b94209a448cb72c6adae4f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8990e088bd584d108b3b67f167d02e78_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8c4d9ba8d16c449c80e25e34837c0084_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a7ee782a5ac4726825924882652fb3b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i864f0448c9b44f6abc0aa0fc934ca527_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ed96d628e884154a23064db50466351_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f0db448912c4166941130ebb1e99a3a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f8aa68dc9bd43a0878ae2aa5eaa1801_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4702b7d22d1a40a59e7c037cc5eef2a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d7ed4748adc465582c5b79aad061342_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0886aab4e9464bd081f28baaadbc2c24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79caa187be2c4546967d3d07d999a1f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82f9aab73bb74d4eb978e25668f669a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35b094dd513647c39d1b0a77a875ab5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0693226ab445409dac81b6a1a31b8e74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbe3473f98e7473a96d28715e29fab03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i027bc0bdf8734670ba15f197c3fa9de7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5b505ad720547b7906b11f5bbf2fbdb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i73fdcaf51beb4164910ff49230c96c68_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5ea0497ce3b1475f81a9c6c00b0c512b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32dc6dca82f54b3997404bec4ab31270_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if7c87ccb914d486b82d6cfe0e26711e6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i0c12d1da942447109063cebb275e8ba0_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ie8b27155c8474ab98f936002ff227c64_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:SecondPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="ie87e6a507693455e82f8b7d021987453_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="ic360f0c60b9e4bd4a3301ef5a705c91f_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:SecondPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="iec4ce25ed9c841df9c17121f68205ba4_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i0619a3b111784379874d71f11398ec42_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingSharesFromCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i856f24feae584b14a8bc751fcb0a507a_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingSharesFromExistingShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ifa0280538aac42a28763dda42b85838a_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ifd8381d4b2db4351a5d965b163ba7b2f_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="i827e3aa981f94e4497963dc63008de63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1750d8abb53f482ab006e6bbcc0efe15_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47ab4f535e3f49f092f4f09308ca5685_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0b870409832446b94306158afef68a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74860ed5b6ab4871aeb814ec7a0a16b6_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="if853e1713db04046a3e29718f77e312d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i82a8a6cae4d84ca78f3412deeef72360_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i0a23db6a3861435b9f2516a8cd29279a_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i1cc64e5be1b148b388a24c6ea4bc296c_D20190501-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29d32e7c3bb6454a8aac9d997e7acdc7_D20190501-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8bdec6a3f3f428d912d079b56925396_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="id91c2dc9412d49f38b2911de8b92a20c_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i75afb4faf7c744e2b28602b04897dd79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64b54eeb36b1445a892442bd09bf6ddc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f6cfd36e8754556bf275ccd4408ac9d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idc08d2bf3b1d4a4db5e64a2c8d4dc1eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f590d47a7f349109aeb1d59166be0f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5af5a51a24f74e2abff8b55e1f406aac_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic05cef1eab034c14aabf2595f65c6875_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d19235df8b24d9391e616dafdce6fe6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e6007a041b04fe18293a2b10afdf234_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9af4d8ce709e4c3a9540ae056f21e76a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0208f9e90c6a42fda50fc3adb6581207_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib88ecc9d7eb744238cc66553830ad1a1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4c1b45f2b2f54a72b7d8efc23d3f0bb1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i070da31579db44ef9c24774b3df5e7d7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3673ffce8656493c860435c0fb39bfb4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i88621eee6a92415596259056062149ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i59487565bf824f58aa85388dbb1688de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf154cdda1c64eb98fa4cb83db6a1660_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2975ca8ff7e249fdbd6927130f924215_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0b799836f284366bc42899fe369b6df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic870ec31c6844cae91979478b320f851_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ee5649064aa4f26bf11ca63f1d732f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ae39ce199b8414db9c118472a65f406_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81f2c499fbaf46cabadb242b9424f8cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i357686f6ae35429994f069e2387042a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i848eba092bd94a8eb9a2e17f4201aecc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82ec25c5c50d45fc9b7ac1bcf6ed42c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fa5d33e615f45ee93d158502b82303c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c7a65d68ecf48be802607860d75752b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f0fd943be2845489302e8030bd481fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8db444997bb6463980bb4456c1bf3dc6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic98cf98f0f8c4bdbb7f693b02e6b6929_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie23170ae30bd4aa09beb7fe13e61ced2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ecc085e11174791b09ea7310d702ac7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i433402cf26a940318305dcd5eb794a03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e033ae2fd394f23bcf5460a5a476a6d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3306f9c046324cf5b42a9b1bac4a0df4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if0704a28bb0740d0ae4c8aa19953a7c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i98694aaa0a3e4704bba4075c12779e77_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i737fbec56ae2400498ccdfd111434ebd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i942c1c56732d4c25a0dce9c90e7135bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93aba04a024740cab28993b7f08897a6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib9ad97bd146043ccb94ce8bb1534c274_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i39f54e063bd140a59132d57ef7c54d00_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5276c031eb8401ab73fc33a537f9a9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec0f25b2baff49b08a617afd300f27b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i318e00b0a9b344bda4f823f595370143_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b13adf4f0254c9cac128597de2f1736_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4cb08f575e4245cb9aca4fe1623d37ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0dc412721304b3b9720878497766ff1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i14399a34c4744effb088c2e934ae2d39_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1bcb916e401b434c9e7347ae76804c6c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65720dad45e548d784f15ef6efe4dfce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40fbd6b3dba34ba6ac8a848b3683d371_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf8480cdb559440dba9a27448e6c477b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7abdb02107cf49099d5551ac177162e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaaabfa66f9d644e5b250778ca77caced_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if0af3756b9464f89a2924477109ebf89_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f81260903074be0978bdc8c0d05b714_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9ec2284f03df4813bfbdf100ea317939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11882955ba914a4abd7f7f72b573da68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c6e1731892948749cc2a36087515f22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i889ad813d9384574aeee41f8e250fdd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6666fe4580be47429377090735b4b572_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibda1fee3df294d8280213184a71db82b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2210e9a79df74613aaba46b9b6c9d830_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6207be23c9e413d86cc481a1129e296_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a569c77aa3c40dd9b99313f06d7bd3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i66c76492ae1149d3aa274942d50fabd3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2533cb6af194baeb29f893a563753d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if68f3a12f75a43e0a5f0f1a0e2ed2345_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="silk:LossContingencyReceivableTypeAxis">silk:LossContingencyReceivableInventoryExcessAndObsolescenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc53679edcca491daa58c1d5d9e40d2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89117551e1cd4e1894164ae6a96705b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28498ef5e5d649ccab003692d7a48278_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58bbd4394762445f9a301c74072434aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6603001cf648480982c9106b4e14992e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4bfd4cf869646a3aabf0014c3294512_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i82c17ea580834042872a256eb3032b57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i719a20f0f78a457f87d7472704e63aa1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie69721672eec41c2a595f99de0a0defc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6b0413075134cc583c0faa97c7be5d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf16e6187b0a4304bc8897195133e968_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="ib85c4555200f4f429465863d9f50f535_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i9f5ec93120bb4972be5e2507b780398c_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i40ecba85ef204349b335af3072288f5f_D20170401-20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="iecdd1fc58174421a9bfdd8f134ae6e23_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i5ed5ecc368374169a71abc3cc9f49aa5_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="icdeb572f838a40fdaa6ba2d0bfd368c1_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i103121e7190f43fabe96184573d85e5a_I20190501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-01</instant>
        </period>
    </context>
    <context id="i7abc563c49034717a7c3322581f18eb8_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i5936ba61c97f46c9abe460c3748fc302_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i36fa0eb7334c455888e30aa07d6532a5_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="ie5c39c1b02c34d54a55c972e504f4f10_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="ifcb3cbb6159547ebb60630ca78155e84_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="silk:DebtInstrumentRateScenarioAxis">silk:RateScenarioOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i51b6bd6e7c434a7c95a35ff5a9531de1_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="silk:DebtInstrumentRateScenarioAxis">silk:RateScenarioTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ifa3b08c2ee1f40f29b52fda52abcfcbd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ifeb1a73d258b47deacf93ec34c1d3916_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="silk:DebtInstrumentRateScenarioAxis">silk:RateScenarioOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i65ad62ac27904958945aa2aa614f9585_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="silk:DebtInstrumentRateScenarioAxis">silk:RateScenarioTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="idb2c47acc6f844248688d675a456ddad_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:SuccessFeeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i907e8be526f045dba75ef70a204b7872_D20201029-20201029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-29</startDate>
            <endDate>2020-10-29</endDate>
        </period>
    </context>
    <context id="i907e1c4c4cf446efb027c2d919844c24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c3729f2464e47ab98755aaf4d5239ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66136b6bed6c411a82f197a4d3385b6a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i62faf7ea655c489e8fb700ba32e5a72a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib33b63c59a7142df9c638019a56d357b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb165d229e594aed955a8ab2194b3631_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8035f9f9ec5d4b46adb98b3f8e400ff1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i603554706e704e14a87cd579bfc1f1cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionExercisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i096b9866423f47bfbd8c84a4319b04fc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionExercisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idbdb361087f54a5fbd3ebc590fca7604_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03ab7ad3a56f48299ce1b6e914d7b413_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i480f0a71d7df4da79168f1094a28dc8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09057e7a1c6b4809a7a1631278acc9b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf29cfa1d6194741a8ec14f28d1e4578_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a1e51514e02474c89b155e4a5550726_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ae992978a7d4deda30dcb028e032db0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic097536e6675494dbb4e914fc5bcd668_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i360f4f24adde40d8b482c84b661efed8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i470f2ac36ec446a29f50d256c7548d9e_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i214a26dd5e864dbeba676287ebd8859d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f4737d591bc4039af44f3bd9c4891fd_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="icd542f1734634f0a802415b0d28a90a1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3bf45438ba5c4c2aa9a094bb5bd64ede_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idf1037c5333249bbbd1ae376d9910c53_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie77759ae85f849f99b4e3b1e0c06210e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a8b1f2479ef489b833a827057b3ee5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c0182ac39bf451580f9e5a338dd2281_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i708be08da99c40d39705d37410604fa8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:NonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63c59c6933b34539813d0d966133cca9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i659d64912c544b77817ed68d2f7ce05c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ea3f51adc9c4505b898323c41931f67_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i490bf68acdbb4450bf64bafef197e4fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i715cd558a0134ebba2c8252d957a7ce6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2c087f244e24d669ad5f5b19aa67a98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e3dc08fdedf4e33bd6817d15104fe6e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6fdd1471eaa54f92a52745ec56a48110_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8945e1adfb3b4ab09fa3fa5891d357c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8c8d5b84586400b86587503b81287f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc46ca644c744b70aac67133ea9f52f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36011f19453e484790ec3753ef0eb829_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19b4be470462491987f832241f434403_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b5473c83d5146e19f1b3858891c78b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f9b2814a79c4dd08d65788445d6db8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74888ea9613946dd8a212a7d91cda76a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd4ed4e74601414e92a601aa67b10327_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idfd02705d3de468ba9f3a47573c3dde9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia49153bfeb6f42bdb3736ba316591747_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice0a90922eee49f89e3692455daf46fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia787b8a99022442987a046c7b0ae1e90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c7bb98d16e744c886f33a907325392b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1ab64a372d04ae8b13ae564c7b1d519_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8621a9d17f8c4c759e18a0b9f4998461_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d07d3d83db94418805af6f5704d41c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67a74532b17b4cbeb8fc651e11ede5be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a577dab858449659f2138be0247edb3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">silk:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6691dffc917441fa983264255b9af82b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia05420dcc8d84d7787c80598f1ef5734_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4be24da3ca849f38e1fe9ffb7f6d2ba_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i727cdef9482140249c0cb804bb673e7c_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i321ada78d4e34140b6929a8c206aa114_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ccbf5504e084eaeb3d0c1e776fc48ea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61cd83f3fb4e4e00b85103543a357d2e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if15e03a06afa4556856fc6b3d9b3f42e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia5fe2fcafee2473d94c7bb24e4dee4b2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i39165a89986a4d5fa6d41c395d548242_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0309977823e74b8bb43d525e2c1862f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5a041d34a42449bda00947d0a4241c05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb3f38d9acbf408aab3a51c21d51d4d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b5e58dd5ca74c379c458d4f10ca54f9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i95c8f7f1217049b0ac9c547630982b6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9cc78fcf595b4b6b89684111bad3f5a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79c98c09f3d34127ac384e5836c541d5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic9f27a96dad34a63a114ecba634391a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9290967454ec461ab5eab6e110e7984c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0b062b857ecd47d58f12e164875b8b8e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic2a66f92a0c54ee4abd3a59a6da8d88b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0efe8bfdcede4d06a33afef06da15dc1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib74c8c93648e47c981153a6846f18a61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ee605997eef429381c095e0eaf512c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e58304a7fe546fa982e73d2e64be31d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3bb7213b7c542eb8d9d50fda0c137d5_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silk:NeuroCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="if9c1f3c48bdb4a6ea8c16f7a38160b11_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silk:NeuroCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i3380644612b74549867fb107a4a32b56_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silk:NeuroCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i326ed72d5faa4423a7380a120ab921a4_I20181217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">silk:NeuroCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-17</instant>
        </period>
    </context>
    <context id="i6dca7000583a43869c1389cf6ac8d3d2_D20181217-20181217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">silk:NeuroCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-17</startDate>
            <endDate>2018-12-17</endDate>
        </period>
    </context>
    <context id="i4ea6234882cf424bb9e6d52bf97c9471_I20181217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2018-12-17</instant>
        </period>
    </context>
    <context id="i74e220b1dfe342f2bad86c21ce171b0e_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="ibaa4295aab3c4fd19f5369890a74eb95_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ic3233352a710471b8cc9cd69d34e703f_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i01975501aeed437d860ef21eff36403e_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i39997c7638c9433ca55684c8301b703a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="silk:LossContingencyReceivableTypeAxis">silk:LossContingencyReceivableInventoryHeldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79e280b94b7942cf91af6b3df5b509da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="silk:LossContingencyReceivableTypeAxis">silk:LossContingencyReceivableInventoryInProcessOfRecallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i637453fe4b3642f9aa11f791b415ea8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">silk:VoluntaryRecallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="silk:LossContingencyReceivableTypeAxis">silk:LossContingencyReceivableDirectCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4fa9083290c443aa2e74fa476c35c40_D20210226-20210226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-26</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ief509a5e508844398122e436481d4a37_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i218af6b8a4044434bc70398d3d719486_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d98a257f74a444e815e2acdecdd06e8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4bfdb1605af43cb8614f33f8d1a6537_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2401d30b2e994f16b50e95b7e08d7413_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibe63293076b44c03b2d249cf8f39228c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i515fd7b45a0d4244a919c02bb006219a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie1814d8a10cb43efae417d1231483bf2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>silk:segment</measure>
    </unit>
    <unit id="vote">
        <measure>silk:vote</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl80L2ZyYWc6MTI1ZWQ3ZjhkOWUwNGZmMTk1YzVkZTYwZDYzZmU0YmIvdGFibGU6MmZmMDI4Y2FlMmIwNDU2ODkxZWU3MzFmZDY1MGY0NTgvdGFibGVyYW5nZToyZmYwMjhjYWUyYjA0NTY4OTFlZTczMWZkNjUwZjQ1OF8zLTEtMS0xLTA_615d4611-41a8-4f28-b1fe-808f3062905c">0001397702</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl80L2ZyYWc6MTI1ZWQ3ZjhkOWUwNGZmMTk1YzVkZTYwZDYzZmU0YmIvdGFibGU6MmZmMDI4Y2FlMmIwNDU2ODkxZWU3MzFmZDY1MGY0NTgvdGFibGVyYW5nZToyZmYwMjhjYWUyYjA0NTY4OTFlZTczMWZkNjUwZjQ1OF8xMS0xLTEtMS0w_583324b3-ac86-489c-84c8-51d09401b84c">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl80L2ZyYWc6MTI1ZWQ3ZjhkOWUwNGZmMTk1YzVkZTYwZDYzZmU0YmIvdGFibGU6MmZmMDI4Y2FlMmIwNDU2ODkxZWU3MzFmZDY1MGY0NTgvdGFibGVyYW5nZToyZmYwMjhjYWUyYjA0NTY4OTFlZTczMWZkNjUwZjQ1OF8xMi0xLTEtMS0w_c1051ba0-a530-4473-8b14-4a339f697946">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl80L2ZyYWc6MTI1ZWQ3ZjhkOWUwNGZmMTk1YzVkZTYwZDYzZmU0YmIvdGFibGU6MmZmMDI4Y2FlMmIwNDU2ODkxZWU3MzFmZDY1MGY0NTgvdGFibGVyYW5nZToyZmYwMjhjYWUyYjA0NTY4OTFlZTczMWZkNjUwZjQ1OF8xMy0xLTEtMS0w_03c66ea3-3d89-42d2-ad85-7ef3157ccd27">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ifd8381d4b2db4351a5d965b163ba7b2f_D20190313-20190313"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83OS9mcmFnOjQzYzY0NWRkMWIwMTRkY2ZhMjM0MTM0NjJkNzM2NjY2L3RleHRyZWdpb246NDNjNjQ1ZGQxYjAxNGRjZmEyMzQxMzQ2MmQ3MzY2NjZfMTM_ec25cec9-cf0f-45fb-ad9e-689486fcfad2"
      unitRef="number">0.3704</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i47ab4f535e3f49f092f4f09308ca5685_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA3ODg_1daeb587-69ed-44f7-8b16-4ee5917c9839">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_79e4f10b-3b5e-4ec2-876c-6e585e344f6b">us-gaap:OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_da5af1e9-78c6-47d2-b916-faffbda32183">us-gaap:OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_0c14a90d-c468-4d50-8bda-f4b6abb57993">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_df5558d5-a823-4bc7-8d24-11cd3b6290f9">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_14124f2c-b99c-42a3-914f-b88bb1e2da04">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_eb1aa98b-cafb-4393-b523-5f94410b69b5">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF84OQ_aea317ef-bd3a-4049-8f4f-c708dc0ae7e7">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6N2JjYWRlZTEzZWU3NDY3OWE3Zjc4Nzc0OTA0NTQ4ZTQvdGFibGVyYW5nZTo3YmNhZGVlMTNlZTc0Njc5YTdmNzg3NzQ5MDQ1NDhlNF8wLTAtMS0xLTA_fe09ddb1-c74d-4eac-865d-fe6b5a09dbf0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8xMzE_c8d39cd2-e22c-48ef-8b4e-86afbc036f7a">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8xMzE_fa3a0bdf-0c2f-4409-9d9d-3a3f2157238c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NmM3ZGM4YzM1OWI1NDIwYmI1YTBkN2U2N2Q3OGRhMTkvdGFibGVyYW5nZTo2YzdkYzhjMzU5YjU0MjBiYjVhMGQ3ZTY3ZDc4ZGExOV8wLTAtMS0xLTA_b8f5e3f9-1aa4-4064-a5a9-f46ecd561d50">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yODI3_2828ffce-141e-4a54-9b43-912af953407c">001-38847</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yMjI_41fcbabe-9c27-4427-9246-62ebc6482205">SILK ROAD MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NjY5OWM1MjA0ZjMwNGI0OGFlMDEyZjEyNjFmMTdmMzcvdGFibGVyYW5nZTo2Njk5YzUyMDRmMzA0YjQ4YWUwMTJmMTI2MWYxN2YzN18wLTAtMS0xLTA_9a475793-42a8-44c7-897f-c7d2faacb8a6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NjY5OWM1MjA0ZjMwNGI0OGFlMDEyZjEyNjFmMTdmMzcvdGFibGVyYW5nZTo2Njk5YzUyMDRmMzA0YjQ4YWUwMTJmMTI2MWYxN2YzN18wLTItMS0xLTA_ae818f7a-79fb-4561-9c73-53e73e8de316">20-8777622</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yODc_dd00d5b2-6779-4918-8e28-0e3c00dcf20d">1213 Innsbruck Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yOTA_b31c26ac-1b76-430d-aa45-391a3b483ab8">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yOTQ_ac01e3e7-f823-4ffc-ad0b-6d0cb6732bb0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yOTc_9b559257-fcba-4ec2-8473-dcd9c8bed31b">94089</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8zMDI_d5a303a5-2225-4386-8464-48023f5ab8d5">408</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8zMDY_11a7ad66-8c22-41a7-bad3-d0ee2d5ce0f4">720-9002</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NDk3OWIyZTk0Njk0NGZmMDk4MTIyZTQxYjNiOGFiYTMvdGFibGVyYW5nZTo0OTc5YjJlOTQ2OTQ0ZmYwOTgxMjJlNDFiM2I4YWJhM18xLTAtMS0xLTA_297a6d7e-548e-4e72-9699-fc9fc5576417">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NDk3OWIyZTk0Njk0NGZmMDk4MTIyZTQxYjNiOGFiYTMvdGFibGVyYW5nZTo0OTc5YjJlOTQ2OTQ0ZmYwOTgxMjJlNDFiM2I4YWJhM18xLTEtMS0xLTA_62f23321-0436-4e44-a895-ab3c0be9cd1c">SILK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6NDk3OWIyZTk0Njk0NGZmMDk4MTIyZTQxYjNiOGFiYTMvdGFibGVyYW5nZTo0OTc5YjJlOTQ2OTQ0ZmYwOTgxMjJlNDFiM2I4YWJhM18xLTItMS0xLTA_02d7e0d6-a79d-4458-8fdb-cfce51e2af68">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8zMjk4NTM0ODk1NDEw_127e01f3-cb2f-40d8-b9fa-724d6042b28f">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF84Mjk_fa607275-0fe1-42e8-9b3a-ffbe7b76caef">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8xMTg0_4a8be9d2-dfcb-4d43-aea5-9e4ced74ad30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8xNTEw_04473caa-1770-44bd-b17c-9ed1e8a68be6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6ODZkY2QxYTI3ZTAxNGExYmFjNWFkYmJiYzA2N2JlYmQvdGFibGVyYW5nZTo4NmRjZDFhMjdlMDE0YTFiYWM1YWRiYmJjMDY3YmViZF8wLTAtMS0xLTYyNTk_9115d21a-0874-4b7f-846e-37359f0e40d9">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6ODZkY2QxYTI3ZTAxNGExYmFjNWFkYmJiYzA2N2JlYmQvdGFibGVyYW5nZTo4NmRjZDFhMjdlMDE0YTFiYWM1YWRiYmJjMDY3YmViZF8xLTQtMS0xLTA_ebc9757d-3491-42a0-9f9b-f93d25308db2">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGFibGU6ODZkY2QxYTI3ZTAxNGExYmFjNWFkYmJiYzA2N2JlYmQvdGFibGVyYW5nZTo4NmRjZDFhMjdlMDE0YTFiYWM1YWRiYmJjMDY3YmViZF8yLTEtMS0xLTA_43128282-0b4e-4e6b-9740-2201669abf5e">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8zMjk4NTM0ODk1NDA4_44367f83-51fc-4f05-89ef-bfdbb76271e7">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yMjU3_f841a1d3-6699-4fed-ad08-fcad6f52dfea">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i57b888d1afed467eb6e8156312b035a4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yMzg1_c201a84f-73fb-45de-80ef-ed57af4fa4f9"
      unitRef="usd">1400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ifb6f5fd1061f4f56989bc588eebd18c4_I20210226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xL2ZyYWc6MTdhNmY3N2FhZWJlNDkxMWFhM2JiNGMxMzkwMmM3ZWQvdGV4dHJlZ2lvbjoxN2E2Zjc3YWFlYmU0OTExYWEzYmI0YzEzOTAyYzdlZF8yODIy_58f65cc0-fcac-4936-b1ed-6189af24cb8e"
      unitRef="shares">34365398</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNS0xLTEtMS0w_5fe78cb0-30e9-48e0-ac81-b21dffa3482d"
      unitRef="usd">69466000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNS0zLTEtMS0w_ad02ab82-7d09-4d5f-8673-d1f3020e70ce"
      unitRef="usd">39181000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNi0xLTEtMS0w_2928ed48-4ad8-4e84-835d-1e951d7a8232"
      unitRef="usd">78016000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNi0zLTEtMS0w_13c153c9-19a2-42b7-bcad-c0a2bb0c32b1"
      unitRef="usd">51508000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNy0wLTEtMS0wL3RleHRyZWdpb246MWUzY2NkOWU0MmMzNDA1MjkzYTIyMjEzNTQ3OWI4OGNfNDY_3b3c0e82-e2c0-47f6-b279-16fefd2e3b10"
      unitRef="usd">13000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNy0wLTEtMS0wL3RleHRyZWdpb246MWUzY2NkOWU0MmMzNDA1MjkzYTIyMjEzNTQ3OWI4OGNfNTM_ca01ce24-b504-4d0c-8389-a20990e89d96"
      unitRef="usd">45000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNy0xLTEtMS0w_5dae2fe3-eb1a-4aba-a3d6-e73e1825c4ee"
      unitRef="usd">9070000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNy0zLTEtMS0w_26302b6d-e5f4-41fe-b176-7842b97aee3a"
      unitRef="usd">8601000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfOC0xLTEtMS0w_a1340a19-fc18-47cc-b802-f61d0f7216f8"
      unitRef="usd">9989000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfOC0zLTEtMS0w_759686d3-9859-4619-b527-4fb691724969"
      unitRef="usd">10322000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfOS0xLTEtMS0w_16c5d081-abb6-4919-9c22-7e99f00c86da"
      unitRef="usd">6787000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfOS0zLTEtMS0w_2702362b-7747-4a56-badc-e19c821a9b6e"
      unitRef="usd">2878000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTAtMS0xLTEtMA_aeaa3b8b-5e8a-4320-a5f8-e36155553d17"
      unitRef="usd">173328000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTAtMy0xLTEtMA_1fc1134e-0816-463f-8232-a88234b8c8ff"
      unitRef="usd">112490000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTEtMS0xLTEtMA_e117f540-b336-4a99-a794-e917f8c599cc"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTEtMy0xLTEtMA_4c7e7f54-0808-45f7-9f30-be5a0f637aa9"
      unitRef="usd">18224000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTItMS0xLTEtMA_fdaeb885-2cf4-4165-982e-b1ac8f22479f"
      unitRef="usd">2844000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTItMy0xLTEtMA_cb48bc69-0f57-4038-b8e1-ad687da13960"
      unitRef="usd">2734000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTMtMS0xLTEtMA_91ac1c68-4e98-40ce-ac5c-a089afa6ce38"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTMtMy0xLTEtMA_c50e97ed-1f69-434b-bf34-1fb7ccabc230"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTQtMS0xLTEtMA_16f44668-ab5b-4e5f-a3e2-05224a5ca8ee"
      unitRef="usd">2832000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTQtMy0xLTEtMA_066afb1f-5f68-41fc-958c-5eeec721fdc2"
      unitRef="usd">3644000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTUtMS0xLTEtMA_c2c6f6c2-eec8-4ad0-8542-e102d2836fde"
      unitRef="usd">179314000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTUtMy0xLTEtMA_82b43faa-6672-4481-84db-e77ee1fd56da"
      unitRef="usd">137402000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTktMS0xLTEtMA_e25d4195-b1ab-4fd2-9edc-36b303b9bc31"
      unitRef="usd">2598000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMTktMy0xLTEtMA_8ca6706c-3e39-4d6e-9ba5-1142f4ef29fb"
      unitRef="usd">1898000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjAtMS0xLTEtMA_ecb0bedc-c7e9-4288-803f-739b4fad9761"
      unitRef="usd">16957000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjAtMy0xLTEtMA_02ba214c-4797-4279-978e-c4eb3c66420d"
      unitRef="usd">15034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjEtMS0xLTEtMA_0e8f5753-67a4-4d93-8237-285914e7d1f1"
      unitRef="usd">19555000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjEtMy0xLTEtMA_b0d816dd-8449-479e-82da-a6a4d72f750a"
      unitRef="usd">16932000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjItMS0xLTEtMA_32e13da8-c5f3-437d-b8fb-f8eee0322b0e"
      unitRef="usd">48533000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjItMy0xLTEtMA_46e2d0e1-0102-4b3c-8c69-f7ae0f6bb5b4"
      unitRef="usd">44879000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjQtMS0xLTEtMA_0b0106b2-988c-41ed-9dc2-f5573b41b058"
      unitRef="usd">3726000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjQtMy0xLTEtMA_aa3535e8-584d-49af-9038-e2baf495c7ac"
      unitRef="usd">3700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjUtMS0xLTEtMA_d1dc85be-71a5-4d12-a858-04b0d998e7eb"
      unitRef="usd">71814000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjUtMy0xLTEtMA_20483946-b998-450b-a92a-1ee1d40b2688"
      unitRef="usd">65511000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjctMS0xLTEtMA_1f032063-5cf0-4ee0-b4f6-e36ee21de134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMjctMy0xLTEtMA_f7bd5dcf-f3f8-4536-ae32-166f07b5aaad"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjNiYjVjMzBiM2M0YTRlYzRiNDdlNTdjMjhmNzEzMjkwXzIx_af624094-e749-4005-9a50-39cf8ba2c059"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjNiYjVjMzBiM2M0YTRlYzRiNDdlNTdjMjhmNzEzMjkwXzIx_ba6763af-99fb-4a51-a548-b631e2db33a4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFhNDM2MDYxYzQzMTQ2NTdhNTZiODI2ZmNkNDYyMDQ1XzMyOTg1MzQ4ODM0NjM_0b4dedde-aa69-4463-8d03-2a9f9dd530a2"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFhNDM2MDYxYzQzMTQ2NTdhNTZiODI2ZmNkNDYyMDQ1XzMyOTg1MzQ4ODM0NjM_607ba188-1fdf-4ea3-8561-1bcfd1854fd7"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmJiMGJjMWFkNTA3YzQwNTRiZTkwZGIwNTAxNjA5YWUzXzM1_5e3cffdf-195e-48b0-b40a-8b84944a34d3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmJiMGJjMWFkNTA3YzQwNTRiZTkwZGIwNTAxNjA5YWUzXzM1_b71f439f-fe22-4661-bd3d-09ddb3d041f4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmJiMGJjMWFkNTA3YzQwNTRiZTkwZGIwNTAxNjA5YWUzXzM1_c089e634-76f9-42e3-bd89-55af794afd02"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmJiMGJjMWFkNTA3YzQwNTRiZTkwZGIwNTAxNjA5YWUzXzM1_ff053595-15f7-4ad6-aab3-844e74d373bc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMS0xLTEtMA_bdf63c72-d016-4787-84cd-37ca785d13e1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzctMy0xLTEtMA_893972cb-7640-4342-b548-6a5fa688cfa7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmExMGQyZGUzOWUyZTRiMDY4YWI3YzhlNzVkMmJjYzM2XzE4_6cde1fa8-19e3-425f-8d32-c4cdc6edb695"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOmExMGQyZGUzOWUyZTRiMDY4YWI3YzhlNzVkMmJjYzM2XzE4_e4c311c2-5007-4927-a307-df85dfa213c2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOmIyMmQ1ZDRiNTI3OTQ5ZDRiOTRlMGVkNTgyODZmZjA0XzIz_091acddc-6c03-4ec0-a134-a67a4b58e87b"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjY3Njg0NWI4ZWZjYTRjMmU5MWI3MjFlMWRlYmY4NTA2XzM1_a3167292-54c4-4db4-8b13-e440d9e6f896"
      unitRef="shares">34249649</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjY3Njg0NWI4ZWZjYTRjMmU5MWI3MjFlMWRlYmY4NTA2XzM1_dadec27c-2754-4d53-a2be-c25436d4f8fa"
      unitRef="shares">34249649</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjY3Njg0NWI4ZWZjYTRjMmU5MWI3MjFlMWRlYmY4NTA2XzQy_33ae8c54-ae59-4803-ad37-a0bed8003713"
      unitRef="shares">31255267</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOjY3Njg0NWI4ZWZjYTRjMmU5MWI3MjFlMWRlYmY4NTA2XzQy_35b30280-a3ed-4283-a92e-11f08ff2bdf9"
      unitRef="shares">31255267</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMS0xLTEtMA_6676c460-b29e-4306-b84d-6d3651c12a01"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDAtMy0xLTEtMA_092de956-4879-4d7e-af7a-8d898c7a4f84"
      unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDEtMS0xLTEtMA_e8d2e00f-925b-4940-8ff8-05081a638ded"
      unitRef="usd">346318000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDEtMy0xLTEtMA_1020ea6c-da14-4f6b-9032-9b8c17d94212"
      unitRef="usd">263384000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDItMS0xLTEtMA_6c5268d1-db08-4bf1-9945-73c56a5f99c3"
      unitRef="usd">39000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDItMy0xLTEtMA_93ea384a-db2e-46fb-88c9-5419d5fcb622"
      unitRef="usd">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDMtMS0xLTEtMA_900336ef-9c45-4e3b-88ce-7ab97b7cfe11"
      unitRef="usd">-238891000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDMtMy0xLTEtMA_cc272cef-14c4-430b-96ab-a0732fca1fad"
      unitRef="usd">-191526000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDQtMS0xLTEtMA_2dcc562a-114b-46a6-baba-3a607fd9e0f7"
      unitRef="usd">107500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDQtMy0xLTEtMA_0818c4ae-e778-4403-a08d-423e7b061e44"
      unitRef="usd">71891000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDUtMS0xLTEtMA_85189458-c375-4ef9-97be-b5b259ba609b"
      unitRef="usd">179314000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl81NS9mcmFnOjBjMmUwMmJhMTcxYjQxNDNhYjYwNGNiMjcyNjc2NGFkL3RhYmxlOmNiMmNhOTI5MGVlZjQyNTFiOTlmMjQwYmMxYzU1MjVlL3RhYmxlcmFuZ2U6Y2IyY2E5MjkwZWVmNDI1MWI5OWYyNDBiYzFjNTUyNWVfNDUtMy0xLTEtMA_0585be80-4ac4-4af6-af0c-153cfcc594a4"
      unitRef="usd">137402000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMi0xLTEtMS0xOTU4_6b9b9267-e2c5-4de5-9f91-868caaeb502b"
      unitRef="usd">75227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMi0xLTEtMS0w_a3e2e642-6b7d-4726-bd32-e874d1ca4498"
      unitRef="usd">63354000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMi0zLTEtMS0w_690bc153-30b9-4c61-a9ec-a4a0c3b1fc5a"
      unitRef="usd">34557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMy0xLTEtMS0xOTU4_b30e0358-1ddb-4adb-8f25-0156a2aa3147"
      unitRef="usd">21291000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMy0xLTEtMS0w_386b22a0-db51-40dc-b921-c53e0a07d1a4"
      unitRef="usd">15927000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMy0zLTEtMS0w_ec284171-1c35-4e45-8240-dd8587a5c658"
      unitRef="usd">10874000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNC0xLTEtMS00Mzg_38086ddb-4206-4022-9306-b57cffc64226"
      unitRef="usd">53936000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNC0xLTEtMS0w_afa19bd3-73b4-4f1a-8512-f17f2116e48e"
      unitRef="usd">47427000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNC0zLTEtMS0w_920dc876-f2a0-466f-9e52-5036ef27d59a"
      unitRef="usd">23683000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNi0xLTEtMS0xOTU4_9e1c3289-60f0-4d6a-8941-ee230ebf33a6"
      unitRef="usd">21271000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNi0xLTEtMS0w_1f5b8627-e6f0-4940-b7b8-35aba05343f4"
      unitRef="usd">12272000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNi0zLTEtMS0w_2d20a93f-4449-448a-9d1e-e3fce9a528db"
      unitRef="usd">10258000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNy0xLTEtMS0xOTU4_7c537c7d-6ac9-44c6-967e-c04fa47f4bfd"
      unitRef="usd">75524000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNy0xLTEtMS0w_a148e4ed-93b0-4a80-9f7d-1add7eea3160"
      unitRef="usd">63220000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfNy0zLTEtMS0w_dad62029-ae7d-4c2c-b289-c093d5d2f510"
      unitRef="usd">34820000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOC0xLTEtMS00Mzg_d528bf04-1dd8-4444-a726-3fb6ea4d100d"
      unitRef="usd">96795000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOC0xLTEtMS0w_7bd0af60-7fd8-4e47-8dc1-a0985765a8ac"
      unitRef="usd">75492000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOC0zLTEtMS0w_51e79759-7960-47c4-8881-b3861b9bbafd"
      unitRef="usd">45078000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOS0xLTEtMS0xOTU4_08e2b6a2-9913-463c-8107-523458a6e3dc"
      unitRef="usd">-42859000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOS0xLTEtMS0w_db79eb8a-fc7f-4348-a647-c62f6931c314"
      unitRef="usd">-28065000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfOS0zLTEtMS0w_94eb90ba-337a-4821-a337-5befbf60f5ac"
      unitRef="usd">-21395000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTAtMS0xLTEtMTk1OA_a20d2658-af0d-4296-a935-7502a742d0a2"
      unitRef="usd">1104000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTAtMS0xLTEtMA_3905a7b8-f1cb-4faa-a095-c6d315d80da0"
      unitRef="usd">1656000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTAtMy0xLTEtMA_f73839ad-a530-4486-abbc-721e2d0acbfa"
      unitRef="usd">189000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTEtMS0xLTEtMTk1OA_180896c4-b105-4751-b2e3-13a40c10fe50"
      unitRef="usd">4411000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTEtMS0xLTEtMA_c17f937c-b9f4-4693-901b-213be6aa002d"
      unitRef="usd">4952000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTEtMy0xLTEtMA_111928fa-af7b-42a8-ad39-67cd2cbb08a6"
      unitRef="usd">4361000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItMS0xLTEtMTk1OA_54fb68c0-2e11-4f20-a4f5-4f443f8f1bcd"
      unitRef="usd">-1119000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItMy0xLTEtNDM0_f6907ecd-d3b0-4cf5-90eb-dcbee9328026"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItNS0xLTEtNDM0_a3cc3c65-c441-408d-8202-40b547b3f51f"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTMtMS0xLTEtMTk1OA_569af0d9-cdc4-4efe-8a11-eb317090c0db"
      unitRef="usd">-80000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItMS0xLTEtMA_874c4df8-9c75-47f0-9fb9-9c929ca34978"
      unitRef="usd">-21054000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTItMy0xLTEtMA_f9c7de27-0d57-4978-b93b-a04f8e145139"
      unitRef="usd">-12063000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTQtMS0xLTEtNDM4_2ca8aaad-8791-4e7a-9733-5e0bc1ff9069"
      unitRef="usd">-47365000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTMtMS0xLTEtMA_0ead4990-9065-4886-9e5d-201d5b954b84"
      unitRef="usd">-52415000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTMtMy0xLTEtMA_a4b578b1-ab1e-4132-9b45-9e0201179281"
      unitRef="usd">-37630000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTUtMS0xLTEtMTk1OA_2992678b-7eb0-4754-9935-ac154f3edba8"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTQtMS0xLTEtMA_509e4bcd-300e-4dcc-b3fd-e5be00f4c1a8"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTQtMy0xLTEtMA_a6ff0983-8daf-4848-aadd-62ae37d9e591"
      unitRef="usd">-1000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTYtMS0xLTEtNDQy_37ffc5d6-9100-44dd-a5a6-d66cc7c9c79b"
      unitRef="usd">-47365000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTUtMS0xLTEtMA_7682c77b-4ea7-4c13-b558-078574790b91"
      unitRef="usd">-52415000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTUtMy0xLTEtMA_26db3b64-37e8-4624-8ca0-ac8798709c2f"
      unitRef="usd">-37629000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTgtMS0xLTEtMTk1OA_4d0510e9-b49d-417b-96a4-2ecaf23100c4"
      unitRef="usd">37000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTctMS0xLTEtMA_2c65c997-3fb2-401c-9f86-8f0b0b8e4f23"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTctMy0xLTEtMA_f1f7078e-9c5b-4344-b866-dcaf5fcccbd8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTktMS0xLTEtNDQy_82855d4b-69a2-4caf-be8b-2fef454c0769"
      unitRef="usd">37000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTgtMS0xLTEtMA_660a7b46-e547-4345-b0d2-dc29f9d2484e"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTgtMy0xLTEtMA_c9497007-44b0-47b4-8d91-d079e5d960d7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjAtMS0xLTEtNDQy_d7abdc0d-404d-426f-ab79-344d468ae62f"
      unitRef="usd">-47328000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTktMS0xLTEtMA_5fa9b221-c1a9-4cc8-a5f5-9660329f79dd"
      unitRef="usd">-52413000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMTktMy0xLTEtMA_4213d119-92ee-441d-9e32-4c54ab3d06a9"
      unitRef="usd">-37629000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjEtMS0xLTEtMTk1OA_d58108fa-4b89-4615-a10f-55fd9c46d52f"
      unitRef="usdPerShare">-1.44</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjAtMS0xLTEtMA_878d5131-1b7d-49b3-8a33-687506fce9af"
      unitRef="usdPerShare">-2.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjAtMy0xLTEtMA_d73e595a-e264-4836-bf7c-24f6c295835c"
      unitRef="usdPerShare">-39.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjItMS0xLTEtMTk1OA_2058f712-9ffc-4ffe-9bcb-056a768eab59"
      unitRef="shares">32965539</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjEtMS0xLTEtMA_38c88b8d-f7a0-40d2-b09a-af75201f6d17"
      unitRef="shares">22956679</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82MS9mcmFnOjU4NzhjODUxZWYwZjQ3ZWQ4N2VmOWEwZDllMjg0MDljL3RhYmxlOjIwYjVkODg0MmI4MTRkMTdhOWVjNjA4NjExMGU1MjUyL3RhYmxlcmFuZ2U6MjBiNWQ4ODQyYjgxNGQxN2E5ZWM2MDg2MTEwZTUyNTJfMjEtMy0xLTEtMA_0180b0e4-f537-40f7-8689-d18bf19726cb"
      unitRef="shares">960882</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i309aa475c33d46f1bcb008fc1f8ff1b4_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMS0xLTEtMA_6dc47b9e-61d7-422b-bdb5-6355f6664ee1"
      unitRef="shares">21233190</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i309aa475c33d46f1bcb008fc1f8ff1b4_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMy0xLTEtMA_c598980a-dd1a-4922-8e95-bba1627af814"
      unitRef="usd">105235000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="iab4311acf1a24c2d80c7837fb213c678_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtNi0xLTEtMA_b7a5b46d-2fcf-45b5-8bd3-ba9bd7dee898"
      unitRef="shares">663270</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab4311acf1a24c2d80c7837fb213c678_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtOC0xLTEtMA_f968fff8-5578-4605-aa19-2c2a7dfc5364"
      unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad606b34524243b1a8e5075ac03d3736_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTAtMS0xLTA_cf803ec3-3952-476c-be5e-372f51d6c1f1"
      unitRef="usd">2977000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29b884248218456fa51f8f0609280bfe_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTItMS0xLTA_c580caaa-9146-4958-8b29-858547ea2411"
      unitRef="usd">-101556000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9001a76c96354d44be43663ad10864e5_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTQtMS0xLTA_d1232b28-b883-4e61-b6a2-5fc74966004e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cd1291d3588454f997c52cc2495c69d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTYtMS0xLTA_8d903a8a-4423-435c-a34d-2aa25c91a281"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTUtMTgtMS0xLTA_8cc3369a-e795-4767-8b01-f91e9c82f0a9"
      unitRef="usd">-98578000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8c754289625a475e91ebf3960393d1df_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTYtNi0xLTEtMA_6a17ad43-e2e8-4f05-b049-e2dd1d1c8096"
      unitRef="shares">438578</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic8b0757eda174b29929c9539b4972205_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTYtMTAtMS0xLTA_7a3ffec8-a585-4867-a146-3b7034774bdb"
      unitRef="usd">656000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTYtMTgtMS0xLTA_c8a443aa-2000-41a9-b0f1-6277a34f4967"
      unitRef="usd">656000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="ic8b0757eda174b29929c9539b4972205_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTctMTAtMS0xLTA_8c329463-997c-498d-909c-7f67baa81cb7"
      unitRef="usd">911000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTctMTgtMS0xLTA_d88a628d-28c9-43d6-873a-1e971baad335"
      unitRef="usd">911000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i55d9057d66f44539a8d04ef9162bb079_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTktMTYtMS0xLTA_8fcfc5b0-4163-4579-b325-24820ffaf216"
      unitRef="usd">1000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMTktMTgtMS0xLTA_28256cd5-5e8f-4e38-ad4f-4785f77c21e9"
      unitRef="usd">1000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i8c754289625a475e91ebf3960393d1df_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjAtNi0xLTEtMA_90072b5a-d96f-481c-a779-c21fcafa5dff"
      unitRef="shares">33462</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjAtMTgtMS0xLTA_f4bbdc27-881d-4247-a609-9acfcdf64d49"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ce8733a67e34fdbb3a3c3db64b74607_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjEtMTItMS0xLTA_586d9086-57bc-4712-b595-dde6e4fe97e7"
      unitRef="usd">87000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52336bc12b324590bba4f1ab5687f560_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjEtMTgtMS0xLTA_e9638a42-c843-4bca-93bc-be801222cd33"
      unitRef="usd">87000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22ad6abb0fc2410f8d14252857b9b662_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjItMTAtMS0xLTA_bfcb6fe5-686c-42f2-b789-7af1957a9f5c"
      unitRef="usd">13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a224585ac174008bad3bf2831eec2f0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjItMTItMS0xLTA_445c835e-8605-4fc2-b6b2-cfc19bcd82b8"
      unitRef="usd">-13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61c86486a74044d0b4999de7a19e56b8_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjItMTgtMS0xLTA_76f05786-8296-4114-b250-08237a9179d1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c78658e347043038c35c1cacd0e7415_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjMtMTItMS0xLTA_1942bb50-b273-4a1f-af26-0b270cb087ad"
      unitRef="usd">-37629000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i55d9057d66f44539a8d04ef9162bb079_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjMtMTYtMS0xLTA_57c2ca89-eddb-4df1-bb9d-59750458a5b4"
      unitRef="usd">-1000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjMtMTgtMS0xLTA_aa8ed86d-9b1a-4098-ad7c-d157206fcdba"
      unitRef="usd">-37630000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i9452f0bca2304c67ac02c051e36f8823_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMS0xLTEtMA_a035de72-b794-4230-93c0-4eac01a4ea20"
      unitRef="shares">21233190</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9452f0bca2304c67ac02c051e36f8823_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMy0xLTEtMA_007871f3-f3c3-4aa9-93f7-00288fe35861"
      unitRef="usd">105235000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="ib95c642c97784f95b54de6ac4683cf00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtNi0xLTEtMA_2dac167d-371d-41fe-bbef-96d457b1aa8b"
      unitRef="shares">1135310</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib95c642c97784f95b54de6ac4683cf00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtOC0xLTEtMA_011feaca-3a2e-4c84-96f2-46c9597ef77d"
      unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5363da9b40b8433589b18ba5d4349ec4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTAtMS0xLTA_c08a7a95-e288-437a-8da2-f92b98ff2402"
      unitRef="usd">4557000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i168f9b03b66f4d37bb7151521137ed70_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTItMS0xLTA_add8e822-abd0-4a40-873c-2f2a5a49ff62"
      unitRef="usd">-139111000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i268ced4ae9024a918193193003914ad4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTQtMS0xLTA_a38285e4-b868-43ad-a687-974a0269f7d2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie206f45400684e03b789ee66287deddc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTYtMS0xLTA_81c0f660-f539-4e73-8afe-09b956fd0c97"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjQtMTgtMS0xLTA_d36efe67-5f6c-4202-91bc-53fb72dc7688"
      unitRef="usd">-134553000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="iad40d41effba4a3785f2f35c5cc9b839_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjUtMS0xLTEtMA_80ea311f-50ae-46d4-b345-0a0dbaff74fd"
      unitRef="shares">292361</silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="iad40d41effba4a3785f2f35c5cc9b839_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjUtMy0xLTEtMA_281008e2-7b4d-4402-a908-60deed68a8ea"
      unitRef="usd">1784000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjYtNi0xLTEtMA_4765e639-547a-4c02-bb6f-f43f76e75bb6"
      unitRef="shares">3764</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjYtMTAtMS0xLTA_06340415-3872-4610-b143-d10c7e849802"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjYtMTgtMS0xLTA_fa130500-c7c2-43ed-aa87-e9e2202ddeb3"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="icd4f40364954436caf47b6d23cb6d6e4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQxNTE3MDZlZjAxNzRiZmQ4MDgyODQ5OGViODM3ZjBkXzE2NDkyNjc0NDE3ODM_223c44dc-1258-4b2d-a401-f9393d88d0f7"
      unitRef="usd">10961000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctNi0xLTEtMA_ff9623e2-aaaa-4086-9bd6-713113bbf4d0"
      unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctOC0xLTEtMA_684a035d-4bf9-4d18-b85c-72437563f988"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2f23accfdbc34e51924d5a95ddcb0253_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctMTAtMS0xLTA_a8935bed-116b-4363-b7ce-4e7a49e3ca30"
      unitRef="usd">109113000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icd4f40364954436caf47b6d23cb6d6e4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjctMTgtMS0xLTA_aefb17b9-eb12-447b-9510-44cfa3178094"
      unitRef="usd">109119000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares
      contextRef="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtMS0xLTEtMA_fb737128-3c09-40f2-aa80-ba635ddb227f"
      unitRef="shares">23178555</silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares>
    <silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue
      contextRef="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtMy0xLTEtMA_651e78d5-cbf6-4825-bc4e-fa79bb7ff65a"
      unitRef="usd">144140000</silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtNi0xLTEtMA_30e52158-c5a1-4a96-854a-5586d0b03239"
      unitRef="shares">23178555</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtOC0xLTEtMA_8134e888-329b-45b2-a8cd-f0fc8c14d47b"
      unitRef="usd">23000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i2f23accfdbc34e51924d5a95ddcb0253_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtMTAtMS0xLTA_c7b6abcf-c8a3-4671-a410-97996098a1e1"
      unitRef="usd">144117000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="icd4f40364954436caf47b6d23cb6d6e4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjgtMTgtMS0xLTA_c5a731da-a3df-48da-9b3a-a2e1e41210c0"
      unitRef="usd">144140000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjktMS0xLTEtMA_9333d810-cf6f-45e3-9a70-04a2ac3aaefc"
      unitRef="shares">1653004</silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="ibad2310f53cd4f459651e7786c382daa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMjktMy0xLTEtMA_f687fc03-3de4-4b28-928a-a5dccb952787"
      unitRef="usd">37121000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <silk:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="ia848f1dbee4541a4a86af1767b3bb4bf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzAtNi0xLTEtMA_0ac58aca-44af-4e0c-9773-d17e2adebeab"
      unitRef="shares">2204</silk:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzEtNi0xLTEtMA_d39f5bdc-41d4-498c-b480-659d0e07abea"
      unitRef="shares">873786</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzEtOC0xLTEtMA_e2e6305c-1f43-4575-81c3-2b29cd70637d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzEtMTAtMS0xLTA_72f2a593-5939-4e2f-884a-e8ec1df026b9"
      unitRef="usd">1541000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzEtMTgtMS0xLTA_758bb789-d6f9-473e-8cdb-ae5e38b6ac1d"
      unitRef="usd">1542000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia478d162c54e4e14a020c87c047b1f39_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzItNi0xLTEtMA_b90c559b-2f59-495f-95b2-8a976dac7e0c"
      unitRef="shares">61648</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzItMTAtMS0xLTA_9f6a3b9e-4a19-4dcb-992d-40070983f000"
      unitRef="usd">1048000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzItMTgtMS0xLTA_63d03419-dda5-47fd-bf4f-50944d16c04c"
      unitRef="usd">1048000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i34ee7a5d8893480face076dc0bce4809_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzMtMTAtMS0xLTA_5f6f33c8-180d-4367-8aa0-b59365072adb"
      unitRef="usd">2977000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzMtMTgtMS0xLTA_645b112d-b083-4110-9907-0511a14572a3"
      unitRef="usd">2977000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="ia65d3e7d28b94209a448cb72c6adae4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzUtMTItMS0xLTA_e2ea8f03-c234-43bc-ad3c-755a7ef7ff48"
      unitRef="usd">-52415000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzUtMTgtMS0xLTA_a7038c84-d3cd-436b-8438-9d35002a493e"
      unitRef="usd">-52415000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i8990e088bd584d108b3b67f167d02e78_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMTQtMS0xLTA_c8c284a7-7ecb-4c09-85c5-8dd9fae45e85"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMTgtMS0xLTA_07df0bc6-a6d3-4ccd-b142-37d7306e2f36"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i8c4d9ba8d16c449c80e25e34837c0084_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMS0xLTEtMA_3b2c5cca-85f8-4325-8f5b-e3d69ff48d19"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i8c4d9ba8d16c449c80e25e34837c0084_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMy0xLTEtMA_457a5c6a-1cbd-4195-95d1-f142cc65e8c0"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i4a7ee782a5ac4726825924882652fb3b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctNi0xLTEtMA_3b3383ae-cec9-4aa2-ac52-23648dcc24b8"
      unitRef="shares">31255267</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a7ee782a5ac4726825924882652fb3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctOC0xLTEtMA_94e04dba-e0a8-4ea5-9f06-72e6b90fdcc2"
      unitRef="usd">31000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i864f0448c9b44f6abc0aa0fc934ca527_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTAtMS0xLTA_baafc4c5-0a5a-4dbd-b965-4cd2a32a3ff8"
      unitRef="usd">263384000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ed96d628e884154a23064db50466351_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTItMS0xLTA_a522d20e-fa4c-40e5-bf8d-5761b9a8b3a4"
      unitRef="usd">-191526000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f0db448912c4166941130ebb1e99a3a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTQtMS0xLTA_827bc1d1-350c-417b-95c3-675774c3174e"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f8aa68dc9bd43a0878ae2aa5eaa1801_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTYtMS0xLTA_c35d187c-607f-4843-88da-b3fea9177687"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTgtMS0xLTA_0cc8e3a2-614a-4fbb-97f4-27679e779db2"
      unitRef="usd">71891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMC0xLTEtNTEwL3RleHRyZWdpb246NDc4ODgyODZjN2I0NDZiYmI4YzU0ZDE1NTgwOTMzY2VfMTY0OTI2NzQ0MTc5NA_ac225780-88c9-45ff-a924-93bdb91d6d03"
      unitRef="usd">4457000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtNi0xLTEtNTE3_179c21a7-29e1-4e02-ab47-449c5ad4fd1f"
      unitRef="shares">1923076</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtOC0xLTEtNTE3_66718621-5e83-4aa8-a9fc-b837e9c25d48"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMTAtMS0xLTUxNw_ccd26bc6-293d-445c-aee7-4629259e568d"
      unitRef="usd">70541000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzYtMTgtMS0xLTUxNw_fa9aaa96-4289-4621-a02a-1a17cc19ba3a"
      unitRef="usd">70543000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctNi0xLTEtNTE3_293fc076-8b68-4d91-a7b1-9581d40822b2"
      unitRef="shares">1018779</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctOC0xLTEtNTE3_3cb16b0e-4193-4ad0-907a-82d9ab467b10"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTAtMS0xLTUxNw_5ae395dc-56cd-41d4-8efc-8783cce4f764"
      unitRef="usd">3486000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzctMTgtMS0xLTUxNw_bce9a7ec-27d8-436f-a379-a75973b5ea17"
      unitRef="usd">3487000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8248d3e0f7844e22a50a99b0f7e36a43_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzgtNi0xLTEtNTE3_6f0d9c25-8e45-4bbc-9578-148a2cac1a00"
      unitRef="shares">52527</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzgtMTAtMS0xLTUxNw_8fab0a58-a2ee-414b-9427-857c97e4efc0"
      unitRef="usd">1681000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzgtMTgtMS0xLTUxNw_b779417d-0ef2-4671-be9c-13cc973c54be"
      unitRef="usd">1681000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i7690a9daae7b474aa4ee8840b6fba358_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzktMTAtMS0xLTUxNw_28ae70c8-46af-4757-b8ea-27d1d04da767"
      unitRef="usd">7226000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfMzktMTgtMS0xLTUxNw_4a37af56-c09e-43a0-ae03-7cc8b7519ed7"
      unitRef="usd">7226000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="i4702b7d22d1a40a59e7c037cc5eef2a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDAtMTItMS0xLTUxNw_2c16f0d9-7594-4e1e-84b1-8bd722640b7e"
      unitRef="usd">-47365000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDAtMTgtMS0xLTUxNw_1f617f21-457d-46cf-8a7c-cca24dffe999"
      unitRef="usd">-47365000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i9d7ed4748adc465582c5b79aad061342_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDEtMTQtMS0xLTUxNw_b56ce339-11ed-4b44-b4e4-4985eec10b89"
      unitRef="usd">37000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDEtMTgtMS0xLTUxNw_c370f543-d852-4982-adbc-ad1f17024673"
      unitRef="usd">37000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i0886aab4e9464bd081f28baaadbc2c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMS0xLTEtNTEz_c22bd362-4b26-4d84-bbc7-246a0b7268d7"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i0886aab4e9464bd081f28baaadbc2c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMy0xLTEtNTEz_28eb3276-3005-4923-8298-aead1efbfb98"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i79caa187be2c4546967d3d07d999a1f2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItNi0xLTEtNTE3_192f8f78-ef32-49c0-93fc-8edabe283b35"
      unitRef="shares">34249649</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79caa187be2c4546967d3d07d999a1f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItOC0xLTEtNTE3_6b002963-eacf-47d8-914e-75fe9fb24e72"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i82f9aab73bb74d4eb978e25668f669a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTAtMS0xLTUxNw_aab952c1-e68c-4da2-a7f3-6d1eb38215e7"
      unitRef="usd">346318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35b094dd513647c39d1b0a77a875ab5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTItMS0xLTUxNw_82b2be47-2240-4cfb-99db-46cb87fee6b1"
      unitRef="usd">-238891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0693226ab445409dac81b6a1a31b8e74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTQtMS0xLTUxNw_7ca6c958-37f9-4e77-8b7d-4c8ad5e1c840"
      unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbe3473f98e7473a96d28715e29fab03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTYtMS0xLTUxNw_c2182c4f-0b6a-4397-be98-e5c75c72fbbc"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl82Ny9mcmFnOjBjMDY2NTYyNDFmMDQxMmFiYzVhNzU2NjBhMzFjZTQwL3RhYmxlOmE0OGVkZDBjMWMwMjQyNmJhODZiNTU4MjAzMWYwMGYzL3RhYmxlcmFuZ2U6YTQ4ZWRkMGMxYzAyNDI2YmE4NmI1NTgyMDMxZjAwZjNfNDItMTgtMS0xLTUxNw_2bd41c1a-70d7-4715-9d5e-91ee9a2a2ffa"
      unitRef="usd">107500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMy0xLTEtMS0yNDcx_e86b9774-aaa1-492a-a0b5-fbdf98eaad18"
      unitRef="usd">-47365000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMy0xLTEtMS0w_ffe4e115-0021-4df2-bd02-314fc0db5ce1"
      unitRef="usd">-52415000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMy0zLTEtMS0w_6c297243-c0ec-4a12-abb7-5e4ce29f19f4"
      unitRef="usd">-37630000</us-gaap:ProfitLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNS0xLTEtMS0yNDc1_46652e5f-fa28-463c-9085-f6119bacd39c"
      unitRef="usd">789000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNS0xLTEtMS0w_7e530f2f-e623-4a68-9c46-5a859a286f2d"
      unitRef="usd">712000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNS0zLTEtMS0w_ec7bfa2f-2adf-45f9-90dc-2b44f83d28b5"
      unitRef="usd">517000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNi0xLTEtMS0yNDc1_f803d35d-ed05-4f77-b145-89fcf22eaff5"
      unitRef="usd">7226000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNi0xLTEtMS0w_3996060f-2b06-4b14-bc79-9b8a24fbe5ca"
      unitRef="usd">2977000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNi0zLTEtMS0w_5e31f0b8-6367-4e1e-9a9c-9192d5f59289"
      unitRef="usd">911000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNy0xLTEtMS0yNDc1_84573b5b-5fc4-4d28-8704-a0a5db5d5fe6"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNy0xLTEtMS0w_3dc66c01-ed2e-4302-9d64-da58004d44e0"
      unitRef="usd">21030000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNy0zLTEtMS0w_2fb1edb8-40a4-402b-ab36-415bae8f96d7"
      unitRef="usd">11906000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOC0xLTEtMS0yNDc1_f893494d-bcba-4999-acfc-4e5f36b0e41a"
      unitRef="usd">-304000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOC0xLTEtMS0w_e2a4110f-211d-45bf-a6ac-737a90d71db5"
      unitRef="usd">309000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOC0zLTEtMS0w_cd2ab901-3675-4d4f-ab66-9bd3ebbf709e"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOS0xLTEtMS0yNDc1_bfa86aa0-9975-4b33-91cf-e72c9e93d2c8"
      unitRef="usd">66000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOS0xLTEtMS0w_16b1a176-0bee-44fe-86a1-02109cbef904"
      unitRef="usd">46000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfOS0zLTEtMS0w_8a78fc40-3a3e-4dd4-94c3-e8d5f53d2c73"
      unitRef="usd">68000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTAtMS0xLTEtMjQ3NQ_a9e1fb95-9794-431f-bd81-30f8fb4d080e"
      unitRef="usd">602000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTAtMS0xLTEtMA_32db6623-362c-47bc-978e-b3f5a29730ff"
      unitRef="usd">582000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:PaidInKindInterest
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTEtMS0xLTEtMjQ3NQ_4cb8f5fe-bab2-4816-bdf4-729edf1fedfa"
      unitRef="usd">241000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTEtMS0xLTEtMA_ce428221-c73f-4b86-8207-fb4000b51eab"
      unitRef="usd">672000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTEtMy0xLTEtMA_d878aa96-7fd4-483b-b1ea-e99dc9901205"
      unitRef="usd">1555000</us-gaap:PaidInKindInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItMS0xLTEtMjQ3NQ_acde8203-2c7c-4163-b646-ecb9c3175a1f"
      unitRef="usd">-1119000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItMy0xLTEtMjQ3OQ_dba02469-d58e-4755-aa54-0e3c3a04516b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItNS0xLTEtMjQ3OQ_6d7b09ab-9953-4402-bb8b-f1ecae4da7c2"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTQtMS0xLTEtMjQ3NQ_474059fa-5ace-4629-84ce-add9e11c761f"
      unitRef="usd">-52000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItMS0xLTEtMA_c6062a57-d83b-436f-8a80-a18f2aaf1506"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTItMy0xLTEtMA_30ef1f95-d5fb-401a-89d3-bcc5bd50d251"
      unitRef="usd">-159000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTUtMS0xLTEtMjQ3NQ_a5886554-3aee-4fbc-a5fd-570cb8ac8818"
      unitRef="usd">-32000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTMtMS0xLTEtMA_0ab1926b-c4f2-4430-8811-51239542455d"
      unitRef="usd">23000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTMtMy0xLTEtMA_4531a074-3246-4250-83b4-c70e2f5ebfc2"
      unitRef="usd">-123000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryWriteDown
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTYtMS0xLTEtMjQ3NQ_3ed2aca4-4d15-4124-b58d-213e8514e218"
      unitRef="usd">117000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTQtMS0xLTEtMA_3e6b4640-a8e1-421f-b485-b5542bb8be39"
      unitRef="usd">118000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTQtMy0xLTEtMA_fef8f03f-e2a5-42c7-ab5b-21e7de0773b7"
      unitRef="usd">23000</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTgtMS0xLTEtMjQ4NQ_7d7625b6-2020-40c3-8446-c1f7e8d11f8c"
      unitRef="usd">437000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTYtMS0xLTEtMA_f8216878-a31b-4a7c-9ef8-b24f42b72a3d"
      unitRef="usd">2241000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTYtMy0xLTEtMA_c7870cab-bfdf-4269-927c-6b1d4e131ff3"
      unitRef="usd">446000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTktMS0xLTEtMjQ4NQ_063ae58c-5362-42a0-8c5d-d1bec9d88975"
      unitRef="usd">2161000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTctMS0xLTEtMA_f26f260e-e062-4dcf-b564-38176087e9d1"
      unitRef="usd">4696000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTctMy0xLTEtMA_75febab3-d701-454f-9c53-86cf4f17b5e9"
      unitRef="usd">2565000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjAtMS0xLTEtMjQ4NQ_4b01b26c-4462-4d60-a88b-f5e4167c552e"
      unitRef="usd">-250000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTgtMS0xLTEtMA_620bdcab-5f62-4d9f-a6bf-c3ad4c3717a5"
      unitRef="usd">1471000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTgtMy0xLTEtMA_683cd6a8-1399-41e1-b47c-4f0377b4c864"
      unitRef="usd">1128000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjEtMS0xLTEtMjQ4NQ_17419e06-997d-40b5-af7b-3ced761f7ead"
      unitRef="usd">-210000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTktMS0xLTEtMA_3edcd164-645a-4ca2-aaf8-22eaec8eea3b"
      unitRef="usd">-552000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMTktMy0xLTEtMA_15059aba-9b47-41bf-8f30-cea827f935ec"
      unitRef="usd">62000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjItMS0xLTEtMjQ4NQ_f7fff9ac-5030-4178-8759-03a3d1da0509"
      unitRef="usd">592000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjAtMS0xLTEtMA_0c4969ac-27f4-49cf-b0a3-bea245e34dca"
      unitRef="usd">615000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjAtMy0xLTEtMA_4d95bb6b-424b-4e32-b071-bc285883277c"
      unitRef="usd">-309000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjMtMS0xLTEtMjQ4NQ_91b13b4c-e1d6-4fe1-8fea-6b35093995c7"
      unitRef="usd">146000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjEtMS0xLTEtMA_c82e5665-c5fa-49f4-93ef-2b01d77e8033"
      unitRef="usd">4964000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjEtMy0xLTEtMA_ed0629a4-74e6-4a24-bd5f-a9840d3d11ae"
      unitRef="usd">5023000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjQtMS0xLTEtMjQ4NQ_48a5754d-318f-4ea8-9086-c40dc0cd0df5"
      unitRef="usd">26000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjItMS0xLTEtMA_3311d7a6-70ea-4e6b-9397-1fae4b435eba"
      unitRef="usd">-769000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjItMy0xLTEtMA_ec7e35a7-a068-47f2-a56c-e28848a1eb1a"
      unitRef="usd">406000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <silk:RepaymentOfPaidInKindInterest
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjQtMS0xLTEtNzc4Ng_c91f01c7-fbc8-4c0a-b0d7-9832af59a808"
      unitRef="usd">3813000</silk:RepaymentOfPaidInKindInterest>
    <silk:RepaymentOfPaidInKindInterest
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjQtMy0xLTEtNzc4Ng_705d11c0-8c01-4b33-aa3d-66c0df9c4ef4"
      unitRef="usd">0</silk:RepaymentOfPaidInKindInterest>
    <silk:RepaymentOfPaidInKindInterest
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjQtNS0xLTEtNzc4Ng_a98a46bf-5c8d-4157-8290-c477c0b77545"
      unitRef="usd">0</silk:RepaymentOfPaidInKindInterest>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjMtMS0xLTEtNTIy_75907d8b-a958-42a8-8b57-dce160b70f0a"
      unitRef="usd">-42068000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjMtMS0xLTEtMA_722d6577-ca8a-4bdb-b60c-e269fdaa7083"
      unitRef="usd">-29610000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjMtMy0xLTEtMA_2eff823e-e9e7-44f5-a90c-d63890238a76"
      unitRef="usd">-21695000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjctMS0xLTEtMjQ5Mw_084b7a28-b9aa-41f6-9a5a-cac2c9d6613c"
      unitRef="usd">842000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjUtMS0xLTEtMA_ae7cfa70-a2ce-48cb-bfdc-c94b417bf291"
      unitRef="usd">535000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjUtMy0xLTEtMA_64567c06-f584-4c6e-a5cb-3b1fefb73a15"
      unitRef="usd">2276000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjgtMS0xLTEtMjQ5Mw_cc2085bf-17b9-40c3-9b2f-d878f1d920e5"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjYtMS0xLTEtMA_aa553bf8-3f51-4e28-92aa-b5b1ec176bfb"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjYtMy0xLTEtMA_ed928f6e-4c13-4b4b-b338-9ded67a37110"
      unitRef="usd">6000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjktMS0xLTEtMjQ5Mw_01675c5f-436b-43ff-b71b-b22b21c214a1"
      unitRef="usd">79906000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjctMS0xLTEtMA_1e374267-5bfb-4e8d-bb09-320d0b06c1ea"
      unitRef="usd">69421000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjctMy0xLTEtMA_89f0b691-7ac4-483a-a888-7d48e00115de"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtMS0xLTEtMjQ5Mw_822c4946-ca88-4d6e-9ded-62be5892d519"
      unitRef="usd">71355000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtMy0xLTEtMjQ5Nw_92c19cca-591f-4d82-80a8-9d1e7fb975a5"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtNS0xLTEtMjQ5Nw_aabf70b1-7da9-40b0-824b-4ed33a73af1f"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjgtMS0xLTEtNTI2_48154048-4e94-487b-825b-5539e5bd21f6"
      unitRef="usd">-9393000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjgtMS0xLTEtMA_ae62c984-164d-4d88-ab61-2454d5eb27cb"
      unitRef="usd">-69956000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMjgtMy0xLTEtMA_13336a7d-5da8-4115-a46e-f10d9980e05f"
      unitRef="usd">-2270000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzMtMS0xLTEtMjUwMg_653a6281-d894-4d80-9911-cd4ea00e366b"
      unitRef="usd">70568000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtMS0xLTEtMA_6f093f9a-4e7b-4dbf-86d6-fb98fe128558"
      unitRef="usd">109352000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzAtMy0xLTEtMA_b860ed83-b1aa-445f-94b9-34514a9bcf73"
      unitRef="usd">-233000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzQtMS0xLTEtMjUwMg_9eefe07d-1136-448b-947a-2f1aeba07908"
      unitRef="usd">48506000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzEtMS0xLTEtMA_9672601d-294c-4b88-aba8-f9415f80b8a3"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzEtMy0xLTEtMA_01d74817-9442-4ed2-9ee5-be3dd2729904"
      unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzUtMS0xLTEtMjUwMg_fc1bcfc8-bf7a-40a2-bce5-31fd475a52c6"
      unitRef="usd">5168000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzItMS0xLTEtMA_9dda1eb6-e358-4b53-a54c-c1e7a44335b6"
      unitRef="usd">2590000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzItMy0xLTEtMA_32e8dd0b-2b4e-443c-a6fd-698abd1ce698"
      unitRef="usd">656000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i027bc0bdf8734670ba15f197c3fa9de7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzYtMS0xLTEtMjUwMg_8924e7ae-8fa0-4008-aeef-a82677c05020"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="if5b505ad720547b7906b11f5bbf2fbdb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzMtMS0xLTEtMA_a62d554d-7af5-4159-abd9-07b876339cd1"
      unitRef="usd">1784000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i73fdcaf51beb4164910ff49230c96c68_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzMtMy0xLTEtMA_61318440-6dac-49c2-9967-fa13709126cc"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i5ea0497ce3b1475f81a9c6c00b0c512b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzctMS0xLTEtMjUwMg_9690c31b-f266-44d7-b6ff-663bec85b268"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i32dc6dca82f54b3997404bec4ab31270_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzQtMS0xLTEtMA_1e7d5811-6c29-484a-8798-d9bb2a2efa8e"
      unitRef="usd">31000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="if7c87ccb914d486b82d6cfe0e26711e6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzQtMy0xLTEtMA_351c88aa-ca16-4d4e-a891-6958e3d30dd1"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMS0xLTEtMjUwMg_5da56f69-de4b-472d-b8db-d55dc7e6d7b5"
      unitRef="usd">40000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMy0xLTEtMjUwNg_e6e57df7-4f1e-4a64-949b-1f114cce6602"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtNS0xLTEtMjUwNg_85201000-5145-45ef-84ad-f3b9e9ea7d85"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMS0xLTEtMjUwMg_1f735d8e-65ae-46a2-8957-93f6580ab936"
      unitRef="usd">2496000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMy0xLTEtMjUwNg_fb2116bc-b614-4ee2-96cd-ef78166825fe"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktNS0xLTEtMjUwNg_d3014f1c-1fcd-4a67-af22-294bc346139a"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDAtMS0xLTEtMjUwMg_35d49bd5-48ac-4095-86f0-ca7dddcacd3e"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzUtMS0xLTEtMA_ce39fb58-5c5c-4c4d-9976-c51af23b1737"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzUtMy0xLTEtMA_963226b9-a776-43d9-8667-faf4ee367306"
      unitRef="usd">1000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzYtMS0xLTEtNTMw_4ee4bb1e-09fd-479a-a045-f8e0572bfe53"
      unitRef="usd">81746000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzYtMS0xLTEtMA_22ec9c7f-d84e-4aad-8a18-c1e209a88841"
      unitRef="usd">113757000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzYtMy0xLTEtMA_fbcad84d-f303-477c-9661-4be60f5cb063"
      unitRef="usd">15424000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzctMS0xLTEtNTMw_982cf9f5-8601-459c-b705-fcd65128dbc2"
      unitRef="usd">30285000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzctMS0xLTEtMA_6c767b2b-209c-465c-901e-9fb5608c5136"
      unitRef="usd">14191000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzctMy0xLTEtMA_614e3162-83fb-480f-96ec-b6ec235a8318"
      unitRef="usd">-8541000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMS0xLTEtNTMw_acf86725-e946-466f-aac6-75af06ba8b93"
      unitRef="usd">39491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMS0xLTEtMA_b522d706-767b-44dd-892f-ceaa51d5de1d"
      unitRef="usd">25300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzgtMy0xLTEtMA_17625b7f-4bf1-49fd-aadd-d839eed6529f"
      unitRef="usd">33841000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMS0xLTEtNTMw_d56168a5-60c0-4087-91e6-ea254b8da240"
      unitRef="usd">69776000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMS0xLTEtMA_db749c37-0e46-4da4-accf-dfebb1f7ab97"
      unitRef="usd">39491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfMzktMy0xLTEtMA_16a38968-eb84-41f5-9bd1-c8197c5e9a9e"
      unitRef="usd">25300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDEtMS0xLTEtNTM0_a16a831d-38ac-4de3-ba3b-eea6218ef483"
      unitRef="usd">7917000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDEtMS0xLTEtMA_06b746b9-33eb-4381-998f-75923ade5288"
      unitRef="usd">4234000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDEtMy0xLTEtMA_94f4308e-ec25-4906-a65c-3c285cd82c41"
      unitRef="usd">2738000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDMtMS0xLTEtNTM4_05ce1c6d-6356-407c-9c74-d4616c921e99"
      unitRef="usd">108000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDMtMS0xLTEtMA_7a500a88-e758-4574-bc5c-91759666a0d7"
      unitRef="usd">32000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDMtMy0xLTEtMA_d472dfd5-6f4e-41d3-bc11-52527d0d4777"
      unitRef="usd">6000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDQtMS0xLTEtNTQy_3545ec05-7254-4d0e-8407-2ffbb544002e"
      unitRef="usd">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDQtMS0xLTEtMA_73ad0f3a-06b9-475f-88f0-963ceb9b109d"
      unitRef="usd">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDQtMy0xLTEtMA_95da0f9f-0b5b-4d84-a79d-d244952a5bb7"
      unitRef="usd">794000</us-gaap:PaymentsForTenantImprovements>
    <silk:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDUtMS0xLTEtNTQ2_160e6559-da38-4624-854c-f1f78e8db277"
      unitRef="usd">25000</silk:StockIssuanceCostsIncurredButNotYetPaid>
    <silk:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDUtMS0xLTEtMA_87dbd689-b39c-41a2-b443-20d6524dbec6"
      unitRef="usd">0</silk:StockIssuanceCostsIncurredButNotYetPaid>
    <silk:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDUtMy0xLTEtMA_0d4617f3-9150-4ffc-a06c-ff431ff09a72"
      unitRef="usd">717000</silk:StockIssuanceCostsIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDYtMS0xLTEtNTUw_5148c29e-bc8d-4374-a8d7-9fd7f818d851"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDYtMS0xLTEtMA_d968ad99-9e79-419e-aa2a-32d69f10bbcf"
      unitRef="usd">3982000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDctMS0xLTEtNTUw_036df761-aeb9-4db5-b3ad-e4363760a9fc"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDctMS0xLTEtMA_208940f8-fae4-422e-92e5-d117be5f9d4e"
      unitRef="usd">37121000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDctMy0xLTEtMA_1087b670-d1e9-4f0d-bff1-11996597ba23"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDgtMS0xLTEtNTUw_5b3e06bf-ff06-46e7-b252-e48f0e68b1da"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDgtMS0xLTEtMA_9361fde6-31ec-4ed2-9869-d49dc9676817"
      unitRef="usd">144140000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83My9mcmFnOjBmOWJlY2Y5ZjUzNTQyYzg5MTU2NDFiY2Y4ZDc5ZjgzL3RhYmxlOjkyZTFkOGZkMTRiZTQwOThiZTc3YjY3ZDk5MDE4MmQ0L3RhYmxlcmFuZ2U6OTJlMWQ4ZmQxNGJlNDA5OGJlNzdiNjdkOTkwMTgyZDRfNDgtMy0xLTEtMA_85bced6d-1cc3-4a90-8678-81b68406c9c1"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMzQ4NA_d1a65aa4-fe99-4dea-b0c1-6468e9671557">Formation and Business of the Company &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Silk Road Medical, Inc. (the &#x201c;Company&#x201d;) was incorporated in the state of Delaware on March&#160;21,&#160;2007.  The Company has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke.  The Company&#x2019;s portfolio of TCAR products enable a new procedure, referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles.  The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.  The Company commercialized its products in the United States in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception.  As of December&#160;31, 2020, the Company had an accumulated deficit of $238,891,000.  The Company expects to incur losses for the foreseeable future.  The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; believes tha&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;t its cash and cash equivalents of $69,466,000 and available-for-sale investments of $78,016,000 at December&#160;31, 2020, as well as its expected revenues will provide sufficient funds to allow the Company to fund its planned current operations for the next twelve months from the issuance of these financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 13, 2019, the Company&#x2019;s Board of Directors approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a 1-for-2.7 reverse stock split of the Company&#x2019;s common stock and redeemable convertible preferred stock to be consummated prior to the effectiveness of the Company&#x2019;s planned initial public offering (&#x201c;IPO&#x201d;).  The reverse stock split was effected on March 27, 2019.  The par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split.  All the common stock, redeemable convertible preferred stock, stock options and warrants, and related per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Public Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, the Company issued and sold 6,000,000 shares of its common stock in its IPO at a public offering price of $20.00 per share, for net proceeds of approximately $109,119,000 after deducting underwriting discounts and commissions of approximately $8,400,000 and expenses of approximately $2,481,000. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock and the Company's outstanding warrants to purchase shares of common and redeemable convertible preferred stock were exercised, or automatically net exercised absent a prior election. The exercises resulted in the reclassification of the fair value of the related redeemable convertible preferred stock warrant liability to additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company completed a secondary public offering of 4,200,000 shares of its common stock sold by certain selling stockholders, and the exercise in full of the underwriters' option to purchase 630,000 additional shares of its common stock from certain selling stockholders, at a public offering price of $39.50 per share. The Company did not receive any of the proceeds from the sale of the shares of its common stock from the selling stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company completed an underwritten public offering of 6,808,154 shares of its common stock, of which 1,923,076 shares were offered for sale by the Company and the remaining 4,885,078 shares were offered for sale by certain selling stockholders, at a public offering price of $39.00 per share. &lt;/span&gt;&lt;/div&gt;The Company received cash proceeds of approximately $70,543,000 after deducting underwriting discounts and commissions of approximately $3,750,000 and expenses of approximately $707,000. Also, in May 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common stock from the selling stockholders.  The Company did not receive any of the proceeds from the sale of the shares of its common stock by the selling stockholders.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTA0OA_e462d0ae-4f34-40b4-a3c1-39657121e90e"
      unitRef="usd">-238891000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTE3Nw_668b6e53-0e95-4b43-8ca9-e4e34c8f7556"
      unitRef="usd">69466000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTIxOA_4a8d1d2a-2e03-4791-80be-4574a6ed6ff0"
      unitRef="usd">78016000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjMxMw_f9901ed5-a74d-4d46-aaed-62db5b3353f8"
      unitRef="shares">6000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0c12d1da942447109063cebb275e8ba0_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjM4NA_1f70cc6d-f7e1-4184-bf1d-25cc76e39e24"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjQzMg_8c31b4d6-3703-4a40-8b17-b6867830abb1"
      unitRef="usd">109119000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions
      contextRef="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjUwNw_49c4a40c-5491-4ad9-8e1c-f4534932448c"
      unitRef="usd">8400000</silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i23ee0fdc611048fcb17e8465f44063cd_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMjU0MA_fb7920aa-c5ae-4b44-94b9-873d0d31b3a3"
      unitRef="usd">2481000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie8b27155c8474ab98f936002ff227c64_D20190801-20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMzEwMg_8a7bf1d4-814e-455a-82aa-d4f5d78a9202"
      unitRef="shares">4200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie87e6a507693455e82f8b7d021987453_D20190801-20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMzIzNQ_519c26df-8ecf-4dda-bd8c-828f7f658b9b"
      unitRef="shares">630000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic360f0c60b9e4bd4a3301ef5a705c91f_I20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMzM0MQ_8e8d5003-185e-4ecb-9385-fa11cb955bcd"
      unitRef="usdPerShare">39.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iec4ce25ed9c841df9c17121f68205ba4_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjIzMg_8fc15e2a-e77c-4bbf-a07b-c5d202b56f80"
      unitRef="shares">6808154</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i0619a3b111784379874d71f11398ec42_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjIzNg_f914f44a-195c-4a32-94fc-90cbf2194498"
      unitRef="shares">1923076</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i856f24feae584b14a8bc751fcb0a507a_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI0MA_19b7b58a-ed30-42a0-a127-683aae4d071e"
      unitRef="shares">4885078</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ifa0280538aac42a28763dda42b85838a_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI0NA_18fe5e39-46ed-4594-bac3-ee6513bfa4c1"
      unitRef="usdPerShare">39.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI0OA_634740b8-6ed1-48cf-8f89-4d6ca0009eb3"
      unitRef="usd">70543000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions
      contextRef="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI1Mg_fe54ba88-8178-4ad1-8d03-8b468bb6b33d"
      unitRef="usd">3750000</silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI1Ng_c59640f8-241e-4332-9a85-a2a16235a691"
      unitRef="usd">707000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i293cdb37570b495eb43b970dd39b1361_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl83Ni9mcmFnOmYzNzRhYTE3MjI4MTQyY2E5YTdkOTlmZmE1YjdmY2M0L3RleHRyZWdpb246ZjM3NGFhMTcyMjgxNDJjYTlhN2Q5OWZmYTViN2ZjYzRfMTY0OTI2NzQ0NjI2MA_a41a33eb-4918-42ef-8242-da277373f86e"
      unitRef="shares">1021223</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODU_5aee194d-5fd6-4672-aaa5-8ddaa1df1a12">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Preparation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the coronavirus (&#x201c;COVID-19&#x201d;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2020 and 2019.  The carrying amounts of certain of the Company&#x2019;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020, the Company&#x2019;s cash equivalents are comprised of investments in money market funds and commercial paper.  As of December 31, 2019, the Company&#x2019;s cash equivalents are entirely comprised of investments in money market funds.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash as of December&#160;31, 2020 and 2019 consists of a letter of credit of $310,000 representing collateral for the Company&#x2019;s facility lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy.  Money market funds are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method. Realized gains and losses are included in earnings and are der&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ived for specific-identification method for determining the costs of investments sold and were insignificant for the year ended December 31, 2020 and 2019. Amortization of premiums and accretion of discounts are reported as a component of interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk, and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks related to public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#x2019;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#x2019;s revenue while the pandemic continues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable are due from a variety of health care organizations in the United States.  At December&#160;31, 2020 and 2019, no customer represented 10% or more of the Company&#x2019;s accounts receivable.  For the years ended December&#160;31, 2020, 2019 and 2018, there were no customers that represented 10% or more of revenue.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manufactures certain of its commercial products in-house.  Certain of the Company&#x2019;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis, a Cardinal Health Company (see Note 14 - Subsequent Events).  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#x2019;s financial position and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#x2019;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#x2019;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#x2019;s currently approved portfolio.  If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest.  The Company estimates allowances for doubtful accounts.  Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#x2019; financial condition.  The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected.  These specific allowances are reevaluated and adjusted as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;additional information is received that impacts the amount reserved.  During the years ended December 31, 2020, 2019 and 2018, the Company did not experience any material credit-related losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value.  Cost is determined using the first-in, first-out method for all inventories.  Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.  The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate.  The Company&#x2019;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements.  The estimate of excess quantities is judgmental and primarily dependent on the Company&#x2019;s estimates of future demand for a particular product.  If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The prepaid expenses and other current assets balance at December 31, 2020 included $4,160,000 associated with the Company's voluntary recall (see Note 14 - Subsequent Events). The amount relates to the replacement lots and other direct costs to be received from Cord&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost less accumulated depreciation or amortization.  Repairs and maintenance costs are expensed as incurred.  Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA3ODg_1daeb587-69ed-44f7-8b16-4ee5917c9839"&gt;three&lt;/span&gt; to five years.  Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset.  When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Public Offering Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specific incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No deferred offering costs were capitalized as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  As of December&#160;31, 2019, there were $950,000 of offering costs primarily consisting of legal and accounting fees that were capitalized in other non-current assets on the balance sheet of which $233,000 had been paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable.  If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount.  Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value.  The Company did not record any impairment of long-lived assets during the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  As a result of adopting ASC 842, the Company recorded an operating lease right-of-use ("ROU") asset of $3,982,000 included within other non-current assets and operating lease liabilities of $5,190,000 included within accrued liabilities and other liabilities on the balance sheet related to its facility lease, based on the present value of the future lease payments on the date of adoption.  The operating lease right-of-use asset also includes adjustments for prepayments and excludes lease incentives.  The adoption did not have an impact on prior periods or on the Company's statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The disclosure impact of the adoption of ASC 842 on the balance sheet was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjustments Due to ASC 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#x2019;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the statements of operations and comprehensive loss.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised. Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#x2019; equity. Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#x2019; equity on the balance sheet as events triggering the liquidation preferences were not solely within the Company&#x2019;s control. Upon the closing of the Company's IPO, all shares of convertible preferred stock then outstanding converted into an aggregate of 23,178,555 shares of common stock resulting in the reclassification of $144,140,000 from outside of stockholders&#x2019; equity to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC Topic 606,&#160;&#x201c;Revenue from Contracts with Customers.&#x201d;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of January 1, 2018, the date of adoption, the Company recognized the cumulative-effect of initially applying ASC 606 as an adjustment to decrease accumulated deficit by $87,000.  Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt"&gt;identify the contract(s) with a customer; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt"&gt;determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt"&gt;allocate the transaction price to the performance obligations in the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(v)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the Company recorded $71,000 and $102,000, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#x2019;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#x2019;s standard terms and conditions.&#160;&#160;The Company&#x2019;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For sales where the Company&#x2019;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#x2019;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectibility is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale.  As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short.  Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component.  The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of revenue&#160;in the&#160;statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on our balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manufactures certain of its portfolio of TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#x2019;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses research and development costs as incurred.  Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#x2019;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development.  Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses.  Additionally, research and development expenses include costs associated with our clinical studies including clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical Trials&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements.  The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses advertising costs as incurred.  Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items.  Advertising costs of $194,000, $362,000 and $186,000 were expensed during the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net.  The Company had no material foreign currency exchange gains or losses during the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&#x2013;Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 718,&#160;&#x201c;Compensation-Stock Compensation.&#x201d;  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions.  The Company accounts for option forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made an accounting policy election under Accounting Standards Update (ASU) No. 2016-09, "Stock Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting to account for forfeitures as they occur, resulting in a cumulative-effect adjustment to increase accumulated deficit by $13,000 as of January 1, 2018, the date of adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also follows the provisions of ASC 740-10, &#x201c;Accounting for Uncertainty in Income Taxes.&#x201d;  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  No liability related to uncertain tax positions is recorded on the financial statements.  It is the Company&#x2019;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020 and 2019&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive income.  Accumulated other comprehensive loss is presented in the accompanying balance sheets as a component of stockholders' equity.  For the year ended December 31, 2018, there was no difference between the Company's comprehensive loss and its net loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#x2019;s redeemable convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share was determined as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Silk Road Medical, Inc. common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common stock outstanding used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,965,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,956,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#x2019;s net loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,233,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,306,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,277,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates and manages its business as one reportable and operating segment.  The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Primarily all of the Company&#x2019;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment.  All of the Company&#x2019;s revenue was in the United State&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s for the years ended December&#160;31, 2020, 2019 and 2018, based on the shipping location of the external customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODE_a59031f2-1305-4bd0-9546-0708ef8b73e0">Basis of PreparationThe accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjQ_2eb38d15-2bfc-4131-a750-053bcc99b057">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the coronavirus (&#x201c;COVID-19&#x201d;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTk_dd845088-e706-4fc9-993b-1f4bce318a8e">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2020 and 2019.  The carrying amounts of certain of the Company&#x2019;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTg_a0ba25cb-36e7-4a3b-b3a7-00b4edf3962d">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of December&#160;31, &lt;/span&gt;&lt;/div&gt;2020, the Company&#x2019;s cash equivalents are comprised of investments in money market funds and commercial paper.  As of December 31, 2019, the Company&#x2019;s cash equivalents are entirely comprised of investments in money market funds.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjU_712267db-bb5f-4431-8232-5a4da341c6d5">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzM_9b67d406-94b9-424b-a3c0-f5a84f55ecff">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfMi0xLTEtMS0w_587ab64c-35c6-4853-b253-ff0953a51009"
      unitRef="usd">69466000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfMi0zLTEtMS0w_14d51e6e-d271-4da8-9606-bf59d7fb451b"
      unitRef="usd">39181000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfMy0xLTEtMS0w_d4d38447-ad73-40f8-ae65-9eeb07f9c4d8"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfMy0zLTEtMS0w_33ebec99-2ac5-45d5-9715-f84bbeaff22a"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfNC0xLTEtMS0w_99b28aa3-f2d7-4bf0-b955-5601e2aa1e35"
      unitRef="usd">69776000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOjE4MWJjNjhlM2ZlOTQxNTFiMjUwZDJlODEyZjIxZGEwL3RhYmxlcmFuZ2U6MTgxYmM2OGUzZmU5NDE1MWIyNTBkMmU4MTJmMjFkYTBfNC0zLTEtMS0w_20b9a931-fcf4-42ca-9429-4cb290b412b6"
      unitRef="usd">39491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i827e3aa981f94e4497963dc63008de63_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzczNQ_813945bb-0e2f-4ddf-9269-ebf7dcbd195f"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i1750d8abb53f482ab006e6bbcc0efe15_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzczNQ_baef506e-3abd-4470-aaf3-f849170233f1"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkyOTg1NA_810fe43c-58ba-4e3c-a85d-b0c9a507acb2">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy.  Money market funds are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method. Realized gains and losses are included in earnings and are der&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ived for specific-identification method for determining the costs of investments sold and were insignificant for the year ended December 31, 2020 and 2019. Amortization of premiums and accretion of discounts are reported as a component of interest income.&lt;/span&gt;&lt;/div&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzI_8a7a8c0d-05c0-40da-b226-fa2cc3eca9fc">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk, and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks related to public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#x2019;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#x2019;s revenue while the pandemic continues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable are due from a variety of health care organizations in the United States.  At December&#160;31, 2020 and 2019, no customer represented 10% or more of the Company&#x2019;s accounts receivable.  For the years ended December&#160;31, 2020, 2019 and 2018, there were no customers that represented 10% or more of revenue.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manufactures certain of its commercial products in-house.  Certain of the Company&#x2019;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis, a Cardinal Health Company (see Note 14 - Subsequent Events).  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#x2019;s financial position and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#x2019;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#x2019;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#x2019;s currently approved portfolio.  If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjA_6e1f9171-6d65-4973-a1f1-73e7bf885969">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest.  The Company estimates allowances for doubtful accounts.  Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#x2019; financial condition.  The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected.  These specific allowances are reevaluated and adjusted as &lt;/span&gt;&lt;/div&gt;additional information is received that impacts the amount reserved.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjY_9ec5d0e7-415f-4b05-84e0-1f620ac5833c">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value.  Cost is determined using the first-in, first-out method for all inventories.  Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.  The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate.  The Company&#x2019;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements.  The estimate of excess quantities is judgmental and primarily dependent on the Company&#x2019;s estimates of future demand for a particular product.  If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LossContingencyReceivable
      contextRef="i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA5OTUxMTY3ODAyMA_3bc2690d-3014-45b5-b167-c41b48168e22"
      unitRef="usd">4160000</us-gaap:LossContingencyReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjE_fd4f7ef7-6219-408d-8ec4-5db333a938e8">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost less accumulated depreciation or amortization.  Repairs and maintenance costs are expensed as incurred.  Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA3ODg_1daeb587-69ed-44f7-8b16-4ee5917c9839"&gt;three&lt;/span&gt; to five years.  Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset.  When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia0b870409832446b94306158afef68a2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkyOTg1OA_c2aa4d6e-3b45-42e1-afa4-7823cf4fb939">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Njk_10a58f93-0785-4436-9483-6f1152547387">Deferred Public Offering CostsSpecific incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkyOTg2MQ_e1ab4a62-0d8a-4e0c-a3d8-26b4a1a2b2fa"
      unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTE0Mjk_64c6476d-f005-4524-82eb-7fe4b640bbc8"
      unitRef="usd">950000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTE1ODA_d86a0f1f-10b0-41fe-ac44-2d3d14432386"
      unitRef="usd">233000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzY_5f722ed9-9673-413d-a24c-15e9c6146770">Impairment of Long-Lived AssetsThe Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable.  If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount.  Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NjI_d47a25de-5550-4d49-b79c-dce40c0f47d2">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  As a result of adopting ASC 842, the Company recorded an operating lease right-of-use ("ROU") asset of $3,982,000 included within other non-current assets and operating lease liabilities of $5,190,000 included within accrued liabilities and other liabilities on the balance sheet related to its facility lease, based on the present value of the future lease payments on the date of adoption.  The operating lease right-of-use asset also includes adjustments for prepayments and excludes lease incentives.  The adoption did not have an impact on prior periods or on the Company's statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The disclosure impact of the adoption of ASC 842 on the balance sheet was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjustments Due to ASC 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#x2019;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i74860ed5b6ab4871aeb814ec7a0a16b6_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTI3NTI_e683fbda-66da-4876-ad6b-d771c9291c50"
      unitRef="usd">3982000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i74860ed5b6ab4871aeb814ec7a0a16b6_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTI4MzE_c51747c8-2f04-4678-9fc7-e3745357d73f"
      unitRef="usd">5190000</us-gaap:OperatingLeaseLiability>
    <silk:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Nzc_21168a97-3302-49d3-a74c-a9926f866fd6">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The disclosure impact of the adoption of ASC 842 on the balance sheet was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjustments Due to ASC 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Balance sheet information as of December&#160;31, 2020 consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_79e4f10b-3b5e-4ec2-876c-6e585e344f6b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_da5af1e9-78c6-47d2-b916-faffbda32183"&gt;other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_0c14a90d-c468-4d50-8bda-f4b6abb57993"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_df5558d5-a823-4bc7-8d24-11cd3b6290f9"&gt;accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_14124f2c-b99c-42a3-914f-b88bb1e2da04"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_eb1aa98b-cafb-4393-b523-5f94410b69b5"&gt;other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</silk:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if853e1713db04046a3e29718f77e312d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMS0xLTEtMS0w_9763f940-c5bb-402e-b41a-ddc3f6dd2c04"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i82a8a6cae4d84ca78f3412deeef72360_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMS0zLTEtMS0w_936bb72f-a675-4bb2-8bf5-70125e6d472a"
      unitRef="usd">3982000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0a23db6a3861435b9f2516a8cd29279a_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMS01LTEtMS0w_1fc68387-ed6d-46ed-a118-dbe285539422"
      unitRef="usd">3982000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if853e1713db04046a3e29718f77e312d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMi0xLTEtMS0w_e13e0319-163d-47c2-8009-b4fa6369e6ef"
      unitRef="usd">139000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i82a8a6cae4d84ca78f3412deeef72360_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMi0zLTEtMS0w_6f0facb7-ae41-4156-8d9a-3b202ecd9c9b"
      unitRef="usd">582000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0a23db6a3861435b9f2516a8cd29279a_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMi01LTEtMS0w_fce87e13-0947-4cc6-8c52-65d5f64c7a9a"
      unitRef="usd">721000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if853e1713db04046a3e29718f77e312d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMy0xLTEtMS0w_44b87343-d371-44da-8f1a-9826c4885e0f"
      unitRef="usd">1069000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i82a8a6cae4d84ca78f3412deeef72360_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMy0zLTEtMS0w_2077da0f-1c97-4113-8698-2e9b8d07fd98"
      unitRef="usd">3400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0a23db6a3861435b9f2516a8cd29279a_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmM3NzFkMjQwNGZhOTRlMTBiMjBjZTQxMDdjYjVmZjhiL3RhYmxlcmFuZ2U6Yzc3MWQyNDA0ZmE5NGUxMGIyMGNlNDEwN2NiNWZmOGJfMy01LTEtMS0w_ee2b815e-137f-4ce1-929a-924922c61117"
      unitRef="usd">4469000</us-gaap:OtherLiabilitiesNoncurrent>
    <silk:WarrantsClassifiedAsLiabilitiesPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzQ_a883a221-1c56-47a8-8c00-1e249ac8e5eb">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the statements of operations and comprehensive loss.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised. Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#x2019; equity. Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.&lt;/span&gt;&lt;/div&gt;</silk:WarrantsClassifiedAsLiabilitiesPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTU_4ca9f9c7-46ef-46e9-b437-d22bbe1ef40a">Redeemable Convertible Preferred StockPrior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#x2019; equity on the balance sheet as events triggering the liquidation preferences were not solely within the Company&#x2019;s control.</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="i1cc64e5be1b148b388a24c6ea4bc296c_D20190501-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTY0OTY_ea34bf22-4a3c-488f-8245-b89be3bf7375"
      unitRef="shares">23178555</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i29d32e7c3bb6454a8aac9d997e7acdc7_D20190501-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTY1NTk_0edbe4a7-f746-4fa2-90af-1c81707e9d9d"
      unitRef="usd">144140000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODA_72b02e4c-f9a3-4fe6-806f-e41541ae1acf">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC Topic 606,&#160;&#x201c;Revenue from Contracts with Customers.&#x201d;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of January 1, 2018, the date of adoption, the Company recognized the cumulative-effect of initially applying ASC 606 as an adjustment to decrease accumulated deficit by $87,000.  Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt"&gt;identify the contract(s) with a customer; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt"&gt;determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt"&gt;allocate the transaction price to the performance obligations in the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(v)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the Company recorded $71,000 and $102,000, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#x2019;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#x2019;s standard terms and conditions.&#160;&#160;The Company&#x2019;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For sales where the Company&#x2019;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#x2019;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectibility is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale.  As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short.  Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component.  The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of revenue&#160;in the&#160;statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on our balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manufactures certain of its portfolio of TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#x2019;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8bdec6a3f3f428d912d079b56925396_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkzMzg2OA_6d8fdd13-1ecf-4fd1-be20-5092577e2d16"
      unitRef="usd">87000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTc4MDE_b5f88ea0-b2ca-4973-881a-6a05f4f206b6"
      unitRef="usd">71000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTc4MDg_9de9cd00-6e0e-45ff-ba96-4b12e1e69bae"
      unitRef="usd">102000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTY_59c3c429-51d6-4559-bcd7-b72ab777065b">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses research and development costs as incurred.  Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#x2019;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development.  Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses.  Additionally, research and development expenses include costs associated with our clinical studies including clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical Trials&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements.  The Company &lt;/span&gt;&lt;/div&gt;determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzU_36a063ee-5581-4ff2-aaee-f856705546b2">Advertising CostsThe Company expenses advertising costs as incurred.  Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA5OTUxMTY2NTc4NQ_cb229276-db6d-475d-a2b4-5f324d1ce667"
      unitRef="usd">194000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA5OTUxMTY2NTc4OQ_fd4add6a-234e-4c28-8913-128a0ff5d497"
      unitRef="usd">362000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA5OTUxMTY2NTc5Mw_26892611-3ced-4473-87ea-fb65b63959ea"
      unitRef="usd">186000</us-gaap:AdvertisingExpense>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Nzg_54d3623f-5415-4ad2-86cc-a4048b8c4711">Foreign CurrencyThe Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODI_f5052938-95a3-4054-b243-662f979dc7cf">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&#x2013;Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 718,&#160;&#x201c;Compensation-Stock Compensation.&#x201d;  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions.  The Company accounts for option forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made an accounting policy election under Accounting Standards Update (ASU) No. 2016-09, "Stock Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting to account for forfeitures as they occur, resulting in a cumulative-effect adjustment to increase accumulated deficit by $13,000 as of January 1, 2018, the date of adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id91c2dc9412d49f38b2911de8b92a20c_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkzNDM5OQ_c8c11ba9-faba-4809-89bc-a944e3182848"
      unitRef="usd">13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Njc_64403ee5-fde3-4970-813b-25f3f89d0ce6">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also follows the provisions of ASC 740-10, &#x201c;Accounting for Uncertainty in Income Taxes.&#x201d;  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  No liability related to uncertain tax positions is recorded on the financial statements.  It is the Company&#x2019;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzI5ODUzNDkyOTg2Nw_b838c7fb-d7ba-4d55-8263-7cddc86e69cd"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMjc0NTI_1d7b1a45-8872-4aaa-826c-2f44631f2373"
      unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMjc0NTI_4650de9a-f3fa-4541-9972-3455d1715212"
      unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMjc0NTI_6f918352-294d-4793-a741-bb92fd94d23f"
      unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1Nzk_0b96aad6-5cea-4a42-8ba8-3f7508b9cc48">Comprehensive Loss&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020 and 2019&lt;/span&gt;, the Company&#x2019;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive income.  Accumulated other comprehensive loss is presented in the accompanying balance sheets as a component of stockholders' equity.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODM_cece876e-7446-4dac-833c-0a0edb29e54a">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#x2019;s redeemable convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1ODQ_9194e385-a8be-45af-89ac-4768ea395249">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share was determined as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Silk Road Medical, Inc. common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common stock outstanding used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,965,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,956,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMi0xLTEtMS0w_ec97f9ce-ac86-4c8b-9411-5b37ec6a78fd"
      unitRef="usd">-47365000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMi0zLTEtMS0w_4b26ac4b-00b9-4a9e-aa61-8ee719f13e24"
      unitRef="usd">-52415000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMi01LTEtMS0yNzEy_6d0f51d3-2c79-4a7e-a6c9-fb456931ed15"
      unitRef="usd">-37629000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMy0xLTEtMS0w_696f8d5d-ed07-40cd-9ae0-5376b81495f1"
      unitRef="shares">32965539</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMy0zLTEtMS0w_f3970bec-faf2-4abd-bfa6-6d3c33f073f7"
      unitRef="shares">22956679</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfMy01LTEtMS0yNzEy_68b7069f-2fb6-4f6f-8d62-3f7ed1f45d39"
      unitRef="shares">960882</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfNC0xLTEtMS0w_a548c589-a8da-4e24-8d97-6d4c6e929345"
      unitRef="usdPerShare">-1.44</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfNC0zLTEtMS0w_f2d69e0d-3ff8-4eaa-93bc-ad28221ab53d"
      unitRef="usdPerShare">-2.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmIzZTE1ZWJjYmE4MDRkYjE5MTFjZDIzYjM0NTdjOWMyL3RhYmxlcmFuZ2U6YjNlMTVlYmNiYTgwNGRiMTkxMWNkMjNiMzQ1N2M5YzJfNC01LTEtMS0yNzEy_8cab424b-884d-4f1b-80af-c12732122676"
      unitRef="usdPerShare">-39.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NTc_28f30ce1-2f99-4975-bbfc-b124a8adab00">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#x2019;s net loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,233,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,306,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,277,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i75afb4faf7c744e2b28602b04897dd79_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMi0xLTEtMS0w_508552ad-b790-40d8-af88-726b26d8d7c0"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i64b54eeb36b1445a892442bd09bf6ddc_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMi0zLTEtMS0w_ffd94eff-6d0e-4720-931c-a991c81b18a5"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3f6cfd36e8754556bf275ccd4408ac9d_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMi01LTEtMS0yNzI1_c99004f7-8b6d-4311-897a-968d7cf1df40"
      unitRef="shares">21233190</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idc08d2bf3b1d4a4db5e64a2c8d4dc1eb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMy0xLTEtMS0w_48ac8fa0-7876-441a-aac1-a596203ada88"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7f590d47a7f349109aeb1d59166be0f8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMy0zLTEtMS0w_6f7eaa20-627a-4ff4-b60b-70e3e5dd9861"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5af5a51a24f74e2abff8b55e1f406aac_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfMy01LTEtMS0yNzI1_8817a391-84c4-47ba-a78e-975fce43ea84"
      unitRef="shares">2672502</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic05cef1eab034c14aabf2595f65c6875_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNC0xLTEtMS0w_29bfd6a1-967f-44b4-be48-e73b2ecbc1a7"
      unitRef="shares">4237828</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2d19235df8b24d9391e616dafdce6fe6_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNC0zLTEtMS0w_3024de86-5180-4982-9bf7-5fc203ec07b7"
      unitRef="shares">4310790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8e6007a041b04fe18293a2b10afdf234_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNC01LTEtMS0yNzI1_c82a8ac9-4f38-4e08-8fc3-57f8a589d4a4"
      unitRef="shares">4364377</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9af4d8ce709e4c3a9540ae056f21e76a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNS0xLTEtMS0w_4d1e2e4b-c26c-4d0f-a09d-a2b9d300794d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0208f9e90c6a42fda50fc3adb6581207_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNS0zLTEtMS0w_1203f2d4-740f-4f48-9996-c6d735c49832"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib88ecc9d7eb744238cc66553830ad1a1_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNS01LTEtMS0yNzI1_f37b00e5-4df3-4b10-a8b7-67794262afad"
      unitRef="shares">7527</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4c1b45f2b2f54a72b7d8efc23d3f0bb1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi0xLTEtMS0yNzIw_739664d0-2f4f-4d72-a5f2-efee4c54144d"
      unitRef="shares">68396</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i070da31579db44ef9c24774b3df5e7d7_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi0zLTEtMS01MTkw_dfc9c8e5-319d-4a95-bf0c-450c1439d2d0"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3673ffce8656493c860435c0fb39bfb4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi01LTEtMS0yNzI1_59980690-c2a9-4ba0-a512-ed759790d849"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi0xLTEtMS0w_84973b10-dbe7-45c0-9c86-b471cf1607a6"
      unitRef="shares">4306224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNi0zLTEtMS0w_29307e1c-80f1-45a2-bf79-0b52cb0f20ec"
      unitRef="shares">4310790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RhYmxlOmY5YmFkZTk4YzFiMTRmNDk4ZDBmNDQ2NjI3MWNlZWE2L3RhYmxlcmFuZ2U6ZjliYWRlOThjMWIxNGY0OThkMGY0NDY2MjcxY2VlYTZfNy01LTEtMS0yNzI1_2c3c14d0-890b-4dd3-8660-4d07bb86fb6a"
      unitRef="shares">28277596</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzA1NzE_b55606f0-8a2b-4691-b5c2-fd0799a1e269">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates and manages its business as one reportable and operating segment.  The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Primarily all of the Company&#x2019;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment.  All of the Company&#x2019;s revenue was in the United State&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s for the years ended December&#160;31, 2020, 2019 and 2018, based on the shipping location of the external customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzAwMzQ_1f84d5ce-f753-4e12-8365-297e0fd62a86"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMzAwMzQ_2bd56ecb-ef1f-4c40-90f3-2b8426305aaa"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84OC9mcmFnOjRlZWE0YWRkN2YxOTQ1MTI5YTQ2ZWUyYjM2ZTkzYjk0L3RleHRyZWdpb246NGVlYTRhZGQ3ZjE5NDUxMjlhNDZlZTJiMzZlOTNiOTRfMzE0NQ_0512b368-d4f1-4d57-adfe-3aa9f5e7acc9">Recent Accounting Pronouncements&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 was determined to originally be effective for the Company on January 1, 2023.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  During the year ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020, the Company no longer qualified as a smaller reporting company, accordingly &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;became effective for the Company on January 1, 2021. The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 became effective for the Company on January 1, 2021.  The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84OC9mcmFnOjRlZWE0YWRkN2YxOTQ1MTI5YTQ2ZWUyYjM2ZTkzYjk0L3RleHRyZWdpb246NGVlYTRhZGQ3ZjE5NDUxMjlhNDZlZTJiMzZlOTNiOTRfMzE0Ng_576692ab-7ef3-4fbd-b924-4927a76eeb47">Recent Accounting Pronouncements&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 was determined to originally be effective for the Company on January 1, 2023.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  During the year ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020, the Company no longer qualified as a smaller reporting company, accordingly &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;became effective for the Company on January 1, 2021. The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 became effective for the Company on January 1, 2021.  The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RleHRyZWdpb246ZGQxY2Y0ZDBiZWQ4NDI2NTg5ZGZiNDNlODcwM2MxMmFfMzk5Nw_a7627d1c-6e66-41d8-a70e-d09ff39abf6b">Fair Value Measurements&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, investments, and the Company's previously outstanding preferred stock warrants.  Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.  A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; quoted prices in active markets are identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; observable inputs other than quotes prizes in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.  The Company&#x2019;s cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.  The corporate bonds/notes, commercial paper, asset-backed securities and U.S. government securities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables sets forth by level within the fair value hierarchy the Company&#x2019;s assets and liabilities that are reported at fair value as of December&#160;31, 2020 and 2019, using the inputs defined above (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between fair value hierarchy levels during the years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RleHRyZWdpb246ZGQxY2Y0ZDBiZWQ4NDI2NTg5ZGZiNDNlODcwM2MxMmFfMzI5ODUzNDg5MDcxMw_bb081e8a-55aa-4dc7-8988-54f8583f5dde">The following tables sets forth by level within the fair value hierarchy the Company&#x2019;s assets and liabilities that are reported at fair value as of December&#160;31, 2020 and 2019, using the inputs defined above (in thousands):&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88621eee6a92415596259056062149ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfMy0xLTEtMS0yNzMz_9fa7a850-ea46-4091-bd61-123be763764b"
      unitRef="usd">60295000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59487565bf824f58aa85388dbb1688de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfMy0zLTEtMS0yNzMz_21be9220-8e8b-4771-9126-33322b8af4b6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf154cdda1c64eb98fa4cb83db6a1660_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfMy01LTEtMS0yNzMz_c7612d21-a586-45ba-8a53-5002f223ff37"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2975ca8ff7e249fdbd6927130f924215_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfMy03LTEtMS0yNzMz_e7513fd1-999a-496a-9a5e-85b9dc5dfb26"
      unitRef="usd">60295000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0b799836f284366bc42899fe369b6df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNC0xLTEtMS0yNzMz_bee617f1-a698-4048-8d52-674c55135b57"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic870ec31c6844cae91979478b320f851_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNC0zLTEtMS0yNzMz_cb021367-4076-4d60-97a2-82e1da21eb38"
      unitRef="usd">39577000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ee5649064aa4f26bf11ca63f1d732f7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNC01LTEtMS0yNzMz_e11385f0-483a-4130-a1e5-88e234a4a3b3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ae39ce199b8414db9c118472a65f406_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNC03LTEtMS0yNzMz_04862851-ec14-40ae-a535-d6a71ae7d21c"
      unitRef="usd">39577000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81f2c499fbaf46cabadb242b9424f8cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNS0xLTEtMS0yNzMz_46c12e1a-be14-49cc-ab9d-4c84bc76e40b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i357686f6ae35429994f069e2387042a0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNS0zLTEtMS0yNzMz_481970a9-741e-4602-81c6-a3ae6c140ee4"
      unitRef="usd">7969000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i848eba092bd94a8eb9a2e17f4201aecc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNS01LTEtMS0yNzMz_f29db5f1-93a6-45ae-8f58-d272ffd83356"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i82ec25c5c50d45fc9b7ac1bcf6ed42c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNS03LTEtMS0yNzMz_081e4d8f-046b-447a-a7c2-a1e159463d73"
      unitRef="usd">7969000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8fa5d33e615f45ee93d158502b82303c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNi0xLTEtMS0yNzMz_f684d6d8-4e21-46bb-a8ea-3eb8448c4a2b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7c7a65d68ecf48be802607860d75752b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNi0zLTEtMS0yNzMz_40bc43fe-2a7b-41f3-ac72-81e661d8b450"
      unitRef="usd">38470000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f0fd943be2845489302e8030bd481fa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNi01LTEtMS0yNzMz_438b9c09-ef1a-4016-a5cf-b0ec97a2bf2c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8db444997bb6463980bb4456c1bf3dc6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNi03LTEtMS0yNzMz_f4c6d4b8-386d-4c58-8f51-9c601602e43e"
      unitRef="usd">38470000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic98cf98f0f8c4bdbb7f693b02e6b6929_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNy0xLTEtMS0yNzMz_69e7b15e-fc2c-4b16-80bf-a52c90815b27"
      unitRef="usd">60295000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie23170ae30bd4aa09beb7fe13e61ced2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNy0zLTEtMS0yNzMz_c62623f0-ba0e-4465-af9d-02bf0f9e28f4"
      unitRef="usd">86016000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4ecc085e11174791b09ea7310d702ac7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNy01LTEtMS0yNzMz_951bd12c-ebc7-44e1-887b-796101d10dd6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i433402cf26a940318305dcd5eb794a03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjE5MWQyZWI1MzAwYjQ5Nzc4OWQyZjFiYTk5ZmNlZTFkL3RhYmxlcmFuZ2U6MTkxZDJlYjUzMDBiNDk3Nzg5ZDJmMWJhOTlmY2VlMWRfNy03LTEtMS0yNzMz_74ef6380-e34e-4eed-a4d1-6d64a38da935"
      unitRef="usd">146311000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e033ae2fd394f23bcf5460a5a476a6d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfMy0xLTEtMS0w_67ebc696-a87d-4789-bb75-eeb3b6f4dc68"
      unitRef="usd">34363000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3306f9c046324cf5b42a9b1bac4a0df4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfMy0zLTEtMS0w_e2214f05-41d6-4b76-9d82-62e84af25d3a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0704a28bb0740d0ae4c8aa19953a7c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfMy01LTEtMS0w_2ecb6b07-e397-435e-9815-67d299690444"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98694aaa0a3e4704bba4075c12779e77_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfMy03LTEtMS0w_29a119c7-c8a9-491a-bd21-8b1c13de2226"
      unitRef="usd">34363000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i737fbec56ae2400498ccdfd111434ebd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNC0xLTEtMS0w_e368d7ca-7b58-46bb-bfb6-a2f887089e65"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i942c1c56732d4c25a0dce9c90e7135bc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNC0zLTEtMS0w_ce516335-ba01-4eef-af10-5dc3056f9189"
      unitRef="usd">9919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93aba04a024740cab28993b7f08897a6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNC01LTEtMS0w_9a956252-f760-475b-af00-08cf065477f2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9ad97bd146043ccb94ce8bb1534c274_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNC03LTEtMS0w_9a27f283-7a1b-415b-8001-dc7201049485"
      unitRef="usd">9919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i39f54e063bd140a59132d57ef7c54d00_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNS0xLTEtMS0w_33421d42-5ea3-48eb-bca1-8c2c76b6d3e2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5276c031eb8401ab73fc33a537f9a9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNS0zLTEtMS0w_16fb901b-6eaf-4e73-a226-64bebe009bc3"
      unitRef="usd">10176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec0f25b2baff49b08a617afd300f27b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNS01LTEtMS0w_7547ac9d-7a89-4e57-829b-ec4d26108330"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i318e00b0a9b344bda4f823f595370143_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNS03LTEtMS0w_76fa8c7d-d94f-4e60-9d11-340c44444cf3"
      unitRef="usd">10176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b13adf4f0254c9cac128597de2f1736_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNi0xLTEtMS0w_7795251a-07d8-4955-98e0-2525545d9151"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cb08f575e4245cb9aca4fe1623d37ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNi0zLTEtMS0w_cf56d1f2-f72f-419d-a04e-c51e7b0b11cc"
      unitRef="usd">44456000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0dc412721304b3b9720878497766ff1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNi01LTEtMS0w_30ab3443-910f-4368-82c9-dcce16d18e09"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14399a34c4744effb088c2e934ae2d39_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNi03LTEtMS0w_09abe690-f03b-4e84-8fb5-5ad8e34b361f"
      unitRef="usd">44456000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bcb916e401b434c9e7347ae76804c6c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNy0xLTEtMS0w_ac6b2f08-7574-4205-baa3-ffd67fce0d20"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65720dad45e548d784f15ef6efe4dfce_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNy0zLTEtMS0w_aa375611-a5dd-4c67-8835-13723a8b8d39"
      unitRef="usd">5181000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40fbd6b3dba34ba6ac8a848b3683d371_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNy01LTEtMS0w_dc13e410-72d2-43a5-90de-01656539786d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf8480cdb559440dba9a27448e6c477b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfNy03LTEtMS0w_569e581e-5499-4eaa-8513-956c16b31dc7"
      unitRef="usd">5181000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7abdb02107cf49099d5551ac177162e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfOC0xLTEtMS0w_6054eda1-0810-4d79-8850-ac11354551fc"
      unitRef="usd">34363000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaaabfa66f9d644e5b250778ca77caced_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfOC0zLTEtMS0w_242101ac-61ec-47c4-ab15-2465148a7ebd"
      unitRef="usd">69732000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if0af3756b9464f89a2924477109ebf89_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfOC01LTEtMS0w_cb9514fe-e779-4bee-9501-d6f9e70578f6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9f81260903074be0978bdc8c0d05b714_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85MS9mcmFnOmRkMWNmNGQwYmVkODQyNjU4OWRmYjQzZTg3MDNjMTJhL3RhYmxlOjk3MmM0NjZjZDg5MTQ2ZjBhN2FiYTJhMjEyZjE5Mzk5L3RhYmxlcmFuZ2U6OTcyYzQ2NmNkODkxNDZmMGE3YWJhMmEyMTJmMTkzOTlfOC03LTEtMS0w_66717428-df95-4a45-80a9-2120c869f33e"
      unitRef="usd">104095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTgx_62c55076-fe4d-435b-b817-27fd8c54a2df">Balance Sheet Components&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's available-for-sale investments as of December&#160;31, 2020 and 2019 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of the Company&#x2019;s cash equivalents, short-term and long-term investments classified by maturity as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts maturing within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale investments held as of December&#160;31, 2020 had a weighted average days to maturity of 135 days. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of inventories were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Reserve for excess and obsolete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, there were no work-in-process inventories. The reserve for excess and obsolete inventory at December 31, 2020, included $2,377,000 associated with the Company's voluntary product recall (see Note 14 - Subsequent Events).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:  Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add:  Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was $789,000, $712,000 and $517,000 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recall replacement obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued travel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTgy_11a3daff-5a9b-4000-b4cd-179f76252740">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's available-for-sale investments as of December&#160;31, 2020 and 2019 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9ec2284f03df4813bfbdf100ea317939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMy0xLTEtMS0yNzM5_fc4a6401-3f88-46f7-9af3-416cee965007"
      unitRef="usd">60295000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9ec2284f03df4813bfbdf100ea317939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMy0zLTEtMS0yNzM5_7b515781-ea84-4f1c-8230-d002d76653db"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9ec2284f03df4813bfbdf100ea317939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMy01LTEtMS0yNzM5_672a03a6-2b20-45fd-963a-4e5a09a3a734"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ec2284f03df4813bfbdf100ea317939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMy03LTEtMS0yNzM5_7e8b9090-197b-43dd-a108-089c1c8b387d"
      unitRef="usd">60295000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i11882955ba914a4abd7f7f72b573da68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNC0xLTEtMS0yNzM5_4a08edd1-6f95-44a4-b88a-d5c5305adffe"
      unitRef="usd">39577000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11882955ba914a4abd7f7f72b573da68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNC0zLTEtMS0yNzM5_63a61ec5-4b93-4db9-8c36-5bc330bfc8b5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11882955ba914a4abd7f7f72b573da68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNC01LTEtMS0yNzM5_fcd816de-94aa-49c4-bcac-c165a7ca9f70"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11882955ba914a4abd7f7f72b573da68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNC03LTEtMS0yNzM5_fdba3c10-f54d-476b-9d49-4d5b20e56455"
      unitRef="usd">39577000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0c6e1731892948749cc2a36087515f22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNS0xLTEtMS0yNzM5_9596fa9a-144a-45d5-ac75-f9736635c4fd"
      unitRef="usd">7970000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0c6e1731892948749cc2a36087515f22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNS0zLTEtMS0yNzM5_68b3a9d4-b9be-4694-92ab-d4f07227f789"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0c6e1731892948749cc2a36087515f22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNS01LTEtMS0yNzM5_52c82959-df98-46af-a39c-11f4a42de244"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c6e1731892948749cc2a36087515f22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNS03LTEtMS0yNzM5_a46d3f42-a9a3-4898-b69c-611e24b545c2"
      unitRef="usd">7969000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNi0xLTEtMS0yNzM5_891dd9a7-92d1-42bf-bae6-01ce942759ad"
      unitRef="usd">38430000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNi0zLTEtMS0yNzM5_6899e52e-c815-4632-9c7b-aa0fb261d095"
      unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNi01LTEtMS0yNzM5_829cfc95-3cc9-484d-aa5b-67bec590352a"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNi03LTEtMS0yNzM5_8d571426-2ab2-4f2c-a1ca-0d39ed9c0bbd"
      unitRef="usd">38470000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNy0xLTEtMS0yNzQz_d1ae400a-ff61-42f5-8097-7119c4ea0f70"
      unitRef="usd">146272000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNy0zLTEtMS0yNzQz_e4b7e13e-6470-4ab5-aea3-84a578fa15b7"
      unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNy01LTEtMS0yNzQz_8abf47a2-5a13-4901-978d-01c060837f2d"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfNy03LTEtMS0yNzQz_05c5a840-9299-433e-abb7-94103c81a303"
      unitRef="usd">146311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i889ad813d9384574aeee41f8e250fdd0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMTAtNy0xLTEtMjc1Mw_12793fa5-9047-48e0-8331-d27e7630ab9f"
      unitRef="usd">68295000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6666fe4580be47429377090735b4b572_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMTEtNy0xLTEtMjc1Mw_dc4a122a-6478-4a47-bc54-35a99e802c27"
      unitRef="usd">78016000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmU1NGI2N2E5M2MxNzQwMGRhNGRiNjI4MWNjYmI2ZThmL3RhYmxlcmFuZ2U6ZTU0YjY3YTkzYzE3NDAwZGE0ZGI2MjgxY2NiYjZlOGZfMTItNy0xLTEtMjc1Nw_3c149995-0fd6-4953-aaf3-903b3e079219"
      unitRef="usd">146311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibda1fee3df294d8280213184a71db82b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMy0xLTEtMS0w_0176f45b-7137-41c0-883e-ab83f0a1b6b0"
      unitRef="usd">34363000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibda1fee3df294d8280213184a71db82b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMy0zLTEtMS0w_6e663dae-0bfe-45ff-92c9-de1c4aaab615"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibda1fee3df294d8280213184a71db82b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMy01LTEtMS0w_9028d2d7-60fa-4380-b130-39df9ee1c204"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibda1fee3df294d8280213184a71db82b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMy03LTEtMS0w_9ac909ea-cf47-4940-b3fa-72b9ce423ddb"
      unitRef="usd">34363000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNC0xLTEtMS0w_ce491292-9d8a-4d1b-aaf3-fd27793e61e5"
      unitRef="usd">9919000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNC0zLTEtMS0w_1fa9354c-8c54-4d06-bea1-b5308a56eaf4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNC01LTEtMS0w_7b4330e1-9686-47f8-97bc-94a2c91dc304"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a55b6551f5b4b7cb6b6d96c181c0f6e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNC03LTEtMS0w_6a22f92e-5724-4137-8562-6e61f7c1d6b1"
      unitRef="usd">9919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNS0xLTEtMS0w_2eb559c0-6b21-4afa-b605-58658035dfcd"
      unitRef="usd">10180000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNS0zLTEtMS0w_2b3caa06-6024-4be6-adc2-ec166a2766dc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNS01LTEtMS0w_3ea6e90f-51a7-496d-a9e0-1dd5c64f8121"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNS03LTEtMS0w_ece85b8a-7eb9-428b-85d5-3aad57b6b4bb"
      unitRef="usd">10176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNi0xLTEtMS0w_85cd5272-f4a2-4632-a4c2-1477c3978878"
      unitRef="usd">44450000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNi0zLTEtMS0w_3aff07a1-898b-4ec7-85f3-4fcf89aca54a"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNi01LTEtMS0w_c5902711-6936-4d0f-af7a-e41f98e0d2f1"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNi03LTEtMS0w_f04602ba-6c75-4594-8ca3-91b5b16730c0"
      unitRef="usd">44456000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id6207be23c9e413d86cc481a1129e296_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNy0xLTEtMS0w_4e0d8a7f-c41e-42d8-838e-b007e3e64ee8"
      unitRef="usd">5181000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6207be23c9e413d86cc481a1129e296_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNy0zLTEtMS0w_e3ac904c-6378-4655-8fa7-a0a6c5c1abc9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6207be23c9e413d86cc481a1129e296_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNy01LTEtMS0w_7a405b9c-34cb-4357-8076-7873b3719fb4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6207be23c9e413d86cc481a1129e296_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfNy03LTEtMS0w_a8945095-f48f-402d-a342-eabfc89c5007"
      unitRef="usd">5181000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfOC0xLTEtMS0w_ebaa2cfc-39a6-4731-824c-f836e6fa790f"
      unitRef="usd">104093000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfOC0zLTEtMS0w_3ae697fe-35de-4c33-83b2-58d401de8fe7"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfOC01LTEtMS0w_7536355d-8596-4117-82b6-3a1865fba29b"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfOC03LTEtMS0w_e3679eb3-a0a0-4570-8e4a-0f44a7b22959"
      unitRef="usd">104095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a569c77aa3c40dd9b99313f06d7bd3e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMTEtNy0xLTEtMA_5ac51dda-3ef6-4597-a412-05da75d5a859"
      unitRef="usd">34363000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66c76492ae1149d3aa274942d50fabd3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMTItNy0xLTEtMA_02dc34d0-54f4-4354-92a7-aaaf7f21d0b8"
      unitRef="usd">51508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2533cb6af194baeb29f893a563753d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMTMtNy0xLTEtMA_89225d71-19c4-4b60-98bb-458eb7bf3467"
      unitRef="usd">18224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmJkODJiMjQ3MDE5NDRkMTdiOGUzOGRjZDgwZjczOWU3L3RhYmxlcmFuZ2U6YmQ4MmIyNDcwMTk0NGQxN2I4ZTM4ZGNkODBmNzM5ZTdfMTQtNy0xLTEtMA_09197332-e079-4da5-bb3b-61bc5cae7bfb"
      unitRef="usd">104095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTgz_35973a52-00d5-4501-ae52-f5159f9bf04a">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of the Company&#x2019;s cash equivalents, short-term and long-term investments classified by maturity as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts maturing within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfMi0xLTEtMS0yNzc0_7032bc92-bf94-4e40-87a1-bb6b957391f7"
      unitRef="usd">146311000</silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfMi0xLTEtMS0w_f7aae190-5809-4825-af59-bf78735c77b6"
      unitRef="usd">85871000</silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfMy0xLTEtMS0yNzc0_d91395fa-3728-4e0b-8bf3-c0ca22c53ade"
      unitRef="usd">0</silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfMy0xLTEtMS0w_b5f6337b-59a9-4157-807b-5a066761d59d"
      unitRef="usd">18224000</silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfNC0xLTEtMS0yNzc0_1540f8a8-0cfc-4870-9c88-34f536a5b208"
      unitRef="usd">146311000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjYxNjg5NmE2MzM5ZDRhMjI4YWQyMGYwYjZmODYyMmYxL3RhYmxlcmFuZ2U6NjE2ODk2YTYzMzlkNGEyMjhhZDIwZjBiNmY4NjIyZjFfNC0xLTEtMS0w_0f2d4e05-57f3-4a53-9c70-b6e1ad16d21f"
      unitRef="usd">104095000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyODgzOQ_3f4c72fd-c33d-4e7b-9668-3e2fe41bec7d">P135D</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTg0_58ff5103-1bed-4bc4-b069-1a53dcde0de3">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i0c6e1731892948749cc2a36087515f22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfMy0xLTEtMS0yNzYx_ebd246e4-0591-468c-b45d-aa14d75b54cb"
      unitRef="usd">5369000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i0c6e1731892948749cc2a36087515f22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfMy0zLTEtMS0yNzYx_9b25de14-799a-45e5-9bfa-cf2b40c26911"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfMy0xLTEtMS0w_93ad1b59-6ce8-459d-8be9-2d4010471f52"
      unitRef="usd">10128000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i2a0dabd38fa142bd97f50079ac7b6aa8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfMy0zLTEtMS0w_5c4a2442-c052-42ef-866b-d0ab558870ee"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNC0xLTEtMS0yNzYx_5a62869a-c584-49d3-a2bb-c62d2398eb29"
      unitRef="usd">10128000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib3a59d89726e4dd08d7e9afa9bf71349_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNC0zLTEtMS0yNzYx_201e863a-f53c-45c4-911d-3656c3b33c96"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNC0xLTEtMS0w_5bb9690c-02c9-4282-933d-e941c77af797"
      unitRef="usd">19067000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i2210e9a79df74613aaba46b9b6c9d830_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNC0zLTEtMS0w_f1d35ab6-5f0e-440e-951f-4423ecb09a4c"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNS0xLTEtMS0yNzYx_b4941aa2-022c-412c-a495-6c62c30989a3"
      unitRef="usd">15497000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNS0zLTEtMS0yNzYx_ac908a4b-a2cf-4382-bb0c-6694df17451b"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNS0xLTEtMS0w_76c75fab-efd6-4278-9771-929196ae700a"
      unitRef="usd">29195000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjA1NWJmZTNhZDdhMTQ1ZjBhM2VhZTJkYjZmOTVjNWM1L3RhYmxlcmFuZ2U6MDU1YmZlM2FkN2ExNDVmMGEzZWFlMmRiNmY5NWM1YzVfNS0zLTEtMS0w_4ea76d8c-b694-4bd5-8acf-bf44d81d2507"
      unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTg1_32672263-6c06-453b-a80d-c55519794cb8">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of inventories were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Reserve for excess and obsolete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfMi0xLTEtMS0w_1981f9dd-b93f-46cc-b2a7-9eb82101ffc7"
      unitRef="usd">1785000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfMi0zLTEtMS0w_250dfe7c-4d77-4216-b559-720409eedb97"
      unitRef="usd">1203000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfMy0xLTEtMS0w_529f42a0-265e-458a-b407-a09cc49bcdd4"
      unitRef="usd">10599000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfMy0zLTEtMS0w_e0eb2c3e-6fdf-4dca-b794-d9214bc81fca"
      unitRef="usd">9163000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNC0xLTEtMS0w_dd620708-7bef-433e-831b-f27e11a4027e"
      unitRef="usd">12384000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNC0zLTEtMS0w_552927dd-1e17-4cfc-a9d1-35ee2c5a1f41"
      unitRef="usd">10366000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNS0xLTEtMS01NjYw_8d3fa5ce-b5f2-448f-898b-2745e06397f8"
      unitRef="usd">2395000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNS0zLTEtMS01NjYw_5d379b88-2884-4db7-88bf-5c9b3f82f79c"
      unitRef="usd">44000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNi0xLTEtMS01NjYw_baa59ee5-43b0-4ee2-be09-4b9c62e52d50"
      unitRef="usd">9989000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjljZTQ0YTk4YzU4ZjRiZTJiZmFjNTk4ZTVkZGMxMzM5L3RhYmxlcmFuZ2U6OWNlNDRhOThjNThmNGJlMmJmYWM1OThlNWRkYzEzMzlfNi0zLTEtMS01NjYw_5bed226f-b981-4554-8616-fa06fd311cf1"
      unitRef="usd">10322000</us-gaap:InventoryNet>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfNjY1_52a67ef4-a224-42af-bd2e-88eb316c4116"
      unitRef="usd">0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfNjY1_d768bb63-0c4d-4d00-854c-92fa3c192f05"
      unitRef="usd">0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:LossContingencyReceivable
      contextRef="if68f3a12f75a43e0a5f0f1a0e2ed2345_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyOTA2OQ_ab885a40-9be3-49f0-ba8c-30bbb64643e3"
      unitRef="usd">2377000</us-gaap:LossContingencyReceivable>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTg2_246fb968-4298-4c38-8821-ca2ed4da694f">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:  Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add:  Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icc53679edcca491daa58c1d5d9e40d2b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfMi0xLTEtMS0w_af8c1a9d-fc39-43cd-81fb-a77aab45f057"
      unitRef="usd">726000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i89117551e1cd4e1894164ae6a96705b1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfMi0zLTEtMS0w_a0efb6bc-097e-4a5b-964b-5c56712b3f8e"
      unitRef="usd">657000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i28498ef5e5d649ccab003692d7a48278_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfMy0xLTEtMS0w_77dd8a7b-1908-45ad-b922-cc608347a550"
      unitRef="usd">1699000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i58bbd4394762445f9a301c74072434aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfMy0zLTEtMS0w_1c84dd04-1999-4ecf-b3a2-342bd43639ee"
      unitRef="usd">1295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6603001cf648480982c9106b4e14992e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNC0xLTEtMS0w_8ad79946-f5c6-4b81-acd3-8d57b45b2957"
      unitRef="usd">226000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia4bfd4cf869646a3aabf0014c3294512_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNC0zLTEtMS0w_9ea7fad4-960a-4aa0-b3d6-64837df03226"
      unitRef="usd">18000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i82c17ea580834042872a256eb3032b57_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNS0xLTEtMS0w_73189a69-d355-4ae9-a8cf-d07272b087ce"
      unitRef="usd">2043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i719a20f0f78a457f87d7472704e63aa1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNS0zLTEtMS0w_61b5f01d-925e-4c0c-ad6f-d0c9759d87d6"
      unitRef="usd">1991000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNi0xLTEtMS0w_36e8668a-6240-4919-b0c5-1683a45906a7"
      unitRef="usd">4694000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNi0zLTEtMS0w_40ac4130-97c6-4fad-8549-f2893e1d1e97"
      unitRef="usd">3961000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNy0xLTEtMS0w_ee19a461-80d5-4cfd-9de1-f747b456577e"
      unitRef="usd">2332000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfNy0zLTEtMS0w_752c823b-f5ed-4196-a71d-7667e39f4000"
      unitRef="usd">1550000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie69721672eec41c2a595f99de0a0defc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfOC0xLTEtMS0w_d09cd7bb-3006-4ba7-9b3d-3f3e8c3223e1"
      unitRef="usd">482000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia6b0413075134cc583c0faa97c7be5d8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfOC0zLTEtMS0w_7f2dba1f-e086-4b24-8ce2-01bcf6240f3f"
      unitRef="usd">323000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfOS0xLTEtMS0w_f8413a23-69d2-45a5-a833-813845cb02ce"
      unitRef="usd">2844000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOmNmNDc1NmM3ZGY4ODRiODZiMGQ2MjVlZWEwNmVhMGQ1L3RhYmxlcmFuZ2U6Y2Y0NzU2YzdkZjg4NGI4NmIwZDYyNWVlYTA2ZWEwZDVfOS0zLTEtMS0w_0235f093-45e5-4c9e-85c0-5a4e9a0b493f"
      unitRef="usd">2734000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyODg1MA_a2ea66b4-7a37-4a92-b22d-69e4fd4b5b6d"
      unitRef="usd">789000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyODg1NA_38625576-a8de-4a5f-ae54-41c53d3d9ee1"
      unitRef="usd">712000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfMTA5OTUxMTYyODg1OA_a7df33ff-027b-40e6-b5a4-62ccd0309287"
      unitRef="usd">517000000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RleHRyZWdpb246YWY2MjJmNDM0ZjQ5NDhiMDg5MDMzNTdkNTEwOTA5ZTBfOTg3_1fe2c2a9-cada-4f1b-994e-0c1c9e9c2cdd">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recall replacement obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued travel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMi0xLTEtMS0w_ea70349b-0bbf-4083-abb0-da451a2aae97"
      unitRef="usd">9573000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMi0zLTEtMS0w_c4f1b784-24cf-4ac3-8b5b-7a4550ce71bd"
      unitRef="usd">9151000</us-gaap:AccruedSalariesCurrent>
    <silk:ProvisionsForSalesReturns
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMy0xLTEtMS0w_c75767aa-cbd7-4968-ab04-5fbcd2529a82"
      unitRef="usd">820000</silk:ProvisionsForSalesReturns>
    <silk:ProvisionsForSalesReturns
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMy0zLTEtMS0w_b87eb378-1aff-4c1d-b786-306e12bbe053"
      unitRef="usd">2419000</silk:ProvisionsForSalesReturns>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNC0xLTEtMS0w_071eca8c-b100-4953-aa00-03db399a61e2"
      unitRef="usd">2520000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNC0zLTEtMS0w_d4a29aa5-5d1a-4204-ba04-61317a2c089e"
      unitRef="usd">682000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNS0xLTEtMS02MDg0_604acaf9-6a0c-4ae6-bd23-338d4db3df6c"
      unitRef="usd">1696000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNS0zLTEtMS02MDg0_7d5bc29d-e7c0-4a9d-8586-617e31a586f0"
      unitRef="usd">0</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNS0xLTEtMS0w_e3de8e99-f0d4-4376-b336-a9698a042f72"
      unitRef="usd">850000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNS0zLTEtMS0w_6604681f-f771-475d-8f28-dc4a6266fb26"
      unitRef="usd">769000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNi0xLTEtMS0w_46291c25-e2fa-4b1b-a4ca-185c04c848a4"
      unitRef="usd">518000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNi0zLTEtMS0w_d0258ae5-4b26-4460-a96f-a062c0e81452"
      unitRef="usd">470000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNy0xLTEtMS0w_b234611d-895d-4770-a18e-97977b17bc07"
      unitRef="usd">206000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfNy0zLTEtMS0w_38b2fbce-7dc6-4160-a653-30777df5bbba"
      unitRef="usd">304000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <silk:AccruedTravelExpensesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfOC0xLTEtMS0w_7b09d44f-6c87-4f88-8f67-a83c2740b6a3"
      unitRef="usd">237000</silk:AccruedTravelExpensesCurrent>
    <silk:AccruedTravelExpensesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfOC0zLTEtMS0w_66249753-7f52-4537-8000-5aa035fbbcba"
      unitRef="usd">431000</silk:AccruedTravelExpensesCurrent>
    <silk:AccruedClinicalExpensesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfOS0xLTEtMS0w_abec8e8a-d0a2-4c42-920c-e7908d9dc425"
      unitRef="usd">113000</silk:AccruedClinicalExpensesCurrent>
    <silk:AccruedClinicalExpensesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfOS0zLTEtMS0w_e377d75d-cbc1-4760-92e5-0734c847ab76"
      unitRef="usd">241000</silk:AccruedClinicalExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMTAtMS0xLTEtMA_c01f623a-19ed-4dea-a711-5d26110d76eb"
      unitRef="usd">424000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMTAtMy0xLTEtMA_67b765c5-ba3d-4080-af70-0bc206089e5a"
      unitRef="usd">567000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMTEtMS0xLTEtMA_a17956dd-4abd-470e-ad80-0d595f1ec6f6"
      unitRef="usd">16957000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85NC9mcmFnOmFmNjIyZjQzNGY0OTQ4YjA4OTAzMzU3ZDUxMDkwOWUwL3RhYmxlOjkzYzMwMTFlNzE4ZjRiNzc4ZTFjYmFiZGEwYzcxNjFjL3RhYmxlcmFuZ2U6OTNjMzAxMWU3MThmNGI3NzhlMWNiYWJkYTBjNzE2MWNfMTEtMy0xLTEtMA_57d1cb04-6838-48d0-ae4f-70a02fd31f7c"
      unitRef="usd">15034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfNTE0MA_8bbe2b5a-6d7c-4db3-a7cc-bd428f3c6e9f">Long-term Debt&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CRG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October&#160;2015, the Company entered into a term loan agreement with CRG.  The term loan agreement provides for up to $30,000,000 in term loans split into two tranches as follows: (i) the Tranche A Loans provided for $20,000,000 in term loans, and (ii) the Tranche B Loans provided for up to $10,000,000 in term loans.  The Company drew down the Tranche A Loans on October 13, 2015.  The Tranche B Loans were available to be drawn prior to March 29, 2017.  In January 2017, the term loan agreement was &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amended to extend the commitment period of the Tranche B Loans to April 28, 2017.  In April 2017, the Company drew down $5,000,000 of the available Tranche B Loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the term loan agreement was amended to provide for additional term loans in an aggregate principal amount of up to $25,000,000.  In September 2018, the Company drew down an additional $15,000,000 under the amended term loan agreement with CRG, no additional draw was taken.  U&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nder the terms of the amended term loan agreement, the related fixed interest rate was 10.0%, 8.0% of the interest was due and payable in cash and at the election of the Company, 2.0% of the interest due and payable may be "paid in kind". &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All unpaid principal, and accrued and unpaid interest, was due and payable in full on December 31,&#160;2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 29, 2020, in connection with the consummation of the Loan and Security agreement with Stifel Bank as noted below, the Company repaid all amounts outstanding under the term loan with CRG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stifel Bank&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company entered into a Loan and Security Agreement, or Loan Agreement, with Stifel Bank which provides for a $50,000,000 loan facility, comprised of a $50,000,000 secured revolving credit facility, with a $2,000,000 subfacility for the issuance of letters of credit and other ancillary banking services, and a $50,000,000 secured term loan facility, provided that amounts outstanding under both facilities may not exceed an aggregate principal amount of $50,000,000 at any time.  Any borrowings under the revolving loan facility mature on October 29, 2022, or October 29, 2023 if as of October 29, 2022, no event of default has occurred and we are in compliance with the terms of the Loan Agreement. Borrowings under the term loan facility mature on October 29, 2024.  Interest under the revolving credit facility is the greater of a) 0.5% above the "Prime Rate" as published by &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or b) 4.75%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in October 2020, the Company drew down $49,000,000 under the term loan facility and used the majority of the proceeds to pay off and terminate the prior term loan agreement with CRG totaling $46,674,000, which included a prepayment premium of $305,000, a final interest payment of $365,000 and a facility fee of $2,191,000.  The Company recognized a loss on debt extinguishment of $1,119,000 in connection with the early termination of the term loan agreement with CRG. The principal amount of outstanding term loans under the Loan Agreement with Stifel Bank shall be repaid in equal monthly installments beginning on May 29, 2022, or November 29, 2022 if the Company achieves revenue for the year ending December 31, 2021 of at least 80% of the board-approved financial projections for such fiscal year.  Interest under the term loan facility is the greater of a) 0.75% above the "Prime Rate" as published by &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or b) 4.75%.  The term loan may not be reborrowed once repaid, but the Company may prepay the term loan at any time without premium or penalty. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also concurrently entered in a Success Fee Agreement in October 2020 with Stifel Bank, which requires that the Company pay Stifel Bank the lesser of 0.75% of the original principal amount of all credit extensions made under the Loan Agreement or $375,000 in the event the Company completes a Liquidity Event (liquidation, merger, sale of the Company or change in control).  The Success Fee Agreement terminates on October 29, 2025.  The Company has determined the probability of a Liquidity Event to be remote and accordingly, has not recognized a liability as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Obligations under the Loan Agreement are secured by substantially all of the Company's assets. Beginning on January 15, 2021, the Loan Agreement requires that the Company maintain unrestricted cash and cash equivalents with Stifel Bank or at Stifel Bank Affiliates of at least $20,000,000. In addition, for any fiscal quarter where the Company's unrestricted cash and cash equivalents maintained with Stifel Bank or at Stifel Bank Affiliates (or prior to January 15, 2021, Stifel Bank or certain other banks) are less than $60,000,000 for any day during such fiscal quarter, the Company must comply with a minimum &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue covenant. Additionally, the Loan Agreement contains customary affirmative and negative covenants, including covenants limiting the Company's ability and the ability of the Company's subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The events of default under the Loan Agreement include, among others, payment defaults, material misrepresentations, breaches of covenants, cross defaults with certain other material indebtedness, bankruptcy and insolvency events, and judgment defaults. The occurrence of an event of default could result in the acceleration of our obligations under the Loan Agreement, the termination of the lender&#x2019;s commitments, a 5% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the aggregate outstanding principal balance under the Loan Agreement was $49,000,000 and the annual interest rate was 4.75%.  As of December&#160;31, 2020, the Company was in compliance with all applicable financial covenants.  As of December&#160;31, 2020, management does not believe that it is probable that the above events of default will be triggered within the next twelve months, therefore, the debt is classified as long-term on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities under the Stifel Bank term loan agreement as of December&#160;31, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amount representing debt discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <silk:DebtMaximumBorrowingCapacity
      contextRef="icf16e6187b0a4304bc8897195133e968_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTY4_5c27dfbb-d531-48d1-8ca6-abdc2e8d2553"
      unitRef="usd">30000000</silk:DebtMaximumBorrowingCapacity>
    <silk:DebtMaximumBorrowingCapacity
      contextRef="ib85c4555200f4f429465863d9f50f535_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMjU3_fe978448-1148-4e2e-961e-6adaff1e5950"
      unitRef="usd">20000000</silk:DebtMaximumBorrowingCapacity>
    <silk:DebtMaximumBorrowingCapacity
      contextRef="i9f5ec93120bb4972be5e2507b780398c_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMzIz_3b051b41-eafb-49e8-8834-25f5899cdbea"
      unitRef="usd">10000000</silk:DebtMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i40ecba85ef204349b335af3072288f5f_D20170401-20170430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfNjQ0_ed4604b9-79f1-4657-bed8-d9f5c96814e7"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <silk:DebtMaximumBorrowingCapacity
      contextRef="iecdd1fc58174421a9bfdd8f134ae6e23_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTU5Ng_0c7cca59-d5ea-4a9d-8555-d931f76e6779"
      unitRef="usd">25000000</silk:DebtMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i5ed5ecc368374169a71abc3cc9f49aa5_D20180901-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTkzOA_39b9a7b7-6050-45d1-a6a4-4213d9de0911"
      unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icdeb572f838a40fdaa6ba2d0bfd368c1_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njg4Mg_860b938c-deae-4a0e-a616-ffe73ed42869"
      unitRef="number">0.100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <silk:DebtInstrumentInterestRatePaidInCash
      contextRef="i103121e7190f43fabe96184573d85e5a_I20190501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njg4OQ_7f94fe6c-840b-4f42-a32b-5735cecdd700"
      unitRef="number">0.080</silk:DebtInstrumentInterestRatePaidInCash>
    <silk:DebtInstrumentInterestRatePaidInKind
      contextRef="i103121e7190f43fabe96184573d85e5a_I20190501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njg5Ng_f50b8551-2125-4964-a90a-06937edfa0c0"
      unitRef="number">0.020</silk:DebtInstrumentInterestRatePaidInKind>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7abc563c49034717a7c3322581f18eb8_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NjkyNA_5c12ae7d-19ce-4e87-9dd0-a821f10e3bab"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5936ba61c97f46c9abe460c3748fc302_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk0MQ_1c90dc19-f0d0-47ef-97dc-7f2684cb4fbc"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i36fa0eb7334c455888e30aa07d6532a5_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NjkzNw_d4f6b5d9-475f-4cf5-ba6b-b7685f2f9ab4"
      unitRef="usd">2000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <silk:DebtInstrumentMaximumBorrowingCapacity
      contextRef="i7abc563c49034717a7c3322581f18eb8_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk1NQ_db4bb3ed-e27f-4ce2-8331-0537ab56a8cc"
      unitRef="usd">50000000</silk:DebtInstrumentMaximumBorrowingCapacity>
    <silk:DebtInstrumentCovenantMaximumBorrowingThreshold
      contextRef="ie5c39c1b02c34d54a55c972e504f4f10_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk2OQ_511d6b75-6032-4d8f-9ccf-4e3cffcfcc89"
      unitRef="usd">50000000</silk:DebtInstrumentCovenantMaximumBorrowingThreshold>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifcb3cbb6159547ebb60630ca78155e84_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk3Ng_cc522e0f-194c-49d2-82f5-13f6fe003bc6"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i51b6bd6e7c434a7c95a35ff5a9531de1_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk4NA_c0796e18-c522-4690-8f4f-64a58fb145bf"
      unitRef="number">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ifa3b08c2ee1f40f29b52fda52abcfcbd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3Njk5OA_e13aa9d3-f4c8-47e3-be87-9cbfa9970348"
      unitRef="usd">49000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzAxOA_5b513273-9d46-48d0-8552-c7ceb68b8e71"
      unitRef="usd">46674000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzU4OA_28395fd0-3f00-45ab-8270-cfa749b08850"
      unitRef="usd">305000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzYyMQ_3ca41de5-13b8-4653-a401-d0176a6bfdfb"
      unitRef="usd">365000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="ie5c39c1b02c34d54a55c972e504f4f10_I20201031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzY0Nw_f7fec8f7-5045-46b6-8f15-efe37ce80896"
      unitRef="usd">2191000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie68f78e1157c4ea59e84f07ef1f924dc_D20201001-20201031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzkyOA_2abc35c0-375b-4057-9bae-3d610ee90fce"
      unitRef="usd">-1119000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <silk:RepaymentsOfDebtRevenueTargetPercentage
      contextRef="ie5c39c1b02c34d54a55c972e504f4f10_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzAwNA_486c1020-fcf8-4328-8dea-c6a1e8eee491"
      unitRef="number">0.80</silk:RepaymentsOfDebtRevenueTargetPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifeb1a73d258b47deacf93ec34c1d3916_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzA2MA_6947bb66-a416-4e8f-a775-7110bf775f1f"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i65ad62ac27904958945aa2aa614f9585_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzA2OA_c679e788-a5d7-4d08-856a-6e54640eece1"
      unitRef="number">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <silk:DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold
      contextRef="idb2c47acc6f844248688d675a456ddad_D20201001-20201031"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzA3Ng_348c2daf-fd67-4037-9118-2a037a380bc1"
      unitRef="number">0.0075</silk:DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold>
    <silk:DebtInstrumentCovenantLiquidityEventPaymentAmount
      contextRef="idb2c47acc6f844248688d675a456ddad_D20201001-20201031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzA4Nw_953d38c6-2159-4415-9584-49502855eb40"
      unitRef="usd">375000</silk:DebtInstrumentCovenantLiquidityEventPaymentAmount>
    <silk:DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum
      contextRef="i7abc563c49034717a7c3322581f18eb8_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzEwMQ_452c83fd-fc41-49ab-b9ea-bd22836a8b00"
      unitRef="usd">20000000</silk:DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum>
    <silk:DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions
      contextRef="i7abc563c49034717a7c3322581f18eb8_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzExNQ_89e2afd0-a72a-4e3b-bb94-e96d5cab547b"
      unitRef="usd">60000000</silk:DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions>
    <silk:DebtInstrumentCovenantDebtDefaultRate
      contextRef="i907e8be526f045dba75ef70a204b7872_D20201029-20201029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMzI5ODUzNDkzMzQ4Mw_a4cc573d-3c60-4690-b965-225464f1817a"
      unitRef="number">0.05</silk:DebtInstrumentCovenantDebtDefaultRate>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ifa3b08c2ee1f40f29b52fda52abcfcbd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTA5OTUxMTY3NzEyOQ_e13aa9d3-f4c8-47e3-be87-9cbfa9970348"
      unitRef="usd">49000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i907e1c4c4cf446efb027c2d919844c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfMTY0OTI2NzQ5MTIxOQ_7c4d88fa-7685-4791-a10f-d3a8f1e069f3"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RleHRyZWdpb246NDJiYTQ0NWQxZGI0NDc4ZmI4ZTIxNDEyNTVmYWUzOTNfNTE0MQ_7a73baf5-4c22-424f-babd-1e72dc0df46d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities under the Stifel Bank term loan agreement as of December&#160;31, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amount representing debt discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfMS0yLTEtMS0w_774078a4-a15a-4119-a690-31c812f008d5"
      unitRef="usd">2360000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfMi0yLTEtMS0w_f2a82081-3c4c-4a31-bbcc-9e73a89178bd"
      unitRef="usd">14679000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfMy0yLTEtMS0yODEz_649e9e50-80d6-4c0b-b179-6936c780a23f"
      unitRef="usd">20845000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfMy0yLTEtMS0w_9bf4da7d-f8ef-4829-a0ce-6767f36fb6b7"
      unitRef="usd">17370000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <silk:LongTermDebtGrossBeforeAccretionOfClosingFees
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfNC0yLTEtMS0w_77d5c15b-0477-4500-a510-b6ec9e73d1b1"
      unitRef="usd">55254000</silk:LongTermDebtGrossBeforeAccretionOfClosingFees>
    <silk:LongTermDebtUnpaidInterest
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfNy0yLTEtMS0w_ece1f130-3213-4d6a-99d8-e5ec0b80b1ac"
      unitRef="usd">6254000</silk:LongTermDebtUnpaidInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfOC0yLTEtMS0w_c3e25111-e14d-4c6e-8de6-bfadce5d5cfa"
      unitRef="usd">467000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl85Ny9mcmFnOjQyYmE0NDVkMWRiNDQ3OGZiOGUyMTQxMjU1ZmFlMzkzL3RhYmxlOmQ2YWZiOTQzZTJkZTQ4OTZiYzlkOGJjNjgzN2FmNjQ0L3RhYmxlcmFuZ2U6ZDZhZmI5NDNlMmRlNDg5NmJjOWQ4YmM2ODM3YWY2NDRfOS0yLTEtMS0w_5d76c560-3391-49e2-a980-eb20661c9900"
      unitRef="usd">48533000</us-gaap:LongTermDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM4MzA_9dbaa901-3431-4c09-b851-c4d333823bcc">Commitments and Contingencies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Lease and Rights of Use&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating lease obligation consists of leased office, laboratory, and manufacturing space under a non-cancellable operating lease that expires in October&#160;2024. The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional period of five years.   Operating lease costs were $870,000 for each of the years ended December&#160;31, 2020 and 2019.  Cash paid for amounts included in the measurement of operating lease liabilities was $769,000 and $721,000 for the years ended December&#160;31, 2020 and 2019.  As of December&#160;31, 2020, the weighted average discount rate was approximately 6.50% and the weighted average remaining lease term was 3.83 years.  As of December 31, 2019, the weighted average discount rate was approximately 6.50% and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;weighted average remaining lease term was 4.83 years.  Balance sheet information as of December&#160;31, 2020 consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_79e4f10b-3b5e-4ec2-876c-6e585e344f6b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_da5af1e9-78c6-47d2-b916-faffbda32183"&gt;other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_0c14a90d-c468-4d50-8bda-f4b6abb57993"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_df5558d5-a823-4bc7-8d24-11cd3b6290f9"&gt;accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_14124f2c-b99c-42a3-914f-b88bb1e2da04"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_eb1aa98b-cafb-4393-b523-5f94410b69b5"&gt;other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's operating lease maturities as of December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business.  As of December&#160;31, 2020, the Company had non-cancellable purchase obligations to suppliers of $6,601,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements with suppliers and other parties that contain a variety of representations and warranties and may provide for indemnification of the counterparty.  The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made.  To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company&#x2019;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws.  The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity.  The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance.  The Company believes that the fair value of these indemnification obligations is minimal.  Accordingly, the Company has not recognized any liabilities relating to these obligations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations or cash flows. From time to time, the Company may pursue litigation to assert its legal right and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were no contingent liabilities requiring accrual at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, a former employee, through counsel, advised the Company that he had filed a charge of discrimination against the Company with the California Department of Fair Employment &amp;amp; Housing, or DFEH.  The former employee&#x2019;s complaint alleged sexual harassment and retaliation in violation of the California Department of Fair Employment &amp;amp; Housing Act.  The complaint did not allege specific damages. The Company and the former employee participated in mediation on July 30, 2019 and reached a settlement that required the Company to pay an amount that was not material to its financial statements, which amount was fully paid as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM2NQ_b7e63321-e579-4e2d-b7a0-9f2e05bc1fcd">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM5OA_3f4366bc-b92d-4a3e-8485-e4af3268ef52"
      unitRef="usd">870000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM5OA_8f9aff4c-124f-495b-9e06-eed92e25ebce"
      unitRef="usd">870000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzEwOTk1MTE2MzE4MzE_f062c4d6-928e-4402-a0db-cfb8cf18532d"
      unitRef="usd">769000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzEwOTk1MTE2MzE4MzU_3ae63d48-83a9-46ac-af78-f2d747464998"
      unitRef="usd">721000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzYwMA_f4f582af-d732-4ac6-b798-539c34989631"
      unitRef="number">0.0650</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzY1Mw_ce74ea78-8619-4186-af33-c422947a4ad3">P3Y9M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzEwOTk1MTE2MzIwMDg_19bbc0f5-8e89-46b2-a72f-eb1164c9e060"
      unitRef="number">0.0650</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzEwOTk1MTE2MzIwMTU_fd89226d-2725-441b-b122-156b36d50b32">P4Y9M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMi0xLTEtMA_aad1a0d5-2244-47c7-836e-d1969dc8d88c"
      unitRef="usd">2798000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtNC0xLTEtMjg0NA_ab3daeee-1e4d-4347-81da-a6999a218654"
      unitRef="usd">3400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMi0xLTEtMA_61462177-4255-4622-9411-210d1338e823"
      unitRef="usd">850000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItNC0xLTEtMjg0NA_1877390c-fd37-4a83-8615-a0b506960163"
      unitRef="usd">769000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMi0xLTEtMA_c363c3bf-e8b4-48c3-b103-e869d40154f2"
      unitRef="usd">2850000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtNC0xLTEtMjg0NA_e486c261-7417-4302-b9df-698830a7a8a1"
      unitRef="usd">3700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzQtMi0xLTEtMA_8cbeceaf-2da0-4d11-89c1-5891ccdfd69c"
      unitRef="usd">3700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzQtNC0xLTEtMjg0NA_6f3d7ca6-63d9-4257-874d-53c29d12729e"
      unitRef="usd">4469000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzM4MzI_0bc55911-02e5-4865-924a-bbd4e8d994a8">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's operating lease maturities as of December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzItMi0xLTEtMA_0ebcaa56-a6e7-4e3a-b1fb-1cc16b06bb46"
      unitRef="usd">1066000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzMtMi0xLTEtMA_24704091-a412-4d87-98bb-8871b8d902a7"
      unitRef="usd">1096000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzQtMi0xLTEtMA_0f223ef7-3b63-43fa-8e5c-affc2371f9d4"
      unitRef="usd">1127000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzUtMi0xLTEtMA_e5d15d1c-4aa9-485e-9add-24b8a01c690b"
      unitRef="usd">904000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzYtMi0xLTEtMA_71b6604b-785b-4571-ae60-e8b2f49bfdff"
      unitRef="usd">4193000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzctMi0xLTEtMA_cd998b68-0a12-41d4-9114-7393b26baddd"
      unitRef="usd">493000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpjYjczZDBhZDE2NjM0ODA4OTIxZTA2ZGM0YTc4YzljYy90YWJsZXJhbmdlOmNiNzNkMGFkMTY2MzQ4MDg5MjFlMDZkYzRhNzhjOWNjXzgtMi0xLTEtMA_aa5ccca1-d1da-4bea-a6fa-e4ecf92e443d"
      unitRef="usd">3700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzExNzI_1a26d699-0098-4509-9d3c-ea055ebe4091"
      unitRef="usd">6601000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzMyOTg1MzQ4ODczOTI_0415bcab-c3ee-4aa1-83b5-77c956c9d89c"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90ZXh0cmVnaW9uOmY3ZGQ4MjljYWQwYjRhODJhNGFkMzM5YmQ0YTRmOWM2XzMyOTg1MzQ4ODczOTI_fc0ad889-726a-49ae-821d-1b2ea10c5836"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzgzNw_044960bb-468d-4b96-8309-358885910077">Redeemable Convertible Preferred Stock&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the closing of the Company's IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does not have any redeemable convertible preferred stock issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock Warrant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the closing of the Company's IPO, all of the outstanding redeemable convertible preferred stock warrants were exercised, or net exercised based on the IPO price of $20.00 per share, into 1,945,365 shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does not have any redeemable convertible preferred stock warrants outstanding.&lt;/span&gt;&lt;/div&gt;Stockholders' Equity (Deficit)&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of preferred stock with $0.001 par value per share, of which no shares were issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 34,249,649 shares were issued and outstanding.  The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors.  As of December&#160;31, 2020, no dividends have been declared to date.  Each share of common stock is entitled to one vote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, the Company had reserved common stock for future issuances as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercise of options under stock plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Issuance of options and restricted stock units under stock plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,790,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,554,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Issuance of common stock under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;632,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;372,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,660,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,237,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock Warrant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO, the common stock warrants were cash, or net exercised based on the IPO price of $20.00 per share into 5,968 shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does not have any common stock warrants outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i1c3729f2464e47ab98755aaf4d5239ee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzM1Mw_20ab400e-08ef-40af-a885-81658fcf5d10"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i1c3729f2464e47ab98755aaf4d5239ee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzM1Mw_65bd368c-2d67-4411-984a-3f74b2eb0231"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i66136b6bed6c411a82f197a4d3385b6a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzM1Mw_7fc95ce2-76c6-456b-b8e5-bddfacbf9182"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i66136b6bed6c411a82f197a4d3385b6a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzM1Mw_d323750c-cb98-404d-a10d-46e0bc2244d6"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i62faf7ea655c489e8fb700ba32e5a72a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzYzNQ_983fd72a-0ea4-40ec-9dea-8295502de822"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="ib33b63c59a7142df9c638019a56d357b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzY1NA_e7d6630c-02eb-46fd-a7c8-5961abae5930"
      unitRef="shares">1945365</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="idb165d229e594aed955a8ab2194b3631_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzMyOTg1MzQ4ODQ1NDU_133b35c2-ea99-4ff8-a6de-3db79ff96974"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="idb165d229e594aed955a8ab2194b3631_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzMyOTg1MzQ4ODQ1NDU_155ae54d-9b0b-4731-9729-7b3a1c14774d"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i8035f9f9ec5d4b46adb98b3f8e400ff1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzMyOTg1MzQ4ODQ1NDU_89185a85-90c3-4095-8299-6bcf2ccc62cf"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i8035f9f9ec5d4b46adb98b3f8e400ff1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDMvZnJhZzozMGNmY2RkMWU1YzE0YWI1ODA1NjI0NzExYzliMzkwYy90ZXh0cmVnaW9uOjMwY2ZjZGQxZTVjMTRhYjU4MDU2MjQ3MTFjOWIzOTBjXzMyOTg1MzQ4ODQ1NDU_b34434c7-79b0-4ac5-b060-69e6c1ee553f"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzE2OQ_1e18cf16-e260-4872-ad78-129657a96276"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzIwMw_df592550-b576-4b64-ac69-a11bc5b55f02"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzMyOTg1MzQ4ODQ2MDg_2501990d-967a-4300-a6f2-1e81d0102f82"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzMyOTg1MzQ4ODQ2MDg_3ce31dae-fbef-4dcd-b690-0368f45a2367"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzQwMg_45d14840-ecf4-4a2b-afb5-30eb6e5e4102"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzQzMw_11793c26-534f-4b60-8f18-587b2ff04164"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzQ2Ng_dfcec7a3-4606-47e4-a68a-fcf3f0874511"
      unitRef="shares">34249649</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzQ2Ng_fe52dc00-7b4b-45d1-b4da-1878dd4de319"
      unitRef="shares">34249649</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DividendsCommonStock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzY3MA_46b062bf-8c03-4280-bf00-f0528ed8a70d"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <silk:CommonStockVotePerShare
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzc1NA_c9bb6bdb-ac74-4e9e-9c88-45c92185ae22"
      unitRef="vote">1</silk:CommonStockVotePerShare>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzExMzQ_d42e5993-ec0b-4164-8893-2933aae65d72">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, the Company had reserved common stock for future issuances as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercise of options under stock plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Issuance of options and restricted stock units under stock plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,790,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,554,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Issuance of common stock under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;632,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;372,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,660,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,237,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i603554706e704e14a87cd579bfc1f1cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzYtMS0xLTEtMA_15d32dda-0e68-43c7-95db-98e948f1d006"
      unitRef="shares">4237828</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i096b9866423f47bfbd8c84a4319b04fc_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzYtMy0xLTEtMA_880db812-4576-40e6-b2ef-168737239acf"
      unitRef="shares">4310790</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="idbdb361087f54a5fbd3ebc590fca7604_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzctMS0xLTEtMA_618238c8-eae5-4cf5-8fe3-c95a8797f1b3"
      unitRef="shares">1790687</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i03ab7ad3a56f48299ce1b6e914d7b413_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzctMy0xLTEtMA_463bc497-94af-4b09-af95-f531431da2ac"
      unitRef="shares">1554690</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i480f0a71d7df4da79168f1094a28dc8e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzgtMS0xLTEtMA_1f921fa5-a7b4-45cc-8ea2-c644b9fef45f"
      unitRef="shares">632377</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i09057e7a1c6b4809a7a1631278acc9b9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzgtMy0xLTEtMA_31a39d45-0551-45bf-a309-b4e686593124"
      unitRef="shares">372352</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzEwLTEtMS0xLTA_15e2493c-bb5c-4a81-ba94-ef8c220c84f5"
      unitRef="shares">6660892</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90YWJsZTo4NTNjYzhiOTU2MzU0Njk0OGMzM2FlZDcwZDY3NzZkYy90YWJsZXJhbmdlOjg1M2NjOGI5NTYzNTQ2OTQ4YzMzYWVkNzBkNjc3NmRjXzEwLTMtMS0xLTA_e6e25936-9a7e-45bd-b7b0-3906e872119c"
      unitRef="shares">6237832</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i62faf7ea655c489e8fb700ba32e5a72a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzk4Mg_84800136-05a8-4e68-8447-5156cb217365"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="iaf29cfa1d6194741a8ec14f28d1e4578_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzEwMDA_19853876-729c-4289-a2e2-aeed35805677"
      unitRef="shares">5968</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1a1e51514e02474c89b155e4a5550726_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzMyOTg1MzQ4ODQ2MDA_35a42250-e274-4beb-abbd-8f731aaf44e0"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i0ae992978a7d4deda30dcb028e032db0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDkvZnJhZzpjNWVmZmFiMDhiNzI0MmJhOTZjMDA5NDUzNzJhMzU3MS90ZXh0cmVnaW9uOmM1ZWZmYWIwOGI3MjQyYmE5NmMwMDk0NTM3MmEzNTcxXzMyOTg1MzQ4ODQ2MDA_b3c15f32-51c6-47cf-9699-7b8e60b38745"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMTE_21e26c4a-8f67-4800-b4db-1cee76e34dd7">Stock Option Plans&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2007, the Company established its 2007 Stock Option Plan which provided for the granting of stock options to employees, directors and consultants of the Company.  In connection with its acquisition of NeuroCo in December 2018, the Company also assumed NeuroCo&#x2019;s 2015 Equity Incentive Plan.  In March 2019, the Company's Board of Directors approved the termination of the 2007 Stock Option Plan and the NeuroCo 2015 Equity Incentive Plan and the adoption of the 2019 Equity Incentive Plan, or the 2019 Plan, which became effective immediately prior to the Company's IPO.  The 2019 Plan provides for the grant of ISOs to employees and for the grant of NSOs, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants.  A total of 2,317,000 shares of common stock were initially reserved for issuance pursuant to the 2019 Plan.  In addition, the shares reserved for issuance under the 2019 Plan will also include shares reserved but not issued under the 2007 Stock Option Plan, plus any share awards granted under the 2007 Stock Option Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased.  In addition, the number of shares available for issuance under the 2019 Plan will also include an annual increase on the first day of each fiscal year, equal to the lesser of (i) 3,000,000 shares; (ii) 4.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) an amount as determined by the Board of Directors.  As of December&#160;31, 2020, the Company has reserved 3,635,009 shares of common stock for issuance under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the shares available for issuance under the 2007 Stock Option Plan, NeuroCo 2015 Equity Incentive Plan and 2019 Plan, or the Plans, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;328,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;223,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(629,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;135,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,317,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(848,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,824&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554,690&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,250,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted/Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,079,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;65,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,790,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of ISOs and NSOs shall not be less than 100% and 85%, respectively, of the estimated fair value of the shares on the date of grant as determined by the Board of Directors.  The exercise price of ISOs and NSOs granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors.  To date, options have a term of ten years and generally vest over 4 years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company's Plans is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,308,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(873,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,018,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $47,861,000, $24,867,000 and $787,000, respectively.  The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise.  The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020, 2019 and 2018 was $18.22, $10.17 and $2.93 per share, respectively.  The total fair value of options vested during the years ended December&#160;31, 2020, 2019 and 2018 was $5,138,000, $2,221,000 and $569,000, respectively, based on the grant date fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock options outstanding and vested as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Vested&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.35 - $3.16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.73 - $7.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.27 - $12.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.00 - $30.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$30.93 - $46.40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$47.20 - $70.80&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company began granting restricted stock units, or RSUs, under the 2019 Plan.  RSUs generally vest over four years in annual equal increments, no RSUs vested during the year ended December 31, 2020.  The fair value of RSUs is based on the Company&#x2019;s closing stock price on the date of grant.  A summary of RSUs activity for the year ended December 31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted stock granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;46.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted stock forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;44.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;68,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;46.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;68,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;46.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, the Company's Board of Directors adopted the 2019 Employee Stock Purchase Plan, or the 2019 ESPP, under which eligible employees are permitted to purchase common stock at a discount through payroll deductions.  A total of 434,000 shares of common stock were initially reserved for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issuance and is increased on the first day of each fiscal year by an amount equal to the lesser of (i)&#160;1,200,000 shares (ii)&#160;1.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii)&#160;an amount as determined by the Board of Directors.  As of December 31, 2020, the Company has reserved 746,552 shares of common stock for issuance under the 2019 ESPP.  The price of the common stock purchased will be the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period.  The 2019 ESPP was effective upon adoption by the Company's Board of Directors but was not in use until the completion of the Company's IPO in April 2019.  The 2019 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&#160;423 of the Internal Revenue Code of 1986, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, 114,175 shares of common stock have been issued to employees participating in the 2019 ESPP and 632,377 shares were available for future issuance under the 2019 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the fair value of stock options using the Black&#x2013;Scholes option pricing model.  The fair value of employee and nonemployee stock options is being amortized on a straight&#x2013;line basis over the requisite service period of the awards.  The fair value of employee and nonemployee stock options was estimated using the following assumptions for the years ended December&#160;31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.314%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0% - 50.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4% - 42.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0% - 38.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.32% - 1.41%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47% - 2.54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68% - 2.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to completion of the Company's IPO, the fair value of common stock was determined by the Company&#x2019;s Board of Directors, who considered, among other things, contemporaneous valuations of the Company&#x2019;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.  For stock options granted after the completion of the IPO, the fair value of the underlying common stock is based on the closing price of the Company's common stock on The NASDAQ Global Market on the date of grant.  The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding.  The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the &#x201c;simplified method,&#x201d; whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option.  The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as the Company does not have sufficient trading history for the Company&#x2019;s common stock.  The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the&#160;Company&#x2019;s common stock becomes available.  The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the&#160;Company&#x2019;s stock options.  The expected dividend assumption is based on the Company&#x2019;s history and expectation of dividend payouts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, the Company made an accounting policy election to account for forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the shares to be issued under the Company&#x2019;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the years ended December&#160;31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50 - 0.63&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.4% - 76.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.4% - 47.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10% - 1.58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58% - 2.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation expense included in the statements of operations for all periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was total unrecognized compensation costs of $20,188,000 related to stock options expected to be recognized over a period of approximately 3.02 years, a total of $2,716,000 of unrecognized compensation costs related to unvested RSUs expected to be recognized over a period of approximately 3.48 years and $295,000 related to the ESPP, which the Company will recognize over 0.38 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic097536e6675494dbb4e914fc5bcd668_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzg1MA_bc84b39e-3231-4eaa-acca-daee36323860"
      unitRef="shares">2317000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i360f4f24adde40d8b482c84b661efed8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE0NTk_92f4976f-5d0a-489c-ab6d-c2a9ea604bd0"
      unitRef="shares">3000000</silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i470f2ac36ec446a29f50d256c7548d9e_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE0NzU_1d60b403-b4ea-4889-9d72-d02e57e74b08"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i214a26dd5e864dbeba676287ebd8859d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE2Nzc_94f8c3b3-5ce3-4d70-9b87-1423ecfdaab9"
      unitRef="shares">3635009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyMzQ_d83caff1-132f-4d9c-b101-0ba53983b78b">A summary of the shares available for issuance under the 2007 Stock Option Plan, NeuroCo 2015 Equity Incentive Plan and 2019 Plan, or the Plans, is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;328,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;223,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(629,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;135,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,317,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(848,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,824&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554,690&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,250,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted/Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,079,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;65,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,790,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company's Plans is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,308,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(873,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,018,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock options outstanding and vested as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Vested&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.35 - $3.16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.73 - $7.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.27 - $12.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.00 - $30.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$30.93 - $46.40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$47.20 - $70.80&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i6f4737d591bc4039af44f3bd9c4891fd_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzEtMi0xLTEtMzA5Mw_3edcb848-359b-48b2-8964-c2b880cca5b8"
      unitRef="shares">328290</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized
      contextRef="icd542f1734634f0a802415b0d28a90a1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzItMi0xLTEtMzA5Mw_34f331cb-58e9-4a54-b26a-695139126104"
      unitRef="shares">223664</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross
      contextRef="icd542f1734634f0a802415b0d28a90a1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzMtMi0xLTEtMzA5Mw_35a2a2d8-21ab-454e-be7b-be9f0a0b2f73"
      unitRef="shares">629716</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod
      contextRef="icd542f1734634f0a802415b0d28a90a1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzQtMi0xLTEtMzA5Mw_8263b187-9e0e-441f-85b3-88545d787355"
      unitRef="shares">135651</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i3bf45438ba5c4c2aa9a094bb5bd64ede_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzEtMi0xLTEtMzA2MQ_1217a540-c475-4962-bd20-865332826b96"
      unitRef="shares">57889</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized
      contextRef="idf1037c5333249bbbd1ae376d9910c53_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzItMi0xLTEtMzA2MQ_4613623b-373c-4912-96e7-c5b7993a66cd"
      unitRef="shares">2317000</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross
      contextRef="idf1037c5333249bbbd1ae376d9910c53_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzQtMi0xLTEtMzA2MQ_c8e829be-a736-4cf1-906c-42664f02ae33"
      unitRef="shares">848023</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod
      contextRef="idf1037c5333249bbbd1ae376d9910c53_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzUtMi0xLTEtMzA2MQ_3b47166c-6e6f-44a4-b267-a2ffee0e2b35"
      unitRef="shares">27824</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber
      contextRef="ie77759ae85f849f99b4e3b1e0c06210e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzEtMi0xLTEtMjkwNw_343054b6-f725-4283-9134-86c756005629"
      unitRef="shares">1554690</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized
      contextRef="i7a8b1f2479ef489b833a827057b3ee5a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzItMi0xLTEtMjkwNw_f4982a45-ea7f-4f96-b0c2-976e336cb585"
      unitRef="shares">1250210</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross
      contextRef="i7a8b1f2479ef489b833a827057b3ee5a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzMtMi0xLTEtMjkwNw_943b8029-7699-467f-9b22-f131c05aa89b"
      unitRef="shares">1079883</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod
      contextRef="i7a8b1f2479ef489b833a827057b3ee5a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzQtMi0xLTEtMjkwNw_0ba27499-a084-4426-86fb-6a6e1bb82e9f"
      unitRef="shares">65670</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i214a26dd5e864dbeba676287ebd8859d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyYzM3ZDdkNjQxMWE0Y2JlOTljYjkzZjBjN2MwZWNjNC90YWJsZXJhbmdlOjJjMzdkN2Q2NDExYTRjYmU5OWNiOTNmMGM3YzBlY2M0XzUtMi0xLTEtMjkwNw_7a8825f5-c599-4c14-88fc-201180c5dc3d"
      unitRef="shares">1790687</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber>
    <silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice
      contextRef="i2c0182ac39bf451580f9e5a338dd2281_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE3OTY_59b66205-950e-49a4-900d-41863b76bc46"
      unitRef="number">1</silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice>
    <silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice
      contextRef="i708be08da99c40d39705d37410604fa8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzE4MDM_541e768d-7504-4799-83cc-872589a69a61"
      unitRef="number">0.85</silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice>
    <silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice
      contextRef="i63c59c6933b34539813d0d966133cca9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzIwMTM_c9f9e2bd-4c91-4daa-a666-17079f6511ed"
      unitRef="number">1.10</silk:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i659d64912c544b77817ed68d2f7ce05c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzIxNTM_a399ca49-c563-49f2-926a-60eb5063278c">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i659d64912c544b77817ed68d2f7ce05c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzIxODA_c112bb16-c6f1-4fa9-b6db-4864485ed967">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzctMy0xLTEtMA_fda1a90b-62b4-477e-97ee-a55e5a87c3d6"
      unitRef="shares">4308890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzctNS0xLTEtMA_562ad58f-b0ca-4eab-a12d-acb3e816f40e"
      unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8ea3f51adc9c4505b898323c41931f67_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzctNy0xLTEtMA_d28a3af7-c749-4e48-82f8-486c6bd17e6e">P7Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzctOS0xLTEtMA_49ff7759-c103-499e-9a97-dbbab3faad30"
      unitRef="usd">5073000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzktMy0xLTEtMA_557935ca-91e0-4089-943a-79038a4396d5"
      unitRef="shares">629716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzktNS0xLTEtMA_1e381401-949a-4fec-9c58-b089952cd7da"
      unitRef="usdPerShare">6.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEwLTMtMS0xLTA_79d49285-dace-4344-892f-f4519eef745d"
      unitRef="shares">438578</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEwLTUtMS0xLTA_077be997-3833-4cbc-a87d-b6e4c702aa84"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzExLTMtMS0xLTA_88bcbccc-6da2-4851-bd81-037528f8fc45"
      unitRef="shares">135651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzExLTUtMS0xLTA_54961682-68cc-4326-97c5-4541c988d85b"
      unitRef="usdPerShare">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEyLTMtMS0xLTA_4338f4f5-1b00-49f5-96f9-58907aa19996"
      unitRef="shares">4364377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEyLTUtMS0xLTA_159eaad4-efca-4480-a360-72b1e2fcee39"
      unitRef="usdPerShare">3.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEyLTctMS0xLTA_1080f05a-7595-450b-9dd2-818e3d2a66a4">P7Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzEyLTktMS0xLTA_6c24efda-9a21-4cf5-b859-8ceb5dfaa762"
      unitRef="usd">33132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE0LTMtMS0xLTA_d2d617a2-39ae-44ac-865a-f4fcb781a35f"
      unitRef="shares">848023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE0LTUtMS0xLTA_ff715614-ff84-457c-ba2f-964d6762986c"
      unitRef="usdPerShare">22.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE1LTMtMS0xLTA_29f7b21c-1b47-4fbf-a5d6-4416bea677d3"
      unitRef="shares">873786</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE1LTUtMS0xLTA_91a7b1c1-52a1-4e6b-92ec-9f1cc8498f31"
      unitRef="usdPerShare">1.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE2LTMtMS0xLTA_86491c4a-a858-49f2-a8eb-65b7c8d34744"
      unitRef="shares">27824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE2LTUtMS0xLTA_922c6a38-8951-4092-a115-7df635ecb308"
      unitRef="usdPerShare">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE3LTMtMS0xLTA_2a99185e-8fd7-4dc2-b81b-c6d3c792637b"
      unitRef="shares">4310790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE3LTUtMS0xLTA_befd1f33-4a9d-437b-8eb8-f5e61cc74f91"
      unitRef="usdPerShare">7.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE3LTctMS0xLTA_b1b40877-63d3-4676-a7ae-1b441cd14a04">P7Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE3LTktMS0xLTA_279a74d6-e8ca-407a-bf71-66b2eeae5bbb"
      unitRef="usd">140234000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTMtMS0xLTI5MjY_0bd2a7d3-97f0-4490-946e-ff8d5e93a8b0"
      unitRef="shares">1010843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTUtMS0xLTI5MjY_4a6f5604-4b5b-407f-9ebf-6080fd60634e"
      unitRef="usdPerShare">40.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTMtMS0xLTI5MjY_26aad6a3-2d60-4eff-b596-bc252087c381"
      unitRef="shares">1018779</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTUtMS0xLTI5MjY_831f85d2-37d1-4f62-b170-2f74803d1010"
      unitRef="usdPerShare">3.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIwLTMtMS0xLTI5MjY_bd2cf980-0ca9-4e45-a16e-7618c406e288"
      unitRef="shares">65026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIwLTUtMS0xLTI5MjY_847bfaad-4ed1-4f40-8cd7-ebd9baaf6bac"
      unitRef="usdPerShare">23.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIxLTMtMS0xLTI5MjY_0faf97e0-12a4-4753-8e0e-1452270e5462"
      unitRef="shares">4237828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIxLTUtMS0xLTI5MjY_dcd58872-005f-42b3-ac07-ab277cd2308d"
      unitRef="usdPerShare">16.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIxLTctMS0xLTI5MjY_aaf4c2a9-15a4-4c7f-b4a9-eb15dfbc0cdd">P7Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzIxLTktMS0xLTI5MjY_16644333-58d0-40d2-8498-0e2034ff6fbb"
      unitRef="usd">197407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTMtMS0xLTA_1889caf8-f876-4d63-bccd-e5f1778cf99f"
      unitRef="shares">2392563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTUtMS0xLTA_4f99611f-2af2-4895-86e5-3f5b26f8e825"
      unitRef="usdPerShare">8.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTctMS0xLTA_06ad3786-ee72-4195-8721-938e29c987a3">P6Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE4LTktMS0xLTA_17a3e493-eca5-49dd-a241-11792236bcfb"
      unitRef="usd">130417000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTMtMS0xLTA_a4616c9b-358e-42c6-8914-a01217d61253"
      unitRef="shares">4237828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTUtMS0xLTA_46d70cca-c107-48c4-b59f-7c8072f499ee"
      unitRef="usdPerShare">16.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTctMS0xLTA_97cf382d-0580-4bc4-bee5-d0a25b05e14b">P7Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTplYzVkNGM2Y2UwZjQ0ZjQ3YWQ2OTgxZjJiZWM2ZWQyMy90YWJsZXJhbmdlOmVjNWQ0YzZjZTBmNDRmNDdhZDY5ODFmMmJlYzZlZDIzXzE5LTktMS0xLTA_fcf02801-fc95-419e-bfe7-9f643038427b"
      unitRef="usd">197407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5NTE_3e49d25b-0bdc-4e7f-beb7-7f5609509bb2"
      unitRef="usd">47861000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5NTc_3d32476f-ee6e-4bdc-a31d-0d85c386097e"
      unitRef="usd">24867000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5NjE_6d8d0104-2a46-46cd-908e-2bdf42a26287"
      unitRef="usd">787000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5Nzg_21da1e89-5ca6-4464-8671-952f4c4507b0"
      unitRef="usdPerShare">18.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5ODQ_a541c234-3df2-43fd-bd3c-43d670544361"
      unitRef="usdPerShare">10.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzY5ODg_322b5e82-b4c6-4895-b128-5fe8ce16cc93"
      unitRef="usdPerShare">2.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwMTA_a1332b7a-d48a-4ea5-b354-4418f1af048e"
      unitRef="usd">5138000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwMTY_ee7b8e9c-6fbf-4bbf-a4f6-0eb43649faef"
      unitRef="usd">2221000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwMjA_3af125c5-8a68-4692-9252-17c27701ae87"
      unitRef="usd">569000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="i490bf68acdbb4450bf64bafef197e4fb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItMC0xLTEtMC90ZXh0cmVnaW9uOmU0MmVmODJmZmQ5YjQ3YTRiZTczMDkwYjMwNjFlMWRlXzQ_b590dd17-ee89-449d-ad52-cdc7d5933f3a"
      unitRef="usdPerShare">1.35</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="i715cd558a0134ebba2c8252d957a7ce6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItMC0xLTEtMC90ZXh0cmVnaW9uOmU0MmVmODJmZmQ5YjQ3YTRiZTczMDkwYjMwNjFlMWRlXzk_d7128e8c-2845-4df6-bd3a-14c3598e0134"
      unitRef="usdPerShare">3.16</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if2c087f244e24d669ad5f5b19aa67a98_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItMi0xLTEtMA_58d466f7-d7b0-41bd-93b3-fb923d1ef2b3"
      unitRef="shares">1214279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5e3dc08fdedf4e33bd6817d15104fe6e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItNC0xLTEtMA_16e01d61-6b58-4ca3-9148-8af5f8efa47b">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if2c087f244e24d669ad5f5b19aa67a98_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItNi0xLTEtMA_31bb05aa-1d26-451b-b261-88d87414c490"
      unitRef="usdPerShare">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if2c087f244e24d669ad5f5b19aa67a98_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItOC0xLTEtMA_908a90c1-72d9-4d0d-a49a-89ee03e1973c"
      unitRef="shares">1128865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if2c087f244e24d669ad5f5b19aa67a98_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzItMTAtMS0xLTA_eff85f64-6e98-4088-aafa-c7a55567d95d"
      unitRef="usdPerShare">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="i6fdd1471eaa54f92a52745ec56a48110_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtMC0xLTEtMC90ZXh0cmVnaW9uOjU0YjFiNjQzMGEwZjQ1OTRhZjJlNDMyZTcxNmZkYjRiXzQ_acaa8680-42e6-4ba2-bedb-68c7e601efb1"
      unitRef="usdPerShare">4.73</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="i8945e1adfb3b4ab09fa3fa5891d357c6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtMC0xLTEtMC90ZXh0cmVnaW9uOjU0YjFiNjQzMGEwZjQ1OTRhZjJlNDMyZTcxNmZkYjRiXzk_cbe92416-7b9a-4b7d-b899-23feb11ceff1"
      unitRef="usdPerShare">7.10</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id8c8d5b84586400b86587503b81287f6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtMi0xLTEtMA_2bb2870b-53d1-4e8c-8c11-c3aa0831f267"
      unitRef="shares">722615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="icc46ca644c744b70aac67133ea9f52f4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtNC0xLTEtMA_cb747954-4499-49c8-a9f8-875c6a239dc6">P7Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id8c8d5b84586400b86587503b81287f6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtNi0xLTEtMA_c8914628-9394-4ca7-ace5-ee607b4fb77a"
      unitRef="usdPerShare">5.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id8c8d5b84586400b86587503b81287f6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtOC0xLTEtMA_0180fcc2-2029-4b2f-bb95-7207c0cbd762"
      unitRef="shares">443670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id8c8d5b84586400b86587503b81287f6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzMtMTAtMS0xLTA_3a8de4ce-9639-476c-91f9-a94489dd4651"
      unitRef="usdPerShare">5.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="i36011f19453e484790ec3753ef0eb829_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtMC0xLTEtMC90ZXh0cmVnaW9uOjY2MmRjOGM4NjVkYjQ5MzJhOTViOGEyYWRkOGI5NTM2XzQ_dbc81c7d-9f07-438b-b39b-6bcdd9395b8e"
      unitRef="usdPerShare">8.27</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="i19b4be470462491987f832241f434403_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtMC0xLTEtMC90ZXh0cmVnaW9uOjY2MmRjOGM4NjVkYjQ5MzJhOTViOGEyYWRkOGI5NTM2Xzk_3215b760-8acf-4f37-aca9-78ef94f5ae4b"
      unitRef="usdPerShare">12.41</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6b5473c83d5146e19f1b3858891c78b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtMi0xLTEtMA_c4baaa5a-755d-45db-8c1c-a65b370ff6c4"
      unitRef="shares">564188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i2f9b2814a79c4dd08d65788445d6db8e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtNC0xLTEtMA_9b9f9c5b-cf79-4ea8-809c-fbf0bb26b750">P7Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6b5473c83d5146e19f1b3858891c78b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtNi0xLTEtMA_edbe8213-7252-4384-b09c-aa9a55d18d02"
      unitRef="usdPerShare">11.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6b5473c83d5146e19f1b3858891c78b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtOC0xLTEtMA_967cd241-00b3-404c-a516-02d5603132c1"
      unitRef="shares">394727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6b5473c83d5146e19f1b3858891c78b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzQtMTAtMS0xLTA_7be749e9-4de5-40d3-ae45-7d567ddb1d16"
      unitRef="usdPerShare">11.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="i74888ea9613946dd8a212a7d91cda76a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgyOWM1NTA2Yjc4YjQ0YmFiZGViMjUwZjVjODkxMjVkXzQ_75952813-c78b-421e-91ac-78e57aa3d95a"
      unitRef="usdPerShare">20.00</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="ibd4ed4e74601414e92a601aa67b10327_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgyOWM1NTA2Yjc4YjQ0YmFiZGViMjUwZjVjODkxMjVkXzk_4818146e-01a9-489e-89ae-9e18f7ec5bde"
      unitRef="usdPerShare">30.00</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idfd02705d3de468ba9f3a47573c3dde9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtMi0xLTEtMA_1bd7f87a-a026-4a76-92eb-b1b9c21b83ab"
      unitRef="shares">656009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia49153bfeb6f42bdb3736ba316591747_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtNC0xLTEtMA_1ecd3a01-7bd4-4f26-8ea3-626f073bbcdf">P8Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idfd02705d3de468ba9f3a47573c3dde9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtNi0xLTEtMA_32c77c08-93cb-489c-a354-57fd12f24c80"
      unitRef="usdPerShare">20.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="idfd02705d3de468ba9f3a47573c3dde9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtOC0xLTEtMA_e999465a-466f-4905-9419-cf3ef31804ea"
      unitRef="shares">270305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="idfd02705d3de468ba9f3a47573c3dde9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzUtMTAtMS0xLTA_87ef8103-880a-47d9-8691-6495dd743cbb"
      unitRef="usdPerShare">20.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="ice0a90922eee49f89e3692455daf46fa_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMC0xLTEtMzE4Ni90ZXh0cmVnaW9uOmVhY2QxYTRjMjc3ZTQwNzZiNDgxM2MxNzNiMmFiNWU0XzEwOTk1MTE2Mjc3ODA_34620aad-c2d2-434e-a22a-87153cc60998"
      unitRef="usdPerShare">30.93</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="ia787b8a99022442987a046c7b0ae1e90_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMC0xLTEtMzE4Ni90ZXh0cmVnaW9uOmVhY2QxYTRjMjc3ZTQwNzZiNDgxM2MxNzNiMmFiNWU0XzEwOTk1MTE2Mjc3ODY_75dd3cad-14c1-498b-bfff-397e0bd13a97"
      unitRef="usdPerShare">46.40</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6c7bb98d16e744c886f33a907325392b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMi0xLTEtMzIwNQ_e609561b-f861-47d5-a768-ba158aa987ed"
      unitRef="shares">771966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie1ab64a372d04ae8b13ae564c7b1d519_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtNC0xLTEtMzIwNQ_3ccb2ec2-7345-4adc-8e1c-073e3903152a">P9Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6c7bb98d16e744c886f33a907325392b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtNi0xLTEtMzIwNQ_579ea372-b366-416e-b337-9b08b4c91384"
      unitRef="usdPerShare">33.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6c7bb98d16e744c886f33a907325392b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtOC0xLTEtMzIwNQ_73edf341-f434-40b0-8f09-15491b0be6a9"
      unitRef="shares">136151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6c7bb98d16e744c886f33a907325392b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMTAtMS0xLTMyMDU_298bf0d5-e433-469b-a726-e8c09af52552"
      unitRef="usdPerShare">33.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="i8621a9d17f8c4c759e18a0b9f4998461_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctMC0xLTEtMzE5Mi90ZXh0cmVnaW9uOjBjZDc1NDA5ZjY1MTRmMWQ5NjEwYWM5OTk3ZTBiOWFlXzEwOTk1MTE2Mjc3ODA_c017eddd-6417-4808-8fb5-4e5c4a136d7c"
      unitRef="usdPerShare">47.20</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="i0d07d3d83db94418805af6f5704d41c9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctMC0xLTEtMzE5Mi90ZXh0cmVnaW9uOjBjZDc1NDA5ZjY1MTRmMWQ5NjEwYWM5OTk3ZTBiOWFlXzEwOTk1MTE2Mjc3ODY_73741bf9-3692-4a00-ba04-6a174b0e0b29"
      unitRef="usdPerShare">70.80</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i67a74532b17b4cbeb8fc651e11ede5be_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctMi0xLTEtMzIwNQ_45848052-a6b6-4793-9228-e78d409aaea0"
      unitRef="shares">308771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9a577dab858449659f2138be0247edb3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctNC0xLTEtMzIwNQ_7f7d0537-de5f-4afb-a89e-5790661450ca">P9Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i67a74532b17b4cbeb8fc651e11ede5be_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctNi0xLTEtMzIwNQ_5eba88af-585b-4aac-9c25-213ab7c57f2c"
      unitRef="usdPerShare">58.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i67a74532b17b4cbeb8fc651e11ede5be_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctOC0xLTEtMzIwNQ_cf9c789c-e41c-44da-ac88-2e8fc38f84cc"
      unitRef="shares">18845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i67a74532b17b4cbeb8fc651e11ede5be_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzctMTAtMS0xLTMyMDU_5db55fa4-bc9a-4799-b73e-b3b8b69f00dd"
      unitRef="usdPerShare">51.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMi0xLTEtMA_63d57f5a-03d7-435f-8d87-0d8140c0df25"
      unitRef="shares">4237828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtNC0xLTEtMA_048497e3-d490-4cab-8e01-da57ec7e979b">P7Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtNi0xLTEtMA_2ff50140-608c-44d2-a382-39e5ae2f5f53"
      unitRef="usdPerShare">16.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtOC0xLTEtMA_bb5dcd1e-c089-49c1-a731-5302c47c0226"
      unitRef="shares">2392563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTphOWY1YjVjNWUxYTI0NjRmOTE3MjYyZTc4ZjAxZWNhMC90YWJsZXJhbmdlOmE5ZjViNWM1ZTFhMjQ2NGY5MTcyNjJlNzhmMDFlY2EwXzYtMTAtMS0xLTA_9190e35b-8f03-47d6-81d8-3dbfd4974402"
      unitRef="usdPerShare">8.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyMzU_7f971367-ab7a-47cc-8933-0c28fcfe401b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyNTA_2a7a8c61-017c-4317-9def-c31fadf9cbbb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyMzM_d914ba0b-82f8-4db1-8f5f-56542b709903">A summary of RSUs activity for the year ended December 31, 2020 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted stock granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;46.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted stock forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;44.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balances, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;68,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;46.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;68,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;46.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6691dffc917441fa983264255b9af82b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzEtMi0xLTEtMzE3NA_7fd02ab8-1f10-4648-a332-9ff9f8532ed1"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6691dffc917441fa983264255b9af82b_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzEtNC0xLTEtNTM2NA_e42aa887-9746-4e0b-9d9d-125d52e5e2dd"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzItMi0xLTEtMzE3NA_3d0a345e-247b-49ec-a276-b2457ae6abeb"
      unitRef="shares">69040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzItNC0xLTEtMzE3OQ_dab05314-a57f-47db-a0f2-9ebc56e7258b"
      unitRef="usdPerShare">46.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzMtMi0xLTEtMzE3NA_b56f17d7-f41a-4a84-8264-b747eca7f2fc"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzMtNC0xLTEtNTM2NA_5df56d8f-9740-4bd3-b31e-774d4f5e0cd8"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzQtMi0xLTEtMzE3NA_6683786a-fb0d-4ad4-97e3-7b5990e06939"
      unitRef="shares">644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzQtNC0xLTEtMzE3OQ_53aa6c8c-c14d-465b-8e85-98b6fb6b9ac6"
      unitRef="usdPerShare">44.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzUtMi0xLTEtMzE3NA_b644e625-0797-4ae2-9740-1f340671fd25"
      unitRef="shares">68396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzUtNC0xLTEtMzE3OQ_bcf771ed-3505-4080-a4f6-b0994d1228b6"
      unitRef="usdPerShare">46.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzYtMi0xLTEtMzE3NA_19268a2e-59ea-4809-97ca-fa7ab95997c5"
      unitRef="shares">68396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZToyOWRjY2I0MGE5MzI0ZDAwOGU3ZTg0OWRiMDdjYzU5ZC90YWJsZXJhbmdlOjI5ZGNjYjQwYTkzMjRkMDA4ZTdlODQ5ZGIwN2NjNTlkXzYtNC0xLTEtMzE3OQ_842b0d12-652d-40b0-86f5-724cb8850973"
      unitRef="usdPerShare">46.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie4be24da3ca849f38e1fe9ffb7f6d2ba_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyNzc_ee217688-dcc3-4fe3-a617-985ab98fd769"
      unitRef="shares">434000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="ie4be24da3ca849f38e1fe9ffb7f6d2ba_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzM0NDg_23815bd0-cdaf-4215-8375-90b9605736f7"
      unitRef="shares">1200000</silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i727cdef9482140249c0cb804bb673e7c_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzM0NjM_c7929ecc-e42e-43ab-a5f8-7c619a1fcf93"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i321ada78d4e34140b6929a8c206aa114_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzMyOTg1MzQ4OTYyNjU_d5092568-fff7-454e-81a6-727137539a05"
      unitRef="shares">746552</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i727cdef9482140249c0cb804bb673e7c_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzM2OTE_e8eee6e1-39c5-4adb-ab3f-11a479aa6ca8"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzQxMzg_4388cf64-d5f5-4a4c-8d7a-c292377cf843"
      unitRef="shares">114175000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <silk:CommonStockCapitalSharesAvailableForFutureIssuance
      contextRef="i321ada78d4e34140b6929a8c206aa114_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzQyMjk_9f527540-46f1-4164-a18c-86a0e6d653d0"
      unitRef="shares">632377000</silk:CommonStockCapitalSharesAvailableForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMTA_c6a5ea9f-e5c0-44dc-8398-c4c256552976">The fair value of employee and nonemployee stock options was estimated using the following assumptions for the years ended December&#160;31, 2020, 2019 and 2018:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.314%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0% - 50.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4% - 42.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0% - 38.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.32% - 1.41%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47% - 2.54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68% - 2.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i47ab4f535e3f49f092f4f09308ca5685_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjZlZGYxY2UzMDYzMTRiMTE5NTZhMDhjNzExNjE2ZDJhXzQ_264d85d8-19a9-4602-878d-8a70b4892110">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia0b870409832446b94306158afef68a2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjZlZGYxY2UzMDYzMTRiMTE5NTZhMDhjNzExNjE2ZDJhXzk_2bfae5c4-d073-4a7b-9654-c4b13b92dda2">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6ccbf5504e084eaeb3d0c1e776fc48ea_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMS0xLTEtMC90ZXh0cmVnaW9uOjRmZDY5YTc2Zjk2MDQxYjhiZGNmMTFhN2I3YjFlOWYzXzQ_043de89f-4301-452d-8637-1af32fe79664">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i61cd83f3fb4e4e00b85103543a357d2e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMS0xLTEtMC90ZXh0cmVnaW9uOjRmZDY5YTc2Zjk2MDQxYjhiZGNmMTFhN2I3YjFlOWYzXzk_802da864-cc2d-40f1-b102-229151925b53">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if15e03a06afa4556856fc6b3d9b3f42e_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMy0xLTEtMC90ZXh0cmVnaW9uOmIzNTU5ODg3YzMyMzQyMjk4ZGNlNmQxZGY0MWE0NjE3XzEwOTk1MTE2Mjc3ODg_ce139e6e-5130-4d8f-a32d-585a993ff214">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia5fe2fcafee2473d94c7bb24e4dee4b2_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzItMy0xLTEtMC90ZXh0cmVnaW9uOmIzNTU5ODg3YzMyMzQyMjk4ZGNlNmQxZGY0MWE0NjE3XzEwOTk1MTE2Mjc3OTI_ad249618-1665-4273-b6ab-919d3ecfa450">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjQ0OWE3YTNlOTZlNTQ1NGY5OWM5M2JhNTI5MzcwNTJkXzQ_83c7af69-3ece-46e0-9c3a-a5e22ef41ea4"
      unitRef="number">0.430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjQ0OWE3YTNlOTZlNTQ1NGY5OWM5M2JhNTI5MzcwNTJkXzk_ffbc4469-0838-438b-b623-3227866e5b9c"
      unitRef="number">0.503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMS0xLTEtMC90ZXh0cmVnaW9uOmQxY2ZiODkyZjUzOTQ5NDk4N2ZkOTc1NGIzMzM4OTkzXzQ_dbc4c060-67e6-4078-8362-f6e9f09b6bc5"
      unitRef="number">0.424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMS0xLTEtMC90ZXh0cmVnaW9uOmQxY2ZiODkyZjUzOTQ5NDk4N2ZkOTc1NGIzMzM4OTkzXzk_5dd952e2-05ae-44f0-bb34-850159b34f70"
      unitRef="number">0.429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMy0xLTEtMC90ZXh0cmVnaW9uOmI1MDBmYWQ4YWEzNzRhOGE5NTI4ZTI5OGY2MTMwNzZkXzEwOTk1MTE2Mjc3ODg_17e31ac2-95d2-420c-8dd8-c8c6517f7cdf"
      unitRef="number">0.380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzMtMy0xLTEtMC90ZXh0cmVnaW9uOmI1MDBmYWQ4YWEzNzRhOGE5NTI4ZTI5OGY2MTMwNzZkXzEwOTk1MTE2Mjc3OTI_8f75d2eb-7510-4599-aae4-c8b6a9013556"
      unitRef="number">0.388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjgyOTY2YjJkNTQwNjRjMWFhZTZkNDBmZmNhOWFkY2M5XzQ_88efbfe0-c032-4749-953e-4e228d879673"
      unitRef="number">0.0032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMS0xLTEtMTE5Ni90ZXh0cmVnaW9uOjgyOTY2YjJkNTQwNjRjMWFhZTZkNDBmZmNhOWFkY2M5Xzk_b77f91d8-9ab3-4e1d-a318-6aac4c51a687"
      unitRef="number">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmEzYjlmZDRmNTk0YzRhYzU4YjRlNmUyNjk1OGJjYzA2XzQ_fec4e8d4-1307-4a1c-984e-9a8955714722"
      unitRef="number">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmEzYjlmZDRmNTk0YzRhYzU4YjRlNmUyNjk1OGJjYzA2Xzk_0971d1da-b098-4ed8-861f-1b185e94a69e"
      unitRef="number">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmViOTM3YWViZDFiYjQzMGFhNjg5YTk2MDg3ZWZhZTAzXzEwOTk1MTE2Mjc3ODg_9fa2c03d-04eb-4be7-ac6e-a39fe12e992c"
      unitRef="number">0.0268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmViOTM3YWViZDFiYjQzMGFhNjg5YTk2MDg3ZWZhZTAzXzEwOTk1MTE2Mjc3OTI_78abc53f-2c1d-4a9a-917e-70d1a57ec3e4"
      unitRef="number">0.0298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzUtMS0xLTEtNTM0NA_9b8b56f4-ad0f-4ef3-ae8b-65b88aa07e1b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzUtMS0xLTEtMA_b73a3e34-75fd-4fe0-9940-8e582b031455"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTo5MzBhNDU4MzRlYTc0MTEwODMwMGYzNjM4NDJlY2UwMS90YWJsZXJhbmdlOjkzMGE0NTgzNGVhNzQxMTA4MzAwZjM2Mzg0MmVjZTAxXzUtMy0xLTEtMA_db101879-2549-47d8-9e53-1464fcda971b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <silk:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMTQ_e1c6d95b-be84-45e1-8940-d080496cf8e7">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the shares to be issued under the Company&#x2019;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the years ended December&#160;31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50 - 0.63&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.4% - 76.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.4% - 47.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10% - 1.58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58% - 2.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</silk:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzItMi0xLTEtMzI0Ng_f928b39c-625e-4c4d-9608-b1c871c09fa6">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i39165a89986a4d5fa6d41c395d548242_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzItMi0xLTEtMC90ZXh0cmVnaW9uOjFhYWQ3NTJmOTMwNTQ3NDViYzFiYmE0ZDk4NWNhY2EyXzEwOTk1MTE2Mjc3ODg_92484b85-974b-4359-9539-68455fe691a5">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0309977823e74b8bb43d525e2c1862f0_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzItMi0xLTEtMC90ZXh0cmVnaW9uOjFhYWQ3NTJmOTMwNTQ3NDViYzFiYmE0ZDk4NWNhY2EyXzEwOTk1MTE2Mjc3OTI_578f020b-3686-494c-86b0-879168c5a90c">P0Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzMtMi0xLTEtMzI0OS90ZXh0cmVnaW9uOjE4YTY1NTM1YjdjYzRlNDBhYzJkNzk3ZGQyMGRjMjkyXzEwOTk1MTE2Mjc3ODA_31401562-c283-465b-9d59-b2e6910c3d72"
      unitRef="number">0.444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzMtMi0xLTEtMzI0OS90ZXh0cmVnaW9uOjE4YTY1NTM1YjdjYzRlNDBhYzJkNzk3ZGQyMGRjMjkyXzEwOTk1MTE2Mjc3ODY_1ad9cdaa-c7f0-49a6-9934-89811d4bbf3e"
      unitRef="number">0.764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzMtMi0xLTEtMC90ZXh0cmVnaW9uOjQzZWUwZTJmODliMDQxYTdhYmViMzUwOThkNzdmMmI4XzEwOTk1MTE2Mjc3ODg_34e98194-d822-4b58-a1f7-ee5d1eec45d9"
      unitRef="number">0.444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzMtMi0xLTEtMC90ZXh0cmVnaW9uOjQzZWUwZTJmODliMDQxYTdhYmViMzUwOThkNzdmMmI4XzEwOTk1MTE2Mjc3OTI_0c208073-1668-4b76-8025-83c3b8d9babf"
      unitRef="number">0.478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzQtMi0xLTEtMzI1My90ZXh0cmVnaW9uOjE0YTE5YTU5ZTIxMjRkZmQ5ODIyZWIxODQ3ZDJiMGJhXzEwOTk1MTE2Mjc3ODA_4f6a3045-30e2-4b63-b170-429a43a0a466"
      unitRef="number">0.0010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzQtMi0xLTEtMzI1My90ZXh0cmVnaW9uOjE0YTE5YTU5ZTIxMjRkZmQ5ODIyZWIxODQ3ZDJiMGJhXzEwOTk1MTE2Mjc3ODY_d834f6fd-9d11-49cd-a0e6-2446254b75a0"
      unitRef="number">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzQtMi0xLTEtMC90ZXh0cmVnaW9uOmFlYWFkMWNmNDFiODQ4NTM4ODFmNWY4ZjgxNmYxZmMwXzEwOTk1MTE2Mjc3ODg_d31c8003-45e2-4fd6-91b8-039d6f475481"
      unitRef="number">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzQtMi0xLTEtMC90ZXh0cmVnaW9uOmFlYWFkMWNmNDFiODQ4NTM4ODFmNWY4ZjgxNmYxZmMwXzEwOTk1MTE2Mjc3OTI_0d26bf71-473b-4359-9887-79c9940cffe0"
      unitRef="number">0.0245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzUtMi0xLTEtMzI1OA_95717a0c-c0c4-42f0-9f8e-7156b47fb839"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i669362f3fdfd45759a19575d91a536a1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTowMzVhNjdhNmRhN2I0OWMyYWUzMzNlNTAwNGVlYTAyNC90YWJsZXJhbmdlOjAzNWE2N2E2ZGE3YjQ5YzJhZTMzM2U1MDA0ZWVhMDI0XzUtMi0xLTEtMA_a2277477-66a5-482d-86c0-f119ff7bb1e4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMTY_e0f2a9d1-bf5c-4b9a-b2a9-bd68eb81fd35">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation expense included in the statements of operations for all periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a041d34a42449bda00947d0a4241c05_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzItMS0xLTEtMA_02772f18-8d33-4d20-a47a-cf22ce23cee8"
      unitRef="usd">339000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb3f38d9acbf408aab3a51c21d51d4d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzItMy0xLTEtMA_9a970f4b-59e2-42d5-b55c-d45ec7d3b20c"
      unitRef="usd">179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5b5e58dd5ca74c379c458d4f10ca54f9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzItNS0xLTEtMzI5MA_f1a649c6-b2b8-47b0-8aaa-239d9c3d7e82"
      unitRef="usd">51000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95c8f7f1217049b0ac9c547630982b6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzMtMS0xLTEtMA_54644a65-7cf0-4348-8ee1-61304fb28525"
      unitRef="usd">1110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9cc78fcf595b4b6b89684111bad3f5a3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzMtMy0xLTEtMA_a30ed15d-2ef2-459e-b34d-0cce69c149a6"
      unitRef="usd">426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i79c98c09f3d34127ac384e5836c541d5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzMtNS0xLTEtMzI5MA_c527d994-4bbe-499f-9469-2205e38bc066"
      unitRef="usd">256000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9f27a96dad34a63a114ecba634391a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzQtMS0xLTEtMA_e3ca1535-9cfe-4ec0-81bb-ad8917147a5a"
      unitRef="usd">5777000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9290967454ec461ab5eab6e110e7984c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzQtMy0xLTEtMA_bbdf2e42-9924-47f9-8f29-c38bde2e484c"
      unitRef="usd">2372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b062b857ecd47d58f12e164875b8b8e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzQtNS0xLTEtMzI5MA_7087e45d-320d-4216-a896-7a726f110d03"
      unitRef="usd">604000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzUtMS0xLTEtMA_aa954618-44f2-4b44-8f79-0531b295f289"
      unitRef="usd">7226000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzUtMy0xLTEtMA_0b8f43af-54fd-433b-b649-cbc8f8b591da"
      unitRef="usd">2977000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90YWJsZTpkNmFmZThkY2ZiYzg0NTY4OWEzOTM3Njg5MWFkMGRhZS90YWJsZXJhbmdlOmQ2YWZlOGRjZmJjODQ1Njg5YTM5Mzc2ODkxYWQwZGFlXzUtNS0xLTEtMzI5MA_61a3aa23-0523-4827-9848-3143707f8631"
      unitRef="usd">911000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcwMzY_f4c684b8-73fa-491d-9911-9427bcd00464"
      unitRef="usd">20188000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic2a66f92a0c54ee4abd3a59a6da8d88b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcxMzI_f4bc9018-de04-423f-a374-cc03225306bb">P3Y7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ia05420dcc8d84d7787c80598f1ef5734_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwMzM_d684e606-6eec-4c18-9a46-428c8ee3c370"
      unitRef="usd">2716000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie22fcdd7f8bc4709959e84163a63abf9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzEwOTk1MTE2MzcwNDY_99f57270-658a-4089-917b-cdd4e7ddb418">P3Y5M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i321ada78d4e34140b6929a8c206aa114_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcxMzk_046e2545-76aa-4a1b-8e86-0631fbc9cfed"
      unitRef="usd">295000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib73d3c7fd5284fffa20341f308621149_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTIvZnJhZzo5OWU1YmZhMTRhYjg0MzIyOGU5MGNjYjY2YzU0OWQxZC90ZXh0cmVnaW9uOjk5ZTViZmExNGFiODQzMjI4ZTkwY2NiNjZjNTQ5ZDFkXzcyMDY_2b7bdc2e-9e3b-4832-9850-2ae89b37a7ae">P0Y4M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTQ_87859206-2252-47f0-ac28-839cf9d76251">Income Taxes&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income before taxes are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory U.S. federal rate to the Company&#x2019;s effective tax rate is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on Series C warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's provision for income taxes are included within other income (expense) on the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s net deferred tax assets as of December&#160;31, 2020 and 2019 consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized start-up costs/Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:  Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.  Management believes it is more likely than not that the deferred tax assets will not be realized; accordingly, a valuation allowance has been established on U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net deferred tax assets.  The valuation allowance increased $22,163,000 during the year ended December&#160;31, 2020 and increased by $12,826,000 during the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company had net operating loss carryforwards of approximately $241,908,000 and $209,771,000 for federal and state income tax purposes, respectively.  The federal and state net operating loss carryforwards begin to expire in 2027 and 2028, respectively.  Federal NOL carryforwards generated in tax years beginning in 2018 are not subject to expiration.  Federal NOLs that arose on or after January 1, 2018 can be carried forward indefinitely against future income, but can only be used to offset a maximum of 80% of the Company's federal taxable income in any year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code and similar provisions under state law.  Federal tax legislation enacted in December 2017, commonly known as the Tax Cuts and Jobs Act, contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes.  A Section 382 &#x201c;ownership change&#x201d; generally occurs if one or more stockholders or groups of stockholders, who own at least 5% of the Company&#x2019;s stock, increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period.  The Company may have previously experienced, and may in the future experience, one or more Section 382 &#x201c;ownership changes,&#x201d; including in connection with the Company&#x2019;s initial public offering.  If so, the Company may lose some or all of the tax benefits of its NOLs and tax credits.  The extent of such limitations for prior years, if any, has not yet been formally determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company had $6,275,000 and $3,463,000 of federal and state research and development credit carryforwards, respectively.  If not utilized, the federal credits will expire beginning in 2027.  The California Research and Development credits can be carried forward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company had $2,019,000 of unrecognized tax benefits.  The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized would increase or decrease within twelve months of the year ended December&#160;31, 2020. If recognized, $0 would affect the effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to uncertain tax positions in income tax expense.  There was no such expense recorded during the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the unrecognized tax benefits from January 1, 2018 to December&#160;31, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current years&#x2019; tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to prior years&#x2019; tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has no federal or state tax examinations in progress nor has it had any federal or state tax examinations since its inception.  As a result of the Company&#x2019;s net operating loss carryforwards, all of its tax years are subject to federal and state tax examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTU_282220fc-d44e-4fb7-9b28-b4914e9c1d21">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income before taxes are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzItMS0xLTEtMA_701b9bd3-5dac-4df9-b557-2ab7bb93652c"
      unitRef="usd">-47365000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzItMy0xLTEtMA_6a7fd54a-a2c0-45d5-ad35-39902af346cc"
      unitRef="usd">-52415000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzItNS0xLTEtMzMxMw_0fd66255-2e54-45fb-a430-b5e66a000bdc"
      unitRef="usd">-37630000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzMtMS0xLTEtMA_b5c80ae6-b9ec-498a-b017-a3321c98e996"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzMtMy0xLTEtMA_acf48c92-ae05-4dfa-a93e-c813b681d7e6"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzMtNS0xLTEtMzMxMw_85bc6c71-fd5f-4ed3-b4c6-91873904b25c"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzQtMS0xLTEtMA_65b8b7d8-a408-4dc4-94f0-bc683f91ced1"
      unitRef="usd">-47365000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzQtMy0xLTEtMA_85caf0fd-056d-45fb-a6ae-20391b1dc417"
      unitRef="usd">-52415000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTpkOWY5OWViNTgxNTI0ZjBmOTRhOWQ4YmIyYWJmYjgwNi90YWJsZXJhbmdlOmQ5Zjk5ZWI1ODE1MjRmMGY5NGE5ZDhiYjJhYmZiODA2XzQtNS0xLTEtMzMxMw_f5385427-cb5d-4053-820c-d7e067c28b5c"
      unitRef="usd">-37630000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTY_d6c25b38-e481-498b-9138-c343486d80b5">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory U.S. federal rate to the Company&#x2019;s effective tax rate is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on Series C warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzItMS0xLTEtMA_e6d936d2-b58c-4868-b240-08e3da6593c2"
      unitRef="usd">-9947000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzItMy0xLTEtMA_c7b63b87-97cd-4f0f-8af7-04f2a6ad17c6"
      unitRef="usd">-11007000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzItNS0xLTEtMzMyMw_e853f45a-be52-4e6b-a973-c28d4f3f2b2a"
      unitRef="usd">-7902000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzMtMS0xLTEtMA_cdf0ea4a-1901-4570-b878-1c4e2d7c25da"
      unitRef="usd">-1958000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzMtMy0xLTEtMA_6bb8215f-92a0-4d9e-9265-e3063c6e196a"
      unitRef="usd">-2270000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzMtNS0xLTEtMzMyMw_568e6b62-b7c9-4dce-8a43-1e022ef4d987"
      unitRef="usd">-1582000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzQtMS0xLTEtMA_75f83341-37a0-4722-8321-283e12f032e3"
      unitRef="usd">-8489000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzQtMy0xLTEtMA_906e0232-2d99-4ef8-83a2-33322d37a4cc"
      unitRef="usd">-4731000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzQtNS0xLTEtMzMyMw_ab0e7228-bded-4c1d-ae2b-94eda3e3f7ac"
      unitRef="usd">289000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <silk:EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzUtMS0xLTEtMA_9fcb5d3b-3ae4-4046-acde-5ad0343f02f2"
      unitRef="usd">0</silk:EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount>
    <silk:EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzUtMy0xLTEtMA_46cd6a40-c533-4665-8d6a-fd598567eae0"
      unitRef="usd">5330000</silk:EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount>
    <silk:EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzUtNS0xLTEtMzMyMw_f5cb36d3-0e5f-4d26-8e6e-d6bd77e3b299"
      unitRef="usd">2500000</silk:EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzYtMS0xLTEtMA_f73e7b71-3481-4ade-b1c3-7406d59ca5f8"
      unitRef="usd">22164000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzYtMy0xLTEtMA_2b18a8fc-c516-4d8a-90d8-5feaa643f2f1"
      unitRef="usd">12797000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzYtNS0xLTEtMzMyMw_ea2cb0df-8af2-4878-9d5b-9d1e747001d3"
      unitRef="usd">6197000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzctMS0xLTEtMA_68235020-5166-4a5f-bff2-4e1b9a808e6f"
      unitRef="usd">1268000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzctMy0xLTEtMA_78d29314-5a0c-4ec7-9e2c-0c30e6e4fc22"
      unitRef="usd">319000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzctNS0xLTEtMzMyMw_4ccec77d-6b2d-4fa9-9531-92cc1592ad7c"
      unitRef="usd">-136000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzgtMS0xLTEtMA_581c72db-1b20-4377-911d-af5a770d1c96"
      unitRef="usd">-491000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzgtMy0xLTEtMA_4b9319c3-56fc-49f7-95df-11bb983da9a7"
      unitRef="usd">208000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzgtNS0xLTEtMzMyMw_ffc97d53-6ca0-4a7e-a29e-a990fc8c65a9"
      unitRef="usd">376000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzktMS0xLTEtMA_fe05601b-23e6-45f6-96ba-93e9844a8fdb"
      unitRef="usd">11000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzktMy0xLTEtMA_d16c76bd-f4a4-4e13-952a-562c30189459"
      unitRef="usd">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZTo0YzZmYTJiMzc0NWY0N2I5OGFjYmE1ODBlOTU1OTk0MS90YWJsZXJhbmdlOjRjNmZhMmIzNzQ1ZjQ3Yjk4YWNiYTU4MGU5NTU5OTQxXzktNS0xLTEtMzMyMw_52df7453-0b2c-436a-96c8-75b5067bb5bf"
      unitRef="usd">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTc_904b9265-60e6-40f2-b4ff-abf28b28e16d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s net deferred tax assets as of December&#160;31, 2020 and 2019 consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized start-up costs/Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:  Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzMtMS0xLTEtMA_0aef361e-1dcd-4a24-866b-f57e5f997815"
      unitRef="usd">63069000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzMtMy0xLTEtMA_65bf43e7-35bf-42d0-987f-75fd81dd4eb6"
      unitRef="usd">44574000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzQtMS0xLTEtMA_aed01b51-55b3-4cdf-8f5a-72187d7f221d"
      unitRef="usd">7191000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzQtMy0xLTEtMA_4290465c-7e5b-43f2-825b-760a1edd476d"
      unitRef="usd">5287000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzUtMS0xLTEtMA_68e08d8a-73e0-4e7b-8b84-91f16f214d4a"
      unitRef="usd">8000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzUtMy0xLTEtMA_603bfa4d-2fb1-4ebb-9e07-79b8229e1e93"
      unitRef="usd">11000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzYtMS0xLTEtMA_4fad98c8-6310-4352-945b-dbcd42cdd95d"
      unitRef="usd">2337000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzYtMy0xLTEtMA_431a6ddd-a139-4d04-90d2-b943bc100dd4"
      unitRef="usd">2227000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzctMS0xLTEtMA_efe9e30c-9ba3-4373-96f1-c5fda42ed217"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzctMy0xLTEtMA_5862febc-29f3-477b-ac39-4b043871248b"
      unitRef="usd">188000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzgtMS0xLTEtMA_bdbf0847-f785-4c64-bd57-d77b8550199b"
      unitRef="usd">1859000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzgtMy0xLTEtMA_2c18cbd4-0343-429f-9dc5-ec916289a3da"
      unitRef="usd">568000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <silk:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzktMS0xLTEtMA_3de6edcc-3eb7-4772-8242-f7c5384d8beb"
      unitRef="usd">935000</silk:DeferredTaxAssetsOperatingLeaseLiability>
    <silk:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzktMy0xLTEtMA_be4072f4-48ec-4439-80c2-ee9fa1c62eab"
      unitRef="usd">1133000</silk:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEwLTEtMS0xLTQ5MTU_c2d1ec24-f5bd-4a07-9e07-f55e6ab08246"
      unitRef="usd">813000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEwLTMtMS0xLTQ5MTU_7d5f5fda-74bc-4dd6-b292-ca070db44616"
      unitRef="usd">0</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEwLTEtMS0xLTA_8c56e91e-73ad-4de9-9616-16696faf26dc"
      unitRef="usd">76212000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEwLTMtMS0xLTA_bb4b60fc-c869-40d9-8cc4-8b21697c3586"
      unitRef="usd">53988000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzExLTEtMS0xLTA_2e319846-ba90-4611-906e-6fd2e31f2189"
      unitRef="usd">75289000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzExLTMtMS0xLTA_0749e3f2-999f-403f-a34d-a70d25733893"
      unitRef="usd">53126000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEzLTEtMS0xLTA_384b6273-9019-4e5f-b1e9-fc8685198574"
      unitRef="usd">707000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzEzLTMtMS0xLTA_576a7fdc-a09d-4cbc-8a41-2c2f9507ac67"
      unitRef="usd">862000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE1LTEtMS0xLTQ5MjQ_7ed2645d-5f06-4bb7-b25d-cff4c49d97d1"
      unitRef="usd">216000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE1LTMtMS0xLTQ5MjQ_5004c80e-5731-420b-8928-04c583b4d281"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE0LTEtMS0xLTA_86196b0f-58f0-436c-a769-8d05bb83cc6b"
      unitRef="usd">923000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE0LTMtMS0xLTA_14edf7f0-a45c-41c8-9235-a31632787078"
      unitRef="usd">862000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE1LTEtMS0xLTA_2167e83e-d2a8-4ae9-aa46-d1e4d4c0c769"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxODEwMDFlOTNkNDI0MDJjYjBhZjI3YzdmZDJmMmQzZC90YWJsZXJhbmdlOjE4MTAwMWU5M2Q0MjQwMmNiMGFmMjdjN2ZkMmYyZDNkXzE1LTMtMS0xLTA_a7679ea4-3290-4711-867a-9c5d245fe564"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzEwNjc_6fdbac1d-62fd-42f2-819e-84e5ebb7bc32"
      unitRef="usd">22163000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzExMTI_7c9e1776-8ffd-46f4-b29b-831d85a95eab"
      unitRef="usd">12826000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0efe8bfdcede4d06a33afef06da15dc1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzEyMTg_f510583b-ea0c-47af-a740-739d039b3057"
      unitRef="usd">241908000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib74c8c93648e47c981153a6846f18a61_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzEyMjU_5db78322-d2b6-4d4c-b4af-2d072e48d3db"
      unitRef="usd">209771000</us-gaap:OperatingLossCarryforwards>
    <silk:OperatingLossCarryforwardOffsetMaximumPercent
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzE2NDQ_d8d962aa-961f-41e2-b1fc-a295d61123ec"
      unitRef="number">0.80</silk:OperatingLossCarryforwardOffsetMaximumPercent>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i1ee605997eef429381c095e0eaf512c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzI4NzA_a55a8fea-48d8-47b1-a9bb-de689b5b701a"
      unitRef="usd">6275000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i2e58304a7fe546fa982e73d2e64be31d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzI4Nzc_31d5f038-a3f7-453c-b6ac-b133d66665c8"
      unitRef="usd">3463000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzMxNDM_f7f10208-9821-4ffe-8125-a643c9073f17"
      unitRef="usd">2019000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzMzODY_f44d314e-57f1-45fb-b633-9f4610d75ec5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM1NDE_504c2a63-297c-499b-b10a-3d2da64f04cf"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM1NDE_c281e0e2-b725-46e0-92d9-8710e2afc580"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM1NDE_f37b2916-b72e-4e33-8ac1-a3b0ef9a0131"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90ZXh0cmVnaW9uOmM2ZmQ2M2NkZDI2ZDQxZGJhNmZmMGQ0ZjYzZjFmYzFiXzM5OTg_bfe0a3e3-b370-4ffb-b642-b73587848cef">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the unrecognized tax benefits from January 1, 2018 to December&#160;31, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current years&#x2019; tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to prior years&#x2019; tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzItMS0xLTEtMA_0b0b7810-4191-4e91-a68d-20478831cdf9"
      unitRef="usd">1436000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzItMy0xLTEtMA_bbdaac9e-2b57-484a-bb23-5575930f6450"
      unitRef="usd">1348000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i20487a9e41eb468fb7da6d0324133121_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzItNS0xLTEtMzM2Mg_1099a0f2-66a4-4754-b5d0-9d439f8cbd08"
      unitRef="usd">615000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzMtMS0xLTEtMA_2c0a8b45-ea34-4a41-ac79-069340873e41"
      unitRef="usd">342000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzMtMy0xLTEtMA_4337d783-582c-47e1-8fb8-c0907e83c7f3"
      unitRef="usd">88000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzMtNS0xLTEtMzM2Mg_142e6c9d-4c16-4d8d-8c40-212a85aa184a"
      unitRef="usd">118000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzQtMS0xLTEtMA_4a88eb16-ca15-4527-96c3-4473ae46f63e"
      unitRef="usd">241000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzQtMy0xLTEtMA_f1f27710-7b69-427e-864e-31fab517d3be"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="iea8317ddf5eb474484590b6729a1be10_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzQtNS0xLTEtMzM2Mg_ac2c4d64-478e-4685-a5ad-83d273e50a3e"
      unitRef="usd">615000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib21091e7ea584a0eb4262bf6edfcce74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzUtMS0xLTEtMA_97743374-322c-4350-adc6-89e2c4e5a2e8"
      unitRef="usd">2019000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i65f3a8f4af9542fb8f31ed746073f14b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzUtMy0xLTEtMA_dd13b5fd-eaf8-45f5-ae82-98be974a16b9"
      unitRef="usd">1436000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id50f1ea2e05745ff8b96e3859d79bf00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMTgvZnJhZzpjNmZkNjNjZGQyNmQ0MWRiYTZmZjBkNGY2M2YxZmMxYi90YWJsZToxMWM2NDFiYjQ4NDA0NmNhYThiYzJkZDYxYmRjY2E0Yy90YWJsZXJhbmdlOjExYzY0MWJiNDg0MDQ2Y2FhOGJjMmRkNjFiZGNjYTRjXzUtNS0xLTEtMzM2Mg_da471485-0d56-4880-bd87-f8a0abc84815"
      unitRef="usd">1348000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzQxMDg_ae0e6156-8659-4699-99c7-14f8633e1954">Acquisition of Variable Interest Entity - NeuroCo&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2014, the Board of Directors of the Company approved the sale of certain intellectual property of Silk Road Medical, Inc., to a newly incorporated entity, NeuroCo, Inc.  In consideration for the intellectual property, a promissory note was executed between the two parties for the principal sum of $498,000 with an interest rate of 2.74% per annum, payable on the earlier of 10 years from the date of promissory note, or upon the occurrence of an event of default.  The intellectual property transfer was recorded at its carrying value of zero as of December&#160;31, 2014.  During 2015 NeuroCo issued $154,000 in common stock to stockholders of the Company.  During the year ended December 31, 2018, NeuroCo issued common stock upon the exercise of stock options.  These common stock issuance amounts, as they are related to non-controlling investors, were reported as non-controlling interests in subsidiary in the Company&#x2019;s financial statements and are offset by NeuroCo losses consolidated by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, NeuroCo incurred research and development related expenses paid for by the Company which were added into the original promissory note.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had identified NeuroCo as a VIE of which the Company is the primary beneficiary.  Pursuant to the accounting guidance for consolidating VIEs the main consideration was given to the fact that the amount of total equity investment at risk is not sufficient to permit NeuroCo to finance its activities without additional subordinated financial support.  Additionally, NeuroCo and Silk Road Medical had the same Board of Directors and senior management composition, determining the Company to have the power to direct the activities that most significantly impact NeuroCo&#x2019;s economic performance and the obligation to absorb losses and the right to receive benefits.  Accordingly, the financial results of NeuroCo were included in the Company&#x2019;s financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 17, 2018, the Company and NeuroCo entered into the Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) pursuant to which the Company acquired all assets and assumed all liabilities of NeuroCo (the &#x201c;Merger&#x201d;).  The Merger closed on the same day (the &#x201c;Closing&#x201d;) and was consummated through a stock-for-stock transaction based on the relative values of the Company&#x2019;s and NeuroCo&#x2019;s equity.  In consideration for 100% equity interest of NeuroCo, the Company issued 33,462 shares of its common stock and the above promissory note in the amount of approximately $1,600,000 as of the Closing was settled and canceled.  As a result of the Merger, NeuroCo merged into the Company with the Company being the surviving corporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company already controlled and consolidated NeuroCo and retained the control over NeuroCo&#x2019;s business after the Merger, the Company accounted for the acquisition of equity interest in NeuroCo as an equity transaction.  Therefore, the Company did not recognize a gain or loss in its net loss or comprehensive loss for acquisition of NeuroCo.  As the carrying amount of the non-controlling interest as of the Closing was zero, the Company recorded the consideration paid as a decrease to the Company&#x2019;s additional paid-in capital within stockholder&#x2019;s equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Merger, the Company assumed NeuroCo&#x2019;s 2015 Equity Incentive Plan (the &#x201c;NeuroCo Plan&#x201d;) along with all of NeuroCo&#x2019;s rights and obligations under the NeuroCo Plan, except that the number of shares and exercise price of the assumed options have been adjusted based on the Merger exchange ratio of the Company&#x2019;s common stock and NeuroCo&#x2019;s common stock.  Similarly, the Company assumed outstanding warrants to purchase NeuroCo&#x2019;s common stock such that the number of shares and exercise price of the assumed warrants have been adjusted based on the Merger exchange ratio of the Company&#x2019;s common stock and NeuroCo&#x2019;s common stock.  The options and warrants to purchase shares of the Company&#x2019;s common stock were fully vested upon issuance, as they were replacing fully vested options and warrants to purchase NeuroCo common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:NotesReceivableRelatedParties
      contextRef="ic3bb7213b7c542eb8d9d50fda0c137d5_I20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzM2OQ_c743866c-8b71-4540-a416-43fa0cfbf5e3"
      unitRef="usd">498000</us-gaap:NotesReceivableRelatedParties>
    <silk:NotesReceivableRelatedPartiesInterestRateStatedPercentage
      contextRef="ic3bb7213b7c542eb8d9d50fda0c137d5_I20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzM5Nw_ae0d241a-e714-4fd7-b9f3-b294a90304df"
      unitRef="number">0.0274</silk:NotesReceivableRelatedPartiesInterestRateStatedPercentage>
    <silk:NotesReceivableRelatedPartiesTerm
      contextRef="if9c1f3c48bdb4a6ea8c16f7a38160b11_D20140101-20141231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzQzNw_28d558fa-21d8-4dff-a612-83de37235903">P10Y</silk:NotesReceivableRelatedPartiesTerm>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3380644612b74549867fb107a4a32b56_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzY1Mw_c080f3a1-befc-4281-890f-8977930cb4ed"
      unitRef="usd">154000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i326ed72d5faa4423a7380a120ab921a4_I20181217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzI0MDQ_52ad7ad9-b8d2-4110-9744-14ad0dffd1c3"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i6dca7000583a43869c1389cf6ac8d3d2_D20181217-20181217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzI0NTQ_623ff30a-b032-4350-ba81-7154ae61fbd2"
      unitRef="shares">33462</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <silk:BusinessCombinationConsiderationTransferredNotesPayableForgiven
      contextRef="i6dca7000583a43869c1389cf6ac8d3d2_D20181217-20181217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzI1NDU_0b015cfb-7acd-481f-92af-fa95df6effdb"
      unitRef="usd">1600000</silk:BusinessCombinationConsiderationTransferredNotesPayableForgiven>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i4ea6234882cf424bb9e6d52bf97c9471_I20181217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjEvZnJhZzoyOGY3ZmI5ZTA2OTI0ZDc4YWI0M2IyNGU5Y2YwNDU5ZS90ZXh0cmVnaW9uOjI4ZjdmYjllMDY5MjRkNzhhYjQzYjI0ZTljZjA0NTllXzMxMjc_c926f8a8-35c8-434d-8ebc-b536f52e74e0"
      unitRef="usd">0</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:DefinedContributionPlanDisclosuresTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzY4MQ_162fe4a7-14e9-411e-a6ee-8f89728d5bf5">401(k) PlanThe Company has a qualified retirement plan under section&#160;401(k)&#160;of the Internal Revenue Code (&#x201c;IRC&#x201d;) under which participants may contribute up to 90% of their eligible compensation, subject to maximum deferral limits specified by the IRC.  The Company may make a discretionary matching contribution to the 401(k)&#160;plan and may make a discretionary employer contribution to each eligible employee each year.  Through December 31, 2019, the Company has made no contributions to the 401(k)&#160;plan.  Beginning in January 2020, the Company started matching employees' contributions to the 401(k) plan at 50% of the first 5% of compensation deferred to the 401(k) plan.  The Company's matching contributions were $959,000 for the year ended December 31, 2020.</us-gaap:DefinedContributionPlanDisclosuresTableTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzE2OQ_f0bd91a7-8158-4958-8c51-a28fd482a143"
      unitRef="number">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ide91c7dffab74f4ba57bd590f6040812_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzQ3Nw_95fd5649-9e64-4bdb-b804-d5817580356c"
      unitRef="usd">0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i74e220b1dfe342f2bad86c21ce171b0e_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzYxOA_077c154a-bccc-41d6-9f3e-a5ada21fc0e1"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i74e220b1dfe342f2bad86c21ce171b0e_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzYzNA_1bf681ca-733b-4f41-9adc-e0ee73505b42"
      unitRef="number">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjQvZnJhZzpjNzE5NDZjMTVjZWQ0ZjA3OTc5NWNhNjk4NzM4YmJmMi90ZXh0cmVnaW9uOmM3MTk0NmMxNWNlZDRmMDc5Nzk1Y2E2OTg3MzhiYmYyXzEwOTk1MTE2Mjg2OTQ_617d8290-e5c7-4fba-ab51-05f1037d5f2f"
      unitRef="usd">959000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzY5Mw_e07b9aab-a88a-41c5-a632-5d100d89413d">Subsequent Events&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the number of shares of common stock authorized for issuance under the 2019 Plan was automatically increased by 1,369,985 shares, which was ratified by the Company's Board of Directors in January 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company&#x2019;s Board of Directors approved the grant of options to purch&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ase 19,305 shares of common stock under the 2019 Plan with an exercise price of $59.33 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the number of shares of common stock authorized for issuance under the 2019 ESPP was automatically increased by 342,496 shares, which was ratified by the Company's Board of Directors  in January 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Voluntary Recall&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January and February 2021, the Company announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by one of its third-party suppliers, Cordis. The decision to recall these lots was based on complaints received about tips detaching from the stent delivery system as well as internal testing that the Company conducted. The Company believes the root cause of the detachment was a single operator at Cordis, who, over a specific timeframe, produced lots in which a small number of units were not reliably manufactured to specification.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the voluntary recall the Company reflected a current asset of $4,160,000 on its balance sheet as of December 31, 2020, relating to the replacement lots and other direct costs to be received from Cordis. This amount includes $2,227,000 of recalled ENROUTE stent delivery systems held in the Company's inventory as of December 31, 2020, $1,696,000 of ENROUTE stent delivery systems in the process of being returned from its customers and other direct costs of $237,000. In addition, the Company established an accrual of $1,696,000 relating to its obligation to provide replacement ENROUTE stent delivery systems to its customers as of December 31, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Bonus to be Settled in Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 9, 2021, the Company's Compensation Committee of the Board of Directors approved that the bonus for certain employees would partially be paid in RSUs.  Actual shares were awarded to employees on February 26, 2021 as a fixed dollar amount converted to 14,952 fully vested RSUs using the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;trailing 30-day average stock price.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibaa4295aab3c4fd19f5369890a74eb95_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2Mjg2NDI_d1feeb32-7c3b-4d6b-a83d-1fd974296e37"
      unitRef="shares">1369985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic3233352a710471b8cc9cd69d34e703f_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzczMDY_7167eab9-1d47-43af-b183-b1a585d45ff0"
      unitRef="shares">19305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic3233352a710471b8cc9cd69d34e703f_D20210201-20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzczMTA_935f6e9f-e75e-4a83-b493-d045f223bdf5"
      unitRef="usdPerShare">59.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i01975501aeed437d860ef21eff36403e_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2Mjg2NTI_8594e0b0-18e0-49c5-9d0a-34a815e3613f"
      unitRef="shares">342496</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:LossContingencyReceivable
      contextRef="i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzY4NTA_71431060-b5c1-4717-8d35-63233d9df09d"
      unitRef="usd">4160000</us-gaap:LossContingencyReceivable>
    <us-gaap:LossContingencyReceivable
      contextRef="i39997c7638c9433ca55684c8301b703a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzY4NjA_ea93ca83-b81c-4ef9-a5de-7fe8b2b29732"
      unitRef="usd">2227000</us-gaap:LossContingencyReceivable>
    <us-gaap:LossContingencyReceivable
      contextRef="i79e280b94b7942cf91af6b3df5b509da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzY4NzA_abb882e8-c83c-4255-9189-5b93db46d159"
      unitRef="usd">1696000</us-gaap:LossContingencyReceivable>
    <us-gaap:LossContingencyReceivable
      contextRef="i637453fe4b3642f9aa11f791b415ea8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzcwNjE_e693d25f-a79a-4b11-b627-37b17698cf41"
      unitRef="usd">237000</us-gaap:LossContingencyReceivable>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzY4ODM_90a6ee67-499a-4bc7-9b07-29ed86584c7a"
      unitRef="usd">1696000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id4fa9083290c443aa2e74fa476c35c40_D20210226-20210226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzEwOTk1MTE2MzczNjY_51b77ff4-9566-4c4c-aeeb-ab56b364b390"
      unitRef="shares">14952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod
      contextRef="id4fa9083290c443aa2e74fa476c35c40_D20210226-20210226"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMjcvZnJhZzo0NzEyMDIzZmNiYzM0YTNiOWNmMmQ0OGRiMzgxOGJjOC90ZXh0cmVnaW9uOjQ3MTIwMjNmY2JjMzRhM2I5Y2YyZDQ4ZGIzODE4YmM4XzMyOTg1MzQ4OTQ1OTE_6af59dac-d6a0-423e-a27b-c1da64a32ad4">P30D</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90ZXh0cmVnaW9uOmRlMTU4ZDY2OTBhNDQ0ZTE5NWZhNDRmNmIwN2QyYTg5XzE5OQ_d498d79b-e3dc-4c92-90ea-8ac53f96e4eb">Quarterly Financial Information (unaudited)&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides selected unaudited quarterly financial data for the years ended December&#160;31, 2020, and 2019 (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90ZXh0cmVnaW9uOmRlMTU4ZDY2OTBhNDQ0ZTE5NWZhNDRmNmIwN2QyYTg5XzIwMA_b80ebe70-a123-441d-be56-7389a6158e11">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides selected unaudited quarterly financial data for the years ended December&#160;31, 2020, and 2019 (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzItMi0xLTEtMzM4MA_a0dfe6a9-35ee-461e-9ce2-044f71a20f72"
      unitRef="usd">21133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzItNC0xLTEtMzM4MA_76978ca8-b862-41b2-81d6-08d3f05e684b"
      unitRef="usd">20067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzItNi0xLTEtMzM4MA_824845bc-4d83-4e29-b500-e0b3c23e29d3"
      unitRef="usd">15094000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzItOC0xLTEtMzM4MA_353d06ca-9378-427b-a508-802e73dccc8a"
      unitRef="usd">18933000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzMtMi0xLTEtMzM4MA_bcc532cd-18b3-48cc-9f80-0395992d4c2a"
      unitRef="usd">15916000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzMtNC0xLTEtMzM4MA_aa1c1f10-dda7-4352-9ad3-8b41225163ad"
      unitRef="usd">14579000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzMtNi0xLTEtMzM4MA_c225002a-fb48-4819-8c56-d9e023bbac38"
      unitRef="usd">9758000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzMtOC0xLTEtMzM4MA_52e68a44-4a01-474e-a616-955330344b31"
      unitRef="usd">13683000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzQtMi0xLTEtMzM4MA_3796708d-c0be-4073-b1b1-6739c90767e1"
      unitRef="usd">-16756000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzQtNC0xLTEtMzM4MA_adceeb20-8a50-4389-954b-14e5141dad66"
      unitRef="usd">-10315000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzQtNi0xLTEtMzM4MA_90e78a70-1c90-41ac-99f2-f659e41cdf87"
      unitRef="usd">-10353000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzQtOC0xLTEtMzM4MA_1955d422-65ca-45e4-bd18-52ddaf55b800"
      unitRef="usd">-9941000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzUtMi0xLTEtMzM4MA_d6d2cd8b-2e14-4f39-9c18-c42418fd9895"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7ee1445395184e98af2c34018e666c0a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzUtNC0xLTEtMzM4MA_57ff5b87-550d-4eda-bfb4-c690e8c822a0"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i1b68cfd3b4d8400fb0b14f963d10c897_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzUtNi0xLTEtMzM4MA_10ace032-3e2d-455c-9283-7d599a9cb372"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie70b911718cd4937878404da4ee5b9f6_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTo2MTg1NDlhNjI1Njc0YWUxODJhYTBiOTJlNTgwMjdmZi90YWJsZXJhbmdlOjYxODU0OWE2MjU2NzRhZTE4MmFhMGI5MmU1ODAyN2ZmXzUtOC0xLTEtMzM4MA_8af2a2af-780a-485d-94e8-ebbbd04808d8"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzItMi0xLTEtMA_40be8ad2-454c-4aa2-bc62-0441332273a7"
      unitRef="usd">18634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzItNC0xLTEtMA_2ea96973-0a8e-41fd-8749-884565c75e15"
      unitRef="usd">17026000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzItNi0xLTEtMA_89db2fce-cb86-4b02-af7f-4ed01b3d2ae3"
      unitRef="usd">14928000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief509a5e508844398122e436481d4a37_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzItOC0xLTEtMA_4525ada7-0a89-4059-b14c-735e1ed380b7"
      unitRef="usd">12766000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzMtMi0xLTEtMA_b4cc096e-c7d4-4096-840f-77f353ed555d"
      unitRef="usd">13913000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzMtNC0xLTEtMA_a67805ef-59cf-411d-883c-8ccb63facc2d"
      unitRef="usd">12856000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzMtNi0xLTEtMA_1a8aefed-9c3e-4278-a359-9c04dc217f9c"
      unitRef="usd">11231000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ief509a5e508844398122e436481d4a37_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzMtOC0xLTEtMA_0882ebb8-d291-40b6-af17-f950486b126c"
      unitRef="usd">9427000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzQtMi0xLTEtMA_62d44f8e-24e8-4468-b377-4ab908c12e22"
      unitRef="usd">-8291000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzQtNC0xLTEtMA_3d90a59e-7c7d-4b5e-8e47-c011101a25e6"
      unitRef="usd">-8007000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzQtNi0xLTEtMA_4657bfad-be7a-4f77-a9b0-90e8ac48f84f"
      unitRef="usd">-11959000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ief509a5e508844398122e436481d4a37_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzQtOC0xLTEtMA_59dfd556-421a-4b5b-9150-da14112b209c"
      unitRef="usd">-24158000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i447f155ca20e4d2b81f8ac3a1ab83037_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzUtMi0xLTEtMA_b6ce638f-9bf0-4ff2-8af2-a3b90376701b"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if02a1661218047ccac01b7affaf9e6b5_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzUtNC0xLTEtMA_11e0b652-c6bd-4eb3-8fdf-a17ec3d46d67"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i34174b0d828d41c5aa3bbabab2fa1c78_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzUtNi0xLTEtMA_f2933e42-7fc2-4fe3-b27c-c7a7e33294d2"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ief509a5e508844398122e436481d4a37_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMzAvZnJhZzpkZTE1OGQ2NjkwYTQ0NGUxOTVmYTQ0ZjZiMDdkMmE4OS90YWJsZTpkYzhiOTRhY2NiMmM0MDY4ODgzOGRmMzhjM2M2MTMxZi90YWJsZXJhbmdlOmRjOGI5NGFjY2IyYzQwNjg4ODM4ZGYzOGMzYzYxMzFmXzUtOC0xLTEtMA_d1fcf081-ef7c-4f2e-953d-05932b3d6f67"
      unitRef="usdPerShare">-20.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90ZXh0cmVnaW9uOjM2NzY2YzU4YTQ5MDRhZGM5MmZlYzlhZGJlNjBkZTg0XzMyOTg1MzQ4ODQwNzM_ea49f775-48fd-455f-9c82-565e0c35be60">Financial Statement Schedule.&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. The table below presents Schedule II, Valuation and Qualifying Accounts, detailing the activity of the allowance for doubtful accounts receivable for the years ended December 31, 2020, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Charged to expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Write offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for doubtful accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i218af6b8a4044434bc70398d3d719486_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzItMi0xLTEtNTQxMA_e8ae6836-b680-4a0a-a601-179e35d6f1d8"
      unitRef="usd">45000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i3d98a257f74a444e815e2acdecdd06e8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzItNC0xLTEtNTQxMA_43fe65ba-f4c5-4c4d-a551-f72fdb9ccf6c"
      unitRef="usd">-32000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3d98a257f74a444e815e2acdecdd06e8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzItNi0xLTEtNTQxMA_7e6818cc-bffc-4910-beaa-89c3fd035634"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id4bfdb1605af43cb8614f33f8d1a6537_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzItOC0xLTEtNTQxMA_0dad686b-bb04-4f0c-a291-08c5d8b1dedb"
      unitRef="usd">13000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2401d30b2e994f16b50e95b7e08d7413_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzMtMi0xLTEtNTQxMA_85f39eed-94bd-4760-99a4-7d1c6c5185e5"
      unitRef="usd">22000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ibe63293076b44c03b2d249cf8f39228c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzMtNC0xLTEtNTQxMA_be1da27e-da7a-4763-ad02-ae6d9c4045f6"
      unitRef="usd">23000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ibe63293076b44c03b2d249cf8f39228c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzMtNi0xLTEtNTQxMA_9338ee25-224f-4190-ae1e-a3a128454b51"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i218af6b8a4044434bc70398d3d719486_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzMtOC0xLTEtNTQxMA_4ae99812-1fd9-4d5f-a79e-940a390ba899"
      unitRef="usd">45000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i515fd7b45a0d4244a919c02bb006219a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzQtMi0xLTEtNTQxMA_9692cae6-55f9-463a-b66f-a38a261a6244"
      unitRef="usd">149000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ie1814d8a10cb43efae417d1231483bf2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzQtNC0xLTEtNTQxMA_6a9a8712-edd3-4b7c-802d-0ed995944bad"
      unitRef="usd">-123000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie1814d8a10cb43efae417d1231483bf2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzQtNi0xLTEtNTQxMA_5b18c763-6bf7-43c1-bf8a-f8893f6aefbe"
      unitRef="usd">4000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2401d30b2e994f16b50e95b7e08d7413_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xNjMvZnJhZzozNjc2NmM1OGE0OTA0YWRjOTJmZWM5YWRiZTYwZGU4NC90YWJsZTpiYzFjN2EzYTIyM2I0MTE2ODU3YTU5NWYyOTEyMTgwYS90YWJsZXJhbmdlOmJjMWM3YTNhMjIzYjQxMTY4NTdhNTk1ZjI5MTIxODBhXzQtOC0xLTEtNTQxMA_8c27e2e7-0e65-4426-ac83-fce20ebe7f25"
      unitRef="usd">22000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970138712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SILK ROAD MEDICAL, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8777622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1213 Innsbruck Dr.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunnyvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">720-9002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SILK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,365,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001397702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475965361448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 69,466<span></span>
</td>
<td class="nump">$ 39,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">78,016<span></span>
</td>
<td class="nump">51,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $13 and $45 at December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">9,070<span></span>
</td>
<td class="nump">8,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">9,989<span></span>
</td>
<td class="nump">10,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,787<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">173,328<span></span>
</td>
<td class="nump">112,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,844<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">2,832<span></span>
</td>
<td class="nump">3,644<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">179,314<span></span>
</td>
<td class="nump">137,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,598<span></span>
</td>
<td class="nump">1,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">16,957<span></span>
</td>
<td class="nump">15,034<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,555<span></span>
</td>
<td class="nump">16,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">48,533<span></span>
</td>
<td class="nump">44,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">3,726<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">71,814<span></span>
</td>
<td class="nump">65,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock, $0.001 par value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Shares authorized: 5,000,000 at December 31, 2020 and 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockAbstract', window );"><strong>Common stock, $0.001 par value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Shares issued and outstanding: 34,249,649 and 31,255,267 at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">346,318<span></span>
</td>
<td class="nump">263,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(238,891)<span></span>
</td>
<td class="num">(191,526)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">107,500<span></span>
</td>
<td class="nump">71,891<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 179,314<span></span>
</td>
<td class="nump">$ 137,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970387464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowances for accounts receivables</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock, $0.001 par value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockAbstract', window );"><strong>Common stock, $0.001 par value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">34,249,649<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">34,249,649<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476044243384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 75,227<span></span>
</td>
<td class="nump">$ 63,354<span></span>
</td>
<td class="nump">$ 34,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">21,291<span></span>
</td>
<td class="nump">15,927<span></span>
</td>
<td class="nump">10,874<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">53,936<span></span>
</td>
<td class="nump">47,427<span></span>
</td>
<td class="nump">23,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21,271<span></span>
</td>
<td class="nump">12,272<span></span>
</td>
<td class="nump">10,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">75,524<span></span>
</td>
<td class="nump">63,220<span></span>
</td>
<td class="nump">34,820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">96,795<span></span>
</td>
<td class="nump">75,492<span></span>
</td>
<td class="nump">45,078<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(42,859)<span></span>
</td>
<td class="num">(28,065)<span></span>
</td>
<td class="num">(21,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,411)<span></span>
</td>
<td class="num">(4,952)<span></span>
</td>
<td class="num">(4,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">(1,119)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(21,054)<span></span>
</td>
<td class="num">(12,063)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(47,365)<span></span>
</td>
<td class="num">(52,415)<span></span>
</td>
<td class="num">(37,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Silk Road Medical, Inc. common stockholders</a></td>
<td class="num">(47,365)<span></span>
</td>
<td class="num">(52,415)<span></span>
</td>
<td class="num">(37,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Unrealized gain on investments, net</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net change in other comprehensive loss</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Silk Road Medical, Inc. common stockholders</a></td>
<td class="num">$ (47,328)<span></span>
</td>
<td class="num">$ (52,413)<span></span>
</td>
<td class="num">$ (37,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted (in USD per share)</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (2.28)<span></span>
</td>
<td class="num">$ (39.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares used to compute net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted (in shares)</a></td>
<td class="nump">32,965,539<span></span>
</td>
<td class="nump">22,956,679<span></span>
</td>
<td class="nump">960,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475966441720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
<th class="th">
<div>Redeemable Convertible Preferred Stock </div>
<div>IPO</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,233,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,233,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="num">$ (98,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (101,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance (Cumulative effect of change in accounting principle - ASC 606 adoption) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance (Cumulative effect of change in accounting treatment - ASU 2016-09) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">438,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">NeuroCo common stock issuance</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in connection with NeuroCo merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in connection with NeuroCo merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(37,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(37,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,135,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="num">(134,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Net exercise of Series C preferred stock warrants upon IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,361<span></span>
</td>
<td class="nump">1,653,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Net exercise of Series C preferred stock warrants upon IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,784<span></span>
</td>
<td class="nump">$ 37,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares', window );">Conversion of preferred stock to common stock upon IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,178,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue', window );">Conversion of preferred stock to common stock upon IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (144,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Exercise/issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Exercise/issuance of common stock</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">873,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">873,786<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of preferred stock to common stock upon IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,178,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of preferred stock to common stock upon IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(52,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain on investments, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">71,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Exercise/issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Exercise/issuance of common stock</a></td>
<td class="nump">$ 70,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,018,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,018,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 3,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">7,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(47,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain on investments, net</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,249,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (238,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease For Conversion Of Convertible Securities, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964133576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 4,457<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475971518376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (47,365)<span></span>
</td>
<td class="num">$ (52,415)<span></span>
</td>
<td class="num">$ (37,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,226<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of redeemable convertible preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,030<span></span>
</td>
<td class="nump">11,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums (accretion of discounts) on investments, net</a></td>
<td class="nump">304<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Change in provision for doubtful accounts receivable</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for excess and obsolete inventories</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(437)<span></span>
</td>
<td class="num">(2,241)<span></span>
</td>
<td class="num">(446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2,161)<span></span>
</td>
<td class="num">(4,696)<span></span>
</td>
<td class="num">(2,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">250<span></span>
</td>
<td class="num">(1,471)<span></span>
</td>
<td class="num">(1,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">552<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="num">(309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">4,964<span></span>
</td>
<td class="nump">5,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">26<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_RepaymentOfPaidInKindInterest', window );">Repayment of interest paid in kind</a></td>
<td class="num">(3,813)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(42,068)<span></span>
</td>
<td class="num">(29,610)<span></span>
</td>
<td class="num">(21,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(842)<span></span>
</td>
<td class="num">(535)<span></span>
</td>
<td class="num">(2,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(79,906)<span></span>
</td>
<td class="num">(69,421)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments', window );">Proceeds from maturity of investments</a></td>
<td class="nump">71,355<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(9,393)<span></span>
</td>
<td class="num">(69,956)<span></span>
</td>
<td class="num">(2,270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid</a></td>
<td class="nump">70,568<span></span>
</td>
<td class="nump">109,352<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net</a></td>
<td class="nump">48,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">5,168<span></span>
</td>
<td class="nump">2,590<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayment of long-term debt</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payments of prepayment penalty and lender fees</a></td>
<td class="num">(2,496)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">81,746<span></span>
</td>
<td class="nump">113,757<span></span>
</td>
<td class="nump">15,424<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">30,285<span></span>
</td>
<td class="nump">14,191<span></span>
</td>
<td class="num">(8,541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">39,491<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="nump">33,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">69,776<span></span>
</td>
<td class="nump">39,491<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">7,917<span></span>
</td>
<td class="nump">4,234<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accounts payable and accrued liabilities for purchases of property and equipment</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Landlord paid tenant improvements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_StockIssuanceCostsIncurredButNotYetPaid', window );">Unpaid deferred offering costs</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Net exercise of redeemable convertible preferred stock warrants to preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,121<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">144,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=silk_RedeemableConvertiblePreferredStockWarrantsMember', window );">Redeemable convertible preferred stock warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember', window );">Common stock warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_RepaymentOfPaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Paid-In-Kind Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_RepaymentOfPaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_StockIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_StockIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=silk_RedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=silk_RedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964275992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Formation and Business of the Company</a></td>
<td class="text">Formation and Business of the Company <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Silk Road Medical, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on March&#160;21,&#160;2007.  The Company has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke.  The Company&#8217;s portfolio of TCAR products enable a new procedure, referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles.  The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.  The Company commercialized its products in the United States in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2016. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception.  As of December&#160;31, 2020, the Company had an accumulated deficit of $238,891,000.  The Company expects to incur losses for the foreseeable future.  The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> believes tha</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t its cash and cash equivalents of $69,466,000 and available-for-sale investments of $78,016,000 at December&#160;31, 2020, as well as its expected revenues will provide sufficient funds to allow the Company to fund its planned current operations for the next twelve months from the issuance of these financial statements.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2019, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a 1-for-2.7 reverse stock split of the Company&#8217;s common stock and redeemable convertible preferred stock to be consummated prior to the effectiveness of the Company&#8217;s planned initial public offering (&#8220;IPO&#8221;).  The reverse stock split was effected on March 27, 2019.  The par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split.  All the common stock, redeemable convertible preferred stock, stock options and warrants, and related per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Public Offerings</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company issued and sold 6,000,000 shares of its common stock in its IPO at a public offering price of $20.00 per share, for net proceeds of approximately $109,119,000 after deducting underwriting discounts and commissions of approximately $8,400,000 and expenses of approximately $2,481,000. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock and the Company's outstanding warrants to purchase shares of common and redeemable convertible preferred stock were exercised, or automatically net exercised absent a prior election. The exercises resulted in the reclassification of the fair value of the related redeemable convertible preferred stock warrant liability to additional paid-in capital. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company completed a secondary public offering of 4,200,000 shares of its common stock sold by certain selling stockholders, and the exercise in full of the underwriters' option to purchase 630,000 additional shares of its common stock from certain selling stockholders, at a public offering price of $39.50 per share. The Company did not receive any of the proceeds from the sale of the shares of its common stock from the selling stockholders.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company completed an underwritten public offering of 6,808,154 shares of its common stock, of which 1,923,076 shares were offered for sale by the Company and the remaining 4,885,078 shares were offered for sale by certain selling stockholders, at a public offering price of $39.00 per share. </span></div>The Company received cash proceeds of approximately $70,543,000 after deducting underwriting discounts and commissions of approximately $3,750,000 and expenses of approximately $707,000. Also, in May 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common stock from the selling stockholders.  The Company did not receive any of the proceeds from the sale of the shares of its common stock by the selling stockholders.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962618920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Preparation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the coronavirus (&#8220;COVID-19&#8221;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2020 and 2019.  The carrying amounts of certain of the Company&#8217;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of December&#160;31, </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, the Company&#8217;s cash equivalents are comprised of investments in money market funds and commercial paper.  As of December 31, 2019, the Company&#8217;s cash equivalents are entirely comprised of investments in money market funds.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash as of December&#160;31, 2020 and 2019 consists of a letter of credit of $310,000 representing collateral for the Company&#8217;s facility lease. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy.  Money market funds are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method. Realized gains and losses are included in earnings and are der</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived for specific-identification method for determining the costs of investments sold and were insignificant for the year ended December 31, 2020 and 2019. Amortization of premiums and accretion of discounts are reported as a component of interest income.</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks related to public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#8217;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#8217;s revenue while the pandemic continues.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable are due from a variety of health care organizations in the United States.  At December&#160;31, 2020 and 2019, no customer represented 10% or more of the Company&#8217;s accounts receivable.  For the years ended December&#160;31, 2020, 2019 and 2018, there were no customers that represented 10% or more of revenue.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manufactures certain of its commercial products in-house.  Certain of the Company&#8217;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis, a Cardinal Health Company (see Note 14 - Subsequent Events).  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#8217;s financial position and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#8217;s currently approved portfolio.  If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest.  The Company estimates allowances for doubtful accounts.  Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#8217; financial condition.  The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected.  These specific allowances are reevaluated and adjusted as </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional information is received that impacts the amount reserved.  During the years ended December 31, 2020, 2019 and 2018, the Company did not experience any material credit-related losses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value.  Cost is determined using the first-in, first-out method for all inventories.  Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.  The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate.  The Company&#8217;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements.  The estimate of excess quantities is judgmental and primarily dependent on the Company&#8217;s estimates of future demand for a particular product.  If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Current Assets</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prepaid expenses and other current assets balance at December 31, 2020 included $4,160,000 associated with the Company's voluntary recall (see Note 14 - Subsequent Events). The amount relates to the replacement lots and other direct costs to be received from Cord</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost less accumulated depreciation or amortization.  Repairs and maintenance costs are expensed as incurred.  Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA3ODg_1daeb587-69ed-44f7-8b16-4ee5917c9839">three</span> to five years.  Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset.  When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Public Offering Costs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specific incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No deferred offering costs were capitalized as of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As of December&#160;31, 2019, there were $950,000 of offering costs primarily consisting of legal and accounting fees that were capitalized in other non-current assets on the balance sheet of which $233,000 had been paid.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable.  If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount.  Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value.  The Company did not record any impairment of long-lived assets during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  As a result of adopting ASC 842, the Company recorded an operating lease right-of-use ("ROU") asset of $3,982,000 included within other non-current assets and operating lease liabilities of $5,190,000 included within accrued liabilities and other liabilities on the balance sheet related to its facility lease, based on the present value of the future lease payments on the date of adoption.  The operating lease right-of-use asset also includes adjustments for prepayments and excludes lease incentives.  The adoption did not have an impact on prior periods or on the Company's statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosure impact of the adoption of ASC 842 on the balance sheet was as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjustments Due to ASC 842</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#8217;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock Warrant Liability</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the statements of operations and comprehensive loss.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised. Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#8217; equity. Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#8217; equity on the balance sheet as events triggering the liquidation preferences were not solely within the Company&#8217;s control. Upon the closing of the Company's IPO, all shares of convertible preferred stock then outstanding converted into an aggregate of 23,178,555 shares of common stock resulting in the reclassification of $144,140,000 from outside of stockholders&#8217; equity to additional paid-in capital.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606,&#160;&#8220;Revenue from Contracts with Customers.&#8221;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2018, the date of adoption, the Company recognized the cumulative-effect of initially applying ASC 606 as an adjustment to decrease accumulated deficit by $87,000.  Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">identify the contract(s) with a customer; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">identify the performance obligations in the contract; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">determine the transaction price;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">allocate the transaction price to the performance obligations in the contract; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company recorded $71,000 and $102,000, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#8217;s standard terms and conditions.&#160;&#160;The Company&#8217;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For sales where the Company&#8217;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#8217;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectibility is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale.  As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short.  Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component.  The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of revenue&#160;in the&#160;statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on our balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manufactures certain of its portfolio of TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#8217;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses research and development costs as incurred.  Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#8217;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development.  Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses.  Additionally, research and development expenses include costs associated with our clinical studies including clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements.  The Company </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses advertising costs as incurred.  Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items.  Advertising costs of $194,000, $362,000 and $186,000 were expensed during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net.  The Company had no material foreign currency exchange gains or losses during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock&#8211;Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 718,&#160;&#8220;Compensation-Stock Compensation.&#8221;  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions.  The Company accounts for option forfeitures as they occur.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made an accounting policy election under Accounting Standards Update (ASU) No. 2016-09, "Stock Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting to account for forfeitures as they occur, resulting in a cumulative-effect adjustment to increase accumulated deficit by $13,000 as of January 1, 2018, the date of adoption.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes.&#8221;  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  No liability related to uncertain tax positions is recorded on the financial statements.  It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020 and 2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive income.  Accumulated other comprehensive loss is presented in the accompanying balance sheets as a component of stockholders' equity.  For the year ended December 31, 2018, there was no difference between the Company's comprehensive loss and its net loss.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#8217;s redeemable convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share was determined as follows (in thousands, except share and per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Silk Road Medical, Inc. common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,415)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,629)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common stock outstanding used to compute net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,965,539&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,956,679&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960,882&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#8217;s net loss:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,233,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock warrants outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,306,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,277,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business as one reportable and operating segment.  The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Primarily all of the Company&#8217;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment.  All of the Company&#8217;s revenue was in the United State</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s for the years ended December&#160;31, 2020, 2019 and 2018, based on the shipping location of the external customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475963935128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting Pronouncements<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 was determined to originally be effective for the Company on January 1, 2023.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  During the year ended </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020, the Company no longer qualified as a smaller reporting company, accordingly </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">became effective for the Company on January 1, 2021. The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 became effective for the Company on January 1, 2021.  The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964592984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, investments, and the Company's previously outstanding preferred stock warrants.  Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.  A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; quoted prices in active markets are identical assets and liabilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; observable inputs other than quotes prizes in active markets for identical assets and liabilities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; unobservable inputs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.  The Company&#8217;s cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.  The corporate bonds/notes, commercial paper, asset-backed securities and U.S. government securities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables sets forth by level within the fair value hierarchy the Company&#8217;s assets and liabilities that are reported at fair value as of December&#160;31, 2020 and 2019, using the inputs defined above (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between fair value hierarchy levels during the years ended December&#160;31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964007960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's available-for-sale investments as of December&#160;31, 2020 and 2019 are as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,093&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of the Company&#8217;s cash equivalents, short-term and long-term investments classified by maturity as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.557%"><tr><td style="width:1.0%"/><td style="width:62.152%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts maturing within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale investments held as of December&#160;31, 2020 had a weighted average days to maturity of 135 days. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventories were as follows (in thousands): </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reserve for excess and obsolete</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,989&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, there were no work-in-process inventories. The reserve for excess and obsolete inventory at December 31, 2020, included $2,377,000 associated with the Company's voluntary product recall (see Note 14 - Subsequent Events).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add:  Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $789,000, $712,000 and $517,000 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for sales returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recall replacement obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued travel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,034&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962685416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRG</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2015, the Company entered into a term loan agreement with CRG.  The term loan agreement provides for up to $30,000,000 in term loans split into two tranches as follows: (i) the Tranche A Loans provided for $20,000,000 in term loans, and (ii) the Tranche B Loans provided for up to $10,000,000 in term loans.  The Company drew down the Tranche A Loans on October 13, 2015.  The Tranche B Loans were available to be drawn prior to March 29, 2017.  In January 2017, the term loan agreement was </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amended to extend the commitment period of the Tranche B Loans to April 28, 2017.  In April 2017, the Company drew down $5,000,000 of the available Tranche B Loans.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the term loan agreement was amended to provide for additional term loans in an aggregate principal amount of up to $25,000,000.  In September 2018, the Company drew down an additional $15,000,000 under the amended term loan agreement with CRG, no additional draw was taken.  U</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nder the terms of the amended term loan agreement, the related fixed interest rate was 10.0%, 8.0% of the interest was due and payable in cash and at the election of the Company, 2.0% of the interest due and payable may be "paid in kind". </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All unpaid principal, and accrued and unpaid interest, was due and payable in full on December 31,&#160;2022. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2020, in connection with the consummation of the Loan and Security agreement with Stifel Bank as noted below, the Company repaid all amounts outstanding under the term loan with CRG.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stifel Bank</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company entered into a Loan and Security Agreement, or Loan Agreement, with Stifel Bank which provides for a $50,000,000 loan facility, comprised of a $50,000,000 secured revolving credit facility, with a $2,000,000 subfacility for the issuance of letters of credit and other ancillary banking services, and a $50,000,000 secured term loan facility, provided that amounts outstanding under both facilities may not exceed an aggregate principal amount of $50,000,000 at any time.  Any borrowings under the revolving loan facility mature on October 29, 2022, or October 29, 2023 if as of October 29, 2022, no event of default has occurred and we are in compliance with the terms of the Loan Agreement. Borrowings under the term loan facility mature on October 29, 2024.  Interest under the revolving credit facility is the greater of a) 0.5% above the "Prime Rate" as published by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or b) 4.75%.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in October 2020, the Company drew down $49,000,000 under the term loan facility and used the majority of the proceeds to pay off and terminate the prior term loan agreement with CRG totaling $46,674,000, which included a prepayment premium of $305,000, a final interest payment of $365,000 and a facility fee of $2,191,000.  The Company recognized a loss on debt extinguishment of $1,119,000 in connection with the early termination of the term loan agreement with CRG. The principal amount of outstanding term loans under the Loan Agreement with Stifel Bank shall be repaid in equal monthly installments beginning on May 29, 2022, or November 29, 2022 if the Company achieves revenue for the year ending December 31, 2021 of at least 80% of the board-approved financial projections for such fiscal year.  Interest under the term loan facility is the greater of a) 0.75% above the "Prime Rate" as published by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or b) 4.75%.  The term loan may not be reborrowed once repaid, but the Company may prepay the term loan at any time without premium or penalty. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also concurrently entered in a Success Fee Agreement in October 2020 with Stifel Bank, which requires that the Company pay Stifel Bank the lesser of 0.75% of the original principal amount of all credit extensions made under the Loan Agreement or $375,000 in the event the Company completes a Liquidity Event (liquidation, merger, sale of the Company or change in control).  The Success Fee Agreement terminates on October 29, 2025.  The Company has determined the probability of a Liquidity Event to be remote and accordingly, has not recognized a liability as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under the Loan Agreement are secured by substantially all of the Company's assets. Beginning on January 15, 2021, the Loan Agreement requires that the Company maintain unrestricted cash and cash equivalents with Stifel Bank or at Stifel Bank Affiliates of at least $20,000,000. In addition, for any fiscal quarter where the Company's unrestricted cash and cash equivalents maintained with Stifel Bank or at Stifel Bank Affiliates (or prior to January 15, 2021, Stifel Bank or certain other banks) are less than $60,000,000 for any day during such fiscal quarter, the Company must comply with a minimum </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue covenant. Additionally, the Loan Agreement contains customary affirmative and negative covenants, including covenants limiting the Company's ability and the ability of the Company's subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events of default under the Loan Agreement include, among others, payment defaults, material misrepresentations, breaches of covenants, cross defaults with certain other material indebtedness, bankruptcy and insolvency events, and judgment defaults. The occurrence of an event of default could result in the acceleration of our obligations under the Loan Agreement, the termination of the lender&#8217;s commitments, a 5% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the Loan Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the aggregate outstanding principal balance under the Loan Agreement was $49,000,000 and the annual interest rate was 4.75%.  As of December&#160;31, 2020, the Company was in compliance with all applicable financial covenants.  As of December&#160;31, 2020, management does not believe that it is probable that the above events of default will be triggered within the next twelve months, therefore, the debt is classified as long-term on the balance sheet.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities under the Stifel Bank term loan agreement as of December&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount representing debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962619752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Lease and Rights of Use</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating lease obligation consists of leased office, laboratory, and manufacturing space under a non-cancellable operating lease that expires in October&#160;2024. The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional period of five years.   Operating lease costs were $870,000 for each of the years ended December&#160;31, 2020 and 2019.  Cash paid for amounts included in the measurement of operating lease liabilities was $769,000 and $721,000 for the years ended December&#160;31, 2020 and 2019.  As of December&#160;31, 2020, the weighted average discount rate was approximately 6.50% and the weighted average remaining lease term was 3.83 years.  As of December 31, 2019, the weighted average discount rate was approximately 6.50% and the </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted average remaining lease term was 4.83 years.  Balance sheet information as of December&#160;31, 2020 consists of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_79e4f10b-3b5e-4ec2-876c-6e585e344f6b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_da5af1e9-78c6-47d2-b916-faffbda32183">other non-current assets</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_0c14a90d-c468-4d50-8bda-f4b6abb57993"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_df5558d5-a823-4bc7-8d24-11cd3b6290f9">accrued liabilities</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_14124f2c-b99c-42a3-914f-b88bb1e2da04"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_eb1aa98b-cafb-4393-b523-5f94410b69b5">other liabilities</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's operating lease maturities as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Obligations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business.  As of December&#160;31, 2020, the Company had non-cancellable purchase obligations to suppliers of $6,601,000.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements with suppliers and other parties that contain a variety of representations and warranties and may provide for indemnification of the counterparty.  The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made.  To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws.  The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity.  The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance.  The Company believes that the fair value of these indemnification obligations is minimal.  Accordingly, the Company has not recognized any liabilities relating to these obligations as of December&#160;31, 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations or cash flows. From time to time, the Company may pursue litigation to assert its legal right and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were no contingent liabilities requiring accrual at December&#160;31, 2020 and 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, a former employee, through counsel, advised the Company that he had filed a charge of discrimination against the Company with the California Department of Fair Employment &amp; Housing, or DFEH.  The former employee&#8217;s complaint alleged sexual harassment and retaliation in violation of the California Department of Fair Employment &amp; Housing Act.  The complaint did not allege specific damages. The Company and the former employee participated in mediation on July 30, 2019 and reached a settlement that required the Company to pay an amount that was not material to its financial statements, which amount was fully paid as of December 31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962632744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">Redeemable Convertible Preferred Stock<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Company's IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does not have any redeemable convertible preferred stock issued or outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock Warrant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Company's IPO, all of the outstanding redeemable convertible preferred stock warrants were exercised, or net exercised based on the IPO price of $20.00 per share, into 1,945,365 shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does not have any redeemable convertible preferred stock warrants outstanding.</span></div>Stockholders' Equity (Deficit)<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of preferred stock with $0.001 par value per share, of which no shares were issued and outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 34,249,649 shares were issued and outstanding.  The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors.  As of December&#160;31, 2020, no dividends have been declared to date.  Each share of common stock is entitled to one vote.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company had reserved common stock for future issuances as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercise of options under stock plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,310,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of options and restricted stock units under stock plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,790,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,554,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">632,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">372,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,660,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,237,832&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock Warrant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the common stock warrants were cash, or net exercised based on the IPO price of $20.00 per share into 5,968 shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does not have any common stock warrants outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475963865832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text">Redeemable Convertible Preferred Stock<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Company's IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does not have any redeemable convertible preferred stock issued or outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock Warrant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Company's IPO, all of the outstanding redeemable convertible preferred stock warrants were exercised, or net exercised based on the IPO price of $20.00 per share, into 1,945,365 shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does not have any redeemable convertible preferred stock warrants outstanding.</span></div>Stockholders' Equity (Deficit)<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of preferred stock with $0.001 par value per share, of which no shares were issued and outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 34,249,649 shares were issued and outstanding.  The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors.  As of December&#160;31, 2020, no dividends have been declared to date.  Each share of common stock is entitled to one vote.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company had reserved common stock for future issuances as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercise of options under stock plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,310,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of options and restricted stock units under stock plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,790,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,554,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">632,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">372,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,660,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,237,832&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock Warrant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the common stock warrants were cash, or net exercised based on the IPO price of $20.00 per share into 5,968 shares of common stock.  As of December&#160;31, 2020 and 2019, the Company does not have any common stock warrants outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475963931528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plans</a></td>
<td class="text">Stock Option Plans<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2007, the Company established its 2007 Stock Option Plan which provided for the granting of stock options to employees, directors and consultants of the Company.  In connection with its acquisition of NeuroCo in December 2018, the Company also assumed NeuroCo&#8217;s 2015 Equity Incentive Plan.  In March 2019, the Company's Board of Directors approved the termination of the 2007 Stock Option Plan and the NeuroCo 2015 Equity Incentive Plan and the adoption of the 2019 Equity Incentive Plan, or the 2019 Plan, which became effective immediately prior to the Company's IPO.  The 2019 Plan provides for the grant of ISOs to employees and for the grant of NSOs, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants.  A total of 2,317,000 shares of common stock were initially reserved for issuance pursuant to the 2019 Plan.  In addition, the shares reserved for issuance under the 2019 Plan will also include shares reserved but not issued under the 2007 Stock Option Plan, plus any share awards granted under the 2007 Stock Option Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased.  In addition, the number of shares available for issuance under the 2019 Plan will also include an annual increase on the first day of each fiscal year, equal to the lesser of (i) 3,000,000 shares; (ii) 4.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) an amount as determined by the Board of Directors.  As of December&#160;31, 2020, the Company has reserved 3,635,009 shares of common stock for issuance under the 2019 Plan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the shares available for issuance under the 2007 Stock Option Plan, NeuroCo 2015 Equity Incentive Plan and 2019 Plan, or the Plans, is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">328,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">223,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(629,716)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">135,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,317,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(848,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,824</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,690</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,250,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted/Awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,079,883)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">65,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,790,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of ISOs and NSOs shall not be less than 100% and 85%, respectively, of the estimated fair value of the shares on the date of grant as determined by the Board of Directors.  The exercise price of ISOs and NSOs granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors.  To date, options have a term of ten years and generally vest over 4 years from the date of grant.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's Plans is set forth below:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.137%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2017</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(873,786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,018,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $47,861,000, $24,867,000 and $787,000, respectively.  The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise.  The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020, 2019 and 2018 was $18.22, $10.17 and $2.93 per share, respectively.  The total fair value of options vested during the years ended December&#160;31, 2020, 2019 and 2018 was $5,138,000, $2,221,000 and $569,000, respectively, based on the grant date fair value.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding and vested as of December&#160;31, 2020:</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Vested</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.35 - $3.16</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.73 - $7.10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.27 - $12.41</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.00 - $30.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30.93 - $46.40</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$47.20 - $70.80</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company began granting restricted stock units, or RSUs, under the 2019 Plan.  RSUs generally vest over four years in annual equal increments, no RSUs vested during the year ended December 31, 2020.  The fair value of RSUs is based on the Company&#8217;s closing stock price on the date of grant.  A summary of RSUs activity for the year ended December 31, 2020 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted stock granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">46.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted stock forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">46.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">46.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company's Board of Directors adopted the 2019 Employee Stock Purchase Plan, or the 2019 ESPP, under which eligible employees are permitted to purchase common stock at a discount through payroll deductions.  A total of 434,000 shares of common stock were initially reserved for </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance and is increased on the first day of each fiscal year by an amount equal to the lesser of (i)&#160;1,200,000 shares (ii)&#160;1.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii)&#160;an amount as determined by the Board of Directors.  As of December 31, 2020, the Company has reserved 746,552 shares of common stock for issuance under the 2019 ESPP.  The price of the common stock purchased will be the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period.  The 2019 ESPP was effective upon adoption by the Company's Board of Directors but was not in use until the completion of the Company's IPO in April 2019.  The 2019 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&#160;423 of the Internal Revenue Code of 1986, as amended.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, 114,175 shares of common stock have been issued to employees participating in the 2019 ESPP and 632,377 shares were available for future issuance under the 2019 ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of stock options using the Black&#8211;Scholes option pricing model.  The fair value of employee and nonemployee stock options is being amortized on a straight&#8211;line basis over the requisite service period of the awards.  The fair value of employee and nonemployee stock options was estimated using the following assumptions for the years ended December&#160;31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.314%"><tr><td style="width:1.0%"/><td style="width:43.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.707%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 - 6.25</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0% - 50.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4% - 42.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0% - 38.8%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32% - 1.41%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47% - 2.54%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68% - 2.98%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to completion of the Company's IPO, the fair value of common stock was determined by the Company&#8217;s Board of Directors, who considered, among other things, contemporaneous valuations of the Company&#8217;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.  For stock options granted after the completion of the IPO, the fair value of the underlying common stock is based on the closing price of the Company's common stock on The NASDAQ Global Market on the date of grant.  The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding.  The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the &#8220;simplified method,&#8221; whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option.  The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as the Company does not have sufficient trading history for the Company&#8217;s common stock.  The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the&#160;Company&#8217;s common stock becomes available.  The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the&#160;Company&#8217;s stock options.  The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company made an accounting policy election to account for forfeitures as they occur. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the shares to be issued under the Company&#8217;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:64.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50 - 0.63</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4% - 76.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4% - 47.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10% - 1.58%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58% - 2.45%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation expense included in the statements of operations for all periods presented (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.604%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was total unrecognized compensation costs of $20,188,000 related to stock options expected to be recognized over a period of approximately 3.02 years, a total of $2,716,000 of unrecognized compensation costs related to unvested RSUs expected to be recognized over a period of approximately 3.48 years and $295,000 related to the ESPP, which the Company will recognize over 0.38 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962621992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income before taxes are as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,415)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,365)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,415)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,630)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory U.S. federal rate to the Company&#8217;s effective tax rate is as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:55.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,947)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,007)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on Series C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's provision for income taxes are included within other income (expense) on the statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2020 and 2019 consist of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized start-up costs/Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.  Management believes it is more likely than not that the deferred tax assets will not be realized; accordingly, a valuation allowance has been established on U.S. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net deferred tax assets.  The valuation allowance increased $22,163,000 during the year ended December&#160;31, 2020 and increased by $12,826,000 during the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company had net operating loss carryforwards of approximately $241,908,000 and $209,771,000 for federal and state income tax purposes, respectively.  The federal and state net operating loss carryforwards begin to expire in 2027 and 2028, respectively.  Federal NOL carryforwards generated in tax years beginning in 2018 are not subject to expiration.  Federal NOLs that arose on or after January 1, 2018 can be carried forward indefinitely against future income, but can only be used to offset a maximum of 80% of the Company's federal taxable income in any year.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code and similar provisions under state law.  Federal tax legislation enacted in December 2017, commonly known as the Tax Cuts and Jobs Act, contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes.  A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders, who own at least 5% of the Company&#8217;s stock, increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period.  The Company may have previously experienced, and may in the future experience, one or more Section 382 &#8220;ownership changes,&#8221; including in connection with the Company&#8217;s initial public offering.  If so, the Company may lose some or all of the tax benefits of its NOLs and tax credits.  The extent of such limitations for prior years, if any, has not yet been formally determined.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company had $6,275,000 and $3,463,000 of federal and state research and development credit carryforwards, respectively.  If not utilized, the federal credits will expire beginning in 2027.  The California Research and Development credits can be carried forward indefinitely.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company had $2,019,000 of unrecognized tax benefits.  The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized would increase or decrease within twelve months of the year ended December&#160;31, 2020. If recognized, $0 would affect the effective tax rate.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense.  There was no such expense recorded during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the unrecognized tax benefits from January 1, 2018 to December&#160;31, 2020 is as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"><tr><td style="width:1.0%"/><td style="width:59.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at the beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current years&#8217; tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior years&#8217; tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has no federal or state tax examinations in progress nor has it had any federal or state tax examinations since its inception.  As a result of the Company&#8217;s net operating loss carryforwards, all of its tax years are subject to federal and state tax examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962396104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Variable Interest Entity - NeuroCo<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition of Variable Interest Entity - NeuroCo</a></td>
<td class="text">Acquisition of Variable Interest Entity - NeuroCo<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2014, the Board of Directors of the Company approved the sale of certain intellectual property of Silk Road Medical, Inc., to a newly incorporated entity, NeuroCo, Inc.  In consideration for the intellectual property, a promissory note was executed between the two parties for the principal sum of $498,000 with an interest rate of 2.74% per annum, payable on the earlier of 10 years from the date of promissory note, or upon the occurrence of an event of default.  The intellectual property transfer was recorded at its carrying value of zero as of December&#160;31, 2014.  During 2015 NeuroCo issued $154,000 in common stock to stockholders of the Company.  During the year ended December 31, 2018, NeuroCo issued common stock upon the exercise of stock options.  These common stock issuance amounts, as they are related to non-controlling investors, were reported as non-controlling interests in subsidiary in the Company&#8217;s financial statements and are offset by NeuroCo losses consolidated by the Company.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, NeuroCo incurred research and development related expenses paid for by the Company which were added into the original promissory note.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had identified NeuroCo as a VIE of which the Company is the primary beneficiary.  Pursuant to the accounting guidance for consolidating VIEs the main consideration was given to the fact that the amount of total equity investment at risk is not sufficient to permit NeuroCo to finance its activities without additional subordinated financial support.  Additionally, NeuroCo and Silk Road Medical had the same Board of Directors and senior management composition, determining the Company to have the power to direct the activities that most significantly impact NeuroCo&#8217;s economic performance and the obligation to absorb losses and the right to receive benefits.  Accordingly, the financial results of NeuroCo were included in the Company&#8217;s financial statements.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2018, the Company and NeuroCo entered into the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) pursuant to which the Company acquired all assets and assumed all liabilities of NeuroCo (the &#8220;Merger&#8221;).  The Merger closed on the same day (the &#8220;Closing&#8221;) and was consummated through a stock-for-stock transaction based on the relative values of the Company&#8217;s and NeuroCo&#8217;s equity.  In consideration for 100% equity interest of NeuroCo, the Company issued 33,462 shares of its common stock and the above promissory note in the amount of approximately $1,600,000 as of the Closing was settled and canceled.  As a result of the Merger, NeuroCo merged into the Company with the Company being the surviving corporation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company already controlled and consolidated NeuroCo and retained the control over NeuroCo&#8217;s business after the Merger, the Company accounted for the acquisition of equity interest in NeuroCo as an equity transaction.  Therefore, the Company did not recognize a gain or loss in its net loss or comprehensive loss for acquisition of NeuroCo.  As the carrying amount of the non-controlling interest as of the Closing was zero, the Company recorded the consideration paid as a decrease to the Company&#8217;s additional paid-in capital within stockholder&#8217;s equity. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Merger, the Company assumed NeuroCo&#8217;s 2015 Equity Incentive Plan (the &#8220;NeuroCo Plan&#8221;) along with all of NeuroCo&#8217;s rights and obligations under the NeuroCo Plan, except that the number of shares and exercise price of the assumed options have been adjusted based on the Merger exchange ratio of the Company&#8217;s common stock and NeuroCo&#8217;s common stock.  Similarly, the Company assumed outstanding warrants to purchase NeuroCo&#8217;s common stock such that the number of shares and exercise price of the assumed warrants have been adjusted based on the Merger exchange ratio of the Company&#8217;s common stock and NeuroCo&#8217;s common stock.  The options and warrants to purchase shares of the Company&#8217;s common stock were fully vested upon issuance, as they were replacing fully vested options and warrants to purchase NeuroCo common stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962408472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) PlanThe Company has a qualified retirement plan under section&#160;401(k)&#160;of the Internal Revenue Code (&#8220;IRC&#8221;) under which participants may contribute up to 90% of their eligible compensation, subject to maximum deferral limits specified by the IRC.  The Company may make a discretionary matching contribution to the 401(k)&#160;plan and may make a discretionary employer contribution to each eligible employee each year.  Through December 31, 2019, the Company has made no contributions to the 401(k)&#160;plan.  Beginning in January 2020, the Company started matching employees' contributions to the 401(k) plan at 50% of the first 5% of compensation deferred to the 401(k) plan.  The Company's matching contributions were $959,000 for the year ended December 31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964598152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Equity Incentive Plan</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the number of shares of common stock authorized for issuance under the 2019 Plan was automatically increased by 1,369,985 shares, which was ratified by the Company's Board of Directors in January 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company&#8217;s Board of Directors approved the grant of options to purch</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ase 19,305 shares of common stock under the 2019 Plan with an exercise price of $59.33 per share. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the number of shares of common stock authorized for issuance under the 2019 ESPP was automatically increased by 342,496 shares, which was ratified by the Company's Board of Directors  in January 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voluntary Recall</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January and February 2021, the Company announced the voluntary recall of certain lots of our ENROUTE Transcarotid Stent System, manufactured by one of its third-party suppliers, Cordis. The decision to recall these lots was based on complaints received about tips detaching from the stent delivery system as well as internal testing that the Company conducted. The Company believes the root cause of the detachment was a single operator at Cordis, who, over a specific timeframe, produced lots in which a small number of units were not reliably manufactured to specification.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the voluntary recall the Company reflected a current asset of $4,160,000 on its balance sheet as of December 31, 2020, relating to the replacement lots and other direct costs to be received from Cordis. This amount includes $2,227,000 of recalled ENROUTE stent delivery systems held in the Company's inventory as of December 31, 2020, $1,696,000 of ENROUTE stent delivery systems in the process of being returned from its customers and other direct costs of $237,000. In addition, the Company established an accrual of $1,696,000 relating to its obligation to provide replacement ENROUTE stent delivery systems to its customers as of December 31, 2020.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Bonus to be Settled in Shares</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, the Company's Compensation Committee of the Board of Directors approved that the bonus for certain employees would partially be paid in RSUs.  Actual shares were awarded to employees on February 26, 2021 as a fixed dollar amount converted to 14,952 fully vested RSUs using the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trailing 30-day average stock price.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475963964136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (unaudited)</a></td>
<td class="text">Quarterly Financial Information (unaudited)<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected unaudited quarterly financial data for the years ended December&#160;31, 2020, and 2019 (in thousands, except per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,959)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962705624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text">Financial Statement Schedule.<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. The table below presents Schedule II, Valuation and Qualifying Accounts, detailing the activity of the allowance for doubtful accounts receivable for the years ended December 31, 2020, 2019 and 2018 (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.412%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Write offs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475969927560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Preparation and Adjustment to Prior Period Financial Statements</a></td>
<td class="text">Basis of PreparationThe accompanying financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the coronavirus (&#8220;COVID-19&#8221;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the estimated fair value of its financial instruments as of December&#160;31, 2020 and 2019.  The carrying amounts of certain of the Company&#8217;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of December&#160;31, </span></div>2020, the Company&#8217;s cash equivalents are comprised of investments in money market funds and commercial paper.  As of December 31, 2019, the Company&#8217;s cash equivalents are entirely comprised of investments in money market funds.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy.  Money market funds are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method. Realized gains and losses are included in earnings and are der</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived for specific-identification method for determining the costs of investments sold and were insignificant for the year ended December 31, 2020 and 2019. Amortization of premiums and accretion of discounts are reported as a component of interest income.</span></div>A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk, and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks related to public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#8217;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#8217;s revenue while the pandemic continues.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable are due from a variety of health care organizations in the United States.  At December&#160;31, 2020 and 2019, no customer represented 10% or more of the Company&#8217;s accounts receivable.  For the years ended December&#160;31, 2020, 2019 and 2018, there were no customers that represented 10% or more of revenue.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manufactures certain of its commercial products in-house.  Certain of the Company&#8217;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis, a Cardinal Health Company (see Note 14 - Subsequent Events).  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#8217;s financial position and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#8217;s currently approved portfolio.  If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest.  The Company estimates allowances for doubtful accounts.  Specifically, the Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience and changes in customers&#8217; financial condition.  The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected.  These specific allowances are reevaluated and adjusted as </span></div>additional information is received that impacts the amount reserved.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost to purchase or manufacture the inventory or net realizable value.  Cost is determined using the first-in, first-out method for all inventories.  Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.  The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life prior to sale to record a provision for excess and obsolete inventory when appropriate.  The Company&#8217;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements.  The estimate of excess quantities is judgmental and primarily dependent on the Company&#8217;s estimates of future demand for a particular product.  If the estimate of future demand is too high, the Company may have to increase the reserve for excess inventory for that product and record a charge to the cost of goods sold.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost less accumulated depreciation or amortization.  Repairs and maintenance costs are expensed as incurred.  Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, typically <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl84Mi9mcmFnOjhhNGVjYTY5MzRkYTQ0OGU5YjdlNDgwYjNkNjFhMGM5L3RleHRyZWdpb246OGE0ZWNhNjkzNGRhNDQ4ZTliN2U0ODBiM2Q2MWEwYzlfMTA3ODg_1daeb587-69ed-44f7-8b16-4ee5917c9839">three</span> to five years.  Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset.  When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Public Offering Costs</a></td>
<td class="text">Deferred Public Offering CostsSpecific incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable.  If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying amount.  Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  As a result of adopting ASC 842, the Company recorded an operating lease right-of-use ("ROU") asset of $3,982,000 included within other non-current assets and operating lease liabilities of $5,190,000 included within accrued liabilities and other liabilities on the balance sheet related to its facility lease, based on the present value of the future lease payments on the date of adoption.  The operating lease right-of-use asset also includes adjustments for prepayments and excludes lease incentives.  The adoption did not have an impact on prior periods or on the Company's statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosure impact of the adoption of ASC 842 on the balance sheet was as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjustments Due to ASC 842</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#8217;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock', window );">Redeemable Convertible Preferred Stock Warrant Liability</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock Warrant Liability</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the statements of operations and comprehensive loss.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised. Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#8217; equity. Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">Redeemable Convertible Preferred StockPrior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#8217; equity on the balance sheet as events triggering the liquidation preferences were not solely within the Company&#8217;s control.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Cost of Goods Sold</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606,&#160;&#8220;Revenue from Contracts with Customers.&#8221;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2018, the date of adoption, the Company recognized the cumulative-effect of initially applying ASC 606 as an adjustment to decrease accumulated deficit by $87,000.  Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">identify the contract(s) with a customer; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">identify the performance obligations in the contract; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">determine the transaction price;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">allocate the transaction price to the performance obligations in the contract; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company recorded $71,000 and $102,000, respectively, of unbilled receivables, which are included in accounts receivable, net on the balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#8217;s standard terms and conditions.&#160;&#160;The Company&#8217;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For sales where the Company&#8217;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#8217;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectibility is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale.  As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short.  Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component.  The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of revenue&#160;in the&#160;statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on our balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manufactures certain of its portfolio of TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#8217;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development and Clinical Trials</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses research and development costs as incurred.  Research and development expenses consist primarily of engineering, product development, clinical studies to develop and support the Company&#8217;s products, regulatory expenses, medical affairs and other costs associated with products and technologies that are in development.  Research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses.  Additionally, research and development expenses include costs associated with our clinical studies including clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for clinical trials and internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements.  The Company </span></div>determines these accruals through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsThe Company expenses advertising costs as incurred.  Advertising costs include design and production costs, including website development, physician and patient testimonial videos, written media campaigns, and other items.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">Foreign CurrencyThe Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange gains or losses in other income (expense), net.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock&#8211;Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 718,&#160;&#8220;Compensation-Stock Compensation.&#8221;  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions.  The Company accounts for option forfeitures as they occur.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made an accounting policy election under Accounting Standards Update (ASU) No. 2016-09, "Stock Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting to account for forfeitures as they occur, resulting in a cumulative-effect adjustment to increase accumulated deficit by $13,000 as of January 1, 2018, the date of adoption.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes.&#8221;  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  No liability related to uncertain tax positions is recorded on the financial statements.  It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive Loss<span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020 and 2019</span>, the Company&#8217;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the statements of operations and comprehensive income.  Accumulated other comprehensive loss is presented in the accompanying balance sheets as a component of stockholders' equity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#8217;s redeemable convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business as one reportable and operating segment.  The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Primarily all of the Company&#8217;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment.  All of the Company&#8217;s revenue was in the United State</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s for the years ended December&#160;31, 2020, 2019 and 2018, based on the shipping location of the external customer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting Pronouncements<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 was determined to originally be effective for the Company on January 1, 2023.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  During the year ended </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020, the Company no longer qualified as a smaller reporting company, accordingly </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">became effective for the Company on January 1, 2021. The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 became effective for the Company on January 1, 2021.  The Company does not believe that the adoption of this new guidance will have a material impact on its financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Classified As Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970212792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of ASC 842 Impact of Adoption on Condensed Consolidated Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosure impact of the adoption of ASC 842 on the balance sheet was as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjustments Due to ASC 842</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Balance sheet information as of December&#160;31, 2020 consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_79e4f10b-3b5e-4ec2-876c-6e585e344f6b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_da5af1e9-78c6-47d2-b916-faffbda32183">other non-current assets</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_0c14a90d-c468-4d50-8bda-f4b6abb57993"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_df5558d5-a823-4bc7-8d24-11cd3b6290f9">accrued liabilities</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_14124f2c-b99c-42a3-914f-b88bb1e2da04"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_eb1aa98b-cafb-4393-b523-5f94410b69b5">other liabilities</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Net Loss Per Share Determination</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share was determined as follows (in thousands, except share and per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Silk Road Medical, Inc. common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,415)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,629)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common stock outstanding used to compute net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,965,539&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,956,679&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960,882&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Weighted Average Shares Outstanding</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#8217;s net loss:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,233,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock warrants outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,306,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,277,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475969696888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Liabilities Measure on a Recurring Basis</a></td>
<td class="text">The following tables sets forth by level within the fair value hierarchy the Company&#8217;s assets and liabilities that are reported at fair value as of December&#160;31, 2020 and 2019, using the inputs defined above (in thousands):<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962446296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Fair Value of the Available-For-Sale Investments</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's available-for-sale investments as of December&#160;31, 2020 and 2019 are as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,093&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value of Cash Equivalents, Short-Term and Long-Term Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of the Company&#8217;s cash equivalents, short-term and long-term investments classified by maturity as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.557%"><tr><td style="width:1.0%"/><td style="width:62.152%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts maturing within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Available-For-Sale Investments in Unrealized Loss Position</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds/notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventories were as follows (in thousands): </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reserve for excess and obsolete</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,989&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add:  Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for sales returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recall replacement obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued travel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,034&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475963910168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Future Maturities Under the Term Loan Agreement</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities under the Stifel Bank term loan agreement as of December&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount representing debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962635528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Balance Sheet Information</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosure impact of the adoption of ASC 842 on the balance sheet was as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjustments Due to ASC 842</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Balance sheet information as of December&#160;31, 2020 consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_79e4f10b-3b5e-4ec2-876c-6e585e344f6b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzEtMC0xLTEtMC90ZXh0cmVnaW9uOjc4YjY5NmJhOGE1ZjQwNWRhMjdmNmFhNThjMjFiNWM5XzMyOTg1MzQ4ODM0MTg_da5af1e9-78c6-47d2-b916-faffbda32183">other non-current assets</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_0c14a90d-c468-4d50-8bda-f4b6abb57993"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzItMC0xLTEtMTk0Ny90ZXh0cmVnaW9uOmJkYWU2YWRkYWU1NTRmZGY4MGQ5MDBhZmE3NDE5YjkxXzMyOTg1MzQ4ODMzOTk_df5558d5-a823-4bc7-8d24-11cd3b6290f9">accrued liabilities</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_14124f2c-b99c-42a3-914f-b88bb1e2da04"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI2YTBlZDI1OGRhZTRlZTVhOWVkYjhhM2I5NjNlMWJmL3NlYzoyNmEwZWQyNThkYWU0ZWU1YTllZGI4YTNiOTYzZTFiZl8xMDAvZnJhZzpmN2RkODI5Y2FkMGI0YTgyYTRhZDMzOWJkNGE0ZjljNi90YWJsZTpiNjAyNWIyNDcxZDQ0NmVhYjhkNTEzNWZjODBlYmFkYi90YWJsZXJhbmdlOmI2MDI1YjI0NzFkNDQ2ZWFiOGQ1MTM1ZmM4MGViYWRiXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmVmZWJkOWRiMjE5MDRjM2NhMWY4YTE1MTY0MzJkNTNiXzMyOTg1MzQ4ODMzOTU_eb1aa98b-cafb-4393-b523-5f94410b69b5">other liabilities</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturities</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's operating lease maturities as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962662040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Reserved Common Stock for Future Issuances</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company had reserved common stock for future issuances as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercise of options under stock plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,310,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of options and restricted stock units under stock plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,790,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,554,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">632,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">372,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,660,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,237,832&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962480008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Shares Available for Issuance</a></td>
<td class="text">A summary of the shares available for issuance under the 2007 Stock Option Plan, NeuroCo 2015 Equity Incentive Plan and 2019 Plan, or the Plans, is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">328,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">223,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(629,716)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">135,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,317,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(848,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,824</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,690</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,250,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted/Awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,079,883)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">65,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,790,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's Plans is set forth below:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.137%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2017</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(873,786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,018,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding and vested as of December&#160;31, 2020:</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.732%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Vested</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.35 - $3.16</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.73 - $7.10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.27 - $12.41</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.00 - $30.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30.93 - $46.40</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$47.20 - $70.80</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237,828&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text">A summary of RSUs activity for the year ended December 31, 2020 is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted stock granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">46.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted stock forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balances, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">46.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">46.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text">The fair value of employee and nonemployee stock options was estimated using the following assumptions for the years ended December&#160;31, 2020, 2019 and 2018:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.314%"><tr><td style="width:1.0%"/><td style="width:43.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.707%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 - 6.25</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0% - 50.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4% - 42.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0% - 38.8%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32% - 1.41%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47% - 2.54%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68% - 2.98%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the shares to be issued under the Company&#8217;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:64.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50 - 0.63</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4% - 76.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4% - 47.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10% - 1.58%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58% - 2.45%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense Relating to Stock Options to Employees and Nonemployees</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation expense included in the statements of operations for all periods presented (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.604%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964094216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income before taxes are as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,415)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,365)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,415)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,630)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory U.S. federal rate to the Company&#8217;s effective tax rate is as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:55.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,947)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,007)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on Series C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2020 and 2019 consist of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized start-up costs/Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock', window );">Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the unrecognized tax benefits from January 1, 2018 to December&#160;31, 2020 is as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"><tr><td style="width:1.0%"/><td style="width:59.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at the beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current years&#8217; tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior years&#8217; tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962627256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Unaudited Quarterly Financial Information</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected unaudited quarterly financial data for the years ended December&#160;31, 2020, and 2019 (in thousands, except per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,959)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475966215896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2019</div></th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,891<span></span>
</td>
<td class="nump">$ 191,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,466<span></span>
</td>
<td class="nump">39,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.3704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,457<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued and sold common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions', window );">Payment of stock issuance underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=silk_SecondPublicOfferingMember', window );">Second Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued and sold common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued and sold common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,021,223<span></span>
</td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions', window );">Payment of stock issuance underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued and sold common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,808,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromCompanyMember', window );">Public Stock Offering - Shares From Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued and sold common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromExistingShareholdersMember', window );">Public Stock Offering - Shares From Existing Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued and sold common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,885,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Stock Issuance Underwriting Discounts And Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=silk_SecondPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=silk_SecondPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromExistingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromExistingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476045883224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 69,466<span></span>
</td>
<td class="nump">$ 39,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">69,776<span></span>
</td>
<td class="nump">39,491<span></span>
</td>
<td class="nump">$ 25,300<span></span>
</td>
<td class="nump">$ 33,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962409320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Other Current Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=silk_VoluntaryRecallMember', window );">Voluntary Recall</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivable', window );">Loss contingency receivable</a></td>
<td class="nump">$ 4,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=silk_VoluntaryRecallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=silk_VoluntaryRecallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476044304216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964082536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Deferred Initial Public Offering Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred initial public offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 950,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 4,457,000<span></span>
</td>
<td class="nump">$ 233,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476054870616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 2,798<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 4,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Adjustments Due to ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475969983560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - ASC 842 Impact on Condensed Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">$ 2,832<span></span>
</td>
<td class="nump">$ 3,644<span></span>
</td>
<td class="nump">$ 3,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">16,957<span></span>
</td>
<td class="nump">15,034<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">$ 3,726<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">4,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment | Adjustments Due to ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970599624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">20 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of preferred stock to common stock upon IPO | $</a></td>
<td class="nump">$ 144,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of preferred stock to common stock upon IPO (in shares) | shares</a></td>
<td class="nump">23,178,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970494264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment</a></td>
<td class="nump">$ 107,500<span></span>
</td>
<td class="nump">$ 71,891<span></span>
</td>
<td class="num">$ (134,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (98,578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment</a></td>
<td class="num">$ (238,891)<span></span>
</td>
<td class="num">$ (191,526)<span></span>
</td>
<td class="num">$ (139,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,556)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Cumulative effect of change in accounting principle - ASC 606 adoption | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Cumulative effect of change in accounting principle - ASC 606 adoption | Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964077480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Advertising Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475965386584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment</a></td>
<td class="nump">$ 107,500<span></span>
</td>
<td class="nump">$ 71,891<span></span>
</td>
<td class="num">$ (134,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (98,578)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment</a></td>
<td class="num">$ (238,891)<span></span>
</td>
<td class="num">$ (191,526)<span></span>
</td>
<td class="num">$ (139,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,556)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit | Accounting Standards Update 2016-09 | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475966170392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liability for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475966238488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Silk Road Medical, Inc. common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (47,365)<span></span>
</td>
<td class="num">$ (52,415)<span></span>
</td>
<td class="num">$ (37,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common stock outstanding used to compute net loss per share, basic and diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,965,539<span></span>
</td>
<td class="nump">22,956,679<span></span>
</td>
<td class="nump">960,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in USD per share)</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (20.12)<span></span>
</td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (2.28)<span></span>
</td>
<td class="num">$ (39.16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475972958168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,306,224<span></span>
</td>
<td class="nump">4,310,790<span></span>
</td>
<td class="nump">28,277,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,233,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=silk_RedeemableConvertiblePreferredStockWarrantsMember', window );">Redeemable convertible preferred stock warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,672,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,237,828<span></span>
</td>
<td class="nump">4,310,790<span></span>
</td>
<td class="nump">4,364,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=silk_CommonStockWarrantMember', window );">Common stock warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">68,396<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=silk_RedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=silk_RedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=silk_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=silk_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964176472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment and Geographical Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475971475112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Recurring Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">$ 146,311<span></span>
</td>
<td class="nump">$ 104,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">60,295<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">7,969<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">146,311<span></span>
</td>
<td class="nump">104,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">60,295<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">39,577<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">7,969<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">38,470<span></span>
</td>
<td class="nump">44,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">60,295<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">60,295<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">86,016<span></span>
</td>
<td class="nump">69,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">39,577<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">7,969<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">38,470<span></span>
</td>
<td class="nump">44,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475968023720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 146,272<span></span>
</td>
<td class="nump">$ 104,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">146,311<span></span>
</td>
<td class="nump">104,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">60,295<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">60,295<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">39,577<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">39,577<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,970<span></span>
</td>
<td class="nump">10,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">7,969<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">38,430<span></span>
</td>
<td class="nump">44,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">38,470<span></span>
</td>
<td class="nump">44,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">68,295<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 78,016<span></span>
</td>
<td class="nump">51,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=silk_LongTermInvestmentsMember', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=silk_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=silk_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475965952296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear', window );">Amounts maturing within one year</a></td>
<td class="nump">$ 146,311<span></span>
</td>
<td class="nump">$ 85,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears', window );">Amounts maturing after one year through two years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 146,311<span></span>
</td>
<td class="nump">$ 104,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476044466040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Weighted average days to maturity</a></td>
<td class="text">135 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process inventories</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">789,000,000<span></span>
</td>
<td class="nump">$ 712,000,000<span></span>
</td>
<td class="nump">$ 517,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=silk_VoluntaryRecallMember', window );">Voluntary Recall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivable', window );">Loss contingency receivable</a></td>
<td class="nump">4,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember', window );">Inventory Excess and Obsolescence | Voluntary Recall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivable', window );">Loss contingency receivable</a></td>
<td class="nump">$ 2,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=silk_VoluntaryRecallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=silk_VoluntaryRecallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970264136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 15,497<span></span>
</td>
<td class="nump">$ 29,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss, Less than 12 months</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">5,369<span></span>
</td>
<td class="nump">10,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss, Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">10,128<span></span>
</td>
<td class="nump">19,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss, Less than 12 months</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964471000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,785<span></span>
</td>
<td class="nump">$ 1,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">10,599<span></span>
</td>
<td class="nump">9,163<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="nump">12,384<span></span>
</td>
<td class="nump">10,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: Reserve for excess and obsolete</a></td>
<td class="num">(2,395)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">9,989<span></span>
</td>
<td class="nump">10,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Valuation reserve</a></td>
<td class="nump">$ 2,395<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970345720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,694<span></span>
</td>
<td class="nump">$ 3,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(2,332)<span></span>
</td>
<td class="num">(1,550)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,844<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,043<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 482<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475965902680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">$ 9,573<span></span>
</td>
<td class="nump">$ 9,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ProvisionsForSalesReturns', window );">Provision for sales returns</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">2,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">2,520<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Recall replacement obligation</a></td>
<td class="nump">1,696<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalty expense</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_AccruedTravelExpensesCurrent', window );">Accrued travel expenses</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_AccruedClinicalExpensesCurrent', window );">Accrued clinical expenses</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 16,957<span></span>
</td>
<td class="nump">$ 15,034<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AccruedTravelExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Travel Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AccruedTravelExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ProvisionsForSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provisions For Sales Returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ProvisionsForSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68070138&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475960547416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - CRG Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th"><div>May 01, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtMaximumBorrowingCapacity', window );">Term loan agreement amount</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentInterestRatePaidInKind', window );">Interest rate paid-in-kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentInterestRatePaidInCash', window );">Interest rate paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheAMember', window );">Term Loan, Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtMaximumBorrowingCapacity', window );">Term loan agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheBMember', window );">Term Loan, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtMaximumBorrowingCapacity', window );">Term loan agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentInterestRatePaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Paid In Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentInterestRatePaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Paid-In-Kind</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=silk_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964302280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Stifel Bank Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 29, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment premium fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,496,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,119,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentMaximumBorrowingCapacity', window );">Debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum', window );">Minimum unrestricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions', window );">Maximum unrestricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentCovenantDebtDefaultRate', window );">Debt default rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentCovenantMaximumBorrowingThreshold', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt pay off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment premium fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,191,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,119,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_RepaymentsOfDebtRevenueTargetPercentage', window );">Percentage of revenue for debt repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement | Term Loan | Prime Rate | Rate Scenario One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement | Term Loan | Prime Rate | Rate Scenario Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement | Secured Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement | Secured Revolving Credit Facility | Line of Credit | Prime Rate | Rate Scenario One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement | Secured Revolving Credit Facility | Line of Credit | Prime Rate | Rate Scenario Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember', window );">Loan Agreement | Letter of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silk_SuccessFeeAgreementMember', window );">Success Fee Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold', window );">Percent of original principal threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantDebtDefaultRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Default Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantDebtDefaultRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantLiquidityEventPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Event, Payment Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantLiquidityEventPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantMaximumBorrowingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Maximum Borrowing Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantMaximumBorrowingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Threshold For Revenue Restrictions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_RepaymentsOfDebtRevenueTargetPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Debt, Revenue Target, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_RepaymentsOfDebtRevenueTargetPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silk_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentRateScenarioAxis=silk_RateScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentRateScenarioAxis=silk_RateScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentRateScenarioAxis=silk_RateScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentRateScenarioAxis=silk_RateScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silk_SuccessFeeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silk_SuccessFeeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476067670632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Future Maturities Under the Term Loan (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">14,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">20,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">17,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LongTermDebtGrossBeforeAccretionOfClosingFees', window );">Long-term debt, gross before accretion of closing fees</a></td>
<td class="nump">55,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LongTermDebtUnpaidInterest', window );">Less: Amount representing interest</a></td>
<td class="num">(6,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Amount representing debt discount and debt issuance costs</a></td>
<td class="num">(467)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Present value of minimum payments</a></td>
<td class="nump">$ 48,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LongTermDebtGrossBeforeAccretionOfClosingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Gross, Before Accretion Of Closing Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LongTermDebtGrossBeforeAccretionOfClosingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LongTermDebtUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Unpaid Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LongTermDebtUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476043998472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 870<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liabilities</a></td>
<td class="nump">$ 769<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 9 months 29 days<span></span>
</td>
<td class="text">4 years 9 months 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475964474120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset in other non-current assets</a></td>
<td class="nump">$ 2,798<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability in accrued liabilities</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability in other liabilities</a></td>
<td class="nump">2,850<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 4,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating lease, right-of-use asset, statement of financial position extensible list</a></td>
<td class="text">us-gaap:OtherAssets<span></span>
</td>
<td class="text">us-gaap:OtherAssets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, current, statement of financial position extensible list</a></td>
<td class="text">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, noncurrent, statement of financial position extensible list</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970167576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">4,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 4,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475969642616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Obligation and Contingencies Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Purchase obligation</a></td>
<td class="nump">$ 6,601,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities requiring accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970095272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=silk_PreferredStockWarrantsMember', window );">Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=silk_PreferredStockWarrantsMember', window );">Preferred Stock Warrants | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares of common stock converted (in shares)</a></td>
<td class="nump">1,945,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=silk_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=silk_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475965306744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">34,249,649<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">34,249,649<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_CommonStockVotePerShare', window );">Number of votes entitled per share of common stock | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share) | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember', window );">Common stock warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember', window );">Common stock warrants outstanding | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares of common stock converted (in shares)</a></td>
<td class="nump">5,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CommonStockVotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Vote Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CommonStockVotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475965406856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">6,660,892<span></span>
</td>
<td class="nump">6,237,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionExercisedMember', window );">Exercise of options under stock plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">4,237,828<span></span>
</td>
<td class="nump">4,310,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionIssuedMember', window );">Issuance of options and restricted stock units under stock plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,790,687<span></span>
</td>
<td class="nump">1,554,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">632,377<span></span>
</td>
<td class="nump">372,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionExercisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionExercisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475965140680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,861<span></span>
</td>
<td class="nump">$ 24,867<span></span>
</td>
<td class="nump">$ 787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.22<span></span>
</td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,138<span></span>
</td>
<td class="nump">$ 2,221<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,660,892<span></span>
</td>
<td class="nump">6,237,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation expensed not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember', window );">ISO and NSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember', window );">ISO and NSO | 10% Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice', window );">Exercise threshold as a percentage of fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveStockOptionMember', window );">ISO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice', window );">Exercise threshold as a percentage of fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_NonqualifiedStockOptionsMember', window );">NSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice', window );">Exercise threshold as a percentage of fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable under the plan (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percent of outstanding shares of common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">434,000<span></span>
</td>
<td class="nump">746,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of purchase of price of common stock</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_CommonStockCapitalSharesAvailableForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expensed not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expensed not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expensed not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs of unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">2,317,000<span></span>
</td>
<td class="nump">3,635,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percent of outstanding shares of common stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable under the plan (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CommonStockCapitalSharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CommonStockCapitalSharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_NonqualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_NonqualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475971073112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Activity Under Compensation Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">4,310,790<span></span>
</td>
<td class="nump">4,364,377<span></span>
</td>
<td class="nump">4,308,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,010,843<span></span>
</td>
<td class="nump">848,023<span></span>
</td>
<td class="nump">629,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(1,018,779)<span></span>
</td>
<td class="num">(873,786)<span></span>
</td>
<td class="num">(438,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled (in shares)</a></td>
<td class="num">(65,026)<span></span>
</td>
<td class="num">(27,824)<span></span>
</td>
<td class="num">(135,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">4,237,828<span></span>
</td>
<td class="nump">4,310,790<span></span>
</td>
<td class="nump">4,364,377<span></span>
</td>
<td class="nump">4,308,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">2,392,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expect to vest (in shares)</a></td>
<td class="nump">4,237,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share)</a></td>
<td class="nump">$ 7.91<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in USD per share)</a></td>
<td class="nump">40.67<span></span>
</td>
<td class="nump">22.77<span></span>
</td>
<td class="nump">6.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in USD per share)</a></td>
<td class="nump">3.42<span></span>
</td>
<td class="nump">1.77<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options cancelled (in USD per share)</a></td>
<td class="nump">23.32<span></span>
</td>
<td class="nump">8.71<span></span>
</td>
<td class="nump">1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share)</a></td>
<td class="nump">16.56<span></span>
</td>
<td class="nump">$ 7.91<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in USD per share)</a></td>
<td class="nump">8.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in USD per share)</a></td>
<td class="nump">$ 16.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding</a></td>
<td class="text">7 years 4 months 17 days<span></span>
</td>
<td class="text">7 years 3 months 7 days<span></span>
</td>
<td class="text">7 years 4 months 9 days<span></span>
</td>
<td class="text">7 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
<td class="text">6 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">7 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Awards outstanding</a></td>
<td class="nump">$ 197,407<span></span>
</td>
<td class="nump">$ 140,234<span></span>
</td>
<td class="nump">$ 33,132<span></span>
</td>
<td class="nump">$ 5,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable</a></td>
<td class="nump">130,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">$ 197,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,554,690<span></span>
</td>
<td class="nump">57,889<span></span>
</td>
<td class="nump">328,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="nump">1,250,210<span></span>
</td>
<td class="nump">2,317,000<span></span>
</td>
<td class="nump">223,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross', window );">Granted/Awarded (in shares)</a></td>
<td class="num">(1,079,883)<span></span>
</td>
<td class="num">(848,023)<span></span>
</td>
<td class="num">(629,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod', window );">Canceled (in shares)</a></td>
<td class="nump">65,670<span></span>
</td>
<td class="nump">27,824<span></span>
</td>
<td class="nump">135,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,790,687<span></span>
</td>
<td class="nump">1,554,690<span></span>
</td>
<td class="nump">57,889<span></span>
</td>
<td class="nump">328,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970841544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Information by Exercise Price (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">4,237,828<span></span>
</td>
<td class="nump">4,310,790<span></span>
</td>
<td class="nump">4,364,377<span></span>
</td>
<td class="nump">4,308,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years)</a></td>
<td class="text">7 years 4 months 17 days<span></span>
</td>
<td class="text">7 years 3 months 7 days<span></span>
</td>
<td class="text">7 years 4 months 9 days<span></span>
</td>
<td class="text">7 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 16.56<span></span>
</td>
<td class="nump">$ 7.91<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in shares)</a></td>
<td class="nump">2,392,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 8.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceOneMember', window );">Exercise Price One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">1,214,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years)</a></td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in shares)</a></td>
<td class="nump">1,128,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceOneMember', window );">Exercise Price One | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceOneMember', window );">Exercise Price One | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceTwoMember', window );">Exercise Price Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">722,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years)</a></td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in shares)</a></td>
<td class="nump">443,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 5.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceTwoMember', window );">Exercise Price Two | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">4.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceTwoMember', window );">Exercise Price Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">$ 7.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceThreeMember', window );">Exercise Price Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">564,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years)</a></td>
<td class="text">7 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 11.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in shares)</a></td>
<td class="nump">394,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceThreeMember', window );">Exercise Price Three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">8.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceThreeMember', window );">Exercise Price Three | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">$ 12.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFourMember', window );">Exercise Price Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">656,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years)</a></td>
<td class="text">8 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in shares)</a></td>
<td class="nump">270,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFourMember', window );">Exercise Price Four | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFourMember', window );">Exercise Price Four | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFiveMember', window );">Exercise Price Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">771,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years)</a></td>
<td class="text">9 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 33.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in shares)</a></td>
<td class="nump">136,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 33.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFiveMember', window );">Exercise Price Five | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">30.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFiveMember', window );">Exercise Price Five | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">$ 46.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceSixMember', window );">Exercise Price Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">308,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years)</a></td>
<td class="text">9 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 58.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in shares)</a></td>
<td class="nump">18,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 51.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceSixMember', window );">Exercise Price Six | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">47.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceSixMember', window );">Exercise Price Six | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Exercise Price (in USD per share)</a></td>
<td class="nump">$ 70.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding And Exercisable, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=silk_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476044139528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - RSUs (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares) | shares</a></td>
<td class="nump">69,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock forfeited (in shares) | shares</a></td>
<td class="num">(644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">68,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock granted (in USD per share) | $ / shares</a></td>
<td class="nump">46.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock vested (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">44.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 46.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476044274936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">42.40%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">50.30%<span></span>
</td>
<td class="nump">42.90%<span></span>
</td>
<td class="nump">38.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.32%<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
<td class="nump">2.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.41%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">44.40%<span></span>
</td>
<td class="nump">44.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">76.40%<span></span>
</td>
<td class="nump">47.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.58%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">2019 ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">2019 ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476050411192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,226<span></span>
</td>
<td class="nump">$ 2,977<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,777<span></span>
</td>
<td class="nump">$ 2,372<span></span>
</td>
<td class="nump">$ 604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962562920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Before Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (47,365)<span></span>
</td>
<td class="num">$ (52,415)<span></span>
</td>
<td class="num">$ (37,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total</a></td>
<td class="num">$ (47,365)<span></span>
</td>
<td class="num">$ (52,415)<span></span>
</td>
<td class="num">$ (37,630)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970491272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of U.S Statutory Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="num">$ (9,947)<span></span>
</td>
<td class="num">$ (11,007)<span></span>
</td>
<td class="num">$ (7,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(1,958)<span></span>
</td>
<td class="num">(2,270)<span></span>
</td>
<td class="num">(1,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(8,489)<span></span>
</td>
<td class="num">(4,731)<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount', window );">Loss on Series C warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,330<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">22,164<span></span>
</td>
<td class="nump">12,797<span></span>
</td>
<td class="nump">6,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">General business credits</a></td>
<td class="num">(1,268)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="num">(491)<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Warrant Liability Adjustment, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970176840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 63,069,000<span></span>
</td>
<td class="nump">$ 44,574,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">7,191,000<span></span>
</td>
<td class="nump">5,287,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Capitalized start-up costs/Intangibles</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">2,337,000<span></span>
</td>
<td class="nump">2,227,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">188,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,859,000<span></span>
</td>
<td class="nump">568,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">935,000<span></span>
</td>
<td class="nump">1,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest limitation</a></td>
<td class="nump">813,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">76,212,000<span></span>
</td>
<td class="nump">53,988,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(75,289,000)<span></span>
</td>
<td class="num">(53,126,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease asset</a></td>
<td class="num">(707,000)<span></span>
</td>
<td class="num">(862,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(216,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(923,000)<span></span>
</td>
<td class="num">(862,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475965431928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in deferred tax asset valuation allowance</a></td>
<td class="nump">$ 22,163,000<span></span>
</td>
<td class="nump">$ 12,826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_OperatingLossCarryforwardOffsetMaximumPercent', window );">Percent maximum of federal taxable income to offset with net operating losses</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 2,019,000<span></span>
</td>
<td class="nump">1,436,000<span></span>
</td>
<td class="nump">$ 1,348,000<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, income tax penalties and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">241,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">209,771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">6,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">$ 3,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_OperatingLossCarryforwardOffsetMaximumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforward, Offset Maximum, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_OperatingLossCarryforwardOffsetMaximumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475970229528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of year</a></td>
<td class="nump">$ 1,436<span></span>
</td>
<td class="nump">$ 1,348<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current years&#8217; tax positions</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior years&#8217; tax positions</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 2,019<span></span>
</td>
<td class="nump">$ 1,436<span></span>
</td>
<td class="nump">$ 1,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475965329400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Variable Interest Entity - NeuroCo (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 17, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,543,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Carrying amount of the non-controlling interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=silk_NeuroCoIncMember', window );">NeuroCo, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Equity interest acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued as consideration (in shares)</a></td>
<td class="nump">33,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven', window );">Consideration given, amount of notes payable forgiven</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=silk_NeuroCoIncMember', window );">NeuroCo, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedParties', window );">Promissory note amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 498,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage', window );">Notes receivable, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.74%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_NotesReceivableRelatedPartiesTerm', window );">Notes receivable, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Notes Payable Forgiven</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Related Parties, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_NotesReceivableRelatedPartiesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Related Parties, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_NotesReceivableRelatedPartiesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=silk_NeuroCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=silk_NeuroCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=silk_NeuroCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=silk_NeuroCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475962505048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage employee contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer discretionary contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 959,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer contribution match percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percent of matching contribution of the employee's pay</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475971152648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,010,843<span></span>
</td>
<td class="nump">848,023<span></span>
</td>
<td class="nump">629,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.22<span></span>
</td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.67<span></span>
</td>
<td class="nump">$ 22.77<span></span>
</td>
<td class="nump">$ 6.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,660,892<span></span>
</td>
<td class="nump">6,237,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities requiring accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=silk_VoluntaryRecallMember', window );">Voluntary Recall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivable', window );">Loss contingency receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities requiring accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableInventoryHeldMember', window );">Loss Contingency Receivable, Inventory Held | Voluntary Recall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivable', window );">Loss contingency receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableInventoryInProcessOfRecallMember', window );">Loss Contingency Receivable, Inventory in Process of Recall | Voluntary Recall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivable', window );">Loss contingency receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableDirectCostsMember', window );">Loss Contingency Receivable, Direct Costs | Voluntary Recall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivable', window );">Loss contingency receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,635,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,317,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares)</a></td>
<td class="nump">14,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod', window );">Trailing stock price period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Trailing Stock Price Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=silk_VoluntaryRecallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=silk_VoluntaryRecallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableInventoryHeldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableInventoryHeldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableInventoryInProcessOfRecallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableInventoryInProcessOfRecallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableDirectCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LossContingencyReceivableTypeAxis=silk_LossContingencyReceivableDirectCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140476044303672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 21,133<span></span>
</td>
<td class="nump">$ 20,067<span></span>
</td>
<td class="nump">$ 15,094<span></span>
</td>
<td class="nump">$ 18,933<span></span>
</td>
<td class="nump">$ 18,634<span></span>
</td>
<td class="nump">$ 17,026<span></span>
</td>
<td class="nump">$ 14,928<span></span>
</td>
<td class="nump">$ 12,766<span></span>
</td>
<td class="nump">$ 75,227<span></span>
</td>
<td class="nump">$ 63,354<span></span>
</td>
<td class="nump">$ 34,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">15,916<span></span>
</td>
<td class="nump">14,579<span></span>
</td>
<td class="nump">9,758<span></span>
</td>
<td class="nump">13,683<span></span>
</td>
<td class="nump">13,913<span></span>
</td>
<td class="nump">12,856<span></span>
</td>
<td class="nump">11,231<span></span>
</td>
<td class="nump">9,427<span></span>
</td>
<td class="nump">53,936<span></span>
</td>
<td class="nump">47,427<span></span>
</td>
<td class="nump">23,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (16,756)<span></span>
</td>
<td class="num">$ (10,315)<span></span>
</td>
<td class="num">$ (10,353)<span></span>
</td>
<td class="num">$ (9,941)<span></span>
</td>
<td class="num">$ (8,291)<span></span>
</td>
<td class="num">$ (8,007)<span></span>
</td>
<td class="num">$ (11,959)<span></span>
</td>
<td class="num">$ (24,158)<span></span>
</td>
<td class="num">$ (47,365)<span></span>
</td>
<td class="num">$ (52,415)<span></span>
</td>
<td class="num">$ (37,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in USD per share)</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (20.12)<span></span>
</td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (2.28)<span></span>
</td>
<td class="num">$ (39.16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140475969625848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts - Schedule II (Details) - Allowance for doubtful accounts receivable: - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to expenses</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Write offs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M&\Y"KNP >+^2TAQN[ >*?P",_@-02P,$%     @ ;(EA4KI+)T>P!0  0A8
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MBK$Z>(.=.FY#X:@NO &1E"@-_6'39+E P#L7P&Z.O@I[/F*]R'2C!TM8XM>
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M/N'4P6L3N?,4]LC'L+V$Z8"T"9-L)/2?KU&(Y"%Q\_#H&H7HU(-CA+W \M2
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ML-1(L^7-FK8?&.= WRNM<7=P 89]FO\"4$L#!!0    ( &R)85(!, :2)PH
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MG%J*MZ=I#(P3B"XX 4U4G"XQ7!<!2?S\7!5T1WUM1>8E*3/6>1L,B:OO3DB
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M%IB(G9T#^OL6=5@[11^A2/,\6RQ.(&?Q73G_*V;C \R.?008[7V;P5O%FK]
M403 NO$S3;_:?^2ZCM]V=MOC%S*,"6L-:J[4"D?'P[.3 =Z ^*M3O FVX2\]
M2QO -7Q9*@E?: .>KZP-W0TIZ#_]7?T.4$L#!!0    ( &R)85)M_";!%"D
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M4 JXC=9-A[LK2N3*/3(U &7=-CLYG6WZ%K:W2*ZJ;MOT&^)O&_%"2[LS!)H
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M0OSE,"BW<WE>E/MV$VV? ^FG5[*TFH'1L603K:6L)+-1M]BH-X,O0 EZ*Z*
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MHY]50K%TT<H<5<IB;7FRNS,K$CN1^MIO#[8$7,OC?"T;B^-=4R-YX]$;]!?
MH^[P12J@E<#\S;"98%,KAW5<XFAV=FJGE-*^/.<LTJ.SB],@N?3B@OZ0DA$I
M!?N3K0AQBHJBB09!PSU^^6&B+L92#FIT_:A/TY,]O9:)7'PZ"B&,'0(=G^O"
M[D%>"4->O)"KRI\L !K&]M$:]M;APU?YTZT=5,)"NF#Y[6L2/=>!;A]*3G:3
MB 5FK($I<>,ORYOL%GG=8'I'VT2^O[IY[?I$,)_\'-&N;R )5CKFZIOP*U]^
MP,\E[K5%4HCA<MTB8]RN!2FI] UF5']S'-YFS,'85,H0!YZ3*S@1B+B:S('Y
MI(6BT2L0^)>^+M79XL(2NHA-([WDXJN%Q@^X?OD]>.F+\9'];3/HI&O/+N7@
MXTMDI_>NU:D9)::&U7<;JMX28-4Z5L.?NZ8PE=RU'JT5 6&0^G3:3()00M(2
MJ]0UC EO.@DOKG&Z85P18:+#I/3J'9?UH[E(<#I]P!MXW(.*X9Y/D]RR 2N_
M ?-R%7+46TK%QYSB""+I M8!_L,8!M^71-%.-896P?T<T15$+O4)"HF S]<L
MR17*N5Y"[[<:-1 K"J885WV_ "54K,)7!PI,PIMV[S\B)8YNL?HG*EN7_6K^
M!3L \G+/IDCXTWI47#&3]8W%DN 9/JY-R6$81O.!DT'W/#H+&([H3;/KN$YU
MT,^DA6KABQC&56M1!=D4JVFXP?=(AYPS0XJ>I>9H/+P]=9;8_RS,OB:S8D#=
M5ZFJ)#4+F8FK<RB?3%**A@>3WBNU.$R%C.3WZJ'PYS'@VIBG8+JC.X7JL'59
MKK-P[^9D-3"I/S_Q*Y@>7]U\>I+\U"Q0LU\<GURFR=%812:/N;0/5,63;["=
M%6]@<B7#;Q5=-Z@0BF.V"#3U%*P>E.@CP&;Y+8WK(;.)@KZX6,_=#C%7K+<\
MDWL6'EQ@B%%D,KT^4EIIEIC%0./DDT^P^A)E-0$H"KTZ3+W]CTW,L$VR]>T@
MW)_B29[?,$6I@##_/OO:+ER&7\S7S+[!SM][8.J,0_3P%+]M"%4$PSRZZKX,
M"PW]GOQ5#*XI0][DF'V14&TNE]3[]Q#Z&Y9*&^1*I+ INCM,[EJ: F)TX=+H
MIB5]@P(EQ$,]BBEAGVFA:X4EYQ!T@\J[%B2#'&XQH];VR</H-0DHTM"=F'SO
MHVM[XO>K#>ZX":EKHNM,FR]%_P?M%V38G9\<+T^<&1PP(D[M+\LG;S^D]M@B
MIEFH>BAORY51K\9GU;P('!C,:9@]31-?TB"1NK )M9ZFX(;?5^!NZ2;8:?>]
M!(7\JU3Q38>4J1L@7[Y'44*$3=DNNIO"\VE@I,RM5HYOQ)Y^Z>B[3F\^G;EP
MJ'.Q=!#MM>8[-2Z'/7'>L/)MT*&HP?J!K T3[;-D<QUAZP>\12'^BBY6"',8
M2*WTY>!.MG[^121TC7/XVINOO-OF@?<4NY+49/H]3U_9T5?>3N+[X;@<0MK^
M!TTXXQRR#YU+]4%0$^K>U!$!T3W@+U+^X^EK)SN_\KH66K6TX[6BUQ(/7C(U
M#E>$+05_<RTT(=JFL19<)TU7@,^IK,B2'6Z?F$$$)Z?M\7HU(EX $9L:R=7@
MIIMKMHAO@HW3.YISCPQ\F!Q7!!"NVW<<F*4 J'MKA</=8(70YM85I)#KCMY4
MCO0N5Z#Z-UK,='V$+21!+,99V24VU'<3%3/N;0&PZZJG^@.=F%;"FX^K/B+"
M_T_GIJ!B\,(#=XC@(J(0-JXJ2:Q@\I7[%J\T\E=SS!]8+W@BC?309BJ\UE=Z
MV-(!UM0;YPJ<:1<O?E.?1(+O/_(BN2GK/"Y4N,OD70-\)+UU1B\O\:]\%D8G
M/W*6W$G<T.OB['WPRERW==7KZVMIM:]077A?*JEC]-./=>S0?.$V"<O]=I:C
M^G1]'#KV%/ORQ!!4*LF5<+6/X--M5J[ND#H MY+5)$M<E$'D/?-F/'E.I[@>
M1"E^TT9#'\12=,4IOH@I:\WH_F!M/^U<P_N86F: P8)P@#*DD_B:R<E[.5*J
MI=AWBNBZ".; 3"-X=_^%<OWMC#8F34QW=OPT)RENRNIS\J')BN1'SE2G:%LN
M)B7(H^3Q^?/T[.+9$_SX[#0]7_+'L^?IQ>GED^2?0]DR*S_YVI]&1=L$72MO
ML.7)U']VFEY>/$N?G<&IX..SB_3B^65R>7&2OGAQ.@7HOW#:J?7AJ,O%^3F=
M^71Q^H(/?[E87CP9O'3RC\A+SX%C\X3AX]]%+QL9"7'EC6!:Y4))9,'2+Y]V
MKUX^+2W\D\-_;7,'_Y(]\0:(Z=7+G6DWYMI@L17Y'M\=+8^";[&+[;NCJ^4W
M5Z='3^%)/_S5RSULXL>LW:!-5YDU/'JR>/[LB"MW]8^NV>.4>&%(U^SH(V9T
M38L#X/=U U"3/W !3(72]E[]+U!+ P04    " !LB6%243US,[H%   P#P
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MM(L-NZHA;+..<4J.#$H94HVL]HSKHF+EMA$_H+JUN;;$U-E)[)BAN0/KP!-
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;+586V_CMA+^*X0;G,:
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M8=$@Z78?BC[0TM@B0I%:DK+C?GV'E*S(N2&+MF@?$I$4Y\S,F8O&BYW2=Z9
MM'!?"FE.!X6UU4D8FJS DIFAJE#2F[72);.TU9O05!I9[H5*$291- E+QN5@
MN?!GUWJY4+457.*U!E.7)=/[<Q1J=SJ(!X>#&[XIK#L(EXN*;? 6[>?J6M,N
M[%!R7J(T7$G0N#X=G,4GYR-WWU_XC>/.]-;@/%DI=><V5_GI('(&H<#,.@1&
MCRU>H! .B,SXVF(..I5.L+\^H'_TOI,O*V;P0HDO/+?%Z6 V@!S7K!;V1NU^
MQM:?L</+E##^/^R:NREIS&IC5=D*T[[DLGFR^Y:'GL L>D$@:042;W>CR%OY
M@5FV7&BU ^UN$YI;>%>]-!G'I0O*K=7TEI.<7=Y:E=T52N2HS7NX_%ISNX<?
M/N":9]S^N @MZ7 WPZS%.V_PDA?PX@0^*6D+ Y<RQ_P8("3C.@N3@X7GR:N(
M'S ;0AH'D$1)] I>VGF<>KST!;S6Q]_/5L9J2HH_7L$<=9@CCSGZQUA\'>\&
M<Z3B6PF$"R6WJ"UWZVO*6-0:<_ *X7-%>6T+A$PHP^4&U-IO+U19,;E_;^#J
M^I< F!!@"J;1N OZ 3OK85<=MO'8A".!JMA8)G.'W5ZF"UQ:U0/,5%F2'5YL
M"&?^C(*&Y0IU%S@@%%K$\Z!O(>2*,*2R4+ M@CMYHWG<F)HV2O=M',(;B?O"
MM&;2@OD6"MLW?4[>:.RN46=@AQH![U%GW& >./,E-=[NQ#<8\JHQB303%,_0
MJ7Z71,,H@HHX]=0'31CB8#X:!^ED_%\'I//Q*!Z/B3^S3RTY,N#[[V9)//W)
M0.844?TPZ]WG,E.Z4IJY7D[Q,,#HTT =QOM!CENZ2(RRVA9*\S_)B[Y;Q)3/
M&*@KMQX'412YOQYK3QSBMH!WCO08*J9ARP3)]_@GF5W!LX+H.L#X^+:IZ>PZ
MXN*B"<O_BHBXH>$1%?T$^@8>TE&0C.;!9#1_$Q^_DEEMSWRBE*2IYHP"E)9;
M0>)DK";"Z!,..=_RG'PF?&I22"D)Z]IMG93 #17K'MB6<>&R-O"WO'J^I@]V
M)I@+\FKO>3E73.>^0#C!6Z7-BQ43N$ _Z/8%LD*"[C#)QIS8'\(E(SH\!T\\
MX^;()R41MLK)/)<1+Q1IP7RD46\)Y B=IC3BPM8M[4QF% 7*D;42-'Z9DV=4
M.'BX;#N0,U=5+K4,$*4NR!ZW$DP"A3>=!K-D1JLTCH+I/(*K5DM?\)"(U+IL
M5TZUY/89S-BA!)/9E%;C\2B8/,(\\JZ1QK(2:H]X@*EU5E#;;/ F:1*DTRFD
M4WJ.$Y@$DTD4S.9NY:U/D^-"?/@47$G7X&0[+OJT;[MPP_YQ51RU](R9XF]U
M\Z:9CX/Y9/:O-?+G[>^7Y'.34-B;+4O4&S]!4U=2M;3-F-F==D/Z63.;/EQO
M)OQ/3&\XY8? -8E&P^EX +J9FIN-596?5%?*TMSKEP7]T$#M+M#[M:)*:3=.
M0??39?D74$L#!!0    ( &R)85*#S)_<Y \  )0O   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$W+GAM;-U:67/CQA'^*U.*E.Q601!N@'M5:0_;FRJOE97M
M5"J5!Q <BJ@%,30.:>E?GZ][!B! @I3LK;SD02*.F9[NGNZOC\&K!U5]J5=2
M-N+KNBCKUV>KIMF\N+JJLY5<I[6M-K+$FZ6JUFF#V^KNJMY4,EWPI'5QY3E.
M=+5.\_+LS2M^=E.]>:7:ILA+>5.)NEVOTVK[5A;JX?69>]8]^)S?K1IZ</7F
MU2:]D[>R^65S4^'NJJ>RR->RK'-5BDHN7Y]=NR_>!C2>!_R:RX=Z<"U(DKE2
M7^CFX^+UF4,,R4)F#5%(\7,OW\FB($)@XS=#\ZQ?DB8.KSOJW['LD&6>UO*=
M*OZ9+YK5Z[/D3"SD,FV+YK-Z^$$:>4*BEZFBYO_B08\-_#.1M76CUF8R.%CG
MI?Y-OQH]#"8DSI$)GIG@,=]Z(>;R?=JD;UY5ZD%4-!K4Z()%Y=E@+B]I4VZ;
M"F]SS&O>W#8J^R)^VK"*;HJTK%]=-:!+;Z\R0^.MIN$=H>%ZXD=5-JM:?"@7
M<C$F< 6&>JZ\CJNWWDF*[V5F"]^UA.=XS@EZ?B^ES_3\8U*NTDI>TNXMQ$VZ
MA5$UXKJJTO).\O6_K^=U4\%"_G-BL:!?+.#%@F]2Z1^E(3Z6T(836Z)92?%.
MK3=IN16R;M)YD6/_%R)O:AXA#B:+AU6>K<2F4O<Y-DC EYG*'330Y.6=4$M1
M\R3%DVK1*"'7FT)MI:PML<@K.)&J:I&6"Y%A &P>4VN:.&#')B;QNC0N]Y W
M*V8KS7YK\SKGAYCR2;:5>J=$7@KLM%S/907.W60L6UK42J0UX (LFRE__4OB
MN?%+$M0-Q0=0;;98-,,FPKE96&;BQ[2"P!@T&]'\6RW>JK1:$!/O=T)M2#-8
MA$8VLH*;I1VK].B(4DD7]+J3YCA+_=!TH16\H^S.IJ=8PNP1#]%/]"[.99:N
MI9#+I61$$_D:"LK31A9;;'%.\]2>T!]O?K+%ST-JG3'48V,@QC[>_C0V &;_
M8-@G#+. RW"</&N@/;:@PR>B+6$"EKDA7<LLU_JM"#+Q:B,K#B_0@![-*PZ?
MUN3 3S9+6UQC:),6Q*=G^6YL.8[3$<&S3*W76%^S]" K*!'+YFD!%6*(K.Z-
ME^0P/V9@TU9TU72Z[17)YI8N%FS<VMC,.M.$6D#DWL["3XI"FWM>9D6[."0Q
M;QM1JH;)X'9(9,HVH=*B);5L-261/L#J:[UY3YB/5VDCY-<--,R&:)Q"LDLC
MMHM5>D_ ,9>RQ#A993EA*QQZV4(6MA50H*4A_5+FM"J>5A**S%8$Q!.**UN&
M D(C+7]ZG^8% $[^&1VRWY4MK !/D+#4$*7D6<N\JANQ2+>TE$SA5,N\SC!P
M*]/*$O(WFF0VNI!UK7EZEC\7/AG2P)A>XBD>![9ST?DTM -0+A>DGB,6E_;
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MG.+3(DM4;3UAFAGO.$2IPA>;$4L:,L 1NH/ML3NY4'(N9Q3/_6(\AD+*,::
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MQ)<%X,Q+!Q@Z'.)B%0@M^@:G'H>SY7-O@9YC,U$[.DCTCEL3D^Z0P\>-^,#
MWK'7U?W.V_]*F(7_CP/ZJ7>$/P*V=[=_HUR'?P]VR\-_,!^X61!]*\4<6P>]
M;'3"3/A?(_QP>N7_2YAJYW3E+Y>"PVI:@.=SK5W[@Q1L_URZ^A]02P,$%
M  @ ;(EA4G^<'R4/"   '14  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&ULQ5A;<]NX%?XK&#6[T\[(NEE.W(WM&=O)3O.0UI.TZ<-.'T 2$K$! 2X
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;+55WV_;-A#^5PBA#S%
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M6<R1VP]V^;L88CW*NKU0V %>";J6'M%%]A/0OOUH]@>T4:;.-,^V7E# NLT
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MOROV-@,? 0&"Z40D<T%YE)3'2'^,-,!1=M6$0N@$1:><8RD$!DWETH2,//6
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M8#_U7@HUX@CJV&+PA$H0:T":,Q;@\ I@#]^*$27FYAA@8"^AYT-J.Y+6$YW
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MDLKP_'E3-C(EH2332F=OKO6N)554/DSO:@I)(]2,*KIQL!.&B[V+"FW<%C6
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M:[4"!( =9E9T1L*V!)X(.&- Y5'D'#1KT93@LLLJM2SEND,9$RP>6O-OD/=
M!_]*3*XA&'OH^CY)XE&K5GM> KUW B;#E.#AX;U8":V104#U@B[ _)@$?C@L
MA&/K5I2C\RQ(2!C0X7L.:$FP>.2@-" L'#D4(*''SR',$E&,%9_&7A8E70_P
M7\F]Q=%U!0SZ:W<I@TC#,-/=7 S4X=[GMKON&-F[2Z-?N5[CZ:,4*UCJ7R0P
M5.KN(J9[L:IQEQ]+9:VJW.-&\$)H9(#O*P4=L']!!<-MV,W_ %!+ P04
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M?H[#BNG^0KH'IY?^Y#_5#O\1?KG CYLP)(#O,ZW=^H$,]+^"Q_\ 4$L#!!0
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M!40/%\!@6+7WA^Y&63S"/6SPS@3M G!]JY0]&J[ = NO_P%02P,$%     @
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M50R<U$$YS/&*JD>^^0+U>F+#EW$J[1-MZEC/0=E**E[68*V@)*QZX_?:ARV
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MM7RY8,I]T:[S]3V4;Y0630<V&324MRO9=W48 (+Q"4#8 <+W@/@$(.H T:6
MN .X4N-6BJM#1C1)$REV2%IOPV8WKI@.;>13;MN^U-+<4H/3Z;)M-Q(E6M**
MTY+FA&LTS7.QX9KR"BT$HSD%A3ZB:;$%J:FRYKE06J'K##2A3-V8V^=EAJZO
M;M 5HAQ]K\5&$5ZH!&N3I@V&\RZE69M2>"*E($2/@NM:H<^\@.(M 3;Z>I'A
M0>0L/,N803Y"4? !A7[H'TEH?C$\N#\"SRZ'WYU1$_4MBQQ?=(+O6&]^35=*
M2_.(?I\)$/<!8A<@/A5@T&;8FP&CX%@76Y);1V*GRS8-[N,$;X>%_=\G&H=O
M?;(C/'?CWJ=5@ =_> .R<I-"(5>(]C_HK?TPFKHW^,X^,T.JG2G_:-H)]TAD
M1;E"#$I#Z8\^F8QD.S7:@Q9K]XY60IM7Z;:U&;0@K8.Y+X70AX,-T(_N]"]0
M2P,$%     @ ;(EA4I1^A[)! P  HPL  !D   !X;"]W;W)K<VAE971S+W-H
M965T-#0N>&ULS59=;YLP%/TK5V@/K=0$#(&$*HG4)HW6:9NB9MT>ICVX8!*O
M8#/;:3II/WXV4$H:TF6=-/4EL>&<Z^/[Q1UNN+B5*T(4W&<IDR-KI51^:MLR
M6I$,RR[/"=-O$BXRK/16+&V9"X+C@I2EMNLX@9UARJSQL'@V%^,A7ZN4,C(7
M(-=9AL7/<Y+RS<A"UL.#*[I<*?/ '@]SO"0+HJ[SN= [N[82TXPP23D#09*1
M=89.9\@UA +QF9*-;*S!7.6&\UNSN8Q'EF,4D91$RIC ^N^.3$B:&DM:QX_*
MJ%6?:8C-]8/U67%Y?9D;+,F$IU]HK%8C:V!!3!*\3M45W[PEU85\8R_BJ2Q^
M85-A'0NBM50\J\A:0499^8_O*T<T"*BWA^!6!/=0@E<1O$,)O8K0.Y3@5P3_
M4$)0$8+"]Z6S"D]/L<+CH> ;$ :MK9E%$:Z"K1U,F<FLA1+Z+=4\-5Z4&04\
M@05=,IK0"#,%9U'$UTQ1MH0Y3VE$B80.+!2/;COG.I Q3'BFLUOB(C^.ID1A
MFLIC#;I>3.'HS3&\ <K@TXJO)6:Q'-I*JS5GVE&E[+Q4YNY1-B51%SQT J[C
M.BWTR<%T%+;0IX?3!RWTB^?I[S#K@K.?/CO\]/XVW=8!KJ/LUE%V"WO>'GL?
M=84W0RHXT^N(Z!:A)' !DQ5F2V(BM@6C+*)Y2N#K>VT0+A7)Y+=GY'BU'*^0
MT]LCYRS^KC/;'-Z6%B77+[BF,=Z-D=/W'9T#=\WP[\+Z:!"B;=1T%]5!7L_W
MO6W<K 47#OS^H(9M7;177[3W_$4?G;E0N@RPB"5<YS%6Q(0VZ#@A_(+).ENG
MV'18N$@2W7)/8$X$Y;&IRK.8YZ;&3F"?U[:4^;4R_S5D1%#+"5Z>$;.2&S2"
MX[3'I5\?U_]37$J?ZT8V);KGT>=\.JBM#EZ#3\-:3O@/51;N)KSK#78*:-*"
M0R'RW>!)H;7AO!"A)_9FX4XL.\A!OA^T1Q0YCQ\RYV]CJFOK_U<@:GQZT6O(
M%_3XE4#NRS/FHB)O->:G;;0%TVF 2EUV8UPQX^L'+):424A)HEE.MZ_IHIP(
MRXWB>3'!W'"EYZ%BN=)3-!$&H-\GG*N'C1F*ZKE\_!M02P,$%     @ ;(EA
M4EX"&6$[ @  N@4  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULC511
M;YLP$/XK%MI#*VV! %V[BB"E0=,J;5+4K-O#M >''&#5V,PV(?WW.QN"4BE)
M\P(^?-]WWWWFG'12O>@*P)!=S86>>94QS;WOZ[R"FNJ);$#@3B%530V&JO1U
MHX!N'*CF?A@$G_V:,N&EB?NV5&DB6\.9@*4BNJUKJEX?@,MNYDV]_8<G5E;&
M?O#3I*$EK, \-TN%D3^R;%@-0C,IB()BYLVG]UEL\UW"+P:=/E@3V\E:RA<;
M/&YF7F % 8?<6 :*KRTL@'-+A#+^#9S>6-("#]=[]J^N=^QE334L)/_--J::
M>7<>V4!!6VZ>9/<-AGYN+%\NN79/TO6YMYB<M]K(>@"C@IJ)_DUW@P\'@&E\
M A .@/!20#0 HDL!\0!P5OM]*\Z'C!J:)DIV1-EL9+,+9Z9#8_M,V&-?&86[
M#'$F7?7'361!5JP4K& Y%8;,\URVPC!1DJ7D+&>@R2?R*')9 _E)=QA>96 H
MX_H:-YY7&;GZ<)WX!B598C\?RC_TY<,3Y3/()R2:?B1A$ 9'X(N+X=,O1^#9
MY?"[MW ??1S-#$<S0\<7G> [YMJ?^5H;A;_WWS,%HK% Y K$)PHLE=PR-W$X
M\(3UQV'L<1RSON>Z<5QV_+<I6KP]=/=<QAN!\2@P/BOP.Z-KQIEY=0);D8/"
MGT18C:21FME9/ZHU?E?KNQG9N8R^&_]@4.RM]H.JD@E-.!2("2:W"%;]3=$'
M1C9N=M;2X"2Z9867*RB;@/N%E&8?V'$<K^OT/U!+ P04    " !LB6%2VX(@
M<-<#  !&#0  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RE5UMOXC@4
M_BM6- ^MU"'W !4@E=).8=H5*MN=A]4^F,2 U<1F;:?,_OL]3D(64I.--"_@
MR_>=>TY.1@<NWN6.$(5^9BF38VNGU/[6MF6\(QF6/;XG#&XV7&18P59L;;D7
M!"<%*4MMSW$B.\.469-1<;84DQ'/54H960HD\RS#XI\I2?EA;+G6\>"5;G=*
M']B3T1YOR8JHM_U2P,ZNI20T(TQ2SI @F[%UY]X^1QI? /Z@Y"!/UDA[LN;\
M76_FR=ARM$$D);'2$C#\?9![DJ9:$)CQ=R73JE5JXNGZ*/VQ\!U\66-)[GGZ
M@R9J-[8&%DK(!N>I>N6')U+Y$VIY,4]E\8L.%=:Q4)Q+Q;.*#!9DE)7_^&<5
MAQ,"R#$3O(K@-0G!!8)?$?RNA* B!%T)844(NQ*BBA!U)?0K0K\K85 1!ET)
MPXHP;!*B2XESCIESNNIPZV1_RO9%RC'=;I%ONRRLHBIG6.')2/ #$AH/\O2B
M*.V"#\5(F7X(5TK +06>FJS*AP_Q#5K1+:,;&F.FT%T<\YPIRK9HR5,:4R+1
M5[2"%I#D*='H!RP87$NT) *M=E@0=#4C"M-47@/T;35#5U^NT1=D(ZEO):(,
MO3&JY T<POKW'<\E9HD<V0H<T>;8<67TM#3:NV"TCUXX4SN)'EA"$@-_T<YW
MO18!-D2P#J-W#./4:Y4X(W$/^>X-\AS/,1ATWTY?D3W0G8OT63M]D;-6^D,[
M_06+5N,?._ON#@WT;YU]-]*?.OMNI,\[^VZD+WXM[]]_+73/W>F#EBKVZV;@
M%_+\"_),3_V?=VNI!+PL_VI1$-0*@D)!<$'!;S!5I%Q*A)42=)TKO(9NHCCT
MGO0=O7*<H!>20 M*;]"<@7,QSS)X5T,CC-]W/$V(,+6+1:DU++3JL>-C\C7H
M^U$XLC].DV& A5[@-F#/!IC?C[QA#3OS/:Q]#UM]_U$,!"1!^(,(F&_.?$,P
M'TD%W5#'/I> @J  8)\K@M@Q:GMHM44SO=&3!XT1$%!"TUR+O8*>6G;::U.(
M2N.B$Z=\;QB%H3]L!.DST/.&813U&\#GS\!AY P&GCE,41VFJ%N)_*^S^A53
M@TP^3TM-@]-$.KV@X<>]$>6[YZB9&>6=HQXZH1Z-**]_COIF1D7GJ">SCPV-
M<P/*<WIN [8PP-Q>$#0JQ"2LYPT:Y6% ^<.>&S7*PSZ973(BML5$+E'1B,K.
M59_60_]=,?LTSJ?N[=PUG"_@(Z&<Z?\37WYA0._?4B912C:@RNGUH:)%.;67
M&\7WQ>2TY@HFL6*Y@P\=(C0 [C><J^-&*Z@_G2;_ E!+ P04    " !LB6%2
M@=J^_L@#  "R$   &0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6S-6%%O
MXC@0_BM6GFZEW29V(($5(+6DIZMT>T)%=_=PN@<W&<"J8[.V4[K__NPD3:"$
ME)/V(2\E=KX9S\SWX6$Z.TCUK'< !KWF7.BYMS-F_]7W=;J#G.H;N0=AWVRD
MRJFQ2[7U]5X!S4JCG/LD""(_ITQXBUFYMU*+F2P,9P)6"NDBSZGZ<0=<'N8>
M]MXV'MEV9]R&OYCMZ1;68/[<KY1=^8V7C.4@-),"*=C,O5O\-<%39U B_F)P
MT$?/R*7R).6S6SQD<R]P$0&'U#@7U'Z\P!(X=YYL'-]KIUYSIC,\?G[S_FN9
MO$WFB6I82OXWR\QN[DT\E,&&%MP\RL-O4"<T=OY2R77Y%QUJ;."AM-!&YK6Q
MC2!GHOJDKW4AC@QP=,& U ;DO<'H@D%8&X37&HQJ@U%9F2J5L@X)-70Q4_*
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M@&:@',"^WT@[_=4+=T#S;XK%?U!+ P04    " !LB6%2_.?^0S<"   0!0
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M;W)K<VAE971S+W-H965T-34N>&ULO5==;],P%/TK5L3#D+8E=C[:3&TEUH%
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M@70-XK:[&'9!R[]MHI+H4I2= GWXD;(BVI5$*2N<BU@'_F?R(RE.]D)^33<
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M7TQ*9KH*>G4#BO$H?:U;?)[?H%>_O9[TE;9OM/3#PM;UP19IL/4Q5)>(C/]
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MI*&273=S>B11V04TOY32O'=LW>Z>W>D?4$L#!!0    ( &R)85+>.;37S0(
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MQ1#> %ET2,5$BS1O,M9"0\N2#V-H*HDT!K ?":%W$].W5&WJ[!=02P,$%
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M/T>H84<-+34Z0-6Y^WVE:U0#JS*G<Y/Z7AR/W4T/*^I8T4>LH(_5J.)WK.0
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M0/ -$L9:LYF%3:9%Z_ I,^]]IH1^2C5.C6XA!EU)\Q30F+,U"$7->JJS#T)
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M%PD6 K ->-0ARB1@')BZ!7__H43!@R2I^,=B**@,!<90<,;02I4BX9Q$)7>
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MQ$G,V09Q7:W8](7QQJ"5&E+I&)>2JZ=$X62RE"R]+QC-@(L/Z/*A(?(1?;R
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MM0_Q]N!O!Y+5YNR\8U*=Q.:R4!]+P'6!>IXS)G<#?1SWGU_)7U!+ P04
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M#?#]5$JS_F %;/YKX.)?4$L#!!0    ( &R)85*@9ERT(@8  -$;   9
M>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;)U977/:.A#]*QJF#^U,"Y9D6W8G
M828!;F\?>F^FZ<?<1P4$>.H/*HO0]-=?R38VV&MAFH=@F[/+'DFKHUW?'#+Y
M(]\*H="O)$[SV]%6J=W[R21?;D7"\W&V$ZG^9IW)A"M]*S>3?"<%7Q5&23PA
MCN-/$AZEH^E-\>Q!3F^RO8JC5#Q(E.^3A,N7>Q%GA]L1'AT??(XV6V4>3*8W
M.[X1CT)]W3U(?3>IO:RB1*1YE*5(BO7MZ Z_7U!J# K$MT@<\I-K9*@\9=D/
M<_-Q=3MR3$0B%DME7'#]\2QF(HZ-)QW'S\KIJ/Y-8WAZ??3^5T%>DWGBN9AE
M\?=HI;:WHV"$5F+-]['ZG!W^%A4AS_A;9G%>_$>'"NN,T'*?JRRIC'4$2926
MG_Q7-1 G!L3K,2"5 6D;N#T&M#*@0PW<RL =&I)7&134)R7W8N#F7/'IC<P.
M2!JT]F8NBM$OK/5X1:E9*(]*ZF\C;:>FCRI;_D#_[HI9>XAYFJ-WZ,[,7J1>
MT-=T)22:98E>ESFO,>CU7"@>Q?D;#?[Z.$>O7[U!K] $Y5LN18ZB5%M&*G^K
M'^KK+]MLG_-TE=],E [9_/!D685W7X9'>L+#!'W*4K7-T4*'LCIW,-%<:\+D
M2/B>6#W.Q7*,*'Z+B$,<(*#98',< N;SX>8!8+X8;LXL@T'KV:>%/]KC[Y]]
M\J0G.%NCQV+F+"[=VJ5;N'1[7-Z+392F4;K1^:N7RE*@UWH)E OC#;0 2G=^
MX<YL:\]3EV*'A7IRGD_G!<+Y+F7L'#>'<$X0G/@[X^75O#PKKS)%<K21/%5B
M=8F5UXD".]@)7-IBU<4%;N"0%FS>A?DD9-B'.?DU)W\0)_%+R&647V;E=\)X
MIVD%C(4M6@ P8)0%?HL7@'-IX+$ )L9J8FP0L:59@'%\F1CKQN%[#FF%.P-@
MA 7$;;$"8)AZOH=A5D'-*K"RTEO@%7D5=/. Z!D@08L3@(/R;P[A@/Q;0#A+
M_H4U^=!*_IO(3=II&3DN5_X47QR$L!,,H2'Q? H'@YU&-IWAX>STJ0>I##WK
MAY<BJOS:YN4\I!,EQ];-_'MQ*-)!W3T+J0]Y:%&E-7J0T5)8]G9,FM\@?["[
MFR/ 3NM(01MF7;H-3EBS<8A;2Q% T7%[;YF#*"?L&;Y&"C&]>H,?0*QT:F:U
MF4]G[+,V-0!'R+BC7A#.'_?M'+A196R797BK'\#/[<9#QRYITP-@&& 'PKP>
M<HTTXV':?+[=#R#G 9-"Q[3##L %8X:=DS_<I@K8:*H]BHT;R<9VS09$8 !1
M'PC&/XVF(NH/2-,Y@.JFZ0)$]:9IH^S8+NT6'1@P#@R:2+=OZVV$&=N5N:,&
M^N94#P9$%G1&ZWR"SB-K5!.'UXG"9V':!V8)S71A)76AON<Q^B)D4D3ZG^"R
M+5SG=58CD<0ND7<'+E<YRO8J5[Q8M1#Q"TX8>C$1(1<E91V(&5KQ%ZB4G UT
M18^N>CW-KPTJ[/.T&.@I/'HB&'!U/@'-@8#@/T@5<!+LCOPJ2K^>!.=BE,V1
M@MB/%);< 4.U>QNV7LY#;8X(Q%XNWVTV4FRX$NBC3ITHS:,E^L;C?;G]J&.;
MPYH^C6(3NV(/3)_2B7>Z;X3,==KG#PCGZCJS7;H .$IQ6Q$7 ,QS6,^IFC1"
M3NQ"?L6*!0ILZKB8]830Z"NQZ^NUR]&_-/[G<30Z1^PZ9_I+:/%S;]IP'[72
MIZ:A6G3?;*NK42P26)=RV>_1JL"CN!#0=2;1!W/TM;EO9(?8J[6KNT"D6ZEA
MSW/]3AL( 'I,EY?M==R%41*0OBJ4-JI&+ZC:7N>YC'Y?[BG0;J6'B><0W*8$
M  G%3!\J6Z0@(*&^[_:0:I2"VC?X#V7-,RGVG ',,-0'8F$0M-M;$!)L<$%
M6XN+-OI"[8HP*XJ" :1(M\?F^:PS65T8U ("8+86$#WIV-K+U.N:0)6SLS!8
MZ/A!6Q\@()1_<P (Y-\"@('Y-SEY=9$(N2G>&>E*+MNGJFSJUT_K]U)WQ=N8
MUO-[_'Y1OEUJW)0ONSYQJ3>C',5BK5TZ8Z8W:UF^/RIO5+8K7I \94IE27&Y
M%7PEI 'H[]=9IHXWY@?JMWC3_P%02P,$%     @ ;(EA4O,H0@YR!P  /C8
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M+-H30P#?Q$W5/5]^?4Q=702>DK&OC@C@E1Q]?42:?)6$"&RY3PC@E;S62N5
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MH)_X3LE>'!V#(I47QEZ+DZ_)U/&+B$A*EK*@P.KOC<Q)FA9,*HZ_*E*G'K,
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MA 'HYPO.U=O$;%!WXY/_4$L#!!0    ( &R)85)VH2;^D0(  # '   9
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M\1CEQ-?%'L/!VEYD!@_KC#TK7=O)F7/T<3B'3!K"L'-2MI\IWZC:\DK#,MR
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M 3+H?1NY'UBU\6W/L[+81/G'-;;>H-T"?+]4&+]JX#JINIF?_@]02P,$%
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M% T^DA&FZ9/-!'7M.\=2(_4A/RSIUP+&!=!ZH34^35PSZGY6V3]02P,$%
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M&@O'[FRG9?]^GYT00F_CI;6=<X[/=XF=T5JJ%UT &/):<J''7F',\LKW=5I
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MA@5^!H"R 'R>2VG>)G:#]L-B\@]02P,$%     @ ;(EA4CAG/!)( @  9 L
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M-Z*=U=O?[?*">5.P?U?'?P!02P,$%     @ ;(EA4I>*NQS     $P(   L
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M 5.X3R9Q="F=_\%:]9WB!6&, &/$R[CHKML=4PN[$I\WRFV/$=(4XM02R!A
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M2]2^/)=E?NE$]](G1X9QTB5(KMJR//5EG\T'*XN'_T0]_)_KS7]02P,$%
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M!]>-+_EL_F/\]6]02P$"% ,4    " !LB6%2!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &R)85)S
M*'Q>[0   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( &R)85*97)PC$ 8  )PG   3              "  <L!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ;(EA4OT]E,:U!0
M#!@  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( &R)85*Z2R='L 4  $(6   8              " @?<-
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !LB6%2B,;:
M"0X#  #*"@  &               @('=$P  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ ;(EA4A>%"&JI!0  /18  !@
M ("!(1<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &R)
M85)5HK2"$PD  "<R   8              " @0 =  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " !LB6%2FB;F &$"  !;!0  &
M        @(%))@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ ;(EA4@$P!I(G"@  ["\  !@              ("!X"@  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( &R)85+<@2AIX@<   84   8
M              " @3TS  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " !LB6%2;?PFP10I  "?A0  &               @(%5.P  >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ;(EA4E$]<S.Z!0
M, \  !D              ("!GV0  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " !LB6%2CO1B8U4&  "4$   &0              @(&0
M:@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &R)85)!
MWJ ;,P<  .H1   9              " @1QQ  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ ;(EA4IB3MKP0"P  4QX  !D
M     ("!AG@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &R)85*I=#JP+ H  &@:   9              "
M@6RF  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ;(EA
M4G^<'R4/"   '14  !D              ("!S[   'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " !LB6%2=$$BJC8#  !1!P  &0
M        @($5N0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( &R)85)&XE5-F04  &D-   9              " @8*\  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ;(EA4GG_R"4[ P  M@<
M !D              ("!4L(  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " !LB6%2]RZ?T#T#  "#!P  &0              @('$Q0
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( &R)85)L'PDT
M:BH  $.1   9              " @3C)  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ ;(EA4D-8HKOJ!0  3Q$  !D
M ("!V?,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !L
MB6%24Q;,_&D#   %"   &0              @('Z^0  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &R)85*L-2": P<  !D3   9
M          " @9K]  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#
M%     @ ;(EA4NBPDG/* @  W@4  !D              ("!U 0! 'AL+W=O
M<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !LB6%2SF9E=:@#  "K
M"   &0              @('5!P$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM
M;%!+ 0(4 Q0    ( &R)85+;@-V]N0(  .,%   9              " @;0+
M 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ;(EA4B0Y
MBDC]!P  M!4  !D              ("!I X! 'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6Q02P$"% ,4    " !LB6%21XJP&Z\%   6#@  &0
M    @('8%@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M &R)85)5^U-,20,  )$'   9              " @;X< 0!X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ ;(EA4BA8#@TV!0  !1<  !D
M             ("!/B ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " !LB6%25B?6R,,"  "U"   &0              @(&K)0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( &R)85*"I^CK(0(
M %<$   9              " @:4H 0!X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ ;(EA4B\Z[,Q+ @  0P8  !D              ("!
M_2H! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !LB6%2
MMT+ 8&H"  #L!0  &0              @(%_+0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( &R)85)3)T-FK@(  -('   9
M      " @2 P 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ ;(EA4I ?:#UD P  XPL  !D              ("!!3,! 'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !LB6%2Y^I5JXL"   I!@
M&0              @(&@-@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( &R)85*O2K-5: ,  (4,   9              " @6(Y 0!X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ;(EA4G=HU>M9
M @  Q@4  !D              ("! 3T! 'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " !LB6%2E'Z'LD$#  "C"P  &0
M@(&1/P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( &R)
M85)> AEA.P(  +H%   9              " @0E# 0!X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ ;(EA4MN"('#7 P  1@T  !D
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M=#4P+GAM;%!+ 0(4 Q0    ( &R)85)P3T(2H (  $,&   9
M  " @<]; 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
M;(EA4F0'JC,8 P  @0D  !D              ("!IEX! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    " !LB6%2:H6^:/$"  #."0  &0
M            @('U80$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4
M Q0    ( &R)85+$J_HCMP(  )@'   9              " @1UE 0!X;"]W
M;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ ;(EA4O)F2]!@ P
M- T  !D              ("!"V@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX
M;6Q02P$"% ,4    " !LB6%2,,L5]I4#  #("P  &0              @(&B
M:P$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( &R)85+F
M'+'L2P,  $H,   9              " @6YO 0!X;"]W;W)K<VAE971S+W-H
M965T-3<N>&UL4$L! A0#%     @ ;(EA4N%*<.=K!0  4AL  !D
M     ("!\'(! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &R)85)R8XT:-P(  #8%   9              "
M@=>$ 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ ;(EA
M4L$V(^TK P  B0L  !D              ("!18<! 'AL+W=O<FMS:&5E=',O
M<VAE970V-"YX;6Q02P$"% ,4    " !LB6%27:B!)P4$   .$   &0
M        @(&GB@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0
M   ( &R)85)FT>?9X0(  (H)   9              " @>.. 0!X;"]W;W)K
M<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ ;(EA4LAJU:R.!@  02
M !D              ("!^Y$! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q0
M2P$"% ,4    " !LB6%2H&9<M"(&  #1&P  &0              @(' F $
M>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( &R)85+S*$(.
M<@<  #XV   9              " @1F? 0!X;"]W;W)K<VAE971S+W-H965T
M-CDN>&UL4$L! A0#%     @ ;(EA4N4[.'L2 P  H@H  !D
M ("!PJ8! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " !L
MB6%2OZ15_C<$  "R%@  &0              @($+J@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( &R)85)810,L,P,  )D+   9
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M970W-BYX;6Q02P$"% ,4    " !LB6%2I/XT?PT#  "R"   &0
M    @('?P $ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    (
M &R)85)5_*=E; ,  -@+   9              " @2/$ 0!X;"]W;W)K<VAE
M971S+W-H965T-S@N>&UL4$L! A0#%     @ ;(EA4M3UUH%L @  N 8  !D
M             ("!QL<! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"
M% ,4    " !LB6%2JUZ3/UD%  "1&@  &0              @(%IR@$ >&PO
M=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( &R)85([ZKM=1P0
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( &R)85+-R=8P!P8  %,V   /
M      "  0_; 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !LB6%29LT1
M.G0"  !M,   &@              @ %#X0$ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !LB6%2$@%B4"$"   @+P  $P
M    @ 'OXP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     6@!: *T8  !!
%Y@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>301</ContextCount>
  <ElementCount>474</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>93</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Formation and Business of the Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FormationandBusinessoftheCompany</Role>
      <ShortName>Formation and Business of the Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2120103 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2121104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2133106 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2138107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2144108 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2146109 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2150110 - Disclosure - Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlans</Role>
      <ShortName>Stock Option Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2158111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2165112 - Disclosure - Acquisition of Variable Interest Entity - NeuroCo</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo</Role>
      <ShortName>Acquisition of Variable Interest Entity - NeuroCo</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2167113 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2169114 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2171115 - Disclosure - Quarterly Financial Information (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited</Role>
      <ShortName>Quarterly Financial Information (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2174116 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2322302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2325303 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/BalanceSheetComponents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2334304 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/LongtermDebt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2339305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/CommitmentsandContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2347306 - Disclosure - Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2351307 - Disclosure - Stock Option Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansTables</Role>
      <ShortName>Stock Option Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/StockOptionPlans</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2359308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2372309 - Disclosure - Quarterly Financial Information (unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables</Role>
      <ShortName>Quarterly Financial Information (unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Formation and Business of the Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails</Role>
      <ShortName>Formation and Business of the Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/FormationandBusinessoftheCompany</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Deferred Initial Public Offering Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Deferred Initial Public Offering Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - ASC 842 Impact on Condensed Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - ASC 842 Impact on Condensed Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413409 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414410 - Disclosure - Summary of Significant Accounting Policies - Advertising Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Advertising Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2415411 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2416412 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2417413 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418414 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2419415 - Disclosure - Summary of Significant Accounting Policies - Segment and Geographical Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment and Geographical Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2423416 - Disclosure - Fair Value Measurements - Recurring Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Recurring Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2426417 - Disclosure - Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2427418 - Disclosure - Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails</Role>
      <ShortName>Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2428419 - Disclosure - Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2429420 - Disclosure - Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails</Role>
      <ShortName>Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2430421 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2431422 - Disclosure - Balance Sheet Components - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails</Role>
      <ShortName>Balance Sheet Components - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2432423 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2435424 - Disclosure - Long-term Debt - CRG Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails</Role>
      <ShortName>Long-term Debt - CRG Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2436425 - Disclosure - Long-term Debt - Stifel Bank Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails</Role>
      <ShortName>Long-term Debt - Stifel Bank Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2437426 - Disclosure - Long-term Debt - Future Maturities Under the Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails</Role>
      <ShortName>Long-term Debt - Future Maturities Under the Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2440427 - Disclosure - Commitments and Contingencies - Lease Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2441428 - Disclosure - Commitments and Contingencies - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2442429 - Disclosure - Commitments and Contingencies - Operating Lease Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2443430 - Disclosure - Commitments and Contingencies - Purchase Obligation and Contingencies Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Obligation and Contingencies Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2445431 - Disclosure - Redeemable Convertible Preferred Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2448432 - Disclosure - Stockholders' Equity (Deficit) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2449433 - Disclosure - Stockholders' Equity (Deficit) - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2452434 - Disclosure - Stock Option Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansNarrativeDetails</Role>
      <ShortName>Stock Option Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2453435 - Disclosure - Stock Option Plans - Activity Under Compensation Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails</Role>
      <ShortName>Stock Option Plans - Activity Under Compensation Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2454436 - Disclosure - Stock Option Plans - Information by Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails</Role>
      <ShortName>Stock Option Plans - Information by Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2455437 - Disclosure - Stock Option Plans - RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansRSUsDetails</Role>
      <ShortName>Stock Option Plans - RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2456438 - Disclosure - Stock Option Plans - Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails</Role>
      <ShortName>Stock Option Plans - Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2457439 - Disclosure - Stock Option Plans - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails</Role>
      <ShortName>Stock Option Plans - Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2460440 - Disclosure - Income Taxes - Components of Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2461441 - Disclosure - Income Taxes - Reconciliation of U.S Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of U.S Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2462442 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2463443 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2464444 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2466445 - Disclosure - Acquisition of Variable Interest Entity - NeuroCo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails</Role>
      <ShortName>Acquisition of Variable Interest Entity - NeuroCo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2468446 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/A401kPlan</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2470447 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/SubsequentEvents</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2473448 - Disclosure - Quarterly Financial Information (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails</Role>
      <ShortName>Quarterly Financial Information (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="silk-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2475449 - Disclosure - Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="silk-20201231.htm">silk-20201231.htm</File>
    <File>silk-20201231.xsd</File>
    <File>silk-20201231_cal.xml</File>
    <File>silk-20201231_def.xml</File>
    <File>silk-20201231_lab.xml</File>
    <File>silk-20201231_pre.xml</File>
    <File>silk202010-kex231consent.htm</File>
    <File>silk2020ex311certification.htm</File>
    <File>silk2020ex312certification.htm</File>
    <File>silk2020ex321certification.htm</File>
    <File>silk2020ex45descriptionofr.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>silk-20201231_g1.jpg</File>
    <File>silk-20201231_g2.jpg</File>
    <File>silk-20201231_g3.jpg</File>
    <File>silk-20201231_g4.jpg</File>
    <File>silk-20201231_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "silk-20201231.htm": {
   "axisCustom": 2,
   "axisStandard": 30,
   "contextCount": 301,
   "dts": {
    "calculationLink": {
     "local": [
      "silk-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "silk-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "silk-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "silk-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "silk-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "silk-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 651,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 8,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 12
   },
   "keyCustom": 44,
   "keyStandard": 430,
   "memberCustom": 34,
   "memberStandard": 53,
   "nsprefix": "silk",
   "nsuri": "http://silkroadmed.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://silkroadmed.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120103 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://silkroadmed.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121104 - Disclosure - Fair Value Measurements",
     "role": "http://silkroadmed.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124105 - Disclosure - Balance Sheet Components",
     "role": "http://silkroadmed.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133106 - Disclosure - Long-term Debt",
     "role": "http://silkroadmed.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138107 - Disclosure - Commitments and Contingencies",
     "role": "http://silkroadmed.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144108 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://silkroadmed.com/role/RedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146109 - Disclosure - Stockholders' Equity (Deficit)",
     "role": "http://silkroadmed.com/role/StockholdersEquityDeficit",
     "shortName": "Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150110 - Disclosure - Stock Option Plans",
     "role": "http://silkroadmed.com/role/StockOptionPlans",
     "shortName": "Stock Option Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158111 - Disclosure - Income Taxes",
     "role": "http://silkroadmed.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165112 - Disclosure - Acquisition of Variable Interest Entity - NeuroCo",
     "role": "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo",
     "shortName": "Acquisition of Variable Interest Entity - NeuroCo",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Balance Sheets",
     "role": "http://silkroadmed.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167113 - Disclosure - 401(k) Plan",
     "role": "http://silkroadmed.com/role/A401kPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169114 - Disclosure - Subsequent Events",
     "role": "http://silkroadmed.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171115 - Disclosure - Quarterly Financial Information (unaudited)",
     "role": "http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited",
     "shortName": "Quarterly Financial Information (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2174116 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "role": "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://silkroadmed.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325303 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334304 - Disclosure - Long-term Debt (Tables)",
     "role": "http://silkroadmed.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://silkroadmed.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347306 - Disclosure - Stockholders' Equity (Deficit) (Tables)",
     "role": "http://silkroadmed.com/role/StockholdersEquityDeficitTables",
     "shortName": "Stockholders' Equity (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351307 - Disclosure - Stock Option Plans (Tables)",
     "role": "http://silkroadmed.com/role/StockOptionPlansTables",
     "shortName": "Stock Option Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359308 - Disclosure - Income Taxes (Tables)",
     "role": "http://silkroadmed.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2372309 - Disclosure - Quarterly Financial Information (unaudited) (Tables)",
     "role": "http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables",
     "shortName": "Quarterly Financial Information (unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Formation and Business of the Company (Details)",
     "role": "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
     "shortName": "Formation and Business of the Company (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i827e3aa981f94e4497963dc63008de63_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Other Current Assets (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ia0b870409832446b94306158afef68a2_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ia0b870409832446b94306158afef68a2_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Deferred Initial Public Offering Costs (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails",
     "shortName": "Summary of Significant Accounting Policies - Deferred Initial Public Offering Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
     "shortName": "Summary of Significant Accounting Policies - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i74860ed5b6ab4871aeb814ec7a0a16b6_I20190101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - ASC 842 Impact on Condensed Consolidated Balance Sheet (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails",
     "shortName": "Summary of Significant Accounting Policies - ASC 842 Impact on Condensed Consolidated Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "silk:AssetsAndLiabilitiesLesseeTableTextBlock",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i0a23db6a3861435b9f2516a8cd29279a_I20190101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i29d32e7c3bb6454a8aac9d997e7acdc7_D20190501-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails",
     "shortName": "Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i29d32e7c3bb6454a8aac9d997e7acdc7_D20190501-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413409 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnbilledReceivablesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414410 - Disclosure - Summary of Significant Accounting Policies - Advertising Costs (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails",
     "shortName": "Summary of Significant Accounting Policies - Advertising Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415411 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails",
     "shortName": "Summary of Significant Accounting Policies - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "id91c2dc9412d49f38b2911de8b92a20c_I20180101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416412 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails",
     "shortName": "Summary of Significant Accounting Policies - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LiabilityForUncertainTaxPositionsCurrent",
       "us-gaap:LiabilityForUncertainTaxPositionsCurrent",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LiabilityForUncertainTaxPositionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417413 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418414 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419415 - Disclosure - Summary of Significant Accounting Policies - Segment and Geographical Information (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment and Geographical Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423416 - Disclosure - Fair Value Measurements - Recurring Assets and Liabilities (Details)",
     "role": "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Recurring Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i433402cf26a940318305dcd5eb794a03_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i309aa475c33d46f1bcb008fc1f8ff1b4_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i309aa475c33d46f1bcb008fc1f8ff1b4_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426417 - Disclosure - Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
     "shortName": "Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427418 - Disclosure - Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails",
     "shortName": "Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428419 - Disclosure - Balance Sheet Components - Narrative (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
     "shortName": "Balance Sheet Components - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429420 - Disclosure - Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
     "shortName": "Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430421 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails",
     "shortName": "Balance Sheet Components - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431422 - Disclosure - Balance Sheet Components - Property, Plant and Equipment (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails",
     "shortName": "Balance Sheet Components - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432423 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i5ed5ecc368374169a71abc3cc9f49aa5_D20180901-20180930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435424 - Disclosure - Long-term Debt - CRG Narrative (Details)",
     "role": "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails",
     "shortName": "Long-term Debt - CRG Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "iecdd1fc58174421a9bfdd8f134ae6e23_I20180930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "silk:DebtMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i5ed5ecc368374169a71abc3cc9f49aa5_D20180901-20180930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436425 - Disclosure - Long-term Debt - Stifel Bank Narrative (Details)",
     "role": "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails",
     "shortName": "Long-term Debt - Stifel Bank Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i7abc563c49034717a7c3322581f18eb8_I20201031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437426 - Disclosure - Long-term Debt - Future Maturities Under the Term Loan (Details)",
     "role": "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails",
     "shortName": "Long-term Debt - Future Maturities Under the Term Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440427 - Disclosure - Commitments and Contingencies - Lease Narrative (Details)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails",
     "shortName": "Commitments and Contingencies - Lease Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441428 - Disclosure - Commitments and Contingencies - Balance Sheet Information (Details)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails",
     "shortName": "Commitments and Contingencies - Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442429 - Disclosure - Commitments and Contingencies - Operating Lease Maturities (Details)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails",
     "shortName": "Commitments and Contingencies - Operating Lease Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443430 - Disclosure - Commitments and Contingencies - Purchase Obligation and Contingencies Narrative (Details)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Purchase Obligation and Contingencies Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i62faf7ea655c489e8fb700ba32e5a72a_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445431 - Disclosure - Redeemable Convertible Preferred Stock - Narrative (Details)",
     "role": "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesOutstanding",
       "us-gaap:TemporaryEquitySharesIssued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i8035f9f9ec5d4b46adb98b3f8e400ff1_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448432 - Disclosure - Stockholders' Equity (Deficit) - Narrative (Details)",
     "role": "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails",
     "shortName": "Stockholders' Equity (Deficit) - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449433 - Disclosure - Stockholders' Equity (Deficit) - Shares Reserved for Future Issuance (Details)",
     "role": "http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails",
     "shortName": "Stockholders' Equity (Deficit) - Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i603554706e704e14a87cd579bfc1f1cb_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452434 - Disclosure - Stock Option Plans - Narrative (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
     "shortName": "Stock Option Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i65f3a8f4af9542fb8f31ed746073f14b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453435 - Disclosure - Stock Option Plans - Activity Under Compensation Plan (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
     "shortName": "Stock Option Plans - Activity Under Compensation Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454436 - Disclosure - Stock Option Plans - Information by Exercise Price (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails",
     "shortName": "Stock Option Plans - Information by Exercise Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "if2c087f244e24d669ad5f5b19aa67a98_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i6691dffc917441fa983264255b9af82b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455437 - Disclosure - Stock Option Plans - RSUs (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansRSUsDetails",
     "shortName": "Stock Option Plans - RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i6691dffc917441fa983264255b9af82b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456438 - Disclosure - Stock Option Plans - Fair Value of Stock Options (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
     "shortName": "Stock Option Plans - Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457439 - Disclosure - Stock Option Plans - Stock-based Compensation (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails",
     "shortName": "Stock Option Plans - Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460440 - Disclosure - Income Taxes - Components of Income Before Taxes (Details)",
     "role": "http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails",
     "shortName": "Income Taxes - Components of Income Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461441 - Disclosure - Income Taxes - Reconciliation of U.S Statutory Rate (Details)",
     "role": "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails",
     "shortName": "Income Taxes - Reconciliation of U.S Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462442 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)",
     "role": "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "ib21091e7ea584a0eb4262bf6edfcce74_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463443 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i65f3a8f4af9542fb8f31ed746073f14b_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464444 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466445 - Disclosure - Acquisition of Variable Interest Entity - NeuroCo (Details)",
     "role": "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails",
     "shortName": "Acquisition of Variable Interest Entity - NeuroCo (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i4ea6234882cf424bb9e6d52bf97c9471_I20181217",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NoncontrollingInterestInVariableInterestEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468446 - Disclosure - 401(k) Plan (Details)",
     "role": "http://silkroadmed.com/role/A401kPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Formation and Business of the Company",
     "role": "http://silkroadmed.com/role/FormationandBusinessoftheCompany",
     "shortName": "Formation and Business of the Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470447 - Disclosure - Subsequent Events (Details)",
     "role": "http://silkroadmed.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9a7388efa2fa460bbb4d823a2c4e6d18_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473448 - Disclosure - Quarterly Financial Information (unaudited) (Details)",
     "role": "http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails",
     "shortName": "Quarterly Financial Information (unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i59ede1db84fb43669caad1f2aa9d9c5f_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i218af6b8a4044434bc70398d3d719486_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475449 - Disclosure - Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)",
     "role": "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails",
     "shortName": "Schedule II - Valuation and Qualifying Accounts - Schedule II (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i515fd7b45a0d4244a919c02bb006219a_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20201231.htm",
      "contextRef": "i9d3c1dcd13d24a688fb5ee18572ed32b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 93,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "silk_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Expenses, Current",
        "label": "Accrued Clinical Expenses, Current",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_AccruedTravelExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Travel Expenses, Current",
        "label": "Accrued Travel Expenses, Current",
        "terseLabel": "Accrued travel expenses"
       }
      }
     },
     "localname": "AccruedTravelExpensesCurrent",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Balance Sheet Information",
        "verboseLabel": "Schedule of ASC 842 Impact of Adoption on Condensed Consolidated Balance Sheet"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesTables",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silk_BusinessCombinationConsiderationTransferredNotesPayableForgiven": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Notes Payable Forgiven",
        "label": "Business Combination, Consideration Transferred, Notes Payable Forgiven",
        "terseLabel": "Consideration given, amount of notes payable forgiven"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNotesPayableForgiven",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years",
        "label": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years",
        "terseLabel": "Amounts maturing after one year through two years"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year",
        "label": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year",
        "terseLabel": "Amounts maturing within one year"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_CommonStockCapitalSharesAvailableForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Available For Future Issuance",
        "label": "Common Stock, Capital Shares Available For Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesAvailableForFutureIssuance",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_CommonStockVotePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Vote Per Share",
        "label": "Common Stock, Vote Per Share",
        "terseLabel": "Number of votes entitled per share of common stock"
       }
      }
     },
     "localname": "CommonStockVotePerShare",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "silk_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrant [Member]",
        "label": "Common Stock Warrant [Member]",
        "terseLabel": "Common stock warrants outstanding"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_DebtInstrumentCovenantDebtDefaultRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Default Rate",
        "label": "Debt Instrument, Covenant, Debt Default Rate",
        "terseLabel": "Debt default rate"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtDefaultRate",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails",
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_DebtInstrumentCovenantLiquidityEventPaymentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Liquidity Event, Payment Amount",
        "label": "Debt Instrument, Covenant, Liquidity Event, Payment Amount",
        "terseLabel": "Redemption amount"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLiquidityEventPaymentAmount",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold",
        "label": "Debt Instrument, Covenant, Liquidity Event, Percent Of Original Principal Threshold",
        "terseLabel": "Percent of original principal threshold"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLiquidityEventPercentOfOriginalPrincipalThreshold",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_DebtInstrumentCovenantMaximumBorrowingThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Maximum Borrowing Threshold",
        "label": "Debt Instrument, Covenant, Maximum Borrowing Threshold",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMaximumBorrowingThreshold",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Minimum",
        "label": "Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Minimum",
        "terseLabel": "Minimum unrestricted cash and cash equivalents"
       }
      }
     },
     "localname": "DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsMinimum",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Threshold For Revenue Restrictions",
        "label": "Debt Instrument, Covenant, Unrestricted Cash And Cash Equivalents Threshold For Revenue Restrictions",
        "terseLabel": "Maximum unrestricted cash and cash equivalents"
       }
      }
     },
     "localname": "DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsThresholdForRevenueRestrictions",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_DebtInstrumentInterestRatePaidInCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Paid In Cash",
        "label": "Debt Instrument, Interest Rate, Paid In Cash",
        "terseLabel": "Interest rate paid in cash"
       }
      }
     },
     "localname": "DebtInstrumentInterestRatePaidInCash",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_DebtInstrumentInterestRatePaidInKind": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Paid-In-Kind",
        "label": "Debt Instrument, Interest Rate, Paid-In-Kind",
        "terseLabel": "Interest rate paid-in-kind"
       }
      }
     },
     "localname": "DebtInstrumentInterestRatePaidInKind",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_DebtInstrumentMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maximum Borrowing Capacity",
        "label": "Debt Instrument, Maximum Borrowing Capacity",
        "terseLabel": "Debt amount"
       }
      }
     },
     "localname": "DebtInstrumentMaximumBorrowingCapacity",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_DebtInstrumentRateScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Rate Scenario",
        "label": "Debt Instrument, Rate Scenario [Axis]",
        "terseLabel": "Debt Instrument, Rate Scenario [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRateScenarioAxis",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silk_DebtInstrumentRateScenarioDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Rate Scenario",
        "label": "Debt Instrument, Rate Scenario [Domain]",
        "terseLabel": "Debt Instrument, Rate Scenario [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRateScenarioDomain",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_DebtMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt, Maximum Borrowing Capacity",
        "label": "Debt, Maximum Borrowing Capacity",
        "terseLabel": "Term loan agreement amount"
       }
      }
     },
     "localname": "DebtMaximumBorrowingCapacity",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Warrant Liability Adjustment, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Warrant Liability Adjustment, Amount",
        "terseLabel": "Loss on Series C warrant liability"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five [Member]",
        "label": "Exercise Price Five [Member]",
        "terseLabel": "Exercise Price Five"
       }
      }
     },
     "localname": "ExercisePriceFiveMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ExercisePriceFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four [Member]",
        "label": "Exercise Price Four [Member]",
        "verboseLabel": "Exercise Price Four"
       }
      }
     },
     "localname": "ExercisePriceFourMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price One [Member]",
        "label": "Exercise Price One [Member]",
        "terseLabel": "Exercise Price One"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ExercisePriceSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Six [Member]",
        "label": "Exercise Price Six [Member]",
        "terseLabel": "Exercise Price Six"
       }
      }
     },
     "localname": "ExercisePriceSixMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three [Member]",
        "label": "Exercise Price Three [Member]",
        "verboseLabel": "Exercise Price Three"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two [Member]",
        "label": "Exercise Price Two [Member]",
        "verboseLabel": "Exercise Price Two"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_IncentiveStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Option [Member]",
        "label": "Incentive Stock Option [Member]",
        "terseLabel": "ISO"
       }
      }
     },
     "localname": "IncentiveStockOptionMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_IncentiveandNonqualifiedStockOptionExercisedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive and Nonqualified Stock Option, Exercised [Member]",
        "label": "Incentive and Nonqualified Stock Option, Exercised [Member]",
        "terseLabel": "Exercise of options under stock plan"
       }
      }
     },
     "localname": "IncentiveandNonqualifiedStockOptionExercisedMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_IncentiveandNonqualifiedStockOptionIssuedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive and Nonqualified Stock Option, Issued [Member]",
        "label": "Incentive and Nonqualified Stock Option, Issued [Member]",
        "terseLabel": "Issuance of options and restricted stock units under stock plan"
       }
      }
     },
     "localname": "IncentiveandNonqualifiedStockOptionIssuedMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_IncentiveandNonqualifiedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive and Nonqualified Stock Option [Member]",
        "label": "Incentive and Nonqualified Stock Option [Member]",
        "terseLabel": "ISO and NSO"
       }
      }
     },
     "localname": "IncentiveandNonqualifiedStockOptionMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan And Security Agreement",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_LongTermDebtGrossBeforeAccretionOfClosingFees": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Gross, Before Accretion Of Closing Fees",
        "label": "Long-Term Debt, Gross, Before Accretion Of Closing Fees",
        "totalLabel": "Long-term debt, gross before accretion of closing fees"
       }
      }
     },
     "localname": "LongTermDebtGrossBeforeAccretionOfClosingFees",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_LongTermDebtUnpaidInterest": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Unpaid Interest",
        "label": "Long-Term Debt, Unpaid Interest",
        "negatedTerseLabel": "Less: Amount representing interest"
       }
      }
     },
     "localname": "LongTermDebtUnpaidInterest",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Investments",
        "label": "Long-Term Investments [Member]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_LossContingencyReceivableDirectCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Receivable, Direct Costs",
        "label": "Loss Contingency Receivable, Direct Costs [Member]",
        "terseLabel": "Loss Contingency Receivable, Direct Costs"
       }
      }
     },
     "localname": "LossContingencyReceivableDirectCostsMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_LossContingencyReceivableInventoryExcessAndObsolescenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Receivable, Inventory Excess And Obsolescence",
        "label": "Loss Contingency Receivable, Inventory Excess And Obsolescence [Member]",
        "terseLabel": "Inventory Excess and Obsolescence"
       }
      }
     },
     "localname": "LossContingencyReceivableInventoryExcessAndObsolescenceMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_LossContingencyReceivableInventoryHeldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Receivable, Inventory Held",
        "label": "Loss Contingency Receivable, Inventory Held [Member]",
        "terseLabel": "Loss Contingency Receivable, Inventory Held"
       }
      }
     },
     "localname": "LossContingencyReceivableInventoryHeldMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_LossContingencyReceivableInventoryInProcessOfRecallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Receivable, Inventory In Process Of Recall",
        "label": "Loss Contingency Receivable, Inventory In Process Of Recall [Member]",
        "terseLabel": "Loss Contingency Receivable, Inventory in Process of Recall"
       }
      }
     },
     "localname": "LossContingencyReceivableInventoryInProcessOfRecallMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_LossContingencyReceivableTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Receivable, Type",
        "label": "Loss Contingency Receivable, Type [Axis]",
        "terseLabel": "Loss Contingency Receivable, Type [Axis]"
       }
      }
     },
     "localname": "LossContingencyReceivableTypeAxis",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silk_LossContingencyReceivableTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Receivable, Type",
        "label": "Loss Contingency Receivable, Type [Domain]",
        "terseLabel": "Loss Contingency Receivable, Type [Domain]"
       }
      }
     },
     "localname": "LossContingencyReceivableTypeDomain",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_NeuroCoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NeuroCo, Inc [Member]",
        "label": "NeuroCo, Inc [Member]",
        "terseLabel": "NeuroCo, Inc"
       }
      }
     },
     "localname": "NeuroCoIncMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_NonqualifiedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonqualified Stock Options [Member]",
        "label": "Nonqualified Stock Options [Member]",
        "terseLabel": "NSO"
       }
      }
     },
     "localname": "NonqualifiedStockOptionsMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_NotesReceivableRelatedPartiesInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Receivable, Related Parties, Interest Rate, Stated Percentage",
        "label": "Notes Receivable, Related Parties, Interest Rate, Stated Percentage",
        "terseLabel": "Notes receivable, interest rate"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesInterestRateStatedPercentage",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_NotesReceivableRelatedPartiesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Receivable, Related Parties, Term",
        "label": "Notes Receivable, Related Parties, Term",
        "terseLabel": "Notes receivable, term"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesTerm",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "silk_OperatingLossCarryforwardOffsetMaximumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforward, Offset Maximum, Percent",
        "label": "Operating Loss Carryforward, Offset Maximum, Percent",
        "terseLabel": "Percent maximum of federal taxable income to offset with net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwardOffsetMaximumPercent",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Stock Issuance Underwriting Discounts And Commissions",
        "label": "Payment Of Stock Issuance Underwriting Discounts And Commissions",
        "terseLabel": "Payment of stock issuance underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_PreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock Warrants",
        "label": "Preferred Stock Warrants [Member]",
        "terseLabel": "Preferred Stock Warrants"
       }
      }
     },
     "localname": "PreferredStockWarrantsMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ProvisionsForSalesReturns": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provisions For Sales Returns",
        "label": "Provisions For Sales Returns",
        "terseLabel": "Provision for sales returns"
       }
      }
     },
     "localname": "ProvisionsForSalesReturns",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_PublicStockOfferingSharesFromCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering - Shares From Company",
        "label": "Public Stock Offering - Shares From Company [Member]",
        "terseLabel": "Public Stock Offering - Shares From Company"
       }
      }
     },
     "localname": "PublicStockOfferingSharesFromCompanyMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_PublicStockOfferingSharesFromExistingShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering - Shares From Existing Shareholders",
        "label": "Public Stock Offering - Shares From Existing Shareholders [Member]",
        "terseLabel": "Public Stock Offering - Shares From Existing Shareholders"
       }
      }
     },
     "localname": "PublicStockOfferingSharesFromExistingShareholdersMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_RateScenarioOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate Scenario One",
        "label": "Rate Scenario One [Member]",
        "terseLabel": "Rate Scenario One"
       }
      }
     },
     "localname": "RateScenarioOneMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_RateScenarioTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate Scenario Two",
        "label": "Rate Scenario Two [Member]",
        "terseLabel": "Rate Scenario Two"
       }
      }
     },
     "localname": "RateScenarioTwoMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_RedeemableConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Stock Warrants [Member]",
        "label": "Redeemable Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Redeemable convertible preferred stock warrants outstanding"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_RepaymentOfPaidInKindInterest": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment Of Paid-In-Kind Interest",
        "label": "Repayment Of Paid-In-Kind Interest",
        "negatedTerseLabel": "Repayment of interest paid in kind"
       }
      }
     },
     "localname": "RepaymentOfPaidInKindInterest",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_RepaymentsOfDebtRevenueTargetPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Debt, Revenue Target, Percentage",
        "label": "Repayments Of Debt, Revenue Target, Percentage",
        "terseLabel": "Percentage of revenue for debt repayment"
       }
      }
     },
     "localname": "RepaymentsOfDebtRevenueTargetPercentage",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1 [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silk_SecondPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Public Offering",
        "label": "Second Public Offering [Member]",
        "terseLabel": "Second Public Offering"
       }
      }
     },
     "localname": "SecondPublicOfferingMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Forfeitures And Expirations In Period",
        "verboseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingForfeituresAndExpirationsInPeriod",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Grants In Period, Gross",
        "negatedLabel": "Granted/Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingGrantsInPeriodGross",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Outstanding, Number Of Additional Shares Authorized",
        "terseLabel": "Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsOutstandingNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding And Exercisable, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding And Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise Price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Trailing Stock Price Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Trailing Stock Price Period",
        "terseLabel": "Trailing stock price period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTrailingStockPricePeriod",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan",
        "terseLabel": "Number of additional shares allowable under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]",
        "terseLabel": "Shares Available for Grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silk_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Threshold as a Percentage of Share Price",
        "terseLabel": "Exercise threshold as a percentage of fair value of shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExerciseThresholdasaPercentageofSharePrice",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_StockIssuanceCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs Incurred But Not Yet Paid",
        "label": "Stock Issuance Costs Incurred But Not Yet Paid",
        "terseLabel": "Unpaid deferred offering costs"
       }
      }
     },
     "localname": "StockIssuanceCostsIncurredButNotYetPaid",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "label": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_SuccessFeeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success Fee Agreement",
        "label": "Success Fee Agreement [Member]",
        "terseLabel": "Success Fee Agreement"
       }
      }
     },
     "localname": "SuccessFeeAgreementMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares",
        "label": "Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares",
        "negatedTerseLabel": "Conversion of preferred stock to common stock upon IPO (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Decrease For Conversion Of Convertible Securities, Value",
        "label": "Temporary Equity, Decrease For Conversion Of Convertible Securities, Value",
        "negatedTerseLabel": "Conversion of preferred stock to common stock upon IPO"
       }
      }
     },
     "localname": "TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Net exercise of Series C preferred stock warrants upon IPO (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan [Member]",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_TermLoanTrancheAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan, Tranche A [Member]",
        "label": "Term Loan, Tranche A [Member]",
        "terseLabel": "Term Loan, Tranche A"
       }
      }
     },
     "localname": "TermLoanTrancheAMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_TermLoanTrancheBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan, Tranche B [Member]",
        "label": "Term Loan, Tranche B [Member]",
        "terseLabel": "Term Loan, Tranche B"
       }
      }
     },
     "localname": "TermLoanTrancheBMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_TwoThousandNineteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Stock Option Plan [Member]",
        "label": "Two Thousand Nineteen Stock Option Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenStockOptionPlanMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_VoluntaryRecallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voluntary Recall",
        "label": "Voluntary Recall [Member]",
        "terseLabel": "Voluntary Recall"
       }
      }
     },
     "localname": "VoluntaryRecallMember",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Classified As Liabilities [Policy Text Block]",
        "label": "Warrants Classified As Liabilities [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "localname": "WarrantsClassifiedAsLiabilitiesPolicyTextBlock",
     "nsuri": "http://silkroadmed.com/20201231",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r140",
      "r151",
      "r238",
      "r386",
      "r387",
      "r388",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r140",
      "r151",
      "r238",
      "r386",
      "r387",
      "r388",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r140",
      "r151",
      "r238",
      "r386",
      "r387",
      "r388",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r346",
      "r348",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r548",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r346",
      "r348",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r548",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r334",
      "r346",
      "r348",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r548",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r334",
      "r346",
      "r348",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r548",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r143",
      "r144",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r156",
      "r157",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Restatement Adjustment"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r143",
      "r144",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r170",
      "r241",
      "r242",
      "r390",
      "r436",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r143",
      "r144",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r170",
      "r241",
      "r242",
      "r390",
      "r436",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r136",
      "r138",
      "r139",
      "r143",
      "r144",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r156",
      "r157",
      "r170",
      "r241",
      "r242",
      "r390",
      "r436",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r134",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r134",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]",
        "terseLabel": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Cumulative effect of change in accounting principle - ASC 606 adoption"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Adjustments Due to ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201609Member": {
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.",
        "label": "Accounting Standards Update 2016-09 [Member]",
        "terseLabel": "Cumulative effect of change in accounting treatment - ASU 2016-09",
        "verboseLabel": "Accounting Standards Update 2016-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201609Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r212",
      "r213"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $13 and $45 at December\u00a031, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums (accretion of discounts) on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r50"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r50"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalty expense"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r50"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll and related expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r45",
      "r268"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r69",
      "r70",
      "r71",
      "r593",
      "r613",
      "r617"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r136",
      "r137",
      "r139",
      "r465",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r29",
      "r390"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r139",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r147",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r433",
      "r434",
      "r435",
      "r436",
      "r550",
      "r551",
      "r552",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdvertisingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r350",
      "r379",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "Allowance for doubtful accounts receivable:"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r218",
      "r243",
      "r245",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowances for accounts receivables"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r108",
      "r496"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r228",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r121",
      "r192",
      "r201",
      "r207",
      "r234",
      "r458",
      "r466",
      "r483",
      "r569",
      "r590"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r65",
      "r121",
      "r234",
      "r458",
      "r466",
      "r483"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r224",
      "r252"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r222",
      "r225",
      "r252",
      "r576"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "verboseLabel": "Available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r223",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails",
      "http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Preparation and Adjustment to Prior Period Financial Statements"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r345",
      "r347",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Shares issued as consideration (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Equity interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition of Variable Interest Entity - NeuroCo"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCo"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accounts payable and accrued liabilities for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r41",
      "r110"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r13",
      "r111",
      "r117",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r104",
      "r110",
      "r116"
     ],
     "calculation": {
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r104",
      "r484"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r119",
      "r121",
      "r161",
      "r162",
      "r163",
      "r165",
      "r167",
      "r175",
      "r176",
      "r177",
      "r234",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r313",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r313",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r335",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r56",
      "r276",
      "r577",
      "r597"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r272",
      "r274",
      "r275",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)",
        "verboseLabel": "Par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Shares issued and outstanding: 34,249,649 and 31,255,267 at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r75",
      "r77",
      "r78",
      "r83",
      "r580",
      "r601"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Silk Road Medical, Inc. common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r77",
      "r82",
      "r455",
      "r470",
      "r579",
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r180",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk, and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r315",
      "r316",
      "r327"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Net exercise of redeemable convertible preferred stock warrants to preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Shares of common stock converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r335",
      "r343",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds/notes"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r86",
      "r549"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r19",
      "r20",
      "r570",
      "r572",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Facility fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails",
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r54",
      "r123",
      "r304",
      "r307",
      "r308",
      "r309",
      "r494",
      "r495",
      "r497",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r291",
      "r496"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Amount representing debt discount and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r231",
      "r254",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair Value, Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r231",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized Loss, Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Fair Value of the Available-For-Sale Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Weighted average days to maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Public Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r22",
      "r422",
      "r571",
      "r587"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r64",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred initial public offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "terseLabel": "Interest limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestCarryforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Capitalized start-up costs/Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r428",
      "r430",
      "r431"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer discretionary contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan Disclosures [Table Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Percent of matching contribution of the employee's pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer contribution match percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage employee contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r108",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Summary of Shares Available for Issuance"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r310",
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock [Abstract]",
        "terseLabel": "Common stock, $0.001 par value"
       }
      }
     },
     "localname": "DividendsCommonStockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted (in USD per share)",
        "verboseLabel": "Net loss per share, basic and diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails",
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to the ESPP"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expensed not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs of unvested RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation expensed not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "2019 ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r139",
      "r144",
      "r154",
      "r157",
      "r174",
      "r238",
      "r303",
      "r310",
      "r386",
      "r387",
      "r388",
      "r435",
      "r436",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r608",
      "r609",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Debt pay off"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r108",
      "r297"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of redeemable convertible preferred stock warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r472",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value of Cash Equivalents, Short-Term and Long-Term Equivalents"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r473",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r472",
      "r473",
      "r475",
      "r476",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r335",
      "r336",
      "r341",
      "r343",
      "r473",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r335",
      "r336",
      "r341",
      "r343",
      "r473",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r473",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r477",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r117",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r244",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r255",
      "r256",
      "r257",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r108",
      "r294",
      "r295"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on debt extinguishment",
        "terseLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails",
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r85",
      "r121",
      "r192",
      "r200",
      "r203",
      "r206",
      "r208",
      "r234",
      "r483"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails",
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r265",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r124",
      "r442"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r124",
      "r442"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "International"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r124",
      "r192",
      "r200",
      "r203",
      "r206",
      "r208"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesComponentsofIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r412",
      "r420",
      "r427",
      "r440",
      "r443",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r156",
      "r157",
      "r191",
      "r410",
      "r441",
      "r444",
      "r603"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r117",
      "r408",
      "r409",
      "r420",
      "r421",
      "r426",
      "r432",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedTerseLabel": "General business credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r80",
      "r190",
      "r493",
      "r496",
      "r581"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r90",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Debt interest"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r102",
      "r105",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Inventory, gross"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r62"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails",
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r63",
      "r117",
      "r171",
      "r258",
      "r260",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r62",
      "r134",
      "r261"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedTerseLabel": "Less: Reserve for excess and obsolete",
        "terseLabel": "Valuation reserve"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r35",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process inventories"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Provision for excess and obsolete inventories"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r89",
      "r189"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r233",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r49",
      "r121",
      "r202",
      "r234",
      "r459",
      "r466",
      "r467",
      "r483"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r121",
      "r234",
      "r483",
      "r573",
      "r595"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r51",
      "r121",
      "r234",
      "r459",
      "r466",
      "r467",
      "r483"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Liability for uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Facility amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r20",
      "r292",
      "r572",
      "r591"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Present value of minimum payments"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r126",
      "r289"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 1.0,
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r126",
      "r289"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 2.0,
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r126",
      "r289"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 4.0,
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r126",
      "r289"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 3.0,
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails",
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r54",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails",
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities requiring accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyReceivable": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable",
        "terseLabel": "Loss contingency receivable"
       }
      }
     },
     "localname": "LossContingencyReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r104",
      "r106",
      "r109"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r73",
      "r76",
      "r81",
      "r109",
      "r121",
      "r143",
      "r149",
      "r150",
      "r151",
      "r152",
      "r156",
      "r157",
      "r164",
      "r192",
      "r200",
      "r203",
      "r206",
      "r208",
      "r234",
      "r483",
      "r578",
      "r599"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Silk Road Medical, Inc. common stockholders",
        "verboseLabel": "Net loss attributable to Silk Road Medical, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r73",
      "r76",
      "r156",
      "r157",
      "r461",
      "r469"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r141",
      "r142",
      "r145",
      "r146",
      "r158",
      "r159",
      "r160",
      "r239",
      "r240",
      "r328",
      "r329",
      "r330",
      "r331",
      "r389",
      "r437",
      "r438",
      "r439",
      "r553",
      "r554",
      "r555",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r140",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r151",
      "r170",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r433",
      "r434",
      "r435",
      "r436",
      "r550",
      "r551",
      "r552",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestInVariableInterestEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).",
        "label": "Noncontrolling Interest in Variable Interest Entity",
        "terseLabel": "Carrying amount of the non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestInVariableInterestEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r311",
      "r457",
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "NeuroCo common stock issuance"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r139",
      "r310",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableRelatedParties": {
     "auth_ref": [
      "r125",
      "r513",
      "r598"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.",
        "label": "Notes Receivable, Related Parties",
        "terseLabel": "Promissory note amount"
       }
      }
     },
     "localname": "NotesReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r192",
      "r200",
      "r203",
      "r206",
      "r208"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r505",
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails",
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Operating lease liability in accrued liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating lease, liability, current, statement of financial position extensible list"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability in other liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating lease, liability, noncurrent, statement of financial position extensible list"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r502",
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset in other non-current assets",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating lease, right-of-use asset, statement of financial position extensible list"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r508",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Formation and Business of the Company"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r50"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "terseLabel": "Unrealized gain on investments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gain on investments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r74",
      "r77",
      "r455",
      "r456",
      "r464"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Net change in other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r87",
      "r108",
      "r266"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Landlord paid tenant improvements"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Payments of prepayment penalty and lender fees",
        "terseLabel": "Prepayment premium fee"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering costs",
        "verboseLabel": "Payments of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesDeferredInitialPublicOfferingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock, $0.001 par value"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred shares (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Shares authorized: 5,000,000 at December 31, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r39",
      "r40"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.",
        "label": "Principal Owner [Member]",
        "terseLabel": "10% Stockholders"
       }
      }
     },
     "localname": "PrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtCRGNarrativeDetails",
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term debt, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Other Investments",
        "terseLabel": "Proceeds from maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r50",
      "r284",
      "r287"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Recall replacement obligation"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r73",
      "r76",
      "r103",
      "r121",
      "r143",
      "r156",
      "r157",
      "r192",
      "r200",
      "r203",
      "r206",
      "r208",
      "r234",
      "r455",
      "r460",
      "r462",
      "r469",
      "r470",
      "r483",
      "r582"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails",
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r45",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r44",
      "r267"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r269",
      "r596"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r117",
      "r269",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r84",
      "r246"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Change in provision for doubtful accounts receivable"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Information (unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/QuarterlyFinancialInformationunaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable convertible preferred stock outstanding"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r342",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r342",
      "r512",
      "r514",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Principal repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r406",
      "r627"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r117",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development and Clinical Trials"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r16",
      "r116",
      "r623"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r310",
      "r390",
      "r594",
      "r612",
      "r617"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r139",
      "r144",
      "r154",
      "r157",
      "r238",
      "r386",
      "r387",
      "r388",
      "r435",
      "r436",
      "r608",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r187",
      "r188",
      "r199",
      "r204",
      "r205",
      "r209",
      "r210",
      "r211",
      "r325",
      "r326",
      "r549"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedDetails",
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition and Cost of Goods Sold"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Secured Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r507",
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Issued and sold common stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock issued, price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Weighted Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Net Loss Per Share Determination"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r350",
      "r378",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r350",
      "r378",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense Relating to Stock Options to Employees and Nonemployees"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Liabilities Measure on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Future Maturities Under the Term Loan Agreement"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r45",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Unaudited Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/QuarterlyFinancialInformationunauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r13",
      "r116",
      "r568",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r13",
      "r116",
      "r568",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r57",
      "r119",
      "r175",
      "r176",
      "r298",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r299",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Reserved Common Stock for Future Issuances"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Available-For-Sale Investments in Unrealized Loss Position"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Option vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted stock forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted stock vested (in shares)",
        "terseLabel": "Restricted stock vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock vested (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)",
        "verboseLabel": "Number Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in USD per share)",
        "verboseLabel": "Weighted Average Exercise Price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares of common stock reserved for issuance (in shares)",
        "verboseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Awards outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r360",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Options Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)",
        "terseLabel": "Weighted Average Exercise Price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expect to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percent of outstanding shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r349",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails",
      "http://silkroadmed.com/role/StockholdersEquityDeficitSharesReservedforFutureIssuanceDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in USD per share)",
        "verboseLabel": "Exercise price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r117",
      "r351",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Option term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r375",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Awards outstanding",
        "verboseLabel": "Weighted Average Remaining Contractual Term (in Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
      "http://silkroadmed.com/role/StockOptionPlansInformationbyExercisePriceDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of purchase of price of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r18",
      "r574",
      "r575",
      "r589"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r119",
      "r121",
      "r161",
      "r162",
      "r163",
      "r165",
      "r167",
      "r175",
      "r176",
      "r177",
      "r234",
      "r303",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r59",
      "r136",
      "r137",
      "r139",
      "r144",
      "r154",
      "r157",
      "r174",
      "r238",
      "r303",
      "r310",
      "r386",
      "r387",
      "r388",
      "r435",
      "r436",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r608",
      "r609",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r136",
      "r137",
      "r139",
      "r174",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r26",
      "r27",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock in connection with NeuroCo merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r26",
      "r27",
      "r303",
      "r304",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Conversion of preferred stock to common stock upon IPO (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r26",
      "r27",
      "r303",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r303",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Exercise/issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r303",
      "r310",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r59",
      "r303",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock in connection with NeuroCo merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r59",
      "r303",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of preferred stock to common stock upon IPO"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r26",
      "r27",
      "r303",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r303",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Exercise/issuance of common stock",
        "verboseLabel": "Value of common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/AcquisitionofVariableInterestEntityNeuroCoDetails",
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r59",
      "r303",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r32",
      "r33",
      "r121",
      "r220",
      "r234",
      "r483"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheets",
      "http://silkroadmed.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r121",
      "r136",
      "r137",
      "r139",
      "r144",
      "r154",
      "r234",
      "r238",
      "r310",
      "r386",
      "r387",
      "r388",
      "r435",
      "r436",
      "r453",
      "r454",
      "r468",
      "r483",
      "r485",
      "r486",
      "r490",
      "r609",
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Adjustment"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r310",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "verboseLabel": "Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStock",
      "http://silkroadmed.com/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r23",
      "r24",
      "r117",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r491",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r491",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails",
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r491",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r491",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r515",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.",
        "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "verboseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r12",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity, ending balance",
        "periodStartLabel": "Temporary equity, beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]",
        "terseLabel": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, ending balance (in shares)",
        "periodStartLabel": "Temporary equity, beginning balance (in shares)",
        "terseLabel": "Temporary equity, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net exercise of Series C preferred stock warrants upon IPO"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r147",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r433",
      "r434",
      "r435",
      "r436",
      "r550",
      "r551",
      "r552",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesASC842ImpactonCondensedConsolidatedBalanceSheetDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r335",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r335",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.",
        "label": "Unbilled Receivables, Current",
        "terseLabel": "Unbilled receivables"
       }
      }
     },
     "localname": "UnbilledReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r407",
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at the beginning of year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails",
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current years\u2019 tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior years\u2019 tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).",
        "label": "Unrecorded Unconditional Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation Allowance [Line Items]",
        "terseLabel": "Valuation Allowance [Line Items]"
       }
      }
     },
     "localname": "ValuationAllowanceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceTable": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.",
        "label": "Valuation Allowance [Table]",
        "terseLabel": "Valuation Allowance [Table]"
       }
      }
     },
     "localname": "ValuationAllowanceTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r127",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at End of Year",
        "periodStartLabel": "Balance at Beginning of Year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Charged to expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "terseLabel": "Write offs"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails",
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails",
      "http://silkroadmed.com/role/ScheduleIIValuationandQualifyingAccountsScheduleIIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtStifelBankNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares used to compute net loss per share attributable to Silk Road Medical, Inc. common stockholders, basic and diluted (in shares)",
        "verboseLabel": "Weighted average common stock outstanding used to compute net loss per share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(ColumnA))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=116854557&loc=d3e20905-112640"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79507997-165333"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79507997-165333"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508013-165333"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508013-165333"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508029-165333"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508029-165333"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508043-165333"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508043-165333"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508057-165333"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508057-165333"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r628": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r629": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r631": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r632": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r633": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r634": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r635": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r636": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001397702-21-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001397702-21-000021-xbrl.zip
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M@S>GD= E'("Y:3W=<KLN2DBI?>#"$ZDJT4:/D#EZI:W)2K.55%=*JA=%K(3
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M@ZJ+)D7258LQ@%;*BJ"\<8B1:2Y!+!^J<X^BS =H9JU&]) <:/"169Z%]4A
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MI(YSS$CE@8:C9;!XNT>]_G O]3M;W0]I,.Q4"!T?D>>4B,#1>!2ML$QP&IT
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M.<R=A!L=<Z\1?V(J'VJXOVW9[];DS5Z_-CQ*M=P:$"2UBX3]&KGN*5XQXX>
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M G%*M.Q[!#V9&>V#,B-5@B>DZ@JW0HPR45BQ(/[)R!//BY@Y"S/2R#*T41X
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M2C--AJ,.&"=A8,_)=3D'/0@T *B<SM5*+1J[IS"^RF3!.FB5E#JC5;_)L89
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MF7TB T$1*\H62EKP(:P!6B9C?PY;PA5=>EF>%97)SMD/P+,5]=#+32&/-:8
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M0,!"MV7!9 O=PT2O.\O23"+2^%6D4_E WE$C/BG)M-;'%]\%T#IPL)PY6!B
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MH.9(2^V3ZY;+EO2Y*3/Z<\(>-[@4K;3EWAF&9WIY,LT;+@'+A-EZ):@ +KY
MG44I<[FB"*W9#,J54HVA34%@5R 4[1L4&5<ECV6^<CMH(#3)4,RJO)84+N]
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M,+/$DE-7%\^(B]<H@8I8.\W;SEJ2J^A$#Y(?R9VW%$176_B)_C*_>[E$P:N
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M3&>A#4D*WO:1(?>H1J^G-\8OI>#^Y;G@?BZXOV_!_6P<[S*.K^[*XC-IG>E
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M'YI1J5$>Q)P>8E<A7F),3?4(.^7<')N;>F/*[2$UD_9_O1H!FFXJ AQU+@>
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MJ>1&U^:4Y?'@  X='QOL%G68V)<MATK=1(83^]K#]16E[,N/BSF3W#K%-:M
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M;/$G(&+\H4HQ\^3;+#WTVC2>"PPONU1,+ S[1]E5*H=KAC)]U[:4]XV4]+?
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M\"OSOO&IR>TC:$],FWNGE*O>M!Z'ZKAY?/2ZV7I<G"E?I50RS;63T&\^J)_
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M46$^X)/B#T3+M#HP;Z+=6&I9AZUDNAEHG:0XG>5\SJ'#1TP!!"9,H*FX?<P
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MQJ(SCDCI% R46-@^SB/,6QH9JRZ:5;C+6!Y=EI8B /*EKP525MZ<ZFM54D
M*XJ] -TENT6+JW-P!RNZ>ZI)FT5KR'G[T$HL*A]XZBZ&AV.XD7![DUUM[".#
M,=P*'DX*+\1VY^I+>IS:\>-V1:P[Q-QZP=M+^'R5=DU&O97![T_:;J2!KW(:
M6C+E-'$.CS&K5L,#$" X12".;%+>_<GXIUU;2\Z "CM4R]$OMDQ@:/M\7Y:@
MCU-)_IF=K@_W9A5II(!/YV!BN2%.N=SE4[5ELIT:T90D,8LA,Z@'D([OP_5-
MW8-2TQ:KV! 35/%+T)XNAOY?<V352(#)OW6I/1 V@YAC.N92C3E0YA;A$J+.
MC66 TKPC'YU9-?3&HM?B:"QMGE\TU=6F[4TK>YQP8T+J_$J^!'M_FDMID\HI
MHNU*M,I>\)WD(K2,,;_JQ)]"MM!!D1>A:=,H>43R@>V9NYY*8&9 1*ISS<3=
MQLIA,)*QPU*3T/ELZVD.[MGOSYG=CY/9?9TW"84T5,T4B%MIWCJ&!. L4'6)
MSMK0VXH^-,$4! [LU/+D\FYF%#G^!NX[B0B:S@_"!]"(G=?\SC4WUAC*MR@#
MC!+41@8/<6*GM@!8FM_BQ[YEDK700']Z9 =]'5MO;(FX;^V-4.#.>6D_%EW0
MYN#ZJ=V@L)(L;KI;-FZ>&_8O&JYJB,'"VIV7Y2,MRU\V"'*-K5]+L!)6T/DJ
M%/)\'2:K:K^97Y^/QT>M8X:.+0=+"*:./G0H4"_W'>/K=Y?_SPOTD1;HA1T-
M7D YDIQF8(33?13L'CA4 "H!MC8[J"QC1F)Z/\97^-1YM3X2"@GNO(E/LIYR
M>]SK)\A<9H-,.?M$"*-- 80/9!Z"(]_3$M;RZ#-[_:?G&ORY!O_>-?C[E+$1
MXA#<L?7R*&^Z[0#XW15-E)X12)$'";(M$2YL[%/-V:9 $\^C4@OS$*'>;U13
M\I?>H%2%-$9!=(SLYM*DS/=KD28-?O-=',G.=^RH8*976T()!IG,RF2!.F8Y
MK0G"BF/2THUBR;SV#$EN)NT" L[1F[D+UG1Y @UY@1*>QB*CBIP=I5^,*[VA
M<FB X#$;)N+?2*9%UMEC2GSTXM;=/4[%WKUC8Z)[5DN^'/,L%:U0ST+&.N8A
M0SGKSGRAH>8.EL\_NO^.ZEN5I'/3+>6$:6S)8>I3\)-%9NZ(2W$T^)L*N-SY
M;9#NEP(;8)Z6^\Q9P7M&B7;/,O8_#='T/9J/=ZI1E[H9FO\)1;45ZC]L6!""
MXV."#:_POC.S+1.*PERR9O;KD'NTAJ?QE)5<(^RPMA1EP9)[G)H\,W[7):U(
M?#>($-9AI42#(#;ZQ)6I-R8YUD/T)-D:7H1ZU3:9F3H/<(M.?E&\4PY9-!#4
MR7VO-@IB7]4GK!S?J)P^7M!6?%FR>2#HB7J_P+D6\;'#R3^E??&(#032:AK[
MJZ3TY7ED@3$TWJ*DK55^Q;$,JFT$?D/1,80R7V:BJ]<S='!&/A!I&K&(-;WB
MLEZW'16GBWW/IU@'Y?.+RW,.Z&/U*0<:+&#VTA:H2[9ZK&Y$4]$!56LF(O;1
M9MFZ'4'7?&N<E^YC5990$&+-/".6V/^CR#LXQ2HV:^5LW*SL 1^DC\X%HI_&
MQD+;&JFYO%+\R3*2)+FW84T[L:B[@I6&MZ*^B I4%YC)65KNY-J=E^UC+=N;
M&@")2J60-#6 4++CX3F?G)_)MFU#LW@9.W3HI"2F='.N,7Q,4B^P9< ];S0:
M0=[NK1 QYJ)IU.3M@(?O%/'-.AY&V*1K7T'RC#MAZ>:'.W!.#S5%%0+1+3HD
M2YZZ#DDBMD1*P&DI3.6\8]NT!C_>XY\CK=/AWPC^C*#.PU8Z/OT1 O'5=B@/
MO*1'7%VXA21D=1C2E[5LYWM-<R'U-(V(>_CQ:<E*2'CN,4@_-,>/7<FUMWM7
MS9H027ZX%KFYKBF"4P\:1AXQ1PHXK>550]4::$WF?VWJ?3?XEWU2,M;:BR#!
M*X8N-"\QKVS FVV[58H'G3[MDN<E*]ZO0@U=NN_]X=62=LH3V'HG-<2MMW+I
MN&X@^7;"B+6GI_ZQ0F\L<=B*5QS,HX9E'=*#O>93&LHO;MM&H&04NIS++BND
M@_ :[/Q@$B$CS;SG'G\@*IK^.03Q^=N]_,@].-80(-G5MJ_S(Z2;/\5YE<#I
MV0L?\B([TP!5P\-?F5\;(Y!\&P^QTCVQZF7J:'[=ME(F$'),S0M3@'QUT*Z)
M6I6]D1'9M8#LC6P6'5K.18FAX[BEKE&%7%K.-_5L7++,[8VV]@_8R^6[I1AK
M,X:=@%2+$0V1.<30?,]?7DS6S>*1S\9@ 1U]:U!D9:-AI0?_M-%+^_A:L86N
M 8.M*(@-&J*,NE7OR+ZTV?E7XOBHTCJY3-_V6,,U0TC'X49=OW$I+L^:,7V9
M6^&YYVT<<ER%(13I=#EW))5A=M(9$HXRP&8M8^G*WD!XI=+K=M6V(0,.RTX9
M;A0U<GZV9@*QV;_XROQGY\K\N3+_#U;F?]:=>L)5,/QN21-Y[#R<\A?N$$B]
MV!QBH]#H-R%SG]:E7QX,CZY<=?KEZ[J"_PK>FI$1"),9&XR$CY+B8,9 .9 +
M5W[*>U*[O$_A1.&NL#-,ZR]*KI3&M4_7W<&CA9BW'W*ZX1[D&;-:'JYU)VR=
MB?:;JLIA)K_9IV6?7":OD2EY:8<T!IE7P@*;]H1*)C,3_]VK/\HX7]2 _JVU
M3>&_TR";N>#:7WSWW],)5=!!7]9VF_K0FS\>&:"-LYLEAN2HX0F!6V^2#/=F
M+A"100MA9.L#3UL*#O;6#!Q)Y^1AYHR.5#QBE8P\$]H5;3(S=%Y,.T*YHW4:
M.1%WO6IF6AIY)ZOGEQU[?G[^$8W7>[:K*8 ^KU@;G0G^*&Q44  =49-Z2VO3
MI<^"OW/ F+E.NXQ$$ 0&UPMEQ>2:5&X._Y\^)NRP##?5BE2KJ-4VO:8[=G6M
M\D4UEG"YE.C<>W32KX3]<=(?4I"R9BAF(O 2MGHO>E8_BMD1N@.RA]"RW,VO
M$<D;-WIZWF5\BK(-\N-KB['N?H1!AI!LR)Q-(>5?S%Z:I.*.R'0L7JGNK?O9
M,W!!8E1AV\6K@Q,Q#_%H@'*LY$#L K3FF*_EB)-ZY U<V3+$"/D)C#S.*)F[
M4#*_$+7K^V0)O[<>O9%>/DFVGFYS759SU/BL@SL#9)(-2Z;I!MFW9K-,MHU$
M)K-#.?-P Y/Y(H<)/G^ILP^C^5=+MUTB:1;<"XXK_?"F3D>4IN!UUQ+%R?11
M0W!F^@(JD\@"$RS0:?N9)F(RSXJF'O!:PJ>[2 OS"/][Q.*D-SN.=FA1C#!W
M(1?"9[!+;I)'X HK'M];1A'Y$($.C+,]#E?CB.>1+-Z:C7US5-S&VGVK^_I;
M)V[EY%[TA_4V;<8*#HT]X3)%+BUNGWM$E?_LYZY!_-M_#18=6SEWUR_W3%6K
MA_7G2JE DB>Z:W;[G9P3\5^SWA<WC*0\CY@.ZQ3+,'!,>P$+EC:#<CPG)\_-
M4N;=G3#AH2D6/SSH8T\C6%O.Z1ZM8+I]H=_(L?-2-78UY5($9'K7K$";]"FJ
MS*-C_VF'F#ZU]IN4)H%, <D;KPG%&R5MWVG5A&^AAU383O;=(_#?I/^"+_9H
MO]5*2"?7-SF86^6(E;+5\2I7*R1;-<[M<\(3WGJUK?<XMS9BM23:G!NL270U
M<CHWJQ.=L#%?-VI>HB1=VQG^>*C F>QB:_;SF!IO.<P=["@=Q1_B(<Q1"@'6
M7S;+ZJ85.6;QM=(N;X18MKRPN2#UCXVP=[8G2?>R54\'=M\?OU$[4-69*C.O
MJO<5?*(>+!TY#\MF(QJK"F&Q'/D2OC)7,V;2[Q]2^CYY(Q=]#,*D)R+Z#U?[
M!HU^H*H7,NDB:$A3?U5M] (,-^V[G(MI9BKXF%X00; X'N.^T#N<3@F 9NEM
MD>MZ;__(V6U?*RIV\D>?,P8[EW^]+'ZD%34YCGQD,A'00%>PB4/3Z['"8+8;
M<"0EIM9&VO*+S.($*X<BRV@Q.3?,0)4-*D.D(NBOA8SEV9.G3Z?6VH(<$!,4
M\+C6RD5O;1'5>]6N4_R?;%*&J*4?S_?I?L9E? (DNJZ3(5M$%/!D";@RFBZZ
MM%=T/J!G1^:6_5;$0?_Q.>$Z94]$N!D*)U,H[]9:91=JP*_K6;='D16W:[IC
MGTH-RQG;,-IP>PV&IU.<8?#>%](LW[DCY8!*_4WCKK;S&A9S4J*OXB5O>?KV
M))"^*PAZ$'^/IHU/5PA_W@I8Z:RG&7M;'])?I..9/IA\"V)5;Z_;R-XD6#I5
M=)%40SN8_^'[3O\IUB]+=(PH=/SBRW>?G\MWY_+=>Y?O'E0J+:O>QVZJ75<1
M$:9YS$TR4?^[IU^COY ,!5(CR2RY63?DB1)LPZ<0$SKJ2?V?S:*92O1PPE59
MTRY[ 2_JA5MP*1G.9>!%;EQLVG6\U-M+<\F^9G'4BC75)9'.)[L"1,QWDIR8
MZTWSO[B<'7'7Y-5/'^K[1F1/0P!%2@W[D^3SILOD,$1_W>I6&8B4L4[ TK+U
M-X?DN4F(_/GU91QDFKU5>S"?*/XA0\*(=2M(Q03PI^UYR1UKVGT?>L9T_$.V
MN^MZ,T0:.46@UB"N]A7E8#1JKT@H6E*::8U9W?6LP.-:*/S:S:+-8$)L!@&K
MR;>7BX\8X+I9U5*_0610-#]">VDAU6XY1I*5M)=,C[GJJK7*)LO/I*J8GK]K
ME:)7G3SCYCOB:;.!F>]QG=S<-5[<GTD45UI6]!.4G9#P;D*2U5(^Q5;RW2;>
MWB9YUC6;)(.,=!R#>+"G!DAHU1I$_<(,*VS_(97 "8!V!R5MZD*S:)K;S,@P
M$Y@,B;4:] ]:-H.GD!/1&MO92J"IHR\Z+9M'W6Q&)OGA@*FK97^G>:&%T0#D
MBO4@ X+2;PI.:M,)8YM<W1=!6]-;DS>__J@UG/O1H>\!J>;X4PF/7<U%$MBC
MIO_]8^=_I:=^(IT@V2Y&(ODOYEV-"P>4U&F%0W9"ZJ2.6LP7*#)#9$^DVDR:
MA$VY2_30'NWR,F>8SZV71NVN+KXO0"P!(,2Q6C5OL;S> GV"Y/,XA_C+2U5]
MH,L%)^#Y=W]]]>+1TR\GH!2OU\W<VJJM2$VYT9H6J$_W4Z6S*Z?-B&D%>1Q)
MIG%5M8O^^("6X9\LY+TL!;_;?Y+I@!]NDV@Z2^B_KDP^S'X[M2GZRX8IA<L=
ME5I!]2L;S=V:-%TNZR@,LYPZL]"2VT-7B%AH ZQ)MOU0-)HPW93V YAE<+M9
MQ)[^-IU9=TF$O[9>+1Y)._^N3O>P92]Z;7 OZH-%Z!_KE'5#T][00>D%U7W3
M=)"N7R4'[%M*3WAJDE\J7[>&5MZUC4A1Y3 9#MO(^#QEF4DKX'EU/[IHT.<W
MXSQ?MX:B0JNTN!'FC;:=M-\&:3E'2(]_GV-91.;W\>3%OC,/N*\Q@DDR:LB#
M$5+!4@/\G=5*&D;2!*EZ\4)RCSH+0VOJRJ64^]I,EO5MW0D()W0HX$.ULT>4
M"^'4S4[@LB)(I8#'Y?<3(5&>=$)W',V>!@G?(J/+<^V8DGC:[@RXO!T"X&9$
M@[-@D6%F<]BR0&?!/OEX<HGV@CPJL>.813L-,HT.+)< 9DFYQLVC7++.6<Y_
MXKS8G8(#>F3&U"O4$93-&_KL@F_CN]-&+ZA 5Q:\8*E]LR5#E18LE,G9D;PB
MC8 (IS#5VR:35XJ*&/YGX54D(^T."MEMNQ8TZ6'6-8O!;V2%TDKG1>%]SI59
MU"8):;LC+SA;/^*NR%-Q)/X8P/_BOVXR<DE-YGZ37&N+KY@D#2(L5B(,AAA3
MZOP_#&Z<+6O;[L0#&NQ"Q::Y8$4$.61:(3F)1G&.Z9ZL6A[._ 7!&)*-H[]N
MEDH1YH='GEUU0;U;"D89VBA*VH\AVI-G7\R):GR@@4@"9I ,,(W-JF"ST\/<
MZSZ,XN@R6_:;$=+RZ$GE%S\2T#ZB>U*:&'8=0<HF[=L;U!D? _&"+FPJDX9;
M34R4Q"&^<O/3T*4P?<8M92]V:^SWL:5ON-7ZTKJ(?#P)%_IK*8>D;T@7P%I$
MW;EW%BT&Z"?W[EWG@7P^W,/II(DM-V0>T2VR(]Z HW&B-M",SD@@&TJ'GZ0Q
M(DOC(]UG8C/?!'&&'HK#]4-6<V%3W_PZK6E->?NAO$N. _,<#[P4J<H]>RJ5
MM$ 0G^7TTCV>GIG<DX44:$#\1RS%=V.)K:+]CS>69VO,/X![T,+!SAN'D RM
M/IK__?@___WIYT^^(C<1#*'6-G<Y*9/O>(1&\FHQ8)*>V.1^LX%8(C9EEN'/
M&A>[*:]BRWVL<'9E'_^MG6G%=;GO5JC0P>/G7\E67K ++6WAO3A2^-/TDX[3
M-FOW!COA\C@^H21&<HN;#$5L9>0T$@$L7 (TH3=-GZS;+[[4\[MSJ>=<ZGG?
M4L_/NC75\0W>L!F3EMTPO8"ECF.K)4!HVE7=:;2;(X,1NKI9'5/@52_JQ^J:
M 7$&O61O@FABC[9Z#RF8M4M7;A7Y1-75X?(-7Y>N]<U4 B38-\U@K:A=@-^)
MG4^V#MRP50H/:<7E"\K4F-]6$A5%?&N.8H+<3C+I8W\C?;IX?3J#G600. _L
M%&%Z&4ZP#B)[696)'MHZ>-H0;Q^Z:!X3&$)K;PJ9@RGV6-&SC#32CD[+GKP/
MTM],TD<Y0YNNEH;8O4[E'-5#9#>$^-Z\T,07J!='%[O,1EX]C1_LEJTW-TW7
MTK]^,+FF/WI((*#+!=-&028R1MZM)E^(VT4I2>$X_5C:[C8Z5>MQ1TH[AIA0
MV6CD$?ZUFT3:^C2Z/:A;)2NBR?(F"Y&6F:]0!X#/*K&+L\9*LDG\6Q7'Q#FP
MI.Y :RZ]9K=7]DJ2YX.7 "&IXDS5\U;6X;2\*2SYFI9(.(JG4?H5BJBALT]5
M#7MWV3!:DBM>I@-239ZOJJ[Z27# 'YC0G8YBX7_:W2F&!?.*%@3-?J7%<8Y#
M2UH4==.^K]>SE=+;5/.WU578, <J=K5,+4P--UGIUH>J17]=@ZTBG<A'VU6%
M944F3RS5<,VX[47J5Y^D:3\<H!^9./3D16@50UR0:R(HGEH,F'>S[H/!L=''
MT#'68O*B#?ZTP(&O$8NBC(ML)])L?4/9.ZTH2Y';!#V41$6>I[<3&^Z$,Z@5
M\TA/W/(N5KSD0-/7IEN6!Y$AND8Y_C<^HL>Y?"N1L;X7OT>"6E4Z2/,$ FG)
MRM1ZF#$[DEK)/X< 8T.5NXT$6:S>XXMIT7)(T/0A^9$MG4;.@?@Y!+TVI$AH
M07U!Q7>WFZM68"#1+DDB=E11=P+'XZ81(O5[U)80>7((K$2]-6UC)@?"O'NB
M0KJ6*ZB(S.E#2E-M;NN])5GE#L=UH6:QF*.<GESD'+>@S_60/YZ8NG9&#H12
M- MHU6TVV-@*UTQEX/\'\$?,8R*O;C2IGM3\%W358&H,PAL/>#E+^0:+]=G[
M6R"\.\5B1S_[!"/EP9QA*1G]35BYOV9Y"7R+H*Y5;5O/V\&OJY'3$*XK]P@)
M=K9*2;+@[54MS#AFBG;5V^1+][=(I>KFJ.:J!%?U?#@4DII-LP8%4<[8B6/@
M--/(7Y+5*6<^EZOZQ\:,B@*169N2CAAT<HH\LA/]T%<XT%,(J4C7,;>R#M7-
MV_31JZP4^=U\UR(IA<\^OD<6AI6AGI@/+9NTMQM)C<+8I"E36[VUO&8M1F;7
MMF]9B(/6!.[:7;V5I-P>]^H*)15A2):2.OTPE&NRU5**M(+2H%I@+4E,A*>:
M9K36B.R?L=1SC M4EK@^)U!W32^"/FD+IQB'KX%@S0.3=@*WNI/^*2MB^^:D
MJ4QN39HVEM(8[]TX35Q(8H?*J0!,1A+8N<3GV@?:]RX[7HOO_X(.,^E4MSO<
MDIPYU3?U?&#^JZD7$"MT=>('+(/C\F'Y:=/G"I81K@HXW[P!YJ4UT(1SEV(X
M9 5_J',^L.<%L9O<M*OD?.'*6=75C6"$4C1/=%S6]\C>"7+>QYM9-:P/DM4U
M;^&.TES(G;,=,GQ!OY<\1%9<!W>AKS3JI&)DJ+0B535IU,J@';N9 XQ(@MY<
M6"N*\-U^$Y500KWA-M8;3.M$3@Q<6ZVR8$;'U36R82\5MT>+"'&!T@K +4YC
MSDNT(+4)]WTK;05YXC3[@Y2%MR1VM2Q$-0_TI6YOTD7P&& C/"='HB@+0Y$!
M@@W[K>,+\A<YQP.^XZ;I]J8QX$,?>_T!/L4./:A\A$]C<#^9\3.8DRG2AF,2
M+!;_R)PK\VOQD3QL<^S%X5;_UD\,<7HJQ"Y_;+B,Z& =UXL#I)8CW,!'S]_*
M)?521GDM!'T<&CD,F>""'!9MX,>X5^^5C0?J%WTO6$8FTCW]0;"C]).YU6\V
MTHNYL3YKTX:W_:L;!;KQ=18K+C^3SFD::T-?N1<"DII>2SI"E=?O"5RDVJ90
M8:?_S1]4]-;CR9LL!(G-*DB_91""I#1.NZYS B8T%.MW2UB=P4ZLS@_32W%7
M9[Q3L#*YD"Q)0<_L+'/*IK%P6:018S"!D*V():2T"8LIKW: #DG3/]9N,<3?
M^#^5^*.5<!9*8FBJN[2W&EQ?QR"E^%X!MFD&4SBWE%$H1*%VUDN\+8:&+WF4
M-4ILB!N<D8T"W85]<W.PM)4-V,^3(.IPO:[D-I4(MWARVAY(A&C+O=P4(7&=
M+PU<>O30TV_(395[S;1?6C[(JQ=37.C8=*Y: ITPOF G=]M"DM QUSNJR#WF
M-JGM+_<!EP^;H>D]^-H6ZHWX>]X!RDN4EVUJ(;WD;N1XU3XQOA.L-M"?N1\_
M^>)<43Q7%!\$]V.VSL8K+=$:/'OZX-,@S&BV$M#3[S/. UX5_>1\>2LLJG!Q
M;H6W'0$L+*=BFT.^T/UM.$O7:93)J+BFHGRY(TI4()(Y;;\L80I31!BP?<CS
MZ<W(%@/UGN36<H^8WF:&9PMC1YK5==-;@W2^ARU%D2)QHWN646^@2;G*T)3@
M[1:(6E[?\':%)Y,IK_L,A'\G9X/GSY4:Y_G%FY>7DPN4N\Q/RSF!:_>,D:GO
M[/Y1K[JOYWM!VE0_JN=<E@-NFOK64?)$QZG4F5_*%@UKUM8'\[B@E!-Y4>V_
MWPC$6I:1_I\_Q%ND5UI#X26OZ11-&<=&L5.$Z[,LB:8PU_)[FN!\Z8@"M_5S
M/0.ZC0>O6,QY;KFR!CBX<W!!BU$KSID)/+@Y\VI5L&GG.FE)E'+PQK*04T*1
MF<[=&H0',6H/NUY#]XQ8;(?AMA\M?S\\E.M[V]!C$M>0P"PX</52"MBW&B>E
M?966R-S6R5\>7SZ.&%"Z^H<CVDOTM.QWUX+PJJXZ#13MV^9=TS?^?6E])?#+
MO3A"B.'4XCH)HX4PG?6NGC=;)4V7H59-8<B&\U3_F,Z%L"A(*:Y( L%$4ZL'
MG!0,;KQU$DG3J23-*G\:,ZDYV]ZGWZ(=L?C2K-10N7-7:0Z/@\8E0;?%QC_A
M)&WQ7U(BKFO%#$!E-IZ^X1D1?SV=AK!6)V?=>:1*<M*<%TQW.C+BNSJ4GS"B
M&?UUY-)#9U]F'6(,]%A(+XN9X*;DIX9HVO=(<3Q0J^XT4". \K%*QCU*O<]%
M1N'GS_,>HV:](3,P_R)]L$9S*\#HV5_2Y 1U[3)G&O0O![16U;QK14/T%!>S
MWX[6A[^1#@A] ,'=<Q@VH43M]W69L(6[MZ?;(Z_+"K- "O01AC^1ENV7>_1L
M\S05,%W#(87WX3N.-2U@N*$C.\R5?,2:7249(ZJ>Z>JOI(\W9&N,I+=H%V=B
M!LJ25;?(R%]*TP7A!9G4KU]<,%=TQ/NF;3@"N\^-.$%<>P3$_KALHA#%Z%A$
MXXFZN\\R<[;1NI4$A9(KI(FRG-0_*$XZ,#]G6:H[9*E>^*:4QG=F1L2%,. ?
M]P]<QE7<S>9GL*!3)Z]J'OB>>R7>$#I)K7J(PSMKT];5]%'Z-)D 5O 2CVA*
M/T3Q[;SD'[SD;,?3<%BA>&+?@L5S:W5>FG_QTO@"L""C1X<.<W:UAY]))[K;
M-Z6BI7[<N/>-#[/\/9',YS7^J2UN,>E],,#,R4C&V[3 K0RQJ>N%0X\$RW9\
M/..F8!7)+^GTK5>K=H;OO&ZV6_DRJW6*D^4I(Y8+ ;PO[VD?RWF#_$2ZT51%
MY5H5MZZ$<+V2,"VESNYMUN.HK-BJ*O!3*=V8\BKDPG0WRI^.["8#%@J%TGC[
MZW[CR'MD506_,:C2L+HV?+0CNA[6;OI  /:]VE\OFL"6*=W-<VDX=BS)+2I]
M#!NNZVQHAJ:@/TI8%T_V1A[@:K059\3O%^,76TY4)20(,@^&\> ]DH>\?5Z%
M"\5@.X,ES=FJS%T\LNJ3=;L!@;649B3?,,CO*>F))"(U&Y>E5F=IEZ;K4#6
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M+4""W8EGHQ=0?"T:8KFB\Q,7-J]88V-S2Q'!1EW$M5_.C*+OL<0#^F$N!=V
MP&5 ?OW51&P(@\Z*+U/FRPFU=T9M8J?TQ1X-KZ1UAWK$^DU7KXD_;-]70OW*
M5D&6PO)!+),&LBI6AQ?;>WZ.!981QL*6(LKI(&G@+1+V5^P<G3<=<C31 R(V
M+*S&7B _B2N&MVJ@8B';51[AI]2!T;++H6M)B__!R"-Q'0W-R$!H%J.O-J,R
MO7NHFCZ4;WDAMH3&C4XR-&JPF-D[[B77=:IPB+IA5F.9";[L\L-PDF2'S:.
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M2QY?P_[OM\N*M(]9$U$H$QAXE_1^ "7:AM=J#;+CJM879EEIC-3I/N\BJ2C
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M)K5"%ZKP,KUR.1S HZ@WP)&DD/WY]:TY.=!&'7*.CVG &1YW<U>IT-*(X!/
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MK%,>OD=EQCXRABZ^E=*;<"4"JB>*F;?DNE"6J$C11B*/8!?V1'WG>]"XIBB
M,M$>F;24B;#$^0<2R@U+%6?"<3H.F@AY?-HX/&%;.\$!HZ#ZZ!C-S,<2+]^%
M6A]$8$F&3.60G"4/TQZBPCN5BDFZEY@=<D+/ Q$_-P$(("@UV'CM5";/-^$F
M9E&R,K5KWH_,; (^ZY.:^0]G9)W0<,\'"'"+\DJ):%',=XI6SK*^T:1?=I)'
MG]- \FGR+W+%J:Q1_0.3@/C HMU7=Y4O)^$\4UU);0[VVH\*8@7A;J< _ZP6
M@U6%2_'@,YDV*W/8N$I+_B7W',/ 2M:#W39+$XS'L& ,(AU6'R]=OZ=@.'G
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MLP@M#'>IQ..EIB$,C#8@U4PQ[L<VOAV'F^K#WZ/KIZYV-OU\2,A*DDOV X&
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MB!!%#;&3P&ZO"5N!/8V-_N!7%V[QT1>!GEZ+0-<BT"44@2+MP"NG_7CFC,A
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M_@,Y/&]@+8X0F3I.^V^W)-8+ZCC??4+W29**NACJAMW1M)H-^ FLG(2POB!
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M\4%**)RL)A"'83'8RU:U-J,!W%.ZN4)1?Q(M#IVEP3N#B$L:#!:>@>9QBT:
M$&2E-/ 1"@$E .BLZFBW.+GNR_!'!*E+0G9=X01_NQ)%C=',R7P)"!;YW<*2
MA.')1!=G*RNCDX8!40<S"15(9Z](U0\@/Y?II5$0FA]2?^.3)J^*5]5*2J,;
MYG7U6=<9LJLQI!]@]([7:SM$ZM7,@[&V2^0565:W:17I[$&V]:A@U3_;,&AK
M%U/,.^*S&QG$ N!.J,G (ILVK)3T6DF*$@DK_58Z2WII4#/IR(*R,N]H-2F\
MA4N*)0K]6T?;R3.Q>%4[R:&.@ R)2H:R(M3/50$+FV5" 2UY&F;R9!'A [VQ
M9-&5[3HJL4(!1'254:+46U:/@C ]Y3SV$!!.-9@*^;%0^ZZ<9Q9 MNX8Y06X
M]JC4HDN;2O *I.X9VWZ0<_21SLEN2^0#.C+1!\=$^K-EI('?:@YI>RVM?Y@$
M3JXQI7.Q6F*I,1,?9&QS:!J/\0/Z'./7N#M%9R[<0S7YV&X/^\WE1E;"?@I)
M9.2F,:K171"/8$C.I_;C7%(-B @@WJKLKWH33VD1/L#>$EOO[LYPAUV_4ZSZ
MFM V/\-+*:L':MQ%V[I&R^<395T#R(&/HPIC@(@=\$:45K+8#(*'I;H(^9TX
M#PO>5XT?B$8=X=9/YX7M87[%7JT,1C"CG72]:S[T;W>0H 5:5_GL96:F]=_V
MVD+T\JM+$2$7#G_0+_A:+P[G8;@_.,#O?JV'#YI<9$&\!WF$B7EY9J1B_!T3
M.J+Z%,;H-V"8I7536\L6[,#(G=[3):,MA"4@5X.5,^DP+@H&V/.(/#/+1DV%
MLU+1R'N"DMU:,FOIS]F,YIM^^.:S< =]%J[/PMTZ"]=KQ&LTXAO%LQ!ZA%G5
M!(S&-E+EF51)9'MR+-*,P]FS,IFCS:XWCV"ME;R:F#A*#--?%-A&A@B&F=<X
M37(_02!MA$KN-3^G0 >=AE8A4KS@S\9QCANA-ADO?:H-WXJ3;NK6(Z2A>=\Y
M+R8FX]!T?\ ^T %++5P$!PG.]2P5QW<,YR.&?0E:\I:*"-.)RL_6FLB_6YJS
MI9%.0YQ"S3*'1F/?NMN ]6%I'2BT.OEL M;B=0^R*#&<_\K+YCI;%>5D>/0#
M&!]%9JRYW/)\8"*;"NL5.6:H 9V)4> 2XOF[6G+$X/=?$3@SG8^0O6TN<%#8
M;+BMM1.8"QT%$#6/U.V1 &H\H3^BS19U[951,OXT(S362Y&9*?W?#X]=P^>C
M-;_V)O[N/]M L'Q6:NH .V,I'9>0<PK45?WF#DGT/'#FUFJ3@)8&(6:<CJ/V
M85*=\A;QP>JSLR?T,?D<G362V?AG,2(8.BXK>(5'OO,G?A[(E.=U(8DH!L!+
M,R_0XUS Q5FM#.N$(44Z5*I<LWA65].* <6)\(+ UBC5*V0G#QU"]/*""DR2
M:(0R8XC9P]ZNV[#:40.]42:,6P$=8G^)8I).4_Q(GCI../B4:(XB2$^Z/V !
MQN+<<EQW?:@6=RU[QI5VB^<^BEY3 .4Z)[I3XC\A,J*5*SL[8'RCL1.7Y6!Y
M]",A&G-P813,SI.2YQDL%B08:2Y-D6Z(?F#\-8].FQDH[__XM^'AS@^[L5?9
M\6,SF<'YA%8T*']O%PV[:C=NV$TL"7R$EY:.6GNPB14'BG_WWQ'  ,M=H?^[
M- @%]\CI8+C@-F<\VB&-=H\/D@D'DKIV!1X0\+:)?2,AU^L$O?.83U/8[@D5
M+NNYH7MB=V?W)&IR@NE[."A5>?Q38ENE45] GM=_)GF3E$M_8O<D5L-E,CFJ
M*CKH,.B:FJDWQ;L/.\45%@9S609/M1_R]*SL$&[L31,%Y5 ?2W";6;\MXM?9
M"YSTH1U/48_NA9:L:6D,H_MAA7"I];RUWW#*'9.(5.L?;][#/ 6=XKP).R#T
MQ]O3LP^GL8WNM<3E,)8KK4K4(MPF2U#X6-G9MW, ,,^I=%/YTR=_--P?C#\I
M=$OD<'(/-J5]/IT6T_0S[59Z9K.8,"@RU[B2^%"D4/%,HW;L.H,\NI&9;9 A
MPK3J,*LG4?WUS1"M(+8I(-OU@S%0!"RSC69<>QQ<+S%LI>8D7=C&L7!<<Q=)
M-_?B\]DD()+ -]*SG20E:'^#D>B:6[NX>A/5*[C*OC^J;U"?Q@+)5)9=O^%;
M6++QFEP4990K$#\XN+?V=/R='!7B.W.*&/431SVG4G5PT4KS:!F%%&A8<9"L
M@QR:(8R5%8;74*_2[+927F*9A,=[J04[V=*CP!3XK)=2)GE J:P$_@$:42LG
M5KA>"Q_<&&M2EWE.ZC(=D5H.'"H,6+IW^*] <53>7?VZCYB<;5MV>HQ@%I6!
MQ]< XH*"OY1AGG@JMJ90XM <%[I+69'U*UV1'05_E)"Z C'%Q(GW+K61$/M'
M7=&TFF;9AB;&%LZMYFG1=D1+4L]!\]DU\Z*&,HI14]H*+Z$4#U/Y(83B>KQJ
M=^6YG;8'<G)Y_K2>VVT6F]YB.DP8P6^Y/DJ;EZTPN#.'R9@XI5>9Y.WG* *"
M/V&;$7QG82KP[.TYM0^IL+(7VX&("I=TL!)6TASR&E#:F19F6U6SAQ3@R(T[
MQCA%5GD1/$%JVW#>N41<:</"[&'Y+J-.DLHF1X5.-3!.TX#5<RQ^"L=_JSH6
M3G37" [.<.3D)9W>$?%%_"K9I=@W!+T$^/]Q1Y3C(JD(PXZFK+A>J1</']\D
M#@RV_@-4D^,$&Y&OA2!KSY>' 7U =2QG^'0U3&8GU ^/3KE)K*WQ1>NCJVFR
M-U#!0[@XC=.)>ORY)[JUY5AN5VDU&34QDVY03;EOM@O5VL@$\S9MSWWX^;9/
MS:J")D7IDU&(2:6GO_*7!97O$F'$@13C,6IH%CI7DM1>R452U8KBQ-W*5H,>
MF-9,7S?](0>>I^:=L,-\VBI/"QGE7Y*]P:U\/OL6!5[VS6=V#_O,;I_9W8;Z
M2I]EX;+5V-%68 ?,R^S4Q.SGQ%1%DCG^7E^7!3P/Q(TIZN^Z+(EK>H,:;IW1
M[QG=7JKI5#0SG$->GSH> Y'0*^M<>-9(7#.YJF)_R/'*F(DZ96/X!S;,Z R[
MCW%.0DR)LD@F$A+QK!QGLP= M& %+(8;G$X3P-VF.+T<L+ )D56 ;'?P@42J
M8UD< =FS*37YZ!>"(.LI=27"Z;^ JXA&D:8;\S*20KN.J9$-GJYB*P<,O%)6
M$L.1;$I1T6[S*9)6VHR'\8XH>H<64%DFTJA#B,-=N"QV86(&SHLU,Q;SGMZ-
MC7<J!>>3'.)[77?$:9DTDJL8H4GD9)(*HKW:,L>1)"EE<#*%I,6)4C!>FQK#
M6R_2A0-PV'GB"$I,9'[L$'0'4F0ZNFF#M0^&I?>WA:O4>HB8CZG2)*U0U)&'
MSG7CF3,#H-<@R _$=W4 ]I;?%8[RMX9GAT2_J'R08F+>WK]^=KOI^G3P;G?;
M3HTX,.SLY1("/=3T@9 PJ\O8N7;.48,%R[3*1=A6;:K";3Q8SX]GIQ_:U9OV
MV'8MTKE2J^NEZP&D_1K?;8U?G;H.>'1 .D)/6[EDV(&&Z^:%-6*T]&@%2D,6
MVW3ZDBY ;Y/-*?Q'T.#-5OYB]MW6J4F%H"*%8'S]6C_06A.KA.SI4S"E7OY7
M.OZ$N3JJ->#\,Z?UY+14P:BZL[Q8OBBLU!0O0? 8L9Q9BA0.*Y/A06@::0Q"
M_^9R3A(@!4]R_&;>Y&*NQ7 HPF7"Q(YBPC]1U:7Y+)8%R5O)5+_$3&!2&28:
M+/!J_%YD^,M]; S<9>D@%TT)ST**]Z*<,#TKIHWGF*=WU?OXN;.B(.R*UNOB
MNWG.;'9.("^8KN6N2EVYH)4$FT;G+)P0^67;E-_1I##,'9<;KHIBCX0)?7'Z
M,S.Q<3*7+B_]O59+8IP[EU'^2!^$GYS6Q"OI&IL%? *M_#J=V-QFBPDLI6^+
M,R-2;B17.BBK:PTMM))!"[7Z)ADE\X>+&9#Z8@HV('TAF7--AJ/B,5#HJRF9
M(Z/UY#%(01;]1/>>\4$%#B1\Z?_H6%9NZ1Y,B#'DQUH.<>>=- N<X[\,CP[C
M_9,#&AJUT+&?#LHU:_0ZP2*D5.Y-0NRV!&*EBHQ+J,_H=2$HC#G8Q5Q"6U[1
M;^C:P$I5Z(FQ7/I?=_U4X'/( ?8^M412W<1[O6\\VK^RJP93J3.PLQ.#NM,X
M=9E6VJ1;+QGN< )((1@>)=-E."(W&,:YD5?R&89 X%$2KI5\NB>[G=O1?4)G
M>J _BA[A*&K+GIY"-YP^/F9/-:3M0.N.(F'MIB.'D ?"V%]P[U_Z(WK K$B4
MP%PZ7_$C^ Z^@.S@.3-4NJRZ*G]+P*#?YN3-DO"2.4L[:H%ADC"SCL[KA04G
M(9$]I@.X,,]C[,]M3@3=04:JLH7L)R18@Z6>:88@(3I3^#5HKW?D(:A-I98#
MNDFFR "1-K173/E^P0F,ZF2N3+^)DAE@8;2Y2+*I*E5O&Y)ST5"VVD-KXDE$
MM*I<ZPT'I+P"1*.J,S,BT&<5ZZM0#U<7TI\,I*5!+WR!"2BQ(^4 %;R=]WZ,
M:[*2*J67A:S6[Q=,MR!WIE4T,4SHXQV]<HA.;G&Z=!Z>C(N7.[KB6AA4L&?E
M7X;#^/#@@#3I[EZ\MS=T1XDGOW*8U*5!=\MULL"*D\],_NQ-2;>B5/47NU2>
M"Y!<8]'T&O*!G6][E#J:/MN$A%M#<5D3IG0Y73DQ&MH*RH!')C?3U"MX0MJ=
M3]UZD8D.VQI/0EI\E??D.;:1+?NE?XS#D6V\MVI2OK>*X1<+P;WIH%3W2U@_
M\@I=HK:K)2V(5C<VB\TXI9Y";..+6X*JF=7F!07/J7;HFT__'O7IWS[]>__"
MWJ\JK&#3"(<M!4^F66.T6L/;]K;J#H%TE>@*/U!"K%Q=CCX;HS118H9YYH]X
M_XYFWT+RZ2G"X-D?*@]XJ/QT]OY4063_-8A^+-,1(M!<X<*.SWJHZ?TZ?>EH
M'STSQ/HOVN6YM*75+J74K]\C& 7O-1,:O1?'\[S!/&-N;)>;=^!"Z%_1G\(.
M64'D1UA#P-.S[,FX])WUD(@&PUBH"\LS?1%?@K>]!O]2JF#D 9R[^P!Z-A_#
MOVV)#(VN^RWM_A1LH_B0 #)W)-E8M?QFD.!)V:#!$X+;*NKPBCW?QNU\L2B9
MJB.,"ZHQN4S2C,;(L[;J$MD \ME%FDU*DUM5*?/SQL).WHO5315)6%PI=3>9
M]4D)U_G*H#Y4[UV>@D/^1P-?&Z)3__&/\S@("Y2.+<L" &VZ5RT_FBAN@L6=
M7 IMLS@),NS*1L!WAY[>5(O-Q*NLT0/MJ-ZR*^5E_\)%PZNP4FBA,7BV4[T"
MEKAKRAR1+Q>)71HN@XJT\6<%(\Y(6EM%41P02><H AC@X%T+$D'5HROUL#"K
M[\9U@9Q+N_M4L74<PUJ:BHASHH]E,U^T*^-H-25<<<ZP%1" WRKS\E5:\;GY
MGIN_T5F*JO0]9=:0NF>1%N!J?^"B-4ZD?,2]RT<FK*;L6ZE#*^9S)()$&88]
MI-$0"_]'88I>--*>R/:L<5V!9)@_H?+1DF@9P^L%?.,\'7/J7Q6,O.)[\#W!
MZIEH@)K*A27S2Y(&;R9>BU4XKEL/@7VL:+,J4&=!91LU5*T$^Y!CI N^"D\;
MG$NC[*;2YSF=@ J]-%EX2?1"L PZYF"(LX+A8DC]P5 $*BG;W?6QQ!5O'?[+
M\'N4FK4"7EIDW41*0N>I2K(,@N)R9V_/!>JAQ._N:ON 5A"0 ,JW3$' KL?P
MT='A(=>TRDLXZ(X3.YMA(I^K*VVF B_%2'ST C.X:ZX=#(^.8+:SC/A!]0Z<
M+Q$O":7J2RL5(NJR0#7G"WM2=>BIPF_M6Y3=^]UV\,3T&#.-QY%&3[.E1<K
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MZHD:P"9H[%=H 2@&G9+U])PNH&E?=OU P=KW+#QX/H'V#_L$\S:W4;D^O_A
M<_X+F "E]/T%&\SV/.)*=OD!-B/7$6GI,UR;C#]1ST:T,@HB*0NX'#!OUZ_1
M0^T+XV+!G<2B_50_T%0C_JB<1)^,6<#?^FE]8,UNQ;C-J>"UBHW%2U]1)WU>
M] $7!#MV.*6"_8A-FF6H5\(^G(H50Y"I2>H+35\2P7>:8_-F7*L-(D,G)Q1.
MK4RY>\O22Y)11Q&PYK?5R/Z1VVPS47UHN,;<P 3_0&0'"!9"?YV@9D@;P=W3
MU4:/E?&*Q6!M&\Y$LL;+:-Z T$S3LJH=FF]BZR"$?.)@N//BT_?>,;5HRJI)
MF'KA7%9"+A(G]Z>B /_H5=G,!-M9S4$LQQ8TS4["V6D<<&ECS --%F'DUM_3
M1>_?(F;*M0%W01=P-F+;22)WP7'I K^U<O%&NJICPE":D5)HD=,$["OCXL/,
M>%,EI%S445LB%-I,XO6O'][]]O$UC)[")FD%RX]X!I2^,IT5L+$IO%\1+0F&
M\^N+I>2A-?U:7R0L4JM"P6-S_<[771%;%Y&DSU8BVY(\[;TBF?O4%DQ[Q'G8
M2-@"/31X3F%(N8O">0BOYL$H19FMP4[TH2!OY.PK'-AN/71(">&,$1[J-R!+
M$(QNZJ?U,>!+H;P;!FQKO;N>2+,2IJ2#S2\,*W;<=L!4%,U;-KR]5A0A,\M=
M)(@A!J$$Y3&NUCV/$$SX&$ZJ$]/*]<^!UV-TI$P0[^'N^K-!7T.R.9BLJHD"
M)VS!:N6J/0SD!E&G98(@ Q 'S&<QI4@(1UX0HL.G5[133@\2P<0-\\WGUD_Z
MW'J?6]\*:E^U#NY_?%"&G+2C;7A%.0/$2?N:U;:[<;%-5#D!\ E5("HCBJV\
MU'A*[$56\)-C+[*EX49+,H?/E-0@JB(]U+'+U7*!S\B6X>&M44Q7VN6=KWH[
MF'Z<[,-/F4C"3NH()L;,!==62))S1JAK;/*75I^(%VM"R1G)\Q0>T8H^Q?+9
M*0%HHK:'-<I</Q%B]6*.>ERKT,;#VZA@30E*/&8D BO,@]$H.M .B8[C8" R
M&5SCP, _MIOY#W&D?%+^D^GR15,+T)O%):?C/H$9??/FC5_Z%1A:LG[P:38?
MN,[>@?60XKCDDVFWZ!KN(G(;G#!NSX@#RI ./RORF2GE+9UF'\^BFW#OZ8B^
ML-Q;1#Y%WT\)4WYP[,QG[@P@LHB;A?P P;#I5FO@.,TB)OI9[7O#^2U*DE"2
MT<'=):/3F<1Q:9BB]#,T5W=H9/.-]3$4D2,WCZ8[9JY8:EYD\N6:'D6TYP)[
M-<>52"K*HUOEUF<]'B@4\XZP(1[G[\3,D>FOE :F;)C7:3452(1ZS;"TXJMY
M .R J)IHCC@-26U(HU$Q$3*38B59A\>>;VFK)YB6P;G7EW8]9&'[)*T2.%Q]
MVK(U"ZL(#F^!:36]VB/.FGE\U[:N*X"9A,:'!>\D>9(M*TYZAY <"OZA-\4
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M25J\:]Z$EX'DX?.HQ)I$E37/E3?2>WJ9>T_'=,)<5=Q*#-#7;O4@UPB-Q;5
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MABV(F(=FN;D7L'@D;3'>8AV./DZ$^EH%*B_#<;BME S[<QU&.@'2IM5(>R4
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MVIL,$=J6\>Z)R9TP\N3'%'B%1^3RAG%Y7T>98"H<MH4^O0C3T*S^)H[048O
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M>YCVC]H->S4:S]P7E_2&G=&PG<=XM%]/__UV/:-*!:1'S$L %T81>H5,Y1@
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MG;EL4HM96>5"3LIH[432T?H0,C-<*C%WX^C=Z0<<MT24,7[ X63P";>':72
MS0)]%B8??MX???YOS._QGU5M;T_^A-66Q5\P[8?)9%#JK6OGO%6F.'X;_B2C
M=2ZC]44U6E]?*IS3)J&4'CC':K1&I2 J5*"\TXB)L^BJT2J[U,F-H$W$NZ+2
M>5AG(!%OMXCWDK<P2<N*5A*RTZ+1K8"08ZH_>.&6"66L[!CQKD7^G[T1F#^%
M_=9!<](+T]YS3'@0<=R3O-]KV%HD*?#4UW%R33_*>N?SZ"CNXXF[X_35Z>CP
M-D?("G/:C1W\F',FA*IB>&54S,SQ(EP,H:U]D83:V[Y3X[XO.![E2EI72>XM
M'AR.QF%\_.(_1X/I\4FOOMVCZ60:ANU^4G.^N5CK+*H_:\[W92\)$;,TE:ZB
M,*"RJ\IB3!8J6046K3"NI2V?JB!+ZK.P#  ]<F3ST3BB*\&8OSV&T.<0=A?8
M\KH&^'U4>;5\Y(Y,^2R,Q\?UUFT=5'%,MZ;3\2 >34.]YV]'KRJ)#J>D\,U+
MG<<7J%,XC%)8 Y(Q7=4](<$)[R!@5?BPQ!*](^KL<@XY:7)7*OQ]"H$[&U$D
MI97QQF:9F<W>^U"IZHZ:W+=[:9'^MB )76JNS+THKE@'6&2S.1.#-AD2'.90
MQ>ADE+K:G*HOE.\;M? @R/7A(5+A2(7[GBXHW\61MTS;_##:K_=L<J*O;0_3
M_E&[4:]&XYE;[I+&MC,:MO,8C_;KZ;_?KF=4:90TN'G)\]((3A,9$]Y(P)!:
MNY+LP'.%8'5!7Z)0:$4C3R)-(DTBS85F%1=?[5XK8[0J*XS>.A3:&%>,J;1Y
M-[OWKWNT$I\^N$5\N0%4%;+7(G% XQ*H' 0$6R28:A%'62UAC6V0F#)]R1W1
M*M$JT>HBY2521^95SII+HVR2/O/(@K7!61VBCK?SZOQ5)42PCT2PE^HPG8@B
MHK(@A&*@4HG@?8ZM-B4Z6Q!-Y!N;0KJ^\]?[8L]=DD+<2MRZ1MPZ3ZC&>"F$
M"5%5*Y_Y')+CT00>)(\.[3="-42;G:#-2SF1-@63O'8@;?%0[7H++K:2ON1"
MULB34ZSJI>0>)=HDVER$-DM$J:PLOG&DE<&;+)RM9I_P;1"97"S"363Z2&3Z
M[E*>H^!.)%6 U0T1E/2V369Q@#K9^D^4&!,%OHE1B5&7P:A1<.8Y6@S:J< P
M*F%$+ 9S2>F;BBB9]EVGU4OIXR)FQ1,/8%FVH.JF";[JIE"%CSZ(($H)&YN<
MV;YF; UH=99[_O?9DJJ_\^#3YO^I/\Y.^2",WP^&9V?F+S-:PK;F3IX9#'/]
MZT?N9F1[<OEQ_/?-K[?BZB>? M&*^IF'H\FL^_&/8]P/T\$G_,?G09Y^.$/I
MA7>=G@@[?TN(]88<36]_R[437@['</97%"/:F;S]@+V0VJ"N,&QI@+WA:-JR
MX<?UZ=8X8XKOQV&_=QC&T]ZH]*8?<(*],AB&8:K?7<\Q3''66..'6^_DXUX@
M9^KRF5W\V<YR1D+5A&>8A78YH$+4P6..+LCHC40>RUZKR3A]TX?QV9D?AO<(
M<8SA(X16'?-CV/\<CB<;?[^\1NL"/3TEW\[YMH5P>2W+F];RW9;N/7W0G=$U
M ^LY(F;L4(6\'PXG^./9@W_DP>1P/QS_.!C.A#9[TS\N?V/;):^0P^SK3EX^
MOY$_L).;>5JB<OK-IR__,'OI"M6=O.;=#Y[=_C+[@?^O2S3TC1*82PQYF09O
M8,([ZUT/ "/Q5W4R,QB]&>Q_[/TR"KGW$G,[TWZO[OX/#_J_/-O3(81GM-1(
MJQ6Y]5J5V^0*$]RROSS@+G.'3UX,4%?A,SI<'#:&_Z#-W6 SS\=R]H/G_KL^
M]MNO*?5][URKDQ5W%M@-]':VM*HJB?,?^1?<^9A5@F=L,ON8']O0C$&Z2_1U
M,*RJT.BH?FB>7 N7?;U&KN]RD:<$\A"7^4W2?(=AW'M1&2Q?JH2\]>H>>'G<
MI4+@KI9(%V__-PM.Y[G&];]1W-.-NMN-<H^-WDZVDKS3W9MIC:5IC;TR'AWT
M1H<XKL9_-9&;+^53M>[Q]JDQ=V^&M^#Z?(!V?:MXAG.>Y -#X$H(H ,0F&\X
MTCP7]CBQAON)-#QBQ(!Z3M]/&$"^/ \#'.S^]C_[[\0[_?L?OW[9>?OZ^-V7
M]_KEVU_%SO.?!_5Y]?OS5%][_]6EO_O'Q^/Z.1]W__G[QY=O?QFT$,'NVP_U
M=Y+O_G@G?W_^4;]\_D*]/'C-KH8!=M_^3SWGU^KW@]=_[OSS?_9WGF_IW?;[
M2Q[L_)$_[K[]^/GEV_?'OS__I9P5%+]\PXYWGJ<_]]"9Z*U5$$+@K:@X0&!1
M0XFYQ=1#R-QUJ^/T T5'B7FZSSP9/4\VEQ*B547%H&W,VK-BF&*.SSH+<G_*
M/-P3\W2#>3[OE8(*.=? 6&MVGXN F)D R55)+$>=D&]L:M%7G%B'6*=;K(/!
M26YS+AJCLDHY52DG&BM\X!$YF[&..V,=1ZSSN*SSY2OKF"2\%4I"8IA !2X@
MQ&A!HTHM7Y#[HEJ_O+Z1U_,=.L0Z3][-<C.&+PRR[DU'O3%6U*;!/K8Y'3/C
MLSW;'J?FCSF:8.X-AC<Z8WY<Q!O3%8_&"GY&)YPG)[NN^$'H+B[RYWA8%_9@
MUD>U%X:Y%PY:QMR7DR?PSS:<'5=\!/5J],&]*(FM8=ZZ( ?:HN?8HG?>7'))
M\#UEC!:H2UTLPH$R,H%G3D,QG/NZ;K/T:6/3NF45SW3(/'CB0%V"/4] ?0B@
M?MZSJ"4KH@ :(:&Q*OBD#.C@M*^X-47D"E(N"*1K!M(EF+\$TOL$Z;G!B\G&
MNHD6$"$74+KXNI/F!"(J55S5AES4&YN:+]PA_FF8O-VV#&9%-1!#LVM;%GXU
M!!8W"KHS'J.#1L%\/4A_:I)Y=D$PQ&OS\-K@BI50')-9Z@R86S?D8BU$KC0X
M7U(1 D,IE=ML7PC3H?D73W.T30?M!,+NHV#W\Y[TWC##JDX2F0%5,0LQV:J8
M1!>$*A%U"AN;HN]ME^;6$&X[:3H0.)<!SG.#0:/DA44'1AH+"CF"#SZ!YUYD
M7;07;92?Y]<[?74-FA1*^$O@/OL0AN^QQ<!*&(Q[G\+^$;8BMS%FQ(-9H5A%
M[^PTV^-JGQ<<UQ?KR55+H_<YC,=A..WM#T(<[ ^FQQ1UN$\#X[86-3]7V?V[
MB>X\_+E;?CN1#>4*S,6$QU=,C+H]61EU!%V2 I6% V>9@L""SE%70D2S[+XS
MY.?L"GX?TL@@$-\#B*NMD9,QJ0H(LT!0D@GPV2C(03O&5%8*6;4U>)_=D/!#
M^%UM_"[!V"#\/@9^S\T142)OW5- L5 W8"8BA"@-**YC0%>\:<,B.>][MK"3
MCT(8CX_NBU&_9HE4D^-@<'0PZ?U72&F,9T_7^Y/:B,')_^Z-6F>A3WB:]M=O
MZ7T4Y[BWZJS+I+=U)I.+8MLMS\^DLS7,KTX%N'TN(V+#.=CP;'K0A:B'E\JK
M##'% ,I[#R&5! IUD28R5#QL;$JV\ @A\IUVK>Q@Z<E1A-^'Q._G/11!<=XB
M'YQG4#H6""8DL-(&S[+EN65C2'8]K_'NM0<$VXYMOTNV0F[S A*6'P++YY9)
MRB+$2K8@C=6@LJI8CL: CUEBC,4RCTMS#5*PY/$A?]4TR1BG7PV162'&[)G!
M9'(4AJE%3B;3VYNZ/$V/S-+K,"Z3W<\GO62'[Y^U>U\9[RO[$<_-PW-7ZS%B
M"<Z$P,#[QG512JB:: &T(GGT59C);6R:[GM@R(/ZR.48A-?[Q>OG/6XB#]P:
M8!$1E"H(%;L<6&OJGR(6S]3&IB*LKAM6EYY:15B]'ZR>VQ N6%>28B"#K%C-
M68%720*ZEFK5MM76*MXL:VSMVI@/ZQ#9F-UK&!4XFF O3"84MKCWFNVS/@__
MPC#!7]I9[99?)[C5;OY%\;PX*9<A7INGS<K7J=R5V_YX+7=>[P6/O$2OP5NO
M0$E>(&;'0;)29:DR<ZQ2@&$+%XB2R[-CT%U^%3=!]X&@N[4G18ZFE71+(Q(H
M&U,%L$.(LN@@O*WP+1N;VA%L5P*VIQ[HKLF&',Y_W3%Y-(19HZK!Z;@[:N[S
M,(KBJS#(V\/_.QCFK@T:7)']Y,5555"EZ(HN=1,)48!RW%15L"BPPF,NO-0?
MK>1/+5Q51%ZICH%SZ:H@@7-YX-S:2ZB$$X)#LK* BLZ $\Q"M<_JNHF:8XC5
M1K/4Q&?=@/F0R?&$V<4Q>_P5L]E9%X(W8$M6=3.5$6+%*:#W.?G*I8+IC4W>
MU_IZY^RNH98<QW^)Z=;QN3=KXM,<($>#R8>6N766@4).X\>?1/+/,!A.FIAP
MLCM\<4E,N^5Y%1*QW5QLMWW-DYPR5K5$@D@V@>)&0C3* *;H4]W%=."E,1[G
M"W<$):=4QQ"]Y"+<V])G"<-+Q_#Q.89W7^_E&)A0QD/6#D%9K2$$K8"A3#(P
MI;F)JY,O2RCN9!(\H7C9*-YY<PG%)MO(?(C@O9:@%!,0HXM0.*: *@>;Q.J@
MF((0=[8^V@T83<+^25%N&YDQ/9XEO>-_C@:'#6 4E7B@JMM&<DTLN\,WE<IV
MRZM3<;S:#\/IBS-Q$-/-Q72OKX4LK&+:EP ZI*JO&.'!J?JHKE2/O*JDIMD<
MFARCZP;<!S0X",7WYSG8VDN&&5&E![FY2)4T!5QP# )W1810N&;4O&MM8;S,
M&7V$W(?T%VSM28:%%Z\AZU*1RW@ 5_4IB"GIRL4L"\TW-KGN_OP?BF_,T82T
MVA6?!I.&Z[J!]O+H*$[+T7XOI),ZDS;/#P>?6EO2IQ#U>*P![->FCI[(Y.?1
M^/FI1+82%?Y\!\7]>BVLH9TS6BN0H97JE9@@Z))!6Y:B"\FY-GE=7C<QJ!M(
MMZ#ZJ/E0!-!E ?3E1>N!A<B],!&2*@*4D@PJ'CGH*A*OE5!:YXU-(3OOY"2$
M/N)T;\+J_6'UW%Y06O+ ;-U(A3*@A*Y8E5%!L@Q%$V-I40E^ U@[M)-2,.(O
M4?SJDH& ?R:<3&9!B%&<C/9QBK-6H,/I:#Q :KUSSU42VZ>W^OBW\6"*ST>?
M:>K*?!3V[JH](#&+D%J?X\PU*"X41.TR""[1::Y0-'N K\"P1G)6/K)50.!<
M7CQPJP+31&44@^"05_VB5;(KIRLZJR'0\A]0^@;,[C?J(& ^<E,= N;BP#Q7
M_ L65Y@L@"+4'5,D"Z&-ZQ$<;49FK8QV&48ZQ0D>'[4G<8))"Q3,VN6<:/YG
ML\>^I? OPQ="G]&1I?L-* K]@^WDTMU:4@1KQ?;9!XY@7=UHT[@UBWF.)[^W
MAV=2^.6K$&CKG6OK?7_18%758+79&J&CF8D$%$L2G%(&$B\67>:\N+2QJ>1U
M@_7N?C=2B;L&U8<<BT<HOD^W4U6@G>#&60=!\@@JV 2^ZM00196LB%8$V:)<
M_9M:<Q"&5Q?#]V#7$E"7#]1S2S=99UD*$6+)I5JZQH,7%:TF\JR02UZ*K%OM
M#7V=.P33[EBYG345MA<,8*UQ7'[)X[3GU#LN"(9X;"X>^WC5;&!&!M0N@99&
M5"X+#%S2&7+=>I+/SGFKF]+!S2)*!R76= W CVLX$("_%\#IDL4@3/W'$) U
M\.94(&JC0#IN#7,6?>95$>D;OX@J0N#M&G@?LE\8@7>IX#VW(JPN&$.4D&V5
MD]*J@$]:@C.IJ,)M5:A\VWFUN=XZK$/@I9##'5+E\# ,\EG+X-,TN>D''/?2
MT7C<.HB=1-&>0B"B$Y4TUTGM5$;/L6"52#[M7;\US+M-3K/>]L1V<['='UM7
M;0T5&8_")%!JIJZ8EL33&I9H5-S8I+6HQ" TZWR* /DX5\K<('#?9_QQ:\\(
M%G-SB.HR [9OL[1C@21#5DE:;L.L"ZJR%+E8)U0_KAU"J+X/5)\;*,;)E$UP
MP*7WH#ARJ%*NNW=ATMJHDC-JUNE37,^U[1"J*=#QEYB? 681&V3%?"T=M4%F
M8M@9#4^-0F*P[S Z7EPU.KA5W",S;5YV!L6BAE!L!)DPM[YA%D/+JN +&QWD
M)NT8=)=@<Q!T'R<VV<I\&ND:!4;I "H% 2$4!T)@P.00@XP;FWKQGG\$VS6T
M*@BN#P+7<UN!:Z9]B %\%5FU%:KQ[XIDD*HPA2U>:DP;FZ;3[7,HDG'WXHG#
M</Q4*B>Z63CQZD0 Q%ES60?;5ZV#8NM2]"&!9I6M%+<.G-4>F PR\QR89KZJ
M&9Y:"Z\;5N^AS)^P>D_APZT]EI0W#:=5F5"@?,MT8D%"Q""41JER"E6_X-V?
MLD8X[4P+,$+LTA%[H0]8]CI&$T$)57^@%!6QED-,PFGGI+"V6@227>\;3+&#
M%3,)QD=XM^+_-7)H=,XJ:$+XU[D,B+KFHJZ75PT#SR.7425 G@VH@AQ<P0 F
MRFH22.]ULAN;_(8:+_(_KC9<'[VDFI"\I #@UEYR K4Q&I(NH9H-U7;P$@N(
MR'BV%AV3K5*S[XTB'*\9CA\W.8EPO#B.SXT)S,Q4N2FP"NMN'%HWSJP+!.\4
MRS)S'JK6K?ML!7J 4YCACOE(BUH4*^83Z99%,1/![B&.0QO<2C3VO33V^EH1
MA*L*I589)'<%5-VEP#-G(%4B2RQE5C>LC4VQL%U!CLRN.3(?/!^)X+O,@.'6
MGI2\6@W!@&58K0DTL5H3W@(O 554LBJ:86/3FDZ[- FVC]YUF,!Z;V"]8#(D
MBU('"X$9!\H6 4&;!"B<JWLPQ\@K6!7K_D9+08B_Q/,O>!B.VZ3/-A)]4-$[
MQLFT-RNZ'@Q['P?#_!1B$EUKX#09['_\\:MH=LNK*H_MX?^MTM@^%1$1W'<:
M$SM?DMIYOY<\+ZPJE5!BJB276(#(L@7OI A%^^!8FUK8=[S3XY;(M=FIL>B$
MV^7C]O@2;BW3F?/4>JVUWB]12@A!9C F5?O?)X5%+6T<.L&W8_!=<F2"X'OO
M\-VYO.T&[X)J#0YT<AD4UQ:<\ R2LC:Q:*U6>G7@VYV A'(=G7>R@]->JA#K
M'4UP9E*,SJSU7A/JIX6#%'$TSCB&Z>CPQW8S)J/]:KJTBUD9_GNL$>EWCM%6
M&3ZK(IS-K<R8?SK^M<IR>_C5[[+U59!$C]^9.[7S=OMXS];-S&87(7CM6D=9
M!RY6ALP)*^]%RPIKCA?19V8)?2/N!IP5<J$^+2989DR$F* [3-#Z6PJ1C;86
M4G"AVC@Y0C2L.6"-+SD$RYS<V!2^;V[HO4 \\+1X8)E%'L0#'>"!\T",J-:+
M$Q(!/5I0JNBJ&50>R$8ZSX1TP9K6@*5O_"*-;A^1!SH1H'E,H\G>/"2R&4QE
M?_1YTBOCT<%L'OSDKC93]V8KKM-G=,+D[YZ9_^IHG#Z$";8HXN&XV?C3XUFS
M9OS/T>"P>=.>0B+BHXZ*?'7BM9R\'6VE>M/'^.I4#J_VPW"Z-<POSD1!>_)<
M>W*ZF(BH7W[>8TY%&X2#Z$/5SWDQX(,.55U/(OEL#)=I8].I17JV4#93UP"[
M]+8'!-A[ NRO%XWI@#:5:C)#$ E!N30;/I<@>145M[$(SS<VM5R"!DU@[0Q8
M'[*$B7!\?SB^T%-9:6,3,U"T4Z"200BZ@EE&7K!$*P.?C5L3EH9'=MGBO6W0
MRZB>:3ZU=R<5)$NV)-8W)V+)^8A7<R*^LMRIA'ZN GI3Y;-;B.:60W/OK]H7
M*0GF="Q0U1-_,I#>1U$@.^L*SUXP7*$D"<IQZE2*(N'YOO%\:31]"%K+6!S(
MHCDH% Z\" &BCAP3MR:62%A>5RPOO02*4'N/J+W8-<$+5ZJ)H1*7H***$*6L
MT,V8C0W2<LXV-KO?P8BB%=^,5DQ.BIY:<&UFP5.,XO%FU5_SHFR?RX6H;"XJ
M^W@M8,&-U4D74+*UE92E0+2\<IH04? DN I\8]/ZOK^AJ+-#SA-R@W9X>"0!
M^#XBCEM['*55PEC0U52H%H3+$"/S( 7++#*3.+8&SKZO!,V([#IXNU/K1+"]
M#]B>FQ#.ERHMS\&&I$ Y&=K(9@<V*X=59^(ZX](,?PI;="%L4;%V-!Y,CY=A
M5:RO3^1!C8H+[I*7)](9X&0V_O:$];:&^5G8WY_LEEDK&>*^[^2^+UM7;0XG
M1%)>F5;$X$!E@S/O"1@143LOLN:^VAR\+_7"HR?([]DQC#]"#(/@?<_P/CZ'
M]\[G/2\2]RD%T)Z7"F\GP+'6D3%SM"5ZJP/%*-<6WP]EFQ"^'PS?.V\NX3N$
M6"R+U7S)H>4@1 ;N9!Q-EC)8&0HOJX/O3L1!5JQ1PUQ%1U26V>%&#=MGDJ2R
MS(53M';>;HL]Y;A63%6S!GWS[=A8R5%'T%IZU#$+7LS&IN]+OTCS.*K/7@<B
MZ%*?!B*")>9JMM(2(Y)W"KA1N=E #D(T58Y*JUPU8V%3G$5FO%Y"6)5X8*5Y
MH$M]&H@'EL #YZ$>+J4TP6;0.52=@',-01F$PEGVWC%DNIR4IJQHNY8G'_VY
M6YN&,AB&85I>FX9;17U1VH_=.^%)G60G_ C=\QU<#H,>'L7]0>J-2JD?-GP_
MZ?>&.&LO7Z\,QY^;$Z]"I-Z@V<3H?KT5!P>#R:2RX616Z'7VQOK"9#J9]:)_
M"HF9*Q!"W9Y,CBK#X78]M7JYKV:"WCT5%VD0<WE<+\[-_?7SR_=[1LM@A..0
M77,J9,? >\XA986!,93&5&O"LKZ^H?MCU_)%*-FKNZ-S"='WG@*QM6<*\[+X
M-NS*QHKF6,"9;*!$[PIRX;1V&YN<^;[4U_O$$)P[".?'LO8)O0^<X;"U%YUA
MF)V$R%N')Z4+>!4]2*6Y"CZF8EL'5KD$]SY9[8]JK.R/AN]ABN.#BKXXG9DJ
ME*_9*6-CM_RKRNAM%='S*B%BM;E8[?55*\/798K,9N!<FLIL+E9FLP%$X0%C
M8-:WN5?*]?7B\_TH;:MC4'Z$M$Q"\1)0_.*B9>&K%FD8SR"\2J#B+.H8'!2O
MN"Z.11?DZF1F$80?-?.2=N,'QO&YC5$A;)7CMNZ_2K2\2@%U<]804>8LJD ]
M4QN;7/?K@NL\C"DP<@=;8W"*H18+:4&/43N)4?I(T8V.&1S/9L)YTV1###<7
MP_UZU=XHB<=4DH-8JI6A6! 04V4YR4M6K4A$)+.QJ?N<@AIK!^3'#FH0D+\?
MR-N73(Z< \=H &4;3!>UA*"K\9$XVJ"4E#JV033]*EL"\9J!^%Y;V!%2EX+4
M<Z-""G0YLP@B*H0*S03!E S&NQ S3U@?;&R:&_*1NX93BE[<P:+ /W&<!B=C
M=\:8$0]"W,<&X-F)ML>'8RPXKB^>V!J]SV$\#M25XBK-,6%C8C$79Z4REL7
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M<_!+B&>\^ON@B64$(VC5"V*4PS\6P7R; V.9/[#PQ7/POC^A>FT7];4;<&'
MA9Z4L/'Z=%;C,^'Y H]M-FYW>\4ZT9T J;'XZ.$-GSL,]RK/O:# %3<]LL.P
M?N]W@# 9U"<N:'+F)^,&-WF5E #'Y1,&+,P$O@]^O/.MC(OCA+=#B210W,'9
ME!J=;Q?N]>&#8W2K B$&"ECUZC^>O5=+HK\]X1T$PJM__#K7NL&[P&;C91'D
ME$&0''4YUH.U5HTCB7K!L&&Q,9'5*J4TXKE5DF8FYVEB.8_26.E0P,5# 5?$
MXZAOX;S:?WD+$P?-FE!XL#]#O0N_N$7Y'HQ7DT.,O/EU/U[[YG3O\][%D2V*
MB!J=$)%Q3;CF*1'": +>J$QD'">QS<$*1M-FM7GCC[L)F<P).Q '^#>0KF@$
MB27Q"Y3FC8LK3>2_3>5.;X&B(D496&:BX(SS#,SFR,T&D2Q+3"Y%A*;R&D):
M2RU_XX*ZYSU>RL D$K59I' JLLT,)9SFG$A+-6&)4EEJXL(P_N0IBW96446K
M&X9.KD_,U(=HC7:DXHR6SR/4ZZ ";N,A?:,@N96KU*,,S$6"#>Z-HC=@SH,^
MT@=;0>+(Y?67O>.C7,54<IV2.$-'2?"(Y' X1*98G11'0DJ*%1/%D()J6>TI
M89T#')8+^8-\<.GV"W1'X1<]JI6W,EP0!N0,:"1GH6P\/3F4US!E)=!3 _?Z
MKO>*SYLWQ-!-]WZ/F+#>7>Q?'/%"(34IDG!POKG0!<D-5<3R).9%#-(_5T^>
MYD.^3D,AO:!K/:G- R"6Q:D\"P3C\($?,TE$>[M'5F8%BX0@*L&(N>2<%%P"
M762QCC3(H5C$H)J&/%\7*G^'+8#.11J7-8J7X$^!K3)T7DAGUMS47ST!UZ:<
M3<'EF6@_Y254NV*E6]F[X9)#V#.S_Z>>N\<<.-$,W$U,52_=Z;9.98.2I%UR
M6<S U1#3D%:?]%"4P-J7Z(*AZ>9\;S,VRF>LT-5M+JN#3]KE_2NCQ@*DEPLJ
MA%Y-YQB*4?"..__5^Y*W VL:C!NL/Q<#T]J50[I2PI$FL CE!TK?.!_Z0QRM
MV3$XOBL\+2R8'!OG\ ]J ]NA176Y9#S#!M[.!0.KF&'EC\IYQH4L<EO$:10Q
M:QG+5,J#\,H;X97/!YFW+M@=5&N]N$#+261H6'.24YS,G22"Y R$F^8VT5DN
M0-2Q)T_YD'V%"^9<=7GI8GP"2RC,>(S4XSX]@0]-%:(ZTQY'(Q_;&4C!P*6M
M(097_T^(#,V)I-M28F92D4196L3PNB9G-I>9CA@M\@RT^I82[Y\27WW9?WV4
MT$*Q5%LPL)0E7&M!I,X5D&-N,YLFN2SDDZ=IO,[0Z@3Q%23IT@O7T.-WCQ8H
M$'4V4FDD"\.EYB*.(VIL(K(H406U(5JPBM*VT8)K2&<OVGM]A .OD@@\/YHG
M(,2,DJ2(\P1T)J5*%DDBE7[R-"YVDJNB!3MS)0QZI%T O/+^]@#_%B12&TQH
MDU4N]1H^O8[ZW#4K*&\#XL=KS84]<;FB'*AG*TPZ,3T%4_3;[07%E6&)T058
M#%3;0E$L1+%ISJ)$"AZJN9-0S1TE6RE]YRGI]]'!X2NV_^5UM'_ZRD5=K**)
M88*8+%/@"4E+1)1)<(PT'(I,4IM'&+[-HWQ(D^5!HU>PRA#_Z(LY;T<X44H+
M$4M*:9;S.$.=KC-J*8T+T"N<;0GG1Q/._O&1+2BWG M"BP0(1\0,7&BK2!$I
M:<$0X[S(GSREPX+%0S#4UA*.<RB=D DI/">'P>+L2ZG&OJS Q1MA > M*2H'
M.F;<&F&2G$O*12Y5EE"K9(1FI-A2U ^F* S*T$)F,LE!%.DX(IR)B C*,I+F
ML1"&ZRBC!MV8/$^ HO+;4]1]VXQ61"P'6LJ% *DE6)ZE,9C$G,D\R>&OOAAK
M);%M;<9;40]FFW)K$A,7B*VCP0DN.)%"Q<28-*&QM()C5S/8CU=FFQ8#/O]:
MZ#!ZC%VX-$K7-ZEN^TVW_::;X."L;@6\OK6O[RX&-S%4:'^G=',1*RWC+,DB
MR=VS8:>S2.NXD#1.Z366QS;=?.>ZXV#W*(UYQB.9$U =E/!<69+;'!M?4R6
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MZ,52$+8([@G;I3OHG*_KMORA:F4UJ.&;EH17?_Z(M<WQD8BD8(F2),:!A5R
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M6W.89^"1*K&$?G1F<"L\BF;W +\K<+8G\X_Q^[70LX@-C:$<OP7WE&9BK&O
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M;![G_V]'G]'.=548SBPMYUVQ>>/?'9[K*@LNM;LN/*XR_H?ZI*S0D_B[?\W
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M_;>C\<?!FU+HP9X'^QYB<<_.JBC XO9?MRLWH[=HL+F[]K_OZ)7[K^IFT&W
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MTC)G*#AB)$M$:HH^/ N:@("$*BYI2G)ES:PZ[:H6+YL66VF3!^JXCTX"_NX
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M1^_=2F*S5T1!M$D@*FN6%] "+^FV>U,GA931IWA?UWV)XX;,(]]G.DG*O$0
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M* O)26Z4 W3XA5V5XMX>?]T^6!YUKK[]HROR1=_>N:1X(L$RA0Z!X,0%XPD
MS9YK%JE3*VORWF7@JQ(OG%O_V%I<W?I[:/&L6X\^?<C!*2)"<.@9R(@*K#S1
MQJ>@'!6*P\K:926^N5M?]7=YC'!UZQ]9>6?=>AN589)KPL%S(C,/!%@ 0J-P
M*;I O1]SZ?OOGBW0'GX]KU3/*XV C#/J6#()E)5 DT==0(=2IYAQ'HRLP8$%
M![29NAOO3G<C@X12 21G78(#N30(<(88QERIKDN;Y$(F]2HW<^XO58]D5HA;
M*HBK 9-'![?3&7!+TIO$1"(:Z1B1X!6!!(+@NI;>4,"4-_,(F%1<J[CV!&)(
MCPQL-89T#V!C,\!FP6=I@!,%3!#I*"/.V%BV=*BF5IC,BQMZ_]20"FD5TI:1
MJM6PVB/CF9C!,ZJ" BLI<=PY(@52-O#>$"<9%<$R$%2,O%#!+B>\+2);&T?<
MSD8QEG UZG<QQSK7%]OKW:'D<?W".WSA,IR*NKK,],L.# ;MW$ZQ!8/GUV9'
MS2/)L]YC<>YQI4 SNPRY?R]AL-=*_SUJ?T4+/=UJ:XX[G/?>U5R0N;HYT[SJ
MP9XXG[360;1,1">L5$9"2DFR;!-7-,=(*Y]<3#ZYL?UB>+ZSL1_8QO$NX\:)
M#(HX*@V1-E%BA6 D<I.,%A2\RRMKVLZC'MO/WJC]+@HO(*^X6@\_[/7Z0S),
M_8/I;G,_E5_\HH=(-/Z7DU26^B2-Y$X80QTU0GGIE:F'2!86QEY=A+$8)##.
MH>Q@V-*_W1 ?E"1"@7/)4AZX65DS=I4RO>CG2&Y#)N]$;^])T>;1MWZIJ-U<
M)N2)8VD-,3Y5+'T[@Z6;Q[LB,.F<4P2YO";2*4&@M)AQ5'B1J'&<N;D%&>>H
M0O<"X=^:/KEK-VC$.[I[NQN1ECUG]KQG\=J_?/^WM=K0]_)[M:%O;>A;&_K>
MM*$O<[6A[R(O5VWH6QOZUH:^M:%O;>C[4(]=&_K6AKXUE6L<9XG <DHB9NYD
MM-Q2S@2S$@R+WG)?XBS,U8-%MX^W_/EE:_W/]L;^.[&Q_DIMKK__LK$=VUMO
M_CK%L>Y_6O]\_&D_G.(UXF*\9>?@G=PX>'NRN1Z.-[:_T,TW[[YM\K?RT_:&
M_/1F$^_[QT$Y%?EI.TXW]#W>I<SH+)4GA@E#) N46-OD=%F1*3"O/5U9$W)5
MZ,LYJHN8S54352NZ/3ZZU;*K"X1VI^=HIY/6(D(BU.=4NEIFXGAP)"86) !X
MS>;7?Z7"786["G?U_-%#PQT[ASM'N8T\&J)I!B*%I<0S08EP,;N$F,=I;>);
MX:["W<_T79<\1^#!8$U,8 V"HRX!";DDC#J)L"80X SW+B3)18S^2?FLRUO+
MMS;P_3X>*5#*:Z58+@F?)GCM=70Z,,L"S3K56-IBX])4 ]_C7<0>7"K'B8L6
MZ59D?I2UE",WQHFD64+OTJTZ=N]"XK5NX')J<HT;+9!F3^)&+(,32@9B2T:W
MC%03GX 1KP2UH'2"/#]'JNIVU>T:)/G)NCT)DA@OA:")$:>M)M)D2YSQH;3P
MY<&Q&,0<@R15MY=3MVM$X!%T>!(1T,!Y=CP193C:Y[*5;97F1"/GSB:PJ#U;
M/.:]O-E#M5WO#9"' XW@HRC5#27WT9FL*#4.@O$:P%;??\$1Z,.4[\^35\H%
M2K3GC$C(0+RFBBBKE:5"Q1SBRAJCJ\S67KU5E:OSO^BJ/7'^N1<! %U^30NY
M\$D3B(&3%)A&XF&TCJ'VZ7U:NGV;8JQW5^[JYS^Z&D_\?)% )T<S40S*KJ&.
M!%RBA,6H@I;9,HX^@JP]>A===Q>;8E?G?CZ*.W'N4TA6>0O$).^(Y-:C<Q\5
M$0!1X3IZZ?V(6IN%+ZRR%)OZM4'OC?&',YH<&!>SD9JAQ'J0VCNO@XM6T.KB
M+S@.M:=<?*M"5-QPDB7P44]/D.@',&E,$,Y8:RP2"+DJU2(U%*O[!(^LRM69
M?W0EGCCS G*F!ABQ#GF$3*'L%&1!9 [9(B\$)6%E;9%V":K^SLF-?V0%KF[\
M/11XXL:7OKO<,$:T$[JDXF0"V0 IU7^=333RS.[73Z7J[O+8WNK&/[+B3MSX
M3*6FW /1P2@BE9/$!A#$,:\\TT;00,?T^=YN?-VDOX$"OA@,TI"4!TCQOC[\
M$L<0H^;4^,1%<&AC1+0Z!&D9,,9=XDY7'W[!06BZW(5$@F#!9!(D2T3R:(D5
M-A%/J4DB:9D2^O!JE=EY]2ZJNP%+ILEUEWZ!-'OBV"=13@7*0+0HY=>U4L1F
M, 0HZ* " Q]<W:6ONEU3])^*;D^EZ(.DRKM A R>2*$,L=1H8JP17ACFLI][
M'8.JVTNFV]7]?P0=GKC_8)U4U"F2I<U$4AX)",E) I^#=:'D92P>\[[O)OX=
M&YO\$H5';O?(3QS#M,H";):0G9(\>YL%2]%(38W(3-:BF0N.95O3!_V3!^ A
M(Q]Q4(X,"D8L1]<C6Z&31J_#T5PRDN0J=?>N0'(K-7GDC8H*;Q7>;@EO-8CR
MZ, VG1V1M#,Y$:%B(C((0:SPG"@;)64QV9S,_+(C*J152%O@A)''QK0:/+H'
MIDT%CY300JE(K')(UA@S2-:\)@*8Q27VP)U?63/W3QBI<%;A;!D96@VB/3*6
M31V%$=JXY$79U:)$*D.)31((S5*"\9P[Y<X<SWGU2G^0TI=GHQA+MQKUIIQC
M3ZJ+_3SOT)ZH?N$=OG 9TJ>N;@GUL@.#03NW4VS!X/E-FH?=>=^GWF-Q[G'O
M?NF+(-'75.V!P5XK_?>H_16M<W=XHX9X\^:?2\LREXE+*E#:!6, 1) T1N>=
M$TQDJJ/Q4=2::0O*)3>01YZG0[[851 4BQ&(2%F7C&Q#0#).J(I@5%1@"YN<
M3QWUGYV1_5T$7D!.<;4.?MCK]8=DF/H'K7;W:QH,#^Z,PS6GY/ONL Y&2\<A
M,29=% #<2"=Y5#27BA$5PA85PMY.0QCE,0@9*5$RRY(9)@FN*>(80#:9LTA]
MR>=FJXK:14\K60X2^>]>]_-\$*P>BOLN@@6NA A>0V9.>DB>NVR=0&HFC!(5
MP187P3:F$<PZSE4TC# 72G4Y38FSWB,=L\D;GX749F6-V57.+]>F>L(D[&<X
M]S^Z;AR\&CW)I?C5K[3U,<\)>>(X6C=&GBJ.OIMA@HXY(P0GB1I'9 1%O!>>
M:.:#"I 02OW<MD;FJ#[W N#?AD6J\-_8_KIV]E";1P>H-&'M7\V+#Z)SO.A<
MZWSZSD=3%*W=/8)FCLMX+NSS&(YW/NP-VN4#S_NI@Y_\FGX_;L?AWIDF3UTU
MGF@ZN00\3NO1\/I+IB8U(!--_8>"H69*6*DW/S,I4S_WSG>]#N%S(KZ?X N!
MC&-\#IUC.!FL_#;S* ?M[MG=7?GZZQ[Y /J?\:/CR7*-A1R-P??QCC/CN<%E
M5\Q4SK>8*7Z#F1K)/J)G*1I?UA5U+?7+IW 0\,@C:.WUBZ'XGS;70%/DRD9(
M,B4%+D5O07BG16(^[R)1VRX*V>KEULMB8QK7!]:NDH$+VC'">^HSI]RAW>%,
MFJ0\L\#PNWRBI6JI&9DNO";%%\7P^ 0&* _"2".! ^A,0=K 7.:E,O&Y(1QC
MPJSE<U$$%D-D(G()VMKL54K,*L-3%-SOKN-@*&64D?++R 3.6K;7T.[_#9VC
M],?)']"!;D@?]E(:OD&T/$2$V\;O^J/3"U^>ICWKI/_W_N33QWCHN=0['W?X
MQOZ?!YOK&Q2O1[NVU]Y8_ZPVUC=.-[?CE\WM5\=X'[1-?^2M[<^GNT*A00+%
M":6Q%+S :82$?V;%E,O.9RIAI970Y!\6H.H?I>_I<9'B!\6N[;V$#*?3Z1WC
M0K8:0],:'!W@J/ F@]:PO(VKW_I:EK](?'GE9>\ !WC2',4SOP]:X<*6TFIK
M, EQ0C>V.E>%"UIALK?J3UI(L@I!.FG!H'S/>@KIP*?^R&8+MMHJTMG<K3"U
MUC_:71Q+[P@?/@[^^?Q6@#=^S)F];ISF#AP.TO.S7WZ/[<%A!TZ>M[O-M#47
M7;36:/;'".WL,Z5, >FQOS2^_1B_GS7X?8%RC-[3_!E3_-JWZ3-V[7O?NRW3
MSYRT=[KM]]]#&?\I@[WA;7^0:_!#S]-=^N@5KMZ(1?Q,%\?=*/W@3 M:J  S
MO/6^LW!EKL?W">PBSD_!A)N$'7_XC,L_45,D=5E2=JZI>'2 PT;S,C(H:-6.
MV\,]M!:];FJ=)+C4G?B&_M\O&#%:\IB0YXPZEDP"9262?B^YYC[K%#/.@Y$E
M)G1&B&\9$QJT.U^>ETR;%]U8_GDU(4?G9'J]/0B=WN"HGS;&DOJQ$=2M;MI!
M,5V.,-'^SK?-_<\*OX]OE)#.^ON]C7W\#OSNC3<[QSO[GPZVUG=.-@YVOET,
M$VWNO^);ZU_PV7;P_ITOFV]>G6S@\^!S'G_:_Z.]>; C1^-YG3<F)9Q/-D\#
MW34479O@./'922*3I,26@K#>:^^4$8[E$G"7>E6P>1U%7XRC ?.)GE>T6S:T
M^XD1\(IVCX9VQ[O9 "3F*%&6.B(M5P2R<@A\I7"."L9XO;)FU:HU3P/HEK>E
MQB5FVL2!SXEI:[B'S_5YKS4\[C4OU$X;/X6Q7:S_=3?X>E'6;HQ>VZ.%VS[N
ME;^69(?OH<#LY )UBXX)IS(08;A%ZD8]L3X+$F@ SH,2$%-MU;VT.KYP/*4J
M^MP5_7C7JZR%,)XH!\A:V*C8'_X)5&NC650N/I6$J)K+5'.9GAX+^FXNTXU!
MLB+@+1!P\^4%JL.4I-F");34&9/64.*"M43(K(0&Y3FU/RE*]2CI3!4U*VHN
M(:^LJ/E J'F\2S./Z!(JHDSIYP9*(&(B;'J=&$2F(V?YUTL _6$RT:VR A\\
M">D\<YJ@JI$!:L9,GM!>ZL3O9P7M 7Z@-?J.4JD!IQ0^IU:$DT%KV)ND%N$=
MOI<J=QMB-04*^-CA>3SJX]==1(0+5< N9(AOI_[!TP2 .^?,;>"_6]MXK^V=
MDZWUSZ=;[W9%EL'PC%HG1"0RH1?HM$82E'A.DOD43'$%A;HH^<WZ/KN0D/QS
M,R$_A+T4CSII*\]6<-OJOIT(;),=^@LG1=)=97-6C J"JX=+ZH,DGFI'&.(U
M+D"B,8DGEA1YV$^#!HVF$B#_=X!0\UWH&N[!$'&I7UYM0>$G9U+30B8P:)VE
MN#_1I$<D8<_HB(C=-NM1T&=.W2T%\;N)A.J9I/IG9#W*.M@G-MB;);_.+Y]T
MEB<^O1S!Z633U@TS*W_=Z;E=/N7MY^EIYIG^.PT:J]=M,=XZP(_OW:0L0)V=
M6PG1(D2FKG[ IMOHS>KD/>5U+"&=5A/3J<GG-YBNB:_4*L[2/ !A26:F"M+<
M!&EY#S2\[/4/RX'5U/(]]/M^Z_:&EQLXU[S>7S2OEP:=F!',.NZD-=*%P$%H
M:HUB*G,^A]W@[T<Q7XX.*_>.+G0U^,\XME%(SS9R'L8W&L:S))L?+]@F?N^G
M[<V]3^MQ;V/['?NT_P>.Z6\<YY]?FLV/[;_W-S]NL(N;'QOK.*:#3YT-_OK+
M)G_U;7/][X.--Z]./WU\W=DX>%\V/U2Y;N?T[PO9<3O?=I./7.HD"56.$:EM
M(%ZJ2 "8C$9Y)8,O'?:$OG<#EWJLH<+?XC=PN3O^_4R0FVKX4CY6,>]VF'<Z
M@WG.<Q43D\0X!T2JI(CS&4C(W$L:N':,K:Q=3I"Y>7.7"G45ZA:>Z7&@L52M
MM1EM/??1F5SZZ3H(QFL .X<,ELKT%H'I'>\Z 9%YY8@.R9:BW9%8GQSAI4,?
ME89EQ4N:RRKC\ZIX6[&O8M\"T[R[@U^E>0L+>).>I"I(X%)R$JCB1/*4B=7:
MDTC!*V6MH2FMK%T^"K)@%&]YSZ[^]>S#L];G'@ZD6U);6H-S':J'5"]D$0I
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M302**3+0)1IKDPN:UHDAM\6Z[EP[9/>]@R[0YRP=[=Z@R*0*L PY-V$"H=\
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MQD=RJW/Z9@6<T:E[P2#*8],<@):/)$M&4:^YL]-K+"!_I'3.W"0^XW/8@J@
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MR>V%B:*8,\%O'NHU0;9@Z?POX:Q_#LH7#(XIMI4+<L8K 2ODZVOY=)F$?3P
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M3I&S 5Q8).5R9)OLEG3PC#IYNR^J[^A?A:9HE/#ZYF.\U7'T*3J8Z/Y%,9>
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MOVM=68!7S;#;\KBL_\]9JTS6SI]IQK-^[[=>;L]ZE3\%.U9??[BB# 9H/1"
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MQKG\G4!&)H.$-EA92XPQ9?J.A/_4,U>17NSH]2I2]J-$RMY"MA^'AE7ZSM+
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M_D>^QYEZU"?O&BQAJXK1%QBL,"\P6+Y*R6,'].J#I:M*B649[%*) <RL?MB
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MZW1&1_5%K+Q<=8AXOM1J$5D 2$@AAL0C8RY(350@@F">HHQ5AXCW"!#-WZX
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M*F5J5=-Y];.9D^(MRB'%!]SCP2^TP!AR>]HV,$^"#X0%RJW4>9,W1J*%HC&
M_U*E;=\B@DQ0A&&NN5&1H< -SNW='=(15CM8H:)7T2CC<I,<MA!-<IY@T9<N
M/'K<*R\P\#R*6/BG/)@JS;LLP'/MNM"4! 8G!4FLBVP/199IBIB)PD::1!)L
M99W(-3&O X?+Y954 = ;#8"JO/'<JBXV#IP3V7N-R&-M$#>>(*L808)AZKGR
MF%*YLDY7F:&K0LXR?;SG *ARMBIG:Q&<K2I+_=PE'AL'AA@<F7"Y'HUE&@N)
M- D:L> 21'Z*\]S&4*_Q.>>(G@D!B]3U+\,L,E?'=6'86;I;W3-;GN:%/X^'
MV;']PU9W#-BF@,'G4$TUK9HTJ^:G.!B"!(-<USX/>_ZD]@5T<W#SM/&=@R7T
MV48[ R3%:+>[M;KM^Z-:5O[5VO HUK)>V^Y%S<5#&,4A*#9,\V&M?_U>@^*]
M,N8,5FN]?NW3YR_P"XA%[!=W !@QM;_:MKM6*SZK'<8NJ'B[?5'[!G>I]6"Y
M:S]DYZ T^9 [%SBPZ]@88:+F1#(+_W?IP>P<YR"7@]B=&X85/_Z&5X ) 9AM
M]0)94GBZ>0K_1,"86ON=K>^-CQ]:.YN[E_7C;;Z_=W+>I(U6XWC_N+&W*_8W
M/YS\^[)^L;-W2.J7NQS&<5&__'*@DE&$286L4WE#S'ND#6,(>ZJ33Y%CXE;6
M4^^L7\N9P\%T;JG6ZM9L%S2Y78O_R3];7=\OU@&DZG$AP4\)SMVQ02%'$!_,
M6XZV_G/6&EYL=T&CSHKWW &UZ>\=V>[(2F89BV&[6PK9TAO#>4E; XP;M<IJ
M+PG"1'G$&5'(A)B09R39D(QWF?FSVYNM5"J@Z%LQLS4 APQJ&:VR3-8B@%>H
M;48?<Y!68V2U0$0 L#VX)-E6O_;-ML]BK9?*^[0&M2*570.9G$#-_^^_-"7J
MMT'-MWN#_(02*T^S3S.^--AA<9\"6N$)<T_93TFI/XKAK!UWTNWR>FVP"GM5
MF*L2[6#>OH&<[F7+NP=#^KT-G[]S$:Q?U@^"(=Q9#/X531KQX AX6B(A(06G
M+L,.9B4P@7\"_FT&$R<<$\&&&)GBLFC/4O!."4N)!@1:J450\E-8-\"$N+*^
M41N<=< YN+B2.#M:C@Q0]PINED\[@$O;[=[YX-<[T_D_=D=*WVG*URK7_][W
M <<QR\V5[UBZB.#-M.WI(/XZ_N6WT!J<MNW%KZUNX9T47YKV!\&Q_.V\%89'
M.?Q9PV4(-#K,,+K_Z..UXJ,IO[7\3*@U9MB='^,U\I.?2?QSW_S18(E>,XP^
MPV Y?Z;!/FQF[SF&\HCMVY^X]);<A0?K&_O/&=&;-7%?W%#(<YD>++3]QQ'$
M^YF2<8*@-LH0U#YFBUG;S/;S0S;)?V>3?&-B7IIA^P5GXW<+$96/X!-/H3TQ
M3]F=O3-VGPS?Y[!QL9#[$K-S/Y<#[=*0D)+/?=<X>*5&,RHY%<(9FW3)ID+,
MO1L3E['?"W9P]')A1Z/7+?WC-[57T;O8^?H)/MG&]8]; J['^YL;Y_ =MK]W
M"-=^:M4WPS%\3^Q/)^&.M\5^<=_=\^;>"3B)GT[JFQO@*,)GF^ @?MP^;U!X
ML[TV.(I;$P6Q6ZRQ 8%QP-0ZC4@B&'')-;*,4612,DD+!BX\65DO0@;ZVU*D
MXA;I--9M^/03A[<?H:O?!ZU?NZWVR$5_>:V<2I@7UC ;PVP+"U-8*>PC%79\
M-JJQ5Z>@L)%3:[56R$!,@WB$$,\$$Q"A(@@:1:3Y:/<M5!*O04_T@N;OTW3N
MMTA=Q/ <A;S+51#W/ [$G-.8SW3$X5[@*@!J\&:RF"\+3MO3W@0+V#(N(J)<
M.<1-],A2)9&C7"@;I74QMW(VJ_B67A%5Q=RB8.D2E<P]&=SN=KN>B'#S.Y;P
M2!"K7+!YH]PUJ\@6V]D]"-9AP0A'5JB4SRXX9'&"F"DZ+V145&A7-,0A?(%
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MV[[<\,!W-@[ @A%EL4<>>P[17<+()!V1(D(ZKI+3S%0\,<OC%%>J^094<^/
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MGL+Z866]5"OK6LXFTQ=(21?"=5UL!Z-,B;[C6O3%\3.J<M8Y 1FY<7+I>/=
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M0H<'?2J'Q]DP*L1_AX"MAWAHHM@>ST9<[<!9L"!&K8.CZZ_=X_3BNF7)>[^
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MFACJ87N*NZ?K@4#LV([CN#;SB47!+@OB.(RY!PR!"M]R$DD%")( 4_U@!T^
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M&#$;%N- 4M46&< AX17S>EYB])?,T(D' P;E*.!*RAKJ= 2K-LICZ%%7)#G
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MC$X*79"#TECZT+(1+89Q^TF&E<7QL#OLR(6";84W=X<],)('ZMOC;\$HU1%
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M$C[7/I=82*%Q!1GBLM..1*YV[%)5H_'FE.^?_8.Z)4<#]&CL;Y.QW@=)I5:
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M".N9)"R R//1@R06MEC"4+ \2LZLP&+,H[='RVP.9\;=\]@3[[M5#-O#ADD
M=\);CEP4.K=5=,CJ","I2T$IY6B=%H;[@/L.\AS':M;=;E>%95:VX\"+^*F+
M?GYUP?GD/%_!_N_UMS,>2/9-+0I.0>Q,7<[ 8(\@:*:*AQ"YJS?I?0>P[^!\
MK+06%975T1J4:V._A3IOTF;HS/^>-^&Z>1&S#HND#/*91" P( /N!DJ!8VTB
MZ+J^E2:[6]+[^#+?PT%6*54HS/1R5W)RTO9GL&SKGM6QZ3<*F9@3PC&)5$R
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M'X,7&Y'!CU"ZS?'+^#S_D_OM_>,O_P]02P,$%     @ ;(EA4ER@C5K8B@
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M@.CI]VPIBKO0R2G9_HQ'H]0^9=G@/7[S&:?/1J/)8@3$FT]UL2M@J>BHZW!
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M9-)^*>>[Z*=!A<)->=3N(*OL99')K%)!0&&L@$H589 !LC5>(#J68Z/JE<V
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MY7DOZ/6D">0\."V\"S4!W 6;8W&:Y.V0VUP&]WWXX;V;KDJ!KRX 9!+2A)C
M.+(C%5<.0J&#E$NO8_$$$)N,;-^"YZ#$K?J9OX8OP[/SL^>3Z73RUW#\X47X
M%-)P_G50E"'YIPA6T-&G5*23T!$N)"44K70,H=N\U;N><GR;H@^]WLC<ZDV(
M#:(7BX%FF&<O20RO9K/S>OJ]*17QP!FN-:_%>U9Y4,E%"-%Q<,QK+ 8]63^-
M@J!;('W;7.A9Y(VZT5VM]E7M08"S^;LPQ_?SF@GQ%J>)?A ^X$!9R8H1!KQC
M$50N&B)3G%CL:1?FCLO8)&&E.\3'099&*NDQDG&YQ6V&^38,\ZOQ_QZ.\X"1
MPR6+D&!=9#50&\"'5*!$905Z:]QZIZ4[SHO[GO9MJ[^-4'N,470"6&<V#Z*S
MGFD"*$I.1$M,$"01M+9AE(EEH8+H1>OU:4] ZSL+M4%UYDV,R_0#HB%JRQ3M
M-[1J,F0R.!\MD'$>R<9Q1,TFT<H-6(Z5#=1^P]]=M \EV^>&8WMQ1VPME]Q(
M#;9H <J2I>-RE,"0ZZ)0>]K,FD2T-X Y9:O1@Q1\:US'@8)N8$BN8[H8E=<!
M5=OY/YM@G6KTSZ%JNX<'!\C\>(S0@ND4C !I<@:% @E=;34O4S3%UZ*H)LTW
MC\F$>Z?Z'(<(NXBZ[_J_WPG.ZTD8KRY.E"JU)9X 4<O?5. (P0D-WG*O<M")
MN6Z!HYN?>XIA/8>+>M*/G'J,#=V 4OLDIH_X[&(\82D2K9(U0]W7>L.*1M;
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M]_R*5-X[F?LE54F5+-L[2OE8BBQ[5YY0<^F14(<"O %0MLZO/ST 2)$@0"P
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M':E5,*+=:,E^>7D!_0 PTB I\-$FX'?SIV]FK>41\L0SDO"29[(.5)-DZ,H
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MP%K9BOLYC[UQ+D;)ZJ1-'<Y5FQ&KY!!B\H(.8J8*2I?0JF9GSWEYO43UVA/
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M^E?C9M%W7SHX]-Y\_>/Z)88Y_N__\I]02P,$%     @ ;(EA4K= >!%"/
MK3T  !0   !S:6QK+3(P,C Q,C,Q7V<Q+FIP9Z6[!5!<7=,N.H-[<'=W'1R"
M!G>' ,'=W8.[N[N[:W 9W-V"NP0/(<#E??_O_'^=>^M4W:K3LV?6FM6SNF;6
M[N[G67OWO*^^[P!0922D)0# #V$$,@( [QL L7_?_=_(/T;^;VT WP< :'
M->!G2" :  (-"(D&?!\"$ &    L\./EOP4( 04- PL'"?^A)@3^JP;\;VK(
M?_7OZP D2"   A42]6/PY3< @$HJ_J&'@&&R3BZKLD1H70  H$8D-/P_!A$X
M=+&H5N\!$ #T>"BDSS,L=W%97K+<4R>O+]T.IV-2Z(GHB9F;@S%_;$D_+$0?
MBMFG"5OEN#O/9>:)WZR"_L[8'SW:"I68)#,W1?=T!.VY,3VTW5GG6!O 9E/<
M]69Z*:3F^!V<$9N@D@H'F+(;.^)#34Z- -@@H(I#P]F<"R/Z\YNW,V8Z[>4W
M7BDB3/ N%:>W+Q5:Y/03%1VZP#;:Q:,&J%0\<5\N_\95/"A,7/0(/D:3"B</
MR56OP/SFHUTT>_ZP:T47J1)]-%#\$\; ZY^%@$/EJ1._(M0N=?M\<Z$OW+NU
M[[O/4L#*ZW*"?FLC1LYB-L ")1*4"P6/8L+*84J 60> (/4'0"8_,-?=361X
MR9:\2,:Q\_\@J9'YO"!]B:L@W)"ZUWXR6(?L8C-?#<D%P+]_OC4]FDJULE!K
M^Y(F"[I)E"Z6T%6QM&1T\G0]XL;,Q=32"R.M$HW<BQLGYKR(><U>8B4..K8[
M&;7.<)G7C>KP9 E9?63',$YO*%2H_/C"G/##M.?\ FV<3HK:BJ89)][5"N?G
M^EK->H:7JALGEL7'[1/ZAM0R[L\S?[Y_/=#3K+CVBSJ>3ANWZD)A[4Q3N=)'
MG/.@E\*E\^';*?]G ?:0/O^\D4W\T[8ML^7]#>?A9ZO'PC3[N/%<V.B^=PZF
M_G0X4W)MPQE.F_6D.'Q$G*B1DY,134=N2OX_DU4'^-@G.&3A[Q >OVKL$_^/
M?V%#O '^-R'Y\$.Z#Q^# 4)!? CD?X;_=4,@+ 8F-A8.&BL<*2HYNK#2AU/"
M?;@L$!KBSV?'O+H#GQT&?KB %R(/-[Y?%^HWJU7[#9I@H[K8X6]$D3W\6#Y&
M@\#XJ-0KV4?F3J9$T-YTM-YD8#N;XSC/(:%3+*\,BC*8=C\Y_Y"65Y*P!/:C
MZ\B&@R<0,I+!I,F)O:OAXJ-F-0)6K$;)T2+BJN<S-7#I;#_E=)RG'U"4-=(E
M8;"2!VG4_'H,]DM#+%["*B'4(FX1+B_[^_5"1I/BX!I;ZJAA/8Z3#*%F6H/W
MY>OB0ND,,[JML=[DJ.%<==.A=*FNZ:?98;J)"DR8!CC+UN+/08X7'@'_'HX7
MX887Z887Y4K'&M8V@X(2M3_DDX/H*)E<<AXL6Q/7<-]R38%'"<26:,=H.)YO
MHJ@2=$ZZ?_=_=RX3:^?P5F\Y='DMCI!K2\BTV43;/!/L$7LVE@]-<-C]X%\9
MS> 7A8Z9C/WZEEEC;]Q7F?_ 2_B->;!;3]*C"^7&E6C[A.1,KU!PJ./@"CK4
M)/#NDB$50732KKZ1_ OZT 8_I./JU]BA53?J0991#G+E#')(&51M72=3"LUW
M &!<[$^*$ZY=\O_Q@6D%4XH6:V@L2WT8;0Q%L)M)@8Q&"))$1AL4US=&UY"G
MC%SRH,-]FM!G?&.:LNM7U^<:V2W8I<BEW V]%?,D^Q$OJ-!8T.FKY7)6?IHB
MXAIJB?1:V0NL\@^*.^_A'OG]DV#?QS[FYC]=%1;)<)%"7H>J[^CB23Y;$)[)
M]0+C%).% IUBX\6$%<07MUQ8Q@EU<BG!U7*@G'7AYK,"#@\^9 K4JG[RL*\!
M1'90KNTDRU.($:M-]NP.:Z-6^P>U*MH#1R8'?:$;U+\.4(39[9())9\I@HC4
MVF<<3->D:+5N>:UHRN8"(]T>-*>-)@C0X,84V=_H2P!+&58/A(%JISLI"&ZB
M+N-F(K3WV8&S%FO$/PIAU!&J"$LC+>$M2Q/DSYERM$O]LCB_Y 0G.C0]W$GI
M9DN +KDD,RZP@;#&:4:!J=1]RV:_$;Y^C?]J/S_69&M>7X[5J%"LSJ)Z"-+(
M'RO<0YFL#G:KD"MW6= :KTC53M%!URB"VDSC094M!E"M ]#O]/NH;CO\Y45J
M##"4*W\33U3N$*A9C:6,E'4D">A16]F.2U,'?M?O:#+;CI16+=65JP3MR;>4
MVI>HC5@\(,5&*:*O6\NGQO@6<Y=[PGT"9YCO"H%]>>@=UV%+YZX:5*IW! H7
M#J3T6!;VLE86$\[7A1\>:%T0M$[4YN;H!HM4P9+EL4G*1-3%&*5+Z./(62V*
ME^J4:?*VS O#BP\2V>%>@A(]QZ^K;?0"AN__9@;1#S"#^( L"&@8! 3(_TH,
M0"AH-'0 # 89+!LFN8BR(2D%N["H"BH6-B6'DFI 0C+5%W4#(\?$AOZY@OE?
M_Z8,2"!0"/BGDM6SBB%,8\B4D;8G2EET0^/;@;4RTMOIWA2_2UR)4TUF]-WI
MFIB2E_<C2+SWYD_>I]R)'<:8:OEC-1,YZ7#L"A?)-2]$=1X_)+R%29<<FECU
MXUS]X_6YX",9-?4DGGGZ53@^]RAYOF2MM:0O>38T[KI^B?A3B&4SQ&A:(XA.
MV0TH7>+N1-$F9QLM,/QCRRPEMI#$AFQ<FOB*,R-[GZIOA1@8,F]3JW3:0;3&
M#:U.:;9X@>)J$3K#SH:%PQI!QI*^0:H%]-@<A5-='H,>GN.>UNV5OLPVTB:5
M@E=KSH2/QE.,";#KBGOJH[MUP7;#AP>AS#@5)U5_=#VRQI)Y:=AD0KD.LZS:
MXJ(2N?E4[F?T1J^&:D@-G"H2G@L2UI79];\'08_][OIMA<<PT]K1BC?AEIZ5
M CG+ENX7/K5D-)YT;6I>J7!.WZ1:CX4N 4G95S3Z.RO#;$=ZC7.CD/#'1@:>
MK;VHIYG]KF5KC5>39GD0< )SL=[=1FR\@' 9U2RJ) @LSZ+0S@L3Y9G.RAD?
M!5=NUE&]W# /5FFI0A\KIX$HCR&@8*44826LF!!_LWR>C)R;R(C\;9I2/870
MX%KCIVWV_'V/*]#8C$>*P27C<Q.UC1R2) YY^ZK#$DS@EVK4, %&XE%V_Z6H
M.BT9-\L*T5 47PO4B T24BG__% 3*3,X*7-1]-@;-K9M:IH?<NX1^P/7Z%<F
MMIJ'V3=344@0A'9299J@9':_*/O'Z)0(F6I?CH35K2.E:0&M7^\ XDG?:<MA
M2JOMBJ);*:6^TC/*_*_F9<25EPPNG*5\8JF,J>)=ECC+ D+'^ (%LEGXPPFF
MU_OHT:!$PR6O'<5M;(I5=GFQ9MK3>NMX/*11N[*I'A(L$VZ&Z>Q=<]HA>J=/
M\E=&Q45-31J1ULI0&C+8 VS"3(X0W?R39ZK3'39^YGSG/&FF>;$JZCI5SIHV
MVYU&W4/FB\W'+98T;,'%UP^B[E*02",\^J)_O(@86I=.\@^73M<<O/@NKN]3
MBBS!XHRN>,O0E]@/GWRP;W<[HKNJ"HN<,F"6JA@RE];<Q@I_5#66(%!+T:L3
MI9&AD1&%2>UM?V/RK?"]R'F)K=GNLM6M?R1W%SE+LH9+XQ^254K/F8,^)E2?
M-BO/"569.#AMW.!KC:UYD>)G6BRK,$B>2^/0(+PVVUN<=ETLTVBI-28\(LC>
MIVZI(>?B#%61&,&32\A('D/#G$R0FYSN91C0E^AUIE',M O0&%$VY$K]G6XF
M.B3"*"VV;E0I8Q*QL%;*6G(56P ;N3DAB3:AV> TRYAKUJ%6IT%-.=(E:YHE
M%\>J5%6.F/%*44KJZF\2# 8_L(1NXRH8%^0>827>Z Q:*C&)9##1*#O_#:=]
MG;O0*/HA521JSW?70JQ0B%492))F!0+O%PFKH'_.UZHG*U.HMVR1(6J\A=>2
M C14CIO8']9I]2;53W S$A^U]'B] (SK _M<L*K)/\B>**D11<2K]&X<11B;
MWE_;Y&_W3# CD;27\:U\F!3[>CH1VGDMY:7\&)2\07S5*$R/*@4-IJY;H(JA
M/D1XA*3%XV;F1G%W4+?6@E6@5XU2JO::[$JUR6WP?H=E(IBWNTB/G!2G^ (+
M, 21B@_':"!!:JR %&K^XRJ/Y3L&&]B^LN\<7)3@Z7A2O<>0+>GQ#LBE4B6T
MS>LOPZURK> ;9%8C.#?EE\(_;C+IF%A-Q8 SK0QF-QHB,M*+H!H(J8+!\T,6
M>NG%%<@5(F2.6KWI96R)M7IBKKB'J(I(I?0ZM;OS*K6ZQ^O,@(QY1#]:J6EB
M\HNY%KMGM&IXA<+ET]!Y"-]>KG:Y+%=3#E'G[99U@_;]JF@8'_GK=Q=>=8Z
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MEW29O2@/PE"K;,\$205^T9:W.!114<N /X(Y!O3=NISD)^K>,6:!7,O&JVA
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MT3WN@0(93-+L^NAKK-_(R H%R-LX!C&R!B;(@'J(7RT]XJ350F]D24V!A96
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M^[0=HZC+WBI"M>D[8+3W?>W_ 5!+ P04    " !LB6%2\@\29VS%"P 0TPL
M%    '-I;&LM,C R,#$R,S%?9S(N:G!GG+=Y.-O;]S\:$I(><SE2-:5*RS%5
MZ8E9%*VA5$=:,U4</0DQ)$',2JFAQM:8*CJ96NT)$E%4%<=\2@=)A 1I2&)J
MS+W.YW/O_?[Q>Y[[>^[O]7[>S_NUI[77WN^U]E[KY^>?,P!IQW,.YP!"0@"
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M#/ 8Z+"!]26^B%_X@0ZBLG*7#_3X58VQ I8_??9*_OAQPZO)U3:V_NB";FC
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M3_.EAG>>8.Z2\^^S(Q$Q*Q<LF\AY4%(^Z*(U#@8:>,M<.OS;K[;N#QGSJ*C
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ML?^8I^ZTUJI3I7!,N@>F1^1S-G*F_'O]$P]H;9]LLT4FZJWMQ,Y>AR)FL%^
M$%M+TBS !DEH%MM#TB:P>3=-\-2SH]FDJ&+23/*<["@3U/*L_+1KL7S[O8 E
MM1UH@A.JK*W1#BSF6AX;ZQ-T6]!UY+WZVUD*X'^ 8R'YX>V_I3/,IE7(WN;J
M_ZA8AF17;-3 ;MZ3K#+&?D<T+01U__'P^4K">T?YJZ2E]V,?MQ!1CZWF-:_(
MV/NNM]W,)C?MU/8<F/:+RSUNZA\F7U%M3& GGO996;B%*94=P?=J/$W"(AFM
MI.C$@X?( !.7WR9A08:/BFUYZC6ZPZ#*L&=!QO[)N27]LQGW]W)RHEX2 ']/
MLO]Z0=E#.^0^'SVX'OKQY\70*#.6HP=D)8TUT5&<9&=_*.CR*K:HPF'L$-_A
MDM9XT4QKO19Z*:T8-[T+O76_8_NG,I7@0SM[=Q>KAZDZ6^(E/Z!SW_<%^=F5
M8IY^VB$YW6.W"I]W3":/<0#3JYQX'8[5_ALV$/=DQT$TM=[XIT;:X<Y%RI?-
MCH1&2?IHN#7FOD/K!-$8\UW,E11I@F$FO3KV<P_I(R_.3NZ1CC"!U)MWFU@\
MGGOFD/Q+"62ITL(EJ=6;[WF:0QU+9F38][^0^/R^F/@JT+T2T'HRF6?\S<@N
M[G*LZY-U<E;9,*\&@,RO/T90GX?YJYQR[[XL;'1OX^XBM UFLD2D^98C)'P-
M<NGOKT=%=Q\Z\PKS9XY'.F1QD*HU>VOQ+P9<2U%OJ0"MR"Y4V<8"*'HGZ8ZI
M\]BBA$20/.@F-KN]V*(S9\5NC@0C2.EJQ!W'SN02;^T$@D+]T!9/$0JW@X6I
M3/]F<WAN_6:\:>WQA3#8I,/W(Q%]'\Z3_8N3$OJ\I'OX!DT\#17QJ]T8OT=]
M<X_S#"[+<8:RX":D52.>6O;2IK1,P/=+5\IXFZT[,5F7Y+8'@6EVYP]10_TV
M!<$ B[:?)V4G%1JJ&5.+!!"S\\-DI[$*!H2GBB7FIR^WM/^6. I$UL[D<$9=
MSA7OY18&3,X5RZAW6'(=#_/9LM,1C#1U(GSM=B DSIC<OC>5QY1M(: 0KQBE
M*SW(J.&/EKKIZ=DW0,O)U@<M?G1,:.1?@+9@FD(#]'-GC*G#] N2.>8:[E$U
M[97E;!J(C%-I1[G]5A+-<]2H%'EGZ!_[3Q"SJICHC73%C.A$SZ0E-)^HVDRC
MHZBAKC%@TE=U9G2Q6K_+U!OEW)6H:J>"B)PJ%Q G81.$&_Y(?H1)O 9:3LW\
M5_<*F8KU7_4$,<Q UKF\P-:6Y'+CK\Q2HQ%2^Y&";Z-;OW"V6<]MV[7\#4;9
MPY [VV)>\;TRC$]*E3:[<WXE57*4UP =P&&N983'[CA&$:'#BR/AOV76L9#D
M-\Z'B(*6K%3QQ)=]Q.FWF E5C3;XT8J-0!<QTCN:MNJR)D$Z"(2>P"3D&B]9
M#+&[Y&%B2>%P\*'W<3KFO\)+9EU ZI>[[Z-.J"6-BPF-GK_M2/3H5:CR-WT$
MV-N93F,GX!O##",Z5L1,<_2U-G+P?S0[#V3G)09>A_%32"F8,QG_ [Q-M744
M;7:7!@J]C@F_*[TZ.[U",ZU$7Q#Q1 ZY=N(*"UP7]17)E()T(BRUMX2R#_T1
MC+T]J=RW:'7>#0X=Y.GG6$$]4)4EI<-+_!1;LY?-E\%CC2-FM:= Y8IRMU;Z
MUUV,=D2.@<)J>*.1&?5VGYR0??=R$S=,0TYW:D'_Z;LX"IX@AE4AWDJ+S/PS
M6@:Y^(0W'MJK=C?. 43'@<_N!9#,-8?=[+0[Y,^2P]1)Z!%XP'OB">/0K80\
M'#WQJ1';^Z=?WBU8A<?E/6*M0R1J+M\/[UUJ?.P[22'_^1G*SK'EE!0R+%5^
MHU>CQ0<79%J;+BZ%?AU>.CRW\2C0ESEI\03)S=)>A+'9P'<,?<TE!?5I:ZK4
MUX$.7>2@>M\-_XEH+HN?\RD@R074.%55EP7$\,$X+CLX."8!*A7/'*7LK._Z
M\2JF\139*X,\QX5">53T=HT-*[1R'EA1ZFJLE-+]&#E=LI*\<=\1A8<.@E82
MKY]J'AYKZQ(_P),D6W 4O!44WM?WF\!WE SI0HE[YR-0&+3\2@S,*V)I'9QD
M#_LN/1;80M97Q3*=H8FF;*H;YY6*KI<"E]0"UK(+>'K)I*=+68V[8X3<J3%-
M&C7=;<\S@+U2T3)]<GV;SI8MEF5'PO3DYD7+&1K:T<J^&\3C,[92G=JG4_4"
M3B^E.-Z.W7"H&+(V0I8>K4IXBA5"KUKAOMW@G6A;;^[I$@_;8X\#=VKW3T!P
MIWW4YY_TF7Q$7.!JC*B&68E\_\LYR\TX0JR6"]B_D[:"(K^IR'S,TVLF=5.D
MI?L2J1C<I4V?LXOOYO&&J;*\4U?2G\"8FM?%A9XHU!0O7URVJNM67+CK'F+_
MBGH^\$QHPLA9=K?A$GZJB3+<0=>,0(03@+)<D!CFMJ-IB?GXJ4I5B<,\F$E7
M:!P9-Z:I??O!Z6M2OD&C4IJ\FF'!%RUUFB9K4,%>6\:BDBO#:F1..2J4W#$)
M!V(>R7+LN4LJ)P_ 5E%.&XMZZO[D_?&;)@<%8OU^% _DUS;HY(!Z3WB=Y@2%
M]\]33-\=\1WB3F,<UJ^8?&TUR\9.<EU?"B_0"\(2C3C('G'3(>[7LXLLD:WB
M1L5\:ST9_VLL#&-I .+ T0H,OY09L4.3[A<A9Y++^OIN%G*&HQ=R( 5-JB=X
M"Q!'N2]V]#=*E^7:GS8$TMM?3!:V((1/V*D](%)^+]MAT?'8?_6YE=2 NQAJ
M*..^=(G$YZF#-UT '89()YHV3@A+_XGNNGD*NP,%?!NNL7FQ13*7"\6]QB?L
MLKPDA?R/@AL[#G*B"(<J%"FJ0&N30)"-148=/#46 ]8 ) 7M8!UOI$_9VS&U
M ':^A%4 WR<"TS\T^9$6&L5+R#M[<C/B][DG7%IH-"?)H"]Q*%X2VV.R[CR,
M_ H,]88\+N[E%W5(Q12V;B?;^T(8,IO:+KB8Z,=YZBNF9^(GWS%D0C#NAO)X
MY#3XM"TY_7K25!/]D;P ,Z[= /7L#^CS]12W87!E'LF*0OI?D]=36M(PG)K/
M0:XUWT?G]+K$RV960-8[Z&)#[6R\D0$*X6BR#[UR*L32:-_XJ[9MI7]R&C_N
MXFUW'RRJ+MMV$F/1_'D]S;Z%N@W&V'FUWWG/8^T/#FKE<KXOR6WMN&(3YI\L
M<[F.6A4>TN'LT &7LI;WQV+//V;]]I"+F*QDDWD63=S7=B+L4G(![G@597B8
M2.'7B'/7'7Y'+03K>J73=L:(IOCI_)6B(86EM,BJJ15J,(-GD8QG;Q  "<R_
MP9"H+'KA!\?8:(+T-L;0,$C[V 8B:/3@O@P.&=D[-^<:3\?^+EA65;#]4"^)
M'ZZ]/H>)\*',:]IXA-[#,LTE&2<@]$V_V798]1 [)QP8V:'W"1(SCYA)J32$
M-SP[0NLK* Z/G*24\%,R]@;6Q"KZIUOP],3B_H,S#KF#.[.M!]JNLZV[VQ6"
M2*8Z*_#UZ8'#/+^737R?:PIM\\D4D0<41G0VE5$+A)/43F(2AHG2PT92[>!0
M#]: .Z?"*#]MRV72J9T)YF:9_0^P7GSRP%"RRL3P,$^>1Y ZQX47 W_K;*Y0
MP7Y8GTG;CT#\.W:Y NTGQX!7[_6&%101YU(EK>[,.Y'JP@/F6_=B6O/%]XC6
M;^T2]H.4*U<;SY/&+OZ 1W]''%H;4O_GQD:]S>M6[BK4:)I8K2/LS"Z&Q+V$
M]QY<C^8A$JVJ#SSG$E4@WP*SJFSOIDGAVXZ/"IR704'A5( .MS?<ONGG7G7Z
M?**GSEWV?83T$(?A0L9WYS,U[:XG.2#K9,Z2?G(+\FPPUCG1GXUV(EB1OA/[
MS8X VNE53LREU? D;8.J4,P/63AS"&3O.S<NYF[:[JD\O43K$NL84/RQ?K[?
M;B511NSH<(,G0X0VJ,*2&@U,\A^ ;T?H<F[&A40YTS,"4/'RO!E[HO@!K<U-
MP:3(-'^2&EX'1M@(2I 7!>_UNTX\3O?\4P15P+];ZV\OG\\AX4\E:O P7M(@
M[,F4'0YQW4>KFPT)# /8_DT7R&3\TRU#!ULD%)/%I"A1/L!8:C".5/4Q%[F7
M!QGP$?IRYQ)&0G&%C'E5"= Y\_::$KH %'D*]-]5?_ MU ,[LT?=M4*F4\8F
M\&INV7P*2>'5[UI<[X&C.0J/>7WFJB!\;;AA9V:=> SO8[-E-*%:->3NOM'!
M8GZ?7W0/ '4FF3O!LTB9QM+U6NKPD8S2/@49%7[T Z>M(_E&.VK[]LKO@C&,
MHP@7\EO9I60;Q;[8G41;_S1,Y^.\%>TS?K(OTA4UFW.5E73FW'FS6>T8M$'/
MQ);/(1 5L/I;"BHG]_+?/_22<#S$^<#3M-![6S1@^>G!\<N#E)GD_6B2H?V_
ML:/KCJAZ_6IK+7K>V2:^RQALA!NOL_-+6N4136,<./L+X[6=RSZ\:!Q ]H=F
M$KUQF).=#=A!@PGZ>DK'%-[@(UGD]_3D+G1>5OJ2Z++DTE4Z[\+.[P=Y*.0?
MN^TJB25(&@H3F"5K8O$++Z?3J7_5IK7Y^*SOSJ;=PQAFD#$-$@$_)0 47)X%
M_3-TCPQ2&VJ=S=XEY2W]#EC]T*GD)A!L;*;Q!GNDJTT)MM^,%@/VC5:FHQRO
MSH.!6':]K*(R71![PE@VV)!@]/.KS"Z"40<Y94RIL%[.U)I>1WR>$NWK['$,
M?.+[^BH\[,X,B:":K_>#8E&. A(51#[K@VY#_IK=;;]&J\4X'9.%-16=G30)
MU<C5E?'P=D$7*HUI& \A"TK%_QZE\'_?/6QDZG+>Z]OT2SY8?C[P'X<-8LV5
M:T37H&/5ZGO11.@N.Q1GU.@^1]DWDH*IT\2BIXNC'S>GZJ_CJ^7[>0V]NX'*
M/H'(]=:/F64Y,@I$KJN2(:GF6AR&=GIC!.J-.<N.\%GL!#VVJ3DHF0@C[V#C
M$"9]Z.'BIW,UWHRV$+3#Y("CK"F,G2_/(U(DZ!O.=$R(5#3]T;O8\.KY3Y##
M+W+VZ%2@'8'(ZY=G)H;ANW=L]_/LPKW4L4V%*XY!V-S1;E^D[]+I(_-9*BNL
MND.!6;:1W<4N<EDQCA^?,!WE"()\>39F,\UN2W""C-TW?FQ7WMJ<H<K*!QPV
M5E>Y/B8_ 6OD3IC('++%RUY-?9(#LT@FNR_JB0_^/:#!Q]]]2.I^D ?I$NOM
M2KU-V:D5OW9^X=A<!4WJ"W\..=]Z -=98=].[6F ?O<OS]#VZ_\\<"R Z[8Y
M#T!'<R!04YPP'T+V=%8-+I7E^/=TQT,#X;0%U)<C9.Y2<@?J;\&\!UF3AFW6
M !NVTWL@ 8O?S]IKQD$/8OD.50GEA8J8#DO2>^4' 7PJ\&G]#^_8QJ9@:89+
MY^-$, Q/E/"=^0N-4/__\V895\9,\R_^^=B*LM1O<4X;9 W_30!\Q2F9J"<5
MH 3$:L9"3;B9$U*V8TJ@[I);A<*),&!+5R@.Q'PU0JZXCBL-U%>GCXNZQOBM
M_-Z.ZZ1V%5V*&*F"=UFVW2 -]OONXB-3A/O>KZR4>;E%!3AK:Q"6DC^<(1 @
M0UN7L%%/9IX%B:^(')JX1\ZW8ZSUR7YOHR.'.\OSI/TXD8[9G4TR"L?/+FK4
MFOX#R!&R!N+("7G3B<V4X%&1$R#19\-G7\O%OFS?Q[%,XPP" 'Z-8VQE8+#E
MK21!ANJ#5RL"+]E8^GR*1M.@BB[H*#/8\%<X@6]C8E^\P4A\F5\9-*QH-IY*
ME97"VEP\QPE&4<6V,B UNH]!;W\)RQ%2@[0E7>"(FHM@YFO&NT0@3.>T08&S
M+9 %@\^SZ)I#CZS-FGNN3C %#:AL[OM6.TLT0A,)9?'-W(^U3W_*]]T?T="V
MK[3(\72.B44[[+LN=J_=_"NJZ(%J:T+[BRVL31TLCB8/BT T.94E]6;?IX^1
M'R*&9$#_5/#V?$!]KC3-^<!P^:08\-WTQ)')S/X$"-G<MUOV=K\0*A;*^1?J
M_, 7ME@J[LNC3J+\'L<:[0=C".$=I[K$;'(LC5;_'E_8,L-\/[=,%*0")#=W
M?-0W"L8.NTFS!E(!YBN&54<K4C;F6(KN0J+M]:1P\A)PU]();'F!^_M%TP]0
MUFT)U1JP= ;WW.9I4KS4?S%$*ZU/-F[&G9DED8[H=H_0E]SB-N$EKO+:=@Y$
MRZ8QX]1JD(T'O<X;&0_#Y!_SXQ'%+W@($HHA_/?_D5QSD3)*!>LCMY*#CW^E
MSS[?N3@9<3%]E.Y(F2M!JS\E/?)K)QC?[QC NI8\D,M$YD8"7DZPF1Q3R#K"
MZ5>_UEQON["KXUPVDY)CBX5*0;"/AMO\)I*F=;NDK ,U^<[Q 5/+6>^S:T,E
MI+OWZX EPQ0OWS[07K>7K#FI0;ZO3%AC1^**7-:P<?%28ZS_ ?R/-*Y0^+Z2
M%TG+F14GLOPTA8N4;TM64$H)[NFR>9=)*=,BN;U)QFQN062\H&THEM"<JA?#
MF^2(X5 /\M@XNV)2G\GK,@)4:O?/]"V-PR<%+7;7=>&B<8 67/Y65N4D^6U,
M5'WO4NL!.-058UC:]VY]/HW+JCFWRO)+G!<33O8/S:Z^R?C#+9;?<815:U(.
M-NM>'&C74U7^%G3I#X.^XGQ8EQCL8;V>]L-<]1J[E>4UDRP%"!J!JN!(DM^2
M!=1@K(D^:*5367HJR?"P<+EU,8&&"0M.TC^ZX_)G5=TSJFN/Y'[-)?&1?^F%
M'<WU$%T,X?:TO5P\-+AYFI:(?Q=,<'N:^9\G*_=//F)^NYVD_"I(3QRZS]TI
M!<C!3]$C)4URR(0:.)8C(<6;\SK49IQ9EG_!B8>8 U%#@PRGH:V+1!$O?GAU
M,6K,]JM9W<%714S$Y?\!8-A1?A< "!K<\81OX*\\NH!BF:EIX*&A(D3@'DT\
M(G)HM,2;X6(&*1*=-^J%@")-%T$=BE;PCYUL<1YN8 ADS0*P._ #I59T['V$
M\62L;K?<7\:"1COL<6SBS5CH9_KTA$JPE?KNC;V@!Q=6;!ON1\J:[/$1QXQN
MKEFR-%6T/,[!M)\7DICUT/F+%&9\H]5&L[^'0;MIOTF):\NS;/(]"^"<H]S4
M^WAHP,]:'4'GH71&%J1GO>I$Q7Q@5AG+DF'N(O($D@,^ULBO1+2KA![NLU4J
M^"[.H4Z:!V!R);1A02"9M J34I%#.K]$9BGS,ME#%W:EQF\F-6/'5MP4,PKL
MF::$\LD.XF2V^9<($49/;*SBFUNJI,4"?"B,&&:.2@JI3 ON_&20O*+7D1S5
M=O\RUVLYY4H/FP;I;BIQA&^88DQ<Z.QZ1W76#Z8RT(J%HBFF?_-A_L(6=NST
M-?G]"R"[O2X#352JK--<H*O]8^0UPDL!6> KU!/G]6N\.NV6"6\?@2UL.3RK
M[1B03T;[(4Q4KA.<60 8Y6 D:9RJZ^;]3UQ=J'1?+IP*%$OR/8&!L_+?,",B
MY1>Q(SK0NKNBXW$7]]\CFGF.LYL75E+[3 C0()G6Q>C](C**%8Q)!:S,C7KZ
M#=_Y<D*<VV<N05]'W*Z_LV_ZP1LS_JU'BHSGIVCNGH1T+QL&[HD01OU<_2=&
M=,+MN:JJ0NE<:R@E.V!JZ9,4TV\]2VV@:$!/-4>(S8O> 6EGTZA! X,]8O=9
MFRUG.F"-\9TRJ+GMCZ8F5M5_<\E, S>D,.S]N\WVIYI[P1$(S2OU\_.(U6RN
M1Y_DF7&T: _!X'9ZL_YRU[*CDT% Y. 47^3#V.$S5L&P[%3@Q_U! ":ZP707
MO#+Q6O-7LXY+H3Y(+WX<J>[VTU2)9CH]01-"^"U']^KOR$HT*Z>!4M*:\S%;
M:[BKS.P&P.^Z6?%Z="$C^>QT1.U"\N$PE%> ?@ 5*9/]"!"R56_0J("D^3P4
M=2S!Y37JDNW6VY6L?0-F/JV:(MZ_[\?T2 U\[/ZC8D)&J?OCOW4T<1(<TL!0
MN2LL2Y(8(K6#I64"O==;R-DQT4LJ&&5U#;2/?,7M4!:PQS/%B%6[CDCEOBXC
M'8KJZ)&>:F:+V1Z8I(.M*NX\&7C"=9WC)5'DMHC_)BHF[F@*%US5!S[(DZ-Z
ME62.;:\V>\EAHF!=ADV?9I],;#AD]A;#/.^V^?I6%7J VDE%9,EI)7\+4N1P
MQ])1H961@C.(KNRVS\7T R8@+#%Q7K,$=L;R>)+[&A1O)8(TR FHH=>@)K,M
M@I&:TXW6U< J%W6:\<3>R5#U"FXAS8@3.9,2,/4@8>JI13IC$PF1QM5:=)P9
M%P/.I??V:AQG[!NATM)X3D001NL8U!8;%)*^E;A9S5B)-QTS#KA=(WLP&1$_
MQ"1I9?L[>I"K_TR3_Q_@-AME@X5;Z@RNHYLC>X4Q21*J D+<S$?NGEF/^IP=
M1ED;M;B>=CB.'KWTOOVTSUQDTJCW%0PD""T/^Q?M(&)C&IQYN'V=GZ;^8 _0
M0K)YH[0$_HXNY4 K#8LJ/T-\@>5],"71ZU[?ZSOUK2UCEXY5)+?XX&)SOR)$
M>"H@AI?=4J;^P+1!Z_M^X&M.H2C\E@L0-L*IT>'9%SH'3#HV=VL&)8)#SU=,
ME3]\-]L"^^VSQH1QP 9"$]X%TX=3M%96<*.L=!$CF6Y98VTGJI:MQ7S7N&=F
M/-;_&F">"!YJB@3BO=SG$N.@V$BRC/Q>FPXJ?3[%-@!3*EEV+.B!:DYWU<U2
M482+A^I66W621G.JW-42I%/5 QF$RW!&H,8\F8';O#([=]]A8B]2"H/2&.5$
M14+IX[<2JF7+[]'57Y$UJ4"72!KX],OZS&&*Q%XO5P9(EH3$;7SGI)#A>4=.
MD-=!(,[M#PJD7 H3AJ:)D3;XA2(FQO%S(+Q%()E,MBU/<5F^IA&1>?3AG.R(
MX+\'ZA<'$DUH1TYA'LFO"+OU$$0FS:&)CIU8R["XL'\B26:;8^)B]GK<D##\
M-#_I[72>;-="FO5B%YQL&>@"JB8O=;;C)<1$Z-J-?#E_@^_@.YKW:;;9- G>
M@T3/^!\SFMD;/F-!;[E@ '*N-%3PA+%LM+I.!^E;246/RG<,J WG?)K_<GUZ
M93J-(/^36'T,Z<#=9270PJ.+*FK+.'IR MQH04KM1HWI6A+(7CY+D;ZHJ43D
M18HO8AYAP0HPJN&[:91> )S<=E&L1)4U!!\)MTG\)S4T<&_<Q-N0^I4<=+_=
M0SSV=Q\CF+\5U#D7\OVFR4[#Z;;15>7AEUQLXHC1D@F;;JCV<"P_A1X!^2Z5
M_3:^$95_X8GHEPT&=9JTAQ!.TT9$UP!CLL&Q-;+W7#N6?KOB_E"!B;Q8==NI
M/6JE!L!]F?;>9[LQEG&O*DZO!]A9Q!L4<V;'A1_--,E&[SHT)[0XJWYS&&.L
M$(T<MSHK]6$YORRH_2EDJ$+&E7*E=BDY).["8JINCZECG9 I@9M4E@@(BO";
MXP52I4UZXX/S]0;2A8@;MI%M4/GB@)Q#@+4,59$[UR-)ER4IMDB5^T^]N90R
MEV3N\'+*7*),(Z,-XROLNJR=6X MDN' 'S2DX820+@.(P86=D_02=Y,)$%R:
M$08KA1K49U//W8@]6^QR.^*(0]56!WT$@JG1V?*98L96RW,&91V7/+=?= GO
M(RZ8DM9+A<K/ H)Q!7;,OE))'%^@%S3*2_W&Q3^0'+NXY'&V_5KG'[FA*&>Z
MX<O1@J'%Q1HQ+I^+H0(B_Q.VS90*D<LEAAB*-*R]VD3^W;=+)@&>),*=-/L&
M:%3,I^4[GV;P7_+"2?,MM3\]U8G'A5HH!)J\[O<54:6)JOFR/18C(\;")48X
MJN,\$O?>TEBCZP[_].Y56Z-7GS'A(A_NN^T!1XG#E<\'2L]W38[#1@'^*'49
ME9U+\U6:G( ?!Q,[9.TS".&L/_A]S*;)CC&?NS\"3OCNUQG&?* YEU#1 88'
M/?;0;^<I]QDU[=>>9+HNE)F>V],';[*3";J-V)R-F4U3+,I-D2[_]>PI&3;.
M4RI<=]+;E0T POG/1XF!#YV1-A%.!U(K+<GH#7W&O72[QS9NX8OI!,,]N '3
M2R+7E(-VK5,+N%O*+H%'2K$6\*F2F) J/3$268:\#Z7P:DR'X2VM'TCLHP]Y
M<5#H[)$',% =/\T>/"M)DY126$>[K(K8U%&#9DQ/EVZ+"#^33++<KD$UX9\A
M@FXPY@']7!<9JVV_A*>MQC"?\Q@ETII4-%GI401*E7'1?8D)>,+CW'<H[=#\
MUH@-ODU4H M-=NIL>>>]E("6]/*GB7O+987D*-?/V6AA-93_;I$:&L#R>OG
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M88]1<R<JK) U0V.1<ICOBK@)B_=5<M=Q\Z;Y0*X@GM452N8N%*I'$T+7236
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M0:4ZO()\.<M0?ND>(Q8:/OT0$F=[JMSNNC"P*B$O>+&AK[F,!EFY*X2&WR=
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MLELHZ[ZO \:QZB4;#J6]&0ETV7D0T*T,^+E?PQ%TKS;:N1'"!SCB!6.*,=>
MJ==(D3<Q4&\4F]Q_NW=^*WT.B?AYC2->I:.1<+0]*/)3&RF?Z?U=[.0*470\
MU+7F7$B$QG5^'/3:DWVW4,S:ILI.A]GEP>7D-!2$967@NV:JKQ;TWTV/(\A
MI(LU"TN3Y1)?KLT%3E5%(2PC:S[/%O=\<YKL/SK4+]7YS_7=IZF?;RL:FR/:
M6>GM)QUH3>"B=2?)0^WE/W<;J3,IS**MEF<B>)Z^J*65?;\39+W!2#&/9MZ1
M8)YXW_9'\*G K>:%72C3)9M5.B2PI!G8<)=2TO>K0YL?5B^SZW"TF*HK[ U'
M,5$@_FCSXIS7ETT";B:MB=,C#O_<H<0\%GGI!(Q"(-7T23M,4J7.<2[LU=V)
M[3A2WI)O&WS;2Y(34+$M4U#J-Y.RZ^^!KL!TYWMNJ#(O_4;&.RJ1"L;L^PP9
M>6.&(L?@8^O/$&MQ:^C4WW^#P7NZU((N1_B.3_"\U'@?Q!<SO0*()<,U7R)V
M5],"IO*@UV;WJG<>3>%KU$@J'B9-I'CX<+^=W+[._1V*M@N,-+ONG-"0/'L@
M*.J02B<?C-P9'I,9<,0+2:G/PRM*#D,;5<A_)BY?/UL\SQW2E_I)Y><MZKT\
MYISSL&/XU[L6M9]^__L'J.%VA:XFTS6.2 >+HR)[S; %UKS )7C=IL03LQAO
M@NZ%WS6XQ'K=!W66?X!><,8!VXL"63)8^E 0=?S60)5Z*3!;.-7T^NR:*$2/
M:4[*!UR1]L]_FE(R_JNTZ]$;OJ+'UE!8Y<^F-S\G]AY)H ]>N(Y).&TZ'I[;
MBH7Z$H+<]4'.9.Y%%WRPQ-#H4JOH9Y#YX;WHGM-M4=-YT1 -\8AQIB<-&&M[
MFU]8OF=D]I7AEU^,9]Z1W#\^A_44;A!\+Z)J5:18!$FI(YEZ:HMT4.7I?"AW
M-=G^-VT0V@USL4^R8OB#V$M63H3OWBK::<'^F*=^G^^TM*.$A>D_%%Z^]P2W
M?WARH>I8M01#TZ[(B^Y?2\HL[)NU'F:+B7O'O_D9=#.7B(ZQ;4M)]1Y=2NE9
M6@J4X9A@QB_3Z=?.G*K3A_T3.F[(3T+/N\9X?S=\O]*)]K U[]A]\1!71 R"
MY]N\[]CV0*60136[K-@XEUV,3_#S/CU9B7:C<-+;O6'E:M>7(H:K_3NZ!YRT
MK:_2>'T344::QRN^HTE<Y'71CZJ.G\*O+!\[>=-:6R.JV5'Y)&_-<-8.U0_=
M1[YMO)F+5V_K JBY!%$8"9&K.<6+_AL(NK!&W!EN-O9))L@.]S2,?VGO51QU
M"4@ B;I@_\;'S+[/\$!'=]96&3U&BJKE@EQG,TF&RY[6EY&,>E\^25]?3C-K
M]IF:=R).N2F,F'C;#59=W6X:0+V2&'')H'-(_K)[/$58;?INL@8PX"IZ<OV4
M+;_SD-AP%M,P4EHU/&&E]-;:;R6EPVC1:)@2EH_[Z]1N0]E*PGO\R00A_2_H
MB48X/[%X_IC%RQ81<_"O*@I(O50JW4[W4?1I=$OV!N**\^?H,S[+!\((AZ9)
M"9--C!? [N#T=5PV]6**7WYDW*5U!"C0BGDG8256[\Y^8 S;>6KDN(7EYE*.
M#0Q>&5L',QQ+N>@V5T0%<MM-7+"TOY 1K#&GCC;F.!@2&?\E\ 6$SIBWG<00
MQ"NUE2;4C%_IZ#^;X'T\LG>?U/U!2K2<YOP%7Q,F212>$!?R:\0/Z%K/34H,
M^673*;8=5N/'[RX=Q#?8URN;&M( QZK>MM79FJQ6PV<?;LQ _=I8CD$W@V/
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MF<,@KW#[2^*/>P^@/4[#JU#3K6YHG[*,]O8'5N&I<FA2O&2C JQQS9*89)B
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MDN]JY2&8@AY]4U'%*$SBF?7IR\32V@6.ZTZ894I1)KO$*5DV"W$1VW#U6(_
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MID48":71^/)]ZWJF),\%E(!0(+6^B)S!5>1O)6PVV 6XZ&\$W#Q!!P7ZE8V
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MI@'!_ :P3^[=HE$QJ;)(7G7F(ZIR^:-AJ)F?8SWW.L>$K]LK:#F=<L:/O_Z
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MZ5OU&[9)(,J9RRE4S]K2: >UT&E<=AE(+H$X=!3BBKGDKW2"USV=8MI31^J
M-8_ LK+7^OU50."MZ)6I1MW#P=)9(W]IA&$6S7F@^**V/'1E1'^=]+9GB63N
MMYZTTW/"S .$:NL^)4LM7HM[B8%=N)<B<]>\-IYQ]'B9X787\,>^GG*)!.QM
M2*OC\=US<:$*9D0!+,/:R&OFM-]KFT6MNO7M1#\Q:;FZ#:<_'O+-;M+3C7<+
M-M#RBE$3_..)%B_72.]3KJ[,VATJJU_[0LENW(' !F.$<^(K"B3L >7Y-:.
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MI&=3'WGBA%,1U!<52 @[.TLTGI$1^F#W>E3_*"@) PS><VSX/92$:SKA8)R
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MI])\DMMC#<-]D4.[80=TW[D]ZI.?F95^0#'N[1,01BY.GC;=^<-50R]M.'W
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MHF<J4E-4YKW?-@>O@(#_,&\*1@U59T;[/BVV@5 ?("^WZ9Y)0%#O ]SJ'BR
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M!(WMHY>QE(OH49#^RJRT@\;Q<<6'2VG6YX/+Y%*3F5(V<>UJXX!UU\#//^S
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M',7P)26YHVIR/0DH(+F*\5%UPI26%;=!^;U+(SI'=%_Q-Q8O6Q]'"H^-N@^
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M^F+?O4 WMR3S=3(?>&3Z\XI:UIL]N@@\NS8+_3^S6MV6P5K LPRA;9>GS<.
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M)%>1_1E"SM3(,W:PE;*J%^XI5=K_!-M0'\H("N9GC<)9C;&#VTMG'"1CR!G
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M<VFE,N[B,L+L%:L4P*V2FS$N_',L(+Q^E]IP<CGEQNJ48G)(O,\EG4%KBF/
MD5X<S>DQ#XW6EBC5HSU4,$V>E&.((L<C: /T#)435U4$TEW@/$\P)N^G+4\J
MS\/+NNR$(Q2J3TYWEC,_:PNVR@^*9G%"1-,W=;0[5W/3O8DCU4FG- W%UUT<
MQ+./&K)-9"G9 W?#XE$8K2AJY5.L_5;U"=)-ECVDUBLV(3]QSG&D=R?E-.E
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MDNX][XCWD07#A8UH0P;<VOMN*VGQFN;)Q:?-&I;:(FQ--SIV4\>*0O+ND_E
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MDRDD@UA. 9)J6PX+XK*9-G\R$_ 8N+GE_949*R'C+[]4QL'T[8-.42L(&IU
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MI\*)9FI6\)J?T&X:D* :42-!GZ 5\/^J"H]G>B;J'$+:7#].;_E,].[?XFH
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MEG#9L 8H[(]LF]*YI9];XYN^D)(M_16KN>-A;;:Z]5[.SZL,&.K[85TA_[<
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M.G;@C3:[8I=K!>:7*\<S%2/;\2E>6_AF!^+1G)O) *+M'*K!'[E,JC' OYX
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MQ6Y2J,/Z%"HV3^P:I"=D-OD2@C0O4([MD-JN9@])$Q'4,#\]'555)2^^9V+
M<A40&@=BG2[[D\Y;<K$WU7#?(N7#/E;3VD9@D'V.O8V;5C52X'1+4_9$UZ$.
M&],A)-7&<0D9,?")IL0MPU"3R\T^?GPCOH [VE=?P-$^9$$>M^,I5<KDR.VF
MI/,VR?$*H22KUKB5?%$57!SX B(L7TOJL.N?!.+M3D7,'(T=LI>\%!UZB;D
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MM./ 5Y[C<.L:L$A]K%D1=[N\OL SRM$;G=;#$(NRPFFT>K](+,.&%QUHR>>
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MX=R.Z DV+^;)+_B<4X_ML[A$?_[.QSGY7#IEY_$7/BMFRWP%:SY9Y%W6T(/
M=M/HAA\&3^ &)EBHL]V1U['*8+5V&=.DPP_EQTZ8KI;17E^YC,+,9&Q%.4QO
ML&]+FZ/J3-[*_F5>AD U.6!<FN@D?$[== NOR;C(R]Y4^3;?7^!)HR#1YNQ/
MVD[&4Z9G/ML<A)R]4NZ>FV,#OI=\Z+D+?X(F/9O:%=N1B7:I>R7N'\4_*!(H
M]60^08^8D4WQ@&K^^;2^A\5OVEA1SVFE%N./H-.>.'E6O%"^R>Y(N]+7KY=N
M8T,MSH<M+.Z?PW=^SZ1.O2<E.URTH?9R\J*N_B,L$UI\MM(TCFNU^!VU$RB,
M&G9TSQ$B:-L-BJ(O/PK2:X)<VKBY-!C1%IRC?]#-'M:>[016@2$;#37YCJ^J
MF<EUSWG&F ?\/35PX68&UZ=!>]YFN]#O?K@'NG3TJP3J,#3LC:)4)$JF#_B.
M]4:PYU0V@9A@&%8!4[I27'_-3H;VV\=4[+OYBB14D+8M#ATEXY>2IIM^;%@*
M360S.CABC;?J^5T2 XF8&Q*>3;8-Z^1_)RW2OJO)#"VS:Q3W?A.[?QP0X*>Q
M,&$&YG:$='F012*:H^_N$KQ'M89?L,7'0K@J8S0G?WE,T.)!,,_D#<NRG0X-
MS1."DD6M_X#8CN26T!+"VDXBS/WQ!C7>!L!W<!T85R2O?:\2M;%_78N5W]76
MWLDAJ$;M32U9\8":8![:VY$?KM,XR%DSI5ZJOU<3#LSP#H%[ZWYL2GN+&334
M&\X_:PJ.V;^A$-0;\L=V4?@G(^J=X=3Q(-Y&AHWYS('G%KS\?O.!G "23YO!
M>_&J5'NK(.]J NQ,C['=&VX6&KT5:>-[(9F)ZNR-BU1)]D<FGX+O>%Q."<X6
M/&M1VG@(=923RKAR$%T(IN9@^\]_J,GCT+%E= B869K<*1V>$_!!O39HKV,(
MD1+[9M,WT49,BR(1 #^Z@].S3%/B#6!NX=:/B/;:RGB0^*\!K&4%?6'XK7ZH
M=II^8BD=J28M-<#2G':]8F#YG!X[JJB8W5(]5F01&+SU3 # ?"(SZO"3=HXV
M=#=-':-"CJ8:Y(A?K.>4>"K4 9DW#+'UWRLG,2TE9E%LRQW<)]!10A?-+RR3
MSQ'!A$L,Z6F="5*/MS-V[HTN&]$'C?:Y(V5_0P8A/NQ.GV>/(UVTS&E#@#1,
M>\E0E U?@^:82O3DSQ X4"3F>[:F8KQP;3\WZP-F5(^!7\*!D8<69<SJH<?&
M.-9.8N7 <]+U]N;H.SG;HFNEJ=L6#4CI^:>8TN1"FZ72N@+?JY- K8===B5P
M;692E<Y  :.YW%]J-=$775]CI,)'P8SC\0LQ[Q@4Q'RBYNUTN2AR![<O!$EZ
MSBK?B SB"6=::]X4GODPZ/##YC\V2!*0%;Q9HE/!0H[I:"QQ@N(^U>7!_US^
M7JF:! _#*M!Q]]^W$.8<^L1EQ[<Q(B:*YLWJ-\UJWAO$;FO#OP9/>_<[,'#5
MIT>G<@A[QZC[B0!G E[SVCIY=[[Y??(82@?$_870A RDA7B\7?"3.38)MT@8
M)QD9:3 CKHN["5;X*Y=KD0A6; .^?WO=>:E'*$7;)K4MB;%?Y1O:$D%\/43&
MJ6)C&V6>BJ!"X"D;T>TU%L2C1EX[J;?C3[LJW'#L&*.5J0W+R+2KOT!F__,(
MMV(W)Y_Y9C[<:J(LTJC[&D+[Y] (W.KG=1T:N)AC]6>IUS[_4XA$^'(R<%>J
M"8K%;W3Y] 'L&^4N2AQS4GEG$G,KLY:?U+U_12BY_4-UMX;5WX]8[Q,/:_UW
MQ6KREGJ_'^E87E@&2]R_56:0S2@!2)*9E\V)AGL6E^T(YZR>/R1T"T?1BJ=$
M/"H$R8'Y;$S"AS;_SIDLAQNT3$\Q9HW$KQ"KB="9K&UZ 4QS-0!5K<42O4@?
M&*$L#YANOD&&5#L%>C%7)#/Q537/>CP<9?KP-\/VLT5$!EC0_]CRLKMQ*:7W
M_>N$[0<CEP^2AIH]SK@[2QDA$RS?33-:-:\#L>0.=M3#:V/UWB13Q2?L/>#V
MPLIA2(CEQR"&AM"[/YOPAE+S"XNE"VJ#%=&>[^UUZ0TZ21"PN>Z&B BJ ^BH
M70G1Y]\I3)&BQK94'X<,6+MY[E]:/97)T_V?$7X?RH\GA[G[0(8@0=?:P+<"
M8A3HE=_!0#?UX+-V\VM$)\NLN>X'7$N"YW+BA)L><'OWV_(\'9L8D$JW]:"C
M.O[9[WI&)= TO%^KV2T ][J(\\/4^FMJ_DO8<):2L.;4_M:DF,>J,:@T_]71
M! _4,9B4F%X+>TV(FCUQ(3(9KV)#4!E5T^4X&*$FFK<[<).8<8U #J=SLE%R
M-I[=>$8P 4GU=CZ_3PN+Q5IQ\;Y&Y[.&CL\?7>:+>]$/^[+UP8]=?/D]10/C
MP@L)@9>FAH3%<.P/2S79YW$<:4H. X30+CF^:F=9X1\39PP#9CMOJ=ZF?""R
M+$4 JM:7GAD@,+O=1D1?=9UJ#EU,;Y)KUU*[3H-P%1)QY.!OZ[WM\6;:L\X1
MZ?2@(H@7AB&"@:9R2C->K,5389=A&W'I$%[2LQQ2;+MH[DJ<"._,//O..Y(0
MWY+VBITQ=S"*L[<G'&XM[I]Y(W6'J'$F.V1 M2F^1MQ7%37D[\!2;[CBAO\+
M((R9A.30SMA:FO1\E/=J 9]U!>A)Y,Z9GZU!A207D=F@%#X&5J#]_JWH_6O&
M._G2Y-^ @OTJ?LX&+ 0C$_[/HDXGVQUZRT,X=]F&O;US1/:VQ\OINGD^!\5B
M3M!<R(&M;N,SROS\4J ^>P*=J-[6]AYN,!%>'F[IDNLJ,=W.;WZ#XR"T8%3%
MY2 .974QXLHKZ4]"=WZVUR12 ^/_*GT()TYLAK5.[5$!KE\?_GU@]Q;HM"-6
ML9@; 2>=;U'0^<C'3-'QGN8T(<]DS-.;QKE"'JT52D@MH*J?>@74U.>_A/H_
MM,AFM@V$M%YZE]6V<.UL#)!;\9>N3!0]2OE.1).96%>\OL"Z*X.ES"U"V@#G
MCU!'"IU<J<ED;D13+B[$@@IZ:BXX/IO,MU47)'F/M9=&@)CP$<.M)>1*-Q+)
MV51+([*.55-6GFB\G2PX>*'Z.WUQY&PZ_1>WK]T66.[?DY_NY+DE3E[W^6((
M<PV1+L>LTXA]I7U:),M/ 1G7-_UK"(W_=\>6?V0IRC)KA,9-%X3H<TH12'EI
MVZW7[B6NAQ"O>EQ(Q0& (4OY+KG6._8F6NM3_Z@!OEUHWLHX6):O]DR+43FT
M:&NY_9G1MF)&4CLU]<EZ<-#!<125'D9<)C*KO[Y8SS6RS>F,JM+KW')<JTHQ
M:.<"1I.=5#[UK$&O5_QO[496M[]D&9-_I1\2YG+46_)_%)W[/Q.*_\?=*<Q"
MYFZYB]R=N;<5N>92"C&20D=G<Y_+)M?<<K_?ET+)K=09&Q-RSSU4;#/FSN;:
MW/+YGN_?\'X_GJ_GZ_'^X7TQ TF-K#\]/>VRU2M=0G6HJ)M4\J/#88%O>,C&
M8(@^13S$Y1+JH/ERW^G<N-Q-CL;)M67GN:Q0S<[Z&UR2]&,UY(:E+EPG^04/
M!X?8_?<B_X&>^,[RJ\ G[M[Y2\<=77*DH8Y5L]X?ICNM8%/S_A)PH-!RI/SZ
MJ-7!AXDU3DHQF.MFZ,%\RVHGVGBAN6/6BXMO7L?EHD>%X[+7(Z4VMNR&J2#I
MLTSY!_X027B5QO"_7BR*5C;.2TX+3WJ9([9;)-=E*M?O[P&])&TG,6:KM!_K
M2K=_F,Y>#($UW%Q9E$)Q:FH=='Q/C0 [((ZQ(0(+:Z[FN2 )'")'O0/YD0-#
M(5]\"3)Z;I,*_=9VOXG(&T*(X_X[*)%A,[*ZQ9OS==ACRH:^K^(ISX?8]-(Y
M39M6UDH?T92B'T!-WGL]5\Y&WR"9(19B(C)NKOMZQSR@,\U95QD\N[#R2<9+
M)9S3U%)J]N7*48@\(\^N FA"4E*WN;1X]MM&=5M]L#):/5E38AGI8E_;#7IT
MW1)_"V<+ =_=C[XL]5^ ]OX9D&5<CF/1/2'D8+TEXIG+<<[('HT\&^?1 U96
MC)1[76VTP;"95:$K?/H:J8N=CX&':\]P"D:AZA0S/MB%8QU"<4,G5?SJNR=F
M%]Q>_5!S#>7W?43%JD 2D25?[*B=!8<I%?1L\R/IJ!/P&&/W#5!.XF0A&52]
M%@/:#X2.->QG)'M>-)Q/P_[Y?8+58DS5=K-!5BM0;7+T]0 G277FM:32-JS%
M:M@!>1,MC;ZIC(UPW][$_)B/(4GB3-T/K3E>4:(-!#[!")6_6&S;UE5II1GV
M/<W67/?5>>*_AP2QIA_4*"]WNQ>00EHX6-:CQJ4A<<Z6;GM;96=!-Q@H@!\[
M;+2]-L#BZXQ<>0=%.;O2*'V-Y3>Y2-)]<[FN5.[SL9.LZXRG=H$EJP99?_#:
M'Y((&H<5[PO;7(MM+$-8/>@X\DA)7(\&=B]?6],T]L8?)V9F//QIN]5,6,DK
MG\_RQRGZCH$A'( MS8Y+C]%P!_;)T(5/$*^.W[014+?+F8*,\VH5W]92AOU;
MZL%GLJI1[JO._NY^)?34.E=G(190&.;8 _"46"MZ=H+&Y+&N"*]?3C>5_.!3
MCBR9G>"B8D*MD?V3/4;M!:!!=D/Z=:&;&Y)Q/:-P!T6Y6IFXF-*.:3=6)9=C
MJ-_9R<U(I9='ALDL?VW/"'6J[5S"*;"[6/Q+_Z4(.22Q280]K326&B$#(4&X
M:]O4LLUEMM-W"7O/*]\LGD/>_)[__]=XRI*E;0D"20B<FH!S4%*_,"MMM7@M
MYA+U7#L.*>]RLZDLT-9UXRQP*UXWJ$1DS6W/UM4ZJ)/H .UF<,/6[65*1KV&
M>0D\E&DZM./D#KJ@CQ$4-7H^[E^NCX7JWVSZV07!R;22$LN+!G_X<VRS3OT7
M9845/ZQ 82?MCICYAF'3IK*F$",LB+<HT);+^!VZY>[CT2+?FB<BYNC25"[9
M++>N^)5+?'M#3V__P6J,,,=T >*>>NEG8&[4K!G?)A:O((U,E2U@?.*IY4<L
MQGL(P\YP<'"*(?GN(/]T)SN5'<-(.VB?(6#4WTN,28M>*RB6R.'$4*[>UAQ^
ML3]0O^V%'E=;:GU2< P&3.*F0? )2<#YJ$M@S6LJEW#UW.0GE:!3^K]YA"_7
MMAO_"LW]!+M6"LB-6<> ;@''%B_82YRN);>O/F&1I=;^\H7O'=\H[[-Z ,E'
MK5+9-6?=.GG2EA'6(SO7></WSGE80$NZ3!L5EJ']216</6\<"R?EP496T::I
M=0P5_6XO5I"@K,-6:#2A0]^UWM+M9+N0,D2WU'$B%&3P>B'; ZVY?_T3N+T3
M?PF^PDAU]I30LUC:6(_KJ=Y?UF41L\GJB';<3Y^?_8ORV#8M.3CC8^IK%L)9
M*_:5B38U9 08K2I==O\Y+W$-T=J?RIIDHGE\>Q^SEC0F-X?7QXZ19I.>O "\
MC2%V%,C5\O^"_G ]Q+E'@F=?8.X<$KYQ,(A!Q&1>0@A0_8$IW:\"\W'M/K^G
MVXO#S H>L:8+YN:M16!-7(TH? _*0D3T=W/L-@SJ;*+Q];:OQ Q+\29LF8 ,
MU/1U7'"KA=$TMTVY^YKL,6_HPQC A#6]=[*_1B4Q@GS=WU/U8TR\*B6\?LN?
MMTN5F1Q*M.R\%+X1:]D'X<W12)+V4,0-SX22$MA.D*% 1<?RM>2DM(6TQ)7X
M*'_+X+H1T4?QZZ@);O@0CQAS&)7 2FCK!9GN-AX%S?/@7OK^Y.+NV(C_^/UF
MPP0H_'B6P[(#'$-HJY[+^1@8]GGB+PV#XX46?3( BCV+L$@2#N?YVP UGS2=
MH0.%_W)V9ZH]15@MI2=7_8^ED+00LTM!5/Z2LV\D.:";7H2XN$=0'HNF-2#E
M(\^(3CWK?\.!Q">_'93_HKL>V8YO7T+ONP!PP<H5,+96PYNW_\=BF8M!O"6H
M++\,M-Z.\$#"REG#$,F8&^>.I#*??0ZHM%QG*HM.H3!T2'.0N9= G.#.B_",
MP/9_993A5/#VIOX+5RN%Z1^DEN6%KI#NQF;V;;7D:(3N4"5X3!<T(B]D=T/0
MEUFV?XWI$N>6)SU5;)91)1>UD:E?GZSV=]__9P4 6QRAQ4?ASL[<9D+'V$H!
MY$NMHSK$M2O/+\2,5H7_,%24[$,%UAFW81V2C:_4:]0%:/!XRJ?#*1P 8XK\
MJP9U9M5MC9@V1%=EFXU-$(ON*JAJL-4M1RBGWX5W,Q#*6/;B0C:V"Z:2W??-
MGNYV\L;Q!254(^S.*8#./&Z0$<Z,/+?YDZV0&@G>C.NW$W0M">]EBR^TD;IK
MFMB_Q./6?)N0EI?Q (4'LYREM70X"-3VT9]B6I%56)]S_!GVEOKFB[NVG-/7
M_KA&?O7B-PR$PN=2G5>#,DPO^=_Y9^\F%@>B" /.C:JCA=AY"(4A];OA'3+?
MU)X.'O&V8EGNH\CS\4N1P75?D9+>X3"=:F28C+(4LYJ@IY@)B#I?*)]U:@C&
M@=5BC48A@X*3]_V.08%5CT9%X8.LH#!!2=70J8^/(+P=PU+^>,WE &AK6$@3
M?JS6]!U"LV^YI,>-'O@&Z%L&5_KJ'>@6II*XA#F$G84_1H-)&GP3?O.(A>+%
MQN>]@I^^D_@G%F(,6Q9:G&:$.]F%;QJU3.6,2(O"_T.7#6\W"F]CBG1Y,MR;
MQR&U'R?;3 E'#ZH<&V)JPS?19?%"D? $TT3:8=J]?OD:4Z #7P-S0O4&A;/X
M*>46W>ICY?0\4 '>OUGR:(0N-0-!C<B=J^0Y:$[^M7G93&I<'\S?4T![8Q35
M#GZD$5J1W'J'%L,KJ=%G*13_83UJYDEIWFOCMYFCJI>64!5^K!OQ]'81-F2'
M#(D+CW:VX]'9GLO-#5FH890+];_&B2[$X#?3'^>?4=.9UG9T8\?=%YN1[/'-
MZQ*]@B>4/F6=@"Q\_8R4 =CG:0+WKX>&R,[JOR*^=?WR3.R898NE1V5%>W"J
M_K0DTKN]5DA43C$3%%J.L'T[7CG03(Q0QRW;6"O?P&?("%-]PL3XI>%D\BYN
MMNW%J1.#B5:PC_&,T"CP^QL(W(SG!98/832349Q'<JYWPAF6PT-:SP;YXB"P
M""_+58*VXF)KZ9BRMK=KAC%G:\45E[MZV6@QD"GXO8ZB&WMQ%A[B<O=N?^/'
M'U4A2$^N-*(#-CX8EVWF:#^2XUD/M T)3.AS'E3"LP5)+ 7<3K)/FV#Y;M3Y
MZZ$O+RVQ[RUK+G,R^P,'_P@W7%\V*/$G5()P&0J@(2X1NMCT>V)K;7CAWC^9
M9AP4WROTR3VWVY?8@SA#TKO)!UV"]]G@>UVL87]XT][4N%8H+E4%J.A:+@7!
M-$?_QR*M"9O=A<",VH>E52,H;6PBOH1O!Y4<O=7)U,R'@MG=S@FJ9H#;"?PL
MQ7WT]WS5832K6H>8"]1PFP1'+L9EG<1E<O=#0UX<6*[NV>D$=0#P7+(@FMW4
M':A)&+E":*LZI29-7O.A"^=P2+S.U[+E:[2"(X<_JA.:S(1_4VQZ5??B!-XW
MV5E]D6K'DN<3-]&Y;I\MS6K[*%X/]9=6%F)6 V9S!*B9)D=JX3/.P=:R](JK
M<?45/Q=;G*T53DF!D6 4+-ZN/4>)O=!M(9O5GS5D>2=>C5S6>A7=$P17JN,V
MHDLMY!_DZ\LKVB]+%S>8A&*.H>3IV!FE>KF>L(-W\>YG!JR8]3D.$PI*3-9\
MOE$Y-@#4Q<$D'9OQWW*K1MC31\\7\FO>V38,\"H6>XJI58TD>^9#QU\X#[)K
M/\EE_H;5-./,ZL_J[3,5_AH54;<4_7R'O[O 46(M>P]'2NC:2U\/QX:9=Q>'
MF*4'YU02P@H/2DF(AODL2<]*FZ">S._Z-88W]BROKGIFQ<9:T3MTW3#+$5C7
M/&081)>?LJT%&MJQCO+(6BAF<@@1\++#SKH0T\P99@T?:2[KBGA91@%-?V_Q
MN$X(=4V8!#&R2];T<:/:U&&1H'>9[[MD0D<X95#\0'(0(>B._BWQX!%(2QV7
M+$[4@R;3N!77WVE6_TG5KJF7/7Y.(R'F[[7CMD%-?<\4RVOT3507EUSCL8GE
M1:].2>4R<J'P2RDR=R06&2H7VL65DO@? A@?99EPH.;3\;3VU9^0UL"=-?#/
MQ#&@H?PW^$:\R!/#"/.!7"7B%B(G '% CP%H$48$(7<+*Y39\6@&1D0QDG0,
MC7])>PNI?M2VVF,R0,GCD&B_\VGJ72>/2R3:,-CP2=P=PP49#LZ"EOZJW@_E
MM&9A8OY*]BOX[B8::-0\PZAROJ7Q868M;9E85'V2P\GT4EK*6PZYQUU[6]BR
MO;'N);M+7[''.OB1QX?7GXU%4,.-RMFH >P-L-.R,2GG0_?GB4<C%'E1SPNR
MW-*C/2&"5H?Q3>9I]Z2 @K(G8<7/'W>C@5SSJH&PTX8!@?ZHH%LC9S"M&;KV
M2BV]L;F-_)8G2370C+$O/TJUH>6_1C-262Q[I%"H057ZSEJ*<FRX+]Y/1[;/
MX_X_*18;1*$XK>A<&'V$C2LTI769(\'3YL*?61K*R5>,$(VSQ/*];#O$=/C<
MUFG#\A^1X^V(QN..TQ@RS32@F59Q0AEZZ"!V]C1JYN&R:J%Y=6?(XYCJB36Q
M_59NL#U_$(].I9'*3U\#Z<Z@'/ZQ33/L 'J(G:%0,CV+'.1201$M)7 I.["=
MEYJW$Z[U_H_E@CTZRI-#5/(#(>>+=X^1@/E!7_,$*'33L8J59J%)^^(5?J9P
M<F)[##^&_55<SLB<9+&)UK&GO<S1FP(4MG&R=N]L_N2JHC;)B_TM4!F3MFS_
MAD5B<KXXM]M 02V=ONXTUE?;3\J[:+NB+I'%_U^$6ZVHHEN@VIOMFCG\]$+0
MXX,'T>'=:P@5:!AZ6B;@/V[%OM3 @W]G:C:+!_"D%5#W8H2@&NLGX&&=R@0;
M""H.EM_%_DE]'_9Z4E)$V>24T<0!.'T5UW\%K05+R^]"P%&20!&[>UNQ6H7I
MFX_5*]$%;%0;>CSB:%#I7W?*KI<FZ'<Q\\TX7^-# Q!J(\U= 37!5[<-Y,O8
M)K4%WVP@+)+/Y4)N$AF-:YKMNR#YL>#CMEG>. LKBI9RO+$T<L625W:W=JRP
M!H(2?Y<=VIX:B$Q?C>/\<N^/J8CDNQK)Z$MJLP6@X?]($93#J4;N4,-:F$Q.
MZ#3C/=X;2;:6@*^\"WWN9&O)V$=$.B+$/&_\B]8PXW,=#J/A:LF\O(2U]#Y2
M2"2?X;WSNRWQC-N#7-%(W6U6)K+5A%T$983Y\RYM&SVCQ(=SL3P- TE;*@_V
M42/5W+"=S5D5N2,Z:F)G9-I%6TKZ@>WYNR@[AEXZ0\C$X2'RC85N-WU=OK%B
M5?_.&7B@WXB8+!-\'MEE$_SB\M#%1BIJIR9@UT<IB&V0A+FBGI*\NQ_ @X^@
M_!)HVX$U0@BZ/6YMCP2'& 4'3=UT7=BMC <[ECK#>+E.2?TPBZ5&.%#%]AA5
M+S7 P;^</JBZ/<!/R.$()G1)$ ?846VL<GEZPWJ5E*_988PR#3-8*WR0S4AN
MU[EJG;'0TCI",IWI8U0#0<=K@EQX13_,VJJ=E:MOQ@GV"Z,&9VZGNY?%"K\?
M2N:Y,):H,>2[;QD=G9 +Z#Z I1P3BSI\_WC=B:]&!;G ?T-'GB92'M<?@*(=
M053_/K@N5,J..60.*ON4I%K2D]?J?E^1Y?;,9AV;15_Y@36"(?R L"TO8VI\
M;4#LX"6IP%2D/9"6]-+3E,!4F^4A,6"Q)QL:J>!O2YSQFD7T$Y5/ 2&-M)AT
M8P<3S;^.'?_'HB*F/_RZ"O'NRY!6*WAL^=M+'9>PW0CP[?7K26K^W1FPS*Z"
M366"='L!#@NXD^_@8V\<-'Q13<!3-("7'4-0&SE+$-M?+:PHRU:DYT!#1.%2
M.?(4@4^B>B@S5Q-=:K=DEESK?$O#K"M8WME9[8-_\?"V<HVX$6!-RZ2U3?I/
M8SB'*2?CP0G6BZGD8_PXEC!+5=_<*6:&AT M5#=>%,\_;N[>[N(F3;,JVITN
M)3G=,F:4N(7NJ6!^@OW+R39!ZI.GLL=S#.$&2>ZH^=C8ZN%*IUI,T2[T\Z.C
M6JG3$%C:@SGZ_+\R;L?Q3_QW?^=YI2LRZ@;9^?5_+"8OYAJ1 FXG3L['!+4@
M;R%FI67NW7U:VK,J[SJR\Y9';-8B-E)!+V7GDFYO3_I/M[E(;'=N&;[JZNG'
M%OP?3V'?_NA*HRR5X3Z0D_G,GLM16!"U!/P3U\7UW,.H496O'GX_;#O<OF1T
M3:^="/0=-FH77#E'BAN @G5<^,R+P +Y>VUJ5&SPZ\0]EXP_9PI^ 6U/GK!K
M!T2+. JW>_&+^)0VA8Q3TMG8!*Q?+_= [LE=F>T1G=:7VE[3.>F1FI4WF#NI
M=\6I;8!G,REFO.ZD:.!SX7G$,=@AN$VIXX26)0#0O5 _U,?#([%+B+1']P&M
MW5"J<7Q+*CTV"W%C[1Z>.X6TM.6]TL;<('8>]S:PW*<F%;KU;8);$-@WZFVL
M.D5JF54*CKZDU]/2P^ 0^_M43?T(:[")5 TGU(U53S\T='?P9;1Z7F[:3!)N
MHB*.%;1V=^+1^X4)MTQ0"GC&OA?0M.QTNX,M6W70\87GL*2Q N((>"!J-/[H
MVPYN)64Y$] !-"33\8XL06E;&S&Y%M+.3Z2F";TL*J@<P/OA]TY\IVW]G&V>
M8QP:+<3[7/2X9-[W<R%U'_ZFPPN>__-C%\9L.()]I-,NU+C58]?:_L<".OC@
M:[03&[O@VU\%) S^$4*C(%7S5;&>)LP.G7T3#?F:K>!>P;'"IU%9+"K6GKI1
M-PYH+8UVDVV[-]W/GNS%2Q#]!#\8> E;U@=1@NDQN6[MZ.K?RX@%QP\<GH_6
MKR>(7O0/:%70*Y0>+)9";M7?9!1L8)TG4;9W30]/;\X%[S0KV4RP"YY[4Q52
M)MT-:WR-:G73)2$E/O%13:H%;T^O[B]5"R'SK@3?(+T\@@.]=JN^44WNAU$Q
M@CJAD_I^<0F>FK&$Y5Y[DFKGA>03DL0B38#^?HW)NY("44E41+T_ ^<O8?3K
M.<G,QP?FA2^?53]7/872//GR^KB:VGH-TI-OB&'>J/6KKILFZ\A)?-MH>6!C
M "XB%PZRQ9?Y,<GL5<]1TYMMB-)F<OB[,A7D/-#!BAGPG[&5DW3N/9XX#K-T
MZ6Q,UAQ;+*R3U8G6&NZ^8R[B:V22=:^;OF\YT243%A"J>60Y#/\['M'N/2T8
M5)AT8S&F'><I#&N;EXTM?H_C1O*:UH3@^X9ZOHE$7NA,:WWT[NK8&WW&+<I,
MMV=80 =0X!_/VJ' !/@H/?7)6[3GI,^#V-X5MR8.WNW<EVKB[@7JM7+H.Y^C
M:FME<?A6^#07O]<*U0EF*ATO2Y)H+EJ7?J0>W@;FHP#.<F52U7@73NON*%EW
M]O&(DS^ IN4>,!I/U])D&=E03(W3=E#5Z_+*+W>CQ14?+Z53\CC/93P_H;TB
M'S?[T[=DS\NNJ*_Q",Z6W G='.0];>M"AC)&V(A[*EV478QPGWNH.@GAQ,FZ
MM'L]\\V%!7K)!BW)A1(B#C&[$#QD5?[HO(#1ZX,XQ7I%K-2,EWX<-;AJ,DEH
M?>,?$D0#N#OXF%4Z$XSZ<Y[_8W5CR'3[-[**%656CO<OO_B:4?+0&$W5%5K7
M**=8OGABVV)[XF(8;#5DB/4QH[R<B,K)#5<PU9V*-LDR128]AN;[6L(%15J&
MSM^\Y><DBF.[UZ>]D[ZVUY]/M8DI8.:MV5QGHS^[77L(.&@BZDQN%,E(JW^$
MFO-3AGH;-.Z5]X<1K3TU6L&FC/>C-I+O]G6KPD/;@6$1X+! R%*=]ZONWD%[
M2[*_9'_4"(L,!K(1[W9N*M()ZI6 2"NSZ,W'R-RS6X/MM_6LR]7$DG:E QLO
ML"X'3(A8.]J0)N_ [%'VE>5W<LX+J_[Y3:<HSV7=WBL78@WH6!^6)6\)Y@YR
MA> /3Z$Z!B&$$N>I,,"$?F, K/)]J^>]V,ZT5'<]^K]4S+AF9]+"YS0<-LIC
MZ5 WB7L_'ZASZS-(5VNJ,(&X[A\UL;[:S1=,).1>?[#?:@4<LXE6-?H$%''Y
M*L7W9%?M3?$/FYP;S]S:JOKO]F]:8$%#IZ]^X><U78Y)$6?5ST&\"_ 1]M/7
M I )S=<;IZ<%?R,[C#9-AO4BP3X#[7E$I46JPAT]XKH8*$'E%73^;ST01U]6
MR)%_Z@WD7<Q"VNKNZ!'8E#Y#)]X'20U$^8;"9C1S^*9";,=*.OMLC)Q)1J^>
MNXT;X3J33#'C.RWGC4=@\7:-=59"_J J425I4O'T9OL,FWW9TX"]^.OTCUME
MI(3&QDH0"=#.D ><4K[O69^E+ V'B(1QDK@0HFH6TXNQ24J&QX>N/^8*^$.)
M/!<MA%#"G$>/3NFQNB ,4+%PMTZ>M .M"14-#WM*/UBHL?#X/EPVQ5XY_34,
M6ETQ0=LLZ2I.\OU)46G2_3+/T+W(Z8#I$)QIQ&YZA.]8GA+O;,1[=4RVTX6Y
MI51&4R#PG<5D(E.>;[,]3GV46372UZX#>_7\O@.;H=5>:5.DVW,_1:[\;F>.
M.(I."'2L[6BQ2+BPIM+.C(<B+"Q9((V^&0)1Y,8,IQ;/BH)1Y-B' 73-783+
M!4:/$DF(%>-P"T?<,=<B2L4Y<13[[Q9(W_<-)O$V2A1$[;2F#3[FN<J(G<(_
MU"+$C5P<HHO+ HR;2O@8&87+O@<OUFO"'#IVK:=TJ9UXSJ?O"55CI&](ZW6$
M^3X#Y23V<Z_DD?H)M6H62>PG830X1+\O,X>_=''=#L20TW1'I>Z+[;6/&XB'
M)TE^_X;$!_S#2!J33Y=HSU*]&5O(^UP>EB=YFE$Z@Y'<T@>;+_G*\TUW<>FU
M-U[1Q*FT0+QLFN.QF-U>94E4Z&:<@Y]&Q,C=.4)^9PF??73EQ=O>PSRA78X/
M%79B^".IPI;C1U"@RDN+1)-7]?5A4-J/=L@;[@*;Z]R4EW>C$'YB4XG$$O-!
M=DCD#Z>^#[1<F_Q#*.O8M8&":W3<&SE369R9&&2EFI/=K7PIFLX;U4C;6(RW
M:_V/4C_I,9](5  K&U>$<\[7Y8@&B>VI.)8KZOE?:]EZR2DO'M&+KA0$9-!8
M7QOVUU.J^)95&Q8*Q\RD$O3_&\SO&3*-W9 TX?/@E84UQL-/XB=RJ\5AK&$G
MQQ[#NQ<2H?)IQE=>)+@?L(^K]A$YC0L3[U*U6!1U#J;%)IZYO](5%VIR.#\(
M<K:C#ZF]W/1V$I*^Z%L83LAY#WWXQA3.XZ&L//C5K:GJ*\S+CI<5"4M*H4SD
M6$PE5B1W DZP \=CPH"1E&!K^]&FCL'&<-0T&]<?]IUV(-BX%=[EX"FVU&4/
MLMH?)O*P18^[TIN+2H^L68QP!LK? ,IBS.'591WZ8LUINV!NTJ@@S$,&3;BM
MW/GI56G4JYT6)762WPD8640[$+],H*4Q,'27SZAPK.<_NTWN(K_Q)CMCIH,5
M<DC\NQ>UB:9-\H!AMZ:F9^,-F\BX,<(J9ZP4-D;DG].FU)^FGUI]BO:Z#MN_
MDX+_ NJ0),H:'<Q,+P7B;\"58\56>XRBLGW3X5%9/HGP:W-,V:Z.54R;4/K/
MR%ND"=9K]^EKL8^<;2M'5%W(%2BE)Z5OVQ\#'XYN39XNN[4A[#;,YB8-Z3O0
ML6VCKNO(]Y$5P6@-4P=[ P^I4RQXRDZB5?8V.599+ E^4.7P"*Y$7VJ2O\R&
M,KDCTB+)P >CRS%Y?RI1J5Q<D,Z2N^6E"YF(W:-;)8>M6$G=-KA0?"*>>E"-
MJ%XKSYX\H<-PSA='I)U-16AB[4\"'QQ-_4MC.5M^;,"R'8 R%5<R#$N]^[I.
M.;9RG%P7O;'K].5)P9K\E9\!L*;<IA+U]NK=$5^OF1W*('#V4B\KZG%]V>M0
M!E69;$KPZC4PO&&4W#&@M)3Z-3QQU\F@[VND@GPH2;T5_.T^0_>+&V.9RR(:
MI*>%B@"WW&)Z_K(]540W,F%FC,80V%UW?2M?+_&E*L^GE2$O0@EAR>H&*>[M
M;_Q,)<V1FQRB;;6R.YUY%P$6Z=34?PQ(7<-/O>]R0-,U\)S<?!,@=/;Q=IR[
MW%00'QI#IM&H(3;I%/=+KZBHUUF^9.<._]$6FWH%S+'::3]O%_O'L0LW&.8E
M0X4(%5Z3AH%.(GT \"#<[LLR*O66/_7A5'.>^4+<2 C-Z.UGC]E>3=WL88G0
M/!Y<OQG[];J&/OT9N3 ;B=T.I.A"/-^S,UHL*++^W"/J3_TM!G&9W7 5DRJP
M3.(+A11\=GH8 <W &[ IQ.P:33CB?;;T*4/%4ZX\^+>:!NM\;^/Q@ 4O,Q[C
M#T3E10VW'):C(7JVD^]3?NWEO>QL==  RGR.%D-860-NCU$'N!#K$SH'IR.S
M3A)S<SDC8IY\.T=!/\X<ZL^T,8>P]&NS9F^<MP\L"BKUL?Q#U%X6_OL'29I%
MI<%,SN3R'1R87L'&-U[ $*_GRB+><%E+3R.GK?9\9 U7B^@^QG)?\-LD%[G#
MH%8XC\MW?'3QO48?:P4W-U-9+'?#7+%@UX8C,VJ0"R4:PH$]O+0=B47L[07Q
M2,UFF@@/4SO')K%K9]7,959V1G>?A9T!VN<#MIWZ +R5V7."Y9<\;_3]>*6Q
M].-^#B"]L'Z@D4G5"@=KK"],^/:KU_!DIL\B7;/=3A=B+D&X_QQ,<;X %<X<
M0'Q2+K7.X[ S7$Z2ZOZ7N#T>  _+"[:BL-R C[A'\5'^8@EF5X7@\X*?368/
MG43/>D8Z?+VLD)D2D6,45K1/BDG31TXYU-TE[FN'PPHIPY\]/J@G?M\YAD8S
M;YP[=B]-F6GDTTL$CJH[U=]J 5]$D"98#.&#FJ;(>Q_8;C%*.&ET9NO5Z]Q]
M9PSKS?9HR7]!$=AGF\%;A0T9ZBZI@;-.U;4. ^NF^UNQL>N_EB8T>S0:@B;L
M2<F9>:.$Z ('T%.VM3'6WS&@5YO3/AFH:)'GF>E&8*6E>QTXU*#W_B!_^-_Q
MJ$Y#+,"HL:?9;'60[Q,4_HON1^!9G@^Q]N]?PH<AZ,J<F?7-O &5L\ZRR!4K
M3U3F$/N!WLFQ2UJKJROI!/#7<DIYDML6F'V5YGXD.[I!.K0 ;9QV*;<>3K-
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M]ZJE],^N#=)&0T/.J) FLQ$#<DA4D[#8B=U!F(I4(OEI<C>N?"7KXV;W:#+
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M M?"UMWE43 >">?@]LR-.!9NM\M<2@0^GTJT$CS0=(?5^!^A3>D?%6,P_V[
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M5X%0'/[CN1SC)<X\&9W&_>FSC[-.-O4Q<=(Q.E=WDEX;!DJFH%T]&!%O !*
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MX"=>[NDFBUA^#]GR0#C*=\:LJ.FFF[XW6S$#2Z RVK_B:E(S158H!K?NK!7
M53'\'''R^DDX6+9R"N;/7?#5E*!Q@\KSL8U+)#=6D$OT%M+7NDAC)?]+JS%M
M*Y@G=">%LTMZ'U58V!U8)5@CE1K]QXIV2C6[SZ45AG6S3NU]'H%.NDBO.4@8
MK(>/Q::V(7=]??"\UKU,R99#T#=WJ1J[4/Q3@^; +6GU^'%QN,;-,-5LW;8\
MQLKI':A3:'UH+[<?KH?(HB)@?#=37\F4Z4!I)<4KVYU%_>%M%0P<2V_^?2!K
MAFX>JSB*H_(!0D?P_"P./"A:51_@KV6*WZ=9-2J()4QO?^%%QD/D-]>YOOU+
M_G+-D!5$8H1W_4IG]_F.<=IW_S"_!JO]4-#4S9W5]Y]Y7IOT3^)GJ1_4(].N
MR"S,J%3-M\2W$2F (?.DG:(8BIROF&HDG:M2MYFGO^C)A#SE&(YA+]^"@;ZM
M6KJS.K+6T@S(N53E5'CHQKU8,MVKI7GN+DHJMI\MQ,\RM@IC[FFO)T:A%1XS
M-AQ>M*XV^&VAJHJ9'PN8#;!U[R*6;6@0\S/6)?6XE]&Q4<^Y 953LT-R_4(]
MEX.6ZFE1AWU?-JK1^9U E?!)01CH:W0;?]T0TQ;#4K%UBKN?NE:?95(GT.+M
M\%OT"(L_=&]&6R56=8ICA.N?UL.SB<<SWP(X!64XHO<V!%($';A6$H"4Y9:'
M%V1NNL-A#.,A(7J:J9V*/RX8(Q:LEPS\'P7G_<@&P[5AQ!9;[9':BMA/$"):
M:E:M%K5IT>IC$[LVM;?:JD:'5=J7)!*K=E$450EBU$YB-58]7[^_X=SGW-?U
MR[' 'XQS7=A$5TKRS^3T%*)2<4H\ACW4QC(TUC&C5(#B;L\0^&-M/0,QY\6B
MI/9Z"215Z5"@>3A4MF^!W-EE85'^ON.N935+KQ7-22J0V</[7<>:+^/C\&7M
M)I4%=8&R'BVS+?5ARRL?DIQY)9=2&2 99PELGS]Q_-3R2)J:-(3:BZZH_BD?
MU2(K;39"R.2N)/%AR08H</( "K2G]\\)-T+ 1=3R^2^$C#:VX/W],'&_R@EZ
M\1A2F9U[+6WJR%VV; 0YYW]'V.P@FG$'A+E)>Z&(V_6DJ-73=UU&Y;G0@Q-\
M:O^7<287D_MI?NT/!'Q[W!)IU- )&9^:/B"M!DQ^C*.L7>^XX!*HB:_F9D+^
M'34Y8&G[G_7Y<'9%WM-2?_();7"W)7[ 0JW,7^-0W16M5\@X4J&%J'5GZ!$9
MAR60TA7R<&?ZB4YM=[*.ES_)Z?B*KMRJN7O:S2'_?M5=YTGZ75_O755;?Q@>
M@K!ZICI.W(C/<-(R:GTZ0158W%) MM]\B<;5L4%0/DK$,PSX94<LT0+Y+DYE
MMFT_#3H!?E7CX;6S-"_P*E@>AFDYM?C#8:X2COR/"OI-O&M\;Q/J8$B9EAU@
M.8ICICESN2Z\W<(1,:%FX!!DI<+D+=2=*RJBU<RFQ;=3\:LP=2'F-!]&HGDK
MLA;A_$>*-#"(!"/\+LJ^]%UV>R6J[SX+9FS_+B'H LT_ 6-8)R"=D"Z0W?VH
M=H)A4A<W=M,PK@@=J<C$#+N/L:3Q,KR:&P$X9&SYF\^JK5?M14X5*9RFTX_S
M=Q&B9[FT8ASF9*=>=KDGW T>PQ#31*Z.VX)P)0QCJU:^G^G.S>I7;($"_9J_
MSGITN1A?61T7G$L+HEX9>K%U7!S%4:L&(Z8J1WLWDW'%,IR%6GZ[Q>0QMO,@
M>NW']'QE0QAKB'$$(;#6(_SO5-0D K +-SXJ)5*<'NH$\7N^*Z-&19/A$WG1
M,^U0S,()5T%V<"C1@+TG6Y\>4#3;#MMO[T_CS%AA_OKJAZF%Q0L)<)J*2FRI
M"WOMFY:][+7<JO^H@DPO1643DE_+(PW-?Z#[.%0&BH7R@$<[F_0QSBL&K>CM
M#))Z(.)KPUX"D+:K]+Z%3XK'UGJX8K53T"B-OU#_6X5975)[!HE=*]2PN+,@
MB\#SZ'5*-)[01[,GY_-*':K[X_91I*D?)M0A;VR0 A^*8'(>A*# A'!)/D3Z
M3%KIT*<@AF21!=>Z)%+ED5'22=4+^3LZJ_'4\SN;D Q\/H.$T"8M0*581&<)
M%[=>>(U<FFV;\+N44CC'1TA3M"A #BCR-H5UC]?C\FP_]T#TBI74_8W51AX[
MPK;?2E(W,9X^R!P<I7(U<CN[+PE@P-*'R)6QKXP=ZK\><4X:%LHQ\=$"4>=<
M_DOL%&7A+)*]^I!C@-VYPS)>JU3LWPT%T6ZYC9=/H_?>"^&/%<E="L'__SHE
ML \B.F.ZX[GTOUOML\6ZEB"A%(B[9\!>EJ4OLV_F^H]GI91T6AE^8$"J\:'!
M9^^2@9G5PPC0H]Q<=/8&/R1XHT-QIA-,P!6'^)>Y^D3MR6,9;QG2.VLE5_(M
M"[=->,PCZ$JW!G9/]+.T]C+RJX2.)<E]?.3#F-RH-; 8-%=-ZK)32KIDZE;M
M%9'<8NH1$:1O&9NK"'1FB;P],6BI'=Y_"#?Y&&A"C,TM)-72XG<2K$6TE[J^
MDN$.SPX/(Q2)K;,M3EPISV(UEYEPX)W";S0!?/9GQN<;BNL]DG[!II/07 U2
MB);X?U09_=6R!7->6>A;F::T/MT^X0SFM70*85FJN,\N>Y6#:A(R3I5&-?X^
MZ/Z'FPAFCZH+:&L$K>'.TB;-\[WDE0=>X:%G[0VCORXQ(X!4L4]TQX>QSW*B
M+E<_:KU&-(X!8?[J+:B[9[=@1+GG3&,4D)L!ZK:):P[X63;6KO9VN._,6\#>
MZ1,5/]Z] 2 7O1&X),A15/MP.ZYC-;CDWCAWU*^T,5(VDYE=&3VQ<.0J@$#[
MNDF,]>;)QB.^%_8@V']4'T;'>3\+>N(Y%*!A*)##>1+6TCVB08*P5%G!E2E9
M1D[>C;\O?U1ZB5XF-X@%XRKLBI9]U"Z,$%&,T%?#;"-:D^F@T_;XTXM#6K%;
MNI3PYE7%$,QVIU*WBWJU+1/Q%0%E<[[?\'4BR5 J&FRL<[\1NLFSO.@\89Q%
MB?2)[T,7?W8DJJGNULDG+],\ZUV.<$D3G5#J+WW6 RE1X"Z($5F$]Q\LV+(Y
M$HQ.CA/\0_:732&K&*%NQ1'9^WS,/IW_0W=+*?JA9%B]=O&K"?^JZ;\08RH=
MZ";B/I9 ,:,6R)+EM^SHE$=RJQ'^EP9,U2_/ $'@4' WAYN[/&;._O,+OG3'
M&&(RK_BG');]^ GRHY/UPN+-?E)&^7Z\6'^_2ZCY7@QYMPB+>.'#.'/-^]OY
M//]KV;@+GVQM:/+2-^Z MBSPIJ'NPE)DF"$LER5%J$E\NNW$K 5K&?U-3K>U
M9T9R9;+JME*/J"6RQKN?W(]A'E#80-13;$C#SYI&X$:]%58RP]E];O-*QTCZ
M%)[0U</?B:JN?J;A1@:]IA;K0B\9-2?/:Z"Y#!W$]7P1BI_^A?U&_$]1)11O
M4 ^C^W>^$ZP/9ROSB;[5:68++L7Q<ZC?T\"BI12?^.RMPZP98Y&CE1))P:V?
ME[3^]80L#GXTXV\8AQRI%S%.FWW(GOTLNV@,UW%';GBOXC/\]4SW>(ML&<RN
M;\:^=,O/@,E)RV^6EKO3)=9&5;V'16-]\%>'C([Z>-U'^ 9+4YN-'A_\5<ED
MR31(3)>#2W6K_H\,0TBL7)&J37!+$((6'T%^3Y],;_VKT9XE$_R6M]/ZG&)^
M?2-93)+6L?D_*MFX#DB0H#2Z"[2\[Q^*<8^&Z,LIG4=-<X[^6%_CA#=G[# #
M\U&;)=,/0XGDHI5'(?!&;-O7!QP='0=3V@U "YU_MZDR"0BIRJPJ?)[7C>Z\
M,7Z"XW*\*T*=#9 5LOU11WFVGR'%?V<MC45Z)_:&[HIC:VWY\29?KY957C[3
MY6=!JCC?+?D:\UG(Z-#;-&U^ C0?H$B^*+-;R8OF4" JAWB*[KPDA%EZ.S8F
ML*C/5RK=R/.(XGF.LRZ7N/7N?Q?!P>].2HM;>/^C2M)_O(XMO</"-%0:CK*2
MXT2OIC7XO[C?,D(-H42 1BO'UC;J/V#Y;Q+#8[FVLHF,LF:KX(>GB> BO_[B
M*8OW7\B$TP2@0-'RA@G2<5X(+X13'.D<>DV1F:.YW#>M9FQ7:F64^CT5G 0^
M,6JX3*"QJ+Z]@I%H<M/:+NKTK,R<V4/W,X]2ZDGYY??<ARCOK;<$*7U> >BI
M?%IZJQY NLROP3Y_GX'H8B!%'&+ KX:0EP=H6DMS720PM&@J?,MY#KL"^5<A
MF.4ROP2,'6P7.Q^_8/OU=>FUB<L&6]\8?P@^('TX52?\7?O3B(U7?JF"HS2<
M7;_V.AO?8'/%B3V^ZE,*%VSUU("BS:1BWY2($/N@P,[?YOL1XV&,-RKPF\I<
MERD;=6[[T3_,)K7&>=B3EWWT1%>\^X<!@9@=D2B2@J6R6C=)\J;PDR?R0.^3
MTH+,CZBE;] V[@'E;%'PL4D+\97,)"F?NGG%H#[7BPV:\)KF0DNV&W1OCIH'
M.X>2$C]!IVOJH2>?L$ZJP>]GB^1BB;BWEYN'_'*?U.NSNW/ENKS[V)_?J8'<
M=GX8C#3*WC=MPU=7OP3='5PQ07),?',J8,%6RW(?8R,'JMZJ&8G&14PHH1NN
M7^*]$+1)(4B00GI:_=-KA%$VG8C2C@J\IB?G&1"/% L?<L0+M=5J.H/?):KE
MAEX-T@$-UWB&DM=(-U+L LU9110I_OK5I71KFD[<L'-7R=;A:O8L&]7QEN5$
M6/8KC,I:XAU0R S3Y>'<#CLC0\TK[T3B-3?#>/5@,'BCD90MJO:ZK7J)#]M/
M(W?+=T(-Q4J9&S. ?CRNDEODXZ'58)DQT_V)WWWY9(%EFB:2&'H"7\6+5&*\
MC*)E-OW_%<&2-24]LQ9J:;:9W(@]X2!!31_72 7J).^A?LG#AOS=1+72(^)E
MGB_0.>Q41PS1I^FEA)-,9,^L>M6AN+EV+JECT!0:^9R\&E<L@CTUG><+:J]\
M\R0XI=&QOBN)3:V?W-; U%TDH!F?$!38'+CBS"%_L2;B9TO_AJWBN_& 5>(>
M1MD["[R<J'[A6AEJ/MJBVK>G$6G\FBB&"($;SXM%'9KNA^.1ROW='E+]#DT+
MF>$U@Y53QQ%-="KL/86,>M 53]H-SX'U%F.NCT-7;N7$]5#SD9*JE\Z:1U@>
MN*"6CS_LP9U5'4.N[]4UEW. ,4("Z\%(%?/ BT4K@"-&N/1[_S4N/GL;=[B)
MH5'9&9<4H]D[F_!*[,1VGY+C'_DVTI4^):/;&H KRSPI6K6,,Y.\EEPPWPC%
M ^S\QM>O[H;5ZLS?1414L$6U?2U\TPQC][OT!"1D)XLWV*8T'P::WW]>P94R
M.,[P[(!7T2:6Q ^B;D' =*T "L4B!_,GJ1G[L%4.#]>A3[U#A_850 E@ZQ@0
MR_Y67GT;7;0I2<LWQ8*WR+48=YCXOE-[5V"XDFS+[SG[-=?;IGRE43T_*_^5
MF=E%;<$O4K:LK!%#VN+ AVF&SV33Z<0&BLM_5-1>@5PRE?-IPDXM8_-7WA$;
M#>-@[>/$)K>-J8(&,9:-^%)-7.1-8H12DM(7-<>E@E8D+IX+?TR@?SXZI NI
M);4L('E3[L>D'_<_4S3\$0(GM#BWZ'AL3$WJ"2R?O"[-A+@FW=%Y>CI*_>2'
M>Z'RF;EYVV1T2+[E[FFQV-,4QY;SFK L$3\FXW7!P9'P+$*M*\(XJ+,FV'M2
MEMN/-$US[@.Y>VS/$B(<?X?SQ74A8?S@'[85-,8FI>7F0MG=)#'-W^3X2IE3
M9,V^EB]8^"%#U'G, [?(]5A+9?Z$+:'41S6/JMX",#C%RXHTT&AOU0*2BJ^"
M1@&O/O$3!*@T72^HR#CJPWG$H6F48-M4 ;5 <G?@$$OTY"/0S\79&V7:QM9<
MR=L??65=^)E6MQYX1)"3T<(<;BIGXM?<'25:XTGA[]9S5Q-UH*L)PS76FF6O
MPC"CE/4W^=C:@HV$N!FA+T$)UN#U'%J4U3\?2X0Y>(-:2(5UY$Q-O3 3S-P6
MS,3,LHBP4 M\-!:KY,*47)&O-ZD+?K?8HYNKHJ[3:2(5/IZ'C5=SC739U%-K
M_@T_QZ^FR+ M<_TY;'S.Z8T1,TN@.;<K0KV\\YH]":'IV0.\! '_&LD]-6)"
M]O3"O5$+T9L6)H]T)[:FQ0+[?NPP]*CS_SJ_8Y9N0=HZW+1*O".+LLN_K[&\
MY>+#<B2LPO=^<O2X1#+.?)DA=,[VV7[T%O@ME?*Z<%MHI(*TUI_:2?HV4:7$
M_!_E9U;TB.',@VV PH?L\ED+O7\0XM^B*BN?Q45A2=WO2S#=M>9#,17[\]2;
MUY9JTN=0MAQ3<T^)9,2Y_@Q]3/WD1N;EG?I10'7C>B,$%(GCTB,2TS,_9Q(?
M;C :1 :*.15H_8RPA8B:.+-D)7%%=Y,CPY)D7L)S?F?](C)^DC:@'/;18)U;
M!1MDLE.+1?(]%(\OIJ&:A\?#M323967(*ZY/1L+K)5(I%.<D(0]=E95C WYU
MBO]9E\+(!CQY1O]YJV.=C=9T6+9@#3\;98Y37F579%JB3F>Y^R'-23[-W="8
MC8ZW>\US*L)$WHUF#5&9^K6X^"XN?R:/C!T:,$1=</UP[C\J1FK9*?G5>&?^
MP65W;7>IN[%XA.TZ1-&94DW+-#CX333X30'G3\H@[J&W:6D_7Y^*5V?,;3J!
M>UZ?.EUM26@"3U;NNN+ZEB2S8#)=0/*\3TK4>?V@<GW 7H24+]N#[CI+N7K#
M@!1$'XT.<89 9W0;P((Y-CF85%9Y-1:=2T6OL;-D"*=%20KM"<.^>4LL\X,4
M!5!AX ^ .E7,";SJ []>X99\'S5](?>X8;:V*8?I5= ADH.$5>Y,$LB_Q/HL
M;]:(BL"R.VM4&Y]3[4@8\ 23BAVD>OAHJ7-,]0(O@CR9 N"9JWME=<XPB1":
M\G\]F6$/K\V8TM,-Z24*)DC1Q2(B-3'GYA*<B%'Z8.Y*5?B &'-B7[&522(2
MAY+R&;J!!"EZDTG9<@Y:=SLGO)V/X!V(*0.&CPL&(I X<(K%W':\@MD$_F'?
M40M7L1$MPR)3L$/9'YA=OG\JS^>U*YW-?'H=D618 1L.>9YN%#Q4GD<],]1
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M@U6=C7W7WK2>PEX2FK:)2!CX' !GS!O8*RE*I&ET"C0='6[QT4!D?..[.\Q
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M" ?4";]BK^*V8=4FY=_YU'^L[Y6B"F:".,-X_N#\P&6^T:YE])2 Y*WJ_H"
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M:24E8+500[\*=D/DS<<ND,;YV005_8[\V0./7$$CLPN3T[5+\<EH<#^]CWO
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MF9X*#?@;\POMU3;NBQ+Y/H65@=@[*(35?U2QL=^XYHFO0&Q\$7Z.G%&S[33
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M1,(W<#0<!0056(P!E<=$\D:L+VY30"A_D8A)&7/YH4/IN$ 73:#C5ENAXC#
MOQ.:U^H])4,Z>!;XJ)L5OV,IH=)S>K9+G9^[%0:M_?0*'C_T6;V:TW!FQ/7=
MUL[2@Y@?X3/Y9U"3K 1^&B6ED<*IAS_H,/\N^Q9<WU4)MLG\@^6XEU)QL@P
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MF_F<%/Q'PC3%9G(O7I.9CH<7+*E-8F!ZF?A4[+;/ZQ:U5/!&P(BWQ'FW7=2
M<B,N XNX'?&M[!4B?\KQ.;Q98LLK_"O9+?^\:7ZY,WN>N4\/*VAA/J:)\_F$
M0A7%5I$)!G><J?%4L^K"37NXG.V:V%,%&$J=4]YI)MDXRE?M5O#V@]3F_5:F
MYNN/@;4)>/NIHR\T6P![J ]=8U1NH7WZUU#]$7AOC)^J_GEIRD$DY,O]P$-)
M0 -(:@X]2RIH2;QXI<H?BD'I)C$XPL$*?-;-P"\GZ16&46.2$F:[65C5=^+%
M;G;*5 9?X%!;V?FRZK<UKST97R ,D^*'QM:R:;4@65+$#!9B?,Z'P)'K>$ZY
M3FN\?'(8?.JZREQL]C+.==0.(^[,AR98]K@Y4VGH]1Z1^E"5=GH4LO?RKDKQ
M5*ZW1HB7* =C,[\#<?)]^RBJ0Z*)J4<\?'C]ZC#V8[N^!H_%%W0_:,ZAHS#\
MJ8N.B"LK+2"0DAO3=HU.9T9R'Y?GAJ]E"K%,E]13\:<I:)K4V%P.3!9XG.+C
MVQTG.?C>9M"1Y[\@V'\G[H;897,4CRU1@TRL!C^Z.OH3A!_MXM;P4UZ1P]^4
MS:$]4QKL'GDE,$-<_&O3]@\,6B>9H/J[SM_!^V^[IB@CC(PIU<PY>BRT/_PP
M#;G(W[Y1WHX=/#XLXB)-O]XO1.LI$ZNYYO-PC;S?W==/C2_9HUEN/X;Z!^_(
M*QW-3; ;4])[1A)T*H*$2:9Z$^Z1"ZEP\^RMD=S/NZ_2;.W?)_55R>(>,O_X
MQ@59_TKH26?/I69+NZ2\F$J^IU(X-0_/Z[T3+FR[Q'\D-%Q'(]M7GXXX7)!:
M.J#[XR7P\F<^GV%0[X1^"OUK])HA>B8LR';'/NR5!O439Q_N=6NG<FD;-__]
M%+GYM*:DA P;YVD V%NE<.5*AY@4S8JY#-"@35*YY@1#BFRZ100I_?/[C8+1
M=*.I3;*"<)4XFG=\)V$IN*MJ!KX H*PA;H2'4"4Y-1J:I^![E5^3F'>0;R*I
M<U71[:1'R3#]HZ%\0^7U*4OO?HOI&&^P)K7C'4[G-<,@/)6Q#'9--*%TK O0
M+%8ZJT,SEW4ZZGH /BL,4!?:3G\,)H-],16.'>%IKR8C!GZ&G,QL=U5-/&3I
M0"F$!F$Z6%CF52-Z@X=+L.>>9-GQ%!0;N<CO"G$ 5^3!PPDK<L>F5)*%$>YE
M3^ZN!@%T,I:AR7F)^*Q1FN..T[[  [J78['2[0^E.T8>49O -A(N3H6BNZ.M
M W-(/ ,K_KFB#I$>G9@VVXCN;BX=$PLS.^J9)F-3>-.G[P(WQTV_Y!)6::>M
M>E.NYZ]WE_P2H(-AS_G\!4--PM.IVK,C"HE";KXF&A'H_:.9LZ=MUK8<8I7W
M^:N]2@QQ?>>Z_ZJKG&L6#[/435YA\HN\?ZK0L;QD!W!P8K<) DL$08HY]HOW
M9]P3IM2L>PR=KI0V X,6D2YS;TT.0@Y]'QB308;;5VGC&VA>8<K1!'0\9_V'
M1*:&RH=D!).P/U-V7N:=$3; @+=QM$[6CH=(Q6_I.Q3W(X!PS0V6+D^X*^7]
MCP/FS=]-;.S+/:69_B%=<O:E,DVFBZ,D\R.Y]C5)CAC@63DZD,B#\J^'[F>P
MH][>VE24JR^(H&%0KL[-3[G ]H>+)/[%&L$ YY!S;0:NJ3WB4[&VGL/W6K _
M($*80E )E9#!ION1R\JI9$ZI,H9-SFA^7/HL%K,[CXKML\([-2;V5KEVC5_E
M+IUPM"R;C=)B&7A6*"_J=SE_\[O=BG1N/E7 Z+]2Q494"1:FW0GDJ_OU!O/=
M4!7YKL"E4IZ?W0Z3BN!IJ\/%WZE7YK@M].U4!9/<M?->U_FV*8S]W"TFJC-&
MS#ZT;KV$?OY C#8)..H^!!$&,@8E#694.A(22E@J'L]1\[Q'G8>L /7^-OAG
M[["#![! '!)ZK@LYP?=64Q0'A"ZR6P6MABZ2\$8ZCP 'T_&K(Y]^]6**.%<8
M,F3[0'R@Z[U?*-&Q#2_D0$;H%#]O%FC%.F&8[<TL^K:.+.I-5(M@0 [P]_9>
M#J-VX34?^-0G]HC^CR!RC3,@%X]\C-^CPI2]J(Z@"QT"C_26J4/4W%?;1SY1
M.W^WS[BNDE@U/)7JX(4X):B(PM,08-UO V+D;3C]<CB->,G/ @9\\VB9.@QJ
MJFC0F9;/K-6GZ+]??N]5BW]K4M43ANF?F2.?W%4&&ID,X<8OJF4U&#\OSC 5
M= \4L9)NX:@_!#&^-(H$"^U%Q&O9:CQB)I]CD['#J#X3^T<A>F6$_&0B5-<W
M::DX:2X'.IP[PP1PUG6[[1RG=6UB\G(P"$L;:.<"6X?#T\P9*G*/@FV\)'"-
M4=JJQ"ZPA>"5EB@H(BB/YP/1@C-BJTPV\W_RBX"4:6E=M)[ARR47J<T=Z68S
MTNX\\K6$HZNBMPF;UF 5,Z>=L6&OTILMI%,P?-YCPOXDT.!:<R+W8^Z9[16L
M%BM'@13[<AYX:_2G;05=#5W9\K^IB]"$;TNJ+A"<U_;Z!4387->8+Q-^IE(2
MC.<8>T[&6![]3KBK=2U14;*D?^H(?#T+V/@=N#FE".K:7"I\&+JH6J<P3M 2
MHC^MP?-G-'D4Y^;!0V0*K<B?Q/%'=595E!^7/EA-$\!*GR3Y'SDF2$:2,7!F
M]EO*!'4AFMZ7G?,]J"Q41YA185(\13DO1H,#7C3XJ[4>JO0UHEA:"*4JV:*!
MO6-NGP';A#TX*)EC,T,2VCZ8D<P5V+O25"[]0!T?R8<6B>4+(<[T!,J,3;P]
MRM+C'$#('1;)*QSU],23-E]@IZ1\]!8^X]IV6S(0?<]&+/VK*94T1L].6/5;
MX,OS:.8X KO*>#Y1%_+0>)(;79R=-"$WFON&^C!+MC=W66Y>85.OZEGZJWKI
MU(4WIQL;#?E"A$_KN:21$;O(^*W+ ;R5B2#'Q"DFPKB@K>>!!=.X'GF3P7/Q
MO>,7>\J&"82GT?1K%K]&N$8K;H?)Y;ZT;WFGONXC-#T8&*1FPN*&O<)[Z\ZA
M[Q_Q Z6&B553]8J8=NB.":$F2Y:RR!T 3:QP76&TP\\U,G:&KRC6"FR:#1P6
MO!WLJCKW.I:@IN;T[MELIO<Y77P8505VGXCVWF.?O9A@9+<B[698FP9!>7P_
ME5$ZL; @Y,5MI',WF5[J<68_K+")UPPK-HSD4._?2JYXAN\'B0NK1*1XW8!U
M%-16<SYM2_5^I:P*RE B?S@%=,TF0@\C-(D0(<A?F#9/"T@42WQ^Z)Y^%DEY
M#U;](U>]7+)W&B"J+LDXBEIQ35T;#1_7TRB7RQ-#&0?EH\T""H,.^I6:8/4'
MIJQIJ16<]0BT)QF4SW8@D\<RW?'<Z*X6X;!3OEY1M"OV)Z>GJD:4O.Y2L_[)
MP0YKR\!C!KA*3LB.-H!$R V?(DX>#1>E["&3@3K;/GX\#9RQ@@E/,RPKX1ZK
MO+K&_"QNG=GVDPGJW:LF3U1U=I5^7C8A^4&YYZ=Y*Z^)]PDM^/"1!==X^4=+
M/P.#RS%^#R4/%AJF:7PD0Q +JG/P).[0!TO]Y5KOF'KG5XHL>:U 9)60(975
M^,9[V+W1^1'2EM>!_2=RL/0Y GA(2W;.LADBWPK':S:ZCQ->XU;;[!>L-UGT
M-._:4NCLGMSK IN2TQ@<(U'-<<AD+IZ3B_](XMM:,MGOTM19>&MY26X[]K@&
M)*2C(:%0_!QKK[ACT43F_R:7Y$)J"6YBL2]<'Q_"-(LY3&HDIM*:TO ]P*]#
MW$=RZ1_H/B%139ZD+E^PAFF>N<L3$T"5[0)F4 (.#A@N65@U!D'.XP0:4D#A
M<_U6DT&!8R#J+UYQ%3B&"MCT7]WZB? +UONJ/(0(-OHD\B/#IJKQNR4L7,=U
M["'D:E]UAO?([KE_>K%G.+BC9DLBY]I@97%YZ&2PYLM1^+*!X$931.@6$DFE
M=LA\2([]%F% (.$C50<?"]K&SFW%_O.<)X#55D0R>1J^ 1EF4E(?\V,0+[D7
MR)@YM+%+-@[/=ZEE8(Q^<6Y$P2<WO?N^:Z]\BM)[@+ YXE62U:H>Y97C$'-_
MEJWJ=CM\'UFFWW?KR$)?AG%6"]YM: W/5&JFR>#GC\Y2N9"H*1?0CEV3&V'7
M?MWLKCV$I0M<[B$[W_ZA!B)-%K%O.\R3N;[*'M!_U?YO(TAQ<H]%]1U-&J^=
M,W6M:]$,Q[1"G-"X='PW&8J<3+A0#U'U [VK[_:Y#Q44\L&$,VIC6ZO]B-0W
MQX%DTW*[[8E)AE1(ZUH=R2^)^H!WN;&AH^+@X)4K+G^J@[ 3F 6;QPZ]M ):
MD27&=E.(EIX1PT8400!Y-XV7AA\:#7(\8]C$LFE7Z +;4ZG<$<IW#D*A31.&
MBOF5E^,$R,)\Z4$0-)3UOG2P/NYV:/?^F-N?YU4&>$B6T7+:#=R$BB^BZ<.C
MJ=A-]M2@?22*;-#S1$X[7DZB[A"%ESGB*?"M4.6[NP-SJ,==&-HPRXV,#)<U
M\-2>W.JN]TA,GF?&D\Z]Y(XV#\V-"*7.+L#J&L:\(378"9+? ]#AT*1\\<MQ
M7G62R<MRU+!R'N?A$_F, P!)-C>Z)! <Z:B^I'&@V@8RC:K"R8F1<(_]C:6B
M995KFT)_U53,(>8_$C$Z)<M$0U*'H%DRN:$ECM_5F/B]RPQ.L%!JH7NWRU=8
MH7F"C 5P1=0^^:F0_A5_ -3_+OAQ(?VDK/']E5GF@C)L=)8Y^E4#4WPWSB9)
M;8ZW1?Q=: :.(3[WW4I>&L_AG1?*U9IVY^I]XU$(XF_5>[,3.SI[SFM![-UG
M19548+O^^]5\1VGGG<#%7UNNB"CPN'6F=@N+*%/Q::3(_E%H6<&VQ'9L5-5Q
MU\KIU'L.@Y[:[X]1='"UR0R&(*&M(_\22L0&#(%G\+4;)AA.>4$"C*C*T*W]
ME-YZ>TX+W77?.8$_RP<!GX9*<':H[3\+;DHTK-!1^]$A&R['C9SNBPZ5JUGR
MC]&>*ZD>3G]OH?1M(E8G5MNDI[0AGE545)D ?J!NKBZN=17[0Q4!%HT)3 *0
M[GS]O4+%;B"]L9U?[^DL4:F_CTQRLGV>PJS<+]Q;:;4U#\GRUF)8Q8K[?8S0
M$$-4&QX30[N>DO#&MVMS?Y =)LA==1VA\NJPXSM6?]8<:NC2S202&26BTZYL
M4&2_X2=N/MF[CR,VLCG4L,NC.#WY[HO5J +@Y&"H.V;D<]IKR#[^@]X^_XP&
M2!.YITK$1P[-?7P[)>3S ]\3'*$L> EM^5?@I:-"<YPDW=;KTUQGE4NKM6+-
MF_ER&:C^"E85M!K\R"U6.@_D#Q=;S[I71OPM0E#>' VU&-TG>IE)J4EP"0FV
ME75D0@;,"-;Q4DE?1#)PFVX64.K1-OU*TB[_DXB6SYM+8J _PAOX2*!4WEZY
M&4'YH!9>;8/^,DSBB:K'E6<I%;R^/FB<$JMUK:"J[3-7L;'\UW&D2(;32S@,
M1%ZF@[FG0Z2;E\Q;*("Z*[O%,",W"U6S>$Y66*MM5Y5FIF7+>L,MGV_%I1=3
M(1U'] T5GU]K"0DPS:7FH=W_%H2J %WUD)>RITKJV/+2' 69Y[E[S'%5T "H
MPY\:*#4!X+J<4%DQT:.1#2,S;SW33 X%/(EF48%/JXEW!8]=:>)#A[AV *3+
M&P3NCO+;)HZF?];3/%OO1!X%0K7WL&N>GBR7O8;[2+EQGK:MS$Z'5!HYOQ$[
M@XVGMN=]V'I?K@.!<:D!/]J<B.X5D)0:FKLO5_U:['A;O-=>PHB?=FR7!"1=
MJXKC[1+V+?_4*^:]3E:6>ME=%\,12"VFLW5,(>.=W<Z]'2N=OP,S6F"8)@QR
M@DV]/-1D&T1#NZK_K+;YZDNJU1Z!'>B%^0)'3\UH7?77.VXLIP')$5:4_D-!
M,K>I0-N*$USB3HXZ/MN$5RS[@NKE;#>ES^!'\%&WK/1 .0@85K=A3A:8D$?+
MS7T'/R[;2^M$6R1JRT_?@A=6,Q_):CX6_7XC[$$5Q#3_:>3%ZWI#4B/WG]]%
M<X F?][F +:.XJ&PMYUE=Q *HR#NF05Q&03.:E5H8"/R+"[L?3E=0SP$3%[Q
MYU\S2KU"$XEG;ETN=ZS?T>'VN71<NTA#20;5[L?$1Z27#=_=[K=*Y>9\6*[%
M);-2S7&C^6L;HJG2=^(@@\>\7LF+Q*TK$ND^+JN2""-%+@;'G)X:0Z(.KGMX
M2T6(XN]H(]^ZC&"CK)9D#@LY1DJ$!40E(919@<N/S;(#9RGM+M3_=\C%9**0
ME_W/C3JBR8I#7EJB/1CS0^>PWDA[0"(U7N]9=);7QTR>;D3U&%@ KE/&YSI
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MK!I+<=NQA]?H17<D@OCX0FL]$O*#_KH#N=F;)!FO]H4+P\M,3CU(K_Z54F:
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M/C#=3Q[_Y'0%]YK=5P"U\1Q0$HR#,^/)\_\9^4^4=K^14QQ;WZOY$OTQHA(
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M$^L8$=0 3_$ (7[AWFG^%*6/R?5Z 4)@<05/G<4@PUQ0*,3[^!H/ZG(Q\\O
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M^::1,M@M: G_SLS_@KO YWJ>P96*D'@%A-VK'&'DEWIG@4H85.T"4PB42_8
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M-=<\SPOT: 294HK:'U@*W2R%23[E]RY<37V#5I744,GBC9QQ*+A-E]!C$>?
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M](TU2)=AJ@5DS=]I^>FMPJE9-7=MZ+ZR'VZXH,XK8PO+4H>[K)RSY3Q,+K%
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MS&]T@+BG: _Q<.NG6&M$&&)T\SADD::BZ-)R^QPB]!23Z0=EKUB@2]X=VO%
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M$KW76B"C(^.&%O2G*(Q/?M1 WG<M5-HR#SG=NWH*/ZFEQ=N3LNA&DJ_/E3?
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MS\W!3J[?E'1*6Z&&_#I@4#.@8NP=;T SG;II@UEKF<KT2-9WAE! W7J,)8K
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MQQ^."H##A?TEA/")OG819DK6^[\(-9\]$SGORX.=R=U0+. %Q'PB& ITOY0
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MD"(N-+A>10*U#X@;%U3,G 1SYF\5GSE#%W3/DB!,CZIO0$ASZ0I<(ZK!E\^
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M09UG.X8(W)S\T#*&%,\DA9YW>2!P)P$^=P0::YRO \4CW0IG<<Z)R:.TNB
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MHZ\%V@4=GDZL*[N#EFK%!<.R!@90IB)I&CA(Q=SI5.-<?G1_VIM-NN-GF$#
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M[Z#ZG[J5<3*W<U5F- ZIW<]R_GS^M?WU;#\KZ<^O_#?B_3;+TWO;V8VWY?\
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M=L_5_EMHPSM_XO0^G]+MO]2=ILB60-KL@R3L6"V[_-MP#+VLE_$OT?\ 7_\
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MJ8SQW_"DT8U=%^7GL$Y(P><1]H& =8I<DON^KQYN1!U?"(A1YG;TKY[HW>"
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M-8>0@9PN^?PX98]'WHMNKNO5)[NV7P4#CYL)R?J+[?BN?W<.-]E@UA+'=/1
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M+258Y^X>3UPI\0S04^U%4D]2K>.(N3OC*/X/W+R-\5WAS0V56)W9;8!/  .
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M]E?X/)^PV_6T"?J0RTTEOZ,>LS8$.$73=W;PJ\Q/.M<[UD#+[.1<_.Q_W0X
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M>Z/R9E=7K3N R%G*S1/7S[OWS;^7Y+><2OSED+ J/94]M[_!LYR^E!T66LN
M<7U V)&Q7M)U/XDD=R7 SYG'6*[B(G72UMP=QL64A6T"+S3?'<88^]=PRA/P
M1TDY)B Y-RSYCN;^;&!HF&W0UW/RLW^?'OQ!+@8.CKMOWL+/(%.6D/@4!D9_
M4-%UP5:_E E#-K[+0'[*+2YD@*C%B)!6:NC"=?D,6W!#>9G=$$@"D@C^HLA+
MAX$APGP1= WR!)PNC/?-":T)ZX>CSP5 YTE38]U4&MS6CAH\.%!>%0*CUHT
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MPY8 :\I[?5GK[SB2]3I(<TWH*;HM3A0KKFX!/HF=Q,H<ZG<^Y#)OQ;7:+F<
MFT\GUM+AW@S8L%U96.VP6?=X2(^\5E%_=&[MLQ 5/W*N-H&STHZ5E;,DB2#]
M<5(PLT'F$ HI:[01G1W(=W;4J3G'M1C14YH1]8CBH56(/E35 DD.A7<;*F9J
M533G_V^Z#+;$"*EVB)4'_':3&FM\Q,//Z?]&BN-[^81?8BL:W[:NA,VT+6(&
M5'/DS:O9,^^6Q4=!A>]6H,&R!EN 0X!]NP&2,W>*_F)?ZUMA#X'EB4Q3L5WQ
M6B<JI40JF ))9J",+U=)4 U@PPQ6-M.2&/T,RCA\I#&;Y^E=&5J$Q)#_]T)%
MN7H+H/*2-L!7O$:1R!)D;:#02='Z7_ ;T6^UI?YXL1"CV ^00I.. .A"#A2A
M L:MB0L)W@NVW=';5!'8.IP(9>V-_"X<V#1F"0;K:M@L3'&U*!Y>R3"OL8$3
MIE7!*?3**1:]FKH.=UDWZS%^2/]V0A![Q$;9$VJ[!7 ^^A**[67C^[<;0@2%
M#15L :X*'KQGUBZ^T0VJ&JZKIH.0*Q)%&N)KY+2$>'I@#?-09@.5^XKL)M;@
MG^&/U[QJYT@#_1&(!8J!Y9*.&5.!6\D\\C,COEEJ!-QZ?&WEO9B.-28".S8A
M%+%N;Z5MXQ]T-":SWQHO>(O,.3PB+?7F8=;QCBJ1F="J>,-T$1LA#'@6Z0,^
M,\<,S=><-1ML"V]23(T\K+COX37C[]9+N);RSW_H9&>L-]9\CNS%)B<+BR?!
MRKP_=(8X<@V;PBF'.[J$V"I.@U)@('$!C94E;_&_V1TL+E3L0;<D0D/4=3+.
M\\$+>#*L 5HJ)$^]H0,]%\C*F\97>8/9H?DTNWQ4,,C'&>W\XS,PG 8E^0EV
M11ONC&=(+*[-SH-[P4UBSR$64D[LR<5UHR#NV]F[7!,V('8<@)$/5C.T"O1P
M[I5TE23?-MPC_R+R#S. WJ/QQ=E%<([P>#2B&Y-3Q< XD-OA=":?B_9:Y[,(
MA9S.;8[)QEWKD$\I9;.65.DI1$"-Q/!G,ZDS-Z=L1PRK2E\R.=/SHC+! TX*
M:J43A3M7S<84T,2> RQTF"'INH9[3G1$!R*0:6CB2Z&;[E@VW@O1$A9S5S8-
MGQE:\LAG?X/;*X<*8/8-,QG=[;6QX.629"_L'+D1,SM/%Q(^BHCA;9\0@UL
M6;O$7E:#+"8Q:![I T12-I':.;TP;@X2A"FI[Z_IIH4*GQ)6-Z+]&C('L=ZV
MJ= !EO.0$-L6P$,7,>%5(=40%@>8IK%30OX<82(_>C([HN9OH[$<-6D2SZ_F
M:*B0<N[R1BNZ<K.W -W#2PTNE4JRT'&6H:EX9X2!(&2#@!8:;^S>Q#M3U[8
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M[D /&"5N6TQ'&DOJC:&DK7U$X"NOX^ U5:%+$1/HN;D3#%SD^H!(.=M7ZO'
M/N*"'@'7W:*U%S?#,&F1"E'WS]^&J!7XCTKUX./+8KP@5WAPFN1(JUH@&_,:
MBDOH)LQMZ-I6)D9U*SV5N;WWA@75^4E2W$@M[DLCD[L4[G5_NUH=#/I)\HWF
MLE96+%'U4]D8A-#EMRUT&HSKWR8\/JNB[<Y8NR5)CW"QRH]%*H>1I.#B'!C-
MYRBWRX0F%3A;C4Y)7X(=V/B#=6*#8]GUGE2,*ZVJ5CL^M!)6P\1\B*UF\%/P
MQ1H!-<QHD@'+EGF!9J"TG9[8$%7<"SRKG@/QWI3:1&*C1;$$[SJ./"JEKIB!
M8A&* Q"DT SO0!;(#A\P3R$Y)+AJ@!P-S(8VK5>P0PU0;KJX(%"=@5G9W.8-
M'O;*=0WL3U1#*8-O2*BJJJ%G>#,LA<7#S$/YH'(0Q5DOR_"G\MZA(0[%J/V7
M8/UL\E_\/TD;X%M+ZD%%JO"LA&QYLY _,0;U4?<A.J+Z/G%02EG &@:_AB'W
ML!37M1*GU:*C#0FBL9:C6>'^*P:9DXVU<VB=X26276[&&WCNRXZ4K%#"!G J
MT$3]CN/(S77']U^S#T3E_PUO/_ E:!/1+W8<--LE),_9)0W WD[5"GVB=^9(
M]-I]IQB"=TTW:@A6V-%L</<6H$<X5"2D+HX5%HA'*VB#?)!:R)\6=YCL8:-'
MW/]$^^\#(LR?FLD.@,,X8-PP['_?5,GSM7 %?LHU3-145<#M]N=WP^[\WKB(
M7[=0S+M_J"1/X]&H%1:(M=IVX-AF_KM:#J14/ CNA^M6,[8 )F'PZD,LL^N,
M)77#*K''1JI::)%OQZ%%&E97E+8%N$3>T\/ D$7G1>E!<]QPPVV%^9-7-E2M
MZI_@"FFK1(3OEB=UR"VU4H6@0#-9N&T!7YF?([K(UJY'$(58]BR'VHZBMK/:
M0_$4% CMF<]>,D%W,V%(N6J*SZWT('R8!KJ$OO3F86A,SR/(.W(AN$@\53VL
M>%5P<"D'W )S\F8WEL&K./7(ZU); "A<72J0XH&KS<B)REOE=&<]HUNZ:,#P
MN[^)#0>N,&T>M&RN$1G8R]<#0L:GL:7:Y%X C>L.QP*WG2VM6DU10ZMR"Y!9
M5?,(O,Q,*0W$$GFB#S78*G(OED$:?R4$3V+U%B6V !<7T.:ZL%YZ;34TK&9;
M+6@(.-&_4EUL6-&;D$.W8DDT9 =5VI;O:*D4?Q#;)MQ@UR-N8&]SY'%3&H:X
M=_[EV;#O>@D*5,;??30G:[3-V@S3-E7#M&K;A9-@,10;DSD3*5V&6K!#JN;O
M@^<1N7_6ZNN^J^9U/SXT ;;B(PHX$.'E;<?C_"1'BEXSPM0>_-(:-D#F!%73
MVWKX*QVHPWI"#"%DC(JAWO$)G&N8Y1H/-UB]8X\1UB%I' WC<W-HE9;0!;17
M*1,83@VH'#89I(76A+3*57<8*1[9)?,%XRH2"%X+TP-H2V![44" P/,C!]*Z
M[1P7L/I$MC:NUY3$U7K)[%]ZV<E/R()GM/@789L3 FKA;^A9+R,]$]-9><2
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M702=2:N_8__27KJ&XQEVT8+3=E\<P0%#:D6?K6KH&/U58(78,-,VE]1I6O-
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M1+%OTQ\IST<*'U>UB4.8KFI%8=TB,$XH;I?40/1E@'R0"6XD.0_9[?1]Q5[
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M%F.29K3<<AG-;8;EEMOFNHW-+K_U^V>/Q_YY?S[OU^5YV>.U][NH#<MGU@W
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M:G(9@Q_FT.TI[SC')NK4=54# RZQXV%6VC0S:IP]J:Y'#(!CJAOP-"1&8+$
M+!_]V$<)74Q04'@4G*'A-9I(3*V_1K4;OZ2S>C)]@T&'+-(5LKRAG>BF;<B%
M1=KM<,)H1,#@OI:@U JP&# @/VP;\^YIX7I3VK+KOX+:@O>Q6Q"L&$#/@E#;
MN73G)(EQ 2U;R58+TOI9!,8S-N:=R.Z',8LNHQ8JB7]3".;8TEAHB*H8<(A2
MP>Y-(MRD?/E7:"_ +(L!20+(&W77GP+,E'"?O(GO9&]JEF\_('1\>& G9 P
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M-BV!>^<?O#73EKMRC=5M70?8+*WUN 9\E'/RW:[#2O<[WMV7]U%A(/]*4%8
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MB^GS1!?JIK>D-DAU L@R-%,02?'?QKKR0-]9YG%@YR4QX&"#"/H5;1> *##
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M/8I71]>II1D!D5ND$0P>T\O_T3>R*09\0H)'K)0,0&Q(/!N.% .Z8'GA.,1
MXN]A?ZX=]3'M=GAA3GEX]N'[?GFXA^H&#3,2@&B##A<2*'!\D&9YB<"%AOVG
M?@LS+FV;/;;EG/%K=T 3 3*AM]R</M91&L'%T1#,.K*WN1AP9)G['D9(31#I
M;6M9,6:EN(69#]X<*G7[F[=<-&EPU;E<G]7,N/D%^T$,*"'15Z<Q4'54PPPJ
M:I9T<IGH4#[*C[J^3#JQ#!GD)]32Q( L?7Q-<&%1-S6Q:ZM.IM-L\*C-'XQ\
MT0NTJ_\R<!;C(> )8LO'X.8%F.O;4,^/UN7K!= K-(-3=;2DU/(RD3UITOR\
M+#9&^^ &: '*@F(%#?/$6*86:=VW:AWZE..;FN[2UP&O&8-96?IB_>38O7A!
M:S9W$C=)M>.I!4GCPQ[_[#ZYI?+YYH3U'6FY#YGA:?Y-/:[0NR0]T?5^]!1A
M[%"^ +QH:;<*X7#+852XE!B X<$<'WS*FKC#)!W8B5  S0JCV%@WD*[Z&*Q(
MT9KU-.;S!^S2UE;6-J0%.;,MO8BQY(D!%(4$K1)<FZAINQHW:TZW*AI6!\]S
M=*ISWHX65B;(U]>'%]]<DY-Z6.4OO"4J$;6R0)7H!$GA7F$K))WBI4\0+]'Y
MA;D&AQR]P6U\UVG:3IYBE.@#C1 VHX-U=S6=*RB+V:GKN#F')I)DF_DL["_5
MT(@Z#I8*'B0ZRB>Q",^0C$OXH-H>,2"SNJ%<?L<FA9LJ]5KP5M+NGRC#B*(:
M4AL<\I:$$WEO'"F5A$L,4!J9(9U@P9]/X<-)CA_':O>!8W=^SEL#P&AA O_(
M J%:# !S ODO>9AQE+_U%+]CBL#B@[[)5.(#US'/],6 8\>$I)W]&^>[H)%"
M]75ZE&M-Z  Z@>\P+09<$\1 ICMF(<<6"7&0:]%CQHL$R1-/GH_?8JF##=T"
MX"\H3]"0/3LU7^/ RCDW^]!_H-/Y.66<0"J?( :\83P56%,"I-BBTA&6E5Y9
MA%\/V<FHKX.'B-:U??X%R_'F@+_R,[=[TZ=0H!G@BF_!"#_JGX4"@:,3@?$Z
ME,KRL"ZI_C!XR%-=A@AI"NBG[]T1 UJ3XHEYZ0M%C&'E.F$!%_P=[5F6WHAS
MK!F3%#+[""7NF'_-[?#G6Y@LU[LJ0Q@W(5""\VE^IML,VT6BWN<]Q )IWN$@
MS"+\,'J@/(]8>C#\*0,+T=4-,'_@.QF#T6MB@EA^=:LQ>0H WVG ?30NYM6[
M[:CT*,T77,MS?IW'LU_UZ;F\&G&8)4I[6V4YLQ3'3?J/T1<1#O"&8$YPAG:T
MH:%WS!T^S@=/DZZCL\R]#P$>C,&]0X/(^/#:W:>>\Y)F,>^\#Q'I8#(2Y,T3
M?O&4YRL\U2H8W[(,7R9,I;MTR@1GU45G&-[AY; 8132DW0J;] ;=)JG-&U8L
MXR7(7]YC,.%H(J+)N3C(4>!!JYW25B%#C@GO"E9&ZQ>%D0RJJ&3!(T8!)H04
M<_3YB1*0'4.PF/MV*3V2?W7.U5($^B=Y?FV,/[^"I:9#>?;[,'@^I06-VVYQ
M=$;"TRA4/M:+;@@P)7!V$)YA@W5]K:D%W4F?XJ$+I"<"X*(8D YIVZ;8\5S'
MK/P@*VRZ5:GW_O[RQDP\3<;%E_GS$TF*AQM,"1Q$0S?+-T05*G6,.2M$+\&*
M4M9:7:5]OC/AM5!G&[($76;6]E'Z^8QV6!X T-Y*<I%5*$!HW%A=I<UG^4*
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M .):$Y[AN5]K^E+"R#?2/5$_YA),$U<M\&?3[6VU^1C/!G5[F[AN=?/\L7C
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M:".L->3$4O+2TX:O 2I>]WNV?"<A#O-BP+(%-V_'M4HBIC%7!"-,:#(=[@5
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MALPFVE,B*6_@Q8<M#7)*=M<O2NM*97.="(#;WF7CK-6I/L=(:XW9S1W(."1
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ML1+R4=NC+1NQ#HI'7WSH>5+E_5YZXO:>CZ>'=JLO__C4>#2\+_CCNRX5-6B
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MT\Q0 %7V@TMRZ&_#IA/XA\)SV%S!#D&Z;R4-O$%"BP77=>[,).C&QWWB(R9
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M#4N6!^CM"#6>A28,_ @"Q1[U3(NL0C*F:!'3[EU/\+757=U0N+!3Y[W8OHN
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M-6K_YT:N!3_.6E";<J9P!BP#K[)01GUU&XAO2S"$F$C%&CE:!%@-&,^'6J#
M91)A,LW+I]PC6XPD3K5S9B^?Y"<*K,49_680[.%++X"Q FN/<DDZ!]UFV#\-
MN@R6J%' /Q27Y';9I3ON\D??=42'(%H6=BG$4?U_-#9.[>6NC(%F@EU]QF5N
M+MSB#A?^QVJ?>3)D7F#:Z.EY .U3X9.1W.JYNI,=_5E8#]^S ,)%@.D@5P1<
MZ!B%J3MUV+%U:H,\29 \9MQBNM V'7S-C.7&Y5%\^;8I^V$Z:_H]Z=H(6R^N
M#,S<RY<'641D\"DHA24CK2 B"9H-T6'AK.? .-Q$Z [M>FP$7S-[@&MG5\+
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MAB%M7F&$+,'M^,A EI0P3&.ZN;"D0[4XNQ(WS]$C8INM.M/SVK-F)SP7GL!
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M>+'B8J"MC1-D#9JV"8S8EH<!$QBT"\%WJ$NI)X+(UA7.3:6W?5YK_#!M88@
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M,U+RR)-XX:Y0M==ZH_2L_>-FKL(F;EZNA:76G\67GL],9TDNLT1 ._SXG-)
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M@BU=#Y+^AY^7GH+MBIX&]XW07"6D^[&&^*ME#\1^@Q0NB?Q]>%09<UQL&[Z
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M7J"L^&+/E4/OK^P(?'^/>G!X%;4@]2P\WC^#83&RM;7U8I20JM808>8_=J7
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M^Q/SY"0XN3^T[VO9KZYJ+CA<=7AH9:!T?8#H_,1+^)D4F*F(*V:*H%TJ=]A
M5QFNFAN$_R6R1_#CHG%HNP[,%."@U>]^/5K4-- #SJ*?_L-A7S@**!X4ERD_
M@$],$C?1?"=,C!<VKLU(JJ[Y2H&?0*N25+2__=!RJ_7OI5Y41Q)ZOH8IH8U7
MD?^--_M2^-6%: L4NH--8SW<;I)'DI*49+?AQBL,>^1ZA?[5Q]+.$,Y<U;*D
MHRXK!N9&M:B3_K>$&L^)(NQH\+\F"^IGCG&DNS]1X(,R;*N ;O ON<'RY7X5
M]1.[J1DFN'=YJ$Y(BV/#YU</E"5"$%*&AWEU:(JT9<T>B;#Q\WB LM1*BS*
M<D M:CED\P@4RQ"7&@O?Q::^!!WC=3['8\NV;**#NJM6%EO\FQ7+46V:'P.4
MT-E5,;F\=\O84,V;Z0U;5=L^O8NN+:5-=) S['>Q%3Y V"OT'Q*R I'IQV)0
MJ=/S+HFBF:]QYZA.1<%F'8:WQN-W).MH8ENHZMBX4O9BZGC6:"1#%JP_&SC;
M/!38C,5#ZS41(08,65H&QF>/H?/*35G.UQ\ZCE<XI%RV8*5K^C0EV7,2]%/J
M7V'6[[OG"46B7HB'",K=)2:I/2YZF8/IPC'V)62UOE(9O^L62KN1M&MW:M>Y
M44;6GH$1'6B=Y@RH5#6<BN]XG^UU.Z]77QHY\^S;_LFE5^$,RXNM LJ*_J+N
M$W=&TS6#>7$EVX$9@YXWO#NWC'OCT4PY=>9/?C;%291/+>%[Z*LRKAQ\A87_
M9_C<C,\IE,X[!OBCU[,C3Z["[;1H6:%%'0/7?YV6_9,,_J"CC!?*+9\D+IA(
M4#G-M[;W_X&&^!UIA>M?_+-C?+=)ZN4]Y"F+.6]9&'#,)/.$>.D$$\W]26Y&
M)O&$1(./2/GYMQX8H"3^,0O_7G7ZU]14.?JNHH) ?;=NQ%C=/HN^*BU:.I$K
M N@%8ME):SNO\&U+=EO.?3G.%IF-GM6'@=-^JU9^7A,$R&^.9=>P?Z,ZJ0R_
M-,/GM:@7P5R.ZWX5Y7NC"@C[]3#TY(;P!)'<#O-D"6O3REBGM\%M%_<CA4+S
MTR5 !]*.2U_61ILG/[CW76FH17FA[Z5"^U^<U]7<^S+&B%CE^GPUFFO14J]%
M/>4_8F?77TPY<!G;5Y!(D5\KL(%<'1ZI/.UVU2=K4=L0[A \HK[D:+#VUS+;
M Y!4* W!:E&%U[YL:_ME#YQOH,+K/1:M7M)F51_WX2+UCI( N@&_?P4_219$
M&M>&Z,6\/WO<@:,*'-^X(C%^P8+O31)F/BXY\6UY:U'^<LT>[ :X&/"WW\,0
M&KHD?_D/W0-9"C7N2-#7M:K(>R+">,0#7?&;BP<T[NQ=\Q7TE/O2/ /OHW%4
MXUE+7.X9.)MD",!^IU!VQ!?_+@.^[=*B_HO/D@YT'W@P#SWZO(Q/+#B<H$5]
M2=ZD^2=#%O<$O(5+9T_ME')ZVMARU1]7/>A*]%.*Y@1R/51LW$%'),K$GH@%
MIJ[<+@9'HI6G3-L76IMDA<!OL6N5ST%WEM$I#;D#U8V'!"Z9_YC&#[+FKIS[
M^NPU_)_*J]#>8-.W1)?:\#%KMZ)#7:8GL7U3=^#%8"?06T7"B\Z![\+K5B-X
MX2B]P(6W";.L0EHMW"N>V9SK!)MH<ZLW%1> RA.-^A#CY[U;Y,O!*F_1(ZSJ
M[Y$Y^Z*&N$=!8_L.]EW7QT);I9U+?$P>Z5;J'1^9_Z/EPF5KORV/#QEJ[/V4
M&EX95_\O.O5\?9J*J>!F3.F!345SE_28*RB0^:U%H;#^W1D)HHD)<RTZD4R#
MI!E5]%/YE=C4'P(+T;IZU^[;>O$%HE,7F][,IITB@L^,-N@[T17'XF*CS/^H
M.5R??V[_3OOEGRK@21M!5)F5R/N9)Y'[,PA&J\BK%)TE&A=V((HZ)EC@(1G4
M#4(X]5+K7?<2C3,[<"592!@) $7_ Q7[PV1ST][0)EYB+A[2^5NN9OJZ9X<6
M386L5R.I>XWBYM8VU+N_R'35J4:@"3N*<<O*S$&W:%%7J[(,*X^;?-)L'BN3
M8QW!?R@690S2$=%1Q#5LWK\37D"B]+/I.-S\7;@>/\$Z;*M%F6=8I";![?<2
M#)NO026:(V# 7F#2/F!U)K]PZY&<M.?^ 2RC"&B'5.U!M\,VD>*?A*BS%82M
MQZ/WI&9\>U? 41VO#,"XC,3&62[;:OQ@1:4?[$Z)ONP>NK2$%Z^_&@RA_(_\
MZLKEL6<&5@8]9Z(15#?QZR[+RYA#S^S4]-=GQE(?RLBB)>MEBYFW5FM19M;#
M"7=ESNR1=.6@.MZ%9GD5OIZH1452SRTI8_> AX$-#(%EK) B[;0=XE%!R-+5
MJ5#O^()ILD&INJ55_;?&+@5]3\I=PZM<JF]K&?,Z^D>-B\ME=]HAVZL>ZSZK
M_E-A>P97_S82,3_X7P?>ZES3Q>SDY+0:P HQQ3MJ?2@/]!GQ0Y]RI7JC-OUY
M+ACUS@5!G12A^%4X?2(^X'*;S.[8 J3T"Z\DE'Y7ZR)*3 3N\!CV['O2IV_-
MYK-MR'^;#5^$8U2Z\_E9);+RBOEIM_8X\]00L(=7$^=2"P_G+XA>>:F3A#[*
M-7!H0[?_%4 *[=GG[>[0E_ZH&1!ZUUT#S,F[X6WH"@D_EC.@ZA_,<"JOZTX\
MNZD[;D'A.?]%NF\^)5#%NO F7&4VVG,B"$DHS2;E)?D"'4E<@=5N(> $%Y!_
M)QA%4)61)D\E/OC(US([9VCWBLJ-IK8<U<65GU8MVJH89[511.S"2(VO5(LJ
M7Q>AWT9*MF^ ^Q^Y,?S"/ZGV!ED\Z8YS_E HL"!(]EQ.>FILY;SM<G=)L(>[
M391DUZOMQ#IS@VMU[2XQPWI:% A4VBI45*_C^EN4K.N_&L+\9ZWZHRG FR+X
MU<"CTA7R?B&LEA%8RC7M7_WV3D';6Z5E,UUZX%.-34Q(>M(D3(]:T=57Z//1
MU/.Z?9*T=N8K"M"O0)+^+*T/VFW=4/[FP;4);]+E$VD4Q2$PTVSX:BNMQS^O
M*[[N7<U(D$M+LF8>0"/GM<Z"9S)<+; -T57U\Y)@?O]G8_2:15;GTL$XH-(P
M86)C6*!P;D?=:R.OM,5FRVB"//0GUNZM(/HK\]-51*';05U18)Z[];$#GNT=
M-JJISBP]ZO"&."U*CB_5[&V69ACM./0T=[>7H7.KN@ ]V_.ORHF[#ZSS''#H
MKH9\H_KP7]UIB@2UC9M:'N=7&_+N(-6[BF_X*?%LF.FCY9]_K_-3LJ=+Y%0L
MTTZ/R9G5F>= SK=DAZTWAHH?-I@,KSCV9.%N%0M!Q[6:.^F9 Y\J1+'NMCIQ
MQ*3OK&5VF/.\P/0\\S6FYSIP:W^R!>RG!:FAR)&6C495:F@E6M3FH>[\,CN<
MQ[A<\.</7]GBA_%?78>.+$'=7.!_@W3Y8')?]\4(YE4UW29JGF@EO-HW?J^
MRPH]'7'(_X^AG7<W/W+SJ9-Y1$UOKG59GU*E+D0 -A8<HHKMO&)UN43[L$]5
MQK7F>K6#0>D+5_#/!Q8?67BWH$3]'$H?@F@O!-:+@<Z9^WMYA@<?H@V3[J@:
M5<$JW&B.0F)/'N"*X[T&@F(+4O$,&5K$)%:V.V7F\(GK%S_FF=HNB,NQ7#YI
MA.UE+M*_P)DA6B,(-O9J]<68>QT-@\._0V=.C_M4Q!LL]XG)]_-U20>6_[PD
MVOL?]^+,[L8BMY[B7/RNLM+G_777/?>YCUA$\NUFP4-R\// &#]I5I59-K4"
MHPC4HAZ.*CR=@1IPT"VI=/L_!/LCB[)OZM@M?7?PQ][EJJV<"?^"6N"PL:X6
M-;+D2%I[8B?_PA%V+\M"BSJ/,O53KU\@6]"1<.Y8W^4TH@&^<O@[HE'=<^=%
MQGN#[7<?I\QY @I')<(B-(O!O"4F+QES"RIEAW4/6P-RD]7_AN[+@\O)G9)M
M#R9OI>C.LX[H?#:=@;.SC__$?9*#?TNMHR+&>4L0'&6,6,:D?M'M^5\!5<8Y
MW(&) UL[6)F(Q_)M=ZU([NNZ1(*,8M/O&.?2;7A9]O>BBT5Q>+>>L%AQ:?]P
MIEF;YJ5&*!N3RS$)@94\\I'"7UV2>B0)JQJ*>=?#.SMN I)L?\X\=4(HB7..
M-<+(R;6A$_(IN^V86OMJ96)J2F@BQCUDMEM^4P9MTK2*_+_4-0Z0?H ;QMD&
MHE@]V]A:>[J11U7(;1] MD$AB:T]C H63,4,;?8N(C\<E/F_@[$]^UY']FE1
MN]U(N%:)JQT&0[YU\ZP6M?VSJ[EE(__:*N)/"W_2Y7R37,DAS&^=9SM.E(]D
MB].*\>]MXDL9+PGN)J7C/=%!C_8<H)YU]^S<%X3\@L%^1K.5(6UG<DZRP.)C
MG(4FDG&=;Z-<=V1!*YZQ1Q> /W%*PFO8ANFK@#3H0Q.E#<PT<B\[L:#7Y'[K
M'T$R:+FL@#I#M!U0T3Q%@_QW^45[8+ W:1_ZXHK;7T=-40M-=U".S->;M#Z7
M2M8?1."2R%OY&+AA6&JK60Y],5IHYU KS"QE.3Q_)^)CSSDO]A*T#K2<[#BK
M03 M QZ:@W%9FT:A(L)1_&J1;D?8 W8]+%@*AWX#IUCEZ).B2(<KN$]1(U*D
MHI&2*8I$7Q4/O?B6O^))\5TQ[)2HPXQ#M[SY"8KS8E8>;-U1#A4EP6C=MUO&
M]JY.*HGB1I</G*!!<QG*-BTJ";AH!@DS(K*:P!)!)4J+$MQK;O4^:G$::I11
MOC#]\R(F6("J?SV/T6[G+*^]V*@K7.)HA!GD,5P_7#1-7C5F,>&*9DC.7M2B
MW.<I$3?E,'@>XARH.1H64 ,0I.QT6:U>@@-MUN'7K7OWC8)B[0!EJC^])S-)
M[=R7 0-CVWWDM]O*L.<J2']NSW->\ML)$>/&EMGX$Y3FUL:6QD?G;OPU+CA]
M-+*YT(S@_*&.7XY)4P /V2](6A2?,DM@[V3P*P<J:,'NJ@?T325@2IS)F*T"
M9-6S/OF/BMA_08S7RUT&F#[1"OI$;,E0YT9T*T.>]/[ <3)30QVUMS.I[D.L
M8!\C-)&UOZH1+]'M77(NEMS3;AT5%O#9]*B_3&43RM <"0X!C1B:W78ZE0&5
MK:51_5;,111YE08O@+>OS&ORNGC(=6?=NK6^A3M+#MRSR6>;\46Y$86EY]_3
M-FY9M[FT-+7K-_?"H!VE@ND"K]%'0':CE,9?GA-!\1\UK*J2Z:VYI/\D+VTU
M^C'<@9OBJ69<XEC'KA7Q8!>4OINA5!C)D-938L!7!S_I]I&&%RJ\C'L8 Z,?
M3*"2R3-L"'S9]A/<K-@[TQ,'N1OG5@A9RHGG_=1IJZC_)#<TQ"_-FD_H'BIO
MX[:QWLIV!!EBR$_?# ]S^'^LWE%S/@L/&4+_/)B."F\VX?H_H5T 1[JWC43?
M3URN.B'4E(]]84 A* 4HOEHZNJ']\KDWL;C9^SB-\&4V6XM*C7<^D3"TT_P4
MR1^\DX3^3J%9?@Z?FQ8AG)/U<VZ>_0C(@2EP2Q<G_*S,"%_9[DYHW",)\EOH
MBRSX3?14>,VX]W,R'=*'4L.[!8C!;F.8Y.$K(HE51%:12\@&74U*'/!M=--"
MM^U_PDPQ)HTH]R\)G"=6?P7R62EZ5:_Y1&9Y!=UBB?F:]JUO%S\^%^28U<0^
M#V5TD_3=7VLLYL0L[^<"8J)@5H#]:V#6LN77XZ#_B380#IFOEQBCAD\99J"?
ME:;T]Q::[2C>GMT5Q1S@&9'D#FSG[A/;]H5+.ST]]YU@T6A)=WX;>I%_/BCW
M?+::X?1#YG:!' K%J0,UU>4\BF>E)G-0[!NN=GG.4Y5GF.LVB7D\Y@_>;PK;
M]E*96( 3"V>1RVHLI?5'1J&]O**:JHF+7>LM!G#)4/6OVX>E+U7%;&3%]NH!
MG^@3T E!8#4^+.AL1'[>R>AK<4X2ZQ''SR^0D CJ N"(R2S8.J#Z='#?GO!:
MCNN(NN8&$&11>Y#1FC#LW=W7Z0D2GQX]VG'TI-.!!ZO7NAV-='..WN#6S+S0
MIM31HBZ.#:#LAQX3E]?OJ1!AOC(T^JJ:/PYDGW\$AI/+L]1 7^<H[S5AV<FA
M\I\)13IK51HR=SY)S01GPQ)U9QV8ERVVZZ_]]_<<]A#+8 M\'[JQ<':9#'[]
MIG=;D_U@M->A8!.,DWVOARQKV7A*?DV-7(NZNZMD&$,^ O#1+_8DT946<05<
MION!$51D?TU7?"^T7WYE<B.ZR>4Y_@OL,'WR-3\_SS3K-G>/:A2U^=B2S0LF
M9<5<U:/&1<89N/*:I: XJFQ;U_J;?BV[JWO TZS=Q"7V<;A;^(!NN<1W4#5]
MRFBAQ9[*PWH.E/!#=W!,VY2ZDQNB"O/VR9T*5;).NKIJQ-/KW,Y<NICW%?8@
M=T-/5<+CDZSCZ/Q( L;H4KL+5_RY/@/7PH'^/!((]XS5I-29C0MI6A2A@S32
M,H!7]K?PTJE*0KS''D*[_UA<NVXXUQ>3T%)Y\R$4KW;@SFRCG)R,U_T6&P<Z
MOI;I1# 'Q5AV+\$QM%63&Z[WJ@FMOJFP1B+G]LA:J?Y$TM=!/BF_@!/66L*7
M8(+G,6JL*UR>:!0*3ZM,JR5+0FXOV+?*_P^3C-;BLDB/@NB-%7;5_@>K#2=5
M?[[\W7WCKA+]C2_==@6O+/UA[_]R:'/PF@."@W<C\FF=YF#XT).'.B:U88.1
M\ _.XY@?QTWZV2T)]J)LF)L7AVN?E.]9=SC.A3C_8X,MHMC%QP^LL<8Q,>Q>
MO]0&_&S=/U;HJ^R?=G\.O[TS._1X0.;=C0SZNX8SHG,'7%P5TCQ_S]BP\I#+
ML7RJ"M#]ON\BYL30BV8V7@&ZC#)!1B<%[M P._XX:C/!0K7#7V[="V@]/:8^
MJ;FHA_"VY4:''\=#J;ZBX-]9#A5%=Z$+X$LD"*)'0)OYFI/4!HEE<Y/)9%8$
M=$EC8Z$'1\[02X:-]#]N&;GCT-U#9 J_:XS#BY;@=T7'*/"&M1?T.Y6U""&=
M%Z:%ZT>]"F0Z;ET%;JJ,<T'#9ELW4H(?#><J%5-LWG1)<(2(G8%G&NG5=18S
MCY*8S'3BUF5[ V\O+]RPXN91_%KU<>KDP(@;!J!*[7:!E&'7IHOR59N2;Z5F
M)4(9"DJK.%:@WTF.E -.U=*7A 1?XXP  J9SB2./)\:L6+4LO+-P@2[4XW_#
M#SB6_:[/RHU8(.+]3C8JF+K7]+ZQ-;G*1^;A7=:8&WV^J:G4/+Q8>G+UZKA.
MWR=*X4\JWWO$WE!EX33!1#^4%50/6&/22/&4TG"]@O;/R]$?VO\V7Y^YX6*"
MA3FJ3O(:[M"BUIEB:=+A3WJ(B9U9],>2W(C,O/"$A<<5&[IOY"&+$6.23\,Q
M96DJRE^<,H$DQ^'1?@:OEBO.CK%;MW$K*_V7!;/Y8[?= NK2E193RW^F,P3D
MZC[RVR%>]3Y&!-5C@CH=DW)ML\7SA=BS]2+S[:51[C&1BEAGSCH5[LF+M+_,
MUNQFG3XZ8%5^KN]TQ]"5J/,1J<VV@H-5W\5($ FGIH7H1\@$X?;P=.O11BWJ
M^*U' 9Y:E,(0,&E D8%^"74U#*;ON1VVS#0XRC\52;7 P#EYO,N(C^5-359Y
MR"JG!7%%=?J73D*-\&J*ALE>&C!6I<2>/AKR\ZC)U"6_+:X]-7VMCX285_^\
MIWZA:0:CL8UK3"8K81ZT-.*Q<#(OG@[(V<1Q^\X_'10'LQ\M=^I*WEU.D7!_
M-16D3)A7FHSETT9S'YFVF45;<-;.&;,5Q^?[T6(DEZ2HL2HMZA17M-]>4$GZ
M&JENEKY\0P6_HO):G\L6\Z@7NK:X8#WCRUP%-TY,"D9#U,N78! 3U?1YKVLO
M6_.%4P3/017DW1'C\1Z^V,.<4=:3)(*<*EH@6W1?0JWEOJG>9Z% _9R_Z3VF
MWP@>81N/VSOW%8-Z(I9+B>Z\_%9G6J-C>$.XY>#>U-3MIJQX@UG@2])D75$P
M8Q#&$<?E=J<^V9E7/X:)3T(:-<G\N".=]Y=N6<CRGM6BOK!'H$W!P2)'$QK7
M.,/..59M>2:T&."##QYR($P#4A3;9BQ(LQ'K<YUL:)Y7/"+Q!=[3PH%_V8Z?
MN,[K?A^'B_QWE[[(W=Y[,JHV?VW'4)AYYM5A_2JRCDIOWKBN+;_ZJ70%*8Q9
M,%H53!QGJB\:Y9%;Y/[]/F8;Z]?RP6KJX39 "NT,.5A/WGTAOBN#U6FPE-5E
M<5O)G@2'+(ID_I0@3@D/QO?85$1&T&%<JY6HI95P/(7,JV>@T9%5A9E"]6.>
M]>S -_;Y3=,+\K.*(OA:5)[R ,W=H<\K>A__ZE#PM_GLP?GUU_[C>CTS<+_B
M_.RD\Y[FDC"&QWYF:]\@?)>\CZH@Q:<5:< [A%M(@2]T+1ZU/*=Z18%.DW]'
M&4F=7E!G- ;8&WI.?H:-*^H. +6 6WN#AB(ISW(PR> >.&6Y.X<]O;O[=7 U
MU!AN99(: )E@\*5]9WQ.$W/N*2^5N-67[2@^KT5EYD9H495[U-&0SL\B+2H_
MSB5K@1;U?O/7$95ANG'S=9H3M$,#/M>B])TJ>(38]*PE>1K#F<JVF,_]W4S7
MA0]:%I-_32X>O*=O=$2=?%VNSI7Z&J)^F@Q7V.S3W7(@N@+Z!@.]&(P;V4-.
M<VN,"F7*A[+PE8-BJE]9<(A]VLC \9>D\NV7WLEQ3,E(\$FW2-++OS9;'.*Z
ME"=+BG=2]:;+R#8JM$@@R\.Y,P<)S'("Y$N0,,7B0:,U[5L^"T(?HX+YQK!E
M3+ZI-Y(^_M*8/8F,F(#V/], 13R5.865R,+/@@;$R@;$ORUF&>WL#[>/A YU
M&]+>HRNT*!)(D9KD]9&!GVKWDF]:U*:)5$(ZW902K/=.$EO.X&TK+W.C1NZI
M_(J>6F^1"U.A<4GLWPX<[&NY<4%W?BW+T<YY@44@^X2)ZZ9O^M%K<^>.!K68
ME=7%A6TFV_0UQDP'N8D.V5_C7BO.\TAPOSR0="T5M\ZR<%_A^8\[4M)J@'()
MN6B>F3\E^&N+0%FT,!0=:Y]U&/*8$3OE,WL?#FM1 _5N6[P>3RT =T/>BI+Q
MQQ!U)"^BT#5I%+JWOJ%"CW=GU >6QML"E,!YKWMZ*ON2^1%35\4:9]>^0R86
MZV<X#;,1]7F$5G%O:?]TL=DWN +\:+\#+4T@UB#G3-EBEH9[M5P$/H7M0MJW
M%0,-Y4^T*-/^056"[BT)/VOAQFQY VB  8<RG(K7#XK9J.7N2XSAK,BI%-0"
M>-&:D \6<>^A3M6TK.^)!F4EB6W+NGE.9W#5BI38F[B'TJ+^P&XGPX]O<O+9
MM<HOT!9I3/=EDN;<C6,YI7>#<O<51AEX(H&H;UU[K$*Z+?WFQ>C0DC7V3?4A
M4]__%F] /71LN3CL37M/152,?UNPA_D!Q=59<4Y]28";TB>X5&M^U[FE;[7!
M(#DV[,#:>3^?-RIV9>0IJ+XM\-O]]E+_(/$-1Q+=E_@(ZECBYV+GG97?_O,(
M_%;B?TZH_N<H;^&?^J0?,MR ?9E;XH(P@YBFK6'!W\9?/>V2/3I&5FI1WG0K
M/7H2Q$IM#35/*N.MT:+B'+XJ;A\M-#E\<!7<KI2VRN@7EK=\TJMO]>YPQO[(
MT*+\:L'92.4&<R:'427!?Y&L7I%QX*1@HOCIC'W(U9^@XWJ9P$"+NF9[:R77
M^Z);Z[?8!87M0\X7/P?L8#]*4GV9 "2")0&BI4XSG0-;:[&342_VFA&"4/=7
M_J;<?GSB>WP(4&0.>X=T'-%/7)F2>7"X%)B39&\^27GS]<"'/X_,/O5;K!F*
M4G$F0C7?'K'>Z-[<]/CA*-"//>5(>1ZNRX8:E%FWTC?9/MJ)/:LOVHW+Y367
M)"4-6+4_S4(_A[+"%BV]=C B+6ON"GM"\=Q&IO>F$1:Q1E-OTO9U#,B"+^"K
M^<ZZFI\W'*T7:X)+*Q+_"P*>YF$'SYB"V=L+\PK%"]7>4C-5ZGBL2=$LF=JO
M$KJ*F +WK&*^^,2 C'U2R:*[)3 "B\\(Q!@BO2+TH0[3/(F!K3' CNZ'JUG'
MXE@>?U^,-F4UC'HGI+Y7L'O8[Z;/SOO1GDO%9+P">Y3S@D>0=R*0Y:'!C@!;
MYRJ)3""COUJ)U13[@/0PS 7% 77*JG.VV7W%^-VXZO;9D>DB;T7A026;G0Z>
MAHQ,C:D_0-/A3>/LPS)+(\C@PCV/VS+.6:B#;->]CEE0T@\K)G,&J=&#)+ [
M/G(/T=%J3P)=$ZQW\,E2S,9_EN):L-Y:U&KAA\H/!'(;Y!=:.!UCA!T W7AT
M2=:;;_6Z?[S5S]'W'X8 !!%:A-Q]&I@>!1W63'&"&3'^60.PA0QPI0N6OLF4
M%_Q741VP&OXA#RW.L;7 [7IY35%XZ,=FAZ@7;B[+A2&X@V(U;=)"NELU/4_C
MVV/%N#R-0RMQ'$B(JI#Z1K6JOF289,TNH/S5CI7!U=V&1!:&V\OH#DS$",<T
MODM<<=]^ I:PNDHS+69G:13?@-.:DM%XPU$M:L$X!$[DQ0) E<P.:"*[]JOD
ML28E1!$+K;(O;NP5V^-'F02QKP ^DE]=K<04]20N#:QTP*M A6(>W;Y?B:BG
ML8H.%L.32LE]:0$BF=YXN@E%KN\]#MG$16''F3"=FY[G:W&6,6C+DPJ\F$2K
MJO.+64\6H7_@9*XS; 9\=09W2VH4U4Q@&\Z#S>2XV:$J6HL^1_*K]<EG8*?2
MK\BE3\+G$W+,]S&DY34$S$LQP*VFF]0;KQWM(>%T=/M4G_^*2#N>&U%VN<^H
MZ)6YS?Z/F[>'"O7_I!GX>E%YC,[]*=DI//OHMP>$J7+J,QC)CT%X 4.3]!Q.
M$\M?6K=OB9BTWU\JJ_WSK)P=/L3M)?U([&8^ZHX4KG)U>LA2<T%7>W T.S*2
M 9> QX&SQ(JI2-@7T9^1,W8V2\7RH9(^+6J+]:,C!YO(2^VPQ^<EE*)!N %:
M*5C"O_K,R(_R_5?J-8IG-E"#B?M>RQQJN:0$!B$Q-3#S<%S[IO9>,!P:D\4P
M>*0HC7DEY%E>$TXXH\D:KZOME12T._1P'6BA59K,3MHH8;5>PF'V9Y,WX]#.
MPJ"3:P-& X.X^W//-S8UEIIYA>UB<&T,(MYA5TYNQZ2DN'O15M94,;O_Q1U0
M,%M:I69R?6$\NMCHR*\&"+@&<=N>=3P-'C&3U8R(ASJF>MD\^H3/@L?+&SEO
MI"1EZPN824*T;@0H$_9&#<8*]E?J(^$2BX^H(&I1H_ V2DN<T:/E[F_U<S4<
M:!O\%-:9$41]DR+Y$\Z&.R?_P<0!73"NGVS12^ %L!YR"F5#&3-#J6&"40U8
M+W"$ZKZK4W\*AUHE#E2N5;4474Q.G9 3*P=F8#O9=%LZ<X!+.!/);^FN$!F%
M[Y]:";0T6JSX\-#[+Y7C_])]6[9&NC7YKGSSY<:/G0R/W_%34REY#2?2;>A>
MVS%-?4DGU(3L% DY#FK]1%8JEX!Y4BH4I:)]%/OP) !Z$K!Y+44G:XXY_/3A
MD]+O#80UQCGKK'A'X =K"L9LUJJ25!N@1#AR%F9WPZ,07M,(9&F22GBJ6,AP
MQ-Z"'BIB&KD_T,N,/\$)I@<'?(AX#/Q+N!75B]:T0*]TV\7L=U@ATR0K4&GA
MI\)-"ISCO9I9S/89M1[[>[8L;\D&2[NK%55:U/:$5#N+8/,,77LK> Z\.DB0
MVX$?R$]4W5&]8LJ+X!G_O%E_>H32_E[#&*]*0,@)+2[XS$XFW I!MN_Q$9R#
M_<Y/9EZ#_SE7>7+=?\X$1249[(/[K,X';0X[_S'E8U3%9%$A([FNW+:CR3G:
MS\"J/-*GCUBP6G_2U<Z]H.W^AQ5B7HAUXXHDZP^H@YEG5RVH1^U<8=C(O@%_
M9_MKCD3AE=A!P/@U__5RUEY.+WW"WH.X=-U9Z5"VA-G\]L#KS>P'PL]9,HJ"
M.HC 6NLP!DS2@*/VOKY8K-*=V?H3>"#S+QL08^S,2^9)V#,MG:P,/'YB,)QR
MLB*T>&7G0T>^*2V=7*N:EJ!3! 06=A1P@= #L&]P)8_(PA5)34IF'>C]8N!^
MY3&962^1Y=Q!/+M-8C,57KELM?Q-6/S>3YLWO^@)+]R>\TK6?-KG;ACWW*3'
M1L;/4J([KM8ZX]-;)\G$CS#5&W<;1;%%9%.'F\RY<WH".P;6Z56_4(A!-P@M
MQ_%BRPT)+ ]_2L2\%G78Y_)&V)VN2^CO\-:<^=!W@SX[1%71E/(<1<4X>$)J
MY'PL,E 4CR^1PD5\G![M!8%$.^T3'0V;YZWLNV;A#8W"W/D,$4OW.[L$I@R0
MTHLY 1MYY#?*8DPGR4M>;]UH%)_@GVU#)W[3CV+S5WQ8_IFMV,]RYD!>[0/P
M$[7A$YG)@T;"="O8@2!\D=L27G 40Q-5RK==%K9UG<X)2E7L>VG2D:;BW!<]
M/XMS17=?P#VYVR/*=N1Y6EG%/_C77RY<N4\::V]8IW?6K:63F$<D/&M7T>0;
M)GP)),X@.Q09=U]]/MTD@ZBDG-FXVI3$Z2"N;+)#<%9*'LRVZ %3X %@>:4"
M?"F <;-#R.>1H1/@EBKI4%KBKR^]!_5;?GV-U[4W)G6)OO[NF49P1@<AG0B:
MXX06==HN8#"8I\0I%<.\0:+_:*6@JEH:YYX=#FA2B/=M[\K-LQ1$];I>@AQ,
MU>#'A=DR(Z_!X%#DW%>)<P>KIO:HV>.,@3D;R76=SR."QSJ?675?$MQ_[/LQ
M\*YYGW=X,FOV'6$ZO\N_R* T/_,=]\20 '@L? F> %?/<Z<UV&%@P[RDC#T7
MO[]H4"S_@560;K<)UH@R&%M[F^/N"0:L-Q >?OT0_E"S8+O-Q4OP97([U 1+
MQC$%U&X2M0=8.\G"OXIQR(@8!S9-;)"6V[K4\H>Z607=F>L#_I!@RHD; K."
MOK(\^L K0B;U[X$1)E!,-NQ7%0I\S4M*I<+<2-A3Q ^DQ/:2:']S]9:L;,Y*
M;*^/>"()<;K!9YF/JZS+C$[UDMKNOI[9F5TH[\_.#8IX]WVUE<'I[ZNM92<_
M\=U!^E'/ZWWOO(\.Q5VICLJG/%9QYE-@PR^3/ TXS,9KF)R9.EH$XJ8EW? !
M?5>X+$S@:U-I1'S5=_-X1)8-O&W^Y/7I5BW*7XNZH'D.#@,E L11-Z8ZT.6X
MCX3X]7L8I@,JG%N7(&JSX@BX [";I_%8WM]C!;@^</D$VY\/8P>(&)C>1S::
M;:;52V+3'O8+^ZKI,B/S$H1:AZ?T,%QYL>D?;^)3I1P!^+R#R'1X1(IR4AL^
M)DAXD;-Y?J\UQWA:5(G)#RTJ8Y:<&@G_2W0US5P>MR3A5-NE)FEKT<^)[*:>
M\"*OG3D#=U_<O:)%A>UZ5)A;6OVED'CZ9Y28N,7\W,Y2!3.ZX-47>?8]._0G
MXQ)INYSV835#,R"!$WZJM[.%(C9.<W56<C;LI1;U2I/JZU4P1HDQVNXXLLCP
MON:J_-D\$&.':R<".]7KA%#G/B6MC91?UU2UG^)*C\2+&JWN\][>PZ4!QM @
M8M]N1EI4;@62ZAM!HP8^&?>)KJ34TS7$N!/=U';R[A#.<WR86[S +V?1JK]4
MPJ_@&S1'-8-@,-I1Q1Z#'#@A_=R(R7BS,4=?R_85:E8)UX9N\B*]Z%)P*$-_
MD1;U !?TZK^&N_@UNUBVDK*5]J%O2_HB?6;>QDQ<8V6M4=%/O)SJKS(4YU1I
M<&^ Q2KL"&LI'C\O;(3W?ZK4N2F%*8'TJPP[J($2'5TF])PBD&HJ?_]Q>('X
MS<]QJXL)67-Q/> E=#51OXR_3P4\UH!%F@OU$@CW4E/R+7:(&B+0HF:9_JE?
MZ'C((^X\N&$31?W:3H:;<I5/XYA\L1QX!MM](A&3GCI4L'V12+"E&EF1H0[;
M'R=:P]?SQ'GX""TJT @;L]4I!?@>I KNECI=\:2L_LWS-\]#51QAGD_:B_SS
M=$JM8;9PE<SCTUMW+Z;Q],9NQ7,F;4,^H8C)$9$Y P?KJY8VIMEL^(E;#I?]
M>DE+JF:EX),*_4'?;P+<ICPE -(T5T?E:,X$*XP;AL1GRV,!A_2WUH>S=XA_
MI12!O*0/-!RG4J2UZ",51E%G)X%-RD2Y0Q[?48ZKY_$L,9U$MC@X3. _0(F^
M'CV?)+-04#O@M@K^?F64:'H4PC3^'.JLX\PZT.;L<.X322_XE0 %/Y__JGT^
M-KV:&5)35<E?=P88&7CS?(-WL3$Z@OG C5\:GN=Q&D(J)"RMZ! RQ0U->$QJ
MN?VRIQU:U)6WYZ'2+5,MO"[0GM--+1:#%J_Y9"Q1A1?5ZO=AT#FR6NP'4CGM
M!VC&B!1.R*=AG*<6M5<*2ENZ7Z@W$NY,"BO)"6I7_\<DJL >_PIB_Y2 8P@*
M:%'G6D>8<9A(+>KU481I^BK'#.A1%S:&)Z]_0T9K<*, DKO*)T'#"HUBTC^K
M9W\ESSI6BZI4=9:HV'_SXNST72LU">963#S_B)WSV<BPWN*Z9M68;(LJ?USN
M4#:@DB0]DSE0>DCI6<^0I,DAN5-*9$.UYP>4MIQB/@G#]"4^#\VRQ0C?<\U9
M7Y?M72W*<FX^Z<)H\O0DEV97X>(,XFV_>S&XS#*WYH.3;F'"P5ROF(FYNU=*
M#K#HS)B#5_ &%D(J%_T9\.$M ='S^5G/-&;E*]&STQ](6"7N6WS#R![2XP:9
MN?UT5&"5(&B>UFUDX36V)GQFP]?#9>/C1T!SEHMB\01[VSC3]U=3SV*'QRKS
MZA<.J?@))M ZZ4I^#'R!J3VJ6R+V9ONGAL;9X8V:X_YW1$!Y.;R_]W7K5R 8
MN#=8.5!!0>)XJ,R?WK-JY&L+!Z^DG> Z/%H87S1O[UV]P"P^;6].]P0\N2;-
M[TV@Y]H^15B?3VX8?N?':W^<R5VY#ZAV.CV36[2CKKWK WNE0FY..:=%75S4
MN+1F>.RFGR_P]U>3[@/+=,_]\Q&.)^NKE.HP04!\6+LLJ@%V#(DMKZA $G"Z
M9M2AI&\_/4!7PIF)&USQ4'XV0#_FJ,."R^C)ZJD5I!@EVE.%@)5;516_HD)S
M5=,8I4591Z2G"JM7(-.R1EV/;=F,>OA]K,=^6[=E84[3J]+-I6,K<\KTUUB<
M\P_;,B5.Q0Y!.<Q30VCG8._X,\7$U3;GQWD8IH\@9A!J4Z-_R&LMW"?D0QEX
M34%1Z&N^!&-DIG8>(+1T5-%YWZ<C&J0D. (\P:X1=I)#B$R0"C7.@$])_?%>
M0F[U/$49;&>!>XW',^PPQV7^+-IH1/ECDZ^"/0SCM1(@"_X&$*4"<\H+&>XI
M^0^D)GF(U0OO#<(>$56:)]*.6@2O,'7Y^3E1^*D;&+(PYO&Y@#IO-46&G\OS
M2^1$*2DBSM=X7__JD"$AC(.?JFB^KZ4=S>GLY^CZH<%U#7K&J7887UZ3[9';
M<W#UN,&+U10W52?1K=CB-W+?21OWJB!A];7BJR=:BP\9'*OR?L\J-SC_/,]-
MG/ZF0Q@V,&GA!/VNN?K*"/!4TKK(WO*L#RIAVSK6LM^N/I/B\2*H9.%/44-<
M&%>EIU+ ^">:8"!1MH<2:4+_Z5\4.<\Y-;/*)XI;I8G#KUK.5-L7V4;CVOU*
M)JETPMG@6> ?"(Q4"<ME)M2(20R0KM']SG*,"[,_$*F)'2J9(9<I,:'YCQVF
M1^S6&2W4M7@+FZDXZI)A)IF"5UM\C;<8$_!5Q$SA^=813(?X5]_O,_PJ"4_?
M4Y1MK@JNL@G7H=MF[R[0?P89I_H=."VR=?=T\O18Z[_%B\HOG5MW%QS)]PF+
M=7OFM_PIUQTZ)]A1)6*-72F,*;"JO0&<U^\#@?%Z=")4%*PTSC"])0*"I3C9
M4DI5@A+= J[[], B=J 'X^Y-;E=1E>"Q>'8VY#JPGQYZ'_M*LWT@5$EQFX%_
M)+8'Q3K4ANW2\7]0J'-K*ZTM';QFIHR%DT)%+'21INY#I?X("# %L%'?:^X1
ML>40CXF!'U2Z/CK+M_J??7OM'/NS[A02BDJD=4DR?2>E,;LL*K12*@!;29)B
M83=!GN?E>)A$.;T^(K^@[<&40M+N9OD[1$X$W,/G3Y9[;6T^1/=B>'A>(U4P
MRZ^E%/=W.6AP5X;.VZ[P&?/:F1[)YUJY>W>91^1>E;G*<,7P&+AH*8_$:4/T
MTFABF0X$?./QX?T7EEU<D4^A\53!4^'9*->!+Z"Q,KU $-8BY!+/\,6Q+Q/E
M<7X%GVP;W1XL27#+O-76W/7O_V ;+<H7"(78LR]5G'HR=N8E[-U#Y/-^]9G1
M>'%[)/$&=L0R-SODA^-2<ED?P='\?KMO8%5H)I_W+C_/9A;W6,R.@/;1G.;9
MC63#/C(NA&="C1P_H^D2#,#F%.^)#0J"W.1Q=26_:AYZU4E3,\W%L7OW$F_M
MFQWE^BW9?7=7<U]_4;\SPW/M^9E2F[Y4_$95AE5E3E;EH>4F$>].@JPR]6F^
M4IS7JM=]H5I,FVR5"N>&JF?)2;-@JLP.:(/7IM_BJ80#]MA7,O2]00GF*SKJ
MA5$4UOBI::SO$<DN'(W<CD3U-2A$7$]@"AY9HR*CYK$>XVQ3WL)G^8]YI,3\
M%[:YRNKO6E2-\+.] Q<__P,\KL%] S8Q^%85_'WCX!XN^5=#_>"A6(?J"V<C
M\A_P=!/EZ>L<ZQ?</^:?/\%^P_[,%]B,QQN.:U%ILJ&BB GL,Y.2P$FF&O<G
M)DV+0L+A7MXM39Q>05L6.Z**;[UL4=P1T[WL<I:QU;XX)\S=H#>YA35]A;%N
M0YOY7+45)I<=:[9%[+=[A\SWQY9ICT<M7_[#7[ 8I*; W\%E51%4[ 3+?V#&
MY"DU2@5VD(C5HWEZ=E =1-<)Z%\L^'/9S=U=<(/*XBO;%D.F18GBS4H%KW^P
M@&_Q*WL)4%C;\W6Q>6@_D2^>T/Y"B_H[*?DV>ZV*.D%!SN:#/? !.&7>XF,B
MA%5A/2;Y,G;[/.(D*?Q]3#ZF$=>"(5 @"]6]F&W?R9<TE&?0'?8'<;SA!/AJ
MWWS4!^-:-R*P;1[X2.JDC-QK#_&!HTYQ[9Q]I3HA]?IRS,";QX<3AC_&8\9Y
MN2+YW;"+HN)WQW+/LW[K4]N<=G-^V36!G^[R>N;0V'.)ZFUE8+/Z4.^)3OJ_
M38)7_: [9P+]&K8:E4T/8L!'TIOJI%$P7&__A,YV,_QK#:=$+CE\=?YUO%<K
M8=R^1/?># 3R29;M !VF*]F-#$#XZS4H0)8F!&C];.\]VL(-[^IL_'QB(*!A
M1?)=BR;A$X3EM*CG+YG"$@$):"('=XLQOL07FJR7.CV$V#S@1'<H#?_-WL8Q
MD,&W=<P)(?"WAS9,<LB1ZH>:[$$D^(C!)(B-I!EW43R@HGI.@BN$10+2.OLM
MCV)'"8TK2(GR@#6NN0I=PSM26W]JMU5Q\'*3G-)\7^[^5/>S3?$0CA7U)24G
MM7G$Y!SY7DOAYO-%1(F5U?5)AKM$8$P9MT#\554VS^E4A?WJ;(/^( :WB9 1
MEA1'15;H449E1C9PG'F1D?,9ON7@7E-,X]:4Q?H3.%$MNH.\'Q%P63J34XSL
M5Q27Z,.KDO MC59%/-S5AGKKU/4 UX4;I\H\>FTJ\%S0'328U_\(&\WZET0I
M]3V50F^E?:V1%[- 2!X@*LU38KFA$\OBS,'= 1GK_#OJBCG(G.5?F%_8+B+0
M7>,+B.3N)(JGT@+Y,V;K3 <IS+X1<C5RE@=@VD,?8N(PON;W1P+\WT20_PL_
ML+8OB9(Z,5F8>[XT]P5M1]D.1C.F=&Z#A_M$P<IL>P-*RFHO8\.4G.3\\T%!
M@BC#=[ZO.'8JO)0MQPVP,(T(DR3*A#<UM$*I&ZA?PB,)G86%,J+XS-;*1G))
M@-R'?\A$GF-:L\;[#0&H$9X<]X$M! !.DS1\.$GU)0&80[>L1TS[KKVEN3@'
M4<$7=-3_DFE)9#OU?U!)GR3>N9T+Y\QK4=C7TK@E<KADEDR?]252'^^Q;HO(
M9-FY6_YJSK-S\?T/$>+#V:NP=Z3LSX#$H8+FU09MF1G*Z":9)]CAO!'EV:+4
M*W+(BM3<4F/LK1 $(1#Y_*0:2U^Y85R3MT7_%"4]"MZ<UVW+W5]<UNQ)[K0*
M[WJA(.X[2DR^4G"G)[9KG:!3]B*MB"!AN%PXAZX#O>&G)/T/EEV"&9C=H^K,
M*,"6"*P%3Y;XA*!C+&S#=3UCX1A5*C+R/SES9)=9_XQN<7L]3*PULN8UW/=9
M_+)>;PV; KR&B]3ZW^(1%VPM@H(C5!<U9 [D"-R7 AD\LCW%3_. I^_6;FHU
MR1> ?&[P8".KW'*9']##GC"4Q)F7O$3V_3\(VPTWOM;\C8>PB%I6\%06;83E
M[B!W4!P[].26B.4_>'OYEJ!ZQ1I%TIW+H-LAP-#7XWACU=H68P^[S6\8YW$A
M P67)26*\HI<E>&Q8B&O*[H\LJ5+(&@9^ R)U"Z()/MK&O&1(N"TAOJ=Y;LU
M$]PV']5*8K<0<9ACFN(FE0XCE?*FO+C[ 3SR>]U?K<- W"#9]Q.)TF=O1N.1
M]3+])G^]K(CZG8V>.)-P6(L2[R^7"MLFY2=XK$SG7@G4N9Z^,&L6/>3 X=+I
MP7U(\OX:[WHKDDMN$+&B"@/JT1?:^PBQOEBWHV!SC;6HH0T"%%>5F$$^B=H*
M&_T$<J0OB;%QVV/!-"@)/Q$?QBLOVIJ$!$YP0X@UV/QZ=D9R5W7F+7G%R4FS
M-<$KMYOU!SJ)'DF8V:4YPPXW_'UL;[@3_<[-I?^%&/E5 #G:[NS2--B=]I$,
M]))BV49*6@,IT][L.VM)'S.6W1);"WR7PD5<XMF+ A7@28_SU7L>FGV[W:WR
MTR4%N@/6Z2$E$>VQA=*A)T_T8X6!=/YJW8.22E?*8LTHA%.U*SM+7FFJIVHM
M/ND^M<-AQ]GZ$V<%*JBXO1\)P5M\W5]UIF<VE]]K%U;I$B6*=;X7@S4^,0/5
M),I4K7RUB//=!UH^#ZZ/[238 W.P-V\R_D)?%E+?_]\*V_P!/8(:02R.+P<'
MW08ZWDO;BR)SBFU?'BI-.][(\(_"+67@,5W$:VEJUA7I]HP-JA?)C!/\2U\*
M;L0Z?\D!L$C-;D-L&?;%-JG\[GUR4<9O,>N6\"Q61N332NRLEQ:4<>74'G:;
MRK!:-2TALX/I*_>H+#JL.=_M=^I?"R!B"H0>]$6''S"V+E8.("ATE4K%<\7@
M%B9,)6+(U-[\$E64,[B5H^ED8CSX5:+$CFKZHMOM>T C]X<_;D;KRUALQ38U
M2).ZD5UZX%)PP3BF4[+D@PUC4 +NKN*]WL10P*YAZZ7B(X^U*&E#)??#WDO2
M;M'VI',>MD&3S5<Z?YMH]BCWM(E(3C\WLGW['+W\8UU:SXYWWL[E1?;G7WPT
M.R XZ#_=5U"B:E9RFBLTU-<PTQ[_C)<D <SF@5,M7+P$K;:B'9\XP0EO6K M
MT3>\^[[W4]A7Q5.AQ7M ]'?YT!V:5V."[@#!5P-^M[=SQHF@DS#Z9"5AO4Z%
MX 1V^4PCNA>).%R"BOH9.L&)@IW*J8]E[,JJ2=99!**523TD\P)N*+TMOZ S
MLRDABT6'\)J5 X+Q>&#<I&2VUH_YH?HUC\!>(7"7,'$J C$^9@\Q-JT6_KG%
M\OMT&?9],H)DN9NY -_M9'AR%UGN=>_@T2M_](X/9OQGZWFPR?_1R-S;F1M"
M%XVB5#/])&HFSD)$0XYPL(93'#D@7B]S2)#K(30N3!XDVS.I541*NR07?3\\
M,; R-)/YU-K?YYH^G$: 7'EXI6X5.WA;\9&;D?SEAST[&#]7ZJS5V,$O2--=
MXD8C0*00:5%4*&KN"<U]$BV"8NS<$QS^K88=^\AVH57\Q+-$N&=C*#6\@7Q?
MXZU(4((MB2 .*I%U9H!, K"N]14^4 1N;N"1CV1NT(V0$*P8L/XI]!1?O#3\
M=N#"=]G&]D_ZO,N*CK]_]:91QNAVCSZMJH'FJSSC!5$?S0A15VE%5B/Y$8W9
MZ<3C7Q3_Q]&Y!S*]_W_\XQ)UD% NN2P2YQ3-K5%BY)*^;J>+Y+I<Y[8H)5DV
MI5R2D'*-%35RB8Q1FE7NN1NQS2W*9<Q]&[O^=G[_;7_L\WF_WZ_7Z_E\//?'
MYX.]NQ")96UG;Z&?C<<5%7H)<PW3M^SZ.+.ACEK;3PH>O^,1<L#'P>Z^Y!:1
M.C##?$N':"2@C$?05!KZ4 ,E3@8G<YAXG:0GKR-F]?#/!J@7?1M4&P=S7N*Y
M5_(D1XRFJ\<CA$WLMV012Z4SG1".FEDTO&X@Y*D).<3 HNJGWR"7P[/B-_.7
M:RF*Z*,[-;ULUP55?9PPIRF2-FPBESRH.<1$$KL:WSG$GKZ(0Y35=8?42VD_
MI%JEQ-;R#!9I\T7.)_830BK*"\+P5X+<W OCQU\UX.\T\]+>V?M^*)\,[XC^
MKF]\'U.)/K&S-DX4[?$M$YIO\38FCQO\[;GG]G0M'8+*N-$CQI_$_.[$!3K(
MFP<'7')7HL&F.N=BV@D9?RR@%5S7]V3,'"LNR1&60<5#=T&;7A#/[69[3X.@
M.NJ1@5.[)\:$+!KO^L9<IF8%1(+^0"$W^R)B--Y@=C/FF<0"2ESD?%)G4,,V
M7::E)YC:R<&CBG)48H4T9,B() O97;8[(M[8,DUX%4=5AFY$Q[<LH07:X;>;
MXW/+^#$^N'$VUKZ=JEALHV^R%J#+:P/;668ONH51'5HK??,_%/H&A[+J,LC+
M>7F%?[[]^)#:F=[D9E=V-1JK;]P<T3:0',UP+^&QMH2(;"D 6B.@(CO35J0T
MC>:?;"'=_X.G&#@=)K-A-BMDHPTE4YJ3]X;= IE?C')$\&%9/.KF[_K!\!WB
MH24H:&<R6U( 6.=0QME%GX*V6'1?GR?\,+[[(#^<A"B@H!K98[_15[BIT@C5
M@"%4I%\#U\:N]C#?HO$MM>YG.S9//+UL X<+FJG[5L$"_1  T0*@GB\YU+@,
M/;V$]N62+/,S4%3X$B%TV_*+00\XM!070H?H-XA)>+.L['J6%BF^&OJ&/@I7
M2(:QPHK[EQ=M0%+RBHUO=-TS- C.+X!?W7A!B@M&THT5+ 3 ^>7X#&;B3I+%
MW2I>,C^2HS/&A%YECG-;2)OMZ2T#8?U=$?AC;VK'5\:I$7B_HD(A_[70'T@#
MUW1.+&&H:ZO$3"$GI"$RQB$R$43#'4PWRF9]"G?C&E,87;7&YO#TB&O<9]^R
M@,[W 12O0'2::G#,TV1)<#MT>& M>Q-=&R=,T!ECZ'/<LJK(37UZOF1DHT;N
M4-S-VG JGB(4*"1TQMPB3P"8<A+M\D7=:_DUO&%4=-"N3.,< 2IDYLA=";3N
MKOH'4J *-[EQ*"+>(]!P&<_/'5N)T:^;QE(:ZN"1^'&ZH[;)_J%$?M#+34/"
ML47N7QM1M.&H\DJILV%W:MX;MU3:MCE1XA:2=IBDH3BWFT[L"NSQ'ZF%<+F7
M)5M(^#C_&1W_,K\XRQ>*: CDY(=V3LI+6W=(Y"L/H0[S,)P/O)0XXJ[K'!1+
MM:BIIIARD9"!/Q!JI'TG3@"8ATU-4BTPZRL/6*!HI^>^DDTUSX4@%LZCADV-
M!35N-T/;5M O(JB4.)B7L)_;V/'%_<Z-_/(5YA0NK%7+&G.I!^$DMV?EZ](D
M2-'?@/;*D73(OOJ0U]48MS-#BMB[9W<*]A\#-<JYQ/17Q'2LE*VCIGAS[,L[
MB$H>NB( OA-YJ8<"WRR4O30PBZ]"T\\C5LD&$SX2B=>[^Q]REVGH2F(6UV6,
M!YT1 $:=:Y9%.82RX88E?"^[2'CJ0P&;S?J9V\W!CR4;ZH(];\9Q&1_Y57Q9
M4@-7 !2&"[MWS A-,Q%60+:?[ML-9JX(]<OBXP$9A)7DN9;N'=?5HS_I9+\,
MH6U9,^@1^$(9+!6^'._2X[=#[!0 ^[O0A?#(!J25$90._6W]:_I_2SX@T?3[
M$??/'@:'S[HY&\8/A6$MMSNZRBRE?RWFC?:5MU:T=$W&-TZJKY6QIU>3IVN%
M_+Y+_ D1YO+PL!Y\(72< )FLZ7Q^';T<%Y]#3AKOG.;ZC8/=^$_1%P@0*M,G
M8Y68(6S91UPX=AP%#5]2Y>K2O.)+H>D,.CW--BZCBQW#LQ^;Q%\_)1G!U'PN
M N36#$Q5LND<84F+*X?CH*-$E8_C*Q!59SR9>!7"B?Q?9YDLJ"L^>*@H]QVB
MZ(W&3XMTDPNE3]$FJ&RVTBI'MH_OSH)VLA&YOX3<]M24%B\Q<'WZ+1=6>1_B
MI6-/QE]CF+O^Z]]/\F>=/7-2ZL\<VWVHZ8Y+2^YC!><KI#"XYZC;2T..L6G%
M;IN[L=RK]C=+I24F^81:6DI!<)4P0:HC_773>/L@@X4"8&*C4V._MY=/Y92X
M]=M0(W%NS4*-<$8X..Y8C9#^-RTQC/B,<HTT$CUC0;:<,;U8N(VJ(35R$7'.
MA:KV4!J"68W^G2BOQ@;O^\@G\-%;U7P8"3-L@>I9IT*=E_!3KT_M"H"+.^C+
MBS&%BJEB<!KA9&<0GF)*RP/S%2GAU\?U\+U3GT.+7RX>/CNF3'%15TBN/#3%
M3/V@%=H_';<1'C8=X3O6;&:A\-;?UEGY\A5G>F@9*S(>IZ9?A,&ARVW6I[]3
MH1@!((1.D61^1T-=8$Z!  @A)TW6L[(UZ_94Y<[+.K,%P&\/"JZ!)U?SPW#Q
M_&X]U*0'"?YNTJZ\3:3QB%F($K'\\  <W%^L9-3R(AO.<!Q9*63P2]>)PP%+
M3- 3;?;:#U3 IJ\ N 1YG<CU EVD,1%T/"?^];,!X01^*WOH*9OQB4_@C0@=
M2H]-O+A(+&NI@2]9J$@CO!BP+'@ GD)W]"75;C?KX/701R-P?-]-=(K1VJ9V
MP@?)MY\5M7O]E@Z.AKW'WM%ZSQE%]1FS@L&F3W'UB(\PN]"#G5.M]4Y./%KY
MTU(T/:CO UM2B%!W&< *SW35-V.S)9ED+(,=VV@IBYB>Y0D3S1]^Z7!2_-6!
MP/ ZBB+DA@"X>1+V&GJ.RYKU&!?JBQ9\@VJ1F#A0H@J^F2  >BE&O$IG!>CO
MT)*=Y\33;!AMX0^DBD/49Z^]YKJ60E<%@-=N>@XI8E +[)>>L9'LE%00?4YJ
M%OH9169OF5OCMZDQ/*4:BGR\ *AIH.V?Q!:O.UKF8V8IZM<TXS$^+N0?G 7P
M\9;+ZAD8VOQN[&56Z8_@ =K^GJVG>82-V]TUZ3=AHOPR%&9)<@6$Y?^B%5 C
M5+C0"D9+;B0-#V!^638/TBV@6$I<SC4->ME;I._ OZT9GS#A+L<2E+9P#-"R
MTJIE]B8B;MY"]@_:@ATM+0 4!W@QG? EXK%ZQL$ $CI--TQ%C$OH51A%O:6B
MA>[X/'PX@A!9P2]"N0HMV/<G%?YQO)&&5X6Y-09<;Z52,?^#H'C%[;D@=KJM
MHF]7-A^2NP1Y\-C-Q#_TFN&5_HNG$ 71>6DPLWZN*35@.GG(T^ZBL<NARW(J
M_3VPF&@5!K34LBD"8IG"AX^@; 8CT(H]FJ7+KN7F/LGU B E&JFH"KZOMI!H
ML -.0!";0-\@5"]P)WL MEN-Z]',:.6K;EJ6FYSGE4;BR7$PIW[9\!"@@NLF
M%$=3)K1S)9^;.T>\R$O;@#WE?A@+FYXC:@Q4"=$!.QV$"U0D7-CV0F3?&(=H
M*.NOV(^6(;T'HQTG_WN"R2]4'V[;9JN%R(Y?8F+2*'1(;T2^I1 CA;1"D^C%
MQ)"+<DO)[.!G?:]E/V'Q0;5H^HENC;SMP#X%>AZ4XF9R\0QER.<BLOWPI]%P
MEYMU_CZHMF%<BPPL!NQ&EU/_1*<1ILOPQ#I^^,]D%)3QWR.@G-.L'BQ#_1G2
M[)I+*EHR0HM7620T X-R3#K/GF(0^IR@.X:V@YA?%0 _^0&;Q;@Q_KD(.L%T
M V4._WA?"'>+XV2DQ\%  B-.J"-S J 9X[5L80Q]3D$["2U^T0)4'HJW.$F"
M[Z*=J*C71F(PVK7MJ5+_'J>XF!(Q9[I*R&?@\0R9/_]5,GPWLB,.W59+.K_#
M1*)[5B!3574[BDQSB</2G$=6>[#)O'Y8@/V2GG3$^L>C\B3#:N=YK5"J4LH/
M_YCU55Q[>LFL7U]EV=587S#FBO.T'7P#_9*+1*UUQ-$QOR%B B"=>*0+'DG_
MAO'  9S71^L#O_36_/?F@"K$BFSCIM!MN,FOH2Q$/AGDMO1,&Q&C62(^L&NP
M5UX!=HB!GMS?_GJ,V[P.R^8^&QOW.DJ*BW\CDB4 T,TA/>)UQTEZF8LUQ0+@
M,K1& -3&J3_KC*01Q>JX[EB&.6B>3+=P)2+J P(GE,U]<OJ>QZ!^Z:;DFN\Q
MC NP;_U08&CR]'!XA4YH27@9["JDORI^^4ZO1\C@QXHTTF/O=GHL%H%2LXR<
M1E>BO8AR^-#T-%#>-CRT_HCQ1PK"@XQPO'1TAUG\L^S%V)*L=;V,A%>P7J:4
MMK+2#[&_:<0!^.]K#-_*$;XL$T01 +X\S&@$Q,L>JKG(T_U%/-C?&DX3TW^
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MRYB=R  !@.W:LW%?\MFHC0#8OP)EW>@3LFR8! M,5&Z(EBTR:;-XBUI;@@F
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M[RH%2-C_ K:0HJRXHBQF+GI>=.YB36#GEKDLWX&,7OM%;OG=(CRSQPF2_/)
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M4,FZDV."5J-X%>KTNLS*U*)2WM(<ZL2NN@#XY$!E%D__.ZX[_M__&<$JG1-
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MSXHY9YBE(T6"POE<HN)T&4,5_(>:@R]4K]28O9;M\N#FO2,;!G*P!:%:>@J
MR8RGXF^4?VA)7O@ ]N"(!>40^]8D[!7*OSZ1S*_R#U$V=NJ<(I^>TOV3[6E:
M.C+D=FJJJB*U/Q;:#".MK9EO+ P79;S6J/2C09"(4J_XEIZ-0J@OU7=.XH(^
M\.V@9JGKAF]W(W^C%[0L  */"8U!B"%IVX6B_@&*/0E/+SSD2Z :.)8C!E,]
M\'J&JHY'2'H9&]%$1A: M0F-=4/,_@/M@[[A/-BN!:'Q=Z%X/EL ..R['PQ!
MV!PV^R%%.*.H6&UL:&PLA^SW-DISLKT_L4V7J/%)#2LOT7E?>=:L[<-6:'X!
MK4+W!GTHFQ,IC$-?DGRM!4"'Y6LWH8DHO=M#EJPWOEFQCHQ<.Y8HLH/N1SRH
MJ> E^[>FZ* F/_2*7%+7[]DA\IL.J 0$X85!OI];W/NI0U;/Z%MTSU/_O\NA
MVEU('K@T=)J#&Z5[:G>O,^1F%BZ=N+*89[Z4M\ _7SCB[XDP[3?MDT-5.^N<
MU>-W(*!?(&H"@&N^E!\537!?T=A2.2OK=HYM]D2<([MFEW-4.-T\=* #:(W!
MT7]?+>6<+>V8NR'$0SF3GJ):[F49R523H;?0GEVI/IMKW^57X"S0I:,XAD9R
ML/=,?R?)^/ 9C<RV?6WSN]5(#9D%YKQNS482 :,4;Z909\FXALNY'U;3P,L2
MYIC[OEE9JPS?C'6_+#Z]N"^['H$-4]$S '1@JR+]-WW3V&NLOIU)3#5C+F I
MIAG<&3<\]I:Z LW/R8<'-(I+)(361./U"=B]H-FU4 /8CS[BJN7'ME,T<KB$
MZ[L 2J"W)X4=<^WFO7PQY0,MQW9ENQ,;*46%?CD%8: .*;VDC%V3+I%O.?X"
M()(#IUL.?CES0T+]#+Z@&NGD0D[?P-^]CX&7?#;^>3G=^:*3\Y5V[!/LD$G?
M[)W@?QHN0O)>;77SEGG&G$:N>PDU+@M/5B>^IV3,C2-B"D&,Q&%(][&<PNV5
MC&BD>N5)B@%)^^+#X#5H(Y^!?UP"@69QC?4XKP:V4$2:A^:6OE%']VM /K4;
M+4N4Y#DP]I-79-\S5(V^Z@F X:A(BIHZ]VD"*3HV",][:#W@V]/ &QNUQ>VB
MNVO59GI01?A7M.>=%?+R)\&WKQ,\(>F)[YWG*^A(9X:^T@\=K?)^" PYL\23
MRS ;'35V/C4J=^_#J[->%"VM -CY#_^DV7H>_7O.B-^3L08. W$Q.3QO3B#T
M-PK'+7;>WW767 "$/4R#386#.,:;L K,YGWHGN6]T15,B=7PG5]U/-9(@A0L
MGYMZ0(RZY&EXVP']_DA+<ULVB'9R=/K/+K2K7I*?TY[R&<1">$9)&)Z44P%[
MA[#/GE_I11>\%P!$3/*/XL1A.-CKT)W+CTM)ZX-X:"T2MF8^9%U=5L5S(VYJ
M-Z];EK,.='\_!';?QDQ-SXV?#!CEB^3TN* Z&7V5SD)&I?#>^HC.F;FAU3SY
M6(@(^@.C+==JA>FWBW0\]GLX[:D ^)<:P4FN9KQY'2S1]QPXD*:9?#:UY634
MK8*\L^8MS/X:PLX9U(>Y?C<7;4;;#/6[B5GJRCP4._T3O*84-EVQC4 0(LNX
M96\BKY.\=&*<&A:A) G7W95.K';=X="5G&"2T]?D9+ #5Y:5B ] U%'8Z-GM
M%1,0ORSPYUA(?Y=R RY$]CJB1&> USYS&JT/#>#F;M+'$=4M8V$]UM_PK85[
MUD(?SA>\1S<U'"WE\,#SA3*&2\Q(>'"7OAS?.:\M1T5"YO2:ENS)8_?/F!S7
MU:B8/_$D,@3+6?C ,5WK^1NUF:Y892$E)1J.A8_21L^\N.Q2%3F*S2LY_A1_
M6<[X$R^0@9X6;MP&";.GNEHR\[CGL4#[[P9NH>O=II',3;;\%Q<29U;??,>+
M&ZV7BA0 4DN'HS>8]*=WHKHW^5&G.%?;,\6\7"\#@$S#1^GD2WJF36T/3O4)
M553Y[@X[O5(S6WG%\?4O_D^5]J'8\NRQ\2=1L^A@C#D7AN&<B74_O5'Z2_EJ
M/Z3C(GA)##U%K$XELXEM==IBL ?C"9I*GTK@">F&>P=8U;NNFWRPSTZ"U"L!
M\#U95"1! &"'#E3.F((7#'AOL_B6-6%BW^3&/XM\%6JH0G+@]!;]K90E+D)=
MU%%O,V806JQ\,MM%L<]A%</K7E'Y(\</P:)YF)S[L"$QWCSJ>I(')6ZZ75%%
MF%=Q.P2<OA.& [$Z(*T.!#UD$">(!$0S4C^I$X';+H1=[2PG%V$JR!&R6/V(
M 0X^*$LQ7_NAE W74Q9.(4H9[@J 2S8"8)1.>9 ?SBU5D,&]LE5W[AE%AW!)
MS@:2[R-WXZM%ZF2:()[W$Y#."1[[0W^G*MDM=[_[=9%&&\62<B9)\62&!4'E
MC6VH<O29W'[*"Y+3@E/GZJ^AV/J^67BS+@,<P.M'V8RM$$"5D1OI[*(/W9@9
M<V=,8P3))IC$1- !B@#(%A, ^A_Y:Y'U"2U]N[*KT4Q8)!;NMTA _\([KZ"7
M(F)@#\AL[&%FG46?,3XRI/LN;ZI5-_DL>$YV&=/()J2IV@L A44!\"#9'%&_
MS;' DFY\\_\O.WFY,L^V8Y6ED=8'@1H$UY3AM:D*\906+LBTC@'[TSA.][(L
M]<,'ZW*9R%L70I2$:Y&I]3XRN-]77S&5X&9WL-<MM*)@WC]2+IP44<)!U,7A
M/]].MIYQ-U1(Y8V,.LO)N1PSL;N:CZTX_C.EWJYD9&HHQSUYNV<3.@E:4=4U
MI:&#(@.']$4^0FM65"D.[5@(,KB(7OD[4.W+/_PUJ% 7MWC94QY +K_VVX.G
M:?ZQRGNX9&[&RN/J-^$D>GQ,3_!T P[',JQGF@CC>FG]O>L89AV5(BIC0BIN
MRN=EATDEES,P?V1O"O<ORUM3]LN'P?[Z<B)^Q2QUC?_^OC3:?C[&GV0H],@H
MK<F<KZMHQT+^.@^IC=:=QR.MM*'K'_K!0#('7Q8]L_NW(6^&G> []L=#B-7R
M4(_MF8>W0G'6HFIFX/DM$(Y^(8H:-Y\BD_W?^UHW@GX3N1<F%<X[O,=,>LE*
MAB[;=(M1&RGHU.C9_?U:$O)/IYJ7KW>N=C[F3@0,^4XM?B^#!RM]XVEQ%UCW
M=M6)6(8E9HC?0R-(.:^HJD+PZ.1M?C:\7B^9 RGTR6?5]EBOY.1K)W<EUW1K
M9'#RN&D4,L@#OP?KJ&_RE>_\8:C.WU/;Z2^#V5%?T1W0;Z+9%"G8@Q]YA9FO
MB4'Z,F'"2*;)]RNR^'K.;^T6 ]QJ0!*R7!*D&M)SE.N1JO^EF2)LELQWUK&W
M=B@H"8V3QR E0W*F>2G]DSY>F.I%RXQT!3'%4\S1:KDS+WJ=&_M,2+&%J&WG
M1@].S<;T1%DU.8+7[/HCKKI0I'>%B5B!F"/*=E)RT@)K.ZPS'<0EGAXDG&>9
MTBZ(P7=A5PZG/FL=/J-LU"5[LFUT>3,22T'D@;IIUR@K8K9&7T/2\X5-\(F.
M?'#D#SWMI.XA(4V<)C?AN-4&TTT6N(8]F'"#!%51:YV6A2C8N8(E;('_/RGU
MY^EV"X39&KN2S[3*-?=7_+:.FI?&R)OY=%0AG)/!^/,;%1XVP!^.URT+LUL5
M (J/WB3]38<VU73GR?;A'7+YWR7%8$S3]V9N*/]M8O[U4P*@N#NHQ,8I9V[E
MQ6&][UFSFYEQPYZQ#.BL2!3?AC\G^5!-VJGQK/,=1OW *FE2<;?)Y4'R:B^Z
M[^  +X,4P-[8C<5WSGN%4]:BX,,(UX8- = PH_#(_^T82V3WJO=/TB:Z5]RE
MF^@PUO!16:%^3]:#_1F<,.*I"$+PQ-D(7HC&@D0Q*4 )/:W@D7@IT0O13!P8
MY3RR24, OB+'7I.<+_VK]3\7;1<ZZ?OT0:;>"0& 6\YP=W+-44.L4MBYLP+@
M0TL-G&9AHVJ!'RI*K@@/Z_$R\%*%WAC6KP6TD5KQ#_</VBS"*@4 #*WYD8(8
MW^Z+JTZA1)#'<4*U@(AY0:[%0CL;$,\U2+P!\(L9QD[G#:HS8K(VY*&7=$2A
M>-TW2N:<8N(1HY'$B2Z=?WT'8UIJ L>W6\H1RB%&GM(&TYL&&F+=3!.2GHG-
M*ZNJDI;@5-A4:EX:Z4J[,(2V>[7<_,8Z<[FT]N8_*87Q['\J*HX7]M)H_0W$
M.'^$P@0OOH%?S_=XSX]FZMB^BBF4OQZX%C69>K/[7[0[\;B*#*:/']]GXG%/
M59'0/A"EL1G5E?O9<6.1?VENE6$]H-DFOW-6::7-*J%'%ZN*:.:UL>M^5GTY
MO<W_^\Q](]BE(IVCK/M_=MF?I?:7_XB:JQR]N)6\ N)%\Z_("X ^_AULOFS.
M=^7< [Y+![1IVM QUQ]F)NA_=DFN3':4QH(H]&ON_[14P%WP<+R<.=2-@'VE
MH2N3IZ/=9#UX G01+XOJ&:EW8#ZD5[:6 \#IC=M%<J;5H]CS>S.R7[!//4:/
MMU9R\^[MV-YO!E7%$'].=[5H$+>"WN<B\$C3KU]L_'=S[?JSO^]*KF)&XIN1
M/AE"EKI,PU>;M#JI8ZJI: C)?QRL'S%)#Q*J3J/=QI[RYGD]M"%T5^.U2@KB
MT9^K:;1[GV(S>E%B(PUT2M&S"4.Z]$-?CWO'^@\85FGLI!R:(7VT"%9KZY2>
M.W$?JC8=4!('DI14/)[N>2NOT,ML6O5^:>(B+)W7&>$92L@@8*GAE)_3X0U)
M'; _HIO!K$5US54OU\FNP%,-C-<Y-FD$T[(!/G."Y!K-ZWRRP^]A0#WJX'XX
M^'4QI'LNQ,=8:Q/:=8'TPKU8:"/XSAVZAS2^)S]$\??(GY4PN<3NU';XN?SO
MZ=>FPZ>#^X9R%DJ=&6;9G,M7)WTN<$A.SK@OSB5<?=G7H&FK-(WJ!$?BSAA)
M)8]#*-OK,/L;L\,*=?6I$]D2 .?KQ*^@&[(56BX6;.M I36%1^;?,RT HF+%
M04(?Z$%NGDSP.<I@SG@P5/<V]3X4JYC_1]36,(Z!O+)1AC?:_6+9EU@W&L%;
M)/((-5$"H+/X=4H<+_,5[ZS(9!TR96I]<6\UCO\Z[JN# /"J8UIDW&U(K[T?
MN/4QG%JNFEN.8S,I&I,M;40!8(=]Y*/[M8UTOL*8/5UY#SI0!PSPL8.6%Q_D
M;9DP4^<L#1FN%Q^T/-&!SI98WCZ;L0)M1GB2Z<K4N/2<05$OOYI99HYC5[1^
M?:M^'OI9I';RR^7I=-Y R%1W=29%7EELO"NTEI4E^>5LW4C"(ZW"30%03G?I
M"?DY'=)CW3FNS(*0G%7VML1R7OO[$HR'^,V-@3EXU,_#@9*U-BX(H08!L]U"
MK'ZD(3;[9^MVD=8=_O94/I94QVQQG\Q>NXU*?WQ5FC8D%U;WPU_+_V?*#UU\
M!.=\*2_M!LG<HGB$#HF0%0+'Q?&BPGG/>TEOSV5AH-Q90RH;?U-LK!8N&H [
M:?[GJ5(E&T2*]R5G-UABPGSCWS7*=XAG;+*:),V4__U/RRMA0C?]C&_O,$20
MK<R>+U@YU-P.O1S2'ZQU-()EZ>QY\J";VWQ!<'!DI8O[-!'!(A1AQCWEJ>SO
MXEV,9DLXV0FDJ^;NRM>E&/,GB;^/@OCZ-_N^BISYG ]VA[,C:6U,KUO"$FK!
MTK!SG]@ZT#?LS#6V3+Z0?.J<7ODRIS^_BZ3>ZN>R#*\^?KQVV1)T.KG.F/.!
MXBL NIJNL/O>(.L"9WRN?; H6W7.'**@:_3L<@A3[^IZP)44<<N:(QT'?54%
M@"B[("Z^AN/-C'$Z>SB#V_EK];&A3TLN&TD['*T;4!^8*^K2G;#H) !&)#*C
MCWS6$8DN.AG+B-STO*WWU]W+U$->-7=<BQ$"(# \J"%"@A)A\0;',MD<^/0;
M61@T-9\?>VQ5O//8BD;B%CWK8V0(2<](V?(G'@EQ=$[R3";D)G@B>WJ_WCOI
M%L"^V!@^8ES+BF FAGF&X'NL.1:%^K)WFT2M3,1[[%9;V3!:/E4]$;0D!,$D
MFXLBQ/5NK.>]D/H=435;V+'-=8,6[BQ<X9"G\>8*NZ4__^U,&,G6SG3D9WX>
M_BK>^_\H.A.H)+,WC--86O\T*R=-27%:=&;2S#2J<90<4VL4F<9RG2177"!K
M+"H8^"HGS<RHG%Q32@O<44&T!<EQJW'+< -*2DM%(3= 9?GX?WD.GH,'#O=[
M[[W/\WN^(_>U3\-$)*L8VSS%W'[@N9:'8MCK805.E=W^C$;0/AI\WP2#ZLI0
M+'OI6(/S%WY1Q:%^C0$F]M<6ZF$+R*;X@$.')E?K8<OV,8 JKN4+HY/P_8N?
M36^>;KXE=3\WJ?PKKV"'KBCEO=D"B<[4W6>$"\V1,CULHM979YV7\O4+'2.N
M=R^EYBJ-YOC/[H+T=R-+^^N%;1;I17FV68JB(\.+#\";V]P+"5?*#"(;+AV\
ML<XG^0,,6\-?MSPT$OVV-BRAI/<U;2'^'F:9IK///S3BU$H*S*@^>%FB*IWA
M:?0P+R4AHS*@ZC.YO1GS#/&.QJO[<B7..6.[V5\3R]TE?5^PFL#'1R];'>DX
M9)"9^Y_O> $9$]^DB5KQ.''CRNV?_BU]TX"ZO/FUYM6C?]I/\[\SZY$\S9NF
M8/2PK0C=]TF; Q9A4FO;?Z@?#U@D3H[-G2MR^7.%IN55< 2?0/?Z%F@?OGE%
M?D5^%S59<,2_16&UJR?D@_J0#A*11.MW<XN_YMY9^FF5GQYF 2%X$[I_;\JC
ML,6S$7^CMF&_63GVA6BUR?Z8O;;Y>*;4Z)=S+Z^H4W[+>R[!R.LR0ZP_+EMT
MDN=V/P!%T6#LE[^G/LBN=M"(S=!<[2'/$7_O<'':7D.* RR=YI-<[IZ]].FH
MJ>':G(_9XG1YPY)-"6:SK;$]8QU&SMCC<CN9_'Y=[\[#3Q>N*8G 5KM5NUJT
M43MWA'XY@9O?!UWH_S9._X2Y;-O=]>U03W7HY#QY/;8Q/Z?@ NS<.6J>1\JW
M)<4"E=;XH4O'+^3:ORTRHN=/J+)#TE^\>''0>Z&UP)&ZUP6,Z/PW#F/_5RNS
M[:#[OCKTL A\TW]W[U^>-?LN4W9*!TF^<@+>/4[<#Y0+2;/'V4*U(_,IS6_%
MA#[NRZM^?CCM=C\#R,^Q<:\[ZW)U]]1HH9*?@NKA&$36YBX0+&T;]#".+*1X
ML.P8?7[CDGE$LU"W5GLX:9 D+^Z<ESS0%AH(KLVV4P_,>S0FL6.+*E&3TT@@
M.W[?2Z<48YF5HWFF*.8I%.Y.+L4)ZB2&CB=2)K3GOI[+%3 X#H:O^#89PI,A
M_Z$E7//\BP+Q\^I],:&K>C8N[>E)5_2]D4.Q%/"=0E:1&*W1L=/A.E:T5$5V
MK(M\5.?F0[%?/)1CI8?97?FN!-4^^R=8 *;,-:?&J:"(!UQ02,;\?!-T*"VF
M2I5ZH%%*=/O-B['Z#U?L+B6B'KPK)=YR7D&<FM$A%I!0ZOV8JU@:()EDBSWZ
M9Y5PZ[26-&O$N81:RU6S,/>_FC)[*6+<ZUG^B15^#J1(6 D_6HLHTUZ<H>=K
MF4SM[<&BQH?:=*:V%-$U@RS.CA<7*,C)?C.%1#%X)3H.>;7L0)W)-SW!7Q#3
M*&7?P%[ 7XFZI\L> #<QB' ?H?;B$ZVA9-&#'SG#K4D:V%^KC!:R1:#;$,$2
MQ/K+:X0/>_M?DD.2Q.K=2J<IU#2J#NQ%8O_690NH3[\><GI5*.\5+Q3GLX(A
MD=H-,L^$C,CYYIW58C9;4>7"!N.VBHI*7]DOIS=J:4_ ][H?]+!61"T!%:!+
M'MJO:1RS!,UUOVGYX\A"K.<4)0*RA%A:)RDKO4Q,<#\HK.U/8)VL-Y;EIYKL
M&QANZYB:ZJBI.%?[?5L+HYSU/UY\P=@S:4$2#ZFI2^ &_M3O4M]7[G/?-1 =
M<BD;G1)0L\L%S=KT #UAA^P(1^Q2\IO9*Z=*X>A&.?8%U6^ 1"D-)^1'*_X5
MAR.M'!'1W]%_T\/4!-=3'."9K7EF+DQW%QJ'D-33^!E%4D8PHRC-^3S^M <]
M;O1U[8+5B F_ZG2:</6=5[F:&]CG[O8*P5R/S%V#\=+#[)7RO5[1I\6.&C]'
M=UYAN(\*O@]:+$T&'!6G[VG[3!_57OT#6[S/Z*&V<YP7[N_R!8X*KETB6!II
M*=7(WF%\R*4DD<#SCM_>?YHBU<X//_:[1D[EN0HJ3_Z4C3[N4YWB<NJ0?^R)
M[M$#DNH,*?YR8>^NE ?H!;$YITTT?&,4!*CA:N:RY'@#'(NMU[$6BEGQK6Y.
MNIM:IQE_ZZ=Q-K/C8M(]]T^TA221ZM7ENQ'K%Q"U8,VHL+1!YZ9RI)>+&F<!
MIIC*7WX/N62HL$Y*B7M5^XHP.8*P@(5>P;Z1-ZH:ZA-X->(!:L,R*DCL9I?O
M!G22>G):!_ JPD9X4LR0(+9.9?XRPR0G;<^NOSH7Z2+6!Y4_P5 \3Z^G6O-J
M>GB%-NQ8=M*"/YZ(WACF(%>AI@NBXZ*\KEPVVQ=66J+#+%EYT/R]-Z7[^]@Y
M(AF:[7959<S=1Y*%,97^-V=GG)U3"KMUPK[;@8W/^CH@7P,K93K[)\IPQ) 5
M^! \L-@:X_M0!,7F"PJ-$Z9.5 ]T)DR['U#+63H[6.S7\\B:V 4*IU? 7ZAG
M@--X;P_+MU&7.3^:550L7G1#'.D0#)"J2QW-.")"F+$&J=F\K0N=9M@5+[99
MVMB/Y>AA9KI,T'00.#!'E8G#K4N-97"W4^F,K__6W[73'(G7P]RH^?QHP]4$
M))[W)?8SI5$-Z&'&F Y"9[FB!U2N6 !F#G++$1 1*56UYUQ5&4 H0##LS_U&
M%1+_LU'3'LJN_F5UD,FE_1\^].P/R[_)B"LHW?W9A0RT_M/#G<QE>KVMK:UD
M;G9VWE[6:Q>5;%8<[GB(V!FXXCD%\)W$*IM*/*92BQO3!7]"BA%*;(Y(?8K1
MES#5(>0&")(:C$9UJ6<N0^XO:-V58[GS&WXD%:ZYH64R/"J'0#=UKOHW900K
MMEY$H."86M])BL]P-&>#XWXV4*J2H^ZDFQ=N--UT3<U7IFI@N#EO&F8%<7P&
M2-0%+AC74BY6"*D'</5*,(L? $@!IS*A')Z0QC6^(F$DE" =#]8?.8HB@70]
M[ P]$]>OQAQ7!RO=%#J&(+F.0#^^G"SF>M#G0&9<;R_<,4<R,M3UGA/O7O0\
MHF/$<14GEMNRNS5UBIB>F7[**B#+._"$SY:@BOF,=/] 5^_C^+'Y^RYLA\_2
M3JDLI( 2Y""RQ_X4Y7A"7MA-D#6F+*P#9W@!?02N4@:.+V<UED,JA1M">*J9
MDRJ9*S'*<6]8=%27(V']:X_)>C_AWD#=14VO$D$#B3Q$I;;FG;KZJ1CT6P9.
MX 1U,X:#]PS@1!WP*7]53ENABOSWVNU^2CWL"TI\6TR0J@J=^JCTY=G7:F2A
MB1RP5YM.\BP^K4OHA0=*>4BQ0,TH\8KH9XL*#MY?:1S0PY(0UY15#<LL;\W%
M2JU?+)>8V@\FO:%#3IDCO!<:@Z2$*JI)M.@;.\#'#]9MB"#8O\DRWZL[966^
M88]U8#KZQ,G,C$NMK739Y!(NC/X^@_NJ;_OMXK9\C<C[_. F9%Y)1E9",R?6
M+$G9G+*,F&7AI"-:VB,%_V]E,3]Z!C70.,/U8"<LHPO=,)_7T%/PM7V5A#2N
MG3%R6^BJOMV?]##-7<E-,9XKWJ%&C!,[XY!H C)UT0 WG4?X_%#.?*RP47T'
MSJU_]V$[_Q1U-VB%QJO@!!I#)XYDVSSB?Q;+58CK*CG%RTN;#Q)8BYK"&-?9
M)(?]\O*_@N^+@%86>'7$19.A&'U2W21NF'9'C(5$ZP+Z[YHPRQT)E)X[_FOW
M;+A[:J_:L,JJ#K?>^R5S:"QR\%1$HUD8Y0_ONMT:#<'\!K,R3&-9A-I0?0J?
M.!'/B-K^0P/KV4]LR3MM@LX$U.IAA]3@\+ :^(1XH",/JAGY"):ZNK%**:.B
M< V[Z!\4V&P1IU<L( BAE)/Z3N#(F?T<F>O$U<,B@*>(+M"M'S1:Q);0?T4%
MZPJCIP.&!02>DYH6+N4=)MNPWJ@[KMK*B81-LF3A[-78$L%.5I,:L1PK4XD=
M;[^B2C@*#>'V&WF^2(8RMXQ.%/N^&QK&=X7CBA[MMWJV<:F:J?I#\E&'E,R#
M'!)M1 ];Q;5?\&]8[LD8H7K-\W,B<PEP1:%YX9X1DNHP2/3\KJA4I&IJE3Q1
M."3D[>]__.%CTDS@R2V$O 'Z\^H38;C=W=BXKI@.TZ/JF])*H\V5N"V=6RM<
M_OL3V(U:IU.#$YU,#]I;-<8'9<D&L7[<I-BI C?4;T,C%M\,/V6$B&2MZ>RX
M#X=5.8?7BX$ />P&30[28]F*"/J\A(;*$)HT,I5D0W?S01ZM,IFP;^@-)Z O
MB9TB-$ZOCS"VY?])12T"5X0DX)B42'\[.YXL0([V%-%JM&F= D-D\VSR(K++
MH0&,!2?$>/+H,7+FL-1) #!MF$/.=7I8#OA$;?K!_8?5,B+8F-"@S>F*$_RV
MQ.U\,N+"-LGG"([DYS;O'H\F&91*OQW<.G+)9<N8S\Z.ALLGT6,%LY?RVVX\
MJ+AQ@[$2T8>=L3X!]G+"]D?A F/DX\@ON0OD>>RHQ1</=C1'@:7IR+K@<565
M'.DO4T5D#D*\1W '57Z'S?.3XB"^W_Q*E7[$HH5L-,9?IYF=< ]J77 S?8L$
MTDZ3(FOA6._ZY+GP4\6#]\)L:M7R''$T1R3'@K.?8QE^&V(?SBEU?^IHFDNZ
M]JP[R9$K>E@G*?E7*#E;LZ;I?RL(ZKC0-:T@6R6FY&U(Y\=T,;>L"""/G)S@
MQ77+5'H8%PP<D'<=05*2RY0]^+5Z6+\>AI&J1HMRL$&4)Q0"O/\4W  EMRNK
M2>)M&;Y4$24X.5$1M[@I:=FK,TMPL*GXDT]-S3G@>6OLH;/+/!=E<B_PF[M-
M>U;Z)"2[.@+=I\5(9R\K;GP#GJBUW)@2O<SSXJMW'+F@[).@>'$ZT^<0VO6H
M38<!Q^4B?HE(7J#-G?$HA73*Z$E2C*ZF2^?+3$X4&\00NZ^%P'W6/UAMR[O.
MDAD-RY&%[J6(?.U%"/B@^DPFOMX#@3Q1C'YTZUA\[WIH9^W6PS;T'9].74U]
MB71P[3(8)/D %O6XM_+,/<ZQ:7GX=%I*AO-CB_ZWG!]W,WXH,G_@%U%6:?9[
MW.X&%CDI(J5WU\3+CH(XW'"8*F,PXU;I]?J\Z=P/]%Z@C:]*#I:&:(-KM+Z/
M1%2WTT0R]LCP/(E&[(JNVY46*B:$[4F.&MC0M[).=>_CEZL1KGH8F?X,/"Q3
M^5-W0_0+-ZL7JU'>=0J/)PR?=MJ\RA5)G4AU/.S,N63LBOHWQDD2T0A:/28
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M"(Y';CSQ2II8M-EG1&ZU^IH8$__S,V>LF:_BQZJ?0UG"$E9H5H"=7;/[A9F
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M&G7A-D5I*A.S+PZ^B:]7<3U3QRU3G,X'_Z>'$< F&66'FR.K0B0GNCES0!3
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MPCT8?6>.[_#IZQG93B]%.R'U*M43Q>O-WV$[AU6SEV6WRE"M<#RTHTN\'B,
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MF ]^1V<EH2=C#YP])&ME0IQQ#JN9-!W"/9[YN/QQCG0MFYJO)'$B?Q5\'^G
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M?XGX;Q$RM@_KOW8I=(6DUFV95V0O.*F'[[TB *8?1F:)L B-3Y>KV-A+(D]
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MX5Z>5B4&4CC>SV\2?3MFG"8T/RWR]%D$$LF<%^+3$0K6I_C_X2N=H4W,W)0
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MFML4/VF:Q_/B^?H.U1VF#>OI!2+ZL7F+CZ)*O)S>A5^KFC"::67W#<$'AP1
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MH))_*2:^9#2KM44 9(E=S=M]T9-NEH01'^14*=B0J+>*3,Z(I.[&?#6L(PN
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MD(5IW#UXPM/4E4%U+=K.E<Y6-F*.&2G[Q1\A!5:9%FSTZEH NSOOHCNA"P(
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M'/WI>KW.>MP\<SPG(AJ^.-KSGE%W/9F)7V1Z$CI]U\3]0\]+R%Z?1M[:_M1
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M9VE8$!CD[ *A+W@$TY)Z2^< _,CW%X"7&5JITOE0@(S(W83_D(+VIMIFO$!
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MX&ST#YC?]1=92O/[O0JT7WS=C'_V="0*O<>4'F,1E@J4_JVD\[)F6>KB A_
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MQ>MJK*6%FSZ-EIG97;IL396$UXYL76%)R 3?&Z+4P+\5Y=$91R/*( ?!)4K
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M]<M^^#MW565LX[+N[;UVW($8_JBNIV)Q+ X5,][.,+V]R0?*.+HVI^?6=?C
M,$C-];OR";Q %0EP:/=:UQXYH)F>%20Z"R90[KLR\T1VT=/80\4"LU\X'-)3
MH5$#!"OLM3UQ^!A[;=1FVREA?NN\QU_+K@:.')3<D:LGF'O[0@*;BQHR?MZ
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M*X?I"K]2NT=3WFO)@2QE<]S;A8NLW[S\[W])Q3U0+R%@?[:+=]VOSJ"XE(3
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M8O.X8JQ7=> T,L]E%WT_VX\;3/2J)B/P>A[2 X$VKNJ%B(8Z) T1T^N+>MN
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M3[2R GZ*6<C8_TF.?38(:U?TT8\K_]"3>UO9;^H5YRF,/-'%![;;!OE EI2
M>&6\LX337AF"KH6P74B*(/I'47?)NV&#"38=$T=8/_E _%WI<$UA.;4=N+&S
MV5-?@HVO2,VF[/$?\I&?;'-OA*PTZ5F7/X)E];*=IZ#EF&_4]N0#*DD;)RP>
MI]+5 U0B^$ ]-+&8EZ>LF"0\+'I,QN10U7/X))8CT\X'2,%%)R7+-Z+ ^P8O
M?G(\@MNG3W7 $2479HO75 Y? /=-"+[L\H<['W 4+A(D-*$%"2_-)LR>'-Y
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M3!9*;;6>^M+#S69N?_LU[^MIEO0@EM-PWN3PKU='-6]N8)%<J(@5VLU=/-Q
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ML!73)GR>U25Y:O^30*!MK>MNGDXK(O$ \SD>U"#90KZN6ZX.:-X<B#?Q)O(
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M7->UG[$#S[O34TE4\.9]E7JK0YOB0"&NQNGQ!X(JM7+KWFAFUF$IU.'SY?'
M:J+\-T&8WNF6XJ9:N<;IZT7ITOH#"G-Y0A.(8JL]P.$'17I#8^EVBR> /P6T
M_O?G1Z#8]Y2W$_'0#],7K;LDCR;J&C_LV:^5Q;_5BU4= DJKV'R>?)"("6[I
MB#3I4IAT>^I@Z.6?='HNWRG$;UH0!F2_6"*QXV?Z0#6#G/:)?6M5VHY*QM]'
MOL(4Q]\7-W[L,;A?B;BJJU*0DE+);5_X@.@Z?T="5UJ6/L'6EZPIJ>ER9GZ]
M>S5JK'4PR=30X_R^3HQ,1Y34!<87?,TK/VNIF 2?]2B#]Y'IU7T'3C6=OY[>
MS1 P1"8:S/6=2M8(L3>_$]UQ%^WHJ!>OISRW1J.LO+O]^J]UJ\2]9ODK*Z6J
M:R:EY>W^^Y+./?>5F)_R$>X9NBE)XE%Z-=QCC+:741*GA^_:I)VZ)GKU\I'S
M9M#"=H!GM0CX8,3\LOQ"7OCZT5*PZ>B?'%-=-3S?*R)^&:S],>X[%4&PY'MK
MGI3@HH32]9!3]V=CW= -#<J.F6YE#S%J[TR&3$;$TDH'7ED#) ,\+*R^/26,
M)KN<,(B1_J5S)2Z*MJ Z*K LU1+7-6)F8@ *PU!G]K+<PZM-&\*'M0X>1RXE
MSP58'/V!JDCY>4Z55!IL5$$HLDU6/Q*PBZG1)N@7]U"%[ JD_9VMG,98?3M^
MUOESD*'X61?5#[Z>UG_'W>L8-NJ?JJ!=@IC'_Z24<ST_=!HL1X4)W!<'15QY
MK&[R:N\B0IK"N6:/HF0 @,]/ G.53YH^FIFJT'N0!1.0NED-9RB/"6GE772*
M!A'DH';5R<M$PTO2_:>LV]W^-3"[:D#QAU"54%VBB<)*PGM%[RB=#CP 4D7.
M3-(XY=.YBM"UEP)+M._%GY7DPE)-\'"'QEEW8R&A0TL,RS),&BBSW@RRWQ]C
MN.8BA.N3][?.[M/5KJ?Q  N4UZHZ5B^'-CXJ_@R)?<&(=^Q^?;C$QEZQL>N<
M@1<H3.Y$1K.07***3?U#V*DLUOUZY=4+5H6X3]X%L6)&:Q?PC_1U2WWR*046
MBE>W8B0KT@^J.?:!]>N*'O7, O!NJ*>D@?FGA.)3,CQ =(WNEYWD=8:MG(*D
M5<K27I8#J=J?<!$4N[0/##J5J7@1].6UDBI@[4?0]G.A$)L>*=0KC0QB<[JM
M7'OW<I56;@CV[>S"7H:H0^S\ZTSM0F,!AV\I7XMT*J?[E'-BR\3&B<1"T7C;
M-Z=-TQW^L8F$V%R3$M25E]*?[U[C=%T&K$LZ[R@4+54.#\08EOU\CS!+WNO4
MK_Q'K5IEP!8<;_LE=UZN^]V7L92NZR0H=UI&&A849EHCGE=^%:8@5J<[)U/R
MRN5DRH+3.^;E: .84U^C7'#>SSTGS]8JK%B2_O">)J.Y?_R5\=WTOS_ 7^\R
M+X%%S5\[N\-=(/GA/$!3Z&L$=E@R92!#?\;WS )]#%\E&1VC>\I,M'74K-3F
M[]E.^Q+)P.R,LIWL2*=GL3]W%T^./:UU@T&C[U=D8DS?%+CA">;;N1JQL?/=
M_1+?I5*5?;MD&PBG1 E1/ !<0(('&$5=^GD]X+6:XVE2][CTK];(/$#7A<+V
MUI\^FLY_I1-<\0/-$K'#GZV'L'O60Y!.T6^%B2OG$RL^3X/W)!7"^+V$(QPX
MTOX10WO& \1(9*GV/'SAY?^X\>H*9#_AE5*RA>^;4K_5DV" 40?^YV?R<^]#
M'<N'%@&0+R&4U0\F\D.+G3W"E8J'"Z7!7'O#WG]]S?[2&-$!:2W[;@)5%L[X
MO-O2N7=@9UW=USH=)"R#J=,!18>H3F?]NZ(EHU]7=AJOOHA6$"Q;)9J:]K+M
MYQUDT"_&!MRC52G)*\"%/]4BAQQ"ZW139F"YDO?45G66322BI>[?=8R=E<D<
M/O*T$O$\,V5N8/5?#%_J)HH>N9VSHEE?(=$HH?3FQ(7YXMZ(_@?B3X>^JT"J
MFZV)( /OC-*-'%6,F%6]\EKZW%K0MZ=#5>;=HS(&O^P&ZHC-0B(!4F92DNIC
MF55!FNJ:WZ7:72XN- 5,=L@_692)/OHV>?7"Q.]1O;)*R8EH YN?&A(RC\#/
M-X+Z=Z L=:SY^PMI/6\4#-/T5GX\4;$7<OKRJZI#!&:CMNX@'F#G%>+O*WBG
MZ:ZU+%D/<&&TQQ-]O,,[5%1^CO4R+_&)_8UV,X$WT;W&]FC1C"/7&B_?G+0'
M/95703R_Z[0@K.PK^MWHTG"J% _P9GL[5,%ZY(8AP-CB75'"F:2P/X)NNV =
MZ9>E@]T=.YE9*36?_G93X)<0LS8UY-GA]ZDNN=&S+[X CUJ^1<<0#Z;%6WY1
M]H0:5#>!9+W.N5TE%S4/9VUIL7]35^>OKNN$0.4PBC;K]OU)ZT>%@A##R@PL
M_#E!RS(XEV!7!<'KOJ1J]3GVF!U!O^\7+BH#<NI26OZQ",TZVI>>L6B7^?;1
M0B+H?L;]?"\Y%8#<W9B>JGN/4E",@]?W@[]I442[OD%6_)PZ%:M>;(X*M]:.
MDJ8$3>_:Y2_\27HVOR ]^D^%GIE-]OTK+@8K<G+?'-HIDE'1>D5%O;Z[=^Q)
M&J!'IRL:/)-\N4;U.?4Q,?>LG9^(#8^.Z 1E[SL%8@X-R>4Y?I7.M2XIGB&4
M:R[.E?85= 'LHT!/F\NLY2[ZP$:^O6:].EGZ=!2*49>#"N7\DC9?LKT77RZ&
ML3IQ*S4G4@R=>I6R)C_9FI</!MK(N%P/<Q-)<+!*DA@KG6/K=UP+H>(+>ZSF
M/SS_W(76O[ -8/3+%A6^#1PI0Y@.XC\E.3:JB:D+2(#/3ON/+QW"G]=@3.K(
MTF3@A6;-(PH!EF$E'TJ5YQ:=GER+$X?CR%PWY+$$4)!"D! X)O.5;?VL\''0
MFR)Y.<C87$:"\[:$P6S:BIH?#W [YHVIQ]E3NDGF@\X^:DL*V#?[WY[)G+CT
MW6K"<R$^-/E#F/+V>H  [K3DT2Y@TP.+=Y %1SV1.Y-!:S?/(H8F?B^>:+N^
M5B-TH2*JUK9MJE?,IBU8Q_'S%6SNL5+3%Y((@X>OSIV)?2E\_J)F\\*+_+]\
M)(2>J_6X"5T- $$*S$FC6^8%V7?2?D<M3C7H[[PNMM#;A933S:\ N#:IAZ74
MXJS-/P&!G"U1;%]B_/;#$H^;T:[4V+Z'2LH!N\E1Y4J=M7>TJ'^=!3X.7G#,
M+MV#NN6T]AD-MBO-?W*4-VO3-]S':Z]9_R<:,RLO,W?MCE"(_^YJG^N>YOM&
MS--/!PD=P@-WI'ZYQK/+;+:C]0:^7Q[WH=AT;"3?^8M2_YLF6>_:KO!5 G]'
MNS#]@NC5D!TWLA%@'>9P*KSH;NII2$ARCI!,D7Y;N,\? ]M?#AP-1O?2F*_O
M;[GNW$,ZRY(V).5=3:4OM".I%P]-N8*.(8H-'5>L<YGK^09[EUZ=-!(]BB/-
M12E'&(SR -+,\<NO<AFVH@7;(UO/HX?UB]N^E;U5WAL1/3XX:9BE].!K7NQ!
MC5)J^+%'SV_:']].<M)0L7)[L[!U3F38L)X-SI=T 7+J)5/*:WTFU?QEDJ*W
M3&^?D6PYT=J;+W76JK"KZWGH6]^._N'!B3^QZ_?^_9L+@9F-(*;J19N_)0'Z
MXY?8O^(T8FK*#18E'T2[W,A:"/);&7@RTV_5O#FS):K1$?OK)'/^M4J!^XG+
MURY,G C5C)H77TU#437,[6:5#.V*UMUGBQ_Y B(4YW(+UA0$8>>6JQ%1.G=]
MV %W]ET4.K8>ZBE;7I'6^NI?D.6VQW"0MZ-_>1_OHS[94M5VZ>Y_U7N<J$^B
MZLVQV<K5A+?J;F9CAXG@?T&E11KJ %])-_.%VZ)J$HJDA$OXGQ3G*NWXW>L,
MIU'0?THZX<,_*AR[N>8J*_^ZV(JIGS1^(:7]6.#!^WACH(!6N9T,)BNA/2LX
M+>/HTI[D>M?3D:5<HWL*Y]?.;E[GFGO(F_FTO&5LQB".K?TMN2=V(MJ4D?=+
M+B-&=_LK#Y ..#PQ2BWXD7LSZL$@L&5A*<DDW>2I]?2.9V5Y<:D+'?%Y^9/
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MD^IZFXO0J%GF 7:EI-?D+569K_ZUJ^W(R(F8":2F_-93%=T<2CB.MG&'PU[
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M_JSY#$NH/)M*LF'"F=C_V(G&G/BHH%G6$QRQ"9_$89Z49].DYP7@]J6GW6,
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MYS=0_LX1X[^E>CX1R45OL-UI:LJ?<T*FZYU!TR$C>VDM9793]\'-"ENM>:[
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M1[4"N"MD[QYSQ%<F.Q'XC7:8:\B:XWC+"'9A1=0;Y$E1ZM)LT1@X*6/9<#=
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MA"L3H@^".XYE=3C^[37?)SWJ BH=MQ*KC8UP"46IA(6FJ@4\_(3Z/\7)CY<
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MD;,MZ-;&/'0#4@'/:T9%E0UJ2 \ S$^6J/5VS/B=3SBDVBB(,8=IBX*'1Y<
M+CX3]W?/Y,>3EV:")*@Q'QK&DM-"]TS+<86[C@2QD-B$CPT>T+;0!^8RL3'S
MC;C6GI\DFX'_?[ZD#[F96M*B0A:U'),-M*F48DS9PIA3#-O( DS6'KK=]$:*
M% ?Q0;=]QJL;8*70[E#&-U%QGL5ICGOM., >N(-I[6-MEM,)TOT@)WWI$?6Z
M3@@WY:QKMVJ;2B/-M8*OK1K_B*ZG;Z( BIWSAK1-,DT>=:3JVV_TDR6]WN"+
MGPV;7&CV*-GC<+T,Z;I3[N'1A"S727M:)JMU],6>R,ZY>8^BTFRV7#EW#<F
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MZ&&!,\(0(EK;U!XS^.N$P*"NOA,P!#/MYRS73_'-PANB^>#H)/XXA\NH&'=
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MR?\ Y?0!S,R:OH+HO9-GZ8 N=GTORK,^E< ^+YCX'=0>FM?CHE\I2N"X=O\
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M4'*&9U(=)'^,E]*T-CNNPLX@[MSH\S1 8.C8A];D'$-A,5)@^1&8P3L;"-.
ME=O7<QLW&,7Q K@>#TY#P82 =<T'CF=B(U(,20=>.&"9GTX_RWW3@NT,2,JD
M'&5>OE*["KHY"+[@@YAL:F D^=(;E-K8C FK_/QV77M&"070>)C0NO%698$
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M<)V<278EP^*6$#LM1*M#<,IKR'M=F74GK&PD]I@_?D^&]Z#B]DK+L(*;>RP
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M>W2V%']BU\>'<Y7\M#ZHOZK+(JW^;*LZ<LR()F]4!H;SKH)354K>=/NEZXW
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M S:$<N0?6*O?GI+DL2U;@HIRHT=C?64#<T ^:I6RPXBQ-JQ.^XN,9&V[XE1
MCKU@)+N=F+>>>M/V"("8+O/4X%V<X+!'<=%S^_>S_6,_<\55=?\!$N^(WX+C
M8GD1O8B#G<8C,PH[A-?]V_9#2V#9./<P3A/,0XV2'473N 3QP$#_BOB+S#T)
M!AEBOTF.AV(.?BL*Y#I#X]FRDS ?";;3]MN]4IPP;^&BDP4,JH9K)\)4US(F
MHX2/_,RNY'VE6!BW?[;VC\M%:]WBV[SUI80'A.[E8O"#!2+CP11.TABBX3^
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MCJC-I03(L05$[A:8V1P.YA<N*A]7"LG?TYTGAK&,\$&&(S1(.\Z@8!6X1EY
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MZ)\_5 8;#CFZ#Q<RUL%:4N2H*EI]T?X\+'6I.@V3.]T42J8G(P@=8"D'#54
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M=LQBA*R,L\XV-"-ZKMW.QFP$-&<;E+NZ&9JG8?L_,0_Y!6<+MK@_.01V,FS
MCKB&OU*5Q"9HV/_LD@:5.7U$:KQ*&7%PT2#$OIW,1PH_[1\X]ZO]92>N.7YV
M=B<3N'0&/"ZH5RNQ_#,P1"9UINW3"(17IKL5 <V$UXUV6K2.X6RC&VS1Y8W\
M?*N,[Z96]9*V^309/4PR]F904G3"5J5,NH_=>!OS>IQ$7?:OPKGG91X#MB]K
MQV&A9)3M]LP</:>X&J;0G)[W(=?8ZW51<N'T<$;<R!J+9,\.&9:,B[2<>9^F
M;Y(.WW]@Y86M[#3Y /QZM=HZ<Z#QXNK%"6HOO1VQ-!S]NU^G61([W9Z6OPJG
MK.SE/.VLX9L/]2.&4/&3@ \'D?:61;J]SP?1R:9T'O&#[=NG]W\B47N0=I-!
MZ!OPWVSLJPN=E9MATGEDQ*)E=0)S-,QES%"IP:K_P>Y--#O0+)0,,S?V-H"!
M\U>5WXZS89L+8^OJC\B;G;1VV&7(&!/X2WQ2RS5&D9\"E_K]:2U:=3//Z=K>
M<NYGI^QC\V(,1S#6W [:'U(:[1(N',_&>C-HA0!#9?T#'2VMY$%QK$G]9<,&
MB/UM/(:LUYAIY" AUY_#Z,<OW7D@\ZRW(FJ3H$ SE,S[V61@HI2O"R7VQLD@
M*9I7C>&%:R&#]! FHOU)K,G@N16$X5PYX/RR:J+_B2E.9U44EH?'#!HKI+JH
M7>[4&DZ1]'WJ+#[NR@ETJ'WJC*#3"=B\9%2@QU-J=_V+K7E3H\B8EU,@DUX5
M [_2Z9/A*P2PCS++Q/S0_#9,]D:^75QNGEXN9!LFG98HY-F@Y';KXP\WJB%"
MA^+A]-F4AX@I4\$\4W*?O06S2C*XN^[AK3(*[IB0 S4&L^L!!+O SJ^C#>C2
MWHO54-D6K 7.F/I6?UF/PM;J'M@)O*3(5U1,F.(SR3[V6V-+CN\@Z^%[;!4_
M5=99,9&*F(O63+;LI\,[\HO4Y$LJ,9 >P!KW\4;?,X#2/LBO\9+-#EOB7JL%
MN;6V,/3O:H^[9:I\JK;@BFG$EI$>M^0XS3-U^"!#!X>6WG=(Q-0%/9)$$>"/
MN.O36\L%,I8OR*B@!W)$V]Q6^2;CZDT-&\ &@8-?; MX=X2YSG2"V2H@^8P-
MY,U:)0V3[$'PM=)HCB?TYM_?[S!3^$:FB5S6:Q=&1K*1&UY5R--ED">-_M".
M)I 6=\XJH'FH61;ISM*.8UAR*X>C)HAJY*1^>)A%DYO[/6Q$EE_;<O*0($E%
MR.C=9UPUM 4'II0D6#/3 2,N8:.>S10[6D.H/WV^<_%)T<2KPXA_S1YZ1WV1
ME=G#(.<*[Y?Y,3&D7.BX6X&1DTT5E$\YZ/#(9$^(EE@Z"-.QZ:Q3GP4P'.K?
MOD=9^'5?;?L3^6\,H6WB3\F)6*$,7B@_F%6Q@"[6"5R4[A$_L)=4O 2"6(LH
M3<R%[W7&)PLLL+-A+ B["^2=YCG$J@CYHF*&$QHGA#P"WYP/H>X975,D*$;O
M]>5Z*/U[10O4<S"HB[5247SJMQKLM%/5"SO?+AX@<W%5TK1:KUB2SN6[X47G
MS)IRG> S<UWL7]O[8U)D53UL^R0N!L"H8YB43(-\87FTSDIQ-KN;8 :C//8T
MHCG(Z"M)DEFU,9D2M6;.FQ?)PPJ:@=HW$#4:17D]W-4=8$?4B(\"=D.^ 3/&
M%AFL6$5A\O4;#J-QFD?(6796GT+UZ23BK_>30:=:-2+J&L4I'\9#7,XD2(.K
M$;'52EH[U_6^_=+"EOR%>/7276C;Q[HUNC,4N90N<Z:@ MW.M]":%URR)XE%
M_X9I^VI="NT9=Y31*E+9?LG\#_"]"0R+8;B%,?D$(!_-@Q(B4(-17.G_..YE
M.TH0ELB21FWE%AB"$S$]"U89Q'^3HT > V.E,IA?U$_?'?2\YZ\P$5JM_O#@
MRP/T=!\Z4:;*UJ031$]K3/'9Z%ZNYK:-[=0!PWQ$D%11G27'4RK54>Q\KJCH
MOI-_NZMF_=-_KOJ7K"?,6(21XE/F(Z1+\N^F0SO#&T)RW'KIDFLR.-U]%=:3
MI=$=]7<T(^XB(C^G$^/RJB1Z9O,C9]P,N9..#)&JY"$E6XZY2!V)FZJ?QKBL
M.!=\4EULO&S)^:U3Y.H3:+]/5X5; <R=S*:)F>'C+3X@J$:R@-6<OK(SFF*0
M,DIZ^/A-+6="(&_,Y-8%P[880"X\\9L,P$^.OFB/?70G,CZABH]=1?;>]'Q(
MWZ36EL.ZN?CK^VY,-<9-BOQGW*<[BF.JIO^,9#$8'(FP@CAD 4-UH9T>+)*9
MIT)*[.Y,2PGAFO K<'O::[A5LPC_M]W8G13=Y"!./(X*"Y<.!>P-);Y2YR3B
MLGD70)S_ 5HQCA%30O>MDXU]9CGSD)_I_Y(>J#^X[ SK1UU(]ZMW>D1$\+*/
MDI-'W?^9B<?$(8G_6GQJ^R<!)"^"5+&HOQ\P6'47O-L/JQ6=P7?52] GD/(X
M1=_P/^:R)'_8[2CZ _,]7<!&C$N+6JX.3.N-5>"@HZ,TQLFS)DK$S2P&?D".
MU@HO")*SJJ[RRD?=':8AF,"23[.R%/B AY"^[40Z/$=P4.2B27L9B/<<\2+%
M_EZ!,"AAC\_?<"6[WY_@:_Y7+TZ!?Z_;M^"L!VRJ^)[ZLF?B(5RJX-CVN:"[
MQSZY6-[5G""ICCY9:7L!-.XSC-U*FU*U4.Z* &!LD!+STA&P KHVQ)DN@Z O
MNA/A,%5K*[O 4I1#R9#Z?)5![GTDV5?KVR<?*(<V;]A1M]Z"3,* S-\OJ$\S
M2SMVXN"&O#GPOSKD(G%(4[#-A4UXW/)_ )&>L@'7]"^&S29_2/DL$?3DJ_\!
M/&2EGM,AMB[H44Y [2_X$MVXTIB>%:JUS6Q99"'V/!H?=!K1U@(B2]VZX#?]
MU&L&#UF3WT!G,":76L /?#'_8".",H W95VU&.D2P0>BY[K_ 7[;PEUP<UU+
ME/;?JPS>]C"T;CX<-<$[GT>YA0KT7JM:+R'95.I,GZ*.(R.*AKW$/HF8&\2C
M5X]UN?+;O4,V"+_WB]:(=MSIT=Y:TJ%)%8CM1?%( H-CS;G\<ZK6JT/;B "9
MS(%$'!!WSW$V6^/FR%!;M-WQSIX@FYS@07>^Q",2GT*<)V&W:P[*],E+>7HI
M#L_D>N:N[UR24  G+WH9-.#D3N15%2<^X:1O+S,7B2^$-N_U;]TD(!WRHZXC
M.4@&SQ]XE]&%\GY18)'SD4ZQY\Q,ZV(G=%#.W,'FX"W<P9#>()>H_H_-I8I%
M"8-"HS6L"A&/-5UC;:DKU668KW=VV$STV[]T"'M0=9R'X7''+<(A_:04.-C_
M= '@NN+TY_VO"K_6LLZ.U>R5QR8H90]R^5A62YCQW>_ _&*FE?^Y<K>X0U:&
ML;B'Q03X9X,9\\_K+>Z(_4A8U5YZ334#KU+_XC9U-J<,'8IG52@#2\#[E5RY
M!]=XY,4I9P2R#VB](^ZSJ;>=-NAM[I$MDD"<J_8RQWM52_)V#$/9I!F!PX.N
M!-;\^A=^+].<)S<C;7Z!C_C_UDW(4,R2+5>8A&K4\\BM+0"?K%LCG$9A8SFV
M$]Y/[:W1N%Z(S$?$1J+P"ZB4-8*6BN;C9K9&9/B!*F4C;M%BQ!M/6(M'+NTQ
M453.-NZ65WSV[UAP3S2P\2!47VYC;FS@*G%WV/STC67YK=4%5#V(_ZJK+#ZG
M$$YC"^C5!;^#P0!Y \-NM_8/ZPEC>=2U"C-ZN$%GA9CF<^[/]_\#5'$+U6KZ
MA1?NJS$5U+@<'AUF ]TEGW0&[&J3UQX3\9B'PRJ?G3MD*@FUO_XTD"#="53V
M^#GF:+0?)J8..SNQ0V)#", U-7_IW>VC,DDFT[>.]W?LVP5<Z7++Y7A7J&T#
MMYX[.AYP\?/5.*,O"B4<,P(XO/8LR<K$G5RN(A'7_$-6J,_KP5BGJ4T]*10Z
M-+':13D0?/=05SQX9JYR7F*D?ZH&5C_=,FL=MI6=+"RFD?SL/2; );XW4/*Y
MB%L:; Q&!7CSS47T(I7*&#:J0)HZ .NAZT.M=7_U22'K<FTAPT8"TCY)V]UF
MZ_![^>B%XY;UQ,B77;#F8ISUNS) !+^M?:DKP.:7Z48BPBV9R!=ZJN-DI%&<
MFN_\2?>9)B8!SD_LN$,08>.Q31=S/(\+1S9HUD#GH,WZ=E#R#0O(#M,X*.J"
M$-UN [?:@M9";0=-#,=#-TK8[0[+)A@.[B;.4!9FE1(:#VIY72Z3=K.:.VK\
M+@*5SG6A7-[W[OHEE=C\$8C$6H"_U+[AT"97G3<ZSD]^'C3I:#@QZ%P\[129
M7RW&MAHHO.ZESLT@(YOU_5..<')8I3WQ6]F^!^8N7CJ6BMU; &PU%IH%#%3N
M><_AULX5-$#Y+/-T:2KM3V.H3SO*+9E2&&[\J5]KJV4#7S$#)/&5L"92@HJU
MQ'+_,'2W?TGI$9#L:N/*X4CFV=N.@>U Q)+Q+S0?NCD,@1U+JN4E=,D+I _J
MU87/XM\Z4EB[Q_NO9@\!T >,XF*QQ'-7HW _HY/L,?7(0I_\X+*M) 3M[*X.
M8DDZ]9U4-?*K8WQ>RC@9:O;17_K:09^2.#%]W=9@M0?,=Y_47^G?+E#Z;3!L
M(3D).01+(A*\6BH$_W#W^_&Q^X$;;F.VQR%R2B$HN#$A,B@B_FL-##IF$7*V
M(-(=Q77NFX&U9NW%3VLT;C)SSDDN#^BL65B$=+AE?W>=DN#UP@9PA@XG2QG
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MN"([ZLN9Y6.4T[=TU]*W#T]$X2U]$"J# .L:7-"O#*Z;^BZSC-ZPS(PKHN0
M\ 7/=:_KK03*VT5&OLLW@ )W$G9?TC7W1'$!=#<U2$7/<S)>A>^TB9K5A>$W
M;DV'\S1*JP"M O'[FL!Y\*.D<>)>C8<CL3=[B%+V>F)<Q,QWA\4ERAG2H]36
M\Z=B=M9;H"Z/QA=ZH SGK)PCB5$:WQ@K+I G++KC93$QR0G5#C?;([J74[XM
MUNSJ;T>OQ5KO&')W@-X94F];T*3^T-$W#K5/L7GU+4-I@-5[LNBM+X0E:/(
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MF63..GM5^3GLA(GF^YZL6=]+_*9Z/G0C\U.7!O&5CX;?+A-%PYO?^$;]IUG
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MDM@WZH7Y']#$LZN\F+P?C;CUI,7%UK$]!E(L=3/FUIQ?Q7UBT"J@>YK09/<
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M*1J;,//03*2>Y/$SGOX_ !I Y;_?*@C6QQFE#3B0XF&Y\?K6!0" B(XQYN3
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MOP?.'"?T@+!#X #<_![WQDF:J'SE3=IWDIS?%QMT9V%F:/)@,;F@S8-(FD7
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M+WH')DYT27.P[.ZJS,G7"W%<K0=&.8Z7X5"U+E?71 Q;BYTX :7-9LG?GS1
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MA 7A6BQ#GEQ ,@@0=-)F"V$'OTPN-9+ OA)\=/A(1$&@E##I>2 DN@1&W"'
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M"A>,A? *AH)PPF[ST0$M1A6]W3%.<W0CQ[PD4 (B--U]42 :/B8$];<@0MX
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MU%[XB)YFQ1,-H[!Q<,P?E%LP,7&#HXSZK$5?&Y<]%A1[A,&L*<%1LNE.IPR
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M@+%4#D4= .WQPIFE Q>^8-)S2B>=72W/N*&!U ?$\-R!B,793A&XT6+=#$/
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MVY[]Y>[=95==[G109QF80<L3'(NC@3)V2!7ZSAE"5\D@$7TG//%4$^6,X_"
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MT7.Z16ZET>O=R! ,:RO"J9HU=TA@5M:C&X7%#W=)UTNB AVF6^=F2<F%]<5
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M.B!FFIY=L=>"0G=IHX+$36 H?O?C=4&#-,K^DS0ICVS19&3L*F\TY-TJ@0&
MZT=?8H/\NOEP0:+U@,XW'R@'NGE8+D=DS5[X2-#3R@V9/%(TC)WA(=H!I??B
M@ZSUO4*+61I65ZR2M;5^.H%[_M%C$EU.!<@44-8?$^2)KROD$0.5P?<W+-8@
M0E]'- 15\;QRYQ0?;NA[)"U*GSWL+!BD<7]>2!P9P+AB[A&Z)V&G887=$E,9
MORP \R6#4WP%+O@@+5>6[? S4MFZL\ZOE#Z1+0/Q0I2R_K=Y(&#\8<4C0GU^
M$6P9 647%W*5O%$&9A!VZ$K<Y$'&<\_MZ+,'OSI'X1+,-.=/!03;,15W-$LX
MPCB_A&]Y2,_/Q>Y8QF:SQ'"<$#-"HWA$P=@Y%SY<IO<+Q6(I&%7H,6G#7<_X
M\H@0UY%(T'Y.GGF539X<;P0 X0FZ#W9HL2<:8UN6.Y([.N^^J#!=,0Z9WV07
M.0T>:X7!2 GUQR@C=Z8]TH!B (5XW#R@=[M,M(;TI.='3G62E[9A_P!3,)J[
MG"$]SD"/J-PHF E!P/>^,UF8PKXO19K#(75 YJ,M1CT4WNHXY1DBP($'">]!
MD.,]!=N08,!X>_>:SY+>W7CEV^D]V?&]9D3?"-NH@5AFKG1M]^$ U)[YZ=:I
MQ>+Q6JGY=C>^2!F3]&."9J@=P[3=51-2-!>E9K/= /\ %]$%#\10(H,=Q3,<
MX;].OE*)V=_V@:;\>^2SM'76%7=%,ETC76LKHJDOPN^*"):F)4&#\M%F0^/B
MP],T)].,'8I3E\F\$%6CGA@XCMY<D:.CLS;[U09S="^MP6#4M3>Z;T&!@X82
MZ\E(%V?<=G>%1MJCGZ4WC[2@TD*&X7F@Q:#XO=<-+Q3 /@)4PEXDH?PZA\'S
MJ^2Z67@'*L]$ ]AB_P#]]IJ<S]T68D7\#=S6? 3%9_&-U19IAAT0 -B=<>0X
M]E)EO7#?ORRFG#/7"2 9T@7H$;)!<*+>PXPPPR"(9CR0::I'-TP!=O"%QSI)
MQF;O%,UOI!*R\S%=_P 7F@_AB1TPLH&:#@:?%4:,QD^'.MA2J J-;.LG4S0$
M"1="7*>3J/[(-&@CCIAC%!\,GRDMCYB3<1H@8MSG.^79(6B7ASG"=]9+-M2R
MFZ2P;P!#Y@SQ=\('?5^&#WP2EDS@!%QNP@*FCH/'.]4 W'VDU&_KP@] S($1
M&;L;"HR12+IG=)!IJ'M9$YYT>3RI!3 ,OH9T0'V2 D\SI>.Y5.$7.="WJ0H1
MF3C\)?=-]'7R0.#QQI6'>$D62]SW3>$AV@F1GI\E9@F9?ON:!_:8T?(7BA[8
MS+W6>;DI;H^(ENS[HDF$)S@[C?9!5_+<^P@2,Y;GI<85?#+KK18FF.^?1R "
M$'/?$GDLR][WNX3MRWNMUVY:;\HX:("6<<W^:RR6?(![\W\E!HE]<*.)=R[I
MA#-X? UY(,,X4+L7U*!:IA#MVT1+I\?.F[%*U6E<*9=4%0S,Y'P+%4GN=I34
MH/D ^G1!^1<^.Z>6""S)@<2>%;P4V69O>Z=Y8%9DS<"\..MX40_DKKP,4&:+
MB,!+I#S)6&>EW*:Y_;4F5@IMYF'NZ1R05W:0N=S5'PE'E?2*YV#-X &L<GIB
M80,!G3#J8H,R,)\SIVXH,@O?(.A!QG$G3%9AJ+GNTY_:/OS\QS/% /8S)T71
M?&.M+DL=P?",1?5#W8#%YW233<'0!C33=B@4&DHS$!P&*S3A&65'9^=%-QH8
MT[C<G:)PA\3T0*TT"[+.N,>>21TI%QT#W4[Z)M1DZ%<TQ=0:"<NY0%IIV),'
MNIC]JK#H0IOO!<[1J8/ KQGQ1]\A[G[Y71!;^7".D>*FV!_ND'RE'XY+$3%<
M<'7"27V&+S")Q>83049,0=T0\#*\$6VA$S(SD[S%R5^X0?YO>C[A,1%:\K<@
M3VO<(Q%33=;JK$QY/H 9G-$-:PAAP>L8"+SR1;LR)%TZX'MDIE@O.8,NG?5,
M294)?W^5@8O>]UV]"#LP=04[)B:2&6F/.$,%-IH80$G6:W%:L("<L$+@TT,8
MA]:02EI\17!^_P 9(N#P!*9?%]U3LP+H..%!DC5M\1E8HQ=KH]SW92T3/U\H
M&%<N-SDF( ?G(&0RN2,Q5D7^(%YCD2;@F$(3)B3NSHE9?%VD+H@91P%; 1!#
M=(BGUHJ,@0HYX?UU4"9N.6? 250SESN*!6A_VB#SNSXHD?XOP_QO!Z0%U7Q-
M!#0WYI[MX?&&$NLT"&@=%SQF;R68I0G>'X:"Y)F*P,W1C"4$1H'$D!W?N@FT
M'O+R. E2?.J 9C$$TCICEW5P:&(=+,B'!9DTD_CX"!0:.H# QT'1R+8 !#HC
MC*/A!D3H3A1W>JS3WDO>Z QE$W) 6*ETG O[7R6::E-QADLT7N/&,["F1+=N
M=CD@#1>7UE.'SOJIMZN<##A$"^"N&<("+Q*W]5/V.)<)2Z/?@@+G.>8 P&OG
MZ6(>)D8]PG+;A)XZ;]7I661*0C ;_+D&8+WB$)9)GNJ_-"%)87$H@4<X&N_H
M@4&DAA1_U1=( (<""10+G?RN7F:8-3%72=+@Y[QO0!K9N-3 5D0D=C">FHKQ
MJF:;Z4OPE9:I$:].]4%#W@[XQ3!IPEC.$X40]SG]1'".ZY)6<Y&,H00+[XQ@
M(]9/Z/18KYHXRC/%*&1]FAE\=DK+48"$01TT<! [D%2[*>9A5^J+0B^QNZ)&
M<H<_I,3B<)V['<@!-(=1+EY2L/T '$=NB(<'$"#X^*\5MI'-YM^[B@#I1,7N
M=+?P5 0($S!A@^Z)?<X2TST7 -J#M2\$'9AD ![O\P]IHA\?_1&#BX10=Y?E
M$N$'4RX+$Q<8@U=-V!Q2D5W"/#0IA(B#WD<HS04#>63@Z[P2DB3JW]52L/=7
M.5P5'2$'YZ7GU038+X$<7.X]%0M3<;^>R1HXD%T/AV."S35'80&E;R0.TU02
M,JB=,Z*!-8SB#K!S]*;TI,7.,"\_:<2@*@SY"Z(&]P$XO,,KX!8M1#BXF)9G
MIY3%C)T)T.X)>9D"@8&;WZ.D*QX7!,D+)>!P.&&J= _NP-'!PWJ9?EG.-\5@
MVXQQI(/'!68(?,%^NY_?L@0-.A.$ :9\))6]F' N>:/I*F*#;B9$'L,46@?]
MTW2')VG1 &1/$"$(2\P2^_(.(EHG+9=&I#W.<-;[IF=G-K%WAR"1-0'X.,=/
ME!AJ'_=_CE$7@JD.UO=DI>TBCWQU=3$(&;; ]HE N<..ARX(O$1U$!RFE9:W
MS(,)ESE@8E[N]*6Y S1? 3G.F3IQFE C7ZZ;T0"'1  XC[XA4:(G_P!NNMR0
M*7'43P(=>]!D"(=44IV=7%*2# &,\QWBD9)CD-8?-$#E\0,)Z7!)L]H7.:Q+
MR0Z$W#26:XO]0W_)_'_&3L_X_<=J\.#;W#9^W_<2YY?*E5Y!V)="IQ"!P/NC
MM>BSY $/-'7<%@SR$!34*1G.$95QSP0=+8Q@0]\:FGPH@8%[N65XK0KO&CKU
M3M'"LKRF@G6+W9=KR6(A[@9R?3!^E$SQ=XXK#0/UCOMST ?",G3O"O!,1!XK
MG"S+DLU,!T(OEO#K>BVRX0C&7_HU0+P%!POJD#/_ '$.@-[I1&L%5\ ^;X@#
M&\$/;RSY_" F3]8"]_PH?Y4<XQ$2J,&CJN=YP[%,"'QAE2$AD@DQLS_N)>1(
M8/RSY*U7BDP9QHC[IF3A"\>20,PGXCP\;T#>[F'#&Z$I'Y97O3.BS)W0K>T1
M,8 %_09H 8@SS&+II66\"#AV?F$0U,>["%12J0,Q+AINC=4!#3P]_";\'\TY
M%1-SW=5S,,S=4D.P-#G@\0<%T!DO!,W.(?#YPXH(%H@N E@>2ILS>M\5BPXN
M=!\^WRG.S=6O! 7?%\X[D S*,';I7O3-:<,D&"[G*A/5!1LS<^8=G0<#T>HS
MU$0\\L+>K,%XSP?2=SP*D1Q#[?I#H@<$.,'/$MTDC)@)4=PZ9I6XN@7>TGL[
MQ].##,J>!E;D%W72ECY0.SC"PE!H8^+X:(DYE[)'T] 0(%T7=*I<)1$7=]47
M:A[\4ONI$X/NW(#[X.([\M[P@' B$2=1GT1VN6A(@,>*#+4SD0^[P0#W3:<2
M'YPQ5?%\/M(# @:W>Y*]V-#Y/P@MLY/JX2PP/S)*>57##F-4S(D/_:=([G3*
MD\S(B@#Q"'WCN0;!+O:0'5\9IB1/K](LU.;QJ>I"  .$YOTWU5@XB-,=.25K
M#"J0&5."!_<ZWSW4$U(D[L!0IFR?\1KC>Y%DO?#=E=$$G[L+RZ*K+<'XRAUO
M<IM />!!SKY*@+Q(Z8_/-TT#LMX87?!!]X6Z(4V1.$7&=Q6!+QAR&N: ,M"8
MQ^\X\50-RP\7JY3(B\9XF)X46!=OG0 Z7!!0YEXX1KC) -QK'EOFE)DZD9UO
M@L&^+KTT0-BZ(-A%K&K^CT!G]=DP+YU?K 3^$&9;E>ZZH-;I];<4&VI=-_DH
M?R:S[NO!!G2S/#Y30>^<H7DA[\/OA7#!$8W]Z505:8?=[L)*3GAU:2PXK .>
M8X(DU,G&CN.N2!#L^7P^]Z<>.5-SD#$3G5]."S)'"W0IAB4%6B'BD9BY"XJ8
M.$1$7F4LW1SG%U?%$ QIH)8[G\4!+3W 0=.$4P,Z'=%WQ1*(!YQO7+PLVU&3
MWP?@\=<ZR0;W#-XN:/@RO7HE:V<WTCDB'!^;C&0U068;@(.APN4%/'"P'13L
ME[LJA3/G"F00!@:S1:/=SHPN"F'T=1P=UK+X0<7A\=,,$%@W485C' PIGBD#
M> =&?1-AVNLE)])='87%!BU%TQ5V"9K$'3SI@2E>XOE$1A%,=J)1TG5 -GM8
MN.?#LJLLA_<J30D102@["WHC$W"7([T#MM9QA*>&Y49V?.4</&*YVAC(1A/&
M\:*FS/"[<@S9C\7AKP3;,YZ2L)]JSB(T-'*/MK "OF*"S3%90^OM2XX9/RYY
MJ[4J5COZ\%#:&W6[L@=\1+%^'VLUE\RO109,\'[U5_ Y/W( X0A@1WS-A.T9
MNN'3Z2B=UXR6(B*NP/3+EBY!5EF!<9@1IKRN"A,Q+G755/B',\:046IRC>_S
MO0,S#(<MZS)H8B7.YYK%OC.-\$'9W#ZR0. Z8D:7=42S_P"BYSQ+%UZ($8_^
ME;TI;=*P@4F?9 M7&=$SQ\9X^$[0)@R!K=,T&:&)=6^Z4-2K2.73) ,OG,&E
M\$Y9 D[*%+@@5MO5VEP09:SI>B!9$R(Y]LDHL<H2J@8DEU!?+.JHUE.7G>E]
MX(=+?QO@E+3SI%]\4#EK,/IIKHG;E"$#WQ7.W%[Y=KI5=#H>>5Z!!,,2+X]-
M;\)O;/ Y(0@/M6+4#D[L^Y((@1G\8"XN2[5@AQ?U??VL_A<^R<M&%_2";C"5
M_79.R82<73[K.RPX9=T!RRUZ("'U+Q"?*^RS.'"G-,TU..FCJO4V>GB+L$#O
M%8.W6]:E'P<:[]$/;O@_1%B+WX?5T08F=WIQ3AJ1^1?T$@PKE&6*.H ?K*EX
MH*'9OCR'*ZJ;#,(QZC-_)4#3NV[!*R1$'64]->R"8?\ '?=<5:F%WUFE=A?=
M._&]=_1 &0[?'#*'?1*^9MUBJ<:G$<8*8.,Y0D@;9B\NNB1MGKS3,M#3.L7_
M "@P=]PT0(1&<9@8WN=)4C,IB9ET[[J1AVO5 [9?!]FX=$K !R=3P@:O,<+G
MW4F#/D^FB"[\+O>YZ9G@(.=%[_E*TUNSO'-4#4L<#OPW(%'2,(7FG?I#IFHM
M:NQ^;<L3(.>7.#J:H*EK#%_+''P@&INGG?&F"+H"N/!\DC&S(BZ.%Y'<@J6L
M3VU@@6:R=5UA0]QNKCX3^XTNE4& G&F.^_"9IB7:%C%3#7"Y=D?>8Z3??T@
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MH]PA/MVZP01V6SQF/,('!'VNG%Q!\:&Y)FA5Y#G2N3TY$C#/=>] XR?KVW)
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M0?C.,G;HZ53>Z@IQEP@@P,0<,J8CYX(5.$\_K%R/NE3M2SBLVV[/#.D<KF@
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M$DCYTH\(&]V0P[?21F6 ^4/9PTMW7>@YP<#QA>* @U%]AHG_ )+SE,\5$CS
M3^508<SG>2"P:$:/P=T6%3D^/-P42R,@:8S<,DWO=GB,'WS04&3ZPA?RD]^(
MN^:SW[OH<8K.B7WASG@@3^2,:FLKJK%H9P%P-X+GA!P?"WOG&PG?F[=?"B"S
M&T\7\K-FO$7]*)9=*7)^7;!,&I0>[K>ZJ!B_=TU[.1(G1[@>80?(8E^6\HEJ
M,(N^$ ]DH\;O!*6G7%UB6 S3GBE;OOG-!MF8$XXV[SBL67NC=">F_);W81/U
M>:#+43VIYG- 691I#?>DTWM@-^5]T0.@C?6*+;6!AG=$ 9 <;+KB@RU]Z4U^
MDAA+@EJ^KW97U0=#6(/EZ(,G85ANT4B'S>_D:7B@# 7](+OY&_I9DQ#S+A>"
MBP^9WO[[]51YC]Z?&Y S59QZ"12^V=F.6$HIV#SMV>J5LW'?J^@03:VCG7IE
MHA[P\3#]V=\$7 W>];V81B_H@IG;Q7Z2@G3DF9>.]'7]K$Z??./- "9'#'C<
M%@3??3F@#CN%)7@F&$X1\T0,6@-8!_.W)6FL!?T%CB<W]D 9W>* ,^,[?5,&
MG4Q.?WCR4_JR@_S&62"I9F9#2YS0?O[Z'@A[I#7.?"BQ8A8U0*=J9"1N.#\4
M[)KR,+MZ0' 1-<I?6B9EFI.5TB@?VOGPRG\*;8F.^/A.,,'_ !?1!V.-WX08
M,P<YSY>5F<';\?NF:P:P?@=QYHD9X10-[J4C?)(TQTTW"'5,X#'P@T'O'66'
MV@&LYN3-&CM^+[DD:9=.<-R#\>N&*!RS .PG4F@4Y9RNX519:>0/N7-$ 83\
MW5 60YT(0^C71.TS@7(1)R=TE?!!]/F-]J(!ORSE?184OADE#/B[R3F=X7J@
M(/Q'"=G-,T1ANO!2UW>%5TCCPC<"@;A>5N0]\Z.YA]G5 3C\&_I*WSYF_M!@
M7S%W1!^YUQWK#3O"5X+-#([[S0.XS)\[Z9+;07C?%!DXVX<XK--81,NZ!2)/
M!WY>$ 1H9V<L]%FAC5PE#)$@30,QM!/+>;R2/Q&G7K5(Z)D+[JS[MR!MFT_3
M/'LY$:G WIY2@X=)WB@&A41PO2W(*9 :7C5(&[A>.Y$BDH8\,]^"0D[\;IH@
MJT(PE5QY)B?OMOX*9S I3HG=E\>4!#,(!$AP=%[I9OQ2L&N4OM*T_7>[3&B!
MLI@7+I@L6! \_.'12?62ILVJG.'V@&6$#><)+?,XS^D@/.>>!\X[DP;?]CIC
M80%\82=>J;W\9$ QO=E) #IX<]$LNS?<7(">,2[*';ABE+4'7*EO2%\J2^KS
M6#.3W&&.=Y('!@: WR@[@BRQPG@[=<D7\8&\5#^2.&CG305=+?UO0+ PY8[O
M'&2+)ESX\CW.J#1QEN0 "E_*);<Z<KOBE))E#XPYK$.SA-V-P<@<-"S+CQQ2
MEMT+A;E,,\#=FB9R!F35U+O>Y,3>B40<[-[MU[EFCEXN+T!#->&?WQ3=A&(2
M1^KOBE9;RNMBJ"K(D9YW80RK3?)^G5!IJ0ZI&3NG"<D#U&'"^B9_25U2/C%T
M9.GPZH,G1_3 _" ^['.MR4@:/=VNG1RH&?)HZBD6<+U0=#(QA\5XT2%D;[^H
M(>^CK[G>F]V[<@4M;G6[&"Q;O'YKP0>'C$.%VX*A=64I64$VCTYSC<=R+/AU
MUBF,8TI>'5*&Q&KQQH@H;NA2OW?&?:2D6J4N]R(#G\ ^XV]!0Y:CN@R^[Y(L
M&EC=?=8PG./E 01(5KB^6B#I9==.\TN=,H.Q0:/$G?KO0,6;/+*#D3".+IE*
MR<7.E#@]_?,HD4[\G>8("_#/S?$*;0GN=]*GNH^,$K8KRYW@@5G'.'TJLG=V
M&GE<_N\.^+<F&,N4+R<@<NKW+U$%[_K+DJ^TZOX!(.+\.[Y=T#,L[W8PC\?"
M+!RC07@L+I3O3DE9SW>7H&]L7FW_ #/DBT< Z=P@BT<<+XI0U7CCIH@S)I]W
MV6;8S=<.*47U^E4#?2]$$R<.$HWX1#<[>1\I=H81#W1O<@P0ZQ7.ZH&;,KCA
M/6X($.G\G6YHOXPO)%H2<(\-;K5 69#C\NR3=77<NBDTTZDW5IHAI@_E>D$%
M"U?-*[3(UX:*1,L33IJ/E-LCG$B/W>*!B,<YW<DI$X:TTN2+3(U'1][U,<KQ
MYA X.L:5O1.&>>=N\I ^NXBX13:[X=4!: I\\.:FTS6/&\$[@Z(W[NR0P>^.
M4(8(&8.%V[@Y,=(Q'RZX(#3XWX)F1SO?D@0"0W45/=1]]DH?)T,1CEY6,S/M
M>2!_=Q=H)I-H<'\;X)3D/N_* 9?WPI8,G($G/.I"M['?)ZW1!^'$5&>*'<XQ
MT[<0@=HT:CK<'*>LB(3Z8ICFZ&-U0;$1D+WXX(,R'&\,,>B+;S;H7<4&6M'T
M\)B:ORC1UYH%U$>N7*>$$C(C*\OE'L'X3Z>5F32L]]Q06]M7/K.)F>"!;G@Y
MSC/=;EFJ3@[Y=W4VFBXOT?XSQ04!?N=5S_H5"YR*6:.W33/^'S)NRY*1G PA
M"W9('9&^ ^']1BF:+M(YI UR<Y.3.1?7MNH@1[Y9/X7T@CVMR+\)F7WF4"/N
MC^N: !@"0KBG$N-_"BRS* ^O.B?W2<(;AO%]4#/IWGIE<9)A*XW2JE[:]<!@
MB[ME"5A 66^'#2&6:4MX2XV40,71 $,KCDI@TUG<(10.Z5#'E7=5*&GPSI=P
M2LL^'RA@K,90?6=U<@(A,CA&Q4^$TWOPAH-<5-]-?O>@/]VZ^* ;1\F2Z$'C
MRE8>XDQ=N?NMRJ31U+G(8)HV(7U0**G+K<4PM^%+XJ(FX0ZR*<L0AE6Y50;O
MAX6F^ID:;KZI'Q@+>BQ/ARGSF@+1@ )/B<-VY!^62 :PC'"%]'K,0,8Z2CC<
M,D%,1/7A82 :X/QQGT0CNX?;DXX")R?'L@7^/ NJ>"+(CDZ1NW(,M\I9PJEF
M[B^]R"I@(1UP??=*=/B^J)F*XWGPWI"9D5AOINJ@:^%<WYI W/..[3#)8#3"
M$"L0'\GZX6<4"G5W:/1V,$Y=<X)"#A=')0Q63LWO^/A!UL-0?&(-_6Y<Y,\'
M0O#+)R9IJCG/$13=BE($)P?O&=ZQ03:+XN+CC <N2H&Z.>Y[I0?CG\%9EC1U
M/B\T&&:XPUG% !LB*?9^+DE#'@.@<M<50&9?&<^W=!K:PF:0$P]T\4#/ UUF
ME]PWNAON#U)H/),@!A7N>R88SD]!5]3A =T66W.N.=RHY19B:SB)IRT!#M!^
M'C1 3LYD8%V7S#BL(4=AG"]Z))P@7/O!'V;SEIV0* 7O@9Q&%P1;BXY]9/SM
MZ =QX;M/*!!B:OD^EUT0'WQ[:7)!ME_#%+@;N,^"8QN-FB @0<2^$"*_/5:_
MCXX)BS723H7RP2"F]VLZX50!HATXX5ROA!-[A_M@^;QHE;8<[/*249AS1&X(
M'/7D_P <$C9DS*W^$X.(H=^CK=HG)TA X?:"0@Y[R3H[?NJF?S?IOKO2DS?
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M"++B8&^CD)DSA./"Z\$C+<8&<KH4[+,(G302O%*P[*&$,.J @U+LG&/B"0B
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MD7PD^-Y+!E\,!.3\1"$4P$"XRQ^?I AS? PO[@FV=#A+?3LEP%W83R<ZM?"
MM?\ HNIWN"5V(E*?!,/_ $CDZ^CTC>76#[W(,&<^_P!=U0NA"=+X<D! /,#<
M=$CWY8:??! S0H_#7"B)-.L(8HESM^_BLS+00OL@DT,.?)(7PC=O=C-5+5.-
M-)U6:9+N+AI?A!O==UAP4]HSG'P/A%EJA>]Z)9$QGSNR@5@NQ@(OKK<-ZL*.
M[T&&20,OQH'=UF83S[4W("SF/DOP[:(MD/ $,1>G! $9Z=7^%FG1Q,*?:#&4
MQ.!??'FIL5!#[I>:HRQ!WCQR2F8P$S]H&%''BG::EE'/.]5/W3<^9L7V6?S
MY3NJ"@;Y9^?I3:C(@'S1$.ED7;^EO0)E?&W( V(!YO&YIA"%*;KW)#+-^B#I
MUCH$#M-<\L9N3;02<>F,_O)1(GT^<II7T.N6FG-!88"+P(]">F 50PZ5<<ES
M[,[QPZ<UF&G\;O@@=MLC.(O!3&TG O'#+&=4V_"[W/3&QSOGF! TC+7! LOA
MA/)WVA,.K C"Z44W$QC\^*H!_&7O)>Z_"L^MYJ?MA%]XT26+[H*N?IBJ# QM
MUY*09@X@OC;\%1U\K" DR=R4V6GO?=R@@69'CX^5MFT>* LD"\2Y9AG![J&X
M>55MFN-A%IKZW(%+5'$CX[(>UU)GORXP"S1?*>'GDE?!Y^$#!HX\9^4Y$R (
MU47B<;NY*C!=G].W=$ 8!6,<]<?C1,\1CGXRO!3:+I1C=ZT0.&9G 06#,'\.
M=]4Q$,))&=X-NARP085SGR=#FBTU''3PZ*)H^_%A9EEYPQ^>R!BR'6Y[^"D#
M=)87DNMID $;QFZ\H+E_C?*X7R0 #"]1G15 &MWEO4O;2^.O5.+.^]Z"HOIU
MDL1&\!N2,EQ=WK\4QBLT:NRO7Z0 -2KD/-Y)V6OLT2;(O>;R<F9-S05]L ;L
MS46FN%P5 70^8^?"D67X](7=$!_EG%[_ (N"#(F<:5=>"P#GPYQL)@> O>@S
M+-)ZW85G4?%39+I7"&[F%@U?<(,T=UNA?529J'"[YJH$X>'=U@S FI'C&2"8
M&'$]!UW)VF84NCL-5-AH1)?I\+/T<9/-N0 ,_!SFJ XV\=DGN<ZD<LKYI6F\
M*V4%RRZXR6!I>%Y(!N SNQHL#=\,"@&=42URCOE>"#)N["=TS"5WO0*2ZGEQ
MGXN*^^76YF$-%00>3'=?P%,LW2Y.^T#@OSUU-E OFZ[Y)& Z=[KY*F6L'WP0
M9H1)L?7! D0[ZWN5&C##Y"F1B!?G@@1D")&[').Z^^;OE#VBEW5,_E6E\WH
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M.)NX*89-8UO/35.6L\G/N"4-XQC8N* EU>1X9<$ UEIG80-7?"'OT=<M8H'
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M>[_;G8R2!G 7!]XJ@9$1;W1=> 0$9NZZ0[H[1J$:3=I<DAD_XE*S,+'2G#!
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M5 TY[^7!YY/<F#S";XZ.J,<Y!!!K9 RH8D%UO3D"!>89S&+KXHM,B1,H/SN
MP0]_ "D\)("'#1T7WU0$'F ?2$*0T"QBZA[ \BDVF+LAW*!6HR.8G0RWHL&0
M)KJ98:P4S5T02''JJL- TBZ@WDX7B@<B1T!?)U,R^>2Q:P)B]3]CB26GAP=*
MF%]57W8:D1?;J(*-[+_$.B[0/!OA!3#3G85^!DF_D=_M!C OH[*,%)IJ( )(
M#CVY(*@B+Y2,8ZH9F8EG37LD;-9.T.[6-R4V"7 O#WN-Y"J!YQP.\OUP^5(F
M8!?C#LFVABZ([OY/RZ*3>Q>YQ 9,21$@##7EB@JR1Q%>@S@BRPX1!#P\NSUR
M"#I?^TY\MYJ@=I-Y+@X83TP0, "" 22]TI/\.K#DIM%P<*N QP5P/]SY6YV/
M=*RS%\7T!I\H#_+(3(OJLWM# .F[G-^[<G#GZ3SX=T3CB)@9H)L"6I)Q&'"2
M5.6I&#SSCVQS2(.MHO !?7B);TA,XF77!!@O!,3(N?QTO%,_C00A=<T" C'*
M4R,;C15=Q&ZF-Q4GUQ/,0OPF8;?"3O%,0@'M/_<,Y]JYXH@?[C6 $+>E;+R[
M!POM&";WN=CPO6:"3G3C/"$))Q,"9(J,?#K@E:F>)E66^WI0S(UE.&?*2 EB
M3J5AP5&6HDBG3L>JF<H' #BJ.A[I/-"Z7;#F@@T(GC+'Y5MFQ6.%YW),V*UE
MN='?](L!U:OXBGR@YVMI / >]SX/GHKG4PCIV2-;.,ZO%X#JE$X4F +AQZ(&
M]L7OB7.OCQ3-"KQ@XI6^<R(WN0?F'XY2L(#LQ-\YXR%%FS)QIJ_Q%,[<^&&]
MV*E(/J21PY(#_,][X_.&8B%5\AD2#CT7,6 ][R_FZ?PJ$O,I.((I** ^V!@X
MPEEYN"8,_P"V#GO'*%R6A<KRS6#;BZ>$L(9D().?VU\]DXC=)^7I3W$,":[L
MIIB7.P,3&1/F,.2#3PI\[N+TQ.>\DW'<E99<\T>/O?R1:,A$A_(89U0 -%U'
MTB*3RC\HAEU8]"ILB)<X ^55K( /,75^0@1IDQJ^.0\=DWNK)T!\YV$[+<,!
M%U/E<SR\9AYU07$QU=?RG.R#WW 8:J($I%XBX]%0M'*%NZ(&?OZ<,LDI:,I"
M8!K7ADL6Y4 '/HD9:XAU;N2#%J3\)CKN^2G@XXWQBE ?.MUO18XB&&;O,WH&
M9H;=W/1%IG NSTMW=3,H"+]'G)8O(C!Q?N0$&HGV[YI2T^[N23VS=!V</KGR
M69W![I(*$BD>Q&5S3!MP&/1_W0 ?0."_T1K9F==W-"8C"(?0TZST0/-X)=R>
M!3=)!@PC%V ?H@T).$(QK=539F!&)$'.^P@7:3A+6F23'%\I!WD\55MF$ ^.
M"S+(G$$>)H")5C\!9G:._P 2("-[N,@@_"4W.CP0+?;CH@'OR=KG+GP*)9@>
M6MP1+<H0OCHIM&( !<)O[6]!9@PMWQ>2B62\/$;K1VB+36&#_CN=4_NB)0=8
MW8(, X.-(X1QNB&-T6;9J'OE0[T3!SP(SW9_&B# 8EX?@8H^[_M ?6]2LR9F
M(A*$Y<E)EJ/6^Z"HJ?I2 CO?VMR=MN&AYB^I08&@$WYF$A1 &FCA PPWOS6#
M5#%YX80O),U_Z,NVEQ6&-#W%+R0 &5.IJ_X3@OE$TO!3(K3A2Y+ 0@^ TO&"
M"Q9E.'?LE.N[$7S0P(>(782DZX:D(*AJF'%Y2-NTS<CLS23^>Y3:.D([K[(+
M 0=EQP4O=R5 U(\!=+Q4S-WC(A!241D[+<$S,*Y_/&"YRVZ=>66ASDB-I,Y@
M7E@@JT+WTZ(,\-;BE8;@XB=<--$YK"W6Y 2=\9Y<8%Z3B$K.EX*@JY!)IXT<
M_CA;UB(B,KNB+^G"[D@RUC*5\]R!6V"7.I@96(+H ="'2D%)DS#JP[?2Q.[7
MM;T%-GU,;[.6:A1\J9UUG\)"90A7@E)YYPU0.&:B-NU^$"8G(AU+L(!L_%]%
MFCOC/H@KCB)<[S2,X.[/&:++7&EWQ1+3HXA^F[1 /;&4,71L(/-!II"\W10=
M"$N_Q\)03,RSGJ@?:,O$8.^>25Q@)4DF9,;Y7A@F?+"L>EB"#,8/E#AWR6<*
MQ=?CHB<H#$=>V](^X=X404(?A26%_*F8:OZX84ZK!J;GS?>Y9J,I7K>2#%H:
MHMTX0PHEU#K@L6J'&D>E+ 0*&:85OAU1]NGQ=O3>V$_B[BD),1*,.P0'VPC"
M_$A@E9,\9?3YW5!V,7V-,_A$99:.W]I('9'FEN* ,=_!R=D1E'E>:#HDEXX=
M4!8#GUK?9#W.B>GW?%$G)UPU4&AE1]-Z#I?(^)W)9DR&:D X#M?RF8-'5TW:
M0G](&=,4I]'?!!TG&([;I1ABMM&LH.09E &Y=T!;I#<Z_I3#6EZ(EN[H_=P6
M]@OF^]Z!G;W90ROBE,^%_$TS]UPYH/-PNX($;9,Z0@.4>Z=^,C"_*#9EXN&L
M%F0( T*#,X7@[Y0::#[OLLT<(]]XNJ#0[5A% P9B'WD.*8LB1I 1YI6C$.$G
M7W5&KOM6#T$_94\<D7/K8NG19DYSDZ<^_-8&-4"LME[A;[\053B\]N\YIO;H
M^W;\TI-/A]Z00$ESLGW7X(WI!/+7A=$YD-;"+(AX09IF<;N JIL8A4(I;OJA
MFN=[HA[L.POH@HV)D1Z5R6:$GNO*N6*IL]I]?=35*VUSYH%9J_= 7Q3,/N:S
MZ <Q;L%@72X(':#G4AE>[PD8,7$2>@T3O$I3QT<BQA(][GB$#M<1S\8)/Y/J
M*&T9-(7C+NA_'V?T0!H">@$79V$VF3P1?SN6_BW_ !AU1-(/=XZ1A@@),]][
MX#11]L7OA/QOLIRU@-TDP&5S*!72^S?/!6]KKPQ?;Y*;G<+[)B8#'1 "X.@Z
MX7184Y7>2Q&FMWU1 D,.6$:=R@<AWF$/M(4K3$8X1O'-8M<+K<T&=3?KGS5
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M@U1:(>Z9#ITS0W5<\'H@V(Q,91 YH"T=3V=76Y(,L\X"K\UFJ7>:9V#X<\-
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M*#H]G=H\E=F $8 \\_*!FFMU,I6]R5DQD(XAVGG@F;,8[H7N6.6?&ZH,^,'
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MQU3[HSO4(%]SGCGW0E*6($;Z(GA /O!%@3!NY( 3UA/7N_Z3/D)=W7-(T0\
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M0B@W5C=5-@<^/#"W+,5>_P"NB B/GE-!MF+P[3NJ^T;Q&Z3\.1:-:'5]]J(
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MY ?&L [MN^9*7M,#!T!]5\N1/.0TJ>,L4%")X"$^:D6HP#QG>][I)V1 O)Z
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MCE?RD;-!IA?0+0?>F;[Q5"1#3K#1 C+.-9NN/VJ QEO'G) FXV.B :C<OF"
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M\+WI8/?*<)7V6V9-'E\GT$T#M (& />>XH&;RO33#>E]T.M,9T<:NCT2^X2
M,)NT^%/VEV]YO2B"A:F<*.>*7#>E!H' $;]'6Y9@TJ^IZY64P G+A3G&A0%A
MK1[IT&_PJ;-F!.>^Z%Z3CP$Q1/M&Q!D#!Y?&*!"8NQ AU3->(]G*89B\C_'S
M>B=K;.$*P><7WI! 'B+Z2Z5C'BF7.PS5HR,?.[RL@LZ<3&6&[P4Q=%\WSE!T
M\$S,'RK=]%S^^(!EG2Z(.@M0A%TG0<Z4;P2%I\[)<Z.9YH2>)/EE2\ JM .9
MB[%!,3.6G)R&S9X/UDI@8/?$.^,D=FS_ +H^1'[*"S0B:B<D&6XX 2\'LHLE
MQB^DRZ_I6V1<3"$)SN+[@!:V,W0=$C#.]%-TR>O&Z*VWV^$S#@77)<[XN?(T
MAAAF@8-.R[U^\H)?:(NE_NS!NX+-M_\ :!F*9SKR1PI\(&8K 72YIW/EHX32
M"4W;G.^U,/!>8YOEER[H*AATA&#P_*^"8UG$6+BD_DC)T,TXJ,QP^,D$2U"M
M'.BG#3P1)V%4'1<(W"PB1O.$K*#,U!T?B'Y8)@*U,M'J3$,[OZ5MH,,*8H)@
M1>[?DL8F.1LIV X%S\8RX*3+4L '0N#G(*-0SAJI1D#GB\ .5)P)@_K;\U(@
M4NYH& ='-^>B9EJO""Y_:<YP?@Z49=58&KLB.AB@8C \)J[Y"&9SRX27+D=X
M?&-[D[)$@=\G\$%294,7NGJ@QB8X.OKH@#-^$'<;H@R[.Y9>$%0U4.#L[?HH
MM-3>)SA&Y! FF,\JFZ+-<1K6DJ=4#,LDO(+R. PO>LS6+\X]\.<$-FT074D=
M#P2EF,Y/)%]$#EJ58.>-:W12;<_,SGN^^2888TNX9IRS-^.D/M K+4RZ(@0;
MLHDTT=-_S](%B.7+)$0@9A!F^67&-+<M-]\ZY(-#A([ZW) %SL#?;<@8&(SI
M1\DQ;F (9Q<1""5K*& >@1PO>@Q:BZG"#TPVF5O@E]NY[KWK-5#[Z(,7QX W
M7Z5F,:B?>/-<^1JXW<%<&$A0WBY 6JN._EKO4?XX^X88W\JK(GQXWU"BTU("
M_ NJ"@ .3OCJ4A,"*$\]0I/XAX=<!H@&35X[8:(*/RJ!]*^S9QIVK+KJH-"8
M=@>EP@BSMG#D_*\D#EJA'S;TC)Z',6,T2T^= _A=A+[<GF\.""NR%3;IWO2[
M08$04_=$B4'EU\LTS-W;T $.FB+4'0>*[Z^$!6>&6,'WR1&Z6]]UU0,3CV4_
M;'MNK>D4S(EP^%FAG/ARF@P:X:1S3OJ8R @HEGF7/UCV3,,TW:F_E PJ9/Y5
M<.VJ(IC&[>E$B:1S4(EP'.G1!T-.<][B^\_A8B!E<II668$/)MZ#6S,Q PE*
MYH'>:PA7M;X(,'?C<D29 ^,^LEMGN='5XRH@:<G7#EFF%792Y\$SA2'S>"D"
MZE8/T^D"$<:7D)56<Z&'3+<B8G2Y8XGBIMMNF)P!SS07#3P]SG:W":+>(RWZ
MP2,LU!/9*6I@XPQ0= ..L[G]J8<<LY70*?N>=*P=?7)9T1AUL(*^Z$ZW]K 8
M<SKQZ*9$8P#]T;WER#;4@/N/CE)!4S$!&XK/Q<X7N*'O\7'@$A?"XW/1!B:.
MAB,$&F:B^VY,1@=V*4MT/QS0#2;N.?DHL-0-3\6Y2]QDZ%OOX19Q=0[M->B!
MV6I$[_E5)C$0Y_8J@-GC/&"0LRN5_: D;^]O3,,]\JP/P@XY4K5 CGS[_3D#
MG*';+4[T U,$1WS69^>CEBU&^8USD@!F\:%,&,7XY[\Z(-&N?AW'DB'N-WCF
M@FR<MR/OB'C*65\-R+L@X"5\4";NAZH"U$X4\WX3NX&YV]<I;\7BKLMTN(04
M99WFD[[HGMS?7"WK!K/IQC<DL<8R\?4D$HTN^V"(?4PN6;U, QWD97+3!4]L
M(4?*X($]N_7 S59NPR>ZPE#5# T\;\"@S"?SIX>@K3A=RW( /JZLNER4WRSN
M57\DP!FZ_/5 WLY>._!)>!%_:;W91Z?<?I8BKT ]SH<Y_"79-4 <X=YOHJ,D
M&!C!, X'K% I-+WK.!W=+NB7W/[ZSOFG,+OC@@+/:0I?VB_EXMSZ%(\",H5)
M&"WNB#2^/9!1JM\$/;!_)]WJL]SH2N^R3WT&@'/N@H!7IHD!W2=\J<M;^EGC
M#C=4%6FLHB>X\!B$&3Q?E*J7K2^6(2/Y<'"^:#I,/]N' I'8AVAW<\JHC$C/
M>_X\)@(8X7B;D@F1>OE!B)Y<+JJ/RWX7#1!^Z^U<9H&OM26N]*<-WS>];WSW
M.%5-[Y2P-TD@8M2^Q86=&]W!8CK;^"S;-12W009HQJ!E+-58Q?A"_*B"8BY9
M51>8B5[N2!ZZ]!VU4/;WOGAR5&8$^)NIHG D>=<O!01]KHX2-R5&6)&...(\
M*GLR>)Y6,UG>V8PO$V)H)M\<_.CY;U/9B;Z]<CHNG+GGKT4&V3NHXH%:+I"#
MZ6Y,Y\<I76Y( 4X/\;W*#;$7OB)TT^:8H.T:7OYHDF8X;K^UF6X7]\<8(0^N
MM;D@S+#^?./*0PJM[#GK/@F8:E<ZK>^E<>K]>2 "&>"=^3QWN"FV/CQP4-HW
M7G*4D%"V3+'="YX9J(-#;NBHP7B'S<>BWLSTY(&O7-./$A7MX4@,:$PDJL-;
M[^$ ?Q/<2S3,YTUI% @:ZV\BP@1*KC"\M\4#ED#K?#RC[]+^?A3)M^/W\I&#
M\==^B"@:QY7PPFI%MU'QG+[#D[^8P[_" 8H>?)VO! W\LH.??TIM'S=NXQ+6
MPJ_LMD0:<,T&9VF-<M*<N"+.0SA?'#1R7VBN]^!ONG8RMWG- 7X@0=>ZA3 F
M/B[FG>/$+T2BI[WD[P@PT!-WT0(OOF$I'^6#N6F2K/*5_:"1#A"N5[M4[(I(
MW#AT2MX3OEN"S6-\4#-B.Z5X)3'1T,5BU$7!U_2H2.3^*!&&#U.%%G8T\XWF
MG#4\?ATK>@S'!U.O.GP@+Q%]TOX22X7?!.1ES@^E^5(B@F[<$%F#VN-E(0Z5
M7W)2]W%5]X='"YRF@FTQ+&,M;[*P,A2-[E-[WG#.W+9\;QR0%HBF5ZK;/7&^
MSDI.. +M>93;,#ENT0%O2[NB4'?SR3-\L[C%^BD!3ATZE!T!K"P,%)H@N?0"
M6C^2F]UR&85'3Q^I_$T#;,UR^N2<CO*YCO@I,B$<[X\ENEWN0,^J(-.6$;W)
M/=C>93YUPQ0,_28^NZ& N75*SFF!C*=Q08#A<DY:Z2W^.2FTTZ&>_P"?A -S
M?];M[D%!3-S]P[?*)9OG-3!,'7!!IJFLLD%&7W.%^%B8QE?2J1A_*%]!Q2AJ
M/*\$%'WWUEFB2^]W- &F%C!U5-EJ;\;XX(*EJ^K[R2MBL!<WH5ZQM_1.W&&%
M;[Z(%-]+JF =VNPHM9<<,?A.RUCO<@#WTM\$';G;[^U=D"??-*V,*:<-4"%4
M!4?;AE?E.R.UZE!BTY^][NZ9DPN%S0:9^GO2@.A2X\=P0((OSC\B\7)_;>@G
M=(A!^2#),0(=$#PH;Q3C<_EOTIJH2B_$71R8M?7CP@<'PL_#"^3]2H@QI?0K
M/I\\NN:!P+P[2WI@U'*^.:1AASR_BAIR04:9OX\(M"!OAW\("W<KQ1^KUMR#
M;-KKCA.64T6]7"#DKG4ATN:)$C6%GO1!(C#IWT0)PN5O5FH!^6=QBD @?J]4
M"/B^\ ,'13C:"[XZ*0:RW4P>."9F'5!5@=],HI&F_K"Z;E-[NW&YK/C+4W]!
M!8LU=O" )BZ0J8V4F5+X=TSKB@SPD>Z+X551L\WB6BE[8N=G.M>" DWDJ"[^
MU#VN@#]X\>"<&[AV05;.#M:\K>ILY7"* X8Q(GTHF>Z1PPO/% 78N'FY8)B8
M'K*]\TK7P#<=$I;OI>,T!=@.--<$WM=4WXY*?NW;\\-/".&9^4&:JXQPOKY0
MV;&)I=]ENKOCZ1Z/0=#&U @.'4)-H7F&5_*FS?SOF@TW>OG!!BR[XPI#559<
M7RAE<J)66L8\LD0,*X<N"!&[@F9'1]G=P0:#J;W]N:S35!VPXH&=)QA9GRYI
M17K!)[I/UO3#<@]UX7Y0/&-RIPZK =-)5@LP9X5IN%O19%WG1 0<ANOZ0]LS
M=S0&5YZOW(M-Y7V08;K\)FFL=?J^2DTU2[.:Q&H@]UP0,TW,4GT'.YH!HXP2
M/IUOHG#5^/"!#M*[J13AG.?*.:0LXW'M]IRP>DM:(-[=^5]$W32XJ;[E"\50
M1&=Z<T$_9KNIEOJ^>Y5(&$99I 79GL[.;T&V\=SM;WH*"I* G;GYT2G>5G.-
MV[I) WNIG)(6L)B7+GT>J /S0_C<\U0+JY]PU5&!CQZW0N0($=U:=-Z++6&O
M@ZT0%ED!\*<5$C3<4S1RC?WU6.D>XE) KINK/@IAA\S WNI853AC ]_M*3'*
M^R!L!E=RDL6L_J5O4P=XYN?;LTW*^TM$%'WB[&XHDAT'2&M]%/XL:\E@S,X1
M^,T!!PW1ONLP)X7.X;T?=E=T19:G=A ??I<LWW-*T*ND]TN%TP3=!.[R2C![
MJ00;%VO*WI7FEN^;B@UB+XVY2>9.?ON""_NQ<[/%3]TR)?=:ZI1 0G .UH[*
MW)AF!F@1HX'GB:Z4Q1!>,XUPY:HM,YX97BLRZ#M_)V] 63IC=P5/<\I73XYY
M7DE?E= @J3>GRX6Y1(/T[,*CW7TN:#(OQ@@B+?6_I,-F,-]?I/['7C;]4 3P
M08LF4(2OFD]N&$IPO/DG)<-VO) ,[L_B]R ,3E?2'6B9^CNVKL4&,Y#AVXIQ
M6_E S0%9G#O@E,W=>+_"#KX36;@+GAVP0$9]*ICRQO@2H,M'#2\?E4IAA<[<
M@.LK/TLR.5V<P]"+G8[I=^SD)2?&WQPY(,T[>1?%%@]=P[_:D6IY NC62;9T
MRP0,T8SLV([D1YRW:W-*&9F,X/IAN2P?73)R"Y'+E<L4'5W?/9*"(8T=K9U6
M?(.ACC#QCW0%H3=SZ)6<27TRL+-"6B#KX('VC3QIDEPQRR)[5[(^S/G=$/=0
M/N;NR#.SMV7(8I3%]'2OPL!]X1ZIF1#B8YRNLT$P*F=!WR3 5#O -=>RS675
M]()&1NGE*YH,U, 81+L,,IP3@2E)VC@[>LPV!/Y\WFB3]7EF@ .,0=UN1+7&
M_I+.<,CQ=Q2-0)+HWVZ/0-[<OB28\X7N2%KG?.X(,CG=YH*,"+QULE%LUF[D
M%A"MY:H-$CK\(-[C4@4C=R4HGG*)W&X16+S&CNZS)(AJZ^G% [?0<;Z(,Y[M
M,E+WQ<*F=4_OB,KO3!!4N N>]3C2=+[K>Z8.MFB5M[]+A<$!]KB"=+QEDAM&
MS1SOEZ4D/#[OC!/[A?*>Y!F"8O(,)! ,S=>.MT0)P$Z]UMC5^/U]_*"I)DZ.
ME\,$,J>.F?9!Y$8FF>'5W)8:0OO#7) X@X#J\[]$2S6>#A6-A)G9N7E8&?#P
MBS)GU$ !+'2WJ)+S(CSKVXIW\83=0;EB>HE*-RH@+ @^._@-=%FS!XWNE>J/
MN+B!P=?RLU+'"[BB R*N<YW2^B?$Q=0FY]G8(B3KL($RTF-+[(,69AX/Q]S4
MRU00CR%OQ6?>&@6%OF<^R+!1)\,GBX)V12#X'QN0VC@("(A=\$&)#&4,,H(3
M-U"79E\?BZ(@0A$TXS2$0WP<B_<.L>^"(0!SSTCI\21)ARB(Z0X\43!^=2D9
M(QAEC@@;W5B,,'D)PS6P^%Z/2@T SUN:;*/2%+WH&;9EKP69$(P[GRB:6Z\%
M._#GS*!8X8<NO*"MLSB(B#];DE9:,G9@&JF#/'*XQTS0(69NQ3!@7IU[JK5"
M:UE-!MJEO[! KW0 <,<G3N"Q&%3O$H)2.'?[@L]TGT,.Z DRJ91CO3BA.(XP
MO624G(B)G=RP2-,$NU>-1=P0%MO"<I2X;T3H'OO@\X*9H7"72L.2L2]S\)\(
M( T7XPS[IQ!P^[S4"8FHJ[DG#7F[F@KST'!(9[K=ITF@#J7!TJ?(3!N7#/?Y
M03#/^XUH_2+LDS+5"("KWV[NL>49SX'?DE<(;^VZX(%>_(93.&X)_:]PPZGJ
M.R0M85@-#>H3@.KGKNP"";;1A"4'_&"9D1EF.VJS0H.<7.^=R8T=&#KJ@#+<
MV@/.[?5 MOJ#"%]/A$,N@3F7U?;E@SE0/W?3T">V &!<7<CGAN528<*0S2EI
MTAOS\7)9H2F_'.:!/<,"^>;_ *JJOA'EA9'TD9<-8E];Y(-,F<A/6\*H*,&H
MH';Z<$I!<'&9()W]E, E]2) 0^0ZLE9HTQO5 C+.['(8>55]!7Z/A2#;W2D[
M?=N0_D$GQRA+R@J!O<Z&7EZ +ZRW7\)<WSE>[Z35$A;M^.$JH)/G/7.3\R@,
MW# /XR6;- )>+U2@/>16F$>/CF@JT*LSGEPZ\5F6W!Y<^8(H9&-4C.S(>)!U
M8Q#G_5'(^W_:)DF+J@8;T'3LR\3$KU4B \%SW#!\\\4[Z,B$L)=[S2^V4Y4(
M=V0E@\E_+*^27WY")<\0^'>$6C43,,J6%6%3'M3GP01;QDZQON2%(S/+>CM&
MNO#0'Z"+$7'4CL@PK'1Y%+<M[^,)/FB!#!QWQ/?DG98<<7\*5ON@S+6K[N"!
MC3+*[DCC#AKG#NE!^,G3A>44 :,30/W7Q0:,P,(/[%$G&42\0AV^EMGO=%P^
M=$&+./\ [UPA-.RS.%(2DZ=Z)??/4;\Q\H,O>X<,+KR0%QZUE>"'OF]Y=NX0
MW)FGOEJ1R0#(/%]NNB#;1IP=/_NA"7A(T 7'"F;IW3-!MM\C5V[M@BTT0YXE
MT$M_2: &$@83=CD?M9"<2' 4Y&&#T4%"T9F#R\#?/2,$VT-.('*^RS,R70F-
M'/\ K5(TR'PA<KRH@#34'.<^>ZY+/+@:!9IG>XTIHIO+R!ANAD@I![P"'O#Z
M/-U3%EV^^0XU2B1CG>7A9H&IK>] Q%W5,RSB86_=4J;,(&,>-XJNT,FA_M?'
M(H(M-O.G;RJ$U,Q&[S0+(Q!OO(^%B' @;\WYWT0, ^D'"=,K@DVAB2!0_>]!
MEO+'5%V!U.J!/=')TM<+>F:?0.PRX[TC,]WUD-%1H3-'.&DO@("!!YWPD+^5
M7EIRXT4&C,4KI2"P.&/#[T0-LP^<#6*!8B^='4X='=D7OA;J]D63GH,]\D 9
MAK!])7JJ>\&&IE=\HNJ*/,X.Q\8/2,B;C7E@+P06#7"P(<U ,_\ I%T;W*[+
M-FN[DD;9!?E26YR!V"#!^$^(5-K5SI#?\FBXF0[>>W#=\*@:I*[TP0.VT^(&
M$Q//DD8$GQ' #/>4_P#)3IP O1!F#Z!]*0BX! &V02\.>YQIVW)V1AB(<(*0
M8PJ3?"-E59A ]<LD%'RH\7- PD,G4N\4&C*4'N&+TQ,AE?V@08G"_GPL^M'R
MO#G!.Z]VX+G::H0<87@@N(N/,_'=*T,[F,W(%J#OK*\$3C.ALH%#4C.X\5<D
M2Q>+RU4O=05PYBB7W8Y1PP05:%(NUK<E(-8A9\_.(Z<N"S)^#=Z(%C'B+S3
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M=VY4:EB\_4I)6FJQEQN:1\O&73'@@?:;-X^D@9-=]\.E%4&IPX+-F\K>=$"
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MHZ[BL6G.SSC=3229FCI1U* LFCJTC=E$<)\G<DK[^5@1&..$N,H20._I.[*
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M9C-(SLQ";]:T>J/=!^F0X8U02#RZ@>]U5U>R='A_'JN9HO.;QG#M!59ED#Q
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MP\9]*(%=PUOP9I SEQNXJA/P;YI#=Z1TS09PNBJSP< 'ZY=T@9X7O?18#D]
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M[AE+@K-/=,$]I#)Z1AK'2\W<$#^T0=,2PX:%R)IAEYHN7:[0@%VZ_*KLV_\
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M$2,+OJ@ZM/G&^Z [20<(W%(PSB91>+GB].6X :]8#))[B+QQT&Y P#RZCL^
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M;C%RGM#Y\0[)B8DW;TK34(#XO'X0;WU(O!/LVI/@^@2@O+G. YY#/FF:8D=
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M!@)7@@5MLAV>)O1,QM __P!MZG"A0!?31\+BC[7;SE<.&] 62.=^$A,R9R&
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MC5!U- %Y9@1?.A2LM0P-:Q@I^Z&;]*(L-[C*]9E!GO=[L]SN5Y+/<YYA=O3
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M9T>Z.MUQQ0*)<_-\$QS+W7?% X"E;PP0#- 3X%?FJ#>^LJ9N$TS(H[.W<DH
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MQR3.\V!]J/OQESWY*@;[/SK8059W:7-;IDHG: :Y7"XK"Y4O1!<F\HW]*/\
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M!YO$H)O,:D2\NQT[)F36@ZW<TH:BXT%>3LHSQ0;?(9<+F@+31D ^>NC[P2M
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MWB^JI@?I3<YRIM!!X=;D"LM[G=*[TVS<93G'.7&JD ^5#R6V<]X-VYR!G3N
M@_RHM!YTD,:_6"ZF\<7VZ]%SD.CE?'#5 =[[Y]$YQ?.7PN8 &()>'=])P<J
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M[?>*C>5_2H#*^-N0,!GEGO18P[BW10+J'AV\)32]>/T@K[M_W8P2O\GZQ2C
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MN%U2%IWW5P<XV_<G+/S;_I3R^=^Y S+5>8P^=)KH!N["Y@SA;K@F+<Q=XN0
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MC#KYZ44]L:1@G? $3Z(-,@V^%SU029)B<^R=\*WS<46&:#2<X7)*\N\B^"#
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MGM$,OHE<XNEYFH50U!PT=6W]4#M#4\J1Z*>-CX6^CGDG9.D^:!0<H1EG=P1
MDZ\^O!;W4&;[QXH$WQ0%V'GEX0=>=]EO?<-4"U=PTZ5079:OXMRFT9X6[+P@
M#<M]\$K600*ZQ@^]RUQQ^,>"8##IC?E'V6>U\$& ?C7CX*#_ !6^V:8#"M_>
M20F4<;Q[(&>87/.]X5?;@_P7V_NHLD&&ZD-Z?W.N3M,4!+-W82,D7@C[N#[Y
M2-$I9=?,H*D7/2>2FYW'=>F]ZS+4LIWA>"KM&A>$A&WH$ --./?I).['737X
M08;'"%W&J)O=RU0$-8NN^*#N3['?>I^YR8MWAON*"C)O=PU3EV%X?*YBUNOL
MB&JW\>,D%66N<+P2M!_=*#AAS[&64DXTMUR0398W3G2_A5+-W*W(>;YP1(W<
M[UJ@G2G2Z(,&&,QE>8@G#-/DW51)E?$6YZ!V"^[[)G0@74\>$C/ W6X)\G87
MNH@5D$1QO'KJG!RL?>Y*3?#Z*+1R0,_<[I?PD:[9=9ZE(=K3M'2Z)!8OD@I[
M#$T,XY(,GX\<%@U/'Z[.Z)2#%PGOO) 77=[E-H&B=EJ%W!-"9[],D",DW'/@
MK.K6YW7)1N%+NB<\\H87&.%$#-"F,,4/8-VG"S)%DTX][$%GQK67+-!B0F#<
MX'E@E(U^'>>*0"\G<$&:$CE?;/>JLF^ [:*;1I\_'1%D[KP0.!'[PZ^"BU>*
M#36YU.RBTUK=Z/Q04]]X_>"WB[P2,C":<='^9\$%'7QZIPT+YW@I>['C404@
MV= $'6+CPX+!KC?V%!EJ\IRAQT1/V@H3<[*3H'PA&-ZI77\=>29V6Z[YH"QO
ML7+HF.Z.+NU5)XN7QIY5'WB@Q/U?'53=A9ODF:-+%P69:O-!,GB(^=Z(:Y_?
MT*)C=WT2"-'1R05%X<>F"0C43X;[Z*+]R9HONS=4#>[K66>J8T^]#P7,7_%]
M51B^&'5 6@[G/P_X3 5TTDGN':WI3A]1PZ($VAEC<]?I%EM\WZW8<D(RM\+P
M3"]<+WH*-A[^%XND@ /GEQR0]W+C"'PBP(;JN-UAO0&FA^+\(DW=P2^Z[@L_
M>@9]NK1*V;J_LLZQR<B16<>2!7UCI26>45FC]WC3X3 Y7?E$T&K_ !TH@E_'
M?549YWO@L85UO!*_+=EA>B!GBMW](!T9W\;JH,BMNORL74N* B@W_:).%P2
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M%9/#C8NBVT.%<!PX>$C3+BX<WO%=^"8BI^[P0%D8"[AD_1=#!?/#A?S)<S.
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MG:I7S!#(=[(==3L=6JM=%>XY]3Q?Y+I*4N]+VS^"1H\')9\G2:=/_#07Z*O
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M6^A1QT=<3.G:>NZ%_OO7+K!1HC$K]>-RJBI6%<-?JYT.X8CYP'!$HPY;\77
M=O);OTVSHU[B7!23C6P>1V,"&]3M"[BG6L@@I!YF]$N=[&#@$*'G CQZB5.E
M&QJ7>LG[W*O,%JO;;W-XXFN]W'@ED47FX=1':^:"7;BJ)[89TX1BMZ.2;1"2
M%(0)L!\SPM^S+A?P%;X(EB3:)/M-YD\[P?X1JC5XAUP^%]IKS 2IQO.Y4@V0
M1_[:H=YSP&FIE_+!:3LO_ 7=Z";7J/K43N@L(Q!9G!N-3\X(8,]\UZ[^'$5Q
MMAZ>I=!6)=I+_FIP%QK=1'@D$%7LAXJG=#L-1_*?G--%7-[:ZU"-1S6YZ$O#
MKZV4F:][R<9QHP3]DM+]+VVRY3WUW_OD/C:ZO[\3;.F2'.:=('A05Y #."LT
M_:7Z*FL7#X$C*ZE.UG2(-P]O7]CXI/[<S5V<WWG.O<5B[POZ\0M6<K"3-D?H
MWA+]UBM&*J2?"AW,6POO4N@[ U'.-3%9LXAG_K%466_4$1+].[!6S 4T?]8C
M.FD95@--ZW1EBBJ2ZC!1%4Z1+*-H4:_YL,6N[$$A+X3Q,970W/Q5,0'>FW[!
MKUTL[G:=18Y'F+[W%X7QL'[A.K7=(6UK[R1N'5/: B=QZ&H,G&IXQLC!)T3E
M G,#5B.)U7.Z/F)E%CG COWMM][[&2FDWGC>J0B3*Z,)!TOEJ='7U&GO[8HK
MEQ5YRQM$N/Y&"YJH(ZZPIDJO(O3 G*H[*GT49/S<=B<Z^JUIM"MQB>P_6?2N
ML%J?]VC+=(@EM'[M;(&%_,//=*SS:?ZX%%0H#E/]/:6^D\*$"-. %7IR'Y,:
MO<0M4@BY&)2I28O(J?]8L]U2#B/B7O)%W&9X#-NVPH3%5X-M,K11+*Q"C)%7
M'>7DR6.%@ZQ8U,('7F<423#P FS 7OWZNIN!3+K3T,W:;\)W@O0_:XV&"THH
MASVTE11YT]^9@_AQ$P$O=S/ 0 1>RG]*L^Z/65B*[S(K+1.E3.PTT/B2(2=U
M-8^L3_2H%K+L9'CM$Z])31UW'/6Y-7NC9DYA*@[2R1RB$0<0H# X##\R]X0I
M.W/"RD18Z#"'D6XFV>VS@<9R1&"Y24D](\S"'>/U)TGF#2K9/LC11Y!LP,W6
MS$ZAHJDTB@OY*P4#QTG%.LLEUNJCHT/+TMWG)IL,L;VK&'B8F,)CF^04QULI
M,)C/CEK4Z!-7=G\]#86(+#B"-O9XH^3F &_.0#H=XQ3T_Z/Q6Y.CU%\9O(43
M9I1B8N<)AZ=H"V]%YZPV>^4X:H)Z*B2L?ZX4\(J7I04PQ3+*)?H&/>@VU[=I
MX68,+24 0#29\/J$W@-B;Y6)OJK"!/Q6M.G+[Z^O>180P$([5:RZB>/6.V<:
MSQX7EO\<,&ZY^9'151^2*U006NQ(2O(?? RT !;H#+;>F11CNE'+"B> !C=N
MACCEF8-'&XKL2A"OVW=UJ8][_V."&'&_,H$!VSRTCZ"U01]14F%<G;60)Q>@
M&",ZNK^YI_YRB$=3E74\T2HA%H\#A =%:'QPHPF)K[VY'Q2N<D9\45'@O5/<
M6P>3RV8.#@*RN/'9]Q3#4LP49J\^MDJ&*<!5,L0$$,:[U]!  WWD0ZL>^3[)
MZ!)D']/:F>P$2B2:M2.1EB&_;]M#D4 ,<&[L@I%4>SW!Z@"L)LHV\,I=Z_SS
M!D';>SJ!K$QY\*2'6^6+IBC_1[Z7;E%6B:D IWJW\V(2[RW-./4Y,69PCO=:
M-)#()VCK:$*%+PZ31!9I<<6G7Y)]+$@LPZ[\8!23" +D:"G^\!=]GP4-EU6V
MS0IM9RW_;#C)\$$=-X(]#BOUD&F]6(2Y?8]T!M$&.K];W6 ]^OPQD$[')KK7
MO]DHNNKP!,(47V-MLR!$X,!I'!"TE)TA.K#\]<A; \7KWW<#_@Q2T'[5S^:M
MP^GH3[;)$\-PI\HGNHI._$VB\Z."U:^2$FW'V"S6<1[K"]*)1G!NI,I14,-1
M='SIZ24F*$NUZA'B9IG>D_*-:,/.'4.9V6U%/JMPOYVT7>?(O#JC]'[SE['G
M([HS >]6O F-/_1'[.4SW9LI&EI0?,(2-7'I*'W\2:Y?/T8IEJN2%3Q&,\RI
MP-V.H"S*9'LJ"Q\G"WF'%,+J_%<^A R:C*9>T%Z6XKX)]7_4SQ(?=X]=C69Y
M1@O/]__R;?//+=^\MKO6XA>F,58<HMC8I%:%K:A?BYFC^E KSR'>G\OZU6'4
M>:JRO&19<HC;RX2 /HQ@,84O7%HK#G+9.Z2?= ](SA%BL2%;?2OH?^R'Z]%\
M'(?S.ZR@VE^.*Q$+8T! Q-)SX)0&ZSVC$U]C(Z8=W?W_9G:\6%&RS<JT3VO?
MSOA*7RLN,:7NX\_/T4!'8X>B<TO?C:+_";1R\E-WOX6PD'#<O]C&*I*DX8;(
MP1:N&?LJ7NF:]+2C.^_O15S !BG:<Z7T"TMGLHGDPM8QI/WOS:H/G]]$OW=X
MDB-$2)M/M)<TGCBGZNGHI_[L>\DC%<=F*;8]SJ!>'W=1&!?37@<ZW-@2E>HP
M?FCDX]LA$HG?P*6+?I!>L493<!H@Z-K#>(-5T98ZXG.F#$!O6CUIOT,6* %K
M!,N*U2/B$,M1B_)]+\@]44"<S CIF-WAQ@W]C\3=/?\X^?\"D[9^+=^WEZS)
MCF?D%_CCDXY+44HZ#)PA"M!DF^&.E#C5)!X\@9K(A1!]R.^]"L8<1_9PJPK6
MB((&Z29W!,*<-Y,M\.0[-H5$]S]XCYE^8!NTV^DOS)Y WU%:LUZ,D!:\5D![
M?S!AF9JR8TKP=Y3TDAND!621*](=H*X% %1S(3Z!K.@ZF7R.M<C"5Y!YNP*;
M+:W)_3 'UV<N!U))U"_G K,1B=$0FO[B3YTH]/]7/$T^NP8Z 9"9.(G.#H4Y
MR)>;OQLB+2P.Z!,A)K,X.C+P?^&!H2#W0HT5?)Z\$F?/[?\T1LE;]Z"=W">)
MAJ,7,VON?&/_^;'DI2-4V%,LC;) M=,S@NY.3<:&"O&!%S)QOG><CSK*1]\P
MA':N3'0_5"5UFDHBE_!>>,GG6I/D$WZ4KJD+TR7#"^,=YE=K2'#DN\5V\\,B
M+X^HPH*]-16,?C'I/+_W]/IA[(KAL,A<V+,',X1I\-/]35DTH,)QD6ISGC1\
M,7PO"Z3U ZL'_+(167T33/'?=&.+'OL6/Z1;J^947N5*R+43 ?%1!RV&;1ZV
MPWH7CHU5C"5N:MZ.?M"><.@DIO<'O(@'LKO2?@Z$I'^9U597Z=0E!@Y JMWV
M?QO@W7^+_R-H)UP\(.JI53EI%$_A691,R)[['L:,&PZ$\19=.+B6V,3G3*95
M8WNJIPG6ZYKI=,M8\AQTV6L)_0Q'OY\E]B3[9;A9)^/MR%Z7HGTN9I4$7]VS
M.ZX(+*P>*[4U=M/_/)L_1U*U@@+.,G\-Y'+!VJ S<4^:>&*8(52JK?., J7(
M.+91;NYLSS;X'I1*>35:0]);OU5!&CY*Q;P"S[WE=0.>,H*7-:PLL**&VV_4
M^7&KQR.DC]W9%G\\0NSOA 2;$KUG!HC&=XVMHC^)LR&6:'?'V>TMN_VB@S4V
MZ=L&L9\DT70?5[34?";YCGH!B![ ##%'>WK,/4,EA[ZIV&/KCY >4!YV+$/&
MF0Z^I<K0$G*BC5JZQ0E4EY%+B4C<1(VY*8W*=#$U6<WUY&AM1"74<J/I6"2+
MLMH6PI#19#*=#O*T\Z-V^[Q;&.]K\ZNB)O/&%0&"]@;C?E* 7[C*\TT5Y?)F
M-3;TRVI\T(7^08O -?KS08>^/ 5-<9AGUM286)J5(&!$: <34MYSK+["B 5F
MM:!.+WJIBFT%FCE]TC697+]\#$O/+?3O_>FKHRV"+O[TP0EB3CW'9H-PCH5S
M28RDE'&:VWN+<)WTX3 <X]U20TMZ+VM*5'F=YV_0GYTZW:E3E?I;;$KI40*T
M\S!9N2GYR!DL!FQ=N[-@BD&1N_G"+D"8Q1SB. 90ZLH[A&A)HWR[M=[MMC3C
M%W<VCX245-]N(HO"T;MV/NW)LJ#R2J5W/S&]8MJ?]@Z9W8YZ<K@6>K'&=*C)
ME1%I %XU0Y(KQ)8AKW:LIX]ZSA83 ':<1^74%,'F<87CP3T45*5;07]W=K\Z
M^RZJ50WT_@CSKG<(&!.@B/#!L@M1[[UG *'63I\LQ@B&E/^$*6P%&I-C&3O%
MC>('/ ?D5"5/0=8+/^4O!YB_-@UR ?-85FMBQ?QVH\(GF3  QWQ4ON2GMHD+
ME+>)$A@586R#BE 69O<X>Z@.S.RLI?U:C#-GNS"Y0A3E4?<0X!#ZRB<PW9'P
MW[Z+263G'2>K!=W'W6,L=J;RWELC9/QYC"%.[X-O>7=>D=MU2NDS&S/XE!Q#
M'2#Y-I7>NFVOKZO34T_6-;F(UPJL0!;[AL-DU6%O]WA2@HQY'=XZQ6"-M.8;
MA.4'/F97Y;3'L2[$$@WBVDG3A.@8_KJT"M7LG)=TOTHK(T-&Z4R:2NGM=2E6
M<^$)]OR=$P!A/XT![?$VE];GUY@EQ9,,5+U-/ GU"$R3!YHL8:8>I[AX(,9G
M')OZJ]! U)V).?RD5)1682H;QJ<UI=;(:$*C]U]D] X]N3A:^RXS6 +H\[1W
MBA>K55![!V_O)95M%(!YR-ETBEP ?,UI?/J*<2'WLI7>E5I"R]HM"7W[D 6-
M]@'0P&?7[6O0-VB_CM,788KV&U7$H>U\]S,CZ/@-3Y5O<[YT(>/4B17G:&Y>
M%$A'[8U]5)?R%@K$E54;#R"9$D<6PV<$^OWEF_KN*7-!PF:860M@]O41ZRMB
M =UNWWM\!U>C_HP<]Q#RG\S@!:7G!\X0=5->7702OX<T<8MQ+ *E_X=KCQ"+
M_ ,BUJY;K BC6*1\8V<=62,V67[QS4-O=1!J<\Y<PT+J :]/QC%6;Y_:,1(0
M(0>2QYLR<^4IUM/W0SB06::(I5(*"I;)[7A:A?<)5?B@$N"S?8;LR<OR;W#_
MH#'-J#J$-&2L4\#EUM/?P!J.\.!!RD_\%F:!1.>PMR_C8_85(+;&,C.'S_&C
MD =J ? */X@K81>N:D%%S\LFYU=_B!-$H+%N.#R'I)B:\PZPY"RQ>-3M]N>H
M+Y^RG!"AJE0N\ X%]0E P05Y?6R@0(QW@;KC8O+CC9<*7TYX7@/W%7KNQ4RN
M1I7A#XTAR=T,<>V^&9ND!8\!X>7\)=W>6$2&]4? AFSLN^T$0.T@(XC,4KU^
M,4#S4$V:':RGDWOK:,P[!6$EM>UT33B,QIMMI<MS2^+ 9 %V)UGZJ; ^9]3I
M=6&!RJ7^UNB]Y)11EO-:;,U]=#J</GCO.&H2PREPH:]8'>!)'\Z05X=([_.\
MOF6U-19Q9]LMJ\D+J^IRE0NK2#SB?+A$S*CY9 &[B D:O=B(DD-&MOPN=/H>
MIK05X9(A%^R8(;O=DP/G_3Y1;RCW!MD&S6R$G'NT_O?.DSJLI%$C>!2!-Z!^
MO+SR5-&I^E!OSFP64$C@'7P%%LRA8+^< NZ.RP/-_SC]>0<?$5$Y!0VD.FW>
MAR3]]3=4K0TV:@7) &U2=Z.TJ/#(!RMFH;.$6\]CV/M6<?3JR0#("[E2[$MA
M&L*@LUXQ+7R^A'TD,3@6J[6X]K>&],S(2=A.]9;7=^)P)5@PW']1&Z*!6F,5
M#2V)^<D);4CC+Q1/J2U,&.JJH]V]N]TDRDZ(>A_#C@D*GA'CCV"[=2Y ?H'\
M*E</;=*T@Y2*9/;M)%;+J]=\C/5AB&PEZ3M2"IO09-0I2TY]05*!93F.G,K9
M.J)\0:2X/F?+6<RN0G>]V:N-DGG/7MXJ;O+;+A]LL!WO&7QNYH*AJOV9^SA<
M;!U&--T^-)K]5O=P/-Y!<\L6D:7P<3^:&'P0*Q!M<U<2],XZ&W55E.4V:;TY
MI$;!Z!)ZTG>F[:%2%#*^\C3 _!PAO2C/N-0B$+)BQYA%(N)PQD'Q]F'L^>II
MO*T/';3TZFRVSO TZX>SQ\%4?_WS<.D4R5&R+L4 @P'4F<[>8J&;L @3K76$
M%-/0BXF#9#P.IAMX'3F\N#X:>;_=XB*'28A=">^L&T\?MK*I?J32C],59S]X
M+R+GE\=C'_QPEF\CS;O[IL4,WP%SN[CAK<1^/=QH.G!&%\]V_]JCX0JG<[)3
MB,9IG@>!O*%&2&R?CU_C/N_4WL)IB 9[H=L_@L=F4>#%)'>7J/.WIN&&L8^7
M>J0''Y4G++>OD*1^F_3;/(0ZY6O;[$?*M3OH/%(!$JG9S;8H'UU-C=+D=5<5
M9%L^4_GD3TE1$K&=?RG"?5U-QU7YY$+(!=(>5&^1 KOHP&J@0K?>J3LJ^<T1
M5!GXET*."[)36M;#9IEK4VJ=CT#]U ,#U,KJ8F%GHV=4;_X,XM;EF5T$A7&?
MX=F5N83]])TZWX* @$$*KH]2R5VSC(2A6#W7.FTC22,RQ9Y[O(Z&-\LS?)\Z
M]"(1='^_ YJD:GF9-H/$J:OBE&!/KCQRY/PV"VDS?L\R=)D72H5YO?<@\[0T
M"TZGBR^8^OD53')^0U4%%Y.?8@E'&0<%RJ:'[?/I'ZS8?0.58#OXV LB;IR"
M!84#UD-GB-_3>E!) *N'1+866RP*&08'HYAURO>K'(\U-K_\Q7[B3CO()PET
MXQN*X>G8C*-D8PFCLV+-]NF)E46+R2,W_1=IZPC"UY=(K?^HL?IW5/3;-'&/
M<N^O>$-]:=-SXA> QJ8^$'M1KD"&]_RU>C7X"SB4#&]]%$:_].T?036EM=Z<
M]^1N)D[9]*+\^TP!&\:Y;_S>"/Z1O2<5)#AUX/DE3?P@H)M<P_ >VE)!>F?2
M"%'W@3@M" \3)'J:N\Y3%"3SY*)G!\W H'\XQUI[WGN]_N=:W#<<26<@Q[K<
M\B3WS^O\T$6%6T\%"S$\U6%4 ?$7/Z:<7X7NBI3*S[')#N]6!!\;"75L0--#
M#UO["=IA::5VY.83G/R2[WS-),PH8<C([L51?>9&VP7/I@(_KJPX 0?8?GFE
M1 >8;3OG&P0J9,<K\]@TVP!G4%)!+9P^TE-MD1*+\@TI$O *F)'QG$]-HQ!8
MF'TJ!^C9X8VX?S1O+.OFC:7L;AL2H$#/Y<O5Y&9/2^BPTO@86HC# 11.F9T"
MYPB?#M[/BMM;F^$,)36=I@<[B8BT7H*)A[,7O*#+8=V+^M#FQ/QT0F?7XVN*
M4/ZBR"M.OL@6=_&+,W0]U86MLDB;=%F\]:5ZWM<P53]UL&)12\V<UC%BZ=CH
M?M%D7][,5+%CA)0F:?3DH=',D&]A$=F+!J0BWS)$-2"+%#^ #//>[#3^QH!A
MY%YQU8V\R/1?&2]XY#GTJ%Q"CG]M:T3:Q0=^J8L=C%I$?^8@0%_[RMEHJ_]>
MGE[*?YJ&&6(7" R(YWY7Z."9/#+,NTWV;BA-5YW>'WE'>E-)*N>?__H,Y'+R
M*SLT@\&>JS:BP%0W;8X:A_&3[J47W)@C9,-J999>6FQ$UWUQR DZ?"_*JQE3
MIC)6B!X;S)@1DTK>%'%U):9\FCGP]Z82YW\*'_ )1QSIM\EP1 XV(:'H_4_K
MG[.C)3-M<<EMT_:B/9F3>X#L/ =28D8NLM;'ILR?T[T.XV;:55@0@1<F;Q0H
M1+$U"@A=78SB,4PH3&ST2,>&"#)#J@&?W,B<4WYZK:X#;$I1?3;:2LY.X[)!
MFN(R=B7H66'/N^/-4F= +0G(*AJ\LGQO3K*&5U0,4Q<3_[%0.7BP&]%G%YUX
M-6"7L47XS.@F(D-T3,00WTG@6Z:G*2@QJYFP2<Y+A8$I\;Y9D9#'!'W$_1H-
MRGDV6:/2<3^FRI& (0)[U4U(8N>0ZEBO0QM@?QM:=^UVH70\PM@**2K]Q,D&
M(X@/)TFA.0J"'X*B5GRV(U\'L?B)<.6IAWT=]K%6;_C\4=PNC8(7IZ@FAJSX
M[P]UF>"U?I_3&\8([<V3.8XUW K\H3O<X>C*I?0_OD2!]9[EFX1E2,'9*% =
MPBX75X/(*KSOZ&[K8?:4-X4(VR:4.K\?['[B"P>[)RYT(-*W3J/?L@;Y?LA=
MSOGP.KT:+N$/K92+N#_[R' \L^LI6S?Q=6W>>H7X ;_P<J.Z6ZS[HTU2.O[.
M[4?+IE+](2'$$$&&>25WQ/<-*Z J+S][,J]7KZI\WV:0 (U3'$"^=!^0YGBS
M$?7G=5QTDZ')>4$A N"D.:CJ%R->ZY(E&UHR3T#T&6B<YAL_I7E E7MFN_DI
M,K@'=L\;!='2)F<=HNWR2*;6P7;=,9W'TS)U3<L1H1C38S;KE,.;]SM_[+A:
MHJA0';P2K+M ^@!YCL_'51RAJ8>8G$40@U2'D[>Z\#/V$>9"F;3KT5&);RQ[
M%<FA1K.7[1[0M(A+4U/KS$?)W4P%KXUR#R/NK1VI/XZ%;$?Y;(Q,CE@=Q=Z.
MD8H8.P67$TQ/HJISW0RX8ET#S<L29M3@H26A=W12+?*J/JUY0FG9%WSZ)8MB
M"5=6^8FH$(@ZT>1./\8Z,Y!IP-AE-HN^>YC'LRT7[>FD@AI@CK[9RY'6C_1O
MU!'_Z7 6GF0">.;L,S&S?IKAJH+839GN<_O/+6GDO*=7<NS7[J2S:!38V)U\
M#>P@)KZ@S7*(PYN\-Q:H)>$6[XB,GIAQ+;Q^$@%K,&94-Z&&^9Z%5HC=#$VE
M%<?!#/&!=60@ %X1;8ARG]LT/I"\K%*RWX-2/V>Y"4K376JU9UL<)5C107OJ
MAXU+7U$\XGIYO#*C6[EB)10A,%3OPM$]M"G']T2E08WC:Q>SR^A=&XB=21:7
MUI7I6H!LY*3C4ZEM_ I2&-E^!)I%_>4R+8KQY_:L<$M%Q2!V? *0CI&VES[6
M^9KH=@Q9"=A -A,7 &K$!*&(T*9MS1VH76AO;2 B1E!(BG,S=KHNKLP/\2EZ
M<H6GBO2[>BM'4I'XF/(H1#*I:LXZ,#^&R[8L:#4*ZI;N76+^X8^!QGNI!N;W
MBLZ<T;+>QSH>NSR2+(5#%>/.3K['43HK0]]@^K8W8/.PLR')8>H![%!KALB#
M$TB%L_=% ^X@=(X#H2.'A7=(A"AC*:58?3JWF[T03;4BY9]A@:H,S%6WBSX5
M[B>!+#/"[7Z#EJ'3Q!UV1X8'"UN'^<OA)9U##PR\].<JJ$>J)9^=:7U<[S\U
M<Q=59YY*Q1]OL X>W#)-K.1\8>W3PT9@G;$B@OMDDO)SI#YO.1_ZS.YFR* #
ME(1WQG97C?EW.!M7B]&D*Q1 DVK)3PXE V3AF_=33UZ^W/NSEOX=$M2G+O;T
M9_UU:0)G_,P_ A9M(:+<68@6[]OMZ/B5&+:FQH36MBHI\FJA_$"&M+]G(??4
M)*W4%X^C($F']3]G[[+D)^D'<5 B#GAS224^D G4;QD0\BG,0:R>A#YOJQC7
M(MZ"?=!W A8L?KC \Y22,P0)*?\VIV.3)>N^/LXSJ_=6C2THPV#P'T%6UB,N
ML9')BN1B>^^[[-(_OG/R5<5#2KP1UP.=,BQA&P?FA;(H=_],<NJ+@ 00IDGR
MBYM=Q:>'>/T2)BF(7%:ET)X["1LZ($PRR373:<5)Z;)KP</6IX52>O%YM"!D
MU.+*YM2,"%OFI48S== HPEHBUV7B^CEW,TM[E[^/SBIYQYV$%AQ:*G$AS,]3
MBXJ5\J%T3;\GA+>GD!.N84BC[#>"YYT1*F(7%9Y9=PYQU%._"E-9TF,S,(AC
M'YKP#]0E/%C .FG#_3^&YKE[!IB^#\-!*\@\UI\S8LPI$5?;N0U>2\A1'E7)
M-6C,R& X4/;XTYCE0PQ( 1)&)^&4*[5)W#9/,U=&LH]"'Y<;IOX>V5GR1'HS
M8$]I(:@I >)61+Y6LJ7*!(%7YLH]K\)[T7-4A>ZC+%68^J<05P!(D 9-!UG0
MD304G.2S$IC*O:W+P]XAXSM0_NV\D!1/[P[21"XQ@-ZA:0!BO2*0%(7P(#?_
M@19TBZ.=E5] ?RCROY.N('XG>\R4>G.!;D<<712:!J.Q"6S'#4,"/YVV)(L!
M=5_+POL/C!7",AAD(O*SN'? -8GL*JUP9#6VV[,IA@GO\%ZYOGG1"JU?DIUZ
MU"'L^GE]N8_<8P^)(*_9L':];?R;43([5>4_8I*]M1>W09 B<KOX(-HT+AU.
MJ:'Q_:6BB3,JPLF<=GHOSB%$P+W17^]QC[U)1N973=J+&Y1IJS+DJZVQ^]K5
M;GJ'0_($(=\%VJ-E6A>[>^ ',61L49A=#^:UZ/!\-Q;BN! B/@//Z-\D>,=R
MTD=!*!4?,1\>)N@S).JO_JDH+5\P\:(O@2*P?<9Z/?KS8MK9N.QPN%MQZ7LC
M4/A4O&W]OG^%B0'2Z&[',,AW1*X))SDL/D2AM9X>TR W:I+.%+ZP?V="8W\W
MS+*"1S_)%%P[";JV_@@#P+,T0AMU6*32:TD&/H\-WC!<'M[>XZL9^8^T7$>Y
M2--O[W7MIOP;)0UHHRN(=NPMM8#M$B<SQF7Q'T>U"$E\<?'N@A)VR$^1>Z$E
MO=27=O>(=L_D.EDFW/5.-^*+@P*L[ [5'<=QEN]T9M(G ,<#8QPI7P2)5/G#
MV]1-1.Q#4$S#*PV],I[]"" #PS^"HO)>8GSG>JP%"_&0_0B/3*#,1C[J:(C"
MCLX_;Z=O_Y-W-S N2<,(LO["">)*1LQQD:\KY(NQV:@=&#CSSR-[SVJ]+4WE
M>EB*"W>I&I[:E;8JFCT%-9UT8PL)1@%IMR.40T"=.+B]2A^5ET\\D"(*8CU!
M;LFGA,_308Q_*2<*G1I,*OK69Z^H1)BF -HLW8=<@AKD_Q%D!HFJ?1[8$><U
M:YNT_57H)7^_U0WA_22;N7:QQRODN3]7A6!3RNE[NFC'4$$^ZZ?<%L*6 8LO
MU (Y,:R\Y2ZO>J9^(@N/<R?]321,9>:@E2KM:8!>8M36M 0.",R)S#E*HPL2
M-"[4,PY'T3',]P O3'0.%''%I0E,M/".ZO/#40PETP,7-:L;_ZR)R&2NV:+<
MVTZR0/,]*.1R9Z["F$YX $;!F@SC&X[+P$SG=$$L#YP:BW [9,)JD5_&+%\P
M_G$0(X;8QL<\>+T54HZ3ONS>=>H\NZ[OK>>-D)V=B.W&YZJ*3[A7+*$/+GF?
M=>@%P,1)SZX-YL _+ZQL&A:AE$5SG\ "Z!>;F^[XZWD5HKMII]#FG0%%]["0
MGO2 4EDU(WU<(($N,6,P1$D0C^I]^&3_B=-]SFF>OS6XRK \_&U_]2@%V3/2
M<ZZ06L)%$I+6HZ JR+Q"!\G=%:,?1K@NNR!=VW<_4M[PPHH#5] I[%K*OC(K
MX.D,S]#"=BR"??UD$_-N3=M\[$T/2TIS$)\HW2PA\I7ATWPS?1>B_P@$_X;P
M]AC>-+5DRB-W;>H_L8\>=@H^P?$C/$376);!).ZJ80* ]:$^],&;  JN8XA-
M5^;YC;<IC?[GQK!YZXZ;\J>+W#\"U;/7L!0+3!&<F0$7,%Y2Q&(WF=RH;5GI
M5ZOXX$,50>7L_[38+LR4N5&X/Z??&]Y1P8:C42GW:ZM%^Q9R7X>UEY.>)4FR
MFJY"4]H/_Q$ J&>\=D#J?\\ZA?#H#18:6]BQJ>IVCD+T ))>(M'BE#.#0:HJ
M8C9%^.&06*PQ]T-\EN7Z&&$$G>5R#L"WO\\B]H9&M7P,<OK)\-WDG;%4.Q 9
M*L OCC?;\$WZ^CKMJ^]J^7,J9%3OOG/&+)#WC>,'CB$I2E3\ @654@-N]C*@
M3T^K@=MA^&*U9F3@UM@!U9<?9OJ=/,2V#CJ.;A\@2V.EX*5.60$'>E79<2VA
MF BOXKE"Q5]&-@GOA2B1*4QN35"[@J_T\-@\5D7,YJO(@Q!_T-HIC#\,7I<B
M0W<$UD9A2*U>KP=7&&++3=8'L?=B.YYBR'FSD=ZHT^)O]]9JIHCCGOD8>>=T
M$Q&P![[KL'[A6D&Z/*5%,%5T\ +D.8UQH*"02I1K?Z>C7PG.O1&2F%8>ZBM(
M4],1>MPQBZ_G407.MI"N)WUTMA0W)O"<$MY$*4DNAJ,]PU$=8_YMHAQ_DG/$
M24B^L2!.-3R6&!Y+LI)^?PN\6LVLU,>(+#(]6/KP[,1 HWWV;Q5'S[>G#E:H
M7D()W5TWP;,O<Z'"J@!#,OVF\A,2)KQQBA28^@.:#&U,>@31O[*N*3D])0<&
M+5;0DI>A*S$/7U^EC5&O\KQ+R;!$^6!(8EN'^%U%.\!:5Y@(XX="%\(!>_/\
M3Z\;<N&;I-R83M07QX1-7U"QWX6I4+ZXS!B&M"?SL-/6E-GK+)SIQX[!@YU:
M _RA.J#$N_]$O7PK0#X9IJO"]UQO3@'TPSDYL@'%]$>E/-K0K&=PJ[R9=>?3
ML>,-O8N*OTMF7".DO +\:%_3/YZ$$@??CG+]1Z"J<MC+7Q\A2?F;Q]+L/U93
MQ9[_C<;N!?%NH_%.68Z"/53QLV0XD;G=U0P%'UQ_'L7C7\T[YTQ++-P>RCQQ
MU_5N+^N&](6VJQ[G]"1VBADZ1W^L-#ODV\]B;CPR$1BSM%O+_.X,4'40X+H_
M&4FU>\H.?!XZP&\Y,YG/:0P??<G[<S>B^;!>^I&CUI:2@SA?LJ'3F2M9X$LU
MF%LL)NZ:DF<>-_6]>UH"F'\8F6;,]>:),8SSVV=XD&UYUX^3]V@CS:?NW/*7
M?Z/^J$H52M6RJO_A_4? V0@T(<\7XZ$ ?%T:!?RG_R4C*"8-K:.@#@0R[>7%
M//%U[\/UP.O91,!39%AD:XW9FS^C+&,5!/M [\1Q2<D?-63!KZK/0(R#K*>=
MO(FO?:(W$9<ULD31G[$O!;S<Z1QLH *^G/*<&8JO<3#'!>-8W$;FVNFL=HO*
MXUC,22&5_#1,0,+4J!TCP"X5+M66TV\-7(V6=]D>O%EMY>V58:5EN,#FGB(X
M,]Q'<>;]W4MFTFG2EV- T63C!7@Y-#T(OO*BF LR0*8?>VCZVOAB->KV^^YK
M7Z-KA)Y!H2IR98:%X49Z". /.OCV]^S"A*P&O%H_'%^ .\S-X(_\&Q(.9V*;
M_3D%X-.2?]9<C3NNF7D7D.JCR>)4KRRC][*/<"NT+B27F:-W\C%7M_4-KLR<
M CV+W8W*""WQ+OP]W9/+ #P=/%/7$'&X7UW BKK9:&X0V<MA?$N1<03'D*R8
MJ?)0""W)"R<@=)A5P+6C M=V5F@P:$M;;:V/1[)K]K\(5=2[\+92T(Z\CJGM
M)7CEL?9?18L=<>-\Q0*S:?0 .J&DV@7N\EWO-'OL?M^75B]P_]$P!@;.B,%Z
MDI9!W*#HQG7!,IG(%1)B-P\9N;$N"Q<UHYXG# CH$T"-:UVQVI]H^2G^,U^1
MMOECJ]?_"(!O!-X,LE)JQWE0^K Z%%J&B+?=]@5:JG7B5LX.S63M'C+VW7#2
MV3J)PJ&^_3%!IJ\EZ\HD1@JE9O.7"&G?908OIG;Z?1,E[W*EEA1I1A,Q7!D^
MC \=TZ0>B>=!J.9VES[W^ U>7VKSG7MO^-QUOE5P ']R'$U/E:\?;-CJ9C6-
M<DXFHB\^*H$G_>Q@L?0'0-:@$;\C;["B1?1'^5*4/&9*-(O0HK>=.$Q<R" %
M9^M\OVUH@,YCEZY#K&TQ&R<*(L*/D\]I4@XO'Y=+28QY-22I_FKL?6B%QL.X
MU0M\!7"7%6B]]CJJ^_0G7+6)!-.A:+K2$YGD\":5%[.X:9H%@-L/"[S\1_!V
MXO'X FTNRC&Y'&],Z< 45>++]5P%3$:>'9L<$GB$HG75T7@W*C]CV)&?A5F#
M\7X=E5)%-(.H 6O[OC*1>K0,87O"ON9X8PK4!8C*CW;ZM L@?J5^DG+V>$-#
M*OFG9+W@#W*C9WFGS*Z?-L*6VP:<D2L_S\UHX 6H])^P!@ +I5JP-"C\Q ]%
M_LC9]MAV/[*E8MF4(6$22)_&]^1S-\EM7,"DI:LR=2MG[=]P^J>3^3W\T? 5
M!6U?DP:XK>V#_N?I2J8?\.I"RRO+'5T,",;%,A9A?Q_JD)Q(PXM\_7M4DQ1R
MX*U[7CT0DB^T4LSR PQN/-IF%>)C0:DTIZ"!V@VLR>8,OYLJ8,?'B&WRU6B1
MIIWW&C2?JGOTK<P=]C#(@"W'[8YQ/:OR8W_MFPP"QR-8F9U+S3-YNB8))/<&
ML62D)( ;2>]:."1/O2P5:*_B7+/\C%C&25&*-@\\QQ$"'C^[4!^=TT)>^/=*
MG5#!D"\*W2S]V45:6R!(*=@]623/H),5&R%5QZGMN(*V[N7\D=*Q5F79Q,BV
M^)C_XX@,SP\^@6IV+N;$)GS8^@,%"F6Y68H')57@S;*1%Y[QV,KRO5SSZ ?^
M[N'T0E8:N.0,&<[UFNLDDZB5JK;C5JU_!-;68C)1<H.'R*@B9PCMISP,K7&7
M&7=NH,-K>R3P6/V9 =GJ1BJU:V@CY3."L*&TI ;NREI9Z)L^H[U2O:F=<)[#
MSC]+/;FV7XAK8Z645J,2)L=PT"T/&#8I5<% *K0.H]Y [=1G"25WK1W97''@
M*"^I'2R6-WOE'B0FCTIN+P?NGK/0)CX/MB.L?QY0U$N)]E^\=PBR\MJ]:Z]7
M"4L!?^5^I 8(G6=[+9P3NAW9Q[JB]JU[-LZL^SJ#;V 1:C<;L:7<1_9FR#9=
M,NE+,=77V)NJ!P'=<M+OF5C.TXQ2\=C*Y'9[O?<C^NT^UC7UQ'7GT*AF(;N%
M]L/X'G*KZK[/Q2D\W$YNUAM>CWI)U3N>[] Y'/OLT"D'<VQO/M:H4Y4"WVL;
M1T@L,E790P@+T5N3@-/3!NIU4%1B)9S;DYWA<\?K9D: N+2!08Q*N05)TP-3
M@5T'VDY1E0'.9I6V RAMU*IC1JL)[;M)3!)H'M'N#3K@$F#Q4#%1@:UE1C^Z
M57\HFWR*:)LP.F7>X-+F=W+VOCHWQD_B-,-/.Y)#R#W"U%J;K=BX.]528U*^
MZ?2+'/Y7,N 'MQ'&*HZ]2U[A2E4-RW?9H9B8GZ](: MV_/Q.1$1^;(4H<54*
M%2' UV;W=Q8;DU(?7\/!!*+]>0HC,N5')=!:+%([0I_LJ)]\^:MZR61[_*R;
MYM74(WMZO9?] E58-EYWY-9?BNRT6]\QRKJXQN!W>D98.(RW<F_^U7O+"0..
M79GQ>3HGZI(@MVB:X$1;=/+F#[M!B@XVG0NL4V7>V]+E#D,"&DO@=,A4*TQR
MN_J@OU9+71]YMRU",T@9OK@TI_=R4E7T'4C^3G(JS9J33M$[J75-<KOJ1P,"
M7X/W>M5"YI3_Y-(>FPB'X%[P+; YO3Q7C'UF9'MI.WW_37..?$^,3VM_'NGR
ME\QN89CW]KY@#05GJ87WS^65P)WMLKCK7I;?ZT?SPT+#0_K;S?)I=)P,;7-?
MOR@Z91$V3"_ND)M]'69J:.T?_+973[V717+(<M)+%AOT9=L4ZTDQ-_1>N89A
M]F!8B$QX,@/[H8];N79P\A\!I4W'C3<HQNY67&KBPO @:&1JCG/:T16_+L#V
MP?Y>2FE+%YU73&?YV,NG'3$D@7NYL(0H8+ ]D\Z<E7?X -G+JV+OC89H^EIS
MLNS.>9.BF@#]MFZ?TB0R>,A].$*4H%9L@"#(HK.< P-;D=B3%_R2<8Y0U B=
M)U9IF&OM)()^]O_<9"WZ715^SP=ZOZA&.(N:_:^8G[D)>8P/_Q/;#SQR[4C;
MJ!$8,L-E)43(:^O[CB@B]WH;V@1O:16.3RO4$JTAS[@8(HWM&:7!]E=O?WV-
MVY'I21?QYVQ1IUOQ4,>_,&E#%%Y,&)YDQ![U@Q6/(/[,X3?)#T"M40V2&YG)
MB$)A"7NP.I_2T65'IQ4@%:MG>,QNDX&_1\MU"L)QWF>IYJ.=S,=W&G"J'NUO
MH.<FD(<CQ/?C'>RVRXI&WOA ))/>*@1</J%[,BA[G+]<.P_'$*:UQVZD]Z@0
M3F]'7@=LPC575\W_>.W[Z4WTM.>P\&$@ E]B$[NH)4?%DP\F*2@\F=.%@>V:
M#:7R(S_=-E@!@\C(ENNT#754F()5L>0= UD+)G3Z164<RQA4/;1+W' GS"WC
MK>1E^<?6<+/6($]P1?+!!:5C,6"=*#*O&8DM-2^00TWJ%#4GC"Q&T,GT\0'P
M BFM_0%2MHQ%_CAN2LKK<,,A*!%I<,W7U!+SWP@PU#WP9(108;O8!SY@H !<
MK/\Y>X::)X-0>Y_J!/0H/B*>O'0R;[B$)Y&XYJKC0RQ)I:?>SC2,6 8DSQ,]
M6;XJOP\$^%FEJ(A/ N[ATO^0$UV./9B^L*?_*CB%S3W<37YVTAG/^PD J2?P
M]SOLU49-K(2W:<5UZ!+L@5$HD<6Z9AGSU[)FU/804=Y/K+<CD\<YOQ&?LG,W
MF+D^)H"\E50##,C=K4"H2YW;V55LL",T9@=XOJ'.X@=QE8[ E7X&X@28/&9O
ME![BG@P5$MPXQ]X@AD$\U%0H26V!OIU@-1AH\ #/A*TIV(T:NO<WS/LPXQ(3
M8#!2FEUZ/>/6\,>63NP&O!X_^QP2YJ-9N@?SUUX.^A]%Y_W.AM?&87MO:JLH
MBMI%;:*HO5NC5FVJM8F1V*OVWJMFB]+2%@E1%+57426)V!$2L['J^_;]!\YU
MKN<YY_G<]R_GA"SKL'&%S1_MQ'GE?[0KOVCZ;H4!"='\1P0;8%+2P*,%>Q:4
M84& +<4 X'"K:'1'5\.+[=")4%:H^2BM6"E)F!^C*/%=C>E>"@/'HO>H)OH]
M^E$J^UF3NIWCWKQT6&20%SP<"EH1A=8(M'4U-NNVXK]R\%"&6RB=?"\'S5/0
MN]&$]%I-!S:IJ;Z/DL*3'<@MH;-_TW3(G>JKI#*FK\=)\517;7J(^E$X]!0P
M!/0I:*]"DM_8*<X4%%*W.F _#5#P.B5<N/42D 5HE,6)M2=BE3(8>/#%J&(.
M$E+T_*BK/L9^^]L'/4=HA %IT:<&V:'X-Z[8F327ALWD+=QAME\,%0"KNE:]
MLK!QE.:JLADMFS:]/7'7FY4YQIM"<3="V:(Q1?Q2*U])3X/;/X^$L]#!6M(1
MDZ>D%S@LZ,GRX4:#BNN?H0OJ[5]ZUFAH)',N6H6BY!G&NFV-I?Y9FFH&P,'/
M3W=E4W)/E"+2.>8+Y5IE%77?"8A:('/XQP-3+K]KX#%'!&"LH#),QM24UUSL
M!WZ(.+SUUA%*AF_)@^ 6R1 3M&4U+\O.GG.!'0OX1![O%C"Y2#J/7TA,!&9U
M@+^4 7UB_$W-^)SB&UIS*3N,%KBLA*LA-S7W0(VPW!B&F^YZ#KJGO3?VL[9<
MN%Z_5)4SQ>9L*>L'[^AY-Z4@.2^F08%ZB*SR-I^2/HR1LAW6A3@<ZL@N\GE'
M.BCG"IUL,&361:K7_P4$J+LGMX9M$OJ+VSI7K43J)V_PBTU4;=$M<,1M)V\1
M%:=Y;;-_S2ZN C]]@PX[27A;58#PT[='G-1SPQ!G5CYYY/<.QV+1-@BH..LN
M[4Y"0V]PWPK L6%4?)Q:6\/]9&O*)DEZG&ZH\V3(-B-'YKJ='C,P%+J7 J/?
M.&B@#QI>ILK(>5;4QF*(0*H5#+4.04!-'/ 7&LC8AU.(O7?<H?YHW5-0M*T%
MIMJMZ.O9':5!92&1S$7Q"T:B\K6O&LHU?D%(;)#-20@H@I8UV7&GLUWK!V,!
M\=]V)<#$TT3ILL=^!#UY'9\EU&]]"1/%T&3VK>S3].J%#K=CHX1>T83$S\#U
MFS!<V8&01QLSMR,KZ2JH6I2*]:/,Q11%:2'\MI"OK:WK14Z9]87&3BPL:0F9
M^V'A>O#B08<'- ]8T3VB2$;%N>&W5^;PRB-]UAL=S<IJ!QDF@1-L=SI)0I=@
M;5F&#%SA>DCE!8DKP O)-9"0]T+.XHOHQOU&;\>M>(LEY< )G5DF[.!@'2D8
M/?Y2Q[[:[U(+Z$;6Q%5^I943>!TF!D$(!EP!M840(ZS%;!\X&%.^9S_(3G(!
MMZ0A)^#OF$LU+D0$-Q1U9LK?1^XWX)H8/C>0D!-.LOUK/RE:@7,]1L,A*JUA
M_O,\\11>8.F@U[<"S4!'FF#.&Z]FS]^Q2A[?^B@H,7/_K&BV444J4$)^J>AL
M4ELU^^>LQ2X'*>V8@/+Z+8<<F6[XH+-R89E;;WL9]9? K@BJ"B4DK[SI@AJE
MZ;X./ON51S.);"]>V!E2T/K581>$=K3F7B35W+A^S^%D"VY\%0AO-I8S'%'
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M,Q6D@6<EGS7^&'IL%5#,QE7D7$Q%]4!FL3O$BCYP(9MN_J-7YMV@D -F(;J
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MS)O#0G9R5/ (-??#(;HB?@US.3-8U,^_'?A0T_^(F+8S>@R(@E E4# @8#H
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MH(7L-&V&X\0:3=TXVHSR_IA89+'_/? H(9_^SAI,3C'BH8AZ^!R9VTEY?O#
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MC D98V/<@Z6S8+$/O06//G(A/%3CD*1XO6"+RW8)V<[!^V#BA4PQZ;;2J@;
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M[]M!ME!=@/Y,.!&]:IXZNC^+2]AGFP<2;>E*+/V8[:&DG;Q&Q#(^@:TXF/\
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M@?Y0 YJ5X"B-5>.3]U]M8MJ]"5X&D3T+&DC/[>*52 N;MSW:M8R<K7O-=*L
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M*$Z=7;R67;JC_IM[S7&)+?D>56E_E$I]-/7F4#G(7GF@B\Z.T \6(N/4,_H
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M,2EYI14"8G%57<<YRKDC>?B4[0LM>(X*[V;72]/A?45(G4KSQ\W[D.;-A@6
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M.(Z(ZGS-^,$#'1/QMRG;8VK0?X$7(@-=5C$GL+O,CW(":^QPT71.NVF;2;L
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M-^IKG?B#.9ZL<14:PA/5GTER-]>*O3S&\FR5MQ6>:T<%"'/S_AQ3WDZ[7#M
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M-435U-4QZ6JM)+XR$'Z_X)&Q[P"K 3;3;.[6-(C\]Q;VGL7?=Z%CP>/JWW8
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M]$6O8! 80ZM3]V(JQ0]1Q-<TP(C_@?H(;+E!TRG;O2DHA.@K#D%EC;K7=MY
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MR9Y>\HL]0M8R$KI)>61NJY(EU<HK!G77V(5;_R-M,8PE<9,SB^! R3^]V%A
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MG_0(642LF&D(2:^*)^,-Z/[NO1R<,[ON['RE7GR0IRN+X'OT]DF4AZ\0:.1
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M6C6F<T]:Z*F3 @7?!U0R/M'Z-3H$SM7V,"O)HX(P:EKQ899[%^G SL_$C7H
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M/C>[8?WV"'G9K,R6%-P_HQ>BET'"\"[D1\+ \T*!$MGH;]7O5^ O&/*H/S4
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MX-73+[P&36FO/6.?^C;K?2\DQHI++\\ CTFE\2P]PSC[!A32YT;2 CF<%?#
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M[K&\<S9F<9HEZ<EH9AV-9<_RC=.PQ-)PRPUJ1^_ZF*O&1LDM'@4=Y$_*8(B
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MF,<2L+2A_MK%*UA/BJNVJF2KZ_4ET?0'\!WV=FH&*7F]J389$_-,/OED3"I
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M93XJP\YL@[F4)-9RLA5,(\)Y_@L[B9.4M^\"4KR9^CM_Y_(<'](^]7!,81#
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M/$"3MC^XU86<WG^!%TC>ZN)]-A+.P3/!7A($:-@2W#%+OKH]Z4[.H95( G+
MM)ZT_"/HC'Z=(!0M+%-1"RG?V\I5+9<&$==;RMBFPY!\/"'.Q61,#(\>&GF,
M_I:!7.V6<BGL*F&9UT0!5^I'\N"NBU"53AU-D=X [3T/,^JBV5_-T;7 <VR-
M @P_Q\3=]D()UT@<R;TP(:)+7XMTD9Z"<Z$R<%K4[Y_'8^85TSWCQGK"G!=.
M:J='\5]@<Q5SM[3&MW(0T\PAN#V%56,IUJ.4,PE6K7+WPK 'SY<*JD%UW')0
M\^#Z0A;6<2<);]S.:WOH7+:FT&]9?OAFR0  ;%:T/'<K1_BNL_3%H?&\H]D
M[6\&?J-1.=NNR B\;JGH[.JY9CQ=6);D)DU]:T]H2%5_Q1=" EZE7W#&$0M
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M6^O&:Z8X8[[W_&'GVG:;)9:E!V[7>^Q5B!:EB*#D,/UW>O'P'9!3FL&V'W"
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M)C^;<JTWN[M\]5R^I7NJ-7^@:SGE8W?-WYQOA:0(N'T;M[+WS>DB&Q'YGV/
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MGYC4#9T1+4@!T*ORUPO> $-3Q;VX@9SGW2B>SJB2V'YD%MGZ[:4G2EU(CP:
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MV1UI(QI77,C=<0/]1VHU!J*"@:*Q4X-UB@:W\YD*"GO5'FUL4S'OSYZ-,3<
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MFFOM10PE.3&0!*1X9$MDP(YOCILQ#5*=43J$UY.OT5M- ?>D0K>/>5!R"S8
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MVTH5RLM8YRQ?>B;WY7NM^2W&6S,5:XFQ<E'VQ=PAOJG+7/?3[2>ZF5WX6(%
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MY?:4FZZZJ36T$9:4HZZBB5AM[H7=45;9F5(PWG#&:I[O@=:%;L]_;1ZG8O!
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MXRWWI&"@RZ<)7\X(M;2^GWO0=0B[.GQ5*=GH^BY!MXZ6/OLKG:9TPY]OE X
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M"S(Q[\-8('!_"N4@[) -7<'E$F>HQ:I>GWT3 8;I8*-QN?(.>JOA&9QANNJ
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M;AJE+,N'QVPDL&ISXRQY8*?ONEY]D#@1YO-:<<E9W>LG* :PW:GRC[[XW@]
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M8]*/.8I\(.QJCU!K+K<2>6"7^2\J9VY3:VD]P%\R4#F\KAV3LWQ\"LESO?\
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MY7'!.&^\,N6+CIHB2JVU*\G0ZY)!I?E_:B0_4(783,GXW^+DBG::F]*&SB1
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MFMWDIAOK3&1*):PW8ZZ(*NU\[PBSO[?6>"1EOAP=](G:>*NMU4#-.S\?"5V
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M:!/@8!T\D'W>]*UJX=!NA>Y":LNLP:M\DA-]?M -3SLTI<D61C&%W421:=C
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M=4'2RUE#MG48(C6L#T4&6N<X>:8XX)RUPQH>.6Y!3W3N"337+?@N<M5??/-
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M6Z=C-<YNAH\70R4H^'=)/R08,G7]_*H32_J8SF%C5MUQS9(G>3W4>_#GSR5
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M4%QLM:UA=>LU4-;]*83TW(Z0H6N&5=4 >7:,*J):UO+'#%Z<-=WXRL)#&O\
M@Z&6I9P-RO%.3?+>N46XB11!Q^-(<-4EJ)R=#]PE96]U/LV]29,\>5ZK'AWA
M<E'.=]]IRU/@.OD)0W@(.SW<GI"?A[C*!XHOQA S.6$T=*MRQVES=U2?RSA>
M$)C12X^7FWI0: 7AKR1*IM#H+>$WQSKPXR@A[K&&6JD_(QQRONL6L#&5YWDM
M6G@S%7%;WT[V+BA[I3B:"&ES4 =T+/PF9+G7#PZYJ0W3-U74[K!J=ZOH[)+[
MIPINUT1<._'PK,\"\+,&ZXV4?<,ST[:1S7._A"?--[[)=R^8*$3?X=RP:O#
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MFI ^_";ZW1$-#&_FLE$;(O?J.%9/-<ET?Q$?5DO%-P5*8R4(PSO2J#LI7>"
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MMC;Y) Z!AP\N/!.S>&%\E!DOKC-6?+/Q2X.46V5S.U[:K.[C=3<_Y2OO2Y(
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MCEGTC3NE]TW6(W@M7R^!"P-,QN/@I2U(8$J);UZ<:Y^%BU@K$=67.;<VX9_
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M536>1(?QKB[QR41LXS@\N'=RNQM'!V%GE'HN7;;6H?4GM;E+03L\.MY39;4
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M\<$)JX9O*%L'XL07)M6;O[BJ[*6>>Z6<YIMJ(:O=H,=<$28W[WC1P .F]RZ
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M87E]I U]Z7%,33I&Q;U-K 7H=5!0;0'[PCT5']?M<!IC&,'>=5T,M0<^/(/
MXR\I(H6K\C+JC@["O%W"1S42UE'@@RU'J[IJK$CI!K.D>7#MH@6KN20F8ID[
MCEAO2D]':'QB5+BONOZ1?A#K@_D5!DW7#AB@#\B\1P21U!K=VP=AVD@R<8;^
M]P7/[KN1\/>B&_JY]))NSX9BQRB_Q]CFI%OA<+U2%J\,ND'I7W 3Y4CP2)_
M5]VOF'SN3>^^CW:='J8-'"-OP%#W2/X9X[Y*556%PU<-P*+1X'CPO%<P;ESG
MCSW43AN?6^!XIK1ND,TUEE4:.[(!KM\NK#FI>Z5WV0?J,^3Q3/)+Y[-HZ"UE
MYWW) -_&N2B6L/&6D-U%)IN<<+X]E9D=GOLE\Z.RIP0)Z.BZHEX7-[Y_3M]G
MBIM;6=-(QN'T%B<^SGO'2<[QNRS,(8]ON6]<[+;]Q=,I_=>'9;IV;+"Q:Z9.
MU?G\)"U?8<M[TH:ITN^"4FFC^MYQ*HN&[Q<[=#5R9EH?,J]L.*YPURPP\T6[
M1LY"907(4W:.C6_M*&N=\=>:H=>G3%$B3@^.XX3PC@E'-^57;L+*F;G>?TB_
M*>'752;;U9H\/MR0&W7QP1;-O=QE@I%J>Z:HZ4P%Y77<%S!O//GRW/Z*C)XX
MP^K@@-N%\!621G/<F)AT=-(^=X=)8:I(?2M=9#ZJ$6;>($]K@IEI_*1@@#C)
MTYW/A"B0+W-U]0D(W[_..K]7I?Y.-UQUIN6]\^0''L@.!O@E=YGTH@&I?.'.
M*7W4Y"64ZH* _'7?96,\_NO *=W\1U0]W/Z^3\(*#A'5UX('+">5X+!J6.A6
M:O/CT4B0 .@TNBWF1?&HRI82CE\3^$K35\E2Q@U%U)\_C,;XJP/&F.@QP=CR
MY!C;H1 S5P<9WR.* ^[P^XU6)ISP\069:\?12M'&M-?K<@)VF'/SV=U3!N[K
MW@N;A;\>+U0<]>-RY(+_ ,F[DL-L?LWOZ*/NPK<\N*5\G[\75WBJ$K_R[S*^
MJ8[2E.M ]\=ZY7XNFXFHH$?=;Y<>R"PVN9C'K)5&WN/#EY7#P[;^ZP/%]>;X
MP&"MTF7=_J*2N.ZRF'J+NWKQWG='#+HE&TEK;])OT36WIF\M_J.^Z^J)]3TW
M7#=HO&!N^%*YG/5 F_A+EHRN\L/42ZRUO@L/5RMV,*PUAP7B/?;ZX9%#WW*?
M-U/"1)$6>;'J):8V?*P]5<>KXKPXVG+?H $/Y+^-]O296SSO\^:3_45BXRK2
M8P=4U7AQMMQSXNN28;:<KR[9*)Y>?.UY<[>F T=AN\8)3ZOA<O$5XD[:3KG<
MMRD=IGG]7%+E_ASSUO8/]5..<;RT5F?4OX7N[KUIC;=XWP5QM\Y9OO=#>MQ,
M9[EF7GQM[W/WPXQ0&W&EX<EX$^H,*OG>=7_"8;?/N[?/+12\<"9L\]_J>>F_
M6P@?4_>E;Y.7@1M^4<Y7JC_-G._JRLEWFSZC[Y=N* ]1WX+PAV^X'._M'^6@
M?='=LD5YX;?'A*G),/42#W9P%A>!&W-R)^$_\\^1=#?WXS0><'J/$UCM9:Y6
M7+PC&WN.D":(_P ^?CG":#S'\UOY.?S3G:Z:Z7HO!_ZJWQANA#RL?49RO'<J
M/.?RC+?AIG]I?Y1*&_*]'KPG^IG'2\[SW^HSNZ3Y*#SHVEPL9)3M!'B!1^O9
M>$_U/+Y?](CU-=!EQQ0>8.T$]^$;HB\0J'"?%WA>$'J#CPE.X]$W^IQCS1'F
M2V.WUW2^\91YUC<=R\2WM\]<AT2CU&?.W]Y!6+'R><)'4"N[P$I=DYWSJO%C
MU,]/,^.4%O\ 4Y][[))#R1OM>Y2(T/+K?%>/'J=7WQMRFUZOZT0N\F6*Y4GE
MPF@.\KP 0$"_OS!>-_UEU=;L,T3ZOS1P$KYI>1W$Y/S0$\+=?RN >KS\\8?:
M'^K^8R^!BKK2:L<'D6F1QNZ! @?#S7K]+D_U<L3?+PIGU7(N?GECF<(*Q5WD
MQ=T-"P=>1W*;0H_1YZ.4SZD.N=UE1*=L,L1F_"X437E-6%V39<+U5PUYXP>O
M'L[0?;NO"B?^;H.$G_*NN33=UD_?*O+-9DOUI02S$AAP@5Q_S>,1/,)F=K*+
M_GXQ&JNO#,4.AH.PN=U42UCQIIPSQ<IM;;3BZ[>H;3:5W<74<FO!J;1VVUQ!
MD[K"$-,."\2UZL3^XXJFVVT"-SWE\Y.Z^%X#:S?1\;I+E13UG4D4\[WM^QVP
M(!?8=W5GB<#D+D#C5>K;+:R%V1P7D=EZAT(_1Y.N:UKPDTV>4+HWE\NX(.'+
M#GQFY<_\TLX^";P0_ER?2?G-\TUX2TNMED>=>Q<7K,AT\7;GS<N'^;%T,+\E
M.=MB/+LO*L50LQ9T[49B6$.<7KC9<"_K=O7CO4^MF[69Y7DN'9^O>9UB7NY8
M*:T+%,]CW39-2W2\4WZ+I]V3H%W<:]W.7J6R]<<Z6_,*X_(&KX\9TRO!->%U
M'LI:UH1*CKRWH^^\XUP>O6QZ\U-1H<<W.R&")_(D1?+/OVPFFO"Q3Y/8"U5]
M!8O-,RU8D>/VO7A^2-Y2XT&]6'KJ\J^')K0U$]3S#1D_=&3\<$@<^FM?OHO#
M-_D,I\QYQ41^1.ET&":T*]D OSCU52UVD7&CX?:]?8_(U.KA\O?Y@I;;\F<9
M2X1?V36ASM,[8^#V%MH&^DC3K52&)&;JWE6J]?8_)RS@[XY]%UC\CA*<Y8G5
M6*KM1&3S0.,C>XRJC_)"&#Q5>'/Y(=(4CAB$G_,A'KPBY^/R$F6GFOY)<<,?
M!43XG'G]+P9_)#%\=\<,+Q4O^;B6Z;GZ7S36A)AY\,::NWQSR[JS+-0(S.4G
M<_"]>9_,BL:#P<=>BZV/R8F\3T^[*:T%GD]HZ$@?ASM[DH9W7*N:\4U^29X]
M3;OI%G\HSKP==E37@W/*EB;I[B[35(RQB+WX_"X!^09Q=RW9_;L53_7#'"7:
MO=(F$FG>ZBQI\WY2?Q5K?4X12L^K9Y0PYW5$>J9J;=;SFK,DT]2S++HNZ91T
MG!5#>Z?##PO'-^L9C&EC1PU4V?6LXRY\:3*FM#$1,/+%GFI'9\ZZ975<K'K&
M<?)OAJJ->J9A%XH(OB'SRN:15W-51FK_ !^?JXE*VSH^.AY2UU43ZQG$.C>]
M'_5,XOEV!LJZT)-.61B*1PMQ<Y+[-(87=4C7J&<>$\'9(G;BIE*G1+PS:>MV
M;'G&*O;X8OO%<3&V9Q'&-CDEVGJAB-WW3@K=N(MGLW?BNT(X"$NO I2S'"&Y
MP. U\KQS?K)A]WQ4_P#6YZ.D98QHC,3Q[N8=S;#[=(4^5R-:/&/A(SZL2)QN
MX*K+0QW\9(L6G<;8C*?3L['-=C+/U"._HY3V9 PAUJ*NM\DYV@RM]>JEVHM\
ME -;NW*;3/.)+L9;G[T@VXQYX:\'C18[08Z? R^U;M)-,:X3COAU7&WLJ>,=
M/A=#?J69/#Y8::FW)/Y635^I\/EC1^"79F?@Y=GLO%'ZG.+X*S6SPB8:N=I"
M"JRT,1QIG<JI3MACIR!+\!<5+L4PY6MGX$;B/L)'4M]<7D:+J:VHRPI5XY*7
MO9Q&[SN5:JC?&X T<';]7;I[E-S]X^!\;E=EH8CH(=>BP:&/P,8>-$2KL[[R
MML!=PLKJ::SA)_?Z7&PV,1'KVQ>G+8C*&> [GPC%G/M6OMU,])ODN#:7!]9K
MR9=C'"5;=EQ7.VP,L!##SC)1JF+N/9Z:=^.*?^+?TT[)V1WCVOPNEAT!=>0P
M2Y:8V!L@Z^0TS<NL&WJ0/GEFL1=_'%(*:;F;+^O##ORJD98PA\T[H$XZ0W/)
M5=DUPP%.TO"3LX-ZL<%&F85A;[?1<#3&6&77 KR):RE8AU7.T!SEYI;DF6::
M>*;+1AO=$/LQ&4DK<8<'NLN3 3UQ<=.@?2BH\?%0X7W5AJJ+N$L&1+J/Q\!=
M&R8,-VF>$58$:UIQNJJ&^$5F:G*)L#H7<Y_23V/\RASTI)6>+=?3.00!N#[\
MK357.=UMDP($_<.B&TJ[#)T[.-0H_P X#HN$:QN.:DUM;?A?VC,,Q.LW_!'/
M<Y=9%96Y<[+N,_BXKI9:E*&\$WS1UM'@XVMB:3X;NSUU,,XSA'#"\%3W?5\E
MB[=JZX*$4N7;'MUW3[*>R)JZ;JP^/M=&T PL71X"7VB#J:0PNJKGJS M%^O
MXWQ4VNVCW7.JL&I4EG6X*1X\YSGCIR1NKY\PY8WA7@BQ Q!X7KHNEAD5QO5^
M"H=F(PE.,*]9N2['795C:G2O)T#7QN7)M^SL\,-,.:Z6!)\O$(]DK;.9I/[^
M8HU-,=B.S8IKR=9P3M"!WX)V71N%RBBV*''4FZ_:$VVQ.QR$GKKSDXH;/:7
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MBYRW5YRDZ7T_BE+7!V.6/)!W#:<L71S?@A[N<;H'&BX?Y.$:NM[^28;3=O\
MBJ#K?G*Y]EO=.FOCE!<_NSGS^701]WQE2\XH+ R?0ET85C==R=\\A.<>GQ-<
MP;RF(7U#H(^^>,J3^>%%+BSY>80?U$(H/DX2C;[<N<MY\. ?TYIO?]%46]U^
M!7A@]%DU?CK 3O5<[34^+JG-^*WNEI%YNE$'06OGA?624&],U'^2EV<>"7WT
MAIIR0=!:SM\41M)0E+R/ERY_?</+WP\/0]_"D<<NR#I?IPOPE]\KQ[7)2+7B
MG 4T\H%K#X\>8H*^^Z/I?&:/\E_2@_=V!Y_&2FTU.\P8H.WW_=])K%H2Z&/
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MX2G821UAK.'-U/I#W<,)C7CN<N<MRO)T/E;WSO7DN<SSEM'8-IB]]X8I??\
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MY5YF6;D'<-IG>F>"/\MNL;EPAK/-^>70RR1#<[ OF@[_ .6G8RB_-(UM/O/
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M7PN[9DR=B'M]G8.JG7,;1=0QG9\OD6*D+5CA>?M_B^+GZIK )&[ [$%XVV2
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MPKM.A\4>%:OXE/WV%KB11N_57B;IIX(>:).CQ^$_5"Z%)"43%^6 "1.>QQ8
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MW",1*OZQ'!0<)V.P]]KGM@TQ=2PX.0I)S!X5KU2AO:/2H*P4N-@\?<Q!J&5
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M3:<89LOA:,5_3C_&1?R3VMJQ<FPM/>G!<1Q-74K!#EKV?!=LI-X;T)7I?9J
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MO4G/TT+.[>7K$R_= @K'?XZ+?/M+)UW>^4SU EC=^]5G8DUEL<?@:81C2?-
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MI[J[]M%^^JS]MOSV$X L(R$M 0![%WHP>@#@;0T@^M?[OY$_@_S?C@'VU@M
M@0%T0,] @*$ P%' (%# WOH!!  P #C$'QSP;_+N?H"$@H:!?8=Q_ZWWOZ,
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MVJ$M!R6"[Z*<W"K-TK_(XNS;:2RQ>@YZ5.#L(Y1NB>V9:_1D[G4928H;,<[
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M<[:^6FF4T<0:Y\\&K2]]-TA(/T^)D(SSP9>CGM=-02@AKZ:K0_+% X$B6P*
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MMK ?1\7_X1\#M7)4/_3*_X8OW:MVZC7Y%]O.O BOYE'5K97S.1%J3_WS-[Z
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M))@O%"5U:,?K'X99D5'ZNDP[]*.K%<0L?QI[;7_-%(^4R^N\2[BVOI7].J/
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M0>M=#DT]D>9C5(]3FDZ !O=EE@J68@SR&I]3'*+,G0Z15IH>V81DG+/[E14
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M.509<)F&\QE5C2(*CG_$$K+67@5'C\HBB&*C"1^[,ADKM!(*5HUB+^$I, B
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M_6FX\A)+!4VH>/KAJ89,7*\;13<_?. -$"7Y(OF$X27_4.H!9KM[W4?<)3(
M/E\"K>AZSTW(QZ2))SW/52V]!S,#1#*9"6<B,;YHL^=G?^%^M<[A^@ICJ@5*
M-GKU[M!R/]G$AX!!@YSA8ZB_![MJGN,GT;^0L/Z+3\U".Q=(Z)DR-F1Y1>85
M&IX7B+Q%(J&B40:VTO)<S+=V$HACM^!K>;D'9/7%U?VE2(T"0T14E,@)PGS$
MH.S'(^#U[P.[7KB4@N7M%AH$2[H\0V6\WM2^766!W5W?F4^%*LA__V,0#I5Y
MVLHU?;)08/L(F$9<3Q .HI!W^R <W[P'\RFE9--A-+#[8O[-BT$2W;6'=D7R
M<2_?P>@C0U\\5&:0,%%BC]+2Y5=I&AS=N/J[)PYT-D9^TO#5@D$.J1K0S;Z@
M=,0TFX/]$0<I&$,8XX=SO) 'T9U &\ "+C!J.?OA6,4&6Q;)EZTZ0?MK[>:@
M0,,M8\2+XDXAEY- H.)>H+Z4;?H(9^OMKL-#V+RR!D!N,X-ZQ7R-TSN%W6,D
MC"S0RZ1QE^WJ_)M!0)2C @V70B@"3,JOWG#=*4ITU75;92?UT>'[[FYC9$'F
MK*2$HF^-/3*.5G&[^#*J-,@J_X>8<(AUY%GZE:KO3BA3?D#+U$3VUP96?!,X
MA+ C YQS!;,(:(-=0Z!;82J^L@I1Z"^(VU7DH,/H[3VURM(Q\ YF\K<5_?OG
MCAP?LBXL!X;<+&4&KT=%]W**RB/K#: R B.>UB<=.UQO%Z&WBU5^\LD+:+CE
M\:],/7_B^M:<A6 YEC)0(FR*+&:>C*GP=CS/F%BB=8&('1T;4;!JH<&0N6(3
M#3=V<@J*=A"V/$Z\^*;I4DUF4;N+A3*D"WPO?GZ@6/_$&SM<'V#:3#NA,Y&#
M_R=+GDJ]+D16.BOE^!B3X7O5+,E9_!6E*(CWL_P@[S-)9CFV2NN@G7T?WV]W
M"U3$MIU906KGE[>W,ZZF?JWU(VB+\T;@*VBK732&*GL(<ODD/W'C^';;Z>:/
M:>( :YD7_AG]0[0$[/G-G"!1:7J&?S0?QVA-%GKO'O5>I8TSSHFD?AA!,$#\
M:1D\2_W5(OT/72>XXZ7*I=7O%_E\F*8MYZ2](N]9^-C3% =A;(OF$YX:(^E]
MFJ<OP-IRNU=^83#1ZANOR1%&_VV4'*;NX)2[;'%8$F1*F_NSD%7E];I^G)QP
M0=LMXV'PL]Z[^HO!C[:TH$/LJ,)HM;=1#RAJOC#0+?X#5P_O$TY,Y[[*T(G)
MO3.L\-EA\ZO)9YIKOGR8PG.C>[9#0"=NR1 %[[([;L1=T&3UGFHD,-(-O>$/
M,R;Z3KJS=CF>LEGU)TWW4CBL4;6$TS2@41H<-T%T>DVQO/4(T*9\!#P19HOI
M28]^/_@T7AK:0_[=@[(LOWKP)RCF6W(6.XF!(XJ)Q.OLWN!M\NP2-+25\4&H
M(MCPR<#M5$15%27\1#KXZU=L?CR;)\!%R7C- Y,=IHP%T]R+&[_P!Y'\!D*#
M.B)ZQ.Q9$24F[2VP\Z[%9XA' :],9WMGL&^PZ!>K64;*69IN^HN_SR(A!(!T
M:A!S>=V.&6F MDL/2\P%O&C==[0NF\18@Q>/EQ.5D-8]2!C$S&\>_0@0T8K)
M=NZIPO.?#*]Y(:W_"#AOJ($KO!E+''NKI3&-D,Q8#<UESOU6_4Z/[&2?ZVF*
M5DM;QY)@I1 G/?NI/M4$$LJVAP"5@(F5$D9O,/XP/3#E*SZ\L7A:03S],,EX
M'6%\+Y%=I7MS/1AO@R?WUP&/_$JX;.+]:30Z1KU%GSWY?&8?EUTQ7B<=4WI[
M_:E]CW!,F>85Q^SU(MKY><,UT^W7J+4D:DU-AJFXSJ=4-5RF&'HL&X,?GL5L
MHG7TS1\!AWZ/FP""IQB )X!_O:I) OC_FTE7_%?2J6O^*^GD1(K_+<6,^F_)
M$TW6/S'_>T^,_P]TG)T4AQ\QFHB);)P/*V?Y2[A?YO^-)\:S_P_T%1Z.2*X'
M D^G43HI,FNL-JTFQ7_C2KKW'Z8_S5ZH) HLIF.?=5-]@M&UA1=#^V]]"?^#
M;)&O .E2#M4E\4I3-P]%->QR-79#G*5_YTU_]1]A8U+,W7&^]4O_4RKTH)%
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M%V["+$I%WVD[6GPNB[?-PR/_3%PB<@C%JPLI)K7*HR!UE4K%SGIF+40?DC%
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MWCD<;^*Y4YF[LV_#K#^W:##0FK/.G(O"EZL^OG+DI-,-/M?LQD$%@DUN%JV
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M^K!B26 W:GX9)-M6YS1";K-0)GY6.L-X#>];M93)_WW9<(=LQ(MWXOR6D5X
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M_5JR>#%U@L-Z6G?]&>G PS_:$8_Q5^^ON$UM.O6 1W)*.>5^6FN%>I[K@,O
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M%RWDP4Q:VL?]U,'OPLK@#,P44@<SM M+TZ@F*/DL"ONQ;W!N#&K_;9K;"PF
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MG*>>-_/\X,?<+-S4E-B$*EK45'H7Z,QIV.U^UMKG;YC,\@%=4#-GS5!T:"%
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MQ^:9F=Y">>K#U=(W7"V/QCVX">?5P)HX5I)04F>ZM_"R58JD#0F=DUP7(V'
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MFTKZ&84A6>G.L"'(7ZE1(#^9Q=;UU<8Y]KJ&97O?W*[K]K+BT"$G6?\SQ;F
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M6$;]OG)E!W.S^'G,]Q-58CEF&=-D?%\W1-0 -D]&>^&:#8U@&LJ[9K"Z\YU
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M$#XNNCEFM>QPR8\&0Q)6';^GQM3#07-X$4)T&[G\_NFW;*P<UK7STUF"DP-
M5R9E6QTX/@VD9]-7+0I:$PG.#%3)9:E$5B&SH62TN20YBM(B&,H.*+4?F4=D
M)[7X>I6P<Y+9*DYV0+0[/Z8SI2<#H72\I6TVR2 ]5$Q"O 6<FIJ='8:Z)Q88
M$[:4%M8%I#.1EG+"5UT3$[\28[)"D4HU)&3E0#G<2)&Z,0C:@3])U/VW.E=Y
M/4NPR7(<B^^ ""3 3L%(55L=(Y' *06?")%FQ '*5+':#[[5T]?\1#B)8 2L
M'S4QKMO:%-^!6='S**;G<L@2,E@QH,/1"*&?1#P4^XW!1CT2V&B36Q+6N0QR
M7Q%Y(5\*J@X'EN^PMI8VS17JEI F(.89?7Q?&="$==/"\#$QH]+E4=LTPT$)
MR%4>7*K&M(1P(R8=:&9U-,88FTP>T932(+FB").N?OH=6;ID"TQ/+3(5F#2(
MBY=F3J?@!.)H>KZ-04&\.P?5R<J3URZAC&<%?(-&858K+.<_Z]8"QEG1,\TA
MM##[&.U454F6+94M]S&LLD#A/O*Z3_$)T'HX13E@%KXI&,?T['WQ!>9./TLJ
M.XISW!)-4S(&CE\HYM3;5O#>KJ8CB8P'B;4\9Q,AQ"5<PMBY3># JB9\.QPY
M:T)'AQ%!3C8(,L.ED!K4']D C$2A^#"9=]6R27AP-,/?OW!AC[$::4*;H$I,
MD.3;N(T)>]J9:S0=@!0 SV?NWV&F8.J<!I/0*='7:EHTM?*AGSFZTSBY"-$&
M$1[DN(P3MI$#6<72U<!\NU8E\;$JC(HV8 . WVKX!A>MD8!&Z,B8C!8;7CJC
M' [;,Z.P!I$EGYN6?XDM]^2SO,)Z'6WUSBA-+Y@ECM#L,@AIF_"J')[1S&DH
M0KZ)N0O,BA7D1]]<2=WPD;'CDP-9T>$2&!0$J :\[>9"M*A!1H"0@BF:R9D9
MCAMII3^N34PY?XY/C69_!7M]BX9(ZD8E"E)%F_2S\/I#QIX?P6)!VKDKKB7+
M9-^:) BY%.)(GLAC/8W*6X%)&%_3<[\!7Q52;P!)3BM]M/>RV+\*&=L,2;UX
MX\X!BS7I9L ]JZ+]B<:5_^%?]E.">[H%@P$ZR\_4YI&$_6+;TB#5XF^)^.*<
M:DU8U((;?' ;)I)-# SG6L<F-W8)@$@D2*TG!5<69PD3RKW'PW_51^V\I3K-
MQZQ17K@4MN2)*. _%TNU*A?,*F [O]2AX7$0"V[L-<RP8MTV AETC0Y^]X!_
MZ*<TXZ9"5X&^4-4:-!!AS:+>SE=9.6LG@"PV7OVVP^%"NKNCV\L^R8=_QQH
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M';,M7JST%JI1<6;$-.1,Y=*18?!P;A'1[%M2(TX,G]@7'$P>^M847>D<I"6
MV &3>)0>VWX)W>QM4F6X"#DIA;=9' L"&_"GD R_F'+.WW=+V.@G6Y70KK:3
M50\ 3X-?( B!I.(0<B IJ<LQ6$9;IK,W;1LUDREK1ME@;,%Q>=7ES;@]/D"D
MP]"0*&%^7\)^B#6/ UEG7:"BYR\TB7\K6!50UU[ORT*<K$Z#QZ>%"&>,IJN
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MAJ%!X:HXU\^Q8F;JU8+CN*D:9S6A[)J$.%G"I%)4/6OU60U?_$& )&^:@C4
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MI*@+<3Z(2N((,78!V,*50T)L@1[2!^$ ? XN1HPU>F ]"]UB!:MIX@'@U<,
M7\GD7UCL*!5@U$]QKT=)79*H("X"LAVA8=_W*3%4,%0->J*^+=D:X%I-*O!I
M/GO<5(\)!!*00$ *E;&5W$- R](!8@>3E$&:E"Q",58.$"0UD(!@!C):HB!B
MB[J%L5B7>I0T4&$:4Z!&4]PQW54X,71!>7V>1*$]*BE<!VOH]"LE+E)V7ET
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MK N0R0&Z .$5S6,J(T0HJNEPF8]RX(W)!4K ( '_ .LO_]E02P,$%     @
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MP+#@E KGIF/V7CU@\X0>^>NST)I\R @;<J0[/5R]E"3ZI::33\$ZL'29"4;
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M8L<K[O@]841SAT'@D3D%O)'O<VIST.(X<KDU%I4GHC,#@WU*<RG!4[0+[>!
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MZG%ZD0P%BK?K13_?NQ+Q\W&N#.3%?89\H%\P5"!TS(<@D0^CJ(7;9!G5P9R
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ML"?<GYU?7Z)G@X(R(^(KJ[)7O"S$9\)K.JQZ1PKI ]BNF.R.*$[S((RU$O.
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M[P2_1)=Z.*5V1W/U9FB]J[:C(+'0>L 7]9,GXO/T0/%+8KW;QG5IJAJ6!CZ
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M9];Z+S*JW3Q[VK&PXHJ&@H*(8?)105:LM9>5<CV1PL*[=I^/3O(.K^1RR+G
MH?1%$?WY@;9I1GJM3K/OF]8QF.B0O:\.'OI\"9C^-;G]F/.RSQ+<3"M9GB20
M,_:G@UT7/#]](%&RJ&<F?ES1"8[N*&!I_?/UO_)T=SWZ"+B>)&(*:QW5V $1
M\I9BIP>[9 I'3S&ZM[I?4K#<U'/;.Q:QK%)T>8<(X)@\1$Q^P'RYHJU?&:UJ
MC9E^IO"^+4D:),#5$K6ZBS*R!ATD_K)47M5W92W,YJ;WH^2AXSX4FUAU0P[#
MUQ]2*99A>G,807>/K:6A"CS:":2Z^@*_2LRT??U)Y  X_ %9R_,:"0A%FZTL
M/WD1!\RHWCKWQ+,8^A&[MZ-E!+:6.+G]%*;E]]CY=L%0'@K^#-3\& QL[I?A
M_6C"19:U4[SJL!K6(D4+8IVGCA9$W'7@Y;Z-<!12#Q=L-!*AG*,S2_7F-=.<
M5,UT-RK\CBQNKC&NU2T\<"N;EMXK8F/E.PZUT*JUVN 9&M7E<UR&3.%7W)O.
ML.MR+])J"QIPF($0+^AV.[%,6'X?GS2]O!\?0RQ@=2R&F'RIPGZ!T>.>V>FW
MU[C5$>NW)PO<XW&M!6Z<E6^QZE@A&%(^,W@%_.,T>W!#X#+L?D;,(A/;UN++
MLZ=W'T,=7T4;.7])'F)80]_?N K"<RW9E]<3N[@2<*YC0>JU6>$<"]]^Z_1:
M\ #]ACO]BX8)R17),!'E/Z(9@L@_I_<$W#4"%E<DRS@_PG:695*D"IH4J1L^
MI>@1BX#?:\L+;[CQ]AX;%@\37VX5!V:;'YU"0:U/J5CM/9[JC5]?B]_R=WKL
M#TTOY-K90AJ]M 438'8>9N4P>V<B157L7#(LN\;8<J*RX=*,7\EYG4?DOZQ%
M6(-AR7<++3;05DD.E;:Q&&Z++:7L8KFG>J:G.$1Y86"X16<NP6Y!ON/D]<&G
M)SE"<H/EK5-\#P<8;& R5%09>$-Y-[^<0F@JB%AZ_4=5@6 Z:_S,M6&L"] T
M371(6E$9I2DI"^65E&#YJ.VF-\\2G<J^=)KVE'SND>_I\7M;QG\ZDI3U^8-&
M &1GVPB@KLG>$[\HFV"85)<0[/L4 OTR;8Q7Q0"K9"X;*B DBPD+S-U0R]_>
MI4,V[5>6@8MIBOSGLU5R$'Q_!^]>*BO=-VXLGQ/\&J.$'%6S$5C!/*C?\8CH
M#&1F!F;N\Y=MV=Q+?%$P3AH[6^#L6B/)/Y5O%VWGV+"R5-O@.EQ:-!)F8U,6
M68(M^>'D%ECV</)888;(IN=UT<E1R<P,;[3Z_NM7XU1@]+7Q1B])7Y/EJDR,
M%]=LY(WWV )3J?W;BNFF 9,CAB'23DSFL[EU6(Q\-\4RQ)GU=2#KZKA*%P(<
MA;Y[=D<I6QZXOH,R;7Z9W>:?I:0VKRU/+KHA6-+5@9:.]##\+U &3#9F</+@
M8*%DAZI[(34E&(/=A$W8#M3:N\A">A&^RF_(V%>8'+:2@7Q=T5N37+%@GU[=
MV'F6QYWC-182$4OKR:5\'K:FD9WC DKJG'#T3'ALV!R,7GAL!. 19C;;46-M
M.SEONL TV:;(8CV$0\<38KV)?LZ+YKSM1SRYLU\712/WZ7W(W8%5&0&.&WJO
M[)TQH=O.C"JW&><.&>[IS8;3A,75F_JC(]>-@.BFT$:O7U*0#?*+"CJRJ?9E
M4W(XW8^(_P6^=FW)"U*<\7SS65!'%?]H%>L@V5X=R0RY#2N<];VO?;5Y0Y8>
MOQKWXY)G2&5YO09?N1>WKT#KUN7K=;<+\>GJJ +)_X81'5J(K_3Q[C #\6?*
MEPUS^I/5+JYY1>L1-Z=9!0NL]'Q[XA%\U*"(/V@$F% OTS,AA_#'G'VY;3:C
M2?'QRZ#M5TONHYU>LXY3(1M3O,%;:L5& YH1(.2V#C# B6SF]]"/4&!P/)>
MB^91[G2C?RI),@(0#3(=;WA4N$0GXV.U4>TJ1G@NM$.P)(\4@-BB&$.34B;;
MHGMI&PJ0(_X9QR8+D='@C,W)Y8[O'0-K7+)/2]^(&WH/]A$U,:WZY234LB'N
M#S5OV4('Y^8VWW\P;;TF[/:,B%LV),.D_@WDI3N2;@?2,'S :V 42/@^^:2+
MB]@Y-&NA>XH.O]PIG5K%\CFNWOE&0$E!T9%MYT2NR@/SOBLRL<\W2I&PW?$P
MG5_5!0:;#P0$'8?2.TRO1(B]MY+'K0\TX4[8M-&AJR97,DW9J]>6C #%@>BU
M%/9GE8[IJ.E-18K / W9/7S;W+M@N_6*$7"&.@@#TRMU,4N:2DA?KA-3+\PF
M('0],^6B,X,*IA(+?+Y9E"C!@["Y$962S%P>.VUM1>3KF9Z^&KSETN;[@RPT
M<R+<9U9AM?(=R5HFG9,]SR")>S[A\;TQ55.-2"&YCX29JELL:<ARUS5_CKIG
M-B]D=G1ORV?:<+>[C(#01BOLARG9;OMYSTDK24*..2>FOJ!J49R].U;*N@^\
M+-/][>J S9<)PS&13@?9<5P-C0:9&^YT+^X?735Y[*5NK]R76:>[1:%<^768
M (?,>]L&6KW='?9WXW5K"X\3Z':.(Z-X3#Q7YHW>[4Z0C?_MOV#\SA>;''-S
MJN]G:A3ZY_!&<X,18"/7S?*5.V&J&YM-*)?3XE5&;MN)#]FWJM8#>T +O%>2
MX@>$LYS8$9?I!<VI*M5&*'D0:WVD4TAO8Y_PK2F*2542,>Y=3U:"'[$7\5C7
MU-$@RZ9AR4:FY0 7V-$$]#,+]:&GF^O 8%=69L3P\N;,;>Y\GK!3Z2XN+GZ3
M^&H(A5AK$O]\'4U!J;>6$;?G6$5W)/:1KX<)@^&N'E<6APG?':_NJQ^K>VX$
M.+MM+/-?IG3W;U<_$^NC5F0$FP-AD(."P_3H=<V;.&0P##9E!Q_Z5G]X%+/)
M3I59 &V:AVQ);I+):E;3Z#=5CI=6^HB!#\K&N72@E30MVBD**S<GY-48 9<S
ME=@-(X!@&'R^9NDMT3%7%__TR=]^;\?XC^;]Q@?O<=.*$=A-O1#6] 9SXL'C
MJ0K)63<Q3")"A$%\:,G=VV7"R@)=?\@*/5GL1^+N^>[$5O)KD[:8[KCDF[I]
MU3+G2@RG$&3U;"!%T5?E+.7Y_+)1T_6EJI;*R5^_&_N7[=G68P,9N%4Z'2S9
MUM/1Y_8MOC3]/DWKCN2K"2GE><LGI5>TYOCCJ/$'-8DN [!/C("]-IY3 JSL
M<6MXK,Y%L@61U7)D,)07W>+U7,!1/O\%7[ 375! *X=.+1#(%<*\XD]ACO!.
M"T3LW88'#=2Z_ER,P;ELK$L+AU\_MC7L4=#W*/5P]Q+5AD"J-P?F+W0$-F%C
MMOK6)PY0KBRVP*M2*T#;I2(=\H414.Y)DH:=A <^P*^DR-+BCF]VA\C-P+F=
M;$U@8'%%N:$B\?Z0(+V7RQTP5 7%1K'-'5>*_#-BIRPSJ6-Z@^_45IVH-V#]
MP0H$_-Q$#%'[<W6N[/Z%P<KRUZN=]3$Y<GOXW3?S1-2AP:#&* $+7W4F074F
M;S4M80/#DWU*>EGTLT_N&ZUD2NK[MXG5QB#@R$%=UU$B\_N,O"_!$><^HG=+
M@&>DTK4$7;LAUD='?P0]R%[EFW3Z-A:<:"SSMYOPO@A+D)L/8\-?]"PEQ:/&
MX"')GW,*^@T=@;EWU+BY>\D=Z-E8&S("=7LAG_%IO(] 3-E?*A.SJAUC\IM/
MIE;S1ZTM0./<TN5.]DA^#FY(N5/8&KD=B&QBG7ZA, (R7-,06]1UJM]/;'N-
MK48CVSUX.+KRH)UL5>FFN#>:W^C_<W;(7Y?*%"]F-EBNW3J']J*[ZV&.B+07
M>E6^U<S=5+QBE/AK?3A0R_U1[H^>;[29%(ZZ0ZZJ"S59L+0+V1Y#OY883OZR
MX>%4>3"A.R5]C& Z,"$8SAO.HZ BA@J903J_)TT9#+SHU8R$J/2V^1HYT_QC
M[>2RN[YXD*S*%//K!V+O%MZ+(1%+818.)/,N+UVTTY69NS;?,'CN6UNIQ]"U
M&0J!I[:P=0D-:\W9=H)W>KR]-MC6[OXV4<!MM;0 )71Y\B=IT7/X*ACLQ/5A
MRV<D!\P9Y)SC5E?Q21+'&BYI\LH<<21W#&Q0RQCNE?6% MDI7"[XT'715Y7U
M>UQA'2U#L,0I#K/,S82)F7%J]BY'TB 8"GJ+,>50/Z0^'9%T'V^/6 )W;_=$
M"TG7287/M^$];,%^*@R5L;+<^K'!:E[#:^5]N<1C *,&(P?KSFBO9FR5C?3W
MA3;:/'ZQN7W*X\4Y[ACY35?RWI--G[_9,K$@DQ_BOP_ 4#]C+0Z2FBMJSZ0O
M3G<%?LTK]STB%KE+W25S6JMC4OFD*(3U%+;AX\.;C3LZ<+>=1.K D\@MES#-
ML[2(G.OPT/HMO,1'OEB?%G]]I)^%NE@4ER4H#*1)LN]RY[C5P@"/9SKA/M^F
M7LMG%=N2##?@8*_+2-5L+X(2/;4J4-Y=!5I-UT[.<OEW:DIT1>4>K;:PPW?J
MQB?2^*DIU+N/@!*03V]@P!I+HO<3[;B<G])V9YN8YK>UQ]W+BK$M[)X9K'_
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MT")!SE%Y:4T7R'8M2_%IP^RXE,94KF;,Q4IS\!?5W_[5D/DWUY\BT#'\WXZ
M&?9L;+3*1#9!/CC\:Z%.*F9=S76++*#6+/BYAY#EQ@35^A[M:2SV?-R4R!L<
ME*<IP$^$+"2G<=;M_G=B2'T>,/C^(.^K8F8OPBI\?8?X5>Z)FW"9542(CDE&
M'&$1@;XMVN&$R>R1(.@2">1=ITV(/>?J]8?;*H$,2PV0 QP=1[0<V[784L9E
MZ ,G,XY)\XY(1)\@E$_T1[9#WDT+(BY7YO$CBH@4)RD+&IV>MMTY16S?"0E>
MH@9'O'H;[<TFSU[DL/(U-HTHI,+UGSMZ"=DQ;*:"[72 >I(2U#=T[\G:]MFO
M#4V[/3MS823JH#2LL&)EB>,#K7< 5<].+S(V423L$>^6QIJ>D.(:YK$1$)&;
M+VCJNBKM=W(,X, =K^RPQ@57M[QHJ^27TTEWG^-CCC &=<?5^96.%?Q,P:WU
MC'N2)53J&R!LO2"9Y(\.4L/"OE_:)2L*U0TW4SK$%UP(]LV,MB>=A1%Y-35U
M(/?X#P62-1SQJV_NWKLY<L@-7]YG8WU9P;M[03#M.,NVKEKX:-+S"> X<H%4
MS2^ZA8#Y=0T8WX8@6IG#+P39=@R:(6^Y.G9XJWN8A1R<<;H$P<,E^ %AKW*_
M=D2-L/4:/19=":LSO5;(YE\2K?=:=9"62]A/=+1W/R\"3#*B[\B>#8W@IIQ8
M8GIM8<@N15 IMH+6B"]M<;;"^.=VAHT6QM[U#3EY\,8$R'6*7M2=\%O%^OU6
M(!\W5C5$N<9D5X_B/Z$&=Y8YE3@8,$ZE'%^*_FPWX_7R4-%UU]C=P=]8L:97
MC(N#<M#C-7ETA8C>OA_[YNT"^3,:,<''O2T),]59%,<\0_NAE2D=6DZOOU<?
MK:[BM9WH0KL,WQTBU.ZH6@I?ZD1T.K%F-4/PJ^Z386"XU='"Q\6!JZF;6WQL
M)M;2Y^*<6PKKV0*,+UE)P\4GIL;\T6U0-MOPJQ(N8/^Q+]<G]9;0C6X?[H76
MKA/S(Y3UG)[X9T(;O.513BCUGNX@<GMXV),,^.K ;H2EW"$G[)"35E,$^L*:
MW4N9JULV/KO,]N9^%3"[7.1_'OJC$ \)5HKX"LK%_(AO'^)V.6>XSR&Q<% V
M65\2V$7=",_2Z@2CVDZ:0*UX-TK?0)I8JZ4'\><=:&Q!C,=HU;)#0-UN!EN%
MEA$?KIH1:*PX9(2W4^B<Y=L5B*T990]E:L4"Y%ES@185X*U8/.^0)(,MX63
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M$4"B86)B(?]E7 S()V\3&@4=@VS!X^GH:)6?<PYIZ@(1R"P@N!>B#RW>3G'
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M4I/ )F97]/0$U,E;Z&K8GJ=W7"PFWLT<5\IK[#.U%W#1?Y]9"'!HV)'27LN
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M>:+OSDWT@^9< L2.F!+N?&X>*P2\ W@\O:#+:]/D.EO_FB6P;1[:"LQ=Z&Z
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M#8%K#(D $U!XHH<$+2 %D?!RHP]:[MH@6 RT=SN-*J]H-H5$0A.=K@T@YR:
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MS[PNT.E5RD.3JU,LVF.^5GK.X>M+.M9R#-N6E_HVE=-U=3?O=LB;XOD&_K$
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M6OL-T(EGIM^O]M@$H.J.EMPLV]^J&1WD"HAPS9@A=J0HVX/=O8@!A1Z+?H+
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M3^BCQ_.JTV1/@;89H#4RF*!LF[CYLS,U=1.C8:GO.FV7[RI/'IHX0IZ#FLE
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MJLN)FU>U1L_B$<VD(,)DPR0/Q_IQ_,[X3E]D5*[ A_$$MW5Q_=@/PS",TMT
M;ATC$AM4OU431]&'79C.!Z]2HL<H/AY)ZTSAO96$Q2:8T<!V&C=6:[%$+K7=
M5#YBNO#'_BVJ\<A+HX@_M]37/26MI"=BLSB?X;E(.N(#:'^N@P^S?&.*)K-&
MASG0)&O99:6/?R_671Q:FB4VX+ BUY$2Q*2R0F*:;KR_%8G>M3MZ>&;)MAZ.
M'&/[OO?6\^N?NZC^&]2^>)\UL!>"_KVFMW;@AY_[=0
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M1&BA$B@H_\MG M$L<^$ -049K%X+#D@M?YGYY5FXP\Q_VQ8![#\JB %7MQ]
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M7@%)KFL^2>Y3GMGU6<M4LP=K>9\$.IR$%TDOY"H6J)>)N4\GVV!5% ?/;4A
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M#&2:-Y3M4WGMO@G<[&E)HHSD15J*$>;!I+)V'-/JXU0>WJ&MB.$>M\]\Z&Q
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M.6(H3\=]I+=3T*Y_$!RW:QZTG_$Y7CS5!IRU4>#!OT#68X2+,HKI)-*0'.*
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M0VD!GZCF=7/IGF;'G<P@>7RY^&43_:?-W.F*S>;%DL@$BM$/^5:^+ 5#9<4
M$E966!EUCJ?%$ICLC))+(2]R;W\ J0EE./W/4>5) 36]4PV$H+BK [#I^7ES
MH4XTJ^O;^6)K>Y1.%W=Y6T[Z]%0EGJ@5*S*Y/<,.&4?GN7;H*%)QNC-4=MR!
MS$W&V>HM<1%W>_ 9T2K?[I).M0%#4G 6)M*C963^?(IGYU$Z^Z.7B2%C:XFH
MG,T6QID<HK2QYH(=%,'^ENVPN@=AC>'3]]\[J14>T"N:+N3]**95DR^:)&VV
MP*])Z^%9??1T@>;^AT\3,[RJ<!&"F32/P,7+W=F7HQ"KU*3NA8C//4(E #>\
M"J7[132'!$@]NE^LMK>%/"PHAL;*@CY7-GCKDC(.Q0.S6Y[0G,/D[DTK/K4)
MA(YRR1I=M2* P\>Q@?V+1PJ4+T>L7IKH/.8([^;\2J*,!Q>MX-3AB4C7-'%U
M+BT25S^K@PSS.T7,! F64LK@2]&.;0)6"NI(3@M$[KI+.5;*FS5-W@",@1,8
MCX@M)^)YCP T/K'\ !L=PNCHB@1]K,1@X)TZ1GP^Z+</"-?1X[]*MVC/)B_)
MZ(BJ5Y;*BEPRLE&:;.]EO,33+M.8)4!CY5-Z;@CPY=M)BJP"/30EOJS(C]BH
MP6I3VW_86'I254A(7:FSD,Z<T(H]GZTZ>Q=U2? 9D^[4>9K>O@'I6,C*T6;D
M1A&&H#F_;XF8D[=!C!@S(92/C(P&)5-.+-$2!NW0?2!/M%YAQU.:E1K33 \2
M4FKF,? WH47N(PGYU"]A"RBHJGN,LN[(P^O$JRBE3QN&.>ZD]*+[824)JH'%
M^S?7KE[FQJ]&++@\>,BP!*CH87@?9=MKER.E:/_T%_6,'%YCF94]=1YRW)4^
MHJ=6]@FF+4-)>@]33(;PJCEV97XI29"4*PRE'2V(,F$1(_O$37(IE"\_)-T&
M-K5]E<G5_,9C<@*J(@80-36VR)IL-]5'=3S=SY9<#'B1BS2!-)SY-U.2YN(#
MI4V!5DW8AE.!$4/\A!DJPV?#3]$VE8YP-%6=*9MPCX UJWDH7'0AYX3,/&^U
MVOO)SL[[;88K&K*,Q*4CB@! KJ]>=,E3,J9.Y!)N*R3=SFQSA<GU9,NJACK>
M>)$*PS !44&7T"P[=!7\.*JSMY5[CXN Y4$M"E)IUWZ';A\-1BVM%I*&%Q:=
M81KI47O(@M+*/N$> @KH0./\J88RA\1WXTO;I 4?ALH5F<D0?0X6M'%J]ZI0
M;9CKO-5\$?MYGKC#W <+":-'&655U4,+E26U5?*)M/+">#.>I_-)HN1+4:'5
M$*C4#]54X?=EZ\'6>9R)_3J)<4&<G.QT7VZ?]G*4&B-*Y"#\/O.QY/$ KAY]
ML2DY>SM%0)GDSK>)YYBY3OSO@W>-]9.<(?'='5#9DL 1^<I &.SQI\4 Y-RP
M-TRN?W.JHX'S:N<.0CO&*4*=;'4D]K6U-UHUMD+G66785X)I-<N%X.,!6=VW
M2SBHLSI2X,SUHLT!JQS^6G^+7N3N\9VO,7'17I\)0?5-S!FAUE@ TYG6@O,P
MT:IZF;Q#"X.&"N\!^>3M2!DA)WD"6^)I$15E=-0=?EJ_>57'Y(+HL1V' LO9
M^5:6B,'R0@Z*6XNJ\:U$[D[P"H%WB;SM9+^$:C80>%MPN E69SV#?:P<[#$7
M;#O@K'WZ^ /5+#^Y3U)T5OH&D2M=V"37^:0^Z["@%(WDH2!Y:>GM0TI:'D0G
MG+>@T?27JK76'97)D##.DA5P[Z9.VGZQF[4Z\'D?_^ZUG:8NY3Y)T6#:,%PL
M&U)J5+%(553^C:[HL8_+%\'$KT5=1G9=#(#X;<:4^Z<\1/&&\9JFXT.:4YV)
MQ2\^*!LL[PM+T5Y&J?Y%:_A%=SK:(R(^0%)6X7$&!+B('6<?9+%8:Y[3<VY]
M#1'D\\=GM>$7G@P6')-X)Z\]B)8,I[_4&(OL%7-^&[F3KWKU'61\]2(24ZMF
MS3:ZGV>7S"Z)*;IGLV8:NE[IA'L[U.W2!TW/ Q?7\,0/J$O)<1JD^+43ZS[$
M]QU@38<LSE#W2.U?[R 2W_NKH<C[*@$3XBA:B*(#4YK9@ :[S KS1SJHNN3F
M5=P9HW3Q4U>JN\#B4YD8J4>&WJA--J$AV,[S:TGI"N@/W^\)R2_@E.MUNMQ.
MIL)\%34L=G6(B3%*WLS5TI'U/GM@O839BA*AHU(X957NH:8\C/>.U"_ :%QI
M@$3EJ-36TU(0/8B&!+F"R^(^]&7HTO8.U\B,U.KT]+14@U2RB8+Z%9,7  #@
M(\QX1B[N,P_,AH.PHQ>#SJU8WBET61F3O5#UF.I=]9A]^[EB=3J#WZ[=(=XH
MUC1M$D-'A$>RDIANV91BXFN,\3N-+TGID68S/^W5\OXDH58CO8KXV\7!'R<E
M$2B@\_ZDO?/+VN!_>@OVM\:AKI_$27Z0_TF23N<Y.CJ-SY[\/Q"H_J]H$F(1
M)!2B0$Q"FD=ATIJ,2'A$?&,T"I]2[J@\!+C>U_QWU(^J&_^^'F#XE^?W.R7H
M_N;<I@6N@7OG3CH'5L&LY7TH,J.0!ZJ!W#&'W?R)RNJ:N"E%#"2T2]/CC;\H
MLBR +Q[6&=[^Q)<;P/&<J0X=X'<=S24E]E^,T\ZLS3H?7U*-E$57*ZDH?NPH
MQORFB&^-MF/F:#:7?=6QWJ^<X9]J251?75,MBFX<Y6TYVCT)]B$' *LZQ434
MF^%B*ON(H -L%NP9%FY!MX> ZYEZF \UCNB7B;!,Y],"C\CRB_ +]_Z\7S0+
MN.'\^R7"%O:F7%;HF=ESCNT%%B_70J8E0F;X-X;31^P'J,1RIAHR(.HR)B4H
M7*8/>^A=4,[TDSNJ=M[M=@QO*167-U;4\KIVR[+Y.CR4GBN[ 9B0Q-RC#N=[
M@=R=K]*D0L41[-NMN+)EPZU?",: /PW121^$4P>1]O9K#D_<P?WZ2IX<E18-
ML;$56)>,(X1!:W9P#FKM#T92U>% OGM"Q>)B_ FR:\7,;5Q;%>,H*]B!1R.]
M$OAM@#0W^/C6VK?1@(,(2NW^+3>K FU)AR\QU*<(MX>J$X6[F@1\2)+?C3H6
M-^>_WD%^J5HR(H*SJ1EH>ND0Z\VZIQTM8T)=YO+02PKI65<3*H*P\A?AGC52
M6M<RSP?[+VM63L+W6^9H"VF)PLA/A_/]MQ=6.*(9AW'SFR54M-\&Z,A@&6V?
M7Q)8J!Z<C$,A*?7#GL-[Y)JV:1=*+B2PH+)G+<^0C&PY;%6]!$&_B$AD2W@A
MJ,JW)@M]W;DL([FCYTD=&D[$:8&$4^'W5 %G, ]@;QD;H3FO:W3;+&EM5555
MS3XBU0[S@3F^WG>HF3X[<W@)L\*KVM!W8:'6SP#&V>=V(E%V2ST7]BRZ2VI>
MZSS4,D%!G=5O&1*L-62J&826"_<CQ=&?(=5;+5#Y52KJ=)DO[-V7I0@.(QR1
M,'S?,C.R!PQO?$+1W$PHG/5!A,J,R$9GPEFK54UUA-$YTU^NTMY!^.Z;*IH-
M78LLYL'-^)@0Y,:H)0ICA;+P7'CNV\;/_5)4;:?]2\D7RR#RL3$'<[W[ZT1#
MFS8;CDNMQ3*9LJQYPE_,&]E;=T(9DW?D4D2OHK[ZS5-T B@K'>9!_J<*+M &
MPOVQ.JUHH2[[+7N=WF9E@T*E-H!@Y!VB691SL'/H:1+A_NAF))?<D.GX-N%8
M8,E7-E3<YQ2?VJU%.!N.3A+%Y]I(O^Z;/<DQN0%,QKMJ?X^0MS3ZD-A&ZW4#
MJ#\J62;2">3@NU/ANI< V8QP+FV+CXG3QQK;.U4NFI4,8VG9?) :0BAUU$W=
M1(3_\&UQV:J7,-G/%F-&)H\$!S66!FYVMC205E?$B;9S"3C4I@>ZXC9;2U1!
MB#L\Z>.IJ(0<B:&XVAJ;KO;,D>8<;2]9#ZR>&.242'X*SY.B,6!_1!4MYJAW
MW_(-" /.;L80/,T:8?78WWD6%X)BL17LS;EM@MSFB;*/"GWP',?7G9=V?/E>
MFH[ =)E!<$BKI;@$C7"NU:_*7V1ZG%T'I&Y\5E8LU/4'%,'$:/TK\RXT O;Y
M"B6XUM*A_D+(3Y]Q4S04B4>GP<[3=.N*!_7KQG;61O44(V?%G5FEM<3/D'P>
ME/;.5ZAW<'ZU19K]';(U6J0O@WB"#&GM!JP+D/&X>\7Y#2XD>C=5I(LWQ=%P
MWJK]]PN(+7&S<'8>;CKA9&[%N_.$/'[:<1"<:^P%=G2!FQD"[;FS9)4=;65&
M&_^IPH?+6? Q#NFT1]#5V\8*GHLDO0F+'A<])\&*E*T.$;\"9]"+@U'2EWGI
M,Q+I+<9T*?4^YJ46>E_0@K_JHQ3J:[BI]5F^KI[7WZZ^SKT&#>P+@G]Y8[F*
MSA(+Z:=/=7\H]MZ7,K5>Y#.6 >J30[1,5"RJ:"L!V'#E&J+D)7,/77[NZW?=
MJVUH<P2*7FU+P7BD9YVNASOX9"$HS0UW*T,,HJ3'RX4%%H4P@[0R$C$@;LR!
MO$B#'* S7W-BA^)FI?O8W5*7E.GN./O'9LA-YWJMU ??.#&LMJ_ 3SON*ETY
MKEE*DFQ$,J4YVRV\V_(1LR!K7E(19L8J*$SRU)G;/*C=/1K)XN[6,1-(V'H-
M?R$#Y$R?W/2FJDBHT+@!E"ZQ6#TZK*O/0"DK7>NE0">W[7MQ)%]15SNR78ZA
MM5=NGF/#X+NW ,R^U]>DSX4O]NC-E[;<=NWW5,YL&.+&"O$2+?S</NF=6>=/
M3AX__C293^1GL92[W;$=3,D>/Y30= / L=@MV+$48EOX F$-8JF3SYK*ZU6V
M?),"T0+@VPS::;/,%J=KGZ-WB) '(H8]7-?41O%[9*6B(:]65X*9:="=<,K/
M].\3VS21Y'D^$=BM+C2#-02\-79M(,83LQ*JM" ($C*T9"6BPWOJL;729MMU
M)CE@C31LED1VKI7:A>HZ&[2 Q;][#[=@IB!?7%M?4!0I*2TKNX#M5_M3ZFE/
MHAH^*<0U2Z*)IP_2YBG9"%TGGYWD8L\.?3PN"QDF"K&=$W%,;.45XF!S8)N\
M,O('Q3F(1-G&VTD\M8W#?BS;])4C)%#<&>CS/06C0N2V [EFQ$2D1D$+&#T]
M2B]/QT\K2J2(L$>JG]%9.Z_5F_X\8/5-8'L?3^[6";Y-Z:183=,GP=6$\4!'
M;#" 'JE(:-P(Y'S^=XU/:&AN>_LQ2$'OOAFG*6PWS2:7"E-O^OP#Z:&$@,5E
M] 2A5'NM'V>VV-1A![:(@@G*&/B?B@X6"C;P7CJF%<A80<R9[;NXS(/LHQ2C
MH1YMS4;3&47=S9X+%VH,)MHC=>P%T]K.D6/ON:=F1#5%'HVFU(UDUKO0A+;+
M=@P//?BH8H.KP?XU,:ZS&R",\8OG):F[MX^ J5-7[1?Z?8M<@%<I'F\Y<%0,
M3RD3+N^H\E%\$,X;L+>P/%UL;\\**(Q52'A6F] FSUPR#8ERI4!&;#%\?QQO
MLY*B%R.TM((&V1#(FYU=CW%T]1W1&"@4KBLT+93-UNKUEX\.[+1O-GCS$/DY
M@WFP-U\3NKGY;70Z&R^>T7!6:W7B.82LK_R(A3:;=[7Q7O_\#IPS$W/G)IWU
MI$I+QI5:^.Q-IF1=3FJ_<'JL?J=3)+#Y;IDHZ2M;ZS$X@7'TU8,$S^X^B4U=
M]DP9+N<<R:H7_][_'\J6OP]G)E,+(A!>+C#.AJ7?Z0K10'MQBKX,ZB]Q^%2G
M@E48)=P)6_I*:%CA;X,R_?'AEG946Q7]!=7)$5WW#-:OMI+9V#J W$DFE(2S
M?TCMK9'PR@L@+-^C8G]\8#&3[5 O8YUEV?/%L9+B0LZSW*'@Y+M]O>06<;@\
M7EDX4T?5XXHDS_4=%;E&X7IHX<GT@VHY$+H[;PQL>)$-^UQEOOZQA:$6V;M*
M5.^FQU-^WU$/DI!RB'^X$2T%MSO[C7ZRB^)T;C994Q>!'\,?0J:])&F$^;C7
M!,A?KQ.!L+DJ\$5BP3;FV9K2+D2'9/Q"YU+;&$\C[*XOT,4(4_6S-VVV')-Q
MLTI*@B0:1G6)ZJ[TXT*"VQ_YVXL_S:U=\GNUQX?92<5.DYZ6%]0*QJ ?3Y;P
M%]__&)_N,O<NIB+3H:FKUWF:;RU#U#3=G:9QS"]6/^N<:4V!^3O+8^^AE>F4
M&#) _S-T(1L?[?:"L9"&U(P-1U+?BAP,9R]M'!Q=T97->/L0&N(H=R6<B(=U
M'VLHUMN(WW2;QL0W1&7#N<):QXE/G42H$9,1!>_?QNDNDJ@I..&_1[>]HZ!=
M#+B#>IR"O2N/ A<.O"1[XLZV\+DF46/A0]F5]2'3DHW*5"2:N.1&A H;G'N_
M4KJALF2,2^^NALX,[B/OU?%Q?KJN)E@^DJ7S4KWMY?5J@5NA61+G2#X+PTB=
MH'-$IRW4LO2N12M&,?D+CH+:OCC..CO2KQ0I*N4'O'YE>(L?#R)"Q<?V@J@?
MPCM'F9=#5*F>>!YG(SWYV#]2%8Y$[R40-'?;K9'W&76CM_U*D%$7WV!(EJ]\
M^7Q3'7)' N330#:%(6JW,(#Q@DU'OYQ#?8HM:=F R=#SG<2C^VM[0ALW *,I
MO&RYV"B>.*-223I\?\$T=&8.LL&O7X^Z( [PJP([L1'(2V_0W<W3&C/B?EKC
MJFY>8<G*4)2O-X >50*DC<9?TAH5UCJR_=EN<9DY;&?-F6%V(',%S[H*A@6F
M;3TON3$T<*&.L\ Y9DT[O#U;E![RJ)$WWLXL:EJF7NJP4O/+2\=4=4:EA^BJ
M"([G^65C+.-D"3,X>HUU]904%;Q176ZT):*VEOKX3XSX0RXNOI&]6';/JPW'
M4?\EMPG<:O($E%28!\W=/[><)>C8,!PI&%)C0*&%"'Q5$^#.4W>7SY/)WXI/
M)QTK/^XQS9CLWAW69";1UCSTE>^=-=5K_-!(Q6*]OQ5E1LI:2>"TNMCO0=F_
M9 *E'R/H9GVFW_!2(1+034%S(='3M.@E+*JZ7]E*@8::H#-81Y?93O->BHUY
M)U7UO3&@B(0ORU07_]P4 B,K>-"*(!BU&.LF*6 NR'C6A*QFZ\WIS7>6"\*W
MNLT%N/?NZH#-36$B/5MAQWVRO,\I+0RHGA[1;'W%^6(KH1LMH7J U9"&]A&6
M',S,,$2YNR@LH3+$&M]])URTAC%).2[8PPY19/D8C;\9L/ESW/D6=OLXXE?-
MG>N "Y7Q6 WO9;*T8L*LOT_S+!O8<NH:9SFW;/:T/IW=G*6N4Z[?'T\]E8)D
M&;@%952_J94@B375OD/F-0^X(W"F]W;IF@?:)D+7,')L^LYGA^TZ@Z[,?=*/
M+!V3Q_#@.PWMDM ATL;O.;P<&JN[23HSY[\2?Z0^_BBRI_DL/J0Z=%>25(HZ
M^N,#20+O7OW[DD+DASB$3DJC#B%,+$KCT-=U,8,5439.W*L9S)[2KVB/PI((
M87<GOAFD(*&PDZ$_0AGZ.:=-%4$Y]V0CZCU7:WVWDL:1CRY7.:N BW%GZBOR
MLX$J"(U4K,(X:QU[ULQ6)<<&U-4OA?!X1G7E8Q&M6X3(J"KO9Z W2F@*4G7#
M^Y[Y %]HL! %.,^,&'].V]ERD7'6K9+*U'DUV&-F2J?","'XJZ60US-TF_]V
M*3VRA3YBZ<$&6O/3&LHXX\RIAJ@LR2&-J7S&7J/Z.Y\4T*P! T5Y<W^[?;S^
M;P+_9+\)_(^Z_R?/$.>3Y6Q/HABLTUK"T+'3&SZ>\A_[%O&NKCZ4V)"'R.LI
MYO..YR2GW(4W  RRV]OA=[Z]';1P\('*;T?/P)FM;D?&RH^10?K\!M"N^ ?L
M7P"F3-.9A$S<L8? OT898/]42:%)28!OC0;'EM>%N][?S/Z-9,W["\DZY!]Q
ML?^ _5? <M#;]%!"D]CWS_<Z<GZCX[+\B;;;\3-MM^X?TWO_'J<T#'^[OR5>
M$3DG>Z#GOQ HM5+E@( &E-*&ZDS%"FL$=#Y/ A;_B7D\^PM#F?<?,I3_P/TW
MX%(/B)N6LH+=100/<G\8JM(O;_;/H>/OK5P9_'\9197AW+DP&Y#9F;7A"=R'
M$Q43/:$ZK9,-Z54_[)=7DB4683]W<LG1,",6 >Y?S:@3\PR#S=N$ZK?*JW!\
M(CKY_ZT,P?DGFO]/#^7?R@'^A7%+[OP%III[;2&>6Z*CVR= ^V'[=9B6H&\<
MX4=H>@Z39/]=OC-"MY\(7+?A]7<I._T?PO#_N/;W6X&_OT[@!A!2P&8EQ).7
MJ='E88.=JN]PZIQ(N*P.68QNB374WA'OD,S^!XJ+7K];U^T/Y!_(/Y!_(/]
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M<KFE:XG/)\-5B^+Y;T56J3>+[_DL2D);\#^%-(YBX^>',22,QU!@(A5%2.C
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M5"=12"*!E?+YUL^+F]IWWVH+'K?4!:4JGC+AFXMX 6<W*N@/O8%I807<MJ;
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M=I YM35=HS(HFZ281U: )ZMNO0+X]<L;\&A6!O5*P',AX )_0!276F-(@]3
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MA[4;F#$-!<$P2E-#:\0X,E3'$LI$4\8UCV2@G)=Q%\5-C<NLPF!+XZWCGC?
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MJ3')2DM0U'DD1L_Z7)S1M'-6PPFH+X0ZA@!P8!XYR%=8@VE5O@%6:?,[\'H
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MGMO5EP8P%C'#")E5# _,*L:.'1,LA91K@C!)D)9T]J0*OGB!(=R6.^8@OL1
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M]WW^96N)]_8?2QOC6\SG[YH3X#,18AWSE,+ )F=C9HB3\(A!A#&Q(3I)S>+
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M3TV;_X<$!]3X;N8EIQQKF(:!"KDVKIO"[0"\S>6+PK^2/PKX1MB0L+M1?.]
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M6:?&34U)&SD.7NPTI(GM&&XBAAN8)3UMYIY8/SR:O6;K#RCNN"4 AL?]K*[
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M-3/%,HAD(B".90P5YG&J*,XB9M71>C!#C<'R1RAK*E/KS2.US[AS0]QF&V,
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M.%*"_9BF=,N0[QGSUFSWOL8:+W.]9W2.LM#[?K9OI%Y]6E*F0=2](.8L2GA
M@@3&<<8A"C($B4HCR%"H:!P((8A36M6U@:8V"=9R@85'NM15-.U<ZSXP&GA2
M.HBX[W!:2]EGM%L[#OW&LUT9:^2(M7:-SV/2;ESOX6I_T0OTKYINZ&:Q?EC5
M>7U9&*9IQA!DB200*1Y!*E $4Q'CC*8T5(G58>?U(:;& $9(4$L)M)@.7M-E
M#"W<U\[(#/S=GX'B4YO_,CH.'F)GE$;R]^Q?(3=OK57_5M_K\IWC>5*MDA_Y
M1>U7=JDO\8W^M6^<^W;]2!>K.>8Q24@L(0HY@@BK!)(XD3 F@>)IR''&/ I,
MG \T-8ZK"B><]!(N9?6J,7$!6UN?ISMB@_L\/F!YUIFXCD3_A28NC/4*E2:N
M:WRYU$3+]1Y>SSNEI&E_)/</-P3T11H5%LM%,5'\HTQ!WN=)W8G_VI7>5QFB
M,(\BA1@G""9IHB!*9 P)C3F,,G/ZH *A2&+M)/4AT=3XYN,ZSX%IE2LW"YF#
M^SJK^Y!VZ>!&]&(R"Y]L;$,,3&-[=4"#T I/Y5BE&:B4.J1P@H-:=1+YV/9R
M\!+'MMM(3N5(]G/S2/O$NM6![66@\?S=/G$Y<H][?;!G?]>UVFK^-@EO]5_?
MRF>Y7#^5.YGY-J^6=@R1!&-A*C(%#"(94T@52R'!J5)4&SE43I'2UB-/;?ZK
MI75LPFH-M)VO/0A\ \]:M:!%&.'^'PVQRVC" 1+<G-'JM=^I]>#C=C)UQ>2L
M1ZGS WPK,9U5>/HDMP]*\^4\HC2*980AX:8\;IRDD"*>0J2R-.,D%3R4\^UZ
M2Y=VK-0REA,/[4<<,&KHJ"+<TGCE]*2RV5<]RX O:RK [U(L.%V:'7[^[T"K
M]:@]^-R[>4J;2>SXJR>@!V:L2U7WP"]F!?1K$?-LXBNTQ+,K->7Z+,MT$ZY^
M:S)='V[D@DPW]3ZOQG3[%D]GR;?8^'NZV)CBN_(NSW>/9>5Q4VG ]&]^NWA>
M"+D2QO6;(TY#(H7FKU@)B-(@@#04,52*:2<:480"IVK?@TL\->>LE@V\+*1M
MC,QXYK5T[:9DM*%=PJ(-!6MO5\'J=A7L4KL*HW51G5R"AMXS4&L.]N^$T;U'
MGW(L,_7JBPXN]+@^[%@V./-]1QO8MZA$5="FJ$>HO9&'35'6611C?Y:;0KIY
M@E(4IS&#J319-"F5$"?:APYE$"8I#0.A'+M5VPP[M4GC\Z$4:=&&J^C(]?WK
M6_ D-^6/+!MS.:)O-QWTC^G G'Z LRI5JF76+V]9VEU45*WE+DF]ST(/+D#U
M6]/!:N21RS>XH'%>J<'I;L^4OJ^_K9_E9F7(\>N3)L*UJ<!EPI^>-HM<YB:L
M\JOD59F(:GLL%%&$>!Q +",$41(ED! E(4="$A82BF,G%]E'B*D1V/=___KO
MX,=>#9#OY75,%/0QB!V+#0WSP)SV_2LXR _S6@'0T*!,C#[H,, V9A<0>TU5
M])%CW(3&#DB=I3UV>9;G3D/5?>E!V9P1?3.[3B;KM4AZG2<1IC%+%*2")!"I
M*(0D3#DD,A),T$BE;@S919BI,66M2Y%!;'D(Z[B+T,5TEAL$(QEDZ+6_ARW
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M*0L2B%1$S>%C#%D0!H%,4IYRIY;MKZ;)U":A[ZO-(8_PJ"T\+[()UPKL*A3
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MX$8_Q8;\W7NL=3"FY53[:B8:>LJ\TE#O9%IL=L[3,]Y>Q:89J[J_PY1G&,8
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M$X:X0$A DK$$(DP8Q"0(8"32+!)A3*1T.S2\U-+4&+\VU&@9;8M\58VMCJ>
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M,(&$I:GZCF.*:1PF!%F5PNYL96H?\\Y(\*2M=%]DGP)IO]*^"9X1EML-,L9
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M"<P1E0KH/!<H"'&0!<Y'UK>B/%)IZF&1M3Y)OA6MX4^$][1G:R,'%9\]A\-
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M2DWC=!"!JVZ@;0_:<>T@_3(PLQYV26LU:,P&M=V@-=RGV)\C5GYE_6P;'UG
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M=GWY"QH=X8MAVJ")G@R=Q%+TO4__WI5-6;KBL$6F;9%0#;5($$(D5SG BE(
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MN5E'"YG?CC60QVC3[,2]I=]MS/VO'!I;7:6://M9%82JSVJ-@2,)YAH@I"6
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ME8*!FW:M"<WIR0H2?(">U8_;$A^OUN6+]2/?ZL=EVXOG@Q*J^%:]_0P)K:F
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M%\&8_.7RW3]?O/WKG??_*3?OYM[[7S8__?[6U?2^-]+'\E_^QU]_>Y\^X5F
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MG+9@VD%#IAT4@P;G:5LVEBMM*.CB1K4 T$[4]0"HHU"P:*V2#G#V_M-BN?Z
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M6!/)=XZDRTP>5T(H0?YBSL11#AR<80A)>(.1D[.W4Y/F0; TYB[6!@)[X.L
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M+H4Y>1PKLNBKU:*L/V$= 1OFWVZ2OYJ>?9[ACQR\'W[F+U?$WF;CXJ-OP&4
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M&PB?6K:_N=HZ@.9O2%S@ICWX'5:\*T$KGB#H@L1*J'>C90(?HDG)<1YS;('
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MX]DY;P/8Y!P9.\\A!!8A)\%Y2BZGTOC,8?A"P/765?EML5I-4$D;.#F>5K$
M2BH%09(_+#DWTC,,PC?Q&6Y0T>TNNH_V[X;&A\IYU).22_+_AM./G]:8G]&'
MAH_X^WG-2+TIF[7XYGR]JJ=")+)?PVJ:GLWSB^GLG-X]D6B,<M&#XYLIFKP
M"5 #"L\,\T$%WF04P6'D=KNY'@.\$VBN"X3>WB%N,Z29SRD30R8PDB%Y$+3D
M1"97Q944.#(GFR03?T#7N"=ZC3 WI"X&!->XGMS;!7DGZVF8S;YMY##]@N\Q
MG2\OYKRMMXDCI,7X/,S2YFA@,;_R?#Z?W@$<F.(Q_,:60F_O;G(;I;/9 .8Z
MM]>'"#Y["Q0'.<P%L^%/K/'TU9",9_3Y^8Y*7G[=ZN,5F:I:#7J^Q<B;.P'
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MVT#*Z11OM_[5ID0NV,BYEP0(A8I<YJ+ FQ3 A>!%93&DDP'N(7&=(&XH1.R
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M_T<DS)?+=[-?9M_R<G4[YN261>N"%Z'V/LEL0 5A 3DG#TD'Q[V).K<I\#R
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MO\YK?=Y37!0C%"_"@S.ICJ@- ;QV!7QD*:>8M'RXC_OQX^#S7[$3DMRK1=*
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M3QG::CQ%7%O;X3!PYDJA^"G5GKA,MXMQ$>ABB2FEDJ0(YV,[;LN1?\/59KW
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MZUXZH0K)4@3ZX]@Z$?L2D5V5Y!X(BV>2M(/J:.RK[+YMW\I25#$J7F=C,!.
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MZDZ3PG^?S[ZM X6U7)?KS/'=/Z\#=7^?K_XGKV[GB-]M_)YX27%[B Q,Y*2
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MM72 J<,%=\OV+-4+\W?\<EW *!3W15B*IDTPH*11@)DB;"V$R P51C^.6WP
M,^,B_ AL#;89;R!%=P#V#YFNGVD=F[)V]OZ<35?5S;MI1HN.)QE!A\A!F1(
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M^5.YWN<CDC7%HN/9"6E+D[K,0;GHUTC>!W\/7J">7-#=6"+?,;_)9:SA1'K
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MC0(DI[Q*B2&9J#L52NSUVEY/SN. U'CY.]!6]T>'+Q0O6H$UC@=D7=1Q%4E
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M_S7OP(R^RP/]LTWE#MEKPI$RK8E_M5.R$! Y+9.UACOKO''\%(?1)3U=H><
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MDXXV+9@95[L=@:V[=O/8@NX [)>Y.!O%OE7GGK:W=C&"R#&3+R(-1%0:)/'
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MY('^<I9WN=S;?E"_Q+#$__N__AM02P,$%     @ ;(EA4AT57>,* P  )0D
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MXBOY;O$^S)AO_&R\?,34YDUH"$C*[6J3C0^NI=_BNW?W!?[%_P!02P,$%
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M76RR<O+F?OUG[^X#_-/_ U!+ P04    " !LB6%2/87XZ#0%  "K&0  '@
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MA_XQ^!_]_EDP_,W'6VCV)] ;#3:VX^&H-^H/>R>5[?FB//RB($_/)M.SWBB
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M!G^!'D'"XB<?*V#?H6)1ITH;@3101I:S:#!C:2/S6/IE<+J$1AII2_)H8FF
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M28G+DS1$IJ;F9.RZ.@ /JT*666&2_^Y+756.(5D7)\R;+!2[V*3 >]C,FC>
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M#Y5L#70R@Q_C,DM_^R]02P$"% ,4    " !LB6%2LL%[A<I@! !E%2D $0
M            @ $     <VEL:RTR,#(P,3(S,2YH=&U02P$"% ,4    " !L
MB6%2\[LL@BH6  #G^0  $0              @ 'Y8 0 <VEL:RTR,#(P,3(S
M,2YX<V102P$"% ,4    " !LB6%2A>Q(89$J  !&P $ %0
M@ %2=P0 <VEL:RTR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @ ;(EA4ER@
MC5K8B@  LRT& !4              ( !%J($ '-I;&LM,C R,#$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( &R)85*W0'@10CP  *T]   4              "
M 2$M!0!S:6QK+3(P,C Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( &R)85+R#Q)G
M;,4+ !#3"P 4              "  95I!0!S:6QK+3(P,C Q,C,Q7V<R+FIP
M9U!+ 0(4 Q0    ( &R)85*, I)O]PP! &@; 0 4              "  3,O
M$0!S:6QK+3(P,C Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( &R)85+/_6L38M$
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M:RTR,#(P,3(S,5]P<F4N>&UL4$L! A0#%     @ ;(EA4AT57>,* P  )0D
M !P              ( !ZXL5 '-I;&LR,#(P,3 M:V5X,C,Q8V]N<V5N="YH
M=&U02P$"% ,4    " !LB6%256\>M[,(  #</P  '@              @ $O
MCQ4 <VEL:S(P,C!E>#,Q,6-E<G1I9FEC871I;VXN:'1M4$L! A0#%     @
M;(EA4ORE]A.E"   VS\  !X              ( !'I@5 '-I;&LR,#(P97@S
M,3)C97)T:69I8V%T:6]N+FAT;5!+ 0(4 Q0    ( &R)85(]A?CH- 4  *L9
M   >              "  ?^@%0!S:6QK,C R,&5X,S(Q8V5R=&EF:6-A=&EO
M;BYH=&U02P$"% ,4    " !LB6%2_CC.'Q49  "\JP  '@
M@ %OIA4 <VEL:S(P,C!E>#0U9&5S8W)I<'1I;VYO9G(N:'1M4$L%!@     0
- !  3@0  ,"_%0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
